"There were no significant difference regarding other secondary outcomes such as secondary ED visits, hospital re-admissions, repeated needs for steroids or dosage increase, needs for antibiotics, WBC, PCT levels and FEV1% between two groups (p > 0.05).","There difference secondary outcomes secondary ED visits, hospital re-admissions, repeated steroids dosage increase, antibiotics, WBC, PCT levels FEV1% (p > 0.05).",G0000000|C1705241|C0027627|C1274040|C0027627|C3538926|C0545082|C0019994|C1548168|C0205341|C0038317|C0178602|C0442805|C0003232|C0023516|C1535922|C0441889|G0000000|G0000000
The study end point was 12 months after baseline data collection.,The study 12 months baseline data collection.,G0000000|C0557651|C0450371|C0439231|C0168634|C1511726|C1516698
Snoring noise and sleep quality were unchanged but daily diary records indicated subjective improvements in nasal congestion and daytime alertness with fluticasone (p<0.02).,Snoring noise sleep quality unchanged daily diary records subjective improvements nasal congestion daytime alertness fluticasone (p<0.02).,C0037384|C0028263|C0037313|C0332306|C0442739|C0332173|C0376660|C0034869|C0439655|C2986411|C0028429|C0700148|C0332169|C1443086|C0082607|C0369773
"For each specimen, the reviewer marked a continuum to indicate degree of tissue abnormality.","For specimen, reviewer marked continuum degree tissue abnormality.",G0000000|C0370003|C1709941|C0522501|G0000000|C0441889|C0040300|C1704258
"Conversely, the effect of antioxidants was stronger in children with the GSTM1 null genotype.","Conversely, antioxidants stronger children GSTM1 null genotype.",G0000000|C0003402|C0442821|C0008059|G0000000|C0456148|C0017431
This finding is consistent with the theory that childcare activities may preferentially expose females to ocular chlamydial infection.,This finding consistent theory childcare activities preferentially expose females ocular chlamydial infection.,G0000000|C0037088|C0332290|C0871935|C0008067|C0441655|G0000000|G0000000|C0015780|C0015392|C0008148|C0009450
Serum ferritin also increased in all the three intervention groups.,Serum ferritin increased intervention groups.,C0229671|C0015879|C0205217|C0886296|C0441833
The primary end point was stroke or death within 30 days after enrollment or after a revascularization procedure for the qualifying lesion during the follow-up period or stroke in the territory of the qualifying artery beyond 30 days.,The primary stroke death 30 days enrollment revascularization procedure qualifying lesion follow-up period stroke territory qualifying artery 30 days.,G0000000|C0205225|C0038454|C0011065|C0450371|C0439228|C1516879|C0581603|C0184661|C1514624|C0221198|C0589120|C0439531|C0038454|C1301808|C1514624|C0003842|C0450371|C0439228
The total score was multiplied by 20/6.,The total score multiplied 20/6.,G0000000|C0439175|C0449820|C1719797|C0450371
The script concordance test was administered to FPs at each data collection point.,The script concordance test administered FPs data collection point.,G0000000|C0871893|C0680240|C0022885|C1521801|C1708010|C1511726|C1516698|C1552961
"Modified Ashworth Scale (MAS) and Action Research Arm Test (ARAT) were evaluated at the baseline, week 12 and week 24 for all the participants.","Modified Ashworth Scale (MAS) Action Research Arm Test (ARAT) evaluated baseline, week 12 week 24 participants.",C0392747|G0000000|C0175659|C1096155|C0441472|C0035168|C0446516|C0022885|C1152215|C0220825|C0168634|C0332174|C0450371|C0332174|C0450371|C0679646
"The 50% threshold was not selected as a benchmark for clinically meaningful pain reduction, but rather to enrich the population of responders so that loss of response after randomization (that is, <30% pain reduction from pre-milnacipran exposure and/or worsening of fibromyalgia requiring alternative treatment) could be measured.","The 50% threshold selected benchmark clinically meaningful pain reduction, enrich population responders loss response randomization (that is, <30% pain reduction pre-milnacipran exposure and/or worsening fibromyalgia requiring alternative treatment) measured.",G0000000|C0450371|C0449864|C1707391|C0525063|G0000000|C0876919|C0030193|C0301630|C0359583|C0032659|G0000000|C1517945|C0871261|C0034656|G0000000|G0000000|C0450371|C0030193|C0301630|C0332152|C0274281|G0000000|C0332271|C0016053|G0000000|C1523987|C0039798|C0444706
Physical activity interventions are reported to be effective in alleviating emotional distress and fatigue in those with breast cancer.,Physical activity interventions reported effective alleviating emotional distress fatigue breast cancer.,C0031809|C0205177|C0886296|C0684224|C1280519|G0000000|C0013987|C0231303|C0015672|C0006141|C0006826
Related adverse events in the UC group included arm tingling (n = 1) during the tread-mill test and knee tendonitis (n = 1).,Related adverse events UC included arm tingling (n = 1) tread-mill test knee tendonitis (n = 1).,C0439849|G0000000|C0441471|G0000000|C0332257|C0446516|C2242996|C0369718|G0000000|G0000000|C0184069|C0022885|C0022742|C0039503|C0369718|G0000000|G0000000
"We assessed for confounding by age (continuous), sex, body mass index (BMI; <18.5, 18.5–24.99, 25–29.99, >30), total calories (continuous), education (high school or less, some college, college or post graduate, unknown), physical activity (<1–2 times per week, 3–4 times per week, 5+ times per week, unknown), race (White, Black, other, unknown), smoking status (never, current, former, unknown), marital status (yes, no, unknown), alcohol intake (≤1, 2, 3, 4+ drinks/day), and micronutrient intake (continuous intake of vitamin C, vitamin E, beta-carotene, and folate).","We assessed confounding age (continuous), sex, body mass (BMI; <18.5, 18.5–24.99, 25–29.99, >30), total calories (continuous), education (high school less, college, college post graduate, unknown), physical activity (<1–2 times week, 3–4 times week, 5+ times week, unknown), race (White, Black, other, unknown), smoking status (never, current, former, unknown), marital status (yes, no, unknown), alcohol intake (≤1, 2, 3, 4+ drinks/day), micronutrient intake (continuous intake vitamin C, vitamin E, beta-carotene, folate).",G0000000|C1516048|G0000000|C0001779|C0549178|C0009253|C0242821|C0577559|G0000000|C0450371|G0000000|G0000000|C0450371|C0439175|C1556156|C0549178|C0013621|C0205250|C0036375|C0439092|C0557806|C0557806|C0687676|C0588053|C0439673|C0031809|C0205177|G0000000|C0040223|C0332174|G0000000|C0040223|C0332174|G0000000|C0040223|C0332174|C0439673|C0034510|C0007457|C0005680|G0000000|C0439673|C0037369|C0449438|C2003901|C0521116|C0205156|C0439673|C0024841|C0449438|C1549445|G0000000|C0439673|C0001962|C1512806|G0000000|G0000000|G0000000|G0000000|C0452428|C0040577|C1512806|C0549178|C1512806|C0042890|G0000000|C0042890|G0000000|C0053396|C0178638
The rates of response to therapy by infection site were similar for both treatment regimens (Table (Table4).4).,The rates response therapy infection site treatment regimens (Table (Table4).4).,G0000000|C0871208|C0871261|C0039798|C0009450|C0205145|C0039798|C2945654|C0039224|G0000000
"Treatment failure was defined as development of chest indrawing, convulsions, drowsiness, or inability to drink at any time; respiratory rate above age specific cut-off points on day 3 or later; or oxygen saturation by pulse oximetry < 90% on day 3.","Treatment failure defined development chest indrawing, convulsions, drowsiness, inability drink time; respiratory rate age specific cut-off day 3 later; oxygen saturation pulse oximetry < 90% day 3.",C0039798|C0231174|C1704788|C0243107|C0817096|G0000000|C0036572|C0013144|G0000000|C0452428|C0040223|C0521346|C0871208|C0001779|C0205369|C1442160|C0332173|G0000000|C0205087|C0030054|C0522534|C0232117|C0523807|G0000000|C0450371|C0332173|G0000000
"Secondary outcomes were maternal hemoglobin and ferritin at 32 wk, and infant length-for-age z-scores, hemoglobin, ferritin, and cognitive development at 6 mo of age.","Secondary outcomes maternal hemoglobin ferritin 32 wk, infant length-for-age z-scores, hemoglobin, ferritin, cognitive development 6 mo age.",C0027627|C1274040|C2347083|C0019046|C0015879|C0450371|C0332174|C0021270|C1444754|C0871421|C0019046|C0015879|C1516691|C0243107|G0000000|C0026544|C0001779
"Fecal samples were collected immediately before and 3, 6, 9, and 12 mo after the start of treatment.","Fecal samples collected 3, 6, 9, 12 mo start treatment.",C0015733|C0370003|C1516695|G0000000|G0000000|G0000000|C0450371|C0026544|C0439659|C0039798
"In a previously published phase II study, belatacept-treated kidney transplant recipients had similar acute rejection rates and 1-year graft survival as compared to the CNI-treated group but significantly better glomerular filtration rate and reduced incidence of chronic allograft nephropathy (19).","In published phase II study, belatacept-treated kidney transplant recipients acute rejection rates 1-year graft survival compared CNI-treated glomerular filtration rate reduced incidence chronic allograft nephropathy (19).",G0000000|C0034037|C0205390|G0000000|C0557651|C1619962|C0022646|C0040732|C1709854|C0205178|C0035015|C0871208|C0439234|C0181074|C0038952|C1707455|C1425101|C0022663|C0016107|C0871208|C0392756|C0021149|C0205191|C0040739|C0022658|C0450371
Once-daily umeclidinium was non-inferior to once-daily glycopyrronium in patients with chronic obstructive pulmonary disease in trough FEV1 at day 85.,Once-daily umeclidinium non-inferior once-daily glycopyrronium patients chronic obstructive pulmonary disease trough FEV1 day 85.,C0332173|C3661274|C1518422|C0332173|C0017970|C0030705|C0205191|C0549186|C0024109|C0012634|C0444506|G0000000|C0332173|C0450371
"A standardized, validated Korean version of the BNT (Kim & Na, 1997), composed of 60 culturally customized pictures, was administered immediately before the first daily session and 1 hour after the end of the fifth daily session of ctDCS+training or sham+training (intervention 1 or intervention 2).","A standardized, validated Korean version BNT (Kim & Na, 1997), composed 60 culturally customized pictures, administered daily session 1 hour daily session ctDCS+training sham+training (intervention 1 intervention 2).",G0000000|G0000000|G0000000|C1556095|C0333052|G0000000|G0000000|G0000000|C0597484|G0000000|G0000000|C0450371|C0010453|C1880202|C0441469|C1521801|C0332173|C1883016|G0000000|C0439227|C0332173|C1883016|C0040607|C0068899|C0886296|G0000000|C0886296|G0000000
The primary outcome was whether a CD was inserted for treatment of a pneumothorax within 6 hours of diagnosis.,The primary outcome CD inserted treatment pneumothorax 6 hours diagnosis.,G0000000|C0205225|C1274040|C0007928|C0441587|C0039798|C0032326|G0000000|C0439227|C0011900
"To evaluate the efficacy of real rTMS versus sham rTMS - in reducing tinnitus severity according to the tinnitus questionnaire of Goebel & Hiller and Tinnitus Handicap Inventory (THI; a self-rating questionnaire; [31]) during the follow-up period (screening versus baseline versus days 5, 12, 18, and weeks 10 and 26), - in changes of quality of life of patients as measured by the SF 12 (a self-rating questionnaire [32]; baseline versus days 5, 12, 18, and weeks 10 and 26), - in changes of depressive symptoms as measured by the Beck Depression Inventory (BDI; a self-rating questionnaire; [33]; baseline versus days 5, 12, 18, and weeks 10 and 26), - in changes of psychometric parameters of tinnitus (tinnitus minimal masking level and tinnitus loudness) as assessed by audiological evaluation (screening versus day 18), - in changes of structural and functional neuroplastic adaption processes as detected by voxel-based morphometry (VBM) and paired-pulse TMS (baseline versus day 12).","To evaluate efficacy real rTMS versus sham rTMS - reducing tinnitus severity tinnitus questionnaire Goebel & Hiller Tinnitus Handicap Inventory (THI; self-rating questionnaire; [31]) follow-up period (screening versus baseline versus days 5, 12, 18, weeks 10 26), - quality life patients measured SF 12 (a self-rating questionnaire [32]; baseline versus days 5, 12, 18, weeks 10 26), - depressive symptoms measured Beck Depression Inventory (BDI; self-rating questionnaire; [33]; baseline versus days 5, 12, 18, weeks 10 26), - psychometric parameters tinnitus (tinnitus minimal masking level tinnitus loudness) assessed audiological evaluation (screening versus day 18), - structural functional neuroplastic adaption processes detected voxel-based morphometry (VBM) paired-pulse TMS (baseline versus day 12).",C0040363|C0220825|C1280519|C0237400|G0000000|G0000000|C0068899|G0000000|G0000000|C0392756|C0040264|C0439793|C0040264|C0034394|G0000000|G0000000|G0000000|C0040264|C0231172|C0021941|C0272238|C4054119|C0034394|C0450371|C0589120|C0439531|C0220908|G0000000|C0168634|G0000000|C0439228|G0000000|C0450371|C0450371|C0439230|C0450371|C0450371|G0000000|C0332306|C0376558|C0030705|C0444706|C0037712|C0450371|G0000000|C4054119|C0034394|C0450371|C0168634|G0000000|C0439228|G0000000|C0450371|C0450371|C0439230|C0450371|C0450371|G0000000|G0000000|C0683368|C0444706|G0000000|C0011570|C0021941|C0006448|C4054119|C0034394|C0450371|C0168634|G0000000|C0439228|G0000000|C0450371|C0450371|C0439230|C0450371|C0450371|G0000000|C0033920|C0449381|C0040264|C0040264|C0547040|C0150112|C0441889|C0040264|C0178733|C1516048|C0004285|C0220825|C0220908|G0000000|C0332173|C0450371|G0000000|C0678594|C0205245|C0027880|C0000934|C1184743|C0442726|C2700259|C0200760|C0078140|C1709450|G0000000|C0168634|G0000000|C0332173|C0450371
"Significant differences by group were noted in Clinician Severity Ratings, diagnostic status, and clinician ratings of global improvement.","Significant differences Clinician Severity Ratings, diagnostic status, clinician ratings global improvement.",C0237881|C1705241|C0871685|C0439793|C0871208|C0011900|C0449438|C0871685|C0871208|C0205246|C2986411
"(Tables 1, ,3).3).","(Tables 1, ,3).3).",C0039224|G0000000|G0000000
A CAM score is considered to be positive if the patient displays both (1) and (2) with at least one of (3) or (4).,A CAM score considered positive patient displays (1) (2) (3) (4).,G0000000|C0597815|C0449820|C0750591|C0439178|C0030705|C0870432|G0000000|G0000000|G0000000|G0000000
"In addition, the number of falls was also investigated as a result of Pilates exercises.","In addition, falls investigated result Pilates exercises.",G0000000|C0332287|C0000921|C1292732|C1274040|C2712430|C0015259
"Secondary outcomes will include (a) MARS self-reported adherence of all secondary preventative medication, (b) systolic and diastolic blood pressure.","Secondary outcomes (a) MARS self-reported adherence secondary preventative medication, (b) systolic diastolic blood pressure.",C0027627|C1274040|G0000000|C0242747|C0681906|C1510802|C0027627|G0000000|C0013227|G0000000|C0039155|C0012000|C0005767|C0033095
"As part of this e-literacy assessment, all participants were administered the eHealth Literacy Scale (eHEALS), an eight-item measure of eHealth literacy developed to measure individuals’ combined knowledge and perceived skills at finding, evaluating, and applying electronic health information to health problems (8).","As e-literacy assessment, participants administered eHealth Literacy Scale (eHEALS), eight-item measure eHealth literacy developed measure individuals’ combined knowledge perceived skills finding, evaluating, applying electronic health health (8).",G0000000|C0023864|C1261322|C0679646|C1521801|C1328956|C0023864|C0175659|G0000000|C0205454|C0079809|C1328956|C0023864|G0000000|C0079809|G0000000|C0205195|C0376554|C0030971|C0678856|C0037088|C0220825|C1632850|C0013850|C0018684|C0018684|G0000000
"The secondary outcomes included proportion of participants expressing interest in the trial and fulfilling eligibility criteria, withdrawal rates and missing data, proportion of participants adhering to and satisfied with the treatment, and incidence of NB-UVB short-term adverse events.","The secondary outcomes included proportion participants expressing trial fulfilling eligibility criteria, withdrawal rates missing data, proportion participants adhering satisfied treatment, incidence NB-UVB short-term adverse events.",G0000000|C0027627|C1274040|C0332257|C1709707|C0679646|G0000000|C0008976|C1550543|C0013893|C0243161|C2349954|C0871208|C1551393|C1511726|C1709707|C0679646|C3714578|C0242428|C0039798|C0021149|C0919442|C0443303|G0000000|C0441471
"Pain behaviors were evaluated immediately after the surgery using a FLACC (faces, legs, activity, crying, and consolability) scale by a trained examiner (Figure 1).","Pain behaviors evaluated surgery FLACC (faces, legs, activity, crying, consolability) scale trained examiner (Figure 1).",C0030193|C0004927|C0220825|C0038894|C4068796|C0015450|C1140621|C0205177|C0010399|G0000000|C0175659|C0336809|G0000000|G0000000|G0000000
"Follow-up was at four weeks, three and 12 months by postal questionnaire.","Follow-up weeks, 12 months postal questionnaire.",C0589120|C0439230|C0450371|C0439231|C1514253|C0034394
"Secondary outcomes include care-giver reported child morbidity, household food security and diet diversity, micro-nutrient status, maternal knowledge of child care and feeding practices, and home stimulation practices.","Secondary outcomes care-giver reported child morbidity, household food security diet diversity, micro-nutrient status, maternal knowledge child care feeding practices, stimulation practices.",C0027627|C1274040|C0085537|C0684224|C0008059|C0026538|C0020052|C0016452|C1519222|C0012155|C1880371|C0040577|C0449438|C2347083|C0376554|C0008059|C1947933|C0204695|C0237607|C1292856|C0237607
"Secondary endpoints: Rate of patients who meet the recommended guideline targets regarding blood pressure, smoking cessation, serum-LDL, physical activity, HbA1c (in patients with diabetes), therapeutic range of INR or regular intake of new oral anticoagulants in patients with atrial fibrillation, Effects on vascular surrogate parameters (microalbuminuria, physical fitness,) Total mortality Frequency of hospital admissions for vascular diseases (including TIA, angina pectoris with vascular interventions, peripheral arterial occlusive disease with vascular intervention) Number of days “alive and at home”.","Secondary endpoints: Rate patients meet recommended guideline targets blood pressure, smoking cessation, serum-LDL, physical activity, HbA1c (in patients diabetes), therapeutic range INR regular intake oral anticoagulants patients atrial fibrillation, Effects vascular surrogate parameters (microalbuminuria, physical fitness,) Total mortality Frequency hospital admissions vascular diseases (including TIA, angina pectoris vascular interventions, peripheral arterial occlusive disease vascular intervention) Number days “alive home”.",C0027627|C2349179|C0871208|C0030705|C1550543|C0034866|C0162791|C1521840|C0005767|C0033095|C0037369|C1880019|C0036816|C0031809|C0205177|G0000000|G0000000|C0030705|C0011847|C0087111|C1514721|C0525032|C0205272|C1512806|C0442027|C0003280|C0030705|C0018792|C0232197|C1280500|C0005847|C4053457|C0449381|C0730345|C0031809|C1456706|C0439175|C0026565|C0376249|C0019994|C0184666|C0005847|C0012634|C0332257|C0007787|C0002962|G0000000|C0005847|C0886296|C0205100|C0003842|C1947917|C0012634|C0005847|C0886296|C0237753|C0439228|G0000000|G0000000
"Aono's four point scale of 1 and 2 were considered as the absence of EA, and scales of 3 and 4 were considered as the presence of EA.","Aono's scale 1 2 considered absence EA, scales 3 4 considered presence EA.",G0000000|C0175659|G0000000|G0000000|C0750591|C0332197|C0014963|C0175659|G0000000|G0000000|C0750591|C0150312|C0014963
"During baseline, participants had to have headache occurring on ≥15 days/4 weeks, with each day consisting of ≥4 h of continuous headache, and ≥50% of headache days being migraine or probable migraine days (referred to as migraine days).","During baseline, participants headache occurring ≥15 days/4 weeks, day consisting ≥4 continuous headache, ≥50% headache days migraine probable migraine days (referred migraine days).",G0000000|C0168634|C0679646|C0018681|C1709305|G0000000|C0439228|C0439230|C0332173|C0332529|G0000000|C0549178|C0018681|G0000000|C0018681|C0439228|C0149931|C0033204|C0149931|C0439228|C0205543|C0149931|C0439228
"The changes in relevant indexes of oxygen metabolism, lung function, time of ventilator treatment, total hospital stay, and St. George's Respiratory Questionnaire (SGRQ) score of the two groups after intervention were compared, and the changes in inflammatory cytokine levels, dopamine receptor-related hormone levels, superoxide dismutase (SOD), malondialdehyde (MDA) and the total antioxidant capacity of the two groups before intervention and at 1 and 4 weeks after intervention were compared.","The relevant indexes oxygen metabolism, lung function, time ventilator treatment, total hospital stay, St. George's Respiratory Questionnaire (SGRQ) score intervention compared, inflammatory cytokine levels, dopamine receptor-related hormone levels, superoxide dismutase (SOD), malondialdehyde (MDA) total antioxidant capacity intervention 1 4 weeks intervention compared.",G0000000|C2347946|C0600653|C0030054|C0025519|C0024109|C0031843|C0040223|C0087153|C0039798|C0439175|C0019994|G0000000|C0036056|G0000000|C0521346|C0034394|G0000000|C0449820|C0886296|C1707455|C0333348|C0079189|C0441889|C0013030|C0597357|C0019932|C0441889|C0038836|G0000000|G0000000|C0024643|C0000379|C0439175|C0003402|C1516240|C0886296|G0000000|G0000000|C0439230|C0886296|C1707455
"Secondary outcomes included child salivary cotinine, self-report of home smoking ban (HSB), and smoking status.","Secondary outcomes included child salivary cotinine, self-report smoking ban (HSB), smoking status.",C0027627|C1274040|C0332257|C0008059|C0442040|C0010194|C0681906|C0037369|C0683610|C1134548|C0037369|C0449438
"Comparison between the incidence of CMV infection and disease in both treatment groups was made using Cox's proportional hazards model, as was the univariate and multivariate analysis of risk factors for CMV infection and CMV disease.","Comparison incidence CMV infection disease treatment Cox's proportional hazards model, univariate multivariate analysis risk factors CMV infection CMV disease.",C1707455|C0021149|G0000000|C0009450|C0012634|C0039798|G0000000|C0205351|C0598697|C3161035|G0000000|G0000000|C0002778|C0035647|C1521761|G0000000|C0009450|G0000000|C0012634
"The second endpoint variables include (1) time to achieve full enteral nutrition; (2) time of parenteral nutrition; (3) time of NICU stay; (4) meconium drainage time; (5) daily spontaneous fecal discharge conditions; (6) growth and development conditions during the NICU stay and within 3 months after discharge, including daily weight growth rate, weekly body length growth rate and weekly head circumference growth rate; (7) different plasma parameter indicators before discharge from the NICU (total protein (TP), albumin, calcium (Ca), phosphorus (P), and alkaline phosphatase (ALP)).","The endpoint variables (1) time achieve enteral nutrition; (2) time parenteral nutrition; (3) time NICU stay; (4) meconium drainage time; (5) daily spontaneous fecal discharge conditions; (6) growth development conditions NICU stay 3 months discharge, including daily weight growth rate, weekly body length growth rate weekly head circumference growth rate; (7) plasma parameter indicators discharge NICU (total protein (TP), albumin, calcium (Ca), phosphorus (P), alkaline phosphatase (ALP)).",G0000000|C2349179|C0439828|G0000000|C0040223|G0000000|C1304890|C0028707|G0000000|C0040223|C0030547|C0028707|G0000000|C0040223|C0021709|G0000000|G0000000|C0025047|C0012621|C0040223|G0000000|C0332173|C0205359|C0015733|C0012621|C0012634|G0000000|C0018270|C0243107|C0012634|C0021709|G0000000|G0000000|C0439231|C0012621|C0332257|C0332173|C0005910|C0018270|C0871208|C0332174|C0242821|C1444754|C0018270|C0871208|C0332174|C0018670|C0332520|C0018270|C0871208|G0000000|C0032105|C0549193|C0021212|C0012621|C0021709|C0439175|C0033684|C0036183|C0001924|C0006675|C3887642|C0031705|C0369773|C1979842|C0031678|C3812647
"Diarrhoea for a given day was defined as ⩾3 liquid or loose stools in the past 24 hours, and longitudinal prevalence of diarrhoea as the percentage of the days that the child had diarrhoea over the observation period.","Diarrhoea day defined ⩾3 liquid loose stools 24 hours, longitudinal prevalence diarrhoea percentage days child diarrhoea observation period.",C0011991|C0332173|C1704788|G0000000|C0301571|C0205407|C0015733|G0000000|C0205127|C0033105|C0011991|C0439165|C0439228|C0008059|C0011991|C0302523|C0439531
"Clinical response to the DC vaccine *Objective response rate (ORR), considers CR and PR.","Clinical response DC vaccine *Objective response rate (ORR), considers CR PR.",C0205210|C0871261|G0000000|C0042210|C0018017|C0871261|C0871208|G0000000|C0750591|C0201975|C0279759
The median length of work absence after surgery was 28 days in both groups.,The median length absence surgery 28 days groups.,G0000000|C0549183|C1444754|C0332197|C0038894|C0450371|C0439228|C0441833
"Secondary outcomes will be overall survival, tumor response according to the modified RECIST criteria, toxicities/adverse events, treatment related effect on total liver function, quality of life, treatment-related costs and cost-effectiveness.","Secondary outcomes survival, tumor response modified RECIST criteria, toxicities/adverse events, treatment total liver function, quality life, treatment-related costs cost-effectiveness.",C0027627|C1274040|C0038952|C0027651|C0871261|C0392747|C1709926|C0243161|C0600688|C0441471|C0039798|C0439175|C0023884|C0031843|C0332306|C0376558|C0039798|C0010186|C0010181
"Treatment compliance was high (93 ± 1%), with no adverse effect identified on clinical examination, complete blood count, laboratory tests, and CF quality of life questionnaire.","Treatment compliance (93 ± 1%), adverse identified clinical examination, complete blood count, laboratory tests, CF quality life questionnaire.",C0039798|C0009563|C0450371|G0000000|G0000000|G0000000|C0205396|C0205210|G0000000|C0205197|C0005767|C0750480|C0022877|C0022885|C0009738|C0332306|C0376558|C0034394
"Additionally, the following measurements of strength were also performed: grip strength (GS) (JAMAR 5030 J1 Hand Dynamometer), lateral pinch strength (LPS) (PG-60, B&L Engineering), and 3-point pinch strength (PPS) (PG-60, B&L Engineering).","Additionally, measurements strength performed: grip strength (GS) (JAMAR 5030 J1 Hand Dynamometer), lateral pinch strength (LPS) (PG-60, B&L Engineering), 3-point pinch strength (PPS) (PG-60, B&L Engineering).",G0000000|C0242485|C0237897|C0884358|C0021400|C0237897|G0000000|G0000000|G0000000|G0000000|C0018563|C0180572|C0205093|C0418416|C0237897|C0023810|C1266240|C0439394|C0014279|C1552961|C0418416|C0237897|G0000000|C1266240|C0439394|C0014279
"Primary endpoint of our RCT was postoperative pain, which was evaluated by a visual analog scale (VAS) and assessed at 6 h, 24 h, and 7 days, as well as 1, 3, and 6 months after surgery.","Primary endpoint RCT postoperative pain, evaluated visual analog scale (VAS) assessed 6 h, 24 h, 7 days, 1, 3, 6 months surgery.",C0205225|C2349179|G0000000|C0032790|C0030193|C0220825|C0234621|C0243071|C0175659|C0042815|C1516048|G0000000|C0033727|C0450371|C0033727|G0000000|C0439228|G0000000|G0000000|G0000000|C0439231|C0038894
"Study 1 demonstrated that CrPic, as compared to placebo, reduced food intake (P < 0.0001), hunger levels (P < 0.05), and fat cravings (P < 0.0001) and tended to decrease body weight (P = 0.08).","Study 1 demonstrated CrPic, compared placebo, reduced food intake (P < 0.0001), hunger levels (P < 0.05), fat cravings (P < 0.0001) tended decrease body weight (P = 0.08).",C0557651|G0000000|G0000000|G0000000|C1707455|C0032042|C0392756|C0016452|C1512806|C0369773|G0000000|G0000000|C0020175|C0441889|C0369773|G0000000|C0450371|C0424612|C0870371|C0369773|G0000000|G0000000|G0000000|C0392756|C0242821|C0005910|C0369773|G0000000|C0450371
"With benefit defined as a 10% or greater improvement on the CVLT slope T1–4 from baseline to immediate follow-up, consistent with studies of pharmacologic agents for cognition in MS,28 62% of patients in the treatment group showed improvement on their CVLT slope T1–4 from baseline to immediate follow-up, as compared with only 37% of the control group: χ2 (1) = 5.64, p = 0.009.","With benefit defined 10% improvement CVLT slope T1–4 baseline follow-up, consistent studies pharmacologic agents cognition MS,28 62% patients treatment improvement CVLT slope T1–4 baseline follow-up, compared 37% control group: χ2 (1) = 5.64, = 0.009.",G0000000|C0814225|C1704788|C0450371|C2986411|G0000000|C0807955|G0000000|C0168634|C0589120|C0332290|C0947630|C0031330|C0450442|C0009240|C0039676|C0450371|C0030705|C0039798|C2986411|G0000000|C0807955|G0000000|C0168634|C0589120|C1707455|C0450371|C0243148|C0441833|G0000000|G0000000|G0000000|C0450371|G0000000|C1442061
"The composite clinical score accounts for the combination of death due to any cause, hospitalization due to heart failure requiring intravenous diuretic treatment, change in the World Health Organisation (WHO) functional class or relevant changes in the patient global self-assessment.","The composite clinical score accounts combination death cause, hospitalization heart failure requiring intravenous diuretic treatment, change World Health Organisation (WHO) functional class relevant patient global self-assessment.",G0000000|C0205199|C0205210|C0449820|C2741673|C0205195|C0011065|C0015127|C0019993|C0018787|C0231174|G0000000|C0348016|C0012798|C0039798|C0392747|C2700280|C0018684|C0029237|G0000000|C0205245|C0456387|C2347946|C0030705|C0205246|C0036591
Infants with gestational age (GA) of ≤32 weeks who started enteral feeding within the first 7 days of life were randomized to receive PDHM or PF as a supplement to the OMM insufficient or unavailable.,Infants gestational age (GA) ≤32 weeks started enteral feeding 7 days life randomized receive PDHM PF supplement OMM insufficient unavailable.,C0021270|C0439671|C0001779|C0016993|G0000000|C0439230|C1272689|C1304890|C0204695|G0000000|C0439228|C0376558|C0034656|C1514756|G0000000|C3815179|C0242295|G0000000|C0205412|C0686905
Variables other than the barrier may possibly have influenced suicide rates at the same time at which the barrier was installed.,Variables barrier influenced suicide rates time barrier installed.,C0439828|C1706912|G0000000|C0038661|C0871208|C0040223|C1706912|G0000000
Time for closure to be completed was recorded.,Time closure completed recorded.,C0040223|C0185003|C0205197|C0034869
"The primary outcome was lung function, measured by the change from baseline of forced expiratory volume in 1 second (FEV1), FVC = forced vital capacity (FVC), and FEF25–75%.","The primary outcome lung function, measured change baseline forced expiratory volume 1 (FEV1), FVC = forced vital capacity (FVC), FEF25–75%.",G0000000|C0205225|C1274040|C0024109|C0031843|C0444706|C0392747|C0168634|C0441722|C0231800|C0449468|G0000000|G0000000|G0000000|C0442732|C1516240|C3714541|G0000000
Vascular and cardiac sympathetic activity will be explored in addition to circulating catecholamine levels.,Vascular cardiac sympathetic activity explored addition circulating catecholamine levels.,C0005847|C0018787|G0000000|C0205177|G0000000|C0332287|C0175630|C0007412|C0441889
This was defined as the duration from the time of introduction of the drug to the appearance of ≤3 formed stools in 24 hours.,This defined duration time introduction drug appearance ≤3 formed stools 24 hours.,G0000000|C1704788|C0449238|C0040223|C1293116|C0013227|C0233426|G0000000|C0205431|C0015733|G0000000
"In contrast, past 90-day alcohol use for participants in Familias Unidas showed a modest and non-significant increase from baseline (10.7%) to 30-month follow up (22.5%; p=0.732).","In contrast, 90-day alcohol participants Familias Unidas modest non-significant increase baseline (10.7%) 30-month follow (22.5%; p=0.732).",G0000000|C0009924|C0450371|C0001962|C0679646|G0000000|G0000000|C4054480|C1518422|C0442805|C0168634|C0450371|C0450371|C0332283|C0450371|C0369773
"In the intervention villages, households who had correctly mounted an ITN over a bed were given the bonus.","In intervention villages, households correctly mounted ITN bed bonus.",G0000000|C0886296|C0562518|C0020052|G0000000|C0449878|G0000000|C0004916|C0870215
"We evaluated activities of daily living function using Korean-Modified Barthel Index (K-MBI), and also evaluated motor function using the Motricity Index (MI) for the assessment of upper and lower muscle strength of the affected side after stroke.","We evaluated activities daily living function Korean-Modified Barthel Index (K-MBI), evaluated motor function Motricity Index (MI) assessment upper lower muscle strength stroke.",G0000000|C0220825|C0441655|C0332173|C0376558|C0031843|C1556095|G0000000|C0918012|C0597277|C0220825|C1513492|C0031843|G0000000|C0918012|C3810814|C1261322|C1282910|C0441994|C0026845|C0237897|C0038454
"In patients with good control of extracellular fluid volume, such as those in daily nocturnal dialysis programs, significant reductions in plasma NE have been documented (42).","In patients control extracellular fluid volume, daily nocturnal dialysis programs, reductions plasma NE documented (42).",G0000000|C0030705|C0243148|C0521119|C0005889|C0449468|C0332173|C0240526|C0011945|C0376691|C0301630|C0032105|C0028219|C1301725|C0450371
[27] in which intranasal 1 µg/kg dexmedetomidine resulted in mean sedation score of 2.94 on the same MOAAS scale.,[27] intranasal 1 µg/kg dexmedetomidine sedation score 2.94 MOAAS scale.,C0450371|C0442118|G0000000|G0000000|C0113293|C0235195|C0449820|C0450371|G0000000|C0175659
"The primary outcome variables were: 1) awareness and knowledge of cervical cancer and Pap tests; and 2) self-reported receipt of, or intention to obtain, a Pap test.","The primary outcome variables were: 1) awareness knowledge cervical cancer Pap tests; 2) self-reported receipt of, intention obtain, Pap test.",G0000000|C0205225|C1274040|C0439828|G0000000|G0000000|C0004448|C0376554|C0027530|C0006826|C1740167|C0022885|G0000000|C0681906|G0000000|G0000000|C0162425|C1301820|C1740167|C0022885
Much of this research is focused on predicting participation in parenting programs that target child mental health symptoms.,Much focused predicting participation parenting programs target child mental health symptoms.,C0205393|C0205234|G0000000|C0679823|C0085092|C0376691|C1521840|C0008059|C0229992|C0018684|C0683368
Intra- and post-operative adverse events were systematically reported.,Intra- post-operative adverse events systematically reported.,C0347985|C0032790|G0000000|C0441471|G0000000|C0684224
"AFR, average flow rate; FUL, functional urethral length; FVS, first voiding sense; MCP, maximal closure pressure; MDP, maximal detrusor pressure; MFR, maximal flow rate; MUP, maximal urethral pressure; RU, residual urine; VV, voided volume.","AFR, average flow rate; FUL, functional urethral length; FVS, voiding sense; MCP, maximal closure pressure; MDP, maximal detrusor pressure; MFR, maximal flow rate; MUP, maximal urethral pressure; RU, residual urine; VV, voided volume.",C1151389|C1510992|C0806140|C0871208|G0000000|C0205245|C0041967|C1444754|C0236026|C0042034|C0036658|C3540820|C0205289|C0185003|C0033095|C1414134|C0205289|C1180419|C0033095|G0000000|C0205289|C0806140|C0871208|G0000000|C0205289|C0041967|C0033095|C0035970|C1609982|C0042036|C0042216|C0042034|C0449468
The primary end point was overall survival.,The primary survival.,G0000000|C0205225|C0038952
"Secondary end points included the expression of Treg-related molecules in lesional tissue, the proliferative capacity of blood circulating T cells and serum cytokine levels to identify biomarkers that are associated with the response to PUVA treatment.","Secondary included expression Treg-related molecules lesional tissue, proliferative capacity blood circulating T cells serum cytokine levels identify biomarkers response PUVA treatment.",C0027627|C0332257|C0185117|C1267822|C0567416|C0221198|C0040300|C0334094|C1516240|C0005767|C0175630|C2603360|C0007634|C0229671|C0079189|C0441889|G0000000|C0005516|C0871261|C0853073|C0039798
"No changes in morning and evening peak flow values, peak flow variability, nor in the use of rescue medication were found in either group.","No morning evening peak flow values, peak flow variability, rescue medication group.",G0000000|C0332170|C0587117|C0444505|C0806140|C0042295|C0444505|C0806140|C2827666|G0000000|C0013227|C0441833
"At 26 weeks, 31 participants completed the 6MWT, 33 completed the HRQoL questionnaires and 30 completed the physical activity measurements.","At 26 weeks, 31 participants completed 6MWT, 33 completed HRQoL questionnaires 30 completed physical activity measurements.",G0000000|C0450371|C0439230|C0450371|C0679646|C0205197|G0000000|C0450371|C0205197|G0000000|C0034394|C0450371|C0205197|C0031809|C0205177|C0242485
The symmetry profiles of the stance and swing phases (temporal gait) and the step length symmetry profile (spatial gait) was calculated using data recorded on the GAITRite system.,The symmetry profiles stance swing phases (temporal gait) step length symmetry profile (spatial gait) calculated data recorded GAITRite system.,G0000000|C0332516|C1979963|G0000000|G0000000|C0585064|C0442043|C0016928|C1261552|C1444754|C0332516|C1979963|C1428114|C0016928|C0444686|C1511726|C0034869|G0000000|C0449913
Acute diarrhoea was defined as having diarrhoea for less than 14 days.,Acute diarrhoea defined diarrhoea 14 days.,C0205178|C0011991|C1704788|C0011991|C0450371|C0439228
"To measure intention to use marijuana, participants first were asked how likely it is that they would use marijuana even once or twice in the next 12 months using a four-point scale with end points “I definitely will not”to “I definitely will”.","To measure intention marijuana, participants marijuana 12 months four-point scale “I not”to “I will”.",C0040363|C0079809|C0162425|C0024808|C0679646|C0024808|C0450371|C0439231|C0205450|C0175659|G0000000|G0000000|G0000000|G0000000
"The secondary outcomes were the times of P. aeruginosa respiratory tract infection or colonization and P. aeruginosa gastric colonization, and the number of patients with persistent gastric colonization with L. casei rhamnosus.","The secondary outcomes times P. aeruginosa respiratory tract infection colonization P. aeruginosa gastric colonization, patients persistent gastric colonization L. casei rhamnosus.",G0000000|C0027627|C1274040|C0040223|C0369773|G0000000|C0521346|C1185740|C0009450|G0000000|C0369773|G0000000|C0038351|G0000000|C0030705|C0205322|C0038351|G0000000|C0439394|G0000000|G0000000
The primary outcome was self-reported continuous smoking abstinence verified by carbon monoxide breath testing at 6 months.,The primary outcome self-reported continuous smoking abstinence verified carbon monoxide breath testing 6 months.,G0000000|C0205225|C1274040|C0681906|C0549178|C0037369|C3843422|C1711411|C0007009|G0000000|C0225386|C0039593|G0000000|C0439231
"Standard laboratory spirometry (Spirotrac III, Vitalograph) was performed at all clinic visits.19 The primary indicator of systemic effect was the standing-height velocity, which was measured at each clinic visit using a stadiometer (Holtain, Crymych, UK) following a standardised procedure.","Standard laboratory spirometry (Spirotrac III, Vitalograph) performed clinic visits.19 The primary indicator systemic standing-height velocity, measured clinic visit stadiometer (Holtain, Crymych, UK) standardised procedure.",C1442989|C0022877|C0037981|G0000000|C0439070|G0000000|C0884358|C0002424|C0545082|G0000000|C0205225|C0021212|C0205373|C0424645|C0439830|C0444706|C0002424|C0545082|G0000000|G0000000|G0000000|C0041700|G0000000|C0184661
"However, in this study, no differences in clinical outcomes were found.","However, study, differences clinical outcomes found.",G0000000|C0557651|C1705241|C0205210|C1274040|C0150312
The perceived efficacy and comfort of each ACT and the incidence of urinary leakage during treatment were measured using 10 cm visual analogue scales (VAS).,The perceived efficacy comfort ACT incidence urinary leakage treatment measured 10 cm visual analogue scales (VAS).,G0000000|C0030971|C1280519|C1331418|C0079613|C0021149|C0042027|C0015376|C0039798|C0444706|G0000000|C0234621|C0243071|C0175659|C0042815
The third part assessed the pain intensity at the time of completing the questionnaire based on the Numerical Analogue Scale for pain as the most reliable tool for measuring pain.,The assessed pain intensity time completing questionnaire based Numerical Analogue Scale pain reliable tool measuring pain.,G0000000|C1516048|C0030193|C0522510|C0040223|C0205197|C0034394|C1527178|C0237753|C0243071|C0175659|C0030193|C3858758|C0336791|C0444706|C0030193
Mean percentage change in efficacy parameters from baseline to 12 weeks Table 3 shows the adverse events in the treatment groups.,Mean percentage change efficacy parameters baseline 12 weeks Table 3 adverse events treatment groups.,C0444504|C0439165|C0392747|C1280519|C0449381|C0168634|C0450371|C0439230|C0039224|G0000000|G0000000|C0441471|C0039798|C0441833
"Patients presenting during the hours of screening were invited to participate in the study if they: 1) reported binge drinking,(five or more drinks in two hours for males and four or more for females); and/or high-risk behaviors in conjunction with alcohol use (unplanned or unprotected sex, driving or riding with a drunk driver, injury, fighting, a car crash, or an arrest); and/or an AUDIT score of ≥ 4 for ages 14–17 years, or ≥8 for ages 18–21 years.","Patients hours screening invited participate study they: 1) reported binge drinking,(five drinks hours males females); and/or high-risk behaviors conjunction alcohol (unplanned unprotected sex, driving riding drunk driver, injury, fighting, car crash, arrest); and/or AUDIT score ≥ 4 ages 14–17 years, ≥8 ages 18–21 years.",C0030705|C0439227|C0220908|G0000000|G0000000|C0557651|G0000000|G0000000|C0684224|C0596170|C0001948|C0452428|C0439227|C0086582|C0015780|G0000000|C0332167|C0004927|C2699427|C0001962|G0000000|G0000000|C0009253|C0004379|G0000000|C0001969|C0684312|C3263722|C0424324|C0004381|G0000000|C0237477|G0000000|C1704774|C0449820|G0000000|G0000000|C0001779|G0000000|C0439234|G0000000|C0001779|G0000000|C0439234
"Primary study outcome: For parenteral nutrition and milk supplement interventions, body composition at 4 months’ corrected age.","Primary study outcome: For parenteral nutrition milk supplement interventions, body composition 4 months’ corrected age.",C0205225|C0557651|C1274040|G0000000|C0030547|C0028707|C0026131|C0242295|C0886296|C0242821|C0486616|G0000000|G0000000|C0205202|C0001779
"Daily treatment with 200 mgs EGCG administered three times a day (total 600 mg/d) for one year significantly reduced progression to prostate cancer in men in the treatment arm (incidence, approximately 3%), compared to men on placebo (incidence, 30%) [44].","Daily treatment 200 mgs EGCG administered times day (total 600 mg/d) reduced progression prostate cancer treatment arm (incidence, 3%), compared placebo (incidence, 30%) [44].",C0332173|C0039798|C1442061|C0024467|C0059438|C1521801|C0040223|C0332173|C0439175|C1442061|C0439422|C0392756|C0242656|C0033572|C0006826|C0039798|C0446516|C0021149|G0000000|C1707455|C0032042|C0021149|C0450371|C0450371
"Efficacy was defined as an increase of 10 percentage points in the proportion of patients with a favorable outcome, as determined with the use of the stratified dichotomy of the Extended Glasgow Outcome Scale score at 6 months after injury.","Efficacy defined increase 10 percentage proportion patients favorable outcome, determined stratified dichotomy Extended Glasgow Outcome Scale score 6 months injury.",C1280519|C1704788|C0442805|C0450371|C0439165|C1709707|C0030705|C3640814|C1274040|G0000000|C0205363|G0000000|C0231448|G0000000|C1274040|C0175659|C0449820|G0000000|C0439231|C3263722
The same version also demonstrated excellent test-retest reliability (ICC 0.99).,The version demonstrated excellent test-retest reliability (ICC 0.99).,G0000000|C0333052|G0000000|C1548784|C0022885|C2347947|C0345905|C0450371
"After an average PD treatment duration of 2.3 years, laboratory profiles of cytokines, growth factors, adipokines, and cardiac biomarkers were determined in serum and effluent.","After average PD treatment duration 2.3 years, laboratory profiles cytokines, growth factors, adipokines, cardiac biomarkers determined serum effluent.",G0000000|C1510992|G0000000|C0039798|C0449238|G0000000|C0439234|C0022877|C1979963|C0079189|C0018270|C1521761|C1955907|C0018787|C0005516|G0000000|C0229671|G0000000
The primary variable was the time to first severe exacerbation.,The primary variable time severe exacerbation.,G0000000|C0205225|C0439828|C0040223|C0205082|G0000000
"In the main secondary outcome (PC-QOL), based on a between-group difference of 0.9 (minimum important difference [42]) (SD 0.9), our sample size provides power of 100% (α = 0.05) for data from at least 147 children (that is, assuming at least 80% retention of the 189 children enrolled).","In main secondary outcome (PC-QOL), based between-group difference 0.9 (minimum difference [42]) (SD 0.9), sample size power 100% (α = 0.05) data 147 children (that is, assuming 80% retention 189 children enrolled).",G0000000|C0205225|C0027627|C1274040|C0031995|C1527178|C0441833|C1705241|G0000000|C1524031|C1705241|C0450371|G0000000|G0000000|C0370003|C0456389|C0032863|C1442061|G0000000|C1511726|C1442061|C0008059|G0000000|G0000000|G0000000|C0450371|C0035280|C1442061|C0008059|G0000000
Technique survival was similar in both fluid groups.,Technique survival fluid groups.,C0449851|C0038952|C0005889|C0441833
RBP: Retinol binding protein; CRP: C-reactive protein; IDA: Iron deficiency anemia; MMN: Multi micronutrient; TfR: Transferrin receptor; NFY: Non fortified yoghurt; FY: fortified yoghurt; SES: Socio economic Status; Hb: Hemoglobin; WAZ: Weight for age z-scores; BMIZ: Body mass index z-scores; HAZ: Height for age Z-scores.,RBP: Retinol binding protein; CRP: C-reactive protein; IDA: Iron deficiency anemia; MMN: Multi micronutrient; TfR: Transferrin receptor; NFY: Non fortified yoghurt; FY: fortified yoghurt; SES: Socio economic Status; Hb: Hemoglobin; WAZ: Weight age z-scores; BMIZ: Body mass z-scores; HAZ: Height age Z-scores.,C1419339|C0042839|C1145667|C0033684|C3890735|C0205332|C0033684|C0020789|C0302583|C0011155|C0002871|G0000000|C0439064|C0040577|G0000000|C0040679|C0597357|G0000000|C1518422|G0000000|C0043419|C0013278|G0000000|C0043419|G0000000|G0000000|C0013556|C0449438|C0019046|C0019046|G0000000|C0005910|C0001779|C0871421|G0000000|C0242821|C0577559|C0871421|G0000000|C0489786|C0001779|C0871421
"Secondary outcomes included the difference between the two groups for change in MiniAQLQ and ACQ score, change in mean FEV1, oral corticosteroid use, and participants' visits to the GP for asthma-related problems.","Secondary outcomes included difference change MiniAQLQ ACQ score, change FEV1, oral corticosteroid use, participants' visits GP asthma-related problems.",C0027627|C1274040|C0332257|C1705241|C0392747|G0000000|C2919686|C0449820|C0392747|G0000000|C0442027|C0001617|C0042153|C0679646|C0545082|C3811116|C0004096|C1546466
"The primary outcome was lung function, measured by the FEV1, FVC, and FEF25–75% change from the baseline.","The primary outcome lung function, measured FEV1, FVC, FEF25–75% change baseline.",G0000000|C0205225|C1274040|C0024109|C0031843|C0444706|G0000000|C3714541|G0000000|C0392747|C0168634
"We analysed 437 patients for survival, HRQoL and use of palliative radiotherapy, and 434 for toxicity.","We analysed 437 patients survival, HRQoL palliative radiotherapy, 434 toxicity.",G0000000|G0000000|C1442061|C0030705|C0038952|G0000000|C0587605|C0034619|C1442061|C0040539
"The secondary end points will be relapse-free period, relapse rate per year and the amount of steroids required to maintain complete and partial disease remission at 6 and 24 months.","The secondary relapse-free period, relapse rate amount steroids required maintain complete partial disease remission 6 24 months.",G0000000|C0027627|C0035020|C0439531|C0035020|C0871208|C1265611|C0038317|C1514873|C0024501|C0205197|C0728938|C0012634|C0544452|G0000000|G0000000
"Secondary measures were the differences in clinical disease activity scores between active and placebo treatment and changes in laboratory measures including FCAL (EK-CAL, Buhlmann, Switzerland).","Secondary measures differences clinical disease activity scores active placebo treatment laboratory measures including FCAL (EK-CAL, Buhlmann, Switzerland).",C0027627|C0079809|C1705241|C0205210|C0012634|C0205177|C0449820|C0205177|C0032042|C0039798|C0022877|C0079809|C0332257|G0000000|C0008415|G0000000|C0039021
Manually assisted cough and mechanical insufflation in combination raised peak expiratory flow rate more than either technique alone in this group.,Manually assisted cough mechanical insufflation combination raised peak expiratory flow rate technique group.,C3842330|C1269765|C0010200|C0443254|C0021634|C0205195|C0442818|C0444505|C0231800|C0806140|C0871208|C0449851|C0441833
Measures collected at baseline from young people Key: CV = Covariate; HE = Health Economics; DE = Demographics; IO = Immediate outcome; ST = Short term outcome; PO = Primary outcome; SO = Secondary outcome; TO = Tertiary outcome.,Measures collected baseline people Key: CV = Covariate; HE = Health Economics; DE = Demographics; IO = Immediate outcome; ST = Short term outcome; PO = Primary outcome; SO = Secondary outcome; TO = Tertiary outcome.,C0079809|C1516695|C0168634|C0027361|G0000000|G0000000|G0000000|C0013556|G0000000|G0000000|C1274040|G0000000|C0233324|C1274040|G0000000|C1274040|G0000000|C1274040|G0000000|C1274040
"Outcome measures are distance and near visual acuity, contrast sensitivity, colour vision, macular visual field, glare recovery, and fundus photography.","Outcome measures distance visual acuity, contrast sensitivity, colour vision, macular visual field, glare recovery, fundus photography.",C1274040|C0079809|C0012751|C0234621|C0750509|C0009924|C0020517|C0009393|C0042789|C0332574|C0234621|C0440042|C0278215|C0237820|C0016823|C0031749
The primary endpoint of the study will be the number of CD8+ cells (cell counts per mm2) in bronchial biopsy tissue specimens (sub-mucosa) evaluated from randomization to the end of the intervention period.,The primary endpoint study CD8+ cells (cell counts mm2) bronchial biopsy tissue specimens (sub-mucosa) evaluated randomization intervention period.,G0000000|C0205225|C2349179|C0557651|C0285590|C0007634|C0007634|C0439157|G0000000|C0205039|C0005558|C0040300|C0370003|C0542339|C0220825|C0034656|C0886296|C0439531
"We conducted outcome assessments 6, 12, 18 and 24 months after the initial practice visit.","We conducted outcome assessments 6, 12, 18 24 months initial practice visit.",G0000000|C0004927|C1274040|C1261322|G0000000|C0450371|C0450371|C0450371|C0439231|C0205265|C0237607|C0545082
"Colorectal cancer (CRC) incidence, mortality rates, and mortality ratios in the intervention and control groups *Adjusted for age and sex.","Colorectal cancer (CRC) incidence, mortality rates, mortality ratios intervention control *Adjusted age sex.",C0555952|C0006826|C0009402|C0021149|C0026565|C0871208|C0026565|C0456603|C0886296|C0243148|C0456081|C0001779|C0009253
"In the control group, antibiotic treatment was applied as standard regimen over eight days.","In control group, antibiotic treatment applied standard regimen days.",G0000000|C0243148|C0441833|C0003232|C0039798|C4048755|C1442989|C0040808|C0439228
"Secondary aims are to compare the three treatment approaches in regards to patient-rated disability, general health status, satisfaction, improvement and medication use, as well as objective outcomes of spinal motion, trunk strength and endurance, and functional ability.","Secondary aims compare treatment approaches patient-rated disability, health status, satisfaction, improvement medication use, objective outcomes spinal motion, trunk strength endurance, functional ability.",C0027627|C1947946|C1707455|C0039798|C0449445|C0030705|C0231170|C0018684|C0449438|C0242428|C2986411|C0013227|C0042153|C0018017|C1274040|C0521329|C0026597|C0225442|C0237897|C0518031|C0205245|C0085732
"RRs were calculated for each of the following 11 lifestyle-related factors in all men combined and in each racial/ethnic group, with adjustment for ethnicity and family history of prostate cancer (yes, no) as strata variables, and age at cohort entry and the remaining risk factors as covariates: body mass index (BMI; <25, 25-29.9, 30-34.9, ≥35 kg/m2), height (≤65, 66-67, 68-69, 70-71, ≥72 inches), cigarette smoking (never smoker; former smoker: <10, 10-19, ≥20 cigarettes/day; current smoker: <10, 10-19, ≥20 cigarettes/day), education (≤8th grade, 9th-12th grade, vocational school/some college, graduated college or higher), history of diabetes (yes, no), physical activity (quintile cutpoints: 1.41, 1.58, 1.71, 1.87 METs/day), and daily intakes of alcohol (0, >0-4.9, 5-14.9, 15-34.9, ≥35 g), calcium (quintile cutpoints: 241, 301, 360, 436 mg/1000kcal), legume (quintile cutpoints: 6.4, 10.8, 16.5, 28.2 g/1000kcal), lycopene (quintile cutpoints: 748, 1073, 1435, 2022 μg/1000kcal), and selenium (quintile cutpoints: 44.0, 49.5, 54.4, 60.1 μg/1000kcal).","RRs calculated 11 lifestyle-related factors combined racial/ethnic group, adjustment ethnicity family history prostate cancer (yes, no) strata variables, age cohort entry remaining risk factors covariates: body mass (BMI; <25, 25-29.9, 30-34.9, ≥35 kg/m2), height (≤65, 66-67, 68-69, 70-71, ≥72 inches), cigarette smoking (never smoker; smoker: <10, 10-19, ≥20 cigarettes/day; current smoker: <10, 10-19, ≥20 cigarettes/day), education (≤8th grade, 9th-12th grade, vocational school/some college, graduated college higher), history diabetes (yes, no), physical activity (quintile cutpoints: 1.41, 1.58, 1.71, 1.87 METs/day), daily intakes alcohol (0, >0-4.9, 5-14.9, 15-34.9, ≥35 g), calcium (quintile cutpoints: 241, 301, 360, 436 mg/1000kcal), legume (quintile cutpoints: 6.4, 10.8, 16.5, 28.2 g/1000kcal), lycopene (quintile cutpoints: 748, 1073, 1435, 2022 μg/1000kcal), selenium (quintile cutpoints: 44.0, 49.5, 54.4, 60.1 μg/1000kcal).",C1849334|C0444686|C0450371|C0023676|C1521761|C0205195|C0034510|C0441833|C0376209|C0015031|C0015576|C0019664|C0033572|C0006826|C1549445|G0000000|G0000000|C0439828|C0001779|C0599755|C1705654|C1527428|C0035647|C1521761|G0000000|C0242821|C0577559|G0000000|C0450371|C0450371|C0450371|G0000000|C0022718|C0489786|G0000000|C0450371|C0450371|C0450371|G0000000|C0439204|C0677453|C0037369|C2003901|C0337664|C0337664|C0450371|C0450371|G0000000|C0677453|C0521116|C0337664|C0450371|C0450371|G0000000|C0677453|C0013621|G0000000|C0441800|G0000000|C0441800|C0087164|C0036375|C0557806|C0588053|C0557806|C0205250|C0019664|C0011847|C1549445|G0000000|C0031809|C0205177|C1508496|G0000000|C0450371|C0450371|C0450371|C0450371|C0812270|C0332173|C1512806|C0001962|G0000000|G0000000|C0450371|C0450371|G0000000|C0439267|C0006675|C1508496|G0000000|C1442061|C1442061|C1442061|C1442061|C0026410|C0023263|C1508496|G0000000|G0000000|C0450371|C0450371|C0450371|C0439267|C0065331|C1508496|G0000000|C1442061|G0000000|G0000000|G0000000|G0000000|C0036581|C1508496|G0000000|C0450371|C0450371|C0450371|C0450371|G0000000
"Intervention (); Control () The patients had fair knowledge about their medication and disease management at baseline, as measured by the COPD knowledge questionnaire.","Intervention (); Control () The patients fair knowledge medication disease management baseline, measured COPD knowledge questionnaire.",C0886296|G0000000|C0243148|G0000000|G0000000|C0030705|C2911689|C0376554|C0013227|C0012634|C0001554|C0168634|C0444706|C0024117|C0376554|C0034394
"ADAS‐cog, cognitive subscale of the Alzheimer's Disease Assessment Scale18; BID, twice daily; GDS, Global Deterioration Scale21; MMSE, Mini‐Mental State Examination17; TID, three times daily.","ADAS‐cog, cognitive subscale Alzheimer's Disease Assessment Scale18; BID, daily; GDS, Global Deterioration Scale21; MMSE, Mini‐Mental State Examination17; TID, times daily.",G0000000|C1516691|G0000000|G0000000|C0012634|C1261322|G0000000|G0000000|C0332173|C0451184|C0205246|C0868945|G0000000|C0451306|G0000000|C1301808|G0000000|C0556984|C0040223|C0332173
"There are a number of predetermined secondary outcomes including: effects of the intervention on plasma fibrinogen levels, feasibility assessments and clinical outcomes including transfusion requirements and mortality.","There predetermined secondary outcomes including: effects intervention plasma fibrinogen levels, feasibility assessments clinical outcomes including transfusion requirements mortality.",G0000000|G0000000|C0027627|C1274040|C0332257|C1280500|C0886296|C0032105|C0016006|C0441889|G0000000|C1261322|C0205210|C1274040|C0332257|C0005841|C1514873|C0026565
The reported study was funded by UCL.,The reported study funded UCL.,G0000000|C0684224|C0557651|C0016820|G0000000
"For the second group, serum zinc level was repeatedly measured 1 and 3 months after commencing the treatment.","For group, serum zinc level repeatedly measured 1 3 months commencing treatment.",G0000000|C0441833|C0229671|C0043481|C0441889|C0205341|C0444706|G0000000|G0000000|C0439231|C3274784|C0039798
"There was no effect of the intervention on any of these including HIV prevalence, HSV-2 prevalence or current pregnancy as measured by pregnancy test.","There intervention including HIV prevalence, HSV-2 prevalence current pregnancy measured pregnancy test.",G0000000|C0886296|C0332257|C0019682|C0033105|C0019348|C0033105|C0521116|C0032961|C0444706|C0032961|C0022885
The Cohen-Mansfield Agitation Inventory (CMAI) scale and the heart rate variability (HRV) index were used to assess differences in agitation.,The Cohen-Mansfield Agitation Inventory (CMAI) scale heart rate variability (HRV) assess differences agitation.,G0000000|G0000000|C0085631|C0021941|G0000000|C0175659|C0018787|C0871208|C2827666|C0010343|C1516048|C1705241|C0085631
"Mean maximum cystometric capacity, bladder compliance, detrusor leak point pressure, and frequency of urination and urinary incontinence were compared between groups at the beginning and end of treatment and at the 3-month follow-up using the two-sample t-test for groups with unequal variance.","Mean maximum cystometric capacity, bladder compliance, detrusor leak pressure, frequency urination urinary incontinence compared treatment 3-month follow-up two-sample t-test unequal variance.",C0444504|C0806909|G0000000|C1516240|C0005682|C0009563|C1180419|C0332234|C0033095|C0376249|C0042034|C0042027|C0021167|C1707455|C0039798|C0332177|C0589120|C0205448|C0871472|C0242503|C1711260
Shortly after the conversation the patient was asked to personally assess the quality of the physician-patient conversation via a patient satisfaction questionnaire (Figure 4).,Shortly conversation patient personally assess quality physician-patient conversation patient satisfaction questionnaire (Figure 4).,G0000000|C0871703|C0030705|G0000000|C1516048|C0332306|C0031830|C0871703|C0030705|C0242428|C0034394|G0000000|G0000000
All SBHCs carried and administered only the quadrivalent HPV vaccine (HPV4).,All SBHCs carried administered quadrivalent HPV vaccine (HPV4).,G0000000|G0000000|C0206243|C1521801|G0000000|C0021344|C0042210|G0000000
"China, with ~250,000 cases diagnosed yearly, lies in the ""esophageal cancer belt"" [2], and contributes to about half of the world's cases [3].","China, ~250,000 diagnosed yearly, lies ""esophageal cancer belt"" [2], contributes half world's [3].",C0008115|C1442061|C0011900|C0332181|G0000000|C1522619|C0006826|C0452227|G0000000|C1880177|C2825407|C2700280|G0000000
"An accrual target was set at 420, and PF (Short Form-36 subscale), physical activity (Community Healthy Activities Models Program for Seniors), and diet quality (index from 3-day recalls) were assessed at baseline and at 6 and 12 months (6 months after intervention).","An accrual target set 420, PF (Short Form-36 subscale), physical activity (Community Healthy Activities Models Program Seniors), diet quality (index 3-day recalls) assessed baseline 6 12 months (6 months intervention).",G0000000|C1510756|C1521840|C0036849|C1442061|C3815179|C1282927|C0348078|G0000000|C0031809|C0205177|C0009462|C3898900|C0441655|C3161035|C1709697|C1456594|C0012155|C0332306|C0918012|C0332173|C0034770|C1516048|C0168634|G0000000|C0450371|C0439231|G0000000|C0439231|C0886296
"The VAS score was then again recorded in the afternoon of the first day of treatment in both groups (AA1 and BA1) and at the end of one week of treatment in both groups, in the morning (AM7 and BM7) and in the afternoon (AA7 and BA7).","The VAS score recorded afternoon day treatment (AA1 BA1) week treatment groups, morning (AM7 BM7) afternoon (AA7 BA7).",G0000000|C0042815|C0449820|C0034869|C0439550|C0332173|C0039798|G0000000|C0219474|C0332174|C0039798|C0441833|C0332170|G0000000|C1384557|C0439550|G0000000|C0219474
"First, the choice of cognitive function as the primary outcome may have been too ambitious.","First, choice cognitive function primary outcome ambitious.",C0205435|C0008300|C1516691|C0031843|C0205225|C1274040|C0870128
"The purpose of this double-blind randomized clinical trial (RCT) was to test the efficacy of activities derived from the NDB model for reducing agitation and passivity and improving engagement, affect and mood in nursing home residents with dementia.","The purpose double-blind randomized clinical trial (RCT) test efficacy activities derived NDB model reducing agitation passivity improving engagement, affect mood nursing residents dementia.",G0000000|C1285529|C0013072|C0034656|C0205210|C0008976|G0000000|C0022885|C1280519|C0441655|C1441547|G0000000|C3161035|C0392756|C0085631|C0679170|C1272745|C0425152|C0001721|C0026516|C0006147|C1320928|C0011265
CONCLUSIONS: A nurse- led asthma home management training programme administered during a hospital admission can significantly reduce subsequent admissions to hospital for asthma.,CONCLUSIONS: A nurse- led asthma management training programme administered hospital admission reduce subsequent admissions hospital asthma.,C1707478|G0000000|C0028661|C1708698|C0004096|C0001554|C0040607|C1709697|C1521801|C0019994|C0184666|G0000000|C0332282|C0184666|C0019994|C0004096
We report here updated overall survival (OS) and disease-specific survival (DSS) data.,We report updated survival (OS) disease-specific survival (DSS) data.,G0000000|C0684224|C1519814|C0038952|C0229090|C0012634|C0038952|G0000000|C1511726
"In literature and clinical practice, 4 hours of nightly PAP usage for 70% of the nights is considered adequate adherence to therapy, corresponding to an average PAP usage of 2.8 hours every night [5].","In literature clinical practice, 4 hours nightly PAP usage 70% nights considered adequate adherence therapy, average PAP usage 2.8 hours night [5].",G0000000|C0023866|C0205210|C0237607|G0000000|C0439227|G0000000|C1740167|C0457083|C0450371|C0240526|C0750591|C0205410|C1510802|C0039798|C1510992|C1740167|C0457083|G0000000|C0439227|C0240526|G0000000
Primary study aims were the rate of complete resection and the rate of progression-free survival at 6 months.,Primary study aims rate complete resection rate progression-free survival 6 months.,C0205225|C0557651|C1947946|C0871208|C0205197|C0015252|C0871208|C0242656|C0038952|G0000000|C0439231
Medical records were reviewed by a team of 2–3 expert neurologists and 2–3 expert neuropsychologists to determine a consensus diagnosis.,Medical records reviewed team 2–3 expert neurologists 2–3 expert neuropsychologists determine consensus diagnosis.,C0199168|C0034869|C0282443|C0871489|G0000000|G0000000|C0237426|G0000000|G0000000|C1555899|G0000000|C0376298|C0011900
Both REM sleep and all stages of non-REM sleep were quantified as a percentage of TST.,Both REM sleep stages non-REM sleep quantified percentage TST.,G0000000|G0000000|C0037313|C1306673|C1518422|C0037313|C1709793|C0439165|C1421210
"Primary efficacy endpoints for marijuana use were the number of grams of marijuana smoked per week, derived from the daily record of self-reported cannabis use obtained by the Timeline Followback Interview (Fals-Stewart et al, 2000), and THC metabolite concentrations derived from weekly urine toxicology.","Primary efficacy endpoints marijuana grams marijuana smoked week, derived daily record self-reported cannabis Timeline Followback Interview (Fals-Stewart al, 2000), THC metabolite concentrations derived weekly urine toxicology.",C0205225|C1280519|C2349179|C0024808|C0439208|C0024808|C0037366|C0332174|C1441547|C0332173|C0034869|C0681906|C0024808|C0145943|G0000000|C0021822|C1862939|C0202311|G0000000|C0039663|C0870883|C0086045|C1441547|C0332174|C0042036|C0040541
"Outcome measurements included star cancellation test, line bisection test, Catherine Bergego scale (CBS), and the Korean version of modified Barthel index (K-MBI).","Outcome measurements included star cancellation test, bisection test, Catherine Bergego scale (CBS), Korean version modified Barthel (K-MBI).",C1274040|C0242485|C0332257|C0995242|C0205544|C0022885|C0184905|C0022885|G0000000|G0000000|C0175659|C1439329|C1556095|C0333052|C0392747|G0000000|C0597277
"The primary outcomes are within-patient change in systolic BP at 12 months, and the rate of stroke recurrence at 24 months.","The primary outcomes within-patient change systolic BP 12 months, rate stroke recurrence 24 months.",G0000000|C0205225|C1274040|C0030705|C0392747|C0039155|C0037623|C0450371|C0439231|C0871208|C0038454|C0034897|C0450371|C0439231
"There were no serious adverse events related to NMES, nor significant differences in quadriceps muscle strength, thigh lean mass or physical activity level between groups.","There adverse events NMES, differences quadriceps muscle strength, thigh lean mass physical activity level groups.",G0000000|G0000000|C0441471|C2985393|C1705241|C0224440|C0026845|C0237897|C0039866|G0000000|C0577559|C0031809|C0205177|C0441889|C0441833
Half of the participants presented because of menstrual disturbances (Table 1).,Half participants menstrual disturbances (Table 1).,C2825407|C0679646|C0025344|C2699787|C0039224|G0000000
"CrPic had no significant effect on other measures of glucose metabolism, body weight, serum lipids, or measures of inflammation and oxidative stress.","CrPic measures glucose metabolism, body weight, serum lipids, measures inflammation oxidative stress.",G0000000|C0079809|C0017725|C0025519|C0242821|C0005910|C0229671|C0023779|C0079809|C0021368|C0311404|C0038435
"DECIDER is the clinical trial investigating the potential benefit of adding VPA or/and ATRA to DAC in view of disease control, overall survival, safety and quality of life in elderly AML patients in a randomized setting.","DECIDER clinical trial investigating potential benefit adding VPA or/and ATRA DAC view disease control, survival, safety quality life elderly AML patients randomized setting.",G0000000|C0205210|C0008976|C1292732|C3245505|C0814225|C1883712|G0000000|G0000000|C0040845|G0000000|C0449911|C0012634|C0243148|C0038952|C0036043|C0332306|C0376558|C0001792|C0023467|C0030705|C0034656|C0542559
"Secondary outcome measurements included severity of symptoms of irritable bowel syndrome, severity of abdominal pain, and quality of life.","Secondary outcome measurements included severity symptoms irritable bowel syndrome, severity abdominal pain, quality life.",C0027627|C1274040|C0242485|C0332257|C0439793|C0683368|C0022107|C0021853|C0039082|C0439793|C0000726|C0030193|C0332306|C0376558
"All patients were assessed by using a visual analogue scale (VAS, 0–100 mm) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale by an investigator blinded to the administered pharmacological treatment.","All patients assessed visual analogue scale (VAS, 0–100 mm) Leeds Assessment Neuropathic Symptoms Signs (LANSS) pain scale investigator blinded administered pharmacological treatment.",G0000000|C0030705|C1516048|C0234621|C0243071|C0175659|C0042815|G0000000|G0000000|G0000000|C1261322|C0442874|C0683368|C0220912|G0000000|C0030193|C0175659|C0035173|C0150108|C1521801|C0031330|C0039798
"The most common adverse events with an incidence ≥5% in either treatment were somnolence (n = 34 [14.1%] and n = 34 [14.1%]), dizziness (n = 22 [9.1%] and 20 [8.3%]), weight increase (19 [7.9%] and 13 [5.4%]), headache (17 [7.1%] and 20 [8.3%]), and dry mouth (12 [5.0%] and 8 [3.3%]) for pregabalin and gabapentin, respectively.","The common adverse events incidence ≥5% treatment somnolence (n = 34 [14.1%] = 34 [14.1%]), dizziness (n = 22 [9.1%] 20 [8.3%]), weight increase (19 [7.9%] 13 [5.4%]), headache (17 [7.1%] 20 [8.3%]), dry mouth (12 [5.0%] 8 [3.3%]) pregabalin gabapentin, respectively.",G0000000|C0205214|G0000000|C0441471|C0021149|G0000000|C0039798|C0013144|C0369718|G0000000|C0450371|C0450371|G0000000|C0450371|C0450371|C0012833|C0369718|G0000000|C0450371|G0000000|C0450371|G0000000|C0005910|C0442805|C0450371|G0000000|C0450371|G0000000|C0018681|C0450371|G0000000|C0450371|G0000000|C0011682|C0226896|C0450371|G0000000|G0000000|G0000000|C0657912|C0060926|G0000000
"On waking, athletes provided a Total Quality of Recovery (TQR) rating and Delayed Onset Muscle Soreness (DOMS) score for the upper body, upper legs, lower legs and overall body.","On waking, athletes provided Total Quality Recovery (TQR) rating Delayed Onset Muscle Soreness (DOMS) score upper body, upper legs, lower legs body.",G0000000|C0442696|C0238703|C1999230|C0439175|C0332306|C0237820|G0000000|C0871208|C0205421|C0206132|C0026845|C0234233|C3539821|C0449820|C1282910|C0242821|C1282910|C1140621|C0441994|C1140621|C0242821
"The first aim of the study is to test the efficacy of repeated use of TENS on movement-related pain in women with fibromyalgia with random assignment to 3 treatment groups: standard care, placebo TENS, and active TENS.","The aim study test efficacy repeated TENS movement-related pain women fibromyalgia random assignment 3 treatment groups: standard care, placebo TENS, active TENS.",G0000000|C1947946|C0557651|C0022885|C1280519|C0205341|C0014518|C0026649|C0030193|C0043210|C0016053|C0034656|C1516050|G0000000|C0039798|C0441833|C1442989|C1947933|C0032042|C0014518|C0205177|C0014518
Families retained in the treatment arm had primary caregivers (mothers) with higher levels of acute stress and partners (usually fathers) with lower trait anxiety.,Families retained treatment arm primary caregivers (mothers) levels acute stress partners (usually fathers) lower trait anxiety.,C0015576|C0333118|C0039798|C0446516|C0205225|C0085537|C0026591|C0441889|C0205178|C0038435|C0682323|C3538928|C0015671|C0441994|C0599883|C0003467
"Table 2 shows urinary excretion rates of sodium and protein, MAP renal function, plasma renin activity, and serum aldosterone levels in hospitalized patients with IgA nephropathy.","Table 2 urinary excretion rates sodium protein, MAP renal function, plasma renin activity, serum aldosterone levels hospitalized patients IgA nephropathy.",C0039224|G0000000|C0042027|C0221102|C0871208|C0037473|C0033684|C0024779|C0022646|C0031843|C0032105|C0035094|C0205177|C0229671|C0002006|C0441889|C0701159|C0030705|C2825347|C0022658
All isolates were typed according to strain and evaluated for antigenic relatedness to vaccine strains by the Influenza Branch at the Centers for Disease Control and Prevention (CDC).,All isolates typed strain evaluated antigenic relatedness vaccine strains Influenza Branch Centers Disease Control Prevention (CDC).,G0000000|C1764827|C0332307|C0080194|C0220825|C0003320|C0439849|C0042210|C0080194|C0021400|C1253959|C0205099|C0012634|C0243148|C0199176|C0007670
"Subjects receiving hydroxyurea and phlebotomy had similar numbers of sickle cell related events to those on chronic transfusions, although there were more serious events in the children who were switched to the hydroxyurea/phlebotomy arm.","Subjects receiving hydroxyurea phlebotomy sickle cell events chronic transfusions, events children switched hydroxyurea/phlebotomy arm.",C0681850|C1514756|C0020402|C0190979|G0000000|C0007634|C0441471|C0205191|C0005841|C0441471|C0008059|C1707719|C0020402|C0446516
Bacteremia was the most frequent site of infection.,Bacteremia frequent site infection.,C0004610|C0332183|C0205145|C0009450
"During phone interviews at 3- and 12-month follow-ups, staff will obtain parent self-reported 7-day point prevalence abstinence and prolonged abstinence [42].","During phone interviews 3- 12-month follow-ups, staff parent self-reported 7-day prevalence abstinence prolonged abstinence [42].",G0000000|C1515258|C0021822|G0000000|C0450371|C0332283|C0851286|C0030551|C0681906|C0332173|C0033105|C3843422|C0439590|C3843422|C0450371
"The measured outcomes of newborns were macrosomia, newborns’ weight, length and head circumference, apgar score, and newborns’ hyperbilirubinemia, hospitalization and hypoglycemia.","The measured outcomes newborns macrosomia, newborns’ weight, length head circumference, apgar score, newborns’ hyperbilirubinemia, hospitalization hypoglycemia.",G0000000|C0444706|C1274040|C0021289|C0158915|G0000000|C0005910|C1444754|C0018670|C0332520|C0741195|C0449820|G0000000|C0020433|C0019993|C0020615
"In this study, a brief combined intervention targeting physicians, patients with advanced cancer, and their caregivers (when available) promoted patient-centered communication in the near term, with clinically meaningful increases in engaging patients in discussions, responding to emotions and discussions of prognosis and treatment choices.","In study, combined intervention targeting physicians, patients advanced cancer, caregivers (when available) promoted patient-centered communication term, clinically meaningful increases engaging patients discussions, responding emotions discussions prognosis treatment choices.",G0000000|C0557651|C0205195|C0886296|C1521840|C0031831|C0030705|C0205179|C0006826|C0085537|G0000000|C0470187|C0033414|C0030705|C0009452|C0233324|G0000000|C0876919|C0205217|C0425152|C0030705|C0557061|G0000000|C0013987|C0557061|C0033325|C0039798|C0008300
"The primary outcome, the occurrence of a relapse at 1 year after first presentation, will be compared between groups using a χ2 test.","The primary outcome, occurrence relapse 1 year presentation, compared χ2 test.",G0000000|C0205225|C1274040|C0243132|C0035020|G0000000|C0449450|C1707455|G0000000|C0022885
"These were: a possible lack of comparability of groups at baseline (crying), an unclear outcome variable, and unspecified problems with the follow up.","These were: lack comparability baseline (crying), unclear outcome variable, unspecified follow up.",G0000000|G0000000|C0332268|G0000000|C0168634|C0010399|G0000000|C1274040|C0439828|C0205370|C0332283|G0000000
"The sleep architecture, expressed as a percentage of total sleep time, including stage 3 and rapid eye movement sleep, was not different, as compared with baseline, for either the PD or CPAP therapy (Figure 4).","The sleep architecture, expressed percentage total sleep time, including stage 3 rapid eye movement sleep, different, compared baseline, PD CPAP therapy (Figure 4).",G0000000|C0037313|C0003737|G0000000|C0439165|C0439175|C0037313|C0040223|C0332257|C0205390|G0000000|C0456962|C0015392|C0026649|C0037313|C1705242|C1707455|C0168634|G0000000|C0199451|C0039798|G0000000|G0000000
Mean Number and Size of Adenomatous Polyps among Subjects Who Were Treated for at Least 40 Months.,Mean Number Size Adenomatous Polyps Subjects Who Were Treated Least 40 Months.,C0444504|C0237753|C0456389|C0001430|C0032584|C0681850|G0000000|G0000000|C1522326|C0439092|C0450371|C0439231
"The WMFT12 and FMA (Arm and Hand section; maximum score 66, where higher scores indicate greater function) were used as clinical markers of UE motor function.","The WMFT12 FMA (Arm Hand section; maximum score 66, scores function) clinical markers UE motor function.",G0000000|G0000000|C2332774|C0446516|C0018563|C0152060|C0806909|C0449820|C0450371|C0449820|C0031843|C0205210|C0005516|G0000000|C1513492|C0031843
"The researcher examined the following 3 outcome measures: the Action Research Arm Test (ARAT)19), the 66-point upper extremity section of the Fugl-Meyer Assessment of Motor Recovery after stroke (FM)21), and the Korean version of the Modified Barthel Index (K-MBI).","The researcher examined 3 outcome measures: Action Research Arm Test (ARAT)19), 66-point upper extremity Fugl-Meyer Assessment Motor Recovery stroke (FM)21), Korean version Modified Barthel Index (K-MBI).",G0000000|C0035173|C0332128|G0000000|C1274040|C0079809|C0441472|C0035168|C0446516|C0022885|C1152215|C0450371|C1282910|C0015385|G0000000|C1261322|C1513492|C0237820|C0038454|C3540627|C1556095|C0333052|C0392747|G0000000|C0918012|C0597277
The primary outcome was the difference between the two groups in dose of inhaled budesonide during the 6-month study period.,The primary outcome difference dose inhaled budesonide 6-month study period.,G0000000|C0205225|C1274040|C1705241|C0178602|C0004048|C0054201|C0332177|C0557651|C0439531
[26] showed that there was no evidence that TENS could relieve symptoms and reduce disability in chronic low back pain.,[26] evidence TENS relieve symptoms reduce disability chronic low pain.,C0450371|C3887511|C0014518|C1301676|C0683368|G0000000|C0231170|C0205191|C0205251|C0030193
Endothelial dysfunction is a key step in atherosclerosis and is characterized by impaired flow–mediated dilation (FMD).,Endothelial dysfunction key step atherosclerosis characterized impaired flow–mediated dilation (FMD).,C0014257|C0031847|G0000000|C1261552|C0003850|C1880022|C0221099|G0000000|C0012359|C0238288
"Volunteers were eligible for the study if: (1) they were between ages 18–65; (2) they met ICHD-II diagnostic criteria for migraine, with or without aura; (3) their migraines had been present for at least one year; (4) they experienced at least 48 continuous hours of freedom from headache or migraine per month; (5) their age of onset of migraine was less than 50 years; (6) they were able to provide informed consent; (7) they had a migraine at least twice a month; (8) they had daily Internet access with email; and (9) they completed the Daily Headache Record for a minimum of 5 out of 14 days during a “run-in” period.","Volunteers eligible study if: (1) ages 18–65; (2) met ICHD-II diagnostic criteria migraine, aura; (3) migraines year; (4) experienced 48 continuous hours freedom headache migraine month; (5) age onset migraine 50 years; (6) provide informed consent; (7) migraine month; (8) daily Internet access email; (9) completed Daily Headache Record minimum 5 14 days “run-in” period.",C0042960|C1548635|C0557651|G0000000|G0000000|C0001779|G0000000|G0000000|C0268621|G0000000|C0011900|C0243161|C0149931|C0236018|G0000000|C0149931|C0439234|G0000000|C0237607|C0450371|C0549178|C0439227|C0016694|C0018681|C0149931|C0332177|G0000000|C0001779|C0206132|C0149931|C0450371|C0439234|G0000000|C1999230|C1522154|C1511481|G0000000|C0149931|C0332177|G0000000|C0332173|C0282111|C0444454|C0013849|G0000000|C0205197|C0332173|C0018681|C0034869|C1524031|G0000000|C0450371|C0439228|G0000000|C0439531
"Progression-free survival (PFS) was calculated from the date of randomization to the time of disease progression, death, or September 30, 2012.","Progression-free survival (PFS) calculated randomization time disease progression, death, September 30, 2012.",C0242656|C0038952|C0242792|C0444686|C0034656|C0040223|C0012634|C0242656|C0011065|C3828193|C0450371|G0000000
2).,2).,G0000000
"The pain, stiffness and function subscales of the WOMAC were normalized to a scale of 0 to 100 units 24.","The pain, stiffness function subscales WOMAC normalized scale 0 100 units 24.",G0000000|C0030193|C0427008|C0031843|G0000000|G0000000|C1882115|C0175659|G0000000|C1442061|C0439148|C0450371
Abstinence from smokeless tobacco was confirmed by measurement of salivary cotinine at baseline and reassessed weekly from weeks 9-12 and at week 26.,Abstinence smokeless tobacco confirmed measurement salivary cotinine baseline reassessed weekly weeks 9-12 week 26.,C3843422|C1450035|C0040329|C0521093|C0242485|C0442040|C0010194|C0168634|G0000000|C0332174|C0439230|C0450371|C0332174|C0450371
"a patient is alive with a functional kidney, without acute rejection episodes, without a decrease in the graft filtration rate (eGFR) higher than 25% estimated by the Levey’s formula [7] and without cancer.","patient alive functional kidney, acute rejection episodes, decrease graft filtration rate (eGFR) 25% estimated Levey’s formula [7] cancer.",C0030705|C0376558|C0205245|C0022646|C0205178|C0035015|C0332189|C0392756|C0181074|C0016107|C0871208|C1739039|C0450371|C0750572|G0000000|C0489829|G0000000|C0006826
Study 2 randomly assigned participants to 6 weeks of 2 different chiropractic techniques or medical care consisting of 3 provider visits for medications.,Study 2 randomly assigned participants 6 weeks 2 chiropractic techniques medical care consisting 3 provider visits medications.,C0557651|G0000000|G0000000|C1516050|C0679646|G0000000|C0439230|G0000000|C0008138|C0025664|C0199168|C1947933|C0332529|G0000000|C1138603|C0545082|C0013227
"Compared with usual care, facilitated family case conferencing for residents with advanced dementia will achieve: improved nurse-rated symptom-related comfort over the last 7 days of life and symptom management over the last 90 days of life; higher scores on resident QOL at last measurement prior to resident death; a palliative approach to medical care of residents with advanced dementia, as evidenced by reduced acute care episodes, non-palliative interventions and adverse incidents at the nursing home level; a person-centred approach by nursing home staff to all aspects of care; improvements in nursing home staff attitudes to, knowledge of and confidence in providing palliative care to residents with advanced dementia and dementia care more generally.","Compared usual care, facilitated family conferencing residents advanced dementia achieve: improved nurse-rated symptom-related comfort 7 days life symptom management 90 days life; scores resident QOL measurement prior resident death; palliative approach medical care residents advanced dementia, evidenced reduced acute care episodes, non-palliative interventions adverse incidents nursing level; person-centred approach nursing staff aspects care; improvements nursing staff attitudes to, knowledge confidence providing palliative care residents advanced dementia dementia care generally.",C1707455|C3538928|C1947933|G0000000|C0015576|G0000000|C1320928|C0205179|C0011265|G0000000|C0184511|C0028661|C1457887|C1331418|G0000000|C0439228|C0376558|C1457887|C0001554|C0450371|C0439228|C0376558|C0449820|C1320928|C0518214|C0242485|C0332152|C1320928|C0011065|C0587605|C0449445|C0199168|C1947933|C1320928|C0205179|C0011265|C3887511|C0392756|C0205178|C1947933|C0332189|C1518422|C0886296|G0000000|C1551358|C0006147|C0441889|C0027361|C0449445|C0006147|C0851286|C1547011|C1947933|C2986411|C0006147|C0851286|C0004271|G0000000|C0376554|C0237529|C1999230|C0587605|C1947933|C1320928|C0205179|C0011265|C0011265|C1947933|G0000000
"Pre/posttesting included measurement of maximum voluntary ventilation (MVV), maximum inspiratory pressure (MIP), and peak oxygen consumption ( ).","Pre/posttesting included measurement maximum voluntary ventilation (MVV), maximum inspiratory pressure (MIP), peak oxygen consumption ( ).",C0332152|C0332257|C0242485|C0806909|C0439656|C0035203|C0024967|C0806909|C0004048|C0033095|C2350701|C0444505|C0030054|C0009830|G0000000|G0000000
The number needed to treat to prevent one acute exacerbation of COPD was 2.86.,The treat prevent acute exacerbation COPD 2.86.,G0000000|C0087111|C0309872|C0205178|G0000000|C0024117|C0450371
"The covariates selected for the adjusted models were baseline AIMS score, duration of illness, and baseline PANSS score.","The covariates selected adjusted models baseline AIMS score, duration illness, baseline PANSS score.",G0000000|G0000000|C1707391|C0456081|C3161035|C0168634|C1947946|C0449820|C0449238|C0221423|C0168634|G0000000|C0449820
"Perioperative anxiety symptoms will be assessed by the Hospital Anxiety and Depression Scale (HADS) at 1, 2, 3, 5, and 7 days after administration.","Perioperative anxiety symptoms assessed Hospital Anxiety Depression Scale (HADS) 1, 2, 3, 5, 7 days administration.",C1518988|C0003467|C0683368|C1516048|C0019994|C0003467|C0011570|C0175659|C0048008|G0000000|G0000000|G0000000|G0000000|G0000000|C0439228|C0001554
"Change from baseline in (A) numerical rating scale-pain intensity (NRS-PI) score, (B) fibromyalgia impact questionnaire (FIQ) score, and (C) Pittsburgh Sleep Quality Index (PSQI) scores in immediate and delayed qigong practice groups compared to the wait-list/usual care control.","Change baseline (A) numerical rating scale-pain intensity (NRS-PI) score, (B) fibromyalgia impact questionnaire (FIQ) score, (C) Pittsburgh Sleep Quality Index (PSQI) scores delayed qigong practice compared wait-list/usual care control.",C0392747|C0168634|G0000000|C0237753|C0871208|C0175659|C0522510|C2240043|C0449820|G0000000|C0016053|C1825598|C0034394|G0000000|C0449820|G0000000|G0000000|C0037313|C0332306|C0918012|C3697468|C0449820|C0205421|C0282077|C0237607|C1707455|C0043010|C1947933|C0243148
Calprotectin and hookworm infection were not associated at either baseline or at seven months.,Calprotectin hookworm infection baseline months.,C0950624|C0002830|C0009450|C0168634|C0439231
"However, to qualify as abstinent at follow-up, participants needed not only to submit a criterion breath CO sample but also to report no smoking in the past week and have a saliva cotinine level ≤ 20 ng/ml.","However, qualify abstinent follow-up, participants submit criterion breath CO sample report smoking week saliva cotinine level ≤ 20 ng/ml.",G0000000|G0000000|C0457801|C0589120|C0679646|C1515023|C0243161|C0225386|C3245499|C0370003|C0684224|C0037369|C0332174|C0036087|C0010194|C0441889|G0000000|C0450371|C0439275
"Through population-based cancer registries, 103 incident cases of breast cancer were identified in Cohort 1 (9 years follow-up with 111 267 person-years) and 119 in Cohort 2 (7 years follow-up with 151 882 person-years).","Through population-based cancer registries, 103 incident breast cancer identified Cohort 1 (9 follow-up 111 267 person-years) 119 Cohort 2 (7 follow-up 151 882 person-years).",G0000000|C0032659|C0006826|C0034975|C1442061|C1551358|C0006141|C0006826|C0205396|C0599755|G0000000|G0000000|C0589120|G0000000|C0027361|C1442061|C0599755|G0000000|G0000000|C0589120|G0000000|C0027361
"Four patients reported serious adverse events: two in the budesonide pMDI group (joint dislocation/accident/fracture, asthma aggravated) and two in the budesonide/formoterol pMDI group (menorrhagia, increase in liver enzyme activity); none were considered (after follow-up) to be related to study treatment.","Four patients reported adverse events: budesonide pMDI (joint dislocation/accident/fracture, asthma aggravated) budesonide/formoterol pMDI (menorrhagia, increase liver enzyme activity); considered (after follow-up) study treatment.",C0205450|C0030705|C0684224|G0000000|C0441471|C0054201|G0000000|C0022417|C0012691|C0004096|C0436331|C1276807|G0000000|C0025323|C0442805|C0023884|C0014442|C0205177|C0750591|G0000000|C0589120|C0557651|C0039798
"Office BP was measured using an automated clinical digital sphygmomanometer (Dynamap) at the upper left arm in supine position, after 10 min of rest in a quiet room with the arm at the heart level.","Office BP measured automated clinical digital sphygmomanometer (Dynamap) upper left arm supine position, 10 min rest quiet arm heart level.",C0442603|C0037623|C0444706|C0205554|C0205210|C0442015|C0183427|G0000000|C1282910|C0205091|C0446516|C0038846|C0733755|C0450371|C0702093|C0035253|C0439654|C0446516|C0018787|C0441889
"Pain at rest, pain on passive stretch, and pain on palpation were significantly improved at day 3 and day 7 for DETP-treated compared with placebo-treated patients (Table 3).","Pain rest, pain passive stretch, pain palpation improved day 3 day 7 DETP-treated compared placebo-treated patients (Table 3).",C0030193|C0035253|C0030193|C3686820|C0600080|C0030193|C0030247|C0184511|C0332173|G0000000|C0332173|G0000000|C0069209|C1707455|C0032042|C0030705|C0039224|G0000000
This service acceptance rate is slightly lower than the fax-based referral system; it is possible that only the most treatment-motivated smokers are referred under a fax referral system (there is a high threshold for referral).,This service acceptance rate lower fax-based referral system; treatment-motivated smokers referred fax referral system (there threshold referral).,G0000000|C0557854|G0000000|C0871208|C0441994|C0085205|C0034927|C0449913|C0039798|C0337664|C0205543|C0085205|C0034927|C0449913|G0000000|C0449864|C0034927
This active protrusion has a favorable effect on the growth and remodeling of the mandible.,This active protrusion favorable growth remodeling mandible.,G0000000|C0205177|C0333056|C3640814|C0018270|G0000000|C0024687
"The primary benefits of robot-assisted training measured here were a small reduction in impairment as measured by the primary outcome measure, the FM score, which focuses on motor ability, and the Nottingham Sensory Assessment, which measures tactile and proprioceptive perception.","The primary benefits robot-assisted training measured reduction impairment measured primary outcome measure, FM score, focuses motor ability, Nottingham Sensory Assessment, measures tactile proprioceptive perception.",G0000000|C0205225|C0814225|C3844190|C0040607|C0444706|C0301630|C0221099|C0444706|C0205225|C1274040|C0079809|C3540627|C0449820|C0205234|C1513492|C0085732|G0000000|C0445254|C1261322|C0079809|C0439815|C0033499|C0030971
"Following the results of this study, alginate silver dressing can be used for the treatment of pressure ulcers with a better wound healing profile than conventional treatment, but without a significant difference in wound size reduction (P=0.504) or PUSH score (P=0.402).","Following study, alginate silver dressing treatment pressure ulcers wound healing profile conventional treatment, difference wound size reduction (P=0.504) PUSH score (P=0.402).",C0231290|C0557651|C0102137|C0037125|C0013119|C0039798|C0033095|C0041582|C0043250|C0043240|C1979963|C0439858|C0039798|C1705241|C0043250|C0456389|C0301630|C0369773|C1719958|C0449820|C0369773
Median OS was 20 months (95% CI: 15.4–24.6) in group A and 25.3 months (95% CI: 22.1–28.6) in group B (p = 0.099).,Median OS 20 months (95% CI: 15.4–24.6) A 25.3 months (95% CI: 22.1–28.6) B (p = 0.099).,C0549183|C0229090|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000
Key secondary events (stroke; myocardial infarction; fatal coronary heart disease and other cardiovascular death) will be reviewed by independent clinicians blinded to treatment to ensure unbiased coding of these events.,Key secondary events (stroke; myocardial infarction; fatal coronary heart disease cardiovascular death) reviewed independent clinicians blinded treatment ensure unbiased coding events.,G0000000|C0027627|C0441471|C0038454|C0027061|C0021308|C1302234|C0018787|C0018787|C0012634|C0007226|C0011065|C0282443|C0085862|C0871685|C0150108|C0039798|C0218063|G0000000|C0009219|C0441471
We conducted a case–control study with 1007 patients with histopathologically confirmed bladder cancer and 1299 healthy matched controls.,We conducted case–control study 1007 patients histopathologically confirmed bladder cancer 1299 healthy matched controls.,G0000000|C0004927|G0000000|C0557651|G0000000|C0030705|G0000000|C0521093|C0005682|C0006826|G0000000|C3898900|C0150103|C0243148
"In our previous case report and one clinical trial, however, treatment failure occurred with symptoms of relapse after azithromycin therapy (5, 12).","In previous report clinical trial, however, treatment failure occurred symptoms relapse azithromycin therapy (5, 12).",G0000000|C0205156|C0684224|C0205210|C0008976|G0000000|C0039798|C0231174|C1709305|C0683368|C0035020|C0052796|C0039798|G0000000|C0450371
Preintervention data were collected January 2001–June 2002; postintervention data were collected July 2002–September 2004.,Preintervention data collected January 2001–June 2002; postintervention data collected July 2002–September 2004.,C2347663|C1511726|C1516695|C3829466|G0000000|G0000000|G0000000|C1511726|C1516695|C3829447|G0000000|G0000000
"We aim to assess the effect of selenium supplementation on CD4 cell count, HIV viral load, opportunistic infections, and quality of life in HIV-infected patients in Rwanda.","We aim assess selenium supplementation CD4 cell count, HIV viral load, opportunistic infections, quality life HIV-infected patients Rwanda.",G0000000|C1947946|C1516048|C0036581|C0242297|C0285590|C0007634|C0750480|C0019682|C0521026|C1550025|G0000000|C3714514|C0332306|C0376558|C0019682|C0030705|C0035978
"By shortening the duration of labour, pregnant women tend to have more normal vaginal delivery.","By shortening duration labour, pregnant women tend normal vaginal delivery.",G0000000|C0441636|C0449238|C0022864|C0549206|C0043210|G0000000|C0205307|C0042232|C0011209
"The number of lesions per participant was calculated and, for every participant having at least one lesion, mean ΔF and area were calculated.","The lesions participant calculated and, participant lesion, ΔF calculated.",G0000000|C0221198|C0679646|C0444686|G0000000|C0679646|C0221198|G0000000|C0444686
"EFFECTIVENESS OUTCOMES Definition of abbreviations: ACQ = Asthma Control Questionnaire; AQLQ = Asthma Quality of Life Questionnaire, BD = bronchodilator, BT = bronchial thermoplasty, amPEF = morning peak expiratory flow.","EFFECTIVENESS OUTCOMES Definition abbreviations: ACQ = Asthma Control Questionnaire; AQLQ = Asthma Quality Life Questionnaire, BD = bronchodilator, BT = bronchial thermoplasty, amPEF = morning peak expiratory flow.",C1280519|C1274040|C1550452|C0000723|C2919686|G0000000|C0004096|C0243148|C0034394|C4055434|G0000000|C0004096|C0332306|C0376558|C0034394|C0005126|G0000000|C0006280|G0000000|G0000000|C0205039|G0000000|G0000000|G0000000|C0332170|C0444505|C0231800|C0806140
Secondary outcomes included actual time to discharge; readmission within 28 days from randomisation; adverse events; healthcare usage and duration of respiratory symptoms postdischarge.,Secondary outcomes included actual time discharge; readmission 28 days randomisation; adverse events; healthcare usage duration respiratory symptoms postdischarge.,C0027627|C1274040|C0332257|C0237400|C0040223|C0012621|C1548168|G0000000|C0034656|G0000000|C0441471|C0086388|C0457083|C0449238|C0521346|C0683368|G0000000
"There were no significant differences between groups in major efficacy, adherence, and outcome (subjective sleepiness, objective vigilance, blood pressure, quality of life) measures.","There differences major efficacy, adherence, outcome (subjective sleepiness, objective vigilance, blood pressure, quality life) measures.",G0000000|C1705241|C0205082|C1280519|C1510802|C1274040|C0439655|C0013144|C0018017|C0699864|C0005767|C0033095|C0332306|C0376558|C0079809
"Also, there was no statistically significant difference in neurophysiologic findings including latency and amplitude of median SNAP and CMAP.","Also, statistically difference neurophysiologic findings including latency amplitude median SNAP CMAP.",G0000000|C0038215|C1705241|C0027901|C2607943|C0332257|C0205275|C2346753|C0549183|G0000000|C1413776
"In summary, this study showed that the intra-articular administration of TXA reduced knee joint swelling as well as blood loss after TKA.","In summary, study intra-articular administration TXA reduced knee joint swelling blood loss TKA.",G0000000|C1552616|C0557651|C0442108|C0001554|G0000000|C0392756|C0022742|C0022417|C0013604|C0005767|C1517945|G0000000
"Teeth with history of swelling or sinus tracts and radiographic signs of internal or external resorption, furcation radiolucency and teeth with non-restorable crowns were excluded.","Teeth history swelling sinus tracts radiographic signs internal external resorption, furcation radiolucency teeth non-restorable crowns excluded.",C0040426|C0019664|C0013604|C0016169|C1185740|C0444708|C0220912|C0205102|C0205101|C2985494|C2825929|C2827491|C0040426|C1518422|C0010384|C1554077
"With several countries having now implemented HPV vaccination programs, data on uptake are beginning to emerge.","With countries implemented HPV vaccination programs, data uptake emerge.",G0000000|C0454664|G0000000|C0021344|C0042196|C0376691|C1511726|C0243144|G0000000
"Differential cell counts were obtained from bronchoalveolar lavage fluid collected daily for 5 days and concentrations of the cytokines interluekins IL-1β and IL-8, and tumour necrosis factor α (TNF-α) were measured.","Differential cell counts bronchoalveolar lavage fluid collected daily 5 days concentrations cytokines interluekins IL-1β IL-8, tumour necrosis factor α (TNF-α) measured.",C0443199|C0007634|C0439157|G0000000|C0022100|C0005889|C1516695|C0332173|G0000000|C0439228|C0086045|C0079189|G0000000|G0000000|C0020898|C0027651|C0027540|C1521761|G0000000|G0000000|C0444706
Each was prescribed for five days.,Each prescribed days.,G0000000|C0278329|C0439228
A new episode was taken into account only after the complete resolution of the previous one.,A episode account complete resolution previous one.,G0000000|C0332189|C2741673|C0205197|C1514893|C0205156|C0205447
The number of falls was asked during the baseline measurement of the current study and after the study.,The falls baseline measurement current study study.,G0000000|C0000921|C0168634|C0242485|C0521116|C0557651|C0557651
"Neither haloperidol nor ziprasidone significantly increased the number of days patients were alive without delirium or coma, compared with placebo, and the duration of both delirium and coma was similar among treatment groups (Figure 3 and Table 3).","Neither haloperidol ziprasidone increased days patients alive delirium coma, compared placebo, duration delirium coma treatment (Figure 3 Table 3).",G0000000|C0018546|C0380393|C0205217|C0439228|C0030705|C0376558|C0011206|C0009421|C1707455|C0032042|C0449238|C0011206|C0009421|C0039798|G0000000|G0000000|C0039224|G0000000
No subject rated the tolerability as “very unpleasant” Routine blood parameters and adverse events did not indicate safety issues.,No subject rated tolerability “very unpleasant” Routine blood parameters adverse events safety issues.,G0000000|C0681850|C0871208|C3274448|G0000000|G0000000|C0205547|C0005767|C0449381|G0000000|C0441471|C0036043|C0033213
The 1RM leg press test is a valid means to assess leg muscle strength in elderly men and women [50].,The 1RM leg press test valid assess leg muscle strength elderly women [50].,G0000000|G0000000|C0023216|G0000000|C0022885|C2349099|C1516048|C0023216|C0026845|C0237897|C0001792|C0043210|C0450371
An external independent data and safety monitoring board monitored the safety of the participants and the overall quality and scientific integrity of the study.,An external independent data safety monitoring board monitored safety participants quality scientific integrity study.,G0000000|C0205101|C0085862|C1511726|C0036043|C0150369|C0972401|C0030695|C0036043|C0679646|C0332306|C0036397|C0205266|C0557651
The primary endpoint is objective best overall response (complete remission (CR) and partial remission (PR)).,The primary endpoint objective response (complete remission (CR) partial remission (PR)).,G0000000|C0205225|C2349179|C0018017|C0871261|C0205197|C0544452|C0201975|C0728938|C0544452|C0279759
"The current study is a prospective randomized study to evaluate role of WBRT combined with SRS compared to SRS alone and to WBRT alone in improvement of the overall survival, brain local control, performance status and its effect on treatment-related morbidity.","The current study prospective randomized study evaluate role WBRT combined SRS compared SRS WBRT improvement survival, brain local control, performance status treatment-related morbidity.",G0000000|C0521116|C0557651|C0023981|C0034656|C0557651|C0220825|C0035820|C1520143|C0205195|G0000000|C1707455|G0000000|C1520143|C2986411|C0038952|C0006104|C0205276|C0243148|C0597198|C0449438|C0039798|C0026538
"Secondary outcomes included differences by intervention in number of visits attended, smoking rates at interim visits (self-report and eCO), number of quit attempts, change in Fagerstrom score, and alterations in self-efficacy.","Secondary outcomes included differences intervention visits attended, smoking rates interim visits (self-report eCO), quit attempts, change Fagerstrom score, alterations self-efficacy.",C0027627|C1274040|C0332257|C1705241|C0886296|C0545082|C1456498|C0037369|C0871208|C2827738|C0545082|C0681906|C2675227|C0748223|C1516084|C0392747|G0000000|C0449820|C1515926|C0600564
"AOM cases were captured when parents sought medical attention for children with AOM symptoms; surveillance was enhanced approximately 2 y into the study through regular telephone calls or home visits by study personnel, who advised parents to visit the clinic if their child had AOM symptoms.","AOM captured parents sought medical attention children AOM symptoms; surveillance enhanced 2 study regular telephone calls visits study personnel, advised parents visit clinic child AOM symptoms.",C0004519|G0000000|C0030551|G0000000|C0199168|C0004268|C0008059|C0004519|C0683368|C0220920|C2349975|G0000000|C0557651|C0205272|C0039457|C0679006|C0545082|C0557651|C0024752|G0000000|C0030551|C0545082|C0002424|C0008059|C0004519|C0683368
"Furthermore, there was a significant decrease in sleeping problems and work related burnout among care providers in the experimental hospital, whereas a deterioration of client related burnout and personal burnout was observed in the control group.","Furthermore, decrease sleeping burnout care providers experimental hospital, deterioration client burnout personal burnout observed control group.",G0000000|C0392756|C0037313|C0476644|C1947933|C1138603|C1517586|C0019994|C0868945|C0008942|C0476644|C1519021|C0476644|C1441672|C0243148|C0441833
Failure criteria were (i) apnoea; (ii) absolute increase in oxygen requirement greater than 15% above that required before extubation; or (iii) respiratory acidosis (pH<7.25 with pCO2 >6.67 kPa).,Failure criteria (i) apnoea; (ii) absolute increase oxygen requirement 15% required extubation; (iii) respiratory acidosis (pH<7.25 pCO2 >6.67 kPa).,C0231174|C0243161|C0021966|C0003578|G0000000|C0205344|C0442805|C0030054|C1514873|C0450371|C1514873|C0553891|C0439070|C0521346|C0001122|C0450407|G0000000|C0450371|C0439474
"We evaluated vaccine efficacy (VE) against 1-year persistent infection, stratified by age and sexual behavior, among young women in Costa Rica.","We evaluated vaccine efficacy (VE) 1-year persistent infection, stratified age sexual behavior, women Costa Rica.",G0000000|C0220825|C0042210|C1280519|C0042469|C0439234|C0205322|C0009450|C0205363|C0001779|C0036864|C0004927|C0043210|C0035561|G0000000
"Subjective measure outcomes for the auto bilevel and CPAP group for each visit* ESS, Epworth Sleepiness Scale; FSS, Fatigue Severity Scale; FOSQ, Functional Outcomes of Sleep Questionnaire.","Subjective measure outcomes auto bilevel CPAP visit* ESS, Epworth Sleepiness Scale; FSS, Fatigue Severity Scale; FOSQ, Functional Outcomes Sleep Questionnaire.",C0439655|C0079809|C1274040|C1441488|G0000000|C0199451|C0545082|C0206630|G0000000|C0013144|C0175659|C0265224|C0015672|C0439793|C0175659|G0000000|C0205245|C1274040|C0037313|C0034394
The primary outcome is carbon monoxide validated 12 months (T1-T4) continuous abstinence from smoking (Russel’s standard) [29].,The primary outcome carbon monoxide validated 12 months (T1-T4) continuous abstinence smoking (Russel’s standard) [29].,G0000000|C0205225|C1274040|C0007009|G0000000|G0000000|C0450371|C0439231|C0041403|C0549178|C3843422|C0037369|G0000000|C1442989|C0450371
(A) Representative flow cytometry plots of interleukin (IL)–17 and interferon (IFN)–γ staining in CD4+ cells in the high- and low-dose groups at baseline and end-study visits.,(A) Representative flow cytometry plots interleukin (IL)–17 interferon (IFN)–γ staining CD4+ cells high- low-dose baseline end-study visits.,G0000000|C1882932|C0806140|C0814048|G0000000|C0021764|G0000000|C0021747|G0000000|C0487602|C0285590|C0007634|C0205250|C0445550|C0168634|C0444930|C0545082
"TMV intervention components directly address RIM protective factors by encouraging AYA to actively engage with their environment (courageous coping); reflect on their experiences and identify what is important (spiritual perspective, social integration, family environment); identify future hopes/desires (hope-derived meaning); involve family, peers, and/or healthcare providers in their project as desired (social integration, family environment); and communicate ideas to others (social integration, family environment).","TMV intervention components directly address RIM protective factors encouraging AYA actively engage environment (courageous coping); reflect experiences identify (spiritual perspective, social integration, family environment); identify future hopes/desires (hope-derived meaning); involve family, peers, and/or healthcare providers project desired (social integration, family environment); communicate ideas (social integration, family environment).",G0000000|C0886296|C0449432|C1947931|C0376649|G0000000|G0000000|C1521761|G0000000|G0000000|G0000000|G0000000|C0014406|C0870365|C0009967|C0558058|C0596545|G0000000|G0000000|G0000000|C0728831|C1158478|C0015576|C0014406|G0000000|C0016884|C0392347|C0392347|C0876919|G0000000|C0015576|C0679739|G0000000|C0086388|C1138603|C1709701|C0871633|C0728831|C1158478|C0015576|C0014406|C0566001|C0459920|C0728831|C1158478|C0015576|C0014406
"Abbreviations: AUC0–12 h, area under the curve from 0 to 12 hours post-dose; BID, twice daily; FEV1, forced expiratory volume in 1 second; LOCF, last observation carried forward; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.","Abbreviations: AUC0–12 h, curve 0 12 hours post-dose; BID, daily; FEV1, forced expiratory volume 1 second; LOCF, observation carried forward; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.",C0000723|G0000000|C0033727|C0205134|G0000000|C0450371|C0439227|C0439568|G0000000|C0332173|G0000000|C0441722|C0231800|C0449468|G0000000|C0205436|C2825507|C0302523|C0206243|C0439780|C0016327|C0060657|C0024974|C0360564|C1507353|C0024974|C0360564|C1507353|C0443218|C0205195|C0524527
"These measurements will be collected at baseline (prior to 18 weeks gestation), 36 weeks gestation and 12 months post-birth.","These measurements collected baseline (prior 18 weeks gestation), 36 weeks gestation 12 months post-birth.",G0000000|C0242485|C1516695|C0168634|C0332152|C0450371|C0439230|C0032961|C0450371|C0439230|C0032961|C0450371|C0439231|C0687676
Infant growth pattern is the measurement of an infant's weight and length plotted over time using z scores.,Infant growth pattern measurement infant's weight length plotted time scores.,C0021270|C0018270|C0449774|C0242485|C0021270|C0005910|C1444754|G0000000|C0040223|C0449820
Girls’ and parents’ BMI and change in BMI were calculated based on height and weight measurements.,Girls’ parents’ BMI change BMI calculated based height weight measurements.,G0000000|G0000000|G0000000|C0392747|G0000000|C0444686|C1527178|C0489786|C0005910|C0242485
"Table 2 Patient demographics at baseline Figure 1 Patient flow chart for intention-to-treat trial population  The primary outcome, serum calcium at each dose in the treatment regimen, was evaluated by repeated measures/mixed modeling procedures.","Table 2 Patient demographics baseline Figure 1 Patient flow chart intention-to-treat trial population The primary outcome, serum calcium dose treatment regimen, evaluated repeated measures/mixed modeling procedures.",C0039224|G0000000|C0030705|C0011298|C0168634|G0000000|G0000000|C0030705|C0806140|C0007963|C0162425|C0008976|C0032659|G0000000|C0205225|C1274040|C0229671|C0006675|C0178602|C0039798|C0040808|C0220825|C0205341|C0079809|C0870071|C0025664
Complete recovery included complete healing without scar or contracture.,Complete recovery included complete healing scar contracture.,C0205197|C0237820|C0332257|C0205197|C0043240|C0241158|C0009917
"Secondary outcomes: other pharmacological pain relief use during labour; induction of labour; augmentation of labour; length of labour; instrumental delivery; CS, postpartum haemorrhage (PPH; >500 mL blood loss); perineal trauma (first/second/third/fourth degree tear/episiotomy); major or severe perineal trauma (third/fourth degree tear/episiotomy); Apgar scores <7 at 5 min; resuscitation of the newborn (with oxygen, suction, bag and mask, intubation, cardiac massage); admission to special care nursery/neonatal intensive care unit (SCN/NICU).","Secondary outcomes: pharmacological pain relief labour; induction labour; augmentation labour; length labour; instrumental delivery; CS, postpartum haemorrhage (PPH; >500 mL blood loss); perineal trauma (first/second/third/fourth degree tear/episiotomy); major severe perineal trauma (third/fourth degree tear/episiotomy); Apgar scores <7 5 min; resuscitation newborn (with oxygen, suction, bag mask, intubation, cardiac massage); admission special care nursery/neonatal intensive care unit (SCN/NICU).",C0027627|C1274040|C0031330|C0030193|C0564405|C0022864|C0205263|C0022864|C1293122|C0022864|C1444754|C0022864|G0000000|C0011209|C0010182|C0086839|C0019080|C1414402|G0000000|C0005767|C1517945|C0031066|C0043251|C0205435|C0441889|C0039409|C0205082|C0205082|C0031066|C0043251|C0205437|C0441889|C0039409|C0741195|C0449820|G0000000|G0000000|C0035273|C0021289|G0000000|C0030054|C0038638|C0179196|C0024861|C0021925|C0018787|C0024875|C0184666|C0205555|C1947933|C0028659|C0162425|C1947933|C0439148|C0038866
Serious adverse events were defined in accordance with the harmonized tripartite guidelines for Good Clinical Practice.,Serious adverse events defined harmonized tripartite guidelines Good Clinical Practice.,C0205404|G0000000|C0441471|C1704788|G0000000|G0000000|C0162791|C0205170|C0205210|C0237607
"Therefore, we feel that it is unlikely that compliance would significantly alter our results related to ovarian cancer endpoints of incidence and mortality.","Therefore, feel compliance alter ovarian cancer endpoints incidence mortality.",G0000000|C0013987|C0009563|C0392747|C0205065|C0006826|C2349179|C0021149|C0026565
"The EMPOWER trial will evaluate the effect of the intervention on physical fitness, HRQoL, physical activity and positive behavioural responses to exercise in the short term.","The EMPOWER trial evaluate intervention physical fitness, HRQoL, physical activity positive behavioural responses exercise short term.",G0000000|C0562342|C0008976|C0220825|C0886296|C0031809|C1456706|G0000000|C0031809|C0205177|C0439178|C0004927|C0871261|C0015259|C1282927|C0233324
"No significant differences were found between the groups at 12 weeks in terms of ESS, AHI, SF‐36, or CPAP usage.","No differences 12 weeks terms ESS, AHI, SF‐36, CPAP usage.",G0000000|C1705241|G0000000|C0233324|C0206630|G0000000|G0000000|C0199451|C0457083
Less than 4% of children in either the intervention or the control group had a Hb concentration of less than 7 g/dL when seen at the end of the malaria transmission season.,Less 4% children intervention control Hb concentration 7 g/dL malaria transmission season.,C0439092|G0000000|C0008059|C0886296|C0243148|C0019046|C0004268|G0000000|C0439267|C0024530|C0040722|C0036497
"A ‘psycho-motor speed domain’ score comprised scores from the Trails A test (Heaton et al., 2004) and the Visual Attention Task overall reaction time (Novakovic-Agopian et al., 1999).","A ‘psycho-motor speed domain’ score comprised scores Trails A test (Heaton al., 2004) Visual Attention Task reaction time (Novakovic-Agopian al., 1999).",G0000000|G0000000|C0678536|G0000000|C0449820|C2700400|C0449820|C1143949|G0000000|C0022885|G0000000|C0202311|G0000000|C0234621|C0004268|C3540678|C0443286|C0040223|G0000000|C0202311|G0000000
"[8] Health status was assessed at months 1, 2, 6 and 12 using the St George’s Respiratory Questionnaire (SGRQ).","[8] Health status assessed months 1, 2, 6 12 St George’s Respiratory Questionnaire (SGRQ).",G0000000|C0018684|C0449438|C1516048|C0439231|G0000000|G0000000|G0000000|C0450371|C0036056|G0000000|C0521346|C0034394|G0000000
"Depressive symptoms refer to patient self-reported depressive symptoms assessed by the nine-item PHQ-9 (Kroenke et al., 2001).","Depressive symptoms refer patient self-reported depressive symptoms assessed nine-item PHQ-9 (Kroenke al., 2001).",G0000000|C0683368|C0205543|C0030705|C0681906|G0000000|C0683368|C1516048|C0205455|C1879301|G0000000|C0202311|G0000000
Instructions in the use of the RPE scale (6-20 scale) and the procedure for the 6MWT were explained in detail.,Instructions RPE scale (6-20 scale) procedure 6MWT explained detail.,C0302828|C0035322|C0175659|C0450371|C0175659|C0184661|G0000000|G0000000|C1522508
Other prespecified efficacy variables were the percentage of subjects with 1 or more exacerbations during the study and the change from baseline in total COPD symptom scores.,Other prespecified efficacy variables percentage subjects 1 exacerbations study change baseline total COPD symptom scores.,G0000000|G0000000|C1280519|C0439828|C0439165|C0681850|G0000000|G0000000|C0557651|C0392747|C0168634|C0439175|C0024117|C1457887|C0449820
The primary endpoint was St George’s Respiratory Questionnaire (SGRQ) total score at day 84.,The primary endpoint St George’s Respiratory Questionnaire (SGRQ) total score day 84.,G0000000|C0205225|C2349179|C0036056|G0000000|C0521346|C0034394|G0000000|C0439175|C0449820|C0332173|C0450371
"Their unmet needs may compromise their quality of life (QoL) [19] and contribute to their distress [20], but also they may adversely impact on their relative’s distress [21].","Their unmet compromise quality life (QoL) [19] contribute distress [20], adversely impact relative’s distress [21].",G0000000|C3274904|C2945640|C0332306|C0376558|C0518214|C0450371|C1880177|C0231303|C0450371|G0000000|C1825598|G0000000|C0231303|C0450371
Our primary outcome measure in MTF was an indicator equal to 1 if the adolescent reported using marijuana in the past month.,Our primary outcome measure MTF indicator equal 1 adolescent reported marijuana month.,G0000000|C0205225|C1274040|C0079809|C1417130|C0021212|C0205163|G0000000|C0205653|C0684224|C0024808|C0332177
"For cross-sectional analysis, second molar outcomes included distal caries experience (either primary or secondary caries), distal alveolar bone loss ≥ 20%, and distal probing depth > 4 mm.","For cross-sectional analysis, molar outcomes included distal caries experience (either primary secondary caries), distal alveolar bone loss ≥ 20%, distal probing depth > 4 mm.",G0000000|C0552389|C0002778|C0026367|C1274040|C0332257|C0205108|C0011334|C0237607|C3844638|C0205225|C0027627|C0011334|C0205108|C1440080|C0262950|C1517945|G0000000|C0450371|C0205108|C0419358|C0205125|G0000000|G0000000|G0000000
Cancer cases were identified through the population-based Shanghai Cancer Registry.,Cancer identified population-based Shanghai Cancer Registry.,C0006826|C0205396|C0032659|G0000000|C0006826|C0034975
We did evaluate outcomes but focused on examining the feasibility and acceptability of the intervention.,We evaluate outcomes focused examining feasibility acceptability intervention.,G0000000|C0220825|C1274040|C0205234|C0332128|G0000000|C0814633|C0886296
"The primary outcome was survival free of disability (defined as a modified Rankin score of 0 or 1 on a scale of 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability despite symptoms, and 6 death) at 3 months.","The primary outcome survival free disability (defined modified Rankin score 0 1 scale 0 6, 0 indicating symptoms, 1 clinically disability symptoms, 6 death) 3 months.",G0000000|C0205225|C1274040|C0038952|C0332296|C0231170|C1704788|C0392747|G0000000|C0449820|G0000000|G0000000|C0175659|G0000000|G0000000|G0000000|G0000000|C0683368|G0000000|G0000000|C0231170|C0683368|G0000000|C0011065|G0000000|C0439231
"Measures used for this study’s analysis included items assessing 30-day frequency and quantity of alcohol use; heavy episodic alcohol use, defined as consuming 5 or more drinks in a row during the last 30 days; 13 items measuring negative consequences (problems) experienced during drinking (alpha=.99); and length of time using alcohol (ranging from “30 days or less” to “six months or more.”) In addition, a measure of the stage of initiation of alcohol use was developed from previous stage research and theory (Prochaska & DiClemente, 1983; Werch, et al.","Measures study’s analysis included items assessing 30-day frequency quantity alcohol use; heavy episodic alcohol use, defined consuming 5 drinks row 30 days; 13 items measuring negative consequences (problems) experienced drinking (alpha=.99); length time alcohol (ranging “30 days less” “six months more.”) In addition, measure stage initiation alcohol developed previous stage theory (Prochaska & DiClemente, 1983; Werch, al.",C0079809|G0000000|C0002778|C0332257|C1551338|C1516048|C0450371|C0376249|C1265611|C0001962|C0042153|C0439539|C1455761|C0001962|C0042153|C1704788|G0000000|G0000000|C0452428|C1552840|C0450371|C0439228|C0450371|C1551338|C0444706|C0205160|C0686907|C1546466|C0237607|C0001948|C0439095|C1444754|C0040223|C0001962|C1514721|G0000000|C0439228|G0000000|G0000000|C0439231|G0000000|G0000000|C0332287|C0079809|C0205390|C0589507|C0001962|G0000000|C0205156|C0205390|C0871935|G0000000|G0000000|G0000000|G0000000|G0000000|C0202311
"Objective memory (immediate and delayed) was assessed by composite scores derived from equally weighted average scores from the Rey Auditory Verbal Learning Test (AVLT) a 15 item list learning task including the Sum Recall (trials 1–5), short delay, and recognition score [18] as well as the immediate recall from the Rivermead Behavioral Paragraph Recall Test [19].","Objective memory (immediate delayed) assessed composite scores derived equally weighted average scores Rey Auditory Verbal Learning Test (AVLT) 15 item list learning task including Sum Recall (trials 1–5), short delay, recognition score [18] recall Rivermead Behavioral Paragraph Recall Test [19].",C0018017|C0025260|C0205253|C0205421|C1516048|C0205199|C0449820|C1441547|G0000000|C0005910|C1510992|C0449820|G0000000|C0439825|C0439824|C0013621|C0022885|C3640516|C0450371|C1551338|C0745732|C0013621|C3540678|C0332257|C1515051|C0034770|C0008976|G0000000|C1282927|C0205421|C0524637|C0449820|C0450371|C0034770|G0000000|C0004927|C0871028|C0034770|C0022885|C0450371
Residual tumor volume (RTV) percentage is used as the primary endpoint to assess EOTR.,Residual tumor volume (RTV) percentage primary endpoint assess EOTR.,C1609982|C0027651|C0449468|C0292818|C0439165|C0205225|C2349179|C1516048|G0000000
"Major eligibility criteria included age 8 to <12 years and refractive error meeting all the following, obtained by cycloplegic autorefraction: spherical equivalent −0.75 to −2.50 D in both eyes, astigmatism ≤1.50 D in both eyes, and spherical equivalent anisometropia ≤1.00 D. Other major eligibility criteria included near esophoria ≥2 PD, by prism and alternate cover test (PACT) at 33 cm, and high accommodative lag, as assessed by noncycloplegic autorefraction.","Major eligibility criteria included age 8 <12 refractive error meeting following, cycloplegic autorefraction: spherical equivalent −0.75 −2.50 D eyes, astigmatism ≤1.50 D eyes, spherical equivalent anisometropia ≤1.00 D. Other major eligibility criteria included esophoria ≥2 PD, prism alternate cover test (PACT) 33 cm, accommodative lag, assessed noncycloplegic autorefraction.",C0205082|C0013893|C0243161|C0332257|C0001779|G0000000|C0450371|C0429585|C0743559|C0556656|C0231290|C0010586|G0000000|C0332501|C0205163|G0000000|G0000000|C0073187|C0015392|C0004106|G0000000|C0073187|C0015392|C0332501|C0205163|C0003081|G0000000|C0073187|G0000000|C0205082|C0013893|C0243161|C0332257|C0152216|G0000000|G0000000|C0814195|C0332270|C0180153|C0022885|G0000000|C0450371|G0000000|C0000936|C1416797|C1516048|G0000000|G0000000
LS mean (SE) change from baseline in trough FEV1 (ITT population).,LS (SE) change baseline trough FEV1 (ITT population).,C0023668|C0036919|C0392747|C0168634|C0444506|G0000000|G0000000|C0032659
Changes in health related quality of life did not differ between groups.,Changes health quality life groups.,C0392747|C0018684|C0332306|C0376558|C0441833
Therapies to improve swallowing were designed to accelerate recovery of swallowing function and reduce the risk of pneumonia.,Therapies improve swallowing designed accelerate recovery swallowing function reduce risk pneumonia.,C0087111|G0000000|C0011167|C1707689|C0521110|C0237820|C0011167|C0031843|G0000000|C0035647|C0032285
"Three children in the prednisolone group had an office visit for additional croup care verified by chart review (2 on day 3, 1 on day 11).","Three children prednisolone office visit additional croup care verified chart review (2 day 3, 1 day 11).",C0205449|C0008059|C0032950|C0442603|C0545082|C1524062|C0010380|C1947933|C1711411|C0007963|C0282443|G0000000|C0332173|G0000000|G0000000|C0332173|C0450371
"Pre-intervention and at the end of 2nd week outcome measures, WMFT and FMA were taken for both the group for determination of motor function.","Pre-intervention 2nd week outcome measures, WMFT FMA determination motor function.",C2347663|G0000000|C0332174|C1274040|C0079809|G0000000|C2332774|C1148554|C1513492|C0031843
"The DASH diet is reduced in total fat (27%), saturated fat (6%), and cholesterol and contains about 3 times as much dietary fiber, potassium, magnesium, and calcium as the control diet.","The DASH diet reduced total fat (27%), saturated fat (6%), cholesterol 3 times dietary fiber, potassium, magnesium, calcium control diet.",G0000000|C2827624|C0012155|C0392756|C0439175|C0424612|C0450371|C0522534|C0424612|G0000000|C0008377|G0000000|C0040223|C0012155|C0012173|C0032821|C0024467|C0006675|C0243148|C0012155
The severity of asthma was assessed using the validated Yung Asthma Severity Score (ASS).,The severity asthma assessed validated Yung Asthma Severity Score (ASS).,G0000000|C0439793|C0004096|C1516048|G0000000|G0000000|C0004096|C0439793|C0449820|C0324145
The study was therefore designed to test for non-inferiority for the primary efficacy measure of the trough FEV1.,The study designed test non-inferiority primary efficacy measure trough FEV1.,G0000000|C0557651|C1707689|C0022885|C1518422|C0205225|C1280519|C0079809|C0444506|G0000000
No statistically significant differences were found for functional status.,No statistically differences functional status.,G0000000|C0038215|C1705241|C0205245|C0449438
The Clinical Global Impression–Improvement (CGI–I)33 and the Modified (nine-item) Simpson–Angus Scale (MSAS) were applied daily.,The Clinical Global Impression–Improvement (CGI–I)33 Modified (nine-item) Simpson–Angus Scale (MSAS) applied daily.,G0000000|C0205210|C0205246|G0000000|G0000000|C0392747|C0205455|G0000000|C0175659|G0000000|C4048755|C0332173
"Secondary objectives included study of the impact of IPT with SP on the incidence of clinical episodes of malaria during the surveillance period, outpatient attendances, the prevalence of parasitaemia and splenomegaly and nutritional status at the end of the malaria transmission season and compliance with the treatment regimen.","Secondary objectives included study impact IPT SP incidence clinical episodes malaria surveillance period, outpatient attendances, prevalence parasitaemia splenomegaly nutritional status malaria transmission season compliance treatment regimen.",C0027627|C0018017|C0332257|C0557651|C1825598|C1426839|C0037747|C0021149|C0205210|C0332189|C0024530|C0220920|C0439531|C0029921|C2827364|C0033105|C0242723|C0038002|C1521739|C0449438|C0024530|C0040722|C0036497|C0009563|C0039798|C0040808
Eligible patients (those with baseline K+ ≥5.5 mEq/L to <6.5 mEq/L and levels ≥3.8 mEq/L to <5.1 mEq/L at the end of week 4) entered an 8‐week randomized withdrawal phase and were randomly assigned to continue patiromer or switch to placebo; the primary efficacy endpoint was the between‐group difference in median change in the serum K+ over the first 4 weeks of that phase.,Eligible patients (those baseline K+ ≥5.5 mEq/L <6.5 mEq/L levels ≥3.8 mEq/L <5.1 mEq/L week 4) entered 8‐week randomized withdrawal phase randomly assigned continue patiromer switch placebo; primary efficacy endpoint between‐group difference median change serum K+ 4 weeks phase.,C1548635|C0030705|G0000000|C0168634|C0597277|G0000000|C0439375|G0000000|C0439375|C0441889|G0000000|C0439375|G0000000|C0439375|C0332174|G0000000|C1521975|G0000000|C0034656|C2349954|C0205390|G0000000|C1516050|C0549178|C4045522|C1707719|C0032042|C0205225|C1280519|C2349179|G0000000|C1705241|C0549183|C0392747|C0229671|C0597277|G0000000|C0439230|C0205390
Knee extensor strength and balance performance were measured four times before and after real and sham stimulation (Fig.,Knee extensor strength balance performance measured times real sham stimulation (Fig.,C0022742|C1184148|C0237897|C0014653|C0597198|C0444706|C0040223|C0237400|C0068899|C1292856|C0349966
"Pneumonia was defined as an acute lower respiratory illness with an opacity or infiltrate seen on chest radiography, which was interpreted as pneumonia by the treating physician.29 Nosocomial infection was diagnosed when a positive culture of a new pathogen was obtained from a lower respiratory tract specimen (sputum, bronchial/tracheal aspirates, or bronchoalveolar lavage fluid) and/or blood samples taken ≥48 hours after admission.13, 35 Invasive pulmonary aspergillosis and mucormycosis were diagnosed in accordance with the revised definitions of invasive fungal diseases from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.36 Systemic corticosteroid treatment was defined as any intended therapeutic use of corticosteroids, including methylprednisolone, prednisolone, dexamethasone, and/or hydrocortisone via oral or intravenous routes during the disease course, but excluding inhalational therapy.","Pneumonia defined acute lower respiratory illness opacity infiltrate chest radiography, interpreted pneumonia treating physician.29 Nosocomial infection diagnosed positive culture pathogen lower respiratory tract specimen (sputum, bronchial/tracheal aspirates, bronchoalveolar lavage fluid) and/or blood samples ≥48 hours admission.13, 35 Invasive pulmonary aspergillosis mucormycosis diagnosed revised definitions invasive fungal diseases European Organization Research Treatment Cancer/Invasive Fungal Infections Cooperative Group National Institute Allergy Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.36 Systemic corticosteroid treatment defined intended therapeutic corticosteroids, including methylprednisolone, prednisolone, dexamethasone, and/or hydrocortisone oral intravenous routes disease course, excluding inhalational therapy.",C0032285|C1704788|C0205178|C0441994|C0521346|C0221423|C0029053|C0332448|C0817096|C0034571|C1285553|C0032285|C1522326|C0031831|C0019994|C0009450|C0011900|C0439178|C0010453|C0450254|C0441994|C0521346|C1185740|C0370003|C0038056|C0302191|C0370199|G0000000|C0022100|C0005889|G0000000|C0005767|C0370003|G0000000|C0439227|C0184666|C0450371|C0205281|C0024109|C0004030|C0026718|C0011900|C1527075|C1550452|C0205281|C0016832|C0012634|C0239307|C0029237|C0035168|C0039798|C0006826|C0016832|C3714514|C0679729|C0441833|C3245503|C0021622|C0002111|C0009450|C0012634|C0026946|C0557651|C0441833|C1516985|C0376298|C0441833|C0205373|C0001617|C0039798|C1704788|C1283828|C0087111|C0001617|C0332257|C0025815|C0032950|C0011777|G0000000|C0020268|C0442027|C0348016|C0449444|C0012634|C0750729|C0332196|C0004048|C0039798
The Toulouse-Piéron test was used to determine the attention score.,The Toulouse-Piéron test determine attention score.,G0000000|G0000000|C0022885|G0000000|C0004268|C0449820
"Clinical outcomes included cephalic presentation at birth, the need for ECV, mode of birth, perinatal morbidity and mortality, maternal complications, and adverse events.","Clinical outcomes included cephalic presentation birth, ECV, mode birth, perinatal morbidity mortality, maternal complications, adverse events.",C0205210|C1274040|C0332257|C0205096|C0449450|C0005615|G0000000|C1513371|C0005615|C0178795|C0026538|C0026565|C2347083|C0009566|G0000000|C0441471
"OBJECTIVE—To determine the efficacy, tolerability, and impact on quality of life and cognitive functioning of anticonvulsant prophylaxis with phenytoin or sodium valproate in patients after craniotomy.","OBJECTIVE—To determine efficacy, tolerability, impact quality life cognitive functioning anticonvulsant prophylaxis phenytoin sodium valproate patients craniotomy.",G0000000|G0000000|C1280519|C3274448|C1825598|C0332306|C0376558|C1516691|C0205245|C0003286|C0033107|C0031507|C0037473|C0080356|C0030705|C0010280
The concentrations of IL-17 and IL-23 in peripheral blood and induced sputum were assessed using ELISAs.,The concentrations IL-17 IL-23 peripheral blood induced sputum assessed ELISAs.,G0000000|C0086045|C0020898|C0020898|C0205100|C0005767|C0205263|C0038056|C1516048|C0014441
"The Shapiro-Wilk test was used to test variables for normality, and the independent t test was used for comparison of static and dynamic sitting balance, and visual perception between the experimental and control groups.","The Shapiro-Wilk test test variables normality, independent test comparison static dynamic sitting balance, visual perception experimental control groups.",G0000000|G0000000|C0022885|C0022885|C0439828|C0949333|C0085862|C0022885|C1707455|C0441463|C0729333|C0277814|C0014653|C0234621|C0030971|C1517586|C0243148|C0441833
Transfer-out increased dramatically after 24 months at regional hospitals.,Transfer-out increased dramatically 24 months regional hospitals.,C0040671|C0205217|G0000000|C0450371|C0439231|C0205147|C0019994
We therefore proposed that a patient with three points in each variable (total score of less than 60) would require inpatient rehabilitation.,We proposed patient variable (total score 60) require inpatient rehabilitation.,G0000000|C1553874|C0030705|C0439828|C0439175|C0449820|C0450371|G0000000|C0021562|C0034991
The rs1799732 CT and rs1800497 TT genotypes were significantly associated with adenoma recurrence in the Polyp Prevention Trial.,The rs1799732 CT rs1800497 TT genotypes adenoma recurrence Polyp Prevention Trial.,G0000000|G0000000|C0007673|G0000000|C1452561|C0017431|C0001430|C0034897|C0032584|C0199176|C0008976
Associations were also noted between girls’ and parents’ change in BMI.,Associations girls’ parents’ change BMI.,C0004083|G0000000|G0000000|C0392747|G0000000
"We assessed adolescent alcohol and drug use by using items from a population-based epidemiological study.6 Adolescent participants were asked whether and how many times they had used alcohol and illicit drugs (e.g., marijuana, LSD, cocaine) during the previous 90 days.","We assessed adolescent alcohol drug items population-based epidemiological study.6 Adolescent participants times alcohol illicit drugs (e.g., marijuana, LSD, cocaine) previous 90 days.",G0000000|C1516048|C0205653|C0001962|C0013227|C1551338|C0032659|C0014507|C0557651|C0205653|C0679646|C0040223|C0001962|C0332266|C0013227|G0000000|C0024808|C0024334|C0009170|C0205156|C0450371|C0439228
"The pain during activities like crossing legs, squatting and climbing steps was significantly reduced in Antarth group as compared with placebo group.","The pain activities crossing legs, squatting climbing steps reduced Antarth compared placebo group.",G0000000|C0030193|C0441655|G0000000|C1140621|C0241236|C0561942|C1261552|C0392756|C1685382|C1707455|C0032042|C0441833
The primary outcome of the study was the number of new T2 lesions and new Gd-enhancing lesions in MRI evaluation after one year of therapy.,The primary outcome study T2 lesions Gd-enhancing lesions MRI evaluation therapy.,G0000000|C0205225|C1274040|C0557651|C0041403|C0221198|C2349975|C0221198|C0024485|C0220825|C0039798
The study will last for 8 weeks.,The study 8 weeks.,G0000000|C0557651|G0000000|C0439230
"Consistent with the notion that neutrophilic inflammation is a self-amplifying process in CF airways, baseline airway neutrophil count (as measured in induced sputum) was highly variable in our CF cohort and followed a logarithmic distribution.","Consistent notion neutrophilic inflammation self-amplifying process CF airways, baseline airway neutrophil count (as measured induced sputum) highly variable CF cohort logarithmic distribution.",C0332290|G0000000|C0746885|C0021368|C0036588|C1184743|C0009738|C0178987|C0168634|C0178987|C0027950|C0750480|G0000000|C0444706|C0205263|C0038056|C0205250|C0439828|C0009738|C0599755|C2986775|C0520511
"Injurious falls were those that resulted in fractures, dislocations, and organ and soft tissue trauma.","Injurious falls fractures, dislocations, organ soft tissue trauma.",G0000000|C0000921|C0016658|C0012691|C0178784|C0205358|C0040300|C0043251
"Secondary outcome measures included the MMSE,11 the most widely used instrument to assess cognitive function and dementia severity; the Alzheimer Disease Assessment Scale–Cognitive Subscale (ADAS-cog),14,15 a commonly used measure to assess memory, language, and praxis functions in AD; the 12-item Neuropsychiatric Inventory (NPI),16 an assessment of the severity and frequency of psychological and behavioral problems in patients with dementia; the Caregiver Activity Survey (CAS),17 a measurement of the time caregivers spend assisting Alzheimer patients in 6 major areas of daily activities; and the Dependence Scale,18 which assesses 6 levels of functional dependence.","Secondary outcome measures included MMSE,11 instrument assess cognitive function dementia severity; Alzheimer Disease Assessment Scale–Cognitive Subscale (ADAS-cog),14,15 commonly measure assess memory, language, praxis functions AD; 12-item Neuropsychiatric Inventory (NPI),16 assessment severity frequency psychological behavioral patients dementia; Caregiver Activity Survey (CAS),17 measurement time caregivers spend assisting Alzheimer patients 6 major daily activities; Dependence Scale,18 assesses 6 levels functional dependence.",C0027627|C1274040|C0079809|C0332257|C0451306|C0348000|C1516048|C1516691|C0031843|C0011265|C0439793|G0000000|C0012634|C1261322|G0000000|G0000000|C3539026|G0000000|C0079809|C1516048|C0025260|C0023008|C1864829|C0542341|G0000000|C0450371|G0000000|C0021941|C1412208|C1261322|C0439793|C0376249|C0205486|C0004927|C0030705|C0011265|C0085537|C0205177|C0038951|C0450371|C0242485|C0040223|C0085537|C0680968|C0557034|G0000000|C0030705|G0000000|C0205082|C0332173|C0441655|C0011546|C0175659|C1516048|G0000000|C0441889|C0205245|C0011546
"The duration of the intervention was eight continuous weeks, with follow-up visits every two weeks.","The duration intervention continuous weeks, follow-up visits weeks.",G0000000|C0449238|C0886296|C0549178|C0439230|C0589120|C0545082|C0439230
Delirium Rating Scale-Revised-98 (DRS-R-98) and mini mental status examination (MMSE) were the primary and secondary efficacy measures respectively.,Delirium Rating Scale-Revised-98 (DRS-R-98) mini mental status examination (MMSE) primary secondary efficacy measures respectively.,C0011206|C0871208|C0175659|C3887968|C0445542|C0229992|C0449438|G0000000|C0451306|C0205225|C0027627|C1280519|C0079809|G0000000
"Demographics and outcomes (change from baseline (12 weeks minus baseline)) for capsaicin responders (capsaicin pain rated ≥2; 0-10 NPRS) Brief Pain Inventory (BPI; Severity range 0-40, Average pain range 0-10, Functional Interference range 0-70); Chronic Pain Sleep Inventory (CPSI, range 0-100); Hospital Anxiety and Depression Scale (HADS Anxiety range 0-21, Depression range 0-21; <8 is normal, threshold for moderate is 11).","Demographics outcomes (change baseline (12 weeks minus baseline)) capsaicin responders (capsaicin pain rated ≥2; 0-10 NPRS) Brief Pain Inventory (BPI; Severity range 0-40, Average pain range 0-10, Functional Interference range 0-70); Chronic Pain Sleep Inventory (CPSI, range 0-100); Hospital Anxiety Depression Scale (HADS Anxiety range 0-21, Depression range 0-21; <8 normal, threshold moderate 11).",C0011298|C1274040|C0392747|C0168634|C0450371|C0439230|C0332288|C0168634|C0006931|G0000000|C0006931|C0030193|C0871208|G0000000|C0450371|C1417814|C1282927|C0030193|C0021941|C1443145|C0439793|C1514721|C0450371|C1510992|C0030193|C1514721|C0450371|C0205245|C0521102|C1514721|C0450371|C0205191|C0030193|C0037313|C0021941|C0006961|C1514721|C1442061|C0019994|C0003467|C0011570|C0175659|C0048008|C0003467|C1514721|C0450371|C0011570|C1514721|C0450371|G0000000|C0205307|C0449864|C0205081|C0450371
The primary end point was PFS.,The primary PFS.,G0000000|C0205225|C0242792
"Participants were assessed at baseline and at 6, 18, and 30 months post baseline.","Participants assessed baseline 6, 18, 30 months post baseline.",C0679646|C1516048|C0168634|G0000000|C0450371|C0450371|C0439231|C0687676|C0168634
The purposes of this study were to investigate how the different corticosteroid treatment modalities would influence glucose profiles in septic shock and to compare the reversal of shock and nursing workload needed between two different hydrocortisone regimens.,The purposes study investigate corticosteroid treatment modalities influence glucose profiles septic shock compare reversal shock nursing workload hydrocortisone regimens.,G0000000|C1285529|C0557651|C1292732|C0001617|C0039798|C0695347|C4054723|C0017725|C1979963|C0333534|C0036974|C1707455|C0443290|C0036974|C0006147|C0085122|C0020268|C2945654
"Among participants who were taking NRT, we considered an anabasine level of less than 3 ng/mL to indicate smoking cessation.","Among participants NRT, considered anabasine level 3 ng/mL smoking cessation.",G0000000|C0679646|C1278444|C0750591|C0002743|C0441889|G0000000|C0439275|C0037369|C1880019
We chose two outcome measures that are among the most relevant in the lives of patients with COPD: being free of exacerbations and having a good quality of life.,We chose outcome measures relevant lives patients COPD: free exacerbations quality life.,G0000000|C1707391|C1274040|C0079809|C2347946|C0595998|C0030705|C0024117|C0332296|G0000000|C0332306|C0376558
The stage of change combining smoking status and intention to quit according to the Health Action Process Approach (HAPA) [10] was assessed every alternate week.,The stage change combining smoking status intention quit Health Action Process Approach (HAPA) [10] assessed alternate week.,G0000000|C0205390|C0392747|C0336789|C0037369|C0449438|C0162425|C0748223|C0018684|C0441472|C1184743|C0449445|C1831791|C0450371|C1516048|C0332270|C0332174
"Secondary outcomes were agitation, patient level quality of life, proportion of patients taking other psychotropic drugs, adverse events (including documented falls), and incidents involving irritable behaviour directed at staff or other residents.","Secondary outcomes agitation, patient level quality life, proportion patients psychotropic drugs, adverse events (including documented falls), incidents involving irritable behaviour directed staff residents.",C0027627|C1274040|C0085631|C0030705|C0441889|C0332306|C0376558|C1709707|C0030705|C0033978|C0013227|G0000000|C0441471|C0332257|C1301725|C0000921|C1551358|C1314939|C0022107|C0004927|C0439851|C0851286|C1320928
"PFS and OS were estimated according to the Kaplan-Meier method, and the changes in QOL scores were calculated with a paired t-test.","PFS OS estimated Kaplan-Meier method, QOL scores calculated paired t-test.",C0242792|C0229090|C0750572|G0000000|C0025663|C0518214|C0449820|C0444686|C1709450|C0871472
"Consistent with Siller and Sigman (2002; 2008), the final measure of maternal synchronization included in this analysis was computed as the percentage of verbal behaviors that were synchronized with both, children’s attention and action, divided by the percentage of time children attended to toys.","Consistent Siller Sigman (2002; 2008), final measure maternal synchronization included analysis computed percentage verbal behaviors synchronized both, children’s attention action, divided percentage time children attended toys.",C0332290|C3411848|G0000000|G0000000|G0000000|C0205088|C0079809|C2347083|C0439580|C0332257|C0002778|C1441526|C0439165|C0439824|C0004927|C0439580|G0000000|G0000000|C0004268|C0441472|C0332849|C0439165|C0040223|C0008059|C1456498|C0040565
"Secondary endpoints were clinical performance, health-related quality of life (HRQOL) and survival.","Secondary endpoints clinical performance, health-related quality life (HRQOL) survival.",C0027627|C2349179|C0205210|C0597198|C0018684|C0332306|C0376558|G0000000|C0038952
"The definition of an asthma exacerbation is any asthma related event that involved one or more of the following; a hospital admission, an unscheduled doctor visit, a course of oral steroids or an increase in medication use.","The definition asthma exacerbation asthma event involved following; hospital admission, unscheduled doctor visit, oral steroids increase medication use.",G0000000|C1550452|C0004096|G0000000|C0004096|C0441471|C1314939|C0231290|C0019994|C0184666|C1699701|C0031831|C0545082|C0442027|C0038317|C0442805|C0013227|C0042153
The primary efficacy variable was percentage change in LDL-C from baseline levels to 12 weeks of treatment (Rsv 10 mg vs. ATV+EZE 10/10 mg).,The primary efficacy variable percentage change LDL-C baseline levels 12 weeks treatment (Rsv 10 vs. ATV+EZE 10/10 mg).,G0000000|C0205225|C1280519|C0439828|C0439165|C0392747|G0000000|C0168634|C0441889|C0450371|C0439230|C0039798|G0000000|C0450371|G0000000|C0210243|C0450371|C0026410
The combination of paclitaxel and cisplatin protocol displayed an ORR of 42.5% with a disease control rate (DCR) of 72.8%.,The combination paclitaxel cisplatin protocol displayed ORR 42.5% disease control rate (DCR) 72.8%.,G0000000|C0205195|C0144576|C0008838|C0442711|C0870432|G0000000|C0450371|C0012634|C0243148|C0871208|G0000000|C0450371
Specific aim 3: to determine whether changes in ocular shape differ between children wearing single-vision and soft bifocal contact lenses to test the hypothesis that peripheral myopic defocus globally slows eye growth.,Specific aim 3: determine ocular shape children wearing single-vision soft bifocal contact lenses test hypothesis peripheral myopic defocus globally slows eye growth.,C0205369|C1947946|G0000000|G0000000|C0015392|C0332479|C0008059|G0000000|C0037179|C0205358|C1275647|C0332158|C0023317|C0022885|C1512571|C0205100|C0027092|G0000000|G0000000|C0439834|C0015392|C0018270
The primary infant outcome is infant weight.,The primary infant outcome infant weight.,G0000000|C0205225|C0021270|C1274040|C0021270|C0005910
Profile of Mood States- Bipolar (POMS-Bipolar)[20]: a 72-item measure comprising six subscales measuring both positive and negative affects (‘agreeable-hostile’; ‘composed-anxious’; ‘clearheaded-confused’; ‘confident-unsure’; ‘elated-depressed’; and ‘energetic-tired’).,Profile Mood States- Bipolar (POMS-Bipolar)[20]: 72-item measure comprising subscales measuring positive negative (‘agreeable-hostile’; ‘composed-anxious’; ‘clearheaded-confused’; ‘confident-unsure’; ‘elated-depressed’; ‘energetic-tired’).,C1979963|C0026516|C1301808|C0443156|C0451394|C0450371|C0079809|C2700400|G0000000|C0444706|C0439178|C0205160|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000
The results at the 12-month follow up were similar to those after four months.,The 12-month follow months.,G0000000|C0450371|C0332283|C0439231
"Estimated mean child dietary diversity was significantly different at impact between comparison and intervention (3·6 and 3·9, respectively).","Estimated child dietary diversity impact comparison intervention (3·6 3·9, respectively).",C0750572|C0008059|C0012155|C1880371|C1825598|C1707455|C0886296|G0000000|G0000000|G0000000
"Recent trials in colorectal surgery have shown that the most significant factors predicting blood transfusion are pre-operative haemoglobin, operative blood loss and presence of a transfusion protocol.","Recent trials colorectal surgery factors predicting blood transfusion pre-operative haemoglobin, operative blood loss presence transfusion protocol.",C0332185|C0008976|C0555952|C0038894|C1521761|G0000000|C0005767|C0005841|C0445204|C0019046|C1882154|C0005767|C1517945|C0150312|C0005841|C0442711
Values are number of nosocomial infections due to microorganism (number of patients).,Values nosocomial infections microorganism (number patients).,C0042295|C0019994|C3714514|C0445623|C0237753|C0030705
"There were no statistically significant differences found between feedback and control groups on ethnicity, gender, family history, baseline marijuana use, consequences, or contemplation scores.","There statistically differences feedback control ethnicity, gender, family history, baseline marijuana use, consequences, contemplation scores.",G0000000|C0038215|C1705241|C0015744|C0243148|C0015031|C0079399|C0015576|C0019664|C0168634|C0024808|C0042153|C0686907|G0000000|C0449820
"The effect of SIME on all staining scores assessed after 30 days was greater than that of control eye drops, although without statistical difference between treatments (Table 2).","The SIME staining scores assessed 30 days control eye drops, statistical difference treatments (Table 2).",G0000000|G0000000|C0487602|C0449820|C1516048|C0450371|C0439228|C0243148|C0015392|C0991568|C0038215|C1705241|C0087111|C0039224|G0000000
The primary outcome of the trial is the mean number of food groups on childcare service menus that comply with dietary guidelines (Caring for Children resource32) regarding food provision to children in care.,The primary outcome trial food childcare service menus comply dietary guidelines (Caring Children resource32) food provision children care.,G0000000|C0205225|C1274040|C0008976|C0016452|C0008067|C0557854|G0000000|C0725694|C0012155|C0162791|C0150499|C0008059|G0000000|C0016452|C1549071|C0008059|C1947933
"Secondary outcomes were ICU and hospital mortality, ICU and hospital length-of-stay, incidence of delirium, delirium and coma-free days in seven days, percentage of time on target SAS, self-extubation and reintubation, accidental removal of catheters, tracheostomy rates, total sedatives doses per patient, differences in hemodynamic and ventilator variables, SOFA score, nurse workload and level of psychological stress six months after ICU discharge.","Secondary outcomes ICU hospital mortality, ICU hospital length-of-stay, incidence delirium, delirium coma-free days days, percentage time target SAS, self-extubation reintubation, accidental removal catheters, tracheostomy rates, total sedatives doses patient, differences hemodynamic ventilator variables, SOFA score, nurse workload level psychological stress months ICU discharge.",C0027627|C1274040|C0021708|C0019994|C0026565|C0021708|C0019994|C1444754|C0021149|C0011206|C0011206|C0009421|C0439228|C0439228|C0439165|C0040223|C1521840|C0605290|C0036588|C0860359|C0521129|C0015252|C0085590|C0040590|C0871208|C0439175|C0036557|C0178602|C0030705|C1705241|C0019010|C0087153|C0439828|G0000000|C0449820|C0028661|C0085122|C0441889|C0205486|C0038435|C0439231|C0021708|C0012621
"Additionally, the MMSE will be used to screen for dementia as well as assessing any global effects of the interventions after 6 months.","Additionally, MMSE screen dementia assessing global effects interventions 6 months.",G0000000|C0451306|C0220908|C0011265|C1516048|C0205246|C1280500|C0886296|G0000000|C0439231
This study was aimed to evaluate two groups of drugs in intravenous sedation method.,This study aimed evaluate drugs intravenous sedation method.,G0000000|C0557651|C1947946|C0220825|C0013227|C0348016|C0235195|C0025663
The static balance ability was measured by the postural sway path length and speed at the COP using the Balancia software.,The static balance ability measured postural sway path length speed COP Balancia software.,G0000000|C0441463|C0014653|C0085732|C0444706|C0205278|G0000000|C0919386|C1444754|C0678536|G0000000|G0000000|C0037585
"Quality of Life, Symptom Impact, and Mood Scores for All Patients After Enrollment Abbreviations: CES-D, Center for Epidemiologic Studies–Depression scale; E−D, early minus delayed; ES, effect size; FACIT-Pal, Functional Assessment of Chronic Illness Therapy–Palliative Care; QUAL-E, Quality of Life at End of Life; TOI, Treatment Outcome Index.","Quality Life, Symptom Impact, Mood Scores All Patients After Enrollment Abbreviations: CES-D, Center Epidemiologic Studies–Depression scale; E−D, minus delayed; ES, size; FACIT-Pal, Functional Assessment Chronic Illness Therapy–Palliative Care; QUAL-E, Quality Life End Life; TOI, Treatment Outcome Index.",C0332306|C0376558|C1457887|C1825598|C0026516|C0449820|G0000000|C0030705|G0000000|C1516879|C0000723|C2699160|C0205099|C0014507|G0000000|C0175659|G0000000|C0332288|C0205421|C0013754|C0456389|C3476791|C0205245|C1261322|C0205191|C0221423|G0000000|C1947933|G0000000|C0332306|C0376558|C0444930|C0376558|G0000000|C0039798|C1274040|C0918012
Complete outcome for any admission point of time after 2 months was noted in 81% and 37% of patients in the honey group and the SSD group.,Complete outcome admission time 2 months 81% 37% patients honey SSD group.,C0205197|C1274040|C0184666|C0040223|G0000000|C0439231|C0450371|C0450371|C0030705|C0019906|C0723179|C0441833
This study measures the effects of two inhaled corticosteroids on bone markers and bone mineral density (BMD) over one year.,This study measures effects inhaled corticosteroids bone markers bone mineral density (BMD) year.,G0000000|C0557651|C0079809|C1280500|C0004048|C0001617|C0262950|C0005516|C0262950|C0006660|C0178587|G0000000|C0439234
Our study is limited because it uses a military population with only 1 year of follow-up.,Our study limited military population 1 follow-up.,G0000000|C0557651|C0439801|C0026126|C0032659|G0000000|C0589120
"The patients rated their overall change at the end of the treatment series on a five point ordinal scale (1=free of symptoms, 5=much worse).","The patients rated change treatment series ordinal scale (1=free symptoms, 5=much worse).",G0000000|C0030705|C0871208|C0392747|C0039798|C0205549|C0439080|C0175659|C0332296|C0683368|G0000000|C0332271
Spontaneous preterm birth (<37 and <34 weeks).,Spontaneous preterm birth (<37 <34 weeks).,C0205359|C0151526|C0005615|C0450371|C0450371|C0439230
FVC was 91% pred.,FVC 91% pred.,C3714541|C0450371|C0032952
"After 3 months, CD20 counts remained undetectable in all these children.","After 3 months, CD20 counts remained undetectable children.",G0000000|G0000000|C0439231|G0000000|C0439157|G0000000|C3827727|C0008059
The primary outcome measure is a change in systolic blood pressure between baseline and 12 months.,The primary outcome measure change systolic blood pressure baseline 12 months.,G0000000|C0205225|C1274040|C0079809|C0392747|C0039155|C0005767|C0033095|C0168634|C0450371|C0439231
"The objective signs were evaluated by means of a slit-lamp IS-600II Topcon (Topcon Corporation, Tokyo, Japan) examination (lid margin inflammation and MG expression), staining of the conjunctiva and cornea with fluorescein (Oxford Test),13 measurement of TBUT,3,4 and the quantification of the tear assessed by Schirmer I test.","The objective signs evaluated slit-lamp IS-600II Topcon (Topcon Corporation, Tokyo, Japan) examination (lid margin inflammation MG expression), staining conjunctiva cornea fluorescein (Oxford Test),13 measurement TBUT,3,4 quantification tear assessed Schirmer I test.",G0000000|C0018017|C0220912|C0220825|C0183355|G0000000|C3492891|C3492891|C0683758|C0040371|C0022341|G0000000|G0000000|C0205284|C0021368|C0026410|C0185117|C0487602|C0009758|C0010031|C0060520|G0000000|C0022885|C0242485|G0000000|C1709793|C0039409|C1516048|C1875738|C0021966|C0022885
The vitality experience occurs more in the healthy organism.,The vitality experience occurs healthy organism.,G0000000|C0424589|C0237607|C1709305|C3898900|C0029235
The questionnaire and physical exam have been designed to optimize the collection of maternal-reported and CHW-observed infant morbidity data.,The questionnaire physical exam designed optimize collection maternal-reported CHW-observed infant morbidity data.,G0000000|C0034394|C0031809|C0582103|C1707689|G0000000|C1516698|C2347083|C1441672|C0021270|C0026538|C1511726
"No any complication (deep vein thrombosis, infection and wound complication) was found in our present study.","No complication (deep vein thrombosis, infection wound complication) study.",G0000000|C0009566|C0205125|C0042449|C0040053|C0009450|C0043250|C0009566|C0557651
"Verbal and graphical feedback was provided regarding their 1) Carbon Monoxide level, associated symptoms, and how quitting could attenuate disease risk and symptoms and 2) child’s SHSe based on objective measurements obtained by passive dosimetry: “Your child breathed in as much smoke as if s(he) smoked ‘X’ number of cigarettes last week.” Feedback on SHSe in their home versus non-smokers’ homes was also provided.","Verbal graphical feedback provided 1) Carbon Monoxide level, symptoms, quitting attenuate disease risk symptoms 2) child’s SHSe based objective measurements passive dosimetry: “Your child breathed smoke s(he) smoked ‘X’ cigarettes week.” Feedback SHSe versus non-smokers’ homes provided.",C0439824|C0681493|C0015744|C1999230|G0000000|C0007009|G0000000|C0441889|C0683368|C0748223|C0599946|C0012634|C0035647|C0683368|G0000000|G0000000|G0000000|C1527178|C0018017|C0242485|C3686820|C0034603|G0000000|C0008059|G0000000|C0037366|G0000000|C0037366|G0000000|C0677453|G0000000|C0015744|G0000000|G0000000|G0000000|C0442519|C1999230
There were no colonoscopy related deaths.,There colonoscopy deaths.,G0000000|C0009378|C0011065
Patient Disposition for the Double Blind Primary Analysis Period MN denotes multiples of normal.,Patient Disposition Double Blind Primary Analysis Period MN denotes multiples normal.,C0030705|C0743223|C0205173|C0150108|C0205225|C0002778|C0439531|C0026405|G0000000|C0439064|C0205307
The efficacy was a proportion of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) at day 42.,The efficacy proportion subjects PCR-corrected adequate clinical parasitological response (ACPR) day 42.,G0000000|C1280519|C1709707|C0681850|C0032520|C0205410|C0205210|C0205468|C0871261|G0000000|C0332173|C0450371
"In particular, there was no suggestion of an effect on length gain.","In particular, suggestion length gain.",G0000000|G0000000|C0038659|C1444754|C1517378
"For the main analysis, the primary end point is minimum 7-day point abstinence at 6 months.","For main analysis, primary minimum 7-day abstinence 6 months.",G0000000|C0205225|C0002778|C0205225|C1524031|C0332173|C3843422|G0000000
The primary outcome parameter is the proportion of participating women with excessive GWG as defined by the Institute of Medicine (IOM) [16].,The primary outcome parameter proportion participating women excessive GWG defined Institute Medicine (IOM) [16].,G0000000|C0205225|C1274040|C0549193|C1709707|C0679823|C0043210|C0442802|G0000000|C1704788|C0021622|C0013227|C1955637|C0450371
"CSF, neuropeptides, matrix metalloproteinase 3 (MMP-3), and inflammatory cytokines were determined.","CSF, neuropeptides, matrix metalloproteinase 3 (MMP-3), inflammatory cytokines determined.",C3540512|C0027895|C1704640|C0025543|G0000000|C0623362|C0333348|C0079189|G0000000
"Reduction of 50% or more of sum of the products of the perpendicular diameters of measurable lesions (SPPD), MTR of 0.33 or less, and negative gallium scan after 3 chemotherapy cycles.","Reduction 50% sum products perpendicular diameters measurable lesions (SPPD), MTR 0.33 less, negative gallium scan 3 chemotherapy cycles.",C0301630|C0450371|C1515051|C1514468|C1295725|C1301886|C1513040|C0221198|G0000000|C0039676|C0450371|C0439092|C0205160|C0016980|C0034606|G0000000|C0013216|C1511572
Results: There were no serious adverse events or cardiovascular complications.,Results: There adverse events cardiovascular complications.,C1274040|G0000000|G0000000|C0441471|C0007226|C0009566
"Secondary outcome measures included death before discharge from the NICU, length of stay in the NICU, time on a ventilator, irritation to the ear, and passing a hearing screen.","Secondary outcome measures included death discharge NICU, length stay NICU, time ventilator, irritation ear, passing hearing screen.",C0027627|C1274040|C0079809|C0332257|C0011065|C0012621|C0021709|C1444754|G0000000|C0021709|C0040223|C0087153|C0441723|C0013443|G0000000|C0018767|C0220908
Adverse events were evaluated after each dose.,Adverse events evaluated dose.,G0000000|C0441471|C0220825|C0178602
Differences of the FLACC scale (at the time of anesthetic infiltration) and heart rate and skin conductance between groups (before and during anesthetic infiltration).,Differences FLACC scale (at time anesthetic infiltration) heart rate skin conductance (before anesthetic infiltration).,C1705241|C4068796|C0175659|G0000000|C0040223|C0002932|C0332448|C0018787|C0871208|C0444099|G0000000|C0332152|C0002932|C0332448
"Secondary outcomes included motor severity, sleep markers, fatigue, depression, and quality of life.","Secondary outcomes included motor severity, sleep markers, fatigue, depression, quality life.",C0027627|C1274040|C0332257|C1513492|C0439793|C0037313|C0005516|C0015672|C0011570|C0332306|C0376558
"The Multidimensional Fatigue Scale consisted of 18 items and 3 scales: general fatigue, sleep/rest fatigue, and cognitive fatigue.","The Multidimensional Fatigue Scale consisted 18 items 3 scales: fatigue, sleep/rest fatigue, cognitive fatigue.",G0000000|C2347299|C0015672|C0175659|C0332529|C0450371|C1551338|G0000000|C0175659|C0015672|C0037313|C0015672|C1516691|C0015672
The primary endpoint in ASSET-2 was change from baseline in 6MWD at Week 16.,The primary endpoint ASSET-2 change baseline 6MWD Week 16.,G0000000|C0205225|C2349179|C2371679|C0392747|C0168634|G0000000|C0332174|C0450371
"If respondents met any one of the following three conditions, the respondents were defined as “engaging in regular physical activity”: (1) engaging in 150 mins/week or more of walking, (2) engaging in daily flexibility activity, or (3) engaging 2 or more days/week in muscle-strengthening activities.","If respondents met conditions, respondents defined “engaging regular physical activity”: (1) engaging 150 mins/week walking, (2) engaging daily flexibility activity, (3) engaging 2 days/week muscle-strengthening activities.",G0000000|C0282122|C0268621|C0012634|C0282122|C1704788|G0000000|C0205272|C0031809|G0000000|G0000000|C0425152|C1442061|C0556975|C0080331|G0000000|C0425152|C0332173|C0242808|C0205177|G0000000|C0425152|G0000000|C0677547|C0026845|C0441655
"Pain, stiffness and physical function were assessed using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 22, LFI 21 and VAS 23 scores.","Pain, stiffness physical function assessed Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) 22, LFI 21 VAS 23 scores.",C0030193|C0427008|C0031809|C0031843|C1516048|C1705493|C0029040|G0000000|C0041740|C0029408|C0918012|G0000000|C0450371|G0000000|C0450371|C0042815|C0450371|C0449820
The pH of the reflux can be derived from the pH channel and the acid clearance is the time taken for the pH channel wave to reach pH 4.,The pH reflux derived pH channel acid clearance time pH channel wave reach pH 4.,G0000000|C0450407|C0017168|C1441547|C0450407|C0439799|C0001128|C0449297|C0040223|C0450407|C0439799|C0678544|C2584321|C0450407|G0000000
"1) Symptoms such as pain, swelling, tenderness to pressure, and signs such as presence of sinus tract, swelling and tenderness to percussion were evaluated as the clinical criteria for failure and; 2) internal and/or external root resorption, interradicular radiolucencies, and periapical lesions were assessed as the radiographic criteria for failure.","1) Symptoms pain, swelling, tenderness pressure, signs presence sinus tract, swelling tenderness percussion evaluated clinical criteria failure and; 2) internal and/or external root resorption, interradicular radiolucencies, periapical lesions assessed radiographic criteria failure.",G0000000|C0683368|C0030193|C0013604|C0234233|C0033095|C0220912|C0150312|C0016169|C1185740|C0013604|C0234233|C0030987|C0220825|C0205210|C0243161|C0231174|G0000000|G0000000|C0205102|G0000000|C0205101|C0040452|C2985494|G0000000|C2827491|C0729269|C0221198|C1516048|C0444708|C0243161|C0231174
"The other primary outcomes were immunogenicity, safety and tolerability of Nicotine-Qβ.","The primary outcomes immunogenicity, safety tolerability Nicotine-Qβ.",G0000000|C0205225|C1274040|C4054739|C0036043|C3274448|G0000000
Disease progression was a relative percent increase in total lesion area of at least 50 percent.,Disease progression relative percent increase total lesion 50 percent.,C0012634|C0242656|C0080103|C0439165|C0442805|C0439175|C0221198|C0450371|C0439165
"The secondary outcomes were days with worse asthma symptoms, number of colds, and days with fever.","The secondary outcomes days worse asthma symptoms, colds, days fever.",G0000000|C0027627|C1274040|C0439228|C0332271|C0004096|C0683368|C0009443|C0439228|C0015967
ESWT is performed at 85% of maximum oxygen consumption (VO2 peak) as predicted from an incremental shuttle walk test conducted at visit 1.,ESWT performed 85% maximum oxygen consumption (VO2 peak) predicted incremental shuttle walk test conducted visit 1.,G0000000|C0884358|C0450371|C0806909|C0030054|C0009830|C0042939|C0444505|C0681842|C1705117|G0000000|C0080331|C0022885|C0004927|C0545082|G0000000
"Additional pulmonary function variables included pre-dose and 1-hour post-dose FVC measured at all clinic visits, and morning and evening peak expiratory flow (PEF) recorded daily in patient diaries.","Additional pulmonary function variables included pre-dose 1-hour post-dose FVC measured clinic visits, morning evening peak expiratory flow (PEF) recorded daily patient diaries.",C1524062|C0024109|C0031843|C0439828|C0332257|C0439565|C0439227|C0439568|C3714541|C0444706|C0002424|C0545082|C0332170|C0587117|C0444505|C0231800|C0806140|C0030771|C0034869|C0332173|C0030705|C0376660
"Figure 2 shows the symptom scores (overall, pain, diarrhoea, and constipation) at baseline, 3-, 6-, and 12-month follow-up.","Figure 2 symptom scores (overall, pain, diarrhoea, constipation) baseline, 3-, 6-, 12-month follow-up.",G0000000|G0000000|C1457887|C0449820|C0282416|C0030193|C0011991|C0009806|C0168634|G0000000|G0000000|C0450371|C0589120
"Attitudes and beliefs about VPDs and vaccination assessed by the HBM16 and IBM17 include perceived severity, perceived susceptibility, perceived benefits, perceived barriers, injunctive social norms, descriptive social norms, and perceived behavioral controls.","Attitudes beliefs VPDs vaccination assessed HBM16 IBM17 perceived severity, perceived susceptibility, perceived benefits, perceived barriers, injunctive social norms, descriptive social norms, perceived behavioral controls.",C0004271|C0004951|G0000000|C0042196|C1516048|G0000000|G0000000|C0030971|C0439793|C0030971|C0012655|C0030971|C0814225|C0030971|C1706912|G0000000|C0728831|C0205307|C0678257|C0728831|C0205307|C0030971|C0004927|C0243148
Other continuous secondary outcomes were analysed using analogous linear regression models.,Other continuous secondary outcomes analysed analogous linear regression models.,G0000000|C0549178|C0027627|C1274040|G0000000|G0000000|C0205132|C0684320|C3161035
Those in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,Those PE tendency shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,G0000000|C0070939|G0000000|C1282927|C0030755|C0162425|C1947933|C0439148|C1046445|G0000000|C0369773|G0000000|C1442061
"The mean and standard deviation of pain intensity in the intervention and control groups, before intervention, immediately, 30 minutes and 1 hour after completion of the intervention are shown in the Table 2.","The standard deviation pain intensity intervention control groups, intervention, immediately, 30 minutes 1 hour completion intervention Table 2.",G0000000|C1442989|C0012727|C0030193|C0522510|C0886296|C0243148|C0441833|C0886296|C0205548|C0450371|C0439232|G0000000|C0439227|C0205197|C0886296|C0039224|G0000000
"Significant or near significant time main effects were seen for children's hair cotinine, per cent confirmed reducers, and, in particular, parent reports of exposure.","Significant time main effects children's hair cotinine, cent confirmed reducers, and, particular, parent reports exposure.",C0237881|C0040223|C0205225|C1280500|C0008059|C0018494|C0010194|C0562018|C0521093|G0000000|G0000000|G0000000|C0030551|C0684224|C0274281
"We hypothesized that youth in families receiving Internet CBT adjunctive to specialty headache treatment would show greater reductions in headache pain (headache days, pain intensity), activity limitations, depression, anxiety, and parent protective behaviors, as well as improvements in sleep compared to youth receiving only specialized headache treatment.","We hypothesized youth families receiving Internet CBT adjunctive specialty headache treatment reductions headache pain (headache days, pain intensity), activity limitations, depression, anxiety, parent protective behaviors, improvements sleep compared youth receiving specialized headache treatment.",G0000000|G0000000|C0001578|C0015576|C1514756|C0282111|C0009244|C2825951|C0037778|C0018681|C0039798|C0301630|C0018681|C0030193|C0018681|C0439228|C0030193|C0522510|C0205177|C0449295|C0011570|C0003467|C0030551|G0000000|C0004927|C2986411|C0037313|C1707455|C0001578|C1514756|C0205555|C0018681|C0039798
BMI was computed as weight/height2.,BMI computed weight/height2.,G0000000|C1441526|C0005910
"Efficacy endpoints were incidence and severity of radiation-induced diarrhea, daily number of bowel movements, and the time from the start of the study to the use of loperamide as rescue medication.","Efficacy endpoints incidence severity radiation-induced diarrhea, daily bowel movements, time start study loperamide rescue medication.",C1280519|C2349179|C0021149|C0439793|C0034519|C0011991|C0332173|C0021853|C0026649|C0040223|C0439659|C0557651|C0023992|G0000000|C0013227
Long-term outcomes will be the incidence of dental decay and referral for care under general anaesthesia among the groups when the child is 5 years of age.,Long-term outcomes incidence dental decay referral care anaesthesia child 5 age.,C0443252|C1274040|C0021149|C0011365|C1265875|C0034927|C1947933|C0002903|C0008059|G0000000|C0001779
The longitudinal prevalence of diarrhoea was defined as the percentage of days a child had diarrhoea out of the days the child was observed.,The longitudinal prevalence diarrhoea defined percentage days child diarrhoea days child observed.,G0000000|C0205127|C0033105|C0011991|C1704788|C0439165|C0439228|C0008059|C0011991|C0439228|C0008059|C1441672
Secondary outcomes were the incremental shuttle walk test (ISWT) and the self-efficacy for managing chronic disease 6-Item scale.10 EuroQol EQ-5D11 and utilisation of healthcare services data were also collected which will be reported separately.,Secondary outcomes incremental shuttle walk test (ISWT) self-efficacy managing chronic disease 6-Item scale.10 EuroQol EQ-5D11 utilisation healthcare services data collected reported separately.,C0027627|C1274040|C1705117|G0000000|C0080331|C0022885|G0000000|C0600564|C1273870|C0205191|C0012634|C1551338|C0175659|C0451150|C0205163|C0042153|C0086388|C0557854|C1511726|C1516695|C0684224|G0000000
There was no significant change in ESR in any of the groups.,There change ESR groups.,G0000000|C0392747|C3811131|C0441833
Smoking status was evaluated by three methods: (1) mother's report (2) CO-oximetry and (3) salivary cotinine levels.,Smoking status evaluated methods: (1) mother's report (2) CO-oximetry (3) salivary cotinine levels.,C0037369|C0449438|C0220825|C0025663|G0000000|C0026591|C0684224|G0000000|C3245499|G0000000|C0442040|C0010194|C0441889
"Participants were followed at the clinics monthly for the first six months, and at nine and 12 months.","Participants clinics monthly months, 12 months.",C0679646|C0442592|C0332177|C0439231|C0450371|C0439231
"In the population of centrally confirmed AOTs, OS remained significantly different between the four genomic groups (p < 0.001) (Fig.","In population centrally confirmed AOTs, OS remained genomic (p < 0.001) (Fig.",G0000000|C0032659|G0000000|C0521093|G0000000|C0229090|G0000000|C0017428|C0369773|G0000000|C1442061|C0349966
Some studies have suggested an association between omega-3 long-chain polyunsaturated fatty acids (n-3 LC PUFAs) and better cognitive outcomes in older adults.,Some studies suggested association omega-3 long-chain polyunsaturated fatty acids (n-3 LC PUFAs) cognitive outcomes adults.,G0000000|C0947630|C1705535|C0004083|C1719844|C0205166|G0000000|G0000000|C0001128|C0369718|G0000000|C0032615|C1516691|C1274040|C0001675
Remission of depression was defined by a combination of mADCS-CGIC score ≤2 and CSDD score ≤6.,Remission depression defined combination mADCS-CGIC score ≤2 CSDD score ≤6.,C0544452|C0011570|C1704788|C0205195|G0000000|C0449820|G0000000|G0000000|C0449820|G0000000
"Non-responders at either or both follow-ups did not differ according to condition, ethnicity, gender, family history, marijuana use, consequences, or contemplation.","Non-responders follow-ups condition, ethnicity, gender, family history, marijuana use, consequences, contemplation.",C1518422|C0332283|C0012634|C0015031|C0079399|C0015576|C0019664|C0024808|C0042153|C0686907|G0000000
"Every patient had a diagnosis of ADHD based on the medical interview, the medical examination and the results of the parent and teacher versions of the Conners’ questionnaires as conducted by two of the investigators (SB and MV) with the subjects and their families.","Every patient diagnosis ADHD based medical interview, medical examination parent teacher versions Conners’ questionnaires conducted investigators (SB MV) subjects families.",G0000000|C0030705|C0011900|C1263846|C1527178|C0199168|C0021822|C0199168|G0000000|C0030551|C0221457|C0333052|G0000000|C0034394|C0004927|C0035173|C0038111|C0428679|C0681850|C0015576
Postoperative recovery of bowel function was evaluated by first flatus and bowel movement.,Postoperative recovery bowel function evaluated flatus bowel movement.,C0032790|C0237820|C0021853|C0031843|C0220825|C0016204|C0021853|C0026649
"Besides, the sevoflurane supplement did not cause more adverse events.","Besides, sevoflurane supplement adverse events.",G0000000|C0074414|C0242295|G0000000|C0441471
Primary outcome is the blinded rating of real physician-patient consultation by means of a checklist covering relevant communication skills.,Primary outcome blinded rating real physician-patient consultation checklist covering relevant communication skills.,C0205225|C1274040|C0150108|C0871208|C0237400|C0031830|C0009818|C1707357|C0180153|C2347946|C0009452|C0678856
"Primary end point was 4-month progression-free overall survival (PFS); secondary end points were objective radiographical response rate (ORR), time to progression (TTP), and toxicity.","Primary 4-month progression-free survival (PFS); secondary objective radiographical response rate (ORR), time progression (TTP), toxicity.",C0205225|C0332177|C0242656|C0038952|C0242792|C0027627|C0018017|C0034571|C0871261|C0871208|G0000000|C0040223|C0242656|C0084795|C0040539
"The Primary failure rate of an AVF ranges between 20–54%, due to thrombosis or failure of maturation.","The Primary failure rate AVF ranges 20–54%, thrombosis failure maturation.",G0000000|C0205225|C0231174|C0871208|C0449215|C1514721|G0000000|C0040053|C0231174|C0678723
"Efficacy (exacerbations, lung function, and symptoms) and tolerability (adverse events and cortisol levels) were measured.","Efficacy (exacerbations, lung function, symptoms) tolerability (adverse events cortisol levels) measured.",C1280519|G0000000|C0024109|C0031843|C0683368|C3274448|G0000000|C0441471|C0020268|C0441889|C0444706
"These included whether they noticed the water jet, how often they used it, where the water in the jet comes from, whether they liked the taste of the water, whether the water is safe, and whether they drink more water now that the jet is there.","These included noticed water jet, it, water jet from, taste water, water safe, drink water jet there.",G0000000|C0332257|G0000000|C0043047|C0336862|G0000000|C0043047|C0336862|G0000000|C0039336|C0043047|C0043047|G0000000|C0452428|C0043047|C0336862|G0000000
Patients commenced cycling at 20 W; this workload was increased by 25 W every minute.,Patients commenced cycling 20 W; workload increased 25 W minute.,C0030705|C3274784|C1511572|C0450371|G0000000|C0085122|C0205217|C0450371|G0000000|C0439232
Subjects completed the Short Form‐36 and Sleep Apnea Quality of Life Index (SAQLI) questionnaires.,Subjects completed Short Form‐36 Sleep Apnea Quality Life Index (SAQLI) questionnaires.,C0681850|C0205197|C1282927|G0000000|C0037313|C0003578|C0332306|C0376558|C0918012|G0000000|C0034394
Delirium was observed in 36 participants.,Delirium observed 36 participants.,C0011206|C1441672|C0450371|C0679646
"Doses of self reported nasal spray (1 mg) For the first 3 months, 91% or more of abstinent participants in either group used patches.","Doses reported nasal spray (1 mg) For 3 months, 91% abstinent participants patches.",C0178602|C0684224|C0028429|C1704413|G0000000|C0026410|G0000000|G0000000|C0439231|C0450371|C0457801|C0679646|C0994894
Change in CD4 count and weight were assessed by comparing the most recent CD4 and weight before enrolment in the study to the last measured during the study.,Change CD4 count weight assessed comparing CD4 weight enrolment study measured study.,C0392747|C0285590|C0750480|C0005910|C1516048|C1707455|C0285590|C0005910|C1516879|C0557651|C0444706|C0557651
"Standard spine outcome measures including Oswestry disability index (ODI), low back outcome score, visual analogue score and shuttle walking test were administered at baseline, 4, 10 and 16 weeks.","Standard spine outcome measures including Oswestry disability (ODI), low outcome score, visual analogue score shuttle walking test administered baseline, 4, 10 16 weeks.",C1442989|C0037949|C1274040|C0079809|C0332257|G0000000|C0231170|G0000000|C0205251|C1274040|C0449820|C0234621|C0243071|C0449820|G0000000|C0080331|C0022885|C1521801|C0168634|G0000000|C0450371|C0450371|C0439230
"Delirium was assessed using the validated NEECHAM scale, sleep perception was reported by the patient in response to five questions.","Delirium assessed validated NEECHAM scale, sleep perception reported patient response questions.",C0011206|C1516048|G0000000|G0000000|C0175659|C0037313|C0030971|C0684224|C0030705|C0871261|C1522634
"However, the extent to which such increases in referral rates reduce smoking prevalence depends upon patient follow-through once the referral is made and the effectiveness of the treatment program to which patients are referred.","However, extent increases referral rates reduce smoking prevalence depends patient follow-through referral effectiveness treatment program patients referred.",G0000000|C0439792|C0205217|C0034927|C0871208|G0000000|C0037369|C0033105|C0725813|C0030705|C0332283|C0034927|C1280519|C0039798|C1709697|C0030705|C0205543
"* Complications in the 7 days after randomization in the endovascular-treatment group and the intravenous t-PA group included death, neurologic deterioration, fatal and nonfatal symptomatic intracranial hemorrhage, fatal and nonfatal symptomatic edema from an original brain infarction, nonfatal recurrent ischemic stroke, and extracerebral events.","* Complications 7 days randomization endovascular-treatment intravenous t-PA included death, neurologic deterioration, fatal nonfatal symptomatic intracranial hemorrhage, fatal nonfatal symptomatic edema original brain infarction, nonfatal recurrent ischemic stroke, extracerebral events.",G0000000|C0009566|G0000000|C0439228|C0034656|C0524425|C0348016|C0032143|C0332257|C0011065|C0205494|C0868945|C1302234|G0000000|C0231220|C0524466|C0019080|C1302234|G0000000|C0231220|C0013604|C0205313|C0006104|C0021308|G0000000|C2945760|C0475224|C0038454|G0000000|C0441471
Complications and outcome of patients.,Complications outcome patients.,C0009566|C1274040|C0030705
Brief qualitative topic-guided interviews were also conducted with all patients and carers to explore their expectations and experiences of BIS.,Brief qualitative topic-guided interviews conducted patients carers explore expectations experiences BIS.,C1282927|C0205556|C1522168|C0021822|C0004927|C0030705|C0085537|G0000000|C0679138|C0596545|C0556985
"There were six serious adverse events (SAEs), one death and five nonfatal SAEs.","There adverse events (SAEs), death nonfatal SAEs.",G0000000|G0000000|C0441471|C1519255|C0011065|G0000000|C1519255
Only grade ≥ 3 adverse events related to the study treatment were summarized.,Only grade ≥ 3 adverse events study treatment summarized.,C0205171|C0441800|G0000000|G0000000|G0000000|C0441471|C0557651|C0039798|G0000000
Hospital-based interventions promote smoking cessation after discharge.,Hospital-based interventions promote smoking cessation discharge.,C0019994|C0886296|C0033414|C0037369|C1880019|C0012621
"Therefore, the aim of this study was to assess the potential therapeutic value of a high dose of cocoa flavanols in patients with chronic HF, by using reductions in N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) as an index of improved cardiac function.","Therefore, aim study assess potential therapeutic dose cocoa flavanols patients chronic HF, reductions N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) improved cardiac function.",G0000000|C1947946|C0557651|C1516048|C3245505|C0087111|C0178602|C0006622|C2348678|C0030705|C0205191|C0018488|C0301630|G0000000|G0000000|C0597421|C0030956|G0000000|C0184511|C0018787|C0031843
"Clinical worsening (death, lung transplantation, hospitalization due to pulmonary hypertension, or clinical deterioration of PAH requiring additional therapy) was assessed at weeks 4, 8, and 12.","Clinical worsening (death, lung transplantation, hospitalization pulmonary hypertension, clinical deterioration PAH requiring additional therapy) assessed weeks 4, 8, 12.",C0205210|C0332271|C0011065|C0024109|C0040732|C0019993|C0024109|C0020538|C0205210|C0868945|C3203102|G0000000|C1524062|C0039798|C1516048|C0439230|G0000000|G0000000|C0450371
"There was no effect of DHA on rate of cognitive change on the Alzheimer’s Disease Assessment Scale (ADAS; linear mixed-effects model: P = .41), Clinical Dementia Rating (CDR) sum of boxes (linear mixed-effects model: P = .68), ADCS activities of daily living scale (linear mixed-effects model: P = .38), or Neuropsychiatric Inventory (NPI; linear mixed-effects model: P = .11).","There DHA rate cognitive change Alzheimer’s Disease Assessment Scale (ADAS; linear mixed-effects model: P = .41), Clinical Dementia Rating (CDR) sum boxes (linear mixed-effects model: P = .68), ADCS activities daily living scale (linear mixed-effects model: P = .38), Neuropsychiatric Inventory (NPI; linear mixed-effects model: P = .11).",G0000000|C0142831|C0871208|C1516691|C0392747|G0000000|C0012634|C1261322|C0175659|C1060325|C0205132|C0205430|C3161035|C0369773|G0000000|C0450371|C0205210|C0011265|C0871208|G0000000|C1515051|C0179400|C0205132|C0205430|C3161035|C0369773|G0000000|C0450371|C0879593|C0441655|C0332173|C0376558|C0175659|C0205132|C0205430|C3161035|C0369773|G0000000|C0450371|G0000000|C0021941|C1412208|C0205132|C0205430|C3161035|C0369773|G0000000|C0450371
"By contrast, in the study of Mataix-Cols et al.","By contrast, study Mataix-Cols al.",G0000000|C0009924|C0557651|C1552838|C0202311
"Baseline to end-of-study means for tender point threshold, physician's global assessment, quality of life, and sleep quality* PedsQL = Pediatric Quality of Life Inventory (see Table 1 for other definitions).","Baseline end-of-study tender threshold, physician's global assessment, quality life, sleep quality* PedsQL = Pediatric Quality Life Inventory (see Table 1 definitions).",C0168634|C0444930|C0234234|C0449864|C0031831|C0205246|C1261322|C0332306|C0376558|C0037313|C0332306|C2698752|G0000000|C0030755|C0332306|C0376558|C0021941|C0042789|C0039224|G0000000|C1550452
"Improvement in asthma symptoms, PEF, and reduction in use of rescue bronchodilators did not reach statistical significance until after six weeks of treatment.","Improvement asthma symptoms, PEF, reduction rescue bronchodilators reach statistical significance weeks treatment.",C2986411|C0004096|C0683368|C0030771|C0301630|G0000000|C0006280|C2584321|C0038215|C0237881|C0439230|C0039798
"Therapeutic effect was assessed after 6 and 12 months using symptoms/medication diary cards, peak expiratory flow (PEF) measures and skin sensitivity to investigated mites.","Therapeutic assessed 6 12 months symptoms/medication diary cards, peak expiratory flow (PEF) measures skin sensitivity investigated mites.",C0087111|C1516048|G0000000|C0450371|C0439231|C0683368|C0376660|C3275277|C0444505|C0231800|C0806140|C0030771|C0079809|C0444099|C0020517|C1292732|C0026231
A secondary outcome was clinical response based upon a 10-point decline in Pediatric Crohn’s Disease Activity Index (PCDAI) scores compared to baseline/pretreatment values.,A secondary outcome clinical response based 10-point decline Pediatric Crohn’s Disease Activity Index (PCDAI) scores compared baseline/pretreatment values.,G0000000|C0027627|C1274040|C0205210|C0871261|C1527178|C0450371|G0000000|C0030755|G0000000|C0012634|C0205177|C0918012|G0000000|C0449820|C1707455|C0168634|C0042295
"Secondary outcomes include standard measures of quality of life, sleep and mood, cognition, arm function, maximal oxygen uptake, and cardiovascular risk factors including blood pressure, pulse, waist-to-hip ratio, markers of inflammation, immunity and the insulin-glucose pathway, lipid profile, and others.","Secondary outcomes standard measures quality life, sleep mood, cognition, arm function, maximal oxygen uptake, cardiovascular risk factors including blood pressure, pulse, waist-to-hip ratio, markers inflammation, immunity insulin-glucose pathway, lipid profile, others.",C0027627|C1274040|C1442989|C0079809|C0332306|C0376558|C0037313|C0026516|C0009240|C0446516|C0031843|C0205289|C0030054|C0243144|C0007226|C0035647|C1521761|C0332257|C0005767|C0033095|C0232117|C0230097|C0456603|C0005516|C0021368|C0020964|C0021641|C1704259|C0023779|C1979963|C1955473
"The primary outcome measure will be NIHSS score, a measure of neurological status, at the end of treatment, at 30 days after TH, and at 90 days after TH.","The primary outcome measure NIHSS score, measure neurological status, treatment, 30 days TH, 90 days TH.",G0000000|C0205225|C1274040|C0079809|C3476804|C0449820|C0079809|C0205494|C0449438|C0039798|C0450371|C0439228|C0039725|C0450371|C0439228|C0039725
"Interrater reliability and stability of the Modified 6-Minute Walk were examined in a previous study (Tappen et al., 1997).","Interrater reliability stability Modified 6-Minute Walk examined previous study (Tappen al., 1997).",G0000000|C2347947|C0205360|C0392747|C0439232|C0080331|C0332128|C0205156|C0557651|G0000000|C0202311|G0000000
"The median PFS and OS were shown in Figures 1 and and2,2, respectively.","The median PFS OS Figures 1 and2,2, respectively.",G0000000|C0549183|C0242792|C0229090|G0000000|G0000000|G0000000|G0000000
"BMD by dual-energy X-ray absorptiometry (DXA); 25-hydroxy vitamin D (25(OH)D) levels, parathyroid hormone (PTH), phosphate metabolism, markers of bone turnover and systemic inflammation.","BMD dual-energy X-ray absorptiometry (DXA); 25-hydroxy vitamin D (25(OH)D) levels, parathyroid hormone (PTH), phosphate metabolism, markers bone turnover systemic inflammation.",G0000000|C1554184|C0034571|G0000000|C1510486|C0450371|C0042890|C0073187|C0450371|C0441889|C0030518|C0019932|G0000000|C0031603|C0025519|C0005516|C0262950|C0031227|C0205373|C0021368
"While the use of ITNs and IRS for malaria vector control has considerably reduced the burden of malaria across the globe over the last 15 years, calls for eliminating malaria and management of insecticide resistance will require additional interventions to be implemented as part of integrated vector management strategies [89].","While ITNs IRS malaria vector control considerably reduced burden malaria globe 15 years, calls eliminating malaria management insecticide resistance require additional interventions implemented integrated vector management strategies [89].",G0000000|G0000000|G0000000|C0024530|C0086022|C0243148|G0000000|C0392756|C2828008|C0024530|C0015392|C0450371|C0439234|C0679006|G0000000|C0024530|C0001554|C0021576|C0237834|G0000000|C1524062|C0886296|G0000000|G0000000|C0086022|C0001554|C0679199|C0450371
"The primary outcomes were confirmed sustained abstinence at 1, 4, 12 and 26 weeks from quit day.","The primary outcomes confirmed sustained abstinence 1, 4, 12 26 weeks quit day.",G0000000|C0205225|C1274040|C0521093|C0443318|C3843422|G0000000|G0000000|C0450371|G0000000|C0748223|C0332173
"Further, the number of falls was self-reported by patients; therefore, it is conceivable that subjects under-reported the incidence of falls.","Further, falls self-reported patients; therefore, conceivable subjects under-reported incidence falls.",C1517331|C0000921|C0681906|C0030705|G0000000|G0000000|C0681850|C0542339|C0021149|C0000921
"Participants assigned to the medical care arm of the study were scheduled to meet with the medical provider at least 3 times, during weeks 1, 3, and 6.","Participants assigned medical care arm study scheduled meet medical provider 3 times, weeks 1, 3, 6.",C0679646|C1516050|C0199168|C1947933|C0446516|C0557651|C0086960|C1550543|C0199168|C1138603|G0000000|C0040223|C0439230|G0000000|G0000000|G0000000
There are currently no data on the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in sub-Saharan Africa.,There data immunogenicity safety HPV-16/18 AS04-adjuvanted vaccine sub-Saharan Africa.,G0000000|C1511726|C4054739|C0036043|C0021344|C0001551|C0042210|C0542339|C0001737
"[3] EA is associated with adverse events such as increased bleeding from surgical site, damage to surgical repair, pulling out a surgical drain or an intravenous access and increased pain at the operative site.","[3] EA adverse events increased bleeding surgical site, damage surgical repair, pulling surgical drain intravenous access increased pain operative site.",G0000000|C0014963|G0000000|C0441471|C0205217|C0019080|C0543467|C0205145|C0010957|C0543467|C0043240|C0580846|C0543467|C0013103|C0348016|C0444454|C0205217|C0030193|C1882154|C0205145
"Following the pulpotomy, the teeth were evaluated for clinical and radiographic success at 3, 6, 9 and 12 months on the basis of the presence of pain, sinus, mobility, internal and external resorption, periapical radiolucency, calcification in the canal and bone loss.","Following pulpotomy, teeth evaluated clinical radiographic success 3, 6, 9 12 months basis presence pain, sinus, mobility, internal external resorption, periapical radiolucency, calcification canal bone loss.",C0231290|C0034104|C0040426|C0220825|C0205210|C0444708|C0597535|G0000000|G0000000|G0000000|C0450371|C0439231|C1527178|C0150312|C0030193|C0016169|C0425245|C0205102|C0205101|C2985494|C0729269|C2827491|C0006660|C0086881|C0262950|C1517945
"The primary outcome measure was Fugl-Meyer Assessment-Upper Extremity (FMA-UE) motor score, and the secondary outcomes were Wolf Motor Function Test-Functional Ability Scale (WMFT-FAS) and Barthel index (BI).","The primary outcome measure Fugl-Meyer Assessment-Upper Extremity (FMA-UE) motor score, secondary outcomes Wolf Motor Function Test-Functional Ability Scale (WMFT-FAS) Barthel (BI).",G0000000|C0205225|C1274040|C0079809|G0000000|C1261322|C0015385|C2332774|C1513492|C0449820|C0027627|C1274040|C0325001|C1513492|C0031843|C0022885|C0085732|C0175659|G0000000|G0000000|G0000000
"Self‐report assessments were conducted for both patients and partners at baseline, postintervention (5 months), and follow‐up (10 months), assessing cancer‐related distress, symptoms of anxiety and depression, and dyadic adjustment.","Self‐report assessments conducted patients partners baseline, postintervention (5 months), follow‐up (10 months), assessing cancer‐related distress, symptoms anxiety depression, dyadic adjustment.",G0000000|C1261322|C0004927|C0030705|C0682323|C0168634|G0000000|G0000000|C0439231|G0000000|C0450371|C0439231|C1516048|G0000000|C0231303|C0683368|C0003467|C0011570|C0870454|C0376209
"The subjects were evaluated before the treatment and after completing the 3-week program, using the K-MMSE and computerized neurocognitive function tests (CNT, MAXMEDICA, Seoul, Korea) to assess cognitive function, and the Korean version of the modified Barthel Index (K-MBI) to assess activities of daily living.","The subjects evaluated treatment completing 3-week program, K-MMSE computerized neurocognitive function tests (CNT, MAXMEDICA, Seoul, Korea) assess cognitive function, Korean version modified Barthel Index (K-MBI) assess activities daily living.",G0000000|C0681850|C0220825|C0039798|C0205197|C0332174|C1709697|C0597277|G0000000|C0518895|C0031843|C0022885|G0000000|G0000000|C3850150|C0022771|C1516048|C1516691|C0031843|C1556095|C0333052|C0392747|G0000000|C0918012|C0597277|C1516048|C0441655|C0332173|C0376558
"Paired primary and recurrence samples were subjected to 3 methods: (i) month of recurrence and genotyping, (ii) by PCR-RFLP, and (iii) PCR sequencing, to differentiate relapse and reinfection.","Paired primary recurrence samples subjected 3 methods: (i) month recurrence genotyping, (ii) PCR-RFLP, (iii) PCR sequencing, differentiate relapse reinfection.",C1709450|C0205225|C0034897|C0370003|C0681850|G0000000|C0025663|C0021966|C0332177|C0034897|C1285573|G0000000|C0032520|C0439070|C0032520|C1294197|C0205615|C0035020|C0205339
"Compared with the children treated with spica cast, those treated with TEN had shorter hospital stay (P < 0.001) and took a shorter time to start walking with support or independently (P < 0.001), returned to school sooner (P < 0.001), and had higher parent satisfaction (P = 0.003).","Compared children treated spica cast, treated TEN shorter hospital stay (P < 0.001) shorter time start walking support independently (P < 0.001), returned school sooner (P < 0.001), parent satisfaction (P = 0.003).",C1707455|C0008059|C1522326|G0000000|C0179686|C1522326|C0014518|C1282927|C0019994|G0000000|C0369773|G0000000|C1442061|C1282927|C0040223|C0439659|C0080331|C0183683|G0000000|C0369773|G0000000|C1442061|C0332156|C0036375|G0000000|C0369773|G0000000|C1442061|C0030551|C0242428|C0369773|G0000000|C1442061
"Following screening and baseline visits, subjects were seen every 2 weeks for 8 weeks.","Following screening baseline visits, subjects 2 weeks 8 weeks.",C0231290|C0220908|C0168634|C0545082|C0681850|G0000000|C0439230|G0000000|C0439230
In 273 patients treated according to protocol tumour response was assessable.,In 273 patients treated protocol tumour response assessable.,G0000000|C1442061|C0030705|C1522326|C0442711|C0027651|C0871261|G0000000
Treatment groups were compared using the χ2 test.,Treatment compared χ2 test.,C0039798|C1707455|G0000000|C0022885
Results were similar for secondary end-points of Modified Rankin Scale outcome at 1 and 3 months.,Results secondary end-points Modified Rankin Scale outcome 1 3 months.,C1274040|C0027627|C2349179|C0392747|G0000000|C0175659|C1274040|G0000000|G0000000|C0439231
Ovarian cancer:Median time to progression for patients (n=14) was 2 months (1 – 6) and median overall survival was 15.0 months.,Ovarian cancer:Median time progression patients (n=14) 2 months (1 – 6) median survival 15.0 months.,C0205065|C0006826|C0040223|C0242656|C0030705|C0369718|G0000000|C0439231|G0000000|G0000000|G0000000|C0549183|C0038952|C0450371|C0439231
"The average reduction in surface area at the end of treatment was 38%, ranging from 29% in those treated for 2 weeks to 52% after treatment for 4 weeks.","The average reduction surface treatment 38%, ranging 29% treated 2 weeks 52% treatment 4 weeks.",G0000000|C1510992|C0301630|C0205148|C0039798|C0450371|C1514721|C0450371|C1522326|G0000000|C0439230|C0450371|C0039798|G0000000|C0439230
4 p<0.05.,4 p<0.05.,G0000000|C0369773
"Secondary outcome measures were lumbar flexion and extension range of motion (ROM), endurance time and rate of decline in median frequency of electromyography spectrum during a Biering Sorensen test.","Secondary outcome measures lumbar flexion extension range motion (ROM), endurance time rate decline median frequency electromyography spectrum Biering Sorensen test.",C0027627|C1274040|C0079809|C0024090|C0231452|C0231448|C1514721|C0026597|C4048784|C0518031|C0040223|C0871208|G0000000|C0549183|C0376249|C0013839|C1883073|G0000000|G0000000|C0022885
"Primary efficacy endpoint is the incidence of symptomatic objectified VTE during ALL treatment; secondary efficacy endpoints are incidence of the composite of symptomatic and asymptomatic objectified VTE, and the value of plasma coagulation assays to predict the risk of VTE.","Primary efficacy endpoint incidence symptomatic objectified VTE ALL treatment; secondary efficacy endpoints incidence composite symptomatic asymptomatic objectified VTE, plasma coagulation assays predict risk VTE.",C0205225|C1280519|C2349179|C0021149|C0231220|G0000000|C0630906|C0444868|C0039798|C0027627|C1280519|C2349179|C0021149|C0205199|C0231220|C0231221|G0000000|C0630906|C0032105|C0005778|C0005507|G0000000|C0035647|C0630906
"Among 170 patients available for matching, cell types included 93 adenocarcinoma (54.7%), 46 squamous cell carcinoma (27.1%), and 31 others (including small cell carcinoma, neuroendocrine carcinoma, mixed cell carcinoma, and unspecific malignant cell).","Among 170 patients matching, cell types included 93 adenocarcinoma (54.7%), 46 squamous cell carcinoma (27.1%), 31 (including cell carcinoma, neuroendocrine carcinoma, mixed cell carcinoma, unspecific malignant cell).",G0000000|C1442061|C0030705|C0150103|C0007634|C0332307|C0332257|C0450371|C0001418|C0450371|C0450371|C1182670|C0007634|C0007097|C0450371|C0450371|C0332257|C0007634|C0007097|C0027912|C0007097|C0205430|C0007634|C0007097|G0000000|C0205282|C0007634
"Treatment Schema The primary endpoints were CR, time to grade 4 toxicity, and death.","Treatment Schema The primary endpoints CR, time grade 4 toxicity, death.",C0039798|C0871287|G0000000|C0205225|C2349179|C0201975|C0040223|C0441800|G0000000|C0040539|C0011065
Families are encouraged to work out for themselves how best to promote weight restoration in their child with AN.,Families encouraged promote weight restoration child AN.,C0015576|G0000000|C0033414|C0005910|C0449982|C0008059|G0000000
"The secondary endpoints (fatigue, headache, nausea etc.)","The secondary endpoints (fatigue, headache, nausea etc.)",G0000000|C0027627|C2349179|C0015672|C0018681|C0027497|C1548556
"Secondary end points failed to show a difference in the incidence of non-bacterial infections (P = 1.00), incidence of severe bacterial infection during the third month in the absence of prophylaxis (C = 3.1%, T = 2.7% and O = 4.82%; P = 0.799), initial response to therapy (P = 0.858) or overall survival (P = 0.863).","Secondary failed difference incidence non-bacterial infections (P = 1.00), incidence severe bacterial infection month absence prophylaxis (C = 3.1%, T = 2.7% O = 4.82%; P = 0.799), initial response therapy (P = 0.858) survival (P = 0.863).",C0027627|C0231175|C1705241|C0021149|C1518422|C3714514|C0369773|G0000000|C0450371|C0021149|C0205082|C0521009|C0009450|C0332177|C0332197|C0033107|G0000000|G0000000|G0000000|C2603360|G0000000|G0000000|C0483204|G0000000|C0450371|C0369773|G0000000|C1442061|C0205265|C0871261|C0039798|C0369773|G0000000|C1442061|C0038952|C0369773|G0000000|C1442061
"In both studies, dysfunction rate, need of thrombolytics, and removal because of catheter thrombosis were not significantly different compared with heparin.","In studies, dysfunction rate, thrombolytics, removal catheter thrombosis compared heparin.",G0000000|C0947630|C0031847|C0871208|C0016018|C0015252|C0085590|C0040053|C1707455|C0019134
"Secondary outcome measures were clinical scores including Fugl-Meyer Assessment (FMA), Modified Ashworth Scale (MAS), Berg Balance Scale (BBS), Timed 10-Meter Walk Test (10MWT), Six-minute Walk Test (SMWT), supplemented by gait analysis.","Secondary outcome measures clinical scores including Fugl-Meyer Assessment (FMA), Modified Ashworth Scale (MAS), Berg Balance Scale (BBS), Timed 10-Meter Walk Test (10MWT), Six-minute Walk Test (SMWT), supplemented gait analysis.",C0027627|C1274040|C0079809|C0205210|C0449820|C0332257|G0000000|C1261322|C2332774|C0392747|G0000000|C0175659|C1096155|G0000000|C0014653|C0175659|G0000000|C0392761|C0450371|C0080331|C0022885|G0000000|C0205452|C0080331|C0022885|G0000000|C0242295|C0016928|C0002778
"The presence of urinary symptoms at 3 days, 1–2 weeks, and at ≥1 month was similar between study groups, with overall no marked differences.","The presence urinary symptoms 3 days, 1–2 weeks, ≥1 month study groups, marked differences.",G0000000|C0150312|C0042027|C0683368|G0000000|C0439228|G0000000|C0439230|G0000000|C0332177|C0557651|C0441833|C0522501|C1705241
"Additional outcome measures to evaluate the clinical changes were: exercise tolerance (6-minute walk test [6MWT]), fatigue (Multidimensional Fatigue Inventory 20), health status (Clinical COPD Questionnaire), dyspnea (Medical Research Council scale, as defined in the Dutch physiotherapy guidelines3) and quality of life (EuroQol-5D).","Additional outcome measures evaluate clinical were: exercise tolerance (6-minute walk test [6MWT]), fatigue (Multidimensional Fatigue Inventory 20), health status (Clinical COPD Questionnaire), dyspnea (Medical Research Council scale, defined Dutch physiotherapy guidelines3) quality life (EuroQol-5D).",C1524062|C1274040|C0079809|C0220825|C0205210|G0000000|C0015259|C0013220|C0439232|C0080331|C0022885|G0000000|C0015672|C2347299|C0015672|C0021941|C0450371|C0018684|C0449438|C0205210|C0024117|C0034394|C0013404|C0199168|C0035168|C1551807|C0175659|C1704788|C0013331|C0949766|G0000000|C0332306|C0376558|C0451150
"The nausea, vomiting, and retch intensity were investigated 24 hours before and during the four days of treatment by means of PUQE-24 (24-hour Pregnancy Unique Quantification of Emesis).","The nausea, vomiting, retch intensity investigated 24 hours days treatment PUQE-24 (24-hour Pregnancy Unique Quantification Emesis).",G0000000|C0027497|C0042963|C0232602|C0522510|C1292732|C0450371|C0439227|C0439228|C0039798|C0450371|C0450371|C0032961|C1710548|C1709793|C0042963
"The objective for scoring assessment was to represent severity of changes, and not to designate any tooth as 'success' or 'failure' based on any isolated signs or symptoms.","The objective scoring assessment represent severity changes, designate tooth 'success' 'failure' based isolated signs symptoms.",G0000000|C0018017|C0449820|C1261322|C1882932|C0439793|C0392747|G0000000|C0040426|C0597535|C0231174|C1527178|C0205409|C0220912|C0683368
Evaluation of clinical response was based on signs and symptoms of pneumonia.,Evaluation clinical response based signs symptoms pneumonia.,C0220825|C0205210|C0871261|C1527178|C0220912|C0683368|C0032285
"FMA-LLparetic: paretic lower limb score of the Fugl-Meyer assessment; BBS: Berg balance test; 6MWT: 6-minute walk test; K-MBI: Korean version of the Modified Barthel Index * p<0.05, ** p<0.01 Values are mean ± standard deviation.","FMA-LLparetic: paretic lower limb score Fugl-Meyer assessment; BBS: Berg balance test; 6MWT: 6-minute walk test; K-MBI: Korean version Modified Barthel Index * p<0.05, ** p<0.01 Values ± standard deviation.",C2332774|G0000000|C0441994|C0015385|C0449820|G0000000|C1261322|G0000000|G0000000|C0014653|C0022885|G0000000|C0439232|C0080331|C0022885|C0597277|C1556095|C0333052|C0392747|G0000000|C0918012|G0000000|C0369773|G0000000|C0369773|C0042295|G0000000|C1442989|C0012727
"The primary outcome was a composite of 4 prespecified communication measures matched to the goals of communication training, described in detail in Table 1—engaging patients in consultations (Active Patient Participation Coding [APPC]39), responding to patients’ emotions (Verona VR-CoDES41,42), informing patients about prognosis and treatment choices (Prognostic and Treatment Choices [PTCC] Informing subscale44) and balanced framing of decisions (PTCC Balanced Framing subscale44).","The primary outcome composite 4 prespecified communication measures matched goals communication training, detail Table 1—engaging patients consultations (Active Patient Participation Coding [APPC]39), responding patients’ emotions (Verona VR-CoDES41,42), informing patients prognosis treatment choices (Prognostic Treatment Choices [PTCC] Informing subscale44) balanced framing decisions (PTCC Balanced Framing subscale44).",G0000000|C0205225|C1274040|C0205199|G0000000|G0000000|C0009452|C0079809|C0150103|C0018017|C0009452|C0040607|C1522508|C0039224|G0000000|C0030705|C0009818|C0205177|C0030705|C0679823|C0009219|C0052145|G0000000|G0000000|C0013987|G0000000|C3476815|C0700287|C0030705|C0033325|C0039798|C0008300|C0220901|C0039798|C0008300|G0000000|C0700287|G0000000|C0205415|C0080089|C0679006|G0000000|C0205415|C0080089|G0000000
"The main measures of whether smoking behavior led to ETS exposure of the child (smoked in front of child, smoked with child at home, and smoked around the child at weekdays and weekend) were determined by self-reporting by caregivers.","The main measures smoking behavior led ETS exposure child (smoked front child, smoked child home, smoked child weekdays weekend) determined self-reporting caregivers.",G0000000|C0205225|C0079809|C0037369|C0004927|C1708698|G0000000|C0274281|C0008059|C0037366|C0205094|C0008059|C0037366|C0008059|C0442519|C0037366|C0008059|C0680189|C0680190|G0000000|C0036588|C0085537
"Overall, we found significant (p < .05) reductions in assaults as reported by police, aggregate emergency medical services (EMS) outcomes, EMS assaults, and EMS motor vehicle accidents.","Overall, (p < .05) reductions assaults reported police, aggregate emergency medical services (EMS) outcomes, EMS assaults, EMS motor vehicle accidents.",C0282416|C0369773|G0000000|C0450371|C0301630|C0004063|C0684224|C0085098|C0205418|C0013956|C0199168|C0557854|G0000000|C1274040|G0000000|C0004063|G0000000|C1513492|C0042444|C0000924
Further covariates may be considered if they affect survival.,Further covariates considered affect survival.,C1517331|G0000000|C0750591|C0001721|C0038952
"Appropriately modified versions of this battery were completed one month after the study-intake assessment, at the end of pregnancy (≥ 28 weeks gestation), and at 2, 4, 8, 12, and 24 weeks postpartum.","Appropriately modified versions battery completed month study-intake assessment, pregnancy (≥ 28 weeks gestation), 2, 4, 8, 12, 24 weeks postpartum.",G0000000|C0392747|C0333052|C0337088|C0205197|C0332177|C0557651|C1261322|C0032961|G0000000|C0450371|C0439230|C0032961|G0000000|G0000000|G0000000|C0450371|C0450371|C0439230|C0086839
"Several studies have associated rs2046210 with breast cancer risk [15,34-36].","Several studies rs2046210 breast cancer risk [15,34-36].",C0439064|C0947630|G0000000|C0006141|C0006826|C0035647|C0450371
"Considering surface EMG parameters, no significant effect of Time or Group was found on median frequency slope of all measured muscles.","Considering surface EMG parameters, Time Group median frequency slope measured muscles.",C0750591|C0205148|G0000000|C0449381|C0040223|C0441833|C0549183|C0376249|C0807955|C0444706|C0026845
Hot flushes and night sweats are assessed by the Hot Flush Rating Scale.,Hot flushes night sweats assessed Hot Flush Rating Scale.,C0444519|C0005874|C0240526|C0038984|C1516048|C0444519|C0016382|C0871208|C0175659
Each morning and evening a participant received a medication score of 0.5 if the dose of the immunosuppressive medication was taken within a three-h window of the prescribed 12-h time frame; 0.25 if the dose of the immunosuppressive medication was not within the three-h window but was taken within a 12-h window; and 0 if the dose of the immunosuppressive medication was not taken within a 12-h window.,Each morning evening participant received medication score 0.5 dose immunosuppressive medication three-h window prescribed 12-h time frame; 0.25 dose immunosuppressive medication three-h window 12-h window; 0 dose immunosuppressive medication 12-h window.,G0000000|C0332170|C0587117|C0679646|C1514756|C0013227|C0449820|G0000000|C0178602|C0021081|C0013227|C0205449|C0557702|C0278329|C0450371|C0040223|C0080089|C0450371|C0178602|C0021081|C0013227|C0205449|C0557702|C0450371|C0557702|G0000000|C0178602|C0021081|C0013227|C0450371|C0557702
Significantly fewer children in the intervention group had visits to their general practitioner for problematic asthma (31 of 78 v 72 of 77 for whom data were available).,Significantly fewer children intervention visits practitioner problematic asthma (31 78 72 77 data available).,G0000000|C0205388|C0008059|C0886296|C0545082|C1709627|G0000000|C0004096|C0450371|C0450371|C0450371|C0450371|C1511726|C0470187
"The primary study end point was RFS as defined by STEEP (Standardized Definitions of Efficacy Endpoints) criteria, measured from study entry until local recurrence, distant relapse, or death without relapse, whichever occurred first.12 All new primary sites, regardless of location, were considered adverse events and not events in RFS.","The primary study RFS defined STEEP (Standardized Definitions Efficacy Endpoints) criteria, measured study entry local recurrence, distant relapse, death relapse, whichever occurred first.12 All primary sites, location, considered adverse events events RFS.",G0000000|C0205225|C0557651|C0341703|C1704788|G0000000|G0000000|C1550452|C1280519|C2349179|C0243161|C0444706|C0557651|C1705654|C0205276|C0034897|C0443203|C0035020|C0011065|C0035020|G0000000|C1709305|C0205435|G0000000|C0205225|C0205145|C0450429|C0750591|G0000000|C0441471|C0441471|C0341703
"Point-prevalence abstinence at the end of pregnancy, 12, and 24 weeks postpartum.","Point-prevalence abstinence pregnancy, 12, 24 weeks postpartum.",C1552961|C3843422|C0032961|C0450371|C0450371|C0439230|C0086839
"ProSAAF effects on parental monitoring and racial socialization will mediate the intervention effects on conduct problems, positive self-concept, and initiation of substance use.","ProSAAF effects parental monitoring racial socialization mediate intervention effects conduct problems, positive self-concept, initiation substance use.",G0000000|C1280500|C0030551|C0150369|C0034510|C0037447|C0086597|C0886296|C1280500|C0004927|C1546466|C0439178|C0036594|C0589507|C0439861|C0042153
"Knowledge of EC, use of EC, and self-reported pregnancy.","Knowledge EC, EC, self-reported pregnancy.",C0376554|C3890233|C3890233|C0681906|C0032961
"Effect of Hypnosis Intervention on Hot Flashes, Sleep, and Mood Abbreviations: HFRDIS, Hot Flash Related Daily Interference Scale; MOS-Sleep, Medical Outcomes Study Sleep Scale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety Subscale; CES-D, Center for Epidemiologic Studies Depression Scale.","Effect Hypnosis Intervention Hot Flashes, Sleep, Mood Abbreviations: HFRDIS, Hot Flash Related Daily Interference Scale; MOS-Sleep, Medical Outcomes Study Sleep Scale; HADS-A, Hospital Anxiety Depression Scale-Anxiety Subscale; CES-D, Center Epidemiologic Studies Depression Scale.",C1280500|C0020587|C0886296|C0444519|C0085635|C0037313|C0026516|C0000723|C3641714|C0444519|C0181637|C0439849|C0332173|C0521102|C0175659|C3813178|C0199168|C1274040|C0557651|C0037313|C0175659|C0048008|C0019994|C0003467|C0011570|C0175659|G0000000|C2699160|C0205099|C0014507|C0947630|C0011570|C0175659
17-item Hamilton Depression Rating Scale (HDRS17) and Sheehan Disability Scale (SDS) scores across study time points Two subjects in electroacupuncture group reported headache as an adverse event and one complained of dizziness.,17-item Hamilton Depression Rating Scale (HDRS17) Sheehan Disability Scale (SDS) scores study time Two subjects electroacupuncture reported headache adverse event complained dizziness.,C0450371|G0000000|C0011570|C0871208|C0175659|G0000000|G0000000|C0231170|C0175659|C3813719|C0449820|C0557651|C0040223|C0205448|C0681850|C0013794|C0684224|C0018681|G0000000|C0441471|G0000000|C0012833
"Our primary outcome, change in BMI z-score from baseline to 2 years post-treatment (27 months), was analyzed as a difference score calculated from baseline for each of the seven follow-up assessment points (post-treatment, 3, 6, 12, 18, and 24 months post-treatment).","Our primary outcome, change BMI z-score baseline 2 post-treatment (27 months), analyzed difference score calculated baseline follow-up assessment (post-treatment, 3, 6, 12, 18, 24 months post-treatment).",G0000000|C0205225|C1274040|C0392747|G0000000|C0871421|C0168634|G0000000|C2709088|C0450371|C0439231|C0936012|C1705241|C0449820|C0444686|C0168634|C0589120|C1261322|C2709088|G0000000|G0000000|C0450371|C0450371|C0450371|C0439231|C2709088
This study aimed to determine the effect of the two methods of educational programs on health- related QOL (HRQOL) in Iranian HD patients.,This study aimed determine methods educational programs health- QOL (HRQOL) Iranian HD patients.,G0000000|C0557651|C1947946|G0000000|C0025663|C0587721|C0376691|C0018684|C0518214|G0000000|C1553355|G0000000|C0030705
"The recruitment strategy was successful in targeting a large number of well-characterized, community-ambulating older adults who were clearly at-risk for falling having experienced one or more falls in the previous year and averaging more than five comorbidities.","The recruitment strategy successful targeting well-characterized, community-ambulating adults at-risk falling experienced falls previous averaging comorbidities.",G0000000|C2949735|C0679199|C0597535|C1521840|C0205170|C0009462|C0001675|C1444641|C0000921|C0237607|C0000921|C0205156|C1510992|C0009488
"Five and two patients of the control and clarithromycin groups developed flap necrosis, respectively.","Five patients control clarithromycin developed flap necrosis, respectively.",C0205451|C0030705|C0243148|C0055856|G0000000|C0038925|C0027540|G0000000
"FEV1, forced expiratory volume in 1 s; FEV1/FVC, forced expiratory volume in 1 second/forced vital capacity; BMQ, Brief Medication Questionnaire; AQLQ, Asthma‐related Quality of Life Questionnaire; CQ, Consumer Asthma Knowledge Questionnaire; PCAQ, Perceived Control of Asthma Questionnaire; reliever, short‐acting β2 agonists or anticholinergic bronchodilators; preventer, inhaled corticosteroids, theophylline derivatives, cromolyns, leucotriene receptor antagonists or oral corticosteroids; LABA, long‐acting β2 agonists.","FEV1, forced expiratory volume 1 s; FEV1/FVC, forced expiratory volume 1 second/forced vital capacity; BMQ, Brief Medication Questionnaire; AQLQ, Asthma‐related Quality Life Questionnaire; CQ, Consumer Asthma Knowledge Questionnaire; PCAQ, Perceived Control Asthma Questionnaire; reliever, short‐acting β2 agonists anticholinergic bronchodilators; preventer, inhaled corticosteroids, theophylline derivatives, cromolyns, leucotriene receptor antagonists oral corticosteroids; LABA, long‐acting β2 agonists.",G0000000|C0441722|C0231800|C0449468|G0000000|C3714541|C0441722|C0231800|C0449468|G0000000|C0205436|C0442732|C1516240|G0000000|C1282927|C0013227|C0034394|C4055434|G0000000|C0332306|C0376558|C0034394|C0282245|C1707496|C0004096|C0376554|C0034394|G0000000|C0030971|C0243148|C0004096|C0034394|G0000000|G0000000|G0000000|C0243192|C0242896|C0006280|G0000000|C0004048|C0001617|C0039771|C0243072|G0000000|C0023545|C0597357|C0243076|C0442027|C0001617|G0000000|G0000000|G0000000|C0243192
Effects of the interventions on hookworm infection risk were analyzed using generalized linear mixed models.,Effects interventions hookworm infection risk analyzed generalized linear mixed models.,C1280500|C0886296|C0002830|C0009450|C0035647|C0936012|C0205246|C0205132|C0205430|C3161035
"The primary outcome was self-reported 7-day point-prevalence abstinence at 52 weeks, with a secondary outcome at 26 weeks.1 During all post-TQD visits with case managers and during follow-up calls (including those at 26 and 52 weeks) with assessors not involved in treatment (but not blind to treatment assignment), participants reported cigarettes per day on each of the last 7 days and whether they smoked on each day since last contact in a timeline follow-back interview [56].","The primary outcome self-reported 7-day point-prevalence abstinence 52 weeks, secondary outcome 26 weeks.1 During post-TQD visits managers follow-up calls (including 26 52 weeks) assessors involved treatment (but blind treatment assignment), participants reported cigarettes day 7 days smoked day contact timeline follow-back interview [56].",G0000000|C0205225|C1274040|C0681906|C0332173|C1552961|C3843422|C0450371|C0439230|C0027627|C1274040|C0450371|C0439230|G0000000|C0687676|C0545082|C0335141|C0589120|C0679006|C0332257|C0450371|C0450371|C0439230|C1707957|C1314939|C0039798|G0000000|C0150108|C0039798|C1516050|C0679646|C0684224|C0677453|C0332173|G0000000|C0439228|C0037366|C0332173|C0332158|C0145943|C0332283|C0021822|C0450371
The above outcomes were measured by the GOPHER database.,The outcomes measured GOPHER database.,G0000000|C1274040|C0444706|C0524713|C0242356
"Behavior problems were assessed with a modified version of the Revised Memory and Behavior Problem Checklist (RMBPC; Teri et al., 1992), which consists of 24 items that inquire about the problem behaviors of the CR.","Behavior assessed modified version Revised Memory Behavior Problem Checklist (RMBPC; Teri al., 1992), consists 24 items inquire behaviors CR.",C0004927|C1516048|C0392747|C0333052|C1527075|C0025260|C0004927|C0033213|C1707357|G0000000|G0000000|C0202311|G0000000|C0332529|C0450371|C1551338|G0000000|C0004927|C0201975
This study was conducted in 26 centers in the US.,This study conducted 26 centers US.,G0000000|C0557651|C0004927|C0450371|C0205099|G0000000
Twenty control patients and 14 who had received glutamine died during their hospital stay (NS).,Twenty control patients 14 received glutamine died hospital stay (NS).,C0724000|C0243148|C0030705|C0450371|C1514756|C0017797|C0011065|C0019994|G0000000|C0038944
"An MSD case was defined as a child with a diarrheal illness <7 d duration comprising ≥3 loose stools in 24 h and ≥1 of the following: sunken eyes, skin tenting, dysentery, intravenous (IV) rehydration, or hospitalization.","An MSD defined child diarrheal illness <7 duration comprising ≥3 loose stools 24 ≥1 following: sunken eyes, skin tenting, dysentery, intravenous (IV) rehydration, hospitalization.",G0000000|C0268263|C1704788|C0008059|C0011991|C0221423|G0000000|C0449238|C2700400|G0000000|C0205407|C0015733|C0450371|G0000000|C0231290|G0000000|C0015392|C0444099|C0237322|C0013369|C0348016|C0022326|C0034997|C0019993
Adverse events and toxicities will be monitored for six months following the last treatment procedure.,Adverse events toxicities monitored months treatment procedure.,G0000000|C0441471|C0600688|C0030695|C0439231|C0039798|C0184661
"In the absence of IVS, PBMCs from all 8 patients showed no CEA-specific CD8 immune responses.","In absence IVS, PBMCs 8 patients CEA-specific CD8 immune responses.",G0000000|C0332197|G0000000|C1321301|G0000000|C0030705|C3463961|C0285590|C0439662|C0871261
"Secondary efficacy parameters included time to next paracentesis, ascites signs and symptoms and overall survival (OS).","Secondary efficacy parameters included time paracentesis, ascites signs symptoms survival (OS).",C0027627|C1280519|C0449381|C0332257|C0040223|C0034115|C0003962|C0220912|C0683368|C0038952|C0229090
"These areas included the following, with their respective scores: (a) interference with play (minimal, 0; moderate, 5; severe, 10); (b) help needed with feeding (none, 0; some, 5; lots, 10); (c) help needed with washing and dressing (none, 0; some, 5; lots, 10); (d) sleep disturbance (none, 0; some nights, 5; most nights, 10); (e) missed days of school (none, 0; 1–5 days, 5; >5 days, 10).","These included following, respective scores: (a) interference play (minimal, 0; moderate, 5; severe, 10); (b) feeding (none, 0; some, 5; lots, 10); (c) washing dressing (none, 0; some, 5; lots, 10); (d) sleep disturbance (none, 0; nights, 5; nights, 10); (e) missed days school (none, 0; 1–5 days, 5; >5 days, 10).",G0000000|C0332257|C0231290|G0000000|C0449820|G0000000|C0521102|C0032214|C0547040|G0000000|C0205081|G0000000|C0205082|C0450371|G0000000|C0204695|G0000000|G0000000|G0000000|G0000000|C1115660|C0450371|G0000000|C0441648|C0013119|G0000000|G0000000|G0000000|G0000000|C1115660|C0450371|C0073187|C0037313|C2699787|G0000000|G0000000|C0240526|G0000000|C0240526|C0450371|G0000000|C1705492|C0439228|C0036375|G0000000|G0000000|G0000000|C0439228|G0000000|G0000000|C0439228|C0450371
"All medications given to the patients, any complications, reversal of organ system failure the duration of hospitalization, the mortality rate, and causes of death were recorded and compared between the groups.","All medications patients, complications, reversal organ system failure duration hospitalization, mortality rate, death recorded compared groups.",G0000000|C0013227|C0030705|C0009566|C0443290|C0178784|C0449913|C0231174|C0449238|C0019993|C0026565|C0871208|C0011065|C0034869|C1707455|C0441833
Main outcome measure was complete healing at 6 weeks.,Main outcome measure complete healing 6 weeks.,C0205225|C1274040|C0079809|C0205197|C0043240|G0000000|C0439230
"For each survey, 80 households were randomly selected in the core area of each cluster.","For survey, 80 households randomly selected core cluster.",G0000000|C0038951|C0450371|C0020052|G0000000|C1707391|C0444669|C1555715
"RESULTS—Adverse events and oxygenation index were not increased by, and thrombocytopenia was not attributable to, treatment with rhG-CSF.","RESULTS—Adverse events oxygenation increased by, thrombocytopenia attributable to, treatment rhG-CSF.",G0000000|C0441471|C0231940|C0205217|G0000000|C0040034|C0596130|G0000000|C0039798|C0376562
"The results suggest that neither Comet nor ParentSteps had beneficial effects on adolescent’s antisocial or delinquent behavior, or on alcohol use.","The Comet ParentSteps beneficial effects adolescent’s antisocial delinquent behavior, alcohol use.",G0000000|C0751980|G0000000|G0000000|C1280500|G0000000|C0233523|C0522175|C0004927|C0001962|C0042153
Outcomes at 12 and 24 weeks for people with stroke randomised to task oriented circuit training intervention or usual care.,Outcomes 12 24 weeks people stroke randomised task oriented circuit training intervention usual care.,C1274040|C0450371|C0450371|C0439230|C0027361|C0038454|G0000000|C3540678|C1704322|G0000000|C0040607|C0886296|C3538928|C1947933
"The a priori primary outcome measure was the change from baseline to the end of study (week 8/early termination [ET]) on the YMRS score, based on last-observation-carried-forward (LOCF) values.","The priori primary outcome measure change baseline study (week 8/early termination [ET]) YMRS score, based last-observation-carried-forward (LOCF) values.",G0000000|G0000000|C0205225|C1274040|C0079809|C0392747|C0168634|C0557651|C0332174|C1279919|C1549081|G0000000|C3640523|C0449820|C1527178|C1517741|C2825507|C0042295
"These data were collected in each HS center during 5 weekdays immediately before implementation of the 2-year intervention and immediately afterwards, in fall 2008 and spring 2010.","These data collected HS center 5 weekdays implementation 2-year intervention afterwards, fall 2008 spring 2010.",G0000000|C1511726|C1516695|G0000000|C0205099|G0000000|C0680189|C1708476|C0439234|C0886296|G0000000|C0085639|G0000000|C0241232|G0000000
"Participants assigned to the two individual-incentive groups were also eligible to receive $200 if they had biochemically confirmed abstinence at each of three times: 14 days, 30 days, and 6 months after their target quit dates.","Participants assigned individual-incentive eligible receive $200 biochemically confirmed abstinence times: 14 days, 30 days, 6 months target quit dates.",C0679646|C1516050|C0027361|C1548635|C1514756|C1442061|G0000000|C0521093|C3843422|C0040223|C0450371|C0439228|C0450371|C0439228|G0000000|C0439231|C1521840|C0748223|C0011008
"Secondary outcomes—We investigated anxiety,23 knowledge, subscales of the decisional conflict scale,22 and satisfaction with the decision.24 The primary follow-up for questionnaire based outcomes was at 37 weeks' gestation.","Secondary outcomes—We investigated anxiety,23 knowledge, subscales decisional conflict scale,22 satisfaction decision.24 The primary follow-up questionnaire based outcomes 37 weeks' gestation.",C0027627|G0000000|C1292732|C0003467|C0376554|G0000000|C0679006|C0009671|C0175659|C0242428|C0679006|G0000000|C0205225|C0589120|C0034394|C1527178|C1274040|C0450371|C0439230|C0032961
"(ii) Health Related Quality of Life as measured by the Hospital Anxiety and Depression Scale scores [41], Stroke Specific Quality of Life Index [42] and Functional Health Status Charts COOP/WONCA [43].","(ii) Health Related Quality Life measured Hospital Anxiety Depression Scale scores [41], Stroke Specific Quality Life Index [42] Functional Health Status Charts COOP/WONCA [43].",G0000000|C0018684|C0439849|C0332306|C0376558|C0444706|C0019994|C0003467|C0011570|C0175659|C0449820|C0450371|C0038454|C0205369|C0332306|C0376558|C0918012|C0450371|C0205245|C0018684|C0449438|C0684240|C3871147|C0450371
"Quit attempts during the intervention phase (number, duration and dates).","Quit attempts intervention phase (number, duration dates).",C0748223|C1516084|C0886296|C0205390|C0237753|C0449238|C0011008
"3) The evolution of other psychological dimensions related to the stress by using the ways of coping checklist [12], the anxiety/depression by using the hospital anxiety and depression scale [13] and by using the post-traumatic growth inventory [14].","3) The evolution psychological dimensions stress coping checklist [12], anxiety/depression hospital anxiety depression scale [13] post-traumatic growth inventory [14].",G0000000|G0000000|C0015219|C0205486|C0439534|C0038435|C0009967|C1707357|C0450371|C0338908|C0019994|C0003467|C0011570|C0175659|C0450371|C0687676|C0018270|C0021941|C0450371
"The primary outcome was sustained abstinence from smoking for 6 months after the target quit date.27 Achievement of sustained abstinence required that submitted saliva samples had a cotinine concentration of less than 10 ng per milliliter28 at 14 days, 30 days, and 6 months.","The primary outcome sustained abstinence smoking 6 months target quit date.27 Achievement sustained abstinence required submitted saliva samples cotinine concentration 10 ng milliliter28 14 days, 30 days, 6 months.",G0000000|C0205225|C1274040|C0443318|C3843422|C0037369|G0000000|C0439231|C1521840|C0748223|C0011008|C0001072|C0443318|C3843422|C1514873|C1515023|C0036087|C0370003|C0010194|C0004268|C0450371|C0028074|G0000000|C0450371|C0439228|C0450371|C0439228|G0000000|C0439231
"From 4 to 6 months, mothers were visited twice per month, or 6 visits; from 7 to 9 months, they were visited 4 times a month, or 12 visits; and from 10 to 14 months, they were visited twice a month, or 12 visits, for a total of 30 planned visits.","From 4 6 months, mothers visited month, 6 visits; 7 9 months, visited 4 times month, 12 visits; 10 14 months, visited month, 12 visits, total 30 planned visits.",G0000000|G0000000|G0000000|C0439231|C0026591|C0545082|C0332177|G0000000|C0545082|G0000000|G0000000|C0439231|C0545082|G0000000|C0040223|C0332177|C0450371|C0545082|C0450371|C0450371|C0439231|C0545082|C0332177|C0450371|C0545082|C0439175|C0450371|C1301732|C0545082
"In the first month of treatment, children in Group I presented 12.2 dry nights, 13.4 in the second month, and 15.9 in the last month.","In month treatment, children Group I 12.2 dry nights, 13.4 month, 15.9 month.",G0000000|C0332177|C0039798|C0008059|C0441833|C0021966|C0450371|C0011682|C0240526|C0450371|C0332177|C0450371|C0332177
"Secondary endpoints included the cumulative risk of P. vivax recurrence by 8 weeks, adverse events within 42 days, and the relationship of day 6 drug concentrations with the risk of recurrence.","Secondary endpoints included cumulative risk P. vivax recurrence 8 weeks, adverse events 42 days, relationship day 6 drug concentrations risk recurrence.",C0027627|C2349179|C0332257|C1511559|C0035647|C0369773|G0000000|C0034897|G0000000|C0439230|G0000000|C0441471|C0450371|C0439228|C0439849|C0332173|G0000000|C0013227|C0086045|C0035647|C0034897
The reduced number of pulmonary exacerbations requiring courses of antibiotics documented in the present study with young CF patients may relate to the anti‐inflammatory properties of azithromycin.,The reduced pulmonary exacerbations requiring courses antibiotics documented study CF patients relate anti‐inflammatory properties azithromycin.,G0000000|C0392756|C0024109|G0000000|G0000000|C0750729|C0003232|C1301725|C0557651|C0009738|C0030705|C0163712|G0000000|C0871161|C0052796
It's obviously…I think my BP had been sneaking up a wee bit”.,It's obviously…I BP sneaking wee bit”.,G0000000|G0000000|C0037623|G0000000|C0153064|G0000000
Surgical excision for non-palpable breast lesions requires a balance between excising a high rate of free tumor margins and a low rate of healthy tissue resection.,Surgical excision non-palpable breast lesions requires balance excising rate free tumor margins low rate healthy tissue resection.,C0543467|C0015252|C1518422|C0006141|C0221198|G0000000|C0014653|G0000000|C0871208|C0332296|C0027651|C0205284|C0205251|C0871208|C3898900|C0040300|C0015252
Celecoxib can be used in prevention and treatment of gastric cancer.,Celecoxib prevention treatment gastric cancer.,C0538927|C0199176|C0039798|C0038351|C0006826
"This effect was not seen from years 1 to 2 or from years 2 to 3,1 suggesting that IFNβ-1b may have more pronounced effects on whole brain inflammation soon after treatment initiation than GA. As with the change in T1-hypointense lesion volume from screening to LAS, whole brain volume is a coarse measurement.","This 1 2 2 3,1 suggesting IFNβ-1b pronounced effects brain inflammation treatment initiation GA. As change T1-hypointense lesion volume screening LAS, brain volume coarse measurement.",G0000000|G0000000|G0000000|G0000000|G0000000|C1705535|G0000000|G0000000|C1280500|C0006104|C0021368|C0039798|C0589507|C0016993|G0000000|C0392747|C0041403|C0221198|C0449468|C0220908|C1424272|C0006104|C0449468|C0205194|C0242485
"The latter finding is in line with the inconclusive findings of previous studies regarding the relation between gait speed and community ambulation.21 22 23 Despite the small effects of the circuit training on gait speed and distance, the covariate of time (baseline to 24 weeks) was significant for almost all primary and secondary outcomes, except the stroke impact scale’s domains of mood and emotions, the fatigue severity scale, the hospital anxiety and depression scale, time to accomplish the letter cancellation task, omissions on the letter cancellation task, and the timed balance test.","The finding inconclusive findings previous studies relation gait speed community ambulation.21 22 23 Despite effects circuit training gait speed distance, covariate time (baseline 24 weeks) primary secondary outcomes, stroke impact scale’s domains mood emotions, fatigue severity scale, hospital anxiety depression scale, time accomplish letter cancellation task, omissions letter cancellation task, timed balance test.",G0000000|C0037088|C0205258|C2607943|C0205156|C0947630|C0080103|C0016928|C0678536|C0009462|C0080331|C0450371|C0450371|G0000000|C1280500|G0000000|C0040607|C0016928|C0678536|C0012751|G0000000|C0040223|C0168634|C0450371|C0439230|C0205225|C0027627|C1274040|C0038454|C1825598|G0000000|C1880389|C0026516|C0013987|C0015672|C0439793|C0175659|C0019994|C0003467|C0011570|C0175659|C0040223|G0000000|C1096774|C0205544|C3540678|C3845736|C1096774|C0205544|C3540678|C0392761|C0014653|C0022885
Main outcome measures Proportion of residents in each home who were prescribed neuroleptics and mean levels of agitated and disruptive behaviour (Cohen-Mansfield agitation inventory) in each home at 12 months.,Main outcome measures Proportion residents prescribed neuroleptics levels agitated disruptive behaviour (Cohen-Mansfield agitation inventory) 12 months.,C0205225|C1274040|C0079809|C1709707|C1320928|C0278329|C0040615|C0441889|C0085631|C0332453|C0004927|G0000000|C0085631|C0021941|C0450371|C0439231
"VAS, visual analog scale; ODI, Oswestry low-back pain disability index; RMDQ, Roland-morris disability questionnaire; FBQ, Fear avoidance beliefs questionnaire.","VAS, visual analog scale; ODI, Oswestry low-back pain disability index; RMDQ, Roland-morris disability questionnaire; FBQ, Fear avoidance beliefs questionnaire.",C0042815|C0234621|C0243071|C0175659|G0000000|G0000000|C0205251|C0030193|C0231170|C0918012|G0000000|G0000000|C0231170|C0034394|G0000000|C0015726|C0870186|C0004951|C0034394
The primary outcome was the proportion of participants in each group who had an improvement in functional walking ability 1 year after the stroke.,The primary outcome proportion participants improvement functional walking ability 1 stroke.,G0000000|C0205225|C1274040|C1709707|C0679646|C2986411|C0205245|C0080331|C0085732|G0000000|C0038454
"The use of PN 3.0 significantly reduced mosquito densities per house, which was coupled with an observation of changes in the bloodmeal origin, sporozoite rate and parity rate in the An.","The PN 3.0 reduced mosquito densities house, coupled observation bloodmeal origin, sporozoite rate parity rate An.",G0000000|C0219433|G0000000|C0392756|C0026584|C0178587|C0442519|C1948027|C0302523|G0000000|C0079946|C0562648|C0871208|C0030563|C0871208|G0000000
"Abbreviations: AChEI; acetylcholinesterase inhibitor; ADAS-cog, Alzheimer Disease Assessment Scale–Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study/Activities of Daily Living; APOE, apolipoprotein E; CAS, Caregiver Activity Survey; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.","Abbreviations: AChEI; acetylcholinesterase inhibitor; ADAS-cog, Alzheimer Disease Assessment Scale–Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study/Activities Daily Living; APOE, apolipoprotein E; CAS, Caregiver Activity Survey; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.",C0000723|G0000000|C0001044|C1999216|C3539026|G0000000|C0012634|C1261322|G0000000|G0000000|C3641947|G0000000|C0012634|C0679729|C2348552|C0332173|C0376558|C0003595|C0003591|G0000000|G0000000|C0085537|C0205177|C0038951|C0451306|C0445542|C1301808|G0000000|C1412208|G0000000|C0021941
bmjopen-2016-011811supp.pdf Medication errors are the most frequent cause of preventable harm in hospitals.,bmjopen-2016-011811supp.pdf Medication errors frequent preventable harm hospitals.,C1431343|C0013227|C0743559|C0332183|C1547273|G0000000|C0019994
"The primary outcome was unilateral neglect assessed by a blinded assessor using the star cancellation test, the line bisection test, and a picture identification task at 1, 3, and 6 months.","The primary outcome unilateral neglect assessed blinded assessor star cancellation test, bisection test, picture identification task 1, 3, 6 months.",G0000000|C0205225|C1274040|C0205092|C0521874|C1516048|C0150108|C1707957|C0995242|C0205544|C0022885|C0184905|C0022885|C0441468|C0020792|C3540678|G0000000|G0000000|G0000000|C0439231
"High age in cancer patients is associated with increased morbidity owing to concomitant diseases and impaired physical, social and cognitive functions (Extermann and Hurria, 2007).","High age cancer patients increased morbidity concomitant diseases impaired physical, social cognitive functions (Extermann Hurria, 2007).",C0205250|C0001779|C0006826|C0030705|C0205217|C0026538|C0521115|C0012634|C0221099|C0031809|C0728831|C1516691|C0542341|G0000000|G0000000|G0000000
"Changes in diet quality and dietary patterns between recruitment, 28–30 weeks and 5 months postpartum [59] Functional health and well-being (SF-12) at 36 weeks and 5 months postpartum [63] Depression and anxiety scores at 36 weeks’ and 5 months postpartum [62, 63] Maternal adiposity at 5 months postpartum (assessed by weight, BMI, waist and arm circumference and fat mass measured by bioimpedance) GDM by NZSSD criteria [66] Pregnancy induced hypertension (preeclampsia and gestational hypertension) [71] Mode of birth Blood lipid concentrations at 28–30 and 36 weeks’ gestation and 5 months postpartum Maternal feedback about participation in the study (survey at post birth visit)  Infant secondary outcomes include: Neonatal anthropometry: head circumference and length, and associated Z-scores [72]; birthweight adjusted for length; girths (chest, arm and abdominal) adjusted for length; subscapular, triceps and suprailiac skin fold thickness adjusted for length; and arm muscle area adjusted for arm length Neonatal body composition (via PEA POD®) including fat mass and lean mass adjusted for length and fat mass adjusted for lean mass Gestational age at birth LGA, by customised [73] and population [72] references.","Changes diet quality dietary patterns recruitment, 28–30 weeks 5 months postpartum [59] Functional health well-being (SF-12) 36 weeks 5 months postpartum [63] Depression anxiety scores 36 weeks’ 5 months postpartum [62, 63] Maternal adiposity 5 months postpartum (assessed weight, BMI, waist arm circumference fat mass measured bioimpedance) GDM NZSSD criteria [66] Pregnancy induced hypertension (preeclampsia gestational hypertension) [71] Mode birth Blood lipid concentrations 28–30 36 weeks’ gestation 5 months postpartum Maternal feedback participation study (survey post birth visit) Infant secondary outcomes include: Neonatal anthropometry: head circumference length, Z-scores [72]; birthweight adjusted length; girths (chest, arm abdominal) adjusted length; subscapular, triceps suprailiac skin fold thickness adjusted length; arm muscle adjusted arm length Neonatal body composition (via PEA POD®) including fat mass lean mass adjusted length fat mass adjusted lean mass Gestational age birth LGA, customised [73] population [72] references.",C0392747|C0012155|C0332306|C0012155|C0449774|C2949735|G0000000|C0439230|G0000000|C0439231|C0086839|C0450371|C0205245|C0018684|C0018684|C0037712|C0450371|C0439230|G0000000|C0439231|C0086839|C0450371|C0011570|C0003467|C0449820|C0450371|G0000000|G0000000|C0439231|C0086839|C0450371|C0450371|C2347083|C0028754|G0000000|C0439231|C0086839|C1516048|C0005910|G0000000|C0230097|C0446516|C0332520|C0424612|C0577559|C0444706|G0000000|C0085207|G0000000|C0243161|C0450371|C0032961|C0205263|C0020538|C0032914|C0439671|C0020538|C0450371|C1513371|C0005615|C0005767|C0023779|C0086045|G0000000|C0450371|G0000000|C0032961|G0000000|C0439231|C0086839|C2347083|C0015744|C0679823|C0557651|C0038951|C0687676|C0005615|C0545082|C0021270|C0027627|C1274040|C0332257|C1552240|C0003188|C0018670|C0332520|C1444754|C0871421|C0450371|C0005612|C0456081|C1444754|G0000000|C0817096|C0446516|C0000726|C0456081|C1444754|G0000000|C0559502|G0000000|C0444099|C0332462|C1280412|C0456081|C1444754|C0446516|C0026845|C0456081|C0446516|C1444754|C1552240|C0242821|C0486616|G0000000|C0030738|G0000000|C0332257|C0424612|C0577559|G0000000|C0577559|C0456081|C1444754|C0424612|C0577559|C0456081|G0000000|C0577559|C0439671|C0001779|C0005615|C1428877|G0000000|C0450371|C0032659|C0450371|C1514811
"In order to clarify further the predictive value of clinical signs in hypoxaemia, a Kenyan study used a logistic regression model.","In clarify predictive clinical signs hypoxaemia, Kenyan study logistic regression model.",G0000000|C2986669|C0681890|C0205210|C0220912|C0700292|C0337839|C0557651|C0242415|C0684320|C3161035
"(8): use of headache frequency as the outcome measure—as opposed to headache index; use of a prospective base-line period and an end recording period of at least 4 weeks each (8 weeks each in the present study); a treatment period of at least 3 months (6 months' MBT treatment and 9 months' hand massage in the present study), and use of 50% or more reduction in headache frequency as the criterion for individual response.","(8): headache frequency outcome measure—as opposed headache index; prospective base-line period recording period 4 weeks (8 weeks study); treatment period 3 months (6 months' MBT treatment 9 months' hand massage study), 50% reduction headache frequency criterion individual response.",G0000000|C0018681|C0376249|C1274040|G0000000|G0000000|C0018681|C0918012|C0023981|C0168634|C0439531|G0000000|C0439531|G0000000|C0439230|G0000000|C0439230|C0557651|C0039798|C0439531|G0000000|C0439231|G0000000|C0439231|C1335267|C0039798|G0000000|C0439231|C0018563|C0024875|C0557651|C0450371|C0301630|C0018681|C0376249|C0243161|C0027361|C0871261
"Thus, these effects may explain the positive outcomes with respect to past 90-day alcohol use observed in the U.S.-born participants.","Thus, effects explain positive outcomes respect 90-day alcohol observed U.S.-born participants.",G0000000|C1280500|G0000000|C0439178|C1274040|C0679133|C0450371|C0001962|C1441672|C0041703|C0679646
"Although the proportion of all bleeding events in the enoxaparin group was significantly greater than in the low-dose heparin group, the rates of major bleeding and reoperation for bleeding were not significantly different.","Although proportion bleeding events enoxaparin low-dose heparin group, rates major bleeding reoperation bleeding different.",G0000000|C1709707|C0019080|C0441471|C0206460|C0445550|C0019134|C0441833|C0871208|C0205082|C0019080|C0035110|C0019080|C1705242
"Subsequently, we presumed that the main parameters of abdominal entry such as entry time, blood loss, and occurrence of vascular and bowel injuries would be improved by using DOE in reproductive-age obese women compared with those of OHT.","Subsequently, presumed main parameters abdominal entry entry time, blood loss, occurrence vascular bowel injuries improved DOE reproductive-age obese women compared OHT.",G0000000|G0000000|C0205225|C0449381|C0000726|C1705654|C1705654|C0040223|C0005767|C1517945|C0243132|C0005847|C0021853|C1510467|C0184511|C0231807|C0035150|C0028754|C0043210|C1707455|G0000000
"Furthermore, because we were examining respondents who became established smokers in young adulthood, those who were already established smokers at baseline were omitted from the study population.","Furthermore, examining respondents established smokers adulthood, established smokers baseline study population.",G0000000|C0332128|C0282122|C0443211|C0337664|C0700597|C0443211|C0337664|C0168634|C0557651|C0032659
"With no other treatment, rTMS increased naming accuracy.","With treatment, rTMS increased naming accuracy.",G0000000|C0039798|G0000000|C0205217|C0233735|C0443131
"The outcome variables mobility measured with the Rivermead Mobility Index [8] number of outdoor journeys taken, functional ability measured by the Nottingham Extended Activities of Daily Living Scale [19]; mood and carer psychological distress measured by the General Health Questionnaire 12 [9] will be analysed using the same method as for the primary outcome measure.","The outcome variables mobility measured Rivermead Mobility Index [8] outdoor journeys taken, functional ability measured Nottingham Extended Activities Daily Living Scale [19]; mood carer psychological distress measured General Health Questionnaire 12 [9] analysed method primary outcome measure.",G0000000|C1274040|C0439828|C0425245|C0444706|G0000000|C0425245|C0918012|G0000000|G0000000|G0000000|C1883727|C0205245|C0085732|C0444706|G0000000|C0231448|C0441655|C0332173|C0376558|C0175659|C0450371|C0026516|C0085537|C0205486|C0231303|C0444706|C0205246|C0018684|C0034394|C0450371|G0000000|G0000000|C0025663|C0205225|C1274040|C0079809
"The primary efficacy outcome was a composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis.","The primary efficacy outcome composite death, cardiac tamponade requiring pericardiocentesis, constrictive pericarditis.",G0000000|C0205225|C1280519|C1274040|C0205199|C0011065|C0018787|C0332459|G0000000|C0191234|C0009813|C0031046
Protective efficacy against clinical malaria will be determined by comparing incidence rates of clinical malaria between arms.,Protective efficacy clinical malaria determined comparing incidence rates clinical malaria arms.,G0000000|C1280519|C0205210|C0024530|G0000000|C1707455|C0021149|C0871208|C0205210|C0024530|C0206655
The trial primary end point (duration of functional independence) was measured from the day of random assignment to the first report of deterioration to a WHO PS of more than 2.,The trial primary (duration functional independence) measured day random assignment report deterioration WHO PS 2.,G0000000|C0008976|C0205225|C0449238|C0205245|C0085862|C0444706|C0332173|C0034656|C1516050|C0684224|C0868945|G0000000|C0242397|G0000000
"Consistent with the population-based findings, approximately 45% lived in households with one or more smoking parent.","Consistent population-based findings, 45% lived households smoking parent.",C0332290|C0032659|C2607943|C0450371|C1548795|C0020052|C0037369|C0030551
"[2, 24, 25].","[2, 24, 25].",G0000000|C0450371|C0450371
"We included 220 patients to give enough power to detect a clinically relevant difference of 5 points (about 11%) on the mobility domain of the stroke impact scale in favour of the experimental group.9 Secondary outcome measures—Secondary outcomes included other domains of the stroke impact scale (version 3.0), the Rivermead mobility index (RMI), the falls efficacy scale (FES), the Nottingham extended activities of daily living (NEADL), the hospital anxiety and depression scale (HADS), and the fatigue severity scale (FSS).","We included 220 patients power detect clinically relevant difference 5 (about 11%) mobility domain stroke impact scale favour experimental group.9 Secondary outcome measures—Secondary outcomes included domains stroke impact scale (version 3.0), Rivermead mobility (RMI), falls efficacy scale (FES), Nottingham extended activities daily living (NEADL), hospital anxiety depression scale (HADS), fatigue severity scale (FSS).",G0000000|C0332257|C1442061|C0030705|C0032863|C0442726|G0000000|C2347946|C1705241|G0000000|C0332232|C0450371|C0425245|C1880389|C0038454|C1825598|C0175659|C0309049|C1517586|C0441857|C0027627|C1274040|G0000000|C1274040|C0332257|C1880389|C0038454|C1825598|C0175659|C0333052|G0000000|G0000000|C0425245|C1654610|C0000921|C1280519|C0175659|G0000000|G0000000|C0231448|C0441655|C0332173|C0376558|G0000000|C0019994|C0003467|C0011570|C0175659|C0048008|C0015672|C0439793|C0175659|C0265224
"(70–126), FEV1 94% pred.","(70–126), FEV1 94% pred.",G0000000|G0000000|C0450371|C0032952
The adverse events (AE) were graded on a scale of 1–4.,The adverse events (AE) graded scale 1–4.,G0000000|G0000000|C0441471|C3887670|C0441800|C0175659|G0000000
"EORTC QLQ‐C30, European Organization for Research and Treatment of Cancer Quality of Life (QoL) Questionnaire‐Core 30; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive functioning; SF, social functioning; FA, fatigue; AP, appetite loss; NV, nausea and vomiting; FI, financial impact; PS, performance status; PG‐SGA, patient‐generated subjective global assessment.","EORTC QLQ‐C30, European Organization Research Treatment Cancer Quality Life (QoL) Questionnaire‐Core 30; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive functioning; SF, social functioning; FA, fatigue; AP, appetite loss; NV, nausea vomiting; FI, financial impact; PS, performance status; PG‐SGA, patient‐generated subjective global assessment.",C1516985|G0000000|C0239307|C0029237|C0035168|C0039798|C0006826|C0332306|C0376558|C0518214|G0000000|C0450371|C3815179|C0031809|C0205245|C0035448|C0035820|C0205245|G0000000|C0013987|C0205245|C0009738|C1516691|C0205245|C0037712|C0728831|C0205245|G0000000|C0015672|C3887950|C0003618|C1517945|C0027951|C0027497|C0042963|C4050619|C0376243|C1825598|C0242397|C0597198|C0449438|G0000000|G0000000|C0439655|C0205246|C1261322
"The intra- and inter-rater agreement for each pathology was measured using Cohen’s kappa (±SD) and found to be at moderate to good agreement range.25 Specifically, intra-rater agreement scores were: no change (NC; 0.57±0.05); dentinal bridging (DB; 0.57±0.11); pulp canal obliteration (PCO; 0.52±0.07); internal root resorption (IRR; 0.54±0.21); external root resorption (ERR; 0.59±0.09); periodontal ligament widening (PDL; 0.49±0.12); and periradicular lesion (PRL; 0.70±0.13).","The intra- inter-rater agreement pathology measured Cohen’s kappa (±SD) moderate agreement range.25 Specifically, intra-rater agreement scores were: change (NC; 0.57±0.05); dentinal bridging (DB; 0.57±0.11); pulp canal obliteration (PCO; 0.52±0.07); internal root resorption (IRR; 0.54±0.21); external root resorption (ERR; 0.59±0.09); periodontal ligament widening (PDL; 0.49±0.12); periradicular lesion (PRL; 0.70±0.13).",G0000000|C0347985|C0205103|C0680240|C0030664|C0444706|G0000000|C0439099|G0000000|C0205081|C0680240|C1514721|G0000000|C0347985|C0680240|C0449820|G0000000|C0392747|C0027964|G0000000|C0011429|C0456378|C1418892|G0000000|C0011399|C0086881|C0332465|C0032460|G0000000|C0205102|C0040452|C2985494|G0000000|G0000000|C0205101|C0040452|C2985494|G0000000|G0000000|C2960678|C0023685|C0332464|G0000000|G0000000|C1882342|C0221198|G0000000|G0000000
Delayed graft function occurred in 31.5% of ATG patients and 44.6% of daclizumab patients (P = 0.044).,Delayed graft function occurred 31.5% ATG patients 44.6% daclizumab patients (P = 0.044).,C0205421|C0181074|C0031843|C1709305|C0450371|G0000000|C0030705|C0450371|C0663182|C0030705|C0369773|G0000000|C1442061
"Primary outcome at 1 month was 51%, with 20% mortality.","Primary outcome 1 month 51%, 20% mortality.",C0205225|C1274040|G0000000|C0332177|C0450371|C0450371|C0026565
"Median progression-free and overall survival times were 16 and 26 months, respectively.","Median progression-free survival times 16 26 months, respectively.",C0549183|C0242656|C0038952|C0040223|C0450371|C0450371|C0439231|G0000000
"The proportions of patients who experienced ≥50% reduction from baseline in frequencies of headache days, migraine days, moderate/severe headache days, headache episodes, migraine episodes, and total cumulative hours of headache on headache days were also determined.","The proportions patients experienced ≥50% reduction baseline frequencies headache days, migraine days, moderate/severe headache days, headache episodes, migraine episodes, total cumulative hours headache headache days determined.",G0000000|C1709707|C0030705|C0237607|G0000000|C0301630|C0168634|C0439603|C0018681|C0439228|C0149931|C0439228|C0205081|C0018681|C0439228|C0018681|C0332189|C0149931|C0332189|C0439175|C1511559|C0439227|C0018681|C0018681|C0439228|G0000000
"To include the broadest possible spectrum of clinical syndromes occurring among enrolled adults (22), during follow-up we defined ILI by the presence of fever (temperature >37.8°C), feeling feverish or a history of fever, >2 symptoms (sore throat, cough, sneezing, runny nose, nasal congestion, headache), or 1 of the symptoms listed plus laboratory confirmation of respiratory viral infection.","To broadest spectrum clinical syndromes occurring enrolled adults (22), follow-up defined ILI presence fever (temperature >37.8°C), feeling feverish history fever, >2 symptoms (sore throat, cough, sneezing, runny nose, nasal congestion, headache), 1 symptoms listed laboratory confirmation respiratory viral infection.",C0040363|C0332464|C1883073|C0205210|C0039082|C1709305|G0000000|C0001675|C0450371|C0589120|C1704788|G0000000|C0150312|C0015967|C0005903|G0000000|C0013987|C0015967|C0019664|C0015967|G0000000|C0683368|C0234233|C0031354|C0010200|C0037383|G0000000|C0028429|C0028429|C0700148|C0018681|G0000000|C0683368|C0745732|C0022877|C0521091|C0521346|C0521026|C0009450
SQ was assessed by the Pittsburgh sleep quality index (PSQI).,SQ assessed Pittsburgh sleep quality (PSQI).,C0560749|C1516048|G0000000|C0037313|C0332306|C3697468
"In the two previously described modeling steps, each of the four outcomes (antisocial behavior, alcohol use, tobacco use, and marijuana use) was examined in separate CACE analyses.","In modeling steps, outcomes (antisocial behavior, alcohol use, tobacco use, marijuana use) examined separate CACE analyses.",G0000000|C0870071|C1261552|C1274040|C0233523|C0004927|C0001962|C0042153|C0040329|C0042153|C0024808|C0042153|C0332128|C0443299|G0000000|C0002778
"VAS is a scale numerated from 0 to 10 with 0, 1–3, 4–6, 7–9, and 10 representing no, mild, moderate, severe, and the worst possible pain, respectively [18].","VAS scale numerated 0 10 0, 1–3, 4–6, 7–9, 10 representing no, mild, moderate, severe, worst pain, [18].",C0042815|C0175659|G0000000|G0000000|C0450371|G0000000|G0000000|G0000000|G0000000|C0450371|C1882932|G0000000|C2945599|C0205081|C0205082|C1522166|C0030193|C0450371
The primary outcome was risk of first episode of late-onset clinically-defined sepsis (culture-proven sepsis and culture-negative clinical infection) within 4 weeks (28 days) from enrollment.,The primary outcome risk episode late-onset clinically-defined sepsis (culture-proven sepsis culture-negative clinical infection) 4 weeks (28 days) enrollment.,G0000000|C0205225|C1274040|C0035647|C0332189|C4025592|C1704788|C0036690|C0010453|C0036690|C0855652|C0205210|C0009450|G0000000|C0439230|C0450371|C0439228|C1516879
"Secondary endpoints included vaccine efficacy for anal bHSIL after week 52, persistent oral HPV infection.","Secondary endpoints included vaccine efficacy anal bHSIL week 52, persistent oral HPV infection.",C0027627|C2349179|C0332257|C0042210|C1280519|C0003461|G0000000|C0332174|C0450371|C0205322|C0442027|C0021344|C0009450
"Thirdly, the HAMD17 scale has only limited capability to assess improvement in melancholic symptoms.","Thirdly, HAMD17 scale limited capability assess improvement melancholic symptoms.",C0205437|G0000000|C0175659|C0439801|C2698977|C1516048|C2986411|C0344315|C0683368
"[Results] Repeated-measures analysis of covariance revealed significant differences in between pre- and post-training VAS, algometer, Oswestry low-back pain disability index (ODI), Roland Morris disability questionnaire (RMDQ), and fear avoidance beliefs questionnaire (FBQ) scores.","[Results] Repeated-measures analysis covariance revealed differences pre- post-training VAS, algometer, Oswestry low-back pain disability (ODI), Roland Morris disability questionnaire (RMDQ), fear avoidance beliefs questionnaire (FBQ) scores.",C1274040|C0205341|C0002778|G0000000|C0443289|C1705241|C0332152|C1709607|C0042815|G0000000|G0000000|C0205251|C0030193|C0231170|G0000000|G0000000|G0000000|C0231170|C0034394|G0000000|C0015726|C0870186|C0004951|C0034394|G0000000|C0449820
"BP, blood pressure.","BP, blood pressure.",C0037623|C0005767|C0033095
Disagreements between the independent adjudicators about whether or not a medication was implicated in a study outcome were uncommon (approximately 3% for ADEs and 5% for potential ADEs) and occurred with similar frequency at each site.,Disagreements independent adjudicators medication implicated study outcome uncommon (approximately 3% ADEs 5% potential ADEs) occurred frequency site.,C0680238|C0085862|C0401783|C0013227|G0000000|C0557651|C1274040|C0522498|C0332232|G0000000|C0057163|G0000000|C3245505|C0057163|C1709305|C0376249|C0205145
"As shown in Table 1, vitamin D supplementation among the intervention group significantly increased serum 25(OH)D levels among both mothers and infants while maintaining appropriate maternal calcium and PTH serum concentrations, indicating efficacy and safety of the intervention.","As Table 1, vitamin D supplementation intervention increased serum 25(OH)D levels mothers infants maintaining maternal calcium PTH serum concentrations, indicating efficacy safety intervention.",G0000000|C0039224|G0000000|C0042890|C0073187|C0242297|C0886296|C0205217|C0229671|C0450371|C0441889|C0026591|C0021270|C0024501|C2347083|C0006675|G0000000|C0229671|C0086045|G0000000|C1280519|C0036043|C0886296
"Related expected adverse events in the BEAT Cancer group included back or lower extremity musculoskeletal pain or injury (n = 14), heart rate monitor rash (n = 1), fall while walking (n = 1), breast reconstruction (n = 3), and chest pain during treadmill fitness test (n = 1).","Related expected adverse events BEAT Cancer included lower extremity musculoskeletal pain injury (n = 14), heart rate monitor rash (n = 1), fall walking (n = 1), breast reconstruction (n = 3), chest pain treadmill fitness test (n = 1).",C0439849|C1517001|G0000000|C0441471|G0000000|C0006826|C0332257|C0441994|C0015385|C0497254|C0030193|C3263722|C0369718|G0000000|C0450371|C0018787|C0871208|C0030695|C0015230|C0369718|G0000000|G0000000|C0085639|C0080331|C0369718|G0000000|G0000000|C0006141|C0020912|C0369718|G0000000|G0000000|C0817096|C0030193|C0184069|C1456706|C0022885|C0369718|G0000000|G0000000
Acceptable wound cosmesis and neck mobility are important outcomes following cervicotomy.,Acceptable wound cosmesis neck mobility outcomes cervicotomy.,C1879533|C0043250|C0010164|C0027530|C0425245|C1274040|G0000000
The percentage of participants obtaining partial remission was also examined as defined by weight above 85% of EBW.,The percentage participants obtaining partial remission examined defined weight 85% EBW.,G0000000|C0439165|C0679646|C1301820|C0728938|C0544452|C0332128|C1704788|C0005910|C0450371|G0000000
Chest drain insertion during hospitalization was a secondary outcome.,Chest drain insertion hospitalization secondary outcome.,C0817096|C0013103|C0021107|C0019993|C0027627|C1274040
"These measures were included to determine whether, as a result of fewer falls, the intervention had beneficial effects on an older person’s abilities and quality of life.","These measures included determine whether, result fewer falls, intervention beneficial effects person’s abilities quality life.",G0000000|C0079809|C0332257|G0000000|G0000000|C1274040|C0205388|C0000921|C0886296|G0000000|C1280500|G0000000|C0085732|C0332306|C0376558
Objective: To examine effect of an educational program on pregnant women’s fear of normal vaginal delivery.,Objective: To examine educational program pregnant women’s fear normal vaginal delivery.,C0018017|C0040363|G0000000|C0587721|C1709697|C0549206|G0000000|C0015726|C0205307|C0042232|C0011209
Primary outcome of the LEARNS study is occurrence of relapses within 12 months after first presentation.,Primary outcome LEARNS study occurrence relapses 12 months presentation.,C0205225|C1274040|C0023185|C0557651|C0243132|C0035020|C0450371|C0439231|C0449450
"Additionally, caregiver diaries and caregiver involvement scales were obtained weekly during the 8-week intervention period and are described below.","Additionally, caregiver diaries caregiver involvement scales weekly 8-week intervention period below.",G0000000|C0085537|C0376660|C0085537|C1314939|C0175659|C0332174|C0332174|C0886296|C0439531|G0000000
Changes in plasma triglyceride and phospholipids contents (%/nmol) of the longer-chain (≥20 carbons) polyunsaturated fatty acids in the different groups.,Changes plasma triglyceride phospholipids contents (%/nmol) longer-chain (≥20 carbons) polyunsaturated fatty acids groups.,C0392747|C0032105|C0041004|C0031676|C0456205|C0439191|C0205166|G0000000|C0007009|G0000000|G0000000|C0001128|C0441833
"The 12-week self-completion postal questionnaire recorded cramp symptoms in a similar manner to that at randomisation, quinine usage and frequency of taught exercises over the previous week.","The 12-week self-completion postal questionnaire recorded cramp symptoms manner randomisation, quinine usage frequency taught exercises previous week.",G0000000|C0450371|C0036588|C1514253|C0034394|C0034869|C0026821|C0683368|G0000000|C0034656|C0034417|C0457083|C0376249|C0348054|C0015259|C0205156|C0332174
Secondary outcomes will include ranking of the gene-based test with other smoking cessation motivators.,Secondary outcomes ranking gene-based test smoking cessation motivators.,C0027627|C1274040|C0699794|C0017337|C0022885|C0037369|C1880019|G0000000
"We hypothesised that tiotropium would modify the overnight change in FEV1, and this would be unaffected by the timing of drug administration.","We hypothesised tiotropium modify overnight change FEV1, unaffected timing drug administration.",G0000000|G0000000|C0213771|C0392747|C0439583|C0392747|G0000000|C2986417|C0449243|C0013227|C0001554
"Both rofecoxib and ibuprofen were significantly effective in relieving pain, associated symptoms at two hours, and in sustained pain relief.","Both rofecoxib ibuprofen effective relieving pain, symptoms hours, sustained pain relief.",G0000000|C0762662|C0020740|C1280519|C0332303|C0030193|C0683368|C0439227|C0443318|C0030193|C0564405
"The clinical events of importance in the model are further stroke events, myocardial infarction (MI) and other cardiovascular related mortality.","The clinical events model stroke events, myocardial infarction (MI) cardiovascular mortality.",G0000000|C0205210|C0441471|C3161035|C0038454|C0441471|C0027061|C0021308|C3810814|C0007226|C0026565
"Clinical outcomes measured included total energy intake and growth over the first six postnatal weeks, sepsis incidence, liver function, milk tolerance, duration of respiratory support, duration of hospital stay and complication incidence.","Clinical outcomes measured included total energy intake growth postnatal weeks, sepsis incidence, liver function, milk tolerance, duration respiratory support, duration hospital stay complication incidence.",C0205210|C1274040|C0444706|C0332257|C0439175|C0424589|C1512806|C0018270|C0443281|C0439230|C0036690|C0021149|C0023884|C0031843|C0026131|C0013220|C0449238|C0521346|C0183683|C0449238|C0019994|G0000000|C0009566|C0021149
"Secondary outcomes included the rates of gain in weight, stature, and mid-upper arm circumference (MUAC), and the development of adverse outcomes such as severe malnutrition or death.","Secondary outcomes included rates gain weight, stature, mid-upper arm circumference (MUAC), development adverse outcomes severe malnutrition death.",C0027627|C1274040|C0332257|C0871208|C1517378|C0005910|C0005890|C0444598|C0446516|C0332520|G0000000|C0243107|G0000000|C1274040|C0205082|C0162429|C0011065
Secondary end points were the median time to return to normal axillary temperature and the proportion of patients shedding virus at each time point.,Secondary median time return normal axillary temperature proportion patients shedding virus time point.,C0027627|C0549183|C0040223|C0332156|C0205307|C0004454|C0005903|C1709707|C0030705|G0000000|C0042776|C0040223|C1552961
"Results of repeated-measures ANOVA with a Greenhouse-Geisser correction on Fugl-Meyer assessment score of paretic upper limb and modified barthel index in patients with chronic stroke Abbreviations: FMA Fugl-Meyer Assessment score, MBI modified Barthel index.","Results repeated-measures ANOVA Greenhouse-Geisser correction Fugl-Meyer assessment score paretic upper limb modified barthel patients chronic stroke Abbreviations: FMA Fugl-Meyer Assessment score, MBI modified Barthel index.",C1274040|C0205341|G0000000|G0000000|C1705565|G0000000|C1261322|C0449820|G0000000|C1282910|C0015385|C0392747|G0000000|C0030705|C0205191|C0038454|C0000723|C2332774|G0000000|C1261322|C0449820|C2985547|C0392747|G0000000|C0918012
"BADL, Barthel Activities of Daily Living; CDR, The Clinical Dementia Rating scale; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; IQCODE, Informant Questionnaire on Cognitive Decline in the Elderly; IQR, interquartile range; MMSE, Mini Mental State Examination; NEADL, Nottingham Extended ADL Index; SD, standard deviation; SPPB, Short Physcial Performance Battery.","BADL, Barthel Activities Daily Living; CDR, The Clinical Dementia Rating scale; CERAD, Consortium Establish Registry Alzheimer’s Disease; IQCODE, Informant Questionnaire Cognitive Decline Elderly; IQR, interquartile range; MMSE, Mini Mental State Examination; NEADL, Nottingham Extended ADL Index; SD, standard deviation; SPPB, Short Physcial Performance Battery.",C1290927|G0000000|C0441655|C0332173|C0376558|G0000000|G0000000|C0205210|C0011265|C0871208|C0175659|G0000000|C1513822|C0443211|C0034975|G0000000|C0012634|C3476797|C1550484|C0034394|C1516691|G0000000|C0001792|G0000000|G0000000|C1514721|C0451306|C0445542|C0229992|C1301808|G0000000|G0000000|G0000000|C0231448|C0001288|C0918012|C2699239|C1442989|C0012727|G0000000|C1282927|G0000000|C0597198|C0337088
Serious adverse outcomes were defined as major congenital abnormalities (which could be attributable to AEDs) or fetal death.,Serious adverse outcomes defined major congenital abnormalities (which attributable AEDs) fetal death.,C0205404|G0000000|C1274040|C1704788|C0205082|C0009678|C0000768|G0000000|C0596130|C0180309|C0015965|C0011065
Waist circumference and systolic BP decreased in both groups after 12 wk (P < 0.05).,Waist circumference systolic BP decreased 12 wk (P < 0.05).,C0230097|C0332520|C0039155|C0037623|C0205216|C0450371|C0332174|C0369773|G0000000|C0450371
The primary outcome was regular smoking (one or more cigarettes per week).,The primary outcome regular smoking (one cigarettes week).,G0000000|C0205225|C1274040|C0205272|C0037369|C0205447|C0677453|C0332174
RESULTS—Video gait analysis showed clinically and statistically significant improvement in initial foot contact following BT-A at six weeks and 12 weeks compared to placebo.,RESULTS—Video gait analysis clinically statistically improvement initial foot contact BT-A weeks 12 weeks compared placebo.,G0000000|C0016928|C0002778|G0000000|C0038215|C2986411|C0205265|C0016504|C0332158|G0000000|C0439230|C0450371|C0439230|C1707455|C0032042
"Subjects also underwent tests of sleep (Chronic Pain Sleep Inventory; CPSI) [13], and depression along with anxiety (Hospital Anxiety and Depression Scale; HADS) [40].","Subjects underwent tests sleep (Chronic Pain Sleep Inventory; CPSI) [13], depression anxiety (Hospital Anxiety Depression Scale; HADS) [40].",C0681850|G0000000|C0022885|C0037313|C0205191|C0030193|C0037313|C0021941|C0006961|C0450371|C0011570|C0003467|C0019994|C0003467|C0011570|C0175659|C0048008|C0450371
"Ambulatory 24 h blood pressure (systolic and diastolic blood pressure of 24 h average, day time and night time separately) was monitored on a day of standard physical activity, with an adequate cuff for the size of the patient’s arm.","Ambulatory 24 blood pressure (systolic diastolic blood pressure 24 average, day time night time separately) monitored day standard physical activity, adequate cuff size patient’s arm.",C0439841|C0450371|C0005767|C0033095|C0039155|C0012000|C0005767|C0033095|C0450371|C1510992|C0332173|C0040223|C0240526|C0040223|G0000000|C0030695|C0332173|C1442989|C0031809|C0205177|C0205410|C0441107|C0456389|G0000000|C0446516
"The estimated mean difference between the groups was –4.1 (95% confidence interval –8.1 to –0.1, P = 0.045) in favour of surgery.","The estimated difference –4.1 (95% confidence interval –8.1 –0.1, P = 0.045) favour surgery.",G0000000|C0750572|C1705241|G0000000|C0450371|C0237529|C1272706|G0000000|G0000000|C0369773|G0000000|C1442061|C0309049|C0038894
Brachial–ankle pulse wave velocity (baPWV) evaluates arterial stiffness and also predicts early outcome in stroke patients.,Brachial–ankle pulse wave velocity (baPWV) evaluates arterial stiffness predicts outcome stroke patients.,G0000000|C0232117|C0678544|C0439830|G0000000|C0220825|C0003842|C0427008|G0000000|C1274040|C0038454|C0030705
"Therefore, preterm infants would benefit from enhanced weight gain, which affects growth and organ development.","Therefore, preterm infants benefit enhanced weight gain, growth organ development.",G0000000|C0151526|C0021270|C0814225|C2349975|C0005910|C1517378|C0018270|C0178784|C0243107
"Blood was obtained at 6 and 9 months for serum zinc, biomarkers of iron status (ferritin and soluble transferrin receptor (sTfR)), and systemic inflammatory markers α 1-acid glycoprotein (AGP) and C-reactive protein (CRP).","Blood 6 9 months serum zinc, biomarkers iron status (ferritin soluble transferrin receptor (sTfR)), systemic inflammatory markers α 1-acid glycoprotein (AGP) C-reactive protein (CRP).",C0005767|G0000000|G0000000|C0439231|C0229671|C0043481|C0005516|C0302583|C0449438|C0015879|C1749467|C0040679|C0597357|G0000000|C0205373|C0333348|C0005516|G0000000|C0001128|C0017968|C0029297|C0205332|C0033684|C3890735
"The primary outcome, survival to hospital discharge, was defined as the patient leaving the hospital alive or being transferred to a long-term care facility; we obtained these data from hospital records.","The primary outcome, survival hospital discharge, defined patient leaving hospital alive transferred long-term care facility; data hospital records.",G0000000|C0205225|C1274040|C0038952|C0019994|C0012621|C1704788|C0030705|G0000000|C0019994|C0376558|C0348011|C0443252|C1947933|C1547538|C1511726|C0019994|C0034869
These results demonstrated the importance of sleep quality in quality of life in patients.,These demonstrated sleep quality quality life patients.,G0000000|G0000000|C0037313|C0332306|C0332306|C0376558|C0030705
Any falls that occurred during the classes were recorded.,Any falls occurred classes recorded.,G0000000|C0000921|C1709305|C0456387|C0034869
"Additionally, the evaluation of outcome will include several secondary endpoints such as the duration and severity of POD, postoperative cognitive function as analyzed with the Mini-Mental State Examination (MMSE), length of intensive care unit (ICU) stay, hospital length of stay, the incidence of postoperative organ dysfunction and the incidence of (serious) adverse events ((S)AE).","Additionally, evaluation outcome secondary endpoints duration severity POD, postoperative cognitive function analyzed Mini-Mental State Examination (MMSE), length intensive care unit (ICU) stay, hospital length stay, incidence postoperative organ dysfunction incidence (serious) adverse events ((S)AE).",G0000000|C0220825|C1274040|C0027627|C2349179|C0449238|C0439793|G0000000|C0032790|C1516691|C0031843|C0936012|C0445542|C1301808|G0000000|C0451306|C1444754|C0162425|C1947933|C0439148|C0021708|G0000000|C0019994|C1444754|G0000000|C0021149|C0032790|C0178784|C0031847|C0021149|C0205404|G0000000|C0441471|C3887670
The primary end point was relapse-free survival based on the period of time until the first relapse.,The primary relapse-free survival based period time relapse.,G0000000|C0205225|C0035020|C0038952|C1527178|C0439531|C0040223|C0035020
"Self-rating Anxiety Scale (SAS) [40], a 20-item instrument with a 4-point Likert scale.","Self-rating Anxiety Scale (SAS) [40], 20-item instrument 4-point Likert scale.",C4054119|C0003467|C0175659|C0605290|C0450371|C0450371|C0348000|C1552961|G0000000|C0175659
"To test the effectiveness of, and explore interactions between, three interventions to prevent falls among older people.","To test effectiveness of, explore interactions between, interventions prevent falls people.",C0040363|C0022885|C1280519|G0000000|G0000000|C1704675|G0000000|C0886296|C0309872|C0000921|C0027361
"At child’s age 6 years, physician-diagnosed asthma ever, wheezing, fractional exhaled nitric oxide (FeNO), airway resistance (Rint), health-related quality of life (HRQOL) and ETS exposure at home ever were measured.","At child’s age 6 years, physician-diagnosed asthma ever, wheezing, fractional exhaled nitric oxide (FeNO), airway resistance (Rint), health-related quality life (HRQOL) ETS exposure measured.",G0000000|G0000000|C0001779|G0000000|C0439234|C0031831|C0004096|C3887636|C0043144|C1264633|C0231800|G0000000|C0030015|G0000000|C0178987|C0237834|G0000000|C0018684|C0332306|C0376558|G0000000|G0000000|C0274281|C0444706
Thirty-one patients with schizophrenia and co-occurring cannabis use disorder were randomly assigned to switch to clozapine or to stay on their current antipsychotic and were then followed weekly for 12 weeks.,Thirty-one patients schizophrenia co-occurring cannabis disorder randomly assigned switch clozapine stay current antipsychotic weekly 12 weeks.,C3816446|C0030705|C0036341|C3245499|C0024808|C0012634|G0000000|C1516050|C1707719|C0009079|G0000000|C0521116|C0040615|C0332174|C0450371|C0439230
"At 12 months, differences favouring the home‐visited group were observed on an independent assessment of maternal sensitivity (p<0.04) and infant cooperativeness (p<0.02).","At 12 months, differences favouring home‐visited observed independent assessment maternal sensitivity (p<0.04) infant cooperativeness (p<0.02).",G0000000|G0000000|C1705241|G0000000|G0000000|C1441672|C0085862|C1261322|C2347083|C0020517|C0369773|C0021270|C0009964|C0369773
"Prespecified key secondary end points were the frequency of relapses, time to first relapse, cumulative prednisolone dosage (milligrams per kilogram per year), changes in serum biochemistry, peripheral blood B-cell count, the number of children not receiving corticosteroids, and the rates of adverse events.","Prespecified key secondary frequency relapses, time relapse, cumulative prednisolone dosage (milligrams kilogram year), serum biochemistry, peripheral blood B-cell count, children receiving corticosteroids, rates adverse events.",G0000000|G0000000|C0027627|C0376249|C0035020|C0040223|C0035020|C1511559|C0032950|C0178602|C0439210|C0439209|C0439234|C0229671|C0005477|C0205100|C0005767|C0004561|C0750480|C0008059|C1514756|C0001617|C0871208|G0000000|C0441471
"Second, the study focuses on two very general outcomes – overall quality of life and pain distress.","Second, study focuses outcomes – quality life pain distress.",C0205436|C0557651|C0205234|C1274040|G0000000|C0332306|C0376558|C0030193|C0231303
"As such, upper limb, sitting balance, standing balance and stepping rehabilitation tasks have been programmed in the JRS WAVE as fun and engaging video games that can be played at a number of different levels of complexity and speed.","As such, upper limb, sitting balance, standing balance stepping rehabilitation tasks programmed JRS WAVE fun engaging video games played levels complexity speed.",G0000000|G0000000|C1282910|C0015385|C0277814|C0014653|C0231472|C0014653|C0427149|C0034991|C3540678|G0000000|G0000000|C0678544|G0000000|C0425152|C0042655|C0150593|C0600138|C0441889|C0439855|C0678536
Secondary outcome analysis of the time spent on the unit did not add to our findings and is not reported.,Secondary outcome analysis time spent unit add findings reported.,C0027627|C1274040|C0002778|C0040223|C0680968|C0439148|C1883712|C2607943|C0684224
Outcome measures The primary outcome was admission to special care baby unit with respiratory distress.,Outcome measures The primary outcome admission special care baby unit respiratory distress.,C1274040|C0079809|G0000000|C0205225|C1274040|C0184666|C0205555|C1947933|C0021270|C0439148|C0521346|C0231303
"We chose post-surgical outcome as primary outcome parameter, as the ultimate goal of epilepsy surgery is to achieve seizure freedom.","We chose post-surgical outcome primary outcome parameter, ultimate goal epilepsy surgery achieve seizure freedom.",G0000000|C1707391|C0687676|C1274040|C0205225|C1274040|C0549193|G0000000|C0018017|C0014544|C0038894|G0000000|C0036572|C0016694
"Sitting balance will be measured by using the standardised sitting balance test, which uses a four-point rating scale to measure sitting balance from poor to normal.","Sitting balance measured standardised sitting balance test, four-point rating scale measure sitting balance poor normal.",C0277814|C0014653|C0444706|G0000000|C0277814|C0014653|C0022885|C0205450|C0871208|C0175659|C0079809|C0277814|C0014653|C0032854|C0205307
Secondary endpoints included the proportion of patients with serum K+ >5.5 mEq/L at any time during the trial and the proportion of patients whose spironolactone dose could be increased to 50 mg/day.,Secondary endpoints included proportion patients serum K+ >5.5 mEq/L time trial proportion patients spironolactone dose increased 50 mg/day.,C0027627|C2349179|C0332257|C1709707|C0030705|C0229671|C0597277|G0000000|C0439375|C0040223|C0008976|C1709707|C0030705|C0037982|C0178602|C0205217|C0450371|C0439422
"At 6 weeks from baseline, the Intervention group was mailed a 6‐week questionnaire with a self‐addressed stamped envelope for returning the questionnaire.","At 6 weeks baseline, Intervention mailed 6‐week questionnaire self‐addressed stamped envelope returning questionnaire.",G0000000|G0000000|C0439230|C0168634|C0886296|C0024492|G0000000|C0034394|G0000000|C1823540|C1622204|C0332156|C0034394
"After four weeks of treatment with B. bifidum triple viable capsules, the levels of B. bifidum increased sharply (P<0.05) and the SCORAD index was notably reduced (P<0.05) as compared with the values prior to treatment.","After weeks treatment B. bifidum triple viable capsules, levels B. bifidum increased sharply (P<0.05) SCORAD notably reduced (P<0.05) compared values prior treatment.",G0000000|C0439230|C0039798|G0000000|G0000000|C0205174|C0443348|C0006935|C0441889|G0000000|G0000000|C0205217|G0000000|C0369773|G0000000|G0000000|C0392756|C0369773|C1707455|C0042295|C0332152|C0039798
"Durations of mechanical ventilation, ICU stay, hospital stay, and total charges were not different between groups (Table 3).","Durations mechanical ventilation, ICU stay, hospital stay, total charges (Table 3).",C0449238|C0443254|C0035203|C0021708|G0000000|C0019994|G0000000|C0439175|C0007961|C0039224|G0000000
"The concentration of CO from the breath was measured, with a cut-off point CO level of ≥ 7 part per million (ppm) as indicative of smoking.","The concentration CO breath measured, cut-off CO level of ≥ 7 (ppm) indicative smoking.",G0000000|C0004268|C3245499|C0225386|C0444706|C1442160|C3245499|C0441889|G0000000|C0439187|G0000000|C0037369
"Box and whiskers plots of FIQ (Fibromyalgia Impact Questionnaire), FAS (Fibromyalgia Assessment Status), and HAQ (Health Assessment Questionnaire) scores for the CG (control group), perceptual surfaces group (PS-group), and physical exercises group (PE-group) at the 3 assessments (T0, T1, and T2).","Box whiskers plots FIQ (Fibromyalgia Impact Questionnaire), FAS (Fibromyalgia Assessment Status), HAQ (Health Assessment Questionnaire) scores CG (control group), perceptual surfaces (PS-group), physical exercises (PE-group) 3 assessments (T0, T1, T2).",C0179400|C0042640|G0000000|G0000000|C0016053|C1825598|C0034394|G0000000|C0016053|C1261322|C0449438|C0102923|C0018684|C1261322|C0034394|C0449820|C0043444|C0243148|C0441833|G0000000|C0205148|C0242397|C0031809|C0015259|C0070939|G0000000|C1261322|C0041403|C0041403|C0041403
Length was measured in a recumbent position by using an infant stadiometer accurate to 0.1 cm (Holtain Ltc).,Length measured recumbent position infant stadiometer accurate 0.1 cm (Holtain Ltc).,C1444754|C0444706|C0444334|C0733755|C0021270|G0000000|C0443131|G0000000|G0000000|G0000000|G0000000
"Potential mediators (e.g., weight loss and change in physical activity level and nutrient intake) and moderators (e.g., socio-demographic characteristics and comorbidities) of the intervention effects also will be examined.","Potential mediators (e.g., weight loss change physical activity level nutrient intake) moderators (e.g., socio-demographic characteristics comorbidities) intervention effects examined.",C3245505|C0127400|G0000000|C0005910|C1517945|C0392747|C0031809|C0205177|C0441889|C0678695|C1512806|G0000000|G0000000|C0011298|C1521970|C0009488|C0886296|C1280500|C0332128
Primary outcome levels of anxiety and depression.,Primary outcome levels anxiety depression.,C0205225|C1274040|C0441889|C0003467|C0011570
"After the third beep, odour levels is measured by grading on the display of instrument; 1 (no odour), 2 (mild odour), 3 (moderate odour), 4 (strong odour) [21].","After beep, odour levels measured grading display instrument; 1 (no odour), 2 (mild odour), 3 (moderate odour), 4 (strong odour) [21].",G0000000|G0000000|C0028884|C0441889|C0444706|C0441800|C1705417|C0348000|G0000000|G0000000|C0028884|G0000000|C2945599|C0028884|G0000000|C0205081|C0028884|G0000000|C0442821|C0028884|C0450371
"The aim of this study was to compare pressure and volume targeted ventilation in terms of diurnal arterial blood gas tensions, lung volumes, hypercapnic ventilatory responses, sleep quality, and effect on daytime function and health status when ventilators were carefully set to provide the same minute ventilation.","The aim study compare pressure volume targeted ventilation terms diurnal arterial blood gas tensions, lung volumes, hypercapnic ventilatory responses, sleep quality, daytime function health status ventilators carefully set provide minute ventilation.",G0000000|C1947946|C0557651|C1707455|C0033095|C0449468|C1521840|C0035203|C0233324|C0332169|C0003842|C0005767|C0017110|C0233494|C0024109|C0449468|C0020440|G0000000|C0871261|C0037313|C0332306|C0332169|C0031843|C0018684|C0449438|C0087153|G0000000|C0036849|C1999230|C0439232|C0035203
No restrictions were placed on the use of concomitant acute medication.,No restrictions concomitant acute medication.,G0000000|C0443288|C0521115|C0205178|C0013227
"Therefore, future pediatric trials that attempt to evaluate ototoxicity must be written with more stringent criteria for exactly what tests should be utilized and exactly how they should be performed.","Therefore, future pediatric trials attempt evaluate ototoxicity written stringent criteria tests utilized performed.",G0000000|C0016884|C0030755|C0008976|C1516084|C0220825|C0235280|C0043266|G0000000|C0243161|C0022885|G0000000|C0884358
"Major outcome variables were depression measured by the Cornell Scale for Depression in Dementia, mood measured by the Dementia Mood Assessment Scale and the Alzheimer’s Mood Scale, and affect measured by the Observed Affect Scale.","Major outcome variables depression measured Cornell Scale Depression Dementia, mood measured Dementia Mood Assessment Scale Alzheimer’s Mood Scale, affect measured Observed Affect Scale.",C0205082|C1274040|C0439828|C0011570|C0444706|G0000000|C0175659|C0011570|C0011265|C0026516|C0444706|C0011265|C0026516|C1261322|C0175659|G0000000|C0026516|C0175659|C0001721|C0444706|C1441672|C0001721|C0175659
"Higher scores reflect great quality of movements of the more affected arm in real world.25  Secondary outcomes included the Fugl-Meyer Assessment of Sensorimotor Recovery after Stroke (FMA)26-28 and the Stroke Specific Quality of life Scale (SSQOL).29-31 The FMA measures the level of motor impairment in stroke patients (best possible score for the upper limb, 66) and has excellent test-retest reliability and construct validity.","Higher scores reflect quality movements arm real world.25 Secondary outcomes included Fugl-Meyer Assessment Sensorimotor Recovery Stroke (FMA)26-28 Stroke Specific Quality life Scale (SSQOL).29-31 The FMA measures level motor impairment stroke patients (best score upper limb, 66) excellent test-retest reliability construct validity.",C0205250|C0449820|C0558058|C0332306|C0026649|C0446516|C0237400|C2700280|C0027627|C1274040|C0332257|G0000000|C1261322|G0000000|C0237820|C0038454|C2332774|C0038454|C0205369|C0332306|C0376558|C0175659|C0450371|G0000000|C2332774|C0079809|C0441889|C1513492|C0221099|C0038454|C0030705|C1522427|C0449820|C1282910|C0015385|C0450371|C1548784|C0022885|C2347947|C2827421|C2349101
"This multi-site RCT will also explore the impact of the PREVENT program on cardiovascular fitness, walking tolerance, fatigue, cognition, mental health, quality of sleep, medication adherence, tobacco use, and health-related quality of life, which may be mitigating factors in reducing vascular risk factors, and, ultimately, stroke recurrence.","This multi-site RCT explore impact PREVENT program cardiovascular fitness, walking tolerance, fatigue, cognition, mental health, quality sleep, medication adherence, tobacco use, health-related quality life, mitigating factors reducing vascular risk factors, and, ultimately, stroke recurrence.",G0000000|C0439064|G0000000|G0000000|C1825598|C0309872|C1709697|C0007226|C1456706|C0080331|C0013220|C0015672|C0009240|C0229992|C0018684|C0332306|C0037313|C0013227|C1510802|C0040329|C0042153|C0018684|C0332306|C0376558|C1553901|C1521761|C0392756|C0005847|C0035647|C1521761|G0000000|G0000000|C0038454|C0034897
"Outcome measures were health status, as measured with the Chronic Respiratory Disease Questionnaire (CRQ),23 exacerbation frequency and postbronchodilator FEV1.","Outcome measures health status, measured Chronic Respiratory Disease Questionnaire (CRQ),23 exacerbation frequency postbronchodilator FEV1.",C1274040|C0079809|C0018684|C0449438|C0444706|C0205191|C0521346|C0012634|C0034394|C0450371|G0000000|C0376249|C2599594|G0000000
The need for urgent abdominal reoperation was 8.6% (10 of 116) in those randomized to stoma and 25.4% (30 of 118) in those without (P < 0.001).,The urgent abdominal reoperation 8.6% (10 116) randomized stoma 25.4% (30 118) (P < 0.001).,G0000000|C0439609|C0000726|C0035110|G0000000|C0450371|C1442061|C0034656|C1955856|C0450371|C0450371|C1442061|C0369773|G0000000|C1442061
"There were no statistically significant differences between the intervention (n = 50) and control (n = 49) participants at baseline in demographic characteristics, anthropometric measures, or behaviors, except that intervention participants drank significantly more juice (Table 1).","There statistically differences intervention (n = 50) control (n = 49) participants baseline demographic characteristics, anthropometric measures, behaviors, intervention participants drank juice (Table 1).",G0000000|C0038215|C1705241|C0886296|C0369718|G0000000|C0450371|C0243148|C0369718|G0000000|C0450371|C0679646|C0168634|C0011298|C1521970|C0003188|C0079809|C0004927|C0886296|C0679646|C0452428|C1268568|C0039224|G0000000
"During follow-up, BP z-scores remained stable on average and none of the survivors used renoprotective drugs during follow-up.","During follow-up, BP z-scores remained stable average survivors renoprotective drugs follow-up.",G0000000|C0589120|C0037623|C0871421|G0000000|C0205360|C1510992|C0206194|G0000000|C0013227|C0589120
We did not detect a significant difference in the rate of catheter removal for dysfunction.,We detect difference rate catheter removal dysfunction.,G0000000|C0442726|C1705241|C0871208|C0085590|C0015252|C0031847
"Secondary outcome measures were the changes in electrolytes, including serum potassium, sodium, chloride, and bicarbonate levels at 60 and 120 minutes.","Secondary outcome measures electrolytes, including serum potassium, sodium, chloride, bicarbonate levels 60 120 minutes.",C0027627|C1274040|C0079809|C0013832|C0332257|C0229671|C0032821|C0037473|C0008203|C0005367|C0441889|C0450371|C1442061|C0439232
"Changes in anxiety symptoms from baseline according to the HADS-A at days 45, 90, 120 and 180; the proportion of patients who believe that their cancer is curable as measured using an adapted instrument to evaluate patient awareness (all of the patients will have incurable advanced cancers; therefore, patients who claim that their disease is curable will be interpreted as not being adequately aware of their prognosis).","Changes anxiety symptoms baseline HADS-A days 45, 90, 120 180; proportion patients cancer curable measured adapted instrument evaluate patient awareness (all patients incurable advanced cancers; therefore, patients claim disease curable interpreted adequately aware prognosis).",C0392747|C0003467|C0683368|C0168634|C0048008|C0439228|C0450371|C0450371|C1442061|C1442061|C1709707|C0030705|C0006826|G0000000|C0444706|C2937289|C0348000|C0220825|C0030705|C0004448|G0000000|C0030705|G0000000|C0205179|C0006826|G0000000|C0030705|G0000000|C0012634|G0000000|C1285553|G0000000|C0004448|C0033325
Mean and median values of anthropometric and biochemical measures for patients with Alzheimer's disease in the different groups CW = Current Weight (kg); BMI = Body Mass Index (Kg/m2); AC = Arm Circumference (cm); TSF = Triceps Skin fold (mm) and AMC = Arm Muscle Circumference (cm); Total prot.,Mean median values anthropometric biochemical measures patients Alzheimer's disease CW = Current Weight (kg); BMI = Body Mass Index (Kg/m2); AC = Arm Circumference (cm); TSF = Triceps Skin fold (mm) AMC = Arm Muscle Circumference (cm); Total prot.,C0444504|C0549183|C0042295|C0003188|C0205474|C0079809|C0030705|G0000000|C0012634|C0009956|G0000000|C0521116|C0005910|C0022718|G0000000|G0000000|C0242821|C0577559|C0918012|C0022718|C0003354|G0000000|C0446516|C0332520|G0000000|C3887665|G0000000|C0559502|C0444099|C0332462|G0000000|G0000000|G0000000|C0446516|C0026845|C0332520|G0000000|C0439175|C0555903
"Eligibility criteria included child age of 6 to 12 years; physician-diagnosed asthma, symptom frequency, and/or controller medication use signifying persistent asthma6; a smoker in the home who smoked more than 5 cigarettes per day and resided in the home at least 4 days per week; and residence in the Baltimore metropolitan area.","Eligibility criteria included child age 6 12 years; physician-diagnosed asthma, symptom frequency, and/or controller medication signifying persistent asthma6; smoker smoked 5 cigarettes day resided 4 days week; residence Baltimore metropolitan area.",C0013893|C0243161|C0332257|C0008059|C0001779|G0000000|C0450371|C0439234|C0031831|C0004096|C1457887|C0376249|G0000000|C0180112|C0013227|G0000000|C0205322|G0000000|C0337664|C0037366|G0000000|C0677453|C0332173|C2982691|G0000000|C0439228|C0332174|C0237096|C0004716|C0599587|C0017446
"In this context, the primary aim of the trial is to assess the effectiveness of a web-based menu planning intervention in increasing the mean number of food groups on childcare service menus that comply with dietary guidelines regarding food provision to children in care.","In context, primary aim trial assess effectiveness web-based menu planning intervention increasing food childcare service menus comply dietary guidelines food provision children care.",G0000000|C0449255|C0205225|C1947946|C0008976|C1516048|C1280519|C0282111|G0000000|C0032074|C0886296|C0442808|C0016452|C0008067|C0557854|G0000000|C0725694|C0012155|C0162791|C0016452|C1549071|C0008059|C1947933
"(B) 1st grader BMI change by paternal BMI categories, P = 0.118.","(B) 1st grader BMI change paternal BMI categories, P = 0.118.",G0000000|G0000000|G0000000|G0000000|C0392747|C0337493|G0000000|C0683312|C0369773|G0000000|C1442061
"Secondary outcomes included disability score, caregivers' quality of life, and parental knowledge of asthma.","Secondary outcomes included disability score, caregivers' quality life, parental knowledge asthma.",C0027627|C1274040|C0332257|C0231170|C0449820|C0085537|C0332306|C0376558|C0030551|C0376554|C0004096
No severe TEAEs requiring hospitalization were reported in the 4-year trial interval.,No severe TEAEs requiring hospitalization reported 4-year trial interval.,G0000000|C0205082|G0000000|G0000000|C0019993|C0684224|C0439234|C0008976|C1272706
Two levels of response were calculated based on a combination of WOMAC and VAS metrics of pain and results are summarized in Table Table4.4.,Two levels response calculated based combination WOMAC VAS metrics pain summarized Table Table4.4.,C0205448|C0441889|C0871261|C0444686|C1527178|C0205195|G0000000|C0042815|C0699680|C0030193|G0000000|C0039224|G0000000
"Comparison of the baseline measurement data and 6-month measurement data between both groups was analyzed using two-sample t tests including age; body mass index; patient's disease history; smoking history; spirometry; cells counts in sputum; concentrations of IL-8, NE, MMP9, TIMP-1, MMP9/TIMP-1, HA, and type IV collagen in induced sputum; and WT% and WA% of CT evaluation.","Comparison baseline measurement data 6-month measurement data analyzed two-sample tests including age; body mass index; patient's disease history; smoking history; spirometry; cells counts sputum; concentrations IL-8, NE, MMP9, TIMP-1, MMP9/TIMP-1, HA, type IV collagen induced sputum; WT% WA% CT evaluation.",C1707455|C0168634|C0242485|C1511726|C0332177|C0242485|C1511726|C0936012|C0205448|C0022885|C0332257|C0001779|C0242821|C0577559|C0918012|C0030705|C0012634|C0019664|C0037369|C0019664|C0037981|C0007634|C0439157|C0038056|C0086045|C0020898|C0028219|G0000000|G0000000|G0000000|C0018510|C0332307|C0022326|C0009325|C0205263|C0038056|C2700323|C0027366|C0007673|C0220825
The smoking abstinence rate was 51% (7-day point prevalence) at the end of 8 weeks of patch therapy.,The smoking abstinence rate 51% (7-day prevalence) 8 weeks patch therapy.,G0000000|C0037369|C3843422|C0871208|C0450371|C0332173|C0033105|G0000000|C0439230|C0332461|C0039798
MAIN OUTCOME MEASURES: Attendance for breast screening in relation to ethnic group in women who had not taken up their original invitation.,MAIN OUTCOME MEASURES: Attendance breast screening relation ethnic women original invitation.,C0205225|C1274040|C0079809|C2827364|C0006141|C0220908|C0080103|C0015031|C0043210|C0205313|C2826348
"The primary outcome evaluated at completion of TB therapy was outcome of TB treatment, as classified by the national programme.","The primary outcome evaluated completion TB therapy outcome TB treatment, classified national programme.",G0000000|C0205225|C1274040|C0220825|C0205197|G0000000|C0039798|C1274040|G0000000|C0039798|C0008902|C3245503|C1709697
Overall virological suppression was good; being greater than 85% at all six-monthly measurement intervals up to 36 months of treatment (figure 1).,Overall virological suppression good; 85% six-monthly measurement intervals 36 months treatment (figure 1).,C0282416|C0205466|C0221103|C0205170|C0450371|C0585339|C0242485|C1272706|C0450371|C0439231|C0039798|G0000000|G0000000
"The secondary outcome measures (3 months after intervention) were the Schirmer's I test for tear production, TBUT, the Rose Bengal score (RBS) as a measure of ocular surface integrity and conjunctival impression cytology (CIC) scores for cellular changes and goblet cell density.","The secondary outcome measures (3 months intervention) Schirmer's I test tear production, TBUT, Rose Bengal score (RBS) measure ocular surface integrity conjunctival impression cytology (CIC) scores cellular goblet cell density.",G0000000|C0027627|C1274040|C0079809|G0000000|C0439231|C0886296|C1875738|C0021966|C0022885|C0039409|C0033268|G0000000|C0035853|C0444826|C0449820|C0392475|C0079809|C0015392|C0205148|C0205266|C0009758|C0596764|C0010818|C0055670|C0449820|C0007634|G0000000|C0007634|C0178587
[Results] Balance and functional reach test outcomes were examined in both groups.,[Results] Balance functional reach test outcomes examined groups.,C1274040|C0014653|C0205245|C2584321|C0022885|C1274040|C0332128|C0441833
"We used cognitive abilities screening scales includes MMSE, MoCA and FIM as the outcome measures in order to track changes in the functional status over the 12-week interventions period.","We cognitive abilities screening scales includes MMSE, MoCA FIM outcome measures track functional status 12-week interventions period.",G0000000|C1516691|C0085732|C0220908|C0175659|C0332257|C0451306|C3541265|C3273671|C1274040|C0079809|C0040594|C0205245|C0449438|C0450371|C0886296|C0439531
"For the patient-based colonoscopies, patients were included if they gave informed consent, were undergoing a screening or surveillance colonoscopy, were between 18 and 75 years of age and had previously undergone colonoscopy without reported difficulty.","For patient-based colonoscopies, patients included informed consent, undergoing screening surveillance colonoscopy, 18 75 age undergone colonoscopy reported difficulty.",G0000000|C1709483|C0009378|C0030705|C0332257|C1522154|C1511481|G0000000|C0220908|C0220920|C0009378|C0450371|C0450371|C0001779|G0000000|C0009378|C0684224|C1299586
The primary efficacy endpoint was changed from baseline in SGRQ total score at day 84.,The primary efficacy endpoint changed baseline SGRQ total score day 84.,G0000000|C0205225|C1280519|C2349179|C0392747|C0168634|G0000000|C0439175|C0449820|C0332173|C0450371
LLITN distribution in Ethiopia primarily focuses on households with children less than five years of age and pregnant women in targeted areas[2].,LLITN distribution Ethiopia focuses households children age pregnant women targeted areas[2].,G0000000|C0520511|C0015024|C0205234|C0020052|C0008059|C0001779|C0549206|C0043210|C1521840|C0205146
"Outcome measurements include mini–mental state examination (MMSE), Montreal cognitive assessments (MoCA), functional independence measure scale (FIM) and adverse events.","Outcome measurements mini–mental examination (MMSE), Montreal cognitive assessments (MoCA), functional independence measure scale (FIM) adverse events.",C1274040|C0242485|G0000000|G0000000|C0451306|G0000000|C1516691|C1261322|C3541265|C0205245|C0085862|C0079809|C0175659|C3273671|G0000000|C0441471
"Participants who reported complete abstinence (not even a puff of a cigarette) for at least 7 days before being contacted during any follow-up interview were asked to come to the hospital to provide a saliva or urine sample for confirmation of smoking cessation with use of a cotinine (half-life, 17 hours) or anabasine test (2 week detection window), respectively.","Participants reported complete abstinence (not puff cigarette) 7 days contacted follow-up interview hospital provide saliva urine sample confirmation smoking cessation cotinine (half-life, 17 hours) anabasine test (2 week detection window), respectively.",C0679646|C0684224|C0205197|C3843422|C1518422|C1533107|C0677453|G0000000|C0439228|C0332158|C0589120|C0021822|C0019994|C1999230|C0036087|C0042036|C0370003|C0521091|C0037369|C1880019|C0010194|C0018517|C0450371|C0439227|C0002743|C0022885|G0000000|C0332174|C1511790|C0557702|G0000000
"The primary outcome evaluated at each 4-week visit for an injection was the number of days with symptoms during the previous 2 weeks, as used in previous studies of inner-city asthma.1,2 Other outcomes included exacerbations, defined as a need for systemic glucocorticoids, hospitalization, or both, in accordance with a recent report by the American Thoracic Society and European Respiratory Society15; the dose of inhaled glucocorticoids needed to maintain asthma control; spirometric measurements; the score on the Childhood Asthma Control Test (C-ACT)16; and the score on the Asthma Control Test (ACT).17 Scores on the C-ACT and ACT range from 0 to 27 and 5 to 25, respectively, with scores of 20 or more indicating asthma control.","The primary outcome evaluated 4-week visit injection days symptoms previous 2 weeks, previous studies inner-city asthma.1,2 Other outcomes included exacerbations, defined systemic glucocorticoids, hospitalization, both, report American Thoracic Society European Respiratory Society15; dose inhaled glucocorticoids maintain asthma control; spirometric measurements; score Childhood Asthma Control Test (C-ACT)16; score Asthma Control Test (ACT).17 Scores C-ACT ACT range 0 27 5 25, respectively, scores 20 indicating asthma control.",G0000000|C0205225|C1274040|C0220825|C0332174|C0545082|C0021485|C0439228|C0683368|C0205156|G0000000|C0439230|C0205156|C0947630|C0557849|C0004096|G0000000|C1274040|C0332257|G0000000|C1704788|C0205373|C0017710|C0019993|G0000000|C0684224|C0596070|G0000000|C0037455|C0239307|C0521346|G0000000|C0178602|C0004048|C0017710|C0024501|C0004096|C0243148|C0037981|C0242485|C0449820|C0231335|C0004096|C0243148|C0022885|C0079613|C0449820|C0004096|C0243148|C0022885|C0079613|C0449820|C0079613|C0079613|C1514721|G0000000|C0450371|G0000000|C0450371|G0000000|C0449820|C0450371|G0000000|C0004096|C0243148
"Mothers' reports of children's exposure to their smoke in the home declined in the counselled group from 27.30 cigarettes/week at baseline, to 4.47 at three months, to 3.66 at 12 months and in the controls from 24.56, to 12.08, to 8.38.","Mothers' reports children's exposure smoke declined counselled 27.30 cigarettes/week baseline, 4.47 months, 3.66 12 months controls 24.56, 12.08, 8.38.",C0026591|C0684224|C0008059|C0274281|C0037366|G0000000|C0341618|C0450371|C0677453|C0168634|C0450371|C0439231|C0450371|C0450371|C0439231|C0243148|C0450371|C0450371|C0450371
Clinical response at the test of cure (TOC) or early termination (ET) visit was the primary efficacy endpoint of the study.,Clinical response test cure (TOC) termination (ET) visit primary efficacy endpoint study.,C0205210|C0871261|C0022885|C1880198|C1835664|C1549081|G0000000|C0545082|C0205225|C1280519|C2349179|C0557651
"Secondary end points were the possible beneficial effects of VSL#3 on the following: activity of relapsing UC; remission, considered as UCDAI ≤2, assessed at week 8; improvement in endoscopic scores, assessed by the endoscopic subgroup score of the UCDAI at week 8; change in objective symptoms (rectal bleeding and stool frequency); change in subjective symptoms (physician rating of disease activity); lack of beneficial effects, defined by the need for pharmacological treatment or inability to remain on the study regimen until week 8.","Secondary beneficial effects VSL#3 following: activity relapsing UC; remission, considered UCDAI ≤2, assessed week 8; improvement endoscopic scores, assessed endoscopic subgroup score UCDAI week 8; change objective symptoms (rectal bleeding stool frequency); change subjective symptoms (physician rating disease activity); lack beneficial effects, defined pharmacological treatment inability remain study regimen week 8.",C0027627|G0000000|C1280500|G0000000|C0231290|C0205177|C0035020|G0000000|C0544452|C0750591|G0000000|G0000000|C1516048|C0332174|G0000000|C2986411|C0014245|C0449820|C1516048|C0014245|C1079230|C0449820|G0000000|C0332174|G0000000|C0392747|C0018017|C0683368|C0205052|C0019080|C0015733|C0376249|C0392747|C0439655|C0683368|C0031831|C0871208|C0012634|C0205177|C0332268|G0000000|C1280500|C1704788|C0031330|C0039798|G0000000|G0000000|C0557651|C0040808|C0332174|G0000000
"Secondary outcomes include participation level, depressive symptoms, and planned-use of health services for health promotion and secondary prevention.","Secondary outcomes participation level, depressive symptoms, planned-use health services health promotion secondary prevention.",C0027627|C1274040|C0679823|C0441889|G0000000|C0683368|C1301732|C0018684|C0557854|C0018684|C0033414|C0027627|C0199176
"The primary endpoint was time to a protocol-defined pulmonary exacerbation requiring oral, inhaled, or intravenous antibiotics, using a prespecified definition (Table 1) (13, 23).","The primary endpoint time protocol-defined pulmonary exacerbation requiring oral, inhaled, intravenous antibiotics, prespecified definition (Table 1) (13, 23).",G0000000|C0205225|C2349179|C0040223|C0442711|C0024109|G0000000|G0000000|C0442027|C0004048|C0348016|C0003232|G0000000|C1550452|C0039224|G0000000|C0450371|C0450371
"Observational Tool: Child behavioral distress was measured by Observational Scale of Behavioral Distress–Revised (OSBD–R), its validity and reliability has been verified by Elliot et al.","Observational Tool: Child behavioral distress measured Observational Scale Behavioral Distress–Revised (OSBD–R), validity reliability verified Elliot al.",C1518527|C0336791|C0008059|C0004927|C0231303|C0444706|C1518527|C0175659|C0004927|G0000000|G0000000|C2349101|C2347947|C1711411|G0000000|C0202311
"No significant differences were observed in the frequency of serious adverse events or of adverse events leading to discontinuation of the study drug, but an audiogram-confirmed hearing decrement occurred in 142 of the participants receiving azithromycin (27%), as compared with 110 of those receiving placebo (21%) (P=0.04).","No differences observed frequency adverse events adverse events leading discontinuation study drug, audiogram-confirmed hearing decrement occurred 142 participants receiving azithromycin (27%), compared 110 receiving placebo (21%) (P=0.04).",G0000000|C1705241|C1441672|C0376249|G0000000|C0441471|G0000000|C0441471|C0332152|C0457454|C0557651|C0013227|C0018786|C0018767|G0000000|C1709305|C1442061|C0679646|C1514756|C0052796|C0450371|C1707455|C1442061|C1514756|C0032042|C0450371|C0369773
"OBJECTIVE: To determine the efficacy of single doses of albendazole, ivermectin and diethylcarbamazine, and of the combinations albendazole + ivermectin and albendazole + diethylcarbamazine against common intestinal helminthiases caused by Ascaris and Trichuris spp.","OBJECTIVE: To determine efficacy single doses albendazole, ivermectin diethylcarbamazine, combinations albendazole + ivermectin albendazole + diethylcarbamazine common intestinal helminthiases caused Ascaris Trichuris spp.",C0018017|C0040363|G0000000|C1280519|C0037179|C0178602|C0001911|C0022322|C0012191|C0453882|C0001911|G0000000|C0022322|C0001911|G0000000|C0012191|C0205214|C0021853|C0018889|C0015127|C0003954|C0040955|C1424276
"The outcome was assessed by intention to treat analyses of the percentage confirmed sustained abstinence at 4, 12, 26 and 52 weeks after quit day.","The outcome assessed intention treat analyses percentage confirmed sustained abstinence 4, 12, 26 52 weeks quit day.",G0000000|C1274040|C1516048|C0162425|C0087111|C0002778|C0439165|C0521093|C0443318|C3843422|G0000000|C0450371|C0450371|G0000000|C0748223|C0332173
Incident cases of overweight or obesity were identified.,Incident overweight obesity identified.,C1551358|C0497406|C0028754|C0205396
A “cold” was defined by the presence of >2 consecutive purple stickers indicating days with cold symptoms.,A “cold” defined presence >2 consecutive purple stickers indicating days cold symptoms.,G0000000|G0000000|C1704788|C0150312|G0000000|C1707491|C0439542|G0000000|G0000000|C0439228|C0009264|C0683368
"The GMU-Gynae Index assesses sexual life quality (sexual difficulties, emotional exchange between the couple, regression of sexual life and sexual desire), symptoms of lower urinary tract infection (urethral burning and frequent urination), autonomic dysfunction (itchy skin, dry skin and formication).","The GMU-Gynae Index assesses sexual life quality (sexual difficulties, emotional exchange couple, regression sexual life sexual desire), symptoms lower urinary tract infection (urethral burning frequent urination), autonomic dysfunction (itchy skin, dry skin formication).",G0000000|C1905948|C0918012|C1516048|C0036864|C0376558|C0332306|C0036864|C1299586|C0013987|C0678640|C0010222|C0684320|C0036864|C0376558|C0036864|C0871633|C0683368|C0441994|C0042027|C1185740|C0009450|C0041967|C0000912|C0332183|C0042034|C0004388|C0031847|C0033774|C0444099|C0011682|C0444099|C0016579
"Although the improvement in the imipramine group was considerable (63% and 67% on the Hamilton depression scale at weeks 6 and 8), indicating effective responder rates for antidepressive treatment, only a strong tendency towards superior efficacy over placebo could be found in the Hamilton depression scale.","Although improvement imipramine considerable (63% 67% Hamilton depression scale weeks 6 8), indicating effective responder rates antidepressive treatment, strong tendency superior efficacy placebo Hamilton depression scale.",G0000000|C2986411|C0020934|G0000000|C0450371|C0450371|G0000000|C0011570|C0175659|C0439230|G0000000|G0000000|G0000000|C1280519|G0000000|C0871208|C0003289|C0039798|C0442821|G0000000|C1282910|C1280519|C0032042|G0000000|C0011570|C0175659
"Patient status was scored: 0 (worst), 1, or 2 (best) on a composite measure that balanced Major Neurological Improvement (MNI)4 against risk of symptomatic ICH.","Patient status scored: 0 (worst), 1, 2 (best) composite measure balanced Major Neurological Improvement (MNI)4 risk symptomatic ICH.",C0030705|C0449438|C0449820|G0000000|C1522166|G0000000|G0000000|C1522427|C0205199|C0079809|C0205415|C0205082|C0205494|C2986411|G0000000|C0035647|C0231220|C0019191
"Confirmation of abstinence was defined as an exhaled CO level of <10 parts per million (ppm) or salivary cotinine concentration of <15 ng/ml on each occasion.12 Participants who were withdrawn (which was commonly due to reverting to smoking) or who were lost to follow‐up (unless they moved to an untraceable address or had died) were counted as smokers, as is standard.10 We also studied NRT use.","Confirmation abstinence defined exhaled CO level <10 (ppm) salivary cotinine concentration <15 ng/ml occasion.12 Participants withdrawn (which commonly reverting smoking) lost follow‐up (unless moved untraceable address died) counted smokers, standard.10 We studied NRT use.",C0521091|C3843422|C1704788|C0231800|C3245499|C0441889|C0450371|C0439187|C0442040|C0010194|C0004268|G0000000|C0521114|C0679646|C0424092|G0000000|G0000000|G0000000|C0037369|C0745777|G0000000|G0000000|C1269909|G0000000|C0376649|C0011065|C0750480|C0337664|C1442989|G0000000|C0557651|C1278444|C0042153
"Pain and function were documented on initial of the program and again 3 weeks later, on the completion.","Pain function documented initial program 3 weeks later, completion.",C0030193|C0031843|C1301725|C0205265|C1709697|G0000000|C0439230|C0205087|C0205197
1].,1].,G0000000
The large effect size observed for the significant time x group interaction (indicating a significant effect of the intervention over time) observed in the scale measuring use of compensatory memory strategies is not surprising.,The size observed time interaction (indicating intervention time) observed scale measuring compensatory memory strategies surprising.,G0000000|C0456389|C1441672|C0040223|C1704675|G0000000|C0886296|C0040223|C1441672|C0175659|C0444706|C0231186|C0025260|C0679199|G0000000
"Baseline characteristics (age, education, attention and executive function test scores) as well as group means and variability in baseline measurements for each of the behavioural and neural variables were assessed.","Baseline characteristics (age, education, attention executive function test scores) variability baseline measurements behavioural neural variables assessed.",C0168634|C1521970|C0001779|C0013621|C0004268|C0871735|C0031843|C0022885|C0449820|C2827666|C0168634|C0242485|C0004927|C3714606|C0439828|C1516048
"Indoor resting density, parity rate, sporozoite and human blood meal index rate of Anopheles gambiae s.l.","Indoor resting density, parity rate, sporozoite human blood meal rate Anopheles gambiae s.l.",G0000000|C0035253|C0178587|C0030563|C0871208|C0562648|C0086418|C0005767|C1998602|C0871208|C0003117|G0000000|C0439394
"The primary endpoint is a composite of CV death, nonfatal myocardial infarction (MI), nonfatal stroke, coronary revascularization, or unstable angina.","The primary endpoint composite CV death, nonfatal myocardial infarction (MI), nonfatal stroke, coronary revascularization, unstable angina.",G0000000|C0205225|C2349179|C0205199|C3538987|C0011065|G0000000|C0027061|C0021308|C3810814|G0000000|C0038454|C0018787|C0581603|C0443343|C0002962
"Significant differences existed in the Standardized Swallowing Assessment, Dysphagia Outcome Severity Scale, Modified Barthel Index, and Swallowing-Related Quality of Life scores of each group after the treatment (P < 0.01).","Significant differences existed Standardized Swallowing Assessment, Dysphagia Outcome Severity Scale, Modified Barthel Index, Swallowing-Related Quality Life scores treatment (P < 0.01).",C0237881|C1705241|C2987476|G0000000|C0011167|C1261322|C0011168|C1274040|C0439793|C0175659|C0392747|G0000000|C0918012|C0011167|C0332306|C0376558|C0449820|C0039798|C0369773|G0000000|C0450371
"When regressing each of the five factors onto the intervention group variable and the IMC covariate, we found no statistical differences between the intervention and control groups for peer use of HLPs, normative beliefs about peer use, and cultural identity.","When regressing factors intervention variable IMC covariate, statistical differences intervention control peer HLPs, normative beliefs peer use, cultural identity.",G0000000|C0684320|C1521761|C0886296|C0439828|C3826992|G0000000|C0038215|C1705241|C0886296|C0243148|C0679739|C1567160|G0000000|C0004951|C0679739|C0042153|C0010453|C0424215
"The primary endpoint was the composite clinical score combining death, hospital admission for heart failure (HF), change in functional class, and patient global self-assessment.","The primary endpoint composite clinical score combining death, hospital admission heart failure (HF), change functional class, patient global self-assessment.",G0000000|C0205225|C2349179|C0205199|C0205210|C0449820|C0336789|C0011065|C0019994|C0184666|C0018787|C0231174|C0018488|C0392747|C0205245|C0456387|C0030705|C0205246|C0036591
The 28-day mortality rate in Tugrul et al.,The 28-day mortality rate Tugrul al.,G0000000|C0450371|C0026565|C0871208|G0000000|C0202311
PCR genotyping was performed for such patients to allow differentiation between relapse and reinfection.,PCR genotyping performed patients differentiation relapse reinfection.,C0032520|C1285573|C0884358|C0030705|C0007589|C0035020|C0205339
"Prior to the intervention, participants were trained how to use a visual analogue scale (VAS ranged 0-10); patients’ pain scores were measured before the intervention.","Prior intervention, participants trained visual analogue scale (VAS ranged 0-10); patients’ pain scores measured intervention.",C0332152|C0886296|C0679646|C0336809|C0234621|C0243071|C0175659|C0042815|C1514721|C0450371|G0000000|C0030193|C0449820|C0444706|C0886296
Outcome measures will be assessed at baseline and again at 3 and 6 months after the interventions.,Outcome measures assessed baseline 3 6 months interventions.,C1274040|C0079809|C1516048|C0168634|G0000000|G0000000|C0439231|C0886296
"Changes from baseline values in daytime asthma and night time asthma symptom scores, usage of rescue bronchodilators, mean peak expiratory flow (PEF) recorded twice daily on diary cards, patients' opinion of treatment, and withdrawals due to treatment failure were measured during the primary treatment period (last six weeks of treatment).","Changes baseline values daytime asthma night time asthma symptom scores, usage rescue bronchodilators, peak expiratory flow (PEF) recorded daily diary cards, patients' opinion treatment, withdrawals treatment failure measured primary treatment period (last weeks treatment).",C0392747|C0168634|C0042295|C0332169|C0004096|C0240526|C0040223|C0004096|C1457887|C0449820|C0457083|G0000000|C0006280|C0444505|C0231800|C0806140|C0030771|C0034869|C0332173|C0376660|C3275277|C0030705|C0871010|C0039798|C2349954|C0039798|C0231174|C0444706|C0205225|C0039798|C0439531|C1517741|C0439230|C0039798
"One month after the treatment, pre and post treatment symptom severity scores of pruritus, erythema and scales were compared.","One month treatment, pre post treatment symptom severity scores pruritus, erythema scales compared.",C0205447|C0332177|C0039798|C0332152|C0687676|C0039798|C1457887|C0439793|C0449820|C0033774|C0041834|C0175659|C1707455
All other adverse neurological events were well tolerated and resolved during or shortly after treatment.,All adverse neurological events tolerated resolved shortly treatment.,G0000000|G0000000|C0205494|C0441471|G0000000|C1514893|G0000000|C0039798
"Secondary endpoints are the effect of glycine on liver injury based on liver biopsy immediately after re-arterialisation (according to pathological report), total blood flow in portal vein and common hepatic artery 1 hour after reperfusion, graft injury based on both AST and ALT serum levels (area under the curve (AUC)), incidence of early graft failure based on peak of transaminases or clotting factor support, early onset of graft dysfunction based on Quick's value, serum bilirubin (AUC), and CyA-induced nephrotoxicity based on retention parameters during the first eight days after transplantation (AUC).","Secondary endpoints glycine liver injury based liver biopsy re-arterialisation (according pathological report), total blood flow portal vein common hepatic artery 1 hour reperfusion, graft injury based AST ALT serum levels (area curve (AUC)), incidence graft failure based peak transaminases clotting factor support, onset graft dysfunction based Quick's value, serum bilirubin (AUC), CyA-induced nephrotoxicity based retention parameters days transplantation (AUC).",C0027627|C2349179|C0017890|C0023884|C3263722|C1527178|C0023884|C0005558|C0556581|C0680240|C0030664|C0684224|C0439175|C0005767|C0806140|C0205054|C0042449|C0205214|C0205054|C0003842|G0000000|C0439227|C0035124|C0181074|C3263722|C1527178|C3891303|C1266129|C0229671|C0441889|C0017446|C0205134|C0376690|C0021149|C0181074|C0231174|C1527178|C0444505|C0002594|C0005778|C1521761|C0183683|C0206132|C0181074|C0031847|C1527178|C0456962|C1522609|C0229671|C0005437|C0376690|C0205263|C0599918|C1527178|C0035280|C0449381|C0439228|C0040732|C0376690
"The gains were calculated by subtracting the SIAS Hip-Flexion, Knee-Extension, and Foot-Pat scores on admission from those at 4 weeks.","The gains calculated subtracting SIAS Hip-Flexion, Knee-Extension, Foot-Pat scores admission 4 weeks.",G0000000|C1517378|C0444686|C1719767|C1225105|C0019552|C0022742|C0016504|C0449820|C0184666|G0000000|C0439230
"Data on urine toxicology results and self-report outcome measures from the Current Opioid Misuse Measure (COMM), and Prescription Drug Use Questionnaire (PDUQ) allowed for group comparisons.","Data urine toxicology self-report outcome measures Current Opioid Misuse Measure (COMM), Prescription Drug Use Questionnaire (PDUQ) allowed comparisons.",C1511726|C0042036|C0040541|C0681906|C1274040|C0079809|C0521116|C0242402|C0549649|C0079809|C3639709|C0033080|C0013227|C0042153|C0034394|G0000000|C0683607|C1707455
The peak amplitude of EMG burst of BoNT-A injected muscles were significantly decreased in both groups.,The peak amplitude EMG burst BoNT-A injected muscles decreased groups.,G0000000|C0444505|C2346753|G0000000|C0439818|G0000000|C1720154|C0026845|C0205216|C0441833
"An analysis of covariance (ANCOVA) model (covariates: baseline FEV1, smoking status and treatment) was used to analyse the 0–24 h wmFEV1 on Day 84.","An analysis covariance (ANCOVA) model (covariates: baseline FEV1, smoking status treatment) analyse 0–24 wmFEV1 Day 84.",G0000000|C0002778|G0000000|C0814908|C3161035|G0000000|C0168634|G0000000|C0037369|C0449438|C0039798|G0000000|G0000000|G0000000|C0332173|C0450371
The means of nausea and vomiting intensity in the second and fourth days in the intervention group were significantly lower than the control group.,The nausea vomiting intensity fourth days intervention lower control group.,G0000000|C0027497|C0042963|C0522510|C0205438|C0439228|C0886296|C0441994|C0243148|C0441833
These analyses used baseline CD4 as a covariate.,These analyses baseline CD4 covariate.,G0000000|C0002778|C0168634|C0285590|G0000000
"OABSS measures four broad domains (daily micturition, nocturia, urinary urgency, and urge UI [UUI]).","OABSS measures broad domains (daily micturition, nocturia, urinary urgency, urge UI [UUI]).",G0000000|C0079809|C0332464|C1880389|C0332173|C0042034|C0028734|C0042027|C0439609|G0000000|C1421312|G0000000
"METHODS—In a randomised controlled trial in 17 Scottish local council areas, with immediate and nine month follow up, 182 children and their foster families were randomly allocated to either standard services alone or standard services plus extra training for foster carers on communication and attachment.","METHODS—In randomised controlled trial 17 Scottish local council areas, month follow up, 182 children foster families randomly allocated standard services standard services extra training foster carers communication attachment.",G0000000|G0000000|C2587213|C0008976|C0450371|C0240966|C0205276|C1551807|C0205146|C0332177|C0332283|G0000000|C1442061|C0008059|C0242298|C0015576|G0000000|G0000000|C1442989|C0557854|C1442989|C0557854|G0000000|C0040607|C0242298|C0085537|C0009452|C0185023
"We therefore employ a monitoring and evaluation framework, combining process evaluation methods and outcome methods (Hubbard and Miller 2004), applying the following criteria; (a) perceptions on treatment outcome by client, parents and service providers; (b) client and therapist treatment satisfaction; (c) therapist burden; (d) level of selection and access to care following the levels outlined above, and; (e) care package costs.","We employ monitoring evaluation framework, combining process evaluation methods outcome methods (Hubbard Miller 2004), applying criteria; (a) perceptions treatment outcome client, parents service providers; (b) client therapist treatment satisfaction; (c) therapist burden; (d) level selection access care levels outlined above, and; (e) care package costs.",G0000000|C0457083|C0150369|C0220825|G0000000|C0336789|C1184743|C0220825|C0025663|C1274040|C0025663|G0000000|C0402830|G0000000|C1632850|C0243161|G0000000|C0030971|C0039798|C1274040|C0008942|C0030551|C0557854|C1138603|G0000000|C0008942|C0871525|C0039798|C0242428|G0000000|C0871525|C2828008|C0073187|C0441889|C0036576|C0444454|C1947933|C0441889|G0000000|C1282910|G0000000|G0000000|C1947933|C0013194|C0010186
None of the serious adverse events were likely related to the study medication.,None adverse events study medication.,G0000000|G0000000|C0441471|C0557651|C0013227
The mean ± standard deviation exercise endurance time was 522 ± 172 seconds.,The ± standard deviation exercise endurance time 522 ± 172 seconds.,G0000000|G0000000|C1442989|C0012727|C0015259|C0518031|C0040223|C1442061|G0000000|C1442061|C0457385
"Secondary outcomes included: fast overground walking speed, 6-minute walk test, and a battery of clinical measures.","Secondary outcomes included: fast overground walking speed, 6-minute walk test, battery clinical measures.",C0027627|C1274040|C0332257|C0015663|G0000000|C0080331|C0678536|C0439232|C0080331|C0022885|C0337088|C0205210|C0079809
Point 1 to 3: Mild pruritus Point 4 to 6: Moderate pruritus Point 7 to 10: Severe pruritus Severity of the disease is measured according to the number of lesions present.,Point 1 3: Mild pruritus Point 4 6: Moderate pruritus Point 7 10: Severe pruritus Severity disease measured lesions present.,C1552961|G0000000|G0000000|C2945599|C0033774|C1552961|G0000000|G0000000|C0205081|C0033774|C1552961|G0000000|C0450371|C0205082|C0033774|C0439793|C0012634|C0444706|C0221198|C0150312
"Similar results were observed for the Box and Block Test and Functional Test for the upper extremity, where both groups did not have statistically significant differences pre- and post-intervention.","Similar observed Box Block Test Functional Test upper extremity, statistically differences pre- post-intervention.",C2348205|C1441672|C0179400|C0028778|C0022885|C0205245|C0022885|C1282910|C0015385|C0038215|C1705241|C0332152|C2347647
Households were eligible for the study if they had children aged 0.5–14 y.,Households eligible study children aged 0.5–14 y.,C0020052|C1548635|C0557651|C0008059|C0001779|G0000000|G0000000
"Outcomes, by follow-up time Note: BCTQ = Boston Carpal Tunnel Questionnaire, CI = confidence interval, DASH = Disabilities of the Arm, Shoulder and Hand Questionnaire, DMMPUT = Dellon–modified Moberg pick-up test, FSS = Functional Status Scale, MD = mean difference, NRS = numeric rating scale, SSS = Symptom Severity Scale, SWMT = Semmes–Weinstein Monofilament Test.","Outcomes, follow-up time Note: BCTQ = Boston Carpal Tunnel Questionnaire, CI = confidence interval, DASH = Disabilities Arm, Shoulder Hand Questionnaire, DMMPUT = Dellon–modified Moberg pick-up test, FSS = Functional Status Scale, MD = difference, NRS = numeric rating scale, SSS = Symptom Severity Scale, SWMT = Semmes–Weinstein Monofilament Test.",C1274040|C0589120|C0040223|C1316572|G0000000|G0000000|C0006037|C0007285|C0337138|C0034394|C0008107|G0000000|C0237529|C1272706|C2827624|G0000000|C0231170|C0446516|C0037004|C0018563|C0034394|G0000000|G0000000|G0000000|G0000000|C1707391|C0022885|C0265224|G0000000|C0205245|C0449438|C0175659|G0000000|G0000000|C1705241|C2240043|G0000000|C0237753|C0871208|C0175659|C0037052|G0000000|C1457887|C0439793|C0175659|G0000000|G0000000|G0000000|G0000000|C0022885
"The IES is designed to assess current subjective distress for any specific life event [47,48].","The IES designed assess current subjective distress specific life event [47,48].",G0000000|G0000000|C1707689|C1516048|C0521116|C0439655|C0231303|C0205369|C0376558|C0441471|C0450371
"Percentage of Opioid-Positive Urine Test Results at Baseline and Weeks 4, 8, and 12 and Follow-up Months 6, 9, and 12 Detox indicates detoxification group.","Percentage Opioid-Positive Urine Test Results Baseline Weeks 4, 8, 12 Follow-up Months 6, 9, 12 Detox detoxification group.",C0439165|C0242402|C0042036|C0022885|C1274040|C0168634|C0439230|G0000000|G0000000|C0450371|C0589120|C0439231|G0000000|G0000000|C0450371|C0674607|C0025516|C0441833
Each patient was assessed with the Boston Carpal Tunnel Questionnaire (BCTQ) and DASH preoperatively and at each followup.,Each patient assessed Boston Carpal Tunnel Questionnaire (BCTQ) DASH preoperatively followup.,G0000000|C0030705|C1516048|C0006037|C0007285|C0337138|C0034394|G0000000|C2827624|G0000000|C0589120
"and placebo was greater at radial (metaphysis and diaphysis) and femoral (neck, trochanter, and diaphyses) sites (7-12 mg/cm2 per yr) than in the lumbar spine (2 mg/cm2 per yr).","placebo radial (metaphysis diaphysis) femoral (neck, trochanter, diaphyses) sites (7-12 mg/cm2 yr) lumbar spine (2 mg/cm2 yr).",C0032042|C0442038|C0222671|C0242696|C0015811|C0027530|C0162370|C0242696|C0205145|C0450371|C0026410|C0439234|C0024090|C0037949|G0000000|C0026410|C0439234
The grade of chondrosarcoma relates to the likelihood of local recurrence and metastases.,The grade chondrosarcoma relates likelihood local recurrence metastases.,G0000000|C0441800|C0008479|C0163712|C0033204|C0205276|C0034897|C0027627
"EDSS: Expanded Disability Status Scale; MADRS: Montgomery-Asberg Depression Rating Scale; BDI: Beck Depression Inventory; EPA: Eicosapentaenoic Acid measured from red blood cell membranes; DHA: Docosahexaenoic Acid measured from red blood cell membranes; MS DMT Use: MS Disease Modifying Therapy use includes: glatiramer acetate, interferon beta-1a, interferon beta-1b.","EDSS: Expanded Disability Status Scale; MADRS: Montgomery-Asberg Depression Rating Scale; BDI: Beck Depression Inventory; EPA: Eicosapentaenoic Acid measured red blood cell membranes; DHA: Docosahexaenoic Acid measured red blood cell membranes; MS DMT Use: MS Disease Modifying Therapy includes: glatiramer acetate, interferon beta-1a, interferon beta-1b.",C0451246|C0205229|C0231170|C0449438|C0175659|C4054475|G0000000|C0011570|C0871208|C0175659|C0006448|G0000000|C0011570|C0021941|G0000000|G0000000|C0001128|C0444706|C0332575|C0005767|C0007634|C0025255|C0142831|G0000000|C0001128|C0444706|C0332575|C0005767|C0007634|C0025255|C0039676|C0027183|C0042153|C0039676|C0012634|C0392747|C0039798|C0332257|C0717787|C0000975|C0021747|C0330390|C0021747|C0330390
"The efficacy of the intervention on fatigue, functional impairments, psychological distress and quality of life will be examined as well.","The efficacy intervention fatigue, functional impairments, psychological distress quality life examined well.",G0000000|C1280519|C0886296|C0015672|C0205245|C0684336|C0205486|C0231303|C0332306|C0376558|C0332128|C0205170
"The primary outcome was the proportion of children under five years old reporting to have slept under an ITN the night before the survey, within households owning at least one ITN.","The primary outcome proportion children reporting slept ITN night survey, households owning ITN.",G0000000|C0205225|C1274040|C1709707|C0008059|C0700287|C0037313|G0000000|C0240526|C0038951|C0020052|G0000000|G0000000
"A recent publication outlined the complexities and challenges in examining other exacerbation endpoints such as number of events, which further supports the decision for the primary endpoint in the present trial.26 Time to first COPD exacerbation avoids major disadvantages of other exacerbation endpoints (ie, the number of exacerbations) such as: (a) separation of exacerbation events from events that are close in time, (b) change in maintenance therapy subsequent to events which may result in underestimation of exacerbation rates and uneven distribution across treatment groups, and (c) the effects of early discontinuation due to an event.","A publication outlined complexities challenges examining exacerbation endpoints events, supports decision primary endpoint trial.26 Time COPD exacerbation avoids major disadvantages exacerbation endpoints (ie, exacerbations) as: (a) separation exacerbation events events close time, (b) change maintenance therapy subsequent events result underestimation exacerbation rates uneven distribution treatment groups, (c) effects discontinuation event.",G0000000|C0034036|G0000000|C0439855|C0805586|C0332128|G0000000|C2349179|C0441471|C0183683|C0679006|C0205225|C2349179|C0008976|C0040223|C0024117|G0000000|G0000000|C0205082|G0000000|G0000000|C2349179|G0000000|G0000000|G0000000|G0000000|C0036679|G0000000|C0441471|C0441471|C0587267|C0040223|G0000000|C0392747|C0024501|C0039798|C0332282|C0441471|C1274040|G0000000|G0000000|C0871208|G0000000|C0520511|C0039798|C0441833|G0000000|C1280500|C0457454|C0441471
Change in the Irritable Bowel Symptom Severity Scale (IBS SSS score) and IBS Quality of Life Questionnaire (IBS-QOL) from baseline to 12 weeks.,Change Irritable Bowel Symptom Severity Scale (IBS SSS score) IBS Quality Life Questionnaire (IBS-QOL) baseline 12 weeks.,C0392747|C0022107|C0021853|C1457887|C0439793|C0175659|C0022104|C0037052|C0449820|C0022104|C0332306|C0376558|C0034394|C0022104|C0168634|C0450371|C0439230
"Among selected lifestyle-related factors including body mass index, height, education, physical activity, and intakes of alcohol, calcium, legumes, lycopene, and selenium, only smoking (RR for current (≥20 cigarettes/day) vs. never smoking = 0.72; 95% CI: 0.63-0.83) and history of diabetes (RR for yes vs. no = 0.78; 95% CI: 0.72-0.85) were significantly associated with prostate cancer risk.","Among selected lifestyle-related factors including body mass index, height, education, physical activity, intakes alcohol, calcium, legumes, lycopene, selenium, smoking (RR current (≥20 cigarettes/day) vs. smoking = 0.72; 95% CI: 0.63-0.83) history diabetes (RR vs. = 0.78; 95% CI: 0.72-0.85) prostate cancer risk.",G0000000|C1707391|C0023676|C1521761|C0332257|C0242821|C0577559|C0918012|C0489786|C0013621|C0031809|C0205177|C1512806|C0001962|C0006675|C0023263|C0065331|C0036581|C0037369|G0000000|C0521116|G0000000|C0677453|G0000000|C0037369|G0000000|C0450371|C0450371|C0008107|C0450371|C0019664|C0011847|G0000000|G0000000|G0000000|C0450371|C0450371|C0008107|C0450371|C0033572|C0006826|C0035647
The primary endpoint was 28-day all-cause mortality; secondary endpoints included survival without organ support on day 28.,The primary endpoint 28-day all-cause mortality; secondary endpoints included survival organ support day 28.,G0000000|C0205225|C2349179|C0450371|C0015127|C0026565|C0027627|C2349179|C0332257|C0038952|C0178784|C0183683|C0332173|C0450371
A 50% remission rate was expected with PEN2.,A 50% remission rate expected PEN2.,G0000000|C0450371|C0544452|C0871208|C1517001|G0000000
"Abbreviations: LOCF, last observation carried forward; VAS, visual analog scale.","Abbreviations: LOCF, observation carried forward; VAS, visual analog scale.",C0000723|C2825507|C0302523|C0206243|C0439780|C0042815|C0234621|C0243071|C0175659
"Primary outcomes were self‐efficacy, reported energy and routine health services utilisation at 6 months.","Primary outcomes self‐efficacy, reported energy routine health services utilisation 6 months.",C0205225|C1274040|G0000000|C0684224|C0424589|C0205547|C0018684|C0557854|C0042153|G0000000
"The primary outcome was smoking initiation, defined as the transition from never smoking to ever smoking at either follow-up.","The primary outcome smoking initiation, defined transition smoking smoking follow-up.",G0000000|C0205225|C1274040|C0037369|C0589507|C1704788|C0599156|C0037369|C0037369|C0589120
"Questions included the number of episodes of binge drinking in the previous week, the number of episodes of being drunk in the previous month, the frequency of traffic accidents or other accidents related to alcohol consumption during the previous 6 months, and the frequency of health care utilization attributable to alcohol in the previous 6 months.","Questions included episodes binge drinking previous week, episodes drunk previous month, frequency traffic accidents accidents alcohol consumption previous 6 months, frequency health care utilization attributable alcohol previous 6 months.",C1522634|C0332257|C0332189|C0596170|C0001948|C0205156|C0332174|C0332189|C0001969|C0205156|C0332177|C0376249|C3840880|C0000924|C0000924|C0001962|C0009830|C0205156|G0000000|C0439231|C0376249|C0018684|C1947933|C0042153|C0596130|C0001962|C0205156|G0000000|C0439231
The interaction (Treatment Group × Depressive Symptoms) was significant for drinks per drinking day and percentage of days used marijuana.,The interaction (Treatment Group × Depressive Symptoms) drinks drinking day percentage days marijuana.,G0000000|C1704675|C0039798|C0441833|G0000000|G0000000|C0683368|C0452428|C0001948|C0332173|C0439165|C0439228|C0024808
"However, breast cancer survivors may experience sequelae years after their diagnosis [30, 38], including fatigue, pain, fear of recurrence, and reduced quality of life.","However, breast cancer survivors experience sequelae diagnosis [30, 38], including fatigue, pain, fear recurrence, reduced quality life.",G0000000|C0006141|C0006826|C0206194|C0237607|C0243088|C0011900|C0450371|C0450371|C0332257|C0015672|C0030193|C0015726|C0034897|C0392756|C0332306|C0376558
Cochrane database reviews suggest a benefit in reducing the need for blood transfusion and reduced length of hospital stay [23–25].,Cochrane database reviews benefit reducing blood transfusion reduced length hospital stay [23–25].,G0000000|C0242356|C0282443|C0814225|C0392756|C0005767|C0005841|C0392756|C1444754|C0019994|G0000000|G0000000
The secondary efficacy parameter was change from randomization to week 10 of the double-blind treatment period in one-week recall VAS pain score.,The secondary efficacy parameter change randomization week 10 double-blind treatment period one-week recall VAS pain score.,G0000000|C0027627|C1280519|C0549193|C0392747|C0034656|C0332174|C0450371|C0013072|C0039798|C0439531|C4082116|C0034770|C0042815|C0030193|C0449820
The primary outcome measure for this pilot trial was the proportion of eligible participants who were willing to be randomised (number of randomised participants/number of eligible participants at baseline).,The primary outcome measure pilot trial proportion eligible participants randomised (number randomised participants/number eligible participants baseline).,G0000000|C0205225|C1274040|C0079809|C0473169|C0008976|C1709707|C1548635|C0679646|G0000000|C0237753|G0000000|C0679646|C1548635|C0679646|C0168634
"Only the Nottingham Sensory Assessment score remained significantly improved at 3 month follow-up for the robot group, although there was a trend in greater improvement in FM score for the robot group (p = 0.06).","Only Nottingham Sensory Assessment score remained improved 3 month follow-up robot group, trend improvement FM score robot (p = 0.06).",C0205171|G0000000|C0445254|C1261322|C0449820|G0000000|C0184511|G0000000|C0332177|C0589120|C0336537|C0441833|C1521798|C2986411|C3540627|C0449820|C0336537|C0369773|G0000000|C0450371
See Table 2 for an overview of the assessments.,See Table 2 overview assessments.,C0042789|C0039224|G0000000|C0814812|C1261322
Changes in adverse events and microbiology were monitored.,Changes adverse events microbiology monitored.,C0392747|G0000000|C0441471|C0025952|C0030695
"Enrolled adults and any siblings of the index child were then evaluated for respiratory symptoms and signs (fever, history of fever or feeling feverish in the past week, myalgia, arthralgia, sore throat, cough, sneezing, runny nose, nasal congestion, headache).","Enrolled adults siblings child evaluated respiratory symptoms signs (fever, history fever feeling feverish week, myalgia, arthralgia, sore throat, cough, sneezing, runny nose, nasal congestion, headache).",G0000000|C0001675|C0037047|C0008059|C0220825|C0521346|C0683368|C0220912|C0015967|C0019664|C0015967|C0013987|C0015967|C0332174|C0231528|C0003862|C0234233|C0031354|C0010200|C0037383|G0000000|C0028429|C0028429|C0700148|C0018681
Sample size calculations were performed to determine the number of participants needed to detect effect sizes based on minimal clinically important differences in the SCORAD index.,Sample size calculations performed determine participants detect sizes based minimal clinically differences SCORAD index.,C0370003|C0456389|C1441506|C0884358|G0000000|C0679646|C0442726|C0456389|C1527178|C0547040|G0000000|C1705241|G0000000|C0918012
"To minimise recall bias, these data are being collected by way of a frequency calendar where each participant notes the health services they used, reasons (e.g.","To minimise recall bias, data collected frequency calendar participant notes health services used, reasons (e.g.",C0040363|G0000000|C0034770|C0242568|C1511726|C1516695|C0376249|C1516147|C0679646|C1317574|C0018684|C0557854|C1273517|C0392360|G0000000
"The speech therapist measured the Urimal Test of Articulation and Phonology, alternative motion rates, sequential motion rates, and maximal phonation time before and after intervention sessions.","The speech therapist measured Urimal Test Articulation Phonology, alternative motion rates, sequential motion rates, maximal phonation time intervention sessions.",G0000000|C0037817|C0871525|C0444706|G0000000|C0022885|C0022417|C0597725|C1523987|C0026597|C0871208|C1548958|C0026597|C0871208|C0205289|C0031577|C0040223|C0886296|C1883016
F and p-values are presented in Table 1.,F p-values Table 1.,C0016327|C1709380|C0039224|G0000000
"We used the Glasgow outcome scale (GOS), barthel index, and modified rankin scale (mRS) to measure the outcomes of patients with TBI.","We Glasgow outcome scale (GOS), barthel index, modified rankin scale (mRS) measure outcomes patients TBI.",G0000000|G0000000|C1274040|C0175659|G0000000|G0000000|C0918012|C0392747|G0000000|C0175659|C1522706|C0079809|C1274040|C0030705|C0876926
"Participants will have a diagnosis of dementia, exhibit behaviors as scored by the Neuropsychiatric Inventory, and the caregiver must have at least 7 h per week contact.","Participants diagnosis dementia, exhibit behaviors scored Neuropsychiatric Inventory, caregiver 7 week contact.",C0679646|C0011900|C0011265|C0015272|C0004927|C0449820|G0000000|C0021941|C0085537|G0000000|C0332174|C0332158
"Plasma lipid analysis shows that while all subjects had high total and LDL cholesterol, and normal HDL and triglyceride concentrations, these concentrations were unaffected in both dietary groups (Figure S2 in Supplementary Material).","Plasma lipid analysis subjects total LDL cholesterol, normal HDL triglyceride concentrations, concentrations unaffected dietary (Figure S2 Supplementary Material).",C0032105|C0023779|C0002778|C0681850|C0439175|G0000000|C0008377|C0205307|C3715113|C0041004|C0086045|C0086045|C2986417|C0012155|G0000000|C1519428|G0000000|C0520510
"Cryo/Laser, cryotherapy or laser therapy for retinopathy.","Cryo/Laser, cryotherapy laser therapy retinopathy.",C0023089|C0010408|C0023089|C0039798|C0035309
We considered a cotinine level of 10 ng/mL or less to indicate smoking cessation.,We considered cotinine level 10 ng/mL smoking cessation.,G0000000|C0750591|C0010194|C0441889|C0450371|C0439275|C0037369|C1880019
"BDI: Beck Depression Inventory; DSMB: Data Safety Monitor Board; GCP: Good Clinical Practice; ICH: International Conference on Harmonization; LOCF: last observation carried forward; MR: magnet resonance tomography; NEO FFI, NEO: Five Factor Inventary; RTMS: repetitive transcranial magnetic stimulation; THI: Tinnitus Handicap Inventory; TQ: Tinnitus Questionnaire of Goebel&Hiller; VBM: Voxel-based Morphometry; RS-11: short for of the German questionnaire to assess resilience; SF 12: Quality of life assessment scale.","BDI: Beck Depression Inventory; DSMB: Data Safety Monitor Board; GCP: Good Clinical Practice; ICH: International Conference Harmonization; LOCF: observation carried forward; MR: magnet resonance tomography; NEO FFI, NEO: Five Factor Inventary; RTMS: repetitive transcranial magnetic stimulation; THI: Tinnitus Handicap Inventory; TQ: Tinnitus Questionnaire Goebel&Hiller; VBM: Voxel-based Morphometry; RS-11: short German questionnaire assess resilience; SF 12: Quality life assessment scale.",C0006448|G0000000|C0011570|C0021941|C0949757|C1511726|C0036043|C0030695|C0972401|G0000000|C0205170|C0205210|C0237607|C0019191|C1512888|C0086047|G0000000|C2825507|C0302523|C0206243|C0439780|C1417249|C0024483|C0231881|C0040395|C1366752|C0206042|C1366752|C0205451|C1521761|G0000000|G0000000|G0000000|C0442348|C0024488|C1292856|C0272238|C0040264|C0231172|C0021941|G0000000|C0040264|C0034394|G0000000|C0078140|C2700259|C0200760|C0035970|C1282927|C1556085|C0034394|C1516048|G0000000|C0037712|C0450371|C0332306|C0376558|C1261322|C0175659
"In addition, the Carer Strain Index24 and patient and carer versions of a 100 mm visual analogue Satisfaction with Care Rating scale (patient and carer versions, adapted from Lincoln et al.25) were also completed at six months.","In addition, Carer Strain Index24 patient carer versions 100 mm visual analogue Satisfaction Care Rating scale (patient carer versions, adapted Lincoln al.25) completed months.",G0000000|C0332287|C0085537|C0080194|G0000000|C0030705|C0085537|C0333052|C1442061|G0000000|C0234621|C0243071|C0242428|C1947933|C0871208|C0175659|C0030705|C0085537|C0333052|C2937289|G0000000|C0202311|C0205197|C0439231
"Secondary endpoints were the duration of mechanical ventilation, the ICU and hospital lengths of stay, and the mortality rates at ICU, at hospital discharge, and at 7, 14, 28 and 180 days and 1 year after randomization.","Secondary endpoints duration mechanical ventilation, ICU hospital lengths stay, mortality rates ICU, hospital discharge, 7, 14, 28 180 days 1 randomization.",C0027627|C2349179|C0449238|C0443254|C0035203|C0021708|C0019994|C1444754|G0000000|C0026565|C0871208|C0021708|C0019994|C0012621|G0000000|C0450371|C0450371|C1442061|C0439228|G0000000|C0034656
The increase in failure rate in the headbox group was due primarily to increased oxygen requirements in this group.,The increase failure rate headbox increased oxygen requirements group.,G0000000|C0442805|C0231174|C0871208|G0000000|C0205217|C0030054|C1514873|C0441833
"The secondary outcome measure was pulmonary response, change in forced expiratory volume in one second (FEV1), calculated as end-of-treatment FEV1 minus the baseline FEV1, in liters.","The secondary outcome measure pulmonary response, change forced expiratory volume (FEV1), calculated end-of-treatment FEV1 minus baseline FEV1, liters.",G0000000|C0027627|C1274040|C0079809|C0024109|C0871261|C0392747|C0441722|C0231800|C0449468|G0000000|C0444686|C0444930|G0000000|C0332288|C0168634|G0000000|C0475211
"Primary outcome (linear growth as length-for-age Z-scores) and secondary outcomes (changes in weight-for-length Z-scores; mean intake of energy, fat, iron and zinc from complementary foods; proportion of children consuming 4 or more food groups and recommended number of semi-solid/soft meals and snacks per day; maternal level of knowledge and performance of recommended practices) will be assessed at baseline and ages 9, 12 and 15 months.","Primary outcome (linear growth length-for-age Z-scores) secondary outcomes (changes weight-for-length Z-scores; intake energy, fat, iron zinc complementary foods; proportion children consuming 4 food recommended semi-solid/soft meals snacks day; maternal level knowledge performance recommended practices) assessed baseline ages 9, 12 15 months.",C0205225|C1274040|C0205132|C0018270|C1444754|C0871421|C0027627|C1274040|C0392747|C0005910|C0871421|C1512806|C0424589|C0424612|C0302583|C0043481|G0000000|C0016452|C1709707|C0008059|G0000000|G0000000|C0016452|C0034866|C0205208|C1998602|C0453863|C0332173|C2347083|C0441889|C0376554|C0597198|C0034866|C0237607|C1516048|C0168634|C0001779|G0000000|C0450371|C0450371|C0439231
Protection against HIV infection was calculated as 1 − RR.,Protection HIV infection calculated 1 − RR.,C1545588|C0019682|C0009450|C0444686|G0000000|G0000000|G0000000
"Acquisition indices were calculated separately for: (1) all asthma controllers (inhaled corticosteroids [ICS], leukotriene modifiers, cromolyn sodium, and theophylline); (2) for ICS alone; and (3) for long-acting β-agonists (LABAs).","Acquisition indices calculated separately for: (1) asthma controllers (inhaled corticosteroids [ICS], leukotriene modifiers, cromolyn sodium, theophylline); (2) ICS alone; (3) long-acting β-agonists (LABAs).",C1706701|C4033634|C0444686|G0000000|G0000000|G0000000|C0004096|C0180112|C0004048|C0001617|C0022521|C0023545|C0205349|C0086073|C0037473|C0039771|G0000000|C0022521|C0205171|G0000000|C0205166|G0000000|G0000000
"SFEMG and RNS studies were done at baseline and days 14, 21, and 28 on the same day as the clinical assessments using methods published previously.7  Laboratory measures included AChRAb and Anti-MuSK antibody levels for all patients at baseline and days 28 and 60, if abnormal at baseline.","SFEMG RNS studies baseline days 14, 21, 28 day clinical assessments methods published previously.7 Laboratory measures included AChRAb Anti-MuSK antibody levels patients baseline days 28 60, abnormal baseline.",G0000000|C1850106|C0947630|C0168634|C0439228|C0450371|C0450371|C0450371|C0332173|C0205210|C1261322|C0025663|C0034037|G0000000|C0022877|C0079809|C0332257|C1277725|C0066964|C0003241|C0441889|C0030705|C0168634|C0439228|C0450371|C0450371|C0205161|C0168634
"The risk factors assessed in this study include blood pressure, cholesterol level, smoking status, and physical activity levels.","The risk factors assessed study blood pressure, cholesterol level, smoking status, physical activity levels.",G0000000|C0035647|C1521761|C1516048|C0557651|C0005767|C0033095|C0008377|C0441889|C0037369|C0449438|C0031809|C0205177|C0441889
"ROM for shoulder abduction, elbow extension & wrist extension, (calculated as active ROM* 100/passive ROM for each joint) was one of our two primary outcome measures.","ROM shoulder abduction, elbow extension & wrist extension, (calculated active ROM* 100/passive ROM joint) primary outcome measures.",C4048784|C0037004|C0086505|C0013769|C0231448|G0000000|C0043262|C0231448|C0444686|C0205177|C4048784|C1442061|C4048784|C0022417|C0205225|C1274040|C0079809
"Using a Numerical Rating Scale (NRS), pain intensity was measured among the patients before the intervention, and immediately, 30 minutes and one hour after the intervention.","Using Numerical Rating Scale (NRS), pain intensity measured patients intervention, immediately, 30 minutes hour intervention.",C1524063|C0237753|C0871208|C0175659|C2240043|C0030193|C0522510|C0444706|C0030705|C0886296|C0205548|C0450371|C0439232|C0439227|C0886296
Each participant was asked to perform a maximal isometric contraction of knee extension.,Each participant perform maximal isometric contraction knee extension.,G0000000|C0679646|C0884358|C0205289|G0000000|C1140999|C0022742|C0231448
"Measured at 24 months only: the number and type of investigations (blood tests, FOBT, colonoscopies and radiological investigations), number and time to detection of recurrences, deaths from all causes at 2 years postentry into the study.","Measured 24 months only: type investigations (blood tests, FOBT, colonoscopies radiological investigations), time detection recurrences, deaths 2 postentry study.",C0444706|C0450371|C0439231|C0205171|C0332307|C1261322|C0005767|C0022885|C0201811|C0009378|C0034599|C1261322|C0040223|C1511790|C0034897|C0011065|G0000000|G0000000|C0557651
"Forty-four in the edaravone group and 25 control group patients showed clinical improvement, from which a significantly better response was observed in edaravone group than that of the control group (61.1 vs. 38.5 %, p = 0.006, Table 2).","Forty-four edaravone 25 control patients clinical improvement, response observed edaravone control (61.1 vs. 38.5 %, = 0.006, Table 2).",C3816449|C0070694|C0450371|C0243148|C0030705|C0205210|C2986411|C0871261|C1441672|C0070694|C0243148|C0450371|G0000000|C0450371|G0000000|G0000000|C1442061|C0039224|G0000000
Percent change in bone mineral content (BMC) from discharge to 24 months after burn.,Percent change bone mineral content (BMC) discharge 24 months burn.,C0439165|C0392747|C0262950|C0006660|C0423896|C0065839|C0012621|C0450371|C0439231|C0006434
"Six children were affected, 2 in each arm.","Six children affected, 2 arm.",C0205452|C0008059|C0392760|G0000000|C0446516
"After three days of treatment, clinical and bacteriological efficacy was assessed.","After days treatment, clinical bacteriological efficacy assessed.",G0000000|C0439228|C0039798|C0205210|C0205465|C1280519|C1516048
"During the prenatal period, healthcare providers provided counseling on appropriate breastfeeding practices, such as early initiation of breastfeeding, feeding colostrum, exclusive breastfeeding up to the age of 6 months, and timely introduction of complementary foods.","During prenatal period, healthcare providers provided counseling breastfeeding practices, initiation breastfeeding, feeding colostrum, exclusive breastfeeding age 6 months, timely introduction complementary foods.",G0000000|C0678804|C0439531|C0086388|C1138603|C1999230|C0010210|C0006147|C0237607|C0589507|C0006147|C0204695|C0009413|C1548966|C0006147|C0001779|G0000000|C0439231|C3827828|C1293116|G0000000|C0016452
This study aimed to investigate the effect of exercise intervention on the quality of life of breast cancer survivors.,This study aimed investigate exercise intervention quality life breast cancer survivors.,G0000000|C0557651|C1947946|C1292732|C0015259|C0886296|C0332306|C0376558|C0006141|C0006826|C0206194
gambiae blood feeding rate associated with the zero washed PermaNet 3.0 was lower than with the zero washed PermaNet 2.0.,gambiae blood feeding rate washed PermaNet 3.0 lower washed PermaNet 2.0.,G0000000|C0005767|C0204695|C0871208|C1548982|G0000000|G0000000|C0441994|C1548982|G0000000|G0000000
The first endpoint variable is the rate of food intolerance in preterm children.,The endpoint variable rate food intolerance preterm children.,G0000000|C2349179|C0439828|C0871208|C0016452|C0231199|C0151526|C0008059
"Outcomes include weight, height, blood pressure, percent body fat, serum, and urinary biomarkers.","Outcomes weight, height, blood pressure, percent body fat, serum, urinary biomarkers.",C1274040|C0005910|C0489786|C0005767|C0033095|C0439165|C0242821|C0424612|C0229671|C0042027|C0005516
Impact of treatment on substance use by depressive symptoms: Drinks per drinking day (top panel) and percentage of days used marijuana (bottom panel).,Impact treatment substance depressive symptoms: Drinks drinking day (top panel) percentage days marijuana (bottom panel).,C1825598|C0039798|C0439861|G0000000|C0683368|C0452428|C0001948|C0332173|C1704458|C0441833|C0439165|C0439228|C0024808|C1511276|C0441833
The primary outcome measure was the proportion of eligible participants who were willing to be randomised.,The primary outcome measure proportion eligible participants randomised.,G0000000|C0205225|C1274040|C0079809|C1709707|C1548635|C0679646|G0000000
"Secondary outcome measures were: tissue induration measured by tonometry; levels of sensations, pain, fatigue, and their limiting effects all measured by a visual analogue scale (VAS) and quality of life based on the Lymphoedema Quality of Life Tool (LYMQOL).","Secondary outcome measures were: tissue induration measured tonometry; levels sensations, pain, fatigue, limiting effects measured visual analogue scale (VAS) quality life based Lymphoedema Quality Life Tool (LYMQOL).",C0027627|C1274040|C0079809|G0000000|C0040300|C0332534|C0444706|C0040420|C0441889|C0036658|C0030193|C0015672|C0439801|C1280500|C0444706|C0234621|C0243071|C0175659|C0042815|C0332306|C0376558|C1527178|C0024236|C0332306|C0376558|C0336791|G0000000
Conclusions: A brief self-management programme during hospital admission reduced post discharge morbidity and readmission for adult asthma patients.,Conclusions: A self-management programme hospital admission reduced post discharge morbidity readmission adult asthma patients.,C1707478|G0000000|C0086969|C1709697|C0019994|C0184666|C0392756|C0687676|C0012621|C0026538|C1548168|C0001675|C0004096|C0030705
"The primary outcome was a measure of seizure severity, including associated injuries and the level of distress manifested by the patient, as perceived by an informant.","The primary outcome measure seizure severity, including injuries level distress manifested patient, perceived informant.",G0000000|C0205225|C1274040|C0079809|C0036572|C0439793|C0332257|C1510467|C0441889|C0231303|C0205319|C0030705|C0030971|C1550484
"The followings were considered: Improved more than 75% = excellent, improved 50–75% = good response, improved 25–50% = moderate response, and improved <25% = poor response.","The followings considered: Improved 75% = excellent, improved 50–75% = response, improved 25–50% = moderate response, improved <25% = poor response.",G0000000|C0231290|C0750591|C0184511|C0450371|G0000000|C1548784|C0184511|G0000000|G0000000|C0871261|C0184511|G0000000|G0000000|C0205081|C0871261|C0184511|C0450371|G0000000|C0032854|C0871261
"The primary outcome measure will be step length when dual tasking over 8 m. Secondary outcome measures include: spatiotemporal gait parameters when walking under single and dual task conditions, measures of executive function, the timed up and go test, measures of community mobility, and quality of life.","The primary outcome measure step length dual tasking 8 m. Secondary outcome measures include: spatiotemporal gait parameters walking single dual task conditions, measures executive function, timed test, measures community mobility, quality life.",G0000000|C0205225|C1274040|C0079809|C1261552|C1444754|C1554184|C3540678|G0000000|C0369637|C0027627|C1274040|C0079809|C0332257|G0000000|C0016928|C0449381|C0080331|C0037179|C1554184|C3540678|C0012634|C0079809|C0871735|C0031843|C0392761|C0022885|C0079809|C0009462|C0425245|C0332306|C0376558
Breast and ovarian cancer risk; cancer-specific and overall mortality.,Breast ovarian cancer risk; cancer-specific mortality.,C0006141|C0205065|C0006826|C0035647|C0006826|C0026565
"The key secondary endpoint is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.","The key secondary endpoint composite cardiovascular death, nonfatal myocardial infarction, nonfatal stroke.",G0000000|G0000000|C0027627|C2349179|C0205199|C0007226|C0011065|G0000000|C0027061|C0021308|G0000000|C0038454
"In addition, we assessed the consumption of green-tea and other variables before cases of prostate cancer were diagnosed, thus avoiding recall bias.","In addition, assessed consumption green-tea variables prostate cancer diagnosed, avoiding recall bias.",G0000000|C0332287|C1516048|C0009830|C1384640|C0439828|C0033572|C0006826|C0011900|G0000000|C0034770|C0242568
"APAP, auto-adjusting positive airway pressure; CPAP, continuous positive airway pressure; HRV, heart rate variability; MSNA, muscle sympathetic nerve activity.","APAP, auto-adjusting positive airway pressure; CPAP, continuous positive airway pressure; HRV, heart rate variability; MSNA, muscle sympathetic nerve activity.",C0000970|C1441488|C0439178|C0178987|C0033095|C0199451|C0549178|C0439178|C0178987|C0033095|C0010343|C0018787|C0871208|C2827666|G0000000|C0026845|G0000000|C0027740|C0205177
"Assessments were by bowel function questionnaire, clinical outcomes, continence scoring, quality of life measurement, anorectal manometry, and endoanal ultrasound.","Assessments bowel function questionnaire, clinical outcomes, continence scoring, quality life measurement, anorectal manometry, endoanal ultrasound.",C1261322|C0021853|C0031843|C0034394|C0205210|C1274040|C0443192|C0449820|C0332306|C0376558|C0242485|C0178825|C0024751|G0000000|C0041618
"Secondary outcome variables include incidence and time to tumor relapse (locoregional relapse, lymph node involvement and metastatic spread), Quality of life as reported by EORTC (QLQ-C30 with H&N 35 module) and time from operation to orofacial rehabilitation.","Secondary outcome variables incidence time tumor relapse (locoregional relapse, lymph node involvement metastatic spread), Quality life reported EORTC (QLQ-C30 H&N 35 module) time operation orofacial rehabilitation.",C0027627|C1274040|C0439828|C0021149|C0040223|C0027651|C0035020|G0000000|C0035020|C0024202|C0746922|C1314939|C0036525|C0332261|C0332306|C0376558|C0684224|C1516985|G0000000|C0033727|C0450371|C1709061|C0040223|C0543467|C2827582|C0034991
Those that gave any answer other than definitely will not were then asked to indicate how likely it is that they would use marijuana nearly every month in the next 12 months (1 = “I definitely will not”to 4 = “I definitely will”).,Those answer marijuana month 12 months (1 = “I not”to 4 = “I will”).,G0000000|C1706817|C0024808|C0332177|C0450371|C0439231|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000
Six other patients failed to complete the study period.,Six patients failed complete study period.,C0205452|C0030705|C0231175|C0205197|C0557651|C0439531
"SHARE is a manualized, health education and multiple health behavior change intervention for adolescent survivors of childhood cancer focusing in part on improving their bone health behaviors, including milk consumption, calcium supplementation, and dietary calcium intake [21,22].","SHARE manualized, health education multiple health behavior change intervention adolescent survivors childhood cancer focusing improving bone health behaviors, including milk consumption, calcium supplementation, dietary calcium intake [21,22].",C0237876|G0000000|C0018684|C0013621|C0439064|C0018684|C0004927|C0392747|C0886296|C0205653|C0206194|C0231335|C0006826|C0000936|C1272745|C0262950|C0018684|C0004927|C0332257|C0026131|C0009830|C0006675|C0242297|C0012155|C0006675|C1512806|C0450371
"On each sampling round, 60 CDC light traps were set in the selected 39 villages and traps were sampled on 97.5% (2,053 of 2,100) occasions during the study.","On sampling round, 60 CDC light traps set selected 39 villages traps sampled 97.5% (2,053 2,100) occasions study.",G0000000|C0441621|C0332490|C0450371|C0007670|C0023693|C0184047|C0036849|C1707391|C0450371|C0562518|C0184047|C0441621|C0450371|C1442061|C1442061|C0521114|C0557651
"Greater improvements in most QoL and symptom severity measurements were observed in children randomized to undergo adenotonsillectomy, including the parent-completed Pediatric Quality of Life inventory (effect size [ES]: 0.37), the 18-item Obstructive Sleep Apnea QoL instrument (ES: –0.93), the modified Epworth Sleepiness Scale score (ES: –0.42), and the Sleep-Related Breathing Scale of the Pediatric Sleep Questionnaire (ES: –1.35).","Greater improvements QoL symptom severity measurements observed children randomized undergo adenotonsillectomy, including parent-completed Pediatric Quality Life inventory (effect size [ES]: 0.37), 18-item Obstructive Sleep Apnea QoL instrument (ES: –0.93), modified Epworth Sleepiness Scale score (ES: –0.42), Sleep-Related Breathing Scale Pediatric Sleep Questionnaire (ES: –1.35).",C1704243|C2986411|C0518214|C1457887|C0439793|C0242485|C1441672|C0008059|C0034656|G0000000|C0193959|C0332257|C0030551|C0030755|C0332306|C0376558|C0021941|C1280500|C0456389|C0013754|C0450371|C0450371|C0549186|C0037313|C0003578|C0518214|C0348000|C0013754|G0000000|C0392747|G0000000|C0013144|C0175659|C0449820|C0013754|G0000000|C0037313|C0004048|C0175659|C0030755|C0037313|C0034394|C0013754|G0000000
"Initial attempts in this direction have been promising, and 6–12‐month‐long complementation of the infants' diet has been associated with improved motor development and reduced incidence of severe stunting in infancy (Adu‐Afarwuah et al.","Initial attempts direction promising, 6–12‐month‐long complementation infants' diet improved motor development reduced incidence severe stunting infancy (Adu‐Afarwuah et al.",C0205265|C1516084|C0449738|C1555307|G0000000|G0000000|C0021270|C0012155|C0184511|C1513492|C0243107|C0392756|C0021149|C0205082|C0018273|C0231330|G0000000|G0000000
The primary outcome was the incidence of delirium up to 10 days postoperatively.,The primary outcome incidence delirium 10 days postoperatively.,G0000000|C0205225|C1274040|C0021149|C0011206|C0450371|C0439228|G0000000
"Table summarizing subjects’ baseline characteristics Table summarizing changes in specific parameters of rheumatoid arthritis including HAQ, DAS-28, Patient and Physician Global Assessments and pain levels.","Table summarizing subjects’ baseline characteristics Table summarizing specific parameters rheumatoid arthritis including HAQ, DAS-28, Patient Physician Global Assessments pain levels.",C0039224|G0000000|G0000000|C0168634|C1521970|C0039224|G0000000|C0205369|C0449381|G0000000|C0003864|C0332257|C0102923|C0051767|C0030705|C0031831|C0205246|C1261322|C0030193|C0441889
"The primary outcome was prospectively defined as area-under-the-curve global severity, with duration and severity assessed by twice daily self report.","The primary outcome prospectively defined area-under-the-curve global severity, duration severity assessed daily report.",G0000000|C0205225|C1274040|G0000000|C1704788|C0017446|C0205246|C0439793|C0449238|C0439793|C1516048|C0332173|C0684224
"Indeed, no patient died due to chemotherapy's side effects.","Indeed, patient died chemotherapy's effects.",G0000000|C0030705|C0011065|C0013216|C1280500
The role of medication in relapse prevention was outlined.,The role medication relapse prevention outlined.,G0000000|C0035820|C0013227|C0035020|C0199176|G0000000
"One year of fortification resulted in an improvement in linear growth with a statistically significant change in height velocity and height for age Z- scores, but not on weight and BMIZ which was likely attributed to the synergetic effects of the micronutrients including the presence of zinc [39].","One fortification improvement linear growth statistically change height velocity height age Z- scores, weight BMIZ attributed synergetic effects micronutrients including presence zinc [39].",C0205447|G0000000|C2986411|C0205132|C0018270|C0038215|C0392747|C0489786|C0439830|C0489786|C0001779|G0000000|C0449820|C0005910|G0000000|C0449234|G0000000|C1280500|C0282575|C0332257|C0150312|C0043481|C0450371
Fever clearance time (FCT) was the time until the patient’s temperature returned to <37.5°C following admission and remained below this for more than 48 hours.,Fever clearance time (FCT) time patient’s temperature returned <37.5°C admission remained 48 hours.,C0015967|C0449297|C0040223|G0000000|C0040223|G0000000|C0005903|C0332156|G0000000|C0184666|G0000000|C0450371|C0439227
"However, the 95% confidence interval for the true difference ranged from 0% to 28%.","However, 95% confidence interval true difference ranged 0% 28%.",G0000000|C0450371|C0237529|C1272706|C0205238|C1705241|C1514721|G0000000|C0450371
"Results: safety * norepinephrine was the only inotropic or vasopressor medication used in any study patient ** excessive prolongation of the QTc interval, necessitating drug discontinuation CI = confidence interval; ICU = intensive care unit; QTc = QT interval corrected for heart rate.","Results: safety * norepinephrine inotropic vasopressor medication study patient ** excessive prolongation QTc interval, necessitating drug discontinuation CI = confidence interval; ICU = intensive care unit; QTc = QT interval corrected heart rate.",C1274040|C0036043|G0000000|C0028351|G0000000|C0042397|C0013227|C0557651|C0030705|G0000000|C0442802|C0439590|G0000000|C1272706|G0000000|C0013227|C0457454|C0008107|G0000000|C0237529|C1272706|C0021708|G0000000|C0162425|C1947933|C0439148|G0000000|G0000000|C1552934|C1272706|C0205202|C0018787|C0871208
"The total FAMS score is calculated by summing all subscale scores, ranging from 0 to 232.","The total FAMS score calculated summing subscale scores, ranging 0 232.",G0000000|C0439175|C3827008|C0449820|C0444686|C1515051|G0000000|C0449820|C1514721|G0000000|C1442061
"Secondary objectives were to compare the proportions who relapsed within the next 6-14 days, the proportions who had resistant strains of S pneumoniae or H influenzae in nasopharyngeal cultures at enrolment and at 14 day follow up, and the direct medical costs of treating clinical failures and relapses, and to assess the proportion of participants whose nasopharyngeal aspirates was positive for respiratory syncytial virus at enrolment.","Secondary objectives compare proportions relapsed 6-14 days, proportions resistant strains S pneumoniae H influenzae nasopharyngeal cultures enrolment 14 day follow up, direct medical costs treating clinical failures relapses, assess proportion participants nasopharyngeal aspirates positive respiratory syncytial virus enrolment.",C0027627|C0018017|C1707455|C1709707|C0205336|C0450371|C0439228|C1709707|C0332325|C0080194|C0565930|C0032285|C0033727|C0021400|C0027442|C0010453|C1516879|C0450371|C0332173|C0332283|G0000000|C0439851|C0199168|C0010186|C1522326|C0205210|C0231174|C0035020|C1516048|C1709707|C0679646|C0027442|C0370199|C0439178|C0521346|G0000000|C0042776|C1516879
Such an initiative would help assess the infectivity and modes of transmission of the virus in the community setting.,Such initiative assess infectivity modes transmission virus community setting.,G0000000|C0424093|C1516048|C0030657|C1513371|C0040722|C0042776|C0009462|C0542559
Short-term effects were evaluated via emotional response and stress levels measured with the autonomic nerve index and the Faces Scale.,Short-term effects evaluated emotional response stress levels measured autonomic nerve Faces Scale.,C0443303|C1280500|C0220825|C0013987|C0871261|C0038435|C0441889|C0444706|C0004388|C0027740|C0015450|C0175659
The presence or absence of suicidal tendencies was assessed using the C-SSRS.,The presence absence suicidal tendencies assessed C-SSRS.,G0000000|C0150312|C0332197|C0438696|G0000000|C1516048|C2754414
"We also examined the ability of the FRD compared to the attention control group to increase serum concentrations of carotenoids and omega-3 fatty acids, while decreasing serum concentrations of omega-6 fatty acids, and if these changes in serum nutrients were associated with changes in either fatigue or sleep quality.","We examined ability FRD compared attention control increase serum concentrations carotenoids omega-3 fatty acids, decreasing serum concentrations omega-6 fatty acids, serum nutrients fatigue sleep quality.",G0000000|C0332128|C0085732|G0000000|C1707455|C0004268|C0243148|C0442805|C0229671|C0086045|C0007271|C1719844|G0000000|C0001128|C0442797|C0229671|C0086045|C1719844|G0000000|C0001128|C0229671|C0678695|C0015672|C0037313|C0332306
"This study examined the relative perceived effectiveness of 30 antidrug public service announcements (PSAs) and assessed the extent to which judgments of effectiveness are related to judgments of realism, amount learned, and positive and negative emotional responses.","This study examined relative perceived effectiveness 30 antidrug public service announcements (PSAs) assessed extent judgments effectiveness judgments realism, amount learned, positive negative emotional responses.",G0000000|C0557651|C0332128|C0080103|C0030971|C1280519|C0450371|G0000000|G0000000|C0557854|G0000000|C3810537|C1516048|C0439792|C0022423|C1280519|C0022423|C0237815|C1265611|C0023185|C0439178|C0205160|C0013987|C0871261
"Analyses of covariance (modified intention-to-treat analysis by last observation carried forward method) for mean scores on primary and secondary outcome measures by group at baseline, posttreatment and six-month follow-up CBT = cognitive-behaviour therapy; CPAQ = Chronic Pain Acceptance Questionnaire; EuroQol VAS = EuroQol Visual Analogue Scale; FIQ = Fibromyalgia Impact Questionnaire; HAM-D = Hamilton Rating Scale for Depression; HARS = Hamilton Anxiety Rating Scale; PCS = Pain Catastrophizing Scale; PVAS = Pain Visual Analogue Scale; RPT = recommended pharmacological treatment; TAU = treatment as usual.","Analyses covariance (modified intention-to-treat analysis observation carried forward method) scores primary secondary outcome measures baseline, posttreatment six-month follow-up CBT = cognitive-behaviour therapy; CPAQ = Chronic Pain Acceptance Questionnaire; EuroQol VAS = EuroQol Visual Analogue Scale; FIQ = Fibromyalgia Impact Questionnaire; HAM-D = Hamilton Rating Scale Depression; HARS = Hamilton Anxiety Rating Scale; PCS = Pain Catastrophizing Scale; PVAS = Pain Visual Analogue Scale; RPT = recommended pharmacological treatment; TAU = treatment usual.",C0002778|G0000000|C0392747|C0162425|C0002778|C0302523|C0206243|C0439780|C0025663|C0449820|C0205225|C0027627|C1274040|C0079809|C0168634|C2709088|C0585339|C0589120|C0009244|G0000000|C0945984|C0039798|G0000000|G0000000|C0205191|C0030193|G0000000|C0034394|C0451150|C0042815|G0000000|C0451150|C0234621|C0243071|C0175659|G0000000|G0000000|C0016053|C1825598|C0034394|C1570167|G0000000|G0000000|C0871208|C0175659|C0011570|C1415473|G0000000|G0000000|C0003467|C0871208|C0175659|C1864389|G0000000|C0030193|C0563150|C0175659|C0139386|G0000000|C0030193|C0234621|C0243071|C0175659|G0000000|G0000000|C0034866|C0031330|C0039798|C1720655|G0000000|C0039798|C3538928
"The independent clinical variables available until discharge were used as predictors (quantitative variables: age at admission, age at AN onset, age at menarche, premorbid BMI and BMI, BMI-SDS, BMI percentile and %EBW (at admission and discharge), duration of hospital treatment; binary variables: premenarchal or postmenarchal state at admission, regular discharge or discharge against medical advice).","The independent clinical variables discharge predictors (quantitative variables: age admission, age AN onset, age menarche, premorbid BMI BMI, BMI-SDS, BMI percentile %EBW (at admission discharge), duration hospital treatment; binary variables: premenarchal postmenarchal admission, regular discharge discharge medical advice).",G0000000|C0085862|C0205210|C0439828|C0012621|C2698872|C0392762|C0439828|C0001779|C0184666|C0001779|G0000000|C0206132|C0001779|C0025274|G0000000|G0000000|G0000000|C3813719|G0000000|C1264641|G0000000|G0000000|C0184666|C0012621|C0449238|C0019994|C0039798|C1706942|C0439828|G0000000|G0000000|C0184666|C0205272|C0012621|C0012621|C0199168|C0150600
"The global assessment of treatment efficacy was recorded at Days 3 and 5 as the response to the question, “Considering how your neck pain has affected you, how would you assess the effect of treatment today?” and rated on a scale from 0 = poor to 4 = excellent.","The global assessment treatment efficacy recorded Days 3 5 response question, “Considering neck pain you, assess treatment today?” rated scale 0 = poor 4 = excellent.",G0000000|C0205246|C1261322|C0039798|C1280519|C0034869|C0439228|G0000000|G0000000|C0871261|C1522634|G0000000|C0027530|C0030193|G0000000|C1516048|C0039798|G0000000|C0871208|C0175659|G0000000|G0000000
"In addition, the Apgar scores at minutes 1 and 5 in test group is significantly increased compared to control group (p <0.0001).","In addition, Apgar scores minutes 1 5 test increased compared control (p <0.0001).",G0000000|C0332287|C0741195|C0449820|C0439232|G0000000|G0000000|C0022885|C0205217|C1707455|C0243148|C0369773|G0000000
Here we have shown that the use of corticosteroids was significantly associated with a longer hospital stay (95% CI 2.06).,Here corticosteroids hospital stay (95% CI 2.06).,G0000000|C0001617|C0019994|G0000000|C0450371|C0008107|C0450371
"At admission, age, age at AN onset (defined as the earliest of the following times: (1) the approximate time at which weight loss first occurred; (2) at which, despite age-appropriate growth spurts, no further weight gain took place; or (3) at which secondary amenorrhea first occurred), duration of illness (the time between the onset of AN and admission), and premorbid BMI (BMI before illness onset) were assessed.","At admission, age, age AN onset (defined earliest times: (1) approximate time weight loss occurred; (2) which, age-appropriate growth spurts, weight gain place; (3) secondary amenorrhea occurred), duration illness (the time onset AN admission), premorbid BMI (BMI illness onset) assessed.",G0000000|C0184666|C0001779|C0001779|G0000000|C0206132|C1704788|C1279919|C0040223|G0000000|C0332232|C0040223|C0005910|C1517945|C1709305|G0000000|G0000000|C0001779|C0018270|C3889133|C0005910|C1517378|C0442504|G0000000|C0027627|C0002453|C1709305|C0449238|C0221423|G0000000|C0040223|C0206132|G0000000|C0184666|G0000000|G0000000|G0000000|C0221423|C0206132|C1516048
"Paired t-test was used to test the mean difference score of the participants at baseline and after 3 months and 6 months in both groups, that is, Yoga and control groups.","Paired t-test test difference score participants baseline 3 months 6 months groups, is, Yoga control groups.",C1709450|C0871472|C0022885|C1705241|C0449820|C0679646|C0168634|G0000000|C0439231|G0000000|C0439231|C0441833|G0000000|C0043418|C0243148|C0441833
Percent change in LDL-C at week 8.,Percent change LDL-C week 8.,C0439165|C0392747|G0000000|C0332174|G0000000
Intervention condition participants were almost twice as likely to be abstinent per self-report at 3 months (odds ratio: 1.90 [95% confidence interval: 1.12–3.24]; P = .017) compared with control participants; at 12 months there were no differences.,Intervention condition participants abstinent self-report 3 months (odds ratio: 1.90 [95% confidence interval: 1.12–3.24]; P = .017) compared control participants; 12 months differences.,C0886296|C0012634|C0679646|C0457801|C0681906|G0000000|C0439231|G0000000|C0456603|C0450371|C0450371|C0237529|C1272706|G0000000|C0369773|G0000000|C1442061|C1707455|C0243148|C0679646|C0450371|C0439231|C1705241
"Developmental outcomes were assessed with the Bayley Scales of Infant and Toddler Development (BSID-III) composite scores for cognitive (primary endpoint), language and motor development.","Developmental outcomes assessed Bayley Scales Infant Toddler Development (BSID-III) composite scores cognitive (primary endpoint), language motor development.",C0458003|C1274040|C1516048|G0000000|C0175659|C0021270|C0682053|C0243107|C0439070|C0205199|C0449820|C1516691|C0205225|C2349179|C0023008|C1513492|C0243107
HRQOL was assessed in both groups using a Farsi version of the Short Form Health Survey (SF-36) before and after the educational programs.,HRQOL assessed Farsi version Short Form Health Survey (SF-36) educational programs.,G0000000|C1516048|G0000000|C0333052|C1282927|C0348078|C0018684|C0038951|C0037712|C0587721|C0376691
"Data-gathering instruments included the information form, observation checklist, and Visual Analogue Scale (VAS) for evaluation of pain severity.","Data-gathering instruments included form, observation checklist, Visual Analogue Scale (VAS) evaluation pain severity.",C1511726|C0348000|C0332257|C0348078|C0302523|C1707357|C0234621|C0243071|C0175659|C0042815|C0220825|C0030193|C0439793
Asthma severity was based on day and night symptom frequency during the past 2 weeks and the number of emergency department visits and hospitalizations in the past 6 months.6 Acute health care utilization was based on report of any emergency department or urgent care visit or hospitalization at baseline or the 6-month follow-up visit.,Asthma severity based day night symptom frequency 2 weeks emergency department visits hospitalizations 6 months.6 Acute health care utilization based report emergency department urgent care visit hospitalization baseline 6-month follow-up visit.,C0004096|C0439793|C1527178|C0332173|C0240526|C1457887|C0376249|G0000000|C0439230|C0013956|C1704729|C0545082|C0019993|G0000000|C0439231|C0205178|C0018684|C1947933|C0042153|C1527178|C0684224|C0013956|C1704729|C0439609|C1947933|C0545082|C0019993|C0168634|C0332177|C0589120|C0545082
"The present study demonstrated that injection of BoNTA, wherever into fixed-sites or acupoint-sites could significantly reduce migraine frequency, density, duration and associated symptoms.","The study demonstrated injection BoNTA, fixed-sites acupoint-sites reduce migraine frequency, density, duration symptoms.",G0000000|C0557651|G0000000|C0021485|G0000000|C0443218|C0001302|G0000000|C0149931|C0376249|C0178587|C0449238|C0683368
"A modified version of the 6-Minute Walk was used as a measure of functional mobility (Tappen et al., 1997).","A modified version 6-Minute Walk measure functional mobility (Tappen al., 1997).",G0000000|C0392747|C0333052|C0439232|C0080331|C0079809|C0205245|C0425245|G0000000|C0202311|G0000000
"The intensities of other adverse events were recorded according to a standard 0 to 3 grade scale: ""absent"", ""easily tolerated"", ""interferes with normal activity"" and ""prevents normal activity"".","The intensities adverse events recorded standard 0 3 grade scale: ""absent"", ""easily tolerated"", ""interferes normal activity"" ""prevents normal activity"".",G0000000|C0522510|G0000000|C0441471|C0034869|C1442989|G0000000|G0000000|C0441800|C0175659|C0332197|C0332219|G0000000|C0521102|C0205307|C0205177|C0309872|C0205307|C0205177
"Axial length was measured with Zeiss IOL-Master and cycloplegic refraction with Nikon Retinomax at −6, 0, 12, 24, and 36 months.","Axial length measured Zeiss IOL-Master cycloplegic refraction Nikon Retinomax −6, 0, 12, 24, 36 months.",C0205131|C1444754|C0444706|G0000000|C0281658|C0010586|C0429585|G0000000|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0439231
No side effect was observed during the treatment.,No observed treatment.,G0000000|C1441672|C0039798
"Specific to the behavioral goals relevant to physical activity, the indirect effect through intention was stronger than the effect through outcome expectancy beliefs about baby’s healthy weight.","Specific behavioral goals relevant physical activity, indirect intention stronger outcome expectancy beliefs baby’s healthy weight.",C0205369|C0004927|C0018017|C2347946|C0031809|C0205177|C0439852|C0162425|C0442821|C1274040|C0679138|C0004951|G0000000|C3898900|C0005910
The secondary outcomes were to compare between the weekly CQ and placebo arms: (1a) changes in erythropoietic response between days 3 and 30; and (1b) between days 3 and 90; (2) changes in urinary neopterin from days 3 to 30 as a marker of macrophage activation; (3) prevalence of submicroscopic malaria parasitaemia using PCR at each time point and (4) Hb change from days 3 to 90 in the two placebo arms to investigate the effects of initial malaria treatment therapy.,The secondary outcomes compare weekly CQ placebo arms: (1a) erythropoietic response days 3 30; (1b) days 3 90; (2) urinary neopterin days 3 30 marker macrophage activation; (3) prevalence submicroscopic malaria parasitaemia PCR time (4) Hb change days 3 90 placebo arms investigate effects initial malaria treatment therapy.,G0000000|C0027627|C1274040|C1707455|C0332174|C0282245|C0032042|C0206655|C1420849|C0312829|C0871261|C0439228|G0000000|C0450371|C1420850|C0439228|G0000000|C0450371|G0000000|C0042027|C0068527|C0439228|G0000000|C0450371|C0005516|C0024432|C1879547|G0000000|C0033105|G0000000|C0024530|C0242723|C0032520|C0040223|G0000000|C0019046|C0392747|C0439228|G0000000|C0450371|C0032042|C0206655|C1292732|C1280500|C0205265|C0024530|C0039798|C0039798
"Non-parametric tests (Mann Whitney and Kruskall Wallis tests) will be used for ordinal level data (i.e., International Physical Activity Questionnaire, Fatigue Assessment Scale, Montreal Cognitive Assessment, Hospital Anxiety and Depression Scale, Pittsburg Sleep Quality Index, Goal Attainment Scaling) or where a normal data distribution is not found.","Non-parametric tests (Mann Whitney Kruskall Wallis tests) ordinal level data (i.e., International Physical Activity Questionnaire, Fatigue Assessment Scale, Montreal Cognitive Assessment, Hospital Anxiety Depression Scale, Pittsburg Sleep Quality Index, Goal Attainment Scaling) normal data distribution found.",C1518422|C0022885|G0000000|G0000000|G0000000|G0000000|C0022885|C0439080|C0441889|C1511726|C0683454|C1512888|C0031809|C0205177|C0034394|C0015672|C1261322|C0175659|G0000000|C1516691|C1261322|C0019994|C0003467|C0011570|C0175659|G0000000|C0037313|C0332306|C0918012|C0018017|G0000000|C0237849|C0205307|C1511726|C0520511|C0150312
Subjects were recruited solely for fibromyalgia pain.,Subjects recruited solely fibromyalgia pain.,C0681850|G0000000|G0000000|C0016053|C0030193
"This can be justified mainly by the lack of evidence of whether accelerated transition from oncological treatment to SPC at home as a whole has any effect on place of care and death, symptoms/problems, quality of life, survival and caregivers’ health and grief.","This justified lack evidence accelerated transition oncological treatment SPC care death, symptoms/problems, quality life, survival caregivers’ health grief.",G0000000|C1552821|C0332268|C3887511|C0521110|C0599156|C0027651|C0039798|C1425074|C1947933|C0011065|C0683368|C0332306|C0376558|C0038952|G0000000|C0018684|C0018235
partial remission was seen in seven children treated with CSA at 12 and 24 weeks compared with two children treated with CPH at 12 and 24 weeks (p=0.04).,partial remission children treated CSA 12 24 weeks compared children treated CPH 12 24 weeks (p=0.04).,C0728938|C0544452|C0008059|C1522326|G0000000|C0450371|C0450371|C0439230|C1707455|C0008059|C1522326|C0054757|C0450371|C0450371|C0439230|C0369773
"Only observations taken during the same time frame as the intervention child’s observations were used, ±1 month for each time period (i.e., baseline, post-treatment, 3-, 6-, 12-, 18-, and 24-month follow-up).","Only observations time frame intervention child’s observations used, ±1 month time period (i.e., baseline, post-treatment, 3-, 6-, 12-, 18-, 24-month follow-up).",C0205171|C0302523|C0040223|C0080089|C0886296|G0000000|C0302523|C1273517|G0000000|C0332177|C0040223|C0439531|C0683454|C0168634|C2709088|G0000000|G0000000|C0450371|C0450371|C0450371|C0589120
"The surveys investigated players' knowledge, behaviours, and attitudes associated with the use of protective eyewear.","The surveys investigated players' knowledge, behaviours, attitudes protective eyewear.",G0000000|C0038951|C1292732|G0000000|C0376554|C0004927|C0004271|G0000000|C1456528
"In the assessment, the number of times the full drinking action was performed in one minute was measured.","In assessment, times drinking action performed minute measured.",G0000000|C1261322|C0040223|C0001948|C0441472|C0884358|C0439232|C0444706
"The sham therapy group also exhibited an increased FMA score after intervention, but of a lesser magnitude.","The sham therapy exhibited increased FMA score intervention, lesser magnitude.",G0000000|C0068899|C0039798|C0015272|C0205217|C2332774|C0449820|C0886296|C0547044|C0449286
"Participants were assessed at baseline (day 0), on days 4, 7 and 14 of treatment, and at follow up on day 42.","Participants assessed baseline (day 0), days 4, 7 14 treatment, follow day 42.",C0679646|C1516048|C0168634|C0332173|G0000000|C0439228|G0000000|G0000000|C0450371|C0039798|C0332283|C0332173|C0450371
"Clinical outcomes included cephalic presentation at birth, the need for ECV, mode of birth; perinatal morbidity and mortality, and maternal complications.","Clinical outcomes included cephalic presentation birth, ECV, mode birth; perinatal morbidity mortality, maternal complications.",C0205210|C1274040|C0332257|C0205096|C0449450|C0005615|G0000000|C1513371|C0005615|C0178795|C0026538|C0026565|C2347083|C0009566
Figures in parentheses are detection rates.,Figures parentheses detection rates.,G0000000|G0000000|C1511790|C0871208
"The scale for this second questionnaire ranges from 29 to 145; the higher the scores, the better the quality of life.","The scale questionnaire ranges 29 145; scores, quality life.",G0000000|C0175659|C0034394|C1514721|C0450371|C1442061|C0449820|C0332306|C0376558
A random sample of 100 children aged 0 to 60 per community were taken from a door-to-door census and were assessed for active trachoma according to the WHO simplified grading system.,A random sample 100 children aged 0 60 community door-to-door census assessed active trachoma WHO simplified grading system.,G0000000|C0034656|C0370003|C1442061|C0008059|C0001779|G0000000|C0450371|C0009462|C0557698|C0007663|C1516048|C0205177|C0040592|G0000000|G0000000|C0441800|C0449913
"Following the treatment maintenance period, the daily ICS dose was reduced by 50 % for 3 months and then removed for patients who did not experience an asthma exacerbation.","Following treatment maintenance period, daily ICS dose reduced 50 % 3 months removed patients experience asthma exacerbation.",C0231290|C0039798|C0024501|C0439531|C0332173|C0022521|C0178602|C0392756|C0450371|G0000000|G0000000|C0439231|C0849355|C0030705|C0237607|C0004096|G0000000
"We tested this hypothesis in a population-based case-control study of 1,204 endometrial cancer cases and 1,212 controls.","We tested hypothesis population-based case-control study 1,204 endometrial cancer 1,212 controls.",G0000000|C0392366|C1512571|C0032659|C0872128|C0557651|C1442061|C0227843|C0006826|C1442061|C0243148
"At all efficacy assessments from Day 14 until Day 42, pyronaridine-artesunate was non-inferior to chloroquine, with cure rates >95% (Figure 2).","At efficacy assessments Day 14 Day 42, pyronaridine-artesunate non-inferior chloroquine, cure rates >95% (Figure 2).",G0000000|C1280519|C1261322|C0332173|C0450371|C0332173|C0450371|C0072768|C1518422|C0008269|C1880198|C0871208|C0450371|G0000000|G0000000
"No association was established between the trial results and the pattern of acupuncture treatment (standardized or individualized), the selection of treatment sites in the sham acupuncture group, the kind of disorders, or the outcome measures employed (objective or subjective).","No association established trial pattern acupuncture treatment (standardized individualized), selection treatment sites sham acupuncture group, disorders, outcome measures employed (objective subjective).",G0000000|C0004083|C0443211|C0008976|C0449774|C0001299|C0039798|G0000000|C1881197|C0036576|C0039798|C0205145|C0068899|C0001299|C0441833|C0012634|C1274040|C0079809|C0014003|C0018017|C0439655
"(vi) Falls Efficacy Scale International, a falls efficacy questionnaire [29].","(vi) Falls Efficacy Scale International, falls efficacy questionnaire [29].",C0205999|C0000921|C1280519|C0175659|C1512888|C0000921|C1280519|C0034394|C0450371
a) The pain intensity was measured with a 100-mm VAS.,a) The pain intensity measured 100-mm VAS.,G0000000|G0000000|C0030193|C0522510|C0444706|C1442061|C0042815
"Students in both groups were requested to write down and report any unwanted adverse effects including diarrhea, upset stomach and heartburn.","Students requested write report unwanted adverse effects including diarrhea, upset stomach heartburn.",C0038492|C1272683|C0043266|C0684224|G0000000|G0000000|C1280500|C0332257|C0011991|C3887804|C0038351|C0018834
Only 2% of the TAU participants met the 75% reduction and none of the participants met the abstinence target.,Only 2% TAU participants met 75% reduction participants met abstinence target.,C0205171|G0000000|C1720655|C0679646|C0268621|C0450371|C0301630|C0679646|C0268621|C3843422|C1521840
Note: WUSPI = Wheelchair Users Shoulder Pain Index.,Note: WUSPI = Wheelchair Users Shoulder Pain Index.,C1316572|G0000000|G0000000|C0043143|C1706077|C0037004|C0030193|C0918012
"The changes in HADS and PHLMS scores from pre-intervention on day 1 to post-intervention on day 3 were computed, and Mann-Whitney tests were used to compare the changes between the two groups.","The HADS PHLMS scores pre-intervention day 1 post-intervention day 3 computed, Mann-Whitney tests compare groups.",G0000000|C0048008|G0000000|C0449820|C2347663|C0332173|G0000000|C2347647|C0332173|G0000000|C1441526|G0000000|C0022885|C1707455|C0441833
Those who did not develop delirium were censored at discharge.,Those develop delirium censored discharge.,G0000000|G0000000|C0011206|C3889990|C0012621
"However, we used only clinical measures that were taken within 3 months of baseline and 2 months of the 6-month assessment dates, which would have had less of an effect on HbA1c data but could have affected other outcomes, such as LDL or blood pressure.","However, clinical measures 3 months baseline 2 months 6-month assessment dates, HbA1c data outcomes, LDL blood pressure.",G0000000|C0205210|C0079809|G0000000|C0439231|C0168634|G0000000|C0439231|C0332177|C1261322|C0011008|G0000000|C1511726|C1274040|G0000000|C0005767|C0033095
"SCORE at baseline, 6 months and 12 months.","SCORE baseline, 6 months 12 months.",C0449820|C0168634|G0000000|G0000000
"After 10 weeks of milnacipran treatment, approximately one third of patients had clinically meaningful improvements in global status (32.9% with PGIC score ≤2) or pain (34.2% with ≥30% reduction in VAS pain score).","After 10 weeks milnacipran treatment, patients clinically meaningful improvements global status (32.9% PGIC score ≤2) pain (34.2% ≥30% reduction VAS pain score).",G0000000|C0450371|C0439230|C1533126|C0039798|C0030705|G0000000|C0876919|C2986411|C0205246|C0449438|C0450371|G0000000|C0449820|G0000000|C0030193|C0450371|G0000000|C0301630|C0042815|C0030193|C0449820
Images were compared to baseline based on VASI.,Images compared baseline based VASI.,C1704254|C1707455|C0168634|C1527178|G0000000
Anderson Symptom Inventory (MDASI) [37].,Anderson Symptom Inventory (MDASI) [37].,G0000000|C1457887|C0021941|G0000000|C0450371
"Upper extremity motor function was measured with the upper-extremity portion of the Fugl-Meyer Motor Performance Test21 and the Wolf Motor Arm Test22 (WMAT), during which Wolf time and Wolf weight were measured, and the University of Maryland Arm Questionnaire for Stroke14 (UMAQS).","Upper extremity motor function measured upper-extremity portion Fugl-Meyer Motor Performance Test21 Wolf Motor Arm Test22 (WMAT), Wolf time Wolf weight measured, University Maryland Arm Questionnaire Stroke14 (UMAQS).",C1282910|C0015385|C1513492|C0031843|C0444706|C1140618|C0449719|G0000000|C1513492|C0597198|G0000000|C0325001|C1513492|C0446516|G0000000|G0000000|C0325001|C0040223|C0325001|C0005910|C0444706|C0041740|C0024858|C0446516|C0034394|G0000000|G0000000
"Baseline characteristics of all patients who received at least one dose of study medication, and who had NL information at year 1 and lesion follow-up at year 2 Abbreviations: EDSS = Expanded Disability Status Scale; GA = glatiramer acetate; Gd = gadolinium; IFNβ-1b = interferon beta-1b; NL = new lesion.","Baseline characteristics patients received dose study medication, NL 1 lesion follow-up 2 Abbreviations: EDSS = Expanded Disability Status Scale; GA = glatiramer acetate; Gd = gadolinium; IFNβ-1b = interferon beta-1b; NL = lesion.",C0168634|C1521970|C0030705|C1514756|C0178602|C0557651|C0013227|C0027778|G0000000|C0221198|C0589120|G0000000|C0000723|C0451246|G0000000|C0205229|C0231170|C0449438|C0175659|C0016993|G0000000|C0717787|C0000975|G0000000|G0000000|C0016911|G0000000|G0000000|C0021747|C0330390|C0027778|G0000000|C0221198
"37 In summary, we did not find, in this small controlled trial, significant differences between groups in our primary outcome of TST or in measures of daytime QoL and functioning.","37 In summary, find, controlled trial, differences primary outcome TST measures daytime QoL functioning.",C0450371|G0000000|C1552616|C0243095|C2587213|C0008976|C1705241|C0205225|C1274040|C1421210|C0079809|C0332169|C0518214|C0205245
"While external reviewers saw short-term improvement in some communication skills, these were not sustained over three months.","While external reviewers short-term improvement communication skills, sustained months.",G0000000|C0205101|C1709941|C0443303|C2986411|C0009452|C0678856|C0443318|C0439231
"Symptoms and side-effects were evaluated subjectively and objectively, using a battery of tests including the MSLT, Maintenance of Wakefulness Test (MWT), and the Wilkinson Addition Test (WAT).","Symptoms side-effects evaluated subjectively objectively, battery tests including MSLT, Maintenance Wakefulness Test (MWT), Wilkinson Addition Test (WAT).",C0683368|C0001688|C0220825|G0000000|G0000000|C0337088|C0022885|C0332257|C0519186|C0024501|C0043012|C0022885|G0000000|G0000000|C0332287|C0022885|G0000000
"Five year (A) paraaortic control, (B) distant control, (C) disease-free survival, and (D) overall survival, after extended-field chemoradiation and WP-CCRT.","Five (A) paraaortic control, (B) distant control, (C) disease-free survival, (D) survival, extended-field chemoradiation WP-CCRT.",C0205451|G0000000|C0442134|C0243148|G0000000|C0443203|C0243148|G0000000|C0012634|C0038952|C0073187|C0038952|C0231448|C0436307|G0000000
"People in the HIT-arm were twice as likely to report continuous abstinence compared with the LIT-arm (18% vs. 9%, p = 0.02).","People HIT-arm report continuous abstinence compared LIT-arm (18% vs. 9%, = 0.02).",C0027361|C0272285|C0684224|C0549178|C3843422|C1707455|C1420803|C0450371|G0000000|G0000000|G0000000|C0450371
"Child catastrophizing and pain coping skills were measured using the Pain Response Inventory (PRI).39,40 The Pain Response Inventory assesses child responses to pain.","Child catastrophizing pain coping skills measured Pain Response Inventory (PRI).39,40 The Pain Response Inventory assesses child responses pain.",C0008059|C0563150|C0030193|C0009967|C0678856|C0444706|C0030193|C0871261|C0021941|C0034044|G0000000|C0030193|C0871261|C0021941|C1516048|C0008059|C0871261|C0030193
"Welch Allyn ABPM 6100 (Welch Allyn Inc, USA) validated according to the protocol of the Finnish Hypertension Society, was used.","Welch Allyn ABPM 6100 (Welch Allyn Inc, USA) validated protocol Finnish Hypertension Society, used.",C0043114|G0000000|G0000000|G0000000|C0043114|G0000000|G0000000|C0041703|G0000000|C0442711|C1711254|C0020538|C0037455|C1273517
"Agitation score : 1 = asleep, 2 = awake and calm, 3 = agitated but consolable, 4 = severely agitated and inconsolable.","Agitation score : 1 = asleep, 2 = awake calm, 3 = agitated consolable, 4 = severely agitated inconsolable.",C0085631|C0449820|G0000000|G0000000|G0000000|C0424522|G0000000|G0000000|C0234422|C0522165|G0000000|G0000000|C0085631|G0000000|G0000000|G0000000|C0205082|C0085631|G0000000
"Overall clinical status was assessed by the Clinical Global Impression (CGI) scale,37 behavioral signs and symptoms by the Neuropsychiatric Inventory (NPI) scale,38 and patients’ well-being by the World Health Organization (WHO)-5 Well-Being Index.39 Caregiver’s sleep was assessed by the Sleep Disorders Inventory (SDI).40 The safety parameters were assessed at each visit and included spontaneously reported adverse events (AEs) or serious AEs (SAEs), and vital signs (heart rate and blood pressure), physical examination, and laboratory tests.","Overall clinical status assessed Clinical Global Impression (CGI) scale,37 behavioral signs symptoms Neuropsychiatric Inventory (NPI) scale,38 patients’ well-being World Health Organization (WHO)-5 Well-Being Index.39 Caregiver’s sleep assessed Sleep Disorders Inventory (SDI).40 The safety parameters assessed visit included spontaneously reported adverse events (AEs) AEs (SAEs), vital signs (heart rate blood pressure), physical examination, laboratory tests.",C0282416|C0205210|C0449438|C1516048|C0205210|C0205246|C0596764|C3639708|C0175659|C0004927|C0220912|C0683368|G0000000|C0021941|C1412208|C0175659|G0000000|C0018684|C2700280|C0018684|C0029237|G0000000|C0018684|C0918012|G0000000|C0037313|C1516048|C0037313|C0012634|C0021941|C0683833|G0000000|C0036043|C0449381|C1516048|C0545082|C0332257|G0000000|C0684224|G0000000|C0441471|C1412268|C1412268|C1519255|C0442732|C0220912|C0018787|C0871208|C0005767|C0033095|C0031809|G0000000|C0022877|C0022885
Complete remission (CR) was defined as a urine protein excretion (UPE) < 0.3 g/d with stable Scr (defined as a change in SCr of 15% or less above baseline values).,Complete remission (CR) defined urine protein excretion (UPE) < 0.3 g/d stable Scr (defined change SCr 15% baseline values).,C0205197|C0544452|C0201975|C1704788|C0042036|C0033684|C0221102|G0000000|G0000000|G0000000|C0439417|C0205360|C1539487|C1704788|C0392747|C1539487|C0450371|C0168634|C0042295
"Baseline samples for the assessment of hematological parameters and bilirubin were drawn on day 3 and for creatinine on day 5. AEs and serious adverse events (SAEs) were defined in accordance with the ICH, and their possible relation to study treatment was documented until 1 day after the end of the last study infusion.","Baseline samples assessment hematological parameters bilirubin drawn day 3 creatinine day 5. AEs adverse events (SAEs) defined ICH, relation study treatment documented 1 day study infusion.",C0168634|C0370003|C1261322|C0018943|C0449381|C0005437|C0013113|C0332173|G0000000|C0010294|C0332173|G0000000|C1412268|G0000000|C0441471|C1519255|C1704788|C0019191|C0080103|C0557651|C0039798|C1301725|G0000000|C0332173|C0557651|C0574032
who investigated the role of chest physiotherapy in the prevention of postextubation atelectasis in neonates (5).,investigated role chest physiotherapy prevention postextubation atelectasis neonates (5).,C1292732|C0035820|C0817096|C0949766|C0199176|G0000000|C0004144|C0021289|G0000000
The observed 12 month sustained abstinence outcomes of GP usual care and Quitline referral in Borland et al.,The observed 12 month sustained abstinence outcomes GP usual care Quitline referral Borland al.,G0000000|C1441672|C0450371|C0332177|C0443318|C3843422|C1274040|C3811116|C3538928|C1947933|G0000000|C0034927|G0000000|C0202311
"Visits to mainland China were associated with SARS transmission, even after adjusting for other variables.","Visits mainland China SARS transmission, adjusting variables.",C0545082|G0000000|C0008115|C1175175|C0040722|G0000000|C0439828
"The two groups were comparable in terms of gender, age, and baseline detrusor leak point pressure, maximum cystometric capacity, bladder compliance, frequency of urination, and frequency of urinary incontinence (all P > 0.05).","The comparable terms gender, age, baseline detrusor leak pressure, maximum cystometric capacity, bladder compliance, frequency urination, frequency urinary incontinence (all P > 0.05).",G0000000|G0000000|C0233324|C0079399|C0001779|C0168634|C1180419|C0332234|C0033095|C0806909|G0000000|C1516240|C0005682|C0009563|C0376249|C0042034|C0376249|C0042027|C0021167|G0000000|C0369773|G0000000|C0450371
There were no significant changes in lesion area and perifollicular pigmentation in each group (P > 0.05).,There lesion perifollicular pigmentation (P > 0.05).,G0000000|C0221198|G0000000|C0031911|C0369773|G0000000|C0450371
"The outcome measurements were changes in the spherical equivalent (SE), and axial length (AL), as well as adverse events (AEs).","The outcome measurements spherical equivalent (SE), axial length (AL), adverse events (AEs).",G0000000|C1274040|C0242485|C0332501|C0205163|C0036919|C0205131|C1444754|C0202311|G0000000|C0441471|C1412268
The primary endpoint was the disappearance of skin lesions and itching at day 14.,The primary endpoint disappearance skin lesions itching day 14.,G0000000|C0205225|C2349179|G0000000|C0444099|C0221198|C0033774|C0332173|C0450371
"• Parental report of child TSE, obtained through questionnaires, including information on frequency of regular exposure, smoking habits of both parents, smoking bans in house and car, smoking behavior of frequent and occasional visitors; exposure to regular smoking elsewhere (such as in daycare or at grandparent).","• Parental report child TSE, questionnaires, including frequency regular exposure, smoking habits parents, smoking bans house car, smoking behavior frequent occasional visitors; exposure regular smoking (such daycare grandparent).",G0000000|C0030551|C0684224|C0008059|G0000000|C0034394|C0332257|C0376249|C0205272|C0274281|C0037369|C0018464|C0030551|C0037369|C0105185|C0442519|C0004381|C0037369|C0004927|C0332183|C0521114|G0000000|C0274281|C0205272|C0037369|G0000000|C0011017|C0337471
"The primary endpoint of this study was performance as assessed by a randomly sorted computerized Korean version of the Boston Naming Test (BNT; Kim & Na, 1997), which involves the use of 60 culturally customized picture items.","The primary endpoint study performance assessed randomly sorted computerized Korean version Boston Naming Test (BNT; Kim & Na, 1997), involves 60 culturally customized picture items.",G0000000|C0205225|C2349179|C0557651|C0597198|C1516048|G0000000|C0237886|G0000000|C1556095|C0333052|C0006037|C0233735|C0022885|G0000000|G0000000|G0000000|C0597484|G0000000|G0000000|C0450371|C0010453|C1880202|C0441468|C1551338
"Treatment failure was defined as the presence of any of the following: (1) fever, fast breathing, or difficulty in breathing as reported by care giver, temperature ≥37.5°C or high respiratory rate; (2) lower chest in-drawings or serious illness; (3) received additional antibiotics; (4) received additional antimalarials; (5) hospitalization; and (6) death.","Treatment failure defined presence following: (1) fever, fast breathing, difficulty breathing reported care giver, temperature ≥37.5°C respiratory rate; (2) lower chest in-drawings illness; (3) received additional antibiotics; (4) received additional antimalarials; (5) hospitalization; (6) death.",C0039798|C0231174|C1704788|C0150312|C0231290|G0000000|C0015967|C0015663|C0004048|C1299586|C0004048|C0684224|C1947933|G0000000|C0005903|G0000000|C0521346|C0871208|G0000000|C0441994|C0817096|C0150312|C0221423|G0000000|C1514756|C1524062|C0003232|G0000000|C1514756|C1524062|C0003374|G0000000|C0019993|G0000000|C0011065
The primary outcome is the time interval in minutes from FIBTEM analysis and clinical scenario suggesting that fibrinogen supplementation is required to the completion of the first administration of fibrinogen supplementation (FC or Cryo).,The primary outcome time interval minutes FIBTEM analysis clinical scenario suggesting fibrinogen supplementation required completion administration fibrinogen supplementation (FC Cryo).,G0000000|C0205225|C1274040|C0040223|C1272706|C0439232|G0000000|C0002778|C0205210|C0683579|C1705535|C0016006|C0242297|C1514873|C0205197|C0001554|C0016006|C0242297|C2983605|G0000000
"At AAR clinics, all 9 smokers who talked with the Quitline enrolled in treatment, resulting in a treatment enrollment rate of 100%.","At AAR clinics, 9 smokers talked Quitline enrolled treatment, treatment enrollment rate 100%.",G0000000|C1151648|C0442592|G0000000|C0337664|C0037817|G0000000|G0000000|C0039798|C0039798|C1516879|C0871208|C1442061
"These will include gait speed (m/s), cadence (steps/min), stride length (m), step length coefficient of variation (CV) and double support time (s).","These gait speed (m/s), cadence (steps/min), stride length (m), step length coefficient variation (CV) double support time (s).",G0000000|C0016928|C0678536|C0439493|G0000000|C1261552|G0000000|C1444754|C0369637|C1261552|C1444754|C1707429|C0205419|C3538987|C0205173|C0183683|C0040223|C0565930
“Cure” was defined as the resolution of fever within 5 days after initiating the antimicrobial therapy.,“Cure” defined resolution fever 5 days initiating antimicrobial therapy.,G0000000|C1704788|C1514893|C0015967|G0000000|C0439228|C1548602|C1136254|C0039798
The primary endpoint was progression of HGPIN to PC over a three-year period.,The primary endpoint progression HGPIN PC three-year period.,G0000000|C0205225|C2349179|C0242656|C1168327|C0031995|C0205449|C0439531
Eligible patients were those already taking insulin and receiving endocrinologist-directed care through a diabetes centre and whose most recent HbA1c level was 0.085 or higher.,Eligible patients insulin receiving endocrinologist-directed care diabetes centre HbA1c level 0.085 higher.,C1548635|C0030705|C0021641|C1514756|C0259863|C1947933|C0011847|C0205099|G0000000|C0441889|C1442061|C0205250
"In Figure Figure2,2, all obtained data for SCORAD (a) and pruritus (b) are shown.","In Figure Figure2,2, data SCORAD (a) pruritus (b) shown.",G0000000|G0000000|G0000000|C1511726|G0000000|G0000000|C0033774|G0000000|C1547282
"Continuous abstinence from quit day to 6 months, n (%) a P-value for chi-square test comparing groups.","Continuous abstinence quit day 6 months, (%) P-value chi-square test comparing groups.",C0549178|C3843422|C0748223|C0332173|G0000000|C0439231|G0000000|C1709380|C1552646|C0022885|C1707455|C0441833
"Recorded urodynamic parameters in addition to the urodynamic tracings were from the uroflowmetry (voided volume, postvoid RU, maximal flow rate, voiding time), cystometrogram (first sensation, first desire to void, capacity, filling rate, detrusor overactivity, urodynamic stress incontinence, abdominal leak point pressure at 200 cm3), and urethral pressure profile.","Recorded urodynamic parameters addition urodynamic tracings uroflowmetry (voided volume, postvoid RU, maximal flow rate, voiding time), cystometrogram (first sensation, desire void, capacity, filling rate, detrusor overactivity, urodynamic stress incontinence, abdominal leak pressure 200 cm3), urethral pressure profile.",C0034869|C0042059|C0449381|C0332287|C0042059|G0000000|C0200008|C0042034|C0449468|C1439885|C0035970|C0205289|C0806140|C0871208|C0042034|C0040223|C0200000|C0205435|C0036658|C0871633|C0042034|C1516240|G0000000|C0871208|C1180419|C0474395|C0042059|C0038435|C0021167|C0000726|C0332234|C0033095|C1442061|G0000000|C0041967|C0033095|C1979963
We observed little modification of the down-referral association with viral load rebound.,We observed modification down-referral association viral load rebound.,G0000000|C1441672|C0392747|C0034927|C0004083|C0521026|C1550025|G0000000
"There were no substantial differences in the secondary endpoints of change in smoking rates (self-report and eCO) at interim visits, change in Fagerstrom score, total number of visits attended, alterations in self-efficacy and number of quit attempts comparing the four interventions.","There substantial differences secondary endpoints change smoking rates (self-report eCO) interim visits, change Fagerstrom score, total visits attended, alterations self-efficacy quit attempts comparing interventions.",G0000000|G0000000|C1705241|C0027627|C2349179|C0392747|C0037369|C0871208|C0681906|C2675227|C2827738|C0545082|C0392747|G0000000|C0449820|C0439175|C0545082|C1456498|C1515926|C0600564|C0748223|C1516084|C1707455|C0886296
"Because of the opportunity the study provided, domains beyond those specific to dietary change and breast cancer outcomes were included.","Because opportunity study provided, domains specific dietary change breast cancer outcomes included.",G0000000|G0000000|C0557651|C1999230|C1880389|C0205369|C0012155|C0392747|C0006141|C0006826|C1274040|C0332257
"Secondary endpoints include all-cause and cancer-related mortality, diabetes mellitus, and oxidative stress biomarkers.","Secondary endpoints all-cause cancer-related mortality, diabetes mellitus, oxidative stress biomarkers.",C0027627|C2349179|C0015127|C2826292|C0026565|C0011847|G0000000|C0311404|C0038435|C0005516
"Questionnaires were administered to obtain the subjects' characteristics, including smoking habits and green tea consumption from 170 primary lung cancer cases and 340 healthy controls.","Questionnaires administered subjects' characteristics, including smoking habits green tea consumption 170 primary lung cancer 340 healthy controls.",C0034394|C1521801|C0681850|C1521970|C0332257|C0037369|C0018464|C0332583|C0039400|C0009830|C1442061|C0205225|C0024109|C0006826|C1442061|C3898900|C0243148
A secondary outcome was patient falls with injury.,A secondary outcome patient falls injury.,G0000000|C0027627|C1274040|C0030705|C0000921|C3263722
The mortality of preterm children in China is very high.,The mortality preterm children China high.,G0000000|C0026565|C0151526|C0008059|C0008115|C0205250
"We will therefore use the MARS as a viable and economic screen for patients demonstrating sub-optimal adherence, but will then use MEMS (Medication Event Monitoring System, MEMS® Aardex Ltd, Switzerland) pill containers which electronically record openings as our primary outcome measure in the evaluation of this pilot RCT.","We MARS viable economic screen patients demonstrating sub-optimal adherence, MEMS (Medication Event Monitoring System, MEMS® Aardex Ltd, Switzerland) pill containers electronically record openings primary outcome measure evaluation pilot RCT.",G0000000|C0242747|C0443348|C0013556|C0220908|C0030705|G0000000|C0542339|C1510802|C1979923|C0013227|C0441471|C0150369|C0449913|G0000000|G0000000|C1136140|C0039021|C0009905|C0180098|G0000000|C0034869|C0175566|C0205225|C1274040|C0079809|C0220825|C0473169|G0000000
"Alcohol use, tobacco use, and marijuana use outcomes were modeled as count variables in all analyses to account for the nature of the data collected and for nonnormal distributions of these variables, but antisocial behavior was modeled as a continuous variable.","Alcohol use, tobacco use, marijuana outcomes modeled count variables analyses account nature data collected nonnormal distributions variables, antisocial behavior modeled continuous variable.",C0001962|C0042153|C0040329|C0042153|C0024808|C1274040|C3161035|C0750480|C0439828|C0002778|C2741673|C0349590|C1511726|C1516695|G0000000|C0037775|C0439828|C0233523|C0004927|C3161035|C0549178|C0439828
"Outcome measures included hospital admissions, emergency department (ED) visits, health-related quality of life (HRQoL) and medication adherence.","Outcome measures included hospital admissions, emergency department (ED) visits, health-related quality life (HRQoL) medication adherence.",C1274040|C0079809|C0332257|C0019994|C0184666|C0013956|C1704729|C3538926|C0545082|C0018684|C0332306|C0376558|G0000000|C0013227|C1510802
"The ability to detect small changes in substance use, knowledge, attitudes and harms experienced is central to this study.","The ability detect substance use, knowledge, attitudes harms experienced central study.",G0000000|C0085732|C0442726|C0439861|C0042153|C0376554|C0004271|G0000000|C0237607|C0205099|C0557651
Measures of patient outcome included frequency of presentation to hospital during the three months after the index presentation and quality of life as measured by the St George's respiratory questionnaire at follow up.,Measures patient outcome included frequency presentation hospital months presentation quality life measured St George's respiratory questionnaire follow up.,C0079809|C0030705|C1274040|C0332257|C0376249|C0449450|C0019994|C0439231|C0449450|C0332306|C0376558|C0444706|C0036056|G0000000|C0521346|C0034394|C0332283|G0000000
The current level of low back pain was measured before each treatment and at week 12 using a 100-mm visual analog scale.,The current level low pain measured treatment week 12 100-mm visual analog scale.,G0000000|C0521116|C0441889|C0205251|C0030193|C0444706|C0039798|C0332174|C0450371|C1442061|C0234621|C0243071|C0175659
"Trial registration number: {""type"":""clinical-trial"",""attrs"":{""text"":""NCT01759680"",""term_id"":""NCT01759680""}}NCT01759680 Falls are a leading cause of morbidity and mortality in older people.","Trial registration number: {""type"":""clinical-trial"",""attrs"":{""text"":""NCT01759680"",""term_id"":""NCT01759680""}}NCT01759680 Falls leading morbidity mortality people.",C0008976|C1514821|C0237753|C0332307|C0000921|C0332152|C0026538|C0026565|C0027361
We estimated the change in atheroma volume in a target lesion located more than 10 mm away from the stent and in the neointimal proliferation of the stent area.,We estimated change atheroma volume target lesion located 10 mm stent neointimal proliferation stent area.,G0000000|C0750572|C0392747|C0264956|C0449468|C1521840|C0221198|G0000000|C0450371|G0000000|C0038257|C2936380|C0334094|C0038257|C0017446
"Similarly, children in the nutrition arms were more likely to receive animal source foods every day in past 7 days than children in the control arm (year 1: N: 39.1%; N+WSH: 37.1% vs. C:15.1%; year 2: N: 72.3%; N+WSH: 75.6% vs. C:58.1%) at both time points (Figure 3).","Similarly, children nutrition arms receive animal source foods day 7 days children control arm (year 1: N: 39.1%; N+WSH: 37.1% vs. C:15.1%; 2: N: 72.3%; N+WSH: 75.6% vs. C:58.1%) time (Figure 3).",G0000000|C0008059|C0028707|C0206655|C1514756|C0003062|C0449416|C0016452|C0332173|G0000000|C0439228|C0008059|C0243148|C0446516|C0439234|G0000000|C0369718|C0450371|C0369718|C0450371|G0000000|C0450371|G0000000|C0369718|C0450371|C0369718|C0450371|G0000000|C0450371|C0040223|G0000000|G0000000
"Secondary efficacy end points included daily delirium risk, duration of delirium, duration of coma, the number of days patients were alive and breathing without assistance during the 21-day study period (ventilator-free days) (32), time to ICU and hospital discharge, and all-cause 21-day survival.","Secondary efficacy included daily delirium risk, duration delirium, duration coma, days patients alive breathing assistance 21-day study period (ventilator-free days) (32), time ICU hospital discharge, all-cause 21-day survival.",C0027627|C1280519|C0332257|C0332173|C0011206|C0035647|C0449238|C0011206|C0449238|C0009421|C0439228|C0030705|C0376558|C0004048|C0018896|C0450371|C0557651|C0439531|C0087153|C0439228|C0450371|C0040223|C0021708|C0019994|C0012621|C0015127|C0450371|C0038952
"We estimated the protective efficacy of IPTi against malaria, anaemia, and hospital admissions by all combinations of timing of IPTi doses.","We estimated protective efficacy IPTi malaria, anaemia, hospital admissions combinations timing IPTi doses.",G0000000|C0750572|G0000000|C1280519|G0000000|C0024530|C0002871|C0019994|C0184666|C0453882|C0449243|G0000000|C0178602
"In paediatric patients (aged 2–<16 years), additional assessments included those of stature, growth velocity and pubertal development according to Tanner staging (Marshall & Tanner, 1969, 1970).","In paediatric patients (aged 2–<16 years), additional assessments included stature, growth velocity pubertal development Tanner staging (Marshall & Tanner, 1969, 1970).",G0000000|C0030755|C0030705|C0001779|G0000000|C0439234|C1524062|C1261322|C0332257|C0005890|C0018270|C0439830|C1627769|C0243107|C0335730|C0332305|C1551881|G0000000|C0335730|G0000000|G0000000
The primary outcome measure is hospitalization (based on the ED physician’s decision to admit) to an inpatient unit within 24 h of the start of the experimental therapy for persistent respiratory distress or for supplemental oxygen.,The primary outcome measure hospitalization (based ED physician’s decision admit) inpatient unit 24 start experimental therapy persistent respiratory distress supplemental oxygen.,G0000000|C0205225|C1274040|C0079809|C0019993|C1527178|C3538926|G0000000|C0679006|C0184666|C0021562|C0439148|C0450371|C0439659|C1517586|C0039798|C0205322|C0521346|C0231303|C2348609|C0030054
"Association between malaria prevalence and malaria incidence with genotypic and phenotypic resistance, respectively, from 2012–2014 Similar analysis was carried out to investigate whether malaria incidence and infection prevalence were associated with Vgsc-1014F frequency, measured in mosquito specimens collected in corresponding clusters and years.","Association malaria prevalence malaria incidence genotypic phenotypic resistance, respectively, 2012–2014 Similar analysis carried investigate malaria incidence infection prevalence Vgsc-1014F frequency, measured mosquito specimens collected clusters years.",C0004083|C0024530|C0033105|C0024530|C0021149|C0017431|C0031437|C0237834|G0000000|G0000000|C2348205|C0002778|C0206243|C1292732|C0024530|C0021149|C0009450|C0033105|G0000000|C0376249|C0444706|C0026584|C0370003|C1516695|C1555715|C0439234
We used data from the Prescribing Audit Reports and Prescribing Catalogues (PARC) (www.nhsbsa.nhs.uk/prescriptions) to determine the primary outcome for each practice: the total number of dispensed oral antibiotic items per 1000 registered patients for the year after the intervention practices were exposed to the STAR programme.,We data Prescribing Audit Reports Prescribing Catalogues (PARC) (www.nhsbsa.nhs.uk/prescriptions) determine primary outcome practice: total dispensed oral antibiotic items 1000 registered patients intervention practices exposed STAR programme.,G0000000|C1511726|C0278329|C1704774|C0684224|C0278329|G0000000|C1332681|C0282111|G0000000|C0205225|C1274040|C0237607|C0439175|C1880359|C0442027|C0003232|C1551338|G0000000|C1514821|C0030705|C0886296|C0237607|C0332157|C0995242|C1709697
"In asthma and other diseases, vitamin D insufficiency is associated with adverse outcomes.","In asthma diseases, vitamin D insufficiency adverse outcomes.",G0000000|C0004096|C0012634|C0042890|C0073187|C0231179|G0000000|C1274040
"Mood disorder was measured using the Hospital Anxiety and Depression scale (HAD), which is one of most widely used instruments to screen for anxiety and depression in cancer patients 43, 44, 45.","Mood disorder measured Hospital Anxiety Depression scale (HAD), instruments screen anxiety depression cancer patients 43, 44, 45.",C0026516|C0012634|C0444706|C0019994|C0003467|C0011570|C0175659|G0000000|C0348000|C0220908|C0003467|C0011570|C0006826|C0030705|C0450371|C0450371|C0450371
"The sensitivity of the test was 5nmol/L and the intra and interassay coefficient of variations (CVs) were 3.37% and 3.891%, respectively.","The sensitivity test 5nmol/L intra interassay coefficient variations (CVs) 3.37% 3.891%, respectively.",G0000000|C0020517|C0022885|C0439394|C0347985|G0000000|C1707429|C0205419|G0000000|C0450371|C1442061|G0000000
"FEV1 and FVC are assessed at several time points: before (trough: 24 hours after the previous dose and 10 minutes prior to the next dose) and after (30, 60, 120, and 180 minutes) inhalation of the study drug.","FEV1 FVC assessed time points: (trough: 24 hours previous dose 10 minutes prior dose) (30, 60, 120, 180 minutes) inhalation study drug.",G0000000|C3714541|C1516048|C0040223|C1552961|C0444506|C0450371|C0439227|C0205156|C0178602|C0450371|C0439232|C0332152|C0178602|C0450371|C0450371|C1442061|C1442061|C0439232|C0004048|C0557651|C0013227
The seven other recurrences appeared between days 29 and 163; day 21 was the median day of recurrence in this group.,The recurrences appeared days 29 163; day 21 median day recurrence group.,G0000000|C0034897|C0700364|C0439228|C0450371|C1442061|C0332173|C0450371|C0549183|C0332173|C0034897|C0441833
"The results showed significant intervention effects at 12 weeks and 6 months follow-up for metres walked in 12 min, minutes of moderate intensity activity reported in a week, shoulder mobility, breast cancer specific subscale of quality of life and for positive mood.","The intervention effects 12 weeks 6 months follow-up metres walked 12 min, minutes moderate intensity activity reported week, shoulder mobility, breast cancer specific subscale quality life positive mood.",G0000000|C0886296|C1280500|C0450371|C0439230|G0000000|C0439231|C0589120|C0475209|C0080331|C0450371|C0702093|C0439232|C0205081|C0522510|C0205177|C0684224|C0332174|C0037004|C0425245|C0006141|C0006826|C0205369|G0000000|C0332306|C0376558|C0439178|C0026516
All patients with local recurrence were treated with the same treatment.,All patients local recurrence treated treatment.,G0000000|C0030705|C0205276|C0034897|C1522326|C0039798
"Each patient performed functional training of the paralytic lower limb for 20 minutes a day for 4 weeks, and changes in the lower limb function were investigated using the Stroke Impairment Assessment Set.","Each patient performed functional training paralytic lower limb 20 minutes day 4 weeks, lower limb function investigated Stroke Impairment Assessment Set.",G0000000|C0030705|C0884358|C0205245|C0040607|G0000000|C0441994|C0015385|C0450371|C0439232|C0332173|G0000000|C0439230|C0441994|C0015385|C0031843|C1292732|C0038454|C0221099|C1261322|C0036849
Keywords: smokeless tobacco; primary prevention; intervention studies; adolescent behaviour; community interventions,Keywords: smokeless tobacco; primary prevention; intervention studies; adolescent behaviour; community interventions,C1708608|C1450035|C0040329|C0205225|C0199176|C0886296|C0947630|C0205653|C0004927|C0009462|C0886296
"According to Liang et al, 42 this study showed that laparoscopy was more expensive than open surgery, although the shorter hospital stay nearly compensated for the additional costs of surgical instruments and devices and the longer operative time.","According Liang al, 42 study laparoscopy expensive surgery, shorter hospital stay compensated additional costs surgical instruments devices operative time.",C0680240|G0000000|C0202311|C0450371|C0557651|C0031150|C0680864|C0038894|C1282927|C0019994|G0000000|C0205432|C1524062|C0010186|C0543467|C0348000|C0025080|C1882154|C0040223
VAS and BPI scores (Mean ± SD) before and after sham and active tDCS.,VAS BPI scores (Mean ± SD) sham active tDCS.,C0042815|C1443145|C0449820|C0444504|G0000000|C2699239|C0068899|C0205177|C3850024
It also demonstrated the effect of health education on improved correct knowledge and attitude about ITN.,It demonstrated health education improved correct knowledge attitude ITN.,G0000000|G0000000|C0018684|C0013621|C0184511|C2349182|C0376554|C0004271|G0000000
We repeated all analysis after excluding breast cancer cases diagnosed in the first 3 years of follow-up (38 in Cohort 1 and 40 in Cohort 2).,We repeated analysis excluding breast cancer diagnosed 3 follow-up (38 Cohort 1 40 Cohort 2).,G0000000|C0205341|C0002778|C0332196|C0006141|C0006826|C0011900|G0000000|C0589120|C0450371|C0599755|G0000000|C0450371|C0599755|G0000000
Secondary Outcomes by Main Effects Group CAM = complementary and alternative medicine; IQR = interquartile range; LBP = low back pain; OMT = osteopathic manual treatment; RMDQ = Roland-Morris Disability Questionnaire; SF-36 GH = Medical Outcomes Study Short Form-36 Health Survey general health scale; UST = ultrasound therapy.,Secondary Outcomes Main Effects Group CAM = complementary alternative medicine; IQR = interquartile range; LBP = low pain; OMT = osteopathic manual treatment; RMDQ = Roland-Morris Disability Questionnaire; SF-36 GH = Medical Outcomes Study Short Form-36 Health Survey health scale; UST = ultrasound therapy.,C0027627|C1274040|C0205225|C1280500|C0441833|C0597815|G0000000|G0000000|C1523987|C0013227|G0000000|G0000000|G0000000|C1514721|C1505993|G0000000|C0205251|C0030193|G0000000|G0000000|C0005940|C0024763|C0039798|G0000000|G0000000|G0000000|C0231170|C0034394|C0037712|C0033993|G0000000|C0199168|C1274040|C0557651|C1282927|C0348078|C0018684|C0038951|C0018684|C0175659|C1424835|G0000000|C0041618|C0039798
The primary outcome is self-reported 7-day PPA at 3 and 6 months.,The primary outcome self-reported 7-day PPA 3 6 months.,G0000000|C0205225|C1274040|C0681906|C0332173|C0031681|G0000000|G0000000|C0439231
The incidence of ovarian malignancies (including borderline ovarian tumours) through 2007 was assessed through linkage with disease registries.,The incidence ovarian malignancies (including borderline ovarian tumours) 2007 assessed linkage disease registries.,G0000000|C0021149|C0205065|C0006826|C0332257|C0205189|C0205065|C0027651|G0000000|C1516048|C0023745|C0012634|C0034975
The primary outcome was oxygen dependency at 28 days of age or death.,The primary outcome oxygen dependency 28 days age death.,G0000000|C0205225|C1274040|C0030054|C0011546|C0450371|C0439228|C0001779|C0011065
A partial response was defined as radiological response >50% in all brain metastases.,A partial response defined radiological response >50% brain metastases.,G0000000|C0728938|C0871261|C1704788|C0034599|C0871261|C0450371|C0006104|C0027627
"The primary outcome was 12-month change in log-transformed Wolf Motor Function Test time score (WMFT, consisting of a mean of 15 timed arm movements and hand dexterity tasks).","The primary outcome 12-month change log-transformed Wolf Motor Function Test time score (WMFT, consisting 15 timed arm movements hand dexterity tasks).",G0000000|C0205225|C1274040|C0450371|C0392747|C1708728|C0325001|C1513492|C0031843|C0022885|C0040223|C0449820|G0000000|C0332529|C0450371|C0392761|C0446516|C0026649|C0018563|C0565699|C3540678
The primary analysis for trough FEV1 at week 12 was performed on the FAS using a mixed model.,The primary analysis trough FEV1 week 12 performed FAS mixed model.,G0000000|C0205225|C0002778|C0444506|G0000000|C0332174|C0450371|C0884358|G0000000|C0205430|C3161035
The primary outcome will be caries increment in children and proportion of caries-free children.,The primary outcome caries increment children proportion caries-free children.,G0000000|C0205225|C1274040|C0011334|C1705117|C0008059|C1709707|C0011334|C0008059
p < 0.01 for aclidinium and tiotropium versus placebo at each time point.,< 0.01 aclidinium tiotropium versus placebo time point.,G0000000|C0450371|C2699757|C0213771|G0000000|C0032042|C0040223|C1552961
"The surgery resident also assessed the skin for lesions (urticaria, redness, desquamation, maceration, pressure sores, and inflammation).","The surgery resident assessed skin lesions (urticaria, redness, desquamation, maceration, pressure sores, inflammation).",G0000000|C0038894|C1320928|C1516048|C0444099|C0221198|C0042109|C0041834|C0237849|C0333525|C0033095|C0234233|C0021368
"PSQI, Pittsburgh Sleep Quality Index.","PSQI, Pittsburgh Sleep Quality Index.",C3697468|G0000000|C0037313|C0332306|C0918012
"Specifically, we were interested in the effects on menopause‐specific quality of life (primary outcome) and on sexual functioning and sexual distress (secondary outcomes).","Specifically, effects menopause‐specific quality life (primary outcome) sexual functioning sexual distress (secondary outcomes).",G0000000|C1280500|G0000000|C0332306|C0376558|C0205225|C1274040|C0036864|C0205245|C0036864|C0231303|C0027627|C1274040
"Five lesions excised without antibiotic treatment and five lesions treated with antibiotics for 2 weeks were culture positive, whereas three lesions treated for 4 weeks, five treated for 8 weeks, and three treated for 12 weeks were culture negative.","Five lesions excised antibiotic treatment lesions treated antibiotics 2 weeks culture positive, lesions treated 4 weeks, treated 8 weeks, treated 12 weeks culture negative.",C0205451|C0221198|G0000000|C0003232|C0039798|C0221198|C1522326|C0003232|G0000000|C0439230|C0010453|C0439178|C0221198|C1522326|G0000000|C0439230|C1522326|G0000000|C0439230|C1522326|C0450371|C0439230|C0010453|C0205160
Details of daily usage of asthma medication and episodes of night-time waking were also recorded.,Details daily usage asthma medication episodes night-time waking recorded.,C1522508|C0332173|C0457083|C0004096|C0013227|C0332189|C0240526|C0442696|C0034869
Figure 3 shows supine time averaged across all nights during each condition.,Figure 3 supine time averaged nights condition.,G0000000|G0000000|C0038846|C0040223|C1510992|C0240526|C0012634
"The primary outcome analyses were based on biochemically verified 7-day point-prevalence abstinence (defined as self-reported no smoking for the 7-days prior to the interview date) immediately post-treatment, and at 3- and 6-month follow ups (Hughes, et al., 2004).","The primary outcome analyses based biochemically verified 7-day point-prevalence abstinence (defined self-reported smoking 7-days prior interview date) post-treatment, 3- 6-month follow (Hughes, al., 2004).",G0000000|C0205225|C1274040|C0002778|C1527178|G0000000|C1711411|C0332173|C1552961|C3843422|C1704788|C0681906|C0037369|C0439228|C0332152|C0021822|C0011008|C2709088|G0000000|C0332177|C0332283|C1551730|C0202311|G0000000
Box and whisker plots for TNF-α in induced sputum at the four study visits when induced sputum samples were collected.,Box whisker plots TNF-α induced sputum study visits induced sputum samples collected.,C0179400|C0042640|G0000000|G0000000|C0205263|C0038056|C0557651|C0545082|C0205263|C0038056|C0370003|C1516695
FVC is analyzed as achieved percent of vital capacity predicted on the basis of age and height.41 Fatigue severity was measured by the 9-item Fatigue Severity Scale (FSS).42 Quality of life was recorded on the SF36™ Health Survey.43 Its physical (PCS) and mental (MCS) components were analyzed separately.,FVC analyzed achieved percent vital capacity predicted basis age height.41 Fatigue severity measured 9-item Fatigue Severity Scale (FSS).42 Quality life recorded SF36™ Health Survey.43 Its physical (PCS) mental (MCS) components analyzed separately.,C3714541|C0936012|G0000000|C0439165|C0442732|C1516240|C0681842|C1527178|C0001779|C0489786|C0015672|C0439793|C0444706|C1551338|C0015672|C0439793|C0175659|C0265224|C0332306|C0376558|C0034869|G0000000|C0018684|C0038951|G0000000|C0031809|C1864389|C0229992|G0000000|C0449432|C0936012|G0000000
"Levels of hemoglobin, folic acid, vitamin B12, retinol and vitamin D were1.01, 1.76, 1.1, 1.08 and 1.1 times higher respectively in the intervention group compared to the control group.","Levels hemoglobin, folic acid, vitamin B12, retinol vitamin D were1.01, 1.76, 1.1, 1.08 1.1 times intervention compared control group.",C0441889|C0019046|G0000000|C0001128|C0042890|G0000000|C0042839|C0042890|C0073187|C0450371|C0450371|G0000000|C0450371|G0000000|C0040223|C0886296|C1707455|C0243148|C0441833
The primary endpoint was the percent change of LDL-C at week 8.,The primary endpoint percent change LDL-C week 8.,G0000000|C0205225|C2349179|C0439165|C0392747|G0000000|C0332174|G0000000
"Maternal venous blood was collected for hemoglobin and iron indices (ferritin and transferrin receptor) at enrolment, 32 wk gestation, and 6 mo postpartum.","Maternal venous blood collected hemoglobin iron indices (ferritin transferrin receptor) enrolment, 32 wk gestation, 6 mo postpartum.",C2347083|C0042449|C0005767|C1516695|C0019046|C0302583|C4033634|C0015879|C0040679|C0597357|C1516879|C0450371|C0332174|C0032961|G0000000|C0026544|C0086839
Survival rates after starting the adaptation to NIV and psychological variables will be considered as secondary outcomes.,Survival rates starting adaptation NIV psychological variables considered secondary outcomes.,C0038952|C0871208|C0439659|C0000934|C0598902|C0205486|C0439828|C0750591|C0027627|C1274040
Secondary end points were overall survival and cancer free survival.,Secondary survival cancer free survival.,C0027627|C0038952|C0006826|C0332296|C0038952
Median survival was 5 months; patients with history of colorectal cancer had better survival than other cancer (median survival 7 months vs. 4 months; p = 0.02).,Median survival 5 months; patients history colorectal cancer survival cancer (median survival 7 months vs. 4 months; = 0.02).,C0549183|C0038952|G0000000|C0439231|C0030705|C0019664|C0555952|C0006826|C0038952|C0006826|C0549183|C0038952|G0000000|C0439231|G0000000|G0000000|C0439231|G0000000|C0450371
"Kidney function, plasma proteins, cell blood counts, and cholesterol were obtained monthly.","Kidney function, plasma proteins, cell blood counts, cholesterol monthly.",C0022646|C0031843|C0032105|C0033684|C0007634|C0005767|C0439157|C0008377|C0332177
The primary efficacy endpoint was the least-square mean percentage change in spleen volume by MRI from baseline to 9 months in the eliglustat group compared with the placebo group.,The primary efficacy endpoint least-square percentage change spleen volume MRI baseline 9 months eliglustat compared placebo group.,G0000000|C0205225|C1280519|C2349179|C0023189|C0439165|C0392747|C0037993|C0449468|C0024485|C0168634|G0000000|C0439231|C3272698|C1707455|C0032042|C0441833
"Secondary endpoints were overall survival (OS), overall response rate (ORR), and safety.","Secondary endpoints survival (OS), response rate (ORR), safety.",C0027627|C2349179|C0038952|C0229090|C0871261|C0871208|G0000000|C0036043
These increments correlate with urinary iron excretion and the change in liver iron concentration over the subsequent year thus predicting response to deferiprone-containing chelation regimes.,These increments correlate urinary iron excretion change liver iron concentration subsequent predicting response deferiprone-containing chelation regimes.,G0000000|C1705117|G0000000|C0042027|C0302583|C0221102|C0392747|C0023884|C0302583|C0004268|C0332282|G0000000|C0871261|C0043832|C3537131|G0000000
This provides a compelling MRI indication to support the concept that the reduction in MS disability measured by EDSS that resulted from inosine treatment may be a consequence of raising serum UA levels.,This compelling MRI indication support concept reduction MS disability measured EDSS inosine treatment consequence raising serum UA levels.,G0000000|G0000000|C0024485|C0392360|C0183683|C0178566|C0301630|C0039676|C0231170|C0444706|C0451246|C0021528|C0039798|C0686907|G0000000|C0229671|C0041580|C0441889
"We took three measurements, discarded the first and averaged the second and third for further analysis.","We measurements, discarded averaged analysis.",G0000000|C0242485|G0000000|C1510992|C0002778
"Postoperative complications such as pain, postoperative nausea and vomiting (PONV) and postoperative convulsions during 1st postoperative hour were noted.","Postoperative complications pain, postoperative nausea vomiting (PONV) postoperative convulsions 1st postoperative hour noted.",C0032790|C0009566|C0030193|C0032790|C0027497|C0042963|C0520909|C0032790|C0036572|G0000000|C0032790|C0439227|C1316572
"Main outcome measures Primary outcome was quality of life, as assessed by the short form health survey (SF-36).","Main outcome measures Primary outcome quality life, assessed short form health survey (SF-36).",C0205225|C1274040|C0079809|C0205225|C1274040|C0332306|C0376558|C1516048|C1282927|C0348078|C0018684|C0038951|C0037712
"Among the intervention group, 1977 tested positive at least once, a cumulative risk of having a positive test of 2.6% (1977 of 76 224).","Among intervention group, 1977 tested positive once, cumulative risk positive test 2.6% (1977 76 224).",G0000000|C0886296|C0441833|G0000000|C0392366|C0439178|G0000000|C1511559|C0035647|C0439178|C0022885|G0000000|G0000000|C0450371|C1442061
"Ischemic stroke (IS, any Oxfordshire Community Stroke Project or Trial of Org10172 in Acute Stroke Treatment type [31,32]) or spontaneous intracerebral haemorrhage.","Ischemic stroke (IS, Oxfordshire Community Stroke Project Trial Org10172 Acute Stroke Treatment type [31,32]) spontaneous intracerebral haemorrhage.",C0475224|C0038454|G0000000|C0454871|C0009462|C0038454|C1709701|C0008976|G0000000|C0205178|C0038454|C0039798|C0332307|C0450371|C0205359|C0442111|C0019080
"Approximately, one-third of patients have seizures after tumor resection [6–8], and in the case of supratentorial craniotomy, 20%–50% of patients have ≥1 seizure [9, 10].","Approximately, one-third patients seizures tumor resection [6–8], supratentorial craniotomy, 20%–50% patients ≥1 seizure [9, 10].",C0332232|C0205447|C0030705|C0036572|C0027651|C0015252|G0000000|C0441938|C0010280|G0000000|C0030705|G0000000|C0036572|G0000000|C0450371
This questionnaire assessed whether patients remembered having been told about the various risks of surgery.,This questionnaire assessed patients remembered told risks surgery.,G0000000|C0034394|C1516048|C0030705|C0034770|G0000000|C0035647|C0038894
The duration of the sensory and motor block as well as the complications were assessed.,The duration sensory motor block complications assessed.,G0000000|C0449238|C0445254|C1513492|C0028778|C0009566|C1516048
Secondary outcomes will include the rate of cephalic presentation at week 38 of gestation (CP38) (determined by echography) and the number of days of treatment received until version occurs.,Secondary outcomes rate cephalic presentation week 38 gestation (CP38) (determined echography) days treatment received version occurs.,C0027627|C1274040|C0871208|C0205096|C0449450|C0332174|C0450371|C0032961|G0000000|C0680730|C0041618|C0439228|C0039798|C1514756|C0333052|C1709305
A laboratory simulation study was conducted using methicillin-susceptible Staphylococcus aureus and antibiotic-sensitive Klebsiella pneumoniae among volunteer HCWs (n = 10 per organism).,A laboratory simulation study conducted methicillin-susceptible Staphylococcus aureus antibiotic-sensitive Klebsiella pneumoniae volunteer HCWs (n = 10 organism).,G0000000|C0022877|C0679083|C0557651|C0004927|C0025643|C0038170|G0000000|C0003232|C0022727|C0032285|C0042960|G0000000|C0369718|G0000000|C0450371|C0029235
"Other studies found no difference in pulmonary function [6-8], sputum production [6,7,9], and in oxygen saturation during or following treatments [8].","Other studies difference pulmonary function [6-8], sputum production [6,7,9], oxygen saturation treatments [8].",G0000000|C0947630|C1705241|C0024109|C0031843|G0000000|C0038056|C0033268|G0000000|C0030054|C0522534|C0087111|G0000000
"If respondents met any one of the following three conditions, they were defined as “engaging in regular PA”: (1) engaging in 150 minutes/week or more of walking, (2) engaging in daily flexibility activity, or (3) engaging in muscle-strengthening activities two or more days/week.","If respondents met conditions, defined “engaging regular PA”: (1) engaging 150 minutes/week walking, (2) engaging daily flexibility activity, (3) engaging muscle-strengthening activities days/week.",G0000000|C0282122|C0268621|C0012634|C1704788|G0000000|C0205272|G0000000|G0000000|C0425152|C1442061|C0556975|C0080331|G0000000|C0425152|C0332173|C0242808|C0205177|G0000000|C0425152|C0026845|C0441655|C0677547
"Survey respondents living in areas where there was a higher prevalence of self-report participation from the survey (table 3, column 2) reported eating more portions of fruit and vegetables and were more likely to report meeting government guidelines on physical activity for obesity prevention (at least seven sessions of 60 min of moderate intensity physical activity per week or equivalent).","Survey respondents living prevalence self-report participation survey (table 3, column 2) reported eating portions fruit vegetables report meeting government guidelines physical activity obesity prevention (at sessions 60 min moderate intensity physical activity week equivalent).",C0038951|C0282122|C0376558|C0033105|C0681906|C0679823|C0038951|C0039224|G0000000|C1185738|G0000000|C0684224|C0013470|C0449719|C0016767|C0042440|C0684224|C0556656|C0018104|C0162791|C0031809|C0205177|C0028754|C0199176|G0000000|C1883016|G0000000|C0205081|C0522510|C0031809|C0205177|C0332174|C0205163
The research nurse tried to contact these participants to obtain a salivary sample for biochemical validation.,The nurse contact participants salivary sample biochemical validation.,G0000000|C0028661|C0332158|C0679646|C0442040|C0370003|C0205474|C1519941
The second objective was to describe the change in the functional status and health related quality of life and the possible modifying factors related to adherence when multifactorial intervention is applied.,The objective change functional status health quality life modifying factors adherence multifactorial intervention applied.,G0000000|C0018017|C0392747|C0205245|C0449438|C0018684|C0332306|C0376558|C0392747|C1521761|C1510802|C1837655|C0886296|C4048755
"The trial has two primary outcomes - the number of occasions that young people report having drunk alcohol in the last 30 days, and drunkenness during the last 30 days, both dichotomised as ‘never’ and ‘1-2 times or more’.","The trial primary outcomes - occasions people report drunk alcohol 30 days, drunkenness 30 days, dichotomised ‘never’ ‘1-2 times more’.",G0000000|C0008976|C0205225|C1274040|G0000000|C0521114|C0027361|C0684224|C0001969|C0001962|C0450371|C0439228|C0001969|C0450371|C0439228|G0000000|G0000000|G0000000|C0040223|G0000000
"Secondary outcomes are duration of untreated psychosis, time to recovery, use of the Mental Health Act, and general practitioner consultation rate.","Secondary outcomes duration untreated psychosis, time recovery, Mental Health Act, practitioner consultation rate.",C0027627|C1274040|C0449238|C0332155|C0033975|C0040223|C0237820|C0229992|C0018684|C0079613|C1709627|C0009818|C0871208
Participant characteristics associated with smoking abstinence during weeks 1–8 after the baseline intervention were evaluated (Table 2).,Participant characteristics smoking abstinence weeks 1–8 baseline intervention evaluated (Table 2).,C0679646|C1521970|C0037369|C3843422|C0439230|G0000000|C0168634|C0886296|C0220825|C0039224|G0000000
Stabilometric assessment (SA).,Stabilometric assessment (SA).,G0000000|C1261322|C0036243
Patients who had a complete response (CR) received one additional cycle of their assigned treatment regimen after the first normal βhCG level.,Patients complete response (CR) received additional cycle assigned treatment regimen normal βhCG level.,C0030705|C0205197|C0871261|C0201975|C1514756|C1524062|C1511572|C1516050|C0039798|C0040808|C0205307|G0000000|C0441889
"Secondary outcome variables include a reduction in intrahepatic lipid accumulation measured by Magnetic Resonance –Spectroscopy (MR-S), normalisation or improvement of alanine aminotransferase (ALT), lipid profile, liver stiffness as measured by transient elastography (Fibroscan®), inflammatory cytokine markers, quality of life measures, anthropometry and body composition, biomarkers of dietary intake and blood pressure.","Secondary outcome variables reduction intrahepatic lipid accumulation measured Magnetic Resonance –Spectroscopy (MR-S), normalisation improvement alanine aminotransferase (ALT), lipid profile, liver stiffness measured transient elastography (Fibroscan®), inflammatory cytokine markers, quality life measures, anthropometry body composition, biomarkers dietary intake blood pressure.",C0027627|C1274040|C0439828|C0301630|C1512948|C0023779|C4055506|C0444706|C0024488|C0231881|G0000000|C1417249|C1882115|C2986411|C0001898|C0002594|C1266129|C0023779|C1979963|C0023884|C0427008|C0444706|C0040704|C1955928|G0000000|C0333348|C0079189|C0005516|C0332306|C0376558|C0079809|C0003188|C0242821|C0486616|C0005516|C0012155|C1512806|C0005767|C0033095
"The contrast between group and emotional function at baseline versus 6 months was significant (F (1,96)=17.503, P⩽0.001, r=0.4) as well as at 6 weeks versus 6 months (F (1,96)=13.079, P⩽0.001, r=0.3) with improved emotional function reported in the CM group.","The contrast emotional function baseline versus 6 months (F (1,96)=17.503, P⩽0.001, r=0.4) 6 weeks versus 6 months (F (1,96)=13.079, P⩽0.001, r=0.3) improved emotional function reported CM group.",G0000000|C0009924|C0013987|C0031843|C0168634|G0000000|G0000000|C0439231|C0016327|C0450371|G0000000|C0205090|G0000000|C0439230|G0000000|G0000000|C0439231|C0016327|C0450371|G0000000|C0205090|C0184511|C0013987|C0031843|C0684224|G0000000|C0441833
"The plasma was used for analysis of lipid profiles (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides).","The plasma analysis lipid profiles (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides).",G0000000|C0032105|C0002778|C0023779|C1979963|C0439175|C0008377|G0000000|C0008377|C3715113|C0008377|C0041004
None of the mothers was determined for breast pain.,None mothers determined breast pain.,G0000000|C0026591|G0000000|C0006141|C0030193
"Time points: 1 (1–2 days of life), 2 (8–9 days of life), 3 (30 days of life).","Time points: 1 (1–2 days life), 2 (8–9 days life), 3 (30 days life).",C0040223|C1552961|G0000000|G0000000|C0439228|C0376558|G0000000|G0000000|C0439228|C0376558|G0000000|C0450371|C0439228|C0376558
"found that specific sight word training had (1) large and significant valid treatment effects on trained irregular words (replicated in this study: d = 1.0), untrained irregular words (replicated in this study: d = 0.9), word reading fluency (replicated in this study: d = 1.4), and word reading comprehension (not replicated in this study: non-significant d = 0.6); (2) a moderate and significant valid treatment effect on nonword reading accuracy (not replicated in this study: d = − 0.1); and (3) no valid treatment effect on nonword reading fluency (replicated in this study: non-significant d = 0.2).","specific sight word training (1) valid treatment effects trained irregular (replicated study: = 1.0), untrained irregular (replicated study: = 0.9), word reading fluency (replicated study: = 1.4), word reading comprehension (not replicated study: non-significant = 0.6); (2) moderate valid treatment nonword reading accuracy (not replicated study: = − 0.1); (3) valid treatment nonword reading fluency (replicated study: non-significant = 0.2).",C0205369|C0042789|C1705313|C0040607|G0000000|C2349099|C0039798|C1280500|C0336809|C0205271|C0205173|C0557651|G0000000|G0000000|G0000000|C0205271|C0205173|C0557651|G0000000|G0000000|C1705313|C0034754|C0870569|C0205173|C0557651|G0000000|G0000000|C1705313|C0034754|C0162340|C1518422|C0205173|C0557651|C1518422|G0000000|G0000000|G0000000|C0205081|C2349099|C0039798|G0000000|C0034754|C0443131|C1518422|C0205173|C0557651|G0000000|G0000000|G0000000|G0000000|C2349099|C0039798|G0000000|C0034754|C0870569|C0205173|C0557651|C1518422|G0000000|G0000000
"We assumed that waist and wrist accelerometers were both worn together, and when the duration of zero counts was ≥60 minutes for data collected from the waist accelerometer, we checked the wrist data to determine if the wrist was active.","We assumed waist wrist accelerometers worn together, duration counts ≥60 minutes data collected waist accelerometer, checked wrist data determine wrist active.",G0000000|C3242379|C0230097|C0043262|C0178951|G0000000|C1883357|C0449238|C0439157|G0000000|C0439232|C1511726|C1516695|C0230097|C0178951|C1283174|C0043262|C1511726|G0000000|C0043262|C0205177
"Children in Group I (oxybutynin) presented with 12.2 dry nights in the first month of treatment, 13.4 in the second month, and 15.9 in the last month.","Children Group I (oxybutynin) 12.2 dry nights month treatment, 13.4 month, 15.9 month.",C0008059|C0441833|C0021966|C0069805|C0450371|C0011682|C0240526|C0332177|C0039798|C0450371|C0332177|C0450371|C0332177
"These will include transfusion requirements (number of PRBC units, platelets and plasma), transplant related mortality at 100 days (yes/no), maximum grade of acute graft versus host disease, incidence of acute graft versus host disease at 100 days, veno-occlusive disease, incidence of grade 4 and 5 infections at 100 days, Bearman toxicity scores, incidence of bleeding, incidence of hospital admissions, incidence of ICU admissions and quality of life.","These transfusion requirements (number PRBC units, platelets plasma), transplant mortality 100 days (yes/no), maximum grade acute graft versus host disease, incidence acute graft versus host disease 100 days, veno-occlusive disease, incidence grade 4 5 infections 100 days, Bearman toxicity scores, incidence bleeding, incidence hospital admissions, incidence ICU admissions quality life.",G0000000|C0005841|C1514873|C0237753|G0000000|C0439148|C0005821|C0032105|C0040732|C0026565|C1442061|C0439228|C1512698|C0806909|C0441800|C0205178|C0181074|G0000000|C1167395|C0012634|C0021149|C0205178|C0181074|G0000000|C1167395|C0012634|C1442061|C0439228|C1519964|C0012634|C0021149|C0441800|G0000000|G0000000|C3714514|C1442061|C0439228|G0000000|C0040539|C0449820|C0021149|C0019080|C0021149|C0019994|C0184666|C0021149|C0021708|C0184666|C0332306|C0376558
No infants in either group developed NEC.,No infants developed NEC.,G0000000|C0021270|G0000000|C0206695
"Overall, there were reductions in all symptoms (fatigue, anxiety, depression, and sleep disturbance) and improvements in physical and mental health scores in the intervention group.","Overall, reductions symptoms (fatigue, anxiety, depression, sleep disturbance) improvements physical mental health scores intervention group.",C0282416|C0301630|C0683368|C0015672|C0003467|C0011570|C0037313|C2699787|C2986411|C0031809|C0229992|C0018684|C0449820|C0886296|C0441833
"The primary composite end point was initially defined as the first occurrence of a 50% decrease in eGFR, the development of ESKD (defined as a need for maintenance dialysis or kidney transplantation and adjudicated by a blinded, independent committee), or death due to kidney disease.","The primary composite initially defined occurrence 50% decrease eGFR, development ESKD (defined maintenance dialysis kidney transplantation adjudicated blinded, independent committee), death kidney disease.",G0000000|C0205225|C0205199|C0205265|C1704788|C0243132|C0450371|C0392756|C1739039|C0243107|G0000000|C1704788|C0024501|C0011945|C0022646|C0040732|G0000000|C0150108|C0085862|C2699414|C0011065|C0022646|C0012634
"Design: Randomised, unblinded, controlled trial with initial assessment and six week follow up by telephone survey.","Design: Randomised, unblinded, controlled trial initial assessment week follow telephone survey.",C1707689|G0000000|G0000000|C2587213|C0008976|C0205265|C1261322|C0332174|C0332283|C0039457|C0038951
Improvement rates for quality of life (Functional Assessment of Cancer Therapy – Lung [FACT-L] total score and trial outcome index [TOI]) and symptom improvement (Lung Cancer Subscale [LCS] and pulmonary symptom improvement [PSI]).,Improvement rates quality life (Functional Assessment Cancer Therapy – Lung [FACT-L] total score trial outcome [TOI]) symptom improvement (Lung Cancer Subscale [LCS] pulmonary symptom improvement [PSI]).,C2986411|C0871208|C0332306|C0376558|C0205245|C1261322|C0006826|C0039798|G0000000|C0024109|C3830268|C0439175|C0449820|C0008976|C1274040|G0000000|C1457887|C2986411|C0024109|C0006826|G0000000|C0268314|C0024109|C1457887|C2986411|G0000000
"Abbreviations: 6MWT, 6-minute walking test; BMI, body mass index (in kg/m2); BPAQ, Baecke Physical Activity Questionnaire; CCQ, clinical COPD questionnaire; COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQol; FEV1, forced expiratory volume in 1 second; m, meters; MFI, Multidimensional Fatigue Inventory (general fatigue scale); MRC, Medical Research Council; VAS, Visual Analogue Scale.","Abbreviations: 6MWT, 6-minute walking test; BMI, body mass (in kg/m2); BPAQ, Baecke Physical Activity Questionnaire; CCQ, clinical COPD questionnaire; COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQol; FEV1, forced expiratory volume 1 second; m, meters; MFI, Multidimensional Fatigue Inventory (general fatigue scale); MRC, Medical Research Council; VAS, Visual Analogue Scale.",C0000723|G0000000|C0439232|C0080331|C0022885|G0000000|C0242821|C0577559|G0000000|C0022718|G0000000|G0000000|C0031809|C0205177|C0034394|G0000000|C0205210|C0024117|C0034394|C0024117|C0205191|C0549186|C0024109|C0012634|C0205163|C0451150|G0000000|C0441722|C0231800|C0449468|G0000000|C0205436|C0369637|C0441074|C1881923|C2347299|C0015672|C0021941|C0205246|C0015672|C0175659|C1540289|C0199168|C0035168|C1551807|C0042815|C0234621|C0243071|C0175659
"The primary outcomes were eating at least five portions of fruit/vegetables per day, doing at least five sessions of 30 min of moderate intensity physical activity per week (or equivalent), a normal score on the GHQ-12 and the Warwick Edinburgh Mental Well-being Scale score.","The primary outcomes eating portions fruit/vegetables day, sessions 30 min moderate intensity physical activity week (or equivalent), normal score GHQ-12 Warwick Edinburgh Mental Well-being Scale score.",G0000000|C0205225|C1274040|C0013470|C0449719|C0016767|C0332173|C1883016|G0000000|C0205081|C0522510|C0031809|C0205177|C0332174|G0000000|C0205163|C0205307|C0449820|C0450371|G0000000|G0000000|C0229992|C0018684|C0175659|C0449820
"[4,5,13,14] We observed that the treatment of PR patients with fixed dose NBUVB of 250 mJ/cm2 for 4 weeks facilitates the reduction of disease symptomology (mainly pruritus) and morphological parameters in terms of erythema, scaling, and induration.","[4,5,13,14] We observed treatment PR patients fixed dose NBUVB 250 mJ/cm2 4 weeks facilitates reduction disease symptomology (mainly pruritus) morphological parameters terms erythema, scaling, induration.",C0450371|G0000000|C1441672|C0039798|C0279759|C0030705|C0443218|C0178602|G0000000|C1442061|C0439254|G0000000|C0439230|G0000000|C0301630|C0012634|G0000000|G0000000|C0033774|C0543482|C0449381|C0233324|C0041834|C0237849|C0332534
"Five serious adverse events were reported: one in the placebo group, two in the 50,000 group, and two in the 100,000 group.","Five adverse events reported: placebo group, 50,000 group, 100,000 group.",C0205451|G0000000|C0441471|C0684224|C0032042|C0441833|C0450371|C0441833|C1442061|C0441833
Functional based exercise should be a focus for protection from falling and for improving and maintaining functional capacity for older people at risk.,Functional based exercise focus protection falling improving maintaining functional capacity people risk.,C0205245|C1527178|C0015259|C0205234|C1545588|C0000921|C1272745|C0024501|C0205245|C1516240|C0027361|C0035647
The measurement at 3 months would help to capture an intermediate benefit that may recede at 6 months.,The measurement 3 months capture intermediate benefit recede 6 months.,G0000000|C0242485|G0000000|C0439231|G0000000|C0205103|C0814225|G0000000|G0000000|C0439231
"""I am satisfied with my present job"".","""I satisfied job"".",C0021966|C0242428|C0028811
"Outcomes include rape myth acceptance, victim empathy, attraction to sexual aggression, sex-related alcohol expectancies, and behavioral indicators, measured across three time points.","Outcomes rape myth acceptance, victim empathy, attraction sexual aggression, sex-related alcohol expectancies, behavioral indicators, measured time points.",C1274040|C0034668|C0870933|G0000000|C0680681|C0013989|C2346874|C0036864|C0001807|C0036864|C0001962|C0679138|C0004927|C0021212|C0444706|C0040223|C1552961
"In addition to their influence on committed never smokers in terms of susceptibility to smoking, advertising and promotions might influence susceptible never smokers to experiment and perhaps even persuade experimenters to become established smokers.","In addition influence committed smokers terms susceptibility smoking, advertising promotions influence susceptible smokers experiment persuade experimenters established smokers.",G0000000|C0332287|C4054723|C1171947|C0337664|C0233324|C0012655|C0037369|C0001690|C0033414|C4054723|C0220898|C0337664|C0681814|G0000000|G0000000|C0443211|C0337664
Physical activity was measured using the short version of the International Physical Activity Questionnaire (IPAQ-SV) [[29]].,Physical activity measured short version International Physical Activity Questionnaire (IPAQ-SV) [[29]].,C0031809|C0205177|C0444706|C1282927|C0333052|C1512888|C0031809|C0205177|C0034394|C0013754|C0450371
"Muscle soreness was assessed using a 7-point Likert scale questionnaire for a variety of muscle groups including the gastrocnemius, hamstrings, quadriceps, gluteus maximus, lower back, abdominals, and the whole body (34).","Muscle soreness assessed 7-point Likert scale questionnaire variety muscle including gastrocnemius, hamstrings, quadriceps, gluteus maximus, lower back, abdominals, body (34).",C0026845|C0234233|C1516048|C1552961|G0000000|C0175659|C0034394|C1883525|C0026845|C0332257|C0242691|C0584895|C0224440|C0448475|C4010247|C0441994|C0004600|C0000726|C0242821|C0450371
"The primary outcome is the 3-year postoperative success rate in lowering intraocular pressure (IOP), and the secondary clinical outcomes will include IOP reduction, visual acuity, HCD, central corneal thickness, axial length, cup–disc ratio, refractive error and postoperative complications.","The primary outcome 3-year postoperative success rate lowering intraocular pressure (IOP), secondary clinical outcomes IOP reduction, visual acuity, HCD, central corneal thickness, axial length, cup–disc ratio, refractive error postoperative complications.",G0000000|C0205225|C1274040|C0439234|C0032790|C0597535|C0871208|C0441994|C3282905|C0033095|C0595921|C0027627|C0205210|C1274040|C0595921|C0301630|C0234621|C0750509|C2000894|C0205099|C0010031|C1280412|C0205131|C1444754|G0000000|C0456603|C0429585|C0743559|C0032790|C0009566
The median treatment duration between the two groups was found to be similar.,The median treatment duration similar.,G0000000|C0549183|C0039798|C0449238|C2348205
The main outcome of the study was the rate of injurious falls (serious and moderate).,The main outcome study rate injurious falls (serious moderate).,G0000000|C0205225|C1274040|C0557651|C0871208|G0000000|C0000921|C0205404|C0205081
HPV vaccine coverage varies across racial and ethnic groups.,HPV vaccine coverage varies racial ethnic groups.,C0021344|C0042210|C1551362|C1548673|C0034510|C0015031|C0441833
"For event-free survival, the time to an event was defined as the time from study enrollment (which occurred after transplantation) until the first occurrence of relapse, progressive disease, secondary cancer, or death or, if none of these events occurred, until the last contact with the patient.","For event-free survival, time event defined time study enrollment (which occurred transplantation) occurrence relapse, progressive disease, secondary cancer, death or, events occurred, contact patient.",G0000000|C0441471|C0038952|C0040223|C0441471|C1704788|C0040223|C0557651|C1516879|G0000000|C1709305|C0040732|C0243132|C0035020|C0205329|C0012634|C0027627|C0006826|C0011065|G0000000|C0441471|C1709305|C0332158|C0030705
"Participants made an overall assessment of response to treatment at the end of the treatment relative to the baseline, on a five point scale: worse, same, improved, much improved, or cleared.","Participants assessment response treatment treatment relative baseline, scale: worse, same, improved, improved, cleared.",C0679646|C1261322|C0871261|C0039798|C0039798|C0080103|C0168634|C0175659|C0332271|C0445247|C0184511|C0184511|C0521097
"For comparison, we also analyzed changes in mean SAS scores and the global BAS score during the study for patients with TD at baseline using mixed models and the same covariates used in the AIMS analysis, plus baseline mean SAS score and BAS global score, respectively, and use of first-generation antipsychotics at baseline.","For comparison, analyzed SAS scores global BAS score study patients TD baseline mixed models covariates AIMS analysis, baseline SAS score BAS global score, respectively, first-generation antipsychotics baseline.",G0000000|C1707455|C0936012|C0605290|C0449820|C0205246|C1862288|C0449820|C0557651|C0030705|C0041061|C0168634|C0205430|C3161035|G0000000|C1947946|C0002778|C0168634|C0605290|C0449820|C1862288|C0205246|C0449820|G0000000|C0205435|C0040615|C0168634
There was no impact of the intervention on prevalence of HIV or HSV-2 or current pregnancy.,There impact intervention prevalence HIV HSV-2 current pregnancy.,G0000000|C1825598|C0886296|C0033105|C0019682|C0019348|C0521116|C0032961
A total of 371 NPC cases and 321 unaffected controls were included in the analyses.,A total 371 NPC 321 unaffected controls included analyses.,G0000000|C0439175|C1442061|G0000000|C1442061|C2986417|C0243148|C0332257|C0002778
Trough FEV1 after first dose (end of day 1) and week 12 (FAS).,Trough FEV1 dose (end day 1) week 12 (FAS).,C0444506|G0000000|C0178602|C0444930|C0332173|G0000000|C0332174|C0450371|G0000000
"The present research addressed the following important question in pediatric medicine: Can participation in a new family-centered preventive intervention, the Strong African American Families–Teen (SAAF–T) program, deter conduct problems, substance use, substance use problems, and depressive symptoms among rural black adolescents across 22 months?","The addressed question pediatric medicine: Can participation family-centered preventive intervention, Strong African American Families–Teen (SAAF–T) program, deter conduct problems, substance use, substance problems, depressive symptoms rural black adolescents 22 months?",G0000000|C0376649|C1522634|C0030755|C0013227|G0000000|C0679823|C0015576|C0445202|C0886296|C0442821|C0027567|C0596070|G0000000|G0000000|C1709697|G0000000|C0004927|C1546466|C0439861|C0042153|C0439861|C1546466|G0000000|C0683368|C0240919|C0005680|C0205653|C0450371|C0439231
The primary outcome measure was ADHD symptoms and secondary outcomes were social skills and emotional competences.,The primary outcome measure ADHD symptoms secondary outcomes social skills emotional competences.,G0000000|C0205225|C1274040|C0079809|C1263846|C0683368|C0027627|C1274040|C0728831|C0678856|C0013987|C0086035
"Key outcomes examined post baseline were z‐scores for weight‐for‐age, length‐for‐age and weight‐for‐length between 3, 6, 9, 12 and 15 months of age, weight and length values at 3, 6, 9, 12, and 15 months of age; maternal knowledge and beliefs about complementary and responsive feeding at 6, 9, 12 and 15 months of age; child development (BSID‐II) at 15 months; as well as consumption of various foods and nutrient intakes for energy, protein, iron, zinc, calcium, and vitamin A at 9 and 15 months.","Key outcomes examined post baseline z‐scores weight‐for‐age, length‐for‐age weight‐for‐length 3, 6, 9, 12 15 months age, weight length values 3, 6, 9, 12, 15 months age; maternal knowledge beliefs complementary responsive feeding 6, 9, 12 15 months age; child development (BSID‐II) 15 months; consumption foods nutrient intakes energy, protein, iron, zinc, calcium, vitamin A 9 15 months.",G0000000|C1274040|C0332128|C0687676|C0168634|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|C0450371|C0439231|C0001779|C0005910|C1444754|C0042295|G0000000|G0000000|G0000000|C0450371|C0450371|C0439231|C0001779|C2347083|C0376554|C0004951|G0000000|C0205342|C0204695|G0000000|G0000000|C0450371|C0450371|C0439231|C0001779|C0008059|C0243107|G0000000|C0450371|C0439231|C0009830|C0016452|C0678695|C1512806|C0424589|C0033684|C0302583|C0043481|C0006675|C0042890|G0000000|G0000000|C0450371|C0439231
Muscle tenderness was assessed using a Force Algometer (Wagner Pain Test Model FPK Algometer) [20].,Muscle tenderness assessed Force Algometer (Wagner Pain Test Model FPK Algometer) [20].,C0026845|C0234233|C1516048|C0441722|G0000000|G0000000|C0030193|C0022885|C3161035|G0000000|G0000000|C0450371
"For the evaluation of our main hypothesis, we will use the observer instrument “Multifocal APProach to the sharing IN Shared Decision-making” (MAPPIN’SDM) [23].","For evaluation main hypothesis, observer instrument “Multifocal APProach sharing IN Shared Decision-making” (MAPPIN’SDM) [23].",G0000000|C0220825|C0205225|C1512571|C0870992|C0348000|G0000000|C0449445|C0237876|G0000000|C0237876|G0000000|G0000000|C0450371
Infant length for age z-score at 1 year was included in this model.,Infant length age z-score 1 included model.,C0021270|C1444754|C0001779|C0871421|G0000000|C0332257|C3161035
The primary outcome measurement will be on the level of activities and participation.,The primary outcome measurement level activities participation.,G0000000|C0205225|C1274040|C0242485|C0441889|C0441655|C0679823
"The stroke impact scale was administered at baseline and at six, 12, 18, and 24 weeks after randomisation.","The stroke impact scale administered baseline six, 12, 18, 24 weeks randomisation.",G0000000|C0038454|C1825598|C0175659|C1521801|C0168634|C0205452|C0450371|C0450371|C0450371|C0439230|C0034656
"In the current study, primary outcomes were including fasting plasma glucose (FPG), insulin metabolism parameters, hs-CRP, biomarkers of oxidative stress, serum calcium, Vitamin D levels, and blood pressure.","In current study, primary outcomes including fasting plasma glucose (FPG), insulin metabolism parameters, hs-CRP, biomarkers oxidative stress, serum calcium, Vitamin D levels, blood pressure.",G0000000|C0521116|C0557651|C0205225|C1274040|C0332257|C0015663|C0032105|C0017725|G0000000|C0021641|C0025519|C0449381|C3890735|C0005516|C0311404|C0038435|C0229671|C0006675|C0042890|C0073187|C0441889|C0005767|C0033095
This comparison was made versus the available archival MRI scans up to 3 months before the enrolment date.,This comparison versus archival MRI scans 3 months enrolment date.,G0000000|C1707455|G0000000|C0003738|C0024485|C0034606|G0000000|C1516879|C0011008
MTG: mirror therapy group; NDTG: neurodevelopmental therapy group; BT: before treatment; AT: after treatment; ASIT: Ayres Sensory Integration Test; FI: finger identification; RLD: right-left discrimination; FMA: Fugl-Meyer Assessment; MI: Motricity Index; SULCS: Stroke Upper Limb Capacity Scale; BI: Barthel Index No adverse event occurred during the training period in the current study.,MTG: mirror therapy group; NDTG: neurodevelopmental therapy group; BT: treatment; AT: treatment; ASIT: Ayres Sensory Integration Test; FI: finger identification; RLD: right-left discrimination; FMA: Fugl-Meyer Assessment; MI: Motricity Index; SULCS: Stroke Upper Limb Capacity Scale; BI: Barthel Index No adverse event occurred training period current study.,G0000000|C0181868|C0039798|C0441833|G0000000|C0599855|C0039798|C0441833|G0000000|C0039798|G0000000|C0039798|G0000000|G0000000|C0445254|C1158478|C0022885|C4050619|C0016129|C0020792|G0000000|C0205090|C0012632|C2332774|G0000000|C1261322|C3810814|G0000000|C0918012|G0000000|C0038454|C1282910|C0015385|C1516240|C0175659|G0000000|G0000000|C0918012|G0000000|G0000000|C0441471|C1709305|C0040607|C0439531|C0521116|C0557651
"The highest VO2 was considered peak VO2 and used in data analysis (4,19).","The VO2 considered peak VO2 data analysis (4,19).",G0000000|C0042939|C0750591|C0444505|C0042939|C1511726|C0002778|C0450371
There was no significant difference in vitality scores after delivery and after intervention (p < 0.083).,There difference vitality scores delivery intervention (p < 0.083).,G0000000|C1705241|C0424589|C0449820|C0011209|C0886296|C0369773|G0000000|C1442061
"Children in the Clinical Trial Group (N = 67) participated in a 9-week, nutrition intervention and were followed at regular intervals (3, 6, 12, 18, and 24 months) for 2 years post-treatment to obtain anthropometric and pulmonary function data.","Children Clinical Trial Group (N = 67) participated 9-week, nutrition intervention regular intervals (3, 6, 12, 18, 24 months) 2 post-treatment anthropometric pulmonary function data.",C0008059|C0205210|C0008976|C0441833|C0369718|G0000000|C0450371|G0000000|C0332174|C0028707|C0886296|C0205272|C1272706|G0000000|G0000000|C0450371|C0450371|C0450371|C0439231|G0000000|C2709088|C0003188|C0024109|C0031843|C1511726
Diarrhea in children is defined as the occurrence of three or more loose or liquid stools per day by the World Health Organization (WHO).,Diarrhea children defined occurrence loose liquid stools day World Health Organization (WHO).,C0011991|C0008059|C1704788|C0243132|C0205407|C0301571|C0015733|C0332173|C2700280|C0018684|C0029237|G0000000
"RM, NB, DA and RB were responsible for the design and conduct of the Transcranial Magnetic Stimulation studies.","RM, NB, DA RB responsible design conduct Transcranial Magnetic Stimulation studies.",C0024851|C0919442|C0011318|G0000000|C1273518|C1707689|C0004927|C0442348|C0024488|C1292856|C0947630
Kaplan-Meier plot of renal survival stratified by urinary protein excretion at the end of initial 2-year treatments in children with IgA nephropathy showing diffuse mesangial proliferation.,Kaplan-Meier plot renal survival stratified urinary protein excretion initial 2-year treatments children IgA nephropathy diffuse mesangial proliferation.,G0000000|G0000000|C0022646|C0038952|C0205363|C0042027|C0033684|C0221102|C0205265|C0439234|C0087111|C0008059|C2825347|C0022658|C0205219|C0017655|C0334094
"Secondary study outcomes included body composition using dual-energy x-ray absorptiometry, physical fitness using the six-minute walk test (6MWT), and concentrations of serum biomarkers.","Secondary study outcomes included body composition dual-energy x-ray absorptiometry, physical fitness six-minute walk test (6MWT), concentrations serum biomarkers.",C0027627|C0557651|C1274040|C0332257|C0242821|C0486616|C1554184|C0034571|G0000000|C0031809|C1456706|C0205452|C0080331|C0022885|G0000000|C0086045|C0229671|C0005516
"Extensively hydrolyzed formula can increase motilin level, improve gastrointestinal feeding tolerance, promote early growth and development, and reduce the incidence of infection in VLBW and ELBW infants.","Extensively hydrolyzed formula increase motilin level, improve gastrointestinal feeding tolerance, promote growth development, reduce incidence infection VLBW ELBW infants.",G0000000|G0000000|C0489829|C0442805|C0026594|C0441889|G0000000|C0521362|C0204695|C0013220|C0033414|C0018270|C0243107|G0000000|C0021149|C0009450|C0282666|C0456065|C0021270
"Secondary efficacy endpoints included time from commencement of study drug to ICU discharge, time taken to achieve a satisfactory sedation score, and the need for supplemental sedative and analgesic medication.","Secondary efficacy endpoints included time commencement study drug ICU discharge, time achieve satisfactory sedation score, supplemental sedative analgesic medication.",C0027627|C1280519|C2349179|C0332257|C0040223|G0000000|C0557651|C0013227|C0021708|C0012621|C0040223|G0000000|C0205410|C0235195|C0449820|C2348609|C0020592|C0002771|C0013227
"Global quality of life, physical functioning, role functioning, emotional functioning, social functioning, fatigue, nausea/vomiting, appetite loss, diarrhoea, financial difficulties, and depression improved from 3 to 24 months.","Global quality life, physical functioning, role functioning, emotional functioning, social functioning, fatigue, nausea/vomiting, appetite loss, diarrhoea, financial difficulties, depression improved 3 24 months.",C0205246|C0332306|C0376558|C0031809|C0205245|C0035820|C0205245|C0013987|C0205245|C0728831|C0205245|C0015672|C0027498|C0003618|C1517945|C0011991|C0376243|C1299586|C0011570|C0184511|G0000000|C0450371|C0439231
"The primary endpoints were RR, OS, and PFS.","The primary endpoints RR, OS, PFS.",G0000000|C0205225|C2349179|G0000000|C0229090|C0242792
Patients with scores between 11 to 21 are considered clinically disordered.,Patients scores 11 21 considered clinically disordered.,C0030705|C0449820|C0450371|C0450371|C0750591|G0000000|C0012634
"Recovery milestones were time to start walking with aids, time to start independent walking, time absent from school, and parental satisfaction, which ranged from weak = 0 to excellent = 4.","Recovery milestones time start walking aids, time start independent walking, time absent school, parental satisfaction, ranged weak = 0 excellent = 4.",C0237820|C2347129|C0040223|C0439659|C0080331|C0001175|C0040223|C0439659|C0085862|C0080331|C0040223|C0332197|C0036375|C0030551|C0242428|C1514721|C1762617|G0000000|G0000000|C1548784|G0000000|G0000000
"7-day point prevalence abstinence at each follow-up point Among the 393 HFTC participants included in the call sample, the overwhelming majority (96.4%) were male, and most reported living in an urban location (84.6%) and being married (72.0%).","7-day prevalence abstinence follow-up Among 393 HFTC participants included call sample, overwhelming majority (96.4%) male, reported living urban location (84.6%) married (72.0%).",C0332173|C0033105|C3843422|C0589120|G0000000|C1442061|C1414953|C0679646|C0332257|C0679006|C0370003|G0000000|C0680220|C0450371|C0086582|C0684224|C0376558|C0442529|C0450429|C0450371|C0024841|C0450371
"Efficacy of each treated arms was expressed in terms of deterency, induced exophily, blood-feeding inhibition, and mortality.","Efficacy treated arms expressed terms deterency, induced exophily, blood-feeding inhibition, mortality.",C1280519|C1522326|C0206655|G0000000|C0233324|G0000000|C0205263|G0000000|C0005767|C0021467|C0026565
"This is a community health worker-delivered intervention study using physician-diagnosed asthma ever, wheezing frequency, FeNO, Rint, HRQOL and (in addition) ETS exposure at home ever at age 6 years as outcomes.","This community health worker-delivered intervention study physician-diagnosed asthma ever, wheezing frequency, FeNO, Rint, HRQOL (in addition) ETS exposure age 6 outcomes.",G0000000|C0009462|C0018684|C1306056|C0886296|C0557651|C0031831|C0004096|C3887636|C0043144|C0376249|G0000000|G0000000|G0000000|G0000000|C0332287|G0000000|C0274281|C0001779|G0000000|C1274040
"Outcome data assessing intentions to use nutritional guidelines and serves of fruit and vegetables provided on menus (primary outcomes) as well as secondary outcomes (attitudes, behavioural regulation and social norms) were collected via a telephone interview with cooks.","Outcome data assessing intentions nutritional guidelines serves fruit vegetables provided menus (primary outcomes) secondary outcomes (attitudes, behavioural regulation social norms) collected telephone interview cooks.",C1274040|C1511726|C1516048|C0162425|C1521739|C0162791|G0000000|C0016767|C0042440|C1999230|G0000000|C0205225|C1274040|C0027627|C1274040|C0004271|C0004927|C0851285|C0728831|C0205307|C1516695|C0039457|C0021822|C1306756
"Maternal age, gestational age at delivery, infant birth weight were compare between case and control groups using Independent sample t-test.","Maternal age, gestational age delivery, infant birth weight compare control Independent sample t-test.",C2347083|C0001779|C0439671|C0001779|C0011209|C0021270|C0005615|C0005910|C1707455|C0243148|C0085862|C0370003|C0871472
"The primary endpoint was the proportion of patients remaining in clinical remission during the 12-month double-blind phase, with remission defined as a mean of <3 stools/day, including a mean of <1 watery stool/day over 1 week.","The primary endpoint proportion patients remaining clinical remission 12-month double-blind phase, remission defined <3 stools/day, including <1 watery stool/day 1 week.",G0000000|C0205225|C2349179|C1709707|C0030705|C1527428|C0205210|C0544452|C0450371|C0013072|C0205390|C0544452|C1704788|G0000000|C0015733|C0332257|G0000000|C0443350|C0015733|G0000000
"questions [27]; Hospital length of stay; Place of residence; Scores on the Barthel Index [26]; Score on the Caregiver Burden Scale [28]; Health-related quality of life (World Health Organization Quality of Life Assessment and EuroQol 5-Dimensional scores) [29, 30]; Patient and caregiver mood (Hospital Anxiety and Depression Scale) [31]; Extended activities of daily living (Nottingham Extended Activities of Daily Living Scale) [32]; Health care resource use (visits to health professionals, hospitalization, and medication use) and direct costs for the patient (e.g.","questions [27]; Hospital length stay; Place residence; Scores Barthel Index [26]; Score Caregiver Burden Scale [28]; Health-related quality life (World Health Organization Quality Life Assessment EuroQol 5-Dimensional scores) [29, 30]; Patient caregiver mood (Hospital Anxiety Depression Scale) [31]; Extended activities daily living (Nottingham Extended Activities Daily Living Scale) [32]; Health care resource (visits health professionals, hospitalization, medication use) direct costs patient (e.g.",C1522634|C0450371|C0019994|C1444754|G0000000|C0442504|C0237096|C0449820|G0000000|C0918012|C0450371|C0449820|C0085537|C2828008|C0175659|C0450371|C0018684|C0332306|C0376558|C2700280|C0018684|C0029237|C0332306|C0376558|C1261322|C0451150|C1704750|C0449820|C0450371|C0450371|C0030705|C0085537|C0026516|C0019994|C0003467|C0011570|C0175659|C0450371|C0231448|C0441655|C0332173|C0376558|G0000000|C0231448|C0441655|C0332173|C0376558|C0175659|C0450371|C0018684|C1947933|C0035201|C0545082|C0018684|C0679924|C0019993|C0013227|C0042153|C0439851|C0010186|C0030705|G0000000
"Measurements included anthropometry; body composition indicators; CD4 count, haemoglobin and albumin; as well as incidence rates of opportunistic infections; depression and quality of life scores.","Measurements included anthropometry; body composition indicators; CD4 count, haemoglobin albumin; incidence rates opportunistic infections; depression quality life scores.",C0242485|C0332257|C0003188|C0242821|C0486616|C0021212|C0285590|C0750480|C0019046|C0001924|C0021149|C0871208|G0000000|C3714514|C0011570|C0332306|C0376558|C0449820
"[27,28,29] The results of this study showed that 10% povidone-iodine solution is more effective than 2% chlorhexidine solution in reducing the skin bacterial flora immediately after disinfection.","[27,28,29] The study 10% povidone-iodine solution effective 2% chlorhexidine solution reducing skin bacterial flora disinfection.",C0450371|G0000000|C0557651|C0450371|C0032857|C0037633|C1280519|G0000000|C0008196|C0037633|C0392756|C0444099|C0521009|G0000000|C0012683
Prevalence of ocular chlamydia infection in children aged 0–5 years in communities randomized to standard (A) or enhanced (B) coverage.,Prevalence ocular chlamydia infection children aged 0–5 communities randomized standard (A) enhanced (B) coverage.,C0033105|C0015392|C0008148|C0009450|C0008059|C0001779|G0000000|C0009462|C0034656|C1442989|G0000000|C2349975|G0000000|C1551362
"This poor compliance may increase the chances of relapse after weeks, months, or years [6].","This poor compliance increase chances relapse weeks, months, [6].",G0000000|C0032854|C0009563|C0442805|C0237506|C0035020|C0439230|C0439231|G0000000
"All patients were assessed by visual analogue scale (100 mm), LANSS, and radiographically.","All patients assessed visual analogue scale (100 mm), LANSS, radiographically.",G0000000|C0030705|C1516048|C0234621|C0243071|C0175659|C1442061|G0000000|G0000000|G0000000
Clinical CVD events and deaths will be analyzed by time-event analysis.,Clinical CVD events deaths analyzed time-event analysis.,C0205210|C0007222|C0441471|C0011065|C0936012|C0040223|C0002778
BACKGROUND AND AIMS—To determine whether the inclusion of 20 g free glutamine as part of the nitrogen source of parenteral feeds reduces length of hospital stay or mortality.,BACKGROUND AND AIMS—To determine inclusion 20 free glutamine nitrogen source parenteral feeds reduces length hospital stay mortality.,C1706907|G0000000|G0000000|G0000000|C0007637|C0450371|C0332296|C0017797|C0028158|C0449416|C0030547|C1510670|G0000000|C1444754|C0019994|G0000000|C0026565
"At 26 weeks, patients in the protocol group reported significantly lower pain intensity, however this difference was absent after 1 year follow-up.","At 26 weeks, patients protocol reported lower pain intensity, difference absent 1 follow-up.",G0000000|C0450371|C0439230|C0030705|C0442711|C0684224|C0441994|C0030193|C0522510|C1705241|C0332197|G0000000|C0589120
None of the child morbidity variables were systematically associated with WTP in Ghana nor were the measures of child nutritional status (length‐for‐age z‐score (LAZ) and weight‐for‐length z‐score (WLZ)).,None child morbidity variables systematically WTP Ghana measures child nutritional status (length‐for‐age z‐score (LAZ) weight‐for‐length z‐score (WLZ)).,G0000000|C0008059|C0026538|C0439828|G0000000|G0000000|C0017516|C0079809|C0008059|C1521739|C0449438|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000
"Secondary outcomes included changes from baseline in SaO2, and sleep architecture.","Secondary outcomes included baseline SaO2, sleep architecture.",C0027627|C1274040|C0332257|C0168634|G0000000|C0037313|C0003737
Analyses examined differences in the severity of delirium (MDAS) over time by treatment groups.,Analyses examined differences severity delirium (MDAS) time treatment groups.,C0002778|C0332128|C1705241|C0439793|C0011206|C0000379|C0040223|C0039798|C0441833
"Although online self-regulatory activities are likely to enhance weight control outcomes, only about 37 percent of pregnant women in the intervention group utilized these features on the program website.","Although online self-regulatory activities enhance weight control outcomes, 37 percent pregnant women intervention utilized features program website.",G0000000|G0000000|C0036588|C0441655|C2349975|C0005910|C0243148|C1274040|C0450371|C0439165|C0549206|C0043210|C0886296|G0000000|C1521970|C1709697|C2349146
"Recent experience with AS03A-adjuvanted H1N1 pandemic influenza vaccine showed that although licensure criteria for immunogenicity against the vaccine strain were consistently fulfilled, postvaccination antibody titers were lower in subjects who had recently received trivalent seasonal influenza vaccination, compared with those who had not [30].","Recent experience AS03A-adjuvanted H1N1 pandemic influenza vaccine licensure criteria immunogenicity vaccine strain consistently fulfilled, postvaccination antibody titers lower subjects received trivalent seasonal influenza vaccination, compared [30].",C0332185|C0237607|C0001551|G0000000|C1615608|C0021400|C0042210|C0023637|C0243161|C4054739|C0042210|C0080194|G0000000|C1550543|G0000000|C0003241|C0475208|C0441994|C0681850|C1514756|G0000000|C0439601|C0021400|C0042196|C1707455|C0450371
"Secondary outcomes were other potentially relevant feeding behaviours, such as child refusals and maternal non‐responsive encouragement, forceful feeding, foods fed to the child and messages recalled by the mother.","Secondary outcomes relevant feeding behaviours, child refusals maternal non‐responsive encouragement, forceful feeding, foods fed child messages recalled mother.",C0027627|C1274040|C2347946|C0204695|C0004927|C0008059|G0000000|C2347083|G0000000|C0870494|C0441722|C0204695|C0016452|C0342895|C0008059|C0470166|C0034770|C0026591
"Intergenerational closure: 7 categories (0, 1, 2, 3, 4, 5, 6 or more) “At this school, how many of your child’s friends do you know?”  Shared expectations with parents: 4 categories (“None”, “A little”, “Some”, “A Lot”) “How much do other parents at this school share your expectations for your child?”   Parent-School Social Capital (from Parent Surveys) Parent-staff trust (α=0.86) 4 items, each with 4 categories (“None”, “A little”, “Some”, “A Lot”); items were averaged and standardized for those answering at least 3 of 4 items.","Intergenerational closure: 7 categories (0, 1, 2, 3, 4, 5, 6 more) “At school, child’s friends know?” Shared expectations parents: 4 categories (“None”, “A little”, “Some”, “A Lot”) “How parents school share expectations child?” Parent-School Social Capital (from Parent Surveys) Parent-staff trust (α=0.86) 4 items, 4 categories (“None”, “A little”, “Some”, “A Lot”); items averaged standardized answering 3 4 items.",C0598500|C0185003|G0000000|C0683312|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0205172|G0000000|C0036375|G0000000|C0079382|G0000000|C0237876|C0679138|C0030551|G0000000|C0683312|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0030551|C0036375|C0237876|C0679138|G0000000|C0030551|C0728831|C0006909|G0000000|C0030551|C0038951|C0030551|C0237935|G0000000|G0000000|C1551338|G0000000|C0683312|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C1551338|C1510992|G0000000|C1706817|G0000000|G0000000|C1551338
Time to decline in KPS and in 10/11 neuroperformance measures was statistically significantly prolonged in the BCNU wafer-treated group ( P </= 0.05).,Time decline KPS 10/11 neuroperformance measures statistically prolonged BCNU wafer-treated ( P </= 0.05).,C0040223|G0000000|C0206065|C0450371|G0000000|C0079809|C0038215|C0439590|C0007257|C0991560|G0000000|C0369773|G0000000|C0450371
Secondary outcomes were observed only at one month and three months.,Secondary outcomes observed month months.,C0027627|C1274040|C1441672|C0332177|C0439231
Patients were followed up every 3 months until death or until the cutoff date of this study on 30 September 2012.,Patients 3 months death cutoff study 30 September 2012.,C0030705|G0000000|C0439231|C0011065|C1442160|C0557651|C0450371|C3828193|G0000000
"The secondary outcome variables were the number of exacerbations of COPD over the active treatment period, and the first and last 24-week periods after treatment; spirometric volume changes (FEV1 and FVC); Chronic Respiratory Disease Questionnaire (CRQ) scores, and adverse events over the 60-week period.","The secondary outcome variables exacerbations COPD active treatment period, 24-week periods treatment; spirometric volume (FEV1 FVC); Chronic Respiratory Disease Questionnaire (CRQ) scores, adverse events 60-week period.",G0000000|C0027627|C1274040|C0439828|G0000000|C0024117|C0205177|C0039798|C0439531|C0450371|C0439531|C0039798|C0037981|C0449468|G0000000|C3714541|C0205191|C0521346|C0012634|C0034394|G0000000|C0449820|G0000000|C0441471|C0450371|C0439531
"Treatment outcomes were changes from baseline in the total score on HAMD-17 [18], CGI-S [19], and the Chinese-version Self-rating Depression Scale (SDS) [25] at baseline and at day 3, 7, 14, and 21.","Treatment outcomes baseline total score HAMD-17 [18], CGI-S [19], Chinese-version Self-rating Depression Scale (SDS) [25] baseline day 3, 7, 14, 21.",C0039798|C1274040|C0168634|C0439175|C0449820|C0450371|C0450371|C3639708|C0450371|C0008120|C4054119|C0011570|C0175659|C3813719|C0450371|C0168634|C0332173|G0000000|G0000000|C0450371|C0450371
GI-CSI = Gastrointestinal Factor of Children’s Somatization Inventory.,GI-CSI = Gastrointestinal Factor Children’s Somatization Inventory.,C1708130|G0000000|C0521362|C1521761|G0000000|C0149779|C0021941
Duration of weaning from mechanical ventilation and intensive care unit (ICU) stay were recorded.,Duration weaning mechanical ventilation intensive care unit (ICU) stay recorded.,C0449238|C0043084|C0443254|C0035203|C0162425|C1947933|C0439148|C0021708|G0000000|C0034869
"We recorded the peak inspiratory pressure (PIP), FiO2, Edi, oxygen saturations (histogram analysis), transcutaneous PCO2, and movement with an Acoustic Respiratory Movement Sensor.","We recorded peak inspiratory pressure (PIP), FiO2, Edi, oxygen saturations (histogram analysis), transcutaneous PCO2, movement Acoustic Respiratory Movement Sensor.",G0000000|C0034869|C0444505|C0004048|C0033095|C0279391|G0000000|G0000000|C0030054|C0522534|C2348974|C0002778|G0000000|G0000000|C0026649|C0001166|C0521346|C0026649|C0183210
Patients with partial response (PR) or stable disease remained on therapy until KS progressed or unacceptable toxicity developed.,Patients partial response (PR) stable disease remained therapy KS progressed unacceptable toxicity developed.,C0030705|C0728938|C0871261|C0279759|C0205360|C0012634|G0000000|C0039798|C0022773|C1272688|C1883420|C0040539|G0000000
The highest mortality rates against An.,The mortality rates An.,G0000000|C0026565|C0871208|G0000000
The primary outcome for the study was a change in induced sputum AcPGP at 12 weeks post-randomization in an intention-to-treat analysis.,The primary outcome study change induced sputum AcPGP 12 weeks post-randomization intention-to-treat analysis.,G0000000|C0205225|C1274040|C0557651|C0392747|C0205263|C0038056|G0000000|C0450371|C0439230|C0687676|C0162425|C0002778
"Event-free survival was calculated from the time of randomization until disease progression, disease relapse, second primary cancer, death, or last follow-up, whichever came first.","Event-free survival calculated time randomization disease progression, disease relapse, primary cancer, death, follow-up, whichever first.",C0441471|C0038952|C0444686|C0040223|C0034656|C0012634|C0242656|C0012634|C0035020|C0205225|C0006826|C0011065|C0589120|G0000000|C0205435
"IL-6, walking speed over 400 meters, physical function (Short Physical Performance Battery), other inflammatory markers, safety, tolerability, frailty domains, and maximal leg strength were measured.","IL-6, walking speed 400 meters, physical function (Short Physical Performance Battery), inflammatory markers, safety, tolerability, frailty domains, maximal leg strength measured.",C0020898|C0080331|C0678536|C1442061|C0441074|C0031809|C0031843|C1282927|C0031809|C0597198|C0337088|C0333348|C0005516|C0036043|C3274448|C0424594|C1880389|C0205289|C0023216|C0237897|C0444706
"We investigated the undefined effects of kefir in patients with IBD, Lactobacillus and L. kefiri flora of feces, and biochemical parameters and disease symptoms.","We investigated undefined effects kefir patients IBD, Lactobacillus L. kefiri flora feces, biochemical parameters disease symptoms.",G0000000|C1292732|C0750600|C1280500|C0524649|C0030705|G0000000|C0022938|C0439394|G0000000|G0000000|C0015733|C0205474|C0449381|C0012634|C0683368
"Primary outcome measures for observational sub-study A secondary focus will be participant self-reported premorbid sleep quality, vision, hearing, functional status, self-reported causes for disruption to sleep in hospital, participant light dosage levels and overall satisfaction with the room physical environment.","Primary outcome measures observational sub-study A secondary focus participant self-reported premorbid sleep quality, vision, hearing, functional status, self-reported disruption sleep hospital, participant light dosage levels satisfaction physical environment.",C0205225|C1274040|C0079809|C1518527|C0542339|G0000000|C0027627|C0205234|C0679646|C0681906|G0000000|C0037313|C0332306|C0042789|C0018767|C0205245|C0449438|C0681906|C0332453|C0037313|C0019994|C0679646|C0023693|C0178602|C0441889|C0242428|C0031809|C0014406
Subclinical mastitis is common in HIV-infected women and is a risk factor for mother-to-child transmission of HIV.,Subclinical mastitis common HIV-infected women risk factor mother-to-child transmission HIV.,C0205211|C0024894|C0205214|C0019682|C0043210|C0035647|C1521761|C0260023|C0040722|C0019682
Anderson Symptom Inventory.,Anderson Symptom Inventory.,G0000000|C1457887|C0021941
"The scores in the usual care group continued to reduce over time, such that differences were no longer statistically significant at 9 and 12 months.","The scores usual care continued reduce time, differences statistically 9 12 months.",G0000000|C0449820|C3538928|C1947933|C0549178|G0000000|C0040223|C1705241|C0038215|G0000000|C0450371|C0439231
The number of pulmonary exacerbations requiring antibiotic treatment (in days) three months before and during the study were evaluated.,The pulmonary exacerbations requiring antibiotic treatment (in days) months study evaluated.,G0000000|C0024109|G0000000|G0000000|C0003232|C0039798|G0000000|C0439228|C0439231|C0557651|C0220825
Thirteen LEV patients (87%) were free from seizure compared with six PHT patients (75%).,Thirteen LEV patients (87%) free seizure compared PHT patients (75%).,C3715149|C0023556|C0030705|C0450371|C0332296|C0036572|C1707455|C1324698|C0030705|C0450371
"In the intervention group, serum folate level was higher than in the control group.","In intervention group, serum folate level control group.",G0000000|C0886296|C0441833|C0229671|C0178638|C0441889|C0243148|C0441833
"At the start and end of treatment bronchoscopy with bronchial biopsies was performed and the numbers of CD8+ T lymphocytes, CD68+ macrophages, neutrophils and eosinophils were measured.","At start treatment bronchoscopy bronchial biopsies performed CD8+ T lymphocytes, CD68+ macrophages, neutrophils eosinophils measured.",G0000000|C0439659|C0039798|C0006290|C0205039|C0005558|C0884358|C0285590|C2603360|C0024264|G0000000|C0024432|C0027950|C0014467|C0444706
Sixty one children older than 3 years admitted to a large teaching hospital and a district general hospital with acute asthma completed the study.,Sixty children 3 admitted teaching hospital district hospital acute asthma completed study.,C3816724|C0008059|G0000000|C0184666|C0039401|C0019994|G0000000|C0019994|C0205178|C0004096|C0205197|C0557651
Box and whisker plots for extracellular glutathione in induced sputum at the four study visits when induced sputum samples were collected.,Box whisker plots extracellular glutathione induced sputum study visits induced sputum samples collected.,C0179400|C0042640|G0000000|C0521119|C0017817|C0205263|C0038056|C0557651|C0545082|C0205263|C0038056|C0370003|C1516695
We performed a multivariable Cox regression analysis to evaluate factors associated with hospital admission.,We performed multivariable Cox regression analysis evaluate factors hospital admission.,G0000000|C0884358|G0000000|G0000000|C0684320|C0002778|C0220825|C1521761|C0019994|C0184666
The secondary outcome was the total number of hospital days used by the 12-month follow-up and the percentage of patients at full remission as defined by an EBW > 95% and an Eating Disorder Examination (EDE) global score within 1 standard deviation (s.d.),The secondary outcome total hospital days 12-month follow-up percentage patients remission defined EBW > 95% Eating Disorder Examination (EDE) global score 1 standard deviation (s.d.),G0000000|C0027627|C1274040|C0439175|C0019994|C0439228|C0450371|C0589120|C0439165|C0030705|C0544452|C1704788|G0000000|G0000000|C0450371|C0013470|C0012634|G0000000|G0000000|C0205246|C0449820|G0000000|C1442989|C0012727|C0565930
"Secondary outcome variables were nuclear colour and cortical and posterior subcapsular opacities as clinically judged using the LOCS III, best corrected spectacle visual acuity, and failure of treatment.","Secondary outcome variables nuclear colour cortical posterior subcapsular opacities clinically judged LOCS III, corrected spectacle visual acuity, failure treatment.",C0027627|C1274040|C0439828|C0521447|C0009393|C0001613|C0205095|C0205152|C0029053|G0000000|C0221191|C0041657|C0439070|C0205202|C0015421|C0234621|C0750509|C0231174|C0039798
"The 6-minute walk distance, peripheral muscle strength, health-related quality of life, dyspnoea, anxiety and depression will be measured by a blinded assessor at baseline, immediately following the intervention and at six months following the intervention.","The 6-minute walk distance, peripheral muscle strength, health-related quality life, dyspnoea, anxiety depression measured blinded assessor baseline, intervention months intervention.",G0000000|C0439232|C0080331|C0012751|C0205100|C0026845|C0237897|C0018684|C0332306|C0376558|C0013404|C0003467|C0011570|C0444706|C0150108|C1707957|C0168634|C0886296|C0439231|C0886296
Outcomes at end of study (median time of 134 weeks) *Median viral load in the 10 deferred arm children who started ART was 1.7 log (IQR 1.7–1.7) which was similar to that in the immediate arm children (p = 0.58) Overall the immediate arm had a lower viral load than the deferred arm (Table (Table2).2).,Outcomes study (median time 134 weeks) *Median viral load 10 deferred arm children started ART 1.7 log (IQR 1.7–1.7) arm children (p = 0.58) Overall arm lower viral load deferred arm (Table (Table2).2).,C1274040|C0557651|C0549183|C0040223|C1442061|C0439230|C0549183|C0521026|C1550025|C0450371|C0205421|C0446516|C0008059|C1272689|C0003826|G0000000|C1708728|G0000000|G0000000|C0446516|C0008059|C0369773|G0000000|C0450371|C0282416|C0446516|C0441994|C0521026|C1550025|C0205421|C0446516|C0039224|G0000000
"It reduced anxiety, as measured by the hospital anxiety and depression scale, and it increased self efficacy—participants were more confident about managing pain and other arthritis related symptoms as a result.","It reduced anxiety, measured hospital anxiety depression scale, increased efficacy—participants confident managing pain arthritis symptoms result.",G0000000|C0392756|C0003467|C0444706|C0019994|C0003467|C0011570|C0175659|C0205217|G0000000|C0205423|C1273870|C0030193|C0003864|C0683368|C1274040
"Demographic information and stroke details were collected at baseline, in addition to the Functional Independence Measure (transfers, walking and stairs) [32], Motor Assessment Scale [30] and the Functional Reach [33].","Demographic stroke details collected baseline, addition Functional Independence Measure (transfers, walking stairs) [32], Motor Assessment Scale [30] Functional Reach [33].",C0011298|C0038454|C1522508|C1516695|C0168634|C0332287|C0205245|C0085862|C0079809|C0728827|C0080331|C1710179|C0450371|C1513492|C1261322|C0175659|C0450371|C0205245|C2584321|C0450371
"The primary objective was to estimate the response rate to both regimens, particularly to irinotecan plus docetaxel.","The primary objective estimate response rate regimens, irinotecan docetaxel.",G0000000|C0205225|C0018017|C0750572|C0871261|C0871208|C2945654|C0123931|C0246415
"Secondary endpoints of observation: interventional or surgical and perioperative complications such as hyperperfusion syndrome, hemodynamic disorders, local hematoma, peripheral nerve injury, or acute carotid occlusion.","Secondary endpoints observation: interventional surgical perioperative complications hyperperfusion syndrome, hemodynamic disorders, local hematoma, peripheral nerve injury, acute carotid occlusion.",C0027627|C2349179|C0302523|C1948041|C0543467|C1518988|C0009566|G0000000|C0039082|C0019010|C0012634|C0205276|C0018944|C0205100|C0027740|C3263722|C0205178|C0741968|C0011382
"Markers of CVD risk, measured at 0 (baseline), 8 and 16 weeks, were: BMI, percentage body fat, waist circumference; fasting plasma lipid profile, glucose and insulin; and indicators of inflammatory, coagulation, and endothelial function.","Markers CVD risk, measured 0 (baseline), 8 16 weeks, were: BMI, percentage body fat, waist circumference; fasting plasma lipid profile, glucose insulin; indicators inflammatory, coagulation, endothelial function.",C0005516|C0007222|C0035647|C0444706|G0000000|C0168634|G0000000|C0450371|C0439230|G0000000|G0000000|C0439165|C0242821|C0424612|C0230097|C0332520|C0015663|C0032105|C0023779|C1979963|C0017725|C0021641|C0021212|C0333348|C0005778|C0014257|C0031843
"Measurement of 24 h urinary sodium, potassium and creatine were undertaken using routine methods at baseline and follow-up as indices of adherence to the intervention and determined by assessors blinded to treatment allocation.","Measurement 24 h urinary sodium, potassium creatine undertaken routine methods baseline follow-up indices adherence intervention determined assessors blinded treatment allocation.",C0242485|G0000000|C0042027|C0037473|C0032821|C0010286|G0000000|C0205547|C0025663|C0168634|C0589120|C4033634|C1510802|C0886296|G0000000|C1707957|C0150108|C0039798|C1706778
"The a priori primary efficacy measure was change from baseline to the end of study (week 8/ET) in the Young Mania Rating Scale (YMRS) score, based on last-observation-carried-forward analysis.","The priori primary efficacy measure change baseline study (week 8/ET) Young Mania Rating Scale (YMRS) score, based last-observation-carried-forward analysis.",G0000000|G0000000|C0205225|C1280519|C0079809|C0392747|C0168634|C0557651|C0332174|G0000000|C0332239|C0338831|C0871208|C0175659|C3640523|C0449820|C1527178|C1517741|C0002778
Table 3 shows the distribution of falls by group allocation.,Table 3 distribution falls allocation.,C0039224|G0000000|C0520511|C0000921|C1706778
"An estimated 11% of children under six years of age are reported to be regularly exposed to household SHS; exposure is significantly higher in households at and below the poverty level[7]; and many children with asthma continue to experience household exposure to SHS[5, 8].","An estimated 11% children age reported regularly exposed household SHS; exposure households poverty level[7]; children asthma continue experience household exposure SHS[5, 8].",G0000000|C0750572|C0450371|C0008059|C0001779|C0684224|G0000000|C0332157|C0020052|G0000000|C0274281|C0020052|C0032854|C0441889|C0008059|C0004096|C0549178|C0237607|C0020052|C0274281|G0000000|G0000000
Cannabis is the most commonly abused illicit drug and accounts for the greatest number of adolescent substance abuse treatment admissions.,Cannabis commonly abused illicit drug accounts adolescent substance abuse treatment admissions.,C0024808|G0000000|C0013146|C0332266|C0013227|C2741673|C0205653|C0439861|C0013146|C0039798|C0184666
"Outcome measures were the Fugl-Meyer Assessment, the Motor Activity Log, and the Stroke Specific Quality of Life Scale.","Outcome measures Fugl-Meyer Assessment, Motor Activity Log, Stroke Specific Quality Life Scale.",C1274040|C0079809|G0000000|C1261322|C1513492|C0205177|C1708728|C0038454|C0205369|C0332306|C0376558|C0175659
"Participants completed assessments during visits at Weeks 1, 4, and 8 (plus Week 16 if receiving Extended Medication) with case managers, and during follow-up calls at Weeks 16, 26, 39, and 52 with assessors.","Participants completed assessments visits Weeks 1, 4, 8 (plus Week 16 receiving Extended Medication) managers, follow-up calls Weeks 16, 26, 39, 52 assessors.",C0679646|C0205197|C1261322|C0545082|C0439230|G0000000|G0000000|G0000000|C0332287|C0332174|C0450371|C1514756|C0231448|C0013227|C0335141|C0589120|C0679006|C0439230|C0450371|C0450371|C0450371|C0450371|C1707957
"Patients were asked to rate their pain, indicating the number that best described their pain on average over the previous 24 h from 0 (no pain) to 10 (unbearable pain).","Patients rate pain, indicating pain average previous 24 h 0 (no pain) 10 (unbearable pain).",C0030705|C0871208|C0030193|G0000000|C0030193|C1510992|C0205156|G0000000|G0000000|G0000000|C0030193|C0450371|G0000000|C0030193
"The contrast between group and fatigue at baseline versus 6 months was significant (F (1,97)=15.945, P⩽0.001, r=0.4) as well as at 6 weeks versus 6 months (F (1,97)=6.910, P=0.010, r=0.3) with less fatigue reported in the CM group.","The contrast fatigue baseline versus 6 months (F (1,97)=15.945, P⩽0.001, r=0.4) 6 weeks versus 6 months (F (1,97)=6.910, P=0.010, r=0.3) fatigue reported CM group.",G0000000|C0009924|C0015672|C0168634|G0000000|G0000000|C0439231|C0016327|C0450371|G0000000|C0205090|G0000000|C0439230|G0000000|G0000000|C0439231|C0016327|C0450371|C0369773|C0205090|C0015672|C0684224|G0000000|C0441833
A sub-group of participants underwent chest computed tomography scans (n = 15).,A sub-group participants underwent chest computed tomography scans (n = 15).,G0000000|C0542339|C0679646|G0000000|C0817096|C1441526|C0040395|C0034606|G0000000
Other lung-function end points included trough FEV1 at other time points; serial FEV1 over 0–6 hours postdose at day 1; the proportion of patients achieving an increase in FEV1 of ≥12% and ≥0.200 L above baseline at any time 0–6 hours postdose on day 1; the proportion of patients achieving an increase of ≥0.100 L above baseline in trough FEV1; and trough and serial FVC and time to onset (defined as an increase of 0.100 L in FEV1 above baseline) 0–6 hours postdose at day 1.,Other lung-function included trough FEV1 time points; serial FEV1 0–6 hours postdose day 1; proportion patients achieving increase FEV1 ≥12% ≥0.200 L baseline time 0–6 hours postdose day 1; proportion patients achieving increase ≥0.100 L baseline trough FEV1; trough serial FVC time onset (defined increase 0.100 L FEV1 baseline) 0–6 hours postdose day 1.,G0000000|C0035245|C0332257|C0444506|G0000000|C0040223|C1552961|C0031082|G0000000|G0000000|C0439227|C0439568|C0332173|G0000000|C1709707|C0030705|G0000000|C0442805|G0000000|G0000000|G0000000|C0439394|C0168634|C0040223|G0000000|C0439227|C0439568|C0332173|G0000000|C1709707|C0030705|G0000000|C0442805|G0000000|C0439394|C0168634|C0444506|G0000000|C0444506|C0031082|C3714541|C0040223|C0206132|C1704788|C0442805|C1442061|C0439394|G0000000|C0168634|G0000000|C0439227|C0439568|C0332173|G0000000
eType 1– and 2–specific serum neutralization data were missing from the visits at 28 and/or 29 weeks of age in 1 of the included subjects in the IPV-IPV-bOPV group and 3 in the IPV-bOPV-bOPV group.,eType 1– 2–specific serum neutralization data missing visits 28 and/or 29 weeks age 1 included subjects IPV-IPV-bOPV 3 IPV-bOPV-bOPV group.,G0000000|G0000000|G0000000|C0229671|C1578828|C1511726|C1551393|C0545082|C0450371|G0000000|C0450371|C0439230|C0001779|G0000000|C0332257|C0681850|G0000000|G0000000|G0000000|C0441833
BEST: Bronchiectasis Exacerbation Study; CF: cystic fibrosis; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; ELISA: enzyme-linked immunosorbent assay; FEV1: forced expiratory volume in one second; IL: interleukin; IP-10: interferon gamma-inducible protein 10; MIC: minimum inhibitory concentration; NS: nasal swab; PC-QOL: parent chronic cough quality of life; QOL: Quality of life; RCT: randomised controlled trial; SAA: serum amyloid A; SD: standard deviation.,BEST: Bronchiectasis Exacerbation Study; CF: cystic fibrosis; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; ELISA: enzyme-linked immunosorbent assay; FEV1: forced expiratory volume second; IL: interleukin; IP-10: interferon gamma-inducible protein 10; MIC: minimum inhibitory concentration; NS: nasal swab; PC-QOL: parent chronic cough quality life; QOL: Quality life; RCT: randomised controlled trial; SAA: serum amyloid A; SD: standard deviation.,C1522427|C0006267|G0000000|C0557651|C0009738|C0205207|C0016059|C0024117|C0205191|C0549186|C0024109|C0012634|C3890735|C0205332|C0033684|C0014441|C0014442|C0021075|C0005507|G0000000|C0441722|C0231800|C0449468|C0205436|C0020898|C0021764|C1308226|C0021747|C0017011|C0033684|C0450371|C0281162|C1524031|C3463820|C0004268|C0038944|C0028429|C0183753|C0031995|C0030551|C0205191|C0010200|C0332306|C0376558|C0518214|C0332306|C0376558|G0000000|G0000000|C2587213|C0008976|C0002723|C0229671|C0002716|G0000000|C2699239|C1442989|C0012727
"Two-way ANOVA with repeated measures revealed significant interactions for time x intervention for both the number of migraine attacks per month (Ftime*PMR = 4.62; p = 0.017) and migraine days (Ftime*PMR = 3.39; p = 0.046), which corresponds to a significant reduction of migraine attacks and days with migraine per month in the group of patients with PMR-training compared to those from the waiting-list.","Two-way ANOVA repeated measures revealed interactions time intervention migraine attacks month (Ftime*PMR = 4.62; p = 0.017) migraine days (Ftime*PMR = 3.39; p = 0.046), corresponds reduction migraine attacks days migraine month patients PMR-training compared waiting-list.",C0205448|G0000000|C0205341|C0079809|C0443289|C1704675|C0040223|C0886296|C0149931|C1261512|C0332177|G0000000|G0000000|C0149931|C0439228|G0000000|G0000000|G0000000|C0301630|C0149931|C1261512|C0439228|C0149931|C0332177|C0030705|C0032533|C1707455|C0043010
"Med = medication condition (1 = placebo, 2 = topiramate), GUD = grams per use day, PUD = percent use days, RMPI = Rutgers Marijuana Problem Index.","Med = medication condition (1 = placebo, 2 = topiramate), GUD = grams day, PUD = percent days, RMPI = Rutgers Marijuana Problem Index.",G0000000|G0000000|C0013227|C0012634|G0000000|G0000000|C0032042|G0000000|G0000000|C0076829|C1704667|G0000000|C0439208|C0332173|G0000000|G0000000|C0439165|C0439228|G0000000|G0000000|G0000000|C0024808|C0033213|C0918012
Toxicity was measured by counting adverse laboratory or clinical events related to study medication and the timing of the first event in relation to doses received.,Toxicity measured counting adverse laboratory clinical events study medication timing event relation doses received.,C0040539|C0444706|C0750480|G0000000|C0022877|C0205210|C0441471|C0557651|C0013227|C0449243|C0441471|C0080103|C0178602|C1514756
"A sample question from this scale is: “During the past month, how distressed were you by heavy bleeding during your menstrual period, feeling tightness or pressure in your pelvic area, or feeling fatigued?” The second scale is the HRQL questionnaire, which measures perceived impact of leiomyoma on activities of daily living, general concern and worry, energy, mood, sense of self-control, self-consciousness, and sexual functioning of the participants.","A sample question scale is: “During month, distressed heavy bleeding menstrual period, feeling tightness pressure pelvic area, feeling fatigued?” The scale HRQL questionnaire, measures perceived impact leiomyoma activities daily living, concern worry, energy, mood, sense self-control, self-consciousness, sexual functioning participants.",G0000000|C0370003|C1522634|C0175659|G0000000|G0000000|C0332177|C3887804|C0439539|C0019080|C0025344|C0439531|C0013987|C0439816|C0033095|C0030797|C0017446|C0013987|G0000000|G0000000|C0175659|G0000000|C0034394|C0079809|C0030971|C1825598|C0023267|C0441655|C0332173|C0376558|C2699424|C0233481|C0424589|C0026516|C0036658|C0684274|C1882997|C0036864|C0205245|C0679646
"All 3 medications significantly improved pruritus, erythema and scales (P < 0.","All 3 medications improved pruritus, erythema scales (P < 0.",G0000000|G0000000|C0013227|C0184511|C0033774|C0041834|C0175659|C0369773|G0000000|G0000000
"Analyses of PFS, OS, and ORR by KRAS mutation status were performed for each KRAS subgroup using similar methods.","Analyses PFS, OS, ORR KRAS mutation status performed KRAS subgroup methods.",C0002778|C0242792|C0229090|G0000000|C0022457|C0026882|C0449438|C0884358|C0022457|C1079230|C0025663
Correlations between endocrine levels and symptom severity ratings over time revealed that hot flash severity was significantly and positively related to FSH [28].,Correlations endocrine levels symptom severity ratings time revealed hot flash severity positively FSH [28].,C1707520|C0014136|C0441889|C1457887|C0439793|C0871208|C0040223|C0443289|C0444519|C0181637|C0439793|G0000000|G0000000|C0450371
was trained and calibrated for QLF assessments against an experienced examiner (M.V.),trained calibrated QLF assessments experienced examiner (M.V.),C0336809|G0000000|G0000000|C1261322|C0237607|G0000000|C0560267
The primary outcome was biochemically verified continuous smoking abstinence at 24 weeks.,The primary outcome biochemically verified continuous smoking abstinence 24 weeks.,G0000000|C0205225|C1274040|G0000000|C1711411|C0549178|C0037369|C3843422|C0450371|C0439230
"The bacterial load did reduce by 10 fold but this was not statistically significant, shown in Table 3.","The bacterial load reduce 10 fold statistically significant, Table 3.",G0000000|C0521009|C1550025|G0000000|C0450371|C0332462|C0038215|C0237881|C0039224|G0000000
"Such alterations are considered to be the major cause of loss of functional membrane capacity, resulting in ultrafiltration (UF) failure.","Such alterations considered major loss functional membrane capacity, ultrafiltration (UF) failure.",G0000000|C1515926|C0750591|C0205082|C1517945|C0205245|C0025255|C1516240|C0041612|G0000000|C0231174
"Diary based assessments: morning and evening peak expiratory flow, visual analogue scale of severity of asthma, quality of life, and daily mood.","Diary based assessments: morning evening peak expiratory flow, visual analogue scale severity asthma, quality life, daily mood.",C0376660|C1527178|C1261322|C0332170|C0587117|C0444505|C0231800|C0806140|C0234621|C0243071|C0175659|C0439793|C0004096|C0332306|C0376558|C0332173|C0026516
"Therefore, we employed HF and HR as stress indices and measured them before and after each music intervention.","Therefore, employed HF HR stress indices measured music intervention.",G0000000|C0014003|C0018488|G0000000|C0038435|C4033634|C0444706|C0026867|C0886296
"One patient in group S had a pneumothorax after the block, and one patient in the group I was unhappy with the prolonged sensory and motor block with ropivacaine.","One patient S pneumothorax block, patient I unhappy prolonged sensory motor block ropivacaine.",C0205447|C0030705|C0565930|C0032326|C0028778|C0030705|C0021966|C1688635|C0439590|C0445254|C1513492|C0028778|C0073571
Respiratory illness data were collected on the infant in the same way as obtained during the Weeks 2 and 3 visits.,Respiratory illness data collected infant Weeks 2 3 visits.,C0521346|C0221423|C1511726|C1516695|C0021270|C0439230|G0000000|G0000000|C0545082
withdrawn from study participation) after their first UTI.,withdrawn study participation) UTI.,C0424092|C0557651|C0679823|C0042029
The reasons for the different response rates are obscure.,The reasons response rates obscure.,G0000000|C0392360|C0871261|C0871208|G0000000
The primary outcome measure was hospitalisation.,The primary outcome measure hospitalisation.,G0000000|C0205225|C1274040|C0079809|C0019993
"No program effects were found in the adolescents’ self-reported antisocial behavior, delinquency, or psychosocial functioning.","No program effects adolescents’ self-reported antisocial behavior, delinquency, psychosocial functioning.",G0000000|C1709697|C1280500|G0000000|C0681906|C0233523|C0004927|C0522174|C0542298|C0205245
"With respect to primary CMV infection, there was no difference in the rates in the 2 groups, but tissue invasive disease and recurrent CMV disease were less frequent in the ganciclovir group.","With respect primary CMV infection, difference rates 2 groups, tissue invasive disease recurrent CMV disease frequent ganciclovir group.",G0000000|C0679133|C0205225|G0000000|C0009450|C1705241|C0871208|G0000000|C0441833|C0040300|C0205281|C0012634|C2945760|G0000000|C0012634|C0332183|C0017066|C0441833
Outcome variables—The outcome variables were diarrhoea and acute lower respiratory infection.,Outcome variables—The outcome variables diarrhoea acute lower respiratory infection.,C1274040|G0000000|C1274040|C0439828|C0011991|C0205178|C0441994|C0521346|C0009450
"Paired t tests were also used to evaluate the change from baseline (pretreatment) in percent body fat, weight, BMI, and serology following each treatment.","Paired tests evaluate change baseline (pretreatment) percent body fat, weight, BMI, serology treatment.",C1709450|C0022885|C0220825|C0392747|C0168634|C1550147|C0439165|C0242821|C0424612|C0005910|G0000000|C0036745|C0039798
"Previous clinical studies have demonstrated that biocompatible peritoneal dialysis (PD) solutions reduce inflammatory responses in the peritoneal cavity, improve ultrafiltration (UF), and increase biochemical markers of peritoneal integrity, including cancer antigen 125 (CA125) (1–4).","Previous clinical studies demonstrated biocompatible peritoneal dialysis (PD) solutions reduce inflammatory responses peritoneal cavity, improve ultrafiltration (UF), increase biochemical markers peritoneal integrity, including cancer antigen 125 (CA125) (1–4).",C0205156|C0205210|C0947630|G0000000|C0596177|C0031153|C0011945|G0000000|C0037633|G0000000|C0333348|C0871261|C0031153|C0011334|G0000000|C0041612|G0000000|C0442805|C0205474|C0005516|C0031153|C0205266|C0332257|C0006826|C0003320|C1442061|G0000000|G0000000
The primary outcome measures of the RCT were functional capacity (mRS score 0-2) and mortality at 3 months.,The primary outcome measures RCT functional capacity (mRS score 0-2) mortality 3 months.,G0000000|C0205225|C1274040|C0079809|G0000000|C0205245|C1516240|C1522706|C0449820|G0000000|C0026565|G0000000|C0439231
Noninvasive preoperative diagnostic factors potentially associated with excellent surgical outcome were examined by univariate analysis in the 40 patients with follow-up of >1 year.,Noninvasive preoperative diagnostic factors excellent surgical outcome examined univariate analysis 40 patients follow-up >1 year.,C0205303|C0445204|C0011900|C1521761|C1548784|C0543467|C1274040|C0332128|G0000000|C0002778|C0450371|C0030705|C0589120|G0000000|C0439234
PPROM was diagnosed via the Fern test and sonography.,PPROM diagnosed Fern test sonography.,C0729264|C0011900|C0331729|C0022885|C0041618
MAIN OUTCOME MEASURE—The prevalence of self reported smoking and smokeless tobacco use in the week before assessment.,MAIN OUTCOME MEASURE—The prevalence reported smoking smokeless tobacco week assessment.,C0205225|C1274040|G0000000|C0033105|C0684224|C0037369|C1450035|C0040329|C0332174|C1261322
"A prospective, consecutive, double blind, randomized controlled clinical trial is proposed to address the effect of dialysis on sleep, pulmonary function, respiratory mechanics, upper airway collapsibility, autonomic nervous activity, depression, anxiety, stress and quality of life in patients with CKD.","A prospective, consecutive, double blind, randomized controlled clinical trial proposed address dialysis sleep, pulmonary function, respiratory mechanics, upper airway collapsibility, autonomic nervous activity, depression, anxiety, stress quality life patients CKD.",G0000000|C0023981|C1707491|C0205173|C0150108|C0034656|C2587213|C0205210|C0008976|C1553874|C0376649|C0011945|C0037313|C0024109|C0031843|C0521346|C0376706|C1282910|C0178987|G0000000|C0004388|C0027769|C0205177|C0011570|C0003467|C0038435|C0332306|C0376558|C0030705|C1561643
Adverse events within 42 days and 1-year recurrence rates were compared and their relationship with day 6 drug concentrations assessed.,Adverse events 42 days 1-year recurrence rates compared relationship day 6 drug concentrations assessed.,G0000000|C0441471|C0450371|C0439228|C0439234|C0034897|C0871208|C1707455|C0439849|C0332173|G0000000|C0013227|C0086045|C1516048
"Decedents' data for the period between the last patient-reported assessment and death, chemotherapy use in last 14 days, and location of death were obtained via medical record review or proxy report.","Decedents' data period patient-reported assessment death, chemotherapy 14 days, location death medical record review proxy report.",C3274946|C1511726|C0439531|C0747307|C1261322|C0011065|C0013216|C0450371|C0439228|C0450429|C0011065|C0199168|C0034869|C0282443|C0600420|C0684224
"Primary outcome parameters were walking time and speed in 10-meter walk test (10MWT), time in timed-up-and-go test (TUG) and distance in 6-min walk test (6MWT).","Primary outcome parameters walking time speed 10-meter walk test (10MWT), time timed-up-and-go test (TUG) distance 6-min walk test (6MWT).",C0205225|C1274040|C0449381|C0080331|C0040223|C0678536|C0450371|C0080331|C0022885|G0000000|C0040223|C1319201|C0022885|C1319201|C0012751|C0702093|C0080331|C0022885|G0000000
Primary endpoint was residual tumor volume (RTV) percentage.,Primary endpoint residual tumor volume (RTV) percentage.,C0205225|C2349179|C1609982|C0027651|C0449468|C0292818|C0439165
"Like the efficacious Diabetes Prevention Program (DPP), the LLDPP intervention targeted weight loss through dietary change and increased physical activity.","Like efficacious Diabetes Prevention Program (DPP), LLDPP intervention targeted weight loss dietary change increased physical activity.",G0000000|C1280519|C0011847|C0199176|C1709697|C1414174|G0000000|C0886296|C1521840|C0005910|C1517945|C0012155|C0392747|C0205217|C0031809|C0205177
Baseline stool and urine specimens were taken prior to isotope dosing.,Baseline stool urine specimens prior isotope dosing.,C0168634|C0015733|C0042036|C0370003|C0332152|C0022262|G0000000
"• The use of earplugs improves the sleep perception of patients • Since delirium is a multifactorial syndrome, sleeping with earplugs is no magical solution in the prevention of delirium • Earplugs are a cheap and easy to use tool to improve the patient's comfort and to prevent confusion.","• The earplugs improves sleep perception patients • Since delirium multifactorial syndrome, sleeping earplugs magical solution prevention delirium • Earplugs cheap easy tool improve patient's comfort prevent confusion.",G0000000|G0000000|C1135964|C0184511|C0037313|C0030971|C0030705|G0000000|C1711239|C0011206|C1837655|C0039082|C0037313|C1135964|C0024460|C0037633|C0199176|C0011206|G0000000|C1135964|G0000000|C0332219|C0336791|G0000000|C0030705|C1331418|C0309872|C0009676
A cognitive composite score (primary outcome) and individual cognitive domains were evaluated.,A cognitive composite score (primary outcome) individual cognitive domains evaluated.,G0000000|C1516691|C0205199|C0449820|C0205225|C1274040|C0027361|C1516691|C1880389|C0220825
"The primary end point of this trial was DFS, which was defined as the time from registration to the recurrence of tumor at any local, regional, or distant location; the detection of a second primary cancer; or death as a result of any cause without documentation of recurrence.","The primary trial DFS, defined time registration recurrence tumor local, regional, distant location; detection primary cancer; death result documentation recurrence.",G0000000|C0205225|C0008976|G0000000|C1704788|C0040223|C1514821|C0034897|C0027651|C0205276|C0205147|C0443203|C0450429|C1511790|C0205225|C0006826|C0011065|C1274040|C0175636|C0034897
The primary outcome was self-reported 7-day point prevalence (PP) tobacco abstinence at 6-month follow-up.,The primary outcome self-reported 7-day prevalence (PP) tobacco abstinence 6-month follow-up.,G0000000|C0205225|C1274040|C0681906|C0332173|C0033105|C0030375|C0040329|C3843422|C0332177|C0589120
"Assessment of outcome measures across the protocol 2MWT- 2 Minute Walk Test, FSST-Four Square Step Test, SPPB- Short Physical Performance Battery, mini-BEST- The mini-Balance Evaluation Systems Test, MOCA- Montreal Cognitive Assessment, TMT- Trail Making Test, FES-I- Fall Efficacy Scale International.","Assessment outcome measures protocol 2MWT- 2 Minute Walk Test, FSST-Four Square Step Test, SPPB- Short Physical Performance Battery, mini-BEST- The mini-Balance Evaluation Systems Test, MOCA- Montreal Cognitive Assessment, TMT- Trail Making Test, FES-I- Fall Efficacy Scale International.",C1261322|C1274040|C0079809|C0442711|G0000000|G0000000|C0439232|C0080331|C0022885|C0205450|C0205120|C1261552|C0022885|G0000000|C1282927|C0031809|C0597198|C0337088|C0445542|G0000000|C0445542|C0220825|C0449913|C0022885|C3541265|G0000000|C1516691|C1261322|C0040604|C1143949|C1881534|C0022885|C0021966|C0085639|C1280519|C0175659|C1512888
"The consistent results across endpoints suggest that treatment of insomnia with eszopiclone had a positive effect on quality of life, work productivity, fatigue, and daytime functioning.","The consistent endpoints treatment insomnia eszopiclone positive quality life, productivity, fatigue, daytime functioning.",G0000000|C0332290|C2349179|C0039798|C0917801|C1436328|C0439178|C0332306|C0376558|C0033269|C0015672|C0332169|C0205245
There were no statistically significant differences between the three groups for the incidence of EA at any time point during recovery from anesthesia nor were there any significant differences in pain scores or side effects.,There statistically differences incidence EA time recovery anesthesia differences pain scores effects.,G0000000|C0038215|C1705241|C0021149|C0014963|C0040223|C0237820|C0002903|C1705241|C0030193|C0449820|C1280500
The secondary endpoint was the rate of change of PSA over time (i.e.,The secondary endpoint rate change PSA time (i.e.,G0000000|C0027627|C2349179|C0871208|C0392747|C3810537|C0040223|C0683454
"Plasma glucose was measured using an enzymatic in vitro test (GOD-PAP kit, Pars Azmun Co. Inc, Tehran, Iran) and 25 (OH) D was analyzed by Eliza (Euroimmun Kit, Nima Pooyesh Teb Company, Tehran, Iran) with an inter-assay coefficient of variation of 7.8% and an intra assay coefficient of variation of 3.2%.","Plasma glucose measured enzymatic vitro test (GOD-PAP kit, Pars Azmun Co. Inc, Tehran, Iran) 25 (OH) D analyzed Eliza (Euroimmun Kit, Nima Pooyesh Teb Company, Tehran, Iran) inter-assay coefficient variation 7.8% intra assay coefficient variation 3.2%.",C0032105|C0017725|C0444706|C0014442|C1533691|C0022885|C0681169|C0812225|C0032405|G0000000|C3245499|G0000000|G0000000|C0022065|C0450371|C0220853|C0073187|C0936012|G0000000|G0000000|C0812225|C0132513|G0000000|G0000000|C0683757|G0000000|C0022065|C0205103|C1707429|C0205419|G0000000|C0347985|C0005507|C1707429|C0205419|G0000000
"[17], and in line with previous studies using this method, we shall use the following main outcomes, counting each opening as a presumptive dose: (a) percentage of doses taken (versus doses prescribed), (b) percentage of days on which the correct number of doses was taken, and (c) percentage of doses taken on schedule.","[17], previous studies method, main outcomes, counting presumptive dose: (a) percentage doses (versus doses prescribed), (b) percentage days correct doses taken, (c) percentage doses schedule.",C0450371|C0205156|C0947630|C0025663|C0205225|C1274040|C0750480|C3640893|C0178602|G0000000|C0439165|C0178602|G0000000|C0178602|C0278329|G0000000|C0439165|C0439228|C2349182|C0178602|C1883727|G0000000|C0439165|C0178602|C0086960
"We recruited 367 male and 240 female cases with adenocarcinomas, and 381 male and 57 female cases with squamous cell and small cell carcinomas.","We recruited 367 male 240 female adenocarcinomas, 381 male 57 female squamous cell cell carcinomas.",G0000000|G0000000|C1442061|C0086582|C1442061|C0015780|C0001418|C1442061|C0086582|C0450371|C0015780|C1182670|C0007634|C0007634|C0007097
"Data were obtained from a national database (time of primary surgery, T0) and self‐assessment questionnaires at preintervention (T1), postintervention 5 months after surgery (T2), and follow‐up 10 months after surgery (T3).","Data national database (time primary surgery, T0) self‐assessment questionnaires preintervention (T1), postintervention 5 months surgery (T2), follow‐up 10 months surgery (T3).",C1511726|C3245503|C0242356|C0040223|C0205225|C0038894|C0041403|G0000000|C0034394|C2347663|C0041403|G0000000|G0000000|C0439231|C0038894|C0041403|G0000000|C0450371|C0439231|C0038894|C0041403
The Visual Analogue Scale (VAS) [29] was used to evaluate the pain level.,The Visual Analogue Scale (VAS) [29] evaluate pain level.,G0000000|C0234621|C0243071|C0175659|C0042815|C0450371|C0220825|C0030193|C0441889
"To our knowledge, we are the first to find that these lifestyle changes decreased body fat, improved physical activity and breast cancer-specific quality of life, and improved adipokine profile in this high-risk population.","To knowledge, lifestyle decreased body fat, improved physical activity breast cancer-specific quality life, improved adipokine profile high-risk population.",C0040363|C0376554|C0023676|C0205216|C0242821|C0424612|C0184511|C0031809|C0205177|C0006141|C0006826|C0332306|C0376558|C0184511|C1955907|C1979963|C0332167|C0032659
Continuity of care: The Picker Ambulatory Oncology survey comprises eight items that assess patient experience of oncology care [76].,Continuity care: The Picker Ambulatory Oncology survey comprises items assess patient experience oncology care [76].,C0595960|C1947933|G0000000|G0000000|C0439841|C0027651|C0038951|C2700400|C1551338|C1516048|C0030705|C0237607|C0027651|C1947933|C0450371
"Further work should determine ways of improving uptake, and longer-term impact of the programme on health status, metabolic and physiological outcomes, and healthcare use.","Further determine improving uptake, longer-term impact programme health status, metabolic physiological outcomes, healthcare use.",C1517331|G0000000|C1272745|C0243144|C0443252|C1825598|C1709697|C0018684|C0449438|C0311400|C0205463|C1274040|C0086388|C0042153
"Secondary outcome measures were change in fasting lipid profile, measures of insulin sensitivity, inflammatory and haemostatic measures, blood pressure and body weight.","Secondary outcome measures change fasting lipid profile, measures insulin sensitivity, inflammatory haemostatic measures, blood pressure body weight.",C0027627|C1274040|C0079809|C0392747|C0015663|C0023779|C1979963|C0079809|C0021641|C0020517|C0333348|C0019116|C0079809|C0005767|C0033095|C0242821|C0005910
"To establish the role of ACTH test before, during, and after treatment with high potency topical steroids; to determine if adrenal insufficiency occurs secondary to the use of high potency topical steroids in patients with vitiligo and intact cutaneous barrier; and also to determine response to treatment and side effects.","To establish role ACTH test before, during, treatment potency topical steroids; determine adrenal insufficiency occurs secondary potency topical steroids patients vitiligo intact cutaneous barrier; determine response treatment effects.",C0040363|C0443211|C0035820|C3539087|C0022885|C0332152|G0000000|C0039798|C3245505|C0332237|C0038317|G0000000|G0000000|C0231179|C1709305|C0027627|C3245505|C0332237|C0038317|C0030705|C0042900|C0205266|C0221912|C1706912|G0000000|C0871261|C0039798|C1280500
1.,1.,G0000000
"The criterion of abstinence was self-reported continuous abstinence from smoking from the beginning of the substitution to the end of the 6th month of follow-up, validated by an expired-air carbon monoxide (CO) concentration of less than 10 parts per million (ppm) at all visits (Bedfont Smokerlyzer, Bedfont Scientific Ltd., Rochester, UK).","The criterion abstinence self-reported continuous abstinence smoking substitution 6th month follow-up, validated expired-air carbon monoxide (CO) concentration 10 (ppm) visits (Bedfont Smokerlyzer, Bedfont Scientific Ltd., Rochester, UK).",G0000000|C0243161|C3843422|C0681906|C0549178|C3843422|C0037369|C1555721|G0000000|C0332177|C0589120|G0000000|C0011065|C0007009|G0000000|C3245499|C0004268|C0450371|C0439187|C0545082|G0000000|G0000000|G0000000|C0036397|C1136140|G0000000|C0041700
"Secondary measures included within-subject change in average daily pain score from baseline to each trial period (titration, maintenance, and entire treatment).","Secondary measures included within-subject change average daily pain score baseline trial period (titration, maintenance, entire treatment).",C0027627|C0079809|C0332257|C0681850|C0392747|C1510992|C0332173|C0030193|C0449820|C0168634|C0008976|C0439531|C0162621|C0024501|C0439751|C0039798
The DRS-R-98 noncognitive and cognitive subscale scores were not significantly different.,The DRS-R-98 noncognitive cognitive subscale scores different.,G0000000|C3887968|G0000000|C1516691|G0000000|C0449820|C1705242
"[31] Serum hs-CRP concentration was quantified by ELISA kit (LDN, Nordhorn, Germany).","[31] Serum hs-CRP concentration quantified ELISA kit (LDN, Nordhorn, Germany).",C0450371|C0229671|C3890735|C0004268|C1709793|C0014441|C0812225|G0000000|G0000000|C0017480
The efficacy of acupuncture for migraine is assessed by the primary outcome measure: change in the frequency of migraine attacks during the 16th week after randomization.,The efficacy acupuncture migraine assessed primary outcome measure: change frequency migraine attacks 16th week randomization.,G0000000|C1280519|C0001299|C0149931|C1516048|C0205225|C1274040|C0079809|C0392747|C0376249|C0149931|C1261512|G0000000|C0332174|C0034656
"Patients demographic and operative data (mean ± SD) Preoperative data and observation Time to eye opening, agitation scoring, postoperative fentanyl consumption, and time of hospital discharge allowance are shown in Table 5.","Patients demographic operative data (mean ± SD) Preoperative data observation Time eye opening, agitation scoring, postoperative fentanyl consumption, time hospital discharge allowance Table 5.",C0030705|C0011298|C1882154|C1511726|C0444504|G0000000|C2699239|C0445204|C1511726|C0302523|C0040223|C0015392|C0175566|C0085631|C0449820|C0032790|C0015846|C0009830|C0040223|C0019994|C0012621|C0556660|C0039224|G0000000
"All complications, such as abdominal wall vessel bleeding, intraabdominal vascular or visceral injuries, related to the trocar deployment were documented.","All complications, abdominal wall vessel bleeding, intraabdominal vascular visceral injuries, trocar deployment documented.",G0000000|C0009566|C0000726|C0677535|C0005847|C0019080|C0230168|C0005847|C0442045|C1510467|C0041158|C2825812|C1301725
"Patients were evaluated via the Auditory Hallucinations Rating Scale, Scale for the Assessment of Positive Symptoms-Negative Symptoms, Clinical Global Impressions, and Quality of Life Questionnaire.","Patients evaluated Auditory Hallucinations Rating Scale, Scale Assessment Positive Symptoms-Negative Symptoms, Clinical Global Impressions, Quality Life Questionnaire.",C0030705|C0220825|C0439825|C0018524|C0871208|C0175659|C0175659|C1261322|C0439178|C0683368|C0683368|C0205210|C0205246|C0596764|C0332306|C0376558|C0034394
Various adjuncts are used to relax the brain.,Various adjuncts relax brain.,C0440102|G0000000|C0035028|C0006104
"The MMR decision was measured at three months post-intervention using a self-report item 'Since this study started, have you taken your child to have the combined MMR vaccine?'","The MMR decision measured months post-intervention self-report item 'Since study started, child combined MMR vaccine?'",G0000000|C3538741|C0679006|C0444706|C0439231|C2347647|C0681906|C1551338|G0000000|C0557651|C1272689|C0008059|C0205195|C3538741|C0042210
Treatment is switched remotely and period 2 of the intervention begins subsequent to that and last 4 weeks.,Treatment switched remotely period 2 intervention subsequent 4 weeks.,C0039798|C1707719|G0000000|C0439531|G0000000|C0886296|C0332282|G0000000|C0439230
"The EQ-5D was conducted at baseline, three months, and 12 months.","The EQ-5D conducted baseline, months, 12 months.",G0000000|C0205163|C0004927|C0168634|C0439231|C0450371|C0439231
Figure 3 shows the individual responses in daytime sleepiness in the two groups.,Figure 3 individual responses daytime sleepiness groups.,G0000000|G0000000|C0027361|C0871261|C0332169|C0013144|C0441833
"We measured the primary outcome, stress, with a multiple-item scale developed by the research team and intended to measure global perceptions of stress and also to capture occupation-specific stress that is particularly relevant to physicians (Appendix A).","We measured primary outcome, stress, multiple-item scale developed team intended measure global perceptions stress capture occupation-specific stress relevant physicians (Appendix A).",G0000000|C0444706|C0205225|C1274040|C0038435|C0439064|C0175659|G0000000|C0871489|C1283828|C0079809|C0205246|C0030971|C0038435|G0000000|C0028811|C0038435|C2347946|C0031831|C0003617|G0000000
"rTMS, repetitive transcranial magnetic stimulation; AMR, alternative motion rate; MPT, maximal phonation time; MBI, Modified Barthel Index; MMSE, Mini-Mental Status Examination; U-TAP, Urimal Test of Articulation and Phonology.","rTMS, repetitive transcranial magnetic stimulation; AMR, alternative motion rate; MPT, maximal phonation time; MBI, Modified Barthel Index; MMSE, Mini-Mental Status Examination; U-TAP, Urimal Test Articulation Phonology.",G0000000|G0000000|C0442348|C0024488|C1292856|G0000000|C1523987|C0026597|C0871208|C3158980|C0205289|C0031577|C0040223|C2985547|C0392747|G0000000|C0918012|C0451306|C0445542|C0449438|G0000000|C0034115|G0000000|C0022885|C0022417|C0597725
BACKGROUND—Discharge planning is becoming an important part of the management of childhood asthma in hospital.,BACKGROUND—Discharge planning management childhood asthma hospital.,G0000000|C0032074|C0001554|C0231335|C0004096|C0019994
"The primary end points related to the efficacy of pleural drainage--namely, the volume of pleural fluid drained and the chest radiographic response to treatment.","The primary efficacy pleural drainage--namely, volume pleural fluid drained chest radiographic response treatment.",G0000000|C0205225|C1280519|C0032225|C0012621|C0449468|C0032225|C0005889|C0013103|C0817096|C0444708|C0871261|C0039798
"Items evaluated were: the number of tender points, Visual Analog Scale (VAS), Fibromyalgia Impact Questionnaire (FIQ), the Six-Minute Walk Test (6MWT), SF-36 physical and mental health scores, and the Beck Depression Inventory (BDI).","Items evaluated were: tender points, Visual Analog Scale (VAS), Fibromyalgia Impact Questionnaire (FIQ), Six-Minute Walk Test (6MWT), SF-36 physical mental health scores, Beck Depression Inventory (BDI).",C1551338|C0220825|G0000000|C0234234|C1552961|C0234621|C0243071|C0175659|C0042815|C0016053|C1825598|C0034394|G0000000|C0205452|C0080331|C0022885|G0000000|C0037712|C0031809|C0229992|C0018684|C0449820|G0000000|C0011570|C0021941|C0006448
"Main outcome measures Primary measure: rate of falls over 12 months, collected by self report.","Main outcome measures Primary measure: rate falls 12 months, collected report.",C0205225|C1274040|C0079809|C0205225|C0079809|C0871208|C0000921|C0450371|C0439231|C1516695|C0684224
Australasian and Canadian studies were combined in a prospective meta-analysis for the primary outcome of survival and also time to ultimate disease progression (time from randomisation until first evidence of progression after chemotherapy).,Australasian Canadian studies combined prospective meta-analysis primary outcome survival time ultimate disease progression (time randomisation evidence progression chemotherapy).,G0000000|C0238884|C0947630|C0205195|C0023981|C0282458|C0205225|C1274040|C0038952|C0040223|G0000000|C0012634|C0242656|C0040223|C0034656|C3887511|C0242656|C0013216
"Secondary outcome measures included the Fibromyalgia Impact Questionnaire (FIQ), Pittsburg Sleep Quality Index (PSQI), and SF-36 Health Survey.","Secondary outcome measures included Fibromyalgia Impact Questionnaire (FIQ), Pittsburg Sleep Quality Index (PSQI), SF-36 Health Survey.",C0027627|C1274040|C0079809|C0332257|C0016053|C1825598|C0034394|G0000000|G0000000|C0037313|C0332306|C0918012|C3697468|C0037712|C0018684|C0038951
All smoking abstinence outcomes were bioverified by either a) expired air CO concentration ≤ 6 ppm and/or b) salivary cotinine < 10 ng/mL.,All smoking abstinence outcomes bioverified a) expired air CO concentration ≤ 6 ppm and/or b) salivary cotinine < 10 ng/mL.,G0000000|C0037369|C3843422|C1274040|G0000000|G0000000|C0011065|C0001861|C3245499|C0004268|G0000000|G0000000|C0439187|G0000000|G0000000|C0442040|C0010194|G0000000|C0450371|C0439275
The percentage of time engaged in moderate to high intensity physical activity was greater on days that participants reported exercising compared to days when they did not exercise.,The percentage time engaged moderate intensity physical activity days participants reported exercising compared days exercise.,G0000000|C0439165|C0040223|C0425152|C0205081|C0522510|C0031809|C0205177|C0439228|C0679646|C0684224|C0015259|C1707455|C0439228|C0015259
"Secondary end-points included dyspnoea, health status, rescue medication use and safety.","Secondary end-points included dyspnoea, health status, rescue medication safety.",C0027627|C2349179|C0332257|C0013404|C0018684|C0449438|G0000000|C0013227|C0036043
"For women in the NC group, significant changes in systolic and diastolic BP occurred by week 12.","For women NC group, systolic diastolic BP occurred week 12.",G0000000|C0043210|C0027964|C0441833|C0039155|C0012000|C0037623|C1709305|C0332174|C0450371
Protective efficacy against clinical malaria and malaria infection will be determined by comparing incidence rates of malaria infection and clinical malaria between arms.,Protective efficacy clinical malaria malaria infection determined comparing incidence rates malaria infection clinical malaria arms.,G0000000|C1280519|C0205210|C0024530|C0024530|C0009450|G0000000|C1707455|C0021149|C0871208|C0024530|C0009450|C0205210|C0024530|C0206655
Falls also occur often among older people in hospital.,Falls occur people hospital.,C0000921|C1709305|C0027361|C0019994
Bladder cancer cases were enrolled from the University of Texas MD Anderson Cancer Center and Baylor College of Medicine.,Bladder cancer enrolled University Texas MD Anderson Cancer Center Baylor College Medicine.,C0005682|C0006826|G0000000|C0041740|C0039711|G0000000|G0000000|C0006826|C0205099|G0000000|C0557806|C0013227
"The serum levels of follicle stimulating hormone (FSH), LH and E2 were detected before and after the treatment.","The serum levels follicle stimulating hormone (FSH), LH E2 detected treatment.",G0000000|C0229671|C0441889|C0018120|C1948023|C0019932|G0000000|C0023879|C1704625|C0442726|C0039798
"There were no significant differences among the three treatment groups [F(2,49) = 0.22, p < 0.80], and all were similar to the prevalence of shoulder pain in other cohorts.24 Group means for the Geriatric Depression Scale were within the normal range for all three groups at all three time points.","There differences treatment [F(2,49) = 0.22, < 0.80], prevalence shoulder pain cohorts.24 Group Geriatric Depression Scale normal range time points.",G0000000|C1705241|C0039798|C0016327|G0000000|C0450371|G0000000|C0450371|C0033105|C0037004|C0030193|C0599755|C0441833|C1704440|C0011570|C0175659|C0205307|C1514721|C0040223|C1552961
Primary outcomes were inspiratory capacity prior to exercise and exercise endurance time during constant work-rate cycle ergometry to symptom limitation at 75% of peak incremental work rate after 6 weeks (2 h post-dose).,Primary outcomes inspiratory capacity prior exercise exercise endurance time constant work-rate cycle ergometry symptom limitation 75% peak incremental rate 6 weeks (2 h post-dose).,C0205225|C1274040|C0004048|C1516240|C0332152|C0015259|C0015259|C0518031|C0040223|C1547014|C0043227|C1511572|C0085143|C1457887|C0449295|C0450371|C0444505|C1705117|C0871208|G0000000|G0000000|C0439568
"Time spent in sedentary, light, and moderate to vigorous physical activity before and after 4 months of intervention and providing useable accelerometry data (n=49) Notes: Sedentary activity ≤100 cpm, light physical activity =100–1,952 cpm, moderate to vigorous physical activity ≥1,952 cpm.","Time spent sedentary, light, moderate vigorous physical activity 4 months intervention providing useable accelerometry data (n=49) Notes: Sedentary activity ≤100 cpm, light physical activity =100–1,952 cpm, moderate vigorous physical activity ≥1,952 cpm.",C0040223|C0680968|C0205254|C0023693|C0205081|G0000000|C0031809|C0205177|G0000000|C0439231|C0886296|C1999230|G0000000|C0441677|C1511726|C0369718|C1317574|C0205254|C0205177|G0000000|G0000000|C0023693|C0031809|C0205177|G0000000|G0000000|C0205081|G0000000|C0031809|C0205177|G0000000|G0000000
"Secondary outcomes included the concordance of our pragmatic definition of septic shock with previous definitions, rate of protocol adherence, frequency of, and reasons for, open-label steroid use, incidence of adverse events and determination of baseline estimates of clinically important outcomes such as time to discontinuation of inotropes, length of mechanical ventilation and PICU length of stay.","Secondary outcomes included concordance pragmatic definition septic shock previous definitions, rate protocol adherence, frequency of, reasons for, open-label steroid use, incidence adverse events determination baseline estimates clinically outcomes time discontinuation inotropes, length mechanical ventilation PICU length stay.",C0027627|C1274040|C0332257|C0680240|C0871858|C1550452|C0333534|C0036974|C0205156|C1550452|C0871208|C0442711|C1510802|C0376249|G0000000|C0392360|G0000000|C1709323|C0038317|C0042153|C0021149|G0000000|C0441471|C1148554|C0168634|C0750572|G0000000|C1274040|C0040223|C0457454|C1258199|C1444754|C0443254|C0035203|C1046445|C1444754|G0000000
"(C) 4th grader BMI change by maternal BMI categories, P = 0.025.","(C) 4th grader BMI change maternal BMI categories, P = 0.025.",G0000000|G0000000|G0000000|G0000000|C0392747|C2347083|G0000000|C0683312|C0369773|G0000000|C1442061
"Participants had to be experiencing arthralgias for at least two months that were at least mild in severity (i.e., a score of at least 3 out of 10 on the worst pain item of the Brief Pain Inventory (BPI)) [6].","Participants experiencing arthralgias months mild severity (i.e., score 3 10 worst pain item Brief Pain Inventory (BPI)) [6].",C0679646|C0237607|C0003862|C0439231|C2945599|C0439793|C0683454|C0449820|G0000000|C0450371|C1522166|C0030193|C1551338|C1282927|C0030193|C0021941|C1443145|G0000000
Measurements were taken after the child removed outer layers of clothing and shoes.,Measurements child removed outer layers clothing shoes.,C0242485|C0008059|C0849355|C0205101|C0934502|C0009072|C0036988
"After 3, 6 and 12 months of drug therapy, the mean GFR of the CsA group was significantly lower than the baseline value (p = 0.048, 0.041, 0.013, respectively); this is in contrast to the MMF group, where no significant changes from baseline were found (Fig.","After 3, 6 12 months drug therapy, GFR CsA lower baseline (p = 0.048, 0.041, 0.013, respectively); contrast MMF group, baseline (Fig.",G0000000|G0000000|G0000000|C0450371|C0439231|C0013227|C0039798|C0017654|G0000000|C0441994|C0168634|G0000000|C1442061|C1442061|G0000000|C0009924|C0083765|C0441833|C0168634|C0349966
2.,2.,G0000000
“Failure” was defined as either persistent fever or the development of any complication after at least 48 h of treatment.,“Failure” defined persistent fever development complication 48 treatment.,G0000000|C1704788|C0205322|C0015967|C0243107|C0009566|C0450371|C0039798
"Outcome measures of the study were: 1) mortality, HIV-1 RNA viral load (VL) per ml and increase in CD4 cell count/µl which were assessed after two years of starting ART.","Outcome measures study were: 1) mortality, HIV-1 RNA viral load (VL) increase CD4 cell count/µl assessed starting ART.",C1274040|C0079809|C0557651|G0000000|G0000000|C0026565|C0019682|C0035668|C0521026|C1550025|C0228339|C0442805|C0285590|C0007634|G0000000|C1516048|C0439659|C0003826
"The baseline assessment protocol entails a detailed multi-dimensional health assessment by means of: a) Physical Function, Strength and Balance: Physical autonomy will be measured using a physical and instrumental ADL scale [31].","The baseline assessment protocol entails detailed multi-dimensional health assessment of: a) Physical Function, Strength Balance: Physical autonomy measured physical instrumental ADL scale [31].",G0000000|C0168634|C1261322|C0442711|G0000000|C1522508|C0439064|C0018684|C1261322|G0000000|G0000000|C0031809|C0031843|C0237897|C0014653|C0031809|C0085862|C0444706|C0031809|G0000000|C0001288|C0175659|C0450371
"The aim of the proposed study is to examine the efficacy of a resilience intervention in decreasing the tobacco, alcohol and illicit drug use of adolescents.","The aim proposed study examine efficacy resilience intervention decreasing tobacco, alcohol illicit drug adolescents.",G0000000|C1947946|C1553874|C0557651|G0000000|C1280519|G0000000|C0886296|C0442797|C0040329|C0001962|C0332266|C0013227|C0205653
"The assessed baseline parameters were: (1) TBUT; (2) tear quantification, (Schirmer I test);3,4 (3) Ocular Surface Disease Index© (OSDI) (American Optometric Association, St Louis, MO, USA); (4) MG expression and secretion; (5) lid margin inflammation evaluation; (6) interpalpebral and corneal dye staining; and (7) fluorescein stain of the cornea.","The assessed baseline parameters were: (1) TBUT; (2) tear quantification, (Schirmer I test);3,4 (3) Ocular Surface Disease Index© (OSDI) (American Optometric Association, St Louis, MO, USA); (4) MG expression secretion; (5) lid margin inflammation evaluation; (6) interpalpebral corneal dye staining; (7) fluorescein stain cornea.",G0000000|C1516048|C0168634|C0449381|G0000000|G0000000|G0000000|G0000000|C0039409|C1709793|C1875738|C0021966|C0022885|G0000000|C0015392|C0205148|C0012634|G0000000|C3896641|C0596070|C0029147|C0004083|C0036056|G0000000|C0026544|C0041703|G0000000|C0026410|C0185117|C0036536|G0000000|G0000000|C0205284|C0021368|C0220825|G0000000|G0000000|C0010031|C0013343|C0487602|G0000000|C0060520|C0038128|C0010031
"The hygiene intervention's primary messages emphasized handwashing with soap at critical times defined as after fecal contact (e.g., after defecation and after cleaning a child who has defecated) and before handling food (e.g., before preparing food, eating, or feeding a child).","The hygiene intervention's primary messages emphasized handwashing soap critical times defined fecal contact (e.g., defecation cleaning child defecated) handling food (e.g., preparing food, eating, feeding child).",G0000000|C0020405|C0886296|C0205225|C0470166|G0000000|C0018581|C0037392|C1511545|C0040223|C1704788|C0015733|C0332158|G0000000|C0011135|C1947930|C0008059|G0000000|C0018578|C0016452|G0000000|C1521827|C0016452|C0013470|C0204695|C0008059
"The only measures to show a significant difference were Wolf Grip strength at midpoint, Motor Activity Log Amount of Use at final and Motor Activity Log number of activities attempted at final with a greater improvement from baseline in the intervention group.","The measures difference Wolf Grip strength midpoint, Motor Activity Log Amount Use final Motor Activity Log activities attempted final improvement baseline intervention group.",G0000000|C0079809|C1705241|C0325001|C0021400|C0237897|G0000000|C1513492|C0205177|C1708728|C1265611|C0042153|C0205088|C1513492|C0205177|C1708728|C0441655|C1516084|C0205088|C2986411|C0168634|C0886296|C0441833
In probiotic supplemented children there was a lower rate of nausea/vomiting (P=0.02) and diarrhea (P=0.039) during treatment.,In probiotic supplemented children lower rate nausea/vomiting (P=0.02) diarrhea (P=0.039) treatment.,G0000000|C0525033|C0242295|C0008059|C0441994|C0871208|C0027498|C0369773|C0011991|C0369773|C0039798
We investigated and compared the effects of fermented kefir drink on the changes of feces Lactobacillus flora and L. kefiri of patients with CD and UC and the effects of their biochemical parameters and symptoms.,We investigated compared effects fermented kefir drink feces Lactobacillus flora L. kefiri patients CD UC effects biochemical parameters symptoms.,G0000000|C1292732|C1707455|C1280500|G0000000|C0524649|C0452428|C0015733|C0022938|G0000000|C0439394|G0000000|C0030705|C0007928|G0000000|C1280500|C0205474|C0449381|C0683368
", apoA-I; ▩, apoB; ■, HDL cholesterol; ▧, HDL particle concentration; □, LDL cholesterol; ▨, LDL particle concentration; ▤, non–HDL cholesterol; , triglycerides; , VLDL particle concentration.",", apoA-I; ▩, apoB; ■, HDL cholesterol; ▧, HDL particle concentration; □, LDL cholesterol; ▨, LDL particle concentration; ▤, non–HDL cholesterol; , triglycerides; , VLDL particle concentration.",G0000000|C0085201|G0000000|C0003593|G0000000|C3715113|C0008377|G0000000|C3715113|C0597177|C0004268|G0000000|G0000000|C0008377|G0000000|G0000000|C0597177|C0004268|G0000000|G0000000|C0008377|G0000000|C0041004|G0000000|C0523560|C0597177|C0004268
"The primary endpoint is a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina.","The primary endpoint composite cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, unstable angina.",G0000000|C0205225|C2349179|C0205199|C0007226|C0011065|G0000000|C0027061|C0021308|G0000000|C0038454|C0018787|C0581603|C0443343|C0002962
Study flow diagram of the GLUCOLD study presenting the bronchial biopsies used in this study at baseline and after 30 months treatment with inhaled fluticasone.,Study flow diagram GLUCOLD study bronchial biopsies study baseline 30 months treatment inhaled fluticasone.,C0557651|C0806140|C0681494|G0000000|C0557651|C0205039|C0005558|C0557651|C0168634|C0450371|C0439231|C0039798|C0004048|C0082607
"Abbreviations: MRI, magnetic resonance imaging; NRS, numerical rating scale; ODI, Oswestry disability index; PGIC, patient global impression of change; ROM, range of motion; SLR, straight leg raising Primary outcome refers to the intensity of low back pain, and it will be evaluated using the NRS.","Abbreviations: MRI, magnetic resonance imaging; NRS, numerical rating scale; ODI, Oswestry disability index; PGIC, patient global impression change; ROM, range motion; SLR, straight leg raising Primary outcome refers intensity low pain, evaluated NRS.",C0000723|C0024485|C0024488|C0231881|C0011923|C2240043|C0237753|C0871208|C0175659|G0000000|G0000000|C0231170|C0918012|G0000000|C0030705|C0205246|C0596764|C0392747|C4048784|C1514721|C0026597|G0000000|C0445291|C0023216|G0000000|C0205225|C1274040|C0205543|C0522510|C0205251|C0030193|C0220825|C2240043
"The length of hospital, but not the length of ICU stay, was significantly longer in the HVT group compared with the LVT group when compared without LVT + HC group (Figure (Figure3).3).","The length hospital, length ICU stay, HVT compared LVT compared LVT + HC (Figure (Figure3).3).",G0000000|C1444754|C0019994|C1444754|C0021708|G0000000|C0309234|C1707455|G0000000|C1707455|G0000000|G0000000|G0000000
There were minimal central apnoeas or SWS (slow-wave sleep) in either condition (<1 % of total sleep time).,There minimal central apnoeas SWS (slow-wave sleep) condition (<1 % total sleep time).,G0000000|C0547040|C0205099|C0003578|C0038505|C0858603|C0037313|C0012634|G0000000|G0000000|C0439175|C0037313|C0040223
The water swallow test was used to assess each patient’s swallow function and effect of rehabilitation as follows [13]: patients were asked to drink 30 ml tepid water.,The water swallow test assess patient’s swallow function rehabilitation [13]: patients drink 30 tepid water.,G0000000|C0043047|C0326374|C0022885|C1516048|G0000000|C0326374|C0031843|C0034991|C0450371|C0030705|C0452428|C0450371|G0000000|C0043047
The primary outcome was additional health care for croup within 11 days of randomization assessed by self-report.,The primary outcome additional health care croup 11 days randomization assessed self-report.,G0000000|C0205225|C1274040|C1524062|C0018684|C1947933|C0010380|C0450371|C0439228|C0034656|C1516048|C0681906
"The mean change of ALSFRS‐R score from Visit 5 (baseline, 0 months) to Visit 9 (+4 months) was considered the primary efficacy outcome for functional assessment.","The change ALSFRS‐R score Visit 5 (baseline, 0 months) Visit 9 (+4 months) considered primary efficacy outcome functional assessment.",G0000000|C0392747|G0000000|C0449820|C0545082|G0000000|C0168634|G0000000|C0439231|C0545082|G0000000|G0000000|C0439231|C0750591|C0205225|C1280519|C1274040|C0205245|C1261322
"Assessed using the Multidimensional Fatigue Inventory (MFI-20), a 20-item scale with five domains (general, physical and mental fatigue, reduced activity, and reduced motivation) [22,23].","Assessed Multidimensional Fatigue Inventory (MFI-20), 20-item scale domains (general, physical mental fatigue, reduced activity, reduced motivation) [22,23].",C1516048|C2347299|C0015672|C0021941|C1881923|C0450371|C0175659|C1880389|C0205246|C0031809|C0229992|C0015672|C0392756|C0205177|C0392756|C0026605|C0450371
"Nine months after the initial urinary cotinine tests, measurements were repeated in both groups.","Nine months initial urinary cotinine tests, measurements repeated groups.",C0205455|C0439231|C0205265|C0042027|C0010194|C0022885|C0242485|C0205341|C0441833
"However, surgically placed drains are not without risk: they have been associated with increased rates of intraabdominal and wound infection, increased abdominal pain, decreased pulmonary function, and prolonged hospital stay.","However, surgically drains risk: increased rates intraabdominal wound infection, increased abdominal pain, decreased pulmonary function, prolonged hospital stay.",G0000000|C0543467|C0013103|C0035647|C0205217|C0871208|C0230168|C0043250|C0009450|C0205217|C0000726|C0030193|C0205216|C0024109|C0031843|C0439590|C0019994|G0000000
Restricted randomisation was used to balance HIV and Chlamydia trachomatis prevalence between the two trial arms [21].,Restricted randomisation balance HIV Chlamydia trachomatis prevalence trial arms [21].,C0443288|C0034656|C0014653|C0019682|C0008148|C2893398|C0033105|C0008976|C0206655|C0450371
"At this visit, vaccine attitudes and knowledge were again assessed, and the second vaccine was administered.","At visit, vaccine attitudes knowledge assessed, vaccine administered.",G0000000|C0545082|C0042210|C0004271|C0376554|C1516048|C0042210|C1521801
"Similar improvements were observed in the resistance-training group: mean increases of 4.3 cm in stride length (P = 0.01), 10.0 cm per second in walking velocity (P = 0.001), 14.6 Nm in knee extension (P<0.001), 8.9 Nm in knee flexion (P = 0.001), and 2.2 cm in functional reach (P = 0.007), as well as decreases of 1.00 second on the up-and-go test and 5.07 points in the UPDRS III score (P<0.001 for both comparisons).","Similar improvements observed resistance-training group: increases 4.3 cm stride length (P = 0.01), 10.0 cm walking velocity (P = 0.001), 14.6 Nm knee extension (P<0.001), 8.9 Nm knee flexion (P = 0.001), 2.2 cm functional reach (P = 0.007), decreases 1.00 up-and-go test 5.07 UPDRS III score (P<0.001 comparisons).",C2348205|C2986411|C1441672|C0814409|C0441833|C0205217|G0000000|G0000000|G0000000|C1444754|C0369773|G0000000|C0450371|C0450371|G0000000|C0080331|C0439830|C0369773|G0000000|C1442061|C0450371|C0312860|C0022742|C0231448|C0369773|G0000000|C0312860|C0022742|C0231452|C0369773|G0000000|C1442061|G0000000|G0000000|C0205245|C2584321|C0369773|G0000000|C1442061|C0442797|C0450371|C1822658|C0022885|C0450371|C3639721|C0439070|C0449820|C0369773|C1707455
These data will be collected prior to receiving chemotherapy.,These data collected prior receiving chemotherapy.,G0000000|C1511726|C1516695|C0332152|C1514756|C0013216
The primary end point was time to first asthma treatment failure during the 28-week study period.,The primary time asthma treatment failure 28-week study period.,G0000000|C0205225|C0040223|C0004096|C0039798|C0231174|C0450371|C0557651|C0439531
"Primary outcomes were: lumbopelvic pain, urinary incontinence (UI), anxiety, and physical activity performed at home.","Primary outcomes were: lumbopelvic pain, urinary incontinence (UI), anxiety, physical activity performed home.",C0205225|C1274040|G0000000|G0000000|C0030193|C0042027|C0021167|C1421312|C0003467|C0031809|C0205177|C0884358|C0442519
"A prospective, consecutive, double-blind, randomized controlled clinical trial is proposed to investigate the effect of dialysis on sleep, pulmonary function, respiratory mechanics, upper airway collapsibility, ANS, depression, anxiety, stress and quality of life in end-stage renal disease patients, as summarised in Figure 1.","A prospective, consecutive, double-blind, randomized controlled clinical trial proposed investigate dialysis sleep, pulmonary function, respiratory mechanics, upper airway collapsibility, ANS, depression, anxiety, stress quality life end-stage renal disease patients, summarised Figure 1.",G0000000|C0023981|C1707491|C0013072|C0034656|C2587213|C0205210|C0008976|C1553874|C1292732|C0011945|C0037313|C0024109|C0031843|C0521346|C0376706|C1282910|C0178987|G0000000|C0004388|C0011570|C0003467|C0038435|C0332306|C0376558|C0205088|C0022646|C0012634|C0030705|G0000000|G0000000|G0000000
Over 40% of children did not recover after RUTF use for 16 weeks.,Over 40% children recover RUTF 16 weeks.,C0205136|C0450371|C0008059|C0521108|G0000000|G0000000
Trained and certified CHILE data collection personnel observed foodservice staff during all meals and snacks prepared on each data collection day using the CHILE Food Service Data Collection protocol and forms.,Trained certified CHILE data collection personnel observed foodservice staff meals snacks prepared data collection day CHILE Food Service Data Collection protocol forms.,C0336809|C0007836|C0008107|C1511726|C1516698|C0024752|C1441672|C0016490|C0851286|C1998602|C0453863|C4082130|C1511726|C1516698|C0332173|C0008107|C0016452|C0557854|C1511726|C1516698|C0442711|C0348078
"By 12 months after starting therapy, only 37% of all enrolled subjects were free from treatment failure on their first medication.","By 12 months starting therapy, 37% enrolled subjects free treatment failure medication.",G0000000|C0450371|C0439231|C0439659|C0039798|C0450371|G0000000|C0681850|C0332296|C0039798|C0231174|C0013227
An electronic digital balance (Sartorious Corp.) was used to obtain naked infant weight.,An electronic digital balance (Sartorious Corp.) naked infant weight.,G0000000|C0013850|C0442015|C0014653|G0000000|C0683758|C0424470|C0021270|C0005910
It is estimated as the difference between the experimental and the control group in the change from baseline to the weighted mean of the three- and eight-week follow-up measured as area under the curve (AUC) for the EORTC QLQ-C30 scale score that constitutes the primary need.,It estimated difference experimental control change baseline weighted three- eight-week follow-up measured curve (AUC) EORTC QLQ-C30 scale score constitutes primary need.,G0000000|C0750572|C1705241|C1517586|C0243148|C0392747|C0168634|C0005910|C0205449|C0205454|C0589120|C0444706|C0205134|C0376690|C1516985|G0000000|C0175659|C0449820|G0000000|C0205225|C0027552
"Primary outcome measures included laboratory safety data, adverse event data and efficacy as measured by change from baseline Modified Hammersmith Functional Motor Scale (MHFMS) scores following six months of treatment versus placebo.","Primary outcome measures included laboratory safety data, adverse event data efficacy measured change baseline Modified Hammersmith Functional Motor Scale (MHFMS) scores months treatment versus placebo.",C0205225|C1274040|C0079809|C0332257|C0022877|C0036043|C1511726|G0000000|C0441471|C1511726|C1280519|C0444706|C0392747|C0168634|C0392747|C0335933|C0205245|C1513492|C0175659|G0000000|C0449820|C0439231|C0039798|G0000000|C0032042
"FPP, falls prevention programme.","FPP, falls prevention programme.",G0000000|C0000921|C0199176|C1709697
"Lung function measured at time 0 (T0), after 4 (T4) and 16 weeks (T16) in the 12 patients who inhaled hypertonic saline Data were expressed as mean values ± SD Lung function measured at time zero (T0), after 4 (T4) and 16 weeks (T16) in the 12 children who inhaled normal saline Data were expressed as mean values ± SD After a 16-weeks treatment with HS, as compared to baseline values, an improvement of FVC (p = 0.02) and %predicted FVC (p = 0.02) was found.","Lung function measured time 0 (T0), 4 (T4) 16 weeks (T16) 12 patients inhaled hypertonic saline Data expressed values ± SD Lung function measured time (T0), 4 (T4) 16 weeks (T16) 12 children inhaled normal saline Data expressed values ± SD After 16-weeks treatment HS, compared baseline values, improvement FVC (p = 0.02) %predicted FVC (p = 0.02) found.",C0024109|C0031843|C0444706|C0040223|G0000000|C0041403|G0000000|C0041403|C0450371|C0439230|G0000000|C0450371|C0030705|C0004048|G0000000|C0036082|C1511726|G0000000|C0042295|G0000000|C2699239|C0024109|C0031843|C0444706|C0040223|C0041403|G0000000|C0041403|C0450371|C0439230|G0000000|C0450371|C0008059|C0004048|C0205307|C0036082|C1511726|G0000000|C0042295|G0000000|C2699239|G0000000|C0450371|C0039798|G0000000|C1707455|C0168634|C0042295|C2986411|C3714541|C0369773|G0000000|C0450371|C0681842|C3714541|C0369773|G0000000|C0450371|C0150312
"After 8 weeks of treatment, both groups benefited significantly with respect to VAS, functional status and walking distance (p < 0.001).","After 8 weeks treatment, benefited respect VAS, functional status walking distance (p < 0.001).",G0000000|G0000000|C0439230|C0039798|C0814225|C0679133|C0042815|C0205245|C0449438|C0080331|C0012751|C0369773|G0000000|C1442061
Exercise tolerance was measured using the 6-minute walk test (6MWT) and cycle ergometry.,Exercise tolerance measured 6-minute walk test (6MWT) cycle ergometry.,C0015259|C0013220|C0444706|C0439232|C0080331|C0022885|G0000000|C1511572|C0085143
The a path tested whether the experimental coping intervention had an effect on the change in the mediating variable (avoidant coping).,The path tested experimental coping intervention change mediating variable (avoidant coping).,G0000000|C0919386|C0392366|C1517586|C0009967|C0886296|C0392747|C0086597|C0439828|C0870186|C0009967
Continuous smoking abstinence was determined at each visit by self-report of no smoking since the previous visit and confirmed by expired-air CO of less than 8 ppm.,Continuous smoking abstinence determined visit self-report smoking previous visit confirmed expired-air CO 8 ppm.,C0549178|C0037369|C3843422|G0000000|C0545082|C0681906|C0037369|C0205156|C0545082|C0521093|C0011065|C3245499|G0000000|C0439187
Table 3 reports continuous abstinence rates (the primary outcome).,Table 3 reports continuous abstinence rates (the primary outcome).,C0039224|G0000000|C0684224|C0549178|C3843422|C0871208|G0000000|C0205225|C1274040
"(1971) To examine the source of nutrients and the variety of food items in the diet, food consumption is sub-divided into the following six groups: cereals, pulses, dairy products, eggs, fish and meat, fruits and vegetables, edible oils and other food items.","(1971) To examine source nutrients variety food items diet, food consumption sub-divided groups: cereals, pulses, dairy products, eggs, fish meat, fruits vegetables, edible oils food items.",G0000000|C0040363|G0000000|C0449416|C0678695|C1883525|C0016452|C1551338|C0012155|C0016452|C0009830|C0542339|C0441833|C0007757|C0034107|C3687582|C1514468|C0013710|C0016163|C0025017|C0016767|C0042440|G0000000|C0028908|C0016452|C1551338
"Discrepancies were classified as: re-start of discontinued medication, discontinuation of prescribed discharge medication, use of higher or lower dose, more or less frequent use than prescribed and incorrect time of taking medication.","Discrepancies classified as: re-start discontinued medication, discontinuation prescribed discharge medication, lower dose, frequent prescribed incorrect time medication.",C1290905|C0008902|G0000000|C0556581|C1444662|C0013227|C0457454|C0278329|C0012621|C0013227|C0441994|C0178602|C0332183|C0278329|C3827420|C0040223|C0013227
Four women died by 6 months post partum.,Four women died 6 months post partum.,C0205450|C0043210|C0011065|G0000000|C0439231|C0687676|C1955347
"on Day 15), spironolactone was increased to 50 mg/day if the patient's serum K+ was >3.5 to ≤5.1 mEq/L; the dose remained at 25 mg/day if the serum K+ level was >5.1 to ≤5.5 mEq/L; and patients were discontinued from the study if their serum K+ was ≤3.5 or >5.5 mEq/L.","Day 15), spironolactone increased 50 mg/day patient's serum K+ >3.5 ≤5.1 mEq/L; dose remained 25 mg/day serum K+ level >5.1 ≤5.5 mEq/L; patients discontinued study serum K+ ≤3.5 >5.5 mEq/L.",C0332173|C0450371|C0037982|C0205217|C0450371|C0439422|C0030705|C0229671|C0597277|G0000000|G0000000|C0439375|C0178602|G0000000|C0450371|C0439422|C0229671|C0597277|C0441889|G0000000|G0000000|C0439375|C0030705|C1444662|C0557651|C0229671|C0597277|G0000000|G0000000|C0439375
"The following outcomes will be investigated (Table 2): Smoking habit cessation, confirmed by a urinary cotinine test.","The outcomes investigated (Table 2): Smoking habit cessation, confirmed urinary cotinine test.",G0000000|C1274040|C1292732|C0039224|G0000000|C0037369|C0018464|C1880019|C0521093|C0042027|C0010194|C0022885
"Using data from the baseline and post‐supplementation surveys as well as the biweekly monitoring visits, the longitudinal prevalence of reported cases of diarrhea and fever was computed based on intention‐to‐treat principle and following similar procedures as described by Sharieff et al.","Using data baseline post‐supplementation surveys biweekly monitoring visits, longitudinal prevalence reported diarrhea fever computed based intention‐to‐treat principle procedures Sharieff et al.",C1524063|C1511726|C0168634|G0000000|C0038951|C0585332|C0150369|C0545082|C0205127|C0033105|C0684224|C0011991|C0015967|C1441526|C1527178|G0000000|G0000000|C0025664|G0000000|G0000000
The scale is scored as 0 cm being ‘no discomfort’ and 10 cm being ‘the worst imaginable’.,The scale scored 0 cm ‘no discomfort’ 10 cm ‘the worst imaginable’.,G0000000|C0175659|C0449820|G0000000|G0000000|G0000000|G0000000|G0000000|C1522166|G0000000
The FPTK was designed specifically to reduce falls.,The FPTK designed reduce falls.,G0000000|G0000000|C1707689|G0000000|C0000921
"Lesion area and degree of pigmentation were assessed at baseline, 2, 4, and 6 months.","Lesion degree pigmentation assessed baseline, 2, 4, 6 months.",C0221198|C0441889|C0031911|C1516048|C0168634|G0000000|G0000000|G0000000|C0439231
Overall physical symptom severity was measured using self- and parent reports of pain on an 8-point Likert scale (0 = no pain to 8 = extreme pain).,Overall physical symptom severity measured self- parent reports pain 8-point Likert scale (0 = pain 8 = extreme pain).,C0282416|C0031809|C1457887|C0439793|C0444706|C0036588|C0030551|C0684224|C0030193|C1552961|G0000000|C0175659|G0000000|G0000000|C0030193|G0000000|G0000000|C0205403|C0030193
"Results from this study suggest that training with a CFR device improves some aspects of HRQoL (eg, vitality and bodily pain) in WR athletes.","Results study training CFR device improves aspects HRQoL (eg, vitality bodily pain) WR athletes.",C1274040|C0557651|C0040607|G0000000|C0025080|C0184511|C1547011|G0000000|C0013715|C0424589|G0000000|C0030193|C1420193|C0238703
"The microflora composition, biochemical indices, inflammatory markers, and activity scores of the two groups were analyzed.","The microflora composition, biochemical indices, inflammatory markers, activity scores analyzed.",G0000000|C2985398|C0486616|C0205474|C4033634|C0333348|C0005516|C0205177|C0449820|C0936012
Mean change in symptom scores at 3 and 12 months.,Mean change symptom scores 3 12 months.,C0444504|C0392747|C1457887|C0449820|G0000000|C0450371|C0439231
"Secondary outcomes included time to recovery from acute respiratory failure, duration of weaning from mechanical ventilation, neurological testing, PICU and hospital lengths of stay, in-hospital mortality, sedation-related adverse events, sedative exposure including measures of wakefulness, pain, and agitation, and occurrence of iatrogenic withdrawal.","Secondary outcomes included time recovery acute respiratory failure, duration weaning mechanical ventilation, neurological testing, PICU hospital lengths stay, in-hospital mortality, sedation-related adverse events, sedative exposure including measures wakefulness, pain, agitation, occurrence iatrogenic withdrawal.",C0027627|C1274040|C0332257|C0040223|C0237820|C0205178|C0521346|C0231174|C0449238|C0043084|C0443254|C0035203|C0205494|C0039593|C1046445|C0019994|C1444754|G0000000|C0019994|C0026565|C0235195|G0000000|C0441471|C0020592|C0274281|C0332257|C0079809|C0043012|C0030193|C0085631|C0243132|C0439669|C2349954
Our primary outcome measure is level of DDKT and LDKT knowledge.,Our primary outcome measure level DDKT LDKT knowledge.,G0000000|C0205225|C1274040|C0079809|C0441889|G0000000|G0000000|C0376554
"HPV, human papillomavirus.","HPV, human papillomavirus.",C0021344|C0086418|C0030358
The primary study endpoint was global symptom relief as assessed by the patient at the end of the 12-wk treatment.,The primary study endpoint global symptom relief assessed patient 12-wk treatment.,G0000000|C0205225|C0557651|C2349179|C0205246|C1457887|C0564405|C1516048|C0030705|C0450371|C0039798
"Falls will be recorded by the use of a ""falls diary"".","Falls recorded ""falls diary"".",C0000921|C0034869|C0000921|C0376660
"Secondary end points were tolerability, possible side effects of the study medication and impact on c-reactive protein.","Secondary tolerability, effects study medication impact c-reactive protein.",C0027627|C3274448|C1280500|C0557651|C0013227|C1825598|C0205332|C0033684
"Neither therapy had a significant effect on the primary composite outcome of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis.","Neither therapy primary composite outcome death, cardiac tamponade requiring pericardiocentesis, constrictive pericarditis.",G0000000|C0039798|C0205225|C0205199|C1274040|C0011065|C0018787|C0332459|G0000000|C0191234|C0009813|C0031046
Follow-up home visits were performed at 6 and 12 months.,Follow-up visits performed 6 12 months.,C0589120|C0545082|C0884358|G0000000|C0450371|C0439231
"Quality of life was determined using PedsQL™4.0 questionnaire at the beginning, then three and six months after completing the treatment period.","Quality life determined PedsQL™4.0 questionnaire beginning, months completing treatment period.",C0332306|C0376558|G0000000|G0000000|C0034394|C0439659|C0439231|C0205197|C0039798|C0439531
Drop-off in uptake of HPV vaccinations over time for each of the trial groups.,Drop-off uptake HPV vaccinations time trial groups.,C1321095|C0243144|C0021344|C0042196|C0040223|C0008976|C0441833
The TLFB measured youths’ substance consumption.,The TLFB measured youths’ substance consumption.,G0000000|C0814210|C0444706|G0000000|C0439861|C0009830
Chi-square tests were used to examine group differences in biochemically confirmed 7-day point prevalence abstinence rates at each time point.,Chi-square tests examine differences biochemically confirmed 7-day prevalence abstinence rates time point.,C1552646|C0022885|G0000000|C1705241|G0000000|C0521093|C0332173|C0033105|C3843422|C0871208|C0040223|C1552961
"At one year, the measures collected at baseline were repeated and included demographics, one-year questionnaire, Stern predictive equation variables, weight, laboratory measures, and 24 HR.","At year, measures collected baseline repeated included demographics, one-year questionnaire, Stern predictive equation variables, weight, laboratory measures, 24 HR.",G0000000|C0439234|C0079809|C1516695|C0168634|C0205341|C0332257|C0011298|C4082117|C0034394|G0000000|C0681890|C0552449|C0439828|C0005910|C0022877|C0079809|C0450371|G0000000
"Height, weight and body composition (total body water) were measured using the Fresenius Medical Care D GmbH Body Composition Monitor; blood samples were obtained for glycosylated haemoglobin (HbA1c).","Height, weight body composition (total body water) measured Fresenius Medical Care D GmbH Body Composition Monitor; blood samples glycosylated haemoglobin (HbA1c).",C0489786|C0005910|C0242821|C0486616|C0439175|C0242821|C0043047|C0444706|G0000000|C0199168|C1947933|C0073187|G0000000|C0242821|C0486616|C0030695|C0005767|C0370003|G0000000|C0019046|G0000000
Two electrodes were placed on the region with pain.,Two electrodes region pain.,C0205448|C0013812|C0017446|C0030193
m/s moderate/severe Facial lesions were taken into consideration.,m/s moderate/severe Facial lesions consideration.,C0439493|C0205081|C0015450|C0221198|C0518609
"In the two patients whose lesions completely healed before they further broke down, the time to healing was prolonged by 12 (week 8 to week 20) weeks and 27 (week 12 to week 39) weeks from the time of the initial healing.","In patients lesions completely healed broke down, time healing prolonged 12 (week 8 week 20) weeks 27 (week 12 week 39) weeks time initial healing.",G0000000|C0030705|C0221198|C0205197|C0205249|G0000000|G0000000|C0040223|C0043240|C0439590|C0450371|C0332174|G0000000|C0332174|C0450371|C0439230|C0450371|C0332174|C0450371|C0332174|C0450371|C0439230|C0040223|C0205265|C0043240
There was no relation between the response measured by symptom score or pulmonary function in individual patients.,There relation response measured symptom score pulmonary function individual patients.,G0000000|C0080103|C0871261|C0444706|C1457887|C0449820|C0024109|C0031843|C0027361|C0030705
"Secondary outcomes included change in scores on the Beck Anxiety Inventory (BAI), Green Climacteric Scale (GCS), Psychological Well Being (PGWB) index, and the proportion of patients with ≥ 50% change in baseline HAM-A scores.","Secondary outcomes included change scores Beck Anxiety Inventory (BAI), Green Climacteric Scale (GCS), Psychological Well Being (PGWB) index, proportion patients ≥ 50% change baseline HAM-A scores.",C0027627|C1274040|C0332257|C0392747|C0449820|G0000000|C0003467|C0021941|C0234880|C0332583|C0008943|C0175659|G0000000|C0205486|C0205170|G0000000|G0000000|C0918012|C1709707|C0030705|G0000000|C0450371|C0392747|C0168634|C3541258|C0449820
"Only 1% (2,468) of these were anophelines.","Only 1% (2,468) anophelines.",C0205171|G0000000|C1442061|G0000000
"For the null hypothesis, it was assumed that the true response rate was less than 25%, with an expected response rate of 45%.","For null hypothesis, assumed true response rate 25%, expected response rate 45%.",G0000000|C0456148|C1512571|C3242379|C0205238|C0871261|C0871208|C0450371|C1517001|C0871261|C0871208|C0450371
"Mean baseline and 6-month follow-up values for outcome measures, stratified by number of facility-based classes Abbreviations: CI, confidence interval; FACT-G, Functional Assessment of Cancer Therapy-General; FACIT, Functional Assessment of Chronic Illness Therapy; MET, metabolic equivalent task; QOL, quality of life; SD, standard deviation.","Mean baseline 6-month follow-up values outcome measures, stratified facility-based classes Abbreviations: CI, confidence interval; FACT-G, Functional Assessment Cancer Therapy-General; FACIT, Functional Assessment Chronic Illness Therapy; MET, metabolic equivalent task; QOL, quality life; SD, standard deviation.",C0444504|C0168634|C0332177|C0589120|C0042295|C1274040|C0079809|C0205363|C1547538|C0456387|C0000723|C0008107|C0237529|C1272706|C1707998|C0205245|C1261322|C0006826|C0039798|C3476791|C0205245|C1261322|C0205191|C0221423|C0039798|C0268621|C0311400|C0205163|C3540678|C0518214|C0332306|C0376558|C2699239|C1442989|C0012727
Diagnosis of chronic HCV infection was based on positive HCV RNA levels with liver biopsy (within 1 year of initiation of study) with or without elevated liver enzymes.,Diagnosis chronic HCV infection based positive HCV RNA levels liver biopsy (within 1 initiation study) elevated liver enzymes.,C0011900|C0205191|C0220847|C0009450|C1527178|C0439178|C0220847|C0035668|C0441889|C0023884|C0005558|G0000000|G0000000|C0589507|C0557651|C0205250|C0023884|C0014442
The main outcome variables in this study were the treatment difference in the numbers of CD8+ T lymphocytes and CD68+ macrophages in bronchial biopsies.,The main outcome variables study treatment difference CD8+ T lymphocytes CD68+ macrophages bronchial biopsies.,G0000000|C0205225|C1274040|C0439828|C0557651|C0039798|C1705241|C0285590|C2603360|C0024264|G0000000|C0024432|C0205039|C0005558
"With treatment, the pulse rate declined significantly (p<0.05) in each group at 120 minutes but there was no significant change in the systolic or diastolic blood pressure.","With treatment, pulse rate declined (p<0.05) 120 minutes change systolic diastolic blood pressure.",G0000000|C0039798|C0232117|C0871208|G0000000|C0369773|G0000000|C0392747|C0039155|C0012000|C0005767|C0033095
"Secondary objectives included median progression-free survival (PFS), 12-month PFS (PFS12), and safety.","Secondary objectives included median progression-free survival (PFS), 12-month PFS (PFS12), safety.",C0027627|C0018017|C0332257|C0549183|C0242656|C0038952|C0242792|C0450371|C0242792|G0000000|C0036043
"CONSORT (Consolidated Standards of Reporting Trials) diagram Demographics, clinical characteristics, and outcomes at baseline, and 12 weeks minus baseline Concomitant medications included anticonvulsants, antidepressants, and opioids; Brief Pain Inventory (BPI; Severity range 0-40, Average pain range 0 – 10, Functional Interference range 0-70); Chronic Pain Sleep Inventory (CPSI; range 0-100); Hospital Anxiety and Depression Scale (HADS Anxiety range 0-21, Depression range 0-21; <8 is normal, threshold for moderate is 11).","CONSORT (Consolidated Standards Reporting Trials) diagram Demographics, clinical characteristics, outcomes baseline, 12 weeks minus baseline Concomitant medications included anticonvulsants, antidepressants, opioids; Brief Pain Inventory (BPI; Severity range 0-40, Average pain range 0 – 10, Functional Interference range 0-70); Chronic Pain Sleep Inventory (CPSI; range 0-100); Hospital Anxiety Depression Scale (HADS Anxiety range 0-21, Depression range 0-21; <8 normal, threshold moderate 11).",G0000000|C0702117|C0038137|C0700287|C0008976|C0681494|C0011298|C0205210|C1521970|C1274040|C0168634|C0450371|C0439230|C0332288|C0168634|C0521115|C0013227|C0332257|C0003286|C0003289|C0242402|C1282927|C0030193|C0021941|C1443145|C0439793|C1514721|C0450371|C1510992|C0030193|C1514721|G0000000|G0000000|C0450371|C0205245|C0521102|C1514721|C0450371|C0205191|C0030193|C0037313|C0021941|C0006961|C1514721|C1442061|C0019994|C0003467|C0011570|C0175659|C0048008|C0003467|C1514721|C0450371|C0011570|C1514721|C0450371|G0000000|C0205307|C0449864|C0205081|C0450371
"In order to investigate the differences in contrast sensitivity between the blue-violet light filtering lenses and ordinary lenses under bright and dark conditions, we simulated night-time driving under glare.","In investigate differences contrast sensitivity blue-violet light filtering lenses ordinary lenses bright dark conditions, simulated night-time driving glare.",G0000000|C1292732|C1705241|C0009924|C0020517|C1260957|C0023693|C0180860|C0023317|G0000000|C0023317|C0423899|C0332582|C0012634|C0284447|C0240526|C0004379|C0278215
Flowchart of the study There were no statistical differences between groups regarding consuming of foods containing calcium and Vitamin D during 1 week before intervention (P = 0.204) and sociodemographic characteristics (P > 0.05) except of prepregnancy body mass index (BMI) (P = 0.024) and BMI during pregnancy (P = 0.008) [Table 1].,Flowchart study There statistical differences consuming foods calcium Vitamin D 1 week intervention (P = 0.204) sociodemographic characteristics (P > 0.05) prepregnancy body mass (BMI) (P = 0.024) BMI pregnancy (P = 0.008) [Table 1].,C0016262|C0557651|G0000000|C0038215|C1705241|G0000000|C0016452|C0006675|C0042890|C0073187|G0000000|C0332174|C0886296|C0369773|G0000000|C1442061|G0000000|C1521970|C0369773|G0000000|C0450371|C2709093|C0242821|C0577559|G0000000|C0369773|G0000000|C1442061|G0000000|C0032961|C0369773|G0000000|C1442061|C0039224|G0000000
"Pain-free, headache relief, cumulative pain-free, associated symptoms, use and efficacy of second dose as rescue medication, total pain-free rate, recurrences, sustained response, relapses, sustained pain-free, use and efficacy of second dose to treat a recurrence/relapse were analysed using χ2-test for each of the two attacks separately.","Pain-free, headache relief, cumulative pain-free, symptoms, efficacy dose rescue medication, total pain-free rate, recurrences, sustained response, relapses, sustained pain-free, efficacy dose treat recurrence/relapse analysed χ2-test attacks separately.",C0908489|C0018681|C0564405|C1511559|C0908489|C0683368|C1280519|C0178602|G0000000|C0013227|C0439175|C0908489|C0871208|C0034897|C0443318|C0871261|C0035020|C0443318|C0908489|C1280519|C0178602|C0087111|C0034897|G0000000|G0000000|C1261512|G0000000
"Secondary outcome measures included acquisition of appropriate CKD-related laboratory measures, specialty referrals, and hospitalization rates.","Secondary outcome measures included acquisition CKD-related laboratory measures, specialty referrals, hospitalization rates.",C0027627|C1274040|C0079809|C0332257|C1706701|C1561643|C0022877|C0079809|C0037778|C0034927|C0019993|C0871208
"These estimates of human exposure distribution across indoor and outdoor environments were calculated and presented graphically for both users and non-users of LLINs, so that the proportions of human exposure that occur indoors in the presence (πi,n) and absence (πi) of a protective LLIN could be quantified and visualized.","These estimates human exposure distribution indoor outdoor environments calculated graphically users non-users LLINs, proportions human exposure occur indoors presence (πi,n) absence (πi) protective LLIN quantified visualized.",G0000000|C0750572|C0086418|C0274281|C0520511|G0000000|G0000000|C0014406|C0444686|G0000000|C1706077|C1518422|G0000000|C1709707|C0086418|C0274281|C1709305|G0000000|C0150312|G0000000|C0332197|G0000000|G0000000|G0000000|C1709793|C0234621
Respondents in the combined arms were observed to have cleaner hands and could report to enumerators more of the critical times for handwashing with soap.,Respondents combined arms observed cleaner hands report enumerators critical times handwashing soap.,C0282122|C0205195|C0206655|C1441672|C0402683|C0018563|C0684224|G0000000|C1511545|C0040223|C0018581|C0037392
"Waist and hip circumferences were measured using a spring-loaded tape measure, and body fat percentage was calculated from skinfold measurement at seven body sites according to American College of Sports Medicine standards [25].","Waist hip circumferences measured spring-loaded tape measure, body fat percentage calculated skinfold measurement body sites American College Sports Medicine standards [25].",C0230097|C0019552|C0332520|C0444706|C0241232|C0183828|C0079809|C0242821|C0424612|C0439165|C0444686|C1446851|C0242485|C0242821|C0205145|C0596070|C0557806|C0038039|C0013227|C0038137|C0450371
Residualized gains from Time 1 to Time 2 and Time 1 to Time 3 on this domain (13 items) were included as child communication outcomes.,Residualized gains Time 1 Time 2 Time 1 Time 3 domain (13 items) included child communication outcomes.,G0000000|C1517378|C0040223|G0000000|C0040223|G0000000|C0040223|G0000000|C0040223|G0000000|C1880389|C0450371|C1551338|C0332257|C0008059|C0009452|C1274040
Conclusions: Budesonide/formoterol pMDI (320/9 μg and 160/9 μg) improved pulmonary function and reduced symptoms and exacerbations over 1 year in patients with moderate to very severe COPD.,Conclusions: Budesonide/formoterol pMDI (320/9 μg 160/9 μg) improved pulmonary function reduced symptoms exacerbations 1 patients moderate severe COPD.,C1707478|C1276807|G0000000|C1442061|G0000000|C1442061|G0000000|C0184511|C0024109|C0031843|C0392756|C0683368|G0000000|G0000000|C0030705|C0205081|C0205082|C0024117
"In addition, VEPs, automated perimetry, and OCT including RNFL thickness was performed.","In addition, VEPs, automated perimetry, OCT including RNFL thickness performed.",G0000000|C0332287|G0000000|C0205554|C0031061|C3828732|C0332257|G0000000|C1280412|C0884358
"In our study, decreases in the concentrations of IL-17 and IL-23 in induced sputum and peripheral blood were observed following erythromycin treatment in patients with COPD.","In study, decreases concentrations IL-17 IL-23 induced sputum peripheral blood observed erythromycin treatment patients COPD.",G0000000|C0557651|C0442797|C0086045|C0020898|C0020898|C0205263|C0038056|C0205100|C0005767|C1441672|C0014806|C0039798|C0030705|C0024117
"Secondary endpoints included the proportion of patients extubated at 6 h, indices of lung mechanics and gas exchange (respiratory system compliance, PaCO2-FIO2 ratio), and patient outcomes (prolonged intubation, length of ICU/hospital stay, patient mortality at 28 days).","Secondary endpoints included proportion patients extubated 6 h, indices lung mechanics gas exchange (respiratory system compliance, PaCO2-FIO2 ratio), patient outcomes (prolonged intubation, length ICU/hospital stay, patient mortality 28 days).",C0027627|C2349179|C0332257|C1709707|C0030705|C0553891|G0000000|C0033727|C4033634|C0024109|C0376706|C0017110|C0678640|C0521346|C0449913|C0009563|G0000000|C0456603|C0030705|C1274040|C0439590|C0021925|C1444754|C0021708|G0000000|C0030705|C0026565|C0450371|C0439228
"Outcome data were collected at 6, 12, and 26 weeks.","Outcome data collected 6, 12, 26 weeks.",C1274040|C1511726|C1516695|G0000000|C0450371|C0450371|C0439230
"A prescription error was defined as an error which occurs in the process of prescribing medication, namely dosing errors, dosage form errors, contra-indications, drug–drug interactions and double-medication.","A prescription error defined error occurs process prescribing medication, dosing errors, dosage form errors, contra-indications, drug–drug interactions double-medication.",G0000000|C0033080|C0743559|C1704788|C0743559|C1709305|C1184743|C0278329|C0013227|G0000000|C0743559|C0178602|C0348078|C0743559|C0392360|G0000000|C1704675|C0205173
"The primary outcome measure was occurrence of relapse, which was defined as an increase of two (or more) points on the SCCAI [31] in association with an increase in treatment (either an increase in maintenance medication dose or addition of new therapies for flare) by the participant’s personal physician.","The primary outcome measure occurrence relapse, defined increase (or more) SCCAI [31] association increase treatment (either increase maintenance medication dose addition therapies flare) participant’s personal physician.",G0000000|C0205225|C1274040|C0079809|C0243132|C0035020|C1704788|C0442805|G0000000|C0205172|G0000000|C0450371|C0004083|C0442805|C0039798|C3844638|C0442805|C0024501|C0013227|C0178602|C0332287|C0087111|C1517205|G0000000|C1519021|C0031831
"When the endpoint was a measure of the entire treatment period, the change from baseline was analysed using the same ANCOVA analysis applied for the primary endpoint.","When endpoint measure entire treatment period, change baseline analysed ANCOVA analysis applied primary endpoint.",G0000000|C2349179|C0079809|C0439751|C0039798|C0439531|C0392747|C0168634|G0000000|C0814908|C0002778|C4048755|C0205225|C2349179
"In addition, the results of the measurement of other outcomes, such as sensation, muscle strength, and muscle atrophy, indicated that there were no significant differences between the two groups.","In addition, measurement outcomes, sensation, muscle strength, muscle atrophy, differences groups.",G0000000|C0332287|C0242485|C1274040|C0036658|C0026845|C0237897|C0026845|C0333641|C1705241|C0441833
"The measure contains questions regarding the patient’s perceived change of cognitive function prior to diagnosis and treatment, how their present cognitive function affects their daily life, and how others perceive the patient’s cognitive function yielding four subscales (perceived cognitive impairment, perceived cognitive abilities, comments from others, and impact on QOL).","The measure questions patient’s perceived change cognitive function prior diagnosis treatment, cognitive function daily life, perceive patient’s cognitive function yielding subscales (perceived cognitive impairment, perceived cognitive abilities, comments others, impact QOL).",G0000000|C0079809|C1522634|G0000000|C0030971|C0392747|C1516691|C0031843|C0332152|C0011900|C0039798|C1516691|C0031843|C0332173|C0376558|G0000000|G0000000|C1516691|C0031843|G0000000|G0000000|C0030971|C1516691|C0221099|C0030971|C1516691|C0085732|C0282411|C1955473|C1825598|C0518214
"Foodservice data were analyzed by 2 registered dietitians from UNM General Clinical Research Center and one registered dietitian from UNM Prevention Research Center using the Food Intake Analysis System Millennium 1.0 Version to calculate food group servings and nutrients offered per child based on the Pyramid Servings Database for USDA Survey Codes 1.0.45 The following outcome variables were retained for analysis: total daily vegetable and whole grain servings; grams of discretionary fat, which is fat in a food above the amount that would be found in a lean, low-fat, or fat-free form of the food; and teaspoons of added sugar provided, which are sugars added to foods during processing or preparation, not including naturally occurring sugars.","Foodservice data analyzed 2 registered dietitians UNM General Clinical Research Center registered dietitian UNM Prevention Research Center Food Intake Analysis System Millennium 1.0 Version calculate food servings nutrients offered child based Pyramid Servings Database USDA Survey Codes 1.0.45 The outcome variables retained analysis: total daily vegetable grain servings; grams discretionary fat, fat food amount lean, low-fat, fat-free form food; teaspoons sugar provided, sugars foods processing preparation, including naturally occurring sugars.",C0016490|C1511726|C0936012|G0000000|C1514821|C3536818|G0000000|C0205246|C0205210|C0035168|C0205099|C1514821|C3536818|G0000000|C0199176|C0035168|C0205099|C0016452|C1512806|C0002778|C0449913|G0000000|G0000000|C0333052|C1441506|C0016452|C1519269|C0678695|C1444648|C0008059|C1527178|C0262324|C1519269|C0242356|C0085410|C0038951|C0919279|C0450371|G0000000|C1274040|C0439828|C0333118|C0002778|C0439175|C0332173|C0042440|C0007757|C1519269|C0439208|G0000000|C0424612|C0424612|C0016452|C1265611|G0000000|C0242970|C0424612|C0348078|C0016452|C1533179|C0007004|C1999230|C0242209|C0016452|C1709694|C1521827|C0332257|G0000000|C1709305|C0242209
"Given concerns about patient compliance rather than cure, the proportion of eligible patients who experienced an objective CR, as determined by a normal βhCG sustained over four weekly measurements, was chosen as the primary study end point.","Given concerns patient compliance cure, proportion eligible patients experienced objective CR, determined normal βhCG sustained weekly measurements, chosen primary study point.",C1442162|C2699424|C0030705|C0009563|C1880198|C1709707|C1548635|C0030705|C0237607|C0018017|C0201975|G0000000|C0205307|G0000000|C0443318|C0332174|C0242485|C1707391|C0205225|C0557651|C1552961
All participants will be closely monitored for adverse events and concomitant medication use throughout the study.,All participants closely monitored adverse events concomitant medication study.,G0000000|C0679646|G0000000|C0030695|G0000000|C0441471|C0521115|C0013227|C0557651
"Its secondary objectives are to assess the effects of EPC on patient-reported outcomes (quality of life, depression and anxiety) and the effect of EPC on the number of patients receiving chemotherapy in their last 30 days of life.","Its secondary objectives assess effects EPC patient-reported outcomes (quality life, depression anxiety) EPC patients receiving chemotherapy 30 days life.",G0000000|C0027627|C0018017|C1516048|C1280500|C0169014|C0747307|C1274040|C0332306|C0376558|C0011570|C0003467|C0169014|C0030705|C1514756|C0013216|C0450371|C0439228|C0376558
"Outcome measures after endoscopic release and mini-incision carpal tunnel release BCTQ-S = Boston Carpal Tunnel Questionnaire symptom severity score; BCTQ-F = Boston Carpal Tunnel Questionnaire functional status score; DASH = Disabilities of the Arm, Shoulder and Hand.","Outcome measures endoscopic release mini-incision carpal tunnel release BCTQ-S = Boston Carpal Tunnel Questionnaire symptom severity score; BCTQ-F = Boston Carpal Tunnel Questionnaire functional status score; DASH = Disabilities Arm, Shoulder Hand.",C1274040|C0079809|C0014245|C0030685|C0445542|C0007285|C0337138|C0030685|C0565930|G0000000|C0006037|C0007285|C0337138|C0034394|C1457887|C0439793|C0449820|C0016327|G0000000|C0006037|C0007285|C0337138|C0034394|C0205245|C0449438|C0449820|C2827624|G0000000|C0231170|C0446516|C0037004|C0018563
Pain while crossing legs was reduced by 34.2% in Antarth group and by 16.8% in placebo group after treatment; during squatting it was reduced by 38.1% in Antarth group and 15.6% in placebo group; and while climbing steps it was reduced by 53.5% in Antarth group and 27.8% in placebo group.,Pain crossing legs reduced 34.2% Antarth 16.8% placebo treatment; squatting reduced 38.1% Antarth 15.6% placebo group; climbing steps reduced 53.5% Antarth 27.8% placebo group.,C0030193|G0000000|C1140621|C0392756|C0450371|C1685382|C0450371|C0032042|C0039798|C0241236|C0392756|C0450371|C1685382|C0450371|C0032042|C0441833|C0561942|C1261552|C0392756|C0450371|C1685382|C0450371|C0032042|C0441833
"Secondary end points were overall survival (OS; date of random assignment to date of death or last date known to be alive), ORR (RECIST),23 quality of life (QOL), pulmonary symptom improvement (PSI), and safety.","Secondary survival (OS; random assignment death alive), ORR (RECIST),23 quality life (QOL), pulmonary symptom improvement (PSI), safety.",C0027627|C0038952|C0229090|C0034656|C1516050|C0011065|C0376558|G0000000|C1709926|C0332306|C0376558|C0518214|C0024109|C1457887|C2986411|G0000000|C0036043
Five patients died within 30 days of surgery for screen detected colorectal neoplasia and a further two died without having surgery.,Five patients died 30 days surgery screen detected colorectal neoplasia died surgery.,C0205451|C0030705|C0011065|C0450371|C0439228|C0038894|C0220908|C0442726|C0555952|C0027651|C0011065|C0038894
The primary outcome measure was time to first relapse over a minimum follow-up of 24 months.,The primary outcome measure time relapse minimum follow-up 24 months.,G0000000|C0205225|C1274040|C0079809|C0040223|C0035020|C1524031|C0589120|C0450371|C0439231
The difference in the systemic cytokine response may have implications on the long-term survival.,The difference systemic cytokine response implications long-term survival.,G0000000|C1705241|C0205373|C0079189|C0871261|G0000000|C0443252|C0038952
Their quality of life was assessed with the help of mini asthma quality-of-life questionnaire (AQLQ) at baseline and then after 3rd and 6th month from baseline.,Their quality life assessed mini asthma quality-of-life questionnaire (AQLQ) baseline 3rd 6th month baseline.,G0000000|C0332306|C0376558|C1516048|C0445542|C0004096|C0332306|C0034394|C4055434|C0168634|G0000000|G0000000|C0332177|C0168634
"The outcome variables were admission to an ICU, in-hospital death and length of hospital stay (in days).","The outcome variables admission ICU, in-hospital death length hospital stay (in days).",G0000000|C1274040|C0439828|C0184666|C0021708|C0019994|C0011065|C1444754|C0019994|G0000000|G0000000|C0439228
"Nutrition was measured as servings of fruits and vegetables usually eaten each day in the past 30 days (ranging from 0 to 9 or more servings), based on public health recommendations (USDHHS & U.S. Department of Agriculture [USDA], 2005).","Nutrition measured servings fruits vegetables eaten day 30 days (ranging 0 9 servings), based public health recommendations (USDHHS & U.S. Department Agriculture [USDA], 2005).",C0028707|C0444706|C1519269|C0016767|C0042440|C0013470|C0332173|C0450371|C0439228|C1514721|G0000000|G0000000|C1519269|C1527178|G0000000|C0018684|C0034866|G0000000|G0000000|C0041703|C1704729|C0001829|C0085410|G0000000
"Outcome measures—The main outcome measure was treatment failure due to pneumonia, admission to hospital, or both.","Outcome measures—The main outcome measure treatment failure pneumonia, admission hospital, both.",C1274040|G0000000|C0205225|C1274040|C0079809|C0039798|C0231174|C0032285|C0184666|C0019994|G0000000
"To assess change in FM pain, both the 24-hour recall NRS score and the 7-day recall pain score from the FIQ-R were analyzed.","To assess change FM pain, 24-hour recall NRS score 7-day recall pain score FIQ-R analyzed.",C0040363|C1516048|C0392747|C3540627|C0030193|C0450371|C0034770|C2240043|C0449820|C0332173|C0034770|C0030193|C0449820|C0205090|C0936012
The scores between 8 and 10 are considered borderline or abnormal and scores of zero to seven are considered normal.,The scores 8 10 considered borderline abnormal scores considered normal.,G0000000|C0449820|G0000000|C0450371|C0750591|C0205189|C0205161|C0449820|C0750591|C0205307
"AL, axial length; CCT, central corneal thickness; HCD, horizontal corneal diameter; IOP, intraocular pressure; VA, visual acuity.","AL, axial length; CCT, central corneal thickness; HCD, horizontal corneal diameter; IOP, intraocular pressure; VA, visual acuity.",C0202311|C0205131|C1444754|C4049005|C0205099|C0010031|C1280412|C2000894|C0205126|C0010031|C1301886|C0595921|C3282905|C0033095|C1549054|C0234621|C0750509
Treg trends did not appear to be correlated to a clinical or immunological response.,Treg trends correlated clinical immunological response.,C1267822|C0040833|C1707520|C0205210|C0205470|C0871261
"CVLT - California Verbal Learning Test ; BVMT - Brief Visuospatial Memory Test - Revised; JLO - Judgment of Line Orientation Test; SDMT - Symbol Digit Modalities Test; PASAT - Paced Auditory Serial Addition Test; COWAT - Controlled Oral Word Association Test; DKEFS - Delis-Kaplan Executive Function System; MSNQ - MS Neuropsychological Screening Questionnaire Change score (Baseline to Time 3) means, standard deviation, and statistical significance CVLT - California Verbal Learning Test ; BVMT - Brief Visuospatial Memory Test - Revised; JLO - Judgment of Line Orientation Test; SDMT - Symbol Digit Modalities Test; PASAT - Paced Auditory Serial Addition Test; COWAT - Controlled Oral Word Association Test; DKEFS - Delis-Kaplan Executive Function System; MSNQ - MS Neuropsychological Screening Questionnaire The RM ANOVA analysis revealed that there were significant time effects observed for six of the seven neuropsychological performance tests, as well as the two self-report measures of use of compensatory strategies, and for the MSNQ (the measure of neuropsychological competence with activities of daily living).","CVLT - California Verbal Learning Test ; BVMT - Brief Visuospatial Memory Test - Revised; JLO - Judgment Line Orientation Test; SDMT - Symbol Digit Modalities Test; PASAT - Paced Auditory Serial Addition Test; COWAT - Controlled Oral Word Association Test; DKEFS - Delis-Kaplan Executive Function System; MSNQ - MS Neuropsychological Screening Questionnaire Change score (Baseline Time 3) means, standard deviation, statistical significance CVLT - California Verbal Learning Test ; BVMT - Brief Visuospatial Memory Test - Revised; JLO - Judgment Line Orientation Test; SDMT - Symbol Digit Modalities Test; PASAT - Paced Auditory Serial Addition Test; COWAT - Controlled Oral Word Association Test; DKEFS - Delis-Kaplan Executive Function System; MSNQ - MS Neuropsychological Screening Questionnaire The RM ANOVA analysis revealed time effects observed neuropsychological performance tests, self-report measures compensatory strategies, MSNQ (the measure neuropsychological competence activities daily living).",G0000000|G0000000|C0006754|C0439824|C0013621|C0022885|G0000000|G0000000|G0000000|C1282927|G0000000|C0025260|C0022885|G0000000|C1527075|G0000000|G0000000|C0022423|C0205132|C0029266|C0022885|C3268430|G0000000|C0679214|C0582802|C0695347|C0022885|C3898036|G0000000|C0287990|C0439825|C0031082|C0332287|C0022885|C3827022|G0000000|C2587213|C0442027|C1705313|C0004083|C0022885|G0000000|G0000000|G0000000|C0871735|C0031843|C0449913|G0000000|G0000000|C0039676|G0000000|C0220908|C0034394|C0392747|C0449820|C0168634|C0040223|G0000000|C1704970|C1442989|C0012727|C0038215|C0237881|G0000000|G0000000|C0006754|C0439824|C0013621|C0022885|G0000000|G0000000|G0000000|C1282927|G0000000|C0025260|C0022885|G0000000|C1527075|G0000000|G0000000|C0022423|C0205132|C0029266|C0022885|C3268430|G0000000|C0679214|C0582802|C0695347|C0022885|C3898036|G0000000|C0287990|C0439825|C0031082|C0332287|C0022885|C3827022|G0000000|C2587213|C0442027|C1705313|C0004083|C0022885|G0000000|G0000000|G0000000|C0871735|C0031843|C0449913|G0000000|G0000000|C0039676|G0000000|C0220908|C0034394|G0000000|C0024851|G0000000|C0002778|C0443289|C0040223|C1280500|C1441672|G0000000|C0597198|C0022885|C0681906|C0079809|C0231186|C0679199|G0000000|G0000000|C0079809|G0000000|C0086035|C0441655|C0332173|C0376558
"ASpreop: agitation scores at the preoperative holding area, ASMAX: maximum agitation scores in the PACU, ASPAR10: agitation scores when the PAR scores were 10, TEM: the period when the agitation scores were 4 or 5 in the PACU, TPACU: total stay time in the PACU, TEM/TPACU: the rate of the period when the agitation score was 4 or 5 out of the period of stay in the PACU, Midazolm in PACU: the number of midazolam injection in the PACU.","ASpreop: agitation scores preoperative holding area, ASMAX: maximum agitation scores PACU, ASPAR10: agitation scores PAR scores 10, TEM: period agitation scores 4 5 PACU, TPACU: total stay time PACU, TEM/TPACU: rate period agitation score 4 5 period stay PACU, Midazolm PACU: midazolam injection PACU.",G0000000|C0085631|C0449820|C0445204|G0000000|C0017446|G0000000|C0806909|C0085631|C0449820|C0034871|G0000000|C0085631|C0449820|C1417826|C0449820|C0450371|C3714516|C0439531|C0085631|C0449820|G0000000|G0000000|C0034871|G0000000|C0439175|G0000000|C0040223|C0034871|C3714516|C0871208|C0439531|C0085631|C0449820|G0000000|G0000000|C0439531|G0000000|C0034871|G0000000|C0034871|C0026056|C0021485|C0034871
The objective response rate (ORR) among patients with measurable disease are summarized in Table 2.,The objective response rate (ORR) patients measurable disease summarized Table 2.,G0000000|C0018017|C0871261|C0871208|G0000000|C0030705|C1513040|C0012634|G0000000|C0039224|G0000000
"In all 11 patients of the ALT group in which initial catheterization failed in our study, USG helped to successfully achieve venous access.","In 11 patients ALT initial catheterization failed study, USG helped achieve venous access.",G0000000|C0450371|C0030705|C1266129|C0205265|C0007430|C0231175|C0557651|G0000000|C1269765|G0000000|C0042449|C0444454
"Therefore, the Chinese version was used to measure agitation in the dementia patients.","Therefore, Chinese version measure agitation dementia patients.",G0000000|C0008120|C0333052|C0079809|C0085631|C0011265|C0030705
"The objective of this prospective crossover study was to compare efficacy, side effects, patient compliance, and preference between AMP and nasal continuous positive airway pressure (nCPAP) in patients with symptomatic mild to moderate OSA.","The objective prospective crossover study compare efficacy, effects, patient compliance, preference AMP nasal continuous positive airway pressure (nCPAP) patients symptomatic mild moderate OSA.",G0000000|C0018017|C0023981|C0010366|C0557651|C1707455|C1280519|C1280500|C0030705|C0009563|C0558295|G0000000|C0028429|C0549178|C0439178|C0178987|C0033095|G0000000|C0030705|C0231220|C2945599|C0205081|C0520679
"Antibiotic prescribing, antibiotic consumption, future consulting intentions, parental satisfaction, perception of the usefulness of information received, reassurance, and enablement were secondary outcomes.","Antibiotic prescribing, antibiotic consumption, future consulting intentions, parental satisfaction, perception received, reassurance, enablement secondary outcomes.",C0003232|C0278329|C0003232|C0009830|C0016884|C0009818|C0162425|C0030551|C0242428|C0030971|C1514756|C0204558|G0000000|C0027627|C1274040
Participants performed three sets of quadriceps leg extensions on their dominant leg (identified during the screening visit and kept constant throughout the study) for 12 repetitions at 120 degrees/sec for evaluation of isokinetic extension.,Participants performed sets quadriceps leg extensions dominant leg (identified screening visit constant study) 12 repetitions 120 degrees/sec evaluation isokinetic extension.,C0679646|C0884358|C0036849|C0224440|C0023216|C0231448|C1527180|C0023216|C0205396|C0220908|C0545082|C1547014|C0557651|C0450371|C0205341|C1442061|C0449286|C0220825|G0000000|C0231448
"There were no significant differences in the crude incidence rates or IRR of opportunistic infections such as LRTI, diarrhea, candidiasis, TB as well as the depression and Karnofsky scores between the two groups of mothers.","There differences crude incidence rates IRR opportunistic infections LRTI, diarrhea, candidiasis, TB depression Karnofsky scores mothers.",G0000000|C1705241|G0000000|C0021149|C0871208|G0000000|G0000000|C3714514|C0149725|C0011991|C0006840|G0000000|C0011570|C0206065|C0449820|C0026591
"The secondary and exploratory ophthalmic outcomes were assessed using Cox proportional hazards models with the Wei, Lin and Weissfeld method for obtaining robust variance estimates that adjusted for dependence among multiple event times (multiple study eyes) adjusted for baseline AMD status only.29 The assumptions for proportional hazards models were tested and met for all outcomes.","The secondary exploratory ophthalmic outcomes assessed Cox proportional hazards models Wei, Lin Weissfeld method obtaining robust variance estimates adjusted dependence multiple event times (multiple study eyes) adjusted baseline AMD status only.29 The assumptions proportional hazards models tested met outcomes.",G0000000|C0027627|G0000000|C0015392|C1274040|C1516048|G0000000|C0205351|C0598697|C3161035|G0000000|C0861352|G0000000|C0025663|C1301820|C2986815|C1711260|C0750572|C0456081|C0011546|C0439064|C0441471|C0040223|C0439064|C0557651|C0015392|C0456081|C0168634|C3539530|C0449438|C0205171|G0000000|G0000000|C0205351|C0598697|C3161035|C0392366|C0268621|C1274040
"However, changes were observed, in per protocol analysis at 12 months, for the number of patients with an improvement of at least 2 points in the INCAT disability scale (p = 0.027), the self-evaluation scale (p = 0.016), and 2 subscores of the Short Form–36 questionnaire.","However, observed, protocol analysis 12 months, patients improvement 2 INCAT disability scale (p = 0.027), self-evaluation scale (p = 0.016), 2 subscores Short Form–36 questionnaire.",G0000000|C1441672|C0442711|C0002778|C0450371|C0439231|C0030705|C2986411|G0000000|G0000000|C0231170|C0175659|C0369773|G0000000|C1442061|C0036591|C0175659|C0369773|G0000000|C1442061|G0000000|G0000000|C1282927|G0000000|C0034394
"Secondary outcomes include patient and oncologist evaluation of communication and decision-making, the decision made, quality of life, potential adverse outcomes such as anxiety and hopelessness, and consultation duration.","Secondary outcomes patient oncologist evaluation communication decision-making, decision made, quality life, potential adverse outcomes anxiety hopelessness, consultation duration.",C0027627|C1274040|C0030705|C0259990|C0220825|C0009452|C0011109|C0679006|C1881534|C0332306|C0376558|C3245505|G0000000|C1274040|C0003467|C0150041|C0009818|C0449238
"The within-assay variability of plasma ferritin, TfR, RBP, CRP, AGP, zinc, and urinary iodine was <6% and between-assay variability was < 10%.","The within-assay variability plasma ferritin, TfR, RBP, CRP, AGP, zinc, urinary iodine <6% between-assay variability was < 10%.",G0000000|C0005507|C2827666|C0032105|C0015879|G0000000|C1419339|C3890735|C0029297|C0043481|C0042027|C0021966|G0000000|C0005507|C2827666|G0000000
"In the first phase of analysis, we tested the mean difference between placebo and DHA-supplemented groups with a 2-sample t test and no covariate for primary efficacy outcomes of gestational age, maternal RBC-phospholipid-DHA, birth weight, and birth length and secondary efficacy outcomes of cord RBC-phospholipid-DHA and head circumference.","In phase analysis, tested difference placebo DHA-supplemented 2-sample test covariate primary efficacy outcomes gestational age, maternal RBC-phospholipid-DHA, birth weight, birth length secondary efficacy outcomes cord RBC-phospholipid-DHA head circumference.",G0000000|C0205390|C0002778|C0392366|C1705241|C0032042|C0142831|C0370003|C0022885|G0000000|C0205225|C1280519|C1274040|C0439671|C0001779|C2347083|C0014792|C0005615|C0005910|C0005615|C1444754|C0027627|C1280519|C1274040|C1550235|C0014792|C0018670|C0332520
"After 4 weeks of intervention, improvements in the FMA (p=0.027) and MBI (p=0.041) were significantly greater in the mirror therapy group than the sham therapy group.","After 4 weeks intervention, improvements FMA (p=0.027) MBI (p=0.041) mirror therapy sham therapy group.",G0000000|G0000000|C0439230|C0886296|C2986411|C2332774|C0369773|C2985547|C0369773|C0181868|C0039798|C0068899|C0039798|C0441833
"The primary outcome will be the reduction in pain intensity, according to the visual analogue scale (iVAS), at 2 weeks after the start of treatment.","The primary outcome reduction pain intensity, visual analogue scale (iVAS), 2 weeks start treatment.",G0000000|C0205225|C1274040|C0301630|C0030193|C0522510|C0234621|C0243071|C0175659|C0268575|G0000000|C0439230|C0439659|C0039798
All-cause mortality was assessed during the first 28 days.,All-cause mortality assessed 28 days.,C0015127|C0026565|C1516048|C0450371|C0439228
"Actiwatches are compact, battery-operated activity monitors with physical characteristics similar to a small wristwatch.","Actiwatches compact, battery-operated activity monitors physical characteristics wristwatch.",G0000000|C1333134|C0337088|C0205177|C0181904|C0031809|C1521970|G0000000
"The predetermined primary outcome was development of symptomatic influenza A or B illness that was laboratory-confirmed, either by isolation of influenza virus in cell culture or by comparison of paired post-vaccination (preseason) and postseason serum samples that showed a ≥4-fold increase in hemagglutination-inhibition antibody titer to a circulating influenza strain.","The predetermined primary outcome development symptomatic influenza A B illness laboratory-confirmed, isolation influenza virus cell culture comparison paired post-vaccination (preseason) postseason serum samples ≥4-fold increase hemagglutination-inhibition antibody titer circulating influenza strain.",G0000000|G0000000|C0205225|C1274040|C0243107|C0231220|C0021400|G0000000|G0000000|C0221423|C0022877|C0204727|C0021400|C0042776|C0007634|C0010453|C1707455|C1709450|C0687676|G0000000|G0000000|C0229671|C0370003|G0000000|C0442805|C0018904|C0003241|C0475208|C0175630|C0021400|C0080194
Secondary outcome measures are depression and aggression which will be assessed with the Child Behaviour Checklist (CBCL; [31]) and the Teacher Rate Form (TRF; [32]).,Secondary outcome measures depression aggression assessed Child Behaviour Checklist (CBCL; [31]) Teacher Rate Form (TRF; [32]).,C0027627|C1274040|C0079809|C0011570|C0001807|C1516048|C0008059|C0004927|C1707357|C1511566|C0450371|C0221457|C0871208|C0348078|C1702088|C0450371
Those participants randomized to waitlist were assessed 2 months following baseline to approximate duration of MAAT completion (8 weeks).,Those participants randomized waitlist assessed 2 months baseline approximate duration MAAT completion (8 weeks).,G0000000|C0679646|C0034656|C0043010|C1516048|G0000000|C0439231|C0168634|C0332232|C0449238|G0000000|C0205197|G0000000|C0439230
"Rectal swabs were collected during cross-sectional surveys performed at baseline, 1, 3 and 6 months after MDA.","Rectal swabs collected cross-sectional surveys performed baseline, 1, 3 6 months MDA.",C0205052|C0183753|C1516695|C0552389|C0038951|C0884358|C0168634|G0000000|G0000000|G0000000|C0439231|C0000379
The primary outcome variable was change (ratio) from baseline to treatment period in FEV1 60-min post-dose.,The primary outcome variable change (ratio) baseline treatment period FEV1 60-min post-dose.,G0000000|C0205225|C1274040|C0439828|C0392747|C0456603|C0168634|C0039798|C0439531|G0000000|C0450371|C0439568
Secondary endpoint included overall survival (OS) and safety.,Secondary endpoint included survival (OS) safety.,C0027627|C2349179|C0332257|C0038952|C0229090|C0036043
"""26  Health outcomes (ie, school absenteeism, office visits, ED visits, hospitalizations for asthma) and asthma control (ie, airway inflammation, medication adherence to ICS) were collected at each time point.","""26 Health outcomes (ie, school absenteeism, office visits, ED visits, hospitalizations asthma) asthma control (ie, airway inflammation, medication adherence ICS) collected time point.",C0450371|C0018684|C1274040|G0000000|C0036375|C0000849|C0442603|C0545082|C3538926|C0545082|C0019993|C0004096|C0004096|C0243148|G0000000|C0178987|C0021368|C0013227|C1510802|C0022521|C1516695|C0040223|C1552961
"Biochemical efficacy and safety outcomes included the first, highest, and lowest serum value for chloride, bicarbonate, and potassium each day from enrollment until hospital discharge or 30 days.","Biochemical efficacy safety outcomes included first, highest, lowest serum chloride, bicarbonate, potassium day enrollment hospital discharge 30 days.",C0205474|C1280519|C0036043|C1274040|C0332257|C0205435|C1522410|C1708760|C0229671|C0008203|C0005367|C0032821|C0332173|C1516879|C0019994|C0012621|C0450371|C0439228
Saliva–cotinine samples were obtained from a 35% subsample of self-reported quitters.,Saliva–cotinine samples 35% subsample self-reported quitters.,G0000000|C0370003|C0450371|G0000000|C0681906|G0000000
For further analysis additional dimensions (e.g.,For analysis additional dimensions (e.g.,G0000000|C0002778|C1524062|C0439534|G0000000
"The primary outcome was the time until the infant was assessed as being ‘fit for discharge’, which was defined as the point at which the infant was feeding adequately (taking >75% of their usual intake) and had been in air with a saturation of at least 92% for 6 h. Data was collected on a daily basis from the routinely recorded clinical observations from which the two key outcomes, time fit for discharge and time to actual discharge were calculated.","The primary outcome time infant assessed ‘fit discharge’, defined infant feeding adequately (taking >75% usual intake) air saturation 92% 6 h. Data collected daily basis routinely recorded clinical observations key outcomes, time fit discharge time actual discharge calculated.",G0000000|C0205225|C1274040|C0040223|C0021270|C1516048|G0000000|G0000000|C1704788|C0021270|C0204695|G0000000|C1515187|C0450371|C3538928|C1512806|C0001861|C0522534|C0450371|G0000000|C1511726|C1516695|C0332173|C1527178|G0000000|C0034869|C0205210|C0302523|G0000000|C1274040|C0040223|C0036572|C0012621|C0040223|C0237400|C0012621|C0444686
Three manoeuvres were performed at each time point to provide three measurements that met ATS/ERS acceptability and repeatability criteria.,Three manoeuvres performed time provide measurements met ATS/ERS acceptability repeatability criteria.,C0205449|G0000000|C0884358|C0040223|C1999230|C0242485|C0268621|C1704489|C0814633|G0000000|C0243161
"The results of similar mean comparisons, using Analyses of Covariance for the parent and teacher reports of inattention symptoms, social skills, and organizational skills were previously reported by Pfiffner and colleagues (2014).","The comparisons, Analyses Covariance parent teacher reports inattention symptoms, social skills, organizational skills reported Pfiffner colleagues (2014).",G0000000|C1707455|C0002778|G0000000|C0030551|C0221457|C0684224|C0424101|C0683368|C0728831|C0678856|C0029246|C0678856|C0684224|G0000000|G0000000|G0000000
"At baseline, there were no significant differences between groups in the MFT and FIM self-care scores (p<0.05).","At baseline, differences MFT FIM self-care scores (p<0.05).",G0000000|C0168634|C1705241|C1822742|C3273671|C0036592|C0449820|C0369773
"The absence of reduction in efficacy against HPV16 persistent infection among HPV18 seropositive women suggests that immune protection, rather than other correlates of sexual activity associated with antibody levels, explains the effect.","The absence reduction efficacy HPV16 persistent infection HPV18 seropositive women suggests immune protection, correlates sexual activity antibody levels, explains effect.",G0000000|C0332197|C0301630|C1280519|G0000000|C0205322|C0009450|G0000000|C0521143|C0043210|C1705535|C0439662|C1545588|G0000000|C0036864|C0205177|C0003241|C0441889|G0000000|C1280500
"FMA, Fugl-Meyer assessment; FMA-U, upper extremity; FMA-L, lower extremity; FMA-B, balance It is difficult for patients with stroke to recover the function of the upper extremity.","FMA, Fugl-Meyer assessment; FMA-U, upper extremity; FMA-L, lower extremity; FMA-B, balance It difficult patients stroke recover function upper extremity.",C2332774|G0000000|C1261322|C2332774|C1282910|C0015385|C2332774|C0441994|C0015385|C2332774|C0014653|G0000000|C0332218|C0030705|C0038454|C0521108|C0031843|C1282910|C0015385
Secondary outcome measures will be: 1) the Fugl-Meyer assessment scale for motor function; 2) the mini-mental state examination and Montreal cognitive assessment for cognitive function; 3) the video-fluoroscopic swallowing study for swallowing ability; and 4) the incidence of adverse events.,Secondary outcome measures be: 1) Fugl-Meyer assessment scale motor function; 2) mini-mental examination Montreal cognitive assessment cognitive function; 3) video-fluoroscopic swallowing study swallowing ability; 4) incidence adverse events.,C0027627|C1274040|C0079809|G0000000|G0000000|G0000000|C1261322|C0175659|C1513492|C0031843|G0000000|C0445542|G0000000|G0000000|C1516691|C1261322|C1516691|C0031843|G0000000|C1660599|C0011167|C0557651|C0011167|C0085732|G0000000|C0021149|G0000000|C0441471
The primary end point was trough FEV1 on Day 85.,The primary trough FEV1 Day 85.,G0000000|C0205225|C0444506|G0000000|C0332173|C0450371
"Consequently, the results from baseline to end of the 8 week intervention (b-8) and end of the week 8 intervention to week 12 follow up (8b-12) were analysed separately.","Consequently, baseline 8 week intervention (b-8) week 8 intervention week 12 follow (8b-12) analysed separately.",G0000000|C0168634|G0000000|C0332174|C0886296|G0000000|C0332174|G0000000|C0886296|C0332174|C0450371|C0332283|C1420850|G0000000|G0000000
A significantly greater proportion of yoga subjects also reported clinical improvements at both 12 and 24 weeks.,A proportion yoga subjects reported clinical improvements 12 24 weeks.,G0000000|C1709707|C0043418|C0681850|C0684224|C0205210|C2986411|C0450371|C0450371|C0439230
"Nevertheless, there is no consensus as to whether and how blood transfusion should be used before invasive procedures, particularly in patients with cirrhosis.","Nevertheless, consensus blood transfusion invasive procedures, patients cirrhosis.",G0000000|C0376298|C0005767|C0005841|C0205281|C0025664|C0030705|C0023890
"In Japan, the rate of breast cancer screening was no more than about 25% in 2010 [31].","In Japan, rate breast cancer screening 25% 2010 [31].",G0000000|C0022341|C0871208|C0006141|C0006826|C0220908|C0450371|G0000000|C0450371
"Clinical parameters included pain, sinus formation, swelling (intra oral), and mobility while the radiological parameters included PDL widening, internal resorption, external resorption, periapical radiolucency, canal obliteration, and furcation radiolucency.","Clinical parameters included pain, sinus formation, swelling (intra oral), mobility radiological parameters included PDL widening, internal resorption, external resorption, periapical radiolucency, canal obliteration, furcation radiolucency.",C0205210|C0449381|C0332257|C0030193|C0016169|C0220781|C0013604|C0347985|C0442027|C0425245|C0034599|C0449381|C0332257|G0000000|C0332464|C0205102|C2985494|C0205101|C2985494|C0729269|C2827491|C0086881|C0332465|C2825929|C2827491
EXACTT instrument used to optimize maximal effort during incremental and endurance exercise tests.,EXACTT instrument optimize maximal effort incremental endurance exercise tests.,G0000000|C0348000|G0000000|C0205289|C0015264|C1705117|C0518031|C0015259|C0022885
"Follow-up visits were conducted at 6, 12, 18, and 24 months after baseline, at which time the physical examination, CMTNS, NIS, nerve conduction studies, SF-36, and serum AA levels were obtained.","Follow-up visits conducted 6, 12, 18, 24 months baseline, time physical examination, CMTNS, NIS, nerve conduction studies, SF-36, serum AA levels obtained.",C0589120|C0545082|C0004927|G0000000|C0450371|C0450371|C0450371|C0439231|C0168634|C0040223|C0031809|G0000000|G0000000|C0142963|C0027740|C0232217|C0947630|C0037712|C0229671|C0282379|C0441889|C1301820
Exclusion of prostate cancer cases diagnosed in the first 3 years of follow-up did not substantially change the results.,Exclusion prostate cancer diagnosed 3 follow-up change results.,C0680251|C0033572|C0006826|C0011900|G0000000|C0589120|C0392747|C1274040
"Secondary endpoints included safety assessment and measurement of other efficacy indicators such as relief of somatic symptoms (eg, insomnia, joint pain, sleep and fatigue), mood changes (eg, depression and anxiety), sexual dysfunction (eg, vaginal dryness, dyspareunia, libido, and difficulty in achieving orgasm), and health-related quality of life.","Secondary endpoints included safety assessment measurement efficacy indicators relief somatic symptoms (eg, insomnia, joint pain, sleep fatigue), mood (eg, depression anxiety), sexual dysfunction (eg, vaginal dryness, dyspareunia, libido, difficulty achieving orgasm), health-related quality life.",C0027627|C2349179|C0332257|C0036043|C1261322|C0242485|C1280519|C0021212|C0564405|C1257909|C0683368|C0013715|C0917801|C0022417|C0030193|C0037313|C0015672|C0026516|C0013715|C0011570|C0003467|C0036864|C0031847|C0013715|C0042232|C1512080|C0013394|C0023618|C1299586|G0000000|C0029260|C0018684|C0332306|C0376558
Tumor assessments were performed at baseline and every 12 weeks.,Tumor assessments performed baseline 12 weeks.,C0027651|C1261322|C0884358|C0168634|C0450371|C0439230
The primary side effect of these treatments is fatigue.,The primary treatments fatigue.,G0000000|C0205225|C0087111|C0015672
"Two patients developed local recurrence, both after intralesional curettage.","Two patients developed local recurrence, intralesional curettage.",C0205448|C0030705|G0000000|C0205276|C0034897|C1512954|C0010468
The primary end point was response rate.,The primary response rate.,G0000000|C0205225|C0871261|C0871208
Changes in attention and executive function composite scores for (A) goals training and (B) education.,Changes attention executive function composite scores (A) goals training (B) education.,C0392747|C0004268|C0871735|C0031843|C0205199|C0449820|G0000000|C0018017|C0040607|G0000000|C0013621
There was no association between the day 6 total chloroquine or piperaquine concentrations and the interval to first P. vivax recurrence within 8 weeks.,There association day 6 total chloroquine piperaquine concentrations interval P. vivax recurrence 8 weeks.,G0000000|C0004083|C0332173|G0000000|C0439175|C0008269|C0071105|C0086045|C1272706|C0369773|G0000000|C0034897|G0000000|C0439230
"Subject diary mean scores for itching, redness, watery eyes, and overall symptoms within the first 4 days of treatment.","Subject diary scores itching, redness, watery eyes, symptoms 4 days treatment.",C0681850|C0376660|C0449820|C0033774|C0041834|C0443350|C0015392|C0683368|G0000000|C0439228|C0039798
"Adverse events were assessed by weekly vital signs, assessments for sedation and withdrawal, and questions about additional medications received and adverse effects in weeks 1 through 12; similar assessments were done at months 6, 9, and 12.","Adverse events assessed weekly vital signs, assessments sedation withdrawal, questions additional medications received adverse effects weeks 1 12; assessments months 6, 9, 12.",G0000000|C0441471|C1516048|C0332174|C0442732|C0220912|C1261322|C0235195|C2349954|C1522634|C1524062|C0013227|C1514756|G0000000|C1280500|C0439230|G0000000|C0450371|C1261322|C0439231|G0000000|G0000000|C0450371
The pancreatic duct was identified during all procedures.,The pancreatic duct identified procedures.,G0000000|C0030274|C0687028|C0205396|C0025664
The patients of the LVT + HC group had lower arterial lactate and bicarbonate excess values by the end of surgery.,The patients LVT + HC lower arterial lactate bicarbonate excess values surgery.,G0000000|C0030705|G0000000|C0441994|C0003842|C0022924|C0005367|C1979886|C0042295|C0038894
There were 31 serious adverse events in the vitamin D and 23 in the placebo group but the number of participants who experienced an event was 16 in each group.,There 31 adverse events vitamin D 23 placebo participants experienced event 16 group.,G0000000|C0450371|G0000000|C0441471|C0042890|C0073187|C0450371|C0032042|C0679646|C0237607|C0441471|C0450371|C0441833
Patients were classified as suffering a relapse when all three of the following criteria were met: CAI >6 or an increase in CAI of at least 3 points with CAI  = 4 being exceeded at the same time; EI >4; and histological signs of acute inflammation.,Patients classified suffering relapse criteria met: CAI >6 increase CAI 3 CAI  = 4 exceeded time; EI >4; histological signs acute inflammation.,C0030705|C0008902|C0683278|C0035020|C0243161|C0268621|C0064494|G0000000|C0442805|C0064494|G0000000|C0064494|G0000000|G0000000|C0040223|C0022067|G0000000|C0205462|C0220912|C0205178|C0021368
Response to Treatment.,Response Treatment.,C0871261|C0039798
The early pregnancy glucose testing follows a strategy supported by the guidelines of the IADPSG [29].,The pregnancy glucose testing strategy supported guidelines IADPSG [29].,G0000000|C0032961|C0017725|C0039593|C0679199|C1521721|C0162791|G0000000|C0450371
"[Results] Compared with under the RAS 0% conditions, the gait velocity, cadence, and stride length on the affected side were significantly decreased under the RAS −10% conditions.","[Results] Compared RAS 0% conditions, gait velocity, cadence, stride length decreased RAS −10% conditions.",C1274040|C1707455|C0034678|G0000000|C0012634|C0016928|C0439830|G0000000|G0000000|C1444754|C0205216|C0034678|G0000000|C0012634
"There were associations between serum HCV RNA and HDL at baseline, and with change in triglyceride levels during therapy.","There associations serum HCV RNA HDL baseline, change triglyceride levels therapy.",G0000000|C0004083|C0229671|C0220847|C0035668|C3715113|C0168634|C0392747|C0041004|C0441889|C0039798
The primary outcome was microbiologically confirmed VAP incidence based on quantitative BAL culture with at least 104 cfu/ml in patients intubated for 48 hours or longer.,The primary outcome microbiologically confirmed VAP incidence based quantitative BAL culture 104 cfu/ml patients intubated 48 hours longer.,G0000000|C0205225|C1274040|G0000000|C0521093|G0000000|C0021149|C1527178|C0392762|C0428249|C0010453|C1442061|C0439361|C0030705|G0000000|C0450371|C0439227|C0205166
All women with at least one diagnosis of invasive cancer during the period 1 January 1953 through 31 December 2010 were identified through linkage of the MBRN data to the Cancer Registry of Norway (CRN) using each woman's unique personal identification number.,All women diagnosis invasive cancer period 1 January 1953 31 December 2010 identified linkage MBRN data Cancer Registry Norway (CRN) woman's unique personal identification number.,G0000000|C0043210|C0011900|C0205281|C0006826|C0439531|G0000000|C3829466|G0000000|C0450371|C3830550|G0000000|C0205396|C0023745|G0000000|C1511726|C0006826|C0034975|C0028423|C3889664|C0043210|C1710548|C1519021|C0020792|C0237753
"The primary outcome measure was vitamin A status at 6 months, determined by SR concentration.","The primary outcome measure vitamin A status 6 months, determined SR concentration.",G0000000|C0205225|C1274040|C0079809|C0042890|G0000000|C0449438|G0000000|C0439231|G0000000|C3813610|C0004268
We used the Epworth Sleepiness Scale as a measure of hypersomnolence and a structured interview of the patient and the partner or housemate as a measure of activity.,We Epworth Sleepiness Scale measure hypersomnolence structured interview patient partner housemate measure activity.,G0000000|G0000000|C0013144|C0175659|C0079809|C0751229|C0678594|C0021822|C0030705|C0682323|C3829617|C0079809|C0205177
"Additional neurological end points in this study included a set of neuropsychological assessments (Purdue Peg Board test, Wechsler Scale, Benton visual retention test, Rey auditory verbal learning test, d2 test of attention, continuous performance test, and Trail Making Test) and a set of neurological assessments (assessing mental state, cranial nerves, motor skills, and other neurological symptoms).","Additional neurological study included set neuropsychological assessments (Purdue Peg Board test, Wechsler Scale, Benton visual retention test, Rey auditory verbal learning test, d2 test attention, continuous performance test, Trail Making Test) set neurological assessments (assessing mental state, cranial nerves, motor skills, neurological symptoms).",C1524062|C0205494|C0557651|C0332257|C0036849|G0000000|C1261322|G0000000|G0000000|C0972401|C0022885|G0000000|C0175659|G0000000|C0234621|C0035280|C0022885|G0000000|C0439825|C0439824|C0013621|C0022885|C3538936|C0022885|C0004268|C0549178|C0597198|C0022885|C1143949|C1881534|C0022885|C0036849|C0205494|C1261322|C1516048|C0229992|C1301808|C0037303|C0027740|C1513492|C0678856|C0205494|C0683368
"One week of sleep-wake activity was measured at each assessment using a Micro-Mini Motionlogger actigraph (Ambulatory Monitoring, Inc., Ardsley, NY).","One week sleep-wake activity measured assessment Micro-Mini Motionlogger actigraph (Ambulatory Monitoring, Inc., Ardsley, NY).",C0205447|C0332174|C0037313|C0205177|C0444706|C1261322|C0085672|G0000000|C1139952|C0439841|C0150369|G0000000|G0000000|C0027976
"To assess the contributions of both microbial larvicides and ITNs in decreasing malaria transmission and infection in an integrated vector management programme we used the incidence of new Plasmodium infections in children as the primary outcome, and anopheline larval and adult abundance as secondary outcomes.","To assess contributions microbial larvicides ITNs decreasing malaria transmission infection integrated vector management programme incidence Plasmodium infections children primary outcome, anopheline larval adult abundance secondary outcomes.",C0040363|C1516048|C1880177|C0599840|G0000000|G0000000|C0442797|C0024530|C0040722|C0009450|G0000000|C0086022|C0001554|C1709697|C0021149|C0032148|C3714514|C0008059|C0205225|C1274040|G0000000|C0023047|C0001675|C2346714|C0027627|C1274040
"First, although MEMS are an objective indicator of adherence, it is possible that adherence was underestimated if the MEMS cap was not used.","First, MEMS objective indicator adherence, adherence underestimated MEMS cap used.",C0205435|C1979923|C0018017|C0021212|C1510802|C1510802|G0000000|C1979923|C0179586|C1273517
"The number of incident breast cancer cases within the cohort is comparable with the expected number of cases based on age- and sex-specific incidence rates of breast cancer for all Chinese in Singapore (24,25).","The incident breast cancer cohort comparable expected based age- sex-specific incidence rates breast cancer Chinese Singapore (24,25).",G0000000|C1551358|C0006141|C0006826|C0599755|G0000000|C1517001|C1527178|C0001779|C0009253|C0021149|C0871208|C0006141|C0006826|C0008120|C0037173|C0450371
"The primary endpoint of this study was the frequency and severity of diarrhea symptoms, and the secondary endpoints were the frequency and severity of gastrointestinal symptoms other than diarrhea (nausea, vomiting, and loss of appetite) and NK cell activity.","The primary endpoint study frequency severity diarrhea symptoms, secondary endpoints frequency severity gastrointestinal symptoms diarrhea (nausea, vomiting, loss appetite) NK cell activity.",G0000000|C0205225|C2349179|C0557651|C0376249|C0439793|C0011991|C0683368|C0027627|C2349179|C0376249|C0439793|C0521362|C0683368|C0011991|C0027497|C0042963|C1517945|C0003618|C0022688|C0007634|C0205177
"At all time points, patients rated their pain levels in 4 areas of the body on questionnaires using a visual analogue scale (VAS; range, 0-100) and localized pain by marking a mannequin.","At time points, patients rated pain levels 4 body questionnaires visual analogue scale (VAS; range, 0-100) localized pain marking mannequin.",G0000000|C0040223|C1552961|C0030705|C0871208|C0030193|C0441889|G0000000|C0242821|C0034394|C0234621|C0243071|C0175659|C0042815|C1514721|C1442061|C0392752|C0030193|C0522501|C0024722
The mean Oswestry disability index changed favourably from 46.5 (SD 14.6) to 34.0 (SD 21.1) in the surgery group and from 44.8 (SD14.8) to 36.1 (SD 20.6) in the rehabilitation group.,The Oswestry disability changed favourably 46.5 (SD 14.6) 34.0 (SD 21.1) surgery 44.8 (SD14.8) 36.1 (SD 20.6) rehabilitation group.,G0000000|G0000000|C0231170|C0392747|G0000000|C0450371|G0000000|C0450371|C0450371|G0000000|C0450371|C0038894|C0450371|G0000000|C0450371|G0000000|C0450371|C0034991|C0441833
"The levels of IL-6, TNF-α, hs-CRP, IL-8 and FIB, and the duration of mechanical ventilation treatment between treatment groups were compared.","The levels IL-6, TNF-α, hs-CRP, IL-8 FIB, duration mechanical ventilation treatment treatment compared.",G0000000|C0441889|C0020898|G0000000|C3890735|C0020898|C1414538|C0449238|C0443254|C0035203|C0039798|C0039798|C1707455
"They could have been associated with any of the following: drug, dosage, frequency, administration route, appropriateness of restarting medication, therapeutic duplicity and/or medications lacking indication.","They following: drug, dosage, frequency, administration route, appropriateness restarting medication, therapeutic duplicity and/or medications lacking indication.",G0000000|C0231290|C0013227|C0178602|C0376249|C0001554|C0013153|C0814634|C1514902|C0013227|C0087111|G0000000|G0000000|C0013227|C0332268|C0392360
"The incidence of the postoperative complications including atelectases, postoperative ileus, nosocomial pneumonia, bleeding, and anastomosis leakage, as well as lengths of the ICU and hospital stay, and mortality were registered up to Day 28 after surgery.","The incidence postoperative complications including atelectases, postoperative ileus, nosocomial pneumonia, bleeding, anastomosis leakage, lengths ICU hospital stay, mortality registered Day 28 surgery.",G0000000|C0021149|C0032790|C0009566|C0332257|C0004144|C0032790|C1258215|C0019994|C0032285|C0019080|C0332853|C0015376|C1444754|C0021708|C0019994|G0000000|C0026565|C1514821|C0332173|C0450371|C0038894
The measure included 16-questions related to general knowledge about labour analgesia risks and benefits.,The measure included 16-questions knowledge labour analgesia risks benefits.,G0000000|C0079809|C0332257|C0450371|C0376554|C0022864|C0002766|C0035647|C0814225
"We also measured time spent in the emergency department, use of adrenaline (epinephrine), and the duration of subsequent croup and viral symptoms as secondary outcome measures.","We measured time spent emergency department, adrenaline (epinephrine), duration subsequent croup viral symptoms secondary outcome measures.",G0000000|C0444706|C0040223|C0680968|C0013956|C1704729|C0014563|C0014563|C0449238|C0332282|C0010380|C0521026|C0683368|C0027627|C1274040|C0079809
"All coronary events, fatal and non-fatal coronary events separately, and strokes alone (secondary end points).","All coronary events, fatal non-fatal coronary events separately, strokes (secondary points).",G0000000|C0018787|C0441471|C1302234|C1518422|C0018787|C0441471|G0000000|C0038454|C0027627|C1552961
"All participants completed identical computer-assisted surveys regarding basic demographics, condom attitudes and behaviors at baseline, 3, 6 and 9 months.","All participants completed identical computer-assisted surveys basic demographics, condom attitudes behaviors baseline, 3, 6 9 months.",G0000000|C0679646|C0205197|C0205280|C2362103|C0038951|C1527178|C0011298|C0009653|C0004271|C0004927|C0168634|G0000000|G0000000|G0000000|C0439231
The primary outcome in both stages was decline in the ALS Functional Rating Scale-revised (ALSFRSr) score over 9 months.,The primary outcome stages decline ALS Functional Rating Scale-revised (ALSFRSr) score 9 months.,G0000000|C0205225|C1274040|C1306673|G0000000|G0000000|C0205245|C0871208|C0175659|G0000000|C0449820|G0000000|C0439231
Our primary outcome the use of pharmacological analgesia during labour and childbirth will be collected from the birth register where all analgesia is documented by the attending midwife.,Our primary outcome pharmacological analgesia labour childbirth collected birth register analgesia documented attending midwife.,G0000000|C0205225|C1274040|C0031330|C0002766|C0022864|C0005615|C1516695|C0005615|G0000000|C0002766|C1301725|C1547429|C0026083
"The raw data of stool frequency and consistency was processed into a series of categories representing thresholds for different levels of disease severity (which were analysed based on event frequency), and then also analysed based on the time of first occurrence (event dated from the start of symptoms) of: stool frequency of two or more a day; stool frequency of three or more a day; stool consistency of type 5 (soft blobs with clear-cut edges, passed easily); and stool consistency of type 6 (fluffy pieces with ragged edges, a mushy stool).","The raw data stool frequency consistency processed series categories representing thresholds levels disease severity (which analysed based event frequency), analysed based time occurrence (event dated start symptoms) of: stool frequency day; stool frequency day; stool consistency type 5 (soft blobs clear-cut edges, passed easily); stool consistency type 6 (fluffy pieces ragged edges, mushy stool).",G0000000|C0001884|C1511726|C0015733|C0376249|C0332529|C1522240|C0205549|C0683312|C1882932|C0449864|C0441889|C0012634|C0439793|G0000000|G0000000|C1527178|C0441471|C0376249|G0000000|C1527178|C0040223|C0243132|C0441471|G0000000|C0439659|C0683368|G0000000|C0015733|C0376249|C0332173|C0015733|C0376249|C0332173|C0015733|C0332529|C0332307|G0000000|C0205358|G0000000|C1709157|C0205154|C2828386|C0332219|C0015733|C0332529|C0332307|G0000000|G0000000|C2982836|G0000000|C0205154|G0000000|C0015733
The effect of additional ZOL was measured using the pathological complete response (pCR) rate as the primary endpoint.,The additional ZOL measured pathological complete response (pCR) rate primary endpoint.,G0000000|C1524062|G0000000|C0444706|C0030664|C0205197|C0871261|C0032520|C0871208|C0205225|C2349179
The main secondary endpoints during the double-label phase included health-related quality of life using the Short Health Scale (SHS)13 and the Psychological General Well-Being Index (PGWBI).14 Further secondary endpoints during the double-blind phase were achievement of histological remission or histological improvement.,The main secondary endpoints double-label phase included health-related quality life Short Health Scale (SHS)13 Psychological General Well-Being Index (PGWBI).14 Further secondary endpoints double-blind phase achievement histological remission histological improvement.,G0000000|C0205225|C0027627|C2349179|C0205173|C0205390|C0332257|C0018684|C0332306|C0376558|C1282927|C0018684|C0175659|C0450371|C0205486|C0205246|C0018684|C0918012|C0450371|C1517331|C0027627|C2349179|C0013072|C0205390|C0001072|C0205462|C0544452|C0205462|C2986411
"The relationship between program format and cessation, however, was statistically significant at 12 months (P = .046) and marginally significant at 24 months (P = .081).","The relationship program format cessation, however, statistically 12 months (P = .046) marginally 24 months (P = .081).",G0000000|C0439849|C1709697|C1301627|C1880019|G0000000|C0038215|C0450371|C0439231|C0369773|G0000000|C1442061|G0000000|C0450371|C0439231|C0369773|G0000000|C1442061
"Survey response rates were 61% and 59% at 6 and 12 months, respectively.","Survey response rates 61% 59% 6 12 months, respectively.",C0038951|C0871261|C0871208|C0450371|C0450371|G0000000|G0000000|G0000000
"The mean OSDI score of patients with ocular Demodex was 20.1, which indicates moderate to severe ocular discomfort.","The OSDI score patients ocular Demodex 20.1, moderate severe ocular discomfort.",G0000000|C3896641|C0449820|C0030705|C0015392|C0323683|C0450371|C0205081|C0205082|C0015392|C0231218
"The patient’s mass transfer area coefficient (MTAC) for creatinine, UF capacity for the same period, and residual renal function (RRF) were calculated as previously described (20).","The patient’s mass transfer coefficient (MTAC) creatinine, UF capacity period, residual renal function (RRF) calculated (20).",G0000000|G0000000|C0577559|C0040671|C1707429|G0000000|C0010294|G0000000|C1516240|C0439531|C1609982|C0022646|C0031843|C1417252|C0444686|C0450371
"Primary outcomes were urinary incontinence, lumbopelvic pain, physical activity, and anxiety.","Primary outcomes urinary incontinence, lumbopelvic pain, physical activity, anxiety.",C0205225|C1274040|C0042027|C0021167|G0000000|C0030193|C0031809|C0205177|C0003467
"Using DOE reduced entry times and blood loss with trends to slightly decrease the occurrence of the minor vascular and bowel injuries, thus enabling a possible alternative to OHT in obese women.","Using DOE reduced entry times blood loss trends decrease occurrence minor vascular bowel injuries, enabling alternative OHT obese women.",C1524063|C0231807|C0392756|C1705654|C0040223|C0005767|C1517945|C0040833|C0392756|C0243132|C0026193|C0005847|C0021853|C1510467|C1171285|C1523987|G0000000|C0028754|C0043210
CAP was scored to assess arousal instability between sleep-maintaining processes (phase A1) and stronger arousal processes (phases A2 and A3).,CAP scored assess arousal instability sleep-maintaining processes (phase A1) stronger arousal processes (phases A2 A3).,C0179586|C0449820|C1516048|C0003808|C1444783|C0037313|C1184743|C0205390|C0336669|C0442821|C0003808|C1184743|C0585064|C0336669|C0336669
"Volume Given Between 10 am Preoperative Day to 9 am First Postoperative Day (47 Hours) Although the choice of incision was left to the surgeon, there were no marked differences in the incision used.","Volume Given Between 10 Preoperative Day 9 First Postoperative Day (47 Hours) Although choice incision left surgeon, marked differences incision used.",C0449468|C1442162|G0000000|C0450371|C0445204|C0332173|G0000000|C0205435|C0032790|C0332173|C0450371|C0439227|G0000000|C0008300|C0184898|C0205091|C0582175|C0522501|C1705241|C0184898|C1273517
We followed participants for ≥1 year to compare risk of relapse (secondary outcome).,We participants ≥1 compare risk relapse (secondary outcome).,G0000000|C0679646|G0000000|C1707455|C0035647|C0035020|C0027627|C1274040
"Secondary objectives are to investigate differences in the number, severity and length of delirium episodes (including persistent delirium); length of stay in hospital; in-hospital mortality; destination at discharge; health-related quality of life and health resource use; physical and social independence; anxiety and depression; and patient experience.","Secondary objectives investigate differences number, severity length delirium episodes (including persistent delirium); length stay hospital; in-hospital mortality; destination discharge; health-related quality life health resource use; physical social independence; anxiety depression; patient experience.",C0027627|C0018017|C1292732|C1705241|C0237753|C0439793|C1444754|C0011206|C0332189|C0332257|C0205322|C0011206|C1444754|G0000000|C0019994|C0019994|C0026565|C0079220|C0012621|C0018684|C0332306|C0376558|C0018684|C0035201|C0042153|C0031809|C0728831|C0085862|C0003467|C0011570|C0030705|C0237607
"All the pulpotomized teeth were evaluated clinically and radiographically at 1, 3, 6, 9, and 12 months of time interval using predetermined criteria.","All pulpotomized teeth evaluated clinically radiographically 1, 3, 6, 9, 12 months time interval predetermined criteria.",G0000000|G0000000|C0040426|C0220825|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|C0439231|C0040223|C1272706|G0000000|C0243161
"In addition, before the switch from motavizumab to palivizumab, the rates of level 3 AEs as the highest severity, level 4 AEs, SAEs, SAEs judged by the site investigator to be related to study drug, and AEs that resulted in discontinuation of study drug were higher among children in the M/P group than in the motavizumab-only (control) group, again suggesting a difference that could not be explained by study treatment since both groups had received the same drug and number of doses.","In addition, switch motavizumab palivizumab, rates level 3 AEs severity, level 4 AEs, SAEs, SAEs judged site investigator study drug, AEs discontinuation study drug children M/P motavizumab-only (control) group, suggesting difference explained study treatment received drug doses.",G0000000|C0332287|C1707719|C2713599|C0672596|C0871208|C0441889|G0000000|C1412268|C0439793|C0441889|G0000000|C1412268|C1519255|C1519255|C0221191|C0205145|C0035173|C0557651|C0013227|C1412268|C0457454|C0557651|C0013227|C0008059|C0369637|C2713599|C0243148|C0441833|C1705535|C1705241|G0000000|C0557651|C0039798|C1514756|C0013227|C0178602
Reflux height was marginally lower after GI (median 66.6% v 77.3% oesophageal length) compared with placebo.,Reflux height marginally lower GI (median 66.6% 77.3% oesophageal length) compared placebo.,C0017168|C0489786|G0000000|C0441994|C1708130|C0549183|C0450371|C0450371|C1522619|C1444754|C1707455|C0032042
"Second, the mean follow-up for our patients in the study was relatively short, and it was just beyond 2 years.","Second, follow-up patients study short, 2 years.",C0205436|C0589120|C0030705|C0557651|C1282927|G0000000|C0439234
"When considering both groups, local recurrence negatively influenced survival.","When groups, local recurrence negatively influenced survival.",G0000000|C0441833|C0205276|C0034897|G0000000|G0000000|C0038952
"Primary outcome variables were number of systemic inflammatory response syndrome (SIRS) criteria at 24 hours, 48 hours and 72 hours and blood C-reactive protein (CRP) levels at 48 hours and 72 hours.","Primary outcome variables systemic inflammatory response syndrome (SIRS) criteria 24 hours, 48 hours 72 hours blood C-reactive protein (CRP) levels 48 hours 72 hours.",C0205225|C1274040|C0439828|C0205373|C0333348|C0871261|C0039082|C0242966|C0243161|C0450371|C0439227|C0450371|C0439227|C0450371|C0439227|C0005767|C0205332|C0033684|C3890735|C0441889|C0450371|C0439227|C0450371|C0439227
"A, Pedobarography for static and dynamic measurements; B, the 5 segments of the foot from pressure image.","A, Pedobarography static dynamic measurements; B, 5 segments foot pressure image.",G0000000|G0000000|C0441463|C0729333|C0242485|G0000000|G0000000|C0441635|C0016504|C0033095|C1704254
Group mean change scores and standard error bars of Fugl-Meyer Assessment score of paretic upper limb and Modified Barthel Index in patients with chronic stroke.,Group change scores standard error bars Fugl-Meyer Assessment score paretic upper limb Modified Barthel Index patients chronic stroke.,C0441833|C0392747|C0449820|C1442989|C0743559|C0687760|G0000000|C1261322|C0449820|G0000000|C1282910|C0015385|C0392747|G0000000|C0918012|C0030705|C0205191|C0038454
Bronchoalveolar lavage to isolate a causative organism was performed if no resolution had occurred after 3 to 5 days.,Bronchoalveolar lavage isolate causative organism performed resolution occurred 3 5 days.,G0000000|C0022100|C1875400|G0000000|C0029235|C0884358|C1514893|C1709305|G0000000|G0000000|C0439228
"Against C trachomatis and N gonorrhoeae, the bacteriological success rates with moxifloxacin were 88.5% (23/26) and 100% (13/13), respectively.","Against C trachomatis N gonorrhoeae, bacteriological success rates moxifloxacin 88.5% (23/26) 100% (13/13), respectively.",G0000000|G0000000|C2893398|C0369718|C0018081|C0205465|C0597535|C0871208|C0536495|C0450371|C0450371|C1442061|C0450371|G0000000
"Moreover, the difference did not make any impact on the length of work absence after surgery.","Moreover, difference impact length absence surgery.",G0000000|C1705241|C1825598|C1444754|C0332197|C0038894
"Changes in axial length and spherical equivalent from baseline were calculated for each eye, and the values were compared between the two groups at 1, 3, 6, 9, and 12 months.","Changes axial length spherical equivalent baseline calculated eye, values compared 1, 3, 6, 9, 12 months.",C0392747|C0205131|C1444754|C0332501|C0205163|C0168634|C0444686|C0015392|C0042295|C1707455|G0000000|G0000000|G0000000|G0000000|C0450371|C0439231
"1, Table 1.","1, Table 1.",G0000000|C0039224|G0000000
"Herbal tea consumption was not associated with the risks of proximal colon cancer or rectal cancer, but the effect of herbal tea differed significantly between the proximal and distal colon (P = 0.04).","Herbal tea consumption risks proximal colon cancer rectal cancer, herbal tea differed proximal distal colon (P = 0.04).",C3146288|C0039400|C0009830|C0035647|C0205107|C0009368|C0006826|C0205052|C0006826|C3146288|C0039400|G0000000|C0205107|C0205108|C0009368|C0369773|G0000000|C0450371
"All 5 patients treated with methylprednisolone, but also 4 out of 5 patients treated with placebo, had a decrease in severity of radicular pain after 4 weeks.","All 5 patients treated methylprednisolone, 4 5 patients treated placebo, decrease severity radicular pain 4 weeks.",G0000000|G0000000|C0030705|C1522326|C0025815|G0000000|G0000000|C0030705|C1522326|C0032042|C0392756|C0439793|C0040452|C0030193|G0000000|C0439230
"The CST efficacy will be assessed at the communicational, psychological and physiological levels.","The CST efficacy assessed communicational, psychological physiological levels.",G0000000|C3539520|C1280519|C1516048|C0009452|C0205486|C0205463|C0441889
Both mother and teacher are asked to rate each item on a 3-point scale ranging from 0 (does not apply to the child) to 2 (clearly or often).,Both mother teacher rate item 3-point scale ranging 0 (does apply child) 2 (clearly often).,G0000000|C0026591|C0221457|C0871208|C1551338|C1552961|C0175659|C1514721|G0000000|G0000000|C1632850|C0008059|G0000000|G0000000|C0332183
"Poly drug and total substance use scores range from 0 to 6 and 0 to 7, respectively, and are composite variables of the dichotomized value for each substance listed parenthetically (e.g., a girl who reported any and only cigarette and marijuana use in the past was coded as 2).","Poly drug total substance scores range 0 6 0 7, respectively, composite variables dichotomized substance listed parenthetically (e.g., girl reported cigarette marijuana coded 2).",C0032400|C0013227|C0439175|C0439861|C0449820|C1514721|G0000000|G0000000|G0000000|G0000000|G0000000|C0205199|C0439828|G0000000|C0439861|C0745732|G0000000|G0000000|C0870604|C0684224|C0677453|C0024808|C0009219|G0000000
"OBJECTIVE: To evaluate the efficacy of and resistance to mebendazole (500 mg) and levamisole (40 or 80 mg), alone or in combination, for the treatment of Ascaris lumbricoides, Trichuris trichiura and hookworm infections on Pemba Island - an area exposed to periodic school-based mebendazole treatment since 1994.","OBJECTIVE: To evaluate efficacy resistance mebendazole (500 mg) levamisole (40 80 mg), combination, treatment Ascaris lumbricoides, Trichuris trichiura hookworm infections Pemba Island - exposed periodic school-based mebendazole treatment 1994.",C0018017|C0040363|C0220825|C1280519|C0237834|C0025023|C1442061|C0026410|C0023556|C0450371|C0450371|C0026410|C0205195|C0039798|C0003954|G0000000|C0040955|C3129718|C0002830|C3714514|C0205801|C0022130|G0000000|C0332157|C0332182|C0036375|C0025023|C0039798|G0000000
"These data were collected at baseline and by postal questionnaire at 3, 6, 9, and 12 months These data were self-reported by patients independent of the research team, thereby avoiding problems of potential differentials between trial arms, such as unblinding, that could lead to bias.","These data collected baseline postal questionnaire 3, 6, 9, 12 months These data self-reported patients independent team, avoiding potential differentials trial arms, unblinding, lead bias.",G0000000|C1511726|C1516695|C0168634|C1514253|C0034394|G0000000|G0000000|G0000000|C0450371|C0439231|G0000000|C1511726|C0681906|C0030705|C0085862|C0871489|G0000000|C3245505|C0443199|C0008976|C0206655|C3897431|C0023175|C0242568
Other outcome measures recorded included duration of time spent in the emergency department and use of nebulised adrenaline.,Other outcome measures recorded included duration time spent emergency department nebulised adrenaline.,G0000000|C1274040|C0079809|C0034869|C0332257|C0449238|C0040223|C0680968|C0013956|C1704729|G0000000|C0014563
The patients’ parents were instructed to contact the investigator if the patients were unable to take the study drug as prescribed.,The patients’ parents instructed contact investigator patients unable study drug prescribed.,G0000000|G0000000|C0030551|G0000000|C0332158|C0035173|C0030705|C1299582|C0557651|C0013227|C0278329
All children within the study completed the Griffiths Mental Development Scale (GMDS14) between 2003 and 2010.,All children study completed Griffiths Mental Development Scale (GMDS14) 2003 2010.,G0000000|C0008059|C0557651|C0205197|G0000000|C0229992|C0243107|C0175659|G0000000|G0000000|G0000000
The primary efficacy measure was the difference in change in the IBD Quality of Life Questionnaire results (QOL) between probiotic vs. placebo at week 4.,The primary efficacy measure difference change IBD Quality Life Questionnaire (QOL) probiotic vs. placebo week 4.,G0000000|C0205225|C1280519|C0079809|C1705241|C0392747|G0000000|C0332306|C0376558|C0034394|C0518214|C0525033|G0000000|C0032042|C0332174|G0000000
"Differences in median VAS scores for all other time points (24 h, 7 days, as well as 1, 3, and 6 months after surgery) were not significant [Table 3].","Differences median VAS scores time (24 h, 7 days, 1, 3, 6 months surgery) [Table 3].",C1705241|C0549183|C0042815|C0449820|C0040223|C0450371|C0033727|G0000000|C0439228|G0000000|G0000000|G0000000|C0439231|C0038894|C0039224|G0000000
"Continuous abstinence from smoking was assessed at 8 and 26 weeks postpartum through self-report of no smoking since delivery date and biochemically verified through expired carbon monoxide levels of <10 ppm (Hajek et al., 2001) and/or a cotinine value of <20 ng/ml (McBride et al., 1999).","Continuous abstinence smoking assessed 8 26 weeks postpartum self-report smoking delivery biochemically verified expired carbon monoxide levels <10 ppm (Hajek al., 2001) and/or cotinine <20 ng/ml (McBride al., 1999).",C0549178|C3843422|C0037369|C1516048|G0000000|C0450371|C0439230|C0086839|C0681906|C0037369|C0011209|G0000000|C1711411|C0011065|C0007009|G0000000|C0441889|C0450371|C0439187|G0000000|C0202311|G0000000|G0000000|C0010194|C0450371|C0439275|G0000000|C0202311|G0000000
BMI: Body Mass Index; CES-D: Center for Epidemiologic Studies Depression Scale; FIQ: Fibromyalgia Impact Questionnaire; FM: fibromyalgia; FME: Fibromyalgia Education Control Group; FSS: Fatigue Severity Scale; LPA: lifestyle physical activity; SD: standard deviation; VAS: Visual Analogue Scale.,BMI: Body Mass Index; CES-D: Center Epidemiologic Studies Depression Scale; FIQ: Fibromyalgia Impact Questionnaire; FM: fibromyalgia; FME: Fibromyalgia Education Control Group; FSS: Fatigue Severity Scale; LPA: lifestyle physical activity; SD: standard deviation; VAS: Visual Analogue Scale.,G0000000|C0242821|C0577559|C0918012|C2699160|C0205099|C0014507|C0947630|C0011570|C0175659|G0000000|C0016053|C1825598|C0034394|C3540627|C0016053|G0000000|C0016053|C0013621|C0243148|C0441833|C0265224|C0015672|C0439793|C0175659|C1096202|C0023676|C0031809|C0205177|C2699239|C1442989|C0012727|C0042815|C0234621|C0243071|C0175659
The Shapiro-Wilk test was used to test the variables for normality.,The Shapiro-Wilk test test variables normality.,G0000000|G0000000|C0022885|C0022885|C0439828|C0949333
"The outcome of success or failure was determined by the following clinical and radiographic criteria: The presence of spontaneous pain, percussion/palpation, abscess, swelling, fistula, or pathologic mobility definitely indicated clinical failure.","The outcome success failure determined clinical radiographic criteria: The presence spontaneous pain, percussion/palpation, abscess, swelling, fistula, pathologic mobility clinical failure.",G0000000|C1274040|C0597535|C0231174|G0000000|C0205210|C0444708|C0243161|G0000000|C0150312|C0205359|C0030193|C0030987|C0000833|C0013604|C0016169|C1521733|C0425245|C0205210|C0231174
"However, Hollis and Wagner displayed that by supplementation of pregnant women with 4,000IU daily, 83.9% of women attained a minimal circulating 25 (OH) D level of at least 32 ng/ml (80nmol/ l) at the time of delivery and suggested 4,000 IU of vitamin D is a suitable dose to sustain a maternal serum level of vitamin D over 30 ng/ml and optimize cord blood 25 (OH) D levels (8).","However, Hollis Wagner displayed supplementation pregnant women 4,000IU daily, 83.9% women attained minimal circulating 25 (OH) D level 32 ng/ml (80nmol/ l) time delivery suggested 4,000 IU vitamin D suitable dose sustain maternal serum level vitamin D 30 ng/ml optimize cord blood 25 (OH) D levels (8).",G0000000|C1256218|G0000000|C0870432|C0242297|C0549206|C0043210|G0000000|C0332173|C0450371|C0043210|G0000000|C0547040|C0175630|C0450371|C0220853|C0073187|C0441889|C0450371|C0439275|G0000000|C0439394|C0040223|C0011209|C1705535|C1442061|C0049272|C0042890|C0073187|C3900053|C0178602|C0443318|C2347083|C0229671|C0441889|C0042890|C0073187|C0450371|C0439275|G0000000|C1550235|C0005767|C0450371|C0220853|C0073187|C0441889|G0000000
"The aim of the INTERACTIVE trial is to establish whether a six month, individualised exercise and nutrition program commencing within fourteen days of surgery for proximal femur fracture, results in clinically and statistically significant improvements in physical function, body composition and quality of life at an acceptable level of cost and resource use and without increasing the burden of caregivers.","The aim INTERACTIVE trial establish month, individualised exercise nutrition program commencing fourteen days surgery proximal femur fracture, clinically statistically improvements physical function, body composition quality life acceptable level cost resource increasing burden caregivers.",G0000000|C1947946|C1704675|C0008976|C0443211|C0332177|G0000000|C0015259|C0028707|C1709697|C3274784|C3715152|C0439228|C0038894|C0205107|C0015811|C0016658|G0000000|C0038215|C2986411|C0031809|C0031843|C0242821|C0486616|C0332306|C0376558|C1879533|C0441889|C0010186|C0035201|C0442808|C2828008|C0085537
"The most frequent exercise barriers were being too busy (n = 300) or having family responsibilities (n = 119), followed by being too tired (n = 106).","The frequent exercise barriers busy (n = 300) family responsibilities (n = 119), tired (n = 106).",G0000000|C0332183|C0015259|C1706912|G0000000|C0369718|G0000000|C1442061|C0015576|C0678341|C0369718|G0000000|C1442061|C0557875|C0369718|G0000000|C1442061
"Last, we documented the types of adverse events in the MP and PL groups.","Last, documented types adverse events MP PL groups.",C1517741|C1301725|C0332307|G0000000|C0441471|C0024944|C3897966|C0441833
GI Symptoms were assessed using the GI Symptom subscale of the Children's Somatization Inventory (33-35).,GI Symptoms assessed GI Symptom subscale Children's Somatization Inventory (33-35).,C1708130|C0683368|C1516048|C1708130|C1457887|G0000000|C0008059|C0149779|C0021941|C0450371
"Therefore, a total of 81 patients were evaluated at 6 months after discharge.","Therefore, total 81 patients evaluated 6 months discharge.",G0000000|C0439175|C0450371|C0030705|C0220825|G0000000|C0439231|C0012621
The primary end point was cognitive deterioration (decline >1 SD from baseline on at least 1 cognitive test at 3 months) in participants who completed the baseline and 3-month assessments.,The primary cognitive deterioration (decline >1 SD baseline 1 cognitive test 3 months) participants completed baseline 3-month assessments.,G0000000|C0205225|C1516691|C0868945|G0000000|G0000000|C2699239|C0168634|G0000000|C1516691|C0022885|G0000000|C0439231|C0679646|C0205197|C0168634|C0332177|C1261322
"Descriptive statistics on demographic and cognitive measures at baseline (n = 13), and primary (NAA/Cr) and secondary (ADAS-Cog) measures at baseline and year 1 (n = 10).","Descriptive statistics demographic cognitive measures baseline (n = 13), primary (NAA/Cr) secondary (ADAS-Cog) measures baseline 1 (n = 10).",C0678257|C0038215|C0011298|C1516691|C0079809|C0168634|C0369718|G0000000|C0450371|C0205225|C0067684|C0027627|C3539026|C0079809|C0168634|G0000000|C0369718|G0000000|C0450371
"Number of days with respiratory and gastrointestinal symptoms, absences from day care because of illness, respiratory tract infections diagnosed by a doctor, and course of antibiotics.","Number days respiratory gastrointestinal symptoms, absences day care illness, respiratory tract infections diagnosed doctor, antibiotics.",C0237753|C0439228|C0521346|C0521362|C0683368|C0424530|C0332173|C1947933|C0221423|C0521346|C1185740|C3714514|C0011900|C0031831|C0003232
The response rate was 48.7%.,The response rate 48.7%.,G0000000|C0871261|C0871208|C0450371
"Knowledge, attitudes, sun protection behavior, melanin index, and sun damage (n = 170) From baseline to the 6-week follow-up, there were statistically significant increases in knowledge, concern about developing skin cancer, recognition of personal risk of developing skin cancer, confidence in sun protection preventing skin cancer, and willingness to change behavior in the intervention group compared with the standard of care group (P < 0.05, Wilcoxon rank sum test) (Table (Table3).3).","Knowledge, attitudes, sun protection behavior, melanin index, sun damage (n = 170) From baseline 6-week follow-up, statistically increases knowledge, concern developing skin cancer, recognition personal risk developing skin cancer, confidence sun protection preventing skin cancer, willingness change behavior intervention compared standard care (P < 0.05, Wilcoxon rank sum test) (Table (Table3).3).",C0376554|C0004271|C0038817|C1545588|C0004927|C0025196|C0918012|C0038817|C0010957|C0369718|G0000000|C1442061|G0000000|C0168634|C0332174|C0589120|C0038215|C0205217|C0376554|C2699424|G0000000|C0444099|C0006826|C0524637|C1519021|C0035647|G0000000|C0444099|C0006826|C0237529|C0038817|C1545588|C0309872|C0444099|C0006826|C0600109|C0392747|C0004927|C0886296|C1707455|C1442989|C1947933|C0369773|G0000000|C0450371|G0000000|C0699794|C1515051|C0022885|C0039224|G0000000
"Eleven and two patients reported 0 exacerbations in years 1 and 2, and 4 and 5, respectively.","Eleven patients reported 0 exacerbations 1 2, 4 5, respectively.",C0205457|C0030705|C0684224|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000
"Comparisons of variables, including weight, length, and MUAC between groups across time at baseline, 10, 20, and 30 weeks were made by repeated-measures analysis of variance (ANOVA), using PROC MIXED on SAS (SAS Institute, 2004, Release 9.1).","Comparisons variables, including weight, length, MUAC time baseline, 10, 20, 30 weeks repeated-measures analysis variance (ANOVA), PROC MIXED SAS (SAS Institute, 2004, Release 9.1).",C1707455|C0439828|C0332257|C0005910|C1444754|G0000000|C0040223|C0168634|C0450371|C0450371|C0450371|C0439230|C0205341|C0002778|C1711260|G0000000|C1418943|C0205430|C0605290|C0605290|C0021622|G0000000|C0030685|G0000000
"In the case of children admitted with bilateral pitting oedema, recovery was defined as the absence of bilateral pitting oedema, being clinically well and a MUAC >11.0 cm (Government of Malawi and Ministry of Health 2007).","In children admitted bilateral pitting oedema, recovery defined absence bilateral pitting oedema, clinically MUAC >11.0 cm (Government Malawi Ministry Health 2007).",G0000000|C0008059|C0184666|C0238767|C0205323|C0013604|C0237820|C1704788|C0332197|C0238767|C0205323|C0013604|G0000000|G0000000|G0000000|C0018104|C0024548|G0000000|C0018684|G0000000
Endoscopic recurrence was defined as grade 2 or higher of Rutgeerts scoring system.,Endoscopic recurrence defined grade 2 Rutgeerts scoring system.,C0014245|C0034897|C1704788|C0441800|G0000000|G0000000|C0449820|C0449913
"Swabs were not obtained from the remaining 435 reported ILI episodes for the following reasons: 72.0% (n=313) did not meet the CDC definition of an ILI and were therefore included in the URI symptom count, 21.4% of episodes (n=93) were reported after 48 hours of ILI onset or the participant refused to be swabbed, and the research staff were unable to reach the participant in 6.7% of episodes (n=29).","Swabs remaining 435 reported ILI episodes reasons: 72.0% (n=313) meet CDC definition ILI included URI symptom count, 21.4% episodes (n=93) reported 48 hours ILI onset participant refused swabbed, staff unable reach participant 6.7% episodes (n=29).",C0183753|C1527428|C1442061|C0684224|G0000000|C0332189|C0392360|C0450371|C0369718|C1550543|C0007670|C1550452|G0000000|C0332257|G0000000|C1457887|C0750480|C0450371|C0332189|C0369718|C0684224|C0450371|C0439227|G0000000|C0206132|C0679646|C1548564|C0183753|C0851286|C1299582|C2584321|C0679646|G0000000|C0332189|C0369718
"This study examined the effectiveness of acute consumption of cocoa-flavanols on indices of muscle recovery including: subsequent exercise performance, creatine kinase, muscle tenderness, force, and self-perceived muscle soreness.","This study examined effectiveness acute consumption cocoa-flavanols indices muscle recovery including: subsequent exercise performance, creatine kinase, muscle tenderness, force, self-perceived muscle soreness.",G0000000|C0557651|C0332128|C1280519|C0205178|C0009830|C0006622|C4033634|C0026845|C0237820|C0332257|C0332282|C0015259|C0597198|C0010286|C0031727|C0026845|C0234233|C0441722|C0036588|C0026845|C0234233
The study’s primary outcome was the amount of exercise participation.,The study’s primary outcome amount exercise participation.,G0000000|G0000000|C0205225|C1274040|C1265611|C0015259|C0679823
"Particularly when the physical exercises be done fixed and regularly, the vitality would be more.","Particularly physical exercises fixed regularly, vitality more.",G0000000|C0031809|C0015259|C0443218|G0000000|C0424589|C0205172
"Figure 2 Treatment differences for CD8 T lymphocytes, CD68 macrophages, eosinophils and neutrophils.","Figure 2 Treatment differences CD8 T lymphocytes, CD68 macrophages, eosinophils neutrophils.",G0000000|G0000000|C1705241|C0285590|C2603360|C0024264|G0000000|C0024432|C0014467|C0027950
"The primary objective of the study was to evaluate changes in eGFR following 52 weeks of daily treatment with 150 μg aleglitazar and 8 weeks’ follow-up observation after the last study medication, in comparison with 45 mg pioglitazone.","The primary objective study evaluate eGFR 52 weeks daily treatment 150 μg aleglitazar 8 weeks’ follow-up observation study medication, comparison 45 pioglitazone.",G0000000|C0205225|C0018017|C0557651|C0220825|C1739039|C0450371|C0439230|C0332173|C0039798|C1442061|G0000000|C2348244|G0000000|G0000000|C0589120|C0302523|C0557651|C0013227|C1707455|C0450371|C0071097
"Smokers had a 1.6 and 3 times higher risk of recurrence and progression to invasive cancer, respectively.","Smokers 1.6 3 times risk recurrence progression invasive cancer, respectively.",C0337664|G0000000|G0000000|C0040223|C0035647|C0034897|C0242656|C0205281|C0006826|G0000000
"Pyrantel has been extensively studied in the past and results demonstrated a good efficacy against Ascaris lumbricoides and the hookworms, but poor efficacy against Trichuris trichiura (DESOWITZ et al., 1976; HSIEH & CHEN, 1973; ISMAIL et al., 1991; LONG Qi et al., 1992).","Pyrantel extensively studied demonstrated efficacy Ascaris lumbricoides hookworms, poor efficacy Trichuris trichiura (DESOWITZ al., 1976; HSIEH & CHEN, 1973; ISMAIL al., 1991; LONG Qi al., 1992).",C0034235|G0000000|C0557651|G0000000|C1280519|C0003954|G0000000|C0002830|C0032854|C1280519|C0040955|C3129718|G0000000|C0202311|G0000000|G0000000|G0000000|C0999213|G0000000|G0000000|C0202311|G0000000|C0205166|C0376586|C0202311|G0000000
"Safety outcomes included serum levels, adverse events, hospitalizations, and mortality.","Safety outcomes included serum levels, adverse events, hospitalizations, mortality.",C0036043|C1274040|C0332257|C0229671|C0441889|G0000000|C0441471|C0019993|C0026565
The subject’s hands were then checked for fluorescent contamination under UVA light.,The subject’s hands checked fluorescent contamination UVA light.,G0000000|G0000000|C0018563|C1283174|C0303920|C0259846|G0000000|C0023693
Children were treated with either HO-RUTF or standard RUTF.,Children treated HO-RUTF standard RUTF.,C0008059|C1522326|C0019905|C1442989|G0000000
Only the quitting benefit tracker was significantly associated with continuous abstinence at 1 month (OR 3.85; CI 2.15 to 6.91) and 6 months (OR 4.27; CI 1.53 to 11.88).,Only quitting benefit tracker continuous abstinence 1 month (OR 3.85; CI 2.15 6.91) 6 months (OR 4.27; CI 1.53 11.88).,C0205171|C0748223|C0814225|C1550489|C0549178|C3843422|G0000000|G0000000|C0450371|C0008107|C0450371|C0450371|G0000000|C0439231|G0000000|C0450371|C0008107|C0450371|C0450371
"Time-to-event analyses will be used to compare the effects of the study drug on the onset of delirium, duration of mechanical ventilation, ICU and hospital length of stay.","Time-to-event analyses compare effects study drug onset delirium, duration mechanical ventilation, ICU hospital length stay.",C0040223|C0002778|C1707455|C1280500|C0557651|C0013227|C0206132|C0011206|C0449238|C0443254|C0035203|C0021708|C0019994|C1444754|G0000000
"The following assessments will be conducted prior to surgery, 4 weeks post surgery and at 4 weeks, 6, 12 and 24 months post treatment: (1) MD Anderson Dysphagia Inventory score (MDADI); (2) Water swallow test (WST); (3) Performance Status Scale-Head and Neck (PSS-HN); (4) Quality of Life questionnaires (EORTC QLQ-C30 and EORTC QLQ-H&N35).","The assessments conducted prior surgery, 4 weeks post surgery 4 weeks, 6, 12 24 months post treatment: (1) MD Anderson Dysphagia Inventory score (MDADI); (2) Water swallow test (WST); (3) Performance Status Scale-Head Neck (PSS-HN); (4) Quality Life questionnaires (EORTC QLQ-C30 EORTC QLQ-H&N35).",G0000000|C1261322|C0004927|C0332152|C0038894|G0000000|C0439230|C0687676|C0038894|G0000000|C0439230|G0000000|C0450371|C0450371|C0439231|C0687676|C0039798|G0000000|G0000000|G0000000|C0011168|C0021941|C0449820|C3641803|G0000000|C0043047|C0326374|C0022885|G0000000|G0000000|C0597198|C0449438|C0175659|C0027530|C0019905|G0000000|C0332306|C0376558|C0034394|C1516985|G0000000|C1516985|C0033727
"The proportion of independent walkers and the time to achieve independent walking will be compared between the two groups using the logrank test, in which those who do not achieve independent walking are censored at the time they are discharged.","The proportion independent walkers time achieve independent walking compared logrank test, achieve independent walking censored time discharged.",G0000000|C1709707|C0085862|C0043016|C0040223|G0000000|C0085862|C0080331|C1707455|G0000000|C0022885|G0000000|C0085862|C0080331|C3889990|C0040223|C0030685
"SAILS eligibility criteria and study intervention have been reported previously, and summarized briefly herein.1 Patients were randomized (stratified by hospital site) to receive either enteral rosuvastatin or placebo until the earliest of 3 days after ICU discharge, study day 28, or death.","SAILS eligibility criteria study intervention reported previously, summarized herein.1 Patients randomized (stratified hospital site) receive enteral rosuvastatin placebo earliest 3 days ICU discharge, study day 28, death.",C0522727|C0013893|C0243161|C0557651|C0886296|C0684224|G0000000|G0000000|G0000000|C0030705|C0034656|C0205363|C0019994|C0205145|C1514756|C1304890|C0965129|C0032042|C1279919|G0000000|C0439228|C0021708|C0012621|C0557651|C0332173|C0450371|C0011065
Why then was vaccine uptake poor?,Why vaccine uptake poor?,G0000000|C0042210|C0243144|C0032854
The primary end point was morning pre-dose (trough) FEV1 at study end (48 weeks).,The primary morning pre-dose (trough) FEV1 study (48 weeks).,G0000000|C0205225|C0332170|C0439565|C0444506|G0000000|C0557651|C0450371|C0439230
Cell size was determined by a χ2 power analysis using one-week point prevalence abstinence at end of treatment and at 4-months follow-up from that study.,Cell size determined χ2 power analysis one-week prevalence abstinence treatment 4-months follow-up study.,C0007634|C0456389|G0000000|G0000000|C0032863|C0002778|C4082116|C0033105|C3843422|C0039798|C0439231|C0589120|C0557651
"The main outcome measures were range and speed of supported arm movement, range, straightness and smoothness of unsupported reaching, and the Rancho Los Amigos Functional Test of Upper Extremity Function.","The main outcome measures range speed supported arm movement, range, straightness smoothness unsupported reaching, Rancho Los Amigos Functional Test Upper Extremity Function.",G0000000|C0205225|C1274040|C0079809|C1514721|C0678536|C1521721|C0446516|C0026649|C1514721|C0445291|C0205357|G0000000|C2584321|G0000000|G0000000|C1823184|C0205245|C0022885|C1282910|C0015385|C0031843
"In-person evaluations at the study medical center were conducted at screening, baseline (immediately prior to randomization), at 10-weeks follow-up (shortly after the completion of the SMART sessions) and at 24 weeks (six months) follow-up.","In-person evaluations study medical center conducted screening, baseline (immediately prior randomization), 10-weeks follow-up (shortly completion SMART sessions) 24 weeks (six months) follow-up.",C1547564|C0220825|C0557651|C0199168|C0205099|C0004927|C0220908|C0168634|C0205548|C0332152|C0034656|C0450371|C0589120|G0000000|C0205197|G0000000|C1883016|C0450371|C0439230|C0205452|C0439231|C0589120
Presence and severity of pain were prospectively scored at randomization and after 4 weeks.,Presence severity pain prospectively scored randomization 4 weeks.,C0150312|C0439793|C0030193|G0000000|C0449820|C0034656|G0000000|C0439230
"A similar improvement in ASS to 2 hours was seen in the two groups (mean difference –0.08, 95% CI –0.97 to 0.80), there was a trend (p=0.07) towards a longer duration of oxygen therapy in the salbutamol group (17.8 hours (95% CI 8.5 to 37.5) v 7.0 hours (95% CI 3.4 to 14.2)), and a significantly (p=0.02) longer length of hospital stay in the salbutamol group (85.4 (95% CI 66.1 to 110.2) hours v 57.3 hours (95% CI 45.6 to 72.0)).","A improvement ASS 2 hours (mean difference –0.08, 95% CI –0.97 0.80), trend (p=0.07) duration oxygen therapy salbutamol (17.8 hours (95% CI 8.5 37.5) 7.0 hours (95% CI 3.4 14.2)), (p=0.02) length hospital stay salbutamol (85.4 (95% CI 66.1 110.2) hours 57.3 hours (95% CI 45.6 72.0)).",G0000000|C2986411|C0324145|G0000000|C0439227|C0444504|C1705241|G0000000|C0450371|C0008107|G0000000|C0450371|C1521798|C0369773|C0449238|C0030054|C0039798|C0001927|C0450371|C0439227|C0450371|C0008107|G0000000|C0450371|G0000000|C0439227|C0450371|C0008107|G0000000|C0450371|C0369773|C1444754|C0019994|G0000000|C0001927|C0450371|C0450371|C0008107|C0450371|C1442061|C0439227|C0450371|C0439227|C0450371|C0008107|C0450371|C0450371
MTG: mirror therapy group; NDTG: neurodevelopmental therapy group; dom: dominant; ndom: nondominant MTG: mirror therapy group; NDTG: neurodevelopmental therapy group; BT: before treatment; AT: after treatment; ASIT: Ayres Sensory Integration Test; FI: finger identification; RLD: right-left discrimination; FMA: Fugl-Meyer Assessment; MI: Motricity Index; SULCS: Stroke Upper Limb Capacity Scale; BI: Barthel Index Primary and secondary outcome results of each subject in both groups are shown in Table 3.,MTG: mirror therapy group; NDTG: neurodevelopmental therapy group; dom: dominant; ndom: nondominant MTG: mirror therapy group; NDTG: neurodevelopmental therapy group; BT: treatment; AT: treatment; ASIT: Ayres Sensory Integration Test; FI: finger identification; RLD: right-left discrimination; FMA: Fugl-Meyer Assessment; MI: Motricity Index; SULCS: Stroke Upper Limb Capacity Scale; BI: Barthel Index Primary secondary outcome subject Table 3.,G0000000|C0181868|C0039798|C0441833|G0000000|C0599855|C0039798|C0441833|C3539821|C1527180|G0000000|G0000000|G0000000|C0181868|C0039798|C0441833|G0000000|C0599855|C0039798|C0441833|G0000000|C0039798|G0000000|C0039798|G0000000|G0000000|C0445254|C1158478|C0022885|C4050619|C0016129|C0020792|G0000000|C0205090|C0012632|C2332774|G0000000|C1261322|C3810814|G0000000|C0918012|G0000000|C0038454|C1282910|C0015385|C1516240|C0175659|G0000000|G0000000|C0918012|C0205225|C0027627|C1274040|C0681850|C0039224|G0000000
"Completed by students, the Participation in Life Activities questionnaire contains 15 yes/no questions summarized into three items designed to measure planning for, interference with, and prevention from participation in chosen life activities (Kintner, 2008; Kintner & Sikorskii, 2008).","Completed students, Participation Life Activities questionnaire 15 yes/no questions summarized items designed measure planning for, interference with, prevention participation chosen life activities (Kintner, 2008; Kintner & Sikorskii, 2008).",C0205197|C0038492|C0679823|C0376558|C0441655|C0034394|C0450371|C1512698|C1522634|G0000000|C1551338|C1707689|C0079809|C0032074|G0000000|C0521102|G0000000|C0199176|C0679823|C1707391|C0376558|C0441655|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000
None of the adverse effects shown in the three groups was severe enough to necessitate withdrawal from the study.,None adverse effects severe necessitate withdrawal study.,G0000000|G0000000|C1280500|C0205082|G0000000|C2349954|C0557651
"The wound was inspected daily and any development of flap necrosis, infection (cellulitis with a purulent discharge), or blister formation was charted.","The wound inspected daily development flap necrosis, infection (cellulitis purulent discharge), blister formation charted.",G0000000|C0043250|G0000000|C0332173|C0243107|C0038925|C0027540|C0009450|C0007642|C0439665|C0012621|C0005758|C0220781|C0007963
"Monitoring of participants for six months via weekly home visits will allow for an account of any change in accommodation, falls and injuries and any change in health status.","Monitoring participants months weekly visits account change accommodation, falls injuries change health status.",C0150369|C0679646|C0439231|C0332174|C0545082|C2741673|C0392747|C0000936|C0000921|C1510467|C0392747|C0018684|C0449438
There were no cases of bacteraemic pneumococcal infection.,There bacteraemic pneumococcal infection.,G0000000|C0004610|C0038410|C0009450
"Follow-up measurements included reported consultations in primary and secondary care in the two weeks after recruitment, prescriptions for and use of antibiotics, intention to consult with a similar illness in the future, parental enablement (using a modification of the patient enablement instrument29), satisfaction with the index consultation, reassurance, and value of any information given to them during the index consultation.","Follow-up measurements included reported consultations primary secondary care weeks recruitment, prescriptions antibiotics, intention consult illness future, parental enablement (using modification patient enablement instrument29), satisfaction consultation, reassurance, consultation.",C0589120|C0242485|C0332257|C0684224|C0009818|C0205225|C0027627|C1947933|C0439230|C2949735|C0033080|C0003232|C0162425|C0009818|C0221423|C0016884|C0030551|G0000000|C1524063|C0392747|C0030705|G0000000|G0000000|C0242428|C0009818|C0204558|C0009818
"Secondary measures included (1) acquisition of appropriate laboratory measures (hemoglobin [Hb], phosphorus, 25-hydroxy vitamin D, parathyroid hormone, LDL cholesterol, HbA1c, and urine albumin-to-creatinine ratio); (2) prescription of renoprotective medications, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs); (3) referral rates to nephrologists and vascular surgeons and for kidney transplantation assessment; (4) achieving BP control (<130/80 mmHg); (5) number of hospitalizations and emergency room visits; and (6) death.","Secondary measures included (1) acquisition laboratory measures (hemoglobin [Hb], phosphorus, 25-hydroxy vitamin D, parathyroid hormone, LDL cholesterol, HbA1c, urine albumin-to-creatinine ratio); (2) prescription renoprotective medications, angiotensin-converting enzyme inhibitors (ACEIs) angiotensin receptor blockers (ARBs); (3) referral rates nephrologists vascular surgeons kidney transplantation assessment; (4) achieving BP control (<130/80 mmHg); (5) hospitalizations emergency visits; (6) death.",C0027627|C0079809|C0332257|G0000000|C1706701|C0022877|C0079809|C0019046|C0019046|C0031705|C0450371|C0042890|C0073187|C0030518|C0019932|G0000000|C0008377|G0000000|C0042036|C0486293|C0456603|G0000000|C0033080|G0000000|C0013227|C0003018|C0014442|C0243077|G0000000|C0003018|C0597357|G0000000|C3888198|G0000000|C0034927|C0871208|C0260039|C0005847|C0582175|C0022646|C0040732|C1261322|G0000000|G0000000|C0037623|C0243148|C1442061|C0439475|G0000000|C0019993|C0013956|C0545082|G0000000|C0011065
The primary objective will be to assess the percentage of wounds healed after 8 weeks.,The primary objective assess percentage wounds healed 8 weeks.,G0000000|C0205225|C0018017|C1516048|C0439165|C0021501|C0205249|G0000000|C0439230
"Of these 19 events, none of them were serious: seven were insomnia, six high blood glucose, three epistaxis, two mild dysfunction of liver and one hypertension.","Of 19 events, serious: insomnia, blood glucose, epistaxis, mild dysfunction liver hypertension.",G0000000|C0450371|C0441471|C0205404|C0917801|C0005767|C0017725|C0014591|C2945599|C0031847|C0023884|C0020538
"In all four panels, the dashed lines indicate no change from baseline.","In panels, dashed lines change baseline.",G0000000|C0441833|C2827624|C0205132|C0392747|C0168634
"Although histological data are not available for that patient, the reaction is unlikely to have been due to treatment failure, as the culture result was negative 4 weeks after antibiotic completion and the lesion went on to heal at week 30 without recurrence after 2 months of follow-up.","Although histological data patient, reaction treatment failure, culture result negative 4 weeks antibiotic completion lesion heal week 30 recurrence 2 months follow-up.",G0000000|C0205462|C1511726|C0030705|C0443286|C0039798|C0231174|C0010453|C1274040|C0205160|G0000000|C0439230|C0003232|C0205197|C0221198|C0043240|C0332174|C0450371|C0034897|G0000000|C0439231|C0589120
"Primary outcome measures were the upper extremity motor subscale of the Fugl-Meyer Assessment (FMA), the Motricity Index (MI) upper extremity score, and the Stroke Upper Limb Capacity Scale (SULCS).","Primary outcome measures upper extremity motor subscale Fugl-Meyer Assessment (FMA), Motricity Index (MI) upper extremity score, Stroke Upper Limb Capacity Scale (SULCS).",C0205225|C1274040|C0079809|C1282910|C0015385|C1513492|G0000000|G0000000|C1261322|C2332774|G0000000|C0918012|C3810814|C1282910|C0015385|C0449820|C0038454|C1282910|C0015385|C1516240|C0175659|G0000000
"Primary outcomes include growth (length/height-for-age z-scores) and child development (mental, motor and social development).","Primary outcomes growth (length/height-for-age z-scores) child development (mental, motor social development).",C0205225|C1274040|C0018270|C1444754|C0871421|C0008059|C0243107|C0229992|C1513492|C0728831|C0243107
"Covariates included the visit week, treatment group, week-by-treatment group and the baseline BMI z-score.","Covariates included visit week, treatment group, week-by-treatment baseline BMI z-score.",G0000000|C0332257|C0545082|C0332174|C0039798|C0441833|C0332174|C0168634|G0000000|C0871421
"Secondary end points included time to intracranial failure, quality of life, functional independence, long-term cognitive status, and overall survival.","Secondary included time intracranial failure, quality life, functional independence, long-term cognitive status, survival.",C0027627|C0332257|C0040223|C0524466|C0231174|C0332306|C0376558|C0205245|C0085862|C0443252|C1516691|C0449438|C0038952
DHP had slightly higher uncorrected and corrected PCR at day 42 ACPR (96.3% and 97.3%) compared to AN (93.7% and 96.3%) for treatment of any malaria (Tables (Tables33 and and4).4).,DHP uncorrected corrected PCR day 42 ACPR (96.3% 97.3%) compared AN (93.7% 96.3%) treatment malaria (Tables (Tables33 and4).4).,G0000000|C4072785|C0205202|C0032520|C0332173|C0450371|G0000000|C0450371|C0450371|C1707455|G0000000|C0450371|C0450371|C0039798|C0024530|C0039224|G0000000|G0000000
Stomatitis grade III/IV occurred in 25% without versus 0% of patients with amifostine (P = 0.01).,Stomatitis grade III/IV occurred 25% versus 0% patients amifostine (P = 0.01).,C0038362|C0441800|C0439070|C1709305|C0450371|G0000000|G0000000|C0030705|C0015020|C0369773|G0000000|C0450371
Adrenal function was assessed by 24 hour urinary free cortisol levels at eight and 12 weeks and ACTH and low dose synacthen tests (LDST) at 12 weeks.,Adrenal function assessed 24 hour urinary free cortisol levels 12 weeks ACTH low dose synacthen tests (LDST) 12 weeks.,G0000000|C0031843|C1516048|C0450371|C0439227|C0042027|C0332296|C0020268|C0441889|C0450371|C0439230|C3539087|C0205251|C0178602|C0592151|C0022885|G0000000|C0450371|C0439230
"At week 12, patients whose mood symptoms were rated as having not improved on the modified Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change (mADCS-CGIC) (described below) had the option of tapering off of study medication and advancing to the treatment of their doctor’s choice.","At week 12, patients mood symptoms rated improved modified Alzheimer’s Disease Cooperative Study Clinical Global Impression Change (mADCS-CGIC) (described below) option tapering study medication advancing treatment doctor’s choice.",G0000000|C0332174|C0450371|C0030705|C0026516|C0683368|C0871208|C0184511|C0392747|G0000000|C0012634|C0679729|C0557651|C0205210|C0205246|C0596764|C0392747|G0000000|C1552738|G0000000|C1518601|C0441640|C0557651|C0013227|C0725066|C0039798|G0000000|C0008300
The primary outcome measure for both trials was change in spherical equivalent refractive error as determined by cycloplegic autorefraction.,The primary outcome measure trials change spherical equivalent refractive error determined cycloplegic autorefraction.,G0000000|C0205225|C1274040|C0079809|C0008976|C0392747|C0332501|C0205163|C0429585|C0743559|G0000000|C0010586|G0000000
"That may be because subjects in the almond group had higher systolic blood pressure at baseline, so the effect of almond on systolic blood pressure was attenuated.","That subjects almond systolic blood pressure baseline, almond systolic blood pressure attenuated.",G0000000|C0681850|C0440286|C0039155|C0005767|C0033095|C0168634|C0440286|C0039155|C0005767|C0033095|C0332161
Time from arrival at hospital to starting treatment and cessation of seizures.,Time arrival hospital starting treatment cessation seizures.,C0040223|C1555577|C0019994|C0439659|C0039798|C1880019|C0036572
Aim: The aim of the study was to evaluate the effect of high-dose probiotic supplementation to women during late pregnancy and lactation on cytokine profile and secretory IgA (sIgA) in breast milk and thus to study if differences in breast milk composition can affect lactoferrin and sIgA levels in stool samples of newborns.,Aim: The aim study evaluate high-dose probiotic supplementation women late pregnancy lactation cytokine profile secretory IgA (sIgA) breast milk study differences breast milk composition affect lactoferrin sIgA levels stool samples newborns.,C1947946|G0000000|C1947946|C0557651|C0220825|C0444956|C0525033|C0242297|C0043210|C0205087|C0032961|C0006147|C0079189|C1979963|C1327616|C2825347|C0020838|C0006141|C0026131|C0557651|C1705241|C0006141|C0026131|C0486616|C0001721|C0022942|C0020838|C0441889|C0015733|C0370003|C0021289
It is likely that this increased compliance with therapy accounts for the improvement in FOSQ score demonstrated in the BiFlex treated group.,It increased compliance therapy accounts improvement FOSQ score demonstrated BiFlex treated group.,G0000000|C0205217|C0009563|C0039798|C2741673|C2986411|G0000000|C0449820|G0000000|G0000000|C1522326|C0441833
1One missing CRF at month 12.,1One missing CRF month 12.,G0000000|C1551393|G0000000|C0332177|C0450371
"Secondary clinical endpoints will include achievement of partial orthodontic treatment success 12 months after implant insertion, quantity of direct implant-bone interface of the removed bone specimens, patient's acceptance rate of palatal implants, anchorage loss of the anchor tooth unit and overall success after completion of active treatment.","Secondary clinical endpoints achievement partial orthodontic treatment success 12 months implant insertion, quantity direct implant-bone interface removed bone specimens, patient's acceptance rate palatal implants, anchorage loss anchor tooth unit success completion active treatment.",C0027627|C0205210|C2349179|C0001072|C0728938|C0332276|C0039798|C0597535|C0450371|C0439231|C0021102|C0021107|C1265611|C0439851|C0021102|C1708533|C0849355|C0262950|C0370003|C0030705|G0000000|C0871208|C0700374|C0021102|C2825961|C1517945|C1293132|C0040426|C0439148|C0597535|C0205197|C0205177|C0039798
"Secondary endpoints included time to exacerbation based on adherence recorded by the I-neb, P. aeruginosa bacterial density, quality of life, and safety parameters.","Secondary endpoints included time exacerbation based adherence recorded I-neb, P. aeruginosa bacterial density, quality life, safety parameters.",C0027627|C2349179|C0332257|C0040223|G0000000|C1527178|C1510802|C0034869|C0021966|C0369773|G0000000|C0521009|C0178587|C0332306|C0376558|C0036043|C0449381
"Average thickness of tertiary dentin at baseline, 6 and 12 months according to the pulp capping material Intergroup comparison of change in distance from reference Point-A to Point-B Internal resorption was found to be present in two cases in Group-2 at 6 and 12 months follow-up, but none of the cases in Group-1 showed any changes.","Average thickness tertiary dentin baseline, 6 12 months pulp capping material Intergroup comparison change distance reference Point-A Point-B Internal resorption Group-2 6 12 months follow-up, Group-1 changes.",C1510992|C1280412|C0205372|C0011429|C0168634|G0000000|C0450371|C0439231|C0011399|C0302167|C0520510|G0000000|C1707455|C0392747|C0012751|C1514811|C2924612|C2924613|C0205102|C2985494|C0441857|G0000000|C0450371|C0439231|C0589120|C0441857|C0392747
Our clinical impression is that following an IVIG treatment the condition has a peak improvement somewhere between 6 months and one year after a single infusion.,Our clinical impression IVIG treatment condition peak improvement 6 months single infusion.,G0000000|C0205210|C0596764|C0085297|C0039798|C0012634|C0444505|C2986411|G0000000|C0037179|C0574032
The time taken for healing was recorded in both groups.,The time healing recorded groups.,G0000000|C0040223|C0043240|C0034869|C0441833
"In contrast, when patients were treated with olopatadine hydrochloride 0.2%, the evening ocular itch relief was significantly lower than the morning ocular itch relief (P < 0.0001).","In contrast, patients treated olopatadine hydrochloride 0.2%, evening ocular itch relief lower morning ocular itch relief (P < 0.0001).",G0000000|C0009924|C0030705|C1522326|C0527189|C1512523|G0000000|C0587117|C0015392|C0033774|C0564405|C0441994|C0332170|C0015392|C0033774|C0564405|C0369773|G0000000|G0000000
"Secondary outcomes were parasite and fever clearance times, recurrence at earlier time points, gametocytaemia at day 28 and 56, haemoglobin recovery, and safety and tolerability of the treatments.","Secondary outcomes parasite fever clearance times, recurrence earlier time points, gametocytaemia day 28 56, haemoglobin recovery, safety tolerability treatments.",C0027627|C1274040|C0030498|C0015967|C0449297|C0040223|C0034897|C1279919|C0040223|C1552961|G0000000|C0332173|C0450371|C0450371|C0019046|C0237820|C0036043|C3274448|C0087111
"Analysis of posttest scores revealed no differences between groups for 30-day reports of alcohol, marijuana, poly drug use, or total substance use (alcohol and drugs).","Analysis posttest scores revealed differences 30-day reports alcohol, marijuana, poly drug use, total substance (alcohol drugs).",C0002778|G0000000|C0449820|C0443289|C1705241|C0450371|C0684224|C0001962|C0024808|C0032400|C0013227|C0042153|C0439175|C0439861|C0001962|C0013227
This was achieved without an increased risk of adverse events [15].,This achieved increased risk adverse events [15].,G0000000|G0000000|C0205217|C0035647|G0000000|C0441471|C0450371
Memory assessment focused on episodic verbal memory tasks.,Memory assessment focused episodic verbal memory tasks.,C0025260|C1261322|C0205234|C1455761|C0439824|C0025260|C3540678
"Relative to placebo, gabapentin significantly reduced cannabis use as measured both by urine toxicology (p=0.001) and by the Timeline Followback Interview (p=0.004), and significantly decreased withdrawal symptoms as measured by the Marijuana Withdrawal Checklist (p<0.001).","Relative placebo, gabapentin reduced cannabis measured urine toxicology (p=0.001) Timeline Followback Interview (p=0.004), decreased withdrawal symptoms measured Marijuana Withdrawal Checklist (p<0.001).",C0080103|C0032042|C0060926|C0392756|C0024808|C0444706|C0042036|C0040541|C0369773|C0145943|G0000000|C0021822|C0369773|C0205216|C2349954|C0683368|C0444706|C0024808|C2349954|C1707357|C0369773
A future efficacy RCT will assess if BP control is sustained beyond 9 months.,A future efficacy RCT assess BP control sustained 9 months.,G0000000|C0016884|C1280519|G0000000|C1516048|C0037623|C0243148|C0443318|G0000000|C0439231
‡Extra oxygen requirement at 36 weeks of gestation.,‡Extra oxygen requirement 36 weeks gestation.,G0000000|C0030054|C1514873|C0450371|C0439230|C0032961
"Secondary objectives were VE against virological and clinical endpoints associated with HPV-16/18 and with high-risk HPV types, immunogenicity and safety.","Secondary objectives VE virological clinical endpoints HPV-16/18 high-risk HPV types, immunogenicity safety.",C0027627|C0018017|C0042469|C0205466|C0205210|C2349179|C0021344|C0332167|C0021344|C0332307|C4054739|C0036043
"Theraputic effects[28]: complete remission (complete disappearance of symptoms with mucous membrane returned to normal in colonoscopy), partial remission (abatement of symptoms with conditions of mucous membrane improved, only a small amount of red blood cells and leucocytes found in routine stool test), no remission(no obvious changes both in symptoms and in colonoscopy).","Theraputic effects[28]: complete remission (complete disappearance symptoms mucous membrane returned normal colonoscopy), partial remission (abatement symptoms conditions mucous membrane improved, amount red blood cells leucocytes routine stool test), remission(no obvious symptoms colonoscopy).",G0000000|C1280500|C0205197|C0544452|C0205197|G0000000|C0683368|C0026727|C0025255|C0332156|C0205307|C0009378|C0728938|C0544452|G0000000|C0683368|C0012634|C0026727|C0025255|C0184511|C1265611|C0332575|C0005767|C0007634|C0023516|C0205547|C0015733|C0022885|C0544452|G0000000|C0683368|C0009378
There were 2 primary analyses: one for SRT change score and one for self-reported memory improvement.,There 2 primary analyses: SRT change score self-reported memory improvement.,G0000000|G0000000|C0205225|C0002778|C0234742|C0392747|C0449820|C0681906|C0025260|C2986411
In most trials symptoms of sore throat disappeared within three or four days of antibiotic treatment.,In trials symptoms sore throat disappeared days antibiotic treatment.,G0000000|C0008976|C0683368|C0234233|C0031354|G0000000|C0439228|C0003232|C0039798
"Benzodiazepine consumption and sleep measures were evaluated by means of the sleep diary completed daily by participants.31 The main outcome measure was benzodiazepine discontinuation, confirmed by blood screening performed at each of 3 measurement points (immediately after completion of treatment and at 3- and 12-month follow-ups).","Benzodiazepine consumption sleep measures evaluated sleep diary completed daily participants.31 The main outcome measure benzodiazepine discontinuation, confirmed blood screening performed 3 measurement (immediately completion treatment 3- 12-month follow-ups).",C0005064|C0009830|C0037313|C0079809|C0220825|C0037313|C0376660|C0205197|C0332173|C0679646|G0000000|C0205225|C1274040|C0079809|C0005064|C0457454|C0521093|C0005767|C0220908|C0884358|G0000000|C0242485|C0205548|C0205197|C0039798|G0000000|C0450371|C0332283
"Acute gastrointesinal complications (Diarrhea and vomiting) were weekly assessed using Common Toxicity Criteria of the National Cancer Institute version 3.0 and functional living index emesis, respectively.","Acute gastrointesinal complications (Diarrhea vomiting) weekly assessed Common Toxicity Criteria National Cancer Institute version 3.0 functional living emesis, respectively.",C0205178|G0000000|C0009566|C0011991|C0042963|C0332174|C1516048|C0205214|C0040539|C0243161|C3245503|C0006826|C0021622|C0333052|G0000000|C0205245|C0376558|C0042963|G0000000
"Secondary end points were distant metastatic control, disease-free survival (DFS), and the overall survival (OS) for each group.","Secondary distant metastatic control, disease-free survival (DFS), survival (OS) group.",C0027627|C0443203|C0036525|C0243148|C0012634|C0038952|G0000000|C0038952|C0229090|C0441833
The primary composite endpoint of the Phase III randomized SWiTCH trial was to compare 30 months of alternative therapy (hydroxyurea and phlebotomy) with standard therapy (transfusions and chelation) for the prevention of secondary stroke and the reduction of transfusional iron overload in pediatric subjects with SCA and previous stroke.,The primary composite endpoint Phase III randomized SWiTCH trial compare 30 months alternative therapy (hydroxyurea phlebotomy) standard therapy (transfusions chelation) prevention secondary stroke reduction transfusional iron overload pediatric subjects SCA previous stroke.,G0000000|C0205225|C0205199|C2349179|C0205390|C0439070|C0034656|C1707719|C0008976|C1707455|C0450371|C0439231|C1523987|C0039798|C0020402|C0190979|C1442989|C0039798|C0005841|C3537131|C0199176|C0027627|C0038454|C0301630|C0005841|C0302583|G0000000|C0030755|C0681850|C0018790|C0205156|C0038454
"In patients with vivax malaria, there was prompt gametocyte clearance in both groups by day 4, but, consistent with more frequent treatment failure in the artemether-lumefantrine group, a significant proportion of patients (40.0%) had become positive for gametocytes by day 42, while none of the artemisinin-naphthoquine-treated children were gametocytemic at that time (see Figure 4).","In patients vivax malaria, prompt gametocyte clearance day 4, but, consistent frequent treatment failure artemether-lumefantrine group, proportion patients (40.0%) positive gametocytes day 42, artemisinin-naphthoquine-treated children gametocytemic time (see Figure 4).",G0000000|C0030705|G0000000|C0024530|C0871157|C0686869|C0449297|C0332173|G0000000|G0000000|C0332290|C0332183|C0039798|C0231174|C0936150|C0441833|C1709707|C0030705|C0450371|C0439178|C0686869|C0332173|C0450371|C0052430|C0008059|G0000000|C0040223|C0042789|G0000000|G0000000
Then patients’ EDSS and Plasma levels of ADMA were measured at baseline and 12 weeks later.,Then patients’ EDSS Plasma levels ADMA measured baseline 12 weeks later.,C1883708|G0000000|C0451246|C0032105|C0441889|G0000000|C0444706|C0168634|C0450371|C0439230|C0205087
"There was no difference in arm volume of lymphoedema or extra-cellular fluid between groups at week 8; however, at week 12, arm volume increased more for the intervention group than the control group (p = 0.032).","There difference arm volume lymphoedema extra-cellular fluid week 8; however, week 12, arm volume increased intervention control (p = 0.032).",G0000000|C1705241|C0446516|C0449468|C0024236|C0007634|C0005889|C0332174|G0000000|G0000000|C0332174|C0450371|C0446516|C0449468|C0205217|C0886296|C0243148|G0000000
The Cohen-Mansfield agitation inventory20 was used to measure the reported agitated and disruptive behaviours of residents.,The Cohen-Mansfield agitation inventory20 measure reported agitated disruptive behaviours residents.,G0000000|G0000000|C0085631|G0000000|C0079809|C0684224|C0085631|C0332453|C0004927|C1320928
This article describes findings examining the efficacy of BIs on peer violence and alcohol misuse at 12 months.,This article describes findings examining efficacy BIs peer violence alcohol misuse 12 months.,G0000000|C1706852|G0000000|C2607943|C0332128|C1280519|C0556985|C0679739|C0042693|C0001962|C0549649|C0450371|C0439231
FVC did not change.,FVC change.,C3714541|C0392747
At each clinic visit urine samples were examined under an ultraviolet (UV) lamp in order to observe fluorescence signifying ingestion of the study capsules.,At clinic visit urine samples examined ultraviolet (UV) lamp observe fluorescence signifying ingestion study capsules.,G0000000|C0002424|C0545082|C0042036|C0370003|C0332128|C1532472|C0006409|C0392223|C1441672|C0016315|G0000000|C0232478|C0557651|C0006935
"Response rate was between 13 and 51%, and OS between 5.3 and 10.3 months.","Response rate 13 51%, OS 5.3 10.3 months.",C0871261|C0871208|C0450371|C0450371|C0229090|G0000000|C0450371|C0439231
"Secondary outcomes included rates of clinical cultures positive for multi-drug resistant organisms, blood culture contamination, healthcare-associated bloodstream infections, and rates of the primary outcome by ICU.","Secondary outcomes included rates clinical cultures positive multi-drug resistant organisms, blood culture contamination, healthcare-associated bloodstream infections, rates primary outcome ICU.",C0027627|C1274040|C0332257|C0871208|C0205210|C0010453|C0439178|C0439064|C0332325|C0029235|C0005767|C0010453|C0259846|C0086388|C0005775|C3714514|C0871208|C0205225|C1274040|C0021708
"Dementia care mapping, an observational tool for quality of life research, was used to develop person centred care practice.21 Baseline assessments were carried out by the trial's clinicians and psychology research assistants.","Dementia care mapping, observational tool quality life research, develop person centred care practice.21 Baseline assessments carried trial's clinicians psychology assistants.",C0011265|C1947933|C1283195|C1518527|C0336791|C0332306|C0376558|C0035168|G0000000|C0027361|C0205099|C1947933|C0237607|C0168634|C1261322|C0206243|C0008976|C0871685|C0033909|C0011327
"Using data of hospitalized adolescent and adult patients with influenza A(H1N1)pdm09 viral pneumonia, prospectively collected from 407 hospitals in mainland China, the effects of low‐to‐moderate‐dose (25‐150 mg d−1) and high‐dose (>150 mg d−1) corticosteroids on 30‐day mortality, 60‐day mortality, and nosocomial infection were assessed with multivariate Cox regression and propensity score‐matched case–control analysis.","Using data hospitalized adolescent adult patients influenza A(H1N1)pdm09 viral pneumonia, prospectively collected 407 hospitals mainland China, effects low‐to‐moderate‐dose (25‐150 d−1) high‐dose (>150 d−1) corticosteroids 30‐day mortality, 60‐day mortality, nosocomial infection assessed multivariate Cox regression propensity score‐matched case–control analysis.",C1524063|C1511726|C0701159|C0205653|C0001675|C0030705|C0021400|G0000000|C0521026|C0032285|G0000000|C1516695|C1442061|C0019994|G0000000|C0008115|C1280500|G0000000|G0000000|G0000000|G0000000|C1442061|G0000000|C0001617|G0000000|C0026565|G0000000|C0026565|C0019994|C0009450|C1516048|G0000000|G0000000|C0684320|G0000000|G0000000|G0000000|C0002778
"There were, however, no significant differences in the percentage of days with symptoms or in the frequency, severity, or duration of episodes of upper or lower respiratory symptoms or of reduced peak expiratory flow rate during the treatment period between the two groups.","There were, however, differences percentage days symptoms frequency, severity, duration episodes upper lower respiratory symptoms reduced peak expiratory flow rate treatment period groups.",G0000000|G0000000|G0000000|C1705241|C0439165|C0439228|C0683368|C0376249|C0439793|C0449238|C0332189|C1282910|C0441994|C0521346|C0683368|C0392756|C0444505|C0231800|C0806140|C0871208|C0039798|C0439531|C0441833
"We compared secondary outcomes—namely, length of hospital stay and blood gas measurements (pH, arterial carbon dioxide, bicarbonate, and arterial oxygen)—by using Student’s t tests after transformation to remove skewness.","We compared secondary outcomes—namely, length hospital stay blood gas measurements (pH, arterial carbon dioxide, bicarbonate, arterial oxygen)—by Student’s tests transformation remove skewness.",G0000000|C1707455|C0027627|G0000000|C1444754|C0019994|G0000000|C0005767|C0017110|C0242485|C0450407|C0003842|C0007009|C0678717|C0005367|C0003842|G0000000|G0000000|C0022885|C0040682|C0849355|G0000000
"Among young persons with chronic migraine, the use of CBT plus amitriptyline resulted in greater reductions in headache frequency and migraine-related disability compared with headache education plus amitriptyline.","Among persons chronic migraine, CBT amitriptyline reductions headache frequency migraine-related disability compared headache education amitriptyline.",G0000000|C0027361|C0205191|C0149931|C0009244|C0002600|C0301630|C0018681|C0376249|C0149931|C0231170|C1707455|C0018681|C0013621|C0002600
Includes patients with onset of sustained EDSS progression at any time during the 8-year period.,Includes patients onset sustained EDSS progression time 8-year period.,C0332257|C0030705|C0206132|C0443318|C0451246|C0242656|C0040223|C0439234|C0439531
"Secondary outcomes included the rates of each individual infection included in the primary outcome, in-hospital mortality, hospital and ICU length of stay, rates of clinical cultures positive for multi-drug resistant organisms (number of positive cultures per 1000 patient-days), blood culture contamination (number of contaminants per 1000 patient-days), healthcare-associated bloodstream infections (HA-BSI), and rates of the primary outcome by ICU.","Secondary outcomes included rates individual infection included primary outcome, in-hospital mortality, hospital ICU length stay, rates clinical cultures positive multi-drug resistant organisms (number positive cultures 1000 patient-days), blood culture contamination (number contaminants 1000 patient-days), healthcare-associated bloodstream infections (HA-BSI), rates primary outcome ICU.",C0027627|C1274040|C0332257|C0871208|C0027361|C0009450|C0332257|C0205225|C1274040|C0019994|C0026565|C0019994|C0021708|C1444754|G0000000|C0871208|C0205210|C0010453|C0439178|C0439064|C0332325|C0029235|C0237753|C0439178|C0010453|G0000000|C0030705|C0005767|C0010453|C0259846|C0237753|C2827365|G0000000|C0030705|C0086388|C0005775|C3714514|C0018510|C0871208|C0205225|C1274040|C0021708
The primary outcome measure is the total change in score (from baseline to post-evaluation) of the affected upper extremity on the Action Research Arm Test (ARAT).,The primary outcome measure total change score (from baseline post-evaluation) upper extremity Action Research Arm Test (ARAT).,G0000000|C0205225|C1274040|C0079809|C0439175|C0392747|C0449820|G0000000|C0168634|C0687676|C1282910|C0015385|C0441472|C0035168|C0446516|C0022885|C1152215
"Data on serious adverse events were collected throughout the duration of the study (6 months), and data on all adverse events were collected during the first week.","Data adverse events collected duration study (6 months), data adverse events collected week.",C1511726|G0000000|C0441471|C1516695|C0449238|C0557651|G0000000|C0439231|C1511726|G0000000|C0441471|C1516695|C0332174
"Treadmill- and HAL-associated parameters like walking distance, speed and time as well as independent parameters like 10-meter walk test and 6-min walk test increased significantly up to 50% (Grasmücke et al., 2017).","Treadmill- HAL-associated parameters walking distance, speed time independent parameters 10-meter walk test 6-min walk test increased 50% (Grasmücke al., 2017).",C0184069|C0720810|C0449381|C0080331|C0012751|C0678536|C0040223|C0085862|C0449381|C0450371|C0080331|C0022885|C0702093|C0080331|C0022885|C0205217|C0450371|G0000000|C0202311|G0000000
"From pre to post intervention, there was a large effect size for the change in all nine social ToP items (r = .64–.86).","From pre post intervention, size change social ToP items (r = .64–.86).",G0000000|C0332152|C0687676|C0886296|C0456389|C0392747|C0728831|C1704458|C1551338|C0205090|G0000000|G0000000
Electrographic response consisted of resolution of the hypsarrhythmic pattern on both sleep and wake EEG.,Electrographic response consisted resolution hypsarrhythmic pattern sleep wake EEG.,G0000000|C0871261|C0332529|C1514893|C0037769|C0449774|C0037313|C0442696|C0013819
"Odds of women in the intervention group having had a mammogram, having had a clinical breast examination, and having performed breast self-examination was 6.75, 12.16, and 20.06, respectively, compared with women in the comparison group.","Odds women intervention mammogram, clinical breast examination, performed breast self-examination 6.75, 12.16, 20.06, respectively, compared women comparison group.",G0000000|C0043210|C0886296|C0024671|C0205210|C0006141|G0000000|C0884358|C0006141|C0080142|C0450371|C0450371|C0450371|G0000000|C1707455|C0043210|C1707455|C0441833
"Secondary outcomes included patient experience, loss to follow-up (failing to attend a scheduled clinic appointment for over 90 days; loss to follow-up was not considered as missing an attendance under the primary outcome), and change in health related outcomes (CD4 count, weight, and death).","Secondary outcomes included patient experience, loss follow-up (failing attend scheduled clinic appointment 90 days; loss follow-up considered missing attendance primary outcome), change health outcomes (CD4 count, weight, death).",C0027627|C1274040|C0332257|C0030705|C0237607|C1517945|C0589120|C0231175|C1999232|C0086960|C0002424|C0003629|C0450371|C0439228|C1517945|C0589120|C0750591|C1551393|C2827364|C0205225|C1274040|C0392747|C0018684|C1274040|C0285590|C0750480|C0005910|C0011065
"NTBI values were then related to the baseline liver iron concentration (LIC), the transfusional iron loading rates, the 24 h urine iron and the concentration of DFP complexes in the plasma in order to gain insight into chelatable iron pools and NTBI.","NTBI values baseline liver iron concentration (LIC), transfusional iron loading rates, 24 urine iron concentration DFP complexes plasma gain insight chelatable iron pools NTBI.",G0000000|C0042295|C0168634|C0023884|C0302583|C0004268|G0000000|C0005841|C0302583|C1708715|C0871208|C0450371|C0042036|C0302583|C0004268|C0022181|C1704241|C0032105|C1517378|C0233820|G0000000|C0302583|C0337051|G0000000
"For QoL analysis, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ‐C30) Version 3.0 was used; in particular, the version validated in Italian language 10.","For QoL analysis, European Organization Research Treatment Cancer Quality Life Questionnaire Core 30 (EORTC QLQ‐C30) Version 3.0 used; particular, version validated Italian language 10.",G0000000|C0518214|C0002778|C0239307|C0029237|C0035168|C0039798|C0006826|C0332306|C0376558|C0034394|C0444669|C0450371|C1516985|G0000000|C0333052|G0000000|C1273517|G0000000|C0333052|G0000000|C0022275|C0023008|C0450371
Mann-Whitney test showed no significant difference between the drug groups concerning Frankl score during the dental treatment (p= 0.83) (Figure 1).,Mann-Whitney test difference drug Frankl score dental treatment (p= 0.83) (Figure 1).,G0000000|C0022885|C1705241|C0013227|G0000000|C0449820|C0011365|C0039798|C0369773|C0450371|G0000000|G0000000
The test battery used in this study had an emphasis on memory and executive functioning.,The test battery study emphasis memory executive functioning.,G0000000|C0022885|C0337088|C0557651|G0000000|C0025260|C0871735|C0205245
Transcranial Magnetic Stimulation (TMS) will be performed on all participants in both groups at baseline then at 3 and 26 weeks post intervention.,Transcranial Magnetic Stimulation (TMS) performed participants baseline 3 26 weeks post intervention.,C0442348|C0024488|C1292856|G0000000|C0884358|C0679646|C0168634|G0000000|C0450371|C0439230|C0687676|C0886296
"It can be concluded that acupoint-site and fixed-site injection of BoNTA are able to significantly reduce migraine attack frequency, intensity, duration and associated symptoms.","It concluded acupoint-site fixed-site injection BoNTA reduce migraine attack frequency, intensity, duration symptoms.",G0000000|C0917903|C0001302|C0443218|C0021485|G0000000|G0000000|C0149931|C0277793|C0376249|C0522510|C0449238|C0683368
"To initially test if TENS was effective in decreasing the pain associated with fibromyalgia, we performed a preliminary study examining the effectiveness of a single treatment with high-frequency TENS.23 The group receiving active TENS showed a reduction in pain during movement, but not resting pain, compared with placebo.","To initially test TENS effective decreasing pain fibromyalgia, performed preliminary study examining effectiveness single treatment high-frequency TENS.23 The receiving active TENS reduction pain movement, resting pain, compared placebo.",C0040363|C0205265|C0022885|C0014518|C1280519|C0442797|C0030193|C0016053|C0884358|C0439611|C0557651|C0332128|C1280519|C0037179|C0039798|C0205212|C0014518|G0000000|C1514756|C0205177|C0014518|C0301630|C0030193|C0026649|C0035253|C0030193|C1707455|C0032042
"On the other hand, in the event pediatric patients are not immediately hospitalized due to RSV infection, the model foresees the possibility of hospitalizations (and the relating respiratory infection-related mortality rate) within the 12-month period following enrollment (administration of prophylaxis) and of recurrent wheezing episodes in the subsequent 24 months.","On hand, event pediatric patients hospitalized RSV infection, model foresees possibility hospitalizations (and relating respiratory infection-related mortality rate) 12-month period enrollment (administration prophylaxis) recurrent wheezing episodes subsequent 24 months.",G0000000|C0018563|C0441471|C0030755|C0030705|C0701159|G0000000|C0009450|C3161035|G0000000|C0332149|C0019993|G0000000|C0163712|C0521346|C0009450|C0026565|C0871208|C0450371|C0439531|C1516879|C0001554|C0033107|C2945760|C0043144|C0332189|C0332282|C0450371|C0439231
Aerobic capacity and the degree of EIB were assessed by both cycle ergometer and swimming ergometer before and after swimming training.,Aerobic capacity degree EIB assessed cycle ergometer swimming ergometer swimming training.,C1510824|C1516240|C0441889|G0000000|C1516048|C1511572|C0180748|C0039003|C0180748|C0039003|C0040607
"In examining fallers, participants are the unit of analysis rather than events (falls).","In examining fallers, participants unit analysis events (falls).",G0000000|C0332128|G0000000|C0679646|C0439148|C0002778|C0441471|C0000921
"In month 5, 157/168 (93%) participants both had a migraine and treated it with a triptan, using a mean of 1.8 (SD 1.1) doses per migraine; in month 10, 124/133 (93%) participants both had a migraine and treated it with a triptan, using a mean of 1.8 (1.1) doses per migraine; finally, in month 16, 89/96 (93%) participants both had a migraine and treated it with a triptan, using a mean of 1.9 (1.1) doses per migraine.","In month 5, 157/168 (93%) participants migraine treated triptan, 1.8 (SD 1.1) doses migraine; month 10, 124/133 (93%) participants migraine treated triptan, 1.8 (1.1) doses migraine; finally, month 16, 89/96 (93%) participants migraine treated triptan, 1.9 (1.1) doses migraine.",G0000000|C0332177|G0000000|C1442061|C0450371|C0679646|C0149931|C1522326|G0000000|G0000000|G0000000|G0000000|C0178602|C0149931|C0332177|C0450371|C1442061|C0450371|C0679646|C0149931|C1522326|G0000000|G0000000|G0000000|C0178602|C0149931|G0000000|C0332177|C0450371|C0450371|C0450371|C0679646|C0149931|C1522326|G0000000|G0000000|G0000000|C0178602|C0149931
"Deafness was defined as a hearing disability that required amplification.33 Blindness was defined as a corrected visual acuity of <20/200.33 Moderate or severe disabilities were defined as survival with at least 1 of the following complications: cerebral palsy, MDI < 70, deafness, or blindness.","Deafness defined hearing disability required amplification.33 Blindness defined corrected visual acuity <20/200.33 Moderate severe disabilities defined survival 1 complications: cerebral palsy, MDI < 70, deafness, blindness.",C0011053|C1704788|C0018767|C0231170|C1514873|C1517480|C0456909|C1704788|C0205202|C0234621|C0750509|C0450371|C0205081|C0205082|C0231170|C1704788|C0038952|G0000000|C0009566|G0000000|C0522224|C0993596|G0000000|C0450371|C0011053|C0456909
"f Follow-up radiograph with complete bone union at 6 months  Significant higher values were obtained in the plate group than in the nail group regarding mean operative time, blood loss, size of surgical wound, and length of hospital stay (P < 0.001) (Table 3).","Follow-up radiograph complete bone union 6 months Significant values plate nail operative time, blood loss, size surgical wound, length hospital stay (P < 0.001) (Table 3).",C0589120|C1306645|C0205197|C0262950|C2825217|G0000000|C0439231|C0237881|C0042295|C0005971|C0027342|C1882154|C0040223|C0005767|C1517945|C0456389|C0543467|C0043250|C1444754|C0019994|G0000000|C0369773|G0000000|C1442061|C0039224|G0000000
"Verification of abstinence from cannabis or other drugs was based on self-reports (smoking diary and TLFB), preliminary urine drug tests (QuickScreenTM Cup Multi Drug Screening Test, Confirm Biosciences, San Diego, CA, USA) and THC and metabolite concentrations in urine and plasma specimens.","Verification abstinence cannabis drugs based self-reports (smoking diary TLFB), preliminary urine drug tests (QuickScreenTM Cup Multi Drug Screening Test, Confirm Biosciences, San Diego, CA, USA) THC metabolite concentrations urine plasma specimens.",C0237944|C3843422|C0024808|C0013227|C1527178|C0681906|C0037369|C0376660|C0814210|C0439611|C0042036|C0013227|C0022885|G0000000|C1533124|C0439064|C0013227|C0220908|C0022885|C0521093|G0000000|C1826357|G0000000|C3887642|C0041703|C0039663|C0870883|C0086045|C0042036|C0032105|C0370003
"Differences in first attempt insertion success, insertion time, Apgar score, resuscitation outcome, and adverse effects were compared.","Differences attempt insertion success, insertion time, Apgar score, resuscitation outcome, adverse effects compared.",C1705241|C1516084|C0021107|C0597535|C0021107|C0040223|C0741195|C0449820|C0035273|C1274040|G0000000|C1280500|C1707455
The sporozoite infection status of each mosquito was determined by enzyme-linked immunoabsorbent assay as previously described [45].,The sporozoite infection status mosquito determined enzyme-linked immunoabsorbent assay [45].,G0000000|C0562648|C0009450|C0449438|C0026584|G0000000|C0014442|G0000000|C0005507|C0450371
"Over weeks 1–12, the mean proportions of patients with satisfactory relief were 62% for tegaserod and 44% for placebo.","Over weeks 1–12, proportions patients satisfactory relief 62% tegaserod 44% placebo.",C0205136|C0439230|G0000000|C1709707|C0030705|C0205410|C0564405|C0450371|C0537147|C0450371|C0032042
"Secondary outcomes evaluated were main axis astigmatism (J0, dioptric power of a Jackson cross cylinder with axis at 0°) and oblique astigmatism (J45, dioptric power of a Jackson cross cylinder with axis at 45°) by using the power vector approach.19 For J0 and J45, the average of the medians of the five autorefraction readings for each measure was used for analysis.","Secondary outcomes evaluated main axis astigmatism (J0, dioptric power Jackson cross cylinder axis 0°) oblique astigmatism (J45, dioptric power Jackson cross cylinder axis 45°) power vector approach.19 For J0 J45, average medians autorefraction readings measure analysis.",C0027627|C1274040|C0220825|C0205225|C0004457|C0004106|G0000000|G0000000|C0032863|G0000000|C2828360|C0181797|C0004457|G0000000|C0205315|C0004106|G0000000|G0000000|C0032863|G0000000|C2828360|C0181797|C0004457|G0000000|C0032863|C0086022|C0449445|G0000000|G0000000|G0000000|C1510992|C0549183|G0000000|C0034754|C0079809|C0002778
"The purpose of this study was to test empirically the efficacy of SAAF–T in preventing increases in conduct problems, substance use, substance use problems, and depressive symptoms among rural black adolescents.","The purpose study test empirically efficacy SAAF–T preventing increases conduct problems, substance use, substance problems, depressive symptoms rural black adolescents.",G0000000|C1285529|C0557651|C0022885|G0000000|C1280519|G0000000|C0309872|C0205217|C0004927|C1546466|C0439861|C0042153|C0439861|C1546466|G0000000|C0683368|C0240919|C0005680|C0205653
"The primary outcome criterion is the use of high-cost health services (that is,, number of hospital admissions and number of emergency department visits) during the 24-month follow-up period.","The primary outcome criterion high-cost health services (that is,, hospital admissions emergency department visits) 24-month follow-up period.",G0000000|C0205225|C1274040|C0243161|C0205250|C0018684|C0557854|G0000000|G0000000|C0019994|C0184666|C0013956|C1704729|C0545082|C0450371|C0589120|C0439531
"Becker's Health Belief Model (HBM) is the most widely used socio-cognitive theory used to explain parental behavior related to vaccination.8 The HBM includes the following: (1) perceived susceptibility (likelihood of getting a disease), (2) perceived severity (seriousness of disease outcome), (3) perceived benefit (efficacy of available preventive actions), and (4) perceived barriers (pain, side effects, or inconvenience of preventive action).8, 9 The HBM is an appropriate theory to explain vaccination behaviors and might be the most appropriate lens through which to observe the behaviors of parents regarding their children.10-12 An early application of the HBM aimed to learn about barriers to polio vaccination and ways to increase vaccination coverage.6 Evidence from previous studies suggests that behavioral changes and the decision to vaccinate one's children relate to perceptions of increased threat when parents recognize the severity and susceptibility of VPDs and/or perceive that the benefits of vaccination outweigh the risks, such as side effects.","Becker's Health Belief Model (HBM) socio-cognitive theory explain parental behavior vaccination.8 The HBM includes following: (1) perceived susceptibility (likelihood disease), (2) perceived severity (seriousness disease outcome), (3) perceived benefit (efficacy preventive actions), (4) perceived barriers (pain, effects, inconvenience preventive action).8, 9 The HBM theory explain vaccination behaviors lens observe behaviors parents children.10-12 An application HBM aimed learn barriers polio vaccination increase vaccination coverage.6 Evidence previous studies suggests behavioral decision vaccinate one's children relate perceptions increased threat parents recognize severity susceptibility VPDs and/or perceive benefits vaccination outweigh risks, effects.",G0000000|C0018684|C0004951|C3161035|G0000000|C1516691|C0871935|G0000000|C0030551|C0004927|C0042196|G0000000|G0000000|C0332257|C0231290|G0000000|C0030971|C0012655|C0033204|C0012634|G0000000|C0030971|C0439793|C0871902|C0012634|C1274040|G0000000|C0030971|C0814225|C1280519|C0445202|C0441472|G0000000|C0030971|C1706912|C0030193|C1280500|G0000000|C0445202|C0441472|G0000000|G0000000|G0000000|C0871935|G0000000|C0042196|C0004927|C0023317|C1441672|C0004927|C0030551|C0008059|G0000000|C0185125|G0000000|C1947946|C0023185|C1706912|C0032371|C0042196|C0442805|C0042196|C1551362|C3887511|C0205156|C0947630|C1705535|C0004927|C0679006|C1116171|C0205447|C0008059|C0163712|C0030971|C0205217|C0749385|C0030551|G0000000|C0439793|C0012655|G0000000|G0000000|G0000000|C0814225|C0042196|G0000000|C0035647|C1280500
This questionnaire will be administered at inclusion and 60 days after hospital discharge.,This questionnaire administered inclusion 60 days hospital discharge.,G0000000|C0034394|C1521801|C0007637|C0450371|C0439228|C0019994|C0012621
"There were no significant main effects on the RBMT Story Memory, nor was the interaction significant.","There main effects RBMT Story Memory, interaction significant.",G0000000|C0205225|C1280500|G0000000|C1547707|C0025260|C1704675|C0237881
Cost-effectiveness analyses with a 9-month time horizon (18 weeks of intervention and 18 weeks of follow-up) within the randomised controlled multicentre PACT study.,Cost-effectiveness analyses 9-month time horizon (18 weeks intervention 18 weeks follow-up) randomised controlled multicentre PACT study.,C0010181|C0002778|C0332177|C0040223|G0000000|G0000000|C0886296|G0000000|C0589120|G0000000|C2587213|C0439743|G0000000|C0557651
"Analysis of self-reported data indicated that compared to their cancer education comparison peers, participants in the HIV prevention interventions were significantly more likely to report consistent condom use during the past three months and HIV testing during the past 12 months.","Analysis self-reported data compared cancer education comparison peers, participants HIV prevention interventions report consistent condom months HIV testing 12 months.",C0002778|C0681906|C1511726|C1707455|C0006826|C0013621|C1707455|C0679739|C0679646|C0019682|C0199176|C0886296|C0684224|C0332290|C0009653|C0439231|C0019682|C0039593|C0450371|C0439231
"Parental monitoring will prove to be most consequential for preventing increases in conduct problems and substance use initiation, whereas racial socialization will be most consequential for fostering positive self-concept.","Parental monitoring prove consequential preventing increases conduct substance initiation, racial socialization consequential fostering positive self-concept.",C0030551|C0150369|G0000000|C0686907|C0309872|C0205217|C0004927|C0439861|C0589507|C0034510|C0037447|C0686907|C0242298|C0439178|C0036594
The primary outcome measure was the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAScog).,The primary outcome measure Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAScog).,G0000000|C0205225|C1274040|C0079809|G0000000|C0012634|C1261322|C0175659|C1516691|G0000000|C3539026
Primary efficacy criterion was intra-individual change in average daily Numeric Pain Rating Scale score from baseline to the last 4 weeks.,Primary efficacy criterion intra-individual change average daily Numeric Pain Rating Scale score baseline 4 weeks.,C0205225|C1280519|C0243161|C0347985|C0392747|C1510992|C0332173|C0237753|C0030193|C0871208|C0175659|C0449820|C0168634|G0000000|C0439230
Before and after training patients performed a maximal symptom limited incremental cycle test to determine peak work rate (Wpeak) followed by a constant work rate (CWR) test at 70% of Wpeak achieved in the baseline incremental test.,Before training patients performed maximal symptom limited incremental cycle test determine peak rate (Wpeak) constant rate (CWR) test 70% Wpeak achieved baseline incremental test.,C0332152|C0040607|C0030705|C0884358|C0205289|C1457887|C0439801|C1705117|C1511572|C0022885|G0000000|C0444505|C0871208|G0000000|C1547014|C0871208|G0000000|C0022885|C0450371|G0000000|G0000000|C0168634|C1705117|C0022885
Hot flash score and frequency changes during treatment week 6 were available for 163 (79%) of 207 patients.,Hot flash score frequency treatment week 6 163 (79%) 207 patients.,C0444519|C0181637|C0449820|C0376249|C0039798|C0332174|G0000000|C1442061|C0450371|C1442061|C0030705
"The pattern and incidence of adverse events does not appear to change over time with long-term treatment [14,29-32].","The pattern incidence adverse events change time long-term treatment [14,29-32].",G0000000|C0449774|C0021149|G0000000|C0441471|C0392747|C0040223|C0443252|C0039798|C0450371
"To determine whether the incidence of cholestasis, defined as a serum direct bilirubin >2mg/dL for ≥2 consecutive weeks, differs between the SIFE and FIFE groups.","To determine incidence cholestasis, defined serum direct bilirubin >2mg/dL ≥2 consecutive weeks, differs SIFE FIFE groups.",C0040363|G0000000|C0021149|C0008370|C1704788|C0229671|C0439851|C0005437|C3642216|G0000000|C1707491|C0439230|G0000000|G0000000|C0454909|C0441833
The primary outcome measure was the Fibromyalgia Impact Questionnaire Revised (FIQR).,The primary outcome measure Fibromyalgia Impact Questionnaire Revised (FIQR).,G0000000|C0205225|C1274040|C0079809|C0016053|C1825598|C0034394|C1527075|C3641329
"Secondary outcomes included time to confirmed disability, Multiple Sclerosis Functional Composite (MSFC) score and MRI metrics.","Secondary outcomes included time confirmed disability, Multiple Sclerosis Functional Composite (MSFC) score MRI metrics.",C0027627|C1274040|C0332257|C0040223|C0521093|C0231170|C0439064|C0036429|C0205245|C0205199|G0000000|C0449820|C0024485|C0699680
"Of the variables entered, only girls’ BMI at age 5 was significantly associated with girls’ change in BMI.","Of variables entered, girls’ BMI age 5 girls’ change BMI.",G0000000|C0439828|C1521975|G0000000|G0000000|C0001779|G0000000|G0000000|C0392747|G0000000
The primary end point was the proportion of patients who were seizure free 6 months after tumor resection.,The primary proportion patients seizure free 6 months tumor resection.,G0000000|C0205225|C1709707|C0030705|C0036572|C0332296|G0000000|C0439231|C0027651|C0015252
"Verbal anxiety scores and verbal pain scores, heart rate, systolic and diastolic blood pressure, intraocular pressure, and quality of operating conditions were recorded.","Verbal anxiety scores verbal pain scores, heart rate, systolic diastolic blood pressure, intraocular pressure, quality operating conditions recorded.",C0439824|C0003467|C0449820|C0439824|C0030193|C0449820|C0018787|C0871208|C0039155|C0012000|C0005767|C0033095|C3282905|C0033095|C0332306|C3242339|C0012634|C0034869
The DiaSorin 25(OH)D assay consists of a two-step procedure.,The DiaSorin 25(OH)D assay consists two-step procedure.,G0000000|G0000000|C0450371|C0005507|C0332529|C0205448|C0184661
Pain intensity: The visual analogue scale (VAS) was used to measure the subject's current level of pain intensity.,Pain intensity: The visual analogue scale (VAS) measure subject's current level pain intensity.,C0030193|C0522510|G0000000|C0234621|C0243071|C0175659|C0042815|C0079809|C0681850|C0521116|C0441889|C0030193|C0522510
"The secondary outcome measures include: functional ability, mobility, the number of journeys (monthly travel diaries), satisfaction with outdoor mobility, mood, health-related quality of life, resource use of health and social care.","The secondary outcome measures include: functional ability, mobility, journeys (monthly travel diaries), satisfaction outdoor mobility, mood, health-related quality life, resource health social care.",G0000000|C0027627|C1274040|C0079809|C0332257|C0205245|C0085732|C0425245|G0000000|C0332177|C0040802|C0376660|C0242428|G0000000|C0425245|C0026516|C0018684|C0332306|C0376558|C0035201|C0018684|C0728831|C1947933
"After baseline testing, the subjects are being followed for two years with three-monthly measurements of constant work rate treadmill exercise endurance time at 90% of the initial maximum work rate.","After baseline testing, subjects three-monthly measurements constant rate treadmill exercise endurance time 90% initial maximum rate.",G0000000|C0168634|C0039593|C0681850|C0205449|C0242485|C1547014|C0871208|C0184069|C0015259|C0518031|C0040223|C0450371|C0205265|C0806909|C0871208
The primary outcome is the variability of the displacement of the centre of mass during gait and a static-balance task.,The primary outcome variability displacement centre mass gait static-balance task.,G0000000|C0205225|C1274040|C2827666|C0012725|C0205099|C0577559|C0016928|C0441463|C3540678
"All aHRs account for the time-varying level of immunosuppression, log viral load, WAZ, and censoring prior to ART, and time fixed age at TB treatment initiation (Table 3).","All aHRs account time-varying level immunosuppression, log viral load, WAZ, censoring prior ART, time fixed age TB treatment initiation (Table 3).",G0000000|G0000000|C2741673|C0040223|C0441889|C0021079|C1708728|C0521026|C1550025|G0000000|C3889990|C0332152|C0003826|C0040223|C0443218|C0001779|G0000000|C0039798|C0589507|C0039224|G0000000
There was no difference in progression-free survival.,There difference progression-free survival.,G0000000|C1705241|C0242656|C0038952
The incidence of non‐bacteraemic pneumococcal pneumonia was 313 per 100 000 patients with COPD per year.,The incidence non‐bacteraemic pneumococcal pneumonia 313 100 000 patients COPD year.,G0000000|C0021149|G0000000|C0038410|C0032285|C1442061|G0000000|C0030705|C0024117|C0439234
"The primary endpoint was the proportion of patients with improvement of MS-related disability at month 9, confirmed at month 12.","The primary endpoint proportion patients improvement MS-related disability month 9, confirmed month 12.",G0000000|C0205225|C2349179|C1709707|C0030705|C2986411|C0039676|C0231170|C0332177|G0000000|C0521093|C0332177|C0450371
"The primary endpoint was the trough forced expiratory volume in 1 s (FEV1) on day 85 (predefined non-inferiority margin −50 mL), and the secondary endpoint was the 0- to 6-h weighted mean (WM) FEV1 on day 84.","The primary endpoint trough forced expiratory volume 1 (FEV1) day 85 (predefined non-inferiority margin −50 mL), secondary endpoint 0- 6-h weighted (WM) FEV1 day 84.",G0000000|C0205225|C2349179|C0444506|C0441722|C0231800|C0449468|G0000000|G0000000|C0332173|C0450371|G0000000|C1518422|C0205284|G0000000|C0439526|C0027627|C2349179|G0000000|C0033727|C0005910|G0000000|G0000000|C0332173|C0450371
"Three instruments were used to assess patients’ functioning and disability: 1) the SF-36 Mental Function scale, 2) the SF-36 Physical Function Scale, 3) The TOPS Total Pain Experience scale.","Three instruments assess patients’ functioning disability: 1) SF-36 Mental Function scale, 2) SF-36 Physical Function Scale, 3) The TOPS Total Pain Experience scale.",C0205449|C0348000|C1516048|G0000000|C0205245|C0231170|G0000000|C0037712|C0229992|C0031843|C0175659|G0000000|C0037712|C0031809|C0031843|C0175659|G0000000|G0000000|C0076833|C0439175|C0030193|C0237607|C0175659
The number of falls before and during the 12-week period was also recorded.,The falls 12-week period recorded.,G0000000|C0000921|C0450371|C0439531|C0034869
"Secondary endpoints included hemoglobin (Hb) on admission, Hb difference from randomization to admission, ICU admission, perioperative morbidity (defined as new onset infection, respiratory failure, renal impairment, deep venous thrombosis), discharge Hb, length of stay, Hb at follow-up, Hb difference from discharge to follow-up, iron status, 30-day mortality, and quality of life (QoL).","Secondary endpoints included hemoglobin (Hb) admission, Hb difference randomization admission, ICU admission, perioperative morbidity (defined onset infection, respiratory failure, renal impairment, deep venous thrombosis), discharge Hb, length stay, Hb follow-up, Hb difference discharge follow-up, iron status, 30-day mortality, quality life (QoL).",C0027627|C2349179|C0332257|C0019046|C0019046|C0184666|C0019046|C1705241|C0034656|C0184666|C0021708|C0184666|C1518988|C0026538|C1704788|C0206132|C0009450|C0521346|C0231174|C0022646|C0221099|C0205125|C0042449|C0040053|C0012621|C0019046|C1444754|G0000000|C0019046|C0589120|C0019046|C1705241|C0012621|C0589120|C0302583|C0449438|C0450371|C0026565|C0332306|C0376558|C0518214
"Secondary outcomes include all-cause hospitalization within 24 h, PRAM, vital signs, number of bronchodilator treatments by 240 min, and the association between the difference in the primary outcome between the groups, age, gender, baseline PRAM, atopy, and “viral induced wheeze” phenotype (Fig.","Secondary outcomes all-cause hospitalization 24 h, PRAM, vital signs, bronchodilator treatments 240 min, association difference primary outcome groups, age, gender, baseline PRAM, atopy, “viral induced wheeze” phenotype (Fig.",C0027627|C1274040|C0015127|C0019993|C0450371|C0033727|C0441454|C0442732|C0220912|C0006280|C0087111|C1442061|C0702093|C0004083|C1705241|C0205225|C1274040|C0441833|C0001779|C0079399|C0168634|C0441454|C0392707|G0000000|C0205263|G0000000|C0031437|C0349966
"Sensory disturbances were tested with Semmes–Weinstein filaments, and sensory deficits were categorized according to the Yale sensory scale.","Sensory disturbances tested Semmes–Weinstein filaments, sensory deficits categorized Yale sensory scale.",C0445254|C2699787|C0392366|G0000000|C0010851|C0445254|C2987487|C0871968|G0000000|C0445254|C0175659
The test was modified to allow the use of an assistive device and/or physical assistance from the examiner.,The test modified assistive device and/or physical assistance examiner.,G0000000|C0022885|C0392747|G0000000|C0025080|G0000000|C0031809|C0018896|G0000000
One patient who had herpetic infection used acyclovir.,One patient herpetic infection acyclovir.,C0205447|C0030705|C0019340|C0009450|C0001367
"Interviewers masked to participants' treatment group will assess outcomes at baseline and 6, 12 and 26 weeks after randomization.","Interviewers masked participants' treatment assess outcomes baseline 6, 12 26 weeks randomization.",C0021821|C0150108|C0679646|C0039798|C1516048|C1274040|C0168634|G0000000|C0450371|C0450371|C0439230|C0034656
FAC: Functional Ambulatory Category; MAS: Modified Ashworth Scale; LeFMA: Fugl-Meyer Assessment scale of Lower Extremity; MI: Motoricity Index; MBI: Modified Barthel Index.,FAC: Functional Ambulatory Category; MAS: Modified Ashworth Scale; LeFMA: Fugl-Meyer Assessment scale Lower Extremity; MI: Motoricity Index; MBI: Modified Barthel Index.,G0000000|C0205245|C0439841|C0683312|C1096155|C0392747|G0000000|C0175659|G0000000|G0000000|C1261322|C0175659|C0441994|C0015385|C3810814|C1513492|C0918012|C2985547|C0392747|G0000000|C0918012
The date of each acute exacerbation was taken as the date treatment was prescribed.,The acute exacerbation treatment prescribed.,G0000000|C0205178|G0000000|C0039798|C0278329
Overall survival (OS) in the two arms was similar; the median OS rates were 7.7 months in the erlotinib arm and 7.3 months in the control arm.,Overall survival (OS) arms similar; median OS rates 7.7 months erlotinib arm 7.3 months control arm.,C0282416|C0038952|C0229090|C0206655|C2348205|C0549183|C0229090|C0871208|G0000000|C0439231|C1135135|C0446516|G0000000|C0439231|C0243148|C0446516
The primary endpoint was a radiological response rate as assessed by the external response review committee.,The primary endpoint radiological response rate assessed external response review committee.,G0000000|C0205225|C2349179|C0034599|C0871261|C0871208|C1516048|C0205101|C0871261|C0282443|C2699414
"Using A-CASI assessment methodology, participants provided data on their depressive symptoms using the Geriatric Depression Screening Scale (GDS) at pre-intervention, post-intervention, and 4- and 8-month follow-up.","Using A-CASI assessment methodology, participants provided data depressive symptoms Geriatric Depression Screening Scale (GDS) pre-intervention, post-intervention, 4- 8-month follow-up.",C1524063|C2828256|C1261322|C0969625|C0679646|C1999230|C1511726|G0000000|C0683368|C1704440|C0011570|C0220908|C0175659|C0451184|C2347663|C2347647|G0000000|C0332177|C0589120
"They will undergo baseline assessment including medical and seizure history, neurological and anthropometric examination, administration of quality of life (Infant and Toddler Quality of Life Questionnaire, [33]) and developmental (Vineland Adaptive Behaviour Questionnaire, [34]) questionnaires and biochemical investigations.","They undergo baseline assessment including medical seizure history, neurological anthropometric examination, administration quality life (Infant Toddler Quality Life Questionnaire, [33]) developmental (Vineland Adaptive Behaviour Questionnaire, [34]) questionnaires biochemical investigations.",G0000000|G0000000|C0168634|C1261322|C0332257|C0199168|C0036572|C0019664|C0205494|C0003188|G0000000|C0001554|C0332306|C0376558|C0021270|C0682053|C0332306|C0376558|C0034394|C0450371|C0458003|C0332020|C0231193|C0004927|C0034394|C0450371|C0034394|C0205474|C1261322
The secondary end point was the time to confirmed disability progression at 2 years.,The secondary time confirmed disability progression 2 years.,G0000000|C0027627|C0040223|C0521093|C0231170|C0242656|G0000000
"Traumatic stress was measured using the 15-item Impact of Events Scale (Horowitz & McElrath, 1979).","Traumatic stress measured 15-item Impact Events Scale (Horowitz & McElrath, 1979).",C0332663|C0038435|C0444706|C0450371|C1825598|C0441471|C0175659|G0000000|G0000000|G0000000|G0000000
"The relative risk of delivery was 4.4 (3.8 to 5.0) at 24-27 weeks, 3.4 (3.1 to 3.7) at 28-32 weeks, and 2.5 (2.4 to 2.6) at 33-36 weeks.","The relative risk delivery 4.4 (3.8 5.0) 24-27 weeks, 3.4 (3.1 3.7) 28-32 weeks, 2.5 (2.4 2.6) 33-36 weeks.",G0000000|C0080103|C0035647|C0011209|G0000000|G0000000|G0000000|C0450371|C0439230|G0000000|G0000000|G0000000|C0450371|C0439230|G0000000|G0000000|G0000000|C0450371|C0439230
The primary outcome of the study is the frequency of diagnosis of GDM at 28 weeks gestation by a 75 g oral glucose tolerance test (OGTT) using the criteria of the International Association of the Diabetes and Pregnancy Study Group (IADPSG) [24].,The primary outcome study frequency diagnosis GDM 28 weeks gestation 75 oral glucose tolerance test (OGTT) criteria International Association Diabetes Pregnancy Study Group (IADPSG) [24].,G0000000|C0205225|C1274040|C0557651|C0376249|C0011900|C0085207|C0450371|C0439230|C0032961|C0450371|C0442027|C0017725|C0013220|C0022885|C0029161|C0243161|C1512888|C0004083|C0011847|C0032961|C0557651|C0441833|G0000000|C0450371
There was no difference in the local recurrence rate between patients treated with intralesional resection and those treated with wide resection.,There difference local recurrence rate patients treated intralesional resection treated wide resection.,G0000000|C1705241|C0205276|C0034897|C0871208|C0030705|C1522326|C1512954|C0015252|C1522326|C0332464|C0015252
"Subjects remained on drug for 40 weeks, followed by a 3-day downtitration and 2-week washout period, and were re-evaluated at 3, 9, 24, 40, 41, and 42 weeks after randomization.","Subjects remained drug 40 weeks, 3-day downtitration 2-week washout period, re-evaluated 3, 9, 24, 40, 41, 42 weeks randomization.",C0681850|G0000000|C0013227|C0450371|C0439230|C0332173|G0000000|C0332174|C1710661|C0439531|C0556581|G0000000|G0000000|C0450371|C0450371|C0450371|C0450371|C0439230|C0034656
"Other prespecified secondary outcomes at 2, 6, and 12 weeks included clinical dysphagia (DSRS9; see the online-only Data Supplement), dependency (modified Rankin Scale [mRS]15,16), activities of daily living/disability (Barthel Index17), impairment (NIHSS18), health-related quality of life (European Quality of Life-5 Dimensions [EQ-5D],19 from which health utility status was calculated [EQ-5D-HUS]), and nutritional measures (weight, mid-arm circumference, and blood albumin).","Other prespecified secondary outcomes 2, 6, 12 weeks included clinical dysphagia (DSRS9; online-only Data Supplement), dependency (modified Rankin Scale [mRS]15,16), activities daily living/disability (Barthel Index17), impairment (NIHSS18), health-related quality life (European Quality Life-5 Dimensions [EQ-5D],19 health utility status calculated [EQ-5D-HUS]), nutritional measures (weight, mid-arm circumference, blood albumin).",G0000000|G0000000|C0027627|C1274040|G0000000|G0000000|C0450371|C0439230|C0332257|C0205210|C0011168|G0000000|C0205171|C1511726|C0242295|C0011546|C0392747|G0000000|C0175659|C1522706|C0441655|C0332173|C0376558|G0000000|G0000000|C0221099|G0000000|C0018684|C0332306|C0376558|C0239307|C0332306|C0376558|C0439534|C0205163|C0018684|C0582205|C0449438|C0444686|C0205163|C1521739|C0079809|C0005910|C0444598|C0332520|C0005767|C0001924
One primary outcome was a composite of fetal or neonatal death or the need for placement of a cerebrospinal fluid shunt by the age of 12 months.,One primary outcome composite fetal neonatal death placement cerebrospinal fluid shunt age 12 months.,C0205447|C0205225|C1274040|C0205199|C0015965|C1552240|C0011065|C0441587|G0000000|C0005889|C0232180|C0001779|C0450371|C0439231
Secondary endpoint measures were survival and functional outcome (Barthel Index [16]; BI) at day 180 after stroke.,Secondary endpoint measures survival functional outcome (Barthel Index [16]; BI) day 180 stroke.,C0027627|C2349179|C0079809|C0038952|C0205245|C1274040|G0000000|C0918012|C0450371|G0000000|C0332173|C1442061|C0038454
(2) External reviewers rated simulation-group encounters on nine communication domains.,(2) External reviewers rated simulation-group encounters communication domains.,G0000000|C0205101|C1709941|C0871208|C0679083|C0545082|C0009452|C1880389
"To reduce the risk of adjustment problems associated with Hematopoietic Stem Cell Transplant (HSCT) for adolescents/young adults (AYA), we examined efficacy of a therapeutic music video (TMV) intervention delivered during the acute phase of HSCT to: (a) increase protective factors of spiritual perspective, social integration, family environment, courageous coping, and hope-derived meaning; (b) decrease risk factors of illness-related distress and defensive coping; and (c) increase outcomes of self-transcendence and resilience.","To reduce risk adjustment Hematopoietic Stem Cell Transplant (HSCT) adolescents/young adults (AYA), examined efficacy therapeutic music video (TMV) intervention delivered acute phase HSCT to: (a) increase protective factors spiritual perspective, social integration, family environment, courageous coping, hope-derived meaning; (b) decrease risk factors illness-related distress defensive coping; (c) increase outcomes self-transcendence resilience.",C0040363|G0000000|C0035647|C0376209|C0018957|C0242767|C0007634|C0040732|C0472699|C0205653|C0001675|G0000000|C0332128|C1280519|C0087111|C0026867|C0042655|G0000000|C0886296|C1705822|C0205178|C0205390|C0472699|G0000000|G0000000|C0442805|G0000000|C1521761|G0000000|G0000000|C0728831|C1158478|C0015576|C0014406|C0870365|C0009967|C0392347|C0876919|G0000000|C0392756|C0035647|C1521761|C0221423|C0231303|C0679190|C0009967|G0000000|C0442805|C1274040|C0036588|G0000000
The effect of ocular protection on the incidence of retinopathy of prematurity was tested in 188 newborns weighing less than 1600 g in a randomised controlled trial.,The ocular protection incidence retinopathy prematurity tested 188 newborns weighing 1600 g randomised controlled trial.,G0000000|C0015392|C1545588|C0021149|C0035309|C0021294|C0392366|C1442061|C0021289|C1305866|G0000000|G0000000|C2587213|C0008976
Hospital admission rate in the 24 hours after enrollment.,Hospital admission rate 24 hours enrollment.,C0019994|C0184666|C0871208|C0450371|C0439227|C1516879
"The primary aim was to compare the myocardial performance index (MPI), between the two groups at the end of six months.","The primary aim compare myocardial performance (MPI), months.",G0000000|C0205225|C1947946|C1707455|C0027061|C0597198|C0663932|C0439231
"For exploratory analyses of patients' preference of treatment, we used the exact binominal test.","For exploratory analyses patients' preference treatment, exact binominal test.",G0000000|G0000000|C0002778|C0030705|C0558295|C0039798|C2828393|G0000000|C0022885
"The Epworth Sleepiness Scale (ESS)13 and the Fatigue Severity Scale (FSS)14 were used to assess subjective estimates of sleepiness and fatigue, respectively.","The Epworth Sleepiness Scale (ESS)13 Fatigue Severity Scale (FSS)14 assess subjective estimates sleepiness fatigue, respectively.",G0000000|G0000000|C0013144|C0175659|C0206630|C0015672|C0439793|C0175659|C0265224|C1516048|C0439655|C0750572|C0013144|C0015672|G0000000
Main outcome measures Number of falls and injuries resulting from falls during follow-up.,Main outcome measures Number falls injuries falls follow-up.,C0205225|C1274040|C0079809|C0237753|C0000921|C1510467|C0000921|C0589120
Subjects experienced 8.6±8.5 pain days in the 30 days prior to randomization; 25% reported pain on ≥50% of diary days and were classified as having “chronic pain”.,Subjects experienced 8.6±8.5 pain days 30 days prior randomization; 25% reported pain ≥50% diary days classified “chronic pain”.,C0681850|C0237607|G0000000|C0030193|C0439228|C0450371|C0439228|C0332152|C0034656|C0450371|C0684224|C0030193|G0000000|C0376660|C0439228|C0008902|G0000000|G0000000
The risk of alcohol and marijuana disorders was nearly twice as high for control males as intervention males.,The risk alcohol marijuana disorders control males intervention males.,G0000000|C0035647|C0001962|C0024808|C0012634|C0243148|C0086582|C0886296|C0086582
Women in the intervention group will undergo an internet-based CBT aimed at alleviating problems with sexuality and intimacy.,Women intervention undergo internet-based CBT aimed alleviating sexuality intimacy.,C0043210|C0886296|G0000000|C0282111|C0009244|C1947946|G0000000|C0036864|C0699756
"AECOPD, acute Exacerbation in COPD; CCQ, Clinical COPD Questionnaire; CRQ, Chronic Respiratory Questionnaire.","AECOPD, acute Exacerbation COPD; CCQ, Clinical COPD Questionnaire; CRQ, Chronic Respiratory Questionnaire.",G0000000|C0205178|G0000000|C0024117|G0000000|C0205210|C0024117|C0034394|G0000000|C0205191|C0521346|C0034394
b“Intervention” is defined as the provision of human papillomavirus (HPV) vaccine through 2 different school-based strategies.,b“Intervention” defined provision human papillomavirus (HPV) vaccine 2 school-based strategies.,G0000000|C1704788|C1549071|C0086418|C0030358|C0021344|C0042210|G0000000|C0036375|C0679199
None of the patients experienced any drug-related complications during the 8 weeks of treatment.,None patients experienced drug-related complications 8 weeks treatment.,G0000000|C0030705|C0237607|C0013227|C0009566|G0000000|C0439230|C0039798
There were 28 deaths at 1 year and 51 deaths overall.,There 28 deaths 1 51 deaths overall.,G0000000|C0450371|C0011065|G0000000|C0450371|C0011065|C0282416
ROSC will be defined as an increase in heart rate > 60/min for 60s defined by cardiac auscultation.,ROSC defined increase heart rate > 60/min 60s defined cardiac auscultation.,G0000000|C1704788|C0442805|C0018787|G0000000|C0450371|C1704788|C0018787|C0004339
"Changes in AIMS total score and global items were compared among the treatment groups for those patients with TD at baseline, using mixed models as described above.","Changes AIMS total score global items compared treatment patients TD baseline, mixed models above.",C0392747|C1947946|C0439175|C0449820|C0205246|C1551338|C1707455|C0039798|C0030705|C0041061|C0168634|C0205430|C3161035|C1282910
Mean SOD activity and serum TAC did not show significant changes in any of the studied groups.,Mean SOD activity serum TAC studied groups.,C0444504|G0000000|C0205177|C0229671|C1883257|C0557651|C0441833
"Following modified radical mastectomy, disfigurement of the chest wall may severely affect a patient's quality of life.","Following modified radical mastectomy, disfigurement chest wall severely affect patient's quality life.",C0231290|C0392747|C0302912|C0024881|C1707791|C0817096|C0677535|C0205082|C0001721|C0030705|C0332306|C0376558
"Univariate analysis (Table S2) showed that many factors other than corticosteroid treatment were correlated with mortality, such as underlying comorbidities, baseline disease severity, NAI treatment, and time duration from disease onset to hospitalization.","Univariate analysis (Table S2) factors corticosteroid treatment correlated mortality, underlying comorbidities, baseline disease severity, NAI treatment, time duration disease onset hospitalization.",G0000000|C0002778|C0039224|C1519428|C1521761|C0001617|C0039798|C1707520|C0026565|G0000000|C0009488|C0168634|C0012634|C0439793|C3537218|C0039798|C0040223|C0449238|C0012634|C0206132|C0019993
"The change from baseline in postbronchodilator forced expiratory volume in 1 second (FEV1), total COPD symptom scores, and health status as well as the percentage of subjects with a COPD exacerbation were assessed.","The change baseline postbronchodilator forced expiratory volume 1 (FEV1), total COPD symptom scores, health status percentage subjects COPD exacerbation assessed.",G0000000|C0392747|C0168634|C2599594|C0441722|C0231800|C0449468|G0000000|G0000000|C0439175|C0024117|C1457887|C0449820|C0018684|C0449438|C0439165|C0681850|C0024117|G0000000|C1516048
"Patients' behavior, sedation status, and wake up behavior were evaluated with modified observer assessment of alertness and sedation scale.","Patients' behavior, sedation status, wake behavior evaluated modified observer assessment alertness sedation scale.",C0030705|C0004927|C0235195|C0449438|C0442696|C0004927|C0220825|C0392747|C0870992|C1261322|C1443086|C0235195|C0175659
Risk factors for hospital mortality were identified with multivariate logistic regression analysis.,Risk factors hospital mortality identified multivariate logistic regression analysis.,C0035647|C1521761|C0019994|C0026565|C0205396|G0000000|C0242415|C0684320|C0002778
"Hospitalized adult patients with 2009 Influenza A (H1N1) in Beijing: risk factor for hospital mortality by logistic regression analysis CI, confidence interval; LDH, lactate dehydrogenase; OR, odds ratio Variables included in model 1: ethnicity, comorbidity (hypertension, diabetes), symptoms at disease onset (dyspnea, sore throat), clinical presentation on admission (dyspnea), laboratory test on admission (lactate dehydrogenase), and corticosteroids treatment.","Hospitalized adult patients 2009 Influenza A (H1N1) Beijing: risk factor hospital mortality logistic regression analysis CI, confidence interval; LDH, lactate dehydrogenase; OR, odds ratio Variables included model 1: ethnicity, comorbidity (hypertension, diabetes), symptoms disease onset (dyspnea, sore throat), clinical presentation admission (dyspnea), laboratory test admission (lactate dehydrogenase), corticosteroids treatment.",C0701159|C0001675|C0030705|G0000000|C0021400|G0000000|G0000000|C4042832|C0035647|C1521761|C0019994|C0026565|C0242415|C0684320|C0002778|C0008107|C0237529|C1272706|C0022917|C0022924|C0030016|G0000000|G0000000|C0456603|C0439828|C0332257|C3161035|G0000000|C0015031|C0009488|C0020538|C0011847|C0683368|C0012634|C0206132|C0013404|C0234233|C0031354|C0205210|C0449450|C0184666|C0013404|C0022877|C0022885|C0184666|C0022924|C0030016|C0001617|C0039798
"For each outcome, we report impact estimates at 6, 12, and 18 months after the start of the intervention.","For outcome, report impact estimates 6, 12, 18 months start intervention.",G0000000|C1274040|C0684224|C1825598|C0750572|G0000000|C0450371|C0450371|C0439231|C0439659|C0886296
"These analyses revealed no differences between groups (based on a Type I error of .05) for the following variables: demographics (age, race, hours worked per week, risk behavior, pregnancy history, and STI history); HIV-related knowledge, motivation (risk perception, readiness to change, behavioral intentions, pros and cons of condom use); behavioral skills (confidence in condom use); and sexual risk behaviors.","These analyses revealed differences (based Type I error .05) variables: demographics (age, race, hours week, risk behavior, pregnancy history, STI history); HIV-related knowledge, motivation (risk perception, readiness change, behavioral intentions, pros cons condom use); behavioral skills (confidence condom use); sexual risk behaviors.",G0000000|C0002778|C0443289|C1705241|C1527178|C0332307|C0021966|C0743559|C0450371|C0439828|C0011298|C0001779|C0034510|C0439227|C0332174|C0035647|C0004927|C0032961|C0019664|C0036916|C0019664|C0019682|C0376554|C0026605|C0035647|C0030971|C1318963|C0392747|C0004927|C0162425|C3813209|G0000000|C0009653|C0042153|C0004927|C0678856|C0237529|C0009653|C0042153|C0036864|C0035647|C0004927
"The outcome of quitting (point prevalence) was measured at 3, 6 and 12 months, with repeated point prevalence measures reported at 6 and 12 months.","The outcome quitting (point prevalence) measured 3, 6 12 months, repeated prevalence measures reported 6 12 months.",G0000000|C1274040|C0748223|C1552961|C0033105|C0444706|G0000000|G0000000|C0450371|C0439231|C0205341|C0033105|C0079809|C0684224|G0000000|C0450371|C0439231
"CI, confidence interval; EVD, Ebola virus disease; OR, odds ratio.","CI, confidence interval; EVD, Ebola virus disease; OR, odds ratio.",C0008107|C0237529|C1272706|G0000000|C0282687|C0042776|C0012634|G0000000|G0000000|C0456603
"Successful palliation, as defined in Patients and methods, was achieved in 14 (70%) of the 20 cases, with a median period of 146 days (range, 61–294).","Successful palliation, defined Patients methods, achieved 14 (70%) 20 cases, median period 146 days (range, 61–294).",C0597535|C0030231|C1704788|C0030705|C0025663|G0000000|C0450371|C0450371|C0450371|C0868928|C0549183|C0439531|C1442061|C0439228|C1514721|G0000000
"The objective of this study was to evaluate the effect of oral cholecalciferol, 100 000 IU given every 2 months, and 1 g/day calcium on monthly serum 25- hydroxyvitamin D (25-OHD) concentrations, serum and urine calcium, and the course of disease in HIV-infected children and adolescents.","The objective study evaluate oral cholecalciferol, 100 000 IU 2 months, 1 g/day calcium monthly serum 25- hydroxyvitamin D (25-OHD) concentrations, serum urine calcium, disease HIV-infected children adolescents.",G0000000|C0018017|C0557651|C0220825|C0442027|C0008318|C1442061|C1442061|C0049272|G0000000|C0439231|G0000000|C0439417|C0006675|C0332177|C0229671|C0450371|G0000000|C0073187|C0450371|C0086045|C0229671|C0042036|C0006675|C0012634|C0019682|C0008059|C0205653
The primary outcome will be a latent variable related to indices of use of NIV equipment and adherence to treatment regime; while survival rates and psychological variables will constitute the secondary outcomes.,The primary outcome latent variable indices NIV equipment adherence treatment regime; survival rates psychological variables constitute secondary outcomes.,G0000000|C0205225|C1274040|C0205275|C0439828|C4033634|C0598902|C0014672|C1510802|C0039798|G0000000|C0038952|C0871208|C0205486|C0439828|G0000000|C0027627|C1274040
"Following recommendations of the PedIMMPACT group[18], we sought to assess multiple, relevant outcome domains that have been evaluated in face-to-face CBT studies including pain intensity, physical functioning (activity limitations), and emotional functioning (depressive symptoms).","Following recommendations PedIMMPACT group[18], sought assess multiple, relevant outcome domains evaluated face-to-face CBT studies including pain intensity, physical functioning (activity limitations), emotional functioning (depressive symptoms).",C0231290|C0034866|G0000000|C0441833|G0000000|C1516048|C0439064|C2347946|C1274040|C1880389|C0220825|C1553514|C0009244|C0947630|C0332257|C0030193|C0522510|C0031809|C0205245|C0205177|C0449295|C0013987|C0205245|G0000000|C0683368
"Not only prepregnancy obesity, but also gestational weight gain (GWG) has been found to be an independent risk factor for maternal and fetal outcomes such as: gestational diabetes [10,11], cesarean delivery [12-16], and accelerated fetal growth; indicating a strong relationship between higher GWG and increased risk of large for gestational age (LGA) births [13,14,16,17].","Not prepregnancy obesity, gestational weight gain (GWG) independent risk factor maternal fetal outcomes as: gestational diabetes [10,11], cesarean delivery [12-16], accelerated fetal growth; indicating strong relationship GWG increased risk gestational age (LGA) births [13,14,16,17].",C1518422|C2709093|C0028754|C0439671|C0005910|C1517378|G0000000|C0085862|C0035647|C1521761|C2347083|C0015965|C1274040|G0000000|C0439671|C0011847|C0450371|C3841297|C0011209|C0450371|C0521110|C0015965|C0018270|G0000000|C0442821|C0439849|G0000000|C0205217|C0035647|C0439671|C0001779|C1428877|C0005615|C0450371
"Serological assessments of serum neutralizing antibody titer to RV-39 were made on V1 (before virus inoculation) and at V21–V25, as described elsewhere [24].","Serological assessments serum neutralizing antibody titer RV-39 V1 (before virus inoculation) V21–V25, [24].",C0205473|C1261322|C0229671|G0000000|C0003241|C0475208|C0035190|C0078433|C0332152|C0042776|C0042196|G0000000|C0450371
"We also tested associations between HRQoL-scales and BMI, body fat, FEV1, physical activity, and anaerobic and aerobic performance at baseline and changes over 6 months by linear regression models with adjustments for age, gender, group allocation (training vs no training) and nationality.","We tested associations HRQoL-scales BMI, body fat, FEV1, physical activity, anaerobic aerobic performance baseline 6 months linear regression models adjustments age, gender, allocation (training training) nationality.",G0000000|C0392366|C0004083|C0175659|G0000000|C0242821|C0424612|G0000000|C0031809|C0205177|C3641081|C1510824|C0597198|C0168634|G0000000|C0439231|C0205132|C0684320|C3161035|C0376209|C0001779|C0079399|C1706778|C0040607|C0040607|C0027473
Only 2% of the TAU participants met the 75% reduction and none of the TAU participants met the abstinence target.,Only 2% TAU participants met 75% reduction TAU participants met abstinence target.,C0205171|G0000000|C1720655|C0679646|C0268621|C0450371|C0301630|C1720655|C0679646|C0268621|C3843422|C1521840
"In a follow-up protocol at 6 months, the Glasgow Outcome Scale and the modified Functional Independence Measure scores were again determined.","In follow-up protocol 6 months, Glasgow Outcome Scale modified Functional Independence Measure scores determined.",G0000000|C0589120|C0442711|G0000000|C0439231|G0000000|C1274040|C0175659|C0392747|C0205245|C0085862|C0079809|C0449820|G0000000
The primary outcome is the change in UE function using the Action Research Arm Test.,The primary outcome change UE function Action Research Arm Test.,G0000000|C0205225|C1274040|C0392747|G0000000|C0031843|C0441472|C0035168|C0446516|C0022885
"Additional outcomes included the numbers of severe asthma exacerbations (i.e., those requiring systemic corticosteroids or doubling of ICS dose) (16), the percentage of subjects experiencing severe exacerbations, respiratory-related unscheduled physician office visits, emergency department (ED) visits, hospitalizations, and days missed from work/school or other activities due to asthma.","Additional outcomes included severe asthma exacerbations (i.e., requiring systemic corticosteroids doubling ICS dose) (16), percentage subjects experiencing severe exacerbations, respiratory-related unscheduled physician office visits, emergency department (ED) visits, hospitalizations, days missed work/school activities asthma.",C1524062|C1274040|C0332257|C0205082|C0004096|G0000000|C0683454|G0000000|C0205373|C0001617|C0205173|C0022521|C0178602|C0450371|C0439165|C0681850|C0237607|C0205082|G0000000|C0521346|C1699701|C0031831|C0442603|C0545082|C0013956|C1704729|C3538926|C0545082|C0019993|C0439228|C1705492|C0043227|C0441655|C0004096
"Secondary outcome measures were common clinical scores in evaluation of robot-assisted gait training [34], including: (1) Fugl-Meyer Assessment (FMA) for motor recovery, consisting of 34-score to examine lower-limb motor function quantitatively in reflex, flexor/extensor synergy pattern, volitional movement, coordination and speed; (2) MAS, consisting of 4-level scale to examine joint spasticity during passive muscle stretching; (3) BBS, consisting of 14-item objective measures to assess static balance for predicting falling risk; (4) Timed 10-Meter Walk Test (Timed 10MWT), to measure walking speed in short distance; (5) Six-Minute Walk Test (SMWT), to assess endurance using walking distance covered in fixed duration.","Secondary outcome measures common clinical scores evaluation robot-assisted gait training [34], including: (1) Fugl-Meyer Assessment (FMA) motor recovery, consisting 34-score examine lower-limb motor function quantitatively reflex, flexor/extensor synergy pattern, volitional movement, coordination speed; (2) MAS, consisting 4-level scale examine joint spasticity passive muscle stretching; (3) BBS, consisting 14-item objective measures assess static balance predicting falling risk; (4) Timed 10-Meter Walk Test (Timed 10MWT), measure walking speed short distance; (5) Six-Minute Walk Test (SMWT), assess endurance walking distance covered fixed duration.",C0027627|C1274040|C0079809|C0205214|C0205210|C0449820|C0220825|C3844190|C0016928|C0040607|C0450371|C0332257|G0000000|G0000000|C1261322|C2332774|C1513492|C0237820|C0332529|C0450371|G0000000|C0023216|C1513492|C0031843|G0000000|C0034929|C1879367|G0000000|C0449774|C0042950|C0026649|C0242414|C0678536|G0000000|C1096155|C0332529|C0441889|C0175659|G0000000|C0022417|C0026838|C3686820|C0026845|C0600080|G0000000|G0000000|C0332529|C0450371|C0018017|C0079809|C1516048|C0441463|C0014653|G0000000|C0000921|C0035647|G0000000|C0392761|C0450371|C0080331|C0022885|C0392761|G0000000|C0079809|C0080331|C0678536|C1282927|C0012751|G0000000|C0205452|C0080331|C0022885|G0000000|C1516048|C0518031|C0080331|C0012751|C0439844|C0443218|C0449238
"Outcomes were exacerbations, exacerbation-free months, quality-adjusted life years (QALYs), and cost(-effectiveness).","Outcomes exacerbations, exacerbation-free months, quality-adjusted life (QALYs), cost(-effectiveness).",C1274040|G0000000|C0332296|C0439231|C0332306|C0376558|C0080071|C0010181
"Secondary outcomes including differences in enteral intake and growth indices (weight, head circumference and length) at 3 weeks, the number of days parenteral nutrition and central venous access was required, as well as the incidence of sepsis, NEC and parental nutrition-associated liver disease were also measured.","Secondary outcomes including differences enteral intake growth indices (weight, head circumference length) 3 weeks, days parenteral nutrition central venous access required, incidence sepsis, NEC parental nutrition-associated liver disease measured.",C0027627|C1274040|C0332257|C1705241|C1304890|C1512806|C0018270|C4033634|C0005910|C0018670|C0332520|C1444754|G0000000|C0439230|C0439228|C0030547|C0028707|C0205099|C0042449|C0444454|C1514873|C0021149|C0036690|C0206695|C0030551|C0028707|C0023884|C0012634|C0444706
Pain intensity was measured by Numerical Analogue Scale for pain before and after the intervention.,Pain intensity measured Numerical Analogue Scale pain intervention.,C0030193|C0522510|C0444706|C0237753|C0243071|C0175659|C0030193|C0886296
Influenza vaccination has been implicated in Guillain Barré Syndrome (GBS) although the evidence for this link is controversial.,Influenza vaccination implicated Guillain Barré Syndrome (GBS) evidence link controversial.,C0021400|C0042196|G0000000|G0000000|G0000000|C0039082|C0018378|C3887511|C1517892|C0680243
"Secondary outcomes includes viral suppression at 6, 12, 18, and 24 months; quality of life; weight gain; presence of opportunistic infections and mortality.","Secondary outcomes includes viral suppression 6, 12, 18, 24 months; quality life; weight gain; presence opportunistic infections mortality.",C0027627|C1274040|C0332257|C0521026|C0221103|G0000000|C0450371|C0450371|C0450371|C0439231|C0332306|C0376558|C0005910|C1517378|C0150312|G0000000|C3714514|C0026565
The clinical global impression scale was completed by the clinicians.,The clinical global impression scale completed clinicians.,G0000000|C0205210|C0205246|C0596764|C0175659|C0205197|C0871685
ACT: acceptance and commitment therapy; ANCOVA: analysis of covariance; ANOVA: analysis of variance; CBT: cognitive-behaviour therapy; CPAQ: Chronic Pain Acceptance Questionnaire; EQ-5D: EuroQol 5-D Questionnaire; EuroQoL: European Quality of Life Scale; FIQ: Fibromyalgia Impact Questionnaire; FM: fibromyalgia; HAM-D: Hamilton Rating Scale for Depression; HARS: Hamilton Anxiety Rating Scale; ITT: intention to treat; PC: pain catastrophising; PCS: Pain Catastrophising Scale; RPT: recommended pharmacological treatment; VAS: Visual Analogue Scale; TAU: treatment as usual.,ACT: acceptance commitment therapy; ANCOVA: analysis covariance; ANOVA: analysis variance; CBT: cognitive-behaviour therapy; CPAQ: Chronic Pain Acceptance Questionnaire; EQ-5D: EuroQol 5-D Questionnaire; EuroQoL: European Quality Life Scale; FIQ: Fibromyalgia Impact Questionnaire; FM: fibromyalgia; HAM-D: Hamilton Rating Scale Depression; HARS: Hamilton Anxiety Rating Scale; ITT: intention treat; PC: pain catastrophising; PCS: Pain Catastrophising Scale; RPT: recommended pharmacological treatment; VAS: Visual Analogue Scale; TAU: treatment usual.,C0079613|G0000000|C0870312|C0039798|C0814908|C0002778|G0000000|G0000000|C0002778|C1711260|C0009244|C0945984|C0039798|G0000000|C0205191|C0030193|G0000000|C0034394|C0205163|C0451150|C0073187|C0034394|C0451150|C0239307|C0332306|C0376558|C0175659|G0000000|C0016053|C1825598|C0034394|C3540627|C0016053|C1570167|G0000000|C0871208|C0175659|C0011570|C1415473|G0000000|C0003467|C0871208|C0175659|G0000000|C0162425|C0087111|C0031995|C0030193|G0000000|C1864389|C0030193|G0000000|C0175659|G0000000|C0034866|C0031330|C0039798|C0042815|C0234621|C0243071|C0175659|C1720655|C0039798|C3538928
Response and SAT rates of 30% were considered to be unacceptable.,Response SAT rates 30% considered unacceptable.,C0871261|C1705827|C0871208|C0450371|C0750591|C1883420
"VSC level was measured by portable sulfide monitor (RH-17, Halimeter, Interscan Corp, CA, USA) as described by the manufacturer.","VSC level measured portable sulfide monitor (RH-17, Halimeter, Interscan Corp, CA, USA) manufacturer.",G0000000|C0441889|C0444706|G0000000|C0038739|C0030695|C0035493|G0000000|G0000000|C0683758|C3887642|C0041703|C0947322
"Secondary outcomes included (1) patients alive without organ support (ventilator, renal replacement therapy, and vasopressors) on day 28, (2) MV-free days up to day 28, (3) vasopressor (dopamine, norepinephrine, or adrenaline)-free days up to day 28 (free days to day 28 for patients who died before or on study day 28 was set to 0), and (4) mortality at study day 60.","Secondary outcomes included (1) patients alive organ support (ventilator, renal replacement therapy, vasopressors) day 28, (2) MV-free days day 28, (3) vasopressor (dopamine, norepinephrine, adrenaline)-free days day 28 (free days day 28 patients died study day 28 set 0), (4) mortality study day 60.",C0027627|C1274040|C0332257|G0000000|C0030705|C0376558|C0178784|C0183683|C0087153|C0022646|C0035139|C0039798|C0042397|C0332173|C0450371|G0000000|C0428679|C0439228|C0332173|C0450371|G0000000|C0042397|C0013030|C0028351|C0014563|C0439228|C0332173|C0450371|C0332296|C0439228|C0332173|C0450371|C0030705|C0011065|C0557651|C0332173|C0450371|C0036849|G0000000|G0000000|C0026565|C0557651|C0332173|C0450371
"Outcome measures were child and parent reports of child pain levels, function, and adjustment.","Outcome measures child parent reports child pain levels, function, adjustment.",C1274040|C0079809|C0008059|C0030551|C0684224|C0008059|C0030193|C0441889|C0031843|C0376209
"Combined treatment with mebendazole and levamisole had a significantly higher efficacy against hookworm infections (cure rate, 26.1%; egg reduction rate, 88.7%) than either drug given alone.","Combined treatment mebendazole levamisole efficacy hookworm infections (cure rate, 26.1%; egg reduction rate, 88.7%) drug alone.",C0205195|C0039798|C0025023|C0023556|C1280519|C0002830|C3714514|C1880198|C0871208|C0450371|C0013710|C0301630|C0871208|C0450371|C0013227|C0205171
"In FS group, two patients showed pain (20% failure) after 3 months, X-ray also showed periapical and furcal radiolucency (Fig.","In FS group, patients pain (20% failure) 3 months, X-ray periapical furcal radiolucency (Fig.",G0000000|C1517317|C0441833|C0030705|C0030193|C0450371|C0231174|G0000000|C0439231|C0034571|C0729269|G0000000|C2827491|C0349966
"Patients who did not receive the intervention were also required to have an appointment with the sleep physician at 1, 3, 6, and 12 months.","Patients receive intervention required appointment sleep physician 1, 3, 6, 12 months.",C0030705|C1514756|C0886296|C1514873|C0003629|C0037313|C0031831|G0000000|G0000000|G0000000|C0450371|C0439231
"Serum 25OHD concentrations correlated negatively with the number of pain days at week 8 (r = −0.680 95% CI [−0.903, −0.102], p=0.019) for vitamin D group compared to the placebo group (r = −0.403 95% CI [−0.816, −0.324], p=0.258) [b]: There was a distinct trend towards fewer pain days between visits over the first 16 weeks of the study in the vitamin D group.","Serum 25OHD concentrations correlated negatively pain days week 8 (r = −0.680 95% CI [−0.903, −0.102], p=0.019) vitamin D compared placebo (r = −0.403 95% CI [−0.816, −0.324], p=0.258) [b]: There distinct trend fewer pain days visits 16 weeks study vitamin D group.",C0229671|G0000000|C0086045|C1707520|G0000000|C0030193|C0439228|C0332174|G0000000|C0205090|G0000000|G0000000|C0450371|C0008107|G0000000|G0000000|C0369773|C0042890|C0073187|C1707455|C0032042|C0205090|G0000000|G0000000|C0450371|C0008107|G0000000|G0000000|C0369773|G0000000|G0000000|G0000000|C1521798|C0205388|C0030193|C0439228|C0545082|C0450371|C0439230|C0557651|C0042890|C0073187|C0441833
"To compare dynamic balance ability before and after the intervention, the Berg Balance Scale (BBS), the Functional Reaching Test (FRT), and the Timed Up and Go (TUG) test were assessed.","To compare dynamic balance ability intervention, Berg Balance Scale (BBS), Functional Reaching Test (FRT), Timed Up Go (TUG) test assessed.",C0040363|C1707455|C0729333|C0014653|C0085732|C0886296|G0000000|C0014653|C0175659|G0000000|C0205245|C2584321|C0022885|C1705150|C0392761|G0000000|C1822658|C1319201|C0022885|C1516048
"Overall mean (SD) score on the decisional conflict scale at baseline was 38.6 (17.0) on a scale of 0-100, with higher scores indicating greater decisional conflict.","Overall (SD) score decisional conflict scale baseline 38.6 (17.0) scale 0-100, scores indicating decisional conflict.",C0282416|G0000000|C0449820|C0679006|C0009671|C0175659|C0168634|C0450371|C0450371|C0175659|C1442061|C0449820|G0000000|C0679006|C0009671
A patient could have more than one ‘paradoxical episode’ if there were further new lesions separated by site or time from the original paradoxical lesion.,A patient ‘paradoxical episode’ lesions separated site time original paradoxical lesion.,G0000000|C0030705|G0000000|G0000000|C0221198|C0086972|C0205145|C0040223|C0205313|C0205310|C0221198
"After they agreed to join the study, patients were assessed for peritoneal creatinine clearance, peritoneal transport characteristics (PET), UF volume in night dwell, and blood biochemistry within a week.","After agreed join study, patients assessed peritoneal creatinine clearance, peritoneal transport characteristics (PET), UF volume night dwell, blood biochemistry week.",G0000000|C3641827|G0000000|C0557651|C0030705|C1516048|C0031153|C0010294|C0449297|C0031153|C0005528|C1521970|C0031268|G0000000|C0449468|C0240526|G0000000|C0005767|C0005477|C0332174
"The inclusion criteria included, primary molars with vital carious pulp exposures that bleed upon entering the pulp chambers, primary molars with no clinical signs and symptoms of pulp degeneration such as swelling, pathologic mobility, excessive bleeding from amputated radicular stumps and tenderness on percussion.","The inclusion criteria included, primary molars vital carious pulp exposures bleed entering pulp chambers, primary molars clinical signs symptoms pulp degeneration swelling, pathologic mobility, excessive bleeding amputated radicular stumps tenderness percussion.",G0000000|C0007637|C0243161|C0332257|C0205225|C0026367|C0442732|G0000000|C0011399|C0274281|C0019080|C1522196|C0011399|C0179874|C0205225|C0026367|C0205210|C0220912|C0683368|C0011399|C0011164|C0013604|C1521733|C0425245|C0442802|C0019080|C0231447|C0040452|C0002690|C0234233|C0030987
"Histologic PD was defined as progression from hyperplasia and/or hyperkeratosis to dysplasia, or from a lower to a higher degree of dysplasia or invasive carcinoma, or appearance of any new lesions.","Histologic PD defined progression hyperplasia and/or hyperkeratosis dysplasia, lower degree dysplasia invasive carcinoma, appearance lesions.",C0205462|G0000000|C1704788|C0242656|C0020507|G0000000|C0870082|C0334044|C0441994|C0441889|C0334044|C0205281|C0007097|C0233426|C0221198
We examined trends in smoking prevalence from 2002 through 2006 in 4 Asian communities served by the Racial and Ethnic Approaches to Community Health (REACH) intervention.,We examined trends smoking prevalence 2002 2006 4 Asian communities served Racial Ethnic Approaches Community Health (REACH) intervention.,G0000000|C0332128|C0040833|C0037369|C0033105|G0000000|G0000000|G0000000|C0078988|C0009462|G0000000|C0034510|C0015031|C0449445|C0009462|C0018684|C2584321|C0886296
"Croup score, adrenaline (epinephrine) use, time spent in the emergency department, and duration of croup and viral symptoms were secondary outcome measures.","Croup score, adrenaline (epinephrine) use, time spent emergency department, duration croup viral symptoms secondary outcome measures.",C0010380|C0449820|C0014563|C0014563|C0042153|C0040223|C0680968|C0013956|C1704729|C0449238|C0010380|C0521026|C0683368|C0027627|C1274040|C0079809
"Use of alternative entry screening approaches and intervals between official confirmation of first imported pandemic influenza A (H1N1) case and official confirmation of first untraceable local case for 26 nations with more than 100 confirmed cases by July 6, 2009.","Use alternative entry screening approaches intervals official confirmation imported pandemic influenza A (H1N1) official confirmation untraceable local 26 nations 100 confirmed July 6, 2009.",C0042153|C1523987|C1705654|C0220908|C0449445|C1272706|C2347387|C0521091|C0699788|C1615608|C0021400|G0000000|G0000000|C2347387|C0521091|G0000000|C0205276|C0450371|C1555720|C1442061|C0521093|C3829447|G0000000|G0000000
"Severity of illness, VAP rates, ventilator/ICU days, and mortality rates are given for the early and no early tracheostomy groups in each study.","Severity illness, VAP rates, ventilator/ICU days, mortality rates tracheostomy study.",C0439793|C0221423|G0000000|C0871208|C0087153|C0439228|C0026565|C0871208|C0040590|C0557651
The primary end point was the LRC (pelvic and paraaortic control).,The primary LRC (pelvic paraaortic control).,G0000000|C0205225|G0000000|C0030797|C0442134|C0243148
Delirium was evaluated using the confusion assessment method before discharge from the PACU on POD 1 [8].,Delirium evaluated confusion assessment method discharge PACU POD 1 [8].,C0011206|C0220825|C0009676|C1261322|C0025663|C0012621|C0034871|G0000000|G0000000|G0000000
Self-perceived muscle soreness was assessed using a 10 cm visual analog scale [18] with anchor points “no pain at all” at the left end and “unbearable pain” at the right end.,Self-perceived muscle soreness assessed 10 cm visual analog scale [18] anchor “no pain all” left “unbearable pain” end.,C0036588|C0026845|C0234233|C1516048|C0450371|G0000000|C0234621|C0243071|C0175659|C0450371|C1293132|G0000000|C0030193|G0000000|C0205091|G0000000|G0000000|C0444930
No association was found between ovulation induction and breast cancer among primiparous women (Table 3).,No association ovulation induction breast cancer primiparous women (Table 3).,G0000000|C0004083|C0029965|C0205263|C0006141|C0006826|C0033150|C0043210|C0039224|G0000000
"The primary objectives were to reduce food neophobia in toddlers, and promote healthy feeding practices among kindergarten staff and parents.","The primary objectives reduce food neophobia toddlers, promote healthy feeding practices kindergarten staff parents.",G0000000|C0205225|C0018017|G0000000|C0016452|G0000000|C0682053|C0033414|C3898900|C0204695|C0237607|C0681406|C0851286|C0030551
"Parental smoking cessation, number of parental quit attempts, use of cessation medications, attendance at behavioral cessation sessions  • Hair nicotine levels.","Parental smoking cessation, parental quit attempts, cessation medications, attendance behavioral cessation sessions • Hair nicotine levels.",C0030551|C0037369|C1880019|C0030551|C0748223|C1516084|C1880019|C0013227|C2827364|C0004927|C1880019|C1883016|G0000000|C0018494|C0028040|C0441889
"At baseline, measures of unilateral neglect (SCT, LBT and PIT) were also similar between randomized groups (table 1).","At baseline, measures unilateral neglect (SCT, LBT PIT) randomized (table 1).",G0000000|C0168634|C0079809|C0205092|C0521874|C0860888|C1879922|C0175697|C0034656|C0039224|G0000000
"On secondary outcomes, intervention patients reported considerably fewer social role limitations, better psychological well‐being, lower health distress, more exercise and relaxation, and greater partnership with clinicians.","On secondary outcomes, intervention patients reported considerably fewer social role limitations, psychological well‐being, lower health distress, exercise relaxation, partnership clinicians.",G0000000|C0027627|C1274040|C0886296|C0030705|C0684224|G0000000|C0205388|C0728831|C0035820|C0449295|C0205486|G0000000|C0441994|C0018684|C0231303|C0015259|C0035028|C1711206|C0871685
"In recent meta-analyses, it was concluded that oral decontamination with chlorhexidine (CHX) could prevent VAP [11], but that strategy does not reduce the time on the ventilator, the length of stay (LOS) in the ICU or rates of mortality [12].","In meta-analyses, concluded oral decontamination chlorhexidine (CHX) prevent VAP [11], strategy reduce time ventilator, length stay (LOS) ICU rates mortality [12].",G0000000|C0920317|C0917903|C0442027|C0011121|C0008196|G0000000|C0309872|G0000000|C0450371|C0679199|G0000000|C0040223|C0087153|C1444754|G0000000|G0000000|C0021708|C0871208|C0026565|C0450371
"COPD exacerbations were assessed during the screening and treatment periods, as well as during the 26-week safety extension, and were categorized as mild, moderate, or severe.","COPD exacerbations assessed screening treatment periods, 26-week safety extension, categorized mild, moderate, severe.",C0024117|G0000000|C1516048|C0220908|C0039798|C0439531|C0450371|C0036043|C0231448|C0871968|C2945599|C0205081|C0205082
"[8] In the present study, no adrenocortical insufficiency was found secondary to the use of class I topical steroids in adult patients with vitiligo and intact cutaneous barrier with a maximum dose of 50 g per week for 12 weeks, this being to our knowledge the first study that clearly proves it and for such duration of treatment.","[8] In study, adrenocortical insufficiency secondary class I topical steroids adult patients vitiligo intact cutaneous barrier maximum dose 50 week 12 weeks, knowledge study proves duration treatment.",G0000000|G0000000|C0557651|C2986474|C0231179|C0027627|C0456387|C0021966|C0332237|C0038317|C0001675|C0030705|C0042900|C0205266|C0221912|C1706912|C0806909|C0178602|C0450371|C0332174|C0450371|C0439230|C0376554|C0557651|G0000000|C0449238|C0039798
Dysmenorrhea severity was determined by a verbal multidimensional scoring system and a visual analog scale (VAS).,Dysmenorrhea severity determined verbal multidimensional scoring system visual analog scale (VAS).,C0013390|C0439793|G0000000|C0439824|C2347299|C0449820|C0449913|C0234621|C0243071|C0175659|C0042815
TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TAG: triglyceride.,TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TAG: triglyceride.,C0039411|C0439175|C0008377|G0000000|C0205251|C0023820|C0008377|C3715113|C0205250|C0023820|C0008377|C0037293|C0041004
Significant improvement in grasp and dissociated movement is noted in group of CIMT while there was no significant improvement in weight bearing and protective extension in CIMT group when compared to BMT.,Significant improvement grasp dissociated movement CIMT improvement weight bearing protective extension CIMT compared BMT.,C0237881|C2986411|C0220843|G0000000|C0026649|G0000000|C2986411|C0005910|C1704689|G0000000|C0231448|G0000000|C1707455|C0005961
"There were 4 patient visits (at baseline, 1 month, 2 months and 3 months).","There 4 patient visits (at baseline, 1 month, 2 months 3 months).",G0000000|G0000000|C0030705|C0545082|G0000000|C0168634|G0000000|C0332177|G0000000|C0439231|G0000000|C0439231
"The Dexterity device of the Objective Parkinson’s Disease Measurement system will be used to quantify bradykinesia with a digitography (keyboard) test, and complex motor functioning is tested with a pegboard test.","The Dexterity device Objective Parkinson’s Disease Measurement system quantify bradykinesia digitography (keyboard) test, complex motor functioning tested pegboard test.",G0000000|C0565699|C0025080|C0018017|G0000000|C0012634|C0242485|C0449913|C1709793|C0233565|G0000000|C0870768|C0022885|C0439855|C1513492|C0205245|C0392366|G0000000|C0022885
"The interviews will be conducted to establish the knowledge, attitudes and practices regarding breastfeeding and complementary feeding and to establish the local contexts and norms, which contribute towards decision-making for MIYCN practices.","The interviews conducted establish knowledge, attitudes practices breastfeeding complementary feeding establish local contexts norms, contribute decision-making MIYCN practices.",G0000000|C0021822|C0004927|C0443211|C0376554|C0004271|C0237607|C0006147|G0000000|C0204695|C0443211|C0205276|C0449255|C0205307|C1880177|C0011109|G0000000|C0237607
"All patients filled out the Numeric Rating Scale (NRS), Oswestry Disability Index (ODI), and Short Form-36 (SF-36) questionnaire at baseline and at the end of treatment.","All patients filled Numeric Rating Scale (NRS), Oswestry Disability Index (ODI), Short Form-36 (SF-36) questionnaire baseline treatment.",G0000000|C0030705|C1708059|C0237753|C0871208|C0175659|C2240043|G0000000|C0231170|C0918012|G0000000|C1282927|C0348078|C0037712|C0034394|C0168634|C0039798
"Pain severity was measured with the four-item pain severity subscale from the Brief Pain Inventory (BPI; α = .87) a well-validated measure that has been widely used to tap acute and chronic pain (Cleeland, 1994).","Pain severity measured four-item pain severity subscale Brief Pain Inventory (BPI; α = .87) well-validated measure tap acute chronic pain (Cleeland, 1994).",C0030193|C0439793|C0444706|C0205450|C0030193|C0439793|G0000000|C1282927|C0030193|C0021941|C1443145|G0000000|G0000000|C0450371|C0205170|C0079809|C0034115|C0205178|C0205191|C0030193|G0000000|G0000000
Adverse reactions and tolerability to all medications were recorded.,Adverse reactions tolerability medications recorded.,G0000000|C0443286|C3274448|C0013227|C0034869
Secondary outcomes will be the self-evaluated communication competence by physicians and an evaluation of the consultations by both physicians and patients.,Secondary outcomes self-evaluated communication competence physicians evaluation consultations physicians patients.,C0027627|C1274040|C0036588|C0009452|C0086035|C0031831|C0220825|C0009818|C0031831|C0030705
"Nonsignificant trends in improvement were seen with tai chi, as compared to usual care, in 6-min walk distance, Center for Epidemiologic Studies Depression Scale score, University of California, San Diego Shortness of Breath score, and COPD Self-Efficacy Scale scores.","Nonsignificant trends improvement tai chi, compared usual care, 6-min walk distance, Center Epidemiologic Studies Depression Scale score, University California, San Diego Shortness Breath score, COPD Self-Efficacy Scale scores.",G0000000|C0040833|C2986411|G0000000|C1720589|C1707455|C3538928|C1947933|C0702093|C0080331|C0012751|C0205099|C0014507|C0947630|C0011570|C0175659|C0449820|C0041740|C0006754|C1826357|G0000000|C1282927|C0225386|C0449820|C0024117|C0600564|C0175659|C0449820
The primary outcome measure of the trial was maternal BP at 36 wk of gestation.,The primary outcome measure trial maternal BP 36 wk gestation.,G0000000|C0205225|C1274040|C0079809|C0008976|C2347083|C0037623|C0450371|C0332174|C0032961
NC helped to collect the data.,NC helped collect data.,C0027964|C1269765|G0000000|C1511726
"Secondary end points for the comparison of CHOP with PMitCEBO and for the addition of G-CSF were response rates, toxicity, progression-free survival (PFS) and overall survival (OS).","Secondary comparison CHOP PMitCEBO addition G-CSF response rates, toxicity, progression-free survival (PFS) survival (OS).",C0027627|C1707455|C2945739|C0668793|C0332287|C0079459|C0871261|C0871208|C0040539|C0242656|C0038952|C0242792|C0038952|C0229090
A secondary objective is to provide evidence for the effect of ITB on the level of body functions.,A secondary objective provide evidence ITB level body functions.,G0000000|C0027627|C0018017|C1999230|C3887511|G0000000|C0441889|C0242821|C0542341
"There were statistically significant improvements in the VRRT group compared with the control group for BBS, FRT, TUG, postural sway (mediolateral sway distance with eyes open and eyes closed, anteroposterior and total sway distance with eyes open but not with eyes closed), and 10 mWV (p<0.05).","There statistically improvements VRRT compared control BBS, FRT, TUG, postural sway (mediolateral sway distance eyes eyes closed, anteroposterior total sway distance eyes eyes closed), 10 mWV (p<0.05).",G0000000|C0038215|C2986411|G0000000|C1707455|C0243148|G0000000|C1705150|C1319201|C0205278|G0000000|C0441992|G0000000|C0012751|C0015392|C0015392|C0587267|G0000000|C0439175|G0000000|C0012751|C0015392|C0015392|C0587267|C0450371|G0000000|C0369773
"When the infant was 3 weeks old, respiratory illness signs and symptoms were recorded.","When infant 3 weeks old, respiratory illness signs symptoms recorded.",G0000000|C0021270|G0000000|C0439230|C0580836|C0521346|C0221423|C0220912|C0683368|C0034869
"Regardless of group assignment, participants demonstrated significant gains on the primary outcome measures: the Wolf Motor Function Test (WMFT) and the Motor Activity Log (MAL)–Amount of Use, and on secondary outcome measures including the Box and Block Test (BBT) and the MAL–How Well.","Regardless assignment, participants demonstrated gains primary outcome measures: Wolf Motor Function Test (WMFT) Motor Activity Log (MAL)–Amount Use, secondary outcome measures including Box Block Test (BBT) MAL–How Well.",C3641650|C1516050|C0679646|G0000000|C1517378|C0205225|C1274040|C0079809|C0325001|C1513492|C0031843|C0022885|G0000000|C1513492|C0205177|C1708728|G0000000|C0042153|C0027627|C1274040|C0079809|C0332257|C0179400|C0028778|C0022885|G0000000|G0000000|C0205170
Lumbar ROM as well as holding time during the Sorensen test and median frequency slope of all measured paravertebral muscles did not change significantly in either group (P > .05).,Lumbar ROM holding time Sorensen test median frequency slope measured paravertebral muscles change (P > .05).,C0024090|C4048784|G0000000|C0040223|G0000000|C0022885|C0549183|C0376249|C0807955|C0444706|C0442150|C0026845|C0392747|C0369773|G0000000|C0450371
"To evaluate the effect of the northwest corridor intervention, we compared overall rates for the study measures among the northwest corridor survey population and among African Americans in the state BRFSS population for the baseline year, 2001, and 2005.","To evaluate northwest corridor intervention, compared rates study measures northwest corridor survey population African Americans BRFSS population baseline year, 2001, 2005.",C0040363|C0220825|C1709274|C0557670|C0886296|C1707455|C0871208|C0557651|C0079809|C1709274|C0557670|C0038951|C0032659|C0027567|C0596070|C1136355|C0032659|C0168634|C0439234|G0000000|G0000000
"For non-Hispanic Whites, the ICC was 0.014 for point prevalence and 0.003 for prolonged abstinence.","For non-Hispanic Whites, ICC 0.014 prevalence 0.003 prolonged abstinence.",G0000000|C1518424|C0007457|C0345905|C1442061|C0033105|C1442061|C0439590|C3843422
We used Kaplan-Meier survival curves to visually present the time to first relapse.,We Kaplan-Meier survival curves visually time relapse.,G0000000|G0000000|C0038952|C0205134|G0000000|C0040223|C0035020
Children were followed fortnightly.,Children fortnightly.,C0008059|C0585332
Scores for the HADS and PHLMS for the treatment and control groups on days 1 and 3.a PHLMS: Philadelphia Mindfulness Scale; HADS: Hospital Anxiety and Depression Scale; SD: standard deviation.,Scores HADS PHLMS treatment control days 1 3.a PHLMS: Philadelphia Mindfulness Scale; HADS: Hospital Anxiety Depression Scale; SD: standard deviation.,C0449820|C0048008|G0000000|C0039798|C0243148|C0439228|G0000000|G0000000|G0000000|C0031525|C0086045|C0175659|C0048008|C0019994|C0003467|C0011570|C0175659|C2699239|C1442989|C0012727
"The primary outcome measure was occurrence of relapse, which was defined as an increase of two or more points on the SCCAI [31], in association with an increase in treatment (either an increase in maintenance medication dose or addition of new therapies for flare) by the participant’s personal physician for manifestations of ulcerative colitis.","The primary outcome measure occurrence relapse, defined increase SCCAI [31], association increase treatment (either increase maintenance medication dose addition therapies flare) participant’s personal physician manifestations ulcerative colitis.",G0000000|C0205225|C1274040|C0079809|C0243132|C0035020|C1704788|C0442805|G0000000|C0450371|C0004083|C0442805|C0039798|C3844638|C0442805|C0024501|C0013227|C0178602|C0332287|C0087111|C1517205|G0000000|C1519021|C0031831|C0205319|C0041582|C0009319
"Diary variables were morning and evening PEF, COPD symptom scores (night-time awakenings due to symptoms, breathlessness, and cough), and use of salbutamol as reliever medication (measured as inhalations/day).","Diary variables morning evening PEF, COPD symptom scores (night-time awakenings symptoms, breathlessness, cough), salbutamol reliever medication (measured inhalations/day).",C0376660|C0439828|C0332170|C0587117|C0030771|C0024117|C1457887|C0449820|C0240526|C1720052|C0683368|C0013404|C0010200|C0001927|G0000000|C0013227|C0444706|C0004048
"Independent scales for function, symptoms, appearance, emotions, are also included in the questionnaire.","Independent scales function, symptoms, appearance, emotions, included questionnaire.",C0085862|C0175659|C0031843|C0683368|C0233426|C0013987|C0332257|C0034394
Calibration of the instruments was done as per the manufacturer's instructions and validation studies were done prior to the test.,Calibration instruments manufacturer's instructions validation studies prior test.,C0006751|C0348000|C0947322|C0302828|C1519941|C0947630|C0332152|C0022885
We also performed a secondary analysis of time to first relapse using the actual relapse date.,We performed secondary analysis time relapse actual relapse date.,G0000000|C0884358|C0027627|C0002778|C0040223|C0035020|C0237400|C0035020|C0011008
The rate of change and absolute change in serum [Na] did not differ significantly between groups.,The rate change absolute change serum [Na] groups.,G0000000|C0871208|C0392747|C0205344|C0392747|C0229671|C0597484|C0441833
"The data collection tools used in this study included a demographic information questionnaire (including items on age, level of education, and occupation), an obstetric information form (including items on the number of days since delivery, the type of delivery, parity, and the number of miscarriages), a lactation status form (including items on previous breastfeeding history, previous breastfeeding problems, the onset of current lactation, the daily frequency of breastfeeding, and the duration of breastfeeding in minutes), and a checklist of breast engorgement score.9,29,30 This checklist assessed participants’ erythema (with a score of 0 for “no redness,” 1 for “redness in patches in a limited area,” 2 for “full redness in a limited area,” 3 for a “shiny redness in a limited area,” and 4 for a “shiny redness over most of the breast tissue”), breast tension (with a score of 0 for “no changes,” 1 for “firm and no tenderness,” 2 for “tense but not uncomfortable,” 3 for “tense and uncomfortable,” 4 for “tense and painful,” and 5 for “very tense and very painful”), and breast pain (a score between 0 and 10).","The data collection tools study included demographic questionnaire (including items age, level education, occupation), obstetric form (including items days delivery, type delivery, parity, miscarriages), lactation status form (including items previous breastfeeding history, previous breastfeeding problems, onset current lactation, daily frequency breastfeeding, duration breastfeeding minutes), checklist breast engorgement score.9,29,30 This checklist assessed participants’ erythema (with score 0 “no redness,” 1 “redness patches limited area,” 2 “full redness limited area,” 3 “shiny redness limited area,” 4 “shiny redness breast tissue”), breast tension (with score 0 “no changes,” 1 “firm tenderness,” 2 “tense uncomfortable,” 3 “tense uncomfortable,” 4 “tense painful,” 5 “very tense painful”), breast pain (a score 0 10).",G0000000|C1511726|C1516698|C0336791|C0557651|C0332257|C0011298|C0034394|C0332257|C1551338|C0001779|C0441889|C0013621|C0028811|C0205484|C0348078|C0332257|C1551338|C0439228|C0011209|C0332307|C0011209|C0030563|C0000786|C0006147|C0449438|C0348078|C0332257|C1551338|C0205156|C0006147|C0019664|C0205156|C0006147|C1546466|C0206132|C0521116|C0006147|C0332173|C0376249|C0006147|C0449238|C0006147|C0439232|C1707357|C0006141|C0020452|C0449820|G0000000|C1707357|C1516048|G0000000|C0041834|G0000000|C0449820|G0000000|G0000000|G0000000|G0000000|G0000000|C0994894|C0439801|G0000000|G0000000|G0000000|C0041834|C0439801|G0000000|G0000000|G0000000|C0041834|C0439801|G0000000|G0000000|G0000000|C0041834|C0006141|G0000000|C0006141|C0233494|G0000000|C0449820|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0233494|G0000000|C0006141|C0030193|G0000000|C0449820|G0000000|C0450371
We then compared the two rate ratios.,We compared rate ratios.,G0000000|C1707455|C0871208|C0456603
Diarrhoea was defined as three or more liquid stools within a 24-hour period.,Diarrhoea defined liquid stools 24-hour period.,C0011991|C1704788|C0301571|C0015733|C0450371|C0439531
Colorectal cancer (CRC)3 is the second leading cause of cancer death in the United States (1).,Colorectal cancer (CRC)3 leading cancer death United States (1).,C0555952|C0006826|C0009402|C0332152|C0006826|C0011065|C0166872|C1301808|G0000000
Table 2 summarises the key topic areas explored with each group relating to intervention feasibility and acceptability.,Table 2 summarises key topic explored relating intervention feasibility acceptability.,C0039224|G0000000|G0000000|G0000000|C1522168|G0000000|C0163712|C0886296|G0000000|C0814633
Mean different between the treatment groups (change score from baseline to end of treatment) in secondary outcome measures.,Mean treatment (change score baseline treatment) secondary outcome measures.,C0444504|C0039798|C0392747|C0449820|C0168634|C0039798|C0027627|C1274040|C0079809
"The primary goal is to demonstrate study feasibility and we will collect clinical outcomes on 1) Transfusion Requirements, 2) Transplant Related Mortality, 3) Maximum grade of acute Graft versus Host Disease, 4) Veno-occlusive Disease, 5) Serious Infections, 6) Bearman Toxicity Score, 7) Bleeding, 8) Quality of Life, 9) Number of Hospitalizations and 10) Number of Intensive Care Unit (ICU) Admissions.","The primary goal demonstrate study feasibility collect clinical outcomes 1) Transfusion Requirements, 2) Transplant Related Mortality, 3) Maximum grade acute Graft versus Host Disease, 4) Veno-occlusive Disease, 5) Serious Infections, 6) Bearman Toxicity Score, 7) Bleeding, 8) Quality Life, 9) Number Hospitalizations 10) Number Intensive Care Unit (ICU) Admissions.",G0000000|C0205225|C0018017|G0000000|C0557651|G0000000|G0000000|C0205210|C1274040|G0000000|C0005841|C1514873|G0000000|C0040732|C0439849|C0026565|G0000000|C0806909|C0441800|C0205178|C0181074|G0000000|C1167395|C0012634|G0000000|C1519964|C0012634|G0000000|C0205404|C3714514|G0000000|G0000000|C0040539|C0449820|G0000000|C0019080|G0000000|C0332306|C0376558|G0000000|C0237753|C0019993|C0450371|C0237753|C0162425|C1947933|C0439148|C0021708|C0184666
BMI: body mass index; SpO2: transcutaneous pulsed arterial oxygen saturation; FEV1: forced expiratory volume in 1 second.,BMI: body mass index; SpO2: transcutaneous pulsed arterial oxygen saturation; FEV1: forced expiratory volume 1 second.,G0000000|C0242821|C0577559|C0918012|G0000000|G0000000|C1947910|C0003842|C0030054|C0522534|G0000000|C0441722|C0231800|C0449468|G0000000|C0205436
Progression-free and overall survival were co-primary end points.,Progression-free survival co-primary points.,C0242656|C0038952|C3245499|C1552961
"The occurrence of white blood cell (WBC) count below laboratory normal limit (4,000 cell/μL) was also compared between treatment groups.","The occurrence white blood cell (WBC) count laboratory normal limit (4,000 cell/μL) compared treatment groups.",G0000000|C0243132|C0007457|C0005767|C0007634|C0023516|C0750480|C0022877|C0205307|C0439801|C1442061|G0000000|C1707455|C0039798|C0441833
"Controls were men, residing in the same geographical area of cases without either PC or prostate diseases.","Controls men, residing geographical PC prostate diseases.",C0243148|C0025266|C2982691|C0017447|C0031995|C0033572|C0012634
Key secondary outcomes included safety and time to first pulmonary exacerbation—after reaching the pulmonary exacerbation endpoint subjects discontinued study drug although remained in the study.,Key secondary outcomes included safety time pulmonary exacerbation—after reaching pulmonary exacerbation endpoint subjects discontinued study drug remained study.,G0000000|C0027627|C1274040|C0332257|C0036043|C0040223|C0024109|G0000000|C2584321|C0024109|G0000000|C2349179|C0681850|C1444662|C0557651|C0013227|G0000000|C0557651
"In the case of fortified flour consumption, the mean serum folate level was 23.84–27.15 nmol/L.","In fortified flour consumption, serum folate level 23.84–27.15 nmol/L.",G0000000|G0000000|C0016260|C0009830|C0229671|C0178638|C0441889|G0000000|C0439282
"Secondary outcomes measures include the following instruments; the Oswestry low back pain disability questionnaire, 24-hour Migraine Quality of Life questionnaire and Patient's Global Assessment of Ankle Injury Scale.","Secondary outcomes measures instruments; Oswestry low pain disability questionnaire, 24-hour Migraine Quality Life questionnaire Patient's Global Assessment Ankle Injury Scale.",C0027627|C1274040|C0079809|C0348000|G0000000|C0205251|C0030193|C0231170|C0034394|C0450371|C0149931|C0332306|C0376558|C0034394|C0030705|C0205246|C1261322|C0003086|C3263722|C0175659
A second outcome end-point was incidence of acute otitis media which will be reported in the near future.,A outcome end-point incidence acute otitis media reported future.,G0000000|C1274040|C2349179|C0021149|C0205178|C0029877|C0009458|C0684224|C0016884
All participants also completed the Client Satisfaction Questionnaire [47] at the end of treatment.,All participants completed Client Satisfaction Questionnaire [47] treatment.,G0000000|C0679646|C0205197|C0008942|C0242428|C0034394|C0450371|C0039798
"What is already known on this topic Interventions to support stroke care givers by using information packages, specialist nurses, or family support workers have little impact on patients and modest psychological or social benefits for care givers What this study adds Training care givers in basic nursing, moving, and handling and facilitation of activities of daily living is feasible during stroke rehabilitation Training care givers significantly reduces their burden, anxiety, and depression and improves quality of life and satisfaction with care among care givers at three and 12 months Patients whose care givers received training reported better quality of life and psychological outcomes at three and 12 months Patients' mortality, institutionalisation, and disability were not influenced by caregiver training","What topic Interventions support stroke care givers packages, specialist nurses, family support workers impact patients modest psychological social benefits care givers What study adds Training care givers basic nursing, moving, handling facilitation activities daily living feasible stroke rehabilitation Training care givers reduces burden, anxiety, depression improves quality life satisfaction care care givers 12 months Patients care givers received training reported quality life psychological outcomes 12 months Patients' mortality, institutionalisation, disability influenced caregiver training",G0000000|C1522168|C0886296|C0183683|C0038454|C1947933|G0000000|C0013194|C0087009|C0028661|C0015576|C0183683|C0024752|C1825598|C0030705|C4054480|C0205486|C0728831|C0814225|C1947933|G0000000|G0000000|C0557651|C1883712|C0040607|C1947933|G0000000|C1527178|C0006147|C0560560|C0018578|C0234112|C0441655|C0332173|C0376558|G0000000|C0038454|C0034991|C0040607|C1947933|G0000000|G0000000|C2828008|C0003467|C0011570|C0184511|C0332306|C0376558|C0242428|C1947933|C1947933|G0000000|C0450371|C0439231|C0030705|C1947933|G0000000|C1514756|C0040607|C0684224|C0332306|C0376558|C0205486|C1274040|C0450371|C0439231|C0030705|C0026565|C0021629|C0231170|G0000000|C0085537|C0040607
"aAbbreviation: OSBD-R, observational scale of behavioral distress–revised.","aAbbreviation: OSBD-R, observational scale behavioral distress–revised.",G0000000|C0205090|C1518527|C0175659|C0004927|G0000000
"Occurrence and degree of adverse effects comprising irregular vaginal bleeding, nausea and headache were reported after 3 and 6 months.","Occurrence degree adverse effects comprising irregular vaginal bleeding, nausea headache reported 3 6 months.",C0243132|C0441889|G0000000|C1280500|C2700400|C0205271|C0042232|C0019080|C0027497|C0018681|C0684224|G0000000|G0000000|C0439231
There is no evidence of local recurrence.,There evidence local recurrence.,G0000000|C3887511|C0205276|C0034897
"Baseline characteristics of individuals according to green tea consumption, the Ohsaki study During the 7-year follow-up (until 31 December 2001), 302 cases of lung cancer were documented and 4928 individuals who withdrew from the NHI were loss to follow-up.","Baseline characteristics individuals green tea consumption, Ohsaki study During 7-year follow-up (until 31 December 2001), 302 lung cancer documented 4928 individuals withdrew NHI loss follow-up.",C0168634|C1521970|C0027361|C0332583|C0039400|C0009830|G0000000|C0557651|G0000000|C0439234|C0589120|G0000000|C0450371|C3830550|G0000000|C1442061|C0024109|C0006826|C1301725|G0000000|C0027361|C2349954|G0000000|C1517945|C0589120
The primary outcome measures are the incidence of dental decay in primary teeth and the prevalence of obesity.,The primary outcome measures incidence dental decay primary teeth prevalence obesity.,G0000000|C0205225|C1274040|C0079809|C0021149|C0011365|C1265875|C0205225|C0040426|C0033105|C0028754
"Violence, school delinquency, and substance use were measured from grade 5 onward; provoking behaviors, recent sexual intercourse, and condom use were added at grade 6.","Violence, school delinquency, substance measured grade 5 onward; provoking behaviors, sexual intercourse, condom grade 6.",C0042693|C0036375|C0522174|C0439861|C0444706|C0441800|G0000000|G0000000|G0000000|C0004927|C0036864|C0009253|C0009653|C0441800|G0000000
"Anyhow, this increase in knowledge and attitude is not as much as that in the study groups.","Anyhow, increase knowledge attitude study groups.",G0000000|C0442805|C0376554|C0004271|C0557651|C0441833
Concentrations of IL-17 and IL-23 in peripheral blood and sputum were measured using enzyme-linked immunosorbent assays.,Concentrations IL-17 IL-23 peripheral blood sputum measured enzyme-linked immunosorbent assays.,C0086045|C0020898|C0020898|C0205100|C0005767|C0038056|C0444706|C0014442|C0021075|C0005507
The secondary efficacy end point was HIV-1–free survival by 28 weeks among infants who were uninfected at 2 weeks and among all infants who underwent randomization.,The secondary efficacy HIV-1–free survival 28 weeks infants uninfected 2 weeks infants underwent randomization.,G0000000|C0027627|C1280519|G0000000|C0038952|C0450371|C0439230|C0021270|G0000000|G0000000|C0439230|C0021270|G0000000|C0034656
Patients’ compliance data were reviewed 2 and 6 weeks following CPAP initiation.,Patients’ compliance data reviewed 2 6 weeks CPAP initiation.,G0000000|C0009563|C1511726|C0282443|G0000000|G0000000|C0439230|C0199451|C0589507
"There was no change between the groups in terms of nasogastric tube reinsertion, overall complication or anastomotic leakage.","There change terms nasogastric tube reinsertion, complication anastomotic leakage.",G0000000|C0392747|C0233324|C0694637|C0175730|C0035139|C0009566|C0332854|C0015376
Balance and falls risk have multiple dimensions and their measure requires a comprehensive approach.,Balance falls risk multiple dimensions measure requires comprehensive approach.,C0014653|C0000921|C0035647|C0439064|C0439534|C0079809|G0000000|C1880156|C0449445
Potential mediators (e.g.,Potential mediators (e.g.,C3245505|C0127400|G0000000
Primary outcome measure will be mean hours of usage at set pressure per night during the last 2 weeks of the intervention.,Primary outcome measure hours usage set pressure night 2 weeks intervention.,C0205225|C1274040|C0079809|C0439227|C0457083|C0036849|C0033095|C0240526|G0000000|C0439230|C0886296
"CST = Coping Skills Training Group; GE = General Education Group; HbA1c = Hemoglobin A1c; QOL = quality of life; CDI = Children's Depressive Inventory There were no significant differences between CST and GE groups over time on metabolic control, QOL, depressive symptoms, coping, self-efficacy or family functioning.","CST = Coping Skills Training Group; GE = General Education Group; HbA1c = Hemoglobin A1c; QOL = quality life; CDI = Children's Depressive Inventory There differences CST GE time metabolic control, QOL, depressive symptoms, coping, self-efficacy family functioning.",C3539520|G0000000|C0009967|C0678856|C0040607|C0441833|C1292300|G0000000|C0205246|C0013621|C0441833|G0000000|G0000000|C0019046|G0000000|C0518214|G0000000|C0332306|C0376558|C0282601|G0000000|C0008059|G0000000|C0021941|G0000000|C1705241|C3539520|C1292300|C0040223|C0311400|C0243148|C0518214|G0000000|C0683368|C0009967|C0600564|C0015576|C0205245
"6MWT, Six-Minute Walk Test, FIQ, Fibromyalgia Impact Questionnaire, MFI, Multidimensional Fatigue Inventory.","6MWT, Six-Minute Walk Test, FIQ, Fibromyalgia Impact Questionnaire, MFI, Multidimensional Fatigue Inventory.",G0000000|C0205452|C0080331|C0022885|G0000000|C0016053|C1825598|C0034394|C1881923|C2347299|C0015672|C0021941
"This clinician performed the Urimal Test of Articulation and Phonology (U-TAP), and measured alternative motion rates (AMR), sequential motion rates (SMR), and the maximal phonation time (MPT) as outcome measures before and after the rTMS sessions.","This clinician performed Urimal Test Articulation Phonology (U-TAP), measured alternative motion rates (AMR), sequential motion rates (SMR), maximal phonation time (MPT) outcome measures rTMS sessions.",G0000000|C0871685|C0884358|G0000000|C0022885|C0022417|C0597725|C0034115|C0444706|C1523987|C0026597|C0871208|G0000000|C1548958|C0026597|C0871208|C0036154|C0205289|C0031577|C0040223|C3158980|C1274040|C0079809|G0000000|C1883016
"Vital signs were monitored at screening, on Days 1, 2, 3 and 7 and at other visits if indicated.","Vital signs monitored screening, Days 1, 2, 3 7 visits indicated.",C0442732|C0220912|C0030695|C0220908|C0439228|G0000000|G0000000|G0000000|G0000000|C0545082|C1444656
"The postoperative collected data were: amount of abdominal drainage in the first 48 hours, white blood cells, hemoglobin, and hematocrit in the first 4 days, first passage of gas and stools, complications, and hospital stay.","The postoperative collected data were: amount abdominal drainage 48 hours, white blood cells, hemoglobin, hematocrit 4 days, passage gas stools, complications, hospital stay.",G0000000|C0032790|C1516695|C1511726|G0000000|C1265611|C0000726|C0012621|C0450371|C0439227|C0007457|C0005767|C0007634|C0019046|C0018935|G0000000|C0439228|C0439799|C0017110|C0015733|C0009566|C0019994|G0000000
The study end point was the first recurrence of urinary tract infection.,The study recurrence urinary tract infection.,G0000000|C0557651|C0034897|C0042027|C1185740|C0009450
"On primary outcomes (table 22),), the intervention patients reported considerably higher scores for overall self‐efficacy and energy, but reported no differences in healthcare utilisation.","On primary outcomes (table 22),), intervention patients reported considerably scores self‐efficacy energy, reported differences healthcare utilisation.",G0000000|C0205225|C1274040|C0039224|C0450371|C0886296|C0030705|C0684224|G0000000|C0449820|G0000000|C0424589|C0684224|C1705241|C0086388|C0042153
"Secondary endpoints were the KPS, wound-related complications, operative time, duration of hospital stay, and cost.","Secondary endpoints KPS, wound-related complications, operative time, duration hospital stay, cost.",C0027627|C2349179|C0206065|C0043250|C0009566|C1882154|C0040223|C0449238|C0019994|G0000000|C0010186
"The primary endpoint was a composite of death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina.","The primary endpoint composite death cause, reinfarction, stroke, coronary revascularization, hospitalization angina.",G0000000|C0205225|C2349179|C0205199|C0011065|C0015127|G0000000|C0038454|C0018787|C0581603|C0019993|C0002962
"The Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), and Fibromyalgia Assessment Scale (FAS) were administered at baseline (T0), at the end of the treatment (T1) (after 10 rehabilitation sessions over a 5-week period), and at the 12-week follow-up (T2).","The Fibromyalgia Impact Questionnaire (FIQ), Health Assessment Questionnaire (HAQ), Fibromyalgia Assessment Scale (FAS) administered baseline (T0), treatment (T1) (after 10 rehabilitation sessions 5-week period), 12-week follow-up (T2).",G0000000|C0016053|C1825598|C0034394|G0000000|C0018684|C1261322|C0034394|C0102923|C0016053|C1261322|C0175659|G0000000|C1521801|C0168634|C0041403|C0039798|C0041403|G0000000|C0450371|C0034991|C1883016|C0332174|C0439531|C0450371|C0589120|C0041403
VRRT – virtual reality reflection therapy; BBS – Berg balance scale; FRT – functional reach test; TUG – timed up and go test; EO – eyes open; EC – eyes closed; APS – anterior-posterior sway distance; MLS – medial-lateral sway distance; TS – total sway distance; 10 mWV – 10 m walking velocity.,VRRT – virtual reality reflection therapy; BBS – Berg balance scale; FRT – functional reach test; TUG – timed test; EO – eyes open; EC – eyes closed; APS – anterior-posterior sway distance; MLS – medial-lateral sway distance; TS – total sway distance; 10 mWV – 10 walking velocity.,G0000000|G0000000|C1553497|C0871222|C0558058|C0039798|G0000000|G0000000|G0000000|C0014653|C0175659|C1705150|G0000000|C0205245|C2584321|C0022885|C1319201|G0000000|C0392761|C0022885|C0332120|G0000000|C0015392|C0175566|C3890233|G0000000|C0015392|C0587267|G0000000|G0000000|C1999039|G0000000|C0012751|C0796070|G0000000|C0205098|G0000000|C0012751|C0041388|G0000000|C0439175|G0000000|C0012751|C0450371|G0000000|G0000000|C0450371|C0080331|C0439830
"At follow-up, participants in the HIV prevention intervention had significantly higher consistent condom use and HIV testing relative to participants in the cancer education arm.","At follow-up, participants HIV prevention intervention consistent condom HIV testing relative participants cancer education arm.",G0000000|C0589120|C0679646|C0019682|C0199176|C0886296|C0332290|C0009653|C0019682|C0039593|C0080103|C0679646|C0006826|C0013621|C0446516
Children's Automatic Thoughts Scale (CATS; Schniering and Rapee 2002).,Children's Automatic Thoughts Scale (CATS; Schniering Rapee 2002).,C0008059|C0205554|C0039869|C0175659|C0007450|G0000000|G0000000|G0000000
"Decreased ORs for squamous cell and small cell carcinomas were observed in males with frequent consumption of raw and green vegetables, fruit and milk, but consumption of carrot, pumpkin, egg and coffee was associated with increased ORs.","Decreased ORs squamous cell cell carcinomas observed males frequent consumption raw green vegetables, fruit milk, consumption carrot, pumpkin, egg coffee increased ORs.",C0205216|C0069590|C1182670|C0007634|C0007634|C0007097|C1441672|C0086582|C0332183|C0009830|C0001884|C0332583|C0042440|C0016767|C0026131|C0009830|C1141640|C0453137|C0013710|C0009237|C0205217|C0069590
"The present study examines effects of a scheduled aerobic exercise and strength training intervention on cancer-related fatigue, physical fitness, and physical activity levels during adjuvant breast cancer chemotherapy compared to general recommended physical activity.","The study examines effects scheduled aerobic exercise strength training intervention cancer-related fatigue, physical fitness, physical activity levels adjuvant breast cancer chemotherapy compared recommended physical activity.",G0000000|C0557651|G0000000|C1280500|C0086960|C1510824|C0015259|C0237897|C0040607|C0886296|C2826292|C0015672|C0031809|C1456706|C0031809|C0205177|C0441889|C0001551|C0006141|C0006826|C0013216|C1707455|C0034866|C0031809|C0205177
"The secondary objectives were to determine whether probiotic administration delayed respiratory tract infection or colonization due to P. aeruginosa, and to evaluate the ability of L. casei rhamnosus to persist in the stomach.","The secondary objectives determine probiotic administration delayed respiratory tract infection colonization P. aeruginosa, evaluate ability L. casei rhamnosus persist stomach.",G0000000|C0027627|C0018017|G0000000|C0525033|C0001554|C0205421|C0521346|C1185740|C0009450|G0000000|C0369773|G0000000|C0220825|C0085732|C0439394|G0000000|G0000000|G0000000|C0038351
"Secondary outcomes included participants’ global assessments of improvement and satisfaction at end-of-study (both Likert scales) ; as well as change from baseline to 72 weeks in: the BPH Impact Index17, the Quality of Life item from the International Prostate Symptom Score18, the nocturia item from the AUASI 16, peak uroflow, postvoid residual volume, prostate specific antigen (PSA) level, indices of erectile and ejaculatory function19, 20, the ICSmaleIS incontinence scale 21, the Jenkins Sleep Dysfunction Scale22, and the NIH Chronic Prostatitis Symptom Index.23 All questionnaires were available in English and Spanish.","Secondary outcomes included participants’ global assessments improvement satisfaction end-of-study (both Likert scales) ; change baseline 72 weeks in: BPH Impact Index17, Quality Life item International Prostate Symptom Score18, nocturia item AUASI 16, peak uroflow, postvoid residual volume, prostate specific antigen (PSA) level, indices erectile ejaculatory function19, 20, ICSmaleIS incontinence scale 21, Jenkins Sleep Dysfunction Scale22, NIH Chronic Prostatitis Symptom Index.23 All questionnaires English Spanish.",C0027627|C1274040|C0332257|G0000000|C0205246|C1261322|C2986411|C0242428|C0444930|G0000000|G0000000|C0175659|G0000000|C0392747|C0168634|C0450371|C0439230|G0000000|C0005001|C1825598|G0000000|C0332306|C0376558|C1551338|C1512888|C0033572|C1457887|G0000000|C0028734|C1551338|G0000000|C0450371|C0444505|G0000000|C1439885|C1609982|C0449468|C0033572|C0205369|C0003320|C3810537|C0441889|C4033634|C0030847|C0013746|G0000000|C0450371|G0000000|C0021167|C0175659|C0450371|G0000000|C0037313|C0031847|G0000000|C0027468|C0205191|C0033581|C1457887|C0918012|G0000000|C0034394|C0376245|C0086409
"We will use a (i) 8-meter walk test and (ii) 4-step (20-cm height each) stairs test, both of which have proven useful to determine leg extension power and functional mobility in the elderly [52].","We (i) 8-meter walk test (ii) 4-step (20-cm height each) stairs test, proven determine leg extension power functional mobility elderly [52].",G0000000|C0021966|C0475209|C0080331|C0022885|G0000000|C1261552|C0450371|C0489786|G0000000|C1710179|C0022885|C0456369|G0000000|C0023216|C0231448|C0032863|C0205245|C0425245|C0001792|C0450371
Gametocyte carriage was still detected in 1.1% subjects on completion of the study on day 42.,Gametocyte carriage detected 1.1% subjects completion study day 42.,C0686869|G0000000|C0442726|G0000000|C0681850|C0205197|C0557651|C0332173|C0450371
The Strengths and Weaknesses in ADHD and Normal Behaviors (SWAN) and Conners’ questionnaires were used to assess changes in ADHD symptoms in 37 children (only 26 children completed the study from zero to 16 weeks).,The Strengths Weaknesses ADHD Normal Behaviors (SWAN) Conners’ questionnaires assess ADHD symptoms 37 children (only 26 children completed study 16 weeks).,G0000000|C0808080|C3714552|C1263846|C0205307|C0004927|C0325528|G0000000|C0034394|C1516048|C1263846|C0683368|C0450371|C0008059|C0205171|C0450371|C0008059|C0205197|C0557651|C0450371|C0439230
"Specific hypotheses to be tested in this study are that: Consumers using a Web-based PCHMS with interactive and social features are more likely to follow evidence-based guideline recommendations for asthma management, as measured by the rates of obtaining or updating a written asthma action plan with their GP and the usage rates with the asthma action plan, measured by questionnaires; Use of a PCHMS will contribute to improved asthma control and reduced rates of asthma exacerbation compared to those using only static websites (usual care arm).","Specific hypotheses tested study that: Consumers Web-based PCHMS interactive social features follow evidence-based guideline recommendations asthma management, measured rates obtaining updating written asthma action plan GP usage rates asthma action plan, measured questionnaires; Use PCHMS contribute improved asthma control reduced rates asthma exacerbation compared static websites (usual care arm).",C0205369|C1512571|C0392366|C0557651|G0000000|C1707496|C0282111|G0000000|C1704675|C0728831|C1521970|C0332283|C3887511|C0162791|C0034866|C0004096|C0001554|C0444706|C0871208|C1301820|C1519814|C0043266|C0004096|C0441472|C0270724|C3811116|C0457083|C0871208|C0004096|C0441472|C0270724|C0444706|C0034394|C0042153|G0000000|C1880177|C0184511|C0004096|C0243148|C0392756|C0871208|C0004096|G0000000|C1707455|C0441463|C2349146|C3538928|C1947933|C0446516
"Consistent with an ecological approach,13 the PATH trial developed a community-based intervention to address access and safety barriers to neighborhood walking in underserved African American communities, with one program including an additional SM component to increase social connectedness and motivation for walking.","Consistent ecological approach,13 PATH trial developed community-based intervention address access safety barriers neighborhood walking underserved African American communities, program including additional SM component increase social connectedness motivation walking.",C0332290|C0013546|C0449445|C0919386|C0008976|G0000000|C0009462|C0886296|C0376649|C0444454|C0036043|C1706912|C0027569|C0080331|G0000000|C0027567|C0596070|C0009462|C1709697|C0332257|C1524062|C0036154|C0449432|C0442805|C0728831|C0449379|C0026605|C0080331
The primary outcome was sustained abstinence from smoking at three and 12 months.,The primary outcome sustained abstinence smoking 12 months.,G0000000|C0205225|C1274040|C0443318|C3843422|C0037369|C0450371|C0439231
"The treatment group had slightly more depressive symptoms on the PHQ-9, slightly more apathy, and slightly poorer quality of life reported on the Cornell-Brown Scale prior to intervention.","The treatment depressive symptoms PHQ-9, apathy, poorer quality life reported Cornell-Brown Scale prior intervention.",G0000000|C0039798|G0000000|C0683368|C1879301|C0085632|C0032854|C0332306|C0376558|C0684224|C0678579|C0175659|C0332152|C0886296
"Data are mean±SEM of serum retinol and β-carotene levels before (pre) and after (post) supplementation of β-carotene in Bangladeshi children;  SEM=Standard error of the mean   In total, 127 (57.5%) children were vitamin A-deficient (serum retinol of ≤0.7 μmol/L), of which 15 (6.8%) were severely deficient (<0.35 μmol/L).","Data mean±SEM serum retinol β-carotene levels (pre) (post) supplementation β-carotene Bangladeshi children; SEM=Standard error In total, 127 (57.5%) children vitamin A-deficient (serum retinol ≤0.7 μmol/L), 15 (6.8%) severely deficient (<0.35 μmol/L).",C1511726|G0000000|C0229671|C0042839|G0000000|C0441889|C0332152|C0687676|C0242297|G0000000|C0422784|C0008059|C1442989|C0743559|G0000000|C0439175|C1442061|C0450371|C0008059|C0042890|C0011155|C0229671|C0042839|G0000000|G0000000|C0450371|G0000000|C0205082|C0011155|C0450371|G0000000
"In the Shanghai study, the improvement in blood pressure and lipids was observed only in a subgroup of diabetic patients.","In Shanghai study, improvement blood pressure lipids observed subgroup diabetic patients.",G0000000|G0000000|C0557651|C2986411|C0005767|C0033095|C0023779|C1441672|C1079230|C0241863|C0030705
Median daily symptom scores were plotted for the treatment groups and compared per day and for the full period.,Median daily symptom scores plotted treatment compared day period.,C0549183|C0332173|C1457887|C0449820|G0000000|C0039798|C1707455|C0332173|C0439531
"The height of each “step” was determined by the number of falls within the group on one day (for example, day 10 since entering the study) divided by the number of participants in the group who had not yet been discharged (censored).","The height “step” determined falls day (for example, day 10 entering study) divided participants discharged (censored).",G0000000|C0489786|G0000000|G0000000|C0000921|C0332173|G0000000|C1707959|C0332173|C0450371|C1522196|C0557651|C0332849|C0679646|C0030685|C3889990
The aim of the present study was to determine the effects of kefir on CD and UC patient’s Lactobacillus flora and their biochemical properties as well as symptoms and quality of life.,The aim study determine effects kefir CD UC patient’s Lactobacillus flora biochemical properties symptoms quality life.,G0000000|C1947946|C0557651|G0000000|C1280500|C0524649|C0007928|G0000000|G0000000|C0022938|G0000000|C0205474|C0871161|C0683368|C0332306|C0376558
"After 84 days (three cycles) of therapy, although methylcobalamin treatment alone was helpful in relieving pain and improving the quality of life, the study showed that acupuncture combined with methylcobalamin for the treatment of CIPN was significantly superior in providing pain relief (VAS pain scores) and life quality improvement (FACT/GOG-Ntx questionnaire scores).","After 84 days (three cycles) therapy, methylcobalamin treatment helpful relieving pain improving quality life, study acupuncture combined methylcobalamin treatment CIPN superior providing pain relief (VAS pain scores) life quality improvement (FACT/GOG-Ntx questionnaire scores).",G0000000|C0450371|C0439228|C0205449|C1511572|C0039798|C0065844|C0039798|C3898897|C0332303|C0030193|C1272745|C0332306|C0376558|C0557651|C0001299|C0205195|C0065844|C0039798|G0000000|C1282910|C1999230|C0030193|C0564405|C0042815|C0030193|C0449820|C0376558|C0332306|C2986411|C3899177|C0034394|C0449820
The primary endpoint was reduction in annualized relapse rate utilizing a strict definition of relapse.,The primary endpoint reduction annualized relapse rate utilizing strict definition relapse.,G0000000|C0205225|C2349179|C0301630|G0000000|C0035020|C0871208|G0000000|G0000000|C1550452|C0035020
"The procedures comprised 2 bone marrow extractions (BMEs), at Visit 3 (−1 month) and Visit 4 (2 days prior to Visit 5), and 2 intrathecal injections, at Visit 5 (0 months) and Visit 6 (+1 month; see Fig Fig1A).1A).","The procedures comprised 2 bone marrow extractions (BMEs), Visit 3 (−1 month) Visit 4 (2 days prior Visit 5), 2 intrathecal injections, Visit 5 (0 months) Visit 6 (+1 month; Fig Fig1A).1A).",G0000000|C0025664|C2700400|G0000000|C0262950|C0086590|C0185115|G0000000|C0545082|G0000000|G0000000|C0332177|C0545082|G0000000|G0000000|C0439228|C0332152|C0545082|G0000000|G0000000|C1370196|C0021485|C0545082|G0000000|G0000000|C0439231|C0545082|G0000000|G0000000|C0332177|C0349966|C1420849
"Secondary outcomes were referral to radiography and rate of recovery at the follow-up consultation after 2 weeks with the following five alternatives: “fully recovered”, “almost recovered”, “slightly improved”, “unchanged”, and “worse”.","Secondary outcomes referral radiography rate recovery follow-up consultation 2 weeks alternatives: “fully recovered”, “almost recovered”, “slightly improved”, “unchanged”, “worse”.",C0027627|C1274040|C0034927|C0034571|C0871208|C0237820|C0589120|C0009818|G0000000|C0439230|C1523987|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000
The families were given the Vaccine Information Sheet for Hepatitis B Vaccine.,The families Vaccine Information Sheet Hepatitis B Vaccine.,G0000000|C0015576|C0042210|C1533716|C2349187|C0019158|G0000000|C0042210
"At baseline, participants will complete two treatment expectancy questions: (1) “At this point, how logical does the program offered to you seem?” (0 = “Not at all logical”; 9 = “Very logical”) and (2) “At this point, how successfully do you think this treatment will be in reducing your PTSD symptoms?” (0 = “Not at all useful”; 4 = “Very useful”).","At baseline, participants complete treatment expectancy questions: (1) “At point, logical program offered seem?” (0 = “Not logical”; 9 = “Very logical”) (2) “At point, treatment reducing PTSD symptoms?” (0 = “Not useful”; 4 = “Very useful”).",G0000000|C0168634|C0679646|C0205197|C0039798|C0679138|C1522634|G0000000|G0000000|C1552961|C0023963|C1709697|C1444648|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C1552961|C0039798|C0392756|C0038436|G0000000|G0000000|G0000000|G0000000|G0000000
"Outcome measures will be collected at baseline, upon completion of the intervention period (nine weeks) and at six months following completion of the intervention (Figure (Figure1).1).","Outcome measures collected baseline, completion intervention period (nine weeks) months completion intervention (Figure (Figure1).1).",C1274040|C0079809|C1516695|C0168634|C0205197|C0886296|C0439531|C0205455|C0439230|C0439231|C0205197|C0886296|G0000000|G0000000
"Also in this study, frequency of vomiting in each day is used to evaluate the intensity of vomiting.","Also study, frequency vomiting day evaluate intensity vomiting.",G0000000|C0557651|C0376249|C0042963|C0332173|C0220825|C0522510|C0042963
"Outcome measures were readmission, additional hospital days, and deaths within 60 days of initial admission.","Outcome measures readmission, additional hospital days, deaths 60 days initial admission.",C1274040|C0079809|C1548168|C1524062|C0019994|C0439228|C0011065|C0450371|C0439228|C0205265|C0184666
"The primary outcome measure was video gait analysis and secondary outcome measures were gross motor function measure (GMFM), physiological cost index (PCI), and passive ankle dorsiflexion.","The primary outcome measure video gait analysis secondary outcome measures gross motor function measure (GMFM), physiological cost (PCI), passive ankle dorsiflexion.",G0000000|C0205225|C1274040|C0079809|C0042655|C0016928|C0002778|C0027627|C1274040|C0079809|C0439806|C1513492|C0031843|C0079809|G0000000|C0205463|C0010186|C4049621|C3686820|C0003086|G0000000
"They have found that ""Chedoke Arm and Hand Activity Inventory (CAHAI) scale would seem to be an appropriate activity scale, but has not been used in RAET"" [28].","They ""Chedoke Arm Hand Activity Inventory (CAHAI) scale activity scale, RAET"" [28].",G0000000|G0000000|C0446516|C0018563|C0205177|C0021941|G0000000|C0175659|C0205177|C0175659|G0000000|C0450371
Rescue medication use was significantly lower in the reparagen group (p < 0.01) at each assessment period.,Rescue medication lower reparagen (p < 0.01) assessment period.,G0000000|C0013227|C0441994|C1721846|C0369773|G0000000|C0450371|C1261322|C0439531
PSA ≤ 0.2 ng/mL at 7 months is prognostic for longer overall survival with ADT for metastatic hormone-sensitive prostate cancer irrespective of docetaxel administration.,PSA ≤ 0.2 ng/mL 7 months prognostic survival ADT metastatic hormone-sensitive prostate cancer irrespective docetaxel administration.,C3810537|G0000000|G0000000|C0439275|G0000000|C0439231|C0220901|C0038952|C0279492|C0036525|C1512498|C0033572|C0006826|G0000000|C0246415|C0001554
Duration of moderately bad symptoms recorded by validated symptom diary over the 7 days from treatment onset present for all participants who returned a complete symptom diary eTable 6.,Duration moderately bad symptoms recorded validated symptom diary 7 days treatment onset participants returned complete symptom diary eTable 6.,C0449238|C0205081|C0205169|C0683368|C0034869|G0000000|C1457887|C0376660|G0000000|C0439228|C0039798|C0206132|C0679646|C0332156|C0205197|C1457887|C0376660|G0000000|G0000000
"Time points measuring patient reported outcomes for the SurvivorCare study BSI-18, Brief Symptom Inventory; CaSUN, Cancer Survivors’ Unmet Needs Measure; DT, Distress Thermometer; EORTC QLQ C-30, European Organisation for Research and Treatment of Cancer core questionnaire; EORTC QLQ CR-29, the colorectal cancer module.","Time measuring patient reported outcomes SurvivorCare study BSI-18, Brief Symptom Inventory; CaSUN, Cancer Survivors’ Unmet Needs Measure; DT, Distress Thermometer; EORTC QLQ C-30, European Organisation Research Treatment Cancer core questionnaire; EORTC QLQ CR-29, colorectal cancer module.",C0040223|C0444706|C0030705|C0684224|C1274040|G0000000|C0557651|C3831288|C1282927|C1457887|C0021941|G0000000|C0006826|G0000000|C3274904|C0027552|C0079809|C1455430|C0231303|C0039818|C1516985|G0000000|C0450371|C0239307|C0029237|C0035168|C0039798|C0006826|C0444669|C0034394|C1516985|G0000000|C0201975|C0555952|C0006826|C1709061
The Cognitive Failures Questionnaire [69] is a 25 item questionnaire which will be used to assess the primary outcome measure of perceived cognitive function.,The Cognitive Failures Questionnaire [69] 25 item questionnaire assess primary outcome measure perceived cognitive function.,G0000000|C1516691|C0231174|C0034394|C0450371|C0450371|C1551338|C0034394|C1516048|C0205225|C1274040|C0079809|C0030971|C1516691|C0031843
"Primary end points were forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0–3) response, trough FEV1 response and St George's Respiratory Questionnaire (SGRQ) total score at 24 weeks.","Primary forced expiratory volume 1 s (FEV1) curve 0 3 h (AUC0–3) response, trough FEV1 response St George's Respiratory Questionnaire (SGRQ) total score 24 weeks.",C0205225|C0441722|C0231800|C0449468|G0000000|G0000000|C0205134|G0000000|G0000000|G0000000|C0871261|C0444506|G0000000|C0871261|C0036056|G0000000|C0521346|C0034394|G0000000|C0439175|C0449820|G0000000
The intention-to-treat analysis focused on the differences in the nine outcomes between the intervention and comparison conditions at Post 1 and Post 2 controlling for baseline levels.,The intention-to-treat analysis focused differences outcomes intervention comparison conditions Post 1 Post 2 controlling baseline levels.,G0000000|C0162425|C0002778|C0205234|C1705241|C1274040|C0886296|C1707455|C0012634|C0687676|G0000000|C0687676|G0000000|C2239193|C0168634|C0441889
"Apart from mild bloating, no significant side effects were reported.","Apart mild bloating, effects reported.",G0000000|C2945599|C1291077|C1280500|C0684224
"There was no significant correlation between improvements in the SGRQ total score in both groups and changes in FEV1 (r = −0.18), FIV1 (r = −0.14), FVC (r = −0.15), IC (r = −0.07), or SVC (r = −0.17) at study end.","There correlation improvements SGRQ total score FEV1 (r = −0.18), FIV1 (r = −0.14), FVC (r = −0.15), IC (r = −0.07), SVC (r = −0.17) study end.",G0000000|C1707520|C2986411|G0000000|C0439175|C0449820|G0000000|C0205090|G0000000|G0000000|G0000000|C0205090|G0000000|G0000000|C3714541|C0205090|G0000000|G0000000|C0020750|C0205090|G0000000|G0000000|C0231957|C0205090|G0000000|G0000000|C0557651|C0444930
Brain relaxation was comparable in two groups and there was no significant difference (P = 0.633).,Brain relaxation comparable difference (P = 0.633).,C0006104|C0035028|G0000000|C1705241|C0369773|G0000000|C1442061
"Adjusted mean HbA1c level was 8.6% at baseline in the intervention group; this level improved to 7.8% at 6 months, for a change of -0.8 percentage points (P < .01).","Adjusted HbA1c level 8.6% baseline intervention group; level improved 7.8% 6 months, change -0.8 percentage (P < .01).",C0456081|G0000000|C0441889|G0000000|C0168634|C0886296|C0441833|C0441889|C0184511|G0000000|G0000000|C0439231|C0392747|G0000000|C0439165|C0369773|G0000000|C0450371
This initial report focuses on the incidence of serious adverse outcomes including major congenital malformations (which could be attributable to AEDs) or fetal death.,This initial report focuses incidence adverse outcomes including major congenital malformations (which attributable AEDs) fetal death.,G0000000|C0205265|C0684224|C0205234|C0021149|G0000000|C1274040|C0332257|C0205082|C0009678|C0000768|G0000000|C0596130|C0180309|C0015965|C0011065
"In infants aged 1, 3, and 6 months, caregivers reported the occurrence of common illness symptoms in the preceding 15 days.","In infants aged 1, 3, 6 months, caregivers reported occurrence common illness symptoms preceding 15 days.",G0000000|C0021270|C0001779|G0000000|G0000000|G0000000|C0439231|C0085537|C0684224|C0243132|C0205214|C0221423|C0683368|C0332152|C0450371|C0439228
"Baseline surveys include questions about patient demographics, exposure to transplant education, transplant knowledge, preferences for treatment, and decisional conflict.","Baseline surveys questions patient demographics, exposure transplant education, transplant knowledge, preferences treatment, decisional conflict.",C0168634|C0038951|C1522634|C0030705|C0011298|C0274281|C0040732|C0013621|C0040732|C0376554|C0558295|C0039798|C0679006|C0009671
"The primary outcome is asthma control score (decrease of 0.5, the minimally clinically significant change).","The primary outcome asthma control score (decrease 0.5, minimally clinically change).",G0000000|C0205225|C1274040|C0004096|C0243148|C0449820|C0392756|G0000000|G0000000|G0000000|C0392747
The number of falls occurring over one year in the community for each participant was normalized to the number of months over which information was collected.,The falls occurring community participant normalized months collected.,G0000000|C0000921|C1709305|C0009462|C0679646|C1882115|C0439231|C1516695
The primary endpoint is the rate of postoperative pancreatic fistula; the secondary endpoint is postoperative morbidity with follow-up of 3 months.,The primary endpoint rate postoperative pancreatic fistula; secondary endpoint postoperative morbidity follow-up 3 months.,G0000000|C0205225|C2349179|C0871208|C0032790|C0030274|C0016169|C0027627|C2349179|C0032790|C0026538|C0589120|G0000000|C0439231
Passage of flatus and stool Various systematic reviews and meta-analyses have also found a significant reduction in time to first flatus as well as bowel movement in the gum chewing group [Table 5].,Passage flatus stool Various systematic reviews meta-analyses reduction time flatus bowel movement gum chewing [Table 5].,C0439799|C0016204|C0015733|C0440102|C0220922|C0282443|C0920317|C0301630|C0040223|C0016204|C0021853|C0026649|C0017562|C0024888|C0039224|G0000000
"The mortality rates at ICU discharge, at hospital discharge, and at 7, 14, 28, and 180 days and 1 year after randomization were also similar in the two groups (Figure (Figure33).","The mortality rates ICU discharge, hospital discharge, 7, 14, 28, 180 days 1 randomization (Figure (Figure33).",G0000000|C0026565|C0871208|C0021708|C0012621|C0019994|C0012621|G0000000|C0450371|C0450371|C1442061|C0439228|G0000000|C0034656|G0000000|G0000000
Table IV summarizes results of the exit questionnaire.,Table IV summarizes exit questionnaire.,C0039224|C0022326|G0000000|C0337094|C0034394
"Higher doses of alpha-tocopherol have been used in other cancer prevention trials (e.g., Selenium and Vitamin E Cancer Prevention Trial (SELECT) [48]).","Higher doses alpha-tocopherol cancer prevention trials (e.g., Selenium Vitamin E Cancer Prevention Trial (SELECT) [48]).",C0205250|C0178602|C0969677|C0006826|C0199176|C0008976|G0000000|C0036581|C0042890|G0000000|C0006826|C0199176|C0008976|C1707391|C0450371
"Changes in the SIAS Hip-Flexion, Knee-Extension, and Foot-Pat scores over the 4 weeks from admission were analyzed using the Wilcoxon signed-ranks test.","Changes SIAS Hip-Flexion, Knee-Extension, Foot-Pat scores 4 weeks admission analyzed Wilcoxon signed-ranks test.",C0392747|C1225105|C0019552|C0022742|C0016504|C0449820|G0000000|C0439230|C0184666|C0936012|G0000000|C1519316|C0022885
"The secondary outcomes concern actual use rate of the written asthma action plan, number of unplanned visit to healthcare for asthma, usage of Healthy.me, asthma symptoms, and competing demands on health and asthma.","The secondary outcomes concern actual rate written asthma action plan, unplanned visit healthcare asthma, usage Healthy.me, asthma symptoms, competing demands health asthma.",G0000000|C0027627|C1274040|C2699424|C0237400|C0871208|C0043266|C0004096|C0441472|C0270724|G0000000|C0545082|C0086388|C0004096|C0457083|C3898900|C0004096|C0683368|G0000000|C0441516|C0018684|C0004096
"They participated in a blood test at baseline, after 15 weeks of exercise, and at 30 weeks of follow-up.","They participated blood test baseline, 15 weeks exercise, 30 weeks follow-up.",G0000000|G0000000|C0005767|C0022885|C0168634|C0450371|C0439230|C0015259|C0450371|C0439230|C0589120
"The primary objective of the study was to determine whether the efficacy of UMEC/VI was non-inferior to that of TIO + IND as assessed by the trough FEV1 at day 85 (the primary endpoint was the trough FEV1 at day 85, defined as the mean of the FEV1 values obtained at 23 and 24 h after dosing on day 84).","The primary objective study determine efficacy UMEC/VI non-inferior TIO + IND assessed trough FEV1 day 85 (the primary endpoint trough FEV1 day 85, defined FEV1 values 23 24 dosing day 84).",G0000000|C0205225|C0018017|C0557651|G0000000|C1280519|C0205999|C1518422|G0000000|G0000000|C4049864|C1516048|C0444506|G0000000|C0332173|C0450371|G0000000|C0205225|C2349179|C0444506|G0000000|C0332173|C0450371|C1704788|G0000000|C0042295|C0450371|C0450371|G0000000|C0332173|C0450371
Screening with flexible sigmoidoscopy was associated with a significant decrease in colorectal-cancer incidence (in both the distal and proximal colon) and mortality (distal colon only).,Screening flexible sigmoidoscopy decrease colorectal-cancer incidence (in distal proximal colon) mortality (distal colon only).,C0220908|C0443220|C0037075|C0392756|C0009402|C0021149|G0000000|C0205108|C0205107|C0009368|C0026565|C0205108|C0009368|C0205171
Adverse events were compared by group.,Adverse events compared group.,G0000000|C0441471|C1707455|C0441833
To compare the non-neurological events in children with sickle cell anemia (SCA) and previous stroke enrolled in SWiTCH.,To compare non-neurological events children sickle cell anemia (SCA) previous stroke enrolled SWiTCH.,C0040363|C1707455|C1518422|C0441471|C0008059|G0000000|C0007634|C0002871|C0018790|C0205156|C0038454|G0000000|C1707719
"Pap Test Awareness, Understanding, Intention, and Receipt in Media Education (ME) versus Lay Health Worker Outreach + Media Education (LHWO+ME) Groups Prior to the intervention, about two thirds of the women in both groups had had at least one Pap test (Table 4).","Pap Test Awareness, Understanding, Intention, Receipt Media Education (ME) versus Lay Health Worker Outreach + Media Education (LHWO+ME) Groups Prior intervention, thirds women Pap test (Table 4).",C1740167|C0022885|C0004448|C0162340|C0162425|G0000000|C0009458|C0013621|G0000000|G0000000|G0000000|C0018684|C1306056|C0683805|G0000000|C0009458|C0013621|G0000000|C0441833|C0332152|C0886296|C0205437|C0043210|C1740167|C0022885|C0039224|G0000000
"Our trial, however, does differ from the previous studies in respect to the cure rate.","Our trial, however, previous studies respect cure rate.",G0000000|C0008976|G0000000|C0205156|C0947630|C0679133|C1880198|C0871208
The probability of long-term survival following surgical resection of residual disease is increased by this treatment.,The probability long-term survival surgical resection residual disease increased treatment.,G0000000|C0033204|C0443252|C0038952|C0543467|C0015252|C1609982|C0012634|C0205217|C0039798
"Secondary outcomes include participation level, depressive symptoms and planned-use of health services for health promotion and secondary prevention.","Secondary outcomes participation level, depressive symptoms planned-use health services health promotion secondary prevention.",C0027627|C1274040|C0679823|C0441889|G0000000|C0683368|C1301732|C0018684|C0557854|C0018684|C0033414|C0027627|C0199176
The economic evaluation was carried out from the perspective of the NHS.,The economic evaluation carried perspective NHS.,G0000000|C0013556|C0220825|C0206243|G0000000|C0796085
"In terms of both DRS-R-98 and MMSE, there was significant improvement in both the study groups from day 1 through day 6 (Table (Table2).2).","In terms DRS-R-98 MMSE, improvement study day 1 day 6 (Table (Table2).2).",G0000000|C0233324|C3887968|C0451306|C2986411|C0557651|C0332173|G0000000|C0332173|G0000000|C0039224|G0000000
"Caregivers recorded axillary temperature and the severity of influenza symptoms (i.e., nasal symptoms and cough) in diaries 4 times daily (morning, afternoon, evening, and bedtime) from day 1 to day 3 and twice daily from day 4 to day 15 (morning and bedtime).","Caregivers recorded axillary temperature severity influenza symptoms (i.e., nasal symptoms cough) diaries 4 times daily (morning, afternoon, evening, bedtime) day 1 day 3 daily day 4 day 15 (morning bedtime).",C0085537|C0034869|C0004454|C0005903|C0439793|C0021400|C0683368|C0683454|C0028429|C0683368|C0010200|C0376660|G0000000|C0040223|C0332173|C0332170|C0439550|C0587117|C0521112|C0332173|G0000000|C0332173|G0000000|C0332173|C0332173|G0000000|C0332173|C0450371|C0332170|C0521112
"Additionally, survivors receiving a magnesium or phosphate supplement were regarded as having abnormal serum levels.","Additionally, survivors receiving magnesium phosphate supplement regarded abnormal serum levels.",G0000000|C0206194|C1514756|C0024467|C0031603|C0242295|G0000000|C0205161|C0229671|C0441889
HPV vaccine uptake in Hopi girls aged 13–17 years is significantly higher than the U.S. national average.,HPV vaccine uptake Hopi girls aged 13–17 U.S. national average.,C0021344|C0042210|C0243144|C0574606|C0870604|C0001779|G0000000|C0041703|C3245503|C1510992
Infant mortality is an important consideration from a clinical and societal perspective as a small reduction in the rate of mortality in children can lead to a large increase in life expectancy.,Infant mortality consideration clinical societal perspective reduction rate mortality children lead increase life expectancy.,C0021270|C0026565|C0518609|C0205210|G0000000|G0000000|C0301630|C0871208|C0026565|C0008059|C0023175|C0442805|C0376558|C0679138
"Hypothesis 2:Over time, adolescents randomized to Familias Unidas + PATH will be less likely to engage in unprotected sex during the 90 days prior to each assessment point compared with adolescents randomized to either ESOL + PATH or ESOL + HEART.","Hypothesis 2:Over time, adolescents randomized Familias Unidas + PATH engage unprotected sex 90 days prior assessment compared adolescents randomized ESOL + PATH ESOL + HEART.",C1512571|C0205136|C0040223|C0205653|C0034656|G0000000|G0000000|G0000000|C0919386|G0000000|G0000000|C0009253|C0450371|C0439228|C0332152|C1261322|C1707455|C0205653|C0034656|G0000000|G0000000|C0919386|G0000000|G0000000|C0018787
"To complete a comprehensive evaluation of improvement in back pain and the movement limited by back pain, we will determine the patient global impression of change (PGIC) [19,23].","To complete comprehensive evaluation improvement pain movement limited pain, determine patient global impression change (PGIC) [19,23].",C0040363|C0205197|C1880156|C0220825|C2986411|C0030193|C0026649|C0439801|C0030193|G0000000|C0030705|C0205246|C0596764|C0392747|G0000000|C0450371
We used paired sample t-tests to evaluate changes in mean BP and LDL-C values between baseline and 12 months within a single group.,We paired sample t-tests evaluate BP LDL-C values baseline 12 months single group.,G0000000|C1709450|C0370003|C0871472|C0220825|C0037623|G0000000|C0042295|C0168634|C0450371|C0439231|C0037179|C0441833
The WMFT is a quantitative index of UE motor ability and is measured using timed and functional tasks.,The WMFT quantitative UE motor ability measured timed functional tasks.,G0000000|G0000000|C0392762|G0000000|C1513492|C0085732|C0444706|C0392761|C0205245|C3540678
"Additional models were used to evaluate the change from baseline to 1 year in fat-free mass, NIH score, CFQOL, and A1C.","Additional models evaluate change baseline 1 fat-free mass, NIH score, CFQOL, A1C.",C1524062|C3161035|C0220825|C0392747|C0168634|G0000000|C0424612|C0577559|C0027468|C0449820|G0000000|G0000000
"Thus, both treatments were effective during drug court.","Thus, treatments effective drug court.",G0000000|C0087111|C1280519|C0013227|C0178572
Radiologically demonstrated leakage without clinical symptoms was not included.,Radiologically demonstrated leakage clinical symptoms included.,G0000000|G0000000|C0015376|C0205210|C0683368|C0332257
The second visit was done seven days after the first visit for measuring weight and evaluating time to diarrhea relief.,The visit days visit measuring weight evaluating time diarrhea relief.,G0000000|C0545082|C0439228|C0545082|C0444706|C0005910|C0220825|C0040223|C0011991|C0564405
"Data were available at 1, 3, and 6 months for 849, 834, and 834 infants, respectively.","Data 1, 3, 6 months 849, 834, 834 infants, respectively.",C1511726|G0000000|G0000000|G0000000|C0439231|C1442061|C1442061|C1442061|C0021270|G0000000
"Two-part telephone interviews were administered at all 3 timepoints and included the following components: 1) 2 random 24-hour dietary recalls were conducted by trained interviewers using the interactive Nutrition Data System-Revised software (NCC Food and Nutrient Database System Version 2006, Minneapolis, Minn) and data regarding total energy intake; energy from solid fats, added sugars, and alcohol; servings of fruits and vegetables, legumes, total and whole grains, dairy, and meat; and intakes of sodium and saturated fat were used to derive a Healthy Eating Index score as defined by Guenther et al21 and using methods described by Miller et al22; 2) physical activity using the Leisure-Time Exercise Questionnaire of Godin et al17; 3) health-related quality of life using the Short Form-36 instrument23; 4) 2 items on self-efficacy: How confident or sure are you that you could walk or do another type of exercise for at least 30 minutes on 5 or more days of the week?","Two-part telephone interviews administered 3 timepoints included components: 1) 2 random 24-hour dietary recalls conducted trained interviewers interactive Nutrition Data System-Revised software (NCC Food Nutrient Database System Version 2006, Minneapolis, Minn) data total energy intake; energy solid fats, sugars, alcohol; servings fruits vegetables, legumes, total grains, dairy, meat; intakes sodium saturated fat derive Healthy Eating Index score defined Guenther al21 methods Miller al22; 2) physical activity Leisure-Time Exercise Questionnaire Godin al17; 3) health-related quality life Short Form-36 instrument23; 4) 2 items self-efficacy: How confident walk type exercise 30 minutes 5 days week?",C0205448|C0039457|C0021822|C1521801|G0000000|C2348792|C0332257|C0449432|G0000000|G0000000|C0034656|C0450371|C0012155|C0034770|C0004927|C0336809|C0021821|C1704675|C0028707|C1511726|C0449913|C0037585|C1420092|C0016452|C0678695|C0242356|C0449913|C0333052|G0000000|G0000000|G0000000|C1511726|C0439175|C0424589|C1512806|C0424589|C0205208|C0015677|C0242209|C0001962|C1519269|C0016767|C0042440|C0023263|C0439175|C0086369|C3687582|C0025017|C1512806|C0037473|C0522534|C0424612|G0000000|C3898900|C0013470|C0918012|C0449820|C1704788|G0000000|G0000000|C0025663|C0402830|G0000000|G0000000|C0031809|C0205177|C0086542|C0015259|C0034394|G0000000|G0000000|G0000000|C0018684|C0332306|C0376558|C1282927|C0348078|G0000000|G0000000|G0000000|C1551338|C0600564|G0000000|C0205423|C0080331|C0332307|C0015259|C0450371|C0439232|G0000000|C0439228|C0332174
"(A) Plasma measurements of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) at baseline, after 4 weeks of low‐flavanol dark chocolate (LFDC), after 4 weeks of high‐flavanol dark chocolate (HFDC), and at follow‐up (median with 25th and 75th percentiles).","(A) Plasma measurements N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) baseline, 4 weeks low‐flavanol dark chocolate (LFDC), 4 weeks high‐flavanol dark chocolate (HFDC), follow‐up (median 25th 75th percentiles).",G0000000|C0032105|C0242485|G0000000|G0000000|C0597421|C0030956|G0000000|C0168634|G0000000|G0000000|C0332582|C0006622|G0000000|G0000000|G0000000|C0332582|C0006622|G0000000|G0000000|C0549183|G0000000|G0000000|C1264641
"Participants reported vitality in the last month using the Medical Outcomes Study Short Form Health Survey (SF-36) Energy Scale [33], which provided a measure of general energy without assessing the overlapping construct of cognitive fatigue.","Participants reported vitality month Medical Outcomes Study Short Form Health Survey (SF-36) Energy Scale [33], provided measure energy assessing overlapping construct cognitive fatigue.",C0679646|C0684224|C0424589|C0332177|C0199168|C1274040|C0557651|C1282927|C0348078|C0018684|C0038951|C0037712|C0424589|C0175659|C0450371|C1999230|C0079809|C0424589|C1516048|C0185027|C2827421|C1516691|C0015672
"The primary endpoint of the OMEMI study is the composite of total mortality, first event of non-fatal AMI, stroke and revascularization (MACE).","The primary endpoint OMEMI study composite total mortality, event non-fatal AMI, stroke revascularization (MACE).",G0000000|C0205225|C2349179|G0000000|C0557651|C0205199|C0439175|C0026565|C0441471|C1518422|G0000000|C0038454|C0581603|C0349381
Points for the Complexity Index were summed up for each hospital.,Points Complexity Index summed hospital.,C1552961|C0439855|C0918012|C1515051|C0019994
This difference remained even when the 141 abortive telephone calls and five missed appointments were allowed for.,This difference remained 141 abortive telephone calls missed appointments allowed for.,G0000000|C1705241|G0000000|C1442061|G0000000|C0039457|C0679006|C1705492|C0003629|C0683607|G0000000
"CIMT, constraint-induced movement therapy; K-MBI, Korean version of Modified Barthel Index.","CIMT, constraint-induced movement therapy; K-MBI, Korean version Modified Barthel Index.",G0000000|C0443288|C0026649|C0039798|C0597277|C1556095|C0333052|C0392747|G0000000|C0918012
Patients who completed the initial treatment phase were eligible to start the randomized withdrawal phase if they had moderate‐to‐severe hyperkalaemia (serum K+ ≥ 5.5 mEq/L to < 6.5 mEq/L) at baseline of the initial treatment phase and were normokalaemic (serum K+ level within target range of ≥ 3.8 mEq/L to <5.1 mEq/L) at week 4 of the initial treatment phase (baseline of the randomized withdrawal phase).,Patients completed initial treatment phase eligible start randomized withdrawal phase moderate‐to‐severe hyperkalaemia (serum K+ ≥ 5.5 mEq/L < 6.5 mEq/L) baseline initial treatment phase normokalaemic (serum K+ level target range ≥ 3.8 mEq/L <5.1 mEq/L) week 4 initial treatment phase (baseline randomized withdrawal phase).,C0030705|C0205197|C0205265|C0039798|C0205390|C1548635|C0439659|C0034656|C2349954|C0205390|G0000000|C0020461|C0229671|C0597277|G0000000|G0000000|C0439375|G0000000|G0000000|C0439375|C0168634|C0205265|C0039798|C0205390|G0000000|C0229671|C0597277|C0441889|C1521840|C1514721|G0000000|G0000000|C0439375|G0000000|C0439375|C0332174|G0000000|C0205265|C0039798|C0205390|C0168634|C0034656|C2349954|C0205390
"The co-primary efficacy end points were: area under the curve from 0–3 hours (AUC0–3) of FEV1; and trough FEV1 responses (ie, change from baseline) at 12 weeks of treatment.","The co-primary efficacy were: curve 0–3 hours (AUC0–3) FEV1; trough FEV1 responses (ie, change baseline) 12 weeks treatment.",G0000000|C3245499|C1280519|G0000000|C0205134|G0000000|C0439227|G0000000|G0000000|C0444506|G0000000|C0871261|G0000000|C0392747|C0168634|C0450371|C0439230|C0039798
"For each of these risks the answer was yes, no, cannot remember or not applicable.","For risks answer yes, no, remember applicable.",G0000000|C0035647|C1706817|C1549445|G0000000|C0034770|C1272460
"Because patients who did not complete cognitive assessment were more likely to have worse prognostic factors (eg, neurologic function) and shorter survival at every time point, this poor compliance was likely due primarily to tumor progression and death.","Because patients complete cognitive assessment worse prognostic factors (eg, neurologic function) shorter survival time point, poor compliance tumor progression death.",G0000000|C0030705|C0205197|C1516691|C1261322|C0332271|C0220901|C1521761|C0013715|C0205494|C0031843|C1282927|C0038952|C0040223|C1552961|C0032854|C0009563|C0027651|C0242656|C0011065
The difference in the median number of stools on intention-to-treat analysis revealed no statistically significant difference.,The difference median stools intention-to-treat analysis revealed statistically difference.,G0000000|C1705241|C0549183|C0015733|C0162425|C0002778|C0443289|C0038215|C1705241
There were three measurement periods: prior to randomization (Time 1) and at 5 and 9 months post enrollment (Times 2 and 3).,There measurement periods: prior randomization (Time 1) 5 9 months post enrollment (Times 2 3).,G0000000|C0242485|C0439531|C0332152|C0034656|C0040223|G0000000|G0000000|G0000000|C0439231|C0687676|C1516879|C0040223|G0000000|G0000000
Outcome measures were WHOQOL Bref for quality of life and straight leg raising test (SLR) using a Goniometer.,Outcome measures WHOQOL Bref quality life straight leg raising test (SLR) Goniometer.,C1274040|C0079809|G0000000|G0000000|C0332306|C0376558|C0445291|C0023216|G0000000|C0022885|G0000000|C0181061
Post-procedure state anxiety (STAI) and pain rating (VAS) were not significantly different between groups (STAI p=0.766; VAS p=0.771).,Post-procedure anxiety (STAI) pain rating (VAS) (STAI p=0.766; VAS p=0.771).,C3272301|C0003467|C0683457|C0030193|C0871208|C0042815|C0683457|C0369773|C0042815|C0369773
Previous research with the SRAHP in adults with and without disabilities demonstrated adequate reliability and sensitivity to change over time.18 Perceived health and QOL were measured by The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36).25 and the Fibromyalgia Impact Questionnaire.,Previous SRAHP adults disabilities demonstrated adequate reliability sensitivity change time.18 Perceived health QOL measured The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36).25 Fibromyalgia Impact Questionnaire.,C0205156|G0000000|C0001675|C0231170|G0000000|C0205410|C2347947|C0020517|C0392747|C0040223|C0030971|C0018684|C0518214|C0444706|G0000000|C0199168|C1274040|C0557651|C0450371|C2964478|C0018684|C0038951|C0037712|C0016053|C1825598|C0034394
Effect of micronutrient supplementation on T cell counts (cells/mm3) and viral load (copies/mm3).,Effect micronutrient supplementation T cell counts (cells/mm3) viral load (copies/mm3).,C1280500|C0040577|C0242297|C2603360|C0007634|C0439157|C0007634|C0521026|C1550025|C1948062
The primary outcome variable is the proportion of cephalic presentations at term.,The primary outcome variable proportion cephalic presentations term.,G0000000|C0205225|C1274040|C0439828|C1709707|C0205096|C0449450|C0233324
"However, if the intervention detected only cases that would have been captured by subsequent PCF, the cumulative reduction in subsequent case notifications should not be more than -100% of additional cases.","However, intervention detected captured subsequent PCF, cumulative reduction subsequent notifications -100% additional cases.",G0000000|C0886296|C0442726|G0000000|C0332282|C1549862|C1511559|C0301630|C0332282|C0422202|C1442061|C1524062|C0868928
"The rates of adverse events at three different periods (days 1–2, days 3–7 and days 14–42) were compared among treatment groups.","The rates adverse events periods (days 1–2, days 3–7 days 14–42) compared treatment groups.",G0000000|C0871208|G0000000|C0441471|C0439531|C0439228|G0000000|C0439228|G0000000|C0439228|G0000000|C1707455|C0039798|C0441833
"We obtained data on basic delivery information, perinatal outcomes and neonatal morbidity (e.g.","We data basic delivery information, perinatal outcomes neonatal morbidity (e.g.",G0000000|C1511726|C1527178|C0011209|C1533716|C0178795|C1274040|C1552240|C0026538|G0000000
Primary outcome: epidural use for pain relief.,Primary outcome: epidural pain relief.,C0205225|C1274040|C0228134|C0030193|C0564405
"BP was measured by a trained, certified nurse blinded to treatment allocation, with an electronic monitor (Microlife 3 BTO-A) after 15 min of rest, back supported, arm supported at the heart level, and cuff placed on the left upper arm.","BP measured trained, certified nurse blinded treatment allocation, electronic monitor (Microlife 3 BTO-A) 15 min rest, supported, arm supported heart level, cuff left upper arm.",C0037623|C0444706|C0336809|C0007836|C0028661|C0150108|C0039798|C1706778|C0013850|C0030695|G0000000|G0000000|G0000000|C0450371|C0702093|C0035253|C1521721|C0446516|C1521721|C0018787|C0441889|C0441107|C0205091|C1282910|C0446516
"The Kaplan-Meier method was used to estimate PFS, median follow-up and OS distributions, while the log-rank test was used to compare these distributions.","The Kaplan-Meier method estimate PFS, median follow-up OS distributions, log-rank test compare distributions.",G0000000|G0000000|C0025663|C0750572|C0242792|C0549183|C0589120|C0229090|C0037775|C1708728|C0022885|C1707455|C0037775
"We tested LBW (<2500 g), VLBW (<1500 g), preterm birth (<37 wk), early preterm birth (<34 wk), preeclampsia, gestational diabetes mellitus, cesarean section, and spontaneous or induced labor as recorded in a hospital record with a one-sided binomial exact tests.","We tested LBW (<2500 g), VLBW (<1500 g), preterm birth (<37 wk), preterm birth (<34 wk), preeclampsia, gestational diabetes mellitus, cesarean section, spontaneous induced labor recorded hospital record one-sided binomial exact tests.",G0000000|C0392366|G0000000|G0000000|C0439267|C0282666|G0000000|C0439267|C0151526|C0005615|C0450371|C0332174|C0151526|C0005615|C0450371|C0332174|C0032914|C0439671|C0011847|G0000000|C3841297|C0152060|C0205359|C0205263|C0022864|C0034869|C0019994|C0034869|C0205092|G0000000|C2828393|C0022885
Time to intracranial progression at (A) new sites and (B) initial sites in patients treated initially by radiosurgery (RS) or surgery (S) after observation or adjuvant whole-brain radiotherapy (WBRT).,Time intracranial progression (A) sites (B) initial sites patients treated initially radiosurgery (RS) surgery (S) observation adjuvant whole-brain radiotherapy (WBRT).,C0040223|C0524466|C0242656|G0000000|C0205145|G0000000|C0205265|C0205145|C0030705|C1522326|C0205265|C0085203|C0035970|C0038894|C0565930|C0302523|C0001551|C1269537|C0034619|C1520143
Endpoints included the change from baseline in serum K+ at the end of treatment (primary); the proportion of patients with hyperkalaemia (K+ >5.5 mEq/L); and the proportion titrated to spironolactone 50 mg/day.,Endpoints included change baseline serum K+ treatment (primary); proportion patients hyperkalaemia (K+ >5.5 mEq/L); proportion titrated spironolactone 50 mg/day.,C2349179|C0332257|C0392747|C0168634|C0229671|C0597277|C0039798|C0205225|C1709707|C0030705|C0020461|C0597277|G0000000|C0439375|C1709707|C1883350|C0037982|C0450371|C0439422
"Ashworth Scale, the Joint Stability Scale, pain assessment, and Beck Depression Scale were comparable on admission and discharge (also Table 3).","Ashworth Scale, Joint Stability Scale, pain assessment, Beck Depression Scale comparable admission discharge (also Table 3).",G0000000|C0175659|C0022417|C0205360|C0175659|C0030193|C1261322|G0000000|C0011570|C0175659|G0000000|C0184666|C0012621|G0000000|C0039224|G0000000
"Change in mean surface areas of lesions before and after treatment with antibiotics for 2, 4, 8, or 12 weeks During 12 months' follow-up after surgery, there was only one case of recurrence, in a subject in group I who had not received antibiotics.","Change surface lesions treatment antibiotics 2, 4, 8, 12 weeks During 12 months' follow-up surgery, recurrence, subject I received antibiotics.",C0392747|C0205148|C0221198|C0039798|C0003232|G0000000|G0000000|G0000000|C0450371|C0439230|G0000000|C0450371|C0439231|C0589120|C0038894|C0034897|C0681850|C0021966|C1514756|C0003232
The primary endpoints were the average nocturnal BP dipping levels of SBP and DBP according to 24-hour ambulatory BP monitoring.,The primary endpoints average nocturnal BP dipping levels SBP DBP 24-hour ambulatory BP monitoring.,G0000000|C0205225|C2349179|C1510992|C0240526|C0037623|C0337426|C0441889|G0000000|C0536221|C0450371|C0439841|C0037623|C0150369
"The interventions had no discernible effect on recovery, resulting in comparable median daily symptom scores for all four groups of patients.","The interventions discernible recovery, comparable median daily symptom scores patients.",G0000000|C0886296|C0205396|C0237820|G0000000|C0549183|C0332173|C1457887|C0449820|C0030705
"Daily dietary intake after treatment, adjusted for age, gender, ethnicity, and pretreatment level of outcome Compared with UC, DASH-WM resulted in significantly lower urinary sodium levels and higher urinary potassium excretion (P < .01) (Table 3).","Daily dietary intake treatment, adjusted age, gender, ethnicity, pretreatment level outcome Compared UC, DASH-WM lower urinary sodium levels urinary potassium excretion (P < .01) (Table 3).",C0332173|C0012155|C1512806|C0039798|C0456081|C0001779|C0079399|C0015031|C1550147|C0441889|C1274040|C1707455|G0000000|C2827624|C0441994|C0042027|C0037473|C0441889|C0042027|C0032821|C0221102|C0369773|G0000000|C0450371|C0039224|G0000000
"Nevertheless, detection of a recurrence should lead to curative therapy with an aggressive surgical approach.","Nevertheless, detection recurrence lead curative therapy aggressive surgical approach.",G0000000|C1511790|C0034897|C0023175|C1880198|C0039798|C0001807|C0543467|C0449445
Changes in mean percentiles for weight and length between 1 and 5.5 mo did not differ between groups.,Changes percentiles weight length 1 5.5 mo groups.,C0392747|C1264641|C0005910|C1444754|G0000000|G0000000|C0026544|C0441833
"Both general practitioners’ use of point of care testing for C reactive protein and training in enhanced communication skills had a clinically important effect on antibiotic prescribing at the index consultation for lower respiratory tract infection and antibiotic prescribing during the 28 days’ follow-up period, without affecting clinical recovery or patients’ satisfaction.","Both practitioners’ care testing C reactive protein training enhanced communication skills clinically antibiotic prescribing consultation lower respiratory tract infection antibiotic prescribing 28 days’ follow-up period, clinical recovery patients’ satisfaction.",G0000000|G0000000|C1947933|C0039593|G0000000|C0205332|C0033684|C0040607|C2349975|C0009452|C0678856|G0000000|C0003232|C0278329|C0009818|C0441994|C0521346|C1185740|C0009450|C0003232|C0278329|C0450371|G0000000|C0589120|C0439531|C0205210|C0237820|G0000000|C0242428
Balance was assessed using the Berg Balance Scale (BBS) and the timed up and go (TUG) test.,Balance assessed Berg Balance Scale (BBS) timed (TUG) test.,C0014653|C1516048|G0000000|C0014653|C0175659|G0000000|C0392761|C1319201|C0022885
The primary outcome measure was the number of days on respiratory support and a secondary outcome the number of blood transfusions required.,The primary outcome measure days respiratory support secondary outcome blood transfusions required.,G0000000|C0205225|C1274040|C0079809|C0439228|C0521346|C0183683|C0027627|C1274040|C0005767|C0005841|C1514873
"Outcomes included safety and clinical parameters, inflammatory (total leukocyte numbers, cell differentials, TNF-α, IL-8) measures in induced sputum, and concentrations of extracellular glutathione in induced sputum and blood.","Outcomes included safety clinical parameters, inflammatory (total leukocyte numbers, cell differentials, TNF-α, IL-8) measures induced sputum, concentrations extracellular glutathione induced sputum blood.",C1274040|C0332257|C0036043|C0205210|C0449381|C0333348|C0439175|C0023516|C0237753|C0007634|C0443199|G0000000|C0020898|C0079809|C0205263|C0038056|C0086045|C0521119|C0017817|C0205263|C0038056|C0005767
"[Results] In the intragroup comparison, both groups showed significant differences between measurements taken before and after four weeks of therapy.","[Results] In intragroup comparison, differences measurements weeks therapy.",C1274040|G0000000|G0000000|C1707455|C1705241|C0242485|C0439230|C0039798
"Secondary patient outcomes relating to the quality of life (at 6 months after randomisation), impact of epilepsy, medication management, psychological distress, and mastery/control of epilepsy will be analysed by using linear mixed models and an approach similar to that described above.","Secondary patient outcomes relating quality life (at 6 months randomisation), impact epilepsy, medication management, psychological distress, mastery/control epilepsy analysed linear mixed models approach above.",C0027627|C0030705|C1274040|C0163712|C0332306|C0376558|G0000000|G0000000|C0439231|C0034656|C1825598|C0014544|C0013227|C0001554|C0205486|C0231303|C0243148|C0014544|G0000000|C0205132|C0205430|C3161035|C0449445|C1282910
"Adequacy of nerve sparing, radicality, bladder function, and oncologic safety were assessed by quantifying the nerve fibers in the paracervix, measuring the extent of paracervix and harvested lymph nodes (LNs), urodynamic study (UDS) with International Prostate Symptom Score (IPSS), and 10-year disease-free survival (DFS), respectively.","Adequacy nerve sparing, radicality, bladder function, oncologic safety assessed quantifying nerve fibers paracervix, measuring extent paracervix harvested lymph nodes (LNs), urodynamic study (UDS) International Prostate Symptom Score (IPSS), 10-year disease-free survival (DFS), respectively.",C0205410|C0027740|G0000000|C0302912|C0005682|C0031843|C0205478|C0036043|C1516048|C1709793|C0027740|C1304649|C1185878|C0444706|C0439792|C1185878|C1512335|C0024202|C0746922|C0023374|C0042059|C0557651|G0000000|C1512888|C0033572|C1457887|C0449820|C1019118|C0450371|C0012634|C0038952|G0000000|G0000000
The primary outcome will be overall QoL at 12 months using the European Organisation for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30) [73].,The primary outcome QoL 12 months European Organisation Research Treatment Cancer core questionnaire (EORTC QLQ-C30) [73].,G0000000|C0205225|C1274040|C0518214|C0450371|C0439231|C0239307|C0029237|C0035168|C0039798|C0006826|C0444669|C0034394|C1516985|G0000000|C0450371
Cognitive impairments reported by patients have been associated with higher levels of emotional distress.,Cognitive impairments reported patients levels emotional distress.,C1516691|C0684336|C0684224|C0030705|C0441889|C0013987|C0231303
A variety of statistical methods can be used to summarize and compare serial data taken at different time points.,A variety statistical methods summarize compare serial data time points.,G0000000|C1883525|C0038215|C0025663|G0000000|C1707455|C0031082|C1511726|C0040223|C1552961
"At each visit, participants rested 15 min in a seated position, the first blood pressure measurement was taken but discarded, and the subsequent 3 consecutive blood pressure readings, taken at 3-min intervals, were recorded.","At visit, participants rested 15 min seated position, blood pressure measurement discarded, subsequent 3 consecutive blood pressure readings, 3-min intervals, recorded.",G0000000|C0545082|C0679646|C0035253|C0450371|C0702093|C0277814|C0733755|C0005767|C0033095|C0242485|G0000000|C0332282|G0000000|C1707491|C0005767|C0033095|C0034754|C0702093|C1272706|C0034869
"When adjusted for site, age, NIHSS, baseline feeding status, and PAS, there was no difference in PAS at 2 weeks, mean difference 0.14 (95% CI, −0.37 to 0.64; P=0.60; Table Table22 and Figure Figure2);2); the mean change in PAS from baseline to 2 weeks did not differ between the 2 treatment groups: active PES −1.2 (1.8) versus sham PES −1.2 (1.8) and difference 0.14 (−0.37 to 0.64).","When adjusted site, age, NIHSS, baseline feeding status, PAS, difference PAS 2 weeks, difference 0.14 (95% CI, −0.37 0.64; P=0.60; Table Table22 Figure Figure2);2); change PAS baseline 2 weeks 2 treatment groups: active PES −1.2 (1.8) versus sham PES −1.2 (1.8) difference 0.14 (−0.37 0.64).",G0000000|C0456081|C0205145|C0001779|C3476804|C0168634|C0204695|C0449438|C0030125|C1705241|C0030125|G0000000|C0439230|C1705241|C0450371|C0450371|C0008107|G0000000|C0450371|C0369773|C0039224|G0000000|G0000000|G0000000|C0392747|C0030125|C0168634|G0000000|C0439230|G0000000|C0039798|C0441833|C0205177|C0016504|G0000000|G0000000|G0000000|C0068899|C0016504|G0000000|G0000000|C1705241|C0450371|G0000000|C0450371
"A 5-point ratings scale (Strongly Agree to Strongly Disagree) was used to evaluate the TAT program, including the TAT manual (3 items: readability, understandability, and helpfulness), relaxation tapes (1 item: effectiveness in inducing relaxation), home biofeedback equipment (1 item: ease of use), and telephone-based versus clinic treatment format (1 item: preference).","A 5-point ratings scale (Strongly Agree Strongly Disagree) evaluate TAT program, including TAT manual (3 items: readability, understandability, helpfulness), relaxation tapes (1 item: effectiveness inducing relaxation), biofeedback equipment (1 item: ease use), telephone-based versus clinic treatment format (1 item: preference).",G0000000|C1552961|C0871208|C0175659|G0000000|C3641827|G0000000|C3641828|C0220825|C3820394|C1709697|C0332257|C3820394|C0024763|G0000000|C1551338|C0871211|G0000000|C3898897|C0035028|C0183828|G0000000|C1551338|C1280519|C0205263|C0035028|C0005491|C0014672|G0000000|C1551338|C1331418|C0042153|C0039457|G0000000|C0002424|C0039798|C1301627|G0000000|C1551338|C0558295
"Time between decision to operate and surgical revascularization among patients who accessed surgery through direct admission, by calendar period of decision.","Time decision operate surgical revascularization patients accessed surgery direct admission, calendar period decision.",C0040223|C0679006|C3242339|C0543467|C0581603|C0030705|C0444454|C0038894|C0439851|C0184666|C1516147|C0439531|C0679006
"The primary outcome measure will be 7-day point prevalence smoking abstinence, i.e.","The primary outcome measure 7-day prevalence smoking abstinence, i.e.",G0000000|C0205225|C1274040|C0079809|C0332173|C0033105|C0037369|C3843422|C0683454
"Future studies also should examine not only upper extremity function but also the efficiency, angle, and reactivity of such motion.","Future studies examine upper extremity function efficiency, angle, reactivity motion.",C0016884|C0947630|G0000000|C1282910|C0015385|C0031843|C0013682|C0205143|C0443286|C0026597
Primary medical treatment was defined as treatment of a M. ulcerans lesion with either antimicrobials alone or antimicrobials in conjunction with limited surgical debridement.,Primary medical treatment defined treatment M. ulcerans lesion antimicrobials antimicrobials conjunction limited surgical debridement.,C0205225|C0199168|C0039798|C1704788|C0039798|C0369637|G0000000|C0221198|C1136254|C1136254|C2699427|C0439801|C0543467|C0011079
"Self-reported point prevalence and prolonged abstinence at 6-, 12-, 18- and 24-month follow-ups.","Self-reported prevalence prolonged abstinence 6-, 12-, 18- 24-month follow-ups.",C0681906|C0033105|C0439590|C3843422|G0000000|C0450371|C0450371|C0450371|C0332283
Higher scores represent better quality of life or less severe symptoms.,Higher scores represent quality life severe symptoms.,C0205250|C0449820|C1882932|C0332306|C0376558|C0205082|C0683368
"All participants were contacted by telephone at 1, 3, and 6 months after discharge from the hospital.","All participants contacted telephone 1, 3, 6 months discharge hospital.",G0000000|C0679646|C0332158|C0039457|G0000000|G0000000|G0000000|C0439231|C0012621|C0019994
"The periodicity of initial failures in the placebo group also support this; without radical treatment with PQ, failures occur in two distinct periods–between 0–3 months post treatment and between 6–9 months post treatment (table 5 and figures 2 and and3),3), where this is not seen in the 8-week PQ group.","The periodicity initial failures placebo support this; radical treatment PQ, failures occur distinct periods–between 0–3 months post treatment 6–9 months post treatment (table 5 figures 2 and3),3), 8-week PQ group.",G0000000|C0031084|C0205265|C0231174|C0032042|C0183683|G0000000|C0302912|C0039798|C2987314|C0231174|C1709305|G0000000|G0000000|G0000000|C0439231|C0687676|C0039798|G0000000|C0439231|C0687676|C0039798|C0039224|G0000000|G0000000|G0000000|G0000000|C0332174|C2987314|C0441833
"At present, the use of spirometry as a motivational tool for smoking cessation continues to be a controversial topic.","At present, spirometry motivational tool smoking cessation continues controversial topic.",G0000000|C0150312|C0037981|C0026605|C0336791|C0037369|C1880019|C0549178|C0680243|C1522168
"Additionally, by definition, symptoms and quality of life ratings come from the person's perspective, thus making self-report the only appropriate way to measure these outcomes.","Additionally, definition, symptoms quality life ratings person's perspective, self-report measure outcomes.",G0000000|C1550452|C0683368|C0332306|C0376558|C0871208|C0027361|G0000000|C0681906|C0079809|C1274040
"This study will collect day-to-day data of over 600 patients, 2000 platelet transfusions and 24 000 days of follow-up, allowing for several other important issues, for instance the capacity of the current WHO system to grade bleeding complications in predicting major bleeding complications, the possibility of testing other bleeding scales and serving as a platform for several site studies including albuminuria as a predictor for vascular damage, increased platelet consumption and, perhaps, bleeding.60–62 The potential reduction of alloimmunisation through the use of Mirasol-treated platelets would be of additive beneficial value, potentially even more clinically significant in comparison to the reduction of transfusion transmitted infectious diseases.","This study collect day-to-day data 600 patients, 2000 platelet transfusions 24 000 days follow-up, allowing issues, instance capacity current WHO system grade bleeding complications predicting major bleeding complications, possibility testing bleeding scales serving platform site studies including albuminuria predictor vascular damage, increased platelet consumption and, perhaps, bleeding.60–62 The potential reduction alloimmunisation Mirasol-treated platelets additive beneficial value, clinically comparison reduction transfusion transmitted infectious diseases.",G0000000|C0557651|G0000000|C0332173|C1511726|C1442061|C0030705|G0000000|C0005821|C0005841|G0000000|C0589120|C0683607|C0033213|C1550608|C1516240|C0521116|G0000000|C0449913|C0441800|C0019080|C0009566|G0000000|C0205082|C0019080|C0009566|C0332149|C0039593|C0019080|C0175659|C1519269|C1710360|C0205145|C0947630|C0332257|C0001925|C2698872|C0005847|C0010957|C0205217|C0005821|C0009830|G0000000|G0000000|G0000000|G0000000|C3245505|C0301630|C0948201|C0947381|C0005821|C0442796|G0000000|C1522609|G0000000|C1707455|C0301630|C0005841|C0242781|C0009450|C0012634
Difference in Key's index (ESA dosage divided by haemoglobin concentration) between the oxpentifylline and control groups at the end of the 4 month study period.,Difference Key's (ESA dosage divided haemoglobin concentration) oxpentifylline control 4 month study period.,C1705241|G0000000|C3890206|C0178602|C0332849|C0019046|C0004268|C0030899|C0243148|G0000000|C0332177|C0557651|C0439531
The CRQ total and emotions score and the SGRQ symptoms score were the most responsive to change.,The CRQ total emotions score SGRQ symptoms score responsive change.,G0000000|G0000000|C0439175|C0013987|C0449820|G0000000|C0683368|C0449820|C0205342|C0392747
"Changes in (A) Multidimensional Fatigue Symptom Inventory–Short Form (MFSI-SF) fatigue scores, (B) vitality scores (36-item short form [SF-36]), (C) depressive symptoms (Center for Epidemiological Studies–Depression [CES-D]), and (D, E, F) lipopolysaccharide-stimulated cytokine production (interleukin-6 [IL-6], tumor necrosis factor alpha [TNF-α], and interleukin-1β [IL-1β]) immediately post treatment and 3 months post treatment as a function of yoga practice frequency.","Changes (A) Multidimensional Fatigue Symptom Inventory–Short Form (MFSI-SF) fatigue scores, (B) vitality scores (36-item short form [SF-36]), (C) depressive symptoms (Center Epidemiological Studies–Depression [CES-D]), (D, E, F) lipopolysaccharide-stimulated cytokine production (interleukin-6 [IL-6], tumor necrosis factor alpha [TNF-α], interleukin-1β [IL-1β]) post treatment 3 months post treatment function yoga practice frequency.",C0392747|G0000000|C2347299|C0015672|C1457887|G0000000|C0348078|C0037712|C0015672|C0449820|G0000000|C0424589|C0449820|C0450371|C1282927|C0348078|C0037712|G0000000|G0000000|C0683368|C0205099|C0014507|G0000000|C2699160|C0073187|G0000000|C0016327|C0023810|C0079189|C0033268|C0021764|C0020898|C0027651|C0027540|C1521761|C0439095|G0000000|G0000000|G0000000|C0687676|C0039798|G0000000|C0439231|C0687676|C0039798|C0031843|C0043418|C0237607|C0376249
"At follow up, OH sought information on patient satisfaction with care, any readmissions or presentations to the hospital emergency department during the three months, current treatment, frequency of visits to general practitioner, contact with community nurse, smoking habits, immunisation history, knowledge and understanding of the medical condition, help seeking, and self rated health.","At follow up, OH sought patient satisfaction care, readmissions presentations hospital emergency department months, current treatment, frequency visits practitioner, contact community nurse, smoking habits, immunisation history, knowledge understanding medical condition, seeking, rated health.",G0000000|C0332283|G0000000|C0220853|G0000000|C0030705|C0242428|C1947933|G0000000|C0449450|C0019994|C0013956|C1704729|C0439231|C0521116|C0039798|C0376249|C0545082|C1709627|C0332158|C0009462|C0028661|C0037369|C0018464|C0020971|C0019664|C0376554|C0162340|C0199168|C0012634|G0000000|C0871208|C0018684
"The main outcome measure was an increase in spontaneous activity, assessed using a novel structured interview of both the patient and the partner or housemate, if present.","The main outcome measure increase spontaneous activity, assessed structured interview patient partner housemate, present.",G0000000|C0205225|C1274040|C0079809|C0442805|C0205359|C0205177|C1516048|C0678594|C0021822|C0030705|C0682323|C3829617|C0150312
"Toxicity was assessed after each cycle of treatment and scored according to WHO criteria (Miller et al, 1981).","Toxicity assessed cycle treatment scored WHO criteria (Miller al, 1981).",C0040539|C1516048|C1511572|C0039798|C0449820|G0000000|C0243161|C0402830|C0202311|G0000000
"These items allowed us to evaluate program effects on “ever,” “past month,” and “weekly” use.","These items allowed evaluate program effects “ever,” “past month,” “weekly” use.",G0000000|C1551338|C0683607|C0220825|C1709697|C1280500|G0000000|G0000000|G0000000|G0000000|C0042153
"Median PFS was 6.2 months (95% CI, 3.9–10.4 months) and 7.7 months (95% CI, 5.5 months–10.1 months), respectively, in each arm (log-rank P = 0.61).","Median PFS 6.2 months (95% CI, 3.9–10.4 months) 7.7 months (95% CI, 5.5 months–10.1 months), respectively, arm (log-rank P = 0.61).",C0549183|C0242792|G0000000|C0439231|C0450371|C0008107|G0000000|C0439231|G0000000|C0439231|C0450371|C0008107|G0000000|G0000000|C0439231|G0000000|C0446516|C1708728|C0369773|G0000000|C0450371
"In contrast, the subjects treated with naltrexone for 12 weeks exhibited endoscopic mucosal healing (d) and histologic examination showed decreased inflammatory cells with restoration of crypt architecture (d1) The results of both quality of life surveys (IBDQ and SF-36) indicated an improvement over the course of the study in both the naltrexone and placebo treated groups from baseline (Fig.","In contrast, subjects treated naltrexone 12 weeks exhibited endoscopic mucosal healing (d) histologic examination decreased inflammatory cells restoration crypt architecture (d1) The quality life surveys (IBDQ SF-36) improvement study naltrexone placebo treated baseline (Fig.",G0000000|C0009924|C0681850|C1522326|C0027360|C0450371|C0439230|C0015272|C0014245|C0026724|C0043240|C0073187|C0205462|G0000000|C0205216|C0333348|C0007634|C0449982|C1880192|C0003737|C3538936|G0000000|C0332306|C0376558|C0038951|G0000000|C0037712|C2986411|C0557651|C0027360|C0032042|C1522326|C0168634|C0349966
"Pain after one hour, measured using a visual analogue scale (VAS), is the primary outcome.","Pain hour, measured visual analogue scale (VAS), primary outcome.",C0030193|C0439227|C0444706|C0234621|C0243071|C0175659|C0042815|C0205225|C1274040
"Of these eight withdrawals, five belonged to the acupuncture group and three to sham.","Of withdrawals, belonged acupuncture sham.",G0000000|C2349954|G0000000|C0001299|C0068899
"Secondary outcomes included safety assessments, ABS, and results from Sino-Nasal Symptoms (SNOT-14) and modified Leeds Sleep Evaluation Questionnaires (mLSEQ).","Secondary outcomes included safety assessments, ABS, Sino-Nasal Symptoms (SNOT-14) modified Leeds Sleep Evaluation Questionnaires (mLSEQ).",C0027627|C1274040|C0332257|C0036043|C1261322|G0000000|C0064022|C0683368|C0450371|C0392747|G0000000|C0037313|C0220825|C0034394|G0000000
"The Timeline FollowBack (TLFB) calendar (DS 1) was used to obtain reliable and valid self-report data on number of drinks per day, mean number of drinking days per month, and maximum drinks per drinking occasion.23 The I and AC groups reported 30-day alcohol consumption by TLFB at baseline and again at three and 12 months; the MAC group reported alcohol consumption by TLFB at 12 months only.","The Timeline FollowBack (TLFB) calendar (DS 1) reliable valid self-report data drinks day, drinking days month, maximum drinks drinking occasion.23 The I AC reported 30-day alcohol consumption TLFB baseline 12 months; MAC reported alcohol consumption TLFB 12 months only.",G0000000|C0145943|G0000000|C0814210|C1516147|C3714751|G0000000|C3858758|C2349099|C0681906|C1511726|C0452428|C0332173|C0001948|C0439228|C0332177|C0806909|C0452428|C0001948|C0521114|G0000000|C0021966|C0003354|C0684224|C0450371|C0001962|C0009830|C0814210|C0168634|C0450371|C0439231|C3538559|C0684224|C0001962|C0009830|C0814210|C0450371|C0439231|C0205171
"On the basis of part 2 of the questionnaire, the following 5 dependent variables were assessed for each PSA as well as for the control program: perceived effectiveness, perceived realism, negative emotional response, positive emotional response, and amount learned.","On basis 2 questionnaire, 5 dependent variables assessed PSA control program: perceived effectiveness, perceived realism, negative emotional response, positive emotional response, amount learned.",G0000000|C1527178|G0000000|C0034394|G0000000|C0851827|C0439828|C1516048|C3810537|C0243148|C1709697|C0030971|C1280519|C0030971|C0237815|C0205160|C0013987|C0871261|C0439178|C0013987|C0871261|C1265611|C0023185
"PPE2 is relatively more heavily contaminated than PPE1 during doffing in sites, such as hands and wrists, working clothes and the environment (chair).","PPE2 heavily contaminated PPE1 doffing sites, hands wrists, clothes environment (chair).",G0000000|G0000000|C0205279|G0000000|G0000000|C0205145|C0018563|C0043262|C0009072|C0014406|C0179847
"Participants complete questionnaires first followed by testing for postural stability, physical function, and maximal muscle strength.","Participants complete questionnaires testing postural stability, physical function, maximal muscle strength.",C0679646|C0205197|C0034394|C0039593|C0205278|C0205360|C0031809|C0031843|C0205289|C0026845|C0237897
"Effect of fortified wheat flour chapatti on serum retinol (SR), serum ferritin (SF), serum transferrin receptor (STfR) and haemoglobin concentrations at 3‐ and 6‐month interval CI, confidence interval.","Effect fortified wheat flour chapatti serum retinol (SR), serum ferritin (SF), serum transferrin receptor (STfR) haemoglobin concentrations 3‐ 6‐month interval CI, confidence interval.",C1280500|G0000000|C0043137|C0016260|C0452524|C0229671|C0042839|C3813610|C0229671|C0015879|C0037712|C0229671|C0040679|C0597357|G0000000|C0019046|C0086045|G0000000|G0000000|C1272706|C0008107|C0237529|C1272706
Patients with an MRC score of less than 48 of 60 were diagnosed with CIPNM.,Patients MRC score 48 60 diagnosed CIPNM.,C0030705|C1540289|C0449820|C0450371|C0450371|C0011900|G0000000
"QoL is defined as self-perceived well-being related to, or affected by the presence of disease or treatment 5.","QoL defined self-perceived well-being to, presence disease treatment 5.",C0518214|C1704788|C0036588|C0018684|G0000000|C0150312|C0012634|C0039798|G0000000
Knee extensor strength and balance performance were measured three times before and after real and sham stimulation.,Knee extensor strength balance performance measured times real sham stimulation.,C0022742|C1184148|C0237897|C0014653|C0597198|C0444706|C0040223|C0237400|C0068899|C1292856
"The primary outcome variable for this study was pain intensity, assessed using 0–10 numerical rating scales (NRSs), with 0 = No pain sensation and 10 = The most intense pain sensation imaginable.","The primary outcome variable study pain intensity, assessed 0–10 numerical rating scales (NRSs), 0 = No pain sensation 10 = The intense pain sensation imaginable.",G0000000|C0205225|C1274040|C0439828|C0557651|C0030193|C0522510|C1516048|G0000000|C0237753|C0871208|C0175659|C2240043|G0000000|G0000000|G0000000|C0030193|C0036658|C0450371|G0000000|G0000000|C0522510|C0030193|C0036658|G0000000
"The revised Social Provisions Scale (SPS; Cutrona & Russell, 1987) was used as a measure of social support.","The revised Social Provisions Scale (SPS; Cutrona & Russell, 1987) measure social support.",G0000000|C1527075|C0728831|C1549071|C0175659|C3813609|G0000000|G0000000|C1979971|G0000000|C0079809|C0728831|C0183683
"Secondary end points included evaluation of the number of pulmonary exacerbations, the use of antibiotics, modifications of microbiological analysis of sputum or throat cultures (appearance of new pathogens, bacterial culture densities), changes in FVC, nutritional status with measurement of body mass index (BMI), and quality of life.","Secondary included evaluation pulmonary exacerbations, antibiotics, modifications microbiological analysis sputum throat cultures (appearance pathogens, bacterial culture densities), FVC, nutritional status measurement body mass (BMI), quality life.",C0027627|C0332257|C0220825|C0024109|G0000000|C0003232|C0392747|C0025953|C0002778|C0038056|C0031354|C0010453|C0233426|C0450254|C0521009|C0010453|C0178587|C3714541|C1521739|C0449438|C0242485|C0242821|C0577559|G0000000|C0332306|C0376558
Patients' nutritional intake was monitored daily.,Patients' nutritional intake monitored daily.,C0030705|C1521739|C1512806|C0030695|C0332173
"The present study investigated the effects of a flexibility and relaxation programme, walking, and Nordic walking (NW) on walking speed, stride length, stride length variability, Parkinson-specific disability (UPDRS), and health-related quality of life (PDQ 39).","The study investigated effects flexibility relaxation programme, walking, Nordic walking (NW) walking speed, stride length, stride length variability, Parkinson-specific disability (UPDRS), health-related quality life (PDQ 39).",G0000000|C0557651|C1292732|C1280500|C0242808|C0035028|C1709697|C0080331|C0331873|C0080331|G0000000|C0080331|C0678536|G0000000|C1444754|G0000000|C1444754|C2827666|C1021144|C0231170|C3639721|C0018684|C0332306|C0376558|G0000000|C0450371
"While no significant treatment effect for pain severity was found, the SLCBT groups showed significantly greater improvements compared to controls on process measures of parental solicitousness, pain beliefs and catastrophizing, and additional outcomes of parent-reported functional disability, pain behaviors, child healthcare visits for abdominal pain, and (remote condition only) quality of life and missed school days.","While treatment pain severity found, SLCBT improvements compared controls process measures parental solicitousness, pain beliefs catastrophizing, additional outcomes parent-reported functional disability, pain behaviors, child healthcare visits abdominal pain, (remote condition only) quality life missed school days.",G0000000|C0039798|C0030193|C0439793|C0150312|G0000000|C2986411|C1707455|C0243148|C1184743|C0079809|C0030551|G0000000|C0030193|C0004951|C0563150|C1524062|C1274040|C4054215|C0205245|C0231170|C0030193|C0004927|C0008059|C0086388|C0545082|C0000726|C0030193|C0205157|C0012634|C0205171|C0332306|C0376558|C1705492|C0036375|C0439228
Preoperative oral analgesic medications were restarted on postoperative day 1.,Preoperative oral analgesic medications restarted postoperative day 1.,C0445204|C0442027|C0002771|C0013227|C1514902|C0032790|C0332173|G0000000
"During the follow-up period of 7 years (from 1995 to 2001), 302 cases of lung cancer were identified, and the Cox proportional hazards regression model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs).","During follow-up period 7 (from 1995 2001), 302 lung cancer identified, Cox proportional hazards regression model estimate hazard ratios (HRs) 95% confidence intervals (CIs).",G0000000|C0589120|C0439531|G0000000|G0000000|G0000000|G0000000|C1442061|C0024109|C0006826|C0205396|G0000000|C0205351|C0598697|C0684320|C3161035|C0750572|C0598697|C0456603|G0000000|C0450371|C0237529|C1272706|C1504308
"To assess limb salvage, the occurrence of amputation, nature of amputation (toe or transmetatarsal, below or above knee, preserving or not preserving function), and time to amputation were recorded during the 12 month follow-up period.","To assess limb salvage, occurrence amputation, nature amputation (toe transmetatarsal, knee, preserving preserving function), time amputation recorded 12 month follow-up period.",C0040363|C1516048|C0015385|C0085405|C0243132|C0002688|C0349590|C0002688|C0040357|G0000000|C0022742|C0728887|C0728887|C0031843|C0040223|C0002688|C0034869|C0450371|C0332177|C0589120|C0439531
"These measures consisted of a test for deficits in central auditory processing, considered by some authors to constitute the underlying basis of many learning problems29 and by others to be caused by persistent early-life otitis media30; a formal test of intelligence; and teachers’ ratings of the behavior of the children.","These measures consisted test deficits central auditory processing, considered authors constitute underlying basis learning problems29 caused persistent early-life otitis media30; formal test intelligence; teachers’ ratings behavior children.",G0000000|C0079809|C0332529|C0022885|C2987487|C0205099|C0439825|C1709694|C0750591|C3812881|G0000000|G0000000|C1527178|C0013621|G0000000|C0015127|C0205322|C1279919|C0029877|G0000000|C0348078|C0022885|C0021704|G0000000|C0871208|C0004927|C0008059
"CONCLUSION—For efficacy, tolerability, impact on cognitive functioning, and quality of life, no major differences were found between phenytoin and valproate prophylaxis.","CONCLUSION—For efficacy, tolerability, impact cognitive functioning, quality life, major differences phenytoin valproate prophylaxis.",G0000000|C1280519|C3274448|C1825598|C1516691|C0205245|C0332306|C0376558|C0205082|C1705241|C0031507|C0080356|C0033107
"In conclusion, simvastatin at a dose of 40 mg daily, in addition to usual care, did not reduce the exacerbation rate or prolong the time to the first exacerbation among patients with moderate-to-severe COPD who were at high risk for exacerbations.","In conclusion, simvastatin dose 40 daily, addition usual care, reduce exacerbation rate prolong time exacerbation patients moderate-to-severe COPD risk exacerbations.",G0000000|C1707478|C0074554|C0178602|C0450371|C0332173|C0332287|C3538928|C1947933|G0000000|G0000000|C0871208|G0000000|C0040223|G0000000|C0030705|C0205081|C0024117|C0035647|G0000000
Incidence of culture positive typhoid fever in the control group was 1.27% vis-a-vis none in vaccine group during 12 months.,Incidence culture positive typhoid fever control 1.27% vis-a-vis vaccine 12 months.,C0021149|C0010453|C0439178|C0041466|C0015967|C0243148|C0450371|G0000000|C0042210|C0450371|C0439231
The FIQR is a recently updated version of the widely used Fibromyalgia Impact Questionnaire (FIQ) which has been extensively validated in clinical trials.,The FIQR updated version Fibromyalgia Impact Questionnaire (FIQ) extensively validated clinical trials.,G0000000|C3641329|C1519814|C0333052|C0016053|C1825598|C0034394|G0000000|G0000000|G0000000|C0205210|C0008976
"The five subjects followed at that site were excluded from efficacy analyses, but available data were included in safety assessments.","The subjects site excluded efficacy analyses, data included safety assessments.",G0000000|C0681850|C0205145|C1554077|C1280519|C0002778|C1511726|C0332257|C0036043|C1261322
"A rapid, direct RIA developed in the Hollis laboratory and manufactured by Diasorin Corporation (Stillwater, MN) was used to measure total circulating 25(OH)D concentration in serum samples (51).","A rapid, direct RIA developed Hollis laboratory manufactured Diasorin Corporation (Stillwater, MN) measure total circulating 25(OH)D concentration serum samples (51).",G0000000|C0456962|C0439851|C0034580|G0000000|C1256218|C0022877|C0870840|G0000000|C0683758|G0000000|C0026405|C0079809|C0439175|C0175630|C0450371|C0004268|C0229671|C0370003|C0450371
A secondary smoking outcome analysis also used the GEE methodology to examine 24-hour point prevalence abstinence.,A secondary smoking outcome analysis GEE methodology examine 24-hour prevalence abstinence.,G0000000|C0027627|C0037369|C1274040|C0002778|G0000000|C0969625|G0000000|C0450371|C0033105|C3843422
"The two groups were followed up for 36 months and their postoperative cellular immune function, disease-free survival time, cumulative recurrence rate and cumulative survival rate was analyzed.","The 36 months postoperative cellular immune function, disease-free survival time, cumulative recurrence rate cumulative survival rate analyzed.",G0000000|C0450371|C0439231|C0032790|C0007634|C0439662|C0031843|C0012634|C0038952|C0040223|C1511559|C0034897|C0871208|C1511559|C0038952|C0871208|C0936012
"The primary treatment outcome measure was the Total Score of the Fibromyalgia Impact Questionnaire Revised (FIQR) [3,7].","The primary treatment outcome measure Total Score Fibromyalgia Impact Questionnaire Revised (FIQR) [3,7].",G0000000|C0205225|C0039798|C1274040|C0079809|C0439175|C0449820|C0016053|C1825598|C0034394|C1527075|C3641329|G0000000
"Weight reduction in obese patients with asthma improves lung function, symptoms, morbidity, and health status.","Weight reduction obese patients asthma improves lung function, symptoms, morbidity, health status.",C0005910|C0301630|C0028754|C0030705|C0004096|C0184511|C0024109|C0031843|C0683368|C0026538|C0018684|C0449438
"Primary outcomes were attained and gained weight, mouthfuls eaten, self‐fed mouthfuls and mother's responsive acts.","Primary outcomes attained gained weight, mouthfuls eaten, self‐fed mouthfuls mother's responsive acts.",C0205225|C1274040|G0000000|C1517378|C0005910|G0000000|C0013470|G0000000|G0000000|C0026591|C0205342|C0079613
The primary outcome measure was change in sleep onset latency determined from polysomnography at 4 weeks.,The primary outcome measure change sleep onset latency determined polysomnography 4 weeks.,G0000000|C0205225|C1274040|C0079809|C0392747|C0037313|C0206132|C0205275|G0000000|C0162701|G0000000|C0439230
Objective tumor response was evaluated by blinded radiologists using RECIST every 4 weeks until progression.,Objective tumor response evaluated blinded radiologists RECIST 4 weeks progression.,C0018017|C0027651|C0871261|C0220825|C0150108|C0260194|C1709926|G0000000|C0439230|C0242656
"If PD was diagnosed, data on age at onset were elicited.","If PD diagnosed, data age onset elicited.",G0000000|G0000000|C0011900|C1511726|C0001779|C0206132|C0449265
"Distribution of aflatoxin level (ppb) in home-produced maize, by experimental arm.","Distribution aflatoxin level (ppb) home-produced maize, experimental arm.",C0520511|C0001734|C0441889|C1415800|C0442519|C0010028|C1517586|C0446516
The initial report demonstrated non-inferior efficacy with subcutaneous versus intravenous bortezomib for the primary end point: overall response rate after four cycles of single-agent bortezomib.,The initial report demonstrated non-inferior efficacy subcutaneous versus intravenous bortezomib primary point: response rate cycles single-agent bortezomib.,G0000000|C0205265|C0684224|G0000000|C1518422|C1280519|C0443315|G0000000|C0348016|C1176309|C0205225|C1552961|C0871261|C0871208|C1511572|C0037179|C1176309
"To increase feasibility of the study, in the early stages of the trial the original proposal was changed so that parental sensitivity and quality of parent-child interaction is now coded with all National Institute of Child Health and Human Development Scales (NICHD-scales), and parental self-efficacy and parenting stress are secondary outcome measures rather than primary outcome measures.","To increase feasibility study, stages trial original proposal changed parental sensitivity quality parent-child interaction coded National Institute Child Health Human Development Scales (NICHD-scales), parental self-efficacy parenting stress secondary outcome measures primary outcome measures.",C0040363|C0442805|G0000000|C0557651|C1306673|C0008976|C0205313|C1555306|C0392747|C0030551|C0020517|C0332306|C0260096|C1704675|C0009219|C3245503|C0021622|C0008059|C0018684|C0086418|C0243107|C0175659|C1513896|C0030551|C0600564|C0085092|C0038435|C0027627|C1274040|C0079809|C0205225|C1274040|C0079809
"Finally, assays will be performed for cholesterol, triglycerides, C-reactive protein, and hemoglobin A1c.","Finally, assays performed cholesterol, triglycerides, C-reactive protein, hemoglobin A1c.",G0000000|C0005507|C0884358|C0008377|C0041004|C0205332|C0033684|C0019046|G0000000
Predicting smoking at time 2 for baseline never smokers (n = 2716).,Predicting smoking time 2 baseline smokers (n = 2716).,G0000000|C0037369|C0040223|G0000000|C0168634|C0337664|C0369718|G0000000|G0000000
"There was no difference in IGF-1, GH, or change in BMI.","There difference IGF-1, GH, change BMI.",G0000000|C1705241|C0037657|C0033993|C0392747|G0000000
The primary outcomes for symptoms of dementia and well-being are reported in Table 2.,The primary outcomes symptoms dementia well-being reported Table 2.,G0000000|C0205225|C1274040|C0683368|C0011265|C0018684|C0684224|C0039224|G0000000
"Secondary endpoints included percentage change in lumbar spine BMD at 48 weeks, change in plasma 25(OH)D, PTH, markers of bone turnover, soluble inflammatory biomarkers, and CD4 cell counts at 24 and 48 weeks.","Secondary endpoints included percentage change lumbar spine BMD 48 weeks, change plasma 25(OH)D, PTH, markers bone turnover, soluble inflammatory biomarkers, CD4 cell counts 24 48 weeks.",C0027627|C2349179|C0332257|C0439165|C0392747|C0024090|C0037949|G0000000|C0450371|C0439230|C0392747|C0032105|C0450371|G0000000|C0005516|C0262950|C0031227|C1749467|C0333348|C0005516|C0285590|C0007634|C0439157|C0450371|C0450371|C0439230
Bacteriological response was the secondary efficacy variable of this study.,Bacteriological response secondary efficacy variable study.,C0205465|C0871261|C0027627|C1280519|C0439828|C0557651
The primary hypothesis is that yoga is non-inferior to PT for our co-primary endpoints: reduction in back pain intensity and improvement in back-related function.,The primary hypothesis yoga non-inferior PT co-primary endpoints: reduction pain intensity improvement back-related function.,G0000000|C0205225|C1512571|C0043418|C1518422|C0699718|C3245499|C2349179|C0301630|C0030193|C0522510|C2986411|C0004600|C0031843
The rate of cephalic presentation at term will be taken as the primary endpoint variable.,The rate cephalic presentation term primary endpoint variable.,G0000000|C0871208|C0205096|C0449450|C0233324|C0205225|C2349179|C0439828
The primary outcome was a 50% or greater improvement on the Montgomery-Asberg Depression Rating Scale (MADRS).,The primary outcome 50% improvement Montgomery-Asberg Depression Rating Scale (MADRS).,G0000000|C0205225|C1274040|C0450371|C2986411|G0000000|C0011570|C0871208|C0175659|C4054475
"As the primary objective is to assess the efficacy of Pycnogenol® for improving ADHD and ADD behaviour as rated by teachers compared to placebo and Medikinet® Retard, the primary outcome is the summed ADHD score of the ADHD-RS as rated by teachers (Table 2).","As primary objective assess efficacy Pycnogenol® improving ADHD ADD behaviour rated teachers compared placebo Medikinet® Retard, primary outcome summed ADHD score ADHD-RS rated teachers (Table 2).",G0000000|C0205225|C0018017|C1516048|C1280519|G0000000|C1272745|C1263846|C1883712|C0004927|C0871208|C0221457|C1707455|C0032042|G0000000|C0521111|C0205225|C1274040|C1515051|C1263846|C0449820|C1263846|C0871208|C0221457|C0039224|G0000000
"A trained psychologist administered the Bayley Scales of Infant and Toddler Development, 3rd edition (BSID-III) motor, cognitive, and language scales9 at 6 and 24-months corrected age.","A trained psychologist administered Bayley Scales Infant Toddler Development, 3rd edition (BSID-III) motor, cognitive, language scales9 6 24-months corrected age.",G0000000|C0336809|C0033908|C1521801|G0000000|C0175659|C0021270|C0682053|C0243107|G0000000|C0441792|C0439070|C1513492|C1516691|C0023008|G0000000|G0000000|C0450371|C0205202|C0001779
We observed no significant differences between groups in negative control caregiver-reported outcomes including bruising/abrasions (1.4% intervention versus 1.3% control) and itchy skin/scalp (2.5% intervention versus 2.2% control) suggesting that differential outcome reporting bias for diarrhea and HCGI was unlikely.,We observed differences negative control caregiver-reported outcomes including bruising/abrasions (1.4% intervention versus 1.3% control) itchy skin/scalp (2.5% intervention versus 2.2% control) suggesting differential outcome reporting bias diarrhea HCGI unlikely.,G0000000|C1441672|C1705241|C0205160|C0243148|C0085537|C1274040|C0332257|C0009938|G0000000|C0886296|G0000000|G0000000|C0243148|C0033774|C0699772|G0000000|C0886296|G0000000|G0000000|C0243148|C1705535|C0443199|C1274040|C0700287|C0242568|C0011991|C1424157|C0750558
Cardio-respiratory and ventilator parameters Ventilator settings parameters were comparable in the two groups as no significant differences were recorded [Table 2].,Cardio-respiratory ventilator parameters Ventilator settings parameters comparable differences recorded [Table 2].,C0018787|C0087153|C0449381|C0087153|C0542559|C0449381|G0000000|C1705241|C0034869|C0039224|G0000000
"Secondary endpoints included ORR (complete response or partial response), PFS, and OS.","Secondary endpoints included ORR (complete response partial response), PFS, OS.",C0027627|C2349179|C0332257|G0000000|C0205197|C0871261|C0728938|C0871261|C0242792|C0229090
"Schedule of Clinical Assessments According to Study Phase Abbreviations: Rx, Treatment Week; DDS, Descriptor Differential Scale; VAS, Visual Analog Scale.","Schedule Clinical Assessments According Study Phase Abbreviations: Rx, Treatment Week; DDS, Descriptor Differential Scale; VAS, Visual Analog Scale.",C0086960|C0205210|C1261322|C0680240|C0557651|C0205390|C0000723|C1425688|C0039798|C0332174|G0000000|C0282354|C0443199|C0175659|C0042815|C0234621|C0243071|C0175659
"Outcome measures were divided into instruments that quantify spontaneous use of the more affected extremity in the life situation (Pediatric Motor Activity Log and Inventory of New Motor Activities and Patterns), and a laboratory motor function test that measures use of the affected extremity when it is requested (Pediatric Arm Function Test).","Outcome measures divided instruments quantify spontaneous extremity life situation (Pediatric Motor Activity Log Inventory New Motor Activities Patterns), laboratory motor function test measures extremity requested (Pediatric Arm Function Test).",C1274040|C0079809|C0332849|C0348000|C1709793|C0205359|C0015385|C0376558|G0000000|C0030755|C1513492|C0205177|C1708728|C0021941|C0205314|C1513492|C0441655|C0449774|C0022877|C1513492|C0031843|C0022885|C0079809|C0015385|C1272683|C0030755|C0446516|C0031843|C0022885
"The self-report measures included the following: demographics, HIV-related knowledge, motivation (risk perception, general readiness to change sexual behaviors, behavioral intentions to reduce risk, pros and cons of condom use), behavioral skills (confidence in condom use), and risk-related behaviors (sexual risk behaviors and substance use).","The self-report measures included following: demographics, HIV-related knowledge, motivation (risk perception, readiness change sexual behaviors, behavioral intentions reduce risk, pros cons condom use), behavioral skills (confidence condom use), risk-related behaviors (sexual risk behaviors substance use).",G0000000|C0681906|C0079809|C0332257|C0231290|C0011298|C0019682|C0376554|C0026605|C0035647|C0030971|C1318963|C0392747|C0036864|C0004927|C0004927|C0162425|G0000000|C0035647|C3813209|G0000000|C0009653|C0042153|C0004927|C0678856|C0237529|C0009653|C0042153|C0035647|C0004927|C0036864|C0035647|C0004927|C0439861|C0042153
"This trial showed that in obese people with asthma losing weight can improve asthma in terms of lung function, symptoms, and health status.","This trial obese people asthma losing weight improve asthma terms lung function, symptoms, health status.",G0000000|C0008976|C0028754|C0027361|C0004096|G0000000|C0005910|G0000000|C0004096|C0233324|C0024109|C0031843|C0683368|C0018684|C0449438
Depression was assessed using the Center for Epidemiologic Studies Depression Scale (CES-D) [17].,Depression assessed Center Epidemiologic Studies Depression Scale (CES-D) [17].,C0011570|C1516048|C0205099|C0014507|C0947630|C0011570|C0175659|C2699160|C0450371
A mumps elimination goal was set for 2010[8].,A mumps elimination goal set 2010[8].,G0000000|C0026780|C0221102|C0018017|C0036849|G0000000
Pain was assessed by a numeric visual analogue scale (VAS); function was assessed by Patello-femoral joint evaluation scale (PFJES) (0-100 points).,Pain assessed numeric visual analogue scale (VAS); function assessed Patello-femoral joint evaluation scale (PFJES) (0-100 points).,C0030193|C1516048|C0237753|C0234621|C0243071|C0175659|C0042815|C0031843|C1516048|C0015811|C0022417|C0220825|C0175659|G0000000|C1442061|C1552961
Cox proportional hazards and competing risks analysis was performed to assess the impact of corticosteroids on ICU mortality.,Cox proportional hazards competing risks analysis performed assess impact corticosteroids ICU mortality.,G0000000|C0205351|C0598697|G0000000|C0035647|C0002778|C0884358|C1516048|C1825598|C0001617|C0021708|C0026565
"Both primary outcomes will be measured at baseline and during the 10, 26 and 52 week follow-up interviews.","Both primary outcomes measured baseline 10, 26 52 week follow-up interviews.",G0000000|C0205225|C1274040|C0444706|C0168634|C0450371|C0450371|C0450371|C0332174|C0589120|C0021822
"After four weeks of treatment with B. bifidum, however, the SCORAD index was reduced markedly (P<0.05) and was significantly lower than that of the control group (P<0.05) (Table II).","After weeks treatment B. bifidum, however, SCORAD reduced markedly (P<0.05) lower control (P<0.05) (Table II).",G0000000|C0439230|C0039798|G0000000|G0000000|G0000000|G0000000|C0392756|C0522501|C0369773|C0441994|C0243148|C0369773|C0039224|G0000000
The primary outcome measure was the child's temperature at one hour.,The primary outcome measure child's temperature hour.,G0000000|C0205225|C1274040|C0079809|C0008059|C0005903|C0439227
"Relapse was defined as the reappearance of significant proteinuria, defined as > 1.0 g/d and as a UPE increase of > 50% from the lowest level of proteinuria after remission [31–32].","Relapse defined reappearance proteinuria, defined > 1.0 g/d UPE increase > 50% lowest level proteinuria remission [31–32].",C0035020|C1704788|G0000000|C0033687|C1704788|G0000000|G0000000|C0439417|G0000000|C0442805|G0000000|C0450371|C1708760|C0441889|C0033687|C0544452|G0000000
"At that time, youths in the CD-ROM plus parent intervention group reported higher levels of family involvement to help them avoid problems with alcohol, and these youths reported less alcohol use in the past 30 days relative to youths who received only the CD-ROM intervention, who had better outcomes on these variables than control youths.","At time, youths CD-ROM parent intervention reported levels family involvement avoid alcohol, youths reported alcohol 30 days relative youths received CD-ROM intervention, outcomes variables control youths.",G0000000|C0040223|C0001578|C0079090|C0030551|C0886296|C0684224|C0441889|C0015576|C1314939|G0000000|C0001962|C0001578|C0684224|C0001962|C0450371|C0439228|C0080103|C0001578|C1514756|C0079090|C0886296|C1274040|C0439828|C0243148|C0001578
"Five patients treated with CQ were still parasitemic at 72 hours, and all but 1 had cleared by 96 hours.","Five patients treated CQ parasitemic 72 hours, 1 cleared 96 hours.",C0205451|C0030705|C1522326|C0282245|G0000000|C0450371|C0439227|G0000000|C0521097|C0450371|C0439227
Physical fitness was estimated with a 20-m shuttle run test and physical strength was assessed with grip strength and standing broad jump tests.,Physical fitness estimated 20-m shuttle test physical strength assessed grip strength standing broad jump tests.,C0031809|C1456706|C0750572|C0450371|G0000000|C0022885|C0031809|C0237897|C1516048|C0021400|C0237897|C0231472|C0332464|C0221189|C0022885
The Korean version of the Modified Barthel Index (K-MBI) was used to assess activities of daily living functionality.,The Korean version Modified Barthel Index (K-MBI) assess activities daily living functionality.,G0000000|C1556095|C0333052|C0392747|G0000000|C0918012|C0597277|C1516048|C0441655|C0332173|C0376558|C0205245
"If dementia was diagnosed, data on age at onset were elicited.","If dementia diagnosed, data age onset elicited.",G0000000|C0011265|C0011900|C1511726|C0001779|C0206132|C0449265
"Saliva cotinine concentrations were assessed for a random subsample of 654 students using a radioimmunoassay method.40 Only 3 (0.5%) of the 560 students who reported not smoking (in the prior month or 2 days) and produced enough saliva for an assay had a cotinine concentration above the 10-ng/mL cutoff typically used to identify smokers.41 In addition, student responses were internally consistent.","Saliva cotinine concentrations assessed random subsample 654 students radioimmunoassay method.40 Only 3 (0.5%) 560 students reported smoking (in prior month 2 days) produced saliva assay cotinine concentration 10-ng/mL cutoff typically identify smokers.41 In addition, student responses internally consistent.",C0036087|C0010194|C0086045|C1516048|C0034656|G0000000|C1442061|C0038492|C0034580|C0025663|C0205171|G0000000|G0000000|C1442061|C0038492|C0684224|C0037369|G0000000|C0332152|C0332177|G0000000|C0439228|G0000000|C0036087|C0005507|C0010194|C0004268|C0450371|C1442160|G0000000|G0000000|C0337664|G0000000|C0332287|C0038492|C0871261|C0205102|C0332290
"Between-group analysis (ANCOVA) (Table 3) revealed significant differences at both 4 and 8 month follow-ups for all of the outcomes, notably MPQ Pain Typical (p<.0001), CSQ Ability to control Pain (p<.0001), TOPS Total Pain Experience (p<.0001), and SF-36 Physical Composite (p=.0003).","Between-group analysis (ANCOVA) (Table 3) revealed differences 4 8 month follow-ups outcomes, notably MPQ Pain Typical (p<.0001), CSQ Ability control Pain (p<.0001), TOPS Total Pain Experience (p<.0001), SF-36 Physical Composite (p=.0003).",C0441833|C0002778|C0814908|C0039224|G0000000|C0443289|C1705241|G0000000|G0000000|C0332177|C0332283|C1274040|G0000000|G0000000|C0030193|C3538928|C0369773|G0000000|C0085732|C0243148|C0030193|C0369773|C0076833|C0439175|C0030193|C0237607|C0369773|C0037712|C0031809|C0205199|C0369773
SHS measures included child’s urine cotinine levels (ng/mL); household average nicotine level (g/m3) over the two-week monitoring period; total number of hours of smoking weekly in the household; total number of hours of child’s exposure to second-hand smoke weekly; total number of cigarettes smoked in the household daily; and whether or not a full household smoking ban was in place.,SHS measures included child’s urine cotinine levels (ng/mL); household average nicotine level (g/m3) two-week monitoring period; total hours smoking weekly household; total hours child’s exposure second-hand smoke weekly; total cigarettes smoked household daily; household smoking ban place.,G0000000|C0079809|C0332257|G0000000|C0042036|C0010194|C0441889|C0439275|C0020052|C1510992|C0028040|C0441889|C0439267|C0205448|C0150369|C0439531|C0439175|C0439227|C0037369|C0332174|C0020052|C0439175|C0439227|G0000000|C0274281|C0205436|C0037366|C0332174|C0439175|C0677453|C0037366|C0020052|C0332173|C0020052|C0037369|C0683610|C0442504
"Disappearance of active HL (gallium negative, ≥ 70% decrease in SPPD, and negative bone marrow or bone scan if initially positive).","Disappearance active HL (gallium negative, ≥ 70% decrease SPPD, negative bone marrow bone scan initially positive).",G0000000|C0205177|C1453952|C0016980|C0205160|G0000000|C0450371|C0392756|G0000000|C0205160|C0262950|C0086590|C0262950|C0034606|C0205265|C0439178
"After 6 weeks of CPAP treatment, compliance data showed no differences between groups.","After 6 weeks CPAP treatment, compliance data differences groups.",G0000000|G0000000|C0439230|C0199451|C0039798|C0009563|C1511726|C1705241|C0441833
The relative risk of preterm delivery declined during the study period and especially of delivery before 28 weeks’ gestation.,The relative risk preterm delivery declined study period delivery 28 weeks’ gestation.,G0000000|C0080103|C0035647|C0151526|C0011209|G0000000|C0557651|C0439531|C0011209|C0450371|G0000000|C0032961
Secondary outcomes were the frequency of infections and the cumulative amount of prednisolone received in both groups.,Secondary outcomes frequency infections cumulative amount prednisolone received groups.,C0027627|C1274040|C0376249|C3714514|C1511559|C1265611|C0032950|C1514756|C0441833
"Severity and duration of delirium; number of delirium-free days; hospital length-of-stay; adverse events; all-cause mortality in-hospital and within six months post-discharge; cognitive and physical function at baseline, three, and six months post-discharge; new institutionalisation post-discharge; number of hospital admissions within six months post-discharge.","Severity duration delirium; delirium-free days; hospital length-of-stay; adverse events; all-cause mortality in-hospital months post-discharge; cognitive physical function baseline, three, months post-discharge; institutionalisation post-discharge; hospital admissions months post-discharge.",C0439793|C0449238|C0011206|C0011206|C0439228|C0019994|C1444754|G0000000|C0441471|C0015127|C0026565|C0019994|C0439231|C0687676|C1516691|C0031809|C0031843|C0168634|C0205449|C0439231|C0687676|C0021629|C0687676|C0019994|C0184666|C0439231|C0687676
"Secondary outcomes will be development of ‘severe PPH’ defined as: ‘decrease of haemoglobin (Hb) of > 4 g/dl (2.5 mmol/L), transfusion of at least four red blood cell (RBC) units, haemostatic intervention (angiographic embolization, surgical arterial ligation or hysterectomy) or death.","Secondary outcomes development ‘severe PPH’ defined as: ‘decrease haemoglobin (Hb) of > 4 g/dl (2.5 mmol/L), transfusion red blood cell (RBC) units, haemostatic intervention (angiographic embolization, surgical arterial ligation hysterectomy) death.",C0027627|C1274040|C0243107|G0000000|G0000000|C1704788|G0000000|G0000000|C0019046|C0019046|G0000000|G0000000|C0005841|C0332575|C0005767|C0007634|C0014792|C0439148|C0019116|C0886296|C0002978|C0013931|C0543467|C0003842|C0023690|C0020699|C0011065
"Therefore, near falls may have been either over- or under-represented in our results.","Therefore, falls over- under-represented results.",G0000000|C0000921|C0205136|C0542339|C1274040
"Secondary outcome parameters include: – incidence of gestational diabetes (24th-28th week of gestation, via an oral glucose tolerance test), glycosylated haemoglobin concentration (30th-34th week of gestation), – other pregnancy complications such as preeclampsia, – anthropometric measures and health status of the newborns (birth weight, height, head circumference, LGA, small for gestational age (SGA), APGAR-Score, pH), – obstetric complications (mode of delivery, induction of labour, rate of caesarean sections etc.","Secondary outcome parameters include: – incidence gestational diabetes (24th-28th week gestation, oral glucose tolerance test), glycosylated haemoglobin concentration (30th-34th week gestation), – pregnancy complications preeclampsia, – anthropometric measures health status newborns (birth weight, height, head circumference, LGA, gestational age (SGA), APGAR-Score, pH), – obstetric complications (mode delivery, induction labour, rate caesarean sections etc.",C0027627|C1274040|C0449381|C0332257|G0000000|C0021149|C0439671|C0011847|G0000000|C0332174|C0032961|C0442027|C0017725|C0013220|C0022885|G0000000|C0019046|C0004268|G0000000|C0332174|C0032961|G0000000|C0032961|C0009566|C0032914|G0000000|C0003188|C0079809|C0018684|C0449438|C0021289|C0005615|C0005910|C0489786|C0018670|C0332520|C1428877|C0439671|C0001779|G0000000|C0003533|C0450407|G0000000|C0205484|C0009566|C1513371|C0011209|C0205263|C0022864|C0871208|C3841297|C0152060|C1548556
The 23 items that loaded on the avoidant coping factor were summed to create an avoidant coping scale.,The 23 items loaded avoidant coping factor summed create avoidant coping scale.,G0000000|C0450371|C1551338|C1708715|C0870186|C0009967|C1521761|C1515051|C1706214|C0870186|C0009967|C0175659
The date of last contact was used to calculate a censored time at risk for patients without documented progression (PFS) or for those who had no reported death (OS).,The contact calculate censored time risk patients documented progression (PFS) reported death (OS).,G0000000|C0332158|C1441506|C3889990|C0040223|C0035647|C0030705|C1301725|C0242656|C0242792|C0684224|C0011065|C0229090
Data will be collected over 12 months.,Data collected 12 months.,C1511726|C1516695|G0000000
The primary endpoint in ASSET-1 was change from baseline in PVR at Week 16.,The primary endpoint ASSET-1 change baseline PVR Week 16.,G0000000|C0205225|C2349179|C2371679|C0392747|C0168634|C0242852|C0332174|C0450371
"Additionally, laboratory tests (hematology, clinical chemistry, and urinalysis), ECG, body weight, and vital signs were measured.","Additionally, laboratory tests (hematology, clinical chemistry, urinalysis), ECG, body weight, vital signs measured.",G0000000|C0022877|C0022885|C0018943|C0205210|C0007996|C0042014|C1623258|C0242821|C0005910|C0442732|C0220912|C0444706
Further work is needed to determine whether patient satisfaction or related behaviors influence the clinical outcome of low back pain.,Further determine patient satisfaction behaviors influence clinical outcome low pain.,C1517331|G0000000|C0030705|C0242428|C0004927|C4054723|C0205210|C1274040|C0205251|C0030193
"We identified 524 eligible women, of whom 224 (43%) completed the interview.","We identified 524 eligible women, 224 (43%) completed interview.",G0000000|C0205396|C1442061|C1548635|C0043210|C1442061|C0450371|C0205197|C0021822
"Additionally, we collected secondary clinical outcomes data including days free of delirium and coma, days free of mechanical ventilation, ICU and hospital lengths of stay and mortality.","Additionally, collected secondary clinical outcomes data including days free delirium coma, days free mechanical ventilation, ICU hospital lengths stay mortality.",G0000000|C1516695|C0027627|C0205210|C1274040|C1511726|C0332257|C0439228|C0332296|C0011206|C0009421|C0439228|C0332296|C0443254|C0035203|C0021708|C0019994|C1444754|G0000000|C0026565
"RESULTS—The mean (SD) aerobic capacity at LT increased by 0.26 (0.11) kp after training when assessed with the swimming ergometer and by 10.6 (4.5) W when assessed with the cycle ergometer, and these changes were significantly different from the control group.","RESULTS—The (SD) aerobic capacity LT increased 0.26 (0.11) kp training assessed swimming ergometer 10.6 (4.5) W assessed cycle ergometer, control group.",G0000000|G0000000|C1510824|C1516240|C0023376|C0205217|C0450371|C0450371|C0022772|C0040607|C1516048|C0039003|C0180748|C0450371|G0000000|G0000000|C1516048|C1511572|C0180748|C0243148|C0441833
"Secondly, the six month assessment interval may have led to under-ascertainment of fall related outcomes.","Secondly, month assessment interval led under-ascertainment fall outcomes.",C0205436|C0332177|C1261322|C1272706|C1708698|C0542339|C0085639|C1274040
Supplementary Table S3 reported response and survival outcomes by allocated treatment arm.,Supplementary Table S3 reported response survival outcomes allocated treatment arm.,G0000000|C0039224|C1519428|C0684224|C0871261|C0038952|C1274040|G0000000|C0039798|C0446516
"Infants' growth [weight, length, and mid-upper arm-circumference (MUAC), stunting, wasting, and underweight] were measured at four time points.","Infants' growth [weight, length, mid-upper arm-circumference (MUAC), stunting, wasting, underweight] measured time points.",C0021270|C0018270|C0005910|C1444754|C0444598|C0446516|G0000000|C0018273|C0006625|C0041667|C0444706|C0040223|C1552961
The primary efficacy end point was trough forced expiratory volume in 1 second (FEV1) on day 169; secondary end points were Transition Dyspnea Index (TDI) focal score at week 24 and weighted mean (WM) FEV1 over 0–6 hours postdose on day 1.,The primary efficacy trough forced expiratory volume 1 (FEV1) day 169; secondary Transition Dyspnea Index (TDI) focal score week 24 weighted (WM) FEV1 0–6 hours postdose day 1.,G0000000|C0205225|C1280519|C0444506|C0441722|C0231800|C0449468|G0000000|G0000000|C0332173|C1442061|C0027627|C0599156|C0013404|C0918012|C0205976|C0205234|C0449820|C0332174|C0450371|C0005910|G0000000|G0000000|G0000000|C0439227|C0439568|C0332173|G0000000
"Although opportunities to improve care were common, the intervention had no measurable effect on either adherence to the evidence-based guidelines or any clinical or subjective patient outcome.","Although opportunities improve care common, intervention measurable adherence evidence-based guidelines clinical subjective patient outcome.",G0000000|G0000000|G0000000|C1947933|C0205214|C0886296|C1513040|C1510802|C3887511|C0162791|C0205210|C0439655|C0030705|C1274040
"Secondary outcome measures included the validated “short Q” asthma morbidity score, nursing care satisfaction questionnaire score, and length of consultation.","Secondary outcome measures included validated “short Q” asthma morbidity score, nursing care satisfaction questionnaire score, length consultation.",C0027627|C1274040|C0079809|C0332257|G0000000|G0000000|G0000000|C0004096|C0026538|C0449820|C0006147|C1947933|C0242428|C0034394|C0449820|C1444754|C0009818
Weekly improvement in abdominal discomfort/pain or bloating was defined as a ⩾1 point reduction from baseline.,Weekly improvement abdominal discomfort/pain bloating defined ⩾1 reduction baseline.,C0332174|C2986411|C0000726|C0231218|C1291077|C1704788|G0000000|C0301630|C0168634
"Between month 6 and month 12 after transplantation, these cost savings increase to € 419.12 (p = 0.089).","Between month 6 month 12 transplantation, cost savings increase € 419.12 (p = 0.089).",G0000000|C0332177|G0000000|C0332177|C0450371|C0040732|C0010186|C0036245|C0442805|G0000000|C1442061|C0369773|G0000000|C1442061
"Success was defined as an IOP of <16 mmHg16 under GA with no hypotony complications and/or no progression of the disease as evidenced by any progression of the ocular parameters as the corneal diameter, cup/disc ratio and axial length beyond the normal growth curves of the eye for that age group.","Success defined IOP <16 mmHg16 GA hypotony complications and/or progression disease evidenced progression ocular parameters corneal diameter, cup/disc ratio axial length normal growth curves eye age group.",C0597535|C1704788|C0595921|G0000000|C0016993|C0241938|C0009566|G0000000|C0242656|C0012634|C3887511|C0242656|C0015392|C0449381|C0010031|C1301886|C1533124|C0456603|C0205131|C1444754|C0205307|C0018270|C0205134|C0015392|C0001779|C0441833
More than half were smoking a pack a day or less.,More half smoking pack day less.,C0205172|C2825407|C0037369|C1968515|C0332173|C0439092
All eligible women received a package containing 14 copies of Rhodes index of nausea and vomiting.,All eligible women received package 14 copies Rhodes nausea vomiting.,G0000000|C1548635|C0043210|C1514756|C0013194|C0450371|C1948062|C0454812|C0027497|C0042963
Our primary outcome measure will be the IBS Symptom Severity Score (IBS SSS).,Our primary outcome measure IBS Symptom Severity Score (IBS SSS).,G0000000|C0205225|C1274040|C0079809|C0022104|C1457887|C0439793|C0449820|C0022104|C0037052
"In schools with baseline hookworm prevalence below 15%, only UltraRice_original increased infection risk.","In schools baseline hookworm prevalence 15%, UltraRice_original increased infection risk.",G0000000|C0036375|C0168634|C0002830|C0033105|C0450371|C0205313|C0205217|C0009450|C0035647
Recurrence of otitis media during follow up and a normal tympanic membrane at the last valid visit.,Recurrence otitis media follow normal tympanic membrane valid visit.,C0034897|C0029877|C0009458|C0332283|C0205307|C0041445|C0025255|C2349099|C0545082
"Diarrhoea was defined as three or more loose stools per day over at least 2 consecutive days during the 12-day follow-up period.1 Secondary outcome measures included abdominal pain, flatulence, stool counts, self-reported thrush, and whether the antibiotics failed to work.","Diarrhoea defined loose stools day 2 consecutive days 12-day follow-up period.1 Secondary outcome measures included abdominal pain, flatulence, stool counts, self-reported thrush, antibiotics failed work.",C0011991|C1704788|C0205407|C0015733|C0332173|G0000000|C1707491|C0439228|C0450371|C0589120|C0439531|C0027627|C1274040|C0079809|C0332257|C0000726|C0030193|C0016204|C0015733|C0439157|C0681906|C0006840|C0003232|C0231175|C0043227
"The patterns of the results for pain when walking on a flat surface, whether it was the change from baseline to Weeks 2 or 4, or the absolute scores obtained at end of study, were very similar to those of the WOMAC scores.","The patterns pain walking flat surface, change baseline Weeks 2 4, absolute scores study, WOMAC scores.",G0000000|C0449774|C0030193|C0080331|C0205324|C0205148|C0392747|C0168634|C0439230|G0000000|G0000000|C0205344|C0449820|C0557651|G0000000|C0449820
"Incidence density of relapse represents the preferred mathematical treatment for events occurring over prolonged periods [30, 31].","Incidence density relapse represents preferred mathematical treatment events occurring prolonged periods [30, 31].",C0021149|C0178587|C0035020|C1882932|C0558295|C0024934|C0039798|C0441471|C1709305|C0439590|C0439531|C0450371|C0450371
Balance: The FBF group would have greater improvement on the Functional Reach Test (FRT) compared with the other groups.,Balance: The FBF improvement Functional Reach Test (FRT) compared groups.,C0014653|G0000000|G0000000|C2986411|C0205245|C2584321|C0022885|C1705150|C1707455|C0441833
"The second visit information variables included date of stoppage of diarrhoea in case of inter-current recovery, weight of child, daily record of frequency and consistency of stools, tolerance and acceptability of treatment.","The visit variables included stoppage diarrhoea inter-current recovery, weight child, daily record frequency consistency stools, tolerance acceptability treatment.",G0000000|C0545082|C0439828|C0332257|G0000000|C0011991|C0205103|C0237820|C0005910|C0008059|C0332173|C0034869|C0376249|C0332529|C0015733|C0013220|C0814633|C0039798
We previously showed that BATRAC improves arm function in chronic stroke survivors with fixed upper extremity deficits.14 We hypothesized that BATRAC may be associated with reorganization of brain regions involved in motor control.,We BATRAC improves arm function chronic stroke survivors fixed upper extremity deficits.14 We hypothesized BATRAC reorganization brain regions involved motor control.,G0000000|G0000000|C0184511|C0446516|C0031843|C0205191|C0038454|C0206194|C0443218|C1282910|C0015385|C2987487|G0000000|G0000000|G0000000|C0680829|C0006104|C0017446|C1314939|C1513492|C0243148
Psychological testing involved use of the modified somatic perception questionnaire (MSPQ) and the modified zung depression score (MZD).,Psychological testing involved modified somatic perception questionnaire (MSPQ) modified zung depression score (MZD).,C0205486|C0039593|C1314939|C0392747|C1257909|C0030971|C0034394|G0000000|C0392747|G0000000|C0011570|C0449820|G0000000
"The bowel function was not much different, especially at 1 year.","The bowel function different, 1 year.",G0000000|C0021853|C0031843|C1705242|G0000000|C0439234
"Each angle was measured by a goniometer three times, and the mean of the three measures was used for the calculation of ROM.","Each angle measured goniometer times, measures calculation ROM.",G0000000|C0205143|C0444706|C0181061|C0040223|C0079809|C1441506|C4048784
"Results were largely reassuring for all other cancers, although the number of cancer cases was low for some sites, e.g.","Results reassuring cancers, cancer low sites, e.g.",C1274040|C0557055|C0006826|C0006826|C0205251|C0205145|G0000000
"Each study was sufficiently powered to detect differences in three co-primary endpoints (trough FEV1 response, SGRQ total score, and Mahler TDI focal score), but were not sufficiently powered individually to test for between-treatment group differences in exacerbations.","Each study powered detect differences co-primary endpoints (trough FEV1 response, SGRQ total score, Mahler TDI focal score), powered individually test between-treatment differences exacerbations.",G0000000|C0557651|C0032863|C0442726|C1705241|C3245499|C2349179|C0444506|G0000000|C0871261|G0000000|C0439175|C0449820|G0000000|C0205976|C0205234|C0449820|C0032863|G0000000|C0022885|C0039798|C1705241|G0000000
An event is defined as abandonment of the AVF as dialysis access.,An event defined abandonment AVF dialysis access.,G0000000|C0441471|C1704788|C0870084|C0449215|C0011945|C0444454
"The primary end point was overall survival, whereas second end points were local response and progression-free survival.","The primary survival, local response progression-free survival.",G0000000|C0205225|C0038952|C0205276|C0871261|C0242656|C0038952
"Thus, the highest and the lowest possible scores of the questionnaire were 102 and zero, respectively.","Thus, lowest scores questionnaire 102 zero, respectively.",G0000000|C1708760|C0449820|C0034394|C1442061|C0919414|G0000000
ITN use also increased among children five to 14 years old from 37% in 2008 to 68% in 2010.,ITN increased children 14 years 37% 2008 68% 2010.,G0000000|C0205217|C0008059|G0000000|C0450371|G0000000|C0450371|G0000000
Impact was defined as the proportion of all identified smokers that enrolled in treatment.,Impact defined proportion identified smokers enrolled treatment.,C1825598|C1704788|C1709707|C0205396|C0337664|G0000000|C0039798
Unlike the results of single agent i.v.,Unlike single agent i.v.,G0000000|C0037179|C0450442|C0021966
"The second definition was at least two of the following signs and symptoms: fever ≥37.8°C, cough, headache, sore throat, aches or pains in muscles or joints [19].","The definition signs symptoms: fever ≥37.8°C, cough, headache, sore throat, aches pains muscles joints [19].",G0000000|C1550452|C0220912|C0683368|C0015967|G0000000|C0010200|C0018681|C0234233|C0031354|C0234238|C0030193|C0026845|C0022417|C0450371
"Sustained 24 hour pain relief was noted in 36.4% on rofecoxib, 41% on ibuprofen, and 6.1% in the placebo group.","Sustained 24 hour pain relief 36.4% rofecoxib, 41% ibuprofen, 6.1% placebo group.",C0443318|C0450371|C0439227|C0030193|C0564405|C0450371|C0762662|C0450371|C0020740|G0000000|C0032042|C0441833
Change in total UPDRS over time.,Change total UPDRS time.,C0392747|C0439175|C3639721|C0040223
"The secondary endpoint is the postoperative morbidity, including wound infection, intraabdominal collections, delayed gastric emptying, postoperative haemorrhage, pneumonia, abdominal rupture, cardiac events and neurological complications (Table 1), as previously defined [5,30,38-41].","The secondary endpoint postoperative morbidity, including wound infection, intraabdominal collections, delayed gastric emptying, postoperative haemorrhage, pneumonia, abdominal rupture, cardiac events neurological complications (Table 1), defined [5,30,38-41].",G0000000|C0027627|C2349179|C0032790|C0026538|C0332257|C0043250|C0009450|C0230168|C0600644|C0205421|C0038351|C1996907|C0032790|C0019080|C0032285|C0000726|C1881712|C0018787|C0441471|C0205494|C0009566|C0039224|G0000000|C1704788|C0450371
OBJECTIVE: To examine the effect of alpha tocopherol and beta carotene supplementation on the incidence of age related cataract extraction.,OBJECTIVE: To examine alpha tocopherol beta carotene supplementation incidence age cataract extraction.,C0018017|C0040363|G0000000|C0439095|C0042874|C0330390|C0007269|C0242297|C0021149|C0001779|C0086543|C0185115
"The secondary objectives will be to determine whether prophylactic melatonin decreases the severity and duration of delirium, improves sleep quality, reduces hospital and ICU LOS, improves morbidity and mortality, and reduces healthcare costs through reduced LOS and intensity of medical therapy.","The secondary objectives determine prophylactic melatonin decreases severity duration delirium, improves sleep quality, reduces hospital ICU LOS, improves morbidity mortality, reduces healthcare costs reduced LOS intensity medical therapy.",G0000000|C0027627|C0018017|G0000000|C0355642|C0025219|C0442797|C0439793|C0449238|C0011206|C0184511|C0037313|C0332306|G0000000|C0019994|C0021708|G0000000|C0184511|C0026538|C0026565|G0000000|C0086388|C0010186|C0392756|G0000000|C0522510|C0199168|C0039798
Ryding states that the fear of delivery in third trimester can be associated with the occurrence of emergency CS.,Ryding fear delivery trimester occurrence emergency CS.,G0000000|C0015726|C0011209|C0032982|C0243132|C0013956|C0010182
Participants who had biochemically validated abstinence at 6-month follow-up could enter into a lucky draw organized by COSH.,Participants biochemically validated abstinence 6-month follow-up enter lucky draw organized COSH.,C0679646|G0000000|G0000000|C3843422|C0332177|C0589120|C1522196|C0870824|C0013113|C1300196|G0000000
"Secondary end points included overall survival (OS), objective response rate (ORR), quality of life (QOL), pulmonary symptom improvement (PSI), and safety.","Secondary included survival (OS), objective response rate (ORR), quality life (QOL), pulmonary symptom improvement (PSI), safety.",C0027627|C0332257|C0038952|C0229090|C0018017|C0871261|C0871208|G0000000|C0332306|C0376558|C0518214|C0024109|C1457887|C2986411|G0000000|C0036043
"However, the response duration (time to disease progression and overall survival [OS]) was not statistically significantly different between groups [6].","However, response duration (time disease progression survival [OS]) statistically [6].",G0000000|C0871261|C0449238|C0040223|C0012634|C0242656|C0038952|C0229090|C0038215|G0000000
We report the results of the economic analysis of direct and indirect costs for inpatient versus early discharge to outpatient treatment of febrile neutropenia for low-risk patients with cancer.,We report economic analysis direct indirect costs inpatient versus discharge outpatient treatment febrile neutropenia low-risk patients cancer.,G0000000|C0684224|C0013556|C0002778|C0439851|C0439852|C0010186|C0021562|G0000000|C0012621|C0029921|C0039798|C0015967|C0023530|C3272281|C0030705|C0006826
Secondary outcomes included change in number of days with migraine per 30 days and change in migraine related impairments in quality of life (migraine specific quality of life scores) at month 10 relative to the run-in period; longer term changes in all three outcome variables at month 16 were secondary outcomes.,Secondary outcomes included change days migraine 30 days change migraine impairments quality life (migraine specific quality life scores) month 10 relative run-in period; term outcome variables month 16 secondary outcomes.,C0027627|C1274040|C0332257|C0392747|C0439228|C0149931|C0450371|C0439228|C0392747|C0149931|C0684336|C0332306|C0376558|C0149931|C0205369|C0332306|C0376558|C0449820|C0332177|C0450371|C0080103|C3274438|C0439531|C0233324|C1274040|C0439828|C0332177|C0450371|C0027627|C1274040
"Patients were asked to assess pain intensity, patient satisfaction, adverse effects and number of rescue morphine tablets, and a different investigator unaware of the treatments, recorded the data weekly.","Patients assess pain intensity, patient satisfaction, adverse effects rescue morphine tablets, investigator unaware treatments, recorded data weekly.",C0030705|C1516048|C0030193|C0522510|C0030705|C0242428|G0000000|C1280500|G0000000|C0026549|C0039225|C0035173|C0150114|C0087111|C0034869|C1511726|C0332174
We used multivariable analysis to investigate the factors that influenced the length of hospital stay of these patients.,We multivariable analysis investigate factors influenced length hospital stay patients.,G0000000|G0000000|C0002778|C1292732|C1521761|G0000000|C1444754|C0019994|G0000000|C0030705
The average survival period was 1108±52 days in the HRT group and 1086±43 days in the non-HRT group (Fig.,The average survival period 1108±52 days HRT 1086±43 days non-HRT (Fig.,G0000000|C1510992|C0038952|C0439531|G0000000|C0439228|C0282402|G0000000|C0439228|C1518422|C0349966
Baseline resting oxygen consumption (V̇o2) did not differ between the placebo and diamorphine groups but V̇o2 at peak exercise was significantly greater with diamorphine and at six minutes.,Baseline resting oxygen consumption (V̇o2) placebo diamorphine V̇o2 peak exercise diamorphine minutes.,C0168634|C0035253|C0030054|C0009830|G0000000|C0032042|C0011892|G0000000|C0444505|C0015259|C0011892|C0439232
"Secondary outcomes are mood disturbance, quality of sleep, health-related quality of life, functioning in daily life, measured physical activity level, self-reported physical activity level, anthropometric measures, return to work, chemotherapy completion rates, compliance, satisfaction with the intervention, adverse effects and costs from a societal perspective.","Secondary outcomes mood disturbance, quality sleep, health-related quality life, functioning daily life, measured physical activity level, self-reported physical activity level, anthropometric measures, return work, chemotherapy completion rates, compliance, satisfaction intervention, adverse effects costs societal perspective.",C0027627|C1274040|C0026516|C2699787|C0332306|C0037313|C0018684|C0332306|C0376558|C0205245|C0332173|C0376558|C0444706|C0031809|C0205177|C0441889|C0681906|C0031809|C0205177|C0441889|C0003188|C0079809|C0332156|C0043227|C0013216|C0205197|C0871208|C0009563|C0242428|C0886296|G0000000|C1280500|C0010186|G0000000|G0000000
"A range of cost figures of each patient’s medical service utilization were calculated at month 3, 6 and 12 and analyzed using two-part regression models.","A range cost figures patient’s medical service utilization calculated month 3, 6 12 analyzed two-part regression models.",G0000000|C1514721|C0010186|G0000000|G0000000|C0199168|C0557854|C0042153|C0444686|C0332177|G0000000|G0000000|C0450371|C0936012|C0205448|C0684320|C3161035
"Response to Atorvastatin on SPAH, right ventricular size, cardiac output, lung function versus placebo was assessed by analysis covariance, where the response was change from baseline and the baseline value was the covariate.","Response Atorvastatin SPAH, ventricular size, cardiac output, lung function versus placebo assessed analysis covariance, response change baseline baseline covariate.",C0871261|C0286651|G0000000|C0018827|C0456389|C0018787|C1709366|C0024109|C0031843|G0000000|C0032042|C1516048|C0002778|G0000000|C0871261|C0392747|C0168634|C0168634|G0000000
CRB and catheter dysfunction rates (events during 1000 catheter-days) were compared using the log-rank test.,CRB catheter dysfunction rates (events 1000 catheter-days) compared log-rank test.,C2931258|C0085590|C0031847|C0871208|C0441471|G0000000|C0085590|C1707455|C1708728|C0022885
The trial intervention is stopped one month before the first follow-up at 3 months to help reduce unblinding.,The trial intervention stopped month follow-up 3 months reduce unblinding.,G0000000|C0008976|C0886296|C1272691|C0332177|C0589120|G0000000|C0439231|G0000000|C3897431
Smokers in the contemplation stage have seriously considered giving up smoking within the next 6 months.,Smokers contemplation stage considered smoking 6 months.,C0337664|G0000000|C0205390|C0750591|C0037369|G0000000|C0439231
Hospital-based data from Africa suggest that newborn skin-cleansing with chlorhexidine may reduce neonatal mortality.,Hospital-based data Africa newborn skin-cleansing chlorhexidine reduce neonatal mortality.,C0019994|C1511726|C0001737|C0021289|C0444099|C0008196|G0000000|C1552240|C0026565
"Two groups were comparable in terms of wound surface area, pain score during dressing change, and overall comfort score of dressing at baseline (i.e., at 0 week) (P > 0.05).","Two comparable terms wound surface area, pain score dressing change, comfort score dressing baseline (i.e., 0 week) (P > 0.05).",C0205448|G0000000|C0233324|C0043250|C0205148|C0017446|C0030193|C0449820|C0013119|C0392747|C1331418|C0449820|C0013119|C0168634|C0683454|G0000000|C0332174|G0000000
Self- reported use of health services assessment (from month #6 to #9); 5.,Self- reported health services assessment (from month #6 #9); 5.,C0036588|C0684224|C0018684|C0557854|C1261322|G0000000|C0332177|G0000000|G0000000|G0000000
"Macronutrients comprise an index of calorie, protein and fat.","Macronutrients comprise calorie, protein fat.",C1518493|C2700400|C0439259|C0033684|C0424612
Primary study outcomes for the cross-sectional study design in Mali and Burkina Faso are: the prevalence of AM defined by a WLZ < -2 or a MUAC < 125 mm (only in children older than 6 months) or the presence of bilateral pitting edema; AM screening coverage defined as the number of children screened in the month preceding the survey (as reported by the caregiver) over the total number of eligible study children; AM treatment compliance defined as the number of AM children under appropriate treatment at the time of the survey over the total number of AM cases identified in the study sample.,Primary study outcomes cross-sectional study design Mali Burkina Faso are: prevalence AM defined WLZ < -2 MUAC < 125 mm (only children 6 months) presence bilateral pitting edema; AM screening coverage defined children screened month preceding survey (as reported caregiver) total eligible study children; AM treatment compliance defined AM children treatment time survey total AM identified study sample.,C0205225|C0557651|C1274040|C0552389|C0557651|C1707689|C0024581|G0000000|G0000000|G0000000|C0033105|G0000000|C1704788|G0000000|G0000000|G0000000|C0205171|C0008059|G0000000|C0439231|C0150312|C0238767|C0205323|C0013604|G0000000|C0220908|C1551362|C1704788|C0008059|C0220908|C0332177|C0332152|C0038951|G0000000|C0684224|C0085537|C0439175|C1548635|C0557651|C0008059|G0000000|C0039798|C0009563|C1704788|G0000000|C0008059|C0039798|C0040223|C0038951|C0439175|G0000000|C0205396|C0557651|C0370003
"The primary outcome was a combined end point of cardiovascular morbidity and mortality, which included incident MI, stroke, coronary revascularization procedures (coronary artery bypass grafting or percutaneous coronary intervention), and cardiovascular mortality.","The primary outcome combined cardiovascular morbidity mortality, included incident MI, stroke, coronary revascularization procedures (coronary artery bypass grafting percutaneous coronary intervention), cardiovascular mortality.",G0000000|C0205225|C1274040|C0205195|C0007226|C0026538|C0026565|C0332257|C1551358|C3810814|C0038454|C0018787|C0581603|C0025664|C0018787|C0003842|C0741847|C0332835|C0522523|C0018787|C0886296|C0007226|C0026565
It commonly leads to significant disability and compromises quality of life.,It commonly leads disability compromises quality life.,G0000000|G0000000|C0023175|C0231170|C2945640|C0332306|C0376558
Further exploratory outcomes assessed changes in sputum bacterial load as assessed by 16S rRNA gene targeted qPCR and changes in sputum inflammation.,Further exploratory outcomes assessed sputum bacterial load assessed 16S rRNA gene targeted qPCR sputum inflammation.,C1517331|G0000000|C1274040|C1516048|C0038056|C0521009|C1550025|C1516048|C0450371|C0035701|C0017337|C1521840|C1709846|C0038056|C0021368
The exacerbation rate per patient per year was not reported.,The exacerbation rate patient reported.,G0000000|G0000000|C0871208|C0030705|C0684224
"The CVD risk assessment, CVD events and CVD-related deaths will be followed up (Table (Table3).3).","The CVD risk assessment, CVD events CVD-related deaths (Table (Table3).3).",G0000000|C0007222|C0035647|C1261322|C0007222|C0441471|C0007222|C0011065|C0039224|G0000000
"Subjects were measured at baseline, week 6, and week 12 for tear osmolarity, TBUT, OSDI, fluorescein corneal staining, and Schirmer test with anesthesia.","Subjects measured baseline, week 6, week 12 tear osmolarity, TBUT, OSDI, fluorescein corneal staining, Schirmer test anesthesia.",C0681850|C0444706|C0168634|C0332174|G0000000|C0332174|C0450371|C0039409|C0029387|G0000000|C3896641|C0060520|C0010031|C0487602|C1875738|C0022885|C0002903
"Prior to the treatment, all of the patients underwent box and block test, 9-hole Pegboard test, grip strength, Brunnstrom stage, Wolf motor function test, and Fugl-Meyer Assessment (upper extremity, total score) to evaluate the motor functions of the hemiplegic upper extremity.","Prior treatment, patients underwent box block test, 9-hole Pegboard test, grip strength, Brunnstrom stage, Wolf motor function test, Fugl-Meyer Assessment (upper extremity, total score) evaluate motor functions hemiplegic upper extremity.",C0332152|C0039798|C0030705|G0000000|C0179400|C0028778|C0022885|C0544726|G0000000|C0022885|C0021400|C0237897|G0000000|C0205390|C0325001|C1513492|C0031843|C0022885|G0000000|C1261322|C1282910|C0015385|C0439175|C0449820|C0220825|C1513492|C0542341|C0259928|C1282910|C0015385
The main efficacy measure was the change in mean FEV1% predicted from baseline at week 24.,The main efficacy measure change FEV1% predicted baseline week 24.,G0000000|C0205225|C1280519|C0079809|C0392747|G0000000|C0681842|C0168634|C0332174|C0450371
Physical activity (PA) behaviour - • Sufficiently active: sufficient to confer health benefit if total time is greater or at least 150 minutes (using the Active Australia questionnaire).,Physical activity (PA) behaviour - • Sufficiently active: sufficient confer health benefit total time 150 minutes (using Active Australia questionnaire).,C0031809|C0205177|C0030428|C0004927|G0000000|G0000000|G0000000|C0205177|C0205410|G0000000|C0018684|C0814225|C0439175|C0040223|C1442061|C0439232|C1524063|C0205177|C0004340|C0034394
"Royal Hobart Hospital provided data on arterial blood gas results taken within 30 minutes of arrival at the emergency department, requirement for invasive (endotracheal intubation) or non-invasive ventilation, the length of stay in hospital, and mortality.","Royal Hobart Hospital provided data arterial blood gas 30 minutes arrival emergency department, requirement invasive (endotracheal intubation) non-invasive ventilation, length stay hospital, mortality.",G0000000|G0000000|C0019994|C1999230|C1511726|C0003842|C0005767|C0017110|C0450371|C0439232|C1555577|C0013956|C1704729|C1514873|C0205281|C0599554|C0021925|C0205303|C0035203|C1444754|G0000000|C0019994|C0026565
"The sample size was calculated to provide ≥80% power to detect a significant difference of −0.200 L with a common standard deviation (SD) of 0.545 L in change from baseline in trough FRC at Week 4 of treatment, and 100 s with a common SD of 260 s in change from baseline in EET during constant work rate cycle ergometry to symptom limitation at 75% Wmax at Week 8 of treatment, when comparing AB/FF 400/12 μg with placebo, and based on a two-sided test at a significance level of 0.05.","The sample size calculated provide ≥80% power detect difference −0.200 L common standard deviation (SD) 0.545 L change baseline trough FRC Week 4 treatment, 100 common SD 260 change baseline EET constant rate cycle ergometry symptom limitation 75% Wmax Week 8 treatment, comparing AB/FF 400/12 μg placebo, based two-sided test significance level 0.05.",G0000000|C0370003|C0456389|C0444686|C1999230|G0000000|C0032863|C0442726|C1705241|G0000000|C0439394|C0205214|C1442989|C0012727|G0000000|C1442061|C0439394|C0392747|C0168634|C0444506|C0016815|C0332174|G0000000|C0039798|C1442061|C0205214|C2699239|C1442061|C0392747|C0168634|C1537011|C1547014|C0871208|C1511572|C0085143|C1457887|C0449295|C0450371|G0000000|C0332174|G0000000|C0039798|C1707455|G0000000|C1442061|G0000000|C0032042|C1527178|C0205448|C0022885|C0237881|C0441889|C0450371
"Of the 360 patients who did not complete the study with adequate venography, 237 (65.8%) had bilateral duplex ultrasonography performed between day 5 and 9.","Of 360 patients complete study adequate venography, 237 (65.8%) bilateral duplex ultrasonography performed day 5 9.",G0000000|C1442061|C0030705|C0205197|C0557651|C0205410|C0031545|C1442061|C0450371|C0238767|C0444916|C0041618|C0884358|C0332173|G0000000|G0000000
Caregiver outcomes included depressive symptoms and caregiver life changes.,Caregiver outcomes included depressive symptoms caregiver life changes.,C0085537|C1274040|C0332257|G0000000|C0683368|C0085537|C0376558|C0392747
The level of physical activity is additionally measured with a physical activity diary.,The level physical activity additionally measured physical activity diary.,G0000000|C0441889|C0031809|C0205177|G0000000|C0444706|C0031809|C0205177|C0376660
The patient brought the VAS scores and daily morphine consumption recorded each day at the weekly appointments (21-day study).,The patient brought VAS scores daily morphine consumption recorded day weekly appointments (21-day study).,G0000000|C0030705|C0332302|C0042815|C0449820|C0332173|C0026549|C0009830|C0034869|C0332173|C0332174|C0003629|C0450371|C0557651
The most common organisms identified were C trachomatis (n = 47) and N gonorrhoeae (n = 35) (table 33).).,The common organisms identified C trachomatis (n = 47) N gonorrhoeae (n = 35) (table 33).).,G0000000|C0205214|C0029235|C0205396|G0000000|C2893398|G0000000|C0369718|C0018081|G0000000|C0039224|C0450371
Study juice was delivered to participant's home every 1–2 weeks starting on the day of enrollment in order to promote compliance.,Study juice delivered participant's 1–2 weeks starting day enrollment promote compliance.,C0557651|C1268568|C1705822|C0679646|G0000000|C0439230|C0439659|C0332173|C1516879|C0033414|C0009563
"The first definition of clinical influenza was fever ≥38°C or at least two of the following symptoms: headache, coryza, sore throat, aches or pains in muscles or joints, cough, or fatigue.","The definition clinical influenza fever ≥38°C symptoms: headache, coryza, sore throat, aches pains muscles joints, cough, fatigue.",G0000000|C1550452|C0205210|C0021400|C0015967|G0000000|C0683368|C0018681|C0009443|C0234233|C0031354|C0234238|C0030193|C0026845|C0022417|C0010200|C0015672
"The secondary outcome was safety related, comparing overall adverse events and monitoring for potential intervention–specific complications, such as infusion-related reactions, hypogammaglobulinemia, and infections.","The secondary outcome safety related, comparing adverse events monitoring potential intervention–specific complications, infusion-related reactions, hypogammaglobulinemia, infections.",G0000000|C0027627|C1274040|C0036043|C0439849|C1707455|G0000000|C0441471|C0150369|C3245505|G0000000|C0009566|C0574032|C0443286|C0086438|C3714514
"Some studies have shown that although robot-assisted upper extremity rehabilitation therapy improved motor ability and muscle strength, the performance of daily living activities were not significantly improved [30,31,32,33] possibly since previous robot-assisted upper extremity rehabilitation therapy was limited to the proximal part of the upper extremity.","Some studies robot-assisted upper extremity rehabilitation therapy improved motor ability muscle strength, performance daily living activities improved [30,31,32,33] previous robot-assisted upper extremity rehabilitation therapy limited proximal upper extremity.",G0000000|C0947630|C3844190|C1282910|C0015385|C0034991|C0039798|C0184511|C1513492|C0085732|C0026845|C0237897|C0597198|C0332173|C0376558|C0441655|C0184511|C0450371|C0205156|C3844190|C1282910|C0015385|C0034991|C0039798|C0439801|C0205107|C1282910|C0015385
"The outcomes of interest were survival, treatment duration and duration of hospital stay.","The outcomes survival, treatment duration duration hospital stay.",G0000000|C1274040|C0038952|C0039798|C0449238|C0449238|C0019994|G0000000
"We systematically measured indices of BPSD that influence emotion and stress levels 5 min before and 5 min after each of the 10 music intervention sessions, using the autonomic nerve index and the Faces Scale.","We systematically measured indices BPSD influence emotion stress levels 5 min 5 min 10 music intervention sessions, autonomic nerve Faces Scale.",G0000000|G0000000|C0444706|C4033634|G0000000|C4054723|C0013987|C0038435|C0441889|G0000000|C0702093|G0000000|C0702093|C0450371|C0026867|C0886296|C1883016|C0004388|C0027740|C0015450|C0175659
"If a patient had not been treated with methylprednisolone this treatment was offered, otherwise surgical decompression was performed.","If patient treated methylprednisolone treatment offered, surgical decompression performed.",G0000000|C0030705|C1522326|C0025815|C0039798|C1444648|C0543467|C0011117|C0884358
"Cigarette smoking [1], poor nutrition [2-4], insufficient levels of physical activity (PA) [5],and awareness of gestational weight gain GWG) goals [6,7] have been associated with a number of poor outcomes, including an increased risk of caesarean sections [8], low birth weight [1], pre-term birth [1,8], inappropriate GWG [9], and chronic disease in adult life [2,5,8-10].","Cigarette smoking [1], poor nutrition [2-4], insufficient levels physical activity (PA) [5],and awareness gestational weight gain GWG) goals [6,7] poor outcomes, including increased risk caesarean sections [8], low birth weight [1], pre-term birth [1,8], inappropriate GWG [9], chronic disease adult life [2,5,8-10].",C0677453|C0037369|G0000000|C0032854|C0028707|G0000000|C0205412|C0441889|C0031809|C0205177|C0030428|G0000000|C0004448|C0439671|C0005910|C1517378|G0000000|C0018017|G0000000|C0032854|C1274040|C0332257|C0205217|C0035647|C3841297|C0152060|G0000000|C0205251|C0005615|C0005910|G0000000|C0151526|C0005615|G0000000|C1548788|G0000000|G0000000|C0205191|C0012634|C0001675|C0376558|C0450371
"*p<0.05 MFT: Manual Function Test, FIM: Functional Independence Measure aMean±SD.","*p<0.05 MFT: Manual Function Test, FIM: Functional Independence Measure aMean±SD.",C0369773|C1822742|C0024763|C0031843|C0022885|C3273671|C0205245|C0085862|C0079809|G0000000
"Lack of knowledge is, however, likely to be more pronounced in non-intervention areas.","Lack knowledge is, however, pronounced non-intervention areas.",C0332268|C0376554|G0000000|G0000000|G0000000|C1518422|C0205146
Six patients reported 0 exacerbations in the first 2 years of life.,Six patients reported 0 exacerbations 2 life.,C0205452|C0030705|C0684224|G0000000|G0000000|G0000000|C0376558
"In baseline consistent condom users (40%), significantly less relapse was found in the TTM compared with the SC group at 6 and 12, but not at 18 months.","In baseline consistent condom users (40%), relapse TTM compared SC 6 12, 18 months.",G0000000|C0168634|C0332290|C0009653|C1706077|C0450371|C0035020|C0040953|C1707455|C0282380|G0000000|C0450371|C0450371|C0439231
"With both treatment orders, the change in LCI and change in FEV1% predicted at 90 min post treatment was not always in agreement.","With treatment orders, change LCI change FEV1% predicted 90 min post treatment agreement.",G0000000|C0039798|C3244315|C0392747|C0231990|C0392747|G0000000|C0681842|G0000000|C0687676|C0039798|C0680240
"Before enrollment, 70% had experienced one or more adverse effects of steroid or CNI treatment.","Before enrollment, 70% experienced adverse effects steroid CNI treatment.",C0332152|C1516879|C0450371|C0237607|G0000000|C1280500|C0038317|C1425101|C0039798
"All participants were assessed at baseline and at 3 months for RA disease activity (Disease Activity Score 28 and Routine Assessment of Patient Index Data 3), functional disability (Health Assessment Questionnaire), CVD risk factors (blood pressure, lipids profile, body composition, and smoking), and three atherosclerotic measurements: carotid intima-media thickness, flow-mediated dilatation (FMD), and brachial-ankle pulse wave velocity (baPWV).","All participants assessed baseline 3 months RA disease activity (Disease Activity Score 28 Routine Assessment Patient Index Data 3), functional disability (Health Assessment Questionnaire), CVD risk factors (blood pressure, lipids profile, body composition, smoking), atherosclerotic measurements: carotid intima-media thickness, flow-mediated dilatation (FMD), brachial-ankle pulse wave velocity (baPWV).",G0000000|C0679646|C1516048|C0168634|G0000000|C0439231|C3538806|C0012634|C0205177|C0012634|C0205177|C0449820|C0450371|C0205547|C1261322|C0030705|C0918012|C1511726|G0000000|C0205245|C0231170|C0018684|C1261322|C0034394|C0007222|C0035647|C1521761|C0005767|C0033095|C0023779|C1979963|C0242821|C0486616|C0037369|C0333482|C0242485|C0741968|C0162864|C1280412|C0806140|C0012359|C0238288|C0445456|C0232117|C0678544|C0439830|G0000000
"Change in Arm Function (Posttreatment – Pretreatment) in Both Groups* Abbreviations: BATRAC, bilateral arm training with rhythmic auditory cueing (intervention); CI, confidence interval; DMTE, dose-matched therapeutic exercises (control); fMRI, functional magnetic resonance imaging; UMAQS, University of Maryland Arm Questionnaire for Stroke (measuring activities of daily living with a 5-point ordinal scale).","Change Arm Function (Posttreatment – Pretreatment) Both Groups* Abbreviations: BATRAC, bilateral arm training rhythmic auditory cueing (intervention); CI, confidence interval; DMTE, dose-matched therapeutic exercises (control); fMRI, functional magnetic resonance imaging; UMAQS, University Maryland Arm Questionnaire Stroke (measuring activities daily living 5-point ordinal scale).",C0392747|C0446516|C0031843|C2709088|G0000000|C1550147|G0000000|C0441833|C0000723|G0000000|C0238767|C0446516|C0040607|C0031084|C0439825|C0010439|C0886296|C0008107|C0237529|C1272706|G0000000|C0178602|C0087111|C0015259|C0243148|C0376335|C0205245|C0024488|C0231881|C0011923|G0000000|C0041740|C0024858|C0446516|C0034394|C0038454|C0444706|C0441655|C0332173|C0376558|C1552961|C0439080|C0175659
"Our findings showed that CS had comparable treatment effect with CF, with respect to similar results of TTP, RR and OS.","Our findings CS comparable treatment CF, respect TTP, RR OS.",G0000000|C2607943|C0010182|G0000000|C0039798|C0009738|C0679133|C0084795|G0000000|C0229090
"Participants’ PA and other outcomes were assessed at baseline, 12 weeks and 24 weeks.","Participants’ PA outcomes assessed baseline, 12 weeks 24 weeks.",G0000000|C0030428|C1274040|C1516048|C0168634|C0450371|C0439230|C0450371|C0439230
Other findings of this study were improving Apgar scores at minutes 1 and 5 in massage therapy group compared to control group.,Other findings study improving Apgar scores minutes 1 5 massage therapy compared control group.,G0000000|C2607943|C0557651|C1272745|C0741195|C0449820|C0439232|G0000000|G0000000|C0024875|C0039798|C1707455|C0243148|C0441833
"Severity of opioid-related adverse effects (i.e., nausea, vomiting, constipation, daytime sedation, lightheadedness or feeling dizzy, and nightmares) were evaluated each evening using a 0 (did not have) to 4 (very severe) rating scale.","Severity opioid-related adverse effects (i.e., nausea, vomiting, constipation, daytime sedation, lightheadedness feeling dizzy, nightmares) evaluated evening 0 (did have) 4 (very severe) rating scale.",C0439793|C0242402|G0000000|C1280500|C0683454|C0027497|C0042963|C0009806|C0332169|C0235195|C0012833|C0013987|C0012833|C0028084|C0220825|C0587117|G0000000|G0000000|G0000000|G0000000|C0442824|C0205082|C0871208|C0175659
"We defined a healed corneal ulcer as a completely healed epithelial defect with no stain on fluorescein application, and non-progression of the stromal infiltration.","We defined healed corneal ulcer completely healed epithelial defect stain fluorescein application, non-progression stromal infiltration.",G0000000|C1704788|C0205249|C0010031|C0041582|C0205197|C0205249|C0221908|C1457869|C0038128|C0060520|C0185125|C3839460|C0927195|C0332448
"Clinical parameters, Fibromyalgia Impact Questionnaire, Pittsburgh Sleep Quality Index, TMS, and Beck Depression Scale were evaluated at pre-treatment and post- treatment periods, and at the third-month control visit.","Clinical parameters, Fibromyalgia Impact Questionnaire, Pittsburgh Sleep Quality Index, TMS, Beck Depression Scale evaluated pre-treatment post- treatment periods, third-month control visit.",C0205210|C0449381|C0016053|C1825598|C0034394|G0000000|C0037313|C0332306|C0918012|G0000000|G0000000|C0011570|C0175659|C0220825|C2709094|C0687676|C0039798|C0439531|C0205437|C0243148|C0545082
The results also suggest that surface EMG is an effective method in evaluating hand function in children with hemiplegic CP.,The surface EMG effective method evaluating hand function children hemiplegic CP.,G0000000|C0205148|G0000000|C1280519|C0025663|C0220825|C0018563|C0031843|C0008059|C0259928|C4050020
"The number of person‐years of follow‐up was calculated from the date of the 5‐year follow‐up survey until the end of follow‐up, which was the earliest date of any of the following events: moving out of the study area, lost to follow‐up, withdrawal from the study, death, diagnosis of BTC, or the last date of the follow‐up period (December 31, 2009 in Osaka PHC and December 31, 2010 in all other areas).","The person‐years follow‐up calculated 5‐year follow‐up survey follow‐up, earliest events: moving study area, lost follow‐up, withdrawal study, death, diagnosis BTC, follow‐up period (December 31, 2009 Osaka PHC December 31, 2010 areas).",G0000000|G0000000|G0000000|C0444686|G0000000|G0000000|C0038951|G0000000|C1279919|C0441471|C0560560|C0557651|C0017446|C0745777|G0000000|C2349954|C0557651|C0011065|C0011900|C3884533|G0000000|C0439531|C3830550|C0450371|G0000000|G0000000|C1420160|C3830550|C0450371|G0000000|C0205146
Each subject was given a ration sufficient for 2 weeks.,Each subject ration sufficient 2 weeks.,G0000000|C0681850|G0000000|C0205410|G0000000|C0439230
"Adolescents’ healthful behaviors were assessed using 6 items from the Youth Risk Behavior Survey (YRBS).23 Adolescents reported how often during the past 7 days they exercised and consumed fruit, vegetables, 100% fruit juices, milk, and carbonated beverages (reverse scored).","Adolescents’ healthful behaviors assessed 6 items Youth Risk Behavior Survey (YRBS).23 Adolescents reported 7 days exercised consumed fruit, vegetables, 100% fruit juices, milk, carbonated beverages (reverse scored).",G0000000|C0018684|C0004927|C1516048|G0000000|C1551338|C0001578|C0035647|C0004927|C0038951|C0450371|C0205653|C0684224|G0000000|C0439228|C0015259|G0000000|C0016767|C0042440|C1442061|C0016767|C1268568|C0026131|C0007026|C0005329|C1555029|C0449820
"The primary outcome was the proportion of participants achieving remission from depression based on the MINI.22 Secondary measures of depression severity included the BDI, with 21 questions, and the CES-D, with 20 items.23 Suicide risk was determined by the suicide module of the MINI.24 Quality of life was assessed by the 89-item Quality of Life in Epilepsy Inventory (QOLIE-89), for which a total score gives an estimate of overall health-related quality of life.6,25 Medication side effects were determined by the Adverse Events Profile (AEP), which has 19 items.18,19 Seizure rate and severity was assessed by standardized seizure calendars that coded each seizure based on the International League Against Epilepsy classification.26 The statistical plan was initially approved by the NINDS review section and subsequently by the DSMB.","The primary outcome proportion participants achieving remission depression based MINI.22 Secondary measures depression severity included BDI, 21 questions, CES-D, 20 items.23 Suicide risk determined suicide module MINI.24 Quality life assessed 89-item Quality Life Epilepsy Inventory (QOLIE-89), total score estimate health-related quality life.6,25 Medication effects determined Adverse Events Profile (AEP), 19 items.18,19 Seizure rate severity assessed standardized seizure calendars coded seizure based International League Against Epilepsy classification.26 The statistical plan initially approved NINDS review subsequently DSMB.",G0000000|C0205225|C1274040|C1709707|C0679646|G0000000|C0544452|C0011570|C1527178|C0445542|C0027627|C0079809|C0011570|C0439793|C0332257|C0006448|C0450371|C1522634|C2699160|C0450371|C1551338|C0038661|C0035647|G0000000|C0038661|C1709061|C0445542|C0332306|C0376558|C1516048|C0450371|C0332306|C0376558|C0014544|C0021941|C0450371|C0439175|C0449820|C0750572|C0018684|C0332306|C0376558|C0013227|C1280500|G0000000|G0000000|C0441471|C1979963|C1456349|C0450371|C1551338|C0036572|C0871208|C0439793|C1516048|G0000000|C0036572|C1516147|C0009219|C0036572|C1527178|C1512888|G0000000|G0000000|C0014544|C0008902|G0000000|C0038215|C0270724|C0205265|C0205540|C2350584|C0282443|G0000000|C0949757
"Both budesonide/formoterol dosage strengths demonstrated greater improvements from baseline compared with formoterol alone in morning and evening PEF, 12-hour FEV1, symptom scores and rescue medication use.","Both budesonide/formoterol dosage strengths demonstrated improvements baseline compared formoterol morning evening PEF, 12-hour FEV1, symptom scores rescue medication use.",G0000000|C1276807|C0178602|C0808080|G0000000|C2986411|C0168634|C1707455|C0060657|C0332170|C0587117|C0030771|C0450371|G0000000|C1457887|C0449820|G0000000|C0013227|C0042153
"Secondary endpoints were the qualitative and quantitative toxicities of GTE, effects of treatment on the expression of biomarkers, and any potential correlation between treatment efficacy and/or toxicity with plasma concentrations of EGCG or caffeine.","Secondary endpoints qualitative quantitative toxicities GTE, effects treatment expression biomarkers, potential correlation treatment efficacy and/or toxicity plasma concentrations EGCG caffeine.",C0027627|C2349179|C0205556|C0392762|C0600688|G0000000|C1280500|C0039798|C0185117|C0005516|C3245505|C1707520|C0039798|C1280519|G0000000|C0040539|C0032105|C0086045|C0059438|C0006644
"These variables included abdominal pain/discomfort, abdominal bloating, stool frequency, stool consistency, urgency, straining, and sensation of complete evacuation.","These variables included abdominal pain/discomfort, abdominal bloating, stool frequency, stool consistency, urgency, straining, sensation complete evacuation.",G0000000|C0439828|C0332257|C0000726|C0030193|C0000726|C1291077|C0015733|C0376249|C0015733|C0332529|C0439609|C0442694|C0036658|C0205197|C1282573
About two-thirds of all successful SCHIP applicants were enrolled in Medicaid.,About two-thirds successful SCHIP applicants enrolled Medicaid.,G0000000|C0205448|C0597535|G0000000|C0696628|G0000000|C0025071
"The aim of this investigation was to assess whether, by adding VSL#3 to the current standard treatment of patients with mild-to-moderate UC, it would be possible to decrease the ulcerative colitis disease activity index (UCDAI) score by at least 50% and improve some of the symptoms associated with UC.","The aim investigation assess whether, adding VSL#3 current standard treatment patients mild-to-moderate UC, decrease ulcerative colitis disease activity (UCDAI) score 50% improve symptoms UC.",G0000000|C1947946|C0220825|C1516048|G0000000|C1883712|G0000000|C0521116|C1442989|C0039798|C0030705|C1299392|G0000000|C0392756|C0041582|C0009319|C0012634|C0205177|G0000000|C0449820|C0450371|G0000000|C0683368|G0000000
"Assessment Timeline SMS-Spasticity Measurement System, QEK- Quantitative Electromyographic Kinesiology, GMFM-Gross Motor Function Measure (66 & 88) Max Torque-Maximum Torque of the gastroc-soleus ECI indicates Energy Cost Index; COPM-Canadian Occupational Performance Measure (Performance and Satisfaction Scale) PE, Physical Exam measures (PROM, clonus, Ashworth scale, deep tendon reflexes[DTR]); AE Interview, Adverse events interviews.","Assessment Timeline SMS-Spasticity Measurement System, QEK- Quantitative Electromyographic Kinesiology, GMFM-Gross Motor Function Measure (66 & 88) Max Torque-Maximum Torque gastroc-soleus ECI Energy Cost Index; COPM-Canadian Occupational Performance Measure (Performance Satisfaction Scale) PE, Physical Exam measures (PROM, clonus, Ashworth scale, deep tendon reflexes[DTR]); AE Interview, Adverse events interviews.",C1261322|C0145943|C0026838|C0242485|C0449913|G0000000|C0392762|G0000000|G0000000|C0439806|C1513492|C0031843|C0079809|C0450371|G0000000|C0450371|G0000000|C0376590|C0376590|C0242694|C1537624|C0424589|C0010186|C0918012|C0238884|C0521127|C0597198|C0079809|C0597198|C0242428|C0175659|C0070939|C0031809|C0582103|C0079809|C0015944|C0009024|G0000000|C0175659|C0205125|C0039508|C0034929|C3887670|C0021822|G0000000|C0441471|C0021822
Frequency distribution of exacerbations.,Frequency distribution exacerbations.,C0376249|C0520511|G0000000
"Unplanned use of health services for negative events is crucial to consider as a primary outcome as it reflects important health problems for individuals, is very costly to the individual and society and evidence suggests it can be decreased with adequate secondary prevention strategies.","Unplanned health services negative events crucial primary outcome reflects health individuals, costly individual society evidence suggests decreased adequate secondary prevention strategies.",G0000000|C0018684|C0557854|C0205160|C0441471|G0000000|C0205225|C1274040|C0558058|C0018684|C0027361|G0000000|C0027361|C0037455|C3887511|C1705535|C0205216|C0205410|C0027627|C0199176|C0679199
This study also showed a significant improvement in frequency and consistency of stool and reduction in duration of illness in patients who were given S. boulardii along with WHO-CDD protocol.,This study improvement frequency consistency stool reduction duration illness patients S. boulardii WHO-CDD protocol.,G0000000|C0557651|C2986411|C0376249|C0332529|C0015733|C0301630|C0449238|C0221423|C0030705|C0565930|G0000000|C3542927|C0442711
Secondary endpoints were duration of remission and severe adverse events.,Secondary endpoints duration remission severe adverse events.,C0027627|C2349179|C0449238|C0544452|C0205082|G0000000|C0441471
"Parental and kindergarten staff feeding practices; assessed at baseline and after the intervention, and parental feeding practices assessed when the child reaches 4 years.","Parental kindergarten staff feeding practices; assessed baseline intervention, parental feeding practices assessed child reaches 4 years.",C0030551|C0681406|C0851286|C0204695|C0237607|C1516048|C0168634|C0886296|C0030551|C0204695|C0237607|C1516048|C0008059|C0596012|G0000000|C0439234
Time to treatment failure for patients with adenocarcinoma by treatment arm.,Time treatment failure patients adenocarcinoma treatment arm.,C0040223|C0039798|C0231174|C0030705|C0001418|C0039798|C0446516
Isolation of Clostridium difficile was also attempted.,Isolation Clostridium difficile attempted.,C0204727|C0009054|G0000000|C1516084
"Secondary outcomes included helminth infection, anthropometry and intestinal inflammation.","Secondary outcomes included helminth infection, anthropometry intestinal inflammation.",C0027627|C1274040|C0332257|C0018893|C0009450|C0003188|C0021853|C0021368
The study compares the efficacy of MCP using the AIMhi Stay Strong App with two control groups (control app intervention and treatment as usual) on participant-reported psychological distress (the primary outcome) using the Kessler Distress Scale (K10); depressive symptoms using the adapted Patient Health Questionnaire (PHQ-9); quality of life using the EuroQoL instrument (EQ5D) and adherence to dialysis treatment planning through file audit.,The study compares efficacy MCP AIMhi Stay Strong App control (control app intervention treatment usual) participant-reported psychological distress (the primary outcome) Kessler Distress Scale (K10); depressive symptoms adapted Patient Health Questionnaire (PHQ-9); quality life EuroQoL instrument (EQ5D) adherence dialysis treatment planning file audit.,G0000000|C0557651|C1707455|C1280519|C3540820|G0000000|G0000000|C0442821|G0000000|C0243148|C0243148|G0000000|C0886296|C0039798|C3538928|C0679646|C0205486|C0231303|G0000000|C0205225|C1274040|G0000000|C0231303|C0175659|G0000000|G0000000|C0683368|C2937289|C0030705|C0018684|C0034394|C1879301|C0332306|C0376558|C0451150|C0348000|G0000000|C1510802|C0011945|C0039798|C0032074|C0016094|C1704774
the HRQoL questionnaire (SF-36) and the Geriatric Depression Scale-15 (GDS-15).,HRQoL questionnaire (SF-36) Geriatric Depression Scale-15 (GDS-15).,G0000000|C0034394|C0037712|C1704440|C0011570|C0175659|C0451184
"Secondary outcomes include the relapse rate after treatment of MAM and SAM (number of MAM or SAM cases detected after being successfully discharged from MAM or SAM treatment), ponderal and linear growth (monthly WLZ and LAZ increment, respectively), incidence of stunting (LAZ < -2 SD), MUAC gain (MUAC increment per month), longitudinal prevalence (ie.","Secondary outcomes relapse rate treatment MAM SAM (number MAM SAM detected discharged MAM SAM treatment), ponderal linear growth (monthly WLZ LAZ increment, respectively), incidence stunting (LAZ < -2 SD), MUAC gain (MUAC increment month), longitudinal prevalence (ie.",C0027627|C1274040|C0035020|C0871208|C0039798|C0024671|C0036002|C0237753|C0024671|C0036002|C0442726|C0030685|C0024671|C0036002|C0039798|C0005910|C0205132|C0018270|C0332177|G0000000|G0000000|C1705117|G0000000|C0021149|C0018273|G0000000|C2699239|G0000000|C1517378|G0000000|C1705117|C0332177|C0205127|C0033105|G0000000
"All participants completed the Short-Form McGill Pain Questionnaire (SF-MPQ), Arthritis Self-Efficacy Scale (ASES), and Fibromyalgia Impact Questionnaire (FIQ), at baseline, 6, and 10 weeks, and submitted frequency of use report forms.","All participants completed Short-Form McGill Pain Questionnaire (SF-MPQ), Arthritis Self-Efficacy Scale (ASES), Fibromyalgia Impact Questionnaire (FIQ), baseline, 6, 10 weeks, submitted frequency report forms.",G0000000|C0679646|C0205197|C2964478|G0000000|C0030193|C0034394|C0037712|C0003864|C0600564|C0175659|G0000000|C0016053|C1825598|C0034394|G0000000|C0168634|G0000000|C0450371|C0439230|C1515023|C0376249|C0684224|C0348078
There were significant reductions in the peak inspiratory pressure and FiO2 with no difference in the distribution of saturations or the PtcCO2.,There reductions peak inspiratory pressure FiO2 difference distribution saturations PtcCO2.,G0000000|C0301630|C0444505|C0004048|C0033095|G0000000|C1705241|C0520511|C0522534|G0000000
Two types of beliefs relevant to weight control were assessed: outcome expectancy and self-efficacy.,Two types beliefs relevant weight control assessed: outcome expectancy self-efficacy.,C0205448|C0332307|C0004951|C2347946|C0005910|C0243148|C1516048|C1274040|C0679138|C0600564
"However, the time to emergence was comparable among the groups [Table 4].","However, time emergence comparable [Table 4].",G0000000|C0040223|C0750573|G0000000|C0039224|G0000000
The overall time to cessation of seizures after arrival at hospital was faster with intranasal midazolam than with intravenous diazepam.,The time cessation seizures arrival hospital faster intranasal midazolam intravenous diazepam.,G0000000|C0040223|C1880019|C0036572|C1555577|C0019994|C0015663|C0442118|C0026056|C0348016|C0012010
"As a secondary aim, this study will also investigate the associations between cognitive function and blood based biomarkers and cardiovascular function, which have been proposed as mechanisms, or indicators of mechanisms, that may influence the rate of cognitive ageing.","As secondary aim, study investigate associations cognitive function blood based biomarkers cardiovascular function, proposed mechanisms, indicators mechanisms, influence rate cognitive ageing.",G0000000|C0027627|C1947946|C0557651|C1292732|C0004083|C1516691|C0031843|C0005767|C1527178|C0005516|C0007226|C0031843|C1553874|C0441712|C0021212|C0441712|C4054723|C0871208|C1516691|C0001811
Time to first exacerbation COPD.,Time exacerbation COPD.,C0040223|G0000000|C0024117
The time between catheterization and decision measured in calendar weeks.,The time catheterization decision measured calendar weeks.,G0000000|C0040223|C0007430|C0679006|C0444706|C1516147|C0439230
"The primary outcome measures were the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) bodily pain and physical function scores (100-point scales, with higher scores indicating less severe symptoms) and the modified Oswestry Disability Index (100-point scale, with lower scores indicating less severe symptoms) at 6 weeks, 3 months, 6 months, 1 year, and 2 years.","The primary outcome measures Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) bodily pain physical function scores (100-point scales, scores indicating severe symptoms) modified Oswestry Disability Index (100-point scale, lower scores indicating severe symptoms) 6 weeks, 3 months, 6 months, 1 year, 2 years.",G0000000|C0205225|C1274040|C0079809|C0199168|C1274040|C0557651|C0450371|C2964478|C0205246|C0018684|C0038951|C0037712|G0000000|C0030193|C0031809|C0031843|C0449820|C1442061|C0175659|C0449820|G0000000|C0205082|C0683368|C0392747|G0000000|C0231170|C0918012|C1442061|C0175659|C0441994|C0449820|G0000000|C0205082|C0683368|G0000000|C0439230|G0000000|C0439231|G0000000|C0439231|G0000000|C0439234|G0000000|C0439234
"Patients then completed a standard spine assessment questionnaire, including visual analogue score (VAS) for back and leg pain, Oswestry Disability Index (ODI) [3, 4] and Low Back Outcome Score (LBOS) [5].","Patients completed standard spine assessment questionnaire, including visual analogue score (VAS) leg pain, Oswestry Disability Index (ODI) [3, 4] Low Back Outcome Score (LBOS) [5].",C0030705|C0205197|C1442989|C0037949|C1261322|C0034394|C0332257|C0234621|C0243071|C0449820|C0042815|C0023216|C0030193|G0000000|C0231170|C0918012|G0000000|G0000000|G0000000|C0205251|C0004600|C1274040|C0449820|G0000000|G0000000
Comparison of the mean intensity of pain in the three groups before and after the intervention.,Comparison intensity pain intervention.,C1707455|C0522510|C0030193|C0886296
Toxicity profile of both groups was similar.,Toxicity profile similar.,C0040539|C1979963|C2348205
"The primary outcome was 6 months of prolonged smoking abstinence, measured at 18 months.","The primary outcome 6 months prolonged smoking abstinence, measured 18 months.",G0000000|C0205225|C1274040|G0000000|C0439231|C0439590|C0037369|C3843422|C0444706|C0450371|C0439231
Blood feeding rates in Cx.,Blood feeding rates Cx.,C0005767|C0204695|C0871208|G0000000
"To reduce the chance of a Type 1 error in multiple comparisons, Tukey’s adjusted p-values were used.","To reduce chance Type 1 error multiple comparisons, Tukey’s adjusted p-values used.",C0040363|G0000000|C0237506|C0332307|G0000000|C0743559|C0439064|C1707455|G0000000|C0456081|C1709380|C1273517
"The study had some attrition: 83 participants returned at 3 months, 79 at 6 months, and 72 at 12 months (37 control, 35 intervention).","The study attrition: 83 participants returned 3 months, 79 6 months, 72 12 months (37 control, 35 intervention).",G0000000|C0557651|C0004277|C0450371|C0679646|C0332156|G0000000|C0439231|C0450371|G0000000|C0439231|C0450371|C0450371|C0439231|C0450371|C0243148|C0450371|C0886296
"Furthermore, although negative for the primary outcome of infant whole body bone mineral content by DXA, the trial demonstrated in a pre-specified secondary analysis, a greater than 0.5 SD increase in infant BMC in neonates born to supplemented compared to placebo mothers, and who delivered during the winter months.","Furthermore, negative primary outcome infant body bone mineral content DXA, trial demonstrated pre-specified secondary analysis, 0.5 SD increase infant BMC neonates born supplemented compared placebo mothers, delivered winter months.",G0000000|C0205160|C0205225|C1274040|C0021270|C0242821|C0262950|C0006660|C0423896|C1510486|C0008976|G0000000|C2826245|C0027627|C0002778|G0000000|C2699239|C0442805|C0021270|C0065839|C0021289|C0005615|C0242295|C1707455|C0032042|C0026591|C1705822|C0241737|C0439231
"Because infants at 6 months received very little food in addition to breast milk and the 12‐month data were similar to those at 15 months, only the data at 9 and 15 months are compared and shown for clarity (Table 2).","Because infants 6 months received food addition breast milk 12‐month data 15 months, data 9 15 months compared clarity (Table 2).",G0000000|C0021270|G0000000|C0439231|C1514756|C0016452|C0332287|C0006141|C0026131|G0000000|C1511726|C0450371|C0439231|C1511726|G0000000|C0450371|C0439231|C1707455|C0486588|G0000000
Weight and length measurements were corrected to the exact nominal ages by parabolic interpolation.,Weight length measurements corrected exact nominal ages parabolic interpolation.,C0005910|C1444754|C0242485|C0205202|C2828393|G0000000|C0001779|G0000000|C2825517
"Mean of healing time in the honey and glucantime group after omitting the exited patients were 7.04 ± 3.09 and 6.3 ± 2.29 weeks, respectively but this difference was not significant (P = 0.3).","Mean healing time honey glucantime omitting exited patients 7.04 ± 3.09 6.3 ± 2.29 weeks, difference (P = 0.3).",C0444504|C0043240|C0040223|C0019906|C0061366|C0750563|C0337094|C0030705|C0450371|G0000000|C0450371|G0000000|G0000000|C0450371|C0439230|C1705241|C0369773|G0000000|G0000000
"Patients were assessed using a standard 6-min walk, spirometry, plethismography, and each completed the SGRQ.","Patients assessed standard 6-min walk, spirometry, plethismography, completed SGRQ.",C0030705|C1516048|C1442989|C0702093|C0080331|C0037981|G0000000|C0205197|G0000000
"The primary outcome is adoption of SDM, measured by the 9-item Shared Decision Making Questionnaire.","The primary outcome adoption SDM, measured 9-item Shared Decision Making Questionnaire.",G0000000|C0205225|C1274040|C0001593|C0643808|C0444706|C1551338|C0237876|C0679006|C1881534|C0034394
"In Group II, the results were: 14.9 dry nights in the first month, 20.8 dry nights in the second and 24.0 dry nights in the last month.","In Group II, were: 14.9 dry nights month, 20.8 dry nights 24.0 dry nights month.",G0000000|C0441833|G0000000|G0000000|C0450371|C0011682|C0240526|C0332177|C0450371|C0011682|C0240526|C0450371|C0011682|C0240526|C0332177
"Primary end points were liver enzymes, HCV-RNA levels and histology.","Primary liver enzymes, HCV-RNA levels histology.",C0205225|C0023884|C0014442|C1868902|C0441889|C0019638
"Given that is not the case, the cases detected by the intervention include both true additional cases and early-detected cases.","Given case, detected intervention true additional early-detected cases.",C1442162|C0868928|C0442726|C0886296|C0205238|C1524062|C1279919|C0868928
The secondary endpoints were the clinical response rates (complete response [CR] and partial response [PR] rates) based on RECIST ver.,The secondary endpoints clinical response rates (complete response [CR] partial response [PR] rates) based RECIST ver.,G0000000|C0027627|C2349179|C0205210|C0871261|C0871208|C0205197|C0871261|C0201975|C0728938|C0871261|C0279759|C0871208|C1527178|C1709926|C0302357
"The dependent variables were 1) current pain, 2) worst pain over the past 24 hours, 3) which pain provocation test caused the most pain, and 4) pain produced during provocation testing.","The dependent variables 1) current pain, 2) worst pain 24 hours, 3) pain provocation test caused pain, 4) pain produced provocation testing.",G0000000|C0851827|C0439828|G0000000|C0521116|C0030193|G0000000|C1522166|C0030193|C0450371|C0439227|G0000000|C0030193|C0449428|C0022885|C0015127|C0030193|G0000000|C0030193|G0000000|C0449428|C0039593
"All subjects were evaluated by the Hamilton Depression Rating Scale at four time points (0 [baseline], 2, 4, and 6 weeks after treatment).","All subjects evaluated Hamilton Depression Rating Scale time (0 [baseline], 2, 4, 6 weeks treatment).",G0000000|C0681850|C0220825|G0000000|C0011570|C0871208|C0175659|C0040223|G0000000|C0168634|G0000000|G0000000|G0000000|C0439230|C0039798
"The secondary outcomes will be functional status with respect to LBPGP (according to the Roland-Morris disability questionnaire), health-related quality of life (SF12) at 2 weeks after the start of treatment, and iVAS at 12 and 48 weeks postpartum.","The secondary outcomes functional status respect LBPGP (according Roland-Morris disability questionnaire), health-related quality life (SF12) 2 weeks start treatment, iVAS 12 48 weeks postpartum.",G0000000|C0027627|C1274040|C0205245|C0449438|C0679133|G0000000|C0680240|G0000000|C0231170|C0034394|C0018684|C0332306|C0376558|G0000000|G0000000|C0439230|C0439659|C0039798|C0268575|C0450371|C0450371|C0439230|C0086839
"Therefore, main endpoint is the level of physical activity during the entire follow-up period (i.e.","Therefore, main endpoint level physical activity entire follow-up period (i.e.",G0000000|C0205225|C2349179|C0441889|C0031809|C0205177|C0439751|C0589120|C0439531|C0683454
"In this paper we report preliminary short-term effects of CST on child adaptation (HbA1c, coping, self-efficacy, quality of life, and diabetes family behavior) and on parent adaptation (coping, depressive symptoms), diabetes-related conflict, and family functioning as compared to child and parent GE.","In paper report preliminary short-term effects CST child adaptation (HbA1c, coping, self-efficacy, quality life, diabetes family behavior) parent adaptation (coping, depressive symptoms), diabetes-related conflict, family functioning compared child parent GE.",G0000000|C0030351|C0684224|C0439611|C0443303|C1280500|C3539520|C0008059|C0000934|G0000000|C0009967|C0600564|C0332306|C0376558|C0011847|C0015576|C0004927|C0030551|C0000934|C0009967|G0000000|C0683368|C1261139|C0009671|C0015576|C0205245|C1707455|C0008059|C0030551|C1292300
The outcome end-point of the study was the number of decayed primary teeth.,The outcome end-point study decayed primary teeth.,G0000000|C1274040|C2349179|C0557651|C1265875|C0205225|C0040426
Six patients died after 30 days but within two years of surgery for screen detected benign adenomas or stage A cancers; in all cases the cause of death was not related to colorectal cancer.,Six patients died 30 days surgery screen detected benign adenomas stage A cancers; death colorectal cancer.,C0205452|C0030705|C0011065|C0450371|C0439228|C0038894|C0220908|C0442726|C0205183|C0001430|C0205390|G0000000|C0006826|C0011065|C0555952|C0006826
"The severity of breast engorgement was assessed using the total score obtained for the symptoms of engorgement (Severity Index = Erythema + Breast Tension + Breast Pain, with scores ranging from 0 to 19).","The severity breast engorgement assessed total score symptoms engorgement (Severity Index = Erythema + Breast Tension + Breast Pain, scores ranging 0 19).",G0000000|C0439793|C0006141|C0020452|C1516048|C0439175|C0449820|C0683368|C0020452|C0439793|C0918012|G0000000|C0041834|G0000000|C0006141|C0233494|G0000000|C0006141|C0030193|C0449820|C1514721|G0000000|C0450371
"The significant changes between assessment time points, and the significant differences between groups (ANCOVA-adjusted to baseline Pre-assessment) are marked with asterisk NOTE: FAC Functional Ambulation Categories, FMA Fugl-Meyer assessment for Lower-Extremity, MAS Modified Ashworth Scale, BBS Berg Balance Scale, 10MWT 10-Meter Walk Test, SMWT Six-Minute Walk Test * p < 0.05; ** p < 0.01 †Pre-assessment values presented in mean (SD) CONSORT patient flow diagram The baseline 10-min over-ground walking distance were recorded as 287 ± 90 m in Robotic Group and 226 ± 145 m in Sham Group; the baseline 10-min stairs climbed were 257 ± 94 steps in Robotic Group and 204 ± 140 steps in Sham Group.","The assessment time points, differences (ANCOVA-adjusted baseline Pre-assessment) marked asterisk NOTE: FAC Functional Ambulation Categories, FMA Fugl-Meyer assessment Lower-Extremity, MAS Modified Ashworth Scale, BBS Berg Balance Scale, 10MWT 10-Meter Walk Test, SMWT Six-Minute Walk Test * p < 0.05; ** p < 0.01 †Pre-assessment values (SD) CONSORT patient flow diagram The baseline 10-min over-ground walking distance recorded 287 ± 90 Robotic Group 226 ± 145 Sham Group; baseline 10-min stairs climbed 257 ± 94 steps Robotic Group 204 ± 140 steps Sham Group.",G0000000|C1261322|C0040223|C1552961|C1705241|C0814908|C0168634|C0332152|C0522501|C2945706|C1316572|G0000000|C0205245|C0080331|C0683312|C2332774|G0000000|C1261322|C0023216|C1096155|C0392747|G0000000|C0175659|G0000000|G0000000|C0014653|C0175659|G0000000|C0450371|C0080331|C0022885|G0000000|C0205452|C0080331|C0022885|G0000000|G0000000|G0000000|G0000000|G0000000|C0042295|G0000000|G0000000|C0030705|C0806140|C0681494|G0000000|C0168634|C0450371|C0205136|C0080331|C0012751|C0034869|G0000000|C0035785|C0441833|G0000000|C0068899|C0441833|C0168634|C0450371|C1710179|C0561942|G0000000|C1261552|C0035785|C0441833|G0000000|C1261552|C0068899|C0441833
"The incidences of graft rejection, graft loss, and death were calculated by Kaplan–Meier analysis and compared with the log-rank test.","The incidences graft rejection, graft loss, death calculated Kaplan–Meier analysis compared log-rank test.",G0000000|C0021149|C0181074|C0035015|C0181074|C1517945|C0011065|C0444686|G0000000|C0002778|C1707455|C1708728|C0022885
The control group comprised 53 patients with a standardized duration of antibiotic therapy over eight days.,The control comprised 53 patients standardized duration antibiotic therapy days.,G0000000|C0243148|C2700400|C0450371|C0030705|G0000000|C0449238|C0003232|C0039798|C0439228
"From these data we derived: SOL, wake time after sleep onset (WASO), TST, number of awakenings (NWAK), sleep efficiency (SE%), sleep quality (10-point rating), and the degree of restedness upon arising (10-point scale).","From data derived: SOL, wake time sleep onset (WASO), TST, awakenings (NWAK), sleep efficiency (SE%), sleep quality (10-point rating), degree restedness arising (10-point scale).",G0000000|C1511726|C1441547|G0000000|C0442696|C0040223|C0037313|C0206132|G0000000|C1421210|C1720052|G0000000|C0037313|C0013682|C0036919|C0037313|C0332306|C0450371|C0871208|C0441889|C0035253|C0332284|C0450371|C0175659
"As this was a community intervention targeted at identifying and treating symptomatic individuals, all presenting cases not already on TB treatment were included.","As community intervention targeted identifying treating symptomatic individuals, TB treatment included.",G0000000|C0009462|C0886296|C1521840|G0000000|C1522326|C0231220|C0027361|G0000000|C0039798|C0332257
Rating scale scores are at baseline.,Rating scale scores baseline.,C0871208|C0175659|C0449820|C0168634
"[16] To determine if adrenocortical insufficiency occurs secondary to the use of class I (high potency) topical steroids in patients with vitiligo and intact cutaneous barrier; to establish the role of measuring plasma cortisol levels by performing the ACTH test before, during, and after treatment with high potency topical steroids; and finally to determine other side effects and response to treatment.","[16] To determine adrenocortical insufficiency occurs secondary class I (high potency) topical steroids patients vitiligo intact cutaneous barrier; establish role measuring plasma cortisol levels performing ACTH test before, during, treatment potency topical steroids; finally determine effects response treatment.",C0450371|C0040363|G0000000|C2986474|C0231179|C1709305|C0027627|C0456387|C0021966|C0205250|C3245505|C0332237|C0038317|C0030705|C0042900|C0205266|C0221912|C1706912|C0443211|C0035820|C0444706|C0032105|C0020268|C0441889|C0884358|C3539087|C0022885|C0332152|G0000000|C0039798|C3245505|C0332237|C0038317|G0000000|G0000000|C1280500|C0871261|C0039798
"Food intake at breakfast, lunch, and dinner was directly measured at baseline, week 1, and week 8.","Food intake breakfast, lunch, dinner directly measured baseline, week 1, week 8.",C0016452|C1512806|C2698559|C2697949|C2699739|C1947931|C0444706|C0168634|C0332174|G0000000|C0332174|G0000000
"The daily micturition, nocturia, urgent urination, and urge UI in the treatment group significantly improved compared to the control group (P<0.05).","The daily micturition, nocturia, urgent urination, urge UI treatment improved compared control (P<0.05).",G0000000|C0332173|C0042034|C0028734|C0439609|C0042034|G0000000|C1421312|C0039798|C0184511|C1707455|C0243148|C0369773
Contralateral prophylactic mastectomy was associated with improved breast cancer–specific survival.,Contralateral prophylactic mastectomy improved breast cancer–specific survival.,C0441988|C0355642|C0024881|C0184511|C0006141|G0000000|C0038952
"Though Independent Living Skills Survey (ILSS) was adopted after translation and retranslation by professionals, it was not validated.","Though Independent Living Skills Survey (ILSS) translation retranslation professionals, validated.",G0000000|C0085862|C0376558|C0678856|C0038951|G0000000|C0040712|G0000000|C0679924|G0000000
The children’s caries scores were recorded at baseline and 1 year.,The children’s caries scores recorded baseline 1 year.,G0000000|G0000000|C0011334|C0449820|C0034869|C0168634|G0000000|C0439234
Secondary outcomes were relapse after ACTH dose reduction and treatment side effects.,Secondary outcomes relapse ACTH dose reduction treatment effects.,C0027627|C1274040|C0035020|C3539087|C0178602|C0301630|C0039798|C1280500
VAS = visual analogue scale.,VAS = visual analogue scale.,C0042815|G0000000|C0234621|C0243071|C0175659
"The primary end point was estradiol level, mammographic BD, ultrasonic ET, and blood lipid levels.","The primary estradiol level, mammographic BD, ultrasonic ET, blood lipid levels.",G0000000|C0205225|C0014912|C0441889|C0024671|C0005126|C0220934|G0000000|C0005767|C0023779|C0441889
"At 14 weeks, the mean SGRQ total score was (47.3 ± 2.6).","At 14 weeks, SGRQ total score (47.3 ± 2.6).",G0000000|C0450371|C0439230|G0000000|C0439175|C0449820|C0450371|G0000000|G0000000
"This test scores upper extremity exercise, grip strength, and finger manipulation abilities for a possible total of 32 points.","This test scores upper extremity exercise, grip strength, finger manipulation abilities total 32 points.",G0000000|C0022885|C0449820|C1282910|C0015385|C0015259|C0021400|C0237897|C0016129|C0185111|C0085732|C0439175|C0450371|C1552961
The primary endpoints were mean LCQ total and domain scores at 12 weeks.,The primary endpoints LCQ total domain scores 12 weeks.,G0000000|C0205225|C2349179|G0000000|C0439175|C1880389|C0449820|C0450371|C0439230
"Functional balance was assessed using the Berg Balance Scale11,12,13), functional mobility was assessed using the Timed Up and Go test (TUGT)14), and independence in activities of daily living was assessed using the Functional Independence Measure15).","Functional balance assessed Berg Balance Scale11,12,13), functional mobility assessed Timed Up Go test (TUGT)14), independence activities daily living assessed Functional Independence Measure15).",C0205245|C0014653|C1516048|G0000000|C0014653|C0450371|C0205245|C0425245|C1516048|C0392761|G0000000|C1822658|C0022885|C0450371|C0085862|C0441655|C0332173|C0376558|C1516048|C0205245|C0085862|G0000000
"The primary outcome measures were overall physical function (Continuous Scale—Physical Functional Performance [CS-PFP]), balance (Functional Reach Test [FRT]), and walking economy (oxygen uptake [mL/kg/min]).","The primary outcome measures physical function (Continuous Scale—Physical Functional Performance [CS-PFP]), balance (Functional Reach Test [FRT]), walking economy (oxygen uptake [mL/kg/min]).",G0000000|C0205225|C1274040|C0079809|C0031809|C0031843|C0549178|G0000000|C0205245|C0597198|C0010182|C0014653|C0205245|C2584321|C0022885|C1705150|C0080331|C0013556|C0030054|C0243144|C0439402
We used tumor recurrence rate at 2 years after treatment to be the outcome measurement to estimate the sample size for this study.,We tumor recurrence rate 2 treatment outcome measurement estimate sample size study.,G0000000|C0027651|C0034897|C0871208|G0000000|C0039798|C1274040|C0242485|C0750572|C0370003|C0456389|C0557651
"Conclusion: Adding high dose vitamin D3 supplementation during pregnancy to routine care of women with MS had significant effect on the serum 25(OH)D levels, EDSS and number of relapse events during pregnancy and within 6 months after delivery.","Conclusion: Adding dose vitamin D3 supplementation pregnancy routine care women MS serum 25(OH)D levels, EDSS relapse events pregnancy 6 months delivery.",C1707478|C1883712|C0178602|C0042890|C3538936|C0242297|C0032961|C0205547|C1947933|C0043210|C0039676|C0229671|C0450371|C0441889|C0451246|C0035020|C0441471|C0032961|G0000000|C0439231|C0011209
"Secondary end points were frequency of intracranial relapse at initially treated and at new sites, progression-free and overall survival, late toxicities, and quality of life.","Secondary frequency intracranial relapse initially treated sites, progression-free survival, late toxicities, quality life.",C0027627|C0376249|C0524466|C0035020|C0205265|C1522326|C0205145|C0242656|C0038952|C0205087|C0600688|C0332306|C0376558
"The main analysis will be a comparison between both intervention groups and the control group for the proportions of smoking abstinence at 3 and 6 months, using chi-square tests and odds ratios with 95% confidence intervals.","The main analysis comparison intervention control proportions smoking abstinence 3 6 months, chi-square tests odds ratios 95% confidence intervals.",G0000000|C0205225|C0002778|C1707455|C0886296|C0243148|C1709707|C0037369|C3843422|G0000000|G0000000|C0439231|C1552646|C0022885|G0000000|C0456603|C0450371|C0237529|C1272706
"After an average of 11.2 years of follow-up, 298 men had developed prostate cancer.","After average 11.2 follow-up, 298 developed prostate cancer.",G0000000|C1510992|C0450371|C0589120|C1442061|G0000000|C0033572|C0006826
"Sustained quit rate was no different for intervention and control groups (9% vs 14%; [OR] 0.6; 95%[CI] 0.2, 1.4).","Sustained quit rate intervention control (9% 14%; [OR] 0.6; 95%[CI] 0.2, 1.4).",C0443318|C0748223|C0871208|C0886296|C0243148|G0000000|C0450371|G0000000|G0000000|C0450371|G0000000|G0000000
"The secondary endpoints included the proportion of patients regaining continence, and the patients’ quality of life (QoL).","The secondary endpoints included proportion patients regaining continence, patients’ quality life (QoL).",G0000000|C0027627|C2349179|C0332257|C1709707|C0030705|C1875723|C0443192|G0000000|C0332306|C0376558|C0518214
"Secondary outcomes specified per protocol were the theory-based ""cascada"" of intermediate outcomes leading to vaccination uptake: conscious knowledge, attitudes about vaccination, subjective norms, intention to change, agency/self efficacy, and discussion within the household [11].","Secondary outcomes protocol theory-based ""cascada"" intermediate outcomes leading vaccination uptake: conscious knowledge, attitudes vaccination, subjective norms, intention change, agency/self efficacy, discussion household [11].",C0027627|C1274040|C0442711|C0871935|G0000000|C0205103|C1274040|C0332152|C0042196|C0243144|C0234421|C0376554|C0004271|C0042196|C0439655|C0205307|C0162425|C0392747|C0237463|C1280519|C0557061|C0020052|C0450371
"The effect of supplementations on serum zinc and vitamin E, superoxide dismutase (SOD), glutathione peroxidase (GPX), total antioxidant capacity (TAC) and body mass index (BMI) were measured at the beginning and the end of the study.","The supplementations serum zinc vitamin E, superoxide dismutase (SOD), glutathione peroxidase (GPX), total antioxidant capacity (TAC) body mass (BMI) measured study.",G0000000|C0242297|C0229671|C0043481|C0042890|G0000000|C0038836|G0000000|G0000000|C0017817|C0027021|G0000000|C0439175|C0003402|C1516240|C1883257|C0242821|C0577559|G0000000|C0444706|C0557651
It was ensured that none of the patients was immobilized in bed for more than 3 days after the surgery.,It ensured patients immobilized bed 3 days surgery.,G0000000|C0218063|C0030705|C0020944|C0004916|G0000000|C0439228|C0038894
"In multivariable-adjusted models, we further adjusted the following baseline factors: birth cohort (1920s, 1930s, 1940s, 1950s, 1960s), level of education (four categories: elementary school or less, middle school, high school and college or above), income (four categories: low, low to middle, middle to high and high), marital status (four categories), occupation (housewife(women only), manual, clerical and professional), BMI (four categories: <18.5kg/m2, 18.5–24 kg/m2, 24–28 kg/m2, ≥28 kg/m2), physical activity (quartiles of MET-h/week per year, where MET=metabolic equivalent of task), energy-adjusted fat intake (g/4184kj (1000kcal) per d, continues), use of any vitamin supplement (yes/no), smoking status (for men: never, ever and current; for women: never and ever), drinking status(for men: never, ever and current; for women: never and ever), status with regard to a history of hypertension (yes/no), diabetes (yes/no), CHD (yes/no), stroke (yes/no), and family history of cancer (yes/no).","In multivariable-adjusted models, adjusted baseline factors: birth cohort (1920s, 1930s, 1940s, 1950s, 1960s), level education (four categories: elementary school less, middle school, school college above), income (four categories: low, low middle, middle high), marital status (four categories), occupation (housewife(women only), manual, clerical professional), BMI (four categories: <18.5kg/m2, 18.5–24 kg/m2, 24–28 kg/m2, ≥28 kg/m2), physical activity (quartiles MET-h/week year, MET=metabolic equivalent task), energy-adjusted fat intake (g/4184kj (1000kcal) d, continues), vitamin supplement (yes/no), smoking status (for men: never, current; women: ever), drinking status(for men: never, current; women: ever), status regard history hypertension (yes/no), diabetes (yes/no), CHD (yes/no), stroke (yes/no), family history cancer (yes/no).",G0000000|C0456081|C3161035|C0456081|C0168634|C1521761|C0005615|C0599755|G0000000|G0000000|G0000000|G0000000|G0000000|C0441889|C0013621|C0205450|C0683312|C0013879|C0036375|C0439092|C0444598|C0036375|C0036375|C0557806|C1282910|C0021162|C0205450|C0683312|C0205251|C0205251|C0444598|C0444598|C0205250|C0024841|C0449438|C0205450|C0683312|C0028811|C2939438|C0205171|C0024763|C0008935|C0679924|G0000000|C0205450|C0683312|C0450371|G0000000|C0022718|G0000000|C0022718|G0000000|C0022718|C0031809|C0205177|C2828255|C0268621|C0439234|C0268621|C0205163|C3540678|C0424589|C0424612|C1512806|C0439267|G0000000|C0073187|C0549178|C0042890|C0242295|C1512698|C0037369|C0449438|G0000000|C0025266|C2003901|C0521116|C0043210|G0000000|C0001948|C0449438|C0025266|C2003901|C0521116|C0043210|G0000000|C0449438|G0000000|C0019664|C0020538|C1512698|C0011847|C1512698|C0280604|C1512698|C0038454|C1512698|C0015576|C0019664|C0006826|C1512698
"During the study, we kept records of all dosages administered, all study medications that were dispensed and returned, and intervals between visits to determine compliance with the treatment.","During study, records dosages administered, study medications dispensed returned, intervals visits determine compliance treatment.",G0000000|C0557651|C0034869|C0178602|C1521801|C0557651|C0013227|C1880359|C0332156|C1272706|C0545082|G0000000|C0009563|C0039798
"Results from this study do, however, provide the first echocardiographic evidence of improved cardiac function following exercise post-stroke.","Results study do, however, provide echocardiographic evidence improved cardiac function exercise post-stroke.",C1274040|C0557651|G0000000|G0000000|C1999230|C0013516|C3887511|C0184511|C0018787|C0031843|C0015259|C0687676
"Pre-dose FEV1, FVC, PEF, and albuterol use were also similar between the two formulations.","Pre-dose FEV1, FVC, PEF, albuterol formulations.",C0439565|G0000000|C3714541|C0030771|C0001927|C0524527
"Time to first E.coli positive culture or to first urine culture >100,000 cfu/ml was no different between the three groups and history of UTI did not change this association (see Table 1).","Time E.coli positive culture urine culture >100,000 cfu/ml history UTI change association (see Table 1).",C0040223|C0014834|C0439178|C0010453|C0042036|C0010453|C1442061|C0439361|C0019664|C0042029|C0392747|C0004083|C0042789|C0039224|G0000000
"During the six-week follow-up period, secondary ED visits, hospital re-admissions, repeated needs for steroids or dosage increase, needs for antibiotics, white blood cell count (WBC), PCT levels and FEV1% were assessed.","During six-week follow-up period, secondary ED visits, hospital re-admissions, repeated steroids dosage increase, antibiotics, white blood cell count (WBC), PCT levels FEV1% assessed.",G0000000|C0205452|C0589120|C0439531|C0027627|C3538926|C0545082|C0019994|C1548168|C0205341|C0038317|C0178602|C0442805|C0003232|C0007457|C0005767|C0007634|C0750480|C0023516|C1535922|C0441889|G0000000|C1516048
We also obtained the name and location of the bridge associated with the suicide.,We location bridge suicide.,G0000000|C0450429|C0456378|C0038661
"The NNT to achieve a ≥50% reduction in mean pain score in these previous studies ranged from 7 to 12 [10,12,14] (compared with 10 in this study).","The NNT achieve ≥50% reduction pain score previous studies ranged 7 12 [10,12,14] (compared 10 study).",G0000000|C1417750|G0000000|G0000000|C0301630|C0030193|C0449820|C0205156|C0947630|C1514721|G0000000|C0450371|C0450371|C1707455|C0450371|C0557651
The same tester examined the participant at baseline and at 16 weeks.,The tester examined participant baseline 16 weeks.,G0000000|C0183885|C0332128|C0679646|C0168634|C0450371|C0439230
"A statistically superior improvement in FEV1 for indacaterol versus placebo was also observed at all individual post-baseline time points on Day 1 and Week 12, with improvements versus placebo for FEV1 AUCs between 5 min and 1 h, 5 min and 4 h, and 1 and 4 h post-dose.","A statistically superior improvement FEV1 indacaterol versus placebo observed individual post-baseline time Day 1 Week 12, improvements versus placebo FEV1 AUCs 5 min 1 h, 5 min 4 h, 1 4 post-dose.",G0000000|C0038215|C1282910|C2986411|G0000000|C1722260|G0000000|C0032042|C1441672|C0027361|C0687676|C0040223|C0332173|G0000000|C0332174|C0450371|C2986411|G0000000|C0032042|G0000000|C0376690|G0000000|C0702093|G0000000|C0033727|G0000000|C0702093|G0000000|C0033727|G0000000|G0000000|C0439568
"We found no significant differences among the treatment arms in terms of the summary of adverse effects or the frequency of severe adverse effects at weeks 4, 12, and 30 (Table 3; P > .05).","We differences treatment arms terms summary adverse effects frequency severe adverse effects weeks 4, 12, 30 (Table 3; P > .05).",G0000000|C1705241|C0039798|C0206655|C0233324|C1552616|G0000000|C1280500|C0376249|C0205082|G0000000|C1280500|C0439230|G0000000|C0450371|C0450371|C0039224|G0000000|C0369773|G0000000|C0450371
"IDUs surveyed from January 1, 2001, to June 31, 2002, comprised the preintervention sample and those surveyed from July 1, 2002, to September 1, 2004, comprised the postintervention sample.","IDUs surveyed January 1, 2001, June 31, 2002, comprised preintervention sample surveyed July 1, 2002, September 1, 2004, comprised postintervention sample.",C0020811|C0038951|C3829466|G0000000|G0000000|C3829443|C0450371|G0000000|C2700400|C2347663|C0370003|C0038951|C3829447|G0000000|G0000000|C3828193|G0000000|G0000000|C2700400|G0000000|C0370003
"According to the results, a significant difference was observed in the overall breast engorgement severity in the intervention group (P < .001).","According results, difference observed breast engorgement severity intervention (P < .001).",C0680240|C1274040|C1705241|C1441672|C0006141|C0020452|C0439793|C0886296|C0369773|G0000000|C1442061
"Assuming non-responders had lapsed, one-month point prevalence of abstinence was claimed by 30% of intervention customers and 24% of controls (p = 0.12); four months' continuous abstinence was claimed by 16% of intervention customers and 11% of controls (p = 0.094); and nine months' continuous abstinence was claimed by 12% of intervention customers and 7% of controls (p = 0.089).","Assuming non-responders lapsed, one-month prevalence abstinence claimed 30% intervention customers 24% controls (p = 0.12); months' continuous abstinence claimed 16% intervention customers 11% controls (p = 0.094); months' continuous abstinence claimed 12% intervention customers 7% controls (p = 0.089).",G0000000|C1518422|G0000000|C4082115|C0033105|C3843422|G0000000|C0450371|C0886296|C2981734|C0450371|C0243148|C0369773|G0000000|C0450371|C0439231|C0549178|C3843422|G0000000|C0450371|C0886296|C2981734|C0450371|C0243148|C0369773|G0000000|C1442061|C0439231|C0549178|C3843422|G0000000|C0450371|C0886296|C2981734|G0000000|C0243148|C0369773|G0000000|C1442061
"Trachoma, caused by ocular infection with the intracellular bacterium Chlamydia trachomatis, is the leading infectious cause of blindness worldwide.","Trachoma, caused ocular infection intracellular bacterium Chlamydia trachomatis, leading infectious blindness worldwide.",C0040592|C0015127|C0015392|C0009450|C0175996|C0004611|C0008148|C2893398|C0332152|C0009450|C0456909|G0000000
"Fasting lipids including total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides (TG) were measured at baseline (prior to tea intervention) and again at 6 months utilising the Cholestech LDX System (Hayward, CA), according to the manufacturer’s instructions.","Fasting lipids including total cholesterol, density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides (TG) measured baseline (prior tea intervention) 6 months utilising Cholestech LDX System (Hayward, CA), manufacturer’s instructions.",C0015663|C0023779|C0332257|C0439175|C0008377|C0178587|C0023820|C3715113|C0205251|C0178587|C0023820|G0000000|C0041004|C0337445|C0444706|C0168634|C0332152|C0039400|C0886296|G0000000|C0439231|G0000000|G0000000|G0000000|C0449913|G0000000|C3887642|G0000000|C0302828
"Falls are a serious problem among older people, with 30% of people aged 65 years or more falling at least once a year.","Falls people, 30% people aged 65 falling year.",C0000921|C0027361|C0450371|C0027361|C0001779|C0450371|C0000921|C0439234
"The cost of treatment was calculated according to the following factors: 1) Dressing unit cost: including the dressing change workload, gauze, and AgZnSD cream.","The cost treatment calculated factors: 1) Dressing unit cost: including dressing change workload, gauze, AgZnSD cream.",G0000000|C0010186|C0039798|C0444686|C1521761|G0000000|C0013119|C0439148|C0010186|C0332257|C0013119|C0392747|C0085122|C0590323|G0000000|C0700385
"Secondary endpoints were % children with CDC C or with CD4 < 15%, growth, median CD4%, median viral load, ART savings and ART-related adverse events.","Secondary endpoints % children CDC C CD4 < 15%, growth, median CD4%, median viral load, ART savings ART-related adverse events.",C0027627|C2349179|G0000000|C0008059|C0007670|G0000000|C0285590|G0000000|C0450371|C0018270|C0549183|C0285590|C0549183|C0521026|C1550025|C0003826|C0036245|C0003826|G0000000|C0441471
"However, there were no significant differences in responder or imputed quit rates at 6 or 12 months, or rates of relapse.","However, differences responder imputed quit rates 6 12 months, rates relapse.",G0000000|C1705241|G0000000|C2699638|C0748223|C0871208|G0000000|G0000000|C0871208|C0035020
"Outcomes were QOL, symptom impact, mood, 1-year survival, and resource use (hospital/intensive care unit days, emergency room visits, chemotherapy in last 14 days, and death location).","Outcomes QOL, symptom impact, mood, 1-year survival, resource (hospital/intensive care unit days, emergency visits, chemotherapy 14 days, death location).",C1274040|C0518214|C1457887|C1825598|C0026516|C0439234|C0038952|C0035201|C0019994|C1947933|C0439148|C0439228|C0013956|C0545082|C0013216|C0450371|C0439228|C0011065|C0450429
"The Primary end-point is the composite of total mortality, first non-fatal recurring AMI, stroke and revascularization.","The Primary end-point composite total mortality, non-fatal recurring AMI, stroke revascularization.",G0000000|C0205225|C2349179|C0205199|C0439175|C0026565|C1518422|C0034897|G0000000|C0038454|C0581603
"Generally, older patients demonstrate a lower response rate, reduced survival and increased toxicity, although the majority of large randomised trials exclude older patients.","Generally, patients demonstrate lower response rate, reduced survival increased toxicity, majority randomised trials exclude patients.",G0000000|C0030705|G0000000|C0441994|C0871261|C0871208|C0392756|C0038952|C0205217|C0040539|C0680220|G0000000|C0008976|C0332196|C0030705
The primary outcome was severity and incidence of AAD.,The primary outcome severity incidence AAD.,G0000000|C0205225|C1274040|C0439793|C0021149|G0000000
"Therefore, it can be concluded that there is a higher probability of bacterial colonization in those regions where the skin is more wrinkled.","Therefore, concluded probability bacterial colonization regions skin wrinkled.",G0000000|C0917903|C0033204|C0521009|G0000000|C0017446|C0444099|C0037301
"To be considered a success, the subject had to meet 2 criteria: survival for 42 days after randomization and clinical response of the study-qualifying infection, also evaluated at 42 days.","To considered success, subject meet 2 criteria: survival 42 days randomization clinical response study-qualifying infection, evaluated 42 days.",C0040363|C0750591|C0597535|C0681850|C1550543|G0000000|C0243161|C0038952|C0450371|C0439228|C0034656|C0205210|C0871261|C0557651|C0009450|C0220825|C0450371|C0439228
"The initial phase of the study will randomly allocate participants to receive active TENS, placebo TENS, or standard care (no TENS).","The initial phase study randomly allocate participants receive active TENS, placebo TENS, standard care (no TENS).",G0000000|C0205265|C0205390|C0557651|G0000000|G0000000|C0679646|C1514756|C0205177|C0014518|C0032042|C0014518|C1442989|C1947933|G0000000|C0014518
"These beneficial effects of QVA149 on lung function were paralleled by statistically significant improvements in other clinically important end-points: dyspnoea, health status and patient symptoms and reduced rescue medication use.","These beneficial effects QVA149 lung function paralleled statistically improvements clinically end-points: dyspnoea, health status patient symptoms reduced rescue medication use.",G0000000|G0000000|C1280500|G0000000|C0024109|C0031843|C2348042|C0038215|C2986411|G0000000|C2349179|C0013404|C0018684|C0449438|C0030705|C0683368|C0392756|G0000000|C0013227|C0042153
A score of ≥ 5 represents impaired sleep quality.,A score ≥ 5 represents impaired sleep quality.,G0000000|C0449820|G0000000|G0000000|C1882932|C0221099|C0037313|C0332306
The patients’ depression levels were assessed by using the self-rating depression scale developed by Zung [20].,The patients’ depression levels assessed self-rating depression scale developed Zung [20].,G0000000|G0000000|C0011570|C0441889|C1516048|C4054119|C0011570|C0175659|G0000000|G0000000|C0450371
Cardiorespiratory fitness is being assessed with the steep ramp test (an incremental bicycle ergometer test) and a cycle endurance test.,Cardiorespiratory fitness assessed steep ramp test (an incremental bicycle ergometer test) cycle endurance test.,G0000000|C1456706|C1516048|G0000000|C0034646|C0022885|G0000000|C1705117|C0005375|C0180748|C0022885|C1511572|C0518031|C0022885
"The Action4 software package (Ambulatory Monitoring, Inc.), which incorporates Cole and Kripke’s31 sleep scoring algorithm, was used to score sleep/wake.","The Action4 software package (Ambulatory Monitoring, Inc.), incorporates Cole Kripke’s31 sleep scoring algorithm, score sleep/wake.",G0000000|G0000000|C0037585|C0013194|C0439841|C0150369|G0000000|G0000000|G0000000|G0000000|C0037313|C0449820|C0002045|C0449820|C0037313
"Follow-up information, at 3 and 6 months, was collected via self-completed questionnaires.","Follow-up information, 3 6 months, collected self-completed questionnaires.",C0589120|C1533716|G0000000|G0000000|C0439231|C1516695|C0036588|C0034394
"However, a number of the pretreatment outcome variables differed between participants assigned to the two treatment conditions, such that those assigned to the HYP treatment reported significantly more average daily pain intensity, Mean (SD) = 5.72 (1.87) versus 3.95 (2.04), t(35) = 2.71, p < .05; less perceived control over pain, Mean (SD) Survey of Pain Attitudes Control scale score = 1.70 (0.90) versus 2.41 (0.87), t(35) = 2.34, p < .05; more depression, Mean (SD) Center for Epidemiological Studies Depression scale score = 21.99 (11.68) versus 11.64 (8.37), t(35) = 2.89, p < .01; and more pain interference, Mean (SD) Brief Pain Inventory Pain Interference scale score = 4.91 (2.46) versus 3.01 (2.59), t (35) = 2.24, p < .05; than those assigned to the BIO condition.","However, pretreatment outcome variables differed participants assigned treatment conditions, assigned HYP treatment reported average daily pain intensity, Mean (SD) = 5.72 (1.87) versus 3.95 (2.04), t(35) = 2.71, < .05; perceived control pain, Mean (SD) Survey Pain Attitudes Control scale score = 1.70 (0.90) versus 2.41 (0.87), t(35) = 2.34, < .05; depression, Mean (SD) Center Epidemiological Studies Depression scale score = 21.99 (11.68) versus 11.64 (8.37), t(35) = 2.89, < .01; pain interference, Mean (SD) Brief Pain Inventory Pain Interference scale score = 4.91 (2.46) versus 3.01 (2.59), (35) = 2.24, < .05; assigned BIO condition.",G0000000|C1550147|C1274040|C0439828|G0000000|C0679646|C1516050|C0039798|C0012634|C1516050|C0733682|C0039798|C0684224|C1510992|C0332173|C0030193|C0522510|C0444504|G0000000|G0000000|C0450371|C0450371|G0000000|C0450371|C0450371|C2603360|G0000000|C0450371|G0000000|C0450371|C0030971|C0243148|C0030193|C0444504|G0000000|C0038951|C0030193|C0004271|C0243148|C0175659|C0449820|G0000000|C0450371|C0450371|G0000000|C0450371|C0450371|C2603360|G0000000|C0450371|G0000000|C0450371|C0011570|C0444504|G0000000|C0205099|C0014507|C0947630|C0011570|C0175659|C0449820|G0000000|C0450371|C0450371|G0000000|C0450371|C0450371|C2603360|G0000000|C0450371|G0000000|C0450371|C0030193|C0521102|C0444504|G0000000|C1282927|C0030193|C0021941|C0030193|C0521102|C0175659|C0449820|G0000000|C0450371|C0450371|G0000000|C0450371|C0450371|C0450371|G0000000|C0450371|G0000000|C0450371|C1516050|C3844595|C0012634
No other adverse effects of the intervention were reported.,No adverse effects intervention reported.,G0000000|G0000000|C1280500|C0886296|C0684224
"Model outcomes included all cold drink sales per attendance, SSB sales per attendance, non-SSB sales per attendance, non-SSB sales per attendance (excluding water and juice), non-SSB fruit juice, non-SSB water and volume of SSB sold per attendance.","Model outcomes included cold drink sales attendance, SSB sales attendance, non-SSB sales attendance, non-SSB sales attendance (excluding water juice), non-SSB fruit juice, non-SSB water volume SSB sold attendance.",C3161035|C1274040|C0332257|C0009264|C0452428|C0036070|C2827364|C1420423|C0036070|C2827364|C1518422|C0036070|C2827364|C1518422|C0036070|C2827364|C0332196|C0043047|C1268568|C1518422|C0016767|C1268568|C1518422|C0043047|C0449468|C1420423|G0000000|C2827364
Adherence to the guidelines and clinical activity was assessed using patients' electronic medical records.,Adherence guidelines clinical activity assessed patients' electronic medical records.,C1510802|C0162791|C0205210|C0205177|C1516048|C0030705|C0013850|C0199168|C0034869
Knowledge of labour analgesia was assessed by asking women true/false questions at baseline and at first follow-up.,Knowledge labour analgesia assessed women true/false questions baseline follow-up.,C0376554|C0022864|C0002766|C1516048|C0043210|C0205238|C1522634|C0168634|C0589120
"Two items assessed adolescents’ smoking status at baseline and follow-ups: ever smoking, even just a puff, and number of days smoked in the past month.","Two items assessed adolescents’ smoking status baseline follow-ups: smoking, puff, days smoked month.",C0205448|C1551338|C1516048|G0000000|C0037369|C0449438|C0168634|C0332283|C0037369|C1533107|C0439228|C0037366|C0332177
Visual perception was measured using the motor free visual perception test (MVPT).,Visual perception measured motor free visual perception test (MVPT).,C0234621|C0030971|C0444706|C1513492|C0332296|C0234621|C0030971|C0022885|G0000000
"Refractive error and axial length data were obtained at 6-month intervals using cycloplegic autorefraction and partial coherence interferometry, respectively.","Refractive error axial length data 6-month intervals cycloplegic autorefraction partial coherence interferometry, respectively.",C0429585|C0743559|C0205131|C1444754|C1511726|C0332177|C1272706|C0010586|G0000000|C0728938|C4068804|C0021730|G0000000
Daytime sleepiness was assessed with ESS.,Daytime sleepiness assessed ESS.,C0332169|C0013144|C1516048|C0206630
"Demographic Characteristics of the Children Who Underwent Testing, According to Study Component.","Demographic Characteristics Children Who Underwent Testing, According Study Component.",C0011298|C1521970|C0008059|G0000000|G0000000|C0039593|C0680240|C0557651|C0449432
"Nevertheless, we think that our results support the idea that improved metabolic and extracellular fluid volume control ameliorate the deleterious effect of chronic kidney disease on the cardiovascular neurologic balance.","Nevertheless, support idea improved metabolic extracellular fluid volume control ameliorate deleterious chronic kidney disease cardiovascular neurologic balance.",G0000000|C0183683|C1512612|C0184511|C0311400|C0521119|C0005889|C0449468|C0243148|G0000000|G0000000|C0205191|C0022646|C0012634|C0007226|C0205494|C0014653
"For secondary efficacy objectives, blink rate and corneal and conjunctival staining (Oxford grading 0–5 for both; Bron et al.","For secondary efficacy objectives, blink rate corneal conjunctival staining (Oxford grading 0–5 both; Bron al.",G0000000|C0027627|C1280519|C0018017|C0005757|C0871208|C0010031|C0009758|C0487602|G0000000|C0441800|G0000000|G0000000|G0000000|C0202311
Slowly progressive weight lifting compared with standard care reduced the incidence of physical function deterioration among survivors of breast cancer.,Slowly progressive weight lifting compared standard care reduced incidence physical function deterioration survivors breast cancer.,C0439834|C0205329|C0005910|C0206244|C1707455|C1442989|C1947933|C0392756|C0021149|C0031809|C0031843|C0868945|C0206194|C0006141|C0006826
"1) The primary aim of the Leiden Consortium on Individual Development (L-CID) is to study the effect of the VIPP-Twins on parental sensitivity and sensitive discipline of the primary parent, one month after the intervention and two years after the intervention (see Fig.","1) The primary aim Leiden Consortium Individual Development (L-CID) study VIPP-Twins parental sensitivity sensitive discipline primary parent, month intervention intervention (see Fig.",G0000000|G0000000|C0205225|C1947946|G0000000|C1513822|C0027361|C0243107|C0439394|C0557651|C0041427|C0030551|C0020517|C0020517|C0237070|C0205225|C0030551|C0332177|C0886296|C0886296|C0042789|C0349966
"Pain on the WOMAC and VAS increased in the placebo group, and decreased minimally in the vitamin D group on the VAS and WOMAC scale.","Pain WOMAC VAS increased placebo group, decreased minimally vitamin D VAS WOMAC scale.",C0030193|G0000000|C0042815|C0205217|C0032042|C0441833|C0205216|G0000000|C0042890|C0073187|C0042815|G0000000|C0175659
The radiographic criteria were as follows: no evidence of internal or external root resorption; no evidence of intraradicular or periapical bone loss; there is no widening of the periodontal ligament space; no more than one-third of a physiological root resorption.,The radiographic criteria follows: evidence internal external root resorption; evidence intraradicular periapical bone loss; widening periodontal ligament space; one-third physiological root resorption.,G0000000|C0444708|C0243161|C0332283|C3887511|C0205102|C0205101|C0040452|C2985494|C3887511|G0000000|C0729269|C0262950|C1517945|C0332464|C2960678|C0023685|C1883067|C0205447|C0205463|C0040452|C2985494
Survivors using antihypertensive medication were considered hypertensive.,Survivors antihypertensive medication considered hypertensive.,C0206194|C0003364|C0013227|C0750591|C0857121
The current study did not find significant changes in the other primary outcomes: anxiety and alertness.,The current study primary outcomes: anxiety alertness.,G0000000|C0521116|C0557651|C0205225|C1274040|C0003467|C1443086
"Mean (SD) plasma vitamin K1 values (in ng/ml) decreased in both groups over time, but were higher in the oral group at 14 and 56 days: 2.0 (1.6) v 1.3 (1.1) at 14 days; 0.5(0.3) v 0.5 (0.7) at 30 days; and 0.5 (0.8) v 0.2 (0.2) at 56days of life.","Mean (SD) plasma vitamin K1 values (in ng/ml) decreased time, oral 14 56 days: 2.0 (1.6) 1.3 (1.1) 14 days; 0.5(0.3) 0.5 (0.7) 30 days; 0.5 (0.8) 0.2 (0.2) 56days life.",C0444504|G0000000|C0032105|C0042890|G0000000|C0042295|G0000000|C0439275|C0205216|C0040223|C0442027|C0450371|C0450371|C0439228|G0000000|G0000000|G0000000|G0000000|C0450371|C0439228|G0000000|G0000000|G0000000|C0450371|C0439228|G0000000|G0000000|G0000000|G0000000|G0000000|C0376558
"Assessments (eg, of adverse effects) were conducted at baseline and at weeks 0, 4, 8, 12, 16, 20, 24, 30, 36, 42, 48, and 52 by telephone.","Assessments (eg, adverse effects) conducted baseline weeks 0, 4, 8, 12, 16, 20, 24, 30, 36, 42, 48, 52 telephone.",C1261322|C0013715|G0000000|C1280500|C0004927|C0168634|C0439230|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0039457
"Postoperative agitation was measured using a 4-point sedation scale (1 = calm, quiet, 2 = crying but can be consoled, 3 = crying, cannot be consoled, and 4 = agitated and thrashing around) (3).","Postoperative agitation measured 4-point sedation scale (1 = calm, quiet, 2 = crying consoled, 3 = crying, consoled, 4 = agitated thrashing around) (3).",C0032790|C0085631|C0444706|C1552961|C0235195|C0175659|G0000000|G0000000|C0522165|C0439654|G0000000|G0000000|C0010399|C3873699|G0000000|G0000000|C0010399|C3873699|G0000000|G0000000|C0085631|G0000000|G0000000|G0000000
Only four children (two in each arm) required courses of oral steroid throughout the study and there were no asthma-related hospital admissions during this time period.,Only children (two arm) required courses oral steroid study asthma-related hospital admissions time period.,C0205171|C0008059|C0205448|C0446516|C1514873|C0750729|C0442027|C0038317|C0557651|C0004096|C0019994|C0184666|C0040223|C0439531
(A) Progression-free survival (PFS); (B) overall survival (OS).,(A) Progression-free survival (PFS); (B) survival (OS).,G0000000|C0242656|C0038952|C0242792|G0000000|C0038952|C0229090
Another aliquot (0.5 mL) was placed in a tube coated with ethylenediaminetetraacetic acid for the estimation of haemoglobin.,Another aliquot (0.5 mL) tube coated ethylenediaminetetraacetic acid estimation haemoglobin.,G0000000|C1510844|G0000000|C0175730|C1522408|G0000000|C0001128|C0680844|C0019046
"Secondary endpoints comprised mean change in EDSS from randomisation to month 12; mean clinical global impression of change scored by the clinician (clinician-assessed Clinical Global Impression Scale (CGI)) and patient (subject-assessed Clinical Global Impression Scale (SGI)) at month 12; and mean changes from randomisation in the 12-item Multiple Sclerosis Walking Scale (MSWS), Short Form 36 Health Survey (SF-36) subscores, TW25, modified Fatigue Impact Scale (MFIS), nine-hole peg test (9-HPT) and Kurtzke EDSS functional subscores.","Secondary endpoints comprised change EDSS randomisation month 12; clinical global impression change scored clinician (clinician-assessed Clinical Global Impression Scale (CGI)) patient (subject-assessed Clinical Global Impression Scale (SGI)) month 12; randomisation 12-item Multiple Sclerosis Walking Scale (MSWS), Short Form 36 Health Survey (SF-36) subscores, TW25, modified Fatigue Impact Scale (MFIS), nine-hole peg test (9-HPT) Kurtzke EDSS functional subscores.",C0027627|C2349179|C2700400|C0392747|C0451246|C0034656|C0332177|C0450371|C0205210|C0205246|C0596764|C0392747|C0449820|C0871685|C0871685|C0205210|C0205246|C0596764|C0175659|C3639708|C0030705|C0681850|C0205210|C0205246|C0596764|C0175659|C0055635|C0332177|C0450371|C0034656|C0450371|C0439064|C0036429|C0080331|C0175659|C2347078|C1282927|C0348078|C0450371|C0018684|C0038951|C0037712|G0000000|G0000000|C0392747|C0015672|C1825598|C0175659|C3810705|C0205455|G0000000|C0022885|C1384672|G0000000|C0451246|C0205245|G0000000
"Complete success criteria included postoperative IOP value > 6 and ≤ 21 mmHg without additional medical or surgical treatment, stable corneal diameter, decreased corneal edema, improved corneal clarity, and stable or reversed cup disc/ratio.","Complete success criteria included postoperative IOP > 6 ≤ 21 mmHg additional medical surgical treatment, stable corneal diameter, decreased corneal edema, improved corneal clarity, stable reversed cup disc/ratio.",C0205197|C0597535|C0243161|C0332257|C0032790|C0595921|G0000000|G0000000|G0000000|C0450371|C0439475|C1524062|C0199168|C0543467|C0039798|C0205360|C0010031|C1301886|C0205216|C0010031|C0013604|C0184511|C0010031|C0486588|C0205360|C1555029|C1533124|C0180459
3 p<0.10 for interaction.,3 p<0.10 interaction.,G0000000|C0369773|C1704675
Tonzetich25 reported that VSC production is associated with the periodontal pocket depth and the presence of deep periodontal pockets.,Tonzetich25 reported VSC production periodontal pocket depth presence deep periodontal pockets.,G0000000|C0684224|G0000000|C0033268|C2960678|G0000000|C0205125|C0150312|C0205125|C2960678|G0000000
This was a retrospective record review comparing the changes in childhood TB case detection in intervention and control districts.,This retrospective record review comparing childhood TB detection intervention control districts.,G0000000|C0035363|C0034869|C0282443|C1707455|C0231335|G0000000|C1511790|C0886296|C0243148|G0000000
"The general scientific aims were to examine, in detail, the treatment effects of orthodontic interventions in comparison to normal growth effects in the control group in patients presenting functional unilateral posterior crossbite, specifically regarding: 1. the sagittal, vertical and transversal dimensions of the maxilla and mandible 2. the midline deviation between the anterior teeth of the maxilla and mandible 3. the sagittal overjet and vertical overbite.","The scientific aims examine, detail, treatment effects orthodontic interventions comparison normal growth effects control patients functional unilateral posterior crossbite, regarding: 1. sagittal, vertical transversal dimensions maxilla mandible 2. midline deviation anterior teeth maxilla mandible 3. sagittal overjet vertical overbite.",G0000000|C0036397|C1947946|G0000000|C1522508|C0039798|C1280500|C0332276|C0886296|C1707455|C0205307|C0018270|C1280500|C0243148|C0030705|C0205245|C0205092|C0205095|C0242385|G0000000|G0000000|C0205129|C0205128|C0205106|C0439534|C0024947|C0024687|G0000000|C0549183|C0012727|C0205094|C0040426|C0024947|C0024687|G0000000|C0205129|C0596028|C0205128|C1305740
"Outcomes were analyzed using linear regression models that adjusted for baseline values, defined as sputum density measured at screening and FEV1 measured at initiation of antibiotic treatment.","Outcomes analyzed linear regression models adjusted baseline values, defined sputum density measured screening FEV1 measured initiation antibiotic treatment.",C1274040|C0936012|C0205132|C0684320|C3161035|C0456081|C0168634|C0042295|C1704788|C0038056|C0178587|C0444706|C0220908|G0000000|C0444706|C0589507|C0003232|C0039798
"In addition to the 7-point frequency scale, we used a later version of CMAI where a 5-point disruptiveness scale is added (Cohen-Mansfield, 1991).","In addition 7-point frequency scale, version CMAI 5-point disruptiveness scale (Cohen-Mansfield, 1991).",G0000000|C0332287|C1552961|C0376249|C0175659|C0333052|G0000000|C1552961|C0332453|C0175659|G0000000|G0000000
We also recruited a random sample of families in each school to provide non-anonymous and more detailed data on intervention impact and family interactions relevant to the FC component.,We recruited random sample families school provide non-anonymous detailed data intervention impact family interactions relevant FC component.,G0000000|G0000000|C0034656|C0370003|C0015576|C0036375|C1999230|C1518422|C1522508|C1511726|C0886296|C1825598|C0015576|C1704675|C2347946|C2983605|C0449432
"Overall, secondary outcomes remained stable within the groups.","Overall, secondary outcomes remained stable groups.",C0282416|C0027627|C1274040|G0000000|C0205360|C0441833
Patients who develop delirium are evaluated daily by the observer to record delirium severity and duration until symptoms diminish.,Patients develop delirium evaluated daily observer record delirium severity duration symptoms diminish.,C0030705|G0000000|C0011206|C0220825|C0332173|C0870992|C0034869|C0011206|C0439793|C0449238|C0683368|C0205216
"The RA meets with the patient at 6, 12 and 24 months to collect self-report data and BP measurements using the automated BP device.","The RA meets patient 6, 12 24 months collect self-report data BP measurements automated BP device.",G0000000|C3538806|C1550543|C0030705|G0000000|C0450371|C0450371|C0439231|G0000000|C0681906|C1511726|C0037623|C0242485|C0205554|C0037623|C0025080
Study design Patients were screened for inclusion in the study by their SQ score base on the Pittsburgh Sleep Quality Index (PSQI).,Study design Patients screened inclusion study SQ score base Pittsburgh Sleep Quality Index (PSQI).,C0557651|C1707689|C0030705|C0220908|C0007637|C0557651|C0560749|C0449820|C0002055|G0000000|C0037313|C0332306|C0918012|C3697468
Unconjugated estriol was measured using the ELISA.,Unconjugated estriol measured ELISA.,C0522530|C0014927|C0444706|C0014441
"Mean quality of life scores before, during, and after treatment The efficacy of epirubicin and cisplatin both combined with gemcitabine is not significantly different in terms of progression-free survival and tumour response rates.","Mean quality life scores before, during, treatment The efficacy epirubicin cisplatin combined gemcitabine terms progression-free survival tumour response rates.",C0444504|C0332306|C0376558|C0449820|C0332152|G0000000|C0039798|G0000000|C1280519|C0014582|C0008838|C0205195|C0045093|C0233324|C0242656|C0038952|C0027651|C0871261|C0871208
"All teeth in three categories were followed up clinically and radiographically at 1, 3, 6 and 9 months post treatment and the findings were recorded on the prepared proforma Results: Clinically, 86.6% success rate was found in ferric sulfate group whereas 100% success rate was found in electrosurgical and diode laser groups.","All teeth categories clinically radiographically 1, 3, 6 9 months post treatment findings recorded prepared proforma Results: Clinically, 86.6% success rate ferric sulfate 100% success rate electrosurgical diode laser groups.",G0000000|C0040426|C0683312|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0439231|C0687676|C0039798|C2607943|C0034869|C4082130|G0000000|C1274040|G0000000|C0450371|C0597535|C0871208|C2346593|C0038720|C1442061|C0597535|C0871208|G0000000|C1707755|C0023089|C0441833
Morning blood samples collected were immediately centrifuged and stored at – 80°C until analyzed.,Morning blood samples collected centrifuged stored – 80°C analyzed.,C0332170|C0005767|C0370003|C1516695|C0179834|C1698986|G0000000|G0000000|C0936012
"The primary endpoint was the pathological complete response (pCR) rate, which was defined as no invasive cancer in the breast tissue specimen.","The primary endpoint pathological complete response (pCR) rate, defined invasive cancer breast tissue specimen.",G0000000|C0205225|C2349179|C0030664|C0205197|C0871261|C0032520|C0871208|C1704788|C0205281|C0006826|C0006141|C0040300|C0370003
"India alone accounts for a third of those without improved sanitation (814 million), nearly 60% of those who practice open defecation (626 million) [2], and a quarter of the world's deaths from diarrheal diseases among children aged less than 5 years [3].","India accounts improved sanitation (814 million), 60% practice defecation (626 million) [2], quarter world's deaths diarrheal diseases children aged 5 [3].",C0021201|C2741673|C0184511|C0036172|C1442061|C1881839|C0450371|C0237607|C0011135|C1442061|C1881839|G0000000|C2825406|C2700280|C0011065|C0011991|C0012634|C0008059|C0001779|G0000000|G0000000
"Secondary outcomes are clinical function measured with the DASH Outcome Measure, pain scores, cosmetic aspects, quality of life and complications of the allocated treatment.","Secondary outcomes clinical function measured DASH Outcome Measure, pain scores, cosmetic aspects, quality life complications allocated treatment.",C0027627|C1274040|C0205210|C0031843|C0444706|C2827624|C1274040|C0079809|C0030193|C0449820|C0010164|C1547011|C0332306|C0376558|C0009566|G0000000|C0039798
The primary outcome will be change in systolic BP over twelve months.,The primary outcome change systolic BP twelve months.,G0000000|C0205225|C1274040|C0392747|C0039155|C0037623|C0205458|C0439231
Primary endpoint was the infection rate within 11 days after stroke onset.,Primary endpoint infection rate 11 days stroke onset.,C0205225|C2349179|C0009450|C0871208|C0450371|C0439228|C0038454|C0206132
Overall there is a reduction in both red cell transfusion and postoperative infection of around 40%; 30-day mortality and length of stay do not appear to be altered.,Overall reduction red cell transfusion postoperative infection 40%; 30-day mortality length stay altered.,C0282416|C0301630|C0332575|C0007634|C0005841|C0032790|C0009450|C0450371|C0450371|C0026565|C1444754|G0000000|C0392747
"When comparing this rise in systolic blood pressure obtained by the two groups, a trend towards significance was found (p=0.059).","When comparing rise systolic blood pressure groups, trend significance (p=0.059).",G0000000|C1707455|G0000000|C0039155|C0005767|C0033095|C0441833|C1521798|C0237881|C0369773
"The West Haven-Yale Multidimensional Pain Inventory (MPI) [27,28] is a 60-item questionnaire assessing pain intensity, interference of pain, life control, affective distress, social support, significant-other responses, and general activity levels.","The West Haven-Yale Multidimensional Pain Inventory (MPI) [27,28] 60-item questionnaire assessing pain intensity, interference pain, life control, affective distress, social support, significant-other responses, activity levels.",G0000000|C1705493|G0000000|C2347299|C0030193|C0021941|C0663932|C0450371|C0450371|C0034394|C1516048|C0030193|C0522510|C0521102|C0030193|C0376558|C0243148|G0000000|C0231303|C0728831|C0183683|C0682323|C0871261|C0205177|C0441889
The mean of pain score before intervention at CG was 4.43 cm.,The pain score intervention CG 4.43 cm.,G0000000|C0030193|C0449820|C0886296|C0043444|C0450371|G0000000
The primary outcome of the study was MCC as compared between HS and sham visits.,The primary outcome study MCC compared HS sham visits.,G0000000|C0205225|C1274040|C0557651|G0000000|C1707455|G0000000|C0068899|C0545082
"Among the ten patients who completed the treatment period, two had at least a 40% reduction in proteinuria.","Among ten patients completed treatment period, 40% reduction proteinuria.",G0000000|C0014518|C0030705|C0205197|C0039798|C0439531|C0450371|C0301630|C0033687
hospital admissions) can be monitored.,hospital admissions) monitored.,C0019994|C0184666|C0030695
"Enrolment data describing the characteristics of the recruited children (eg, sex, age, anthropometric measures, morbidity and breastfeeding status) and caregivers (eg, age, morbidity and breastfeeding status) will be reported as means±SD for continuous measures.","Enrolment data describing characteristics recruited children (eg, sex, age, anthropometric measures, morbidity breastfeeding status) caregivers (eg, age, morbidity breastfeeding status) reported means±SD continuous measures.",C1516879|C1511726|G0000000|C1521970|G0000000|C0008059|C0013715|C0009253|C0001779|C0003188|C0079809|C0026538|C0006147|C0449438|C0085537|C0013715|C0001779|C0026538|C0006147|C0449438|C0684224|G0000000|C0549178|C0079809
"Secondary outcomes included: Quantitative Electromyographic Kinesiology (QEK) for the pathophysiology domain, Ashworth, deep tendon reflexes (DTR), clonus, ankle dorsiflexion passive range of motion (PROM) and maximum voluntary torque (Max Torque) of the gastrocnemius muscle for the impairment domain.","Secondary outcomes included: Quantitative Electromyographic Kinesiology (QEK) pathophysiology domain, Ashworth, deep tendon reflexes (DTR), clonus, ankle dorsiflexion passive range motion (PROM) maximum voluntary torque (Max Torque) gastrocnemius muscle impairment domain.",C0027627|C1274040|C0332257|C0392762|G0000000|G0000000|G0000000|C0031847|C1880389|G0000000|C0205125|C0039508|C0034929|C3884528|C0009024|C0003086|G0000000|C3686820|C1514721|C0026597|C0015944|C0806909|C0439656|C0376590|G0000000|C0376590|C0242691|C0026845|C0221099|C1880389
(A) Weekly analysis of least squares mean change (± standard error) in Numeric Pain Rating Scale (NPRS) score from baseline for the integrated 30-minute treatment group.,(A) Weekly analysis squares change (± standard error) Numeric Pain Rating Scale (NPRS) score baseline integrated 30-minute treatment group.,G0000000|C0332174|C0002778|C0205120|C0392747|G0000000|C1442989|C0743559|C0237753|C0030193|C0871208|C0175659|C1417814|C0449820|C0168634|G0000000|C0450371|C0039798|C0441833
The numbers of sedentary hours/day were also estimated.,The sedentary hours/day estimated.,G0000000|C0205254|C0556974|C0750572
Knee extensor strength was measured using Biodex System 4 Pro (Biodex Medical Systems).,Knee extensor strength measured Biodex System 4 Pro (Biodex Medical Systems).,C0022742|C1184148|C0237897|C0444706|G0000000|C0449913|G0000000|C0033382|G0000000|C0199168|C0449913
"Clinical remission was defined as a clinical DAI ≤ 2, which even meets a more recent and stringent classification of patient defined endpoints [21].","Clinical remission defined clinical DAI ≤ 2, meets stringent classification patient defined endpoints [21].",C0205210|C0544452|C1704788|C0205210|C0683432|G0000000|G0000000|C1550543|G0000000|C0008902|C0030705|C1704788|C2349179|C0450371
"The Fibromyalgia Impact Questionnaire (FIQ) is a reliable, validated self- assessment questionnaire that measures the disease impact in patients with FM.","The Fibromyalgia Impact Questionnaire (FIQ) reliable, validated self- assessment questionnaire measures disease impact patients FM.",G0000000|C0016053|C1825598|C0034394|G0000000|C3858758|G0000000|C0036588|C1261322|C0034394|C0079809|C0012634|C1825598|C0030705|C3540627
"Efficacy variables that were based on assessment instruments administered over the course of weekly assessments in the study, including the YMRS, the CDRS-R, and the Children's Global Assessment Scale (CGAS),28 were analyzed primarily on the basis of mean change from baseline to end-of-study scores according to LOCF methods.","Efficacy variables based assessment instruments administered weekly assessments study, including YMRS, CDRS-R, Children's Global Assessment Scale (CGAS),28 analyzed basis change baseline end-of-study scores LOCF methods.",C1280519|C0439828|C1527178|C1261322|C0348000|C1521801|C0332174|C1261322|C0557651|C0332257|C3640523|C0205090|C0008059|C0205246|C1261322|C0175659|C0055633|C0936012|C1527178|C0392747|C0168634|C0444930|C0449820|C2825507|C0025663
"They had a partial ban if they allowed smoking in some places or at some times, and had a full ban if smoking was not allowed anywhere inside their home.","They partial ban allowed smoking times, ban smoking allowed inside home.",G0000000|C0728938|C0683610|C0683607|C0037369|C0040223|C0683610|C0037369|C0683607|G0000000|C0442519
"In this randomized clinical trial of 27 patients with mycosis fungoides, 70% of patients had complete response after 12 to 24 weeks of psoralen–UV-A treatment, maintenance therapy prolonged the median disease-free remission, and certain inflammatory mediators of the serum were associated with clinical outcome.","In randomized clinical trial 27 patients mycosis fungoides, 70% patients complete response 12 24 weeks psoralen–UV-A treatment, maintenance therapy prolonged median disease-free remission, inflammatory mediators serum clinical outcome.",G0000000|C0034656|C0205210|C0008976|C0450371|C0030705|C0026946|G0000000|C0450371|C0030705|C0205197|C0871261|C0450371|C0450371|C0439230|G0000000|C0039798|C0024501|C0039798|C0439590|C0549183|C0012634|C0544452|C0333348|C0127400|C0229671|C0205210|C1274040
"There were no differences in morbidity between the phases, as indicated by the Glasgow outcome scale and functional independence measure at discharge and 6 months after discharge.","There differences morbidity phases, Glasgow outcome scale functional independence measure discharge 6 months discharge.",G0000000|C1705241|C0026538|C0585064|G0000000|C1274040|C0175659|C0205245|C0085862|C0079809|C0012621|G0000000|C0439231|C0012621
"Neither were there differences between the groups on any of the secondary outcome measures: activities of daily living level of independence (activities of daily living Barthel Index), the Functional Limitation Profile or the more sensitive motor measures of grip strength or speed of performance on the timed manual dexterity task (Table 3).","Neither differences secondary outcome measures: activities daily living level independence (activities daily living Barthel Index), Functional Limitation Profile sensitive motor measures grip strength speed performance timed manual dexterity task (Table 3).",G0000000|C1705241|C0027627|C1274040|C0079809|C0441655|C0332173|C0376558|C0441889|C0085862|C0441655|C0332173|C0376558|G0000000|C0918012|C0205245|C0449295|C1979963|C0020517|C1513492|C0079809|C0021400|C0237897|C0678536|C0597198|C0392761|C0024763|C0565699|C3540678|C0039224|G0000000
Yet improving women’s knowledge is important.,Yet improving women’s knowledge important.,G0000000|C1272745|G0000000|C0376554|C3898777
"By 31 December 2007, various biological indicators had been monitored in each of the selected counties: serum folate and homocysteine.","By 31 December 2007, biological indicators monitored selected counties: serum folate homocysteine.",G0000000|C0450371|C3830550|G0000000|C0005532|C0021212|C0030695|C1707391|C0079170|C0229671|C0178638|C0019878
"The goal of rehabilitation is to increase function and for this reason, we selected the shortened version of the Chedoke Arm & Hand Activity Inventory (CAHAI-7) as the primary outcome measure.","The goal rehabilitation increase function reason, selected shortened version Chedoke Arm & Hand Activity Inventory (CAHAI-7) primary outcome measure.",G0000000|C0018017|C0034991|C0442805|C0031843|C0392360|C1707391|C1282927|C0333052|G0000000|C0446516|G0000000|C0018563|C0205177|C0021941|G0000000|C0205225|C1274040|C0079809
Reference to population-based cancer registries identified 110 incident cases of prostate cancer (7 years of follow-up with 121 543 person-years).,Reference population-based cancer registries identified 110 incident prostate cancer (7 follow-up 121 543 person-years).,C1514811|C0032659|C0006826|C0034975|C0205396|C1442061|C1551358|C0033572|C0006826|G0000000|C0589120|G0000000|C0027361
"The primary efficacy outcome is time to first event of cardiovascular death, myocardial infarction, stroke, coronary revascularization or hospitalization for unstable angina.","The primary efficacy outcome time event cardiovascular death, myocardial infarction, stroke, coronary revascularization hospitalization unstable angina.",G0000000|C0205225|C1280519|C1274040|C0040223|C0441471|C0007226|C0011065|C0027061|C0021308|C0038454|C0018787|C0581603|C0019993|C0443343|C0002962
"Cigarette consumption, motivation to quit, confidence in ability to quit.","Cigarette consumption, motivation quit, confidence ability quit.",C0677453|C0009830|C0026605|C0748223|C0237529|C0085732|C0748223
"Using a 10-point scale (1 = mild to 10 = very severe), women recorded hot flash severity twice per day (the average severity of hot flashes experienced during the morning and again in the evening) and an approximate number of hot flashes for the entire day.","Using 10-point scale (1 = mild 10 = severe), women recorded hot flash severity day (the average severity hot flashes experienced morning evening) approximate hot flashes entire day.",C1524063|C0450371|C0175659|G0000000|G0000000|C2945599|C0450371|G0000000|C0205082|C0043210|C0034869|C0444519|C0181637|C0439793|C0332173|G0000000|C1510992|C0439793|C0444519|C0085635|C0237607|C0332170|C0587117|C0332232|C0444519|C0085635|C0439751|C0332173
Main outcome will be mean urinary cotinine test differences between the two groups at 12 months.,Main outcome urinary cotinine test differences 12 months.,C0205225|C1274040|C0042027|C0010194|C0022885|C1705241|C0450371|C0439231
"Peri eff, pericardial effusion; LV, left ventricle; RV, right ventricle.","Peri eff, pericardial effusion; LV, left ventricle; RV, ventricle.",C0347985|G0000000|C0031050|C0013687|C0023128|C0205091|C0018827|C0035190|C0018827
"The CIMT combined with mirror therapy group showed higher improvement than CIMT only group in box and block test, 9-hole Pegboard test, and grip strength, which represent fine motor functions of the upper extremity.","The CIMT combined mirror therapy improvement CIMT box block test, 9-hole Pegboard test, grip strength, represent fine motor functions upper extremity.",G0000000|G0000000|C0205195|C0181868|C0039798|C2986411|G0000000|C0179400|C0028778|C0022885|C0544726|G0000000|C0022885|C0021400|C0237897|C1882932|C0205232|C1513492|C0542341|C1282910|C0015385
"To examine neurological defects, we used the Glasgow coma scale (GCS), Barthel index, and mRS neurologic disability scoring systems.","To examine neurological defects, Glasgow coma scale (GCS), Barthel index, mRS neurologic disability scoring systems.",C0040363|G0000000|C0205494|C0243067|G0000000|C0009421|C0175659|G0000000|G0000000|C0918012|C1522706|C0205494|C0231170|C0449820|C0449913
"Aclidinium significantly delayed the time to first moderate or severe exacerbation compared with placebo in ACCLAIM/COPD II, but not in ACCLAIM/COPD I.","Aclidinium delayed time moderate severe exacerbation compared placebo ACCLAIM/COPD II, ACCLAIM/COPD I.",C2699757|C0205421|C0040223|C0205081|C0205082|G0000000|C1707455|C0032042|C0024117|G0000000|C0024117|C0021966
Visual Analogue Rating (VAS).,Visual Analogue Rating (VAS).,C0234621|C0243071|C0871208|C0042815
"The primary outcome of the study was independence in physical and cognitive activities as assessed by FIM,17 which was recorded at admission and discharge from the stroke unit and at two and six months after randomisation.","The primary outcome study independence physical cognitive activities assessed FIM,17 recorded admission discharge stroke unit months randomisation.",G0000000|C0205225|C1274040|C0557651|C0085862|C0031809|C1516691|C0441655|C1516048|C3273671|C0034869|C0184666|C0012621|C0038454|C0439148|C0439231|C0034656
Overall vaccine uptake was low.,Overall vaccine uptake low.,C0282416|C0042210|C0243144|C0205251
"Results: There were no significant differences at the end of the 1 year study period between the two treatment groups in percentage of symptom-free days (mean difference 2.5%; 95% CI -8.8 to 13.8), airway hyperresponsiveness (log10 PD20 0.06; -0.19 to 0.32), functional health status (10.1; -0.3 to 19.8), disease specific quality of life of patients (0.08; -0.9 to 0.7), and disease specific quality of life of caregivers (0.09; -0.2 to 0.3), nor in any other outcome parameters.","Results: There differences 1 study period treatment percentage symptom-free days (mean difference 2.5%; 95% CI -8.8 13.8), airway hyperresponsiveness (log10 PD20 0.06; -0.19 0.32), functional health status (10.1; -0.3 19.8), disease specific quality life patients (0.08; -0.9 0.7), disease specific quality life caregivers (0.09; -0.2 0.3), outcome parameters.",C1274040|G0000000|C1705241|G0000000|C0557651|C0439531|C0039798|C0439165|C1457887|C0439228|C0444504|C1705241|G0000000|C0450371|C0008107|G0000000|C0450371|C0178987|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0205245|C0018684|C0449438|C0450371|G0000000|C0450371|C0012634|C0205369|C0332306|C0376558|C0030705|C0450371|G0000000|G0000000|C0012634|C0205369|C0332306|C0376558|C0085537|C0450371|G0000000|G0000000|C1274040|C0449381
Concomitant disease progression was documented in only one patient.,Concomitant disease progression documented patient.,C0521115|C0012634|C0242656|C1301725|C0030705
The primary outcome variables are maternal sensitivity and child responsiveness as changed from baseline to postintervention.,The primary outcome variables maternal sensitivity child responsiveness changed baseline postintervention.,G0000000|C0205225|C1274040|C0439828|C2347083|C0020517|C0008059|C0205342|C0392747|C0168634|G0000000
Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.,Changes WHO functional class Borg dyspnoea score incidence clinical worsening differ.,C0392747|G0000000|C0205245|C0456387|G0000000|C0013404|C0449820|C0021149|C0205210|C0332271|G0000000
"The comparison between the two groups showed no significant differences with FPG and HbA1c, but there were significant differences in insulin levels and HOMA-IR (16.6 ± 5.9; 3.7 ± 1.5, resp.).","The comparison differences FPG HbA1c, differences insulin levels HOMA-IR (16.6 ± 5.9; 3.7 ± 1.5, resp.).",G0000000|C1707455|C1705241|G0000000|G0000000|C1705241|C0021641|C0441889|C0022065|C0450371|G0000000|G0000000|G0000000|G0000000|G0000000|C0231832
The primary outcome was self-reported use of emergency contraception.,The primary outcome self-reported emergency contraception.,G0000000|C0205225|C1274040|C0681906|C0013956|C0700589
"Secondary end points included characterisation of toxicities, objective RR and progression-free survival (PFS).","Secondary included characterisation toxicities, objective RR progression-free survival (PFS).",C0027627|C0332257|C1880022|C0600688|C0018017|G0000000|C0242656|C0038952|C0242792
"Measurement of infant development was performed at 6 mo of age using the Bayley Scales of Infant and Toddler Development, 3rd edition (BSID III) [31].","Measurement infant development performed 6 mo age Bayley Scales Infant Toddler Development, 3rd edition (BSID III) [31].",C0242485|C0021270|C0243107|C0884358|G0000000|C0026544|C0001779|G0000000|C0175659|C0021270|C0682053|C0243107|G0000000|C0441792|G0000000|C0439070|C0450371
Additional measurements could be made (up to a total of eight tests) if the first three were not acceptable.,Additional measurements (up total tests) acceptable.,C1524062|C0242485|G0000000|C0439175|C0022885|C1879533
"Prothrombin time (INR), plasma vitamin K1, and PIVKA II (undercarboxylated prothrombin) were monitored at 14, 30, and 56 days of age.","Prothrombin time (INR), plasma vitamin K1, PIVKA II (undercarboxylated prothrombin) monitored 14, 30, 56 days age.",C0033706|C0040223|C0525032|C0032105|C0042890|G0000000|C0950246|G0000000|G0000000|C0033706|C0030695|C0450371|C0450371|C0450371|C0439228|C0001779
"TF1-9, ocular infection, and anti-CT antibody responses were assessed at baseline and 12 months later.","TF1-9, ocular infection, anti-CT antibody responses assessed baseline 12 months later.",C0076364|C0015392|C0009450|C0007673|C0003241|C0871261|C1516048|C0168634|C0450371|C0439231|C0205087
"For children admitted with a MUAC <11.0 cm, recovery was defined as follows: a weight gain of at least 15%, MUAC >11.0 cm, no medical complication, the absence of bilateral pitting oedema and a minimum stay in the programme of 1 month (Government of Malawi and Ministry of Health 2007).","For children admitted MUAC <11.0 cm, recovery defined follows: weight gain 15%, MUAC >11.0 cm, medical complication, absence bilateral pitting oedema minimum stay programme 1 month (Government Malawi Ministry Health 2007).",G0000000|C0008059|C0184666|G0000000|G0000000|C0237820|C1704788|C0332283|C0005910|C1517378|C0450371|G0000000|G0000000|C0199168|C0009566|C0332197|C0238767|C0205323|C0013604|C1524031|G0000000|C1709697|G0000000|C0018104|C0024548|G0000000|C0018684|G0000000
"The investigational drug (blinded period) and IDEC-C2B8 (unblinded period) will be provided free of charge from the investigational drug provider, Zenyaku Kogyo Co., Ltd.","The investigational drug (blinded period) IDEC-C2B8 (unblinded period) provided free charge investigational drug provider, Zenyaku Kogyo Co., Ltd.",G0000000|C1517586|C0013227|C0150108|C0439531|G0000000|G0000000|C0439531|C1999230|C0332296|C0007961|C1517586|C0013227|C1138603|G0000000|G0000000|C3245499|C1136140
"Participants were sent follow-up assessments at 3 points: (1) 1 month after their anticipated delivery date, (2) 8 months postpartum, corresponding to the end of the intervention, and (3) 12 months postpartum.","Participants follow-up assessments 3 points: (1) 1 month anticipated delivery date, (2) 8 months postpartum, intervention, (3) 12 months postpartum.",C0679646|C0589120|C1261322|G0000000|C1552961|G0000000|G0000000|C0332177|C3840775|C0011209|C0011008|G0000000|G0000000|C0439231|C0086839|C0886296|G0000000|C0450371|C0439231|C0086839
"However, it did not show significant changes in tidal volume, which in contrast were significantly increased both at rest and during exercise in our study, unaccompanied by significant changes in VE or respiratory rate.","However, tidal volume, contrast increased rest exercise study, unaccompanied VE respiratory rate.",G0000000|G0000000|C0449468|C0009924|C0205217|C0035253|C0015259|C0557651|G0000000|C0042469|C0521346|C0871208
"Second, continuation ratio (CR) logit models were fit for continuous abstinence through weeks 8 and 26 postpartum with baseline measures of motivation as predictors.","Second, continuation ratio (CR) logit models fit continuous abstinence weeks 8 26 postpartum baseline measures motivation predictors.",C0205436|G0000000|C0456603|C0201975|G0000000|C3161035|C0036572|C0549178|C3843422|C0439230|G0000000|C0450371|C0086839|C0168634|C0079809|C0026605|C2698872
"Univariate regression analyses also indicated that meibum saturated FA levels (r2 = .06, P = .09), Schirmer scores (r2 = .09, P = .01), TBUT (r2 = .07, P = .10), meibomian gland stenosis (r2 = .11, P < .01), meibomian gland blockage (r2 = .20, P < .01), fluorescein staining (r2 = .09, P = .03), and rose bengal staining (r2 = .15, P < .01) were significantly correlated with meibum score.","Univariate regression analyses meibum saturated FA levels (r2 = .06, P = .09), Schirmer scores (r2 = .09, P = .01), TBUT (r2 = .07, P = .10), meibomian gland stenosis (r2 = .11, P < .01), meibomian gland blockage (r2 = .20, P < .01), fluorescein staining (r2 = .09, P = .03), rose bengal staining (r2 = .15, P < .01) correlated meibum score.",G0000000|C0684320|C0002778|G0000000|C0522534|G0000000|C0441889|C1425688|G0000000|C0450371|C0369773|G0000000|C0450371|C1875738|C0449820|C1425688|G0000000|C0450371|C0369773|G0000000|C0450371|G0000000|C1425688|G0000000|C0450371|C0369773|G0000000|C0450371|G0000000|C1285092|C0678234|C1425688|G0000000|C0450371|C0369773|G0000000|C0450371|G0000000|C1285092|C1706968|C1425688|G0000000|C0450371|C0369773|G0000000|C0450371|C0060520|C0487602|C1425688|G0000000|C0450371|C0369773|G0000000|C0450371|C0035853|C0444826|C0487602|C1425688|G0000000|C0450371|C0369773|G0000000|C0450371|C1707520|G0000000|C0449820
"Secondary: complete resolution at 48 hours, duration of moderately bad symptoms (based on a Likert scale, 0, normal; 6, as bad as it could be), visual analog symptom scales (0-100 mm; 0, no symptom to 100, worst imaginable), health care attendance, days missed from work or education, consumption of delayed antibiotics or other medications, adverse events.","Secondary: complete resolution 48 hours, duration moderately bad symptoms (based Likert scale, 0, normal; 6, bad be), visual analog symptom scales (0-100 mm; 0, symptom 100, worst imaginable), health care attendance, days missed education, consumption delayed antibiotics medications, adverse events.",C0027627|C0205197|C1514893|C0450371|C0439227|C0449238|C0205081|C0205169|C0683368|C1527178|G0000000|C0175659|G0000000|C0205307|G0000000|C0205169|G0000000|C0234621|C0243071|C1457887|C0175659|C1442061|G0000000|G0000000|C1457887|C1442061|C1522166|G0000000|C0018684|C1947933|C2827364|C0439228|C1705492|C0013621|C0009830|C0205421|C0003232|C0013227|G0000000|C0441471
Recurrence was defined as the reactivation of the disease within 1 year after apparent success upon treatment completion.,Recurrence defined reactivation disease 1 apparent success treatment completion.,C0034897|C1704788|G0000000|C0012634|G0000000|C0750489|C0597535|C0039798|C0205197
"Naturally, improvement of symptoms depression and individual commitment to carry out some behaviors in the long term would increase psychological well-being of the child.","Naturally, improvement symptoms depression individual commitment carry behaviors term increase psychological well-being child.",G0000000|C2986411|C0683368|C0011570|C0027361|C0870312|C0206243|C0004927|C0233324|C0442805|C0205486|C0018684|C0008059
"Median CD4+ T cell counts, plasma HIV RNA levels, and immune activation markers, by treatment arm.","Median CD4+ T cell counts, plasma HIV RNA levels, immune activation markers, treatment arm.",C0549183|C0285590|C2603360|C0007634|C0439157|C0032105|C0019682|C0035668|C0441889|C0439662|C1879547|C0005516|C0039798|C0446516
"Main outcome measures were: proportion of patients with active asthma reviewed within the previous 15 months (Quality and Outcomes Framework target), mode of review, enablement, morbidity, and costs to the practice.","Main outcome measures were: proportion patients active asthma reviewed previous 15 months (Quality Outcomes Framework target), mode review, enablement, morbidity, costs practice.",C0205225|C1274040|C0079809|G0000000|C1709707|C0030705|C0205177|C0004096|C0282443|C0205156|C0450371|C0439231|C0332306|C1274040|G0000000|C1521840|C1513371|C0282443|G0000000|C0026538|C0010186|C0237607
"Age, baseline BMI, and BMI change during the preceding year, baseline lung function and change during the preceding year, body composition, and CFQOL did not differ between patients with CFRD FH− and IGT.","Age, baseline BMI, BMI change preceding year, baseline lung function change preceding year, body composition, CFQOL patients CFRD FH− IGT.",C0001779|C0168634|G0000000|G0000000|C0392747|C0332152|C0439234|C0168634|C0024109|C0031843|C0392747|C0332152|C0439234|C0242821|C0486616|G0000000|C0030705|G0000000|G0000000|G0000000
Parents viewed the treatments as equally acceptable.,Parents viewed treatments equally acceptable.,C0030551|C0449911|C0087111|G0000000|C1879533
The Cornell-Brown QOL [26] was used to measure quality of life.,The Cornell-Brown QOL [26] measure quality life.,G0000000|C0678579|C0518214|C0450371|C0079809|C0332306|C0376558
"The Oucher has been tested for validity and reliability and is widely used for clinical and research purposes.22 The accompanying parent of the child, usually the mother, scored the level of pain they thought the child felt using the same scale, ignoring the score given by the child.","The Oucher tested validity reliability clinical purposes.22 The accompanying parent child, mother, scored level pain child scale, ignoring score child.",G0000000|G0000000|C0392366|C2349101|C2347947|C0205210|C1285529|G0000000|G0000000|C0030551|C0008059|C0026591|C0449820|C0441889|C0030193|C0008059|C0175659|C1554079|C0449820|C0008059
CIPNM is a common complication of critical illness associated with muscle weakness and prolonged duration of weaning and ICU stay.,CIPNM common complication critical illness muscle weakness prolonged duration weaning ICU stay.,G0000000|C0205214|C0009566|C1511545|C0221423|C0026845|C3714552|C0439590|C0449238|C0043084|C0021708|G0000000
The primary endpoints of the study were to evaluate the efficacy of um-PEA in 1) reducing IFN-β1a-related adverse effects in patients with RR-MS (pain and erythema width at the injection site); and 2) improving the patients’ QoL.,The primary endpoints study evaluate efficacy um-PEA 1) reducing IFN-β1a-related adverse effects patients RR-MS (pain erythema width injection site); 2) improving patients’ QoL.,G0000000|C0205225|C2349179|C0557651|C0220825|C1280519|C0030738|G0000000|C0392756|G0000000|G0000000|C1280500|C0030705|C0039676|C0030193|C0041834|C0487742|C0021485|C0205145|G0000000|C1272745|G0000000|C0518214
"Four patients were subsequently found to be unresponsive to methacholine on the screening bronchial challenge prior to randomization, while one patient had a FEV1 of below 60% predicted which precluded a methacholine challenge.","Four patients subsequently unresponsive methacholine screening bronchial challenge prior randomization, patient FEV1 60% predicted precluded methacholine challenge.",C0205450|C0030705|G0000000|C0205269|C0600370|C0220908|C0205039|C0798503|C0332152|C0034656|C0030705|G0000000|C0450371|C0681842|G0000000|C0600370|C0798503
Cancer-Related Mortality According to Type of Cancer.,Cancer-Related Mortality According Type Cancer.,C2826292|C0026565|C0680240|C0332307|C0006826
"A discrepancy was deemed present if a) medications that documentation indicated should be active were not on the list (unintended omission), b) medications were on list without documentation (unintended addition) or c) medications were found with different dose or frequency.","A discrepancy deemed a) medications documentation active list (unintended omission), b) medications list documentation (unintended addition) c) medications dose frequency.",G0000000|C1290905|G0000000|G0000000|C0013227|C0175636|C0205177|C0745732|C1283932|C3845736|G0000000|C0013227|C0745732|C0175636|C1283932|C0332287|G0000000|C0013227|C0178602|C0376249
"Outcome variables included HRQoL (German revised multi-dimensional disease-specific CFQ (CFQ-R)), body composition, pulmonary function, physical activity, short-term muscle power, and aerobic fitness by peak oxygen uptake and aerobic power.","Outcome variables included HRQoL (German revised multi-dimensional disease-specific CFQ (CFQ-R)), body composition, pulmonary function, physical activity, short-term muscle power, aerobic fitness peak oxygen uptake aerobic power.",C1274040|C0439828|C0332257|G0000000|C1556085|C1527075|C0439064|C0012634|G0000000|C0205090|C0242821|C0486616|C0024109|C0031843|C0031809|C0205177|C0443303|C0026845|C0032863|C1510824|C1456706|C0444505|C0030054|C0243144|C1510824|C0032863
"A one-sided test with a significance level of 0.025 was used for analyses other than mean pain score responders (patients with a ≥30% or ≥50% reduction in their mean pain score at final assessment) and PGIC, which used a two-sided test with significance level of 0.05.","A one-sided test significance level 0.025 analyses pain score responders (patients ≥30% ≥50% reduction pain score final assessment) PGIC, two-sided test significance level 0.05.",G0000000|C0205092|C0022885|C0237881|C0441889|C1442061|C0002778|C0030193|C0449820|G0000000|C0030705|G0000000|G0000000|C0301630|C0030193|C0449820|C0205088|C1261322|G0000000|C0205448|C0022885|C0237881|C0441889|C0450371
"NEC is defined according to modified Bell’s criteria stage > 2 with clinical signs and radiological evidence including any of the following: pneumatosis intestinalis, portal venous gas with or without pneumoperitoneum.","NEC defined modified Bell’s criteria stage > 2 clinical signs radiological evidence including following: pneumatosis intestinalis, portal venous gas pneumoperitoneum.",C0206695|C1704788|C0392747|G0000000|C0243161|G0000000|C0205210|C0220912|C0034599|C3887511|C0332257|C0231290|C0333139|G0000000|C0205054|C0042449|C0017110|C0032320
"Across sites, HMTW was implemented with 88% (SD = 4.7) of intended elements present in the group sessions and 89.9% (SD = 7.9) of intended elements in the individual sessions.","Across sites, HMTW implemented 88% (SD = 4.7) intended elements sessions 89.9% (SD = 7.9) intended elements individual sessions.",G0000000|C0205145|G0000000|G0000000|C0450371|G0000000|G0000000|G0000000|C1283828|C0013879|C1883016|C0450371|G0000000|G0000000|G0000000|C1283828|C0013879|C0027361|C1883016
"In addition, the mimicry of mAb WJ02 to CA125 on cellular immune response was detected by human peripheral blood cells.","In addition, mimicry mAb WJ02 CA125 cellular immune response detected human peripheral blood cells.",G0000000|C0332287|C0233577|C0003250|G0000000|G0000000|C0007634|C0439662|C0871261|C0442726|C0086418|C0205100|C0005767|C0007634
"A 10% decrease in FEV1 is considered to be indicative of healthy non-asthmatic subjects (18, 21–23), while a 15% or greater fall in FEV1 is considered by some investigators and guidelines as a diagnosis of EIB.","A 10% decrease FEV1 considered indicative healthy non-asthmatic subjects (18, 21–23), 15% fall FEV1 considered investigators guidelines diagnosis EIB.",G0000000|C0450371|C0392756|G0000000|C0750591|G0000000|C3898900|C1518422|C0681850|C0450371|G0000000|C0450371|C0085639|G0000000|C0750591|C0035173|C0162791|C0011900|G0000000
We utilised an intention to treat analysis for the analysis of family burden scores.,We utilised intention treat analysis analysis family burden scores.,G0000000|G0000000|C0162425|C0087111|C0002778|C0002778|C0015576|C2828008|C0449820
"Student self-reports of violence, provocative behavior, school delinquency, substance use, and sexual behaviors (intercourse and condom use).","Student self-reports violence, provocative behavior, school delinquency, substance use, sexual behaviors (intercourse condom use).",C0038492|C0681906|C0042693|C0449428|C0004927|C0036375|C0522174|C0439861|C0042153|C0036864|C0004927|C0009253|C0009653|C0042153
"Secondary objectives included efficacy against other virological and clinical endpoints associated with HPV-16/18 and other high-risk HPV types, immunogenicity and safety.","Secondary objectives included efficacy virological clinical endpoints HPV-16/18 high-risk HPV types, immunogenicity safety.",C0027627|C0018017|C0332257|C1280519|C0205466|C0205210|C2349179|C0021344|C0332167|C0021344|C0332307|C4054739|C0036043
"The primary outcome was the change in venous serum bicarbonate, as measure by total carbon dioxide by clinical chemistry automated analyzers via local laboratories, between baseline (hour 0) and hour 4.","The primary outcome change venous serum bicarbonate, measure total carbon dioxide clinical chemistry automated analyzers local laboratories, baseline (hour 0) hour 4.",G0000000|C0205225|C1274040|C0392747|C0042449|C0229671|C0005367|C0079809|C0439175|C0007009|C0678717|C0205210|C0007996|C0205554|C0179038|C0205276|C0022877|C0168634|C0439227|G0000000|C0439227|G0000000
The rate of healing of each measurable lesion was calculated by dividing the mean diameter before treatment by the time in weeks to complete healing.,The rate healing measurable lesion calculated dividing diameter treatment time weeks complete healing.,G0000000|C0871208|C0043240|C1513040|C0221198|C0444686|C0332849|C1301886|C0039798|C0040223|C0439230|C0205197|C0043240
5).,5).,G0000000
Data collection tool had two parts: first a questionnaire concerning demographic characteristics of respondents and the second instrument was using scale VAS pain questionnaires.,Data collection tool parts: questionnaire demographic characteristics respondents instrument scale VAS pain questionnaires.,C1511726|C1516698|C0336791|C0449719|C0034394|C0011298|C1521970|C0282122|C0348000|C0175659|C0042815|C0030193|C0034394
"Baseline characteristics of groups WMFT, Wolf Motor Function Test; BBT, Box and Block Test; MAL, Motor Activity Log.","Baseline characteristics WMFT, Wolf Motor Function Test; BBT, Box Block Test; MAL, Motor Activity Log.",C0168634|C1521970|G0000000|C0325001|C1513492|C0031843|C0022885|G0000000|C0179400|C0028778|C0022885|C3540595|C1513492|C0205177|C1708728
"Participants completed the outcome measures 3 and 6 months after completing the intervention (see Figure 1, Consort Diagram).","Participants completed outcome measures 3 6 months completing intervention (see Figure 1, Consort Diagram).",C0679646|C0205197|C1274040|C0079809|G0000000|G0000000|C0439231|C0205197|C0886296|C0042789|G0000000|G0000000|G0000000|C0681494
"The secondary outcome measures include: household nicotine level, the child’s lung function, airway inflammation and oxidative stress, presence of wheezing and questionnaires on respiratory symptoms, and quality of life.","The secondary outcome measures include: household nicotine level, child’s lung function, airway inflammation oxidative stress, presence wheezing questionnaires respiratory symptoms, quality life.",G0000000|C0027627|C1274040|C0079809|C0332257|C0020052|C0028040|C0441889|G0000000|C0024109|C0031843|C0178987|C0021368|C0311404|C0038435|C0150312|C0043144|C0034394|C0521346|C0683368|C0332306|C0376558
"Children in the cohort will be monitored for two years to determine clinical malaria incidence, malaria infection incidence, and prevalence of acute respiratory infections.","Children cohort monitored determine clinical malaria incidence, malaria infection incidence, prevalence acute respiratory infections.",C0008059|C0599755|C0030695|G0000000|C0205210|C0024530|C0021149|C0024530|C0009450|C0021149|C0033105|C0205178|C0521346|C3714514
"Absolute or relative non-transferrin bound iron levels were related to transfusional iron loading rates, liver iron concentration, 24-hour urine iron and response to chelation therapy over the subsequent year.","Absolute relative non-transferrin bound iron levels transfusional iron loading rates, liver iron concentration, 24-hour urine iron response chelation therapy subsequent year.",C0205344|C0080103|C1518422|C0332297|C0302583|C0441889|C0005841|C0302583|C1708715|C0871208|C0023884|C0302583|C0004268|C0450371|C0042036|C0302583|C0871261|C3537131|C0039798|C0332282|C0439234
"The primary end points of this study were feasibility and safety of the three-device method and X-Cone method compared with conventional laparoscopic cholecystectomy, as indicated by intraoperative and postoperative adverse events up to 1 mo, operative time, and estimated blood loss.","The primary study feasibility safety three-device method X-Cone method compared conventional laparoscopic cholecystectomy, intraoperative postoperative adverse events 1 mo, operative time, estimated blood loss.",G0000000|C0205225|C0557651|G0000000|C0036043|C0205449|C0025663|C0206428|C0025663|C1707455|C0439858|C0031150|C0008320|C0456904|C0032790|G0000000|C0441471|G0000000|C0026544|C1882154|C0040223|C0750572|C0005767|C1517945
"The primary outcome measure will be the need for blood transfusion and secondary endpoints will include post-operative recovery, length of hospital stay, health care utilisation and cost analysis.","The primary outcome measure blood transfusion secondary endpoints post-operative recovery, length hospital stay, health care utilisation cost analysis.",G0000000|C0205225|C1274040|C0079809|C0005767|C0005841|C0027627|C2349179|C0032790|C0237820|C1444754|C0019994|G0000000|C0018684|C1947933|C0042153|C0010186|C0002778
The primary endpoint was rate of development of new active lesions.,The primary endpoint rate development active lesions.,G0000000|C0205225|C2349179|C0871208|C0243107|C0205177|C0221198
"We collected data on feeding characteristics such as the timing of first enteral feeding and age at which infants reached full enteral feedings (140 mL/kg/d), and days on parenteral nutrition.","We collected data feeding characteristics timing enteral feeding age infants reached enteral feedings (140 mL/kg/d), days parenteral nutrition.",G0000000|C1516695|C1511726|C0204695|C1521970|C0449243|C1304890|C0204695|C0001779|C0021270|C2584321|C1304890|C0204695|C1442061|C1532579|C0439228|C0030547|C0028707
"The clinical outcome measures consisted of the Action Research Arm Test (ARAT)[19], the Jebsen-Taylor Hand Function Test (JTHFT)[20, 21], the Upper Extremity Portion of the Fugl-Meyer Motor Assessment (FMUE) and the Hand subcomponent (FMH)[22].","The clinical outcome measures consisted Action Research Arm Test (ARAT)[19], Jebsen-Taylor Hand Function Test (JTHFT)[20, 21], Upper Extremity Portion Fugl-Meyer Motor Assessment (FMUE) Hand subcomponent (FMH)[22].",G0000000|C0205210|C1274040|C0079809|C0332529|C0441472|C0035168|C0446516|C0022885|C1152215|G0000000|C0018563|C0031843|C0022885|C0450371|C0450371|C1282910|C0015385|C0449719|G0000000|C1513492|C1261322|G0000000|C0018563|G0000000|C0450371
"The change of axial length in the new-CL and control-CL groups was not different between 12 months and baseline, the change of axial length between 12 months and 1 month in the new-CL group (0.09±0.08 mm) was significantly smaller (47%) than that in the control-CL group (0.17±0.08 mm, P<0.05).","The change axial length new-CL control-CL 12 months baseline, change axial length 12 months 1 month new-CL (0.09±0.08 mm) (47%) control-CL (0.17±0.08 mm, P<0.05).",G0000000|C0392747|C0205131|C1444754|C0205314|C0243148|C0450371|C0439231|C0168634|C0392747|C0205131|C1444754|C0450371|C0439231|G0000000|C0332177|C0205314|G0000000|G0000000|C0450371|C0243148|G0000000|G0000000|C0369773
"There were significant differences in the changes from baseline values during the last six weeks of treatment in favour of nedocromil sodium compared with placebo in the primary variables of daytime asthma and night time asthma, morning and evening PEF, and the usage of rescue inhaled bronchodilators; 53% of patients reported nedocromil sodium to be very or moderately effective compared with 44% placebo.","There differences baseline values weeks treatment favour nedocromil sodium compared placebo primary variables daytime asthma night time asthma, morning evening PEF, usage rescue inhaled bronchodilators; 53% patients reported nedocromil sodium moderately effective compared 44% placebo.",G0000000|C1705241|C0168634|C0042295|C0439230|C0039798|C0309049|C0068483|C0037473|C1707455|C0032042|C0205225|C0439828|C0332169|C0004096|C0240526|C0040223|C0004096|C0332170|C0587117|C0030771|C0457083|G0000000|C0004048|C0006280|C0450371|C0030705|C0684224|C0068483|C0037473|C0205081|C1280519|C1707455|C0450371|C0032042
"Steroids are very effective for the induction of remission, but do not contribute to remission maintenance.","Steroids effective induction remission, contribute remission maintenance.",C0038317|C1280519|C0205263|C0544452|C1880177|C0544452|C0024501
"Sleep was assessed using three items measuring number of hours of sleep each night in the past 30 days, how often do you get enough sleep, and number of days getting enough sleep, which were converted into a scale ranging from 0 (low) to 10 (high) and averaged (Cronbach’s alpha=.68).","Sleep assessed items measuring hours sleep night 30 days, sleep, days sleep, converted scale ranging 0 (low) 10 (high) averaged (Cronbach’s alpha=.68).",C0037313|C1516048|C1551338|C0444706|C0439227|C0037313|C0240526|C0450371|C0439228|C0037313|C0439228|C0037313|G0000000|C0175659|C1514721|G0000000|C0205251|C0450371|C0205250|C1510992|G0000000|C0439095
"This study is registered with ClinicalTrials.gov, number {""type"":""clinical-trial"",""attrs"":{""text"":""NCT00684307"",""term_id"":""NCT00684307""}}NCT00684307.","This study registered ClinicalTrials.gov, {""type"":""clinical-trial"",""attrs"":{""text"":""NCT00684307"",""term_id"":""NCT00684307""}}NCT00684307.",G0000000|C0557651|C1514821|C1419208|C0332307
"Remission was defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 indicating no new or worsened activity or no persistently active disease manifestations within the previous month (18, 19).","Remission defined Birmingham Vasculitis Activity Score (BVAS) 0 indicating worsened activity persistently active disease manifestations previous month (18, 19).",C0544452|C1704788|G0000000|C0042384|C0205177|C0449820|C4053544|G0000000|G0000000|C1457868|C0205177|C0750508|C0205177|C0012634|C0205319|C0205156|C0332177|C0450371|C0450371
"Secondary objectives are 1) to investigate whether teleconsultation influences the number of hospital admissions by acting more pro-active on escalating problems of patients, 2) to consider if the burden of the family caregiver changes by giving them a better opportunity to address their needs and problems, 3) to study the patient experienced continuity of medical care in the last phase of life, 4) to assess patient and caregiver satisfaction with the teleconsultation contact and 5) to investigate patient's problems and needs for palliative care.","Secondary objectives 1) investigate teleconsultation influences hospital admissions acting pro-active escalating patients, 2) burden family caregiver opportunity address problems, 3) study patient experienced continuity medical care phase life, 4) assess patient caregiver satisfaction teleconsultation contact 5) investigate patient's palliative care.",C0027627|C0018017|G0000000|C1292732|C0282675|C4054723|C0019994|C0184666|G0000000|C0033382|G0000000|C0030705|G0000000|C2828008|C0015576|C0085537|G0000000|C0376649|C1546466|G0000000|C0557651|C0030705|C0237607|C0595960|C0199168|C1947933|C0205390|C0376558|G0000000|C1516048|C0030705|C0085537|C0242428|C0282675|C0332158|G0000000|C1292732|C0030705|C0587605|C1947933
"At 18 months of age, LAZ was comparable to the global WHO mean; however, it compared favorably with the regional WHO data [9].","At 18 months age, LAZ comparable global WHO mean; however, compared favorably regional WHO data [9].",G0000000|C0450371|C0439231|C0001779|G0000000|G0000000|C0205246|G0000000|C0444504|G0000000|C1707455|G0000000|C0205147|G0000000|C1511726|G0000000
"In this large, multi-centered, placebo-controlled randomized clinical trial of people at high risk of developing late AMD, daily additional supplementation with lutein/zeaxanthin and omega-3 LCPUFAs (DHA/EPA) combined with modified versions of the AREDS formulation showed no clinically or statistically significant overall effect on progression to late AMD in the primary analyses.","In large, multi-centered, placebo-controlled randomized clinical trial people risk developing late AMD, daily additional supplementation lutein/zeaxanthin omega-3 LCPUFAs (DHA/EPA) combined modified versions AREDS formulation clinically statistically progression late AMD primary analyses.",G0000000|C0549177|C0439064|C1706408|C0034656|C0205210|C0008976|C0027361|C0035647|G0000000|C0205087|C3539530|C0332173|C1524062|C0242297|C2929534|C1719844|G0000000|C0142831|C0205195|C0392747|C0333052|G0000000|C0524527|G0000000|C0038215|C0242656|C0205087|C3539530|C0205225|C0002778
"(1) To investigate the effects of a 6-week intervention of guided imagery on pain level, functional status, and self-efficacy in persons with fibromyalgia (FM); and (2) to explore the dose-response effect of imagery use on outcomes.","(1) To investigate effects 6-week intervention guided imagery pain level, functional status, self-efficacy persons fibromyalgia (FM); (2) explore dose-response imagery outcomes.",G0000000|C0040363|C1292732|C1280500|C0332174|C0886296|C0181090|C0150627|C0030193|C0441889|C0205245|C0449438|C0600564|C0027361|C0016053|C3540627|G0000000|G0000000|C4055118|C0150627|C1274040
Children who did not recover by 16 weeks were evaluated in hospitals.,Children recover 16 weeks evaluated hospitals.,C0008059|C0521108|G0000000|C0220825|C0019994
To investigate potential associations between cognitive function and/or impairment and age-related macular degeneration (AMD) and visual impairment in the Age-Related Eye Disease Study (AREDS).,To investigate potential associations cognitive function and/or impairment age-related macular degeneration (AMD) visual impairment Age-Related Eye Disease Study (AREDS).,C0040363|C1292732|C3245505|C0004083|C1516691|C0031843|G0000000|C0221099|C0001779|C0332574|C0011164|C3539530|C0234621|C0221099|C0001779|C0015392|C0012634|C0557651|G0000000
"Primary outcome measures were the proportion of participants who were reviewed within three months of randomisation and disease specific quality of life, as measured by the Juniper mini asthma quality of life questionnaire.","Primary outcome measures proportion participants reviewed months randomisation disease specific quality life, measured Juniper mini asthma quality life questionnaire.",C0205225|C1274040|C0079809|C1709707|C0679646|C0282443|C0439231|C0034656|C0012634|C0205369|C0332306|C0376558|C0444706|C0022431|C0445542|C0004096|C0332306|C0376558|C0034394
The study data were collected by completing Beck Depression Inventory before and 6 weeks after the intervention.,The study data collected completing Beck Depression Inventory 6 weeks intervention.,G0000000|C0557651|C1511726|C1516695|C0205197|G0000000|C0011570|C0021941|G0000000|C0439230|C0886296
Primary outcome measures included change in proteinuria and change in eGFR.,Primary outcome measures included change proteinuria change eGFR.,C0205225|C1274040|C0079809|C0332257|C0392747|C0033687|C0392747|C1739039
"Primary outcome measures were reduction in vasomotor symptoms (hot flashes and night sweats) by black cohosh and red clover compared with placebo; secondary outcomes included safety evaluation, reduction of somatic symptoms, relief of sexual dysfunction, and overall improvement in quality of life.","Primary outcome measures reduction vasomotor symptoms (hot flashes night sweats) black cohosh red clover compared placebo; secondary outcomes included safety evaluation, reduction somatic symptoms, relief sexual dysfunction, improvement quality life.",C0205225|C1274040|C0079809|C0301630|C1519957|C0683368|C0444519|C0085635|C0240526|C0038984|C0005680|G0000000|C0332575|C0950074|C1707455|C0032042|C0027627|C1274040|C0332257|C0036043|C0220825|C0301630|C1257909|C0683368|C0564405|C0036864|C0031847|C2986411|C0332306|C0376558
"Quality of life (QOL), measured by the Functional Assessment of Cancer Therapy-General (FACT-G)6 and EuroQoL (EQ-5D), was collected pretreatment and every six months for a total of 36 months.","Quality life (QOL), measured Functional Assessment Cancer Therapy-General (FACT-G)6 EuroQoL (EQ-5D), collected pretreatment months total 36 months.",C0332306|C0376558|C0518214|C0444706|C0205245|C1261322|C0006826|C0039798|C1707998|C0451150|C0205163|C1516695|C1550147|C0439231|C0439175|C0450371|C0439231
Rate of global symptom relief (A) per-protocol and (B) per intent-to-treat analysis (aP < 0.05).,Rate global symptom relief (A) per-protocol (B) intent-to-treat analysis (aP < 0.05).,C0871208|C0205246|C1457887|C0564405|G0000000|C1698058|G0000000|C0162425|C0002778|C3887950|G0000000|C0450371
Our study showed that recruitment of ART-naïve children ages 1–12 years with CDC A or B and CD4 15–24% for a randomized trial of immediate versus deferred ART was feasible although the recruitment took longer than anticipated due to almost 40% of children being ineligible mainly from low CD4%.,Our study recruitment ART-naïve children ages 1–12 CDC A B CD4 15–24% randomized trial versus deferred ART feasible recruitment anticipated 40% children ineligible low CD4%.,G0000000|C0557651|C2949735|G0000000|C0008059|C0001779|G0000000|C0007670|G0000000|G0000000|C0285590|G0000000|C0034656|C0008976|G0000000|C0205421|C0003826|G0000000|C2949735|C3840775|C0450371|C0008059|C1512714|C0205251|C0285590
Cure rates (CR) were calculated as the percentage of children with egg counts > 0 before treatment who become negative after treatment.,Cure rates (CR) calculated percentage children egg counts > 0 treatment negative treatment.,C1880198|C0871208|C0201975|C0444686|C0439165|C0008059|C0013710|C0439157|G0000000|G0000000|C0039798|C0205160|C0039798
The time to diarrhea relief and nude body weight seven days after intervention were considered as outcomes.,The time diarrhea relief nude body weight days intervention considered outcomes.,G0000000|C0040223|C0011991|C0564405|C0025932|C0242821|C0005910|C0439228|C0886296|C0750591|C1274040
"Additional secondary efficacy outcomes were the mean change of AALS (30 [normal] to 164 [maximally impaired]) scores at 4 months, mean changes of FVC at 4 months, mean changes of 36‐Item Short‐Form Health Survey (SF‐36) at 4 months, and changes in slope of AALS score and FVC between the lead‐in and follow‐up periods.","Additional secondary efficacy outcomes change AALS (30 [normal] 164 [maximally impaired]) scores 4 months, FVC 4 months, 36‐Item Short‐Form Health Survey (SF‐36) 4 months, slope AALS score FVC lead‐in follow‐up periods.",C1524062|C0027627|C1280519|C1274040|C0392747|G0000000|C0450371|C0205307|C1442061|G0000000|C0221099|C0449820|G0000000|C0439231|C3714541|G0000000|C0439231|G0000000|G0000000|C0018684|C0038951|G0000000|G0000000|C0439231|C0807955|G0000000|C0449820|C3714541|G0000000|G0000000|C0439531
Offering girls financial incentives to undergo the HPV vaccination could increase uptake rates.,Offering girls financial incentives undergo HPV vaccination increase uptake rates.,G0000000|C0870604|C0376243|C0021147|G0000000|C0021344|C0042196|C0442805|C0243144|C0871208
"The cumulative incidence of atopic symptoms at 18 months was 51, 64, and 84% in the N, PH, and RM groups, respectively.","The cumulative incidence atopic symptoms 18 months 51, 64, 84% N, PH, RM groups, respectively.",G0000000|C1511559|C0021149|C0392707|C0683368|C0450371|C0439231|C0450371|C0450371|C0450371|C0369718|C0450407|C0024851|C0441833|G0000000
There was a significant decrement in the number of asthma attacks (day and night) and use of drugs especially to the use of puff (p = 0.044) in the yoga group during and after the 4 week exercise.,There decrement asthma attacks (day night) drugs puff (p = 0.044) yoga 4 week exercise.,G0000000|G0000000|C0004096|C1261512|C0332173|C0240526|C0013227|C1533107|C0369773|G0000000|C1442061|C0043418|G0000000|C0332174|C0015259
Our present study confirms the effect of NHT on surgical margin status.,Our study confirms NHT surgical margin status.,G0000000|C0557651|C0521093|G0000000|C0543467|C0205284|C0449438
Similar efficacy against persistent infection with HPV16/18 in ATP analysis by age indicates that the vaccine is effective at protecting against new infections in unexposed women independent of age.,Similar efficacy persistent infection HPV16/18 ATP analysis age vaccine effective protecting infections unexposed women independent age.,C2348205|C1280519|C0205322|C0009450|C0450371|G0000000|C0002778|C0001779|C0042210|C1280519|G0000000|C3714514|G0000000|C0043210|C0085862|C0001779
"Papules, vesicles, and classical burrows were considered as new lesions suggestive of live parasite.","Papules, vesicles, classical burrows considered lesions suggestive live parasite.",C0332563|C0333262|C0439858|C0332816|C0750591|C0221198|C0332299|C1548795|C0030498
Major congenital malformations were more common for VPA (p ≤ 0.0003).,Major congenital malformations common VPA (p ≤ 0.0003).,C0205082|C0009678|C0000768|C0205214|G0000000|C0369773|G0000000|G0000000
malaria cases averted in children 6–59 months of age at the community level by adding IRS (community incidence); the study is powered based on this outcome cost per malaria case averted in children 6–59 months of age at the community level by adding IRS malaria case averted in children 6–59 months of age at the health facility level by adding IRS (health facility incidence) cost per malaria case averted in children 6–59 months of age at the health facility level by adding IRS.,malaria averted children 6–59 months age community level adding IRS (community incidence); study powered based outcome cost malaria averted children 6–59 months age community level adding IRS malaria averted children 6–59 months age health facility level adding IRS (health facility incidence) cost malaria averted children 6–59 months age health facility level adding IRS.,C0024530|G0000000|C0008059|G0000000|C0439231|C0001779|C0009462|C0441889|C1883712|G0000000|C0009462|C0021149|C0557651|C0032863|C1527178|C1274040|C0010186|C0024530|G0000000|C0008059|G0000000|C0439231|C0001779|C0009462|C0441889|C1883712|G0000000|C0024530|G0000000|C0008059|G0000000|C0439231|C0001779|C0018684|C1547538|C0441889|C1883712|G0000000|C0018684|C1547538|C0021149|C0010186|C0024530|G0000000|C0008059|G0000000|C0439231|C0001779|C0018684|C1547538|C0441889|C1883712|G0000000
"Variables of interest were gait velocity, stride length, and single support time.","Variables gait velocity, stride length, single support time.",C0439828|C0016928|C0439830|G0000000|C1444754|C0037179|C0183683|C0040223
"Apart from these, events around the childbirth process such as mode of delivery, labour experience amongst others have also been noted to significantly influence both early initiation and duration of breastfeeding [5].","Apart these, events childbirth process mode delivery, labour experience influence initiation duration breastfeeding [5].",G0000000|G0000000|C0441471|C0005615|C1184743|C1513371|C0011209|C0022864|C0237607|C4054723|C0589507|C0449238|C0006147|G0000000
"This crossover, randomized, double-blind study (conducted over a 32-week period) was performed to determine, in clinically stable Cystic fibrosis (CF) preschool children: the effects of 7% inhaled hypertonic saline on spirometry and interrupter resistance technique (Rint), and the possible side effects.","This crossover, randomized, double-blind study (conducted 32-week period) performed determine, clinically stable Cystic fibrosis (CF) preschool children: effects 7% inhaled hypertonic saline spirometry interrupter resistance technique (Rint), effects.",G0000000|C0010366|C0034656|C0013072|C0557651|C0004927|C0450371|C0439531|C0884358|G0000000|G0000000|C0205360|C0205207|C0016059|C0009738|C0424930|C0008059|C1280500|G0000000|C0004048|G0000000|C0036082|C0037981|C1708543|C0237834|C0449851|G0000000|C1280500
"The baseline creatinine level was estimated with a previously described three-variable formula when no pre-enrollment measurements were available (for details, see the Supplementary Appendix).16,21 Patients who had received renal-replacement therapy before enrollment were ineligible to meet the criteria for new renal- replacement therapy or persistent renal dysfunction but could qualify for the primary outcome if they died in the hospital.","The baseline creatinine level estimated three-variable formula pre-enrollment measurements (for details, Supplementary Appendix).16,21 Patients received renal-replacement therapy enrollment ineligible meet criteria renal- replacement therapy persistent renal dysfunction qualify primary outcome died hospital.",G0000000|C0168634|C0010294|C0441889|C0750572|C0205449|C0489829|C0332152|C0242485|G0000000|C1522508|G0000000|C0003617|C0030705|C1514756|C1302112|C0039798|C1516879|C1512714|C1550543|C0243161|C0022646|C0035139|C0039798|C0205322|C0022646|C0031847|G0000000|C0205225|C1274040|C0011065|C0019994
"Disease recurrence was defined as the reappearance of an ulcer or another form (nodule, papule, plaque, edema or bone involvement) of the disease at the original site of the lesion or elsewhere during the 12 months that followed the end of antibiotic treatment.","Disease recurrence defined reappearance ulcer form (nodule, papule, plaque, edema bone involvement) disease original site lesion 12 months antibiotic treatment.",C0012634|C0034897|C1704788|G0000000|C0041582|C0348078|C0028259|C0332563|C0011389|C0013604|C0262950|C1314939|C0012634|C0205313|C0205145|C0221198|C0450371|C0439231|C0003232|C0039798
"a Abbreviations: BMI, Body mass index; VAS, Visual analogue scale The changes of pain intensity in two groups in specific times were measured after the end of first cycle (Table 2).","Abbreviations: BMI, Body mass index; VAS, Visual analogue scale The pain intensity specific times measured cycle (Table 2).",C0000723|G0000000|C0242821|C0577559|C0918012|C0042815|C0234621|C0243071|C0175659|G0000000|C0030193|C0522510|C0205369|C0040223|C0444706|C1511572|C0039224|G0000000
The primary end point was the presence of any contamination on the skin or base clothing layer.,The primary presence contamination skin base clothing layer.,G0000000|C0205225|C0150312|C0259846|C0444099|C0002055|C0009072|C0934502
"Comparison of maternal age, gestational age at delivery, infant birth weight, preeclampsia, delivery and preterm labor reported in Table 1.","Comparison maternal age, gestational age delivery, infant birth weight, preeclampsia, delivery preterm labor reported Table 1.",C1707455|C2347083|C0001779|C0439671|C0001779|C0011209|C0021270|C0005615|C0005910|C0032914|C0011209|C0151526|C0022864|C0684224|C0039224|G0000000
"Since children of this age are in a period of growth spurt where their BMI decreases whereas BMI increases in the age 9–16, it may not be possible to compare the results of this study with our data.","Since children age period growth spurt BMI decreases BMI increases age 9–16, compare study data.",C1711239|C0008059|C0001779|C0439531|C0018270|C3889133|G0000000|C0442797|G0000000|C0205217|C0001779|G0000000|C1707455|C0557651|C1511726
Neurodevelopmental outcomes were assessed at 6 and 24-months corrected age.,Neurodevelopmental outcomes assessed 6 24-months corrected age.,C0599855|C1274040|C1516048|G0000000|C0450371|C0205202|C0001779
The primary endpoint of the study is the occurrence of a first relapse within 12 months (week 52) after first presentation.,The primary endpoint study occurrence relapse 12 months (week 52) presentation.,G0000000|C0205225|C2349179|C0557651|C0243132|C0035020|C0450371|C0439231|C0332174|C0450371|C0449450
The primary end point was overall survival (OS).,The primary survival (OS).,G0000000|C0205225|C0038952|C0229090
Main outcome measures Pneumonia and admission to hospital.,Main outcome measures Pneumonia admission hospital.,C0205225|C1274040|C0079809|C0032285|C0184666|C0019994
"For the computer session, the research team set up a classroom with about 30 computers and removed these at the end of the day.","For computer session, team set classroom 30 computers removed day.",G0000000|C0009622|C1883016|C0871489|C0036849|C0870287|C0450371|C0009622|C0849355|C0332173
"We examined the prevalence of owned, installed, and working smoke alarms, 12-18 months after distribution, in a random sample of homes rented from the borough council.","We examined prevalence owned, installed, smoke alarms, 12-18 months distribution, random sample homes rented borough council.",G0000000|C0332128|C0033105|G0000000|G0000000|C0037366|C0336648|C0450371|C0439231|C0520511|C0034656|C0370003|C0442519|C1555586|G0000000|C1551807
Thus the KCAHW questionnaire only gives a point assessment of knowledge.,Thus KCAHW questionnaire assessment knowledge.,G0000000|G0000000|C0034394|C1261322|C0376554
"The Dietary Observation for Child Care is a validated method for recording child-level dietary intake in 2 to 5 year-olds [52] and has been used extensively in the childcare setting [21, 53, 54].","The Dietary Observation Child Care validated method recording child-level dietary intake 2 5 year-olds [52] extensively childcare setting [21, 53, 54].",G0000000|C0012155|C0302523|C0008059|C1947933|G0000000|C0025663|G0000000|C0008059|C0012155|C1512806|G0000000|G0000000|C0439234|C0450371|G0000000|C0008067|C0542559|C0450371|C0450371|C0450371
"We assessed disease activity objectively at each visit by using the six area, six sign, atopic dermatitis (SASSAD) score.14 This well validated scoring system, which has been used in many trials on atopic dermatitis, involves assessment of six signs (erythema, exudation, excoriation, dryness, cracking, and lichenification) at six sites (hands, feet, arms, legs, head and neck, and trunk).","We assessed disease activity objectively visit area, sign, atopic dermatitis (SASSAD) score.14 This validated scoring system, trials atopic dermatitis, involves assessment signs (erythema, exudation, excoriation, dryness, cracking, lichenification) sites (hands, feet, arms, legs, head neck, trunk).",G0000000|C1516048|C0012634|C0205177|G0000000|C0545082|C0017446|C0311392|C0392707|C0011603|G0000000|C0449820|G0000000|G0000000|C0449820|C0449913|C0008976|C0392707|C0011603|G0000000|C1261322|C0220912|C0041834|C0311437|C0015256|C1512080|C1706353|C0023653|C0205145|C0018563|C0016504|C0206655|C1140621|C0018670|C0027530|C0225442
"Baseline and 4-month follow-up assessment outcome measures MIDAS migraine disability assessment scale, HIT-6 headache impact test, HADS-A hospital anxiety and depression scale, Anxiety subscale, HADS-D hospital anxiety and depression scale, Depression subscale, Brief-IPQ brief illness perceptions questionnaire This is the first UK-based pilot trial of a minimal contact CBT with relaxation treatment for migraine headache.","Baseline 4-month follow-up assessment outcome measures MIDAS migraine disability assessment scale, HIT-6 headache impact test, HADS-A hospital anxiety depression scale, Anxiety subscale, HADS-D hospital anxiety depression scale, Depression subscale, Brief-IPQ illness perceptions questionnaire This UK-based pilot trial minimal contact CBT relaxation treatment migraine headache.",C0168634|C0332177|C0589120|C1261322|C1274040|C0079809|C1309950|C0149931|C0231170|C1261322|C0175659|C0272285|C0018681|C1825598|C0022885|C0048008|C0019994|C0003467|C0011570|C0175659|C0003467|G0000000|C0048008|C0019994|C0003467|C0011570|C0175659|C0011570|G0000000|C1282927|C0221423|C0030971|C0034394|G0000000|C0041700|C0473169|C0008976|C0547040|C0332158|C0009244|C0035028|C0039798|C0149931|C0018681
"Weight, height, and blood pressure were measured at each visit.","Weight, height, blood pressure measured visit.",C0005910|C0489786|C0005767|C0033095|C0444706|C0545082
"Muscle strength is a surrogate measure, not a patient-centered outcome.","Muscle strength surrogate measure, patient-centered outcome.",C0026845|C0237897|C4053457|C0079809|C0030705|C1274040
"However, in contrast, we have observed 75% of failure (both clinical and radiographic) in A. vera group within 1 month of follow-up [Figures [Figures11–3 and Table 2].","However, contrast, observed 75% failure (both clinical radiographic) A. vera 1 month follow-up [Figures [Figures11–3 Table 2].",G0000000|C0009924|C1441672|C0450371|C0231174|G0000000|C0205210|C0444708|G0000000|G0000000|G0000000|C0332177|C0589120|G0000000|G0000000|C0039224|G0000000
Achievement of Discharge Criteria Median postoperative stay of patients in the multimodal arm is 5 days as compared with 7 in controls.,Achievement Discharge Criteria Median postoperative stay patients multimodal arm 5 days compared 7 controls.,C0001072|C0012621|C0243161|C0549183|C0032790|G0000000|C0030705|C1513743|C0446516|G0000000|C0439228|C1707455|G0000000|C0243148
"A series of t tests indicated that for the sample as a whole, although number of drinking days rose from 3 to 12 months, the average number of drinking days per month at each follow-up point was significantly lower than at baseline: baseline to 3 months, t96 = 6.82; baseline to 6 months, t91 = 6.09; and baseline to 12 months, t82 = 4.18 (P < .001 for all).","A series tests sample whole, drinking days rose 3 12 months, average drinking days month follow-up lower baseline: baseline 3 months, t96 = 6.82; baseline 6 months, t91 = 6.09; baseline 12 months, t82 = 4.18 (P < .001 all).",G0000000|C0205549|C0022885|C0370003|C0444667|C0001948|C0439228|C0035853|G0000000|C0450371|C0439231|C1510992|C0001948|C0439228|C0332177|C0589120|C0441994|C0168634|C0168634|G0000000|C0439231|G0000000|G0000000|C0450371|C0168634|G0000000|C0439231|G0000000|G0000000|C0450371|C0168634|C0450371|C0439231|G0000000|G0000000|C0450371|C0369773|G0000000|C1442061|G0000000
Acute rejection (AR) after renal transplantation can lead to rapid graft loss from irreversible rejection or to the onset of chronic graft rejection with ultimate graft failure.,Acute rejection (AR) renal transplantation lead rapid graft loss irreversible rejection onset chronic graft rejection ultimate graft failure.,C0205178|C0035015|C2986463|C0022646|C0040732|C0023175|C0456962|C0181074|C1517945|G0000000|C0035015|C0206132|C0205191|C0181074|C0035015|G0000000|C0181074|C0231174
"Key secondary outcome measures were breathlessness on the transition dyspnoea index (TDI) and health-related quality of life (HRQoL) according to the St. George's Respiratory Questionnaire (SGRQ) at Week 26, while important secondary outcomes were time to first moderate or severe COPD exacerbation and mean daily rescue medication use over 26 weeks.","Key secondary outcome measures breathlessness transition dyspnoea (TDI) health-related quality life (HRQoL) St. George's Respiratory Questionnaire (SGRQ) Week 26, secondary outcomes time moderate severe COPD exacerbation daily rescue medication 26 weeks.",G0000000|C0027627|C1274040|C0079809|C0013404|C0599156|C0013404|C0205976|C0018684|C0332306|C0376558|G0000000|C0036056|G0000000|C0521346|C0034394|G0000000|C0332174|C0450371|C0027627|C1274040|C0040223|C0205081|C0205082|C0024117|G0000000|C0332173|G0000000|C0013227|C0450371|C0439230
"The National Cancer Institute (NCI) Common Toxicity Criteria (CTC, version 2.0) were used to evaluate and grade adverse events.","The National Cancer Institute (NCI) Common Toxicity Criteria (CTC, version 2.0) evaluate grade adverse events.",G0000000|C3245503|C0006826|C0021622|C1513882|C0205214|C0040539|C0243161|G0000000|C0333052|G0000000|C0220825|C0441800|G0000000|C0441471
"Outcomes were collected at baseline, immediately following the intervention period and 3 months following the end of the intervention.","Outcomes collected baseline, intervention period 3 months intervention.",C1274040|C1516695|C0168634|C0886296|C0439531|G0000000|C0439231|C0886296
Both the total myalgic score and number of tender points were lower in the wait-list group at the end of their intervention.,Both total myalgic score tender lower wait-list intervention.,G0000000|C0439175|C0231528|C0449820|C0234234|C0441994|C0043010|C0886296
"The primary aims of the study were to examine the effect of micronutrient supplementation on (1) culture negativity at 1 month after initiation of treatment, (2) mortality during at least 24 months of follow-up, and (3) TB recurrences.","The primary aims study examine micronutrient supplementation (1) culture negativity 1 month initiation treatment, (2) mortality 24 months follow-up, (3) TB recurrences.",G0000000|C0205225|C1947946|C0557651|G0000000|C0040577|C0242297|G0000000|C0010453|C0205160|G0000000|C0332177|C0589507|C0039798|G0000000|C0026565|C0450371|C0439231|C0589120|G0000000|G0000000|C0034897
"After 8 wk of supplementation FPG, HbA1c, HOMA-IR, and insulin levels remained unchanged in the probiotic and placebo groups.","After 8 wk supplementation FPG, HbA1c, HOMA-IR, insulin levels remained unchanged probiotic placebo groups.",G0000000|G0000000|C0242297|G0000000|G0000000|C0022065|C0021641|C0441889|G0000000|C0442739|C0525033|C0032042|C0441833
Percentage of surface samples in each barrack that were found to be positive for adenovirus type 4 by means of culture and polymerase chain reaction (PCR) analysis.,Percentage surface samples barrack positive adenovirus type 4 culture polymerase chain reaction (PCR) analysis.,C0439165|C0205148|C0370003|G0000000|C0439178|C0001483|C0332307|G0000000|C0010453|C1335439|C0337112|C0443286|C0032520|C0002778
The scale provides a measure of an individual’s perception of quality of life for the four domains: (1) physical health (seven items) (2) psychological health (six items) (3) social relationships (three items) and (4) environmental health (eight items).,The scale measure individual’s perception quality life domains: (1) physical health (seven items) (2) psychological health (six items) (3) social relationships (three items) (4) environmental health (eight items).,G0000000|C0175659|C0079809|G0000000|C0030971|C0332306|C0376558|C1880389|G0000000|C0031809|C0018684|C0205453|C1551338|G0000000|C0205486|C0018684|C0205452|C1551338|G0000000|C0728831|C0439849|C0205449|C1551338|G0000000|C0014406|C0018684|C0205454|C1551338
[24] modified the test to measure the timed element only.,[24] modified test measure timed element only.,C0450371|C0392747|C0022885|C0079809|C0392761|C0013879|C0205171
"Subgroup analysis of participants with highly positive EGFRvIII status and coexisting PTEN loss highlighted a median PFS of 2.96 months in those treated with afatinib (7/7), 3.65 months with afatinib plus temozolomide (11/13), and 9.03 months with temozolomide monotherapy (2/3).","Subgroup analysis participants highly positive EGFRvIII status coexisting PTEN loss highlighted median PFS 2.96 months treated afatinib (7/7), 3.65 months afatinib temozolomide (11/13), 9.03 months temozolomide monotherapy (2/3).",C1079230|C0002778|C0679646|C0205250|C0439178|C0915629|C0449438|G0000000|C0694888|C1517945|G0000000|C0549183|C0242792|C0450371|C0439231|C1522326|C2987648|G0000000|C0450371|C0439231|C2987648|C0076080|C0450371|C0450371|C0439231|C0076080|G0000000|G0000000
The adjusted relative risks of death ranged from 0.952 to 1.114 (Fig 3B).,The adjusted relative risks death ranged 0.952 1.114 (Fig 3B).,G0000000|C0456081|C0080103|C0035647|C0011065|C1514721|C1442061|C1442061|C0349966|C1420850
"These measurements were made 0, 3, 6, 9, 12 and 18 weeks after the start of the therapy (t0 defined as morning of day of first PDT treatment before curettage).","These measurements 0, 3, 6, 9, 12 18 weeks start therapy (t0 defined morning day PDT treatment curettage).",G0000000|C0242485|G0000000|G0000000|G0000000|G0000000|C0450371|C0450371|C0439230|C0439659|C0039798|C0041403|C1704788|C0332170|C0332173|C0031740|C0039798|C0010468
"Overall, more than half (61%) of the participants reported that their health care provider had recommended that they have a mammogram.","Overall, half (61%) participants reported health care provider recommended mammogram.",C0282416|C2825407|C0450371|C0679646|C0684224|C0018684|C1947933|C1138603|C0034866|C0024671
"Secondary aims of this study were to assess a) 7-day point prevalence abstinence at various times, CARs during 52 weeks and time to sustained abstinence defined as attaining 8 weeks of continuous abstinence at anytime prior to week 46 and maintaining continuous abstinence through 52 weeks; b) impact on compensatory smoking amongst non-abstainers; c) withdrawal symptoms and d) immunogenicity, efficacy and safety of administration of either 4 or 5 of the 200 and 400 µg doses.","Secondary aims study assess a) 7-day prevalence abstinence times, CARs 52 weeks time sustained abstinence defined attaining 8 weeks continuous abstinence anytime prior week 46 maintaining continuous abstinence 52 weeks; b) impact compensatory smoking non-abstainers; c) withdrawal symptoms d) immunogenicity, efficacy safety administration 4 5 200 400 µg doses.",C0027627|C1947946|C0557651|C1516048|G0000000|C0332173|C0033105|C3843422|C0040223|C0004381|C0450371|C0439230|C0040223|C0443318|C3843422|C1704788|G0000000|G0000000|C0439230|C0549178|C3843422|G0000000|C0332152|C0332174|C0450371|C0024501|C0549178|C3843422|C0450371|C0439230|G0000000|C1825598|C0231186|C0037369|C1518422|G0000000|C2349954|C0683368|C0073187|C4054739|C1280519|C0036043|C0001554|G0000000|G0000000|C1442061|C1442061|G0000000|C0178602
The questionnaire on disability designed by Roland and Morris (1983) with acronym Rolland Morris disability Questionnaire (RMDQ) which has 24 questions is one of the tools used frequently to measure disability resulting especially from pain in the lower spinal region resulting from intervention.,The questionnaire disability designed Roland Morris (1983) acronym Rolland Morris disability Questionnaire (RMDQ) 24 questions tools frequently measure disability pain lower spinal region intervention.,G0000000|C0034394|C0231170|C1707689|G0000000|G0000000|G0000000|C1956259|G0000000|G0000000|C0231170|C0034394|G0000000|C0450371|C1522634|C0336791|C0332183|C0079809|C0231170|C0030193|C0441994|C0521329|C0017446|C0886296
Adverse events definitions per NCI CTCAE version 3.,Adverse events definitions NCI CTCAE version 3.,G0000000|C0441471|C1550452|C1513882|C1516728|C0333052|G0000000
Immune responses to MUC-1 and/or CEA were seen following vaccine in 9 of 16 patients tested.,Immune responses MUC-1 and/or CEA vaccine 9 16 patients tested.,C0439662|C0871261|G0000000|G0000000|C3463961|C0042210|G0000000|C0450371|C0030705|C0392366
The results of this pilot study suggest that training with a CFR device improves vitality and reduces bodily pain in WR athletes.,The pilot study training CFR device improves vitality reduces bodily pain WR athletes.,G0000000|C0473169|C0557651|C0040607|G0000000|C0025080|C0184511|C0424589|G0000000|G0000000|C0030193|C1420193|C0238703
"The two trials were combined for analysis of heath outcomes consisting of exacerbations, health resource use, dyspnoea (assessed by the transitional dyspnoea index, TDI), health related quality of life (assessed by St George's Respiratory Questionnaire, SGRQ), and spirometry.","The trials combined analysis heath outcomes consisting exacerbations, health resource use, dyspnoea (assessed transitional dyspnoea index, TDI), health quality life (assessed St George's Respiratory Questionnaire, SGRQ), spirometry.",G0000000|C0008976|C0205195|C0002778|G0000000|C1274040|C0332529|G0000000|C0018684|C0035201|C0042153|C0013404|C1516048|C1182674|C0013404|C0918012|C0205976|C0018684|C0332306|C0376558|C1516048|C0036056|G0000000|C0521346|C0034394|G0000000|C0037981
"The primary outcome is improvement in exercise capacity after 8 weeks, measured by endurance time during a shuttle walk test.","The primary outcome improvement exercise capacity 8 weeks, measured endurance time shuttle walk test.",G0000000|C0205225|C1274040|C2986411|C0015259|C1516240|G0000000|C0444706|C0518031|C0040223|G0000000|C0080331|C0022885
"For evaluation, Short Form-36 (SF-36) health-related quality of life (HRQoL) and the Geriatric Depression Scale-15 (GDS-15) were used.","For evaluation, Short Form-36 (SF-36) health-related quality life (HRQoL) Geriatric Depression Scale-15 (GDS-15) used.",G0000000|C0220825|C1282927|C0348078|C0037712|C0018684|C0332306|C0376558|G0000000|C1704440|C0011570|C0175659|C0451184|C1273517
"The primary outcomes of the study are adolescents’ health behaviours (alcohol, drug, smoking, safe sex) and mental health status.","The primary outcomes study adolescents’ health behaviours (alcohol, drug, smoking, safe sex) mental health status.",G0000000|C0205225|C1274040|C0557651|G0000000|C0018684|C0004927|C0001962|C0013227|C0037369|G0000000|C0009253|C0229992|C0018684|C0449438
"The main outcome measures (at baseline and 12 months) included violence (peer aggression, peer victimization, violence-related consequences) and alcohol (alcohol misuse, binge drinking, alcohol-related consequences).","The main outcome measures (at baseline 12 months) included violence (peer aggression, peer victimization, violence-related consequences) alcohol (alcohol misuse, binge drinking, alcohol-related consequences).",G0000000|C0205225|C1274040|C0079809|G0000000|C0168634|C0450371|C0439231|C0332257|C0042693|C0679739|C0001807|C0679739|C0376695|C0042693|C0686907|C0001962|C0001962|C0549649|C0596170|C0001948|C0524349|C0686907
"It is criterions referenced measure with good reliability.9 It measures four functional abilities including dissociated movement, grasp, weight bearing and protective extension.","It criterions referenced measure reliability.9 It measures functional abilities including dissociated movement, grasp, weight bearing protective extension.",G0000000|C0243161|C1706462|C0079809|C2347947|G0000000|C0079809|C0205245|C0085732|C0332257|G0000000|C0026649|C0220843|C0005910|C1704689|G0000000|C0231448
Arrest frequency and standard errror by treatment condition T-test and ANCOVA analyses of substance misuse outcomes found no statistically significant between-group differences at 3 months post-release (Time 3) (see Table 3).,Arrest frequency standard errror treatment condition T-test ANCOVA analyses substance misuse outcomes statistically between-group differences 3 months post-release (Time 3) (see Table 3).,C0237477|C0376249|C1442989|G0000000|C0039798|C0012634|C0871472|C0814908|C0002778|C0439861|C0549649|C1274040|C0038215|C0441833|C1705241|G0000000|C0439231|C0687676|C0040223|G0000000|C0042789|C0039224|G0000000
Comparisons of end-point Clinical Global Impressions for Bipolar Illness Improvement-Mania (CGI-BP-IM) response rates by medication.,Comparisons end-point Clinical Global Impressions Bipolar Illness Improvement-Mania (CGI-BP-IM) response rates medication.,C1707455|C2349179|C0205210|C0205246|C0596764|C0443156|C0221423|C2986411|C3639708|C0871261|C0871208|C0013227
Improvements in overground walking velocity (10 m/6-min walk) and fitness (peak VO2) were indicators of therapy response.,Improvements overground walking velocity (10 m/6-min walk) fitness (peak VO2) indicators therapy response.,C2986411|G0000000|C0080331|C0439830|C0450371|C0369637|C0080331|C1456706|C0444505|C0042939|C0021212|C0039798|C0871261
"This is the first placebo-controlled investigation to demonstrate that long-term nightly pharmacologic treatment of primary insomnia with any hypnotic enhanced quality of life, reduced work limitations, and reduced global insomnia severity, in addition to improving patient-reported sleep variables.","This placebo-controlled investigation demonstrate long-term nightly pharmacologic treatment primary insomnia hypnotic enhanced quality life, reduced limitations, reduced global insomnia severity, addition improving patient-reported sleep variables.",G0000000|C1706408|C0220825|G0000000|C0443252|G0000000|C0031330|C0039798|C0205225|C0917801|C0020591|C2349975|C0332306|C0376558|C0392756|C0449295|C0392756|C0205246|C0917801|C0439793|C0332287|C1272745|C0747307|C0037313|C0439828
Pfizer supported the quality of life analysis performed by Omega Research.,Pfizer supported quality life analysis performed Omega Research.,C0331888|C1521721|C0332306|C0376558|C0002778|C0884358|C1719844|C0035168
"Mood and health status were measured at baseline, 6 weeks and 6 months using the following questionnaires: – The Hospital Anxiety and Depression Scale (HADS),33 a validated, widely used measure to screen for anxiety and depression in medical settings.","Mood health status measured baseline, 6 weeks 6 months questionnaires: – The Hospital Anxiety Depression Scale (HADS),33 validated, measure screen anxiety depression medical settings.",C0026516|C0018684|C0449438|C0444706|C0168634|G0000000|C0439230|G0000000|C0439231|C0034394|G0000000|G0000000|C0019994|C0003467|C0011570|C0175659|C0048008|G0000000|C0079809|C0220908|C0003467|C0011570|C0199168|C0542559
"The primary outcome is thus a patient-individualized outcome representing the score on one of seven different scales (for example, patients having the pain-scale as the scale with the highest intensity at baseline will have pain as their primary outcome).","The primary outcome patient-individualized outcome representing score scales (for example, patients pain-scale scale intensity baseline pain primary outcome).",G0000000|C0205225|C1274040|C0030705|C1274040|C1882932|C0449820|C0175659|G0000000|C1707959|C0030705|C1504479|C0175659|C0522510|C0168634|C0030193|C0205225|C1274040
Diet was associated with both changes in BMI percentile and body fat.,Diet BMI percentile body fat.,C0012155|G0000000|C1264641|C0242821|C0424612
All outcomes will be administered before the interventions and again at 3 and 6 months.,All outcomes administered interventions 3 6 months.,G0000000|C1274040|C1521801|C0886296|G0000000|G0000000|C0439231
"Regardless of the treatment group, our data suggest that both survival and local control are better for single brain site involvement compared to multiple brain sites involvement.","Regardless treatment group, data survival local control single brain site involvement compared multiple brain sites involvement.",C3641650|C0039798|C0441833|C1511726|C0038952|C0205276|C0243148|C0037179|C0006104|C0205145|C1314939|C1707455|C0439064|C0006104|C0205145|C1314939
"Secondary endpoints included TTP, time to treatment failure (TTF), duration of response, OS, treatment toxicities and clinical benefit.","Secondary endpoints included TTP, time treatment failure (TTF), duration response, OS, treatment toxicities clinical benefit.",C0027627|C2349179|C0332257|C0084795|C0040223|C0039798|C0231174|C1332112|C0449238|C0871261|C0229090|C0039798|C0600688|C0205210|C0814225
"Women with low plasma zinc levels (<60.0µg/dl) at recruitment also had significantly higher Hb but lower serum ferritin and iron concentrations, compared to women with normal values (≥60 µg/dl).","Women low plasma zinc levels (<60.0µg/dl) recruitment Hb lower serum ferritin iron concentrations, compared women normal values (≥60 µg/dl).",C0043210|C0205251|C0032105|C0043481|C0441889|G0000000|C2949735|C0019046|C0441994|C0229671|C0015879|C0302583|C0086045|C1707455|C0043210|C0205307|C0042295|G0000000|G0000000
The primary outcome of this study was patient satisfaction with the decision-making process at the time of treatment decision.,The primary outcome study patient satisfaction decision-making process time treatment decision.,G0000000|C0205225|C1274040|C0557651|C0030705|C0242428|C0011109|C1184743|C0040223|C0039798|C0679006
The change in knowledge and attitude of men and women in the case group eventually caused a significant reduction in elective cesarean section in this group.,The change knowledge attitude women eventually caused reduction elective cesarean group.,G0000000|C0392747|C0376554|C0004271|C0043210|G0000000|C0015127|C0301630|C0206058|C3841297|C0441833
Univariate Analysis of Successful Medicaid or SCHIP Enrollment 90 Days After Emergency Department Interventiona Note.,Univariate Analysis Successful Medicaid SCHIP Enrollment 90 Days After Emergency Department Interventiona Note.,G0000000|C0002778|C0597535|C0025071|G0000000|C1516879|C0450371|C0439228|G0000000|C0013956|C1704729|G0000000|C1316572
A treatment outcome was better in this retrospective study in terms of morbidity and survival.,A treatment outcome retrospective study terms morbidity survival.,G0000000|C0039798|C1274040|C0035363|C0557651|C0233324|C0026538|C0038952
The frequency of grades 3 and 4 diarrhoea was the primary variable.,The frequency grades 3 4 diarrhoea primary variable.,G0000000|C0376249|C0441800|G0000000|G0000000|C0011991|C0205225|C0439828
"Postoperative evaluation after 3 months interval After 6 months, evaluation was done, pain and sinus formation each was noted in 9.1% of primary teeth in Group I while mobility was noticed in 27.3% of teeth in Group I and 57.1% of teeth in Group II [Table 3].","Postoperative evaluation 3 months interval After 6 months, evaluation done, pain sinus formation 9.1% primary teeth Group I mobility noticed 27.3% teeth Group I 57.1% teeth Group II [Table 3].",C0032790|C0220825|G0000000|C0439231|C1272706|G0000000|G0000000|C0439231|C0220825|G0000000|C0030193|C0016169|C0220781|G0000000|C0205225|C0040426|C0441833|C0021966|C0425245|G0000000|C0450371|C0040426|C0441833|C0021966|C0450371|C0040426|C0441833|G0000000|C0039224|G0000000
A 5 ml blood sample was collected from each participant at baseline and after 8 weeks.,A 5 blood sample collected participant baseline 8 weeks.,G0000000|G0000000|C0005767|C0370003|C1516695|C0679646|C0168634|G0000000|C0439230
"At the start of the study, 2 primary outcomes were defined for study eyes in the AMD trial: (1) progression to advanced AMD and (2) at least a 15-letter decrease in visual acuity score.","At start study, 2 primary outcomes defined study eyes AMD trial: (1) progression advanced AMD (2) 15-letter decrease visual acuity score.",G0000000|C0439659|C0557651|G0000000|C0205225|C1274040|C1704788|C0557651|C0015392|C3539530|C0008976|G0000000|C0242656|C0205179|C3539530|G0000000|C0450371|C0392756|C0234621|C0750509|C0449820
Urinary cotinine tests were repeated to evaluate the effectiveness of both interventions at 9 months follow-up.,Urinary cotinine tests repeated evaluate effectiveness interventions 9 months follow-up.,C0042027|C0010194|C0022885|C0205341|C0220825|C1280519|C0886296|G0000000|C0439231|C0589120
"Perception of skin cancer risk, belief that sun protection prevents skin cancer, and having sun protection choices enhance sun protection behaviors by kidney transplant recipients, who are at greater risk of developing skin cancer than the general population.","Perception skin cancer risk, belief sun protection prevents skin cancer, sun protection choices enhance sun protection behaviors kidney transplant recipients, risk developing skin cancer population.",C0030971|C0444099|C0006826|C0035647|C0004951|C0038817|C1545588|C0309872|C0444099|C0006826|C0038817|C1545588|C0008300|C2349975|C0038817|C1545588|C0004927|C0022646|C0040732|C1709854|C0035647|G0000000|C0444099|C0006826|C0032659
"This measure was chosen because the INCAT disability scale has been validated for evaluation of various inflammatory demyelinating neuropathies, including IgM anti-MAG neuropathy.23–28 When developing this protocol, the ISS20 at 12 months was classified as an appropriate primary outcome measure when assessing sensory deficit.","This measure chosen INCAT disability scale validated evaluation inflammatory demyelinating neuropathies, including IgM anti-MAG neuropathy.23–28 When developing protocol, ISS20 12 months classified primary outcome measure assessing sensory deficit.",G0000000|C0079809|C1707391|G0000000|C0231170|C0175659|G0000000|C0220825|C0333348|G0000000|C0442874|C0332257|G0000000|C0443892|G0000000|G0000000|G0000000|C0442711|G0000000|C0450371|C0439231|C0008902|C0205225|C1274040|C0079809|C1516048|C0445254|C0162429
"The main outcomes were GP consultation rates, hospital re-admissions, and attendances at A&E/CAU.","The main outcomes GP consultation rates, hospital re-admissions, attendances A&E/CAU.",G0000000|C0205225|C1274040|C3811116|C0009818|C0871208|C0019994|C1548168|C2827364|C0444892
"Five immunizations with Nicotine-Qβ were administered at months 0, 1, 2, 3 and 4.","Five immunizations Nicotine-Qβ administered months 0, 1, 2, 3 4.",C0205451|C0020971|G0000000|C1521801|C0439231|G0000000|G0000000|G0000000|G0000000|G0000000
"For the active arm, a significant increase was observed in the Connor Davis Resilience Scale [paired t-test, t(19) = 4.54, p < 0.001], and significant decreases were observed in the Perceived Stress Scale [paired t-test, t(19) = -2.95, p = 0.008] and Smith Anxiety Scale [paired t-test, t(19) = -4.31, p < 0.001].","For active arm, increase observed Connor Davis Resilience Scale [paired t-test, t(19) = 4.54, p < 0.001], decreases observed Perceived Stress Scale [paired t-test, t(19) = -2.95, p = 0.008] Smith Anxiety Scale [paired t-test, t(19) = -4.31, p < 0.001].",G0000000|C0205177|C0446516|C0442805|C1441672|G0000000|G0000000|G0000000|C0175659|C1709450|C0871472|G0000000|G0000000|C0442797|C1441672|C0030971|C0038435|C0175659|C1709450|C0871472|G0000000|G0000000|C0554249|C0003467|C0175659|C1709450|C0871472|G0000000|G0000000
"During the single call the parent described his or her smoking status at the time of the index visit, provider activities related to tobacco use, participation in tobacco treatment, and smoking and home policy status 8 weeks later.","During single call parent smoking status time visit, provider activities tobacco use, participation tobacco treatment, smoking policy status 8 weeks later.",G0000000|C0037179|C0679006|C0030551|C0037369|C0449438|C0040223|C0545082|C1138603|C0441655|C0040329|C0042153|C0679823|C0040329|C0039798|C0037369|C0242456|C0449438|G0000000|C0439230|C0205087
"A specific upper limb measure, such as the Wolf Motor Function Test [49], may also have been more appropriate for detecting any changes resulting from the upper limb training component.","A specific upper limb measure, Wolf Motor Function Test [49], detecting upper limb training component.",G0000000|C0205369|C1282910|C0015385|C0079809|C0325001|C1513492|C0031843|C0022885|C0450371|C0442726|C1282910|C0015385|C0040607|C0449432
"Visual field analyses were performed using standard automated perimetry at screening, baseline, and months 6 and 12.","Visual field analyses performed standard automated perimetry screening, baseline, months 6 12.",C0234621|C0440042|C0002778|C0884358|C1442989|C0205554|C0031061|C0220908|C0168634|C0439231|G0000000|C0450371
"The greater reduction in diastolic blood pressure observed in the almond group was statistically significant at the end of the study, but inversely systolic blood pressure in the almond group had less reduction in comparison with the nut-free group [Table 3].","The reduction diastolic blood pressure observed almond statistically study, inversely systolic blood pressure almond reduction comparison nut-free [Table 3].",G0000000|C0301630|C0012000|C0005767|C0033095|C1441672|C0440286|C0038215|C0557651|G0000000|C0039155|C0005767|C0033095|C0440286|C0301630|C1707455|C0028723|C0039224|G0000000
Prescription patterns of neuraminidase inhibitors Table 3 shows the results of the multivariable Cox regression analysis for hospitalization.,Prescription patterns neuraminidase inhibitors Table 3 multivariable Cox regression analysis hospitalization.,C0033080|C0449774|C0027803|C0243077|C0039224|G0000000|G0000000|G0000000|C0684320|C0002778|C0019993
There was also no difference between the treatment groups in the number of courses of oral steroids or antibiotics for the treatment of COPD exacerbations (Table 5).,There difference treatment courses oral steroids antibiotics treatment COPD exacerbations (Table 5).,G0000000|C1705241|C0039798|C0750729|C0442027|C0038317|C0003232|C0039798|C0024117|G0000000|C0039224|G0000000
Subjects had baseline performances in which the C statistic did not indicate progressive increases in performance before treatment was initiated.,Subjects baseline performances C statistic progressive increases performance treatment initiated.,C0681850|C0168634|C0597198|G0000000|C2348149|C0205329|C0205217|C0597198|C0039798|C1548602
"However, for weeks 1–12, there was no difference between the treatment groups (mean proportion was 64% in each treatment group).","However, weeks 1–12, difference treatment (mean proportion 64% treatment group).",G0000000|C0439230|G0000000|C1705241|C0039798|C0444504|C1709707|C0450371|C0039798|C0441833
"As seen in Table 3, the change scores from baseline to Time 3 (5 months) were significantly different between the two groups for two of the measures - the CVLT-Total (a performance measure of learning and memory) and the Strategy Subscale of the Multifactorial Memory Questionnaire (the self-report of the frequency of use of compensatory memory strategies).","As Table 3, change scores baseline Time 3 (5 months) measures - CVLT-Total (a performance measure learning memory) Strategy Subscale Multifactorial Memory Questionnaire (the self-report frequency compensatory memory strategies).",G0000000|C0039224|G0000000|C0392747|C0449820|C0168634|C0040223|G0000000|G0000000|C0439231|C0079809|G0000000|C0439175|G0000000|C0597198|C0079809|C0013621|C0025260|C0679199|G0000000|C1837655|C0025260|C0034394|G0000000|C0681906|C0376249|C0231186|C0025260|C0679199
The primary response variable will be continued abstinence at 12 months after beginning smoking cessation (D-Day).,The primary response variable continued abstinence 12 months smoking cessation (D-Day).,G0000000|C0205225|C0871261|C0439828|C0549178|C3843422|C0450371|C0439231|C0037369|C1880019|C0332173
"In this study, we found the range of Oucher Scale scores, the most direct measure of child perception of pain, was narrow and suggests that, overall, there was a low level of pain in this group.","In study, range Oucher Scale scores, direct measure child perception pain, narrow suggests that, overall, low level pain group.",G0000000|C0557651|C1514721|G0000000|C0175659|C0449820|C0439851|C0079809|C0008059|C0030971|C0030193|C0205168|C1705535|G0000000|C0282416|C0205251|C0441889|C0030193|C0441833
"It is hypothesized that laparoscopic gastrectomy will result in a shorter postoperative hospital stay, lower postoperative morbidity, less readmissions, higher cost-effectiveness, better postoperative quality of life, with similar mortality and oncologic outcomes, compared to open gastrectomy.","It hypothesized laparoscopic gastrectomy result shorter postoperative hospital stay, lower postoperative morbidity, readmissions, cost-effectiveness, postoperative quality life, mortality oncologic outcomes, compared gastrectomy.",G0000000|G0000000|C0031150|C0017118|C1274040|C1282927|C0032790|C0019994|G0000000|C0441994|C0032790|C0026538|G0000000|C0010181|C0032790|C0332306|C0376558|C0026565|C0205478|C1274040|C1707455|C0017118
"There were no occurrences of myocardial infarction, systemic embolic events, or pulmonary embolism during the study.","There occurrences myocardial infarction, systemic embolic events, pulmonary embolism study.",G0000000|C2745955|C0027061|C0021308|C0205373|C0013922|C0441471|C0024109|C0013922|C0557651
"Means and standard deviations for the time needed to control the seizure, O2 saturation and pulse rate were calculated in both case and control groups and paired t-test was performed to compare the results.","Means standard deviations time control seizure, O2 saturation pulse rate calculated control paired t-test performed compare results.",C1704970|C1442989|C0012727|C0040223|C0243148|C0036572|C0300971|C0522534|C0232117|C0871208|C0444686|C0243148|C1709450|C0871472|C0884358|C1707455|C1274040
"The primary endpoint was trough FEV1 on day 85, defined as the mean of the FEV1 values obtained 23 and 24 h after the last study dose, in the per-protocol population.","The primary endpoint trough FEV1 day 85, defined FEV1 values 23 24 h study dose, per-protocol population.",G0000000|C0205225|C2349179|C0444506|G0000000|C0332173|C0450371|C1704788|G0000000|C0042295|C0450371|G0000000|C0557651|C0178602|C1698058|C0032659
"At baseline, there were no significant differences between the LPA and FME groups on FIQ, pain, fatigue, depression, number of tender points, BMI, and six-minute walk distance (see Table Table3).3).","At baseline, differences LPA FME FIQ, pain, fatigue, depression, tender points, BMI, six-minute walk distance (see Table Table3).3).",G0000000|C0168634|C1705241|C1096202|G0000000|G0000000|C0030193|C0015672|C0011570|C0234234|C1552961|G0000000|C0205452|C0080331|C0012751|C0042789|C0039224|G0000000
"In a pilot study where daily bleeding was assessed in the Dutch centres that currently participate in the PREPAReS, we found that 54% of patients present with grade >2 bleeding at some point in their clinical course.29 As this is comparable to the STOP trial, published in 2009, we used these pilot data for the power calculation of the PREPAReS.25 Secondary outcomes contribute to the evaluation of non-inferiority of pathogen-reduced platelet products in this patient population: the frequency of 1 h and 24 h post-transfusion platelet increment failures (defined as 1 h CCI <7.5 and 24 h CCI <4.5), the percentage of days that bleedings ≥WHO grade 2 occur, the incidence of adverse reactions, the transfusion requirement of red cells and platelets, and the platelet concentrate transfusion interval, and the incidence of HLA alloimmunisation.","In pilot study daily bleeding assessed Dutch centres participate PREPAReS, 54% patients grade >2 bleeding clinical course.29 As comparable STOP trial, published 2009, pilot data power calculation PREPAReS.25 Secondary outcomes contribute evaluation non-inferiority pathogen-reduced platelet products patient population: frequency 1 24 h post-transfusion platelet increment failures (defined 1 h CCI <7.5 24 h CCI <4.5), percentage days bleedings ≥WHO grade 2 occur, incidence adverse reactions, transfusion requirement red cells platelets, platelet concentrate transfusion interval, incidence HLA alloimmunisation.",G0000000|C0473169|C0557651|C0332173|C0019080|C1516048|C0013331|C0205099|G0000000|C1521827|C0450371|C0030705|C0441800|G0000000|C0019080|C0205210|C0750729|G0000000|G0000000|C1947925|C0008976|C0034037|G0000000|C0473169|C1511726|C0032863|C1441506|C1521827|C0027627|C1274040|C1880177|C0220825|C1518422|C0450254|C0005821|C1514468|C0030705|C0032659|C0376249|G0000000|G0000000|C1979579|C0005821|C1705117|C0231174|C1704788|G0000000|C1861617|G0000000|G0000000|C1861617|G0000000|C0439165|C0439228|C0019080|G0000000|C0441800|G0000000|C1709305|C0021149|G0000000|C0443286|C0005841|C1514873|C0332575|C0007634|C0005821|C0005821|C1880310|C0005841|C1272706|C0021149|C4049595|C0948201
"Key secondary endpoints, tested hierarchically, include (i) cardiovascular events (cardiovascular death, non‐fatal myocardial infarction, and non‐fatal stroke), (ii) coronary events (cardiac death, non‐fatal myocardial infarction, coronary revascularization, and hospitalization for unstable angina), and (iii) time to cardiovascular death.","Key secondary endpoints, tested hierarchically, (i) cardiovascular events (cardiovascular death, non‐fatal myocardial infarction, non‐fatal stroke), (ii) coronary events (cardiac death, non‐fatal myocardial infarction, coronary revascularization, hospitalization unstable angina), (iii) time cardiovascular death.",G0000000|C0027627|C2349179|C0392366|G0000000|C0021966|C0007226|C0441471|C0007226|C0011065|G0000000|C0027061|C0021308|G0000000|C0038454|G0000000|C0018787|C0441471|C0018787|C0011065|G0000000|C0027061|C0021308|C0018787|C0581603|C0019993|C0443343|C0002962|C0439070|C0040223|C0007226|C0011065
"Body symmetry (baropodometry), static balance (stabilometry), functional balance (Berg Balance Scale), functional mobility (Timed Up and Go test), and independence in activities of daily living (Functional Independence Measure) were assessed before and after the intervention.","Body symmetry (baropodometry), static balance (stabilometry), functional balance (Berg Balance Scale), functional mobility (Timed Up Go test), independence activities daily living (Functional Independence Measure) assessed intervention.",C0242821|C0332516|G0000000|C0441463|C0014653|G0000000|C0205245|C0014653|G0000000|C0014653|C0175659|C0205245|C0425245|C0392761|G0000000|C1822658|C0022885|C0085862|C0441655|C0332173|C0376558|C0205245|C0085862|C0079809|C1516048|C0886296
"z Scores based on healthy, age-matched control norms for the time on the Color-Word portion of the Stroop Test,21 COWAT,21 long-delay free-recall portion of the CVLT-II,22 and PASAT1,23 were used for the analysis of the primary outcome (multivariate test).","Scores based healthy, age-matched control norms time Color-Word portion Stroop Test,21 COWAT,21 long-delay free-recall portion CVLT-II,22 PASAT1,23 analysis primary outcome (multivariate test).",C0449820|C1527178|C3898900|C0001779|C0243148|C0205307|C0040223|C0009393|C0449719|G0000000|C0022885|C3827022|C0205166|C0332296|C0449719|C3899729|C0450371|C0002778|C0205225|C1274040|G0000000|C0022885
Time to cognitive failure was defined as the first cognitive failure on any of the neurocognitive tests.,Time cognitive failure defined cognitive failure neurocognitive tests.,C0040223|C1516691|C0231174|C1704788|C1516691|C0231174|C0518895|C0022885
"The fever clearance time and parasite clearance time were slightly longer in chloroquine treated group (21.8 hr vs 25.3 hr, P = 0.12; and 41.6 hr vs 55.8 hr, P < 0.01, respectively).","The fever clearance time parasite clearance time chloroquine treated (21.8 hr 25.3 hr, P = 0.12; 41.6 hr 55.8 hr, P < 0.01, respectively).",G0000000|C0015967|C0449297|C0040223|C0030498|C0449297|C0040223|C0008269|C1522326|C0450371|G0000000|C0450371|G0000000|C0369773|G0000000|C0450371|C0450371|G0000000|C0450371|G0000000|C0369773|G0000000|C0450371|G0000000
"Postoperatively, all the cases were monitored for any distention, time of appearance of bowel sounds, time of passage of the first flatus and stool, return of appetite, and complications (if any) were recorded.","Postoperatively, monitored distention, time appearance bowel sounds, time passage flatus stool, return appetite, complications (if any) recorded.",G0000000|C0030695|C0012359|C0040223|C0233426|C0021853|C0037709|C0040223|C0439799|C0016204|C0015733|C0332156|C0003618|C0009566|G0000000|G0000000|C0034869
Pneumonia on admission was seen in all the children and was associated with higher mortality if presented with diffuse alveolar infiltrate.,Pneumonia admission children mortality diffuse alveolar infiltrate.,C0032285|C0184666|C0008059|C0026565|C0205219|C1440080|C0332448
"Of the nine outcomes repeatedly measured at Post 1 and Post 2 among adults and youth who received the full dose, all were in the expected direction.","Of outcomes repeatedly measured Post 1 Post 2 adults youth received dose, expected direction.",G0000000|C1274040|C0205341|C0444706|C0687676|G0000000|C0687676|G0000000|C0001675|C0001578|C1514756|C0178602|C1517001|C0449738
The criteria of implant success are: - implant survival - no abnormal mobility Implant stability will be tested post implant placement and throughout the orthodontic controls using the percussion test.,The criteria implant success are: - implant survival - abnormal mobility Implant stability tested post implant placement orthodontic controls percussion test.,G0000000|C0243161|C0021102|C0597535|G0000000|G0000000|C0021102|C0038952|G0000000|C0205161|C0425245|C0021102|C0205360|C0392366|C0687676|C0021102|C0441587|C0332276|C0243148|C0030987|C0022885
"CONCLUSIONS—In a small randomised placebo controlled trial in a highly selected group of neonates, adjuvant treatment with rhG-CSF increased ANC rapidly, and no treatment related adverse events were identified.","CONCLUSIONS—In randomised placebo controlled trial highly selected neonates, adjuvant treatment rhG-CSF increased ANC rapidly, treatment adverse events identified.",G0000000|G0000000|C0032042|C2587213|C0008976|C0205250|C1707391|C0021289|C0001551|C0039798|C0376562|C0205217|C0948762|C0456962|C0039798|G0000000|C0441471|C0205396
The primary end point was reached at 6 months in sustained remission or at time of relapse.,The primary reached 6 months sustained remission time relapse.,G0000000|C0205225|C2584321|G0000000|C0439231|C0443318|C0544452|C0040223|C0035020
"Secondary outcome variables were the common comorbid syndromes of depression, anxiety, and externalizing behaviors.","Secondary outcome variables common comorbid syndromes depression, anxiety, externalizing behaviors.",C0027627|C1274040|C0439828|C0205214|C0009488|C0039082|C0011570|C0003467|G0000000|C0004927
There were no vaccine related grade 3 or greater adverse events after three immunizations with the 0.25 mL dose.,There vaccine grade 3 adverse events immunizations 0.25 mL dose.,G0000000|C0042210|C0441800|G0000000|G0000000|C0441471|C0020971|G0000000|C0178602
The primary outcome was survival to hospital discharge.,The primary outcome survival hospital discharge.,G0000000|C0205225|C1274040|C0038952|C0019994|C0012621
The primary outcomes in this study will be the percentage of women that experienced exacerbations during pregnancy (moderate and severe) defined as events for which the participant sought medical attention (i.e.,The primary outcomes study percentage women experienced exacerbations pregnancy (moderate severe) defined events participant sought medical attention (i.e.,G0000000|C0205225|C1274040|C0557651|C0439165|C0043210|C0237607|G0000000|C0032961|C0205081|C0205082|C1704788|C0441471|C0679646|G0000000|C0199168|C0004268|C0683454
"Of the 4 hypotheses regarding outcome variables measured on patients of surgeons and oncologists (Table 4 ▶), 2 were supported (patient satisfaction and the patients feeling better).","Of 4 hypotheses outcome variables measured patients surgeons oncologists (Table 4 ▶), 2 supported (patient satisfaction patients feeling better).",G0000000|G0000000|C1512571|C1274040|C0439828|C0444706|C0030705|C0582175|C0259990|C0039224|G0000000|G0000000|G0000000|C1521721|C0030705|C0242428|C0030705|C0013987|C0332272
A confirmed EDSS progression was defined as a progression confirmed at a scheduled study visit ≥140 days later.,A confirmed EDSS progression defined progression confirmed scheduled study visit ≥140 days later.,G0000000|C0521093|C0451246|C0242656|C1704788|C0242656|C0521093|C0086960|C0557651|C0545082|G0000000|C0439228|C0205087
"Outcomes assessed at pre‐test, 2‐week post‐intervention and again 5‐months post‐intervention included weight, mouthfuls of food taken, self‐feeding and maternal responsiveness.","Outcomes assessed pre‐test, 2‐week post‐intervention 5‐months post‐intervention included weight, mouthfuls food taken, self‐feeding maternal responsiveness.",C1274040|C1516048|G0000000|G0000000|G0000000|G0000000|G0000000|C0332257|C0005910|G0000000|C0016452|C1883727|G0000000|C2347083|C0205342
We aimed to study the impact of psychoeducation on the burden of schizophrenia on the family in a randomised controlled trial.,We aimed study impact psychoeducation burden schizophrenia family randomised controlled trial.,G0000000|C1947946|C0557651|C1825598|C0871175|C2828008|C0036341|C0015576|G0000000|C2587213|C0008976
"The scales for normative beliefs; decision making, goal setting, and drug resistance skills; stress management; social skills; self-esteem (Fearnow-Kenney et al.","The scales normative beliefs; decision making, goal setting, drug resistance skills; stress management; social skills; self-esteem (Fearnow-Kenney al.",G0000000|C0175659|G0000000|C0004951|C0679006|C1881534|C0018017|C0542559|C0013227|C0237834|C0678856|C0038435|C0001554|C0728831|C0678856|C0036597|G0000000|C0202311
eChange between scores measured at baseline and 2 weeks.,eChange scores measured baseline 2 weeks.,G0000000|C0449820|C0444706|C0168634|G0000000|C0439230
"Moreover, no previous study has focused on the effects of post-stroke exercise on measures of arterial stiffness or cardiac structure and function, yet hemodynamic changes may represent early measurable improvement in cardiovascular function.","Moreover, previous study focused effects post-stroke exercise measures arterial stiffness cardiac structure function, hemodynamic represent measurable improvement cardiovascular function.",G0000000|C0205156|C0557651|C0205234|C1280500|C0687676|C0015259|C0079809|C0003842|C0427008|C0018787|C0678594|C0031843|C0019010|C1882932|C1513040|C2986411|C0007226|C0031843
"Effect of tranexamic acid on total haemorrhage growth among patients with, or at risk of, serious extracranial bleeding and traumatic brain injury who were allocated tranexamic acid or placebo.","Effect tranexamic acid total haemorrhage growth patients with, risk of, extracranial bleeding traumatic brain injury allocated tranexamic acid placebo.",C1280500|G0000000|C0001128|C0439175|C0019080|C0018270|C0030705|G0000000|C0035647|G0000000|C0580586|C0019080|C0332663|C0006104|C3263722|G0000000|G0000000|C0001128|C0032042
"Mean days to relapse, Wald values, p-values, and ORs are provided in Table 4.","Mean days relapse, Wald values, p-values, ORs provided Table 4.",C0444504|C0439228|C0035020|G0000000|C0042295|C1709380|C0069590|C1999230|C0039224|G0000000
"The patients scored their symptoms (lungs and nose), morning and evening peak flow values, and rescue medication for 14 days before and after the intervention period.","The patients scored symptoms (lungs nose), morning evening peak flow values, rescue medication 14 days intervention period.",G0000000|C0030705|C0449820|C0683368|C0024109|C0028429|C0332170|C0587117|C0444505|C0806140|C0042295|G0000000|C0013227|C0450371|C0439228|C0886296|C0439531
"The subjects sustained a cycle ergometer exercise test during which maximal workload, maximal heart rate, maximal oxygen uptake (VO2max) were recorded, and were randomly allocated to placebo or active treatment (2.5 mg Ramipril daily).","The subjects sustained cycle ergometer exercise test maximal workload, maximal heart rate, maximal oxygen uptake (VO2max) recorded, randomly allocated placebo active treatment (2.5 Ramipril daily).",G0000000|C0681850|C0443318|C1511572|C0180748|C0015259|C0022885|C0205289|C0085122|C0205289|C0018787|C0871208|C0205289|C0030054|C0243144|G0000000|C0034869|G0000000|G0000000|C0032042|C0205177|C0039798|G0000000|C0072973|C0332173
"At baseline, 61.4% of participants reported having a partial smoking ban; 38.6% reported having no restriction on smoking in the home.","At baseline, 61.4% participants reported partial smoking ban; 38.6% reported restriction smoking home.",G0000000|C0168634|C0450371|C0679646|C0684224|C0728938|C0037369|C0683610|C0450371|C0684224|C0443288|C0037369|C0442519
"It is hypothesized that laparoscopic gastrectomy leads to shorter hospital stay, lower postoperative morbidity, less readmissions, higher cost-effectiveness, higher postoperative quality of life, and more patients fit for postoperative chemotherapy, with similar mortality and oncologic outcomes compared to the current standard of care, i.e.","It hypothesized laparoscopic gastrectomy leads shorter hospital stay, lower postoperative morbidity, readmissions, cost-effectiveness, postoperative quality life, patients fit postoperative chemotherapy, mortality oncologic outcomes compared current standard care, i.e.",G0000000|G0000000|C0031150|C0017118|C0023175|C1282927|C0019994|G0000000|C0441994|C0032790|C0026538|G0000000|C0010181|C0032790|C0332306|C0376558|C0030705|C0036572|C0032790|C0013216|C0026565|C0205478|C1274040|C1707455|C0521116|C1442989|C1947933|C0683454
SOPLAY has been found to be both valid and reliable in school-aged children [59] and has been previously used to assess physical activity in the childcare setting [60].,SOPLAY valid reliable school-aged children [59] assess physical activity childcare setting [60].,G0000000|C2349099|C3858758|C0036375|C0008059|C0450371|C1516048|C0031809|C0205177|C0008067|C0542559|C0450371
Means and Standard Deviations for Outcome Measures by Race and Group Assignment Note: MSC = minimal support control condition; STC = skills training condition; AA = African American; RMBPC = Revised Memory and Behavior Problem Checklist; CES-D = Center for Epidemiological Studies–Depression scale.,Means Standard Deviations Outcome Measures Race Group Assignment Note: MSC = minimal support control condition; STC = skills training condition; AA = African American; RMBPC = Revised Memory Behavior Problem Checklist; CES-D = Center Epidemiological Studies–Depression scale.,C1704970|C1442989|C0012727|C1274040|C0079809|C0034510|C0441833|C1516050|C1316572|G0000000|G0000000|C0547040|C0183683|C0243148|C0012634|C1364160|G0000000|C0678856|C0040607|C0012634|C0282379|G0000000|C0027567|C0596070|G0000000|G0000000|C1527075|C0025260|C0004927|C0033213|C1707357|C2699160|G0000000|C0205099|C0014507|G0000000|C0175659
A full 48% of CBI participants met the 75% reduction target and 31% of the CBI participants met the abstinence target (cotinine <4ppm) at week 12.,A 48% CBI participants met 75% reduction target 31% CBI participants met abstinence target (cotinine <4ppm) week 12.,G0000000|C0450371|G0000000|C0679646|C0268621|C0450371|C0301630|C1521840|C0450371|G0000000|C0679646|C0268621|C3843422|C1521840|C0010194|G0000000|C0332174|C0450371
"Participants completed follow-up assessments of physical activity, pain, fibromyalgia-related function, fatigue, depression, number of tender points, 6-minute walk test, and perceived improvement at 6 and 12 months after intervention.","Participants completed follow-up assessments physical activity, pain, fibromyalgia-related function, fatigue, depression, tender points, 6-minute walk test, perceived improvement 6 12 months intervention.",C0679646|C0205197|C0589120|C1261322|C0031809|C0205177|C0030193|C0016053|C0031843|C0015672|C0011570|C0234234|C1552961|C0439232|C0080331|C0022885|C0030971|C2986411|G0000000|C0450371|C0439231|C0886296
Depression or persistent depressed mood was measured by the Cornell Scale for Depression in Dementia (CSDD).,Depression persistent depressed mood measured Cornell Scale Depression Dementia (CSDD).,C0011570|C0205322|C0344315|C0026516|C0444706|G0000000|C0175659|C0011570|C0011265|G0000000
"Secondary outcome indicators included AN symptoms or their consequences (eating symptoms, body mass index, amenorrhea, number of hospitalizations in the course of follow-up, social adjustment).","Secondary outcome indicators included AN symptoms consequences (eating symptoms, body mass index, amenorrhea, hospitalizations follow-up, social adjustment).",C0027627|C1274040|C0021212|C0332257|G0000000|C0683368|C0686907|C0013470|C0683368|C0242821|C0577559|C0918012|C0002453|C0019993|C0589120|C0728831|C0376209
"The data regarding the usage of CPAP by the patients were recorded and handled with professional software (ResMed SCAN 5.3, NSW, Australia) at each clinical visit.","The data usage CPAP patients recorded handled professional software (ResMed SCAN 5.3, NSW, Australia) clinical visit.",G0000000|C1511726|C0457083|C0199451|C0030705|C0034869|C1708320|C0679924|C0037585|G0000000|C0034606|G0000000|G0000000|C0004340|C0205210|C0545082
Annualised relapse rate (ARR) by year in the total number of patients observed overall and during each study year.,Annualised relapse rate (ARR) total patients observed study year.,G0000000|C0035020|C0871208|G0000000|C0439175|C0030705|C1441672|C0557651|C0439234
"The Primary endpoint is progression-free survival and secondary endpoints are overall survival, time to treatment failure, tumor response rate and safety.","The Primary endpoint progression-free survival secondary endpoints survival, time treatment failure, tumor response rate safety.",G0000000|C0205225|C2349179|C0242656|C0038952|C0027627|C2349179|C0038952|C0040223|C0039798|C0231174|C0027651|C0871261|C0871208|C0036043
"Secondary endpoints include the sub-measures of the MAPPIN-inventory (MAPPIN-Onurse, MAPPIN-Ophysician, MAPPIN-Opatient, MAPPIN-Qnurse, MAPPIN-Qpatient and MAPPIN-Qphysician), informed choice, decisional conflict and the duration of encounters.","Secondary endpoints sub-measures MAPPIN-inventory (MAPPIN-Onurse, MAPPIN-Ophysician, MAPPIN-Opatient, MAPPIN-Qnurse, MAPPIN-Qpatient MAPPIN-Qphysician), informed choice, decisional conflict duration encounters.",C0027627|C2349179|C0542339|C0006360|C0006360|C0006360|C0006360|C0006360|C0006360|C0006360|C1522154|C0008300|C0679006|C0009671|C0449238|C0545082
The primary endpoint was the rate of new active lesion development on cranial MRI scan.,The primary endpoint rate active lesion development cranial MRI scan.,G0000000|C0205225|C2349179|C0871208|C0205177|C0221198|C0243107|C0037303|C0024485|C0034606
"Baseline characteristics of the sample as a function of treatment condition ARCS, Adults Responses to Children's Symptoms; CDI, Child Depression Inventory; CSI, Children's Somatization Inventory; ES, Education Support; FACES, Faces Pain Scale-Revised; FDI, Functional Disability Inventory; GI, gastrointestinal; IBS, irritable bowel syndrome; PBQ, Pain Beliefs Questionnaire; PRI, Pain Response Inventory; SLCBT, Social Learning/Cognitive Behavioral Therapy.","Baseline characteristics sample function treatment condition ARCS, Adults Responses Children's Symptoms; CDI, Child Depression Inventory; CSI, Children's Somatization Inventory; ES, Education Support; FACES, Faces Pain Scale-Revised; FDI, Functional Disability Inventory; GI, gastrointestinal; IBS, irritable bowel syndrome; PBQ, Pain Beliefs Questionnaire; PRI, Pain Response Inventory; SLCBT, Social Learning/Cognitive Behavioral Therapy.",C0168634|C1521970|C0370003|C0031843|C0039798|C0012634|C1859722|C0001675|C0871261|C0008059|C0683368|C0282601|C0008059|C0011570|C0021941|G0000000|C0008059|C0149779|C0021941|C0013754|C0013621|C0183683|C0015450|C0015450|C0030193|C0175659|G0000000|C0205245|C0231170|C0021941|C1708130|C0521362|C0022104|C0022107|C0021853|C0039082|G0000000|C0030193|C0004951|C0034394|C0034044|C0030193|C0871261|C0021941|G0000000|C0728831|C0013621|C0004927|C0039798
"Cross-sectional disease prevalence surveys occurred prior to MDA and 1, 3 and 6 months post-MDA.","Cross-sectional disease prevalence surveys occurred prior MDA 1, 3 6 months post-MDA.",C0552389|C0012634|C0033105|C0038951|C1709305|C0332152|C0000379|G0000000|G0000000|G0000000|C0439231|C0687676
These findings indicated stable values for shoulder pain report as measured by the WUSPI.,These findings stable values shoulder pain report measured WUSPI.,G0000000|C2607943|C0205360|C0042295|C0037004|C0030193|C0684224|C0444706|G0000000
"Urine weekly creatinine clearances declined at a slower rate in the biocompatible arm (p = 0.024), while peritoneal weekly creatinine clearances did not differ between groups.","Urine weekly creatinine clearances declined slower rate biocompatible arm (p = 0.024), peritoneal weekly creatinine clearances groups.",C0042036|C0332174|C0010294|C0449297|G0000000|C0439834|C0871208|C0596177|C0446516|C0369773|G0000000|C1442061|C0031153|C0332174|C0010294|C0449297|C0441833
Future research should examine the impact of CFFONE™ on social support and family functioning.,Future examine impact CFFONE™ social support family functioning.,C0016884|G0000000|C1825598|G0000000|C0728831|C0183683|C0015576|C0205245
Baseline data were defined as the most recent clinic BP or laboratory value within the prior 12 months.,Baseline data defined clinic BP laboratory prior 12 months.,C0168634|C1511726|C1704788|C0002424|C0037623|C0022877|C0332152|C0450371|C0439231
"Fatigue was determined in 35 (21.6 %) participants: 21 (13 %) with mild (CTCAE grade-1), 11 (6.8 %) with moderate (CTCAE grade-2), and 3 (1.8 %) with severe fatigue (CTCAE grade-3).","Fatigue determined 35 (21.6 %) participants: 21 (13 %) mild (CTCAE grade-1), 11 (6.8 %) moderate (CTCAE grade-2), 3 (1.8 %) severe fatigue (CTCAE grade-3).",C0015672|G0000000|C0450371|C0450371|G0000000|C0679646|C0450371|C0450371|G0000000|C2945599|C1516728|C3814800|C0450371|G0000000|G0000000|C0205081|C1516728|C3814800|G0000000|G0000000|G0000000|C0205082|C0015672|C1516728|C3814800
number 477/13/EC).,477/13/EC).,C1442061
"Current breastfeeding rates as reported by mothers in the intervention and control group, respectively, were as follows: 21% and 18% at baseline, 23% and 20% at 6 months, 22% and 22% at 9 months, 21% and 19% at 12 months, and 20% and 20% at 24 months (final visit).","Current breastfeeding rates reported mothers intervention control group, respectively, follows: 21% 18% baseline, 23% 20% 6 months, 22% 22% 9 months, 21% 19% 12 months, 20% 20% 24 months (final visit).",C0521116|C0006147|C0871208|C0684224|C0026591|C0886296|C0243148|C0441833|G0000000|C0332283|C0450371|C0450371|C0168634|C0450371|C0450371|G0000000|C0439231|C0450371|C0450371|G0000000|C0439231|C0450371|C0450371|C0450371|C0439231|C0450371|C0450371|C0450371|C0439231|C0205088|C0545082
There were no significant differences between the two arms at baseline or for success (defined as a healed or healing ulcer) at final visit (p = 0.79).,There differences arms baseline success (defined healed healing ulcer) final visit (p = 0.79).,G0000000|C1705241|C0206655|C0168634|C0597535|C1704788|C0205249|C0043240|C0041582|C0205088|C0545082|C0369773|G0000000|C0450371
"Secondary objectives were to compare OS time after randomisation and toxicity (assessed according to the Common Toxicity Criteria of the National Cancer Institute, CTC, Version 2.0) in the two treatment groups.","Secondary objectives compare OS time randomisation toxicity (assessed Common Toxicity Criteria National Cancer Institute, CTC, Version 2.0) treatment groups.",C0027627|C0018017|C1707455|C0229090|C0040223|C0034656|C0040539|C1516048|C0205214|C0040539|C0243161|C3245503|C0006826|C0021622|G0000000|C0333052|G0000000|C0039798|C0441833
"Prespecified secondary end points were the number of days survived in 90 days following inclusion, delirium incidence, number of delirium-free and coma-free days over 28 days, duration of mechanical ventilation, and length of ICU and hospital stay.","Prespecified secondary days survived 90 days inclusion, delirium incidence, delirium-free coma-free days 28 days, duration mechanical ventilation, length ICU hospital stay.",G0000000|C0027627|C0439228|C0310255|C0450371|C0439228|C0007637|C0011206|C0021149|C0011206|C0009421|C0439228|C0450371|C0439228|C0449238|C0443254|C0035203|C1444754|C0021708|C0019994|G0000000
"Nineteen years after identification and 8 years after intervention ended, relative to control subjects, individuals randomly assigned to intervention displayed lower prevalence of externalizing problems, internalizing problems, substance use problems, violent and drug crime convictions, risky sexual behavior, and spanking of participants’ offspring, as well as higher well-being.","Nineteen identification 8 intervention ended, relative control subjects, individuals randomly assigned intervention displayed lower prevalence externalizing problems, internalizing problems, substance problems, violent drug crime convictions, risky sexual behavior, spanking participants’ offspring, well-being.",C0450337|C0020792|G0000000|C0886296|C1272693|C0080103|C0243148|C0681850|C0027361|G0000000|C1516050|C0886296|C0870432|C0441994|C0033105|G0000000|C1546466|G0000000|C1546466|C0439861|C1546466|C0242151|C0013227|C0010325|G0000000|C0035647|C0036864|C0004927|G0000000|G0000000|C0680063|C0018684
"Standard microbiologic techniques were used.11 Pneumonia was defined as the presence of new (or progressive) pulmonary infiltrates persisting for more than 48 hours on chest x-ray, in addition to at least 2 of the following criteria: (i) fever ≥38.5°C or hypothermia <35.0°C; (ii) leukocytosis ≥10,000/mm3 or leukopaenia <3000/mm3,11; (iii) isolation of potential pathogens in high concentration of ≥4+ [107 colony forming units/mL] using semiquantitative culture, from unprotected purulent tracheal aspirates.12–14 The diagnosis of pneumonia was made by 1 intensivist (EC) and 1 radiologist (DGS) not involved in the patient care and who were blinded to the treatment assignment.","Standard microbiologic techniques used.11 Pneumonia defined presence (or progressive) pulmonary infiltrates persisting 48 hours chest x-ray, addition 2 criteria: (i) fever ≥38.5°C hypothermia <35.0°C; (ii) leukocytosis ≥10,000/mm3 leukopaenia <3000/mm3,11; (iii) isolation potential pathogens concentration ≥4+ [107 colony forming units/mL] semiquantitative culture, unprotected purulent tracheal aspirates.12–14 The diagnosis pneumonia 1 intensivist (EC) 1 radiologist (DGS) involved patient care blinded treatment assignment.",C1442989|C0025952|C0025664|C1273517|C0032285|C1704788|C0150312|G0000000|C0205329|C0024109|C0332448|G0000000|C0450371|C0439227|C0817096|C0034571|C0332287|G0000000|C0243161|C0021966|C0015967|G0000000|C0020672|G0000000|G0000000|C0023518|G0000000|G0000000|C0450371|C0439070|C0204727|C3245505|C0450254|C0004268|G0000000|C1442061|C0439158|C0205431|C2945590|G0000000|C0010453|G0000000|C0439665|C0040578|G0000000|G0000000|C0011900|C0032285|G0000000|G0000000|C3890233|G0000000|C0260194|C1275573|C1314939|C0030705|C1947933|C0150108|C0039798|C1516050
"Most of our key secondary endpoints such as the use of oxytocics, the mode of delivery, neonatal Apgar score at 5 minutes < 7 and maternal admission to the High Dependency Unit (HDU) or the Intensive Care Unit (ICU) will be obtained from the birth register.","Most key secondary endpoints oxytocics, mode delivery, neonatal Apgar score 5 minutes < 7 maternal admission High Dependency Unit (HDU) Intensive Care Unit (ICU) birth register.",C0205393|G0000000|C0027627|C2349179|C0030094|C1513371|C0011209|C1552240|C0741195|C0449820|G0000000|C0439232|G0000000|G0000000|C2347083|C0184666|C0205250|C0011546|C0439148|G0000000|C0162425|C1947933|C0439148|C0021708|C0005615|G0000000
"At weeks 0, 4, 8, 12, 16, 20, 24, 30, 36, 42, and 48, participants received telephone counseling that focused on managing urges and triggers to smoking and developing strategies to avoid relapse.","At weeks 0, 4, 8, 12, 16, 20, 24, 30, 36, 42, 48, participants received telephone counseling focused managing urges triggers smoking developing strategies avoid relapse.",G0000000|C0439230|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0679646|C1514756|C0039457|C0010210|C0205234|C1273870|G0000000|C0032930|C0037369|G0000000|C0679199|G0000000|C0035020
"Global pain status was assessed separately by the participant and the study physician, who was unaware of the group assignment, with the use of a visual-analogue scale (VAS) (range, 0 to 10, with higher scores indicating greater pain).","Global pain status assessed separately participant study physician, unaware assignment, visual-analogue scale (VAS) (range, 0 10, scores indicating pain).",C0205246|C0030193|C0449438|C1516048|G0000000|C0679646|C0557651|C0031831|C0150114|C1516050|C0234621|C0175659|C0042815|C1514721|G0000000|C0450371|C0449820|G0000000|C0030193
"In addition, patients received a symptom diary and instructions on how to complete it.","In addition, patients received symptom diary instructions complete it.",G0000000|C0332287|C0030705|C1514756|C1457887|C0376660|C0302828|C0205197|G0000000
"A reading was immediately taken, and after 5 minutes rest, 2 additional readings were taken separated by a 2-minute interval.","A reading taken, 5 minutes rest, 2 additional readings separated 2-minute interval.",G0000000|C0034754|C1883727|G0000000|C0439232|C0035253|G0000000|C1524062|C0034754|C0086972|C0439232|C1272706
"Details of symptoms, morning and evening peak flow, and medication use (ICS, bronchodilators, and other medication) were recorded weekly in diaries.","Details symptoms, morning evening peak flow, medication (ICS, bronchodilators, medication) recorded weekly diaries.",C1522508|C0683368|C0332170|C0587117|C0444505|C0806140|C0013227|C0022521|C0006280|C0013227|C0034869|C0332174|C0376660
Participants are evaluated thrice over 6 months.,Participants evaluated thrice 6 months.,C0679646|C0220825|G0000000|G0000000|C0439231
"Differences from baseline to6 months between trainingand control group forsix minute walk test,spiroergometry, St. George’s RespiratoryQuestionnaire score, and ShortForm-12 questionnaire score 6MWT: Six minute walk test; CPET: cardiopulmonary exercise testing; MCS: Mental health component summary score; PCS: Physical component summary score; SF-12: Short form 12 quality of life questionnaire; SGRQ: St. George’s Respiratory Questionnaire.","Differences baseline to6 months trainingand control forsix minute walk test,spiroergometry, St. George’s RespiratoryQuestionnaire score, ShortForm-12 questionnaire score 6MWT: Six minute walk test; CPET: cardiopulmonary exercise testing; MCS: Mental health component summary score; PCS: Physical component summary score; SF-12: Short form 12 quality life questionnaire; SGRQ: St. George’s Respiratory Questionnaire.",C1705241|C0168634|C0040541|C0439231|G0000000|C0243148|G0000000|C0439232|C0080331|C0022885|C0036056|G0000000|G0000000|C0449820|C0450371|C0034394|C0449820|G0000000|C0205452|C0439232|C0080331|C0022885|C0055954|C0553534|C0015259|C0039593|G0000000|C0229992|C0018684|C0449432|C1552616|C0449820|C1864389|C0031809|C0449432|C1552616|C0449820|C0037712|C1282927|C0348078|C0450371|C0332306|C0376558|C0034394|G0000000|C0036056|G0000000|C0521346|C0034394
Attainment of 14 motor milestones was assessed weekly via an interview with the child's caregiver.,Attainment 14 motor milestones assessed weekly interview child's caregiver.,G0000000|C0450371|C1513492|C2347129|C1516048|C0332174|C0021822|C0008059|C0085537
"A Progression-free-Survival (PFS) in days (Progression: PD according to mRECIST): Treatment (trt) 1 SIRT, Treatment (trt) 2 TACE B Overall Survival.","A Progression-free-Survival (PFS) days (Progression: PD mRECIST): Treatment (trt) 1 SIRT, Treatment (trt) 2 TACE B Overall Survival.",G0000000|C0242792|C0242792|C0439228|C0242656|G0000000|G0000000|C0039798|G0000000|G0000000|C1831994|C0039798|G0000000|G0000000|C0723595|G0000000|C0282416|C0038952
"Therefore, this study aimed to determine the effectiveness of stress management training program on depression, anxiety and stress rate of the nursing students.","Therefore, study aimed determine effectiveness stress management training program depression, anxiety stress rate nursing students.",G0000000|C0557651|C1947946|G0000000|C1280519|C0038435|C0001554|C0040607|C1709697|C0011570|C0003467|C0038435|C0871208|C0006147|C0038492
"At baseline, the acute illness prevented the recording of physiological and exercise performance measures other than quadriceps strength.","At baseline, acute illness prevented recording physiological exercise performance measures quadriceps strength.",G0000000|C0168634|C0205178|C0221423|C0309872|G0000000|C0205463|C0015259|C0597198|C0079809|C0224440|C0237897
Main outcome measures Pain intensity both at rest and while walking as assessed by a visual analog scale at baseline and after 30 and 60 days of treatment.,Main outcome measures Pain intensity rest walking assessed visual analog scale baseline 30 60 days treatment.,C0205225|C1274040|C0079809|C0030193|C0522510|C0035253|C0080331|C1516048|C0234621|C0243071|C0175659|C0168634|C0450371|C0450371|C0439228|C0039798
A Bland-Altman plot of supine time agreement is shown in Figure 2.,A Bland-Altman plot supine time agreement Figure 2.,G0000000|G0000000|G0000000|C0038846|C0040223|C0680240|G0000000|G0000000
"Reactions could involve multiple simultaneous lesions, and multiple paradoxical episodes can also occur in the same patient, separated either in site or time.","Reactions involve multiple simultaneous lesions, multiple paradoxical episodes occur patient, separated site time.",C0443286|G0000000|C0439064|C0205420|C0221198|C0439064|C0205310|C0332189|C1709305|C0030705|C0086972|C0205145|C0040223
"Once informed consent was obtained, study participants were asked to complete baseline questionnaires (STAI, VAS for anticipated pain).","Once informed consent obtained, study participants complete baseline questionnaires (STAI, VAS anticipated pain).",C0585347|C1522154|C1511481|C1301820|C0557651|C0679646|C0205197|C0168634|C0034394|C0683457|C0042815|C3840775|C0030193
Birth prevalence measured annually as infants (live and stillbirths) with severe congenital heart defects per 1000 births in Quebec.,Birth prevalence measured annually infants (live stillbirths) severe congenital heart defects 1000 births Quebec.,C0005615|C0033105|C0444706|C0332181|C0021270|C1548795|C0595939|C0205082|C0009678|C0018787|C0243067|G0000000|C0005615|C0034390
Primary outcome: sustained smoking cessation (at 6 and 12 months) confirmed by urine cotinine test.,Primary outcome: sustained smoking cessation (at 6 12 months) confirmed urine cotinine test.,C0205225|C1274040|C0443318|C0037369|C1880019|G0000000|G0000000|G0000000|C0521093|C0042036|C0010194|C0022885
Median overall survival was 5 months (figure (figure11).,Median survival 5 months (figure (figure11).,C0549183|C0038952|G0000000|C0439231|G0000000|G0000000
"Covariates were age, sex, WHZ, HAZ, caretaker, mother alive, father alive, food group, breast-feeding status on enrollment, and weight gain after 2 wk of supplementary feeding.","Covariates age, sex, WHZ, HAZ, caretaker, mother alive, father alive, food group, breast-feeding status enrollment, weight gain 2 wk supplementary feeding.",G0000000|C0001779|C0009253|G0000000|G0000000|C0335350|C0026591|C0376558|C0015671|C0376558|C0016452|C0441833|C0006147|C0449438|C1516879|C0005910|C1517378|G0000000|C0332174|G0000000|C0204695
"Six months after the intervention, general practitioners again received feedback on their prescribing behaviour, based on insurance claims data comparing the period after the intervention (March to May 2001) with the same period before the intervention (March to May 2000).","Six months intervention, practitioners received feedback prescribing behaviour, based insurance claims data comparing period intervention (March May 2001) period intervention (March May 2000).",C0205452|C0439231|C0886296|C1709627|C1514756|C0015744|C0278329|C0004927|C1527178|C0021672|G0000000|C1511726|C1707455|C0439531|C0886296|C3829202|G0000000|G0000000|C0439531|C0886296|C3829202|G0000000|G0000000
Both FDCs significantly improved FEV1 AUC0–3 and trough FEV1 response versus the mono-components in both studies.,Both FDCs improved FEV1 AUC0–3 trough FEV1 response versus mono-components studies.,G0000000|C0340427|C0184511|G0000000|G0000000|C0444506|G0000000|C0871261|G0000000|C1551432|C0947630
"PSVQ at 24 months follow-up – those rating items as ‘excellent' or ‘very good' There were no statistically significant differences between study groups in the percentage of patients rating each item ‘excellent' or ‘very good' on the PSVQ scale, administered at 24 months, and with the exception of ‘contacting the doctor by telephone' and ‘time spent in the waiting room', the combined study group reported high levels of satisfaction with their care.","PSVQ 24 months follow-up – rating items ‘excellent' ‘very good' There statistically differences study percentage patients rating item ‘excellent' ‘very good' PSVQ scale, administered 24 months, exception ‘contacting doctor telephone' ‘time spent waiting room', combined study reported levels satisfaction care.",G0000000|C0450371|C0439231|C0589120|G0000000|C0871208|C1551338|G0000000|G0000000|C0205170|G0000000|C0038215|C1705241|C0557651|C0439165|C0030705|C0871208|C1551338|G0000000|G0000000|C0205170|G0000000|C0175659|C1521801|C0450371|C0439231|C1554961|G0000000|C0031831|C0039457|G0000000|C0680968|C1610166|C1547703|C0205195|C0557651|C0684224|C0441889|C0242428|C1947933
Mediators and smoking status were self-reported at 12 months post-intervention-eligibility (88.8% retention).,Mediators smoking status self-reported 12 months post-intervention-eligibility (88.8% retention).,C0127400|C0037369|C0449438|C0681906|C0450371|C0439231|C2347647|C0450371|C0035280
"The improvement in muscle strength carried over to better performance in the shuttle walk test in the treated group (36.1% v 1.6% in the treated and sham groups respectively, p=0.007, Mann-Whitney U test).","The improvement muscle strength carried performance shuttle walk test treated (36.1% 1.6% treated sham respectively, p=0.007, Mann-Whitney U test).",G0000000|C2986411|C0026845|C0237897|C0206243|C0597198|G0000000|C0080331|C0022885|C1522326|C0450371|G0000000|C1522326|C0068899|G0000000|C0369773|G0000000|G0000000|C0022885
"Smoking cessation was defined as successful in patients with smoking abstinence or ""occasional slips"" with a CO rate ≤ 10 ppm.","Smoking cessation defined successful patients smoking abstinence ""occasional slips"" CO rate ≤ 10 ppm.",C0037369|C1880019|C1704788|C0597535|C0030705|C0037369|C3843422|C0521114|C0337209|C3245499|C0871208|G0000000|C0450371|C0439187
“FRI” was defined either by a body temperature of >38°C and 1 respiratory symptom or by the presence of nonfebrile pneumonia.,“FRI” defined body temperature >38°C 1 respiratory symptom presence nonfebrile pneumonia.,G0000000|C1704788|C0242821|C0005903|G0000000|G0000000|C0521346|C1457887|C0150312|G0000000|C0032285
"The endpoints for the study included the number of attempts at and total number of days of stem cell collection, number of RBC and platelet transfusions during the transplantation period, time-to-recovery after transplantation, and response to intensive therapy for multiple myeloma.","The endpoints study included attempts total days stem cell collection, RBC platelet transfusions transplantation period, time-to-recovery transplantation, response intensive therapy multiple myeloma.",G0000000|C2349179|C0557651|C0332257|C1516084|C0439175|C0439228|C0242767|C0007634|C1516698|C0014792|C0005821|C0005841|C0040732|C0439531|C0040223|C0040732|C0871261|C0162425|C0039798|C0439064|C0026764
A normal score is 34 to 36.,A normal score 34 36.,G0000000|C0205307|C0449820|C0450371|C0450371
Serial standardized tests of cognitive function were performed.,Serial standardized tests cognitive function performed.,C0031082|G0000000|C0022885|C1516691|C0031843|C0884358
One local recurrence developed in each treatment cohort and neither transitioned to a higher grade of tumor.,One local recurrence developed treatment cohort transitioned grade tumor.,C0205447|C0205276|C0034897|G0000000|C0039798|C0599755|C0599156|C0441800|C0027651
"On each postoperative evening, the following side effects were assessed: daytime sedation, lightheadedness, feeling dizzy, nightmares, nausea, vomiting, and constipation.","On postoperative evening, effects assessed: daytime sedation, lightheadedness, feeling dizzy, nightmares, nausea, vomiting, constipation.",G0000000|C0032790|C0587117|C1280500|C1516048|C0332169|C0235195|C0012833|C0013987|C0012833|C0028084|C0027497|C0042963|C0009806
"In our population, patients with a higher VAS score for pain in the legs at baseline had less improvement in pain 6 weeks after vitamin D supplementation.","In population, patients VAS score pain legs baseline improvement pain 6 weeks vitamin D supplementation.",G0000000|C0032659|C0030705|C0042815|C0449820|C0030193|C1140621|C0168634|C2986411|C0030193|G0000000|C0439230|C0042890|C0073187|C0242297
"The secondary endpoints were response rate, progression-free survival (PFS), and overall survival (OS).","The secondary endpoints response rate, progression-free survival (PFS), survival (OS).",G0000000|C0027627|C2349179|C0871261|C0871208|C0242656|C0038952|C0242792|C0038952|C0229090
"In addition, there was no medical restriction to continue exclusive breastfeeding for up to 6 months of age.","In addition, medical restriction continue exclusive breastfeeding 6 months age.",G0000000|C0332287|C0199168|C0443288|C0549178|C1548966|C0006147|G0000000|C0439231|C0001779
"Liver function indexes Serum levels of total protein, albumin, ratio of albumin and globulin, ALT, aspartate aminotransferase (AST), γ-glutamyl transpeptidase (GGT), total bilirubin (TB), direct bilirubin (DB) and alkaline phosphatase (ALP).","Liver function indexes Serum levels total protein, albumin, ratio albumin globulin, ALT, aspartate aminotransferase (AST), γ-glutamyl transpeptidase (GGT), total bilirubin (TB), direct bilirubin (DB) alkaline phosphatase (ALP).",C0023884|C0031843|C0600653|C0229671|C0441889|C0439175|C0033684|C0001924|C0456603|C0001924|C0017649|C1266129|C0085845|C0002594|C3891303|G0000000|C0030962|C1415053|C0439175|C0005437|G0000000|C0439851|C0005437|C1418892|C1979842|C0031678|C3812647
The birth prevalence of severe congenital heart defects was determined annually as the number of infants (live births and stillbirths) born with severe congenital heart defects per 1000 births in Quebec.,The birth prevalence severe congenital heart defects determined annually infants (live births stillbirths) born severe congenital heart defects 1000 births Quebec.,G0000000|C0005615|C0033105|C0205082|C0009678|C0018787|C0243067|G0000000|C0332181|C0021270|C1548795|C0005615|C0595939|C0005615|C0205082|C0009678|C0018787|C0243067|G0000000|C0005615|C0034390
"Incidence of positive blood culture, wound culture, total leucocyte count, hospital-stay and mortality was recorded.","Incidence positive blood culture, wound culture, total leucocyte count, hospital-stay mortality recorded.",C0021149|C0439178|C0005767|C0010453|C0043250|C0010453|C0439175|C0023516|C0750480|C3489408|C0026565|C0034869
The main effectiveness outcome was the freedom from treatment failure rate 12 months after randomization.,The main effectiveness outcome freedom treatment failure rate 12 months randomization.,G0000000|C0205225|C1280519|C1274040|C0016694|C0039798|C0231174|C0871208|C0450371|C0439231|C0034656
"Mood was assessed using the ‘sad’ item of the Visual Analog Mood Scales16 and the Stroke Aphasic Depression Questionnaire 10-item hospital version,17 completed by a nurse, relative or carer.","Mood assessed ‘sad’ item Visual Analog Mood Scales16 Stroke Aphasic Depression Questionnaire 10-item hospital version,17 completed nurse, relative carer.",C0026516|C1516048|G0000000|C1551338|C0234621|C0243071|C0026516|G0000000|C0038454|C0234461|C0011570|C0034394|C0450371|C0019994|C0333052|C0205197|C0028661|C0080103|C0085537
"Secondary objectives included assessment of PFS, OS, toxicity and QOL.","Secondary objectives included assessment PFS, OS, toxicity QOL.",C0027627|C0018017|C0332257|C1261322|C0242792|C0229090|C0040539|C0518214
Patients in cooling group had a higher percentage of good GOS and statistically had a significant difference at 6 months post-trauma when compared to non-cooling group.,Patients cooling percentage GOS statistically difference 6 months post-trauma compared non-cooling group.,C0030705|C0678568|C0439165|G0000000|C0038215|C1705241|G0000000|C0439231|C0687676|C1707455|C1518422|C0441833
RESULTS: Attendance in the intervention group was significantly better than in the control group (9% v 4%).,RESULTS: Attendance intervention control (9% 4%).,C1274040|C2827364|C0886296|C0243148|G0000000|G0000000
Scores were summed across items with higher total scores indicating greater depressive symptomatology (α=.81 for sample).,Scores summed items total scores indicating depressive symptomatology (α=.81 sample).,C0449820|C1515051|C1551338|C0439175|C0449820|G0000000|G0000000|G0000000|G0000000|C0370003
Mortality According to the Underlying Cause of Death.,Mortality According Underlying Cause Death.,C0026565|C0680240|G0000000|C0015127|C0011065
"The atheroma volume index and neointimal volume index were calculated as the volume divided by the length of the measured atheroma, whereas percent atheroma volume was calculated as the ratio of atheroma volume to vessel volume×100.","The atheroma volume neointimal volume calculated volume divided length measured atheroma, percent atheroma volume calculated ratio atheroma volume vessel volume×100.",G0000000|C0264956|C0449468|C2936380|C0449468|C0444686|C0449468|C0332849|C1444754|C0444706|C0264956|C0439165|C0264956|C0449468|C0444686|C0456603|C0264956|C0449468|C0005847|G0000000
"Patients who withdraw due to AEs must be followed until the end of the study (8 weeks), and if necessary until AE resolution.","Patients withdraw AEs study (8 weeks), AE resolution.",C0030705|C2349954|C1412268|C0557651|G0000000|C0439230|C3887670|C1514893
"Outcome measures included symptom duration, prescription uptake, patient satisfaction, patient enablement, and subsequent consultation rates.","Outcome measures included symptom duration, prescription uptake, patient satisfaction, patient enablement, subsequent consultation rates.",C1274040|C0079809|C0332257|C1457887|C0449238|C0033080|C0243144|C0030705|C0242428|C0030705|G0000000|C0332282|C0009818|C0871208
"The dialysis nurse recorded the presence or absence of any bleeding or bruising events such as gastrointestinal bleed, epistaxis, heavy menstruation, prolonged hemostasis, bruising, or bleeding from the fistula or graft.","The dialysis nurse recorded presence absence bleeding bruising events gastrointestinal bleed, epistaxis, heavy menstruation, prolonged hemostasis, bruising, bleeding fistula graft.",G0000000|C0011945|C0028661|C0034869|C0150312|C0332197|C0019080|C0009938|C0441471|C0521362|C0019080|C0014591|C0439539|C0025344|C0439590|C0019116|C0009938|C0019080|C0016169|C0181074
The primary outcome measure will be the proportion of participants with 7-day point prevalence smoking abstinence assessed at 6-months follow-up.,The primary outcome measure proportion participants 7-day prevalence smoking abstinence assessed 6-months follow-up.,G0000000|C0205225|C1274040|C0079809|C1709707|C0679646|C0332173|C0033105|C0037369|C3843422|C1516048|C0439231|C0589120
"In the past decades, several studies have been conducted to determine the effectiveness of various types of nutritional intervention in elderly hip fracture patients on the length of stay, mortality, complications, nutritional and functional status.","In decades, studies conducted determine effectiveness types nutritional intervention elderly hip fracture patients length stay, mortality, complications, nutritional functional status.",G0000000|C2981279|C0947630|C0004927|G0000000|C1280519|C0332307|C1521739|C0886296|C0001792|C0019552|C0016658|C0030705|C1444754|G0000000|C0026565|C0009566|C1521739|C0205245|C0449438
The present study also showed that applying RAS to the gait of stroke patients not only increases the gait velocity but also increases the stride length and gait symmetry at the same time.,The study applying RAS gait stroke patients increases gait velocity increases stride length gait symmetry time.,G0000000|C0557651|C1632850|C0034678|C0016928|C0038454|C0030705|C0205217|C0016928|C0439830|C0205217|G0000000|C1444754|C0016928|C0332516|C0040223
"We found a group × time interaction [Wald χ2(2) = 168.06, p < 0.0001]; there was no between-groups difference at start of treatment but significantly lower seizure frequency at treatment end and a trend for lower seizure frequency at follow-up following CBT (figure 2 and table 3).","We × time interaction [Wald χ2(2) = 168.06, < 0.0001]; between-groups difference start treatment lower seizure frequency treatment trend lower seizure frequency follow-up CBT (figure 2 table 3).",G0000000|G0000000|C0040223|C1704675|G0000000|G0000000|G0000000|C1442061|G0000000|G0000000|C0441833|C1705241|C0439659|C0039798|C0441994|C0036572|C0376249|C0039798|C1521798|C0441994|C0036572|C0376249|C0589120|C0009244|G0000000|G0000000|C0039224|G0000000
"As compared with the routine treatment group, the median antibiotic duration was 5.8 days shorter in the PCT group (P=0.0001), and the patients exposed to antibiotics treatment were fewer in the PCT group.","As compared routine treatment group, median antibiotic duration 5.8 days shorter PCT (P=0.0001), patients exposed antibiotics treatment fewer PCT group.",G0000000|C1707455|C0205547|C0039798|C0441833|C0549183|C0003232|C0449238|G0000000|C0439228|C1282927|C1535922|C0369773|C0030705|C0332157|C0003232|C0039798|C0205388|C1535922|C0441833
"In addition to age and gender, multivariable models were further adjusted for body mass index (BMI) (continuous), smoking (never smokers, former smokers <15 pack-years, former smoker ≥15 pack-years, current smoker <27.5 pack-years, current smoker ≥27.5 pack-years), alcohol intake (continuous), education level (low, intermediate, high), income (low, intermediate, high), energy-adjusted unprocessed red meat (continuous), energy-adjusted processed red meat (continuous), total energy intake (continuous), use of hormone replacement therapy (HRT) (yes vs. no), prevalent diabetes mellitus (yes vs. no), family history of cancer (yes vs. no), Dutch Healthy Diet-index (DHD-index) (continuous), minerals supplemental use (yes vs. no) and physical activity (continuous).","In addition age gender, multivariable models adjusted body mass (BMI) (continuous), smoking (never smokers, smokers <15 pack-years, smoker ≥15 pack-years, current smoker <27.5 pack-years, current smoker ≥27.5 pack-years), alcohol intake (continuous), education level (low, intermediate, high), income (low, intermediate, high), energy-adjusted unprocessed red meat (continuous), energy-adjusted processed red meat (continuous), total energy intake (continuous), hormone replacement therapy (HRT) (yes vs. no), prevalent diabetes mellitus (yes vs. no), family history cancer (yes vs. no), Dutch Healthy Diet-index (DHD-index) (continuous), minerals supplemental (yes vs. no) physical activity (continuous).",G0000000|C0332287|C0001779|C0079399|G0000000|C3161035|C0456081|C0242821|C0577559|G0000000|C0549178|C0037369|C2003901|C0337664|C0337664|C0450371|C1277691|C0337664|G0000000|C1277691|C0521116|C0337664|C0450371|C1277691|C0521116|C0337664|G0000000|C1277691|C0001962|C1512806|C0549178|C0013621|C0441889|C0205251|C0205103|C0205250|C0021162|C0205251|C0205103|C0205250|C0424589|C1709843|C0332575|C0025017|C0549178|C0424589|C1522240|C0332575|C0025017|C0549178|C0439175|C0424589|C1512806|C0549178|C0019932|C0035139|C0039798|C0282402|C1549445|G0000000|G0000000|C0033105|C0011847|G0000000|C1549445|G0000000|G0000000|C0015576|C0019664|C0006826|C1549445|G0000000|G0000000|C0013331|C3898900|C0012155|C0344247|C0549178|C0026162|C2348609|C1549445|G0000000|G0000000|C0031809|C0205177|C0549178
"A case was considered confirmed if was determined to be a definite or probable case by the treating physician (84.6% neurologist, 9.7% internist) or if blinded medical record review by a movement disorder specialist (5.7%) found a final PD diagnosis by a neurologist or 2 of 3 cardinal features (bradykinesia, resting tremor, rigidity) in the absence of evidence suggesting an alternative diagnosis.","A considered confirmed determined definite probable treating physician (84.6% neurologist, 9.7% internist) blinded medical record review movement disorder specialist (5.7%) final PD diagnosis neurologist 2 3 cardinal features (bradykinesia, resting tremor, rigidity) absence evidence suggesting alternative diagnosis.",G0000000|C0750591|C0521093|G0000000|C0439544|C0033204|C1522326|C0031831|C0450371|C0237426|G0000000|C0278602|C0150108|C0199168|C0034869|C0282443|C0026649|C0012634|C0087009|G0000000|C0205088|G0000000|C0011900|C0237426|G0000000|G0000000|C0326926|C1521970|C0233565|C0035253|C0040822|C0026837|C0332197|C3887511|C1705535|C1523987|C0011900
"COPE, Carers of Older People in Europe; EQ-5D, EuroQol 5 dimensions; HADS, Hospital Anxiety and Depression Scale; PAC, Positive Aspects of Caring; PANAS, Positive and Negative Affect Schedule; PGI, Personal Growth Index; QCPR, Quality of Caregiver–Patient Relationship; SF, short form.","COPE, Carers Older People Europe; EQ-5D, EuroQol 5 dimensions; HADS, Hospital Anxiety Depression Scale; PAC, Positive Aspects Caring; PANAS, Positive Negative Affect Schedule; PGI, Personal Growth Index; QCPR, Quality Caregiver–Patient Relationship; SF, short form.",C0009967|C0085537|C0580836|C0027361|C0015176|C0205163|C0451150|G0000000|C0439534|C0048008|C0019994|C0003467|C0011570|C0175659|G0000000|C0439178|C1547011|C0150499|G0000000|C0439178|C0205160|C0001721|C0086960|C0523816|C1519021|C0018270|C0918012|G0000000|C0332306|G0000000|C0439849|C0037712|C1282927|C0348078
"Improvement on the primary outcome measure, the ARAT score, correlated with improvement on the secondary outcome measures of activities of daily living level, (r = 0.23, P < 0.05), manual dexterity performance speed (r = −0.60, P < 0.001), and Function Limitation Profile (r = −0.25, P < 0.01), but not with grip strength (r = 0.12, n.s).","Improvement primary outcome measure, ARAT score, correlated improvement secondary outcome measures activities daily living level, (r = 0.23, P < 0.05), manual dexterity performance speed (r = −0.60, P < 0.001), Function Limitation Profile (r = −0.25, P < 0.01), grip strength (r = 0.12, n.s).",C2986411|C0205225|C1274040|C0079809|C1152215|C0449820|C1707520|C2986411|C0027627|C1274040|C0079809|C0441655|C0332173|C0376558|C0441889|G0000000|G0000000|C0024763|C0565699|C0597198|C0678536|G0000000|G0000000|C0031843|C0449295|C1979963|G0000000|G0000000|C0021400|C0237897|G0000000|C0369718
"Aesthetic outcome was assessed in terms of lid contour, symmetry of eyelid height, and lid crease presence.","Aesthetic outcome assessed terms lid contour, symmetry eyelid height, lid crease presence.",C0014901|C1274040|C1516048|C0233324|G0000000|C0302821|C0332516|C0015426|C0489786|G0000000|G0000000|C0150312
"The anthropometric data included: height (m), current weight (kg), Body Mass Index (BMI) (kg/m2), arm circumference (AC) (cm), arm muscle circumference (AMC) (cm), and triceps skinfold (TSF) (mm).","The anthropometric data included: height (m), current weight (kg), Body Mass Index (BMI) (kg/m2), arm circumference (AC) (cm), arm muscle circumference (AMC) (cm), triceps skinfold (TSF) (mm).",G0000000|C0003188|C1511726|C0332257|C0489786|C0369637|C0521116|C0005910|C0022718|C0242821|C0577559|C0918012|G0000000|C0022718|C0446516|C0332520|C0003354|G0000000|C0446516|C0026845|C0332520|G0000000|G0000000|C0559502|C1446851|C3887665|G0000000
The two fixed-dose groups did not differ with respect to time to first severe exacerbation (Table 2).,The fixed-dose respect time severe exacerbation (Table 2).,G0000000|C0443218|C0679133|C0040223|C0205082|G0000000|C0039224|G0000000
"At both week 6 and week 12, patients were asked about improvement or deterioration (compared with baseline) of their pain on a 5-point Likert scale and about adverse effects.","At week 6 week 12, patients improvement deterioration (compared baseline) pain 5-point Likert scale adverse effects.",G0000000|C0332174|G0000000|C0332174|C0450371|C0030705|C2986411|C0868945|C1707455|C0168634|C0030193|C1552961|G0000000|C0175659|G0000000|C1280500
"These assessments are divided into the following categories related to tadalafil treatment: safety (i.e., patient contact, medical history, physical examination, medication adherence, clinical exacerbation history, adverse event monitoring), exercise response (6-minute walk distance [6MWD], cardiopulmonary exercise test), symptom and quality-of-life response (dyspnea and health-related quality-of-life surveys), and cardiopulmonary and biochemical response (echocardiography, right heart catheterization, plasma N-terminal brain natriuretic peptide concentration).","These assessments divided categories tadalafil treatment: safety (i.e., patient contact, medical history, physical examination, medication adherence, clinical exacerbation history, adverse event monitoring), exercise response (6-minute walk distance [6MWD], cardiopulmonary exercise test), symptom quality-of-life response (dyspnea health-related quality-of-life surveys), cardiopulmonary biochemical response (echocardiography, heart catheterization, plasma N-terminal brain natriuretic peptide concentration).",G0000000|C1261322|C0332849|C0683312|C1176316|C0039798|C0036043|C0683454|C0030705|C0332158|C0199168|C0019664|C0031809|G0000000|C0013227|C1510802|C0205210|G0000000|C0019664|G0000000|C0441471|C0150369|C0015259|C0871261|C0439232|C0080331|C0012751|G0000000|C0553534|C0015259|C0022885|C1457887|C0332306|C0871261|C0013404|C0018684|C0332306|C0038951|C0553534|C0205474|C0871261|C0013516|C0018787|C0007430|C0032105|C0369718|C0006104|C0597421|C0030956|C0004268
"Secondary outcomes are DUP, time to recovery, use of the Mental Health Act (at patient level), and GP consultation rate (at practice level).","Secondary outcomes DUP, time recovery, Mental Health Act (at patient level), GP consultation rate (at practice level).",C0027627|C1274040|G0000000|C0040223|C0237820|C0229992|C0018684|C0079613|G0000000|C0030705|C0441889|C3811116|C0009818|C0871208|G0000000|C0237607|C0441889
Primary objective: With regard to new vascular events the study shall prove that the participation in a patient-centered intensified secondary prevention program increases the event-free survival time during follow up compared to the participation in usual care.,Primary objective: With regard vascular events study prove participation patient-centered intensified secondary prevention program increases event-free survival time follow compared participation usual care.,C0205225|C0018017|G0000000|G0000000|C0005847|C0441471|C0557651|G0000000|C0679823|C0030705|G0000000|C0027627|C0199176|C1709697|C0205217|C0441471|C0038952|C0040223|C0332283|C1707455|C0679823|C3538928|C1947933
Endometrial cancer is mainly caused by prolonged and excessive exposure to unopposed estrogens [1].,Endometrial cancer caused prolonged excessive exposure unopposed estrogens [1].,C0227843|C0006826|C0015127|C0439590|C0442802|C0274281|G0000000|C0014939|G0000000
These data demonstrate that infection modifies the risk for preterm birth at <37 weeks but not at <34 weeks in women with prior LEEP.,These data demonstrate infection modifies risk preterm birth <37 weeks <34 weeks women prior LEEP.,G0000000|C1511726|G0000000|C0009450|C0392747|C0035647|C0151526|C0005615|C0450371|C0439230|C0450371|C0439230|C0043210|C0332152|C0184930
"Data were analyzed for the time to first mild, moderate, or severe COPD exacerbation and for the time to first moderate or severe COPD exacerbation, excluding mild events.","Data analyzed time mild, moderate, severe COPD exacerbation time moderate severe COPD exacerbation, excluding mild events.",C1511726|C0936012|C0040223|C2945599|C0205081|C0205082|C0024117|G0000000|C0040223|C0205081|C0205082|C0024117|G0000000|C0332196|C2945599|C0441471
"Secondary outcomes were antibiotic use within 28-day follow-up (defined as any antibiotic use for the current respiratory tract infection within 28 days after the index consultation, including antibiotic use immediately after the index consultation); additional consultations; and patient satisfaction, enablement, and clinical recovery.","Secondary outcomes antibiotic 28-day follow-up (defined antibiotic current respiratory tract infection 28 days consultation, including antibiotic consultation); additional consultations; patient satisfaction, enablement, clinical recovery.",C0027627|C1274040|C0003232|C0450371|C0589120|C1704788|C0003232|C0521116|C0521346|C1185740|C0009450|C0450371|C0439228|C0009818|C0332257|C0003232|C0009818|C1524062|C0009818|C0030705|C0242428|G0000000|C0205210|C0237820
"The evaluation of cognitive impairment was based on a Computerized Neuropsychological Test (CNT), Korean Mini-Mental State Examination (K-MMSE).","The evaluation cognitive impairment based Computerized Neuropsychological Test (CNT), Korean Mini-Mental State Examination (K-MMSE).",G0000000|C0220825|C1516691|C0221099|C1527178|G0000000|G0000000|C0022885|G0000000|C1556095|C0445542|C1301808|G0000000|C0597277
Other PSG and actigraphic measures of sleep were unrelated to other changes in glucose metabolism.,Other PSG actigraphic measures sleep unrelated glucose metabolism.,G0000000|C0162701|C1139952|C0079809|C0037313|C0445356|C0017725|C0025519
"End points were the duration of mechanical ventilation, length of stay (LOS) in the pediatric intensive care unit (PICU) and in hospital, and the duration of supplemental oxygen administration.","End duration mechanical ventilation, length stay (LOS) pediatric intensive care unit (PICU) hospital, duration supplemental oxygen administration.",C0444930|C0449238|C0443254|C0035203|C1444754|G0000000|G0000000|C0030755|C0162425|C1947933|C0439148|C1046445|C0019994|C0449238|C2348609|C0030054|C0001554
The primary outcome assessed whether this combination would increase the rate of development of new active lesions on cranial MRI scans vs GA alone.,The primary outcome assessed combination increase rate development active lesions cranial MRI scans GA alone.,G0000000|C0205225|C1274040|C1516048|C0205195|C0442805|C0871208|C0243107|C0205177|C0221198|C0037303|C0024485|C0034606|C0016993|C0205171
We included all reported fall events.,We included reported fall events.,G0000000|C0332257|C0684224|C0085639|C0441471
"Overall mortality and mortality divided as in-hospital, at 3, at 6, at 9 and at 12 months follow up did not differ between the groups in the intention to treat analysis (Table 4).","Overall mortality mortality divided in-hospital, 3, 6, 9 12 months follow intention treat analysis (Table 4).",C0282416|C0026565|C0026565|C0332849|C0019994|G0000000|G0000000|G0000000|C0450371|C0439231|C0332283|C0162425|C0087111|C0002778|C0039224|G0000000
"The permission was received on May 5, 2008, at which time the primary outcome for our study became a CD4 cell count of 250/μL or less, confirmed within 1 month of the first measurement.","The permission received May 5, 2008, time primary outcome study CD4 cell count 250/μL less, confirmed 1 month measurement.",G0000000|C0521104|C1514756|G0000000|G0000000|G0000000|C0040223|C0205225|C1274040|C0557651|C0285590|C0007634|C0750480|G0000000|C0439092|C0521093|G0000000|C0332177|C0242485
"For the primary efficacy outcome measures, mean changes from baseline in pain intensity scores (24-hour recall pain NRS and 7-day recall pain from FIQ-R) were analyzed using an MMRM approach.","For primary efficacy outcome measures, baseline pain intensity scores (24-hour recall pain NRS 7-day recall pain FIQ-R) analyzed MMRM approach.",G0000000|C0205225|C1280519|C1274040|C0079809|C0168634|C0030193|C0522510|C0449820|C0450371|C0034770|C0030193|C2240043|C0332173|C0034770|C0030193|C0205090|C0936012|G0000000|C0449445
Recovery slopes are presented as median symptom scores per day in Figure 2▶.,Recovery slopes median symptom scores day Figure 2▶.,C0237820|C0807955|C0549183|C1457887|C0449820|C0332173|G0000000|G0000000
Function was evaluated by grip strength and pinch strength and compared with preoperative values.,Function evaluated grip strength pinch strength compared preoperative values.,C0031843|C0220825|C0021400|C0237897|C0418416|C0237897|C1707455|C0445204|C0042295
"Treatment groups were also equivalent on pre-treatment measures of pain intensity, activity limitations, depression, and parental protectiveness.","Treatment equivalent pre-treatment measures pain intensity, activity limitations, depression, parental protectiveness.",C0039798|C0205163|C2709094|C0079809|C0030193|C0522510|C0205177|C0449295|C0011570|C0030551|C0033613
Clinical follow up and electroencephalography for evidence of epilepsy.,Clinical follow electroencephalography evidence epilepsy.,C0205210|C0332283|C0013819|C3887511|C0014544
"Median overall survival varies from 5–11 months [2,7,8].","Median survival varies 5–11 months [2,7,8].",C0549183|C0038952|C1548673|G0000000|C0439231|G0000000
"A corneal ulcer was considered to be healing if the epithelial defect decreased in size by at least 20%, with non-progression or decrease in the size of the stromal infiltration by at least 20%.","A corneal ulcer considered healing epithelial defect decreased size 20%, non-progression decrease size stromal infiltration 20%.",G0000000|C0010031|C0041582|C0750591|C0043240|C0221908|C1457869|C0205216|C0456389|C0450371|C3839460|C0392756|C0456389|C0927195|C0332448|C0450371
"Effect of Treatment on Risk of Any Severe Lens Event*  In the subset of 823 participants with no or minimal opacity in at least 1 eye at baseline (nuclear, < 1.5 U; cortical, ≤ 5%; and PSC, ≤ 5%), there was no significant effect of treatment on risk of developing lens events in these eyes (OR=0.85, 99% confidence interval, 0.55–1.33).","Effect Treatment Risk Any Severe Lens Event* In subset 823 participants minimal opacity 1 eye baseline (nuclear, < 1.5 U; cortical, ≤ 5%; PSC, ≤ 5%), treatment risk developing lens events eyes (OR=0.85, 99% confidence interval, 0.55–1.33).",C1280500|C0039798|C0035647|G0000000|C0205082|C0023317|C0441471|G0000000|C1515021|C1442061|C0679646|C0547040|C0029053|G0000000|C0015392|C0168634|C0521447|G0000000|G0000000|G0000000|C0001613|G0000000|G0000000|C0566602|G0000000|G0000000|C0039798|C0035647|G0000000|C0023317|C0441471|C0015392|C0450371|C0450371|C0237529|C1272706|G0000000
"The primary end point was the time to alleviation of influenza illness, which was defined as the interval between the start of the trial treatment and the start of the first 21.5-hour period in which the nasal symptoms and cough had improved to “absent” or “mild” and axillary temperature had returned to 37.4°C or below.","The primary time alleviation influenza illness, defined interval start trial treatment start 21.5-hour period nasal symptoms cough improved “absent” “mild” axillary temperature returned 37.4°C below.",G0000000|C0205225|C0040223|G0000000|C0021400|C0221423|C1704788|C1272706|C0439659|C0008976|C0039798|C0439659|C0450371|C0439531|C0028429|C0683368|C0010200|C0184511|G0000000|G0000000|C0004454|C0005903|C0332156|G0000000|G0000000
"Number (%) of patients with at least one bleeding event INR, international normalized ratio; VKA, vitamin K antagonists.","Number (%) patients bleeding event INR, international normalized ratio; VKA, vitamin K antagonists.",C0237753|G0000000|C0030705|C0019080|C0441471|C0525032|C1512888|C1882115|C0456603|G0000000|C0042890|C0597277|C0243076
"The characteristics of the stool, the presence of white or red blood cells in the stool, the use of anti-diarrheal medication and the patient's weight were also recorded weekly.","The characteristics stool, presence white red blood cells stool, anti-diarrheal medication patient's weight recorded weekly.",G0000000|C1521970|C0015733|C0150312|C0007457|C0332575|C0005767|C0007634|C0015733|C0718565|C0013227|C0030705|C0005910|C0034869|C0332174
"In another retrospective study, transfusion rates were halved (37% vs. 15%) as were the number of units transfused, length of acute hospital stay and 30 day mortality [21].","In retrospective study, transfusion rates halved (37% vs. 15%) units transfused, length acute hospital stay 30 day mortality [21].",G0000000|C0035363|C0557651|C0005841|C0871208|G0000000|C0450371|G0000000|C0450371|C0439148|C1549003|C1444754|C0205178|C0019994|G0000000|C0450371|C0332173|C0026565|C0450371
"The secondary outcomes will be (1) overall prevalence of delirium, (2) duration of delirium, (3) severity of delirium, (4) sleep quality, (5) ICU and hospital LOS, (6) morbidity and mortality and (7) healthcare costs.","The secondary outcomes (1) prevalence delirium, (2) duration delirium, (3) severity delirium, (4) sleep quality, (5) ICU hospital LOS, (6) morbidity mortality (7) healthcare costs.",G0000000|C0027627|C1274040|G0000000|C0033105|C0011206|G0000000|C0449238|C0011206|G0000000|C0439793|C0011206|G0000000|C0037313|C0332306|G0000000|C0021708|C0019994|G0000000|G0000000|C0026538|C0026565|G0000000|C0086388|C0010186
"This study will assess the effectiveness of an eMM system to reduce medication errors, ADEs and length of stay (LOS).","This study assess effectiveness eMM system reduce medication errors, ADEs length stay (LOS).",G0000000|C0557651|C1516048|C1280519|G0000000|C0449913|G0000000|C0013227|C0743559|C0057163|C1444754|G0000000|G0000000
"Strength of bilateral knee extensors and flexors was measured at an angular velocity of 60 degrees per second with the use of an isokinetic dynamometer (Biodex System 3, Biodex Medical Systems).","Strength bilateral knee extensors flexors measured angular velocity 60 degrees isokinetic dynamometer (Biodex System 3, Biodex Medical Systems).",C0237897|C0238767|C0022742|C1184148|C1879367|C0444706|C0205143|C0439830|C0450371|C0449286|G0000000|C0180572|G0000000|C0449913|G0000000|G0000000|C0199168|C0449913
"The presence of periapical radiolucency, widened periodontal ligament space (PDL), pathologic internal/external root resorption, or pathological changes of the alveolar bone in the furcation area were recorded as radiographic failures.","The presence periapical radiolucency, widened periodontal ligament space (PDL), pathologic internal/external root resorption, pathological alveolar bone furcation recorded radiographic failures.",G0000000|C0150312|C0729269|C2827491|C0332464|C2960678|C0023685|C1883067|G0000000|C1521733|C0205102|C0040452|C2985494|C0030664|C1440080|C0262950|C2825929|C0034869|C0444708|C0231174
We calculated sample size on the basis of the primary outcome measure (SF-36).,We calculated sample size basis primary outcome measure (SF-36).,G0000000|C0444686|C0370003|C0456389|C1527178|C0205225|C1274040|C0079809|C0037712
"The primary end points were the percentage of BG levels within the range of 100 to 180 mg/dL, and the percentage of subjects experiencing a hypoglycemic event defined as a BG <70 mg/dL.","The primary percentage BG levels range 100 180 mg/dL, percentage subjects experiencing hypoglycemic event defined BG <70 mg/dL.",G0000000|C0205225|C0439165|C0004732|C0441889|C1514721|C1442061|C1442061|C0439269|C0439165|C0681850|C0237607|C0020616|C0441471|C1704788|C0004732|C0450371|C0439269
"Self-reported 7-day point prevalence smoking abstinence was verified by a carbon monoxide (CO) <8 ppm and measured at 1, 4, 8, and 12 weeks.","Self-reported 7-day prevalence smoking abstinence verified carbon monoxide (CO) <8 ppm measured 1, 4, 8, 12 weeks.",C0681906|C0332173|C0033105|C0037369|C3843422|C1711411|C0007009|G0000000|C3245499|G0000000|C0439187|C0444706|G0000000|G0000000|G0000000|C0450371|C0439230
"Secondary endpoints are reduction of RT-related side effects such as headache, nausea and skin erythema.","Secondary endpoints reduction RT-related effects headache, nausea skin erythema.",C0027627|C2349179|C0301630|C0230425|C1280500|C0018681|C0027497|C0444099|C0041834
"Evaluation, at baseline and follow-up, was carried out by blind raters using: the Global Deterioration Scale (GDS), the Severe Mini Mental State Examination (sMMSE), the Mini Mental State Examination (MMSE), the Neuropsychiatric Inventory (NPI), the Apathy Scale for Institutionalized Patients with Dementia Nursing Home version (APADEM-NH), the Apathy Inventory (AI) and the Quality of Life Scale (QUALID).","Evaluation, baseline follow-up, carried blind raters using: Global Deterioration Scale (GDS), Severe Mini Mental State Examination (sMMSE), Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Apathy Scale Institutionalized Patients Dementia Nursing Home version (APADEM-NH), Apathy Inventory (AI) Quality Life Scale (QUALID).",C0220825|C0168634|C0589120|C0206243|C0150108|G0000000|C1524063|C0205246|C0868945|C0175659|C0451184|C0205082|C0445542|C0229992|C1301808|G0000000|G0000000|C0445542|C0229992|C1301808|G0000000|C0451306|G0000000|C0021941|C1412208|C0085632|C0175659|C0562359|C0030705|C0011265|C0006147|C0442519|C0333052|C0042321|C0085632|C0021941|C0003353|C0332306|C0376558|C0175659|G0000000
We described discomfort with particular attention to postpartum pain.,We discomfort attention postpartum pain.,G0000000|C0231218|C0004268|C0086839|C0030193
"Airway inflammation in chronic obstructive pulmonary disease (COPD) is characterised by infiltration of CD8+ T cells and CD68+ macrophages and an increased number of neutrophils, whereas few studies have described the presence of eosinophils.","Airway inflammation chronic obstructive pulmonary disease (COPD) characterised infiltration CD8+ T cells CD68+ macrophages increased neutrophils, studies presence eosinophils.",C0178987|C0021368|C0205191|C0549186|C0024109|C0012634|C0024117|G0000000|C0332448|C0285590|C2603360|C0007634|G0000000|C0024432|C0205217|C0027950|C0947630|C0150312|C0014467
"T0, at the HPN start; T1, after 1 month; T2, after 2 months; T3, after 3 months; T4, after 4 months; EORTC QLQ‐C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30; gQoL, global Quality of Life; PF, physical functioning; RF, role functioning; EF, emotional functioning; AP, appetite loss; KPS, Karnofsky performance status; FA, fatigue.","T0, HPN start; T1, 1 month; T2, 2 months; T3, 3 months; T4, 4 months; EORTC QLQ‐C30, European Organization Research Treatment Cancer Quality Life Questionnaire‐Core 30; gQoL, global Quality Life; PF, physical functioning; RF, role functioning; EF, emotional functioning; AP, appetite loss; KPS, Karnofsky performance status; FA, fatigue.",C0041403|C1415700|C0439659|C0041403|G0000000|C0332177|C0041403|G0000000|C0439231|C0041403|G0000000|C0439231|C0041403|G0000000|C0439231|C1516985|G0000000|C0239307|C0029237|C0035168|C0039798|C0006826|C0332306|C0376558|G0000000|C0450371|G0000000|C0205246|C0332306|C0376558|C3815179|C0031809|C0205245|C0035448|C0035820|C0205245|G0000000|C0013987|C0205245|C3887950|C0003618|C1517945|C0206065|C0206065|C0597198|C0449438|G0000000|C0015672
"Systemic bleeding was defined as epistaxis, fistula hematoma, prolonged fistula bleeding >30 min, hemarthosis, gastrointestinal bleed, hemoptysis, and intracerebral hemorrhage.","Systemic bleeding defined epistaxis, fistula hematoma, prolonged fistula bleeding >30 min, hemarthosis, gastrointestinal bleed, hemoptysis, intracerebral hemorrhage.",C0205373|C0019080|C1704788|C0014591|C0016169|C0018944|C0439590|C0016169|C0019080|C0450371|C0702093|G0000000|C0521362|C0019080|C0019079|C0442111|C0019080
"Colorectal cancer is the third most common cancer worldwide (1) and the third leading cause of cancer mortality in many countries (1,2).","Colorectal cancer common cancer worldwide (1) leading cancer mortality countries (1,2).",C0555952|C0006826|C0205214|C0006826|G0000000|G0000000|C0332152|C0006826|C0026565|C0454664|G0000000
"A follow-up athlete questionnaire assessed ST, cigarette, and cigar use in the past 30 days (yes/no).","A follow-up athlete questionnaire assessed ST, cigarette, cigar 30 days (yes/no).",G0000000|C0589120|C0238703|C0034394|C1516048|C0036056|C0677453|C0678446|C0450371|C0439228|C1512698
"Comparison of the VR and the control groups in the outcome measures Notes: Abbreviations: VR, vestibular rehabilitation; M, mean; SD, standard deviation; BITC, Behavioral Inattention Test Conventional; ADL, activities of daily living; FIM®, Functional Independence Measure®; PASS, Postural Assessment Scale for Stroke patients; ANOVA, analysis of variance.","Comparison VR control outcome measures Notes: Abbreviations: VR, vestibular rehabilitation; M, mean; SD, standard deviation; BITC, Behavioral Inattention Test Conventional; ADL, activities daily living; FIM®, Functional Independence Measure®; PASS, Postural Assessment Scale Stroke patients; ANOVA, analysis variance.",C1707455|C3476815|C0243148|C1274040|C0079809|C1317574|C0000723|C3476815|C0042606|C0034991|C0369637|C0444504|C2699239|C1442989|C0012727|G0000000|C0004927|C0424101|C0022885|C0439858|C0001288|C0441655|C0332173|C0376558|G0000000|C0205245|C0085862|G0000000|C2828386|C0205278|C1261322|C0175659|C0038454|C0030705|G0000000|C0002778|C1711260
"Cerebral palsy was defined for Gross Motor Function Classification System level II or greater.9 Hearing impairment was defined if hearing aids were required, while visual impairment was defined if vision in both eyes was lost.","Cerebral palsy defined Gross Motor Function Classification System level II greater.9 Hearing impairment defined hearing aids required, visual impairment defined vision eyes lost.",G0000000|C0522224|C1704788|C0439806|C1513492|C0031843|C0008902|C0449913|C0441889|G0000000|C1704243|C0018767|C0221099|C1704788|C0018767|C0001175|C1514873|C0234621|C0221099|C1704788|C0042789|C0015392|C0745777
"Primary endpoint is PFS and secondary endpoints are OS, RR, time to treatment failure (TTF), and incidence of adverse events (safety).","Primary endpoint PFS secondary endpoints OS, RR, time treatment failure (TTF), incidence adverse events (safety).",C0205225|C2349179|C0242792|C0027627|C2349179|C0229090|G0000000|C0040223|C0039798|C0231174|C1332112|C0021149|G0000000|C0441471|C0036043
"Improvement in patient perception of communication will be measured using the Communication Outcomes After Stroke (COAST) questionnaire at six months - a patient-centred, patient-reported measure of communication related activity, participation and quality of life [27].","Improvement patient perception communication measured Communication Outcomes After Stroke (COAST) questionnaire months - patient-centred, patient-reported measure communication activity, participation quality life [27].",C2986411|C0030705|C0030971|C0009452|C0444706|C0009452|C1274040|G0000000|C0038454|G0000000|C0034394|C0439231|G0000000|C0030705|C0747307|C0079809|C0009452|C0205177|C0679823|C0332306|C0376558|C0450371
Improved was defined as no symptoms or minor symptoms requiring no further treatment.,Improved defined symptoms minor symptoms requiring treatment.,C0184511|C1704788|C0683368|C0026193|C0683368|G0000000|C0039798
"At each survey, children were questioned and examined for malaria signs and symptoms, including axillary temperature, recent clinical history, drug ingestion, anemia, and splenomegaly.","At survey, children questioned examined malaria signs symptoms, including axillary temperature, clinical history, drug ingestion, anemia, splenomegaly.",G0000000|C0038951|C0008059|C1522634|C0332128|C0024530|C0220912|C0683368|C0332257|C0004454|C0005903|C0205210|C0019664|C0013227|C0232478|C0002871|C0038002
"This study tests for the efficacy of a school-based drug prevention curriculum (Think Smart) that was designed to reduce use of Harmful Legal Products (HLPs, such as inhalants and over-the-counter drugs), alcohol, tobacco, and other drugs among fifth- and sixth-grade students in frontier Alaska.","This study tests efficacy school-based drug prevention curriculum (Think Smart) designed reduce Harmful Legal Products (HLPs, inhalants over-the-counter drugs), alcohol, tobacco, drugs fifth- sixth-grade students frontier Alaska.",G0000000|C0557651|C0022885|C1280519|C0036375|C0013227|C0199176|C0010478|C0039869|G0000000|C1707689|G0000000|G0000000|C1301860|C1514468|C1567160|C0598322|C0013231|C0013227|C0001962|C0040329|C0013227|C0205439|C0205440|C0038492|G0000000|C0001905
"The co-primary endpoint of rate of moderate or severe exacerbations per patient per year was defined by the need for oral or parenteral corticosteroid treatment, hospitalization, or death, and was evaluated using a Poisson regression model with a correction for over-dispersion.","The co-primary endpoint rate moderate severe exacerbations patient defined oral parenteral corticosteroid treatment, hospitalization, death, evaluated Poisson regression model correction over-dispersion.",G0000000|C3245499|C2349179|C0871208|C0205081|C0205082|G0000000|C0030705|C1704788|C0442027|C0030547|C0001617|C0039798|C0019993|C0011065|C0220825|G0000000|C0684320|C3161035|C1705565|C0205136
"For each sample, a series of replicate weights were computed so that jack-knifed estimates of variance properly accounted for the additional variability because of the sampling design and weighting scheme.41 At each interview, adolescents were categorized as committed never smokers, susceptible never smokers, experimenters, established smokers, or current established smokers.","For sample, series replicate weights computed jack-knifed estimates variance properly accounted additional variability sampling design weighting scheme.41 At interview, adolescents categorized committed smokers, susceptible smokers, experimenters, established smokers, current established smokers.",G0000000|C0370003|C0205549|C0205173|C0043100|C1441526|C1708586|C0750572|C1711260|G0000000|C2741673|C1524062|C2827666|C0441621|C1707689|C0005910|C1519193|G0000000|C0021822|C0205653|C0871968|C1171947|C0337664|C0220898|C0337664|G0000000|C0443211|C0337664|C0521116|C0443211|C0337664
"Secondary short-term end points of surgical complication rates (intraoperatively and up to 30 days and 3 months postoperatively), transfusion requirements and quality of life up to 3 months were also similar between groups.","Secondary short-term surgical complication rates (intraoperatively 30 days 3 months postoperatively), transfusion requirements quality life 3 months groups.",C0027627|C0443303|C0543467|C0009566|C0871208|G0000000|C0450371|C0439228|G0000000|C0439231|G0000000|C0005841|C1514873|C0332306|C0376558|G0000000|C0439231|C0441833
"Secondary efficacy endpoints included the following: PaO2/FiO2 ratio, hospital indices (length of hospital stay, ventilator-free days and ICU-free days at day 28), and serum biomarkers of ARDS including IL-6, IL-8 and SP-D. Normal human adipose-derived MSCs were purchased from ATCC (Cat # PCS-500-011, LOT 59753760, passage 2, Manassas, VA).","Secondary efficacy endpoints included following: PaO2/FiO2 ratio, hospital indices (length hospital stay, ventilator-free days ICU-free days day 28), serum biomarkers ARDS including IL-6, IL-8 SP-D. Normal human adipose-derived MSCs purchased ATCC (Cat # PCS-500-011, LOT 59753760, passage 2, Manassas, VA).",C0027627|C1280519|C2349179|C0332257|C0231290|C1427155|C0456603|C0019994|C4033634|C1444754|C0019994|G0000000|C0087153|C0439228|C0021708|C0439228|C0332173|C0450371|C0229671|C0005516|C0035222|C0332257|C0020898|C0020898|C0084692|C0205307|C0086418|C0028754|C2248778|C0870238|C0598079|C0007450|G0000000|C1864389|C1115660|G0000000|C0439799|G0000000|G0000000|C1549054
"For continuous outcomes of LAZ, WLZ, WAZ, length, head circumference and MUAC at 18 months, GEE linear regression analysis was employed to examine food supplementation effects.","For continuous outcomes LAZ, WLZ, WAZ, length, head circumference MUAC 18 months, GEE linear regression analysis employed examine food supplementation effects.",G0000000|C0549178|C1274040|G0000000|G0000000|G0000000|C1444754|C0018670|C0332520|G0000000|C0450371|C0439231|G0000000|C0205132|C0684320|C0002778|C0014003|G0000000|C0016452|C0242297|C1280500
"Association of PDA with perinatal infection has a negative impact on the pharmacological closure of the ductus, increasing need for a second course and for surgical ligation.","Association PDA perinatal infection negative impact pharmacological closure ductus, increasing surgical ligation.",C0004083|C0013274|C0178795|C0009450|C0205160|C1825598|C0031330|C0185003|C1512083|C0442808|C0543467|C0023690
Lin has previously used the Chinese version of the CMAI and improved the scale’s reliability and validity [17].,Lin Chinese version CMAI improved scale’s reliability validity [17].,C0861352|C0008120|C0333052|G0000000|C0184511|G0000000|C2347947|C2349101|C0450371
"Secondary endpoints will be the proportion of transfusion of fresh frozen plasma, platelets and cryoprecipitate; infused volume of blood products; hemoglobin and hematocrit before and after the procedure; intensive care unit and hospital length of stay; 28-day and hospital mortality; incidence of minor bleeding; transfusion-related adverse reactions; and cost analysis.","Secondary endpoints proportion transfusion fresh frozen plasma, platelets cryoprecipitate; infused volume blood products; hemoglobin hematocrit procedure; intensive care unit hospital length stay; 28-day hospital mortality; incidence minor bleeding; transfusion-related adverse reactions; cost analysis.",C0027627|C2349179|C1709707|C0005841|C0443224|C0016701|C0032105|C0005821|C0443121|G0000000|C0449468|C0005767|C1514468|C0019046|C0018935|C0184661|C0162425|C1947933|C0439148|C0019994|C1444754|G0000000|C0450371|C0019994|C0026565|C0021149|C0026193|C0019080|C0005841|G0000000|C0443286|C0010186|C0002778
"Furthermore, these sequelae can safely be treated at the moment of occurrence, and their prevention is not a specific indication for antibiotic treatment in sore throat.","Furthermore, sequelae safely treated moment occurrence, prevention specific indication antibiotic treatment sore throat.",G0000000|C0243088|G0000000|C1522326|G0000000|C0243132|C0199176|C0205369|C0392360|C0003232|C0039798|C0234233|C0031354
"From pre- to post-treatment, there was an improvement in the motor-free visual perception test (MVPT), line bisection test (LBT), star cancellation test (SCT), Catherine Bergego Scale (CBS), Korean version of Modified Barthel Index (K-MBI), and Functional Ambulation Classification in all 3 groups.","From pre- post-treatment, improvement motor-free visual perception test (MVPT), bisection test (LBT), star cancellation test (SCT), Catherine Bergego Scale (CBS), Korean version Modified Barthel Index (K-MBI), Functional Ambulation Classification 3 groups.",G0000000|C0332152|C2709088|C2986411|C1513492|C0234621|C0030971|C0022885|G0000000|C0184905|C0022885|C1879922|C0995242|C0205544|C0022885|C0860888|G0000000|G0000000|C0175659|C1439329|C1556095|C0333052|C0392747|G0000000|C0918012|C0597277|C0205245|C0080331|C0008902|G0000000|C0441833
"The primary end point of the study was the presence or absence of external genital lesions associated with HPV-6, 11, 16, or 18, defined as condylomata acuminata (external genital warts); penile, perianal, or perineal intraepithelial neoplasia (PIN); or penile, perianal, or perineal cancer.","The primary study presence absence external genital lesions HPV-6, 11, 16, 18, defined condylomata acuminata (external genital warts); penile, perianal, perineal intraepithelial neoplasia (PIN); penile, perianal, perineal cancer.",G0000000|C0205225|C0557651|C0150312|C0332197|C0205101|C0559522|C0221198|C0021344|C0450371|C0450371|C0450371|C1704788|C0302180|G0000000|C0205101|C0559522|C1367460|C0030851|C0442158|C0031066|C1512942|C0027651|C0175718|C0030851|C0442158|C0031066|C0006826
"The mean rise in the platelet count was measured daily in both the groups, which was taken as the primary outcome.","The rise platelet count measured daily groups, primary outcome.",G0000000|G0000000|C0005821|C0750480|C0444706|C0332173|C0441833|C0205225|C1274040
Participants wearing E-RCP were more likely to experience contamination of their skin and base clothing layer.,Participants wearing E-RCP experience contamination skin base clothing layer.,C0679646|G0000000|C1419325|C0237607|C0259846|C0444099|C0002055|C0009072|C0934502
No deaths or asthma exacerbations requiring hospitalisation were reported.,No deaths asthma exacerbations requiring hospitalisation reported.,G0000000|C0011065|C0004096|G0000000|G0000000|C0019993|C0684224
"Abbreviations: BFI, Brief Fatigue Inventory; BP, Medical Outcomes Study 36-Item Short-Form Survey (SF-36) Bodily Pain; CES-D, Center for Epidemiologic Studies-Depression; GH, SF-36 General Health; MCS, SF-36 Mental Component Score; PCS, SF-36 Physical Component Score; PF, SF-36 Physical Functioning; PSQI, Pittsburg Sleep Quality Index; RP, SF-36 Role-physical; ST, stretching; WL, waitlist; YG, yoga.","Abbreviations: BFI, Brief Fatigue Inventory; BP, Medical Outcomes Study 36-Item Short-Form Survey (SF-36) Bodily Pain; CES-D, Center Epidemiologic Studies-Depression; GH, SF-36 General Health; MCS, SF-36 Mental Component Score; PCS, SF-36 Physical Component Score; PF, SF-36 Physical Functioning; PSQI, Pittsburg Sleep Quality Index; RP, SF-36 Role-physical; ST, stretching; WL, waitlist; YG, yoga.",C0000723|C2698562|C1282927|C0015672|C0021941|C0037623|C0199168|C1274040|C0557651|C0450371|C2964478|C0038951|C0037712|G0000000|C0030193|C2699160|C0205099|C0014507|C0947630|C0033993|C0037712|C0205246|C0018684|G0000000|C0037712|C0229992|C0449432|C0449820|C1864389|C0037712|C0031809|C0449432|C0449820|C3815179|C0037712|C0031809|C0205245|C3697468|G0000000|C0037313|C0332306|C0918012|C0031529|C0037712|C0035820|C0036056|C0600080|G0000000|C0043010|C1883582|C0043418
Note: MIT = Melodic Intonation Therapy; SRT = Speech Repetition Therapy; CIU/min = Correct Information Units/min; Picture naming = percent of correctly named pictures out of 60 (Boston Naming Test); Post40 refers to assessment after 40 treatment sessions; Post75 = after 75 treatment sessions.,Note: MIT = Melodic Intonation Therapy; SRT = Speech Repetition Therapy; CIU/min = Correct Information Units/min; Picture naming = percent correctly named pictures 60 (Boston Naming Test); Post40 refers assessment 40 treatment sessions; Post75 = 75 treatment sessions.,C1316572|G0000000|G0000000|G0000000|G0000000|C0039798|C0234742|G0000000|C0037817|C0205341|C0039798|C0702093|G0000000|C2349182|C1533716|C1532693|C0441468|C0233735|G0000000|C0439165|G0000000|C0027365|C0441469|C0450371|C0006037|C0233735|C0022885|G0000000|C0205543|C1261322|C0450371|C0039798|C1883016|G0000000|G0000000|C0450371|C0039798|C1883016
"The main outcomes were LAZ change between 6 and 18 months and LAZ, length and stunting (LAZ < −2) at 18 months as well as WLZ and wasting (WLZ < −2) at 18 months.","The main outcomes LAZ change 6 18 months LAZ, length stunting (LAZ < −2) 18 months WLZ wasting (WLZ < −2) 18 months.",G0000000|C0205225|C1274040|G0000000|C0392747|G0000000|C0450371|C0439231|G0000000|C1444754|C0018273|G0000000|C0450371|C0439231|G0000000|C0006625|G0000000|C0450371|C0439231
No difference in mean daily symptom score was observed between the salbutamol and placebo periods.,No difference daily symptom score observed salbutamol placebo periods.,G0000000|C1705241|C0332173|C1457887|C0449820|C1441672|C0001927|C0032042|C0439531
"Primary outcomes were (1) an increase from baseline in nuclear, cortical, or posterior subcapsular opacity grades or cataract surgery, and (2) at least moderate visual acuity loss from baseline (≥15 letters).","Primary outcomes (1) increase baseline nuclear, cortical, posterior subcapsular opacity grades cataract surgery, (2) moderate visual acuity loss baseline (≥15 letters).",C0205225|C1274040|G0000000|C0442805|C0168634|C0521447|C0001613|C0205095|C0205152|C0029053|C0441800|C0086543|C0038894|G0000000|C0205081|C0234621|C0750509|C1517945|C0168634|G0000000|C0282413
"However, skin irritation was reported in a few TENS group subjects.","However, skin irritation reported TENS subjects.",G0000000|C0444099|C0441723|C0684224|C0014518|C0681850
None of the patients in either group developed delirium after the procedure as measured by CAM.,None patients developed delirium procedure measured CAM.,G0000000|C0030705|G0000000|C0011206|C0184661|C0444706|C0597815
The ROLL technique associated with the intraoperative macroscopic examination of margins allows a low re-excision rate and spares normal breast tissue for an optimal surgical technique.,The ROLL technique intraoperative macroscopic examination margins low re-excision rate spares normal breast tissue optimal surgical technique.,G0000000|G0000000|C0449851|C0456904|C0439806|G0000000|C0205284|C0205251|C0184913|C0871208|G0000000|C0205307|C0006141|C0040300|C2698651|C0543467|C0449851
"Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score.","Significantly patients ICS placebo improvement 24 hour sputum volume (OR 2.5, 95% CI 1.1 6.0, = 0.03) exacerbation frequency, forced expiratory volume 1 second, forced vital capacity, sputum purulence score.",G0000000|C0030705|C0022521|C0032042|C2986411|C0450371|C0439227|C0038056|C0449468|G0000000|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000|C0450371|G0000000|C0376249|C0441722|C0231800|C0449468|G0000000|C0205436|C0441722|C0442732|C1516240|C0038056|C0854358|C0449820
"Changes in primary and secondary outcome measures All changes are shown as positive when there was an improvement in the score and negative when there was a worsening of the score ABC aberrant behavior checklist, PPVT peabody picture vocabulary test, EVT expressive vocabulary test, SRS social responsiveness scale, BASC behavioral assessment system for children aEffect sizes are positive when the change in omega-3 is greater (more beneficial or less harmful) than the change in placebo Hyperactivity as measured by the ABC improved 2.7 (±4.8) points in the omega-3 group compared to 0.3 (±7.2) points in the placebo group, but this difference in change scores was not statistically significant (p = 0.40).","Changes primary secondary outcome measures All positive improvement score negative worsening score ABC aberrant behavior checklist, PPVT peabody picture vocabulary test, EVT expressive vocabulary test, SRS social responsiveness scale, BASC behavioral assessment system children aEffect sizes positive change omega-3 (more beneficial harmful) change placebo Hyperactivity measured ABC improved 2.7 (±4.8) omega-3 compared 0.3 (±7.2) placebo group, difference change scores statistically (p = 0.40).",C0392747|C0205225|C0027627|C1274040|C0079809|G0000000|C0439178|C2986411|C0449820|C0205160|C0332271|C0449820|C0152244|C0443127|C0004927|C1707357|G0000000|G0000000|C0441468|C0042926|C0022885|G0000000|C0185117|C0042926|C0022885|G0000000|C0728831|C0205342|C0175659|G0000000|C0004927|C1261322|C0449913|C0008059|G0000000|C0456389|C0439178|C0392747|C1719844|C0205172|G0000000|G0000000|C0392747|C0032042|C0424295|C0444706|C0152244|C0184511|G0000000|G0000000|C1719844|C1707455|G0000000|G0000000|C0032042|C0441833|C1705241|C0392747|C0449820|C0038215|C0369773|G0000000|C0450371
Safety and reactogenicity data were collected throughout.,Safety reactogenicity data collected throughout.,C0036043|G0000000|C1511726|C1516695|G0000000
"The amount of exercise participation was assessed by the leisure score index (LSI) using the Godin Leisure-Time Exercise Questionnaire [23, 24].","The amount exercise participation assessed leisure score (LSI) Godin Leisure-Time Exercise Questionnaire [23, 24].",G0000000|C1265611|C0015259|C0679823|C1516048|C0086542|C0449820|G0000000|G0000000|C0086542|C0015259|C0034394|C0450371|C0450371
Asthma disability scores at two weeks after discharge were significantly improved in the spacer group.,Asthma disability scores weeks discharge improved spacer group.,C0004096|C0231170|C0449820|C0439230|C0012621|C0184511|C0221874|C0441833
Researchers visited households approximately 3 months after harvest to sample stored maize and administer a brief survey concerning maize drying and storage practices.,Researchers visited households 3 months harvest sample stored maize administer survey maize drying storage practices.,C0035173|C0545082|C0020052|G0000000|C0439231|C1512335|C0370003|C1698986|C0010028|C1621583|C0038951|C0010028|C0011682|C0337174|C0237607
"Two measures were used to assess pain: 1) the short form of the McGill Pain Questionnaire (MPQ) (Melzack 1975), and 2) the physical experience of pain dimension (Pain Symptoms) from the Enhanced SF-36 TOPS (Total Pain Symptoms - see below for TOPS description) (Rogers et al 2000a).","Two measures assess pain: 1) short form McGill Pain Questionnaire (MPQ) (Melzack 1975), 2) physical experience pain dimension (Pain Symptoms) Enhanced SF-36 TOPS (Total Pain Symptoms - TOPS description) (Rogers al 2000a).",C0205448|C0079809|C1516048|C0030193|G0000000|C1282927|C0348078|G0000000|C0030193|C0034394|G0000000|G0000000|G0000000|G0000000|C0031809|C0237607|C0030193|C0439534|C0030193|C0683368|C2349975|C0037712|C0076833|C0439175|C0030193|C0683368|G0000000|C0076833|C0678257|C3463939|C0202311|G0000000
Increased neuropsychiatric burden was not mirrored in either the NPI total score or depression subscore; this finding also contradicts Regan et al.,Increased neuropsychiatric burden mirrored NPI total score depression subscore; finding contradicts Regan al.,C0205217|G0000000|C2828008|C0181868|C1412208|C0439175|C0449820|C0011570|G0000000|C0037088|G0000000|C0740201|C0202311
"The active surveillance consisted of twice weekly temperature monitoring of enrolled children by village assistants, while the passive surveillance consisted of mothers referring sick children to the visiting study nurse.","The active surveillance consisted weekly temperature monitoring enrolled children village assistants, passive surveillance consisted mothers referring sick children visiting study nurse.",G0000000|C0205177|C0220920|C0332529|C0332174|C0005903|C0150369|G0000000|C0008059|C0562518|C0011327|C3686820|C0220920|C0332529|C0026591|C0205543|C0221423|C0008059|C0545082|C0557651|C0028661
The initial outcome measures will be: Independent walking will be operationally defined as 'being able to walk 15 m continuously barefoot across flat ground without any aids'.,The initial outcome measures be: Independent walking operationally defined 'being walk 15 continuously barefoot flat ground aids'.,G0000000|C0205265|C1274040|C0079809|G0000000|C0085862|C0080331|G0000000|C1704788|G0000000|C0080331|C0450371|G0000000|C0277844|C0205324|G0000000|C0001175
"However, the only two non-ACT treated patients despite positive RDT result reported full clinical recovery by day 7 and severe malaria did not develop in any of the overall 682 patients in the RDT group who were not treated with ACT.","However, non-ACT treated patients positive RDT result reported clinical recovery day 7 severe malaria develop 682 patients RDT treated ACT.",G0000000|C1518422|C1522326|C0030705|C0439178|C0206743|C1274040|C0684224|C0205210|C0237820|C0332173|G0000000|C0205082|C0024530|G0000000|C1442061|C0030705|C0206743|C1522326|C0079613
"The baseline score in the IRLS severity scale, Zung depression scale, sleep diary, daily sleepiness status and overall QoL score did not differ between the three groups.","The baseline score IRLS severity scale, Zung depression scale, sleep diary, daily sleepiness status QoL score groups.",G0000000|C0168634|C0449820|C0022067|C0439793|C0175659|G0000000|C0011570|C0175659|C0037313|C0376660|C0332173|C0013144|C0449438|C0518214|C0449820|C0441833
in their study concluded that there is a relationship between vitamin D deficiency and gestational diabetes.,study concluded relationship vitamin D deficiency gestational diabetes.,C0557651|C0917903|C0439849|C0042890|C0073187|C0011155|C0439671|C0011847
"For the measurement of gait ability, we used the timed up and go (TUG) test and the 10-m walking test.","For measurement gait ability, timed (TUG) test 10-m walking test.",G0000000|C0242485|C0016928|C0085732|C0392761|C1319201|C0022885|C0450371|C0080331|C0022885
Activity was recorded in terms of the average number of steps and minutes per day spent in daily physical activities of at least moderate intensity.,Activity recorded terms average steps minutes day spent daily physical activities moderate intensity.,C0205177|C0034869|C0233324|C1510992|C1261552|C0439232|C0332173|C0680968|C0332173|C0031809|C0441655|C0205081|C0522510
"At the end of the study, the cost of treatment in the alginate silver wound dressing (AlSD) group was reduced compared to the silver zinc sulfadiazine cream (AgZnSD) group with a statistically significant difference (P<0.001).","At study, cost treatment alginate silver wound dressing (AlSD) reduced compared silver zinc sulfadiazine cream (AgZnSD) statistically difference (P<0.001).",G0000000|C0557651|C0010186|C0039798|C0102137|C0037125|C0043250|C0013119|G0000000|C0392756|C1707455|C0037125|C0043481|C0038675|C0700385|G0000000|C0038215|C1705241|C0369773
"Secondary outcomes were neck mobility, scar cosmesis score and perioperative adverse event rates.","Secondary outcomes neck mobility, scar cosmesis score perioperative adverse event rates.",C0027627|C1274040|C0027530|C0425245|C0241158|C0010164|C0449820|C1518988|G0000000|C0441471|C0871208
The mortality rate is 12.8%.,The mortality rate 12.8%.,G0000000|C0026565|C0871208|C0450371
"The between group differences were statistically significant for both time points (p=0.011 at 24 weeks and p=0.004 at 48 weeks) Summary of BMD, Vitamin D, Bone Turnover Markers, and Soluble Inflammatory Biomarkers at Baseline, 24 weeks, and 48 weeks All data presented as median values with 25th and 75th percentile value in parentheses.","The differences statistically time (p=0.011 24 weeks p=0.004 48 weeks) Summary BMD, Vitamin D, Bone Turnover Markers, Soluble Inflammatory Biomarkers Baseline, 24 weeks, 48 weeks All data median values 25th 75th percentile parentheses.",G0000000|C1705241|C0038215|C0040223|C0369773|C0450371|C0439230|C0369773|C0450371|C0439230|C1552616|G0000000|C0042890|C0073187|C0262950|C0031227|C0005516|C1749467|C0333348|C0005516|C0168634|C0450371|C0439230|C0450371|C0439230|G0000000|C1511726|C0549183|C0042295|G0000000|G0000000|C1264641|G0000000
"The following evaluations were conducted at the time of randomization and 18 months later (see [28] for further details) in the Institut Mutualiste Montsouris department of psychiatry (Paris France): the Mini-Neuropsychiatric Interview (MINI, [40]); the Global Outcome Assessment Scale (GOAS, [41], [42]); the Eating Disorder Inventory (EDI, [43], [44]); the Weissman's Social Adjustment Scale (SAS, [45], [46]).","The evaluations conducted time randomization 18 months (see [28] details) Institut Mutualiste Montsouris department psychiatry (Paris France): Mini-Neuropsychiatric Interview (MINI, [40]); Global Outcome Assessment Scale (GOAS, [41], [42]); Eating Disorder Inventory (EDI, [43], [44]); Weissman's Social Adjustment Scale (SAS, [45], [46]).",G0000000|C0220825|C0004927|C0040223|C0034656|C0450371|C0439231|C0042789|C0450371|C1522508|G0000000|G0000000|G0000000|C1704729|C0033873|C0030561|C0016674|C0445542|C0021822|C0445542|C0450371|C0205246|C1274040|C1261322|C0175659|C1425957|C0450371|C0450371|C0013470|C0012634|C0021941|G0000000|C0450371|C0450371|G0000000|C0728831|C0376209|C0175659|C0605290|C0450371|C0450371
"Outcomes, including weight, blood pressure, and health behaviors, were measured at baseline and 3, 6, and 12 months.","Outcomes, including weight, blood pressure, health behaviors, measured baseline 3, 6, 12 months.",C1274040|C0332257|C0005910|C0005767|C0033095|C0018684|C0004927|C0444706|C0168634|G0000000|G0000000|C0450371|C0439231
"Esophageal squamous cell carcinoma (ESCC), a treatment resistant cancer that can withstand a combination of surgery, chemotherapy and radiotherapy [1], is the fourth most commonly diagnosed cancer and the fourth leading cause of cancer death in China.","Esophageal squamous cell carcinoma (ESCC), treatment resistant cancer withstand combination surgery, chemotherapy radiotherapy [1], fourth commonly diagnosed cancer fourth leading cancer death China.",C1522619|C1182670|C0007634|C0007097|C0279626|C0039798|C0332325|C0006826|G0000000|C0205195|C0038894|C0013216|C0034619|G0000000|C0205438|G0000000|C0011900|C0006826|C0205438|C0332152|C0006826|C0011065|C0008115
"Adolescents whose parents reported higher levels of monitoring of diabetes care have been shown not only to have better illness management but also better metabolic control.19–24 Furthermore, particular styles of parental monitoring appear to be related to better adolescent diabetes management.","Adolescents parents reported levels monitoring diabetes care illness management metabolic control.19–24 Furthermore, styles parental monitoring adolescent diabetes management.",C0205653|C0030551|C0684224|C0441889|C0150369|C0011847|C1947933|C0221423|C0001554|C0311400|G0000000|G0000000|C0489654|C0030551|C0150369|C0205653|C0011847|C0001554
"Protein excretion was evaluated in 24-h urine samples after 6, 12 and 24 months.","Protein excretion evaluated 24-h urine samples 6, 12 24 months.",C0033684|C0221102|C0220825|C0450371|C0042036|C0370003|G0000000|C0450371|C0450371|C0439231
"Moreover, although elderly people are noted to have reduced seroconversion to influenza vaccines, all immunogenicity criteria were met for older persons in this study, albeit with lower GMTs than achieved in younger adults.","Moreover, elderly people reduced seroconversion influenza vaccines, immunogenicity criteria met persons study, albeit lower GMTs achieved adults.",G0000000|C0001792|C0027361|C0392756|C4042908|C0021400|C0042210|C4054739|C0243161|C0268621|C0027361|C0557651|G0000000|C0441994|G0000000|G0000000|C0001675
"The primary variable will be prolonged abstinence from smoking, and a secondary variable occasional abstinence (point prevalent abstinence), both of which will be validated using confirmation by coximetry at 12 months post-intervention.","The primary variable prolonged abstinence smoking, secondary variable occasional abstinence (point prevalent abstinence), validated confirmation coximetry 12 months post-intervention.",G0000000|C0205225|C0439828|C0439590|C3843422|C0037369|C0027627|C0439828|C0521114|C3843422|C1552961|C0033105|C3843422|G0000000|C0521091|G0000000|C0450371|C0439231|C2347647
"The probiotic group was administered a probiotic complex containing B. bifidum, L. acidophilus, L. casei, and L. salivarius for 8 weeks.","The probiotic administered probiotic complex B. bifidum, L. acidophilus, L. casei, L. salivarius 8 weeks.",G0000000|C0525033|C1521801|C0525033|C0439855|G0000000|G0000000|C0439394|C0718215|C0439394|G0000000|C0439394|G0000000|G0000000|C0439230
"On average, children who received CSB++ required 2 d longer to recover, and the rate of weight gain was less than that with either RUSF, although height gain was the same among all 3 foods studied.","On average, children received CSB++ required 2 recover, rate weight gain RUSF, height gain 3 foods studied.",G0000000|C1510992|C0008059|C1514756|C1707866|C1514873|G0000000|C0521108|C0871208|C0005910|C1517378|G0000000|C0489786|C1517378|G0000000|C0016452|C0557651
"From baseline to delivery there was a significant increase in systolic blood pressure both in the vitamin C and control groups, (Table 4).","From baseline delivery increase systolic blood pressure vitamin C control groups, (Table 4).",G0000000|C0168634|C0011209|C0442805|C0039155|C0005767|C0033095|C0042890|G0000000|C0243148|C0441833|C0039224|G0000000
"Forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) were measured by means of a mini-Wright spirometer at baseline, at the end of the dieting period, at the end of the 14 week weight reduction programme, at six months, and at one year.","Forced vital capacity (FVC) forced expiratory volume (FEV1) measured mini-Wright spirometer baseline, dieting period, 14 week weight reduction programme, months, year.",C0441722|C0442732|C1516240|C3714541|C0441722|C0231800|C0449468|G0000000|C0444706|C0445542|C0183441|C0168634|C2945766|C0439531|C0450371|C0332174|C0005910|C0301630|C1709697|C0439231|C0439234
"Incremental cost-effectiveness ratio (ICER) was calculated as additional cost per patient to prevent 1 exacerbation, compared with the next most expensive option.","Incremental cost-effectiveness ratio (ICER) calculated additional cost patient prevent 1 exacerbation, compared expensive option.",C1705117|C0010181|C0456603|C1852403|C0444686|C1524062|C0010186|C0030705|C0309872|G0000000|G0000000|C1707455|C0680864|C1518601
"Major protocol deviations comprised violation of inclusion criteria (CAI ⩽4, EI ⩽4, and no signs of acute inflammation on histological examination) (32 patients in both groups), premature discontinuation of the study without relapse (see below), and unknown or not unequivocally assessed end point (EcN 29 patients, mesalazine 24 patients).","Major protocol deviations comprised violation inclusion criteria (CAI ⩽4, EI ⩽4, signs acute inflammation histological examination) (32 patients groups), premature discontinuation study relapse (see below), unknown unequivocally assessed (EcN 29 patients, mesalazine 24 patients).",C0205082|C0442711|C0012727|C2700400|G0000000|C0007637|C0243161|C0064494|G0000000|C0022067|G0000000|C0220912|C0205178|C0021368|C0205462|G0000000|C0450371|C0030705|C0441833|C0151526|C0457454|C0557651|C0035020|C0042789|G0000000|C0439673|G0000000|C1516048|C0760481|C0450371|C0030705|C0127615|C0450371|C0030705
"Successful outcomes included the following responses, as defined by the Standardization Committee of the International Children's Continence Society (ICCS) [16]: full response, no wet nights; response, ≥90% reduction in the number of wet nights; partial response, 50% to 89% reduction in the number of wet nights.","Successful outcomes included responses, defined Standardization Committee International Children's Continence Society (ICCS) [16]: response, wet nights; response, ≥90% reduction wet nights; partial response, 50% 89% reduction wet nights.",C0597535|C1274040|C0332257|C0871261|C1704788|C0038136|C2699414|C1512888|C0008059|C0443192|C0037455|C0345905|C0450371|C0871261|C0205381|C0240526|C0871261|G0000000|C0301630|C0205381|C0240526|C0728938|C0871261|C0450371|C0450371|C0301630|C0205381|C0240526
Since loss in lean body mass (LBM) is a prognostic marker in HIV infection [27] and changes in body composition are more sensitive in testing interventions [28] we used change in LBM rather than anthropometric measurements alone to assess the effect of the supplement.,Since loss lean body mass (LBM) prognostic marker HIV infection [27] body composition sensitive testing interventions [28] change LBM anthropometric measurements assess supplement.,C1711239|C1517945|G0000000|C0242821|C0577559|C0424678|C0220901|C0005516|C0019682|C0009450|C0450371|C0242821|C0486616|C0020517|C0039593|C0886296|C0450371|C0392747|C0424678|C0003188|C0242485|C1516048|C0242295
"Adherence for the pill intervention will be monitored based on collection of the pills supplement from the health center, 12 out of 18 months will be considered acceptable adherence Vitamin B12 content of fortified and control Bebida Lactea will be monitored in a sample randomly obtained at every health center.","Adherence pill intervention monitored based collection pills supplement health center, 12 18 months considered acceptable adherence Vitamin B12 content fortified control Bebida Lactea monitored sample randomly health center.",C1510802|C0009905|C0886296|C0030695|C1527178|C1516698|C0994475|C0242295|C0018684|C0205099|C0450371|C0450371|C0439231|C0750591|C1879533|C1510802|C0042890|G0000000|C0423896|G0000000|C0243148|G0000000|G0000000|C0030695|C0370003|G0000000|C0018684|C0205099
Participants were tested at the same time of day for pre- and post-testing.,Participants tested time day pre- post-testing.,C0679646|C0392366|C0040223|C0332173|C0332152|C0687676
"Emergence agitation was assessed using a simple four-point scale as follows: 1, asleep; 2, awake but calm; 3, agitated but consolable; and 4, severely agitated and difficult to console.","Emergence agitation assessed simple four-point scale follows: 1, asleep; 2, awake calm; 3, agitated consolable; 4, severely agitated difficult console.",C0750573|C0085631|C1516048|C0205352|C0205450|C0175659|C0332283|G0000000|C0424522|G0000000|C0234422|C0522165|G0000000|C0085631|G0000000|G0000000|C0205082|C0085631|C0332218|C3873699
UMEC/VI improved trough FEV1 versus TIO at day 169 [least squares mean (95% confidence interval): MN: 146 ml (102–189) and ITT: 95 ml (71–118); both P < 0.001].,UMEC/VI improved trough FEV1 versus TIO day 169 [least squares (95% confidence interval): MN: 146 (102–189) ITT: 95 (71–118); P < 0.001].,C0205999|C0184511|C0444506|G0000000|G0000000|G0000000|C0332173|C1442061|C0439092|C0205120|C0450371|C0237529|C1272706|C0026405|C1442061|G0000000|G0000000|C0450371|G0000000|C0369773|G0000000|C1442061
No patients without colorectal cancer died within 30 days of colonic investigation.,No patients colorectal cancer died 30 days colonic investigation.,G0000000|C0030705|C0555952|C0006826|C0011065|C0450371|C0439228|C0009368|C0220825
The main outcome measures were a diary of symptom resolution over seven days and eradication of group A beta-haemolytic streptococcus (GABHS).,The main outcome measures diary symptom resolution days eradication A beta-haemolytic streptococcus (GABHS).,G0000000|C0205225|C1274040|C0079809|C0376660|C1457887|C1514893|C0439228|G0000000|G0000000|C0475329|C0038402|G0000000
The secondary outcomes that were measured included functional status by forced spirometry (following SEPAR guidelines [31]) and health-related quality of life as determined by the St. George respiratory questionnaire (SGRQ) [32] and the EuroQoL-5D questionnaire [33].,The secondary outcomes measured included functional status forced spirometry (following SEPAR guidelines [31]) health-related quality life determined St. George respiratory questionnaire (SGRQ) [32] EuroQoL-5D questionnaire [33].,G0000000|C0027627|C1274040|C0444706|C0332257|C0205245|C0449438|C0441722|C0037981|C0231290|G0000000|C0162791|C0450371|C0018684|C0332306|C0376558|G0000000|C0036056|G0000000|C0521346|C0034394|G0000000|C0450371|C0451150|C0034394|C0450371
There was no significant moderating effect of maternal depressive symptoms at T1 on the VIPI effect on child development measured with ASQ:SE (p = 0.44).,There moderating maternal depressive symptoms T1 VIPI child development measured ASQ:SE (p = 0.44).,G0000000|C0205081|C2347083|G0000000|C0683368|C0041403|G0000000|C0008059|C0243107|C0444706|C3476780|C0369773|G0000000|C0450371
"In patients with respiratory tract infections, we identified practice reconsultation rates using diagnostic READ codes (www.connectingforhealth.nhs.uk/systemsandservices/data/uktc/readcodes) recorded by the general practitioner over seven days, 14 days, and 31 days after an initial consultation.","In patients respiratory tract infections, identified practice reconsultation rates diagnostic READ codes (www.connectingforhealth.nhs.uk/systemsandservices/data/uktc/readcodes) recorded practitioner days, 14 days, 31 days initial consultation.",G0000000|C0030705|C0521346|C1185740|C3714514|C0205396|C0237607|G0000000|C0871208|C0011900|C0034754|C0919279|C0282111|C0034869|C1709627|C0439228|C0450371|C0439228|C0450371|C0439228|C0205265|C0009818
"At 9 weeks and at 6 months follow up participants will undergo repeat measurements of the 6MWT, peripheral muscle strength, CRQ, SGRQ-I, UCSD SOBQ, MMRC, HADS and Global Rating of Change to evaluate the immediate and long term effects of exercise training.","At 9 weeks 6 months follow participants undergo repeat measurements 6MWT, peripheral muscle strength, CRQ, SGRQ-I, UCSD SOBQ, MMRC, HADS Global Rating Change evaluate term effects exercise training.",G0000000|G0000000|C0439230|G0000000|C0439231|C0332283|C0679646|G0000000|C0205341|C0242485|G0000000|C0205100|C0026845|C0237897|G0000000|C0021966|G0000000|G0000000|C3826977|C0048008|C0205246|C0871208|C0392747|C0220825|C0233324|C1280500|C0015259|C0040607
"Baseline assessment was done using Post Graduate Institute general well-being measure (GWBM), Checklist for basic living skills and Indian disability evaluation and assessment scale (IDEAS).","Baseline assessment Post Graduate Institute well-being measure (GWBM), Checklist basic living skills Indian disability evaluation assessment scale (IDEAS).",C0168634|C1261322|C0687676|C0588053|C0021622|C0018684|C0079809|G0000000|C1707357|C1527178|C0376558|C0678856|C1524069|C0231170|C0220825|C1261322|C0175659|C0459920
"All outcomes measures were captured at baseline (pre), immediately after intervention (post), and at 3 months after intervention by an assessor blinded to group assignment.","All outcomes measures captured baseline (pre), intervention (post), 3 months intervention assessor blinded assignment.",G0000000|C1274040|C0079809|G0000000|C0168634|C0332152|C0886296|C0687676|G0000000|C0439231|C0886296|C1707957|C0150108|C1516050
"For the AQ-treated patients, parasitological and clinical evaluation on day 14 showed late treatment failure in 2 of 61 (3.3%) and adequate clinical response with parasitological failure in one (1.6%).","For AQ-treated patients, parasitological clinical evaluation day 14 late treatment failure 2 61 (3.3%) adequate clinical response parasitological failure (1.6%).",G0000000|C0242536|C0030705|C0205468|C0205210|C0220825|C0332173|C0450371|C0205087|C0039798|C0231174|G0000000|C0450371|G0000000|C0205410|C0205210|C0871261|C0205468|C0231174|G0000000
"The severity and frequency of hot flashes and the serum levels of FSH, LH and E2.","The severity frequency hot flashes serum levels FSH, LH E2.",G0000000|C0439793|C0376249|C0444519|C0085635|C0229671|C0441889|G0000000|C0023879|C1704625
"Small numbers of participants—similar numbers in each arm—died, had a primary cancer other than prostate cancer, or had an intercurrent illness.","Small participants—similar arm—died, primary cancer prostate cancer, intercurrent illness.",C0700321|G0000000|G0000000|C0205225|C0006826|C0033572|C0006826|G0000000|C0221423
1 for the timeline of the study.,1 timeline study.,G0000000|C0145943|C0557651
"To measure, activity of daily living cognitive and motor functions, the following assessment tools were used: computerized neuropsychological test and the Tower of London (TOL) test for cognitive function assessment, Korean-Modified Barthel index (K-MBI) for functional status evaluation, and the motricity index (MI) for motor function assessment.","To measure, activity daily living cognitive motor functions, assessment tools used: computerized neuropsychological test Tower London (TOL) test cognitive function assessment, Korean-Modified Barthel (K-MBI) functional status evaluation, motricity (MI) motor function assessment.",C0040363|C0079809|C0205177|C0332173|C0376558|C1516691|C1513492|C0542341|C1261322|C0336791|C1273517|G0000000|G0000000|C0022885|C1710443|C0023973|G0000000|C0022885|C1516691|C0031843|C1261322|C1556095|G0000000|C0597277|C0205245|C0449438|C0220825|G0000000|C3810814|C1513492|C0031843|C1261322
"This study tried to compare the effects of a childbirth training workshop on knowledge, attitude, and delivery method.","This study compare effects childbirth training workshop knowledge, attitude, delivery method.",G0000000|C0557651|C1707455|C1280500|C0005615|C0040607|C0242262|C0376554|C0004271|C0011209|C0025663
Psychological distress did not decrease in the experimental group and there were negative changes in supervisor support and decision latitude.,Psychological distress decrease experimental negative supervisor support decision latitude.,C0205486|C0231303|C0392756|C1517586|C0205160|C0403172|C0183683|C0679006|C1627936
No severe adverse events or side effects were noted during the study period.,No severe adverse events effects study period.,G0000000|C0205082|G0000000|C0441471|C1280500|C0557651|C0439531
"For purposes of survival analysis, the number of days to relapse (defined as latency to smoke on 7 consecutive days after the quit day) in the first six months post-quit (0 to 182 days) was computed.","For purposes survival analysis, days relapse (defined latency smoke 7 consecutive days quit day) months post-quit (0 182 days) computed.",G0000000|C1285529|C0038952|C0002778|C0439228|C0035020|C1704788|C0205275|C0037366|G0000000|C1707491|C0439228|C0748223|C0332173|C0439231|C0687676|G0000000|C1442061|C0439228|C1441526
The duration of administration of the study drug was 8 weeks.,The duration administration study drug 8 weeks.,G0000000|C0449238|C0001554|C0557651|C0013227|G0000000|C0439230
"Therapeutic outcomes were classified according to WHO guidelines (23) into early treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF), and adequate clinical and parasitological response (ACPR).","Therapeutic outcomes classified WHO guidelines (23) treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF), adequate clinical parasitological response (ACPR).",C0087111|C1274040|C0008902|G0000000|C0162791|C0450371|C0039798|C0231174|C1420680|C0205087|C0205210|C0231174|C1334106|C0205087|C0205468|C0231174|C1532175|C0205410|C0205210|C0205468|C0871261|G0000000
"Changes in transplant knowledge, decisional balance, self-efficacy, and informed decision making will be captured with surveys administered before and after the ETH education.","Changes transplant knowledge, decisional balance, self-efficacy, informed decision captured surveys administered ETH education.",C0392747|C0040732|C0376554|C0679006|C0014653|C0600564|C1522154|C0679006|G0000000|C0038951|C1521801|C0015024|C0013621
"In the patients reported here, both groups showed indications of improved extracellular fluid volume and metabolic control; however, the control appeared better in the ICO group, presumably because more efficient ultrafiltration and glucose savings were achieved.","In patients reported here, indications improved extracellular fluid volume metabolic control; however, control appeared ICO group, efficient ultrafiltration glucose savings achieved.",G0000000|C0030705|C0684224|G0000000|C0392360|C0184511|C0521119|C0005889|C0449468|C0311400|C0243148|G0000000|C0243148|C0700364|G0000000|C0441833|C0442799|C0041612|C0017725|C0036245|G0000000
"Despite disparities in adrenal steroids, there was no difference in GH, IGF-1, or BMI during treatment with the three glucocorticoids.","Despite disparities adrenal steroids, difference GH, IGF-1, BMI treatment glucocorticoids.",G0000000|G0000000|G0000000|C0038317|C1705241|C0033993|C0037657|G0000000|C0039798|C0017710
A number of methodological limitations in our study should be noted.,A methodological limitations study noted.,G0000000|C0969625|C0449295|C0557651|C1316572
"Secondary efficacy end points included the proportion of patients achieving EASI 50, EASI 75 and IGA of 0/1 with at least a two‐grade reduction from baseline, and change from baseline in BSA, EASI and single weekly pruritus numeric rating scale (NRS) over time.","Secondary efficacy included proportion patients achieving EASI 50, EASI 75 IGA 0/1 two‐grade reduction baseline, change baseline BSA, EASI single weekly pruritus numeric rating scale (NRS) time.",C0027627|C1280519|C0332257|C1709707|C0030705|G0000000|C1516931|C0450371|C1516931|C0450371|C2825347|G0000000|G0000000|C0301630|C0168634|C0392747|C0168634|G0000000|C1516931|C0037179|C0332174|C0033774|C0237753|C0871208|C0175659|C2240043|C0040223
"Memory training12,27–29 focused on verbal episodic memory.","Memory training12,27–29 focused verbal episodic memory.",C0025260|G0000000|C0205234|C0439824|C1455761|C0025260
"The cases of recurrence were classified as relapse or reinfection based on the three methods, the month of recurrence, and the two genotyping methods: PCR-RFLP and PCR sequencing.","The recurrence classified relapse reinfection based methods, month recurrence, genotyping methods: PCR-RFLP PCR sequencing.",G0000000|C0034897|C0008902|C0035020|C0205339|C1527178|C0025663|C0332177|C0034897|C1285573|C0025663|C0032520|C0032520|C1294197
"These outcome measures will be i) Falls risk assessed using the Physiological Profile Assessment [25] ii) Physical activity assessed via a 7-day pedometer count iii) Community participation using the Adelaide activity profile [26] iv) Quality of life and well-being using the SF 12™ Version 2 v) Health service utilisation using monthly calendars vi) Upper limb function using Items 6,7,8 of Motor Assessment Scale for Stroke [27] and the nine hole peg test [28] vii) Cognition using the Montreal Cognitive Assessment [29].","These outcome measures i) Falls risk assessed Physiological Profile Assessment [25] ii) Physical activity assessed 7-day pedometer count iii) Community participation Adelaide activity profile [26] iv) Quality life well-being SF 12™ Version 2 v) Health service utilisation monthly calendars vi) Upper limb function Items 6,7,8 Motor Assessment Scale Stroke [27] hole peg test [28] vii) Cognition Montreal Cognitive Assessment [29].",G0000000|C1274040|C0079809|C0021966|C0000921|C0035647|C1516048|C0205463|C1979963|C1261322|C0450371|G0000000|C0031809|C0205177|C1516048|C0332173|C2709220|C0750480|C0439070|C0009462|C0679823|G0000000|C0205177|C1979963|C0450371|C0022326|C0332306|C0376558|C0018684|C0037712|G0000000|C0333052|G0000000|G0000000|C0018684|C0557854|C0042153|C0332177|C1516147|C0205999|C1282910|C0015385|C0031843|C1551338|G0000000|C1513492|C1261322|C0175659|C0038454|C0450371|C0544726|G0000000|C0022885|C0450371|C0445385|C0009240|G0000000|C1516691|C1261322|C0450371
"The primary outcome was days free of mechanical ventilation in the first 28 days, while secondary outcomes included 28-day mortality and duration of organ failure.","The primary outcome days free mechanical ventilation 28 days, secondary outcomes included 28-day mortality duration organ failure.",G0000000|C0205225|C1274040|C0439228|C0332296|C0443254|C0035203|C0450371|C0439228|C0027627|C1274040|C0332257|C0450371|C0026565|C0449238|C0178784|C0231174
"Health-outcome measures included caregiver-frequency of asthma symptoms, ED visits, hospitalizations, and courses of oral corticosteroids at baseline and 6-, 12-, and 18-month assessments.","Health-outcome measures included caregiver-frequency asthma symptoms, ED visits, hospitalizations, courses oral corticosteroids baseline 6-, 12-, 18-month assessments.",C0018684|C0079809|C0332257|C0085537|C0004096|C0683368|C3538926|C0545082|C0019993|C0750729|C0442027|C0001617|C0168634|G0000000|C0450371|C0450371|C1261322
The primary outcome is observed SDM in audio-recorded consultations.,The primary outcome observed SDM audio-recorded consultations.,G0000000|C0205225|C1274040|C1441672|C0643808|C3273156|C0009818
"We focused on eight domains that index adult functioning: externalizing psychopathology, internalizing psychopathology, substance abuse, criminal conviction, risky sexual behavior, aggression toward partners and offspring, education/employment, and general well-being.","We focused domains adult functioning: externalizing psychopathology, internalizing psychopathology, substance abuse, criminal conviction, risky sexual behavior, aggression partners offspring, education/employment, well-being.",G0000000|C0205234|C1880389|C0001675|C0205245|G0000000|C0033927|G0000000|C0033927|C0439861|C0013146|C0699726|G0000000|C0035647|C0036864|C0004927|C0001807|C0682323|C0680063|C0013621|C0018684
"High: likely to adversely affect outcome, medications with narrow therapeutic index, medications on Institute for Safe Medication Practices (ISMP) high alert list and/or impending risk to patient.","High: adversely affect outcome, medications narrow therapeutic index, medications Institute Safe Medication Practices (ISMP) alert list and/or impending risk patient.",C0205250|G0000000|C0001721|C1274040|C0013227|C0205168|C0087111|C0918012|C0013227|C0021622|G0000000|C0013227|C0237607|C0618037|C0239110|C0745732|G0000000|C0332190|C0035647|C0030705
"Patient participants will be formally assessed at three timepoints (T1 = rehabilitation discharge, T2 = six months post-stroke, and T3 = twelve months post-stroke).","Patient participants formally assessed timepoints (T1 = rehabilitation discharge, T2 = months post-stroke, T3 = twelve months post-stroke).",C0030705|C0679646|G0000000|C1516048|C2348792|C0041403|G0000000|C0034991|C0012621|C0041403|G0000000|C0439231|C0687676|C0041403|G0000000|C0205458|C0439231|C0687676
We assessed developmental outcomes in 395 of these children at six years of age.,We assessed developmental outcomes 395 children age.,G0000000|C1516048|C0458003|C1274040|C1442061|C0008059|C0001779
"In case of complete response, two more cycles were to be given.","In complete response, cycles given.",G0000000|C0205197|C0871261|C1511572|C1442162
"The scores of intraoperative sedation and operation conditions were evaluated and recorded by dental sedation teacher groups (DSTG) system in the 10th, 20th, 30th and 40th minutes of the operation.","The scores intraoperative sedation operation conditions evaluated recorded dental sedation teacher (DSTG) system 10th, 20th, 30th 40th minutes operation.",G0000000|C0449820|C0456904|C0235195|C0543467|C0012634|C0220825|C0034869|C0011365|C0235195|C0221457|G0000000|C0449913|G0000000|G0000000|G0000000|G0000000|C0439232|C0543467
Clinical activity was assessed by the PCDAI (Pediatric Crohn’s Disease Activity Index) and Quality of life was monitored by the Impact III survey.,Clinical activity assessed PCDAI (Pediatric Crohn’s Disease Activity Index) Quality life monitored Impact III survey.,C0205210|C0205177|C1516048|G0000000|C0030755|G0000000|C0012634|C0205177|C0918012|C0332306|C0376558|C0030695|C1825598|C0439070|C0038951
"The results of the present study showed that husbands’ education can effectively increase the knowledge and improve the attitude of their wives, and reduce the rate of elective cesarean section.","The study husbands’ education effectively increase knowledge improve attitude wives, reduce rate elective cesarean section.",G0000000|C0557651|G0000000|C0013621|G0000000|C0442805|C0376554|G0000000|C0004271|C0242665|G0000000|C0871208|C0206058|C3841297|C0152060
"Patients were followed at 6 weeks, 3, 4, 5, 6, 9 and 12 months after surgery.","Patients 6 weeks, 3, 4, 5, 6, 9 12 months surgery.",C0030705|G0000000|C0439230|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|C0439231|C0038894
"The primary endpoint is defined as the time-to-treatment failure (development of frequent relapses, steroid dependence or steroid resistance).","The primary endpoint defined time-to-treatment failure (development frequent relapses, steroid dependence steroid resistance).",G0000000|C0205225|C2349179|C1704788|C3494202|C0231174|C0243107|C0332183|C0035020|C0038317|C0011546|C0038317|C0237834
"Yet, our main endpoint, group difference in the change in total 25OHD from baseline to 3 months, was not statistically significant.","Yet, main endpoint, difference change total 25OHD baseline 3 months, statistically significant.",G0000000|C0205225|C2349179|C1705241|C0392747|C0439175|G0000000|C0168634|G0000000|C0439231|C0038215|C0237881
Pain behaviors were evaluated immediately postoperatively using a FLACC scale and 4 hours postoperatively by self-report using various scales.,Pain behaviors evaluated postoperatively FLACC scale 4 hours postoperatively self-report scales.,C0030193|C0004927|C0220825|G0000000|C4068796|C0175659|G0000000|C0439227|G0000000|C0681906|C0175659
We report the effect of supplementation with simultaneous zinc and vitamin A on the prevalence of diarrhoea and acute lower respiratory infection in children.,We report supplementation simultaneous zinc vitamin A prevalence diarrhoea acute lower respiratory infection children.,G0000000|C0684224|C0242297|C0205420|C0043481|C0042890|G0000000|C0033105|C0011991|C0205178|C0441994|C0521346|C0009450|C0008059
"Outcomes assessed by VO2peak (primary outcome), arterial stiffness, ambulatory capacity, hemodynamics and cardiac function using echocardiography, and lipid, glucose and homocysteine levels.","Outcomes assessed VO2peak (primary outcome), arterial stiffness, ambulatory capacity, hemodynamics cardiac function echocardiography, lipid, glucose homocysteine levels.",C1274040|C1516048|G0000000|C0205225|C1274040|C0003842|C0427008|C0439841|C1516240|C0019010|C0018787|C0031843|C0013516|C0023779|C0017725|C0019878|C0441889
"In a meta-analysis of 12 studies, it was reported that regular exercises increase total sleep time and sleep slow waves [37].","In meta-analysis 12 studies, reported regular exercises increase total sleep time sleep slow waves [37].",G0000000|C0282458|C0450371|C0947630|C0684224|C0205272|C0015259|C0442805|C0439175|C0037313|C0040223|C0037313|C0439834|C0678544|C0450371
"This 13-item scale is a brief, reliable and valid measure of the physical and functional effects of fatigue [25].","This 13-item scale brief, reliable valid measure physical functional effects fatigue [25].",G0000000|C0450371|C0175659|C1282927|C3858758|C2349099|C0079809|C0031809|C0205245|C1280500|C0015672|C0450371
"Subjects were assessed at 3, 6, and 12 months.","Subjects assessed 3, 6, 12 months.",C0681850|C1516048|G0000000|G0000000|C0450371|C0439231
"The clinical characteristics of the patients MAS: Modified Ashworth Scale; ARAT: Action Research Arm Test However, figures at TZD group showed the reduction of mean scores from 2.79 and 2.77 to 2.32 and 2.31 from baseline to week 24 at joints elbow and wrist, respectively (Table 1).","The clinical characteristics patients MAS: Modified Ashworth Scale; ARAT: Action Research Arm Test However, figures TZD reduction scores 2.79 2.77 2.32 2.31 baseline week 24 joints elbow wrist, (Table 1).",G0000000|C0205210|C1521970|C0030705|C1096155|C0392747|G0000000|C0175659|C1152215|C0441472|C0035168|C0446516|C0022885|G0000000|G0000000|G0000000|C0301630|C0449820|C0450371|C0450371|C0450371|C0450371|C0168634|C0332174|C0450371|C0022417|C0013769|C0043262|C0039224|G0000000
The last valid visit was between days 88 and 92.,The valid visit days 88 92.,G0000000|C2349099|C0545082|C0439228|C0450371|C0450371
"Primary outcomes consisted of two indicators of postural stability — maximum excursion and directional control — as measured by computerized dynamic posturography (Balance Master System, NeuroCom).","Primary outcomes consisted indicators postural stability — maximum excursion directional control — measured computerized dynamic posturography (Balance Master System, NeuroCom).",C0205225|C1274040|C0332529|C0021212|C0205278|C0205360|G0000000|C0806909|G0000000|G0000000|C0243148|G0000000|C0444706|G0000000|C0729333|C0919611|C0014653|C0444649|C0449913|G0000000
The BPI was modified to capture joint pain and stiffness by adding the term “joint pain/stiffness” rather than just the word “pain” throughout the questionnaire.,The BPI modified capture joint pain stiffness adding term “joint pain/stiffness” word “pain” questionnaire.,G0000000|C1443145|C0392747|G0000000|C0022417|C0030193|C0427008|C1883712|C0233324|G0000000|G0000000|C1705313|G0000000|C0034394
"The mixed outcome in correlation (significant for trial A and first 6 months of trial B, but not for second 6 months of trial B) between change in spherical equivalent myopia and change in axial length suggests that there are other factors also involved in myopia progression.","The mixed outcome correlation (significant trial A 6 months trial B, 6 months trial B) change spherical equivalent myopia change axial length suggests factors involved myopia progression.",G0000000|C0205430|C1274040|C1707520|C0237881|C0008976|G0000000|G0000000|C0439231|C0008976|G0000000|G0000000|C0439231|C0008976|G0000000|C0392747|C0332501|C0205163|C0027092|C0392747|C0205131|C1444754|C1705535|C1521761|C1314939|C0027092|C0242656
"Most common grade 3–5 adverse events and adverse events of special interest with bevacizumab (related and unrelated events; safety population) Despite extensive evaluation of multiple chemotherapy regimens, no international consensus exists regarding the optimal first-line treatment regimen for patients with advanced gastric cancer.","Most common grade 3–5 adverse events adverse events special bevacizumab (related unrelated events; safety population) Despite extensive evaluation multiple chemotherapy regimens, international consensus exists optimal first-line treatment regimen patients advanced gastric cancer.",C0205393|C0205214|C0441800|G0000000|G0000000|C0441471|G0000000|C0441471|C0205555|C0796392|C0439849|C0445356|C0441471|C0036043|C0032659|G0000000|C0205231|C0220825|C0439064|C0013216|C2945654|C1512888|C0376298|C2987476|C2698651|C0205435|C0039798|C0040808|C0030705|C0205179|C0038351|C0006826
"The main outcome measure was benzodiazepine discontinuation, confirmed by blood screening performed at each of 3 measurement points (immediately after completion of treatment and at 3- and 12-month follow-ups).","The main outcome measure benzodiazepine discontinuation, confirmed blood screening performed 3 measurement (immediately completion treatment 3- 12-month follow-ups).",G0000000|C0205225|C1274040|C0079809|C0005064|C0457454|C0521093|C0005767|C0220908|C0884358|G0000000|C0242485|C0205548|C0205197|C0039798|G0000000|C0450371|C0332283
"The changes in the relevant indexes of oxygen metabolism, lung function, time of ventilator treatment, total hospital stay, and St. George's Respiratory Questionnaire (SGRQ) score of the two groups after intervention were compared, and the changes in inflammatory cytokine levels, dopamine receptor-related hormone levels, superoxide dismutase (SOD), malondialdehyde (MDA) and total antioxidant capacity of the two groups before intervention and at 1 and 4 weeks after intervention were compared.","The relevant indexes oxygen metabolism, lung function, time ventilator treatment, total hospital stay, St. George's Respiratory Questionnaire (SGRQ) score intervention compared, inflammatory cytokine levels, dopamine receptor-related hormone levels, superoxide dismutase (SOD), malondialdehyde (MDA) total antioxidant capacity intervention 1 4 weeks intervention compared.",G0000000|C2347946|C0600653|C0030054|C0025519|C0024109|C0031843|C0040223|C0087153|C0039798|C0439175|C0019994|G0000000|C0036056|G0000000|C0521346|C0034394|G0000000|C0449820|C0886296|C1707455|C0333348|C0079189|C0441889|C0013030|C0597357|C0019932|C0441889|C0038836|G0000000|G0000000|C0024643|C0000379|C0439175|C0003402|C1516240|C0886296|G0000000|G0000000|C0439230|C0886296|C1707455
"Secondary end points included colorectal-cancer incidence, cancer stage, survival, harms of screening, and all-cause mortality.","Secondary included colorectal-cancer incidence, cancer stage, survival, harms screening, all-cause mortality.",C0027627|C0332257|C0009402|C0021149|C0006826|C0205390|C0038952|G0000000|C0220908|C0015127|C0026565
"Rationale: Chronic infection with Pseudomonas aeruginosa is associated with an increased exacerbation frequency, a more rapid decline in lung function, and increased mortality in patients with bronchiectasis.","Rationale: Chronic infection Pseudomonas aeruginosa increased exacerbation frequency, rapid decline lung function, increased mortality patients bronchiectasis.",C0392360|C0205191|C0009450|C0033808|G0000000|C0205217|G0000000|C0376249|C0456962|G0000000|C0024109|C0031843|C0205217|C0026565|C0030705|C0006267
"In conclusion, we have demonstrated the effectiveness of a multi-faceted intervention in reducing China’s elevated caesarean section rate.","In conclusion, demonstrated effectiveness multi-faceted intervention reducing China’s elevated caesarean rate.",G0000000|C1707478|G0000000|C1280519|C0439064|C0886296|C0392756|G0000000|C0205250|C3841297|C0871208
The intervention did not reduce the length of stay or alter the discharge outcomes.,The intervention reduce length stay alter discharge outcomes.,G0000000|C0886296|G0000000|C1444754|G0000000|C0392747|C0012621|C1274040
"We expect that this study will answer the question whether nutritional intervention in hip fracture patients improves their nutritional and functional status, resulting in a shorter length of stay in hospital and rehabilitation clinics, fewer postoperative complications, lower mortality, and cost-effectiveness.","We expect study answer question nutritional intervention hip fracture patients improves nutritional functional status, shorter length stay hospital rehabilitation clinics, fewer postoperative complications, lower mortality, cost-effectiveness.",G0000000|G0000000|C0557651|C1706817|C1522634|C1521739|C0886296|C0019552|C0016658|C0030705|C0184511|C1521739|C0205245|C0449438|C1282927|C1444754|G0000000|C0019994|C0034991|C0442592|C0205388|C0032790|C0009566|C0441994|C0026565|C0010181
Nor was this study designed to determine the effects of resistance exercise alone on the risk of falls.,Nor study designed determine effects resistance exercise risk falls.,G0000000|C0557651|C1707689|G0000000|C1280500|C0237834|C0015259|C0035647|C0000921
A total of 8 of 24 patients in the intervention arm and 12 of 25 patients in the control group successfully stopped smoking at 6 month follow up.,A total 8 24 patients intervention arm 12 25 patients control stopped smoking 6 month follow up.,G0000000|C0439175|G0000000|C0450371|C0030705|C0886296|C0446516|C0450371|C0450371|C0030705|C0243148|C1272691|C0037369|G0000000|C0332177|C0332283|G0000000
and placebo was greatest in girls with a spontaneous calcium intake below the median of 880 mg/d.,placebo girls spontaneous calcium intake median 880 mg/d.,C0032042|C0870604|C0205359|C0006675|C1512806|C0549183|C1442061|C0439422
"The two studies were combined and had 4 co-primary endpoints (trough FEV1 response, Mahler Transition Dyspnea Index [TDI] and St George’s Respiratory Questionnaire scores all at week 48, and COPD exacerbations per patient-year).","The studies combined 4 co-primary endpoints (trough FEV1 response, Mahler Transition Dyspnea Index [TDI] St George’s Respiratory Questionnaire scores week 48, COPD exacerbations patient-year).",G0000000|C0947630|C0205195|G0000000|C3245499|C2349179|C0444506|G0000000|C0871261|G0000000|C0599156|C0013404|C0918012|C0205976|C0036056|G0000000|C0521346|C0034394|C0449820|C0332174|C0450371|C0024117|G0000000|C0030705
"End-points were: success, no use or no more than once every 15 days; reduced, at least a 50% reduction in initial dose; failure, no change or a decrease smaller than 50%.","End-points were: success, 15 days; reduced, 50% reduction initial dose; failure, change decrease 50%.",C2349179|G0000000|C0597535|C0450371|C0439228|C0392756|C0450371|C0301630|C0205265|C0178602|C0231174|C0392747|C0392756|C0450371
"Questions were asked to fill out the follow up form, regarding pain severity, convenience of treatment, satisfaction with the “one stop” service as well as to document any cast or splint problems or complications.","Questions fill follow form, pain severity, convenience treatment, satisfaction “one stop” service document cast splint complications.",C1522634|C1708059|C0332283|C0348078|C0030193|C0439793|C3831015|C0039798|C0242428|G0000000|G0000000|C0557854|C1301746|C0179686|C0038009|C0009566
To measure the effect of giving out free smoke alarms on rates of fires and rates of fire related injury in a deprived multiethnic urban population.,To measure free smoke alarms rates fires rates fire injury deprived multiethnic urban population.,C0040363|C0079809|C0332296|C0037366|C0336648|C0871208|C0016141|C0871208|C0016141|C3263722|G0000000|G0000000|C0442529|C0032659
The primary endpoint was change in 24-h proteinuria at 24 weeks.,The primary endpoint change 24-h proteinuria 24 weeks.,G0000000|C0205225|C2349179|C0392747|C0450371|C0033687|C0450371|C0439230
(A) TDI total score (LSM) after 26 weeks and (B) percentages of patients achieving the minimum clinically important difference (≥1 units) (FAS).,(A) TDI total score (LSM) 26 weeks (B) percentages patients achieving minimum clinically difference (≥1 units) (FAS).,G0000000|C0205976|C0439175|C0449820|G0000000|G0000000|G0000000|C0439165|C0030705|G0000000|C1524031|G0000000|C1705241|G0000000|C0439148|G0000000
Comparison of the changes in the MFT and FIM self-care scores from baseline to 6 weeks between groups revealed significant improvement in the experimental group (p<0.05) (Table 3).,Comparison MFT FIM self-care scores baseline 6 weeks revealed improvement experimental (p<0.05) (Table 3).,C1707455|C1822742|C3273671|C0036592|C0449820|C0168634|G0000000|C0439230|C0443289|C2986411|C1517586|C0369773|C0039224|G0000000
The use of steroids also independently increased the length of stay.,The steroids independently increased length stay.,G0000000|C0038317|G0000000|C0205217|C1444754|G0000000
Post hoc analysis of the data was performed to determine the time to complete healing and the rate of healing of M. ulcerans disease while the patients were receiving this treatment regimen.,Post hoc analysis data performed determine time complete healing rate healing M. ulcerans disease patients receiving treatment regimen.,C0687676|G0000000|C0002778|C1511726|C0884358|G0000000|C0040223|C0205197|C0043240|C0871208|C0043240|C0369637|G0000000|C0012634|C0030705|C1514756|C0039798|C0040808
"Fibromyalgia Impact Questionnaire (FIQ) total scores Change between conditions on primary and secondary outcome measures CI confidence interval, FIQ fibromyalgia impact questionnaire, BPI brief pain inventory, SE self-efficacy, NS not significant Three functional mobility measures improved.","Fibromyalgia Impact Questionnaire (FIQ) total scores Change conditions primary secondary outcome measures CI confidence interval, FIQ fibromyalgia impact questionnaire, BPI pain inventory, SE self-efficacy, NS Three functional mobility measures improved.",C0016053|C1825598|C0034394|G0000000|C0439175|C0449820|C0392747|C0012634|C0205225|C0027627|C1274040|C0079809|C0008107|C0237529|C1272706|G0000000|C0016053|C1825598|C0034394|C1443145|C0030193|C0021941|C0036919|C0600564|C0038944|C0205449|C0205245|C0425245|C0079809|C0184511
"At the baseline assessment and at subsequent, bi-monthly contacts, adolescent alcohol use was assessed with a three-question panel: “During the past 30 days, on how many days (if any) did you have at least one drink of alcohol”?40 “On the days that you drank alcohol during the past 30 days, what was the usual number of drinks that you had each day”?41 and “During the past 30 days, on how many days, if any, did you have 4 or more drinks of alcohol on the same occasion”?41 Descriptive statistics, percentage responding to an item, along with the mean, median, range and confidence intervals, were used to describe responses to the acceptability measures.","At baseline assessment subsequent, bi-monthly contacts, adolescent alcohol assessed three-question panel: “During 30 days, days (if any) drink alcohol”?40 “On days drank alcohol 30 days, usual drinks day”?41 “During 30 days, days, any, 4 drinks alcohol occasion”?41 Descriptive statistics, percentage responding item, mean, median, range confidence intervals, responses acceptability measures.",G0000000|C0168634|C1261322|C0332282|C0332177|C4036459|C0205653|C0001962|C1516048|C0205449|C0441833|G0000000|C0450371|C0439228|C0439228|G0000000|G0000000|C0452428|G0000000|G0000000|C0439228|C0452428|C0001962|C0450371|C0439228|C3538928|C0452428|G0000000|G0000000|C0450371|C0439228|C0439228|G0000000|G0000000|C0452428|C0001962|G0000000|C0678257|C0038215|C0439165|G0000000|C1551338|C0444504|C0549183|C1514721|C0237529|C1272706|C0871261|C0814633|C0079809
"The primary endpoint will be the number of CD8+ cells (cell counts per mm2) in bronchial biopsy tissue specimens (sub-mucosa) and the key secondary endpoint will be the number of CD68+ cells (cell counts per mm2), assessed by indirect immunohistochemistry.","The primary endpoint CD8+ cells (cell counts mm2) bronchial biopsy tissue specimens (sub-mucosa) key secondary endpoint CD68+ cells (cell counts mm2), assessed indirect immunohistochemistry.",G0000000|C0205225|C2349179|C0285590|C0007634|C0007634|C0439157|G0000000|C0205039|C0005558|C0040300|C0370003|C0542339|G0000000|C0027627|C2349179|G0000000|C0007634|C0007634|C0439157|G0000000|C1516048|C0439852|C0021044
"PSS, Perceived Stress Scale; SF-36, Health Status Survey Short Form.","PSS, Perceived Stress Scale; SF-36, Health Status Survey Short Form.",G0000000|C0030971|C0038435|C0175659|C0037712|C0018684|C0449438|C0038951|C1282927|C0348078
"Secondary outcomes included mortality; time to occurrence of VAP; durations of mechanical ventilation, ICU stay, and hospital stay; Clostridium difficile–associated diarrhea; other ICU-associated diarrhea; antibiotic consumption (total, VAP-specific, and C. difficile-specific); and hospital charges.","Secondary outcomes included mortality; time occurrence VAP; durations mechanical ventilation, ICU stay, hospital stay; Clostridium difficile–associated diarrhea; ICU-associated diarrhea; antibiotic consumption (total, VAP-specific, C. difficile-specific); hospital charges.",C0027627|C1274040|C0332257|C0026565|C0040223|C0243132|G0000000|C0449238|C0443254|C0035203|C0021708|G0000000|C0019994|G0000000|C0009054|G0000000|C0011991|C0021708|C0011991|C0003232|C0009830|C0439175|C0205369|G0000000|C0205369|C0019994|C0007961
"Subjects were seen at baseline, 1 month, 2 months and 3 months after beginning the supplementation.","Subjects baseline, 1 month, 2 months 3 months supplementation.",C0681850|C0168634|G0000000|C0332177|G0000000|C0439231|G0000000|C0439231|C0242297
"Secondary outcomes included changes in documentation of smoking status, tobacco treatment medication prescribing, and referrals to smoking cessation services.","Secondary outcomes included documentation smoking status, tobacco treatment medication prescribing, referrals smoking cessation services.",C0027627|C1274040|C0332257|C0175636|C0037369|C0449438|C0040329|C0039798|C0013227|C0278329|C0034927|C0037369|C1880019|C0557854
"The inclusion criteria for entrance to the study All patients were assessed 1, 3 and 4 months after beginning the treatment.","The inclusion criteria entrance study All patients assessed 1, 3 4 months treatment.",G0000000|C0007637|C0243161|C0337095|C0557651|G0000000|C0030705|C1516048|G0000000|G0000000|G0000000|C0439231|C0039798
The primary outcome was inhaled corticosteroid dose.,The primary outcome inhaled corticosteroid dose.,G0000000|C0205225|C1274040|C0004048|C0001617|C0178602
5 CVD mortality This is defined as any documented death caused by CVD during the study period.,5 CVD mortality This defined documented death caused CVD study period.,G0000000|C0007222|C0026565|G0000000|C1704788|C1301725|C0011065|C0015127|C0007222|C0557651|C0439531
The satisfaction of patients according to the IMPSS was also better in the EPs 7630 groups.,The satisfaction patients IMPSS EPs 7630 groups.,G0000000|C0242428|C0030705|G0000000|G0000000|G0000000|C0441833
"Patients were assigned randomly to esomeprazole (Nexium®; AstraZeneca LP, Wilmington, DE) 5 or 10 mg (children ≥ 8 kg and < 20 kg) or 10 or 20 mg (children ≥ 20 kg) once daily for 8 weeks.","Patients assigned randomly esomeprazole (Nexium®; AstraZeneca LP, Wilmington, DE) 5 10 (children ≥ 8 < 20 kg) 10 20 (children ≥ 20 kg) daily 8 weeks.",C0030705|C1516050|G0000000|C0937846|G0000000|G0000000|C0037943|G0000000|C0011198|G0000000|C0450371|C0008059|G0000000|G0000000|G0000000|C0450371|C0022718|C0450371|C0450371|C0008059|G0000000|C0450371|C0022718|C0332173|G0000000|C0439230
We linked individualised data on vaccination to data on utilisation of inpatient and specialist healthcare in the common healthcare registers for Stockholm County Council (the GVR) from 1 January 1998 to 31 August 2010.,We linked individualised data vaccination data utilisation inpatient specialist healthcare common healthcare registers Stockholm County Council (the GVR) 1 January 1998 31 August 2010.,G0000000|C1517892|G0000000|C1511726|C0042196|C1511726|C0042153|C0021562|C0087009|C0086388|C0205214|C0086388|C0600375|G0000000|C0079170|C1551807|G0000000|G0000000|G0000000|C3829466|G0000000|C0450371|C3831448|G0000000
"In their study, when both lifestyle interventions including the active training or dietary consultancy with brochure given by dietitians in accordance with the national guidelines regarding healthier nutrition were compared with the first trimester, it was observed that they were efficient in developing diet habits in the last trimester but inefficient on physical activity and GWG.","In study, lifestyle interventions including active training dietary consultancy brochure dietitians national guidelines healthier nutrition compared trimester, observed efficient developing diet habits trimester inefficient physical activity GWG.",G0000000|C0557651|C0023676|C0886296|C0332257|C0205177|C0040607|C0012155|G0000000|C0030258|C3536818|C3245503|C0162791|C3898900|C0028707|C1707455|C0032982|C1441672|C0442799|G0000000|C0012155|C0018464|C0032982|C0231185|C0031809|C0205177|G0000000
A progressive disease was defined as either the occurrence of new lesions or an increase in size of more than 25%.,A progressive disease defined occurrence lesions increase size 25%.,G0000000|C0205329|C0012634|C1704788|C0243132|C0221198|C0442805|C0456389|C0450371
"Other information assessed by the health survey questionnaire included the consumption of alcohol during the previous month, number of episodes of binge drinking in 7 days and number of episodes of being drunk in previous month, frequency of accidents and traffic accidents due to alcohol drinking during the previous 6 months, and frequency of health care utilization owing to drinking behaviour in the previous 6 months.","Other assessed health survey questionnaire included consumption alcohol previous month, episodes binge drinking 7 days episodes drunk previous month, frequency accidents traffic accidents alcohol drinking previous 6 months, frequency health care utilization drinking behaviour previous 6 months.",G0000000|C1516048|C0018684|C0038951|C0034394|C0332257|C0009830|C0001962|C0205156|C0332177|C0332189|C0596170|C0001948|G0000000|C0439228|C0332189|C0001969|C0205156|C0332177|C0376249|C0000924|C3840880|C0000924|C0001962|C0001948|C0205156|G0000000|C0439231|C0376249|C0018684|C1947933|C0042153|C0001948|C0004927|C0205156|G0000000|C0439231
The secondary outcome measures at 6 and 12 months are: (i) Nottingham Extended Activities of Daily Living Scale [7] (a measure of functional ability).,The secondary outcome measures 6 12 months are: (i) Nottingham Extended Activities Daily Living Scale [7] (a measure functional ability).,G0000000|C0027627|C1274040|C0079809|G0000000|G0000000|G0000000|C0021966|G0000000|C0231448|C0441655|C0332173|C0376558|C0175659|G0000000|G0000000|C0079809|C0205245|C0085732
"In addition, we can also hypothesize that the weight loss observed was not large enough to see a change in QOL.","In addition, hypothesize weight loss observed change QOL.",G0000000|C0332287|G0000000|C0005910|C1517945|C1441672|C0392747|C0518214
"Perhaps of even greater concern, even when a child had access to a physician in private practice, those who had a Vietnamese provider were less than one half as likely to have had 3 doses of hepatitis B vaccine when compared with children with non-Vietnamese providers.","Perhaps concern, child access physician private practice, Vietnamese provider half 3 doses hepatitis B vaccine compared children non-Vietnamese providers.",G0000000|C2699424|C0008059|C0444454|C0031831|C0033175|C0237607|C0042660|C1138603|C2825407|G0000000|C0178602|C0019158|G0000000|C0042210|C1707455|C0008059|C1518422|C1138603
"The findings indicate that the group-based intervention was efficacious in improving self-reported milk consumption frequency, calcium supplementation, and dietary calcium intake at 1-month follow-up.","The findings group-based intervention efficacious improving self-reported milk consumption frequency, calcium supplementation, dietary calcium intake 1-month follow-up.",G0000000|C2607943|C0441833|C0886296|C1280519|C1272745|C0681906|C0026131|C0009830|C0376249|C0006675|C0242297|C0012155|C0006675|C1512806|C0332177|C0589120
"OUTCOME MEASURES—Sputum inflammatory markers (interleukin-8, tumour necrosis factor-α (TNF-α) and neutrophil elastase—both free and bound to α1-antiprotease), sputum interleukin-10, lung function, and symptomatology.","OUTCOME MEASURES—Sputum inflammatory markers (interleukin-8, tumour necrosis factor-α (TNF-α) neutrophil elastase—both free bound α1-antiprotease), sputum interleukin-10, lung function, symptomatology.",C1274040|G0000000|C0333348|C0005516|C0021764|C0027651|C0027540|G0000000|G0000000|C0027950|G0000000|C0332296|C0332297|G0000000|C0038056|C0021764|C0024109|C0031843|G0000000
Zinc deficiency is defined as serum zinc level of <10.10 mmol/L in NPNL women [25].,Zinc deficiency defined serum zinc level <10.10 mmol/L NPNL women [25].,C0043481|C0011155|C1704788|C0229671|C0043481|C0441889|C0450371|C1532563|G0000000|C0043210|C0450371
"The WHO definitions typically pertain to children 6–24 months of age; however, in our study, we have chosen to include all children surveyed during year 2, approximately 80% of who ranged in age from 6 to 24 months.","The WHO definitions typically pertain children 6–24 months age; however, study, chosen children surveyed 2, 80% ranged age 6 24 months.",G0000000|G0000000|C1550452|G0000000|G0000000|C0008059|G0000000|C0439231|C0001779|G0000000|C0557651|C1707391|C0008059|C0038951|G0000000|C0450371|C1514721|C0001779|G0000000|C0450371|C0439231
"Assessment of depression was done at entry and at 2, 4, 8, and 12 weeks using the Ham-D, the Beck Depression Inventory (BDI), and a questionnaire asking about compliance and side effects.","Assessment depression entry 2, 4, 8, 12 weeks Ham-D, Beck Depression Inventory (BDI), questionnaire compliance effects.",C1261322|C0011570|C1705654|G0000000|G0000000|G0000000|C0450371|C0439230|C1570167|G0000000|C0011570|C0021941|C0006448|C0034394|C0009563|C1280500
"The original 110-item Block Questionnaire was developed using NHANES dietary recall data, which includes representation of African Americans.","The original 110-item Block Questionnaire developed NHANES dietary recall data, includes representation African Americans.",G0000000|C0205313|C1442061|C0028778|C0034394|G0000000|C0376344|C0012155|C0034770|C1511726|C0332257|C1514861|C0027567|C0596070
"Continuous abstinence was defined as self reported; ""not one puff of smoke during the past six months (183 days)"".","Continuous abstinence defined reported; ""not puff smoke months (183 days)"".",C0549178|C3843422|C1704788|C0684224|C1518422|C1533107|C0037366|C0439231|C1442061|C0439228
"A pre-study goal in addition to safety, was to determine if infant RBC DHA levels could be increased by at least 20% as a result of DHA supplementation at age 12 months.","A pre-study goal addition safety, determine infant RBC DHA levels increased 20% result DHA supplementation age 12 months.",G0000000|C1527048|C0018017|C0332287|C0036043|G0000000|C0021270|C0014792|C0142831|C0441889|C0205217|C0450371|C1274040|C0142831|C0242297|C0001779|C0450371|C0439231
"The primary end point of the study was the reduction in the median pain score from baseline, as assessed by the patient’s global assessment of efficacy by the VAS (0–100 points).","The primary study reduction median pain score baseline, assessed patient’s global assessment efficacy VAS (0–100 points).",G0000000|C0205225|C0557651|C0301630|C0549183|C0030193|C0449820|C0168634|C1516048|G0000000|C0205246|C1261322|C1280519|C0042815|G0000000|C1552961
"Outcome measures of the study were pH and changes in electrolytes, including serum potassium, sodium, chloride and bicarbonate levels at 0, 60, and 120 minutes in venous blood gas samples.","Outcome measures study pH electrolytes, including serum potassium, sodium, chloride bicarbonate levels 0, 60, 120 minutes venous blood gas samples.",C1274040|C0079809|C0557651|C0450407|C0013832|C0332257|C0229671|C0032821|C0037473|C0008203|C0005367|C0441889|G0000000|C0450371|C1442061|C0439232|C0042449|C0005767|C0017110|C0370003
"Both treatments remarkably alleviated the clinical symptoms of migraine (intensity of pain, attack frequency, and days with migraine) and improved the QOL.","Both treatments remarkably alleviated clinical symptoms migraine (intensity pain, attack frequency, days migraine) improved QOL.",G0000000|C0087111|G0000000|G0000000|C0205210|C0683368|C0149931|C0522510|C0030193|C0277793|C0376249|C0439228|C0149931|C0184511|C0518214
"The EEG seizure onset type [I, II, or III (Ebersole & Pacia, 1996)] was not associated with outcome class.","The EEG seizure onset type [I, II, III (Ebersole & Pacia, 1996)] outcome class.",G0000000|C0013819|C0036572|C0206132|C0332307|C0021966|G0000000|C0439070|G0000000|G0000000|G0000000|G0000000|C1274040|C0456387
A follow-up was conducted 6 months after study entry for all participants.,A follow-up conducted 6 months study entry participants.,G0000000|C0589120|C0004927|G0000000|C0439231|C0557651|C1705654|C0679646
"This instrument comprises three sub-scales: (1) the Depression sub-scale which measures hopelessness, low self-esteem, and low positive affect; (2) the Anxiety scale which assesses autonomic arousal, muscle-skeletal symptoms, situational anxiety and subjective experience of anxious arousal; and (3) the Stress scale which assesses tension, agitation, and negative affect.","This instrument comprises sub-scales: (1) Depression sub-scale measures hopelessness, low self-esteem, low positive affect; (2) Anxiety scale assesses autonomic arousal, muscle-skeletal symptoms, situational anxiety subjective experience anxious arousal; (3) Stress scale assesses tension, agitation, negative affect.",G0000000|C0348000|C2700400|C0542339|G0000000|C0011570|C0542339|C0079809|C0150041|C0205251|C0036597|C0205251|C0439178|C0001721|G0000000|C0003467|C0175659|C1516048|C0004388|C0003808|C0242695|C0683368|G0000000|C0003467|C0439655|C0237607|C0003467|C0003808|G0000000|C0038435|C0175659|C1516048|C0233494|C0085631|C0205160|C0001721
The primary efficacy endpoint is the between-group difference (spironolactone plus patiromer versus spironolactone plus placebo) in the proportion of patients remaining on spironolactone at Week 12.,The primary efficacy endpoint between-group difference (spironolactone patiromer versus spironolactone placebo) proportion patients remaining spironolactone Week 12.,G0000000|C0205225|C1280519|C2349179|C0441833|C1705241|C0037982|C4045522|G0000000|C0037982|C0032042|C1709707|C0030705|C1527428|C0037982|C0332174|C0450371
"The present study measured zinc deficiency at the community level in a less controlled setting, and absorption of zinc was not measured.","The study measured zinc deficiency community level controlled setting, absorption zinc measured.",G0000000|C0557651|C0444706|C0043481|C0011155|C0009462|C0441889|C2587213|C0542559|C0000854|C0043481|C0444706
"Secondary endpoints included the time to FEV1 recovery after exercise challenge (defined as the amount of time post-challenge needed for FEV1 to return to within 5% of the postdose/pre-challenge value), the mean percent change in FEV1 from visit predose to postdose/pre-challenge to post exercise, and the number of protected/unprotected patients.","Secondary endpoints included time FEV1 recovery exercise challenge (defined amount time post-challenge FEV1 return 5% postdose/pre-challenge value), percent change FEV1 visit predose postdose/pre-challenge post exercise, protected/unprotected patients.",C0027627|C2349179|C0332257|C0040223|G0000000|C0237820|C0015259|C0798503|C1704788|C1265611|C0040223|C0687676|G0000000|C0332156|G0000000|C0439568|C1522609|C0439165|C0392747|G0000000|C0545082|C0439565|C0439568|C0687676|C0015259|G0000000|C0030705
"The second part was a form to record temperatures of the mothers and infants infrared ray thermometer on the forehead, IN4K8210 model.","The form record temperatures mothers infants infrared ray thermometer forehead, IN4K8210 model.",G0000000|C0348078|C0034869|C0039476|C0026591|C0021270|C1532326|C0086894|C0039818|C0016540|G0000000|C3161035
Predicting smoking at time 2 for baseline ever smokers (n = 1668).,Predicting smoking time 2 baseline smokers (n = 1668).,G0000000|C0037369|C0040223|G0000000|C0168634|C0337664|C0369718|G0000000|G0000000
CONCLUSION—Oral β-carotene supplementation in a dose of 1 mg/kg/day only was effective in normalising the plasma concentration of β-carotene and resulted in a decrease in pulmonary exacerbations.,CONCLUSION—Oral β-carotene supplementation dose 1 mg/kg/day effective normalising plasma concentration β-carotene decrease pulmonary exacerbations.,G0000000|G0000000|C0242297|C0178602|G0000000|C3665414|C1280519|G0000000|C0032105|C0004268|G0000000|C0392756|C0024109|G0000000
"This study will provide new information on the impact of arm ergometry on physical fitness, activity, body composition, fatigue, pain, muscle strength, and health related quality of life.","This study provide impact arm ergometry physical fitness, activity, body composition, fatigue, pain, muscle strength, health quality life.",G0000000|C0557651|C1999230|C1825598|C0446516|C0085143|C0031809|C1456706|C0205177|C0242821|C0486616|C0015672|C0030193|C0026845|C0237897|C0018684|C0332306|C0376558
"Comparison between both groups as regards the time of eye opening, agitation score, postoperative fentanyl consumption, and time for hospital discharge allowance Comparison between both groups with regard to postoperative fentanyl consumption The time for hospital discharge of group M (211.± 6 21.8) was longer than group KM (191.7 ± 30.6) P < 0.05.","Comparison time eye opening, agitation score, postoperative fentanyl consumption, time hospital discharge allowance Comparison regard postoperative fentanyl consumption The time hospital discharge M (211.± 6 21.8) KM (191.7 ± 30.6) P < 0.05.",C1707455|C0040223|C0015392|C0175566|C0085631|C0449820|C0032790|C0015846|C0009830|C0040223|C0019994|C0012621|C0556660|C1707455|G0000000|C0032790|C0015846|C0009830|G0000000|C0040223|C0019994|C0012621|C0369637|G0000000|G0000000|C0450371|G0000000|C1442061|G0000000|C0450371|C0369773|G0000000|C0450371
"Length of hospital stay in group A, B and C were similar in each group.","Length hospital stay A, B C group.",C1444754|C0019994|G0000000|G0000000|G0000000|G0000000|C0441833
"Secondary outcome measures include participation and activity status, health-related quality of life, and self-efficacy.","Secondary outcome measures participation activity status, health-related quality life, self-efficacy.",C0027627|C1274040|C0079809|C0679823|C0205177|C0449438|C0018684|C0332306|C0376558|C0600564
Scores for subscales are added to a global QOL scale ranging from 0 to 100.,Scores subscales global QOL scale ranging 0 100.,C0449820|G0000000|C0205246|C0518214|C0175659|C1514721|G0000000|C1442061
"The baseline and follow-up surveys were designed to measure breast cancer screening knowledge, attitudes, beliefs, and behaviors (breast self-examination, clinical breast examination, and mammography).","The baseline follow-up surveys designed measure breast cancer screening knowledge, attitudes, beliefs, behaviors (breast self-examination, clinical breast examination, mammography).",G0000000|C0168634|C0589120|C0038951|C1707689|C0079809|C0006141|C0006826|C0220908|C0376554|C0004271|C0004951|C0004927|C0006141|C0080142|C0205210|C0006141|G0000000|C0024671
Exercise and dietary counseling led to loss of body fat and improved quality of life in survivors of triple-negative breast cancer.,Exercise dietary counseling led loss body fat improved quality life survivors triple-negative breast cancer.,C0015259|C0012155|C0010210|C1708698|C1517945|C0242821|C0424612|C0184511|C0332306|C0376558|C0206194|C0205174|C0006141|C0006826
Muscle tenderness scores were assessed using a standard manual muscle myometer.,Muscle tenderness scores assessed standard manual muscle myometer.,C0026845|C0234233|C0449820|C1516048|C1442989|C0024763|C0026845|G0000000
"The average retention across groups for the prolonged CO-verified smoking abstinence outcome measure was 100% at 2 weeks, 91% at 3 months, 82% at 6 months, and 72% at 12 months.","The average retention prolonged CO-verified smoking abstinence outcome measure 100% 2 weeks, 91% 3 months, 82% 6 months, 72% 12 months.",G0000000|C1510992|C0035280|C0439590|C3245499|C0037369|C3843422|C1274040|C0079809|C1442061|G0000000|C0439230|C0450371|G0000000|C0439231|C0450371|G0000000|C0439231|C0450371|C0450371|C0439231
The impact of the interventions on our primary outcome of cognitive change in the composite score is shown in Figure 3.,The impact interventions primary outcome cognitive change composite score Figure 3.,G0000000|C1825598|C0886296|C0205225|C1274040|C1516691|C0392747|C0205199|C0449820|G0000000|G0000000
"CDI, Child Depression Inventory; ES, Education Support; FACES, Faces Pain Scale-Revised; FDI, Functional Disability Inventory; GI, gastrointestinal; PBQ, Pain Beliefs Questionnaire; PRI, Pain Response Inventory; SLCBT, Social Learning/Cognitive Behavioral Therapy; tx, treatment.","CDI, Child Depression Inventory; ES, Education Support; FACES, Faces Pain Scale-Revised; FDI, Functional Disability Inventory; GI, gastrointestinal; PBQ, Pain Beliefs Questionnaire; PRI, Pain Response Inventory; SLCBT, Social Learning/Cognitive Behavioral Therapy; tx, treatment.",C0282601|C0008059|C0011570|C0021941|C0013754|C0013621|C0183683|C0015450|C0015450|C0030193|C0175659|G0000000|C0205245|C0231170|C0021941|C1708130|C0521362|G0000000|C0030193|C0004951|C0034394|C0034044|C0030193|C0871261|C0021941|G0000000|C0728831|C0013621|C0004927|C0039798|C0041403|C0039798
"The modified Telephone Interview for Cognitive Status (TICS-m)23 was used during the cohort study, replacing the expanded Consortium to Establish a Registry in Alzheimer’s Disease (CERADe) neuropsychological battery24 used during the RCT.","The modified Telephone Interview Cognitive Status (TICS-m)23 cohort study, replacing expanded Consortium Establish Registry Alzheimer’s Disease (CERADe) neuropsychological battery24 RCT.",G0000000|C0392747|C0039457|C0021822|C1516691|C0449438|C0040188|C0599755|C0557651|C1299987|C0205229|C1513822|C0443211|C0034975|G0000000|C0012634|G0000000|G0000000|G0000000|G0000000
"Following parameters (entry time in seconds needed to establish the intra-abdominal vision after pneumoperitoneum, blood loss, occurrence of vascular and/or bowel injuries) were compared during surgery as main outcomes.","Following parameters (entry time establish intra-abdominal vision pneumoperitoneum, blood loss, occurrence vascular and/or bowel injuries) compared surgery main outcomes.",C0231290|C0449381|C1705654|C0040223|C0443211|C0230168|C0042789|C0032320|C0005767|C1517945|C0243132|C0005847|G0000000|C0021853|C1510467|C1707455|C0038894|C0205225|C1274040
The primary outcome is the number of general practitioner referrals of young people with first episode psychosis to Early Intervention Services.,The primary outcome practitioner referrals people episode psychosis Early Intervention Services.,G0000000|C0205225|C1274040|C1709627|C0034927|C0027361|C0332189|C0033975|C1279919|C0886296|C0557854
"Secondary outcomes included a change in asthma symptoms, scores on the Asthma Quality of Life Questionnaire (AQLQ, in which scores range from 1 to 7, with lower values indicating more severe impairment and a change of 0.5 unit considered to be clinically important), forced expiratory volume in 1 second (FEV1) after use of a bronchodilator, airway hyperresponsiveness, and eosinophil counts in the blood and sputum.","Secondary outcomes included change asthma symptoms, scores Asthma Quality Life Questionnaire (AQLQ, scores range 1 7, lower values indicating severe impairment change 0.5 unit considered clinically important), forced expiratory volume 1 (FEV1) bronchodilator, airway hyperresponsiveness, eosinophil counts blood sputum.",C0027627|C1274040|C0332257|C0392747|C0004096|C0683368|C0449820|C0004096|C0332306|C0376558|C0034394|C4055434|C0449820|C1514721|G0000000|G0000000|C0441994|C0042295|G0000000|C0205082|C0221099|C0392747|G0000000|C0439148|C0750591|G0000000|G0000000|C0441722|C0231800|C0449468|G0000000|G0000000|C0006280|C0178987|G0000000|C0014467|C0439157|C0005767|C0038056
"The primary end point was sustained remission, defined as freedom from relapse at the 6 months follow-up visit.","The primary sustained remission, defined freedom relapse 6 months follow-up visit.",G0000000|C0205225|C0443318|C0544452|C1704788|C0016694|C0035020|G0000000|C0439231|C0589120|C0545082
"In spite of the high reliability score of the internal consistency (0.94), sufficient variance in the scale of the patient satisfaction questionnaire was found.","In spite reliability score internal consistency (0.94), sufficient variance scale patient satisfaction questionnaire found.",G0000000|G0000000|C2347947|C0449820|C0205102|C0332529|C0450371|C0205410|C1711260|C0175659|C0030705|C0242428|C0034394|C0150312
"Some women may have reported that they had a Pap test in order to please the LHWs, community-based organizations, or researchers.","Some women reported Pap test LHWs, community-based organizations, researchers.",G0000000|C0043210|C0684224|C1740167|C0022885|G0000000|C0009462|C0029246|C0035173
"The severity of cannabis withdrawal symptoms (overall withdrawal and separate sleep symptoms– woke up early, nightmares/strange dreams, woke up with night sweats, and trouble getting to sleep) was quantified daily on a 10-point self-report scale (0 = Not at all, 10 = Extremely) for each prior 24-h period using the Cannabis Withdrawal Scale (CWS).4 Subjective sleep assessment at baseline for the week prior to admission was assessed using the Athens Insomnia Scale (AIS).24 The AIS is a commonly used, validated global insomnia symptom questionnaire designed to assess the severity of insomnia based on the ICD-10 diagnostic criteria.","The severity cannabis withdrawal symptoms (overall withdrawal separate sleep symptoms– woke early, nightmares/strange dreams, woke night sweats, trouble sleep) quantified daily 10-point self-report scale (0 = Not all, 10 = Extremely) prior 24-h period Cannabis Withdrawal Scale (CWS).4 Subjective sleep assessment baseline week prior admission assessed Athens Insomnia Scale (AIS).24 The AIS commonly used, validated global insomnia symptom questionnaire designed assess severity insomnia based ICD-10 diagnostic criteria.",G0000000|C0439793|C0024808|C2349954|C0683368|C0282416|C2349954|C0443299|C0037313|G0000000|C0442696|C1279919|C0028084|C0013117|C0442696|C0240526|C0038984|G0000000|C0037313|C1709793|C0332173|C0450371|C0681906|C0175659|G0000000|G0000000|C1518422|G0000000|C0450371|G0000000|C0205403|C0332152|C0450371|C0439531|C0024808|C2349954|C0175659|C0332290|C0439655|C0037313|C1261322|C0168634|C0332174|C0332152|C0184666|C1516048|G0000000|C0917801|C0175659|C0450371|G0000000|G0000000|G0000000|C1273517|G0000000|C0205246|C0917801|C1457887|C0034394|C1707689|C1516048|C0439793|C0917801|C1527178|C0021122|C0011900|C0243161
Clinical outcome was assessed by self-reported questionnaires with the modified Rankin (mRS) score at 2 months and at 1 year [11].,Clinical outcome assessed self-reported questionnaires modified Rankin (mRS) score 2 months 1 [11].,C0205210|C1274040|C1516048|C0681906|C0034394|C0392747|G0000000|C1522706|C0449820|G0000000|C0439231|G0000000|C0450371
BP and LDL-C measurements were performed at 1 month (baseline) and 12 months post-discharge.,BP LDL-C measurements performed 1 month (baseline) 12 months post-discharge.,C0037623|G0000000|C0242485|C0884358|G0000000|C0332177|C0168634|C0450371|C0439231|C0687676
"Moreover, there was no difference between the two treatment arms in terms of duration of response, TTP, overall survival and 1-year survival.","Moreover, difference treatment arms terms duration response, TTP, survival 1-year survival.",G0000000|C1705241|C0039798|C0206655|C0233324|C0449238|C0871261|C0084795|C0038952|C0439234|C0038952
"Follow-up will be performed until 60 days after discharge, assessing transfusion needs, morbidity, mortality, safety, costs, and health-related quality of life.","Follow-up performed 60 days discharge, assessing transfusion needs, morbidity, mortality, safety, costs, health-related quality life.",C0589120|C0884358|C0450371|C0439228|C0012621|C1516048|C0005841|C0027552|C0026538|C0026565|C0036043|C0010186|C0018684|C0332306|C0376558
"(A) 1st grader BMI change by maternal BMI categories, P = 0.049.","(A) 1st grader BMI change maternal BMI categories, P = 0.049.",G0000000|G0000000|G0000000|G0000000|C0392747|C2347083|G0000000|C0683312|C0369773|G0000000|C1442061
"Primary outcomes included seven-day point-prevalence abstinence at one week, eight weeks, and six months post-quit, and number of days to relapse.","Primary outcomes included seven-day point-prevalence abstinence week, weeks, months post-quit, days relapse.",C0205225|C1274040|C0332257|C1710063|C1552961|C3843422|C0332174|C0439230|C0439231|C0687676|C0439228|C0035020
"The individual Breathprint (BP, Figure 2) of a patient is represented with a radar plot; equiangular radii shape each radar plot, where each radius represents one of the 28 sensor responses.","The individual Breathprint (BP, Figure 2) patient represented radar plot; equiangular radii shape radar plot, radius represents 28 sensor responses.",G0000000|C0027361|G0000000|C0037623|G0000000|G0000000|C0030705|C1882932|C0034513|G0000000|G0000000|C0034627|C0332479|C0034513|G0000000|C0034627|C1882932|C0450371|C0183210|C0871261
(C) Overall survival by treatment arm.,(C) Overall survival treatment arm.,G0000000|C0282416|C0038952|C0039798|C0446516
No serious adverse events were associated with MDA.,No adverse events MDA.,G0000000|G0000000|C0441471|C0000379
Measured treatment credibility and integrity was high for both groups.,Measured treatment credibility integrity groups.,C0444706|C0039798|C0870373|C0205266|C0441833
All measurements were made manually by one investigator.,All measurements manually investigator.,G0000000|C0242485|C3842330|C0035173
"Hence, we selected two composite co-primary outcomes: biochemical profile of cytokines, growth factors, adipokines, and cardiac biomarkers determined after stable PD treatment for an average duration of 2.3 years, and dialysis adequacy determined by GFR and daily urine output at initiation and at the time of census after stable PD for an average duration of 3.6 years.","Hence, selected composite co-primary outcomes: biochemical profile cytokines, growth factors, adipokines, cardiac biomarkers determined stable PD treatment average duration 2.3 years, dialysis adequacy determined GFR daily urine output initiation time census stable PD average duration 3.6 years.",G0000000|C1707391|C0205199|C3245499|C1274040|C0205474|C1979963|C0079189|C0018270|C1521761|C1955907|C0018787|C0005516|G0000000|C0205360|G0000000|C0039798|C1510992|C0449238|G0000000|C0439234|C0011945|C0205410|G0000000|C0017654|C0332173|C0042036|C1709366|C0589507|C0040223|C0007663|C0205360|G0000000|C1510992|C0449238|G0000000|C0439234
There is a scarcity of in vivo data in humans during pregnancy showing effects of vitamin D supplementation on neonatal immune function.,There scarcity vivo data humans pregnancy effects vitamin D supplementation neonatal immune function.,G0000000|G0000000|C1515655|C1511726|C0086418|C0032961|C1280500|C0042890|C0073187|C0242297|C1552240|C0439662|C0031843
"The significant, albeit relatively weak, correlation between haemoglobin levels and attention score supports this point.","The significant, albeit weak, correlation haemoglobin levels attention score supports point.",G0000000|C0237881|G0000000|C1762617|C1707520|C0019046|C0441889|C0004268|C0449820|C0183683|C1552961
"The secondary outcome measures were body composition, compliance and outcome 1 year after ATT.","The secondary outcome measures body composition, compliance outcome 1 ATT.",G0000000|C0027627|C1274040|C0079809|C0242821|C0486616|C0009563|C1274040|G0000000|G0000000
"Secondary outcomes measures were evaluated throughout the study and included FVC, ALSFRS-R, SF-12 and muscle fatigue.","Secondary outcomes measures evaluated study included FVC, ALSFRS-R, SF-12 muscle fatigue.",C0027627|C1274040|C0079809|C0220825|C0557651|C0332257|C3714541|C0205090|C0037712|C0026845|C0015672
There were no abnormal systolic or diastolic blood pressures in the patients studied (Table 1).,There abnormal systolic diastolic blood pressures patients studied (Table 1).,G0000000|C0205161|C0039155|C0012000|C0005767|C0033095|C0030705|C0557651|C0039224|G0000000
Family/caregivers of the patient will be asked to assess the patients’ situation by filling out the “Quality of Dying and Death” questionnaire [19].,Family/caregivers patient assess patients’ situation filling “Quality Dying Death” questionnaire [19].,C0086279|C0030705|C1516048|G0000000|G0000000|G0000000|G0000000|C0184532|G0000000|C0034394|C0450371
Malarial parasitemia and malaria-like symptoms were assessed in participants older than four years of age while skin prick test (SPT) to allergens as well as reported symptoms of allergy in children aged 5–15 years.,Malarial parasitemia malaria-like symptoms assessed participants age skin prick test (SPT) allergens reported symptoms allergy children aged 5–15 years.,C0024530|C0242723|C0024530|C0683368|C1516048|C0679646|C0001779|C0444099|C0033119|C0022885|G0000000|C0002092|C0684224|C0683368|C0002111|C0008059|C0001779|G0000000|C0439234
Change from baseline in (a) trough FEV1 and (b) TDI total scores with IND/GLY versus comparators at Week 12 (ITT population).,Change baseline (a) trough FEV1 (b) TDI total scores IND/GLY versus comparators Week 12 (ITT population).,C0392747|C0168634|G0000000|C0444506|G0000000|G0000000|C0205976|C0439175|C0449820|C4049864|G0000000|C1707454|C0332174|C0450371|G0000000|C0032659
The primary outcome measure was stipulated to be change in MRS NAA/Cr ratio in inferior parietal cortex in memantine relative to the placebo treatment condition.,The primary outcome measure stipulated change MRS NAA/Cr ratio inferior parietal cortex memantine relative placebo treatment condition.,G0000000|C0205225|C1274040|C0079809|G0000000|C0392747|C1522706|C0067684|C0456603|C0542339|C0442030|C0007776|C0025242|C0080103|C0032042|C0039798|C0012634
Preterm was defined as delivery less than 37 weeks gestation.,Preterm defined delivery 37 weeks gestation.,C0151526|C1704788|C0011209|C0450371|C0439230|C0032961
"Main outcome measures Duration of symptoms, mean consumption of analgesics, number of days of absence from school, occurrence of streptococcal sequelae, eradication of the initial pathogen, and recurrences of sore throat after six months.","Main outcome measures Duration symptoms, consumption analgesics, days absence school, occurrence streptococcal sequelae, eradication initial pathogen, recurrences sore throat months.",C0205225|C1274040|C0079809|C0449238|C0683368|C0009830|C0002771|C0439228|C0332197|C0036375|C0243132|C0038402|C0243088|G0000000|C0205265|C0450254|C0034897|C0234233|C0031354|C0439231
"Main maternal outcomes include a) maternal responsiveness, b) feeding style, and c) feeding practices.","Main maternal outcomes a) maternal responsiveness, b) feeding style, c) feeding practices.",C0205225|C2347083|C1274040|G0000000|C2347083|C0205342|G0000000|C0204695|C0489654|G0000000|C0204695|C0237607
"Similarly, results for mean change from baseline showed significant treatment group differences for ability to function and daytime alertness at all assessed time points and the double-blind average, for physical well-being at week 2, and for ability to concentrate at weeks 2 and 3 and the double-blind average (all P values < .05, data not shown).","Similarly, change baseline treatment differences ability function daytime alertness assessed time double-blind average, physical well-being week 2, ability concentrate weeks 2 3 double-blind average (all P values < .05, data shown).",G0000000|C0392747|C0168634|C0039798|C1705241|C0085732|C0031843|C0332169|C1443086|C1516048|C0040223|C0013072|C1510992|C0031809|C0018684|C0332174|G0000000|C0085732|C1880310|C0439230|G0000000|G0000000|C0013072|C1510992|G0000000|C0369773|C0042295|G0000000|C0450371|C1511726|C1547282
Ongoing HIT: Health information technology; MAP: My Asthma Portal; ED: emergency department; PHR: personal health record; CCM: Chronic Care Model; EHR: electronic health record; MOXXI: Medical Office of the Twenty-First Century; RAMQ: Regie de l'assurance maladie du Quebec; ID: Instructional Design; UCD: User Centered Design; IA: Information Architecture; HCI: Human Computer Interaction; AQLQ: Asthma quality of life questionnaire; TAM: Technology Acceptance Model; HRQL: health-related quality of life; IRB: institutional review board.,Ongoing HIT: Health technology; MAP: My Asthma Portal; ED: emergency department; PHR: personal health record; CCM: Chronic Care Model; EHR: electronic health record; MOXXI: Medical Office Twenty-First Century; RAMQ: Regie de l'assurance maladie du Quebec; ID: Instructional Design; UCD: User Centered Design; IA: Information Architecture; HCI: Human Computer Interaction; AQLQ: Asthma quality life questionnaire; TAM: Technology Acceptance Model; HRQL: health-related quality life; IRB: institutional review board.,C0549178|C0272285|C0018684|C0039421|C0024779|G0000000|C0004096|C0205054|C3538926|C0013956|C1704729|G0000000|C1519021|C0018684|C0034869|C2919945|C0205191|C1947933|C3161035|G0000000|C0013850|C0018684|C0034869|G0000000|C0199168|C0442603|C0724000|C0719214|G0000000|G0000000|C0011198|C0439394|G0000000|C0011535|C0034390|C0600091|C0039401|C1707689|G0000000|C1548600|C0205099|C1707689|C0694634|C1533716|C0003737|G0000000|C0086418|C0009622|C1704675|C4055434|C0004096|C0332306|C0376558|C0034394|C0039286|C0039421|G0000000|C3161035|G0000000|C0018684|C0332306|C0376558|C0086911|C0018704|C0282443|C0972401
"Three primary end points were evaluated after 24 weeks of treatment: forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0–3) response (in each individual trial), trough FEV1 response in each individual trial (response defined as change from baseline; mean of the values of 1 h and 10 min prior to the first dose of study medication); and St George's Respiratory Questionnaire (SGRQ) total score (SGRQ was analysed in a pre-specified combined analysis of data from both studies).","Three primary evaluated 24 weeks treatment: forced expiratory volume 1 s (FEV1) curve 0 3 h (AUC0–3) response (in individual trial), trough FEV1 response individual trial (response defined change baseline; values 1 h 10 min prior dose study medication); St George's Respiratory Questionnaire (SGRQ) total score (SGRQ analysed pre-specified combined analysis data studies).",C0205449|C0205225|C0220825|G0000000|C0039798|C0441722|C0231800|C0449468|G0000000|G0000000|C0205134|G0000000|G0000000|G0000000|C0871261|G0000000|C0027361|C0008976|C0444506|G0000000|C0871261|C0027361|C0008976|C0871261|C1704788|C0392747|C0168634|C0042295|G0000000|G0000000|C0332152|C0178602|C0557651|C0013227|C0036056|G0000000|C0521346|C0034394|G0000000|C0439175|C0449820|G0000000|G0000000|C2826245|C0205195|C0002778|C1511726|C0947630
Round 3 went from September 2005 till May 2006 and round 4 from July 2006 till March 2007.,Round 3 September 2005 till May 2006 round 4 July 2006 till March 2007.,C0332490|G0000000|C3828193|G0000000|G0000000|G0000000|G0000000|C0332490|G0000000|C3829447|G0000000|G0000000|C3829202|G0000000
The overall rate of treatment completion was 79.8%.,The rate treatment completion 79.8%.,G0000000|C0871208|C0039798|C0205197|C0450371
Primary outcome measures were the Clinical Global Impressions for Bipolar Illness Improvement-Mania and the Modified Side Effects Form for Children and Adolescents.,Primary outcome measures Clinical Global Impressions Bipolar Illness Improvement-Mania Modified Side Effects Form Children Adolescents.,C0205225|C1274040|C0079809|C0205210|C0205246|C0596764|C0443156|C0221423|C2986411|C0392747|C0441987|C1280500|C0348078|C0008059|C0205653
"However, during the year 2 follow‐up visit, when the children were an average age of 22 months, the proportion meeting the MDD score among the non‐nutrition intervention arms and controls increased more than twofold from the year 1 measurement.","However, 2 follow‐up visit, children average age 22 months, proportion meeting MDD score non‐nutrition intervention arms controls increased twofold 1 measurement.",G0000000|G0000000|G0000000|C0545082|C0008059|C1510992|C0001779|C0450371|C0439231|C1709707|C0556656|C1269683|C0449820|G0000000|C0886296|C0206655|C0243148|C0205217|G0000000|G0000000|C0242485
Primary outcomes of interest include the estimated number and proportion of additional cases detected during the intervention period and cases reduced after the intervention.,Primary outcomes estimated proportion additional detected intervention period reduced intervention.,C0205225|C1274040|C0750572|C1709707|C1524062|C0442726|C0886296|C0439531|C0392756|C0886296
"Secondary outcomes included ICU-specific and hospital-specific mortality, mean arterial pressure, vasopressor doses, shock reversal, vasopressor-free days, mechanical ventilation-free days and renal replacement-free days (during the first 28 study days).","Secondary outcomes included ICU-specific hospital-specific mortality, arterial pressure, vasopressor doses, shock reversal, vasopressor-free days, mechanical ventilation-free days renal replacement-free days (during 28 study days).",C0027627|C1274040|C0332257|C0021708|C0019994|C0026565|C0003842|C0033095|C0042397|C0178602|C0036974|C0443290|C0042397|C0439228|C0443254|C0035203|C0439228|C0022646|C0035139|C0439228|G0000000|C0450371|C0557651|C0439228
"Efficacy parameters assessed were i) severity of pain measured on Visual Analog Scale (VAS) of 0–10 and it was done in two ways; ii) Functional Disability of joint was assessed by measuring pain while a) walking distance, b) squatting, c) crossing legs and knees, and d) climbing steps and scored as 0 no pain, 1 mild pain, 2 moderate pain, 3 severe pain and 4 acute pain.","Efficacy parameters assessed i) severity pain measured Visual Analog Scale (VAS) 0–10 ways; ii) Functional Disability joint assessed measuring pain a) walking distance, b) squatting, c) crossing legs knees, d) climbing steps scored 0 pain, 1 mild pain, 2 moderate pain, 3 severe pain 4 acute pain.",C1280519|C0449381|C1516048|C0021966|C0439793|C0030193|C0444706|C0234621|C0243071|C0175659|C0042815|G0000000|G0000000|G0000000|C0205245|C0231170|C0022417|C1516048|C0444706|C0030193|G0000000|C0080331|C0012751|G0000000|C0241236|G0000000|G0000000|C1140621|C0022742|C0073187|C0561942|C1261552|C0449820|G0000000|C0030193|G0000000|C2945599|C0030193|G0000000|C0205081|C0030193|G0000000|C0205082|C0030193|G0000000|C0205178|C0030193
"Nonparametric analyses for repeated measures (i.e., Friedman test followed by post-hoc Wilcoxon signed-rank tests) were used for subgroup analyses of women (the subgroup analysis was performed ad-hoc) who had complete measurements of body composition, fish intake, and serum phospholipid fatty acids in all three trimesters.","Nonparametric analyses repeated measures (i.e., Friedman test post-hoc Wilcoxon signed-rank tests) subgroup analyses women (the subgroup analysis performed ad-hoc) complete measurements body composition, fish intake, serum phospholipid fatty acids trimesters.",G0000000|C0002778|C0205341|C0079809|C0683454|G0000000|C0022885|C0687676|G0000000|C1519316|C0022885|C1079230|C0002778|C0043210|G0000000|C1079230|C0002778|C0884358|G0000000|C0205197|C0242485|C0242821|C0486616|C0016163|C1512806|C0229671|C0031676|G0000000|C0001128|C0032982
"First events included the following: local recurrence (n = 54), distant metastasis (n = 76), contralateral breast disease (n = 16), other second primary (n = 17), multiple disease event (n = 7), and death without disease recurrence (n = 7; Table 4).","First events included following: local recurrence (n = 54), distant metastasis (n = 76), contralateral breast disease (n = 16), primary (n = 17), multiple disease event (n = 7), death disease recurrence (n = 7; Table 4).",C0205435|C0441471|C0332257|C0231290|C0205276|C0034897|C0369718|G0000000|C0450371|C0443203|C0027627|C0369718|G0000000|C0450371|C0441988|C0006141|C0012634|C0369718|G0000000|C0450371|C0205225|C0369718|G0000000|C0450371|C0439064|C0012634|C0441471|C0369718|G0000000|G0000000|C0011065|C0012634|C0034897|C0369718|G0000000|G0000000|C0039224|G0000000
"RESULTS: The groups were similar in degree of social deprivation, length of stay, number of previous admissions, acute asthma treatment, and asthma treatment at discharge.","RESULTS: The degree social deprivation, length stay, previous admissions, acute asthma treatment, asthma treatment discharge.",C1274040|G0000000|C0441889|C0728831|C0871712|C1444754|G0000000|C0205156|C0184666|C0205178|C0004096|C0039798|C0004096|C0039798|C0012621
"Secondary endpoints included median progression-free survival (PFS), 12-month PFS, and safety.","Secondary endpoints included median progression-free survival (PFS), 12-month PFS, safety.",C0027627|C2349179|C0332257|C0549183|C0242656|C0038952|C0242792|C0450371|C0242792|C0036043
FMD was defined as the primary outcome.,FMD defined primary outcome.,C0238288|C1704788|C0205225|C1274040
"In Study 1, human participants receiving CrPic reduced food intake, hunger levels, and fat cravings, as compared to participants receiving placebo.","In Study 1, human participants receiving CrPic reduced food intake, hunger levels, fat cravings, compared participants receiving placebo.",G0000000|C0557651|G0000000|C0086418|C0679646|C1514756|G0000000|C0392756|C0016452|C1512806|C0020175|C0441889|C0424612|C0870371|C1707455|C0679646|C1514756|C0032042
A diagnosis of bacteremia as a result of frequent contaminants such as coagulase-negative Staphylococcus required two positive blood cultures.,A diagnosis bacteremia result frequent contaminants coagulase-negative Staphylococcus required positive blood cultures.,G0000000|C0011900|C0004610|C1274040|C0332183|C2827365|C0009118|C0038170|C1514873|C0439178|C0005767|C0010453
"Pain severity was judged as: none, mild (pain but no real complaints), moderate (complaints, but no analgesics necessary) or severe (analgesics necessary).","Pain severity judged as: none, mild (pain real complaints), moderate (complaints, analgesics necessary) severe (analgesics necessary).",C0030193|C0439793|C0221191|G0000000|G0000000|C2945599|C0030193|C0237400|C0277786|C0205081|C0277786|C0002771|G0000000|C0205082|C0002771|G0000000
"Other outcomes were duration of active phase of labour, pain score, need for analgesia, need for oxytocin, time between delivery and initiation of breastfeeding and the emotional experience during labour.","Other outcomes duration active phase labour, pain score, analgesia, oxytocin, time delivery initiation breastfeeding emotional experience labour.",G0000000|C1274040|C0449238|C0205177|C0205390|C0022864|C0030193|C0449820|C0002766|C0030095|C0040223|C0011209|C0589507|C0006147|C0013987|C0237607|C0022864
"Details of maternal side effects will be collected such as; PPH=>600 mls; blood transfusion; death; ICU admission, meconium stained liquor; babies admitted to neonatal unit.","Details maternal effects collected as; PPH=>600 mls; blood transfusion; death; ICU admission, meconium stained liquor; babies admitted neonatal unit.",C1522508|C2347083|C1280500|C1516695|G0000000|C1414402|C0796070|C0005767|C0005841|C0011065|C0021708|C0184666|C0025047|C2986582|C0002638|C0021270|C0184666|C1552240|C0439148
Pulse oximetry was monitored throughout the night while the subjects slept and the tPAD operated continuously.,Pulse oximetry monitored night subjects slept tPAD operated continuously.,C0232117|C0523807|C0030695|C0240526|C0681850|C0037313|G0000000|C3242339|G0000000
"Our confirmed water treatment adoption in intervention households (9%) is lower than water treatment adoption reported after a CARE/Madagascar Safe Water System (SWS) campaign, which promoted chlorine treatment with safe storage.","Our confirmed water treatment adoption intervention households (9%) lower water treatment adoption reported CARE/Madagascar Safe Water System (SWS) campaign, promoted chlorine treatment safe storage.",G0000000|C0521093|C0043047|C0039798|C0001593|C0886296|C0020052|G0000000|C0441994|C0043047|C0039798|C0001593|C0684224|C1947933|G0000000|C0043047|C0449913|C0038505|G0000000|C0033414|C0008209|C0039798|G0000000|C0337174
Bleeding events occurred with an overall low frequency and with few major bleeding events.,Bleeding events occurred low frequency major bleeding events.,C0019080|C0441471|C1709305|C0205251|C0376249|C0205082|C0019080|C0441471
"Additional analyses were performed to compare the between-group changes in plasma AcPGP, sputum neutrophil counts, additional sputum biomarkers, the BCSS and SGRQ scores, and changes in post-bronchodilator FEV1 at the 12-week visit.","Additional analyses performed compare between-group plasma AcPGP, sputum neutrophil counts, additional sputum biomarkers, BCSS SGRQ scores, post-bronchodilator FEV1 12-week visit.",C1524062|C0002778|C0884358|C1707455|C0441833|C0032105|G0000000|C0038056|C0027950|C0439157|C1524062|C0038056|C0005516|C1412777|G0000000|C0449820|C2599594|G0000000|C0450371|C0545082
"MVC torque of the exercised elbow flexors was measured using the isokinetic dynamometer in the same positioning as that of the eccentric exercise, and the elbow joint angle was set at 90°.","MVC torque exercised elbow flexors measured isokinetic dynamometer positioning eccentric exercise, elbow joint angle set 90°.",G0000000|C0376590|C0015259|C0013769|C1879367|C0444706|G0000000|C0180572|C0150305|C0439740|C0015259|C0013769|C0022417|C0205143|C0036849|G0000000
We took Roland and Morris disability questionnaire as the primary outcome and the other measures as secondary outcomes.,We Roland Morris disability questionnaire primary outcome measures secondary outcomes.,G0000000|G0000000|G0000000|C0231170|C0034394|C0205225|C1274040|C0079809|C0027627|C1274040
"The comprehensive massage therapy group had improved function (mean RDQ score 1.54 v. 2.86-6.5, p < 0.001), less intense pain (mean PPI score 0.42 v. 1.18-1.75, p < 0.001) and a decrease in the quality of pain (mean PRI score 2.29 v. 4.55-7.71, p = 0.006) compared with the other 3 groups.","The comprehensive massage therapy improved function (mean RDQ score 1.54 v. 2.86-6.5, < 0.001), intense pain (mean PPI score 0.42 v. 1.18-1.75, < 0.001) decrease quality pain (mean PRI score 2.29 v. 4.55-7.71, = 0.006) compared 3 groups.",G0000000|C1880156|C0024875|C0039798|C0184511|C0031843|C0444504|C3639717|C0449820|C0450371|G0000000|C0450371|G0000000|C1442061|C0522510|C0030193|C0444504|C0358591|C0449820|C0450371|G0000000|C0450371|G0000000|C1442061|C0392756|C0332306|C0030193|C0444504|C0034044|C0449820|C0450371|G0000000|C0450371|G0000000|C1442061|C1707455|G0000000|C0441833
"Overall, 13% mortality (n = 10) was observed.","Overall, 13% mortality (n = 10) observed.",C0282416|C0450371|C0026565|C0369718|G0000000|C0450371|C1441672
"In this study, results regarding breastfeeding were similar in the two groups; however, breastfeeding was only analyzed in the first twelve hours following delivery, while ideally it should be evaluated the first months following delivery [11,15].","In study, breastfeeding groups; however, breastfeeding analyzed twelve hours delivery, ideally evaluated months delivery [11,15].",G0000000|C0557651|C0006147|C0441833|G0000000|C0006147|C0936012|C0205458|C0439227|C0011209|G0000000|C0220825|C0439231|C0011209|C0450371
"Both treatment regimens were well tolerated; the incidence of treatment-related adverse events was 19.9% and 12.3% for azithromycin and levofloxacin, respectively.","Both treatment regimens tolerated; incidence treatment-related adverse events 19.9% 12.3% azithromycin levofloxacin, respectively.",G0000000|C0039798|C2945654|G0000000|C0021149|C0039798|G0000000|C0441471|C0450371|C0450371|C0052796|C0282386|G0000000
"Ovarian stimulation was not associated with colorectal cancer, malignant melanoma of the skin, or thyroid cancer.","Ovarian stimulation colorectal cancer, malignant melanoma skin, thyroid cancer.",C0205065|C1292856|C0555952|C0006826|C0205282|C0025202|C0444099|C0040132|C0006826
"The criteria used for the clinical evaluation included a history of pain, tenderness to percussion, gingival abscess, sinus/fistula, and pathological mobility.","The criteria clinical evaluation included history pain, tenderness percussion, gingival abscess, sinus/fistula, pathological mobility.",G0000000|C0243161|C0205210|C0220825|C0332257|C0019664|C0030193|C0234233|C0030987|C0017562|C0000833|C0016169|C0030664|C0425245
"Subgroup analyses were then conducted for women who had measurements of fish intake, body composition, and serum phospholipid fatty acids in all three trimesters (Figure 2; see Results).","Subgroup analyses conducted women measurements fish intake, body composition, serum phospholipid fatty acids trimesters (Figure 2; Results).",C1079230|C0002778|C0004927|C0043210|C0242485|C0016163|C1512806|C0242821|C0486616|C0229671|C0031676|G0000000|C0001128|C0032982|G0000000|G0000000|C1274040
A 60% reduction in the standard IPV dose without reduction in antibody titers is possible through intradermal administration.,A 60% reduction standard IPV dose reduction antibody titers intradermal administration.,G0000000|C0450371|C0301630|C1442989|G0000000|C0178602|C0301630|C0003241|C0475208|C0150647|C0001554
"Behavioral outcomes included using female or male condoms at least once during vaginal or anal intercourse in the past 3 months and percentage of vaginal and anal sexual acts protected by female condoms, by male condoms, or by any (female or male) condom in the past 3 months.","Behavioral outcomes included female male condoms vaginal anal intercourse 3 months percentage vaginal anal sexual acts protected female condoms, male condoms, (female male) condom 3 months.",C0004927|C1274040|C0332257|C0015780|C0086582|C0009653|C0042232|C0003461|C0009253|G0000000|C0439231|C0439165|C0042232|C0003461|C0036864|C0079613|G0000000|C0015780|C0009653|C0086582|C0009653|C0015780|C0086582|C0009653|G0000000|C0439231
"In the study, 252 children were randomised to the magnesium group and 256 to the placebo group.","In study, 252 children randomised magnesium 256 placebo group.",G0000000|C0557651|C1442061|C0008059|G0000000|C0024467|C1442061|C0032042|C0441833
Postural stability was assessed using the limits of stability (LOS) and one-leg stance (OLS) tests.,Postural stability assessed limits stability (LOS) one-leg stance (OLS) tests.,C0205278|C0205360|C1516048|C0439801|C0205360|G0000000|C0205447|G0000000|G0000000|C0022885
"Clinical changes obtained from repeated measures, with standard error of the mean Abbreviations: 6MWT, 6-minute walking test; BPAQ, Baecke Physical Activity Questionnaire; CCQ, clinical COPD questionnaire; COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQol; IMA, integrated modulus of body acceleration; m, meters; MFI, Multidimensional Fatigue Inventory (general fatigue scale); NA, not applicable; T0, inclusion; T1, 1 month; T2, 3 months; VAS, visual analogue scale.","Clinical repeated measures, standard error Abbreviations: 6MWT, 6-minute walking test; BPAQ, Baecke Physical Activity Questionnaire; CCQ, clinical COPD questionnaire; COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQol; IMA, integrated modulus body acceleration; m, meters; MFI, Multidimensional Fatigue Inventory (general fatigue scale); NA, applicable; T0, inclusion; T1, 1 month; T2, 3 months; VAS, visual analogue scale.",C0205210|C0205341|C0079809|C1442989|C0743559|C0000723|G0000000|C0439232|C0080331|C0022885|G0000000|G0000000|C0031809|C0205177|C0034394|G0000000|C0205210|C0024117|C0034394|C0024117|C0205191|C0549186|C0024109|C0012634|C0205163|C0451150|G0000000|G0000000|C1031041|C0242821|C0000894|C0369637|C0441074|C1881923|C2347299|C0015672|C0021941|C0205246|C0015672|C0175659|C0597484|C1272460|C0041403|C0007637|C0041403|G0000000|C0332177|C0041403|G0000000|C0439231|C0042815|C0234621|C0243071|C0175659
"The primary efficacy end point was the number of days patients were alive without delirium or coma (i.e., delirium/coma-free days) during the 21-day study period.","The primary efficacy days patients alive delirium coma (i.e., delirium/coma-free days) 21-day study period.",G0000000|C0205225|C1280519|C0439228|C0030705|C0376558|C0011206|C0009421|C0683454|C0011206|C0439228|C0450371|C0557651|C0439531
"The Godin leisure-time physical activity questionnaire has shown high agreement and validation (agreement: 70.8%) with minutes spent physically active, in comparison to an accelerometer in breast cancer survivors [69].","The Godin leisure-time physical activity questionnaire agreement validation (agreement: 70.8%) minutes spent physically active, comparison accelerometer breast cancer survivors [69].",G0000000|G0000000|C0086542|C0031809|C0205177|C0034394|C0680240|C1519941|C0680240|C0450371|C0439232|C0680968|G0000000|C0205177|C1707455|C0178951|C0006141|C0006826|C0206194|C0450371
"The primary depression outcome measures were the clinician-rated 17-item Hamilton Depression Rating Scale (HAMD-17)56 and the patient-reported Symptom Checklist-20 (SCL-20).57 The SCL-20 is a more unidimensional depression scale that is less dependent on somatic symptoms than the HAMD-17,58 and, therefore, more sensitive to change in the TBI population.","The primary depression outcome measures clinician-rated 17-item Hamilton Depression Rating Scale (HAMD-17)56 patient-reported Symptom Checklist-20 (SCL-20).57 The SCL-20 unidimensional depression scale dependent somatic symptoms HAMD-17,58 and, therefore, sensitive change TBI population.",G0000000|C0205225|C0011570|C1274040|C0079809|C0871685|C0450371|G0000000|C0011570|C0871208|C0175659|C0450371|C0747307|C1457887|C1707357|C0450371|G0000000|C0450371|G0000000|C0011570|C0175659|C0851827|C1257909|C0683368|C0450371|G0000000|G0000000|C0020517|C0392747|C0876926|C0032659
Main outcome measures Miscarriage and other pregnancy outcomes.,Main outcome measures Miscarriage pregnancy outcomes.,C0205225|C1274040|C0079809|C0000786|C0032961|C1274040
"Secondary outcomes were frequency of culture-proven sepsis, pathogen-specific late-onset sepsis; necrotizing enterocolitis (NEC), duration of hospitalization, overall mortality rate, infection-related mortality, frequency of adverse events, and treatment intolerance.","Secondary outcomes frequency culture-proven sepsis, pathogen-specific late-onset sepsis; necrotizing enterocolitis (NEC), duration hospitalization, mortality rate, infection-related mortality, frequency adverse events, treatment intolerance.",C0027627|C1274040|C0376249|C0010453|C0036690|C0450254|C4025592|C0036690|C0439664|C0014356|C0206695|C0449238|C0019993|C0026565|C0871208|C0009450|C0026565|C0376249|G0000000|C0441471|C0039798|C0231199
"Furthermore, with respect to radiographic criteria i.e., premature exfoliation, PDL widening, internal/external resorption and periapical/furcal radiolucency, we observed a non- significant difference (p<0.05) for each agent after follow up [Table/Fig-6].","Furthermore, respect radiographic criteria i.e., premature exfoliation, PDL widening, internal/external resorption periapical/furcal radiolucency, observed non- difference (p<0.05) agent follow [Table/Fig-6].",G0000000|C0679133|C0444708|C0243161|C0683454|C0151526|C0237849|G0000000|C0332464|C0205102|C2985494|C0729269|C2827491|C1441672|C1518422|C1705241|C0369773|C0450442|C0332283|C0039224
"The main outcome, self-reported 30-day point prevalence of smoking abstinence, was assessed at a 6-month follow up.","The main outcome, self-reported 30-day prevalence smoking abstinence, assessed 6-month follow up.",G0000000|C0205225|C1274040|C0681906|C0450371|C0033105|C0037369|C3843422|C1516048|C0332177|C0332283|G0000000
"The aim of these interviews is to identify beliefs and knowledge regarding smoking around children, perceived social norms regarding parental smoking around children, reliable information sources regarding smoking hazards and smoking cessation, channels of influence and support, and barriers obstacles to the adoption of smoking bans in the home and car.","The aim interviews identify beliefs knowledge smoking children, perceived social norms parental smoking children, reliable sources smoking hazards smoking cessation, channels influence support, barriers obstacles adoption smoking bans car.",G0000000|C1947946|C0021822|G0000000|C0004951|C0376554|C0037369|C0008059|C0030971|C0728831|C0205307|C0030551|C0037369|C0008059|C3858758|C0449416|C0037369|C0598697|C0037369|C1880019|C0439799|C4054723|C0183683|C1706912|G0000000|C0001593|C0037369|C0105185|C0004381
"Were men at least 45 years old, with a peak urinary flow rate ≥ 4 ml/sec, an AUA Symptom Index (AUASI) score ≥ 8 and ≤ 24, and no exclusions.","Were 45 old, peak urinary flow rate ≥ 4 ml/sec, AUA Symptom Index (AUASI) score ≥ 8 ≤ 24, exclusions.",G0000000|C0450371|C0580836|C0444505|C0042027|C0806140|C0871208|G0000000|G0000000|C0439390|G0000000|C1457887|C0918012|G0000000|C0449820|G0000000|G0000000|G0000000|C0450371|C0680251
The concept of self efficacy may differ between cultures and cognitive behavioral skills may not be as meaningful in certain cultures.,The concept efficacy cultures cognitive behavioral skills meaningful cultures.,G0000000|C0178566|C1280519|C0010453|C1516691|C0004927|C0678856|C0876919|C0010453
"The clinical course was assessed by the time to resolution of morbidity (TRM) score, a semi-quantitative score that combines clinical and radiological variables in order to determine the timing of improvement after inclusion [14].","The clinical assessed time resolution morbidity (TRM) score, semi-quantitative score combines clinical radiological variables determine timing improvement inclusion [14].",G0000000|C0205210|C1516048|C0040223|C1514893|C0026538|G0000000|C0449820|C0522525|C0449820|C0336789|C0205210|C0034599|C0439828|G0000000|C0449243|C2986411|C0007637|C0450371
"The primary difference from LWW1 was the mode of delivery—offering treatment by telephone as well as in-person, and a reduction in the length of treatment (6 weeks vs 8 weeks).","The primary difference LWW1 mode delivery—offering treatment telephone in-person, reduction length treatment (6 weeks 8 weeks).",G0000000|C0205225|C1705241|G0000000|C1513371|G0000000|C0039798|C0039457|C1547564|C0301630|C1444754|C0039798|G0000000|C0439230|G0000000|C0439230
The average survival period was 1108±52 days in the HRT group and 1086±43 days in the non-HRT group.,The average survival period 1108±52 days HRT 1086±43 days non-HRT group.,G0000000|C1510992|C0038952|C0439531|G0000000|C0439228|C0282402|G0000000|C0439228|C1518422|C0441833
Eligible children were those with SAM and a good appetite.,Eligible children SAM appetite.,C1548635|C0008059|C0036002|C0003618
"Continuous abstinence at 10 days, 1 month, 3 months and 6 months.","Continuous abstinence 10 days, 1 month, 3 months 6 months.",C0549178|C3843422|C0450371|C0439228|G0000000|G0000000|C0439231|G0000000|C0439231
"The device software was used to calculate total step counts, percent of time during waking hours without any steps (inactive), percent active time at moderate (31–80 steps/min) and high intensity activity (>80 steps/min), and peak performance (average steps/min of the best 30 minutes of the day).","The device software calculate total step counts, percent time waking hours steps (inactive), percent active time moderate (31–80 steps/min) intensity activity (>80 steps/min), peak performance (average steps/min 30 minutes day).",G0000000|C0025080|C0037585|C1441506|C0439175|C1261552|C0439157|C0439165|C0040223|C0442696|C0439227|C1261552|C0205254|C0439165|C0205177|C0040223|C0205081|G0000000|C1261552|C0522510|C0205177|C0450371|C1261552|C0444505|C0597198|C1510992|C1261552|C0450371|C0439232|C0332173
"However, there was no difference in the rate of radiologic and echocardiographic resolution of pericardial effusion.","However, difference rate radiologic echocardiographic resolution pericardial effusion.",G0000000|C1705241|C0871208|C0034599|C0013516|C1514893|C0031050|C0013687
"However, we cannot exclude the possibility that the increased levels of cytokines were the result rather than the cause of acute rejection.","However, exclude possibility increased levels cytokines result acute rejection.",G0000000|C0332196|C0332149|C0205217|C0441889|C0079189|C1274040|C0205178|C0035015
"Secondary outcome criteria were the time to remission, endoscopic mucosal healing (DAI = 0), and disappearance of histological signs of significant inflammation (according to [22]).","Secondary outcome criteria time remission, endoscopic mucosal healing (DAI = 0), disappearance histological signs inflammation (according [22]).",C0027627|C1274040|C0243161|C0040223|C0544452|C0014245|C0026724|C0043240|C0683432|G0000000|G0000000|G0000000|C0205462|C0220912|C0021368|C0680240|C0450371
The Severity Scoring of Atopic Dermatitis (SCORAD) index was recorded at baseline and also at 4 and 8 weeks of treatment.,The Severity Scoring Atopic Dermatitis (SCORAD) recorded baseline 4 8 weeks treatment.,G0000000|C0439793|C0449820|C0392707|C0011603|G0000000|C0034869|C0168634|G0000000|G0000000|C0439230|C0039798
"Subject flow diagram Baseline characteristicsa BMI body mass index, FM fibromyalgia, FIQ fibromyalgia impact questionnaire, PSQI Pittsburg sleep quality index, BPI brief pain inventory Table 2 shows changes from baseline to 12 weeks for all outcomes in subjects in both conditions.","Subject flow diagram Baseline characteristicsa BMI body mass index, FM fibromyalgia, FIQ fibromyalgia impact questionnaire, PSQI Pittsburg sleep quality index, BPI pain inventory Table 2 baseline 12 weeks outcomes subjects conditions.",C0681850|C0806140|C0681494|C0168634|G0000000|G0000000|C0242821|C0577559|C0918012|C3540627|C0016053|G0000000|C0016053|C1825598|C0034394|C3697468|G0000000|C0037313|C0332306|C0918012|C1443145|C0030193|C0021941|C0039224|G0000000|C0168634|C0450371|C0439230|C1274040|C0681850|C0012634
"At the first day of each block (D1), they were asked to fill questionnaires for pain (BPI), fatigue (MFIS), anxiety and depression (HADS).","At day block (D1), fill questionnaires pain (BPI), fatigue (MFIS), anxiety depression (HADS).",G0000000|C0332173|C0028778|C3538936|C1708059|C0034394|C0030193|C1443145|C0015672|C3810705|C0003467|C0011570|C0048008
"Secondary aims are to compare between PREVENT and USUAL CARE groups (i) exercise capacity, walking endurance, daily physical activity, number of cigarettes smoked daily, medication adherence; (ii) fatigue, cognitive function, depression, health-related goal attainment and health-related quality of life; (iii) direct health costs incurred over a 1-year period; (iv) reduction in secondary vascular events, within the limitations in sample size and trial duration.","Secondary aims compare PREVENT USUAL CARE (i) exercise capacity, walking endurance, daily physical activity, cigarettes smoked daily, medication adherence; (ii) fatigue, cognitive function, depression, health-related goal attainment health-related quality life; (iii) direct health costs incurred 1-year period; (iv) reduction secondary vascular events, limitations sample size trial duration.",C0027627|C1947946|C1707455|C0309872|C3538928|C1947933|C0021966|C0015259|C1516240|C0080331|C0518031|C0332173|C0031809|C0205177|C0677453|C0037366|C0332173|C0013227|C1510802|G0000000|C0015672|C1516691|C0031843|C0011570|C0018684|C0018017|G0000000|C0018684|C0332306|C0376558|C0439070|C0439851|C0018684|C0010186|G0000000|C0439234|C0439531|C0022326|C0301630|C0027627|C0005847|C0441471|C0449295|C0370003|C0456389|C0008976|C0449238
Through these measures we ensure that patients who have requested a caesarean section have had a chance to consider their options in an informed way.,Through measures ensure patients requested caesarean chance options informed way.,G0000000|C0079809|C0218063|C0030705|C1272683|C3841297|C0237506|C1518601|C1522154|G0000000
SCQ: Social Communication Questionnaire (Previously Autism Screening Questionnaire).,SCQ: Social Communication Questionnaire (Previously Autism Screening Questionnaire).,C0451482|C0728831|C0009452|C0034394|G0000000|C0004352|C0220908|C0034394
The secondary end points also included proteinuria reduction evaluated by time-averaged proteinuria and eGFR slope across all postrandomization study visits.,The secondary included proteinuria reduction evaluated time-averaged proteinuria eGFR slope postrandomization study visits.,G0000000|C0027627|C0332257|C0033687|C0301630|C0220825|C0040223|C0033687|C1739039|C0807955|G0000000|C0557651|C0545082
"A visual analog scale (VAS) was used to score discomfort at different times during the study (0 cm = no discomfort, 10 cm = unbearable or maximum discomfort).","A visual analog scale (VAS) score discomfort times study (0 cm = discomfort, 10 cm = unbearable maximum discomfort).",G0000000|C0234621|C0243071|C0175659|C0042815|C0449820|C0231218|C0040223|C0557651|G0000000|G0000000|G0000000|C0231218|C0450371|G0000000|G0000000|G0000000|C0806909|C0231218
Cox regression multivariate analysis was performed to identify independent predictors of recurrence and survival.,Cox regression multivariate analysis performed identify independent predictors recurrence survival.,G0000000|C0684320|G0000000|C0002778|C0884358|G0000000|C0085862|C2698872|C0034897|C0038952
"The operative time, intraoperative blood loss, complications, postoperative pain, cosmetic score, length of hospitalization, and hospital costs were compared, with a follow-up duration of 1 mo.","The operative time, intraoperative blood loss, complications, postoperative pain, cosmetic score, length hospitalization, hospital costs compared, follow-up duration 1 mo.",G0000000|C1882154|C0040223|C0456904|C0005767|C1517945|C0009566|C0032790|C0030193|C0010164|C0449820|C1444754|C0019993|C0019994|C0010186|C1707455|C0589120|C0449238|G0000000|C0026544
"These are: the Child Behavior Checklist (CBCL), the Teacher Report Form (TRF) and the Screen for Child Anxiety Related Emotional Disorders (SCARED) and are meant to assess children's level of anxiety and to determine the presence of additional problems.","These are: Child Behavior Checklist (CBCL), Teacher Report Form (TRF) Screen Child Anxiety Related Emotional Disorders (SCARED) meant assess children's level anxiety determine presence additional problems.",G0000000|G0000000|C0008059|C0004927|C1707357|C1511566|C0221457|C0684224|C0348078|C1702088|C0220908|C0008059|C0003467|C0439849|C0013987|C0012634|C0015726|C0444504|C1516048|C0008059|C0441889|C0003467|G0000000|C0150312|C1524062|C1546466
"Parental supervision and monitoring of adolescent diabetes management have been shown to promote better diabetes management among adolescents, but parents typically decrease their oversight during the transition to independent diabetes care.","Parental supervision monitoring adolescent diabetes management promote diabetes management adolescents, parents typically decrease oversight transition independent diabetes care.",C0030551|C0038842|C0150369|C0205653|C0011847|C0001554|C0033414|C0011847|C0001554|C0205653|C0030551|G0000000|C0392756|C1273870|C0599156|C0085862|C0011847|C1947933
Serial LS mean change (95% CI) from baseline in FEV1 over 0–3 h on Day 1 (A) and Day 84 (B; ITT population).,Serial LS change (95% CI) baseline FEV1 0–3 Day 1 (A) Day 84 (B; ITT population).,C0031082|C0023668|C0392747|C0450371|C0008107|C0168634|G0000000|G0000000|C0332173|G0000000|G0000000|C0332173|C0450371|G0000000|G0000000|C0032659
Secondary efficacy measures were AM (morning) pre-dose FEV1 and AM peak expiratory flow (PEF) over weeks 1-12.,Secondary efficacy measures AM (morning) pre-dose FEV1 AM peak expiratory flow (PEF) weeks 1-12.,C0027627|C1280519|C0079809|G0000000|C0332170|C0439565|G0000000|G0000000|C0444505|C0231800|C0806140|C0030771|C0439230|C0450371
"In addition, infants with serious infections frequently have complications that prevent or delay the medical or surgical treatment of the PDA.","In addition, infants infections frequently complications prevent delay medical surgical treatment PDA.",G0000000|C0332287|C0021270|C3714514|C0332183|C0009566|C0309872|C0205421|C0199168|C0543467|C0039798|C0013274
A participant will be discontinued from the study intervention in the following situations: Serious adverse events at Investigator discretion.,A participant discontinued study intervention situations: Serious adverse events Investigator discretion.,G0000000|C0679646|C1444662|C0557651|C0886296|G0000000|C0205404|G0000000|C0441471|C0035173|G0000000
This dose of IFNα is much higher than what we have used because our primary goal was to boost the immune response.,This dose IFNα primary goal boost immune response.,G0000000|C0178602|G0000000|C0205225|C0018017|C1511253|C0439662|C0871261
"Therefore, the mandible does not achieve its optimum genetic growth position.","Therefore, mandible achieve optimum genetic growth position.",G0000000|C0024687|G0000000|C2698651|C0017296|C0018270|C0733755
"Prespecified secondary end points included changes in other measurements of glucose metabolism, oxidative stress, fasting serum lipids, and high sensitivity C-reactive protein.","Prespecified secondary included measurements glucose metabolism, oxidative stress, fasting serum lipids, sensitivity C-reactive protein.",G0000000|C0027627|C0332257|C0242485|C0017725|C0025519|C0311404|C0038435|C0015663|C0229671|C0023779|C0020517|C0205332|C0033684
"Surveillance for influenza was conducted between 14 November 2005 through 30 April 2006 (Season 1), and 13 November 2006 through 30 April 2007 (Season 2).","Surveillance influenza conducted 14 November 2005 30 April 2006 (Season 1), 13 November 2006 30 April 2007 (Season 2).",C0220920|C0021400|C0004927|C0450371|C3828767|G0000000|C0450371|C3715024|G0000000|C0036497|G0000000|C0450371|C3828767|G0000000|C0450371|C3715024|G0000000|C0036497|G0000000
The survival benefit is seen in the stage II patients.,The survival benefit stage II patients.,G0000000|C0038952|C0814225|C0205390|G0000000|C0030705
"The study was based on two sets of cases (216 male single and 35 male multiple stomach cancer cases newly diagnosed and of adenocarcinoma type), and 483 male controls derived from residents of Saitama Prefecture.","The study based sets (216 male single 35 male multiple stomach cancer newly diagnosed adenocarcinoma type), 483 male controls derived residents Saitama Prefecture.",G0000000|C0557651|C1527178|C0036849|C1442061|C0086582|C0037179|C0450371|C0086582|C0439064|C0038351|C0006826|C0750546|C0011900|C0001418|C0332307|C1442061|C0086582|C0243148|C1441547|C1320928|G0000000|C1709636
A random subgroup of 90 patients completed a St George's respiratory questionnaire during the first week of the exacerbation.,A random subgroup 90 patients completed St George's respiratory questionnaire week exacerbation.,G0000000|C0034656|C1079230|C0450371|C0030705|C0205197|C0036056|G0000000|C0521346|C0034394|C0332174|G0000000
The primary outcome measures included the Standardized Swallowing Assessment and the Dysphagia Outcome Severity Scale.,The primary outcome measures included Standardized Swallowing Assessment Dysphagia Outcome Severity Scale.,G0000000|C0205225|C1274040|C0079809|C0332257|G0000000|C0011167|C1261322|C0011168|C1274040|C0439793|C0175659
"We set the frequency and severity of diarrhea symptoms as the primary endpoint, and the frequency and severity of gastrointestinal symptoms other than diarrhea (nausea, vomiting, and loss of appetite) as the secondary endpoint.","We set frequency severity diarrhea symptoms primary endpoint, frequency severity gastrointestinal symptoms diarrhea (nausea, vomiting, loss appetite) secondary endpoint.",G0000000|C0036849|C0376249|C0439793|C0011991|C0683368|C0205225|C2349179|C0376249|C0439793|C0521362|C0683368|C0011991|C0027497|C0042963|C1517945|C0003618|C0027627|C2349179
"After release, many young men initially want to celebrate their return to the free world, often by using drugs or engaging in risky sexual behavior, and lose touch with some of the motivation for change.","After release, initially celebrate return free world, drugs engaging risky sexual behavior, lose touch motivation change.",G0000000|C0030685|C0205265|G0000000|C0332156|C0332296|C2700280|C0013227|C0425152|C0035647|C0036864|C0004927|G0000000|C0152054|C0026605|C0392747
"Data were collected by the trainers during each session, and included (a) the total number of visits over the 12-month study period and (b) resistance used during resistance activities and the number of minutes the participant engaged in aerobic activity.","Data collected trainers session, included (a) total visits 12-month study period (b) resistance resistance activities minutes participant engaged aerobic activity.",C1511726|C1516695|C0453962|C1883016|C0332257|G0000000|C0439175|C0545082|C0450371|C0557651|C0439531|G0000000|C0237834|C0237834|C0441655|C0439232|C0679646|C0425152|C1510824|C0205177
"Despite the large-scale deployment of international responders, few cases of Ebola virus disease have been diagnosed in this group.","Despite large-scale deployment international responders, Ebola virus disease diagnosed group.",G0000000|C0549177|C2825812|C1512888|G0000000|C0282687|C0042776|C0012634|C0011900|C0441833
"Secondary endpoints included the time to treatment failure, 1- and 2-year survival rates, response rate, and safety.","Secondary endpoints included time treatment failure, 1- 2-year survival rates, response rate, safety.",C0027627|C2349179|C0332257|C0040223|C0039798|C0231174|G0000000|C0439234|C0038952|C0871208|C0871261|C0871208|C0036043
"In this method, when hypoesthesia occurred in the radial, median, ulnar and musculocutaneous nerves, this was defined as the start of the nerve block onset time.","In method, hypoesthesia occurred radial, median, ulnar musculocutaneous nerves, defined start nerve block onset time.",G0000000|C0025663|C0020580|C1709305|C0442038|C0549183|C0442044|C0450958|C0027740|C1704788|C0439659|C0027740|C0028778|C0206132|C0040223
The longitudinal outcome was onset of smoking among baseline never-smokers two years later.,The longitudinal outcome onset smoking baseline never-smokers later.,G0000000|C0205127|C1274040|C0206132|C0037369|C0168634|C0425293|C0205087
The CHWs enrolled 2930 fever patients during five months of whom 1988 (67.8%) presented within 24 hours of fever onset.,The CHWs enrolled 2930 fever patients months 1988 (67.8%) 24 hours fever onset.,G0000000|G0000000|G0000000|G0000000|C0015967|C0030705|C0439231|G0000000|C0450371|C0450371|C0439227|C0015967|C0206132
"The two groups took the star cancellation test, line bisection test, and Catherine Bergego Scale (CBS) 24 hours before and after the three-week treatment to assess the severity of unilateral spatial neglect.","The star cancellation test, bisection test, Catherine Bergego Scale (CBS) 24 hours three-week treatment assess severity unilateral spatial neglect.",G0000000|C0995242|C0205544|C0022885|C0184905|C0022885|G0000000|G0000000|C0175659|C1439329|C0450371|C0439227|C0205449|C0039798|C1516048|C0439793|C0205092|C1428114|C0521874
FMA scores increased in the mirror therapy group after intervention.,FMA scores increased mirror therapy intervention.,C2332774|C0449820|C0205217|C0181868|C0039798|C0886296
The increased effect of UMEC/VI compared with FP/SAL was also demonstrated in the 0–24 h serial FEV1 measurements on Day 84 (Fig.,The increased UMEC/VI compared FP/SAL demonstrated 0–24 serial FEV1 measurements Day 84 (Fig.,G0000000|C0205217|C0205999|C1707455|C0016704|G0000000|G0000000|C0031082|G0000000|C0242485|C0332173|C0450371|C0349966
"Several drugs can be used to reduce the frequency of migraine attacks: aspirin, acetaminophen and NSAIDs [3,9,10].","Several drugs reduce frequency migraine attacks: aspirin, acetaminophen NSAIDs [3,9,10].",C0439064|C0013227|G0000000|C0376249|C0149931|C1261512|C0004057|C0000970|C0003211|C0450371
"Data for the study will be collected at baseline (prior to 18 weeks gestation), 36 weeks gestation and 12 months post-birth.","Data study collected baseline (prior 18 weeks gestation), 36 weeks gestation 12 months post-birth.",C1511726|C0557651|C1516695|C0168634|C0332152|C0450371|C0439230|C0032961|C0450371|C0439230|C0032961|C0450371|C0439231|C0687676
"• ICU and HDU length of stay and acute hospital length of stay • Days of antibiotic usage; • Duration of PN usage; • Alive, ventilator-free days as recommended by Rubenfield [26]; • Change in SOFA scores; • Serious Adverse events (excluding deaths) (for reporting of Suspected Serio-s Adverse Reactions (SSARs) and Suspected Unexpected Serious Adverse Reactions (SUSARs).","• ICU HDU length stay acute hospital length stay • Days antibiotic usage; • Duration PN usage; • Alive, ventilator-free days recommended Rubenfield [26]; • Change SOFA scores; • Serious Adverse events (excluding deaths) (for reporting Suspected Serio-s Adverse Reactions (SSARs) Suspected Unexpected Serious Adverse Reactions (SUSARs).",G0000000|C0021708|G0000000|C1444754|G0000000|C0205178|C0019994|C1444754|G0000000|G0000000|C0439228|C0003232|C0457083|G0000000|C0449238|C0219433|C0457083|G0000000|C0376558|C0087153|C0439228|C0034866|G0000000|C0450371|G0000000|C0392747|G0000000|C0449820|G0000000|C0205404|G0000000|C0441471|C0332196|C0011065|G0000000|C0700287|C0332147|C0565930|G0000000|C0443286|G0000000|C0332147|C4055646|C0205404|G0000000|C0443286|G0000000
The primary efficacy endpoint was percent change in spleen volume from baseline to 9 months; secondary efficacy endpoints were change in hemoglobin and percent changes in liver volume and platelet count.,The primary efficacy endpoint percent change spleen volume baseline 9 months; secondary efficacy endpoints change hemoglobin percent liver volume platelet count.,G0000000|C0205225|C1280519|C2349179|C0439165|C0392747|C0037993|C0449468|C0168634|G0000000|C0439231|C0027627|C1280519|C2349179|C0392747|C0019046|C0439165|C0023884|C0449468|C0005821|C0750480
"Secondary sleep measures – WASO, SOL, SE, awakenings, quality, and restedness as well as the ISI.","Secondary sleep measures – WASO, SOL, SE, awakenings, quality, restedness ISI.",C0027627|C0037313|C0079809|G0000000|G0000000|G0000000|C0036919|C1720052|C0332306|C0035253|G0000000
Data are shown for the ATP cohort for immunogenicity.,Data ATP cohort immunogenicity.,C1511726|G0000000|C0599755|C4054739
"Mean baseline and 6-month follow-up values for quality of life, anthropometric, and physical activity measures Abbreviations: Cl, confidence interval; FACT-G, Functional Assessment of Cancer Therapy-General; FACIT, Functional Assessment of Chronic Illness Therapy; MET, metabolic equivalent task; QOL, quality of life; SD, standard deviation.","Mean baseline 6-month follow-up values quality life, anthropometric, physical activity measures Abbreviations: Cl, confidence interval; FACT-G, Functional Assessment Cancer Therapy-General; FACIT, Functional Assessment Chronic Illness Therapy; MET, metabolic equivalent task; QOL, quality life; SD, standard deviation.",C0444504|C0168634|C0332177|C0589120|C0042295|C0332306|C0376558|C0003188|C0031809|C0205177|C0079809|C0000723|C0596019|C0237529|C1272706|C1707998|C0205245|C1261322|C0006826|C0039798|C3476791|C0205245|C1261322|C0205191|C0221423|C0039798|C0268621|C0311400|C0205163|C3540678|C0518214|C0332306|C0376558|C2699239|C1442989|C0012727
The primary outcome is change in SBP from baseline to 3 and 12 months.,The primary outcome change SBP baseline 3 12 months.,G0000000|C0205225|C1274040|C0392747|G0000000|C0168634|G0000000|C0450371|C0439231
"The coprimary end points were the duration of overall survival from randomization, which was defined as the time until death from any cause, and the duration of progression-free survival, which was defined as the time until either disease progression or death.","The coprimary duration survival randomization, defined time death cause, duration progression-free survival, defined time disease progression death.",G0000000|G0000000|C0449238|C0038952|C0034656|C1704788|C0040223|C0011065|C0015127|C0449238|C0242656|C0038952|C1704788|C0040223|C0012634|C0242656|C0011065
an overall response rate of 72%).,response rate 72%).,C0871261|C0871208|C0450371
"While on CsA for the remaining 6 months of the study, this patient had one more relapse.","While CsA remaining 6 months study, patient relapse.",G0000000|G0000000|C1527428|G0000000|C0439231|C0557651|C0030705|C0035020
"Questionnaire-based assessment of pain, stiffness and physical function were done using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) index 28, LFI 29 and VAS 30.","Questionnaire-based assessment pain, stiffness physical function Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) 28, LFI 29 VAS 30.",C0034394|C1261322|C0030193|C0427008|C0031809|C0031843|C1705493|C0029040|G0000000|C0041740|C0029408|C0918012|G0000000|C0450371|G0000000|C0450371|C0042815|C0450371
"Out of the 25 participants contacted at Time 3, seven self-reported criminal activity (arrest or undetected offense) during the first three months post-release.","Out 25 participants contacted Time 3, self-reported criminal activity (arrest undetected offense) months post-release.",C0439787|C0450371|C0679646|C0332158|C0040223|G0000000|C0681906|C0699726|C0205177|C0237477|G0000000|G0000000|C0439231|C0687676
The primary outcome was the day of life when full enteral feeding (FEF) of 150 mL/Kg/d was achieved.,The primary outcome day life enteral feeding (FEF) 150 mL/Kg/d achieved.,G0000000|C0205225|C1274040|C0332173|C0376558|C1304890|C0204695|G0000000|C1442061|C1532579|G0000000
The analysis of safety was carried out according to a tiered approach.,The analysis safety carried tiered approach.,G0000000|C0002778|C0036043|C0206243|G0000000|C0449445
Missing values at 3 months were replaced using the last-observation-carried-forward method.,Missing values 3 months replaced last-observation-carried-forward method.,C1551393|C0042295|G0000000|C0439231|C0559956|C1517741|C0025663
"Among the patients who developed relapses, the mean (SD) level at the time of the first relapse was 5.9 (0.4) μg/L.","Among patients developed relapses, (SD) level time relapse 5.9 (0.4) μg/L.",G0000000|C0030705|G0000000|C0035020|G0000000|C0441889|C0040223|C0035020|G0000000|G0000000|G0000000
"As a result, the EG had better trunk postural stability, balance ability, and upper limb motor function than the CG.","As result, EG trunk postural stability, balance ability, upper limb motor function CG.",G0000000|C1274040|C0013715|C0225442|C0205278|C0205360|C0014653|C0085732|C1282910|C0015385|C1513492|C0031843|C0043444
"Over a total of 4,406,634 person-years of follow-up we identified 592 incident thyroid cancer cases (257 in men and 335 in women) of which 406 were of the papillary histologic subtype (164 in men and 242 in women) and 113 (57 in men and 56 in women) were of the follicular histologic subtype.","Over total 4,406,634 person-years follow-up identified 592 incident thyroid cancer (257 335 women) 406 papillary histologic subtype (164 242 women) 113 (57 56 women) follicular histologic subtype.",C0205136|C0439175|C1442061|C0027361|C0589120|C0205396|C1442061|C1551358|C0040132|C0006826|C1442061|C1442061|C0043210|C1442061|C0205312|C0205462|C0449560|C1442061|C1442061|C0043210|C1442061|C0450371|C0450371|C0043210|C0439682|C0205462|C0449560
"At the six-month follow-up interview, the 30-day point prevalence smoking abstinence, use of the CD in the previous 30 days, use of other cessation aids, BAI, BDI-V, and adverse events were investigated.","At six-month follow-up interview, 30-day prevalence smoking abstinence, CD previous 30 days, cessation aids, BAI, BDI-V, adverse events investigated.",G0000000|C0585339|C0589120|C0021822|C0450371|C0033105|C0037369|C3843422|C0007928|C0205156|C0450371|C0439228|C1880019|C0001175|C0234880|C0006448|G0000000|C0441471|C1292732
"For the 12 months prior to the intervention, 71.6% of patient visit EMR records reflected documentation of smoking status overall, with a range of 54.8% to 95.7% across the 18 clinics.","For 12 months prior intervention, 71.6% patient visit EMR records reflected documentation smoking status overall, range 54.8% 95.7% 18 clinics.",G0000000|C0450371|C0439231|C0332152|C0886296|C0450371|C0030705|C0545082|C0034519|C0034869|C0558058|C0175636|C0037369|C0449438|C0282416|C1514721|C0450371|C0450371|C0450371|C0442592
"Secondary endpoints included percentage change in LS, TH, and FN BMD at 12 and 24 months.","Secondary endpoints included percentage change LS, TH, FN BMD 12 24 months.",C0027627|C2349179|C0332257|C0439165|C0392747|C0023668|C0039725|G0000000|G0000000|C0450371|C0450371|C0439231
"Patients who undergo FES-assisted cycling when compared with cycling alone will have greater improvement in muscle mass, strength and physical function.","Patients undergo FES-assisted cycling compared cycling improvement muscle mass, strength physical function.",C0030705|G0000000|C1269765|C1511572|C1707455|C1511572|C2986411|C0026845|C0577559|C0237897|C0031809|C0031843
"HLC was conducted once every four weeks at each location outdoors from 6pm to 6am for 45 minutes of each hour, allowing 15 minutes break for rest.","HLC conducted weeks location outdoors 6pm 6am 45 minutes hour, allowing 15 minutes break rest.",C1415593|C0004927|C0439230|C0450429|C1709359|G0000000|G0000000|C0450371|C0439232|C0439227|C0683607|C0450371|C0439232|C1881704|C0035253
The improvement of the involved hand function (upper extremity function test) also positively correlated with the increase of iEMG of the involved wrist flexors and extensors during MIVC.,The improvement involved hand function (upper extremity function test) positively correlated increase iEMG involved wrist flexors extensors MIVC.,G0000000|C2986411|C1314939|C0018563|C0031843|C1282910|C0015385|C0031843|C0022885|G0000000|C1707520|C0442805|G0000000|C1314939|C0043262|C1879367|C1184148|G0000000
"We measured the GOS, Barthel Index, and mRS at the time of discharge from hospital and reassessed these measurements at the 6-month follow-up after injury.","We measured GOS, Barthel Index, mRS time discharge hospital reassessed measurements 6-month follow-up injury.",G0000000|C0444706|G0000000|G0000000|C0918012|C1522706|C0040223|C0012621|C0019994|G0000000|C0242485|C0332177|C0589120|C3263722
The primary outcome was the self-reported 7-day point prevalence (PP) of tobacco abstinence at 6-month follow-up.,The primary outcome self-reported 7-day prevalence (PP) tobacco abstinence 6-month follow-up.,G0000000|C0205225|C1274040|C0681906|C0332173|C0033105|C0030375|C0040329|C3843422|C0332177|C0589120
"The primary end point was overall survival, defined as time from randomization to date of death.","The primary survival, defined time randomization death.",G0000000|C0205225|C0038952|C1704788|C0040223|C0034656|C0011065
What these models should comprise and how they should be evaluated is less clear.,What models comprise evaluated clear.,G0000000|C3161035|C2700400|C0220825|C1709157
"Hypoxia, ARDS and use of corticosteroids in children with ARDS who were mechanically ventilated were the factors associated with increased odds of mortality.","Hypoxia, ARDS corticosteroids children ARDS mechanically ventilated factors increased odds mortality.",C0242184|C0035222|C0001617|C0008059|C0035222|G0000000|C0231923|C1521761|C0205217|G0000000|C0026565
"Patients with scores of 17 or more on the 17 items of the Hamilton Depression Rating Scale[34], of either gender and aged between 18 and 60 years, were selected.","Patients scores 17 17 items Hamilton Depression Rating Scale[34], gender aged 18 60 years, selected.",C0030705|C0449820|C0450371|C0450371|C1551338|G0000000|C0011570|C0871208|C0175659|C0079399|C0001779|C0450371|C0450371|C0439234|C1707391
"Secondary outcomes were time to first moderate/severe COPD exacerbation, annual rate of moderate/severe COPD exacerbation requiring treatment with oral corticosteroids, and pre-dose AM FEV1.","Secondary outcomes time moderate/severe COPD exacerbation, annual rate moderate/severe COPD exacerbation requiring treatment oral corticosteroids, pre-dose AM FEV1.",C0027627|C1274040|C0040223|C0205081|C0024117|G0000000|C0332181|C0871208|C0205081|C0024117|G0000000|G0000000|C0039798|C0442027|C0001617|C0439565|G0000000|G0000000
"The primary end point is stroke or death within 30 days after enrollment or after a revascularization procedure for the qualifying lesion during the follow-up period (i.e., angioplasty for symptomatic restenosis in a patient in the PTAS group or placement of a stent in a patient in the medical-management group) or ischemic stroke in the territory of the qualifying artery between day 31 and the end of the follow-up period.","The primary stroke death 30 days enrollment revascularization procedure qualifying lesion follow-up period (i.e., angioplasty symptomatic restenosis patient PTAS placement stent patient medical-management group) ischemic stroke territory qualifying artery day 31 follow-up period.",G0000000|C0205225|C0038454|C0011065|C0450371|C0439228|C1516879|C0581603|C0184661|C1514624|C0221198|C0589120|C0439531|C0683454|C0162577|C0231220|C0333186|C0030705|C3274435|C0441587|C0038257|C0030705|C0199168|C0441833|C0475224|C0038454|C1301808|C1514624|C0003842|C0332173|C0450371|C0589120|C0439531
"As of 31 December 2007 (an average of 11.2 years of follow-up), 298 cohort participants had developed prostate cancer.","As 31 December 2007 (an average 11.2 follow-up), 298 cohort participants developed prostate cancer.",G0000000|C0450371|C3830550|G0000000|G0000000|C1510992|C0450371|C0589120|C1442061|C0599755|C0679646|G0000000|C0033572|C0006826
"Response to therapy[8] was categorized as: (a) Complete response - no new lesions, disappearance of all previous lesions, with or without residual postlesional pigmentation; (b) partial response - a few new lesions, regression or disappearance of some previous lesions; (c) no response - no regression of lesions, appearance of new lesions.","Response therapy[8] categorized as: (a) Complete response - lesions, disappearance previous lesions, residual postlesional pigmentation; (b) partial response - lesions, regression disappearance previous lesions; (c) response - regression lesions, appearance lesions.",C0871261|C0039798|C0871968|G0000000|G0000000|C0205197|C0871261|G0000000|C0221198|G0000000|C0205156|C0221198|C1609982|G0000000|C0031911|G0000000|C0728938|C0871261|G0000000|C0221198|C0684320|G0000000|C0205156|C0221198|G0000000|C0871261|G0000000|C0684320|C0221198|C0233426|C0221198
"Charts were abstracted for age, sex, location of KS lesions at presentation, biopsy results, CD4 T-cell count and percentage, and KS treatment and outcome.","Charts abstracted age, sex, location KS lesions presentation, biopsy results, CD4 T-cell count percentage, KS treatment outcome.",C0684240|C0000857|C0001779|C0009253|C0450429|C0022773|C0221198|C0449450|C0005558|C1274040|C0285590|C0039194|C0750480|C0439165|C0022773|C0039798|C1274040
"The primary outcome measure was a change in spherical equivalent refractive error (SER) in diopters from baseline to the 3-year visit, as assessed by cycloplegic autorefraction.","The primary outcome measure change spherical equivalent refractive error (SER) diopters baseline 3-year visit, assessed cycloplegic autorefraction.",G0000000|C0205225|C1274040|C0079809|C0392747|C0332501|C0205163|C0429585|C0743559|C0523888|C0439484|C0168634|C0439234|C0545082|C1516048|C0010586|G0000000
"In conclusion, eszopiclone increases the arousal threshold and lowers the AHI in obstructive sleep apnoea patients that do not have marked overnight hypoxaemia.","In conclusion, eszopiclone increases arousal threshold lowers AHI obstructive sleep apnoea patients marked overnight hypoxaemia.",G0000000|C1707478|C1436328|C0205217|C0003808|C0449864|C0441994|G0000000|C0549186|C0037313|C0003578|C0030705|C0522501|C0439583|C0700292
"Other GI AEs of interest leading to dose adjustments in patients on DT or FCT, respectively, were abdominal pain (n = 4 and n = 5), nausea (n = 3 in each arm), constipation (n = 1 and n = 2), and vomiting (n = 2 in each arm).","Other GI AEs leading dose adjustments patients DT FCT, respectively, abdominal pain (n = 4 n = 5), nausea (n = 3 arm), constipation (n = 1 n = 2), vomiting (n = 2 arm).",G0000000|C1708130|C1412268|C0332152|C0178602|C0376209|C0030705|C1455430|G0000000|G0000000|C0000726|C0030193|G0000000|G0000000|C0027497|G0000000|C0446516|C0009806|G0000000|G0000000|C0042963|G0000000|C0446516
"Treatment response was defined as a ≥50% reduction in HDRS score, and great improvement was defined as a final HDRS score ≤15.","Treatment response defined ≥50% reduction HDRS score, improvement defined final HDRS score ≤15.",C0039798|C0871261|C1704788|G0000000|C0301630|C1840333|C0449820|C2986411|C1704788|C0205088|C1840333|C0449820|G0000000
"By eight weeks the mean Nottingham extended activities of daily living score in the intervention group was 4.8 points (95% confidence interval −0.5 to 10.0, P=0.08) greater than that of the control group.","By weeks Nottingham extended activities daily living score intervention 4.8 (95% confidence interval −0.5 10.0, P=0.08) control group.",G0000000|C0439230|G0000000|C0231448|C0441655|C0332173|C0376558|C0449820|C0886296|G0000000|C0450371|C0237529|C1272706|G0000000|C0450371|C0369773|C0243148|C0441833
"In addition, we observed no difference in progression of HIV disease as measured by CD4 count, increase in plasma HIV viral load, or rate of failure of antiretroviral treatments.","In addition, observed difference progression HIV disease measured CD4 count, increase plasma HIV viral load, rate failure antiretroviral treatments.",G0000000|C0332287|C1441672|C1705241|C0242656|C0019682|C0012634|C0444706|C0285590|C0750480|C0442805|C0032105|C0019682|C0521026|C1550025|C0871208|C0231174|G0000000|C0087111
Self-reported height and weight were gathered for estimation of BMI and weight loss.,Self-reported height weight gathered estimation BMI weight loss.,C0681906|C0489786|C0005910|G0000000|C0680844|G0000000|C0005910|C1517945
"As for the blood feeding behaviour, the proportion of An.","As blood feeding behaviour, proportion An.",G0000000|C0005767|C0204695|C0004927|C1709707|G0000000
"The gabapentin group, but not the placebo group, showed significant reductions from baseline to the end of treatment on the Marijuana Problems Scale total score (gabapentin change score=3.4, 95% CI 0.8–6.0, p=0.02).","The gabapentin group, placebo group, reductions baseline treatment Marijuana Problems Scale total score (gabapentin change score=3.4, 95% CI 0.8–6.0, p=0.02).",G0000000|C0060926|C0441833|C0032042|C0441833|C0301630|C0168634|C0039798|C0024808|C1546466|C0175659|C0439175|C0449820|C0060926|C0392747|C0449820|C0450371|C0008107|G0000000|C0369773
Sample size for the overall FAST CP RCT is based on the study's primary hypothesis comparison between the effect of FAST compared with usual care immediately postintervention (12 weeks) on muscle volume assessed using MRI.,Sample size FAST CP RCT based study's primary hypothesis comparison FAST compared usual care postintervention (12 weeks) muscle volume assessed MRI.,C0370003|C0456389|C0015663|C4050020|G0000000|C1527178|C0557651|C0205225|C1512571|C1707455|C0015663|C1707455|C3538928|C1947933|G0000000|G0000000|C0026845|C0449468|C1516048|C0024485
"At the time of the first round of post–water jet data collection, a trained interviewer from the DOHMH conducted structured interviews with the cafeteria managers in each intervention school.","At time round post–water jet data collection, trained interviewer DOHMH conducted structured interviews cafeteria managers intervention school.",G0000000|C0040223|C0332490|G0000000|C0336862|C1511726|C1516698|C0336809|C0021821|G0000000|C0004927|C0678594|C0021822|C1004632|C0335141|C0886296|C0036375
"Main outcome measures Total score on decisional conflict scale, and mode of delivery.","Main outcome measures Total score decisional conflict scale, mode delivery.",C0205225|C1274040|C0079809|C0439175|C0449820|C0679006|C0009671|C0175659|C1513371|C0011209
Positive intervention effects on fatigue are not necessarily reflected in higher quality of life.,Positive intervention effects fatigue reflected quality life.,C0439178|C0886296|C1280500|C0015672|C0558058|C0332306|C0376558
6 (17.6%) had > 50% seizure reduction at 1 month using ITT analysis.,6 (17.6%) > 50% seizure reduction 1 month ITT analysis.,G0000000|C0450371|G0000000|C0450371|C0036572|C0301630|G0000000|C0332177|G0000000|C0002778
The primary endpoint was rate of maintaining remission at 6 months after treatment for DDNS and rate of remission achievement for DRNS.,The primary endpoint rate maintaining remission 6 months treatment DDNS rate remission achievement DRNS.,G0000000|C0205225|C2349179|C0871208|C0024501|C0544452|G0000000|C0439231|C0039798|C0619347|C0871208|C0544452|C0001072|C0175392
"Demographic Data for the Study Groups at the Time of Serum and Effluent Collection Compared with baseline values at the initiation of dialysis, total Kt/V, total weekly creatinine clearance, residual GFR, and daily urine output were all lower in patients on maintenance dialysis with conventional PDF for an average of 3.6 years.","Demographic Data Study Groups Time Serum Effluent Collection Compared baseline values initiation dialysis, total Kt/V, total weekly creatinine clearance, residual GFR, daily urine output lower patients maintenance dialysis conventional PDF average 3.6 years.",C0011298|C1511726|C0557651|C0441833|C0040223|C0229671|G0000000|C1516698|C1707455|C0168634|C0042295|C0589507|C0011945|C0439175|C0429662|C0439175|C0332174|C0010294|C0449297|C1609982|C0017654|C0332173|C0042036|C1709366|C0441994|C0030705|C0024501|C0011945|C0439858|C1431343|C1510992|G0000000|C0439234
"They reported significantly lower ED visits (57%), hospital admissions (53%), and unscheduled GP visits (67%) as a result of their programme.","They reported lower ED visits (57%), hospital admissions (53%), unscheduled GP visits (67%) result programme.",G0000000|C0684224|C0441994|C3538926|C0545082|C0450371|C0019994|C0184666|C0450371|C1699701|C3811116|C0545082|C0450371|C1274040|C1709697
"In this multicenter, double-blinded study we followed changes in disease progression: using quantitative measures of strength via maximal isometric voluntary contraction, forced vital capacity, ALSFRS, quality of life, fatigue and survival.","In multicenter, double-blinded study disease progression: quantitative measures strength maximal isometric voluntary contraction, forced vital capacity, ALSFRS, quality life, fatigue survival.",G0000000|C0439743|C0205173|C0557651|C0012634|C0242656|C0392762|C0079809|C0237897|C0205289|G0000000|C0439656|C1140999|C0441722|C0442732|C1516240|G0000000|C0332306|C0376558|C0015672|C0038952
The magnitude of the peak to trough change in FEV1 was not statistically different.,The magnitude peak trough change FEV1 statistically different.,G0000000|C0449286|C0444505|C0444506|C0392747|G0000000|C0038215|C1705242
"Physical fitness was assessed with a 20-m shuttle run test, where the maximum aerobic capacity within 1 min of exhaustive exercise (VO2 max estimate) and the number of 20-m laps completed were recorded.","Physical fitness assessed 20-m shuttle test, maximum aerobic capacity 1 min exhaustive exercise (VO2 max estimate) 20-m laps completed recorded.",C0031809|C1456706|C1516048|C0450371|G0000000|C0022885|C0806909|C1510824|C1516240|G0000000|C0702093|C0392674|C0015259|C0042939|G0000000|C0750572|C0450371|C3173571|C0205197|C0034869
"The incidence of EA was assessed with Aono's four point scale and the severity of EA was assessed with pediatric anesthesia emergence delirium (PAED) scale at 5 min (T5), 15 min (T15) and 30 min (T30) after emergence.","The incidence EA assessed Aono's scale severity EA assessed pediatric anesthesia emergence delirium (PAED) scale 5 min (T5), 15 min (T15) 30 min (T30) emergence.",G0000000|C0021149|C0014963|C1516048|G0000000|C0175659|C0439793|C0014963|C1516048|C0030755|C0002903|C0750573|C0011206|G0000000|C0175659|G0000000|C0702093|C0041403|C0450371|C0702093|G0000000|C0450371|C0702093|G0000000|C0750573
Additional data on determinants of latrine use and safe child feces disposal are also collected to assess change based on the intervetntion.,Additional data determinants latrine safe child feces disposal collected assess change based intervetntion.,C1524062|C1511726|C1521761|C0023124|G0000000|C0008059|C0015733|C1707797|C1516695|C1516048|C0392747|C1527178|G0000000
The change of migraine days outside the menstrual cycle [15] 2.,The change migraine days menstrual cycle [15] 2.,G0000000|C0392747|C0149931|C0439228|C0025344|C1511572|C0450371|G0000000
Cumulative incidence of prostate cancer by study arm.,Cumulative incidence prostate cancer study arm.,C1511559|C0021149|C0033572|C0006826|C0557651|C0446516
"This effect remained after controlling for potential confounding by illness severity, with use of neutropenia as a marker of severity.","This remained controlling potential confounding illness severity, neutropenia marker severity.",G0000000|G0000000|C2239193|C3245505|G0000000|C0221423|C0439793|C0023530|C0005516|C0439793
"The questionnaire covered six fields; nine items on coping with threatening cases, four items on shortage of resources, nine items on personnel conflicts, five items on planning issues, four items on working load, and three items on unpreparedness for the occupational stress of psychiatric wards.","The questionnaire covered fields; items coping threatening cases, items shortage resources, items personnel conflicts, items planning issues, items load, items unpreparedness occupational stress psychiatric wards.",G0000000|C0034394|C0439844|C0440042|C1551338|C0009967|G0000000|C0868928|C1551338|C1282927|C0035201|C1551338|C0024752|C0009671|C1551338|C0032074|C0033213|C1551338|C1550025|C1551338|C4082133|C0521127|C0038435|C0205487|C1305702
Most children in this sample had mild to moderate motor deficits according to a system of grading based on active range of motion displayed in 20 commonly tested movements (see Appendix).,Most children sample mild moderate motor deficits system grading based active range motion displayed 20 commonly tested movements (see Appendix).,C0205393|C0008059|C0370003|C2945599|C0205081|C1513492|C2987487|C0449913|C0441800|C1527178|C0205177|C1514721|C0026597|C0870432|C0450371|G0000000|C0392366|C0026649|C0042789|C0003617
"All participants completed baseline in-person interviews to assess their comorbidities, self-rated current health, duration of HTN and CKD, and medication adherence [as measured by the eight-item Morisky Medication Adherence Scale (MMAS)] [19].","All participants completed baseline in-person interviews assess comorbidities, self-rated current health, duration HTN CKD, medication adherence [as measured eight-item Morisky Medication Adherence Scale (MMAS)] [19].",G0000000|C0679646|C0205197|C0168634|C1547564|C0021822|C1516048|C0009488|C0036588|C0521116|C0018684|C0449238|C0020538|C1561643|C0013227|C1510802|G0000000|C0444706|C0205454|G0000000|C0013227|C1510802|C0175659|G0000000|C0450371
"Standardised AUC measurements for FEV1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (± SEM) differences of 170 ± 24, 180 ± 24, and 170 ± 24 mL, respectively.","Standardised AUC measurements FEV1 (between 5 min 4 h, 5 min 1 h, 1 4 post-dose) Week 12 indacaterol placebo (p < 0.001), LSM (± SEM) differences 170 ± 24, 180 ± 24, 170 ± 24 mL, respectively.",G0000000|C0376690|C0242485|G0000000|G0000000|G0000000|C0702093|G0000000|C0033727|G0000000|C0702093|G0000000|C0033727|G0000000|G0000000|C0439568|C0332174|C0450371|C1722260|C0032042|C0369773|G0000000|C1442061|G0000000|G0000000|G0000000|C1705241|C1442061|G0000000|C0450371|C1442061|G0000000|C0450371|C1442061|G0000000|C0450371|C0439526|G0000000
"We performed the following tests: (1) TBUT; (2) Schirmer I test; (3) Ocular Surface Disease Index© (OSDI©; Allergan, Inc., Irvine, CA, USA); (4) MG expression; (5) evaluation of lid margin inflammation; and (6) interpalpebral and corneal dye staining.","We performed tests: (1) TBUT; (2) Schirmer I test; (3) Ocular Surface Disease Index© (OSDI©; Allergan, Inc., Irvine, CA, USA); (4) MG expression; (5) evaluation lid margin inflammation; (6) interpalpebral corneal dye staining.",G0000000|C0884358|C0022885|G0000000|G0000000|G0000000|C1875738|C0021966|C0022885|G0000000|C0015392|C0205148|C0012634|G0000000|G0000000|G0000000|G0000000|G0000000|C3887642|C0041703|G0000000|C0026410|C0185117|G0000000|C0220825|G0000000|C0205284|C0021368|G0000000|G0000000|C0010031|C0013343|C0487602
The change of migraine days inside the menstrual cycle [15] 2.,The change migraine days inside menstrual cycle [15] 2.,G0000000|C0392747|C0149931|C0439228|G0000000|C0025344|C1511572|C0450371|G0000000
Oncologists’ exercise recommendation may not be enough to increase exercise participation..,Oncologists’ exercise recommendation increase exercise participation..,G0000000|C0015259|C0034866|C0442805|C0015259|C0679823
"), in order to detect febrile UTI as soon as possible.","), detect febrile UTI possible.",G0000000|C0442726|C0015967|C0042029|C0332149
"The symptoms that were included in the severity index included pain, fatigue, nausea, vomiting, insomnia, dyspnea, weakness, anorexia, fever, dry mouth, constipation, and mouth sores.","The symptoms included severity included pain, fatigue, nausea, vomiting, insomnia, dyspnea, weakness, anorexia, fever, dry mouth, constipation, mouth sores.",G0000000|C0683368|C0332257|C0439793|C0332257|C0030193|C0015672|C0027497|C0042963|C0917801|C0013404|C3714552|C0003123|C0015967|C0011682|C0226896|C0009806|C0226896|C0234233
"Secondary outcomes were calculated from daily diary card data during run-in and 4 weeks prior to each clinic visit or telephone contact and from two questionnaires: the Asthma Control Questionnaire (ACQ-5,20,21 all clinic visits) and the Satisfaction with Asthma Treatment Questionnaire (SATQ, after 1 and 12 months of treatment).22 Patients recorded daily the best of three morning and evening peak expiratory flow (PEF) values, asthma symptoms during night and day (3-point scale where 0=no symptoms and 3=incapacitating symptoms), nights with awakenings due to asthma symptoms, total number of budesonide/formoterol inhalations (SMART group), and intake of maintenance and as-needed medication (UC group).","Secondary outcomes calculated daily diary card data run-in 4 weeks prior clinic visit telephone contact questionnaires: Asthma Control Questionnaire (ACQ-5,20,21 clinic visits) Satisfaction Asthma Treatment Questionnaire (SATQ, 1 12 months treatment).22 Patients recorded daily morning evening peak expiratory flow (PEF) values, asthma symptoms night day (3-point scale 0=no symptoms 3=incapacitating symptoms), nights awakenings asthma symptoms, total budesonide/formoterol inhalations (SMART group), intake maintenance as-needed medication (UC group).",C0027627|C1274040|C0444686|C0332173|C0376660|C3275277|C1511726|C3274438|G0000000|C0439230|C0332152|C0002424|C0545082|C0039457|C0332158|C0034394|C0004096|C0243148|C0034394|C2919686|C0002424|C0545082|C0242428|C0004096|C0039798|C0034394|G0000000|G0000000|C0450371|C0439231|C0039798|C0030705|C0034869|C0332173|C0332170|C0587117|C0444505|C0231800|C0806140|C0030771|C0042295|C0004096|C0683368|C0240526|C0332173|C1552961|C0175659|G0000000|C0683368|G0000000|C0683368|C0240526|C1720052|C0004096|C0683368|C0439175|C1276807|C0004048|G0000000|C0441833|C1512806|C0024501|C1879745|C0013227|G0000000|C0441833
"Participants completed a daily migraine diary that yielded information about number, duration and severity of migraines and migraine-related disability, as well as the Migraine Specific Quality of Life Questionnaire - Adolescent.","Participants completed daily migraine diary yielded number, duration severity migraines migraine-related disability, Migraine Specific Quality Life Questionnaire - Adolescent.",C0679646|C0205197|C0332173|C0149931|C0376660|G0000000|C0237753|C0449238|C0439793|C0149931|C0149931|C0231170|C0149931|C0205369|C0332306|C0376558|C0034394|G0000000|C0205653
"FM symptoms will be assessed using the Fibromyalgia Impact Questionnaire, and quality of life will be determined with the 36-item Short Form Health Survey.","FM symptoms assessed Fibromyalgia Impact Questionnaire, quality life determined 36-item Short Form Health Survey.",C3540627|C0683368|C1516048|C0016053|C1825598|C0034394|C0332306|C0376558|G0000000|C0450371|C1282927|C0348078|C0018684|C0038951
Secondary end points included illnesses confirmed by identification of virus in real-time polymerase chain reaction (PCR) assays.,Secondary included illnesses confirmed identification virus real-time polymerase chain reaction (PCR) assays.,C0027627|C0332257|C0221423|C0521093|C0020792|C0042776|C1550177|C1335439|C0337112|C0443286|C0032520|C0005507
A public hospital in Indianapolis.,A public hospital Indianapolis.,G0000000|G0000000|C0019994|G0000000
"Calcium-Vitamin D supplementation did not affect birth size, gestational age, and mode of delivery compared with the placebo [Table 3].","Calcium-Vitamin D supplementation affect birth size, gestational age, mode delivery compared placebo [Table 3].",C0006675|C0073187|C0242297|C0001721|C0005615|C0456389|C0439671|C0001779|C1513371|C0011209|C1707455|C0032042|C0039224|G0000000
"Table 3 displays the cell means and standard errors by condition and wave for students’ substance use intentions, parents’ and friends’ anti-drug injunctive norms, descriptive norms, personal anti-drug norms, and students’ positive substance use expectancies.","Table 3 displays cell standard errors condition wave students’ substance intentions, parents’ friends’ anti-drug injunctive norms, descriptive norms, personal anti-drug norms, students’ positive substance expectancies.",C0039224|G0000000|C0870432|C0007634|C1442989|C0743559|C0012634|C0678544|G0000000|C0439861|C0162425|G0000000|G0000000|C0013227|G0000000|C0205307|C0678257|C0205307|C1519021|C0013227|C0205307|G0000000|C0439178|C0439861|C0679138
"The aim of the study was to determine whether or not SPA can offer a similar operative time, length of hospital stay and complication profile with improved cosmetic results and less postoperative pain in comparison to traditional multiport, multi-incision laparoscopic cholecystectomy, also called standard laparoscopic cholecystectomy.","The aim study determine SPA offer operative time, length hospital stay complication profile improved cosmetic postoperative pain comparison traditional multiport, multi-incision laparoscopic cholecystectomy, called standard laparoscopic cholecystectomy.",G0000000|C1947946|C0557651|G0000000|C1420002|G0000000|C1882154|C0040223|C1444754|C0019994|G0000000|C0009566|C1979963|C0184511|C0010164|C0032790|C0030193|C1707455|C0443324|G0000000|C0439064|C0031150|C0008320|C0679006|C1442989|C0031150|C0008320
"Primary sleep outcomes measured via actigraph* ML 2.5SR refers to treatment with 2.5 mg sustained-release melatonin; ML 10, treatment with 10 mg melatonin; PRE, Pretreatment or baseline; TX, Treatment; D, change in values TX-PRE; NTST, nocturnal total sleep time; DTST, daytime total sleep time; SE, sleep efficiency (ie, TST/time in bed x 100); WASO: time awake after sleep onset until the final awakening While no primary outcome measure reached significance for any tested hypothesis, NTST increased by 16 ± 54 minutes in the ML 2.5SR group and 13 ± 44 minutes in the ML 10 group compared to 3 ± 39 minutes for placebo, indicating a weak trend for more nighttime sleep in the melatonin groups.","Primary sleep outcomes measured actigraph* ML 2.5SR refers treatment 2.5 sustained-release melatonin; ML 10, treatment 10 melatonin; PRE, Pretreatment baseline; TX, Treatment; D, change values TX-PRE; NTST, nocturnal total sleep time; DTST, daytime total sleep time; SE, sleep efficiency (ie, TST/time bed 100); WASO: time awake sleep onset final awakening While primary outcome measure reached significance tested hypothesis, NTST increased 16 ± 54 minutes ML 2.5SR 13 ± 44 minutes ML 10 compared 3 ± 39 minutes placebo, indicating weak trend nighttime sleep melatonin groups.",C0205225|C0037313|C1274040|C0444706|C1139952|C0439526|G0000000|C0205543|C0039798|G0000000|C1710261|C0025219|C0439526|C0450371|C0039798|C0450371|C0025219|C0332152|C1550147|C0168634|C0041403|C0039798|C0073187|C0392747|C0042295|C0041403|G0000000|C0240526|C0439175|C0037313|C0040223|G0000000|C0332169|C0439175|C0037313|C0040223|C0036919|C0037313|C0013682|G0000000|C1421210|C0004916|C1442061|G0000000|C0040223|C0234422|C0037313|C0206132|C0205088|C1720052|G0000000|C0205225|C1274040|C0079809|C2584321|C0237881|C0392366|C1512571|G0000000|C0205217|C0450371|G0000000|C0450371|C0439232|C0439526|G0000000|C0450371|G0000000|C0450371|C0439232|C0439526|C0450371|C1707455|G0000000|G0000000|C0450371|C0439232|C0032042|G0000000|C1762617|C1521798|C0240526|C0037313|C0025219|C0441833
The majority (95%) of down-referred patients and 81% of patients not down-referred had a 12-month CD4 count and viral load available.,The majority (95%) down-referred patients 81% patients down-referred 12-month CD4 count viral load available.,G0000000|C0680220|C0450371|C0205543|C0030705|C0450371|C0030705|C0205543|C0450371|C0285590|C0750480|C0521026|C1550025|C0470187
"For 8 households with home-produced maize in store, measurements of aflatoxin and moisture content are missing.","For 8 households home-produced maize store, measurements aflatoxin moisture content missing.",G0000000|G0000000|C0020052|C0442519|C0010028|C1698986|C0242485|C0001734|C0868994|C0423896|C1551393
"Other endpoints include the following: within-group changes in systolic AOBP from baseline to Week 12, changes in K+ levels over time measured by a central laboratory and by local laboratories, proportion of patients with serum K+ ≥5.5 mEq/L, average daily dose and cumulative dose of spironolactone, time to discontinuation of spironolactone, and changes in albuminuria (urine albumin to creatinine ratio) from baseline to Week 12.","Other endpoints following: within-group systolic AOBP baseline Week 12, K+ levels time measured central laboratory local laboratories, proportion patients serum K+ ≥5.5 mEq/L, average daily dose cumulative dose spironolactone, time discontinuation spironolactone, albuminuria (urine albumin creatinine ratio) baseline Week 12.",G0000000|C2349179|C0231290|C0441833|C0039155|G0000000|C0168634|C0332174|C0450371|C0597277|C0441889|C0040223|C0444706|C0205099|C0022877|C0205276|C0022877|C1709707|C0030705|C0229671|C0597277|G0000000|C0439375|C1510992|C0332173|C0178602|C1511559|C0178602|C0037982|C0040223|C0457454|C0037982|C0001925|C0042036|C0001924|C0010294|C0456603|C0168634|C0332174|C0450371
"In addition, each local TA provider was asked to keep a log of their Go NAPSACC implementation activities (date, length of contact, contents of discussion, assistance provided, etc.).","In addition, local TA provider log Go NAPSACC implementation activities (date, length contact, contents discussion, assistance provided, etc.).",G0000000|C0332287|C0205276|C1506978|C1138603|C1708728|C1822658|G0000000|C1708476|C0441655|C0011008|C1444754|C0332158|C0456205|C0557061|C0018896|C1999230|C1548556
Participants were contacted twice monthly by e-mail or telephone and were instructed to contact study staff in the event of illness with at least two respiratory or systemic signs or symptoms.,Participants contacted monthly e-mail telephone instructed contact study staff event illness respiratory systemic signs symptoms.,C0679646|C0332158|C0332177|C0013849|C0039457|G0000000|C0332158|C0557651|C0851286|C0441471|C0221423|C0521346|C0205373|C0220912|C0683368
"Celebremos La Salud had three major outcome goals including (1) to increase cancer screening behaviors for colorectal cancer, breast cancer, and cervical cancer, (2) to decrease smoking behaviors, and (3) to promote healthy dietary changes.","Celebremos La Salud major outcome goals including (1) increase cancer screening behaviors colorectal cancer, breast cancer, cervical cancer, (2) decrease smoking behaviors, (3) promote healthy dietary changes.",G0000000|C0023031|G0000000|C0205082|C1274040|C0018017|C0332257|G0000000|C0442805|C0006826|C0220908|C0004927|C0555952|C0006826|C0006141|C0006826|C0027530|C0006826|G0000000|C0392756|C0037369|C0004927|G0000000|C0033414|C3898900|C0012155|C0392747
Efficacy outcomes.,Efficacy outcomes.,C1280519|C1274040
"124 participants, mainly adult males or females, whose diagnoses require temporary stationary implant-based anchorage treatment will be randomized 1:1 to one of two treatment groups: group 1 will receive a loading of implant standard therapy after a healing period of 12 week (gold standard), whereas group 2 will receive an early loading of orthodontic implants within 1 week after implant insertion.","124 participants, adult males females, diagnoses require temporary stationary implant-based anchorage treatment randomized 1:1 treatment groups: 1 receive loading implant standard therapy healing period 12 week (gold standard), 2 receive loading orthodontic implants 1 week implant insertion.",C1442061|C0679646|C0001675|C0086582|C0015780|C0011900|G0000000|C0205374|C0439835|C0021102|C2825961|C0039798|C0034656|G0000000|C0039798|C0441833|G0000000|C1514756|C1708715|C0021102|C1442989|C0039798|C0043240|C0439531|C0450371|C0332174|C0018026|C1442989|G0000000|C1514756|C1708715|C0332276|C0021102|G0000000|C0332174|C0021102|C0021107
"Timed function tests had skewed distributions; therefore, in order to analyze the equivalence of change from baseline to 12 months for timed function tests, a log transformation of the data was performed, and the boundaries of equivalence defined as ±0.4 log seconds.","Timed function tests skewed distributions; therefore, analyze equivalence change baseline 12 months timed function tests, log transformation data performed, boundaries equivalence defined ±0.4 log seconds.",C0392761|C0031843|C0022885|G0000000|C0037775|G0000000|G0000000|C0205163|C0392747|C0168634|C0450371|C0439231|C0392761|C0031843|C0022885|C1708728|C0040682|C1511726|C0884358|G0000000|C0205163|C1704788|G0000000|C1708728|C0457385
"and used standardized questionnaires for collecting baseline information, as follows: Socio demographic characteristics of the person with dementia and the caregiver Everyday Abilities Scale for India (EASI): This questionnaire consisting of 12 questions, has been developed and widely used to test the functional abilities of daily living relevant to Indian subjects[11] Neuro-Psychiatric Inventory (NPI) Questionnaire: This instrument consists of two parts; the first measures the severity of the problem behaviours associated with the condition on a scale of 1–3 (NPI- S); the second measures the perceived distress of the problem behaviours by the caregiver on a scale of 0–5 (NPI -D)[12].","standardized questionnaires collecting baseline information, follows: Socio demographic characteristics person dementia caregiver Everyday Abilities Scale India (EASI): This questionnaire consisting 12 questions, developed test functional abilities daily living relevant Indian subjects[11] Neuro-Psychiatric Inventory (NPI) Questionnaire: This instrument consists parts; measures severity behaviours condition scale 1–3 (NPI- S); measures perceived distress behaviours caregiver scale 0–5 (NPI -D)[12].",G0000000|C0034394|C1516698|C0168634|C1533716|C0332283|G0000000|C0011298|C1521970|C0027361|C0011265|C0085537|C0332173|C0085732|C0175659|C0021201|C1516931|G0000000|C0034394|C0332529|C0450371|C1522634|G0000000|C0022885|C0205245|C0085732|C0332173|C0376558|C2347946|C1524069|C0681850|C0027855|C0021941|C1412208|C0034394|G0000000|C0348000|C0332529|C0449719|C0079809|C0439793|C0004927|C0012634|C0175659|G0000000|C1412208|C0565930|C0079809|C0030971|C0231303|C0004927|C0085537|C0175659|G0000000|C1412208|C0450371
"For the primary analysis, regression was conducted to compare groups on the outcome measure scores.","For primary analysis, regression conducted compare outcome measure scores.",G0000000|C0205225|C0002778|C0684320|C0004927|C1707455|C1274040|C0079809|C0449820
"Despite these advances, perioperative morbidity remains a major issue, and the most feared complication is symptomatic anastomotic leakage.","Despite advances, perioperative morbidity remains major issue, feared complication symptomatic anastomotic leakage.",G0000000|C0725066|C1518988|C0026538|G0000000|C0205082|C0033213|C0015726|C0009566|C0231220|C0332854|C0015376
"HIV-specific health status was assessed using the revised HIV Center Medical Staging System (rHCMSS; McCain et al., 1998).","HIV-specific health status assessed revised HIV Center Medical Staging System (rHCMSS; McCain al., 1998).",C0019682|C0018684|C0449438|C1516048|C1527075|C0019682|C0205099|C0199168|C0332305|C0449913|G0000000|G0000000|C0202311|G0000000
"PUQE is a scoring system that assesses symptoms of nausea and vomiting as well as global well being.9,10 Data are reported as mean ± standard deviation, or median and interquartile range, when appropriate.","PUQE scoring system assesses symptoms nausea vomiting global being.9,10 Data reported ± standard deviation, median interquartile range, appropriate.",G0000000|C0449820|C0449913|C1516048|C0683368|C0027497|C0042963|C0205246|C0450371|C1511726|C0684224|G0000000|C1442989|C0012727|C0549183|G0000000|C1514721|C1548787
"The primary outcome was the myopic progression, measured by a change in SE.","The primary outcome myopic progression, measured change SE.",G0000000|C0205225|C1274040|C0027092|C0242656|C0444706|C0392747|C0036919
The primary efficacy variable was the change in the BSS total score from day 0 to day 7 rated by the investigator.,The primary efficacy variable change BSS total score day 0 day 7 rated investigator.,G0000000|C0205225|C1280519|C0439828|C0392747|G0000000|C0439175|C0449820|C0332173|G0000000|C0332173|G0000000|C0871208|C0035173
"Five-year trends of age-standardized prevalence of current smoking among adult men in the US general population and in 4 US Asian communities: REACH, 2002–2006.","Five-year trends age-standardized prevalence current smoking adult US population 4 US Asian communities: REACH, 2002–2006.",C0205451|C0040833|C0001779|C0033105|C0521116|C0037369|C0001675|G0000000|C0032659|G0000000|G0000000|C0078988|C0009462|C2584321|G0000000
The post intervention Haemoglobin estimation was also be done.,The post intervention Haemoglobin estimation done.,G0000000|C0687676|C0886296|C0019046|C0680844|G0000000
We reviewed entry screening policies adopted by different nations and ascertained dates of official report of the first laboratory-confirmed imported H1N1 case and the first laboratory-confirmed untraceable or 'local' H1N1 case.,We reviewed entry screening policies nations ascertained dates official report laboratory-confirmed imported H1N1 laboratory-confirmed untraceable 'local' H1N1 case.,G0000000|C0282443|C1705654|C0220908|C0242456|C1555720|G0000000|C0011008|C2347387|C0684224|C0022877|C0699788|G0000000|C0022877|G0000000|C0205276|G0000000|C0868928
"Our hypothesis is that the weather weight gain due to volume overload observed during interdialytic period will influence the degree of collapsibility of the upper airway due to narrowing and predispose to upper airway occlusion during sleep, and to investigate the influences of different shifts haemodialysis in the physiological variables of sleep and ANS activity, and respiratory mechanics, and depression, anxiety, stress and quality of life in end-stage renal disease patients.","Our hypothesis weather weight gain volume overload observed interdialytic period influence degree collapsibility upper airway narrowing predispose upper airway occlusion sleep, investigate influences shifts haemodialysis physiological variables sleep ANS activity, respiratory mechanics, depression, anxiety, stress quality life end-stage renal disease patients.",G0000000|C1512571|C0043085|C0005910|C1517378|C0449468|G0000000|C1441672|G0000000|C0439531|C4054723|C0441889|G0000000|C1282910|C0178987|C0332463|G0000000|C1282910|C0178987|C0011382|C0037313|C1292732|C4054723|C0333051|C0019004|C0205463|C0439828|C0037313|C0004388|C0205177|C0521346|C0376706|C0011570|C0003467|C0038435|C0332306|C0376558|C0205088|C0022646|C0012634|C0030705
45% were in stage II and 55% in stage III.,45% stage II 55% stage III.,C0450371|C0205390|G0000000|C0450371|C0205390|C0439070
No differences were seen in time to treatment start or treatment completion.,No differences time treatment start treatment completion.,G0000000|C1705241|C0040223|C0039798|C0439659|C0039798|C0205197
"Main outcome measures Treatment failure: defined as development of chest indrawing, convulsions, drowsiness, or inability to drink at any time; respiratory rate above age specific cut points on day 3 or later; or oxygen saturation by pulse oximetry < 90% on day 3.","Main outcome measures Treatment failure: defined development chest indrawing, convulsions, drowsiness, inability drink time; respiratory rate age specific cut day 3 later; oxygen saturation pulse oximetry < 90% day 3.",C0205225|C1274040|C0079809|C0039798|C0231174|C1704788|C0243107|C0817096|G0000000|C0036572|C0013144|G0000000|C0452428|C0040223|C0521346|C0871208|C0001779|C0205369|C0000925|C0332173|G0000000|C0205087|C0030054|C0522534|C0232117|C0523807|G0000000|C0450371|C0332173|G0000000
"Variables regarding breastfeeding were: the ability of the infant to take the breast and suckling in the delivery room and in the 12 hours following delivery, cracked nipples and the number of breast-feeds in the first 12 hours.","Variables breastfeeding were: ability infant breast suckling delivery 12 hours delivery, cracked nipples breast-feeds 12 hours.",C0439828|C0006147|G0000000|C0085732|C0021270|C0006141|G0000000|C0011209|C0450371|C0439227|C0011209|C1706353|C0028109|C0006147|C0450371|C0439227
"We conducted a comparative case‐control study of colorectal cancer and adenoma involving 221 cases with colorectal cancer, 525 cases with colorectal adenoma and 578 neighborhood controls.","We conducted comparative case‐control study colorectal cancer adenoma involving 221 colorectal cancer, 525 colorectal adenoma 578 neighborhood controls.",G0000000|C0004927|G0000000|G0000000|C0557651|C0555952|C0006826|C0001430|C1314939|C1442061|C0555952|C0006826|C1442061|C0555952|C0001430|C1442061|C0027569|C0243148
"Inflammatory markers including IL-8, neutrophil elastase (NE), MMP-9, tissue inhibitor of metalloproteinases-1 (TIMP-1), hyaluronidase (HA), and type IV collagen concentration in induced sputum were recorded at baseline and after 6 months.","Inflammatory markers including IL-8, neutrophil elastase (NE), MMP-9, tissue inhibitor metalloproteinases-1 (TIMP-1), hyaluronidase (HA), type IV collagen concentration induced sputum recorded baseline 6 months.",C0333348|C0005516|C0332257|C0020898|C0027950|C0030306|C0028219|C0623362|C0040300|C1999216|C0025543|G0000000|C0020197|C0018510|C0332307|C0022326|C0009325|C0004268|C0205263|C0038056|C0034869|C0168634|G0000000|C0439231
"Follow-up linear contrasts were used to make specific comparisons between groups at 12, 24 and 48 weeks.","Follow-up linear contrasts specific comparisons 12, 24 48 weeks.",C0589120|C0205132|C0009924|C0205369|C1707455|C0450371|C0450371|C0450371|C0439230
These outcome measures are combined using a GST into a single primary outcome.,These outcome measures combined GST single primary outcome.,G0000000|C1274040|C0079809|C0205195|G0000000|C0037179|C0205225|C1274040
"The spatiotemporal parameters computed were cadence, stride time and length, step time and length, and walking speed.","The spatiotemporal parameters computed cadence, stride time length, step time length, walking speed.",G0000000|G0000000|C0449381|C1441526|G0000000|G0000000|C0040223|C1444754|C1261552|C0040223|C1444754|C0080331|C0678536
There was also a linear relationship between the changes in AHI and body weight.,There linear relationship AHI body weight.,G0000000|C0205132|C0439849|G0000000|C0242821|C0005910
"Feasibility outcomes were primarily assessed: enrollment rates, intervention completion rates, and intervention tolerability.","Feasibility outcomes assessed: enrollment rates, intervention completion rates, intervention tolerability.",G0000000|C1274040|C1516048|C1516879|C0871208|C0886296|C0205197|C0871208|C0886296|C3274448
"on days 7, 14, 21 and 28).","days 7, 14, 21 28).",C0439228|G0000000|C0450371|C0450371|C0450371
"Additionally, patients are required to score 4 or more on the 11-item Chalder fatigue scale [36].","Additionally, patients required score 4 11-item Chalder fatigue scale [36].",G0000000|C0030705|C1514873|C0449820|G0000000|C0450371|G0000000|C0015672|C0175659|C0450371
"The 6-week diary recorded daily cramp symptoms (in order to be able to document any rebound from quinine cessation), intervention compliance, and weekly symptom burden scores.","The 6-week diary recorded daily cramp symptoms (in document rebound quinine cessation), intervention compliance, weekly symptom burden scores.",G0000000|C0332174|C0376660|C0034869|C0332173|C0026821|C0683368|G0000000|C1301746|G0000000|C0034417|C1880019|C0886296|C0009563|C0332174|C1457887|C2828008|C0449820
"Secondary safety endpoints included the change in QTc interval, the duration and rate of vasopressor or inotropic support, and the requirement for re-intubation.","Secondary safety endpoints included change QTc interval, duration rate vasopressor inotropic support, requirement re-intubation.",C0027627|C0036043|C2349179|C0332257|C0392747|G0000000|C1272706|C0449238|C0871208|C0042397|G0000000|C0183683|C1514873|C0556581
Training of the heads of the households by village residents on the proper use of LLITN will reduce the burden of malaria in under-five children and pregnant women.,Training heads households village residents proper LLITN reduce burden malaria under-five children pregnant women.,C0040607|C0018670|C0020052|C0562518|C1320928|G0000000|G0000000|G0000000|C2828008|C0024530|C0205451|C0008059|C0549206|C0043210
"The state of Emergence was characterized on a 3-point scale: 1 = asleep, calm or mildly agitated; 2 = moderately agitated or restless, but consolable; 3 = hysterical, crying inconsolable or thrashing.","The Emergence characterized 3-point scale: 1 = asleep, calm mildly agitated; 2 = moderately agitated restless, consolable; 3 = hysterical, crying inconsolable thrashing.",G0000000|C0750573|C1880022|C1552961|C0175659|G0000000|G0000000|C0424522|C0522165|C0750532|C0085631|G0000000|G0000000|C0205081|C0085631|C0085631|G0000000|G0000000|G0000000|C0009946|C0010399|G0000000|G0000000
"Within-group relative changes for anxiety, depression, mental component summary of the 36-item Short-Form Health Survey (SF-36) (MCS), physical component summary of the SF-36 (PCS), dialysis adequacy (Kt/V), Timed Up and Go test (TUG), and the Six-Minute Walk Test (6MWT) in the intervention group (black symbols) and the control group (empty symbols).","Within-group relative anxiety, depression, mental component summary 36-item Short-Form Health Survey (SF-36) (MCS), physical component summary SF-36 (PCS), dialysis adequacy (Kt/V), Timed Up Go test (TUG), Six-Minute Walk Test (6MWT) intervention (black symbols) control (empty symbols).",C0441833|C0080103|C0003467|C0011570|C0229992|C0449432|C1552616|C0450371|C2964478|C0018684|C0038951|C0037712|G0000000|C0031809|C0449432|C1552616|C0037712|C1864389|C0011945|C0205410|C0429662|C0392761|G0000000|C1822658|C0022885|C1319201|C0205452|C0080331|C0022885|G0000000|C0886296|C0005680|C0679214|C0243148|C1880497|C0679214
"Outcome data were collected 8 weeks later by telephone, including receipt of tobacco treatment (defined as consultation with a health care provider specifically for tobacco treatment, enrollment in a tobacco treatment program, consultation with a quitline, or receipt of tobacco dependence treatment medications), quit attempts, 7-day point prevalent abstinence, and current home and car smoking policies.","Outcome data collected 8 weeks telephone, including receipt tobacco treatment (defined consultation health care provider tobacco treatment, enrollment tobacco treatment program, consultation quitline, receipt tobacco dependence treatment medications), quit attempts, 7-day prevalent abstinence, current car smoking policies.",C1274040|C1511726|C1516695|G0000000|C0439230|C0039457|C0332257|G0000000|C0040329|C0039798|C1704788|C0009818|C0018684|C1947933|C1138603|C0040329|C0039798|C1516879|C0040329|C0039798|C1709697|C0009818|G0000000|G0000000|C0040329|C0011546|C0039798|C0013227|C0748223|C1516084|C0332173|C0033105|C3843422|C0521116|C0004381|C0037369|C0242456
The outcomes included the MSTS score and tumor recurrence.,The outcomes included MSTS score tumor recurrence.,G0000000|C1274040|C0332257|C3891283|C0449820|C0027651|C0034897
A total of 48 patients completed the 12 weeks of treatment.,A total 48 patients completed 12 weeks treatment.,G0000000|C0439175|C0450371|C0030705|C0205197|C0450371|C0439230|C0039798
"Cut-off score of 2 on the item: ""Would you like to discuss these problems with someone"" on the sexual problems subscale Patients received the SIPP before the first consultation with their radiotherapist and before the consultation at the end of their RT period since these time points were considered relevant for psychosocial support [27].","Cut-off score 2 item: ""Would someone"" sexual subscale Patients received SIPP consultation radiotherapist consultation RT period time considered relevant psychosocial support [27].",C1442160|C0449820|G0000000|C1551338|G0000000|G0000000|C0036864|G0000000|C0030705|C1514756|G0000000|C0009818|C0278604|C0009818|C0230425|C0439531|C0040223|C0750591|C2347946|C0542298|C0183683|C0450371
"Paradoxical reactions, as defined by an initial decrease of the lesion followed by two consecutive increases occurred in 22% of cases.","Paradoxical reactions, defined initial decrease lesion consecutive increases occurred 22% cases.",C0205310|C0443286|C1704788|C0205265|C0392756|C0221198|C1707491|C0205217|C1709305|C0450371|C0868928
"Patterns of usage will include the number of days/week and times that patients logged in, and which features of the system they used including number of messages sent to the asthma nurse.","Patterns usage days/week times patients logged in, features system including messages asthma nurse.",C0449774|C0457083|C0677547|C0040223|C0030705|C1708728|G0000000|C1521970|C0449913|C0332257|C0470166|C0004096|C0028661
= depressive symptoms; DPDD = drinks per drinking day; JPD = joints per day; PDM = percentage of days used marijuana.,= depressive symptoms; DPDD = drinks drinking day; JPD = joints day; PDM = percentage days marijuana.,G0000000|G0000000|C0683368|G0000000|G0000000|C0452428|C0001948|C0332173|C0031106|G0000000|C0022417|C0332173|G0000000|G0000000|C0439165|C0439228|C0024808
The sum of the longest diameters for all target lesions was used as a reference for determining objective tumour response.,The sum diameters target lesions reference determining objective tumour response.,G0000000|C1515051|C1301886|C1521840|C0221198|C1514811|G0000000|C0018017|C0027651|C0871261
"To assess the effect of oral re-esterified omega-3 fatty acids on tear osmolarity, matrix metalloproteinase-9 (MMP-9), tear break-up time (TBUT), Ocular Surface Disease Index (OSDI), fluorescein corneal staining, Schirmer score, meibomian gland dysfunction (MGD) stage and omega-3 index in subjects with dry eyes and confirmed MGD.","To assess oral re-esterified omega-3 fatty acids tear osmolarity, matrix metalloproteinase-9 (MMP-9), tear break-up time (TBUT), Ocular Surface Disease Index (OSDI), fluorescein corneal staining, Schirmer score, meibomian gland dysfunction (MGD) stage omega-3 subjects dry eyes confirmed MGD.",C0040363|C1516048|C0442027|C0556581|C1719844|G0000000|C0001128|C0039409|C0029387|C1704640|C0025543|C0623362|C0039409|C1881704|C0040223|G0000000|C0015392|C0205148|C0012634|C0918012|C3896641|C0060520|C0010031|C0487602|C1875738|C0449820|G0000000|C1285092|C0031847|G0000000|C0205390|C1719844|C0681850|C0011682|C0015392|C0521093|G0000000
"The hypothesis tested whether ginger and acupressure were different in reduce nausea, vomiting and retching symptoms.","The hypothesis tested ginger acupressure reduce nausea, vomiting retching symptoms.",G0000000|C1512571|C0392366|C0162751|C0282614|G0000000|C0027497|C0042963|C0232602|C0683368
"We aimed to determine whether a longitudinal dietary intervention during pregnancy could increase fish intake, affect serum phospholipid fatty acids, gestational weight gain and body composition changes during pregnancy in women of normal weight participating in the Pregnancy Obesity Nutrition and Child Health study.","We aimed determine longitudinal dietary intervention pregnancy increase fish intake, affect serum phospholipid fatty acids, gestational weight gain body composition pregnancy women normal weight participating Pregnancy Obesity Nutrition Child Health study.",G0000000|C1947946|G0000000|C0205127|C0012155|C0886296|C0032961|C0442805|C0016163|C1512806|C0001721|C0229671|C0031676|G0000000|C0001128|C0439671|C0005910|C1517378|C0242821|C0486616|C0032961|C0043210|C0205307|C0005910|C0679823|C0032961|C0028754|C0028707|C0008059|C0018684|C0557651
Recovery rate is defined across both treatment arms as MUAC ≥125 mm and no oedema for two consecutive visits.,Recovery rate defined treatment arms MUAC ≥125 mm oedema consecutive visits.,C0237820|C0871208|C1704788|C0039798|C0206655|G0000000|G0000000|G0000000|C0013604|C1707491|C0545082
"Outcome measures were antisocial behavior, substance use, and delinquency, and psychosocial dysfunction.","Outcome measures antisocial behavior, substance use, delinquency, psychosocial dysfunction.",C1274040|C0079809|C0233523|C0004927|C0439861|C0042153|C0522174|C0542298|C0031847
"Primary endpoints in hierarchical order are: peak levels of both aspartat-amino-transaminase (AST) and alanine-amino-transaminase (ALT) as surrogates for the progression of liver related injury, as well as both graft and patient survival up to 2 years after transplantation.","Primary endpoints hierarchical are: peak levels aspartat-amino-transaminase (AST) alanine-amino-transaminase (ALT) surrogates progression liver injury, graft patient survival 2 transplantation.",C0205225|C2349179|C0699032|G0000000|C0444505|C0441889|C0002594|C3891303|C0001899|C1266129|C4053457|C0242656|C0023884|C3263722|C0181074|C0030705|C0038952|G0000000|C0040732
"Secondary endpoints include safety and toxicity, progression-free survival and quality of life.","Secondary endpoints safety toxicity, progression-free survival quality life.",C0027627|C2349179|C0036043|C0040539|C0242656|C0038952|C0332306|C0376558
"As catumaxomab was effective in prolonging puncture-free survival, the observation period for adverse events was distinctly longer in the catumaxomab than in the control group.","As catumaxomab effective prolonging puncture-free survival, observation period adverse events distinctly catumaxomab control group.",G0000000|C1831854|C1280519|G0000000|C0033119|C0038952|C0302523|C0439531|G0000000|C0441471|G0000000|C1831854|C0243148|C0441833
"The primary outcome measures are health behaviour (alcohol, drugs, smoking, safe sex) and mental health status.","The primary outcome measures health behaviour (alcohol, drugs, smoking, safe sex) mental health status.",G0000000|C0205225|C1274040|C0079809|C0018684|C0004927|C0001962|C0013227|C0037369|G0000000|C0009253|C0229992|C0018684|C0449438
"Among the patients with agitation scores 4 or 5 in the peostanesthesia care unit (PACU), Group IV patients were intravenously given a 1-ml mixture of midazolam 0.025 mg/kg and normal saline up to 3 times.","Among patients agitation scores 4 5 peostanesthesia care unit (PACU), Group IV patients intravenously 1-ml mixture midazolam 0.025 mg/kg normal saline 3 times.",G0000000|C0030705|C0085631|C0449820|G0000000|G0000000|G0000000|C1947933|C0439148|C0034871|C0441833|C0022326|C0030705|G0000000|C0439526|C0439962|C0026056|C1442061|C0439272|C0205307|C0036082|G0000000|C0040223
"At 6 and 10 months, infant development and behavior were measured in a clinical setting using the Bayley Scales of Infant Development II.","At 6 10 months, infant development behavior measured clinical setting Bayley Scales Infant Development II.",G0000000|G0000000|C0450371|C0439231|C0021270|C0243107|C0004927|C0444706|C0205210|C0542559|G0000000|C0175659|C0021270|C0243107|G0000000
"Seven-day rate of continuous abstinence at study week 52, the end of the relapse-prevention phase, confirmed by exhaled carbon monoxide.","Seven-day rate continuous abstinence study week 52, relapse-prevention phase, confirmed exhaled carbon monoxide.",C1710063|C0871208|C0549178|C3843422|C0557651|C0332174|C0450371|C0679867|C0205390|C0521093|C0231800|C0007009|G0000000
Alteration in UEs is an active mediator for this effect.,Alteration UEs active mediator effect.,C1515926|C0855073|C0205177|C1363844|C1280500
"Secondary outcomes will be measured at 30 minutes after treatment using the NRS of leg pain, ODI, patient global impression of change, range of motion (ROM) of the lumbar spine, and degrees of straight leg raising (SLR).","Secondary outcomes measured 30 minutes treatment NRS leg pain, ODI, patient global impression change, range motion (ROM) lumbar spine, degrees straight leg raising (SLR).",C0027627|C1274040|C0444706|C0450371|C0439232|C0039798|C2240043|C0023216|C0030193|G0000000|C0030705|C0205246|C0596764|C0392747|C1514721|C0026597|C4048784|C0024090|C0037949|C0449286|C0445291|C0023216|G0000000|G0000000
"Although the primary endpoint did not reach statistical significance, owing in part to adjustments in SQS score for one death in the LAI group (removal of this adjustment yielded a significant difference: P = 0.04), an unanticipated greater proportion of patients treated with LAI relative to placebo achieved negative sputum cultures for NTM, and time to negative sputum culture conversion favored LAI treatment.","Although primary endpoint reach statistical significance, adjustments SQS score death LAI (removal adjustment yielded difference: P = 0.04), unanticipated proportion patients treated LAI relative placebo achieved negative sputum cultures NTM, time negative sputum culture conversion favored LAI treatment.",G0000000|C0205225|C2349179|C2584321|C0038215|C0237881|C0376209|G0000000|C0449820|C0011065|C0443021|C0015252|C0376209|G0000000|C1705241|G0000000|G0000000|C1709707|C0030705|C1522326|C0443021|C0080103|C0032042|G0000000|C0205160|C0038056|C0010453|C1265234|C0040223|C0205160|C0038056|C0010453|C0439836|C0309049|C0443021|C0039798
"Path analyses were performed to test whether or not improvements in positive and negative parenting behaviors mediated the significant intervention group mean differences independent of improvements in inattention symptoms for the parent and teacher-reported outcomes at post-treatment (see Figures 1 and and2,2, respectively) and parent-reported outcomes at follow-up (see Figure 3).","Path analyses performed test improvements positive negative parenting behaviors mediated intervention differences independent improvements inattention symptoms parent teacher-reported outcomes post-treatment (see Figures 1 and2,2, respectively) parent-reported outcomes follow-up (see Figure 3).",C0919386|C0002778|C0884358|C0022885|C2986411|C0439178|C0205160|C0085092|C0004927|C0086597|C0886296|C1705241|C0085862|C2986411|C0424101|C0683368|C0030551|C0221457|C1274040|C2709088|C0042789|G0000000|G0000000|G0000000|G0000000|C4054215|C1274040|C0589120|C0042789|G0000000|G0000000
"Moreover, patients treated with a lower daily dose of corticosteroids (≤ 80 mg methylpredisolone or equivalent dose) exhibited a similar mortality rate compared with those treated with higher daily dose (9/30 vs. 8/22, p = 0.854).","Moreover, patients treated lower daily dose corticosteroids (≤ 80 methylpredisolone equivalent dose) exhibited mortality rate compared treated daily dose (9/30 vs. 8/22, = 0.854).",G0000000|C0030705|C1522326|C0441994|C0332173|C0178602|C0001617|G0000000|C0450371|G0000000|C0205163|C0178602|C0015272|C0026565|C0871208|C1707455|C1522326|C0332173|C0178602|C0450371|G0000000|C0450371|G0000000|C1442061
"In this trial, patients randomized to the ATRA arm had a significantly higher complete remission (CR) rate, better event-free and overall survival [19].","In trial, patients randomized ATRA arm complete remission (CR) rate, event-free survival [19].",G0000000|C0008976|C0030705|C0034656|C0040845|C0446516|C0205197|C0544452|C0201975|C0871208|C0441471|C0038952|C0450371
"Continuous chemoprophylaxis of children in regions of endemicity reduces malaria and severe anemia, outpatient attendance, hospital admissions, and mortality (11).","Continuous chemoprophylaxis children regions endemicity reduces malaria severe anemia, outpatient attendance, hospital admissions, mortality (11).",C0549178|C0282515|C0008059|C0017446|G0000000|G0000000|C0024530|C0205082|C0002871|C0029921|C2827364|C0019994|C0184666|C0026565|C0450371
Infectious complications were judged using CDC criteria [19] and were considered significant if antibiotic therapy was instituted.,Infectious complications judged CDC criteria [19] considered antibiotic therapy instituted.,C0009450|C0009566|C0221191|C0007670|C0243161|C0450371|C0750591|C0003232|C0039798|C0021622
"Neither atopic status, baseline FEV1, nor concomitant DNase therapy had any effect on response to treatment.","Neither atopic status, baseline FEV1, concomitant DNase therapy response treatment.",G0000000|C0392707|C0449438|C0168634|G0000000|C0521115|C0011519|C0039798|C0871261|C0039798
"The GI group significantly improved their self-efficacy for managing pain from baseline to 10 weeks (see Table 1), whereas the Usual Care alone group did not show any difference over time.","The GI improved self-efficacy managing pain baseline 10 weeks (see Table 1), Usual Care difference time.",G0000000|C1708130|C0184511|C0600564|C1273870|C0030193|C0168634|C0450371|C0439230|C0042789|C0039224|G0000000|C3538928|C1947933|C1705241|C0040223
Primary efficacy end points were area under the curve from 0–3 hours of forced expiratory volume in 1 second (FEV1 AUC0–3) and trough FEV1 after 12 weeks (for the individual trials).,Primary efficacy curve 0–3 hours forced expiratory volume 1 (FEV1 AUC0–3) trough FEV1 12 weeks (for individual trials).,C0205225|C1280519|C0205134|G0000000|C0439227|C0441722|C0231800|C0449468|G0000000|G0000000|G0000000|C0444506|G0000000|C0450371|C0439230|G0000000|C0027361|C0008976
Does that mean that the treated patients are making nonfunctional lean body mass?,Does treated patients nonfunctional lean body mass?,G0000000|C1522326|C0030705|C0205300|G0000000|C0242821|C0577559
"At all measurements, using a standardized script with specific instructions for each task, participants were assessed on the Berg Balance Scale (BBS) 24, tandem stance (TS), one leg stance (OLS) 25 the Timed Up and Go test (TUG) 26, and the six minute walk test (6MWT) 27.","At measurements, standardized script specific instructions task, participants assessed Berg Balance Scale (BBS) 24, tandem stance (TS), leg stance (OLS) 25 Timed Up Go test (TUG) 26, minute walk test (6MWT) 27.",G0000000|C0242485|G0000000|C0871893|C0205369|C0302828|C3540678|C0679646|C1516048|G0000000|C0014653|C0175659|G0000000|C0450371|C0075804|G0000000|C0041388|C0023216|G0000000|G0000000|C0450371|C0392761|G0000000|C1822658|C0022885|C1319201|C0450371|C0439232|C0080331|C0022885|G0000000|C0450371
Numerical Rating Scale scores of pain over time are shown in Figure 2.,Numerical Rating Scale scores pain time Figure 2.,C0237753|C0871208|C0175659|C0449820|C0030193|C0040223|G0000000|G0000000
PAED score of 16 or greater was used to define EA.,PAED score 16 define EA.,G0000000|C0449820|C0450371|G0000000|C0014963
"A checklist including VAS, number of pad consumptions, and the amount of drug usage from the day before and the first day until the fourth day of menstruation, and satisfaction with fennel drop was given to all the students to fill.","A checklist including VAS, pad consumptions, amount drug usage day day fourth day menstruation, satisfaction fennel drop students fill.",G0000000|C1707357|C0332257|C0042815|C0182158|C0009830|C1265611|C0013227|C0457083|C0332173|C0332173|C0205438|C0332173|C0025344|C0242428|C0553175|C1321095|C0038492|C1708059
Almost half of the patients included in this analysis were paediatric patients aged <16 years.,Almost half patients included analysis paediatric patients aged <16 years.,C3828842|C2825407|C0030705|C0332257|C0002778|C0030755|C0030705|C0001779|C0450371|C0439234
"The secondary objectives of this study were to evaluate, in patients with FM, the efficacy of CBT, RPT and TAU in primary care for depression (measured using the Hamilton Rating Scale for Depression (HAM-D)); anxiety (assessed using the Hamilton Anxiety Rating Scale (HARS)); pain (measured using the Pain Visual Analogue Scale (PVAS)); global function (assessed using the Fibromyalgia Impact Questionnaire (FIQ)); and quality of life (assessed using the European Quality of Life Scale 5-D (EuroQol-5D) Questionnaire).","The secondary objectives study evaluate, patients FM, efficacy CBT, RPT TAU primary care depression (measured Hamilton Rating Scale Depression (HAM-D)); anxiety (assessed Hamilton Anxiety Rating Scale (HARS)); pain (measured Pain Visual Analogue Scale (PVAS)); global function (assessed Fibromyalgia Impact Questionnaire (FIQ)); quality life (assessed European Quality Life Scale 5-D (EuroQol-5D) Questionnaire).",G0000000|C0027627|C0018017|C0557651|C0220825|C0030705|C3540627|C1280519|C0009244|G0000000|C1720655|C0205225|C1947933|C0011570|C0444706|G0000000|C0871208|C0175659|C0011570|C1570167|C0003467|C1516048|G0000000|C0003467|C0871208|C0175659|C1415473|C0030193|C0444706|C0030193|C0234621|C0243071|C0175659|C0139386|C0205246|C0031843|C1516048|C0016053|C1825598|C0034394|G0000000|C0332306|C0376558|C1516048|C0239307|C0332306|C0376558|C0175659|C0073187|C0451150|C0034394
"Overall, the 9.4% reduction in the incidence of the combined primary end point of fatal or non-fatal myocardial infarction or sudden death was not significant.","Overall, 9.4% reduction incidence combined primary fatal non-fatal myocardial infarction sudden death significant.",C0282416|G0000000|C0301630|C0021149|C0205195|C0205225|C1302234|C1518422|C0027061|C0021308|C1276802|C0011065|C0237881
"No statistically significant differences were noted for PFS, survival or the adverse event (AE) incidence rate.","No statistically differences PFS, survival adverse event (AE) incidence rate.",G0000000|C0038215|C1705241|C0242792|C0038952|G0000000|C0441471|C3887670|C0021149|C0871208
"Whilst objective assessment of illicit cannabis use using urine drug screening should enhance self-report validity, it remains to be seen whether illicit cannabis use can be differentiated from prescribed nabiximols use.","Whilst objective assessment illicit cannabis urine drug screening enhance self-report validity, remains illicit cannabis differentiated prescribed nabiximols use.",G0000000|C0018017|C1261322|C0332266|C0024808|C0042036|C0013227|C0220908|C2349975|C0681906|C2349101|G0000000|C0332266|C0024808|C0007589|C0278329|C2347556|C0042153
"Failure of treatment was defined as cataract necessitating surgery, or best corrected visual acuity of 20/400 or worse.","Failure treatment defined cataract necessitating surgery, corrected visual acuity 20/400 worse.",C0231174|C0039798|C1704788|C0086543|G0000000|C0038894|C0205202|C0234621|C0750509|C0450371|C0332271
"In this study, ear examinations that demonstrated type B tympanogram, reduced mobility on pneumatic otoscopy and a marked or moderately bulging TM were categorised as AOM without perforation (AOMwoP) even if the child was asymptomatic.","In study, ear examinations demonstrated type B tympanogram, reduced mobility pneumatic otoscopy marked moderately bulging TM categorised AOM perforation (AOMwoP) child asymptomatic.",G0000000|C0557651|C0013443|C0031809|G0000000|C0332307|G0000000|C0679573|C0392756|C0425245|G0000000|C0847244|C0522501|C0205081|C0038999|C2744539|G0000000|C0004519|C0549099|G0000000|C0008059|C0231221
"In addition to the Chedoke-McMaster test, the Rancho Los Amigos Functional Test for the hemiparetic upper extremity was used to quantify functional movement ability.","In addition Chedoke-McMaster test, Rancho Los Amigos Functional Test hemiparetic upper extremity quantify functional movement ability.",G0000000|C0332287|G0000000|C0022885|G0000000|G0000000|C1823184|C0205245|C0022885|G0000000|C1282910|C0015385|C1709793|C0205245|C0026649|C0085732
"Changes in the secondary outcomes—irritable bowel syndrome symptom severity score, severity of abdominal pain, and irritable bowel syndrome quality of life at one, two, and three months after the baseline measurements—were also compared.","Changes secondary outcomes—irritable bowel syndrome symptom severity score, severity abdominal pain, irritable bowel syndrome quality life one, two, months baseline measurements—were compared.",C0392747|C0027627|G0000000|C0021853|C0039082|C1457887|C0439793|C0449820|C0439793|C0000726|C0030193|C0022107|C0021853|C0039082|C0332306|C0376558|C0205447|C0205448|C0439231|C0168634|G0000000|C1707455
"Main outcome measures Function (late life function and disability instruments, elderly mobility scale, FICSIT-4 balance test, timed up and go test), quality of life (life satisfaction index, EuroQol), and falls (time to fall over 12 months).","Main outcome measures Function (late life function disability instruments, elderly mobility scale, FICSIT-4 balance test, timed test), quality life (life satisfaction index, EuroQol), falls (time fall 12 months).",C0205225|C1274040|C0079809|C0031843|C0205087|C0376558|C0031843|C0231170|C0348000|C0001792|C0425245|C0175659|G0000000|C0014653|C0022885|C0392761|C0022885|C0332306|C0376558|C0376558|C0242428|C0918012|C0451150|C0000921|C0040223|C0085639|C0450371|C0439231
"Secondary objectives include assessment of the effect of such a program on a range of measures of infant ETS exposure, including mother/caregiver's self-report of infant exposure to ETS and implementation of smoking restrictions in the home and/or car, infant urinary cotinine, household smoking status, mother/caregiver's smoking cessation and quit attempts.","Secondary objectives assessment program range measures infant ETS exposure, including mother/caregiver's self-report infant exposure ETS implementation smoking restrictions and/or car, infant urinary cotinine, household smoking status, mother/caregiver's smoking cessation quit attempts.",C0027627|C0018017|C1261322|C1709697|C1514721|C0079809|C0021270|G0000000|C0274281|C0332257|C0026591|C0681906|C0021270|C0274281|G0000000|C1708476|C0037369|C0443288|G0000000|C0004381|C0021270|C0042027|C0010194|C0020052|C0037369|C0449438|C0026591|C0037369|C1880019|C0748223|C1516084
"The patient-reported outcomes were the 24-item health-related Quality of Life-Radiation Therapy Instrument (QOL-RTI) (34,35), the 14-item Expanded Prostate Cancer Index Bowel (EPIC-Bowel) (36,37), the seven-item Functional Alterations due to Changes in Elimination Bowel (FACE-Bowel) (38), and the four-item Diarrhea Assessment Scale (DAS) (39).","The patient-reported outcomes 24-item health-related Quality Life-Radiation Therapy Instrument (QOL-RTI) (34,35), 14-item Expanded Prostate Cancer Index Bowel (EPIC-Bowel) (36,37), seven-item Functional Alterations Changes Elimination Bowel (FACE-Bowel) (38), four-item Diarrhea Assessment Scale (DAS) (39).",G0000000|C0747307|C1274040|C0450371|C0018684|C0332306|C0376558|C0039798|C0348000|C0518214|C0450371|C0450371|C0205229|C0033572|C0006826|C0918012|C0021853|C1273342|C0450371|C0205453|C0205245|C1515926|C0392747|C0221102|C0021853|C0015450|C0450371|C0205450|C0011991|C1261322|C0175659|C0051767|C0450371
Relapse was defined as the recurrence of disease activity after a period of remission as manifested by a BVAS score > 0.,Relapse defined recurrence disease activity period remission manifested BVAS score > 0.,C0035020|C1704788|C0034897|C0012634|C0205177|C0439531|C0544452|C0205319|C4053544|C0449820|G0000000|G0000000
"In the Netherlands the cumulative risk of ovarian malignancy (including borderline ovarian tumours) is small, i.e.","In Netherlands cumulative risk ovarian malignancy (including borderline ovarian tumours) small, i.e.",G0000000|C0027778|C1511559|C0035647|C0205065|C0006826|C0332257|C0205189|C0205065|C0027651|C0700321|C0683454
"Factors evaluated baseline, 2, 6, and 12 months post hip fracture included demographic variables, adherence to treatment visits, self-efficacy, outcome expectations, stage of change for exercise, social support for exercise, mood, health status, pain, and fear of falling.","Factors evaluated baseline, 2, 6, 12 months post hip fracture included demographic variables, adherence treatment visits, self-efficacy, outcome expectations, stage change exercise, social support exercise, mood, health status, pain, fear falling.",C1521761|C0220825|C0168634|G0000000|G0000000|C0450371|C0439231|C0687676|C0019552|C0016658|C0332257|C0011298|C0439828|C1510802|C0039798|C0545082|C0600564|C1274040|C0679138|C0205390|C0392747|C0015259|C0728831|C0183683|C0015259|C0026516|C0018684|C0449438|C0030193|C0015726|C0000921
The primary efficacy end point was the rate of detection of HIV-1 infection at 28 weeks among infants who were uninfected at 2 weeks and among all infants who underwent randomization.,The primary efficacy rate detection HIV-1 infection 28 weeks infants uninfected 2 weeks infants underwent randomization.,G0000000|C0205225|C1280519|C0871208|C1511790|C0019682|C0009450|C0450371|C0439230|C0021270|G0000000|G0000000|C0439230|C0021270|G0000000|C0034656
"BBS: Berg Balance Scale; MFRT: Modified Functional Reach Test *Statistically significant (p<0.05) in comparison with pre-test data The FAC score, which evaluates a patient’s walking ability, significantly improved in the RAGT group (p<0.05).","BBS: Berg Balance Scale; MFRT: Modified Functional Reach Test *Statistically (p<0.05) comparison pre-test data The FAC score, evaluates patient’s walking ability, improved RAGT (p<0.05).",G0000000|G0000000|C0014653|C0175659|G0000000|C0392747|C0205245|C2584321|C0022885|C0038215|C0369773|C1707455|C0332152|C1511726|G0000000|G0000000|C0449820|C0220825|G0000000|C0080331|C0085732|C0184511|G0000000|C0369773
The risk factors for zinc deficiency among VGD women support this statement: the non-FFR group has significantly higher odds of low serum zinc than the FFR group.,The risk factors zinc deficiency VGD women support statement: non-FFR odds low serum zinc FFR group.,G0000000|C0035647|C1521761|C0043481|C0011155|G0000000|C0043210|C0183683|C1710187|C1518422|G0000000|C0205251|C0229671|C0043481|C1412871|C0441833
The time to cessation of seizure was shorter with intranasal midazolam.,The time cessation seizure shorter intranasal midazolam.,G0000000|C0040223|C1880019|C0036572|C1282927|C0442118|C0026056
The primary endpoint of the study was 28-day mortality from all causes.,The primary endpoint study 28-day mortality causes.,G0000000|C0205225|C2349179|C0557651|C0450371|C0026565|C0015127
"The secondary objectives included the recovery rate from SAM, the time-to-recovery, the weight gain, and the diarrhea longitudinal prevalence in OTP.","The secondary objectives included recovery rate SAM, time-to-recovery, weight gain, diarrhea longitudinal prevalence OTP.",G0000000|C0027627|C0018017|C0332257|C0237820|C0871208|C0036002|C0040223|C0005910|C1517378|C0011991|C0205127|C0033105|C1418198
Our primary endpoint was symptomatic UTI treated by the GP.,Our primary endpoint symptomatic UTI treated GP.,G0000000|C0205225|C2349179|C0231220|C0042029|C1522326|C3811116
Participants in both groups made a total of 811 entries reporting their barriers to exercise.,Participants total 811 entries reporting barriers exercise.,C0679646|C0439175|C1442061|C1705654|C0700287|C1706912|C0015259
The primary outcome of this study was weight-for-length percentile at age 1 year.,The primary outcome study weight-for-length percentile age 1 year.,G0000000|C0205225|C1274040|C0557651|C0005910|C1264641|C0001779|G0000000|C0439234
"Significant events (intubation, seizures, death) were recorded at the time of the event.","Significant events (intubation, seizures, death) recorded time event.",C0237881|C0441471|C0021925|C0036572|C0011065|C0034869|C0040223|C0441471
"Lifetime smoking was assessed through the question: ‘How many cigarettes have you smoked in your life?’ (none, a few puffs, one to 19 cigarettes, 20–100 cigarettes, more than 100 cigarettes).","Lifetime smoking assessed question: ‘How cigarettes smoked life?’ (none, puffs, 19 cigarettes, 20–100 cigarettes, 100 cigarettes).",C4071830|C0037369|C1516048|C1522634|G0000000|C0677453|C0037366|G0000000|G0000000|C1533107|C0450371|C0677453|G0000000|C0677453|C1442061|C0677453
"The case definition of VMCCI required the presence of influenza-like illness (ILI), defined as symptoms that interfered with normal daily activities and that included cough, and at least 1 additional symptom from among fever (oral temperature >37.7°C/99.9°F), headache, myalgia and/or arthralgia, chills, rhinorrhea/nasal congestion, and sore throat.","The definition VMCCI required presence influenza-like illness (ILI), defined symptoms interfered normal daily activities included cough, 1 additional symptom fever (oral temperature >37.7°C/99.9°F), headache, myalgia and/or arthralgia, chills, rhinorrhea/nasal congestion, sore throat.",G0000000|C1550452|G0000000|C1514873|C0150312|C0021400|C0221423|G0000000|C1704788|C0683368|C0521102|C0205307|C0332173|C0441655|C0332257|C0010200|G0000000|C1524062|C1457887|C0015967|C0442027|C0005903|G0000000|C0018681|C0231528|G0000000|C0003862|C0085593|C1260880|C0700148|C0234233|C0031354
The primary end point was progression-free survival (PFS) at 6 months.,The primary progression-free survival (PFS) 6 months.,G0000000|C0205225|C0242656|C0038952|C0242792|G0000000|C0439231
"The primary outcome is a categorical outcome, seizure freedom versus seizure recurrence.","The primary outcome categorical outcome, seizure freedom versus seizure recurrence.",G0000000|C0205225|C1274040|C0683312|C1274040|C0036572|C0016694|G0000000|C0036572|C0034897
"The primary and the secondary outcomes of this study were physical activity level and physical fitness, respectively.","The primary secondary outcomes study physical activity level physical fitness, respectively.",G0000000|C0205225|C0027627|C1274040|C0557651|C0031809|C0205177|C0441889|C0031809|C1456706|G0000000
c Treated previously for BC at another hospital.,Treated BC hospital.,C1522326|C0006041|C0019994
We dichotomized these three HRQOL variables in terms of their frequency in the previous 30 days (≥14 being frequent or <14 being infrequent).,We dichotomized HRQOL variables terms frequency previous 30 days (≥14 frequent <14 infrequent).,G0000000|G0000000|G0000000|C0439828|C0233324|C0376249|C0205156|C0450371|C0439228|G0000000|C0332183|C0450371|C0521114
Secondary study parameters were: the ICDAS score and DMFS index measured before and after treatment with fixed orthodontic appliances; the bleeding scores per participant measured at different time points during treatment with fixed orthodontic appliances; and the extent of the WSL as determined by QLF (fluorescence loss and lesion area) after debonding.,Secondary study parameters were: ICDAS score DMFS measured treatment fixed orthodontic appliances; bleeding scores participant measured time treatment fixed orthodontic appliances; extent WSL determined QLF (fluorescence loss lesion area) debonding.,C0027627|C0557651|C0449381|G0000000|G0000000|C0449820|C0058218|C0444706|C0039798|C0443218|C0332276|C0243112|C0019080|C0449820|C0679646|C0444706|C0040223|C0039798|C0443218|C0332276|C0243112|C0439792|C3890192|G0000000|G0000000|C0016315|C1517945|C0221198|C0017446|C3640033
"There were no differences by condition for depression, state anxiety, trait anxiety or cognitive behavioral self efficacy (see Table 2).","There differences condition depression, anxiety, trait anxiety cognitive behavioral efficacy (see Table 2).",G0000000|C1705241|C0012634|C0011570|C0003467|C0599883|C0003467|C1516691|C0004927|C1280519|C0042789|C0039224|G0000000
"18 There was no significant difference between groups with regard to the rates of death and complications, the length of hospital stay, or the need for subsequent percutaneous drainage.","18 There difference regard rates death complications, length hospital stay, subsequent percutaneous drainage.",C0450371|G0000000|C1705241|G0000000|C0871208|C0011065|C0009566|C1444754|C0019994|G0000000|C0332282|C0522523|C0012621
The primary aim of the trial is to assess the effectiveness of a web-based menu planning intervention in increasing the mean number of food groups on childcare service menus that comply with dietary guidelines regarding food provision to children in care.,The primary aim trial assess effectiveness web-based menu planning intervention increasing food childcare service menus comply dietary guidelines food provision children care.,G0000000|C0205225|C1947946|C0008976|C1516048|C1280519|C0282111|G0000000|C0032074|C0886296|C0442808|C0016452|C0008067|C0557854|G0000000|C0725694|C0012155|C0162791|C0016452|C1549071|C0008059|C1947933
"Secondary outcomes included 3 months of seizure freedom at 6-month follow-up, measures of psychosocial functioning, health service use, and employment.","Secondary outcomes included 3 months seizure freedom 6-month follow-up, measures psychosocial functioning, health service use, employment.",C0027627|C1274040|C0332257|G0000000|C0439231|C0036572|C0016694|C0332177|C0589120|C0079809|C0542298|C0205245|C0018684|C0557854|C0042153|C0014003
We assume that patients will increase their level of physical activity during the first months of intervention and then maintain this level.,We assume patients increase level physical activity months intervention maintain level.,G0000000|G0000000|C0030705|C0442805|C0441889|C0031809|C0205177|C0439231|C0886296|C0024501|C0441889
"The research instruments were reynolds child depression scale (RCDS), eysenck feelings of guilt scale and satisfaction with life scale (SWLS).","The instruments reynolds child depression scale (RCDS), eysenck feelings guilt scale satisfaction life scale (SWLS).",G0000000|C0348000|G0000000|C0008059|C0011570|C0175659|G0000000|G0000000|C0013987|C0018379|C0175659|C0242428|C0376558|C0175659|C3897656
Sleep quality protocol Sleep quality was estimated using Pittsburg Sleep Quality Index (PSQI) questionnaire.,Sleep quality protocol Sleep quality estimated Pittsburg Sleep Quality Index (PSQI) questionnaire.,C0037313|C0332306|C0442711|C0037313|C0332306|C0750572|G0000000|C0037313|C0332306|C0918012|C3697468|C0034394
"The primary outcome of the trial is adherence, appraised at monthly intervals by pill counts and vernacular versions of the Self‐Reporting Medication‐Taking Scale (SRMS) and Brief Medication Questionnaire (BMQ).28, 29 Secondary outcomes include quality of life appraisal by the Personal Impact of Epilepsy (PIES) scale and several seizure‐related parameters including monthly seizure frequency, time to first seizure (in days) after enrollment, and the proportion of subjects experiencing seizure freedom for the duration of the study.24, 30 Outcomes are assessed independently by a study nurse, who not involved in recruitment or dispensing and trained in the use of the instruments described below.","The primary outcome trial adherence, appraised monthly intervals pill counts vernacular versions Self‐Reporting Medication‐Taking Scale (SRMS) Brief Medication Questionnaire (BMQ).28, 29 Secondary outcomes quality life appraisal Personal Impact Epilepsy (PIES) scale seizure‐related parameters including monthly seizure frequency, time seizure (in days) enrollment, proportion subjects experiencing seizure freedom duration study.24, 30 Outcomes assessed independently study nurse, involved recruitment dispensing trained instruments below.",G0000000|C0205225|C1274040|C0008976|C1510802|G0000000|C0332177|C1272706|C0009905|C0439157|G0000000|C0333052|G0000000|G0000000|C0175659|C1420406|C1282927|C0013227|C0034394|C0450371|C0450371|C0027627|C1274040|C0332306|C0376558|G0000000|C1519021|C1825598|C0014544|C1370824|C0175659|G0000000|C0449381|C0332257|C0332177|C0036572|C0376249|C0040223|C0036572|G0000000|C0439228|C1516879|C1709707|C0681850|C0237607|C0036572|C0016694|C0449238|C0557651|C0450371|C1274040|C1516048|G0000000|C0557651|C0028661|C1314939|C2949735|C1880359|C0336809|C0348000|G0000000
"The child’s SHS exposure in the home was based on the care-giver’s self-report of smoking frequency and location in the home, number of cigarettes smoked inside and outside the home, and the number of quit attempts during the caregiver’s lifetime.","The child’s SHS exposure based care-giver’s self-report smoking frequency location home, cigarettes smoked inside home, quit attempts caregiver’s lifetime.",G0000000|G0000000|G0000000|C0274281|C1527178|G0000000|C0681906|C0037369|C0376249|C0450429|C0442519|C0677453|C0037366|G0000000|C0442519|C0748223|C1516084|G0000000|C4071830
"These questions were repeated up to 10 times, depending on the number of partners reported by respondents.","These questions repeated 10 times, depending partners reported respondents.",G0000000|C1522634|C0205341|C0450371|C0040223|C0725813|C0682323|C0684224|C0282122
"Primary outcome The primary outcome is the proportion of individuals with tobacco abstinence at 6 months after the end of the therapy (T3) [35, 36].","Primary outcome The primary outcome proportion individuals tobacco abstinence 6 months therapy (T3) [35, 36].",C0205225|C1274040|G0000000|C0205225|C1274040|C1709707|C0027361|C0040329|C3843422|G0000000|C0439231|C0039798|C0041403|C0450371|C0450371
"Secondary outcomes were uptake of 2 other adolescent vaccines, the meningococcal conjugate vaccine (MenACWY) and the tetanus-diphtheria-acellular pertussis vaccine (Tdap).","Secondary outcomes uptake 2 adolescent vaccines, meningococcal conjugate vaccine (MenACWY) tetanus-diphtheria-acellular pertussis vaccine (Tdap).",C0027627|C1274040|C0243144|G0000000|C0205653|C0042210|C0127526|C0301869|C0042210|C2003457|C0039614|C0043167|C0042210|G0000000
"The secondary outcome measure was the time to defervescence, which was defined as the interval between the time at which the first dose of the study drug was administered and the time at which the oral temperature first returned to ≤37.5°C and was maintained for two consecutive measurements without antipyretics.","The secondary outcome measure time defervescence, defined interval time dose study drug administered time oral temperature returned ≤37.5°C maintained consecutive measurements antipyretics.",G0000000|C0027627|C1274040|C0079809|C0040223|G0000000|C1704788|C1272706|C0040223|C0178602|C0557651|C0013227|C1521801|C0040223|C0442027|C0005903|C0332156|G0000000|C1314677|C1707491|C0242485|C0003419
Treatment was considered “successful” when the lesions were completely healed (scarred without residual inflammation) upon completion of the 8-week antibiotic treatment or during the next few weeks with or without adjunctive surgical excision.,Treatment considered “successful” lesions completely healed (scarred residual inflammation) completion 8-week antibiotic treatment weeks adjunctive surgical excision.,C0039798|C0750591|G0000000|C0221198|C0205197|C0205249|C0008767|C1609982|C0021368|C0205197|C0332174|C0003232|C0039798|C0439230|C2825951|C0543467|C0015252
"There were no significant group differences in the change scores for any of these brief ratings, on any of the 3 days of measurement, nor were there significant group differences in the change scores for the HADS and PHLMS between pre-intervention on day 1 and post-intervention on day 3.","There differences change scores ratings, 3 days measurement, differences change scores HADS PHLMS pre-intervention day 1 post-intervention day 3.",G0000000|C1705241|C0392747|C0449820|C0871208|G0000000|C0439228|C0242485|C1705241|C0392747|C0449820|C0048008|G0000000|C2347663|C0332173|G0000000|C2347647|C0332173|G0000000
All medication prescriptions are reviewed every 6 months.,All medication prescriptions reviewed 6 months.,G0000000|C0013227|C0033080|C0282443|G0000000
"Primary and secondary outcomes Unless specified otherwise, data are reported as mean ± SD aFor continuous variables, p values were calculated using the Wilcoxon-Mann-Whitney test bData calculated for the patients who received vasopressors cData calculated for the patients who received renal replacement therapy dOrgan support includes the use of mechanical ventilation, vasopressors, or renal replacement therapy a Kaplan-Meier estimate of time to removal of organ support by treatment arm after adjustment by Cox regression analysis for Acute Physiology and Chronic Health Evaluation II (APACHE II) score and Lung Injury Score.","Primary secondary outcomes Unless otherwise, data reported mean ± SD aFor continuous variables, values calculated Wilcoxon-Mann-Whitney test bData calculated patients received vasopressors cData calculated patients received renal replacement therapy dOrgan support includes mechanical ventilation, vasopressors, renal replacement therapy Kaplan-Meier estimate time removal organ support treatment arm adjustment Cox regression analysis Acute Physiology Chronic Health Evaluation II (APACHE II) score Lung Injury Score.",C0205225|C0027627|C1274040|G0000000|G0000000|C1511726|C0684224|G0000000|G0000000|C0549178|C0439828|C0042295|C0444686|G0000000|C0022885|G0000000|C0444686|C0030705|C1514756|C0042397|C0640049|C0444686|C0030705|C1514756|C0022646|C0035139|C0039798|G0000000|C0183683|C0332257|C0443254|C0035203|C0042397|C0022646|C0035139|C0039798|G0000000|C0750572|C0040223|C0015252|C0178784|C0183683|C0039798|C0446516|C0376209|G0000000|C0684320|C0002778|C0205178|C0031842|C0205191|C0018684|C0220825|G0000000|C0243030|G0000000|C0449820|C0024109|C3263722|C0449820
"history of contact with a scabies patient, complaint of nocturnal itching, history of involvement of family members, presence of classical burrows on clinical examination, and presence of typical scabetic lesions like papules, nodules, or vesicles.","history contact scabies patient, complaint nocturnal itching, history involvement family members, presence classical burrows clinical examination, presence typical scabetic lesions papules, nodules, vesicles.",C0019664|C0332158|C0036262|C0030705|C0277786|C0240526|C0033774|C0019664|C1314939|C0015576|C0680022|C0150312|C0439858|C0332816|C0205210|G0000000|C0150312|C3538928|G0000000|C0221198|C0332563|C0028259|C0333262
"Tests included measures of verbal memory (Auditory Verbal Learning Test45), working memory (Memory Comparison Test46), attentional functioning (Stroop Color Word Test47), information processing (Letter Digit Substitution Test48), executive functioning (Concept Shifting Test,49 Categorical Word Fluency Test50), and psychomotor speed (Concept Shifting Test, Letter Digit Substitution Test).","Tests included measures verbal memory (Auditory Verbal Learning Test45), memory (Memory Comparison Test46), attentional functioning (Stroop Color Word Test47), processing (Letter Digit Substitution Test48), executive functioning (Concept Shifting Test,49 Categorical Word Fluency Test50), psychomotor speed (Concept Shifting Test, Letter Digit Substitution Test).",C0022885|C0332257|C0079809|C0439824|C0025260|C0439825|C0439824|C0013621|G0000000|C0025260|C0025260|C1707455|G0000000|C0004268|C0205245|G0000000|C0009393|C1705313|G0000000|C1709694|C1096774|C0582802|C1555721|G0000000|C0871735|C0205245|C0178566|C0333051|C0022885|C0683312|C1705313|C0870569|G0000000|G0000000|C0678536|C0178566|C0333051|C0022885|C1096774|C0582802|C1555721|C0022885
For intention and attitude higher scores indicate a more favorable position towards marijuana use.,For intention attitude scores favorable position marijuana use.,G0000000|C0162425|C0004271|C0449820|C3640814|C0733755|C0024808|C0042153
The primary outcome was the occurrence of any episode of microscopically confirmed vivax malaria over the 11 month observation period which classified the patient as a treatment failure.,The primary outcome occurrence episode microscopically confirmed vivax malaria 11 month observation period classified patient treatment failure.,G0000000|C0205225|C1274040|C0243132|C0332189|G0000000|C0521093|G0000000|C0024530|C0450371|C0332177|C0302523|C0439531|C0008902|C0030705|C0039798|C0231174
"At three years post-release, jail officials provided information from participants’ criminal records, including whether participants were arrested during four time periods: the first three months, three months to one year, one to two years, and two to three years post-release.","At post-release, jail officials provided participants’ criminal records, including participants arrested time periods: months, months year, years, post-release.",G0000000|C0687676|C0033168|C2347387|C1999230|G0000000|C0699726|C0034869|C0332257|C0679646|C0018790|C0040223|C0439531|C0439231|C0439231|C0439234|C0439234|C0687676
Relief from sleepiness was significantly better in the CPAP group.,Relief sleepiness CPAP group.,C0564405|C0013144|C0199451|C0441833
The primary end points were the cytokine and C-reactive protein levels.,The primary cytokine C-reactive protein levels.,G0000000|C0205225|C0079189|C0205332|C0033684|C0441889
"Outcomes including blood loss, operative time, complications, length of stay and pain were recorded.","Outcomes including blood loss, operative time, complications, length stay pain recorded.",C1274040|C0332257|C0005767|C1517945|C1882154|C0040223|C0009566|C1444754|G0000000|C0030193|C0034869
"The primary outcome is composite and defined by the absence of major complications until two years post-randomization, i.e.","The primary outcome composite defined absence major complications post-randomization, i.e.",G0000000|C0205225|C1274040|C0205199|C1704788|C0332197|C0205082|C0009566|C0687676|C0683454
"Main outcome measures Mortality, incidence of tuberculosis, and adverse events.","Main outcome measures Mortality, incidence tuberculosis, adverse events.",C0205225|C1274040|C0079809|C0026565|C0021149|C0041296|G0000000|C0441471
Total cholesterol and triglycerides were measured using standard enzymatic procedures.,Total cholesterol triglycerides measured standard enzymatic procedures.,C0439175|C0008377|C0041004|C0444706|C1442989|C0014442|C0025664
"We defined the key secondary efficacy endpoints as the proportion of participants with a 50% reduction (50% responder rate) or 75% reduction (75% responder rate) in 28-day seizure (all partial seizure) from baseline, with a reduction in the proportion of secondary generalized tonic-clonic (SGTC) from baseline (SGTC responder rate), and seizure-free in the last 28 days of treatment (seizure-free responder rate).","We defined key secondary efficacy endpoints proportion participants 50% reduction (50% responder rate) 75% reduction (75% responder rate) 28-day seizure (all partial seizure) baseline, reduction proportion secondary generalized tonic-clonic (SGTC) baseline (SGTC responder rate), seizure-free 28 days treatment (seizure-free responder rate).",G0000000|C1704788|G0000000|C0027627|C1280519|C2349179|C1709707|C0679646|C0450371|C0301630|C0450371|G0000000|C0871208|C0450371|C0301630|C0450371|G0000000|C0871208|C0450371|C0036572|G0000000|C0728938|C0036572|C0168634|C0301630|C1709707|C0027627|C0205246|C3543842|G0000000|C0168634|G0000000|G0000000|C0871208|C1299590|C0450371|C0439228|C0039798|C1299590|G0000000|C0871208
"Our review showed no statistically significant treatment effects either on social skills competences (positive value  =  better for the intervention group) (SMD 0.16; 95% CI −0.04 to 0.36; 5 trials, n  = 392 participants), on general behaviour (negative value  =  better for the intervention group) (SMD 0.00; 95% CI −0.21 to 0.21; 3 trials, n  = 358 participants), or on ADHD symptoms (negative value  =  better for the intervention group) (SMD −0.02; 95% CI −0.19 to 0.16; 6 trials, n  = 515 participants).","Our review statistically treatment effects social skills competences (positive  =  intervention group) (SMD 0.16; 95% CI −0.04 0.36; 5 trials,  = 392 participants), behaviour (negative  =  intervention group) (SMD 0.00; 95% CI −0.21 0.21; 3 trials,  = 358 participants), ADHD symptoms (negative  =  intervention group) (SMD −0.02; 95% CI −0.19 0.16; 6 trials,  = 515 participants).",G0000000|C0282443|C0038215|C0039798|C1280500|C0728831|C0678856|C0086035|C0439178|G0000000|C0886296|C0441833|C0700635|C0450371|C0450371|C0008107|G0000000|C0450371|G0000000|C0008976|G0000000|C0679646|C0004927|C0205160|G0000000|C0886296|C0441833|C0700635|C0450371|C0450371|C0008107|G0000000|C0450371|G0000000|C0008976|G0000000|C0679646|C1263846|C0683368|C0205160|G0000000|C0886296|C0441833|C0700635|G0000000|C0450371|C0008107|G0000000|C0450371|G0000000|C0008976|G0000000|C0679646
"Among college students, disclosure writing led to more fatigue and avoidance after 1 month (10) and to greater homesickness and negative affect after 2 to 3 months (15) than did control writing.","Among college students, disclosure writing led fatigue avoidance 1 month (10) homesickness negative affect 2 3 months (15) control writing.",G0000000|C0557806|C0038492|C0012625|C0043266|C1708698|C0015672|C0870186|G0000000|C0332177|C0450371|C0019871|C0205160|C0001721|G0000000|G0000000|C0439231|C0450371|C0243148|C0043266
"In order to define prognostic parameters for relapse and survival, variables regarding patients' characteristics were dichotomised in the following manner: age <50 or >50 years; juvenile GCT subtype vs adult GCT histology; tumour size measuring <10 or >10 cm; primary surgery at Mito centres or elsewhere; conservative vs radical surgery; laparoscopic vs laparotomic approach; complete staging vs incomplete staging; residual disease at first surgery vs no residual disease; execution of lymphadenectomy vs no lymph nodal dissection; stage I of disease vs advanced stage of disease; adjuvant treatment vs no postsurgery treatment.","In define prognostic parameters relapse survival, variables patients' characteristics dichotomised manner: age <50 >50 years; juvenile GCT subtype adult GCT histology; tumour size measuring <10 >10 cm; primary surgery Mito centres elsewhere; conservative radical surgery; laparoscopic laparotomic approach; complete staging incomplete staging; residual disease surgery residual disease; execution lymphadenectomy lymph nodal dissection; stage I disease advanced stage disease; adjuvant treatment postsurgery treatment.",G0000000|G0000000|C0220901|C0449381|C0035020|C0038952|C0439828|C0030705|C1521970|G0000000|G0000000|C0001779|C0450371|C0450371|C0439234|C3146221|C3538813|C0449560|C0001675|C3538813|C0019638|C0027651|C0456389|C0444706|C0450371|G0000000|C0205225|C0038894|C0002475|C0205099|G0000000|G0000000|C0302912|C0038894|C0031150|C0023038|C0449445|C0205197|C0332305|C0205257|C0332305|C1609982|C0012634|C0038894|C1609982|C0012634|C1278561|C0024203|C0024202|C0443268|C0012737|C0205390|C0021966|C0012634|C0205179|C0205390|C0012634|C0001551|C0039798|C0032790|C0039798
Secondary endpoints were health status measured by St George's Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation.,Secondary endpoints health status measured St George's Respiratory Questionnaire (SGRQ) time moderate severe COPD exacerbation.,C0027627|C2349179|C0018684|C0449438|C0444706|C0036056|G0000000|C0521346|C0034394|G0000000|C0040223|C0205081|C0205082|C0024117|G0000000
"For each imputation, a chain of linear regression equations was used to predict the missing data as a function of caregiver status (i.e., primary or secondary), treatment arm, acute stress at T1, and trait and state anxiety at T1.","For imputation, chain linear regression equations predict missing data function caregiver status (i.e., primary secondary), treatment arm, acute stress T1, trait anxiety T1.",G0000000|C2699638|C0337112|C0205132|C0684320|C0552449|G0000000|C1551393|C1511726|C0031843|C0085537|C0449438|C0683454|C0205225|C0027627|C0039798|C0446516|C0205178|C0038435|C0041403|C0599883|C0003467|C0041403
"This item had seven response categories, reflecting advances in staging the initiation of alcohol consumption (Werch, 2001), ranging from a strong precontemplation stage (will never try alcohol) to a maintenance stage (drinking for longer than 6 months).","This item response categories, reflecting advances staging initiation alcohol consumption (Werch, 2001), ranging strong precontemplation stage (will alcohol) maintenance stage (drinking 6 months).",G0000000|C1551338|C0871261|C0683312|C0558058|C0725066|C0332305|C0589507|C0001962|C0009830|G0000000|G0000000|C1514721|C0442821|G0000000|C0205390|G0000000|C0001962|C0024501|C0205390|C0001948|G0000000|C0439231
An ILI episode was defined as the period from the first day of ILI symptoms until the last day of ILI symptoms.,An ILI episode defined period day ILI symptoms day ILI symptoms.,G0000000|G0000000|C0332189|C1704788|C0439531|C0332173|G0000000|C0683368|C0332173|G0000000|C0683368
"Typically using educational or environmental changes to promote and facilitate changes in health behaviour, community-targeted interventions have attempted to modify the prevalence of one or more CVD risk factors (including hypertension) within specifically identified circumscribed communities, to reduce the overall CVD burden and improve population health outcomes [3,4].","Typically educational environmental promote facilitate health behaviour, community-targeted interventions attempted modify prevalence CVD risk factors (including hypertension) identified circumscribed communities, reduce CVD burden improve population health outcomes [3,4].",G0000000|C0587721|C0014406|C0033414|G0000000|C0018684|C0004927|C0009462|C0886296|C1516084|C0392747|C0033105|C0007222|C0035647|C1521761|C0332257|C0020538|C0205396|C1282914|C0009462|G0000000|C0007222|C2828008|G0000000|C0032659|C0018684|C1274040|G0000000
"The primary outcome measure was the duration of diarrhea, defined as the time from randomization until the last diarrheal stool, or as at least 12 h with no stool.","The primary outcome measure duration diarrhea, defined time randomization diarrheal stool, 12 stool.",G0000000|C0205225|C1274040|C0079809|C0449238|C0011991|C1704788|C0040223|C0034656|C0011991|C0015733|C0450371|C0015733
"Primary outcomes: Global severity and duration of illness SD = Standard deviation CI = Confidence interval Duration = days of illness Global severity = area under the time severity curve, with severity assessed by the WURSS-21 Because echinacea is thought to work through immune stimulation with early dosing important, we did a subgroup analysis on the 351 people who were enrolled within 24 hours of their first symptom (Table 2).","Primary outcomes: Global severity duration illness SD = Standard deviation CI = Confidence interval Duration = days illness Global severity = time severity curve, severity assessed WURSS-21 Because echinacea immune stimulation dosing important, subgroup analysis 351 people enrolled 24 hours symptom (Table 2).",C0205225|C1274040|C0205246|C0439793|C0449238|C0221423|C2699239|G0000000|C1442989|C0012727|C0008107|G0000000|C0237529|C1272706|C0449238|G0000000|C0439228|C0221423|C0205246|C0439793|G0000000|C0040223|C0439793|C0205134|C0439793|C1516048|C0450371|G0000000|C0752270|C0439662|C1292856|G0000000|C3898777|C1079230|C0002778|C1442061|C0027361|G0000000|C0450371|C0439227|C1457887|C0039224|G0000000
The majority of colon cancer survivors do not engage in adequate physical activity (12).,The majority colon cancer survivors engage adequate physical activity (12).,G0000000|C0680220|C0009368|C0006826|C0206194|G0000000|C0205410|C0031809|C0205177|C0450371
"There is no evidence from the accompanying cost effectiveness evaluation to contradict these findings.17 Paracetamol plus ibuprofen are being increasingly used at home and in primary and secondary care for the relief of fever and its associated symptoms Five previous trials of combined therapy mostly tested single doses for children in secondary care and reached conflicting conclusions In the first four hours, temperature is reduced faster and for longer in children given ibuprofen than in those given paracetamol In the first 24 hours, children given both drugs spent 4.4 hours less time with fever than those given paracetamol and 2.5 hours less time with fever than those given ibuprofen.","There evidence accompanying cost effectiveness evaluation contradict findings.17 Paracetamol ibuprofen increasingly primary secondary care relief fever symptoms Five previous trials combined therapy tested single doses children secondary care reached conflicting conclusions In hours, temperature reduced faster children ibuprofen paracetamol In 24 hours, children drugs spent 4.4 hours time fever paracetamol 2.5 hours time fever ibuprofen.",G0000000|C3887511|G0000000|C0010186|C1280519|C0220825|G0000000|C2607943|C0000970|C0020740|G0000000|C0205225|C0027627|C1947933|C0564405|C0015967|C0683368|C0205451|C0205156|C0008976|C0205195|C0039798|C0392366|C0037179|C0178602|C0008059|C0027627|C1947933|C2584321|C0009671|C1707478|G0000000|C0439227|C0005903|C0392756|C0015663|C0008059|C0020740|C0000970|G0000000|C0450371|C0439227|C0008059|C0013227|C0680968|G0000000|C0439227|C0040223|C0015967|C0000970|G0000000|C0439227|C0040223|C0015967|C0020740
"The patients were assessed for pain, tender point count, morning stiffness duration, fatigue, cardiovascular fitness, functional disability, and health-related quality of life (HRqOL).","The patients assessed pain, tender count, morning stiffness duration, fatigue, cardiovascular fitness, functional disability, health-related quality life (HRqOL).",G0000000|C0030705|C1516048|C0030193|C0234234|C0750480|C0332170|C0427008|C0449238|C0015672|C0007226|C1456706|C0205245|C0231170|C0018684|C0332306|C0376558|G0000000
"Baseline characteristics CGI-S clinical global impression-severity, ABC aberrant behavior checklist, PPVT peabody picture vocabulary test, EVT expressive vocabulary test, SRS social responsiveness scale, BASC behavioral assessment system for children Participants had a mean age of approximately 6 years and a mean CGI-S score of 4.4, which is between the categories of moderately ill (score of 4) and markedly ill (score of 5).","Baseline characteristics CGI-S clinical global impression-severity, ABC aberrant behavior checklist, PPVT peabody picture vocabulary test, EVT expressive vocabulary test, SRS social responsiveness scale, BASC behavioral assessment system children Participants age 6 CGI-S score 4.4, categories moderately ill (score 4) markedly ill (score 5).",C0168634|C1521970|C3639708|C0205210|C0205246|C0596764|C0152244|C0443127|C0004927|C1707357|G0000000|G0000000|C0441468|C0042926|C0022885|G0000000|C0185117|C0042926|C0022885|G0000000|C0728831|C0205342|C0175659|G0000000|C0004927|C1261322|C0449913|C0008059|C0679646|C0001779|G0000000|C3639708|C0449820|G0000000|C0683312|C0205081|C0231218|C0449820|G0000000|C0522501|C0231218|C0449820|G0000000
"There were also no differences in ICU mortality (40 versus 23.3%, P = 0.165), hospital mortality (43.3 versus 30%, P = 0.284), incidence of delirium (30 versus 40%, P = 0.472), self-extubation (3.3 versus 6.7%, P = 0.514), and psychological stress six months after ICU discharge.","There differences ICU mortality (40 versus 23.3%, P = 0.165), hospital mortality (43.3 versus 30%, P = 0.284), incidence delirium (30 versus 40%, P = 0.472), self-extubation (3.3 versus 6.7%, P = 0.514), psychological stress months ICU discharge.",G0000000|C1705241|C0021708|C0026565|C0450371|G0000000|C0450371|G0000000|C0019994|C0026565|C0450371|G0000000|C0450371|G0000000|C0021149|C0011206|C0450371|G0000000|C0450371|G0000000|C0036588|G0000000|G0000000|G0000000|G0000000|C0205486|C0038435|C0439231|C0021708|C0012621
"Considering time and intervention concurrency at the end of the fourth week compared to the pre-intervention conditions, weight, head circumference, the number of wet diapers, the frequency of defecation and the number breast feeding times of the infants of the fenugreek group significantly increased (P < 0.001).","Considering time intervention concurrency fourth week compared pre-intervention conditions, weight, head circumference, wet diapers, frequency defecation breast feeding times infants fenugreek increased (P < 0.001).",C0750591|C0040223|C0886296|C0205420|C0205438|C0332174|C1707455|C2347663|C0012634|C0005910|C0018670|C0332520|C0205381|C0180416|C0376249|C0011135|C0006141|C0204695|C0040223|C0021270|C0060207|C0205217|C0369773|G0000000|C1442061
"Asthma Morbidity was assessed by the number of asthma-related hospitalizations, school days missed due to asthma, and days with asthma symptoms, in addition to the Asthma Functional Morbidity Scale (alpha = .72; (42, 43)).","Asthma Morbidity assessed asthma-related hospitalizations, school days missed asthma, days asthma symptoms, addition Asthma Functional Morbidity Scale (alpha = .72; (42, 43)).",C0004096|C0026538|C1516048|C0004096|C0019993|C0036375|C0439228|C1705492|C0004096|C0439228|C0004096|C0683368|C0332287|C0004096|C0205245|C0026538|C0175659|C0439095|G0000000|C0450371|C0450371|C0450371
"At study entry and before each 2-week cycle of chemotherapy, patients had adverse event monitoring.","At study entry 2-week cycle chemotherapy, patients adverse event monitoring.",G0000000|C0557651|C1705654|C0332174|C1511572|C0013216|C0030705|G0000000|C0441471|C0150369
The Ages & Stages Questionnaires: Social Emotional (ASQ:SE) [86]: a screening tool to identify children who might be at risk for social and emotional difficulties.,The Ages & Stages Questionnaires: Social Emotional (ASQ:SE) [86]: screening tool identify children risk social emotional difficulties.,G0000000|C0001779|G0000000|C1306673|C0034394|C0728831|C0013987|C3476780|C0450371|C0220908|C0336791|G0000000|C0008059|C0035647|C0728831|C0013987|C1299586
"FMA-LLparetic: paretic lower limb score of the Fugl-Meyer assessment; BBS: Berg balance test; 6MWT: 6-minute walk test; K-MBI: Korean version of the Modified Barthel Index Our findings demonstrate that task-oriented circuit training for 90 minutes was as effective as individual physiotherapy (NDT) for 60 minutes for functional recovery in terms of lower-extremity motor control, balance, walking endurance and basic ADL.","FMA-LLparetic: paretic lower limb score Fugl-Meyer assessment; BBS: Berg balance test; 6MWT: 6-minute walk test; K-MBI: Korean version Modified Barthel Index Our findings demonstrate task-oriented circuit training 90 minutes effective individual physiotherapy (NDT) 60 minutes functional recovery terms lower-extremity motor control, balance, walking endurance basic ADL.",C2332774|G0000000|C0441994|C0015385|C0449820|G0000000|C1261322|G0000000|G0000000|C0014653|C0022885|G0000000|C0439232|C0080331|C0022885|C0597277|C1556095|C0333052|C0392747|G0000000|C0918012|G0000000|C2607943|G0000000|C3540678|G0000000|C0040607|C0450371|C0439232|C1280519|C0027361|C0949766|G0000000|C0450371|C0439232|C0205245|C0237820|C0233324|C0023216|C1513492|C0243148|C0014653|C0080331|C0518031|C1527178|C0001288
These messages lasted for 3 months and follow-ups continued for 6 months.,These messages lasted 3 months follow-ups continued 6 months.,G0000000|C0470166|C1517741|G0000000|C0332283|C0549178|G0000000
"The grade of inflammation in the sigmoid colon and stool weight correlated significantly (rho=0.53; p<0.001), and a positive correlation between the thickness of the collagen layer and stool weight (rho=0.34; p<0.05) was also found (fig 4 ▶).","The grade inflammation sigmoid colon stool weight correlated (rho=0.53; p<0.001), positive correlation thickness collagen layer stool weight (rho=0.34; p<0.05) (fig 4 ▶).",G0000000|C0441800|C0021368|C0227391|C0009368|C0015733|C0005910|C1707520|C0450371|C0369773|C0439178|C1707520|C1280412|C0009325|C0934502|C0015733|C0005910|C0450371|C0369773|C0349966|G0000000|G0000000
Serotonin levels will be evaluated in salivary samples using a competitive enzyme-linked immunosorbent assay.,Serotonin levels evaluated salivary samples competitive enzyme-linked immunosorbent assay.,C0036751|C0441889|C0220825|C0442040|C0370003|C0679932|C0014442|C0021075|C0005507
"Participants in the intervention group had a mean HbA1c value of 8.6% at baseline, which improved to a value of 7.8% at 6 months, for an adjusted change of -0.8 percentage points (P < .01).","Participants intervention HbA1c 8.6% baseline, improved 7.8% 6 months, adjusted change -0.8 percentage (P < .01).",C0679646|C0886296|G0000000|G0000000|C0168634|C0184511|G0000000|G0000000|C0439231|C0456081|C0392747|G0000000|C0439165|C0369773|G0000000|C0450371
A two-sided α = 0.05 level two-sample t-test will be used to determine if yoga is superior to education for the co-primary outcomes of pain and function.,A two-sided α = 0.05 level two-sample t-test determine yoga superior education co-primary outcomes pain function.,G0000000|C0205448|G0000000|C0441889|C0205448|C0871472|G0000000|C0043418|C1282910|C0013621|C3245499|C1274040|C0030193|C0031843
This study provides Class IV evidence that early compared to delayed treatment prolongs time to CDMS in CIS after 11 years.,This study Class IV evidence compared delayed treatment prolongs time CDMS CIS 11 years.,G0000000|C0557651|C0456387|C0022326|C3887511|C1707455|C0205421|C0039798|G0000000|C0040223|C0006746|C1504308|C0450371|C0439234
Oncologic outcome will be measured by R0 resection rate and the number of lymph nodes resected.,Oncologic outcome measured R0 resection rate lymph nodes resected.,C0205478|C1274040|C0444706|C1425688|C0015252|C0871208|C0024202|C0746922|C0015252
We additionally performed all analyses (post-hoc) using a less strict definition of two consecutive increases without an initial decrease.,We additionally performed analyses (post-hoc) strict definition consecutive increases initial decrease.,G0000000|G0000000|C0884358|C0002778|C0687676|G0000000|C1550452|C1707491|C0205217|C0205265|C0392756
"Failure to achieve adequate sedation (patient awakened or moved, interfered with completion of EEG, inadequate sedation and need to administration of other sedative drug) and procedure abortion due to serious adverse events, were considered as failure of sedation regimen.","Failure achieve adequate sedation (patient awakened moved, interfered completion EEG, inadequate sedation administration sedative drug) procedure abortion adverse events, considered failure sedation regimen.",C0231174|G0000000|C0205410|C0235195|C0030705|G0000000|C1269909|C0521102|C0205197|C0013819|C0205412|C0235195|C0001554|C0020592|C0013227|C0184661|C0156543|G0000000|C0441471|C0750591|C0231174|C0235195|C0040808
"Secondary outcomes included recovery rate, time-to-recovery, and weight gain and diarrhea longitudinal prevalence at OTP discharge.","Secondary outcomes included recovery rate, time-to-recovery, weight gain diarrhea longitudinal prevalence OTP discharge.",C0027627|C1274040|C0332257|C0237820|C0871208|C0040223|C0005910|C1517378|C0011991|C0205127|C0033105|C1418198|C0012621
"Eligible patients received baseline assessments including: maximal voluntary isometric contraction (MVIC), forced vital capacity (FVC), ALS functional rating scale revised (ALSFRS-R), the quality of life questionnaire short form 12 (SF-12), and muscle fatigue.","Eligible patients received baseline assessments including: maximal voluntary isometric contraction (MVIC), forced vital capacity (FVC), ALS functional rating scale revised (ALSFRS-R), quality life questionnaire short form 12 (SF-12), muscle fatigue.",C1548635|C0030705|C1514756|C0168634|C1261322|C0332257|C0205289|C0439656|G0000000|C1140999|G0000000|C0441722|C0442732|C1516240|C3714541|G0000000|C0205245|C0871208|C0175659|C1527075|C0205090|C0332306|C0376558|C0034394|C1282927|C0348078|C0450371|C0037712|C0026845|C0015672
"Adverse events were reported by the participants on their study calendar or via telephone, as has been described previously [8].","Adverse events reported participants study calendar telephone, [8].",G0000000|C0441471|C0684224|C0679646|C0557651|C1516147|C0039457|G0000000
"The levels of inflammatory factors, the clinical effects and the duration of mechanical ventilation of the two groups were statistically analyzed.","The levels inflammatory factors, clinical effects duration mechanical ventilation statistically analyzed.",G0000000|C0441889|C0333348|C1521761|C0205210|C1280500|C0449238|C0443254|C0035203|C0038215|C0936012
"Therefore, the aim of the present study was to identify the factors associated with corticosteroid use and its impact on intensive care unit (ICU) mortality using propensity score (PS) matching analysis in ICU patients with influenza pneumonia.","Therefore, aim study identify factors corticosteroid impact intensive care unit (ICU) mortality propensity score (PS) matching analysis ICU patients influenza pneumonia.",G0000000|C1947946|C0557651|G0000000|C1521761|C0001617|C1825598|C0162425|C1947933|C0439148|C0021708|C0026565|G0000000|C0449820|C0242397|C0150103|C0002778|C0021708|C0030705|C0021400|C0032285
"In addition, for patients who smoked, Dean provided 12 months of post-intervention utilization data on three core components of the EMR-based tobacco dependence treatment intervention: tobacco dependence Smartset usage, tobacco cessation medication prescription rates, and smoking cessation counseling billed.","In addition, patients smoked, Dean provided 12 months post-intervention utilization data core components EMR-based tobacco dependence treatment intervention: tobacco dependence Smartset usage, tobacco cessation medication prescription rates, smoking cessation counseling billed.",G0000000|C0332287|C0030705|C0037366|G0000000|C1999230|C0450371|C0439231|C2347647|C0042153|C1511726|C0444669|C0449432|C0034519|C0040329|C0011546|C0039798|C0886296|C0040329|C0011546|G0000000|C0457083|C0040329|C1880019|C0013227|C0033080|C0871208|C0037369|C1880019|C0010210|C0004895
Intention-to-treat analysis among all live births showed no impact of the intervention on neonatal mortality.,Intention-to-treat analysis live births impact intervention neonatal mortality.,C0162425|C0002778|C1548795|C0005615|C1825598|C0886296|C1552240|C0026565
"A stratified analysis of the effect of steroid treatment on outcome, after controlling for possible confounding by the presence or absence of neutropenia at admission (as a marker of severity), still found evidence of an increased risk of death (Mantel-Haenszel summary OR, 4.11; 95% CI, 1.14–14.83; P = .027).","A stratified analysis steroid treatment outcome, controlling confounding presence absence neutropenia admission (as marker severity), evidence increased risk death (Mantel-Haenszel summary OR, 4.11; 95% CI, 1.14–14.83; P = .027).",G0000000|C0205363|C0002778|C0038317|C0039798|C1274040|C2239193|G0000000|C0150312|C0332197|C0023530|C0184666|G0000000|C0005516|C0439793|C3887511|C0205217|C0035647|C0011065|G0000000|C1552616|G0000000|C0450371|C0450371|C0008107|G0000000|C0369773|G0000000|C1442061
The proteinuria component of the composite was formulated to require a large change (≥50% reduction) to increase the likelihood that changes classified as a positive outcome are clinically relevant and to reduce the influence of small perturbations as might be induced by minor hemodynamic changes.,The proteinuria component composite formulated require change (≥50% reduction) increase likelihood classified positive outcome clinically relevant reduce influence perturbations induced minor hemodynamic changes.,G0000000|C0033687|C0449432|C0205199|G0000000|G0000000|C0392747|G0000000|C0301630|C0442805|C0033204|C0008902|C0439178|C1274040|G0000000|C2347946|G0000000|C4054723|C0332453|C0205263|C0026193|C0019010|C0392747
"The secondary hypotheses regarding the effect of active CES, relative to sham CES, on pain intensity, pain interference, pain quality, pain beliefs, and pain coping strategies were tested using a series of repeated measures ANOVA, with the dependent variables being the Pain Intensity and Interference subscales of the BPI, the Pain subscale of the SF-36, the Paroxysmal, Deep, and Surface subscales of the PQAS, and the Maladaptive and Adaptive Coping subscales of the Two-Item Measures of Pain Beliefs and Coping Strategies.","The secondary hypotheses active CES, relative sham CES, pain intensity, pain interference, pain quality, pain beliefs, pain coping strategies tested series repeated measures ANOVA, dependent variables Pain Intensity Interference subscales BPI, Pain subscale SF-36, Paroxysmal, Deep, Surface subscales PQAS, Maladaptive Adaptive Coping subscales Two-Item Measures Pain Beliefs Coping Strategies.",G0000000|C0027627|C1512571|C0205177|C0265493|C0080103|C0068899|C0265493|C0030193|C0522510|C0030193|C0521102|C0030193|C0332306|C0030193|C0004951|C0030193|C0009967|C0679199|C0392366|C0205549|C0205341|C0079809|G0000000|C0851827|C0439828|C0030193|C0522510|C0521102|G0000000|C1443145|C0030193|G0000000|C0037712|C0205311|C0205125|C0205148|G0000000|G0000000|C0233532|C0231193|C0009967|G0000000|C0205448|C0079809|C0030193|C0004951|C0009967|C0679199
"According to a previous study [20], we anticipated that a mean frequency of migraine attacks in the non-acupoint group is 3.7 whereas, in the individualized acupoint group, it is 2.7.","According previous study [20], anticipated frequency migraine attacks non-acupoint 3.7 whereas, individualized acupoint group, 2.7.",C0680240|C0205156|C0557651|C0450371|C3840775|C0376249|C0149931|C1261512|C1518422|G0000000|G0000000|C1881197|C0001302|C0441833|G0000000
Efficacy was assessed by the International Index of Erectile Function (IIEF) questionnaire that includes questions on achieving (Q3) and maintaining (Q4) an erection as well as a global efficacy question (GEQ).,Efficacy assessed International Index Erectile Function (IIEF) questionnaire includes questions achieving (Q3) maintaining (Q4) erection global efficacy question (GEQ).,C1280519|C1516048|C1512888|C0918012|C0030847|C0031843|C3641331|C0034394|C0332257|C1522634|G0000000|C4053565|C0024501|C4053565|C0030847|C0205246|C1280519|C1522634|G0000000
"In contrast, among girls the counseling intervention did not improve quit rates above that seen in the control group at either time point (6.6% vs 7.0% at 3 months and 16.6% vs 15.5% at 12 months).","In contrast, girls counseling intervention improve quit rates control time (6.6% 7.0% 3 months 16.6% 15.5% 12 months).",G0000000|C0009924|C0870604|C0010210|C0886296|G0000000|C0748223|C0871208|C0243148|C0040223|G0000000|G0000000|G0000000|C0439231|C0450371|C0450371|C0450371|C0439231
The primary outcome was the time to occurrence of major or clinically relevant non–major (CRNM) bleeding.,The primary outcome time occurrence major clinically relevant non–major (CRNM) bleeding.,G0000000|C0205225|C1274040|C0040223|C0243132|C0205082|G0000000|C2347946|G0000000|G0000000|C0019080
Adverse events were monitored throughout the study.,Adverse events monitored study.,G0000000|C0441471|C0030695|C0557651
"Agitation, passivity, engagement, affect, and mood assessed from video-recordings and real time observations during baseline, intervention, random times outside of intervention, and one week post-intervention.","Agitation, passivity, engagement, affect, mood assessed video-recordings real time observations baseline, intervention, random times intervention, week post-intervention.",C0085631|C0679170|C0425152|C0001721|C0026516|C1516048|C0042650|C0237400|C0040223|C0302523|C0168634|C0886296|C0034656|C0040223|C0886296|C0332174|C2347647
Maternal sensitivity and child responsiveness are selected as primary outcome variables because of their specific relevance to the development of secure attachment behaviors.,Maternal sensitivity child responsiveness selected primary outcome variables specific relevance development secure attachment behaviors.,C2347083|C0020517|C0008059|C0205342|C1707391|C0205225|C1274040|C0439828|C0205369|C2347946|C0243107|C0659450|C0185023|C0004927
Time to progression was the duration between the first day of study treatment and date of progression.,Time progression duration day study treatment progression.,C0040223|C0242656|C0449238|C0332173|C0557651|C0039798|C0242656
"These findings stand in marked contrast to data from Indonesia where P. vivax chloroquine-resistance manifests as frequent failure to clear parasites by day 4 [6,29-31] and recurrence rates by day 28 approximate 50% [29-31] or higher [6].","These findings stand marked contrast data Indonesia P. vivax chloroquine-resistance manifests frequent failure parasites day 4 [6,29-31] recurrence rates day 28 approximate 50% [29-31] [6].",G0000000|C2607943|C0596013|C0522501|C0009924|C1511726|C0021247|C0369773|G0000000|C0008269|C0205319|C0332183|C0231174|C0030498|C0332173|G0000000|C0450371|C0034897|C0871208|C0332173|C0450371|C0332232|C0450371|C0450371|G0000000
"The cosmetic result after 6 weeks, 3 and 6 months, and 1 year is assessed by eliciting a patient satisfaction score on a 0 (= very unsatisfactory) to 10 (= very satisfactory) Likert scale.","The cosmetic result 6 weeks, 3 6 months, 1 assessed eliciting patient satisfaction score 0 (= unsatisfactory) 10 (= satisfactory) Likert scale.",G0000000|C0010164|C1274040|G0000000|C0439230|G0000000|G0000000|C0439231|G0000000|C1516048|C0449265|C0030705|C0242428|C0449820|G0000000|G0000000|C0439856|C0450371|G0000000|C0205410|G0000000|C0175659
"Future studies on the intervention could consider examining secondary outcomes that may occur as a result from the intervention/improvement in social skills (i.e., cognitive functioning, communication skills).","Future studies intervention examining secondary outcomes occur result intervention/improvement social skills (i.e., cognitive functioning, communication skills).",C0016884|C0947630|C0886296|C0332128|C0027627|C1274040|C1709305|C1274040|C0886296|C0728831|C0678856|C0683454|C1516691|C0205245|C0009452|C0678856
Acceptability of the intervention Rating system was 1 = strongly disagree to 7 = strongly agree This study sought to test an audit and facilitated feedback intervention to improve the implementation of healthy eating and physical activity-promoting policies and practices in the childcare setting.,Acceptability intervention Rating system 1 = disagree 7 = agree This study sought test audit facilitated feedback intervention improve implementation healthy eating physical activity-promoting policies practices childcare setting.,C0814633|C0886296|C0871208|C0449913|G0000000|G0000000|C3641828|G0000000|G0000000|C3641827|G0000000|C0557651|G0000000|C0022885|C1704774|G0000000|C0015744|C0886296|G0000000|C1708476|C3898900|C0013470|C0031809|C0205177|C0242456|C0237607|C0008067|C0542559
"On the assumption that 20% of participants may be lost to follow-up and that 80% of participants entering rehabilitation achieve basic independent walking [1], there are likely to be 84 participants with ""quality of walking"" data at 6 months.","On assumption 20% participants lost follow-up 80% participants entering rehabilitation achieve basic independent walking [1], 84 participants ""quality walking"" data 6 months.",G0000000|G0000000|C0450371|C0679646|C0745777|C0589120|C0450371|C0679646|C1522196|C0034991|G0000000|C1527178|C0085862|C0080331|G0000000|C0450371|C0679646|C0332306|C0080331|C1511726|G0000000|C0439231
"In this report, we described a systemic evaluation of the association of green tea consumption with risk of all-cause, CVD, and cancer mortality in two large prospective cohort studies, the Shanghai Men's Health Study (SMHS) and the Shanghai Women's Health Study (SWHS).","In report, systemic evaluation association green tea consumption risk all-cause, CVD, cancer mortality prospective cohort studies, Shanghai Men's Health Study (SMHS) Shanghai Women's Health Study (SWHS).",G0000000|C0684224|C0205373|C0220825|C0004083|C0332583|C0039400|C0009830|C0035647|C0015127|C0007222|C0006826|C0026565|C0023981|C0599755|C0947630|G0000000|C0025266|C0018684|C0557651|C1824631|G0000000|C0043210|C0018684|C0557651|G0000000
Clinical responses were evaluated in 56 patients.,Clinical responses evaluated 56 patients.,C0205210|C0871261|C0220825|C0450371|C0030705
Patients continue to be followed for overall survival.,Patients continue survival.,C0030705|C0549178|C0038952
"Tertiary outcomes, evaluated at day 28 after randomisation, included ICU and hospital length of stay, and hospital mortality.","Tertiary outcomes, evaluated day 28 randomisation, included ICU hospital length stay, hospital mortality.",C0205372|C1274040|C0220825|C0332173|C0450371|C0034656|C0332257|C0021708|C0019994|C1444754|G0000000|C0019994|C0026565
"A ≥32-point change in IBDQ score is considered to be a clinically significant response (Hlavaty et al., 2006), and in our sample, the mean IBDQ score in the active intervention group increased by 44.25 points, while the increase was only 19 points in the attention control group (not clinically significant).","A ≥32-point change IBDQ score considered clinically response (Hlavaty al., 2006), sample, IBDQ score active intervention increased 44.25 points, increase 19 attention control (not clinically significant).",G0000000|G0000000|C0392747|G0000000|C0449820|C0750591|G0000000|C0871261|G0000000|C0202311|G0000000|C0370003|G0000000|C0449820|C0205177|C0886296|C0205217|C0450371|C1552961|C0442805|C0450371|C0004268|C0243148|C1518422|G0000000|C0237881
CYP2C19 PM status interacts significantly with environmental risk factors in modifying susceptibility to squamous cell carcinoma of the head and neck [30].,CYP2C19 PM status interacts environmental risk factors modifying susceptibility squamous cell carcinoma head neck [30].,G0000000|C0030266|C0449438|G0000000|C0014406|C0035647|C1521761|C0392747|C0012655|C1182670|C0007634|C0007097|C0018670|C0027530|C0450371
"We compared the number of patients diagnosed as having a recurrence, the time to onset of recurrence after curative surgery, and the time until second-line therapy was started after the confirmed diagnosis of recurrence.","We compared patients diagnosed recurrence, time onset recurrence curative surgery, time second-line therapy started confirmed diagnosis recurrence.",G0000000|C1707455|C0030705|C0011900|C0034897|C0040223|C0206132|C0034897|C1880198|C0038894|C0040223|C0205436|C0039798|C1272689|C0521093|C0011900|C0034897
"The results were controlled after 3, 6, 9, 12 and 18 weeks.","The controlled 3, 6, 9, 12 18 weeks.",G0000000|C2587213|G0000000|G0000000|G0000000|C0450371|C0450371|C0439230
"An intention to treat analysis showed that there was no statistically significant difference in the asthma severity score (ASS) at 2 hours between the two groups (median (IQR) 6 (6, 8) and 6.5 (5, 8) for salbutamol and aminophylline respectively, p=0.93).","An intention treat analysis statistically difference asthma severity score (ASS) 2 hours (median (IQR) 6 (6, 8) 6.5 (5, 8) salbutamol aminophylline respectively, p=0.93).",G0000000|C0162425|C0087111|C0002778|C0038215|C1705241|C0004096|C0439793|C0449820|C0324145|G0000000|C0439227|C0549183|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0001927|C0002575|G0000000|C0369773
"Secondary outcomes included proportion of patients presenting within 24 hours of fever onset, referral rates up to day 7, health outcome by day 3 and 7, compliance to treatment and mortality up to day 28.","Secondary outcomes included proportion patients 24 hours fever onset, referral rates day 7, health outcome day 3 7, compliance treatment mortality day 28.",C0027627|C1274040|C0332257|C1709707|C0030705|C0450371|C0439227|C0015967|C0206132|C0034927|C0871208|C0332173|G0000000|C0018684|C1274040|C0332173|G0000000|G0000000|C0009563|C0039798|C0026565|C0332173|C0450371
"Our secondary objective is to measure intermediate indicators such as knowledge and hygiene, feeding and stimulation practices that can help us model the pathways through which the different interventions might have an effect on child growth and development.","Our secondary objective measure intermediate indicators knowledge hygiene, feeding stimulation practices model pathways interventions child growth development.",G0000000|C0027627|C0018017|C0079809|C0205103|C0021212|C0376554|C0020405|C0204695|C1292856|C0237607|C3161035|C1704259|C0886296|C0008059|C0018270|C0243107
Self-reported and blood chemistry TEAEs were sporadic with no identifiable trends; the exception was 1 participant with a family history of Crohn disease who was sensitive to DHA supplementation.,Self-reported blood chemistry TEAEs sporadic identifiable trends; exception 1 participant family history Crohn disease sensitive DHA supplementation.,C0681906|C0005767|C0007996|G0000000|C0205422|C0205396|C0040833|C1554961|G0000000|C0679646|C0015576|C0019664|C0010346|C0012634|C0020517|C0142831|C0242297
"Safety end points included length of hospital stay and, 1 and 3 months after discharge, respiratory complications, ICU care, death, and healthcare utilization.","Safety included length hospital stay and, 1 3 months discharge, respiratory complications, ICU care, death, healthcare utilization.",C0036043|C0332257|C1444754|C0019994|G0000000|G0000000|G0000000|G0000000|C0439231|C0012621|C0521346|C0009566|C0021708|C1947933|C0011065|C0086388|C0042153
Both class frequencies were similarly effective for reducing pain and improving back-related function.,Both class frequencies effective reducing pain improving back-related function.,G0000000|C0456387|C0439603|C1280519|C0392756|C0030193|C1272745|C0004600|C0031843
"Secondary outcome measures included birth size, gestational age, and mode of delivery.","Secondary outcome measures included birth size, gestational age, mode delivery.",C0027627|C1274040|C0079809|C0332257|C0005615|C0456389|C0439671|C0001779|C1513371|C0011209
Sufficient clinical data for reliable classification of seizure outcome was available in 76 patients.,Sufficient clinical data reliable classification seizure outcome 76 patients.,C0205410|C0205210|C1511726|C3858758|C0008902|C0036572|C1274040|C0450371|C0030705
"However, vaccine uptake was poor.","However, vaccine uptake poor.",G0000000|C0042210|C0243144|C0032854
"Symptoms of shortness of breath, cough, wheeze and sputum production, reliever inhaler use and peak expiratory flow rate were analysed.","Symptoms shortness breath, cough, wheeze sputum production, reliever inhaler peak expiratory flow rate analysed.",C0683368|C1282927|C0225386|C0010200|C0043144|C0038056|C0033268|G0000000|C0021461|C0444505|C0231800|C0806140|C0871208|G0000000
The duration on total parenteral nutrition was significantly longer in the nonstented group.,The duration total parenteral nutrition nonstented group.,G0000000|C0449238|C0439175|C0030547|C0028707|G0000000|C0441833
Acceptability was also assessed by calculating from the application log files the number of days participants used the application during the self-monitoring period.,Acceptability assessed calculating application log files days participants application self-monitoring period.,C0814633|C1516048|C1441506|C0185125|C1708728|C0016094|C0439228|C0679646|C0185125|C0588436|C0439531
One such factor might be the severity of postoperative pain.,One factor severity postoperative pain.,C0205447|C1521761|C0439793|C0032790|C0030193
Determinants of serum ferritin at 34–36 weeks gestation The overall proportion of women with low plasma zinc concentrations (<60 µg/dl) at recruitment (mean gestation = 13.0 weeks) was 70.9% (61/86).,Determinants serum ferritin 34–36 weeks gestation The proportion women low plasma zinc concentrations (<60 µg/dl) recruitment (mean gestation = 13.0 weeks) 70.9% (61/86).,C1521761|C0229671|C0015879|G0000000|C0439230|C0032961|G0000000|C1709707|C0043210|C0205251|C0032105|C0043481|C0086045|C0450371|G0000000|C2949735|C0444504|C0032961|G0000000|C0450371|C0439230|C0450371|C0450371
"Adverse events, vital signs and clinical laboratory tests were monitored for safety.","Adverse events, vital signs clinical laboratory tests monitored safety.",G0000000|C0441471|C0442732|C0220912|C0205210|C0022877|C0022885|C0030695|C0036043
"No RCTs looking at medication adherence or BP self-monitoring have been designed specifically for people in SSA, especially for those at high risk for future stroke.","No RCTs medication adherence BP self-monitoring designed people SSA, risk future stroke.",G0000000|G0000000|C0013227|C1510802|C0037623|C0588436|C1707689|C0027361|G0000000|C0035647|C0016884|C0038454
"The definitive diagnosis of burn wound infection was made only by wound biopsy, the single important sign of burn wound infection being the presence of microbial organisms in unburned viable tissue.","The definitive diagnosis burn wound infection wound biopsy, single sign burn wound infection presence microbial organisms unburned viable tissue.",G0000000|C0443196|C0011900|C0006434|C0043250|C0009450|C0043250|C0005558|C0037179|C0311392|C0006434|C0043250|C0009450|C0150312|C0599840|C0029235|G0000000|C0443348|C0040300
"Changes in the Quality of Life (QoL), Mood, Fatigue, Stress, and Cortisol Levels Abbreviations: POMS, Profile of Mood States; Post, postintervention; Pre, preintervention.","Changes Quality Life (QoL), Mood, Fatigue, Stress, Cortisol Levels Abbreviations: POMS, Profile Mood States; Post, postintervention; Pre, preintervention.",C0392747|C0332306|C0376558|C0518214|C0026516|C0015672|C0038435|C0020268|C0441889|C0000723|C0451394|C1979963|C0026516|C1301808|C0687676|G0000000|C0332152|C2347663
"Serum electrolytes, Ca, Mg, and PO4 were drawn within 24h of every seizure occurrence.","Serum electrolytes, Ca, Mg, PO4 drawn 24h seizure occurrence.",C0229671|C0013832|C3887642|C0026410|C1418945|C0013113|G0000000|C0036572|C0243132
"Some more recent nutritional intervention studies in hip fracture patients showed promising effects on postoperative outcome, such as fewer complications and shorter length of hospital stay, but again most studies were powered only for evaluating changes in blood parameters [18,19,20].","Some nutritional intervention studies hip fracture patients promising effects postoperative outcome, fewer complications shorter length hospital stay, studies powered evaluating blood parameters [18,19,20].",G0000000|C1521739|C0886296|C0947630|C0019552|C0016658|C0030705|C1555307|C1280500|C0032790|C1274040|C0205388|C0009566|C1282927|C1444754|C0019994|G0000000|C0947630|C0032863|C0220825|C0005767|C0449381|C0450371
This form was countersigned by a family member or friend to corroborate self-report.,This form countersigned family friend corroborate self-report.,G0000000|C0348078|G0000000|C0015576|C0079382|G0000000|C0681906
"Ninety-day abstinence rates for drinking at 3 months, 6 months, and 12 months were 28%, 32% and 32% for the placebo gum condition and were 45%, 38%, and 43% for the active gum condition.","Ninety-day abstinence rates drinking 3 months, 6 months, 12 months 28%, 32% 32% placebo gum condition 45%, 38%, 43% active gum condition.",C3816959|C3843422|C0871208|C0001948|G0000000|C0439231|G0000000|C0439231|C0450371|C0439231|C0450371|C0450371|C0450371|C0032042|C0017562|C0012634|C0450371|C0450371|C0450371|C0205177|C0017562|C0012634
"Regular assessment of knowledge, attitudes and practices on MIYCN will be done, coupled with assessments of nutritional status of the mother-child pairs and diarrhea morbidity for the children.","Regular assessment knowledge, attitudes practices MIYCN done, coupled assessments nutritional status mother-child pairs diarrhea morbidity children.",C0205272|C1261322|C0376554|C0004271|C0237607|G0000000|G0000000|C1948027|C1261322|C1521739|C0449438|C0260023|C1709450|C0011991|C0026538|C0008059
"Each children’s weight, temperature, respiratory rate, SpO2 in room air (determined by pulse oximeter, Siemens), heart rate, CS Score and hydration status were recorded.","Each children’s weight, temperature, respiratory rate, SpO2 air (determined pulse oximeter, Siemens), heart rate, CS Score hydration status recorded.",G0000000|G0000000|C0005910|C0005903|C0521346|C0871208|G0000000|C0001861|C0680730|C0232117|C0182117|C1551054|C0018787|C0871208|C0010182|C0449820|C1321013|C0449438|C0034869
State anxiety score (STAI) and VAS pain rating post-biopsy were analyzed using analysis of covariance (ANCOVA) adjusted for the baseline score.,State anxiety score (STAI) VAS pain rating post-biopsy analyzed analysis covariance (ANCOVA) adjusted baseline score.,C1301808|C0003467|C0449820|C0683457|C0042815|C0030193|C0871208|C0687676|C0936012|C0002778|G0000000|C0814908|C0456081|C0168634|C0449820
"The primary endpoint was reached in 47 of the first 100 patients: 34 experienced distant intracranial failure only, while in 13 patients it was accompanied by local failure (Figure 2).","The primary endpoint reached 47 100 patients: 34 experienced distant intracranial failure only, 13 patients accompanied local failure (Figure 2).",G0000000|C0205225|C2349179|C2584321|C0450371|C1442061|C0030705|C0450371|C0237607|C0443203|C0524466|C0231174|C0205171|C0450371|C0030705|G0000000|C0205276|C0231174|G0000000|G0000000
"The lesions of 109 patients (84.5%) were completely healed without any complications, 5 patients (3.9%) had secondary lesions and 15 patients (11.6%) had functional limitations.","The lesions 109 patients (84.5%) completely healed complications, 5 patients (3.9%) secondary lesions 15 patients (11.6%) functional limitations.",G0000000|C0221198|C1442061|C0030705|C0450371|C0205197|C0205249|C0009566|G0000000|C0030705|G0000000|C0027627|C0221198|C0450371|C0030705|C0450371|C0205245|C0449295
"Cluster-specific malaria case incidence and cluster-specific malaria infection prevalence plotted against cluster-specific phenotypic resistance (bioassay mortality after standard exposure to deltamethrin) and against cluster-specific Vgsc-1014F allele frequency for 2012, 2013, and 2014 in Galabat, Sudan.","Cluster-specific malaria incidence cluster-specific malaria infection prevalence plotted cluster-specific phenotypic resistance (bioassay mortality standard exposure deltamethrin) cluster-specific Vgsc-1014F allele frequency 2012, 2013, 2014 Galabat, Sudan.",C1555715|C0024530|C0021149|C1555715|C0024530|C0009450|C0033105|G0000000|C1555715|C0031437|C0237834|C0005507|C0026565|C1442989|C0274281|C0057233|C1555715|G0000000|C0002085|C0376249|G0000000|G0000000|G0000000|G0000000|C0038642
"Enumeration of the CD38 activation marker on total CD4+ and CD8+ T-cells, as well as on naïve, memory and effector cell subsets, will be performed by eight-color flow cytometry.","Enumeration CD38 activation marker total CD4+ CD8+ T-cells, naïve, memory effector cell subsets, performed eight-color flow cytometry.",C1707927|G0000000|C1879547|C0005516|C0439175|C0285590|C0285590|C0039194|G0000000|C0025260|G0000000|C0007634|C1515021|C0884358|C0205454|C0806140|C0814048
"Thus, TUDD for the quality of life scores is defined as the time from randomisation to the first observation of a definitive deterioration of the QLQ-C30 score or the time from randomisation to death.","Thus, TUDD quality life scores defined time randomisation observation definitive deterioration QLQ-C30 score time randomisation death.",G0000000|G0000000|C0332306|C0376558|C0449820|C1704788|C0040223|C0034656|C0302523|C0443196|C0868945|G0000000|C0449820|C0040223|C0034656|C0011065
"There was no difference in weight gain velocity, weight-for-age z-scores or Body Mass Index z-scores.","There difference weight gain velocity, weight-for-age z-scores Body Mass Index z-scores.",G0000000|C1705241|C0005910|C1517378|C0439830|C0005910|C0871421|C0242821|C0577559|C0918012|C0871421
"The Fugl-Meyer Upper Extremity Test (UE-FM) [59–61], the Rancho Los Amigos Functional Test for the upper extremity (UE-FT) [62], and the Box and Block Test (BBT) [63] were used for upper limb assessments.","The Fugl-Meyer Upper Extremity Test (UE-FM) [59–61], Rancho Los Amigos Functional Test upper extremity (UE-FT) [62], Box Block Test (BBT) [63] upper limb assessments.",G0000000|G0000000|C1282910|C0015385|C0022885|C3540627|G0000000|G0000000|G0000000|C1823184|C0205245|C0022885|C1282910|C0015385|C1881534|C0450371|C0179400|C0028778|C0022885|G0000000|C0450371|C1282910|C0015385|C1261322
The criterion for judging the effectiveness of treatment was the complete disappearance of visible lesions and itching at day 14.,The criterion judging effectiveness treatment complete disappearance visible lesions itching day 14.,G0000000|C0243161|C0221191|C1280519|C0039798|C0205197|G0000000|C0205379|C0221198|C0033774|C0332173|C0450371
"The women in the intervention group were 6.75 times more likely to have had a mammogram, 12.16 times more likely to have had a clinical breast examination, and 20.06 times more likely to have performed breast self-examination compared with women in the comparison group.","The women intervention 6.75 times mammogram, 12.16 times clinical breast examination, 20.06 times performed breast self-examination compared women comparison group.",G0000000|C0043210|C0886296|C0450371|C0040223|C0024671|C0450371|C0040223|C0205210|C0006141|G0000000|C0450371|C0040223|C0884358|C0006141|C0080142|C1707455|C0043210|C1707455|C0441833
"Treatment success, treatment failure and patient assessment of the effectiveness of the study medication were also measured.","Treatment success, treatment failure patient assessment effectiveness study medication measured.",C0039798|C0597535|C0039798|C0231174|C0030705|C1261322|C1280519|C0557651|C0013227|C0444706
"Other transplantation outcomes, including relapse rates, mortality unrelated to relapse, and rates of acute GVHD, were also similar with the two types of grafts, except that peripheral-blood stem-cell transplants were associated with better engraftment and bone marrow transplants with less extensive chronic GVHD.","Other transplantation outcomes, including relapse rates, mortality unrelated relapse, rates acute GVHD, types grafts, peripheral-blood stem-cell transplants engraftment bone marrow transplants extensive chronic GVHD.",G0000000|C0040732|C1274040|C0332257|C0035020|C0871208|C0026565|C0445356|C0035020|C0871208|C0205178|G0000000|C0332307|C0332835|C0229664|C0038250|C0332835|C0301944|C0262950|C0086590|C0332835|C0205231|C0205191|G0000000
A secondary goal was to investigate whether the type and amount of other intervention services and interventionist-rated caregiver quality of participation in the intervention or caregiver-rated adherence and competence predicted treatment outcomes.,A secondary goal investigate type amount intervention services interventionist-rated caregiver quality participation intervention caregiver-rated adherence competence predicted treatment outcomes.,G0000000|C0027627|C0018017|C1292732|C0332307|C1265611|C0886296|C0557854|C0871208|C0085537|C0332306|C0679823|C0886296|C0085537|C1510802|C0086035|C0681842|C0039798|C1274040
"The study was powered for its primary outcomes (micronutrient status), which are not reported here.","The study powered primary outcomes (micronutrient status), reported here.",G0000000|C0557651|C0032863|C0205225|C1274040|C0040577|C0449438|C0684224|G0000000
Our primary outcome will be lower-extremity muscle strength at hospital discharge.,Our primary outcome lower-extremity muscle strength hospital discharge.,G0000000|C0205225|C1274040|C0023216|C0026845|C0237897|C0019994|C0012621
"Thus, standard urine sampling for THC metabolites could not be easily used as a measure of abstinence.","Thus, standard urine sampling THC metabolites easily measure abstinence.",G0000000|C1442989|C0042036|C0441621|C0039663|C0870883|C0332219|C0079809|C3843422
"The BODE index was determined at this time using the variables identified in this baseline evaluation, as previously described [16].","The BODE determined time variables identified baseline evaluation, [16].",G0000000|G0000000|G0000000|C0040223|C0439828|C0205396|C0168634|C0220825|C0450371
Results: There were no clinically relevant or statistically significant changes in the active quality of life score.,Results: There clinically relevant statistically active quality life score.,C1274040|G0000000|G0000000|C2347946|C0038215|C0205177|C0332306|C0376558|C0449820
"We will register potential side effects such as: fever, headache, nausea, vomiting, allergic reactions, anaphylaxis and thromboembolic complications (deep venous thrombosis, acute myocardial infarction and pulmonary embolism) [40].","We register potential effects as: fever, headache, nausea, vomiting, allergic reactions, anaphylaxis thromboembolic complications (deep venous thrombosis, acute myocardial infarction pulmonary embolism) [40].",G0000000|G0000000|C3245505|C1280500|G0000000|C0015967|C0018681|C0027497|C0042963|C0700624|C0443286|C0002792|C0333214|C0009566|C0205125|C0042449|C0040053|C0205178|C0027061|C0021308|C0024109|C0013922|C0450371
All patients were assessed for their swallowing function by the water swallow test before and after the treatment.,All patients assessed swallowing function water swallow test treatment.,G0000000|C0030705|C1516048|C0011167|C0031843|C0043047|C0326374|C0022885|C0039798
The information on quality of life and cost should enable patients and their clinicians to make more informed treatment choices.,The quality life cost enable patients clinicians informed treatment choices.,G0000000|C0332306|C0376558|C0010186|C0562342|C0030705|C0871685|C1522154|C0039798|C0008300
Recording AEs: All grades 3 and 4 adverse events should be recorded for up to 28 days after the last day of administration of primaquine in G6PD normal patients (i.e.,Recording AEs: All grades 3 4 adverse events recorded 28 days day administration primaquine G6PD normal patients (i.e.,G0000000|C1412268|G0000000|C0441800|G0000000|G0000000|G0000000|C0441471|C0034869|C0450371|C0439228|C0332173|C0001554|C0033126|G0000000|C0205307|C0030705|C0683454
"Similarly, sedation level and behavior score were also assessed after every 15 min by the evaluators using modified observer assessment of alertness and sedation (MOAAS) scale [Table 1].","Similarly, sedation level behavior score assessed 15 min evaluators modified observer assessment alertness sedation (MOAAS) scale [Table 1].",G0000000|C0235195|C0441889|C0004927|C0449820|C1516048|C0450371|C0702093|C1707957|C0392747|C0870992|C1261322|C1443086|C0235195|G0000000|C0175659|C0039224|G0000000
"Our primary outcome was snoring rate, defined as the number of classified snores > 60 dBA per hour of sleep.","Our primary outcome snoring rate, defined classified snores > 60 dBA hour sleep.",G0000000|C0205225|C1274040|C0037384|C0871208|C1704788|C0008902|C0037384|G0000000|C0450371|C2676137|C0439227|C0037313
"During stage 3, we examined changes and the effect size in the nine social ToP items: pre, post and one-month following the intervention.","During stage 3, examined size social ToP items: pre, post one-month intervention.",G0000000|C0205390|G0000000|C0332128|C0456389|C0728831|C1704458|C1551338|C0332152|C0687676|C4082115|C0886296
"However, these treatment regimens have limited efficacy against hookworm and Trichuris trichiura in terms of cure rates (CR), whereas fecal egg reduction rates (ERR) are generally high for all common STH species.","However, treatment regimens limited efficacy hookworm Trichuris trichiura terms cure rates (CR), fecal egg reduction rates (ERR) common STH species.",G0000000|C0039798|C2945654|C0439801|C1280519|C0002830|C0040955|C3129718|C0233324|C1880198|C0871208|C0201975|C0015733|C0013710|C0301630|C0871208|G0000000|C0205214|C1846860|C1705920
"All participants will also complete outcome measures prior to receiving chemotherapy to familiarise them with study materials, study setting and the researcher.","All participants complete outcome measures prior receiving chemotherapy familiarise study materials, study setting researcher.",G0000000|C0679646|C0205197|C1274040|C0079809|C0332152|C1514756|C0013216|G0000000|C0557651|C0520510|C0557651|C0542559|C0035173
"A standardized, validated Korean version of the BNT (Kim & Na, 1997), composed of 60 culturally customized pictures was administered before and after the series of stimulation sessions as an outcome measure.","A standardized, validated Korean version BNT (Kim & Na, 1997), composed 60 culturally customized pictures administered series stimulation sessions outcome measure.",G0000000|G0000000|G0000000|C1556095|C0333052|G0000000|G0000000|G0000000|C0597484|G0000000|G0000000|C0450371|C0010453|C1880202|C0441469|C1521801|C0205549|C1292856|C1883016|C1274040|C0079809
"Group Comparisons of selected outcomes Note: values are mean ± SD (range) * Pre-post difference within Lokomat group, p < 0.05; † difference within manual group, p < 0.05 Abbreviations: SSWS = self selected walking speed; FWS = Fast walking speed; 6 MWT = 6 minute walk test; SLRabs = Absolute step length ratio; LE FM = Lower extremity Fugl-Meyer; SPPB, short physical performance battery; BBS = Berg Balance Scale; LLFDI = late life function and disability instrument.","Group Comparisons selected outcomes Note: values ± SD (range) * Pre-post difference Lokomat group, < 0.05; † difference manual group, < 0.05 Abbreviations: SSWS = selected walking speed; FWS = Fast walking speed; 6 MWT = 6 minute walk test; SLRabs = Absolute step length ratio; LE FM = Lower extremity Fugl-Meyer; SPPB, short physical performance battery; BBS = Berg Balance Scale; LLFDI = late life function disability instrument.",C0441833|C1707455|C1707391|C1274040|C1316572|C0042295|G0000000|C2699239|C1514721|G0000000|C0332152|C1705241|G0000000|C0441833|G0000000|C0450371|G0000000|C1705241|C0024763|C0441833|G0000000|C0450371|C0000723|G0000000|G0000000|C1707391|C0080331|C0678536|C3150859|G0000000|C0015663|C0080331|C0678536|G0000000|G0000000|G0000000|G0000000|C0439232|C0080331|C0022885|G0000000|G0000000|C0205344|C1261552|C1444754|C0456603|C0023190|C3540627|G0000000|C0441994|C0015385|G0000000|G0000000|C1282927|C0031809|C0597198|C0337088|G0000000|G0000000|G0000000|C0014653|C0175659|G0000000|G0000000|C0205087|C0376558|C0031843|C0231170|C0348000
This study has shown rapid parasite and fever clearance in participants treated with six-dose regimen of AL and one day course of AN.,This study rapid parasite fever clearance participants treated six-dose regimen AL day AN.,G0000000|C0557651|C0456962|C0030498|C0015967|C0449297|C0679646|C1522326|C0205452|C0040808|C0202311|C0332173|G0000000
Full enteral feeds will be defined as 150 mL.Kg− 1.d− 1 or exclusive breastfeeding.,Full enteral feeds defined 150 mL.Kg− 1.d− 1 exclusive breastfeeding.,C0443225|C1304890|C1510670|C1704788|C1442061|G0000000|C1548966|C0006147
"However, the improvement in ESS and FOSQ following therapy did not differ between the treatment arms (Table 3).","However, improvement ESS FOSQ therapy treatment arms (Table 3).",G0000000|C2986411|C0206630|G0000000|C0039798|C0039798|C0206655|C0039224|G0000000
"Wet weight of sputum, spirometry and oxygen saturation were measured.","Wet weight sputum, spirometry oxygen saturation measured.",C0205381|C0005910|C0038056|C0037981|C0030054|C0522534|C0444706
"We defined contact with smoking cessation counseling as documentation that the tobacco counselor reached the patient by telephone, the smoker attended a hospital in-person smoking program, or the state Quitline had reached the smoker for an initial evaluation.","We defined contact smoking cessation counseling documentation tobacco counselor reached patient telephone, smoker attended hospital in-person smoking program, Quitline reached smoker initial evaluation.",G0000000|C1704788|C0332158|C0037369|C1880019|C0010210|C0175636|C0040329|C1561602|C2584321|C0030705|C0039457|C0337664|C1456498|C0019994|C1547564|C0037369|C1709697|G0000000|C2584321|C0337664|C0205265|C0220825
"The secondary outcome measures included the change in QMGS from baseline to days 21 and 28, change in SFEMG jitter, abnormal pairs, blocking pairs, % decrement in RNS from baseline to days 14, 21, and 28, postintervention status at days 14, 21, and 28, and change in AChRAb titers from baseline to days 28 and 60.","The secondary outcome measures included change QMGS baseline days 21 28, change SFEMG jitter, abnormal pairs, blocking pairs, % decrement RNS baseline days 14, 21, 28, postintervention status days 14, 21, 28, change AChRAb titers baseline days 28 60.",G0000000|C0027627|C1274040|C0079809|C0332257|C0392747|G0000000|C0168634|C0439228|C0450371|C0450371|C0392747|G0000000|C4015600|C0205161|C1709450|C0233660|C1709450|G0000000|G0000000|C1850106|C0168634|C0439228|C0450371|C0450371|C0450371|G0000000|C0449438|C0439228|C0450371|C0450371|C0450371|C0392747|C1277725|C0475208|C0168634|C0439228|C0450371|C0450371
The two statins were similarly effective in reducing VLDL particle concentration and serum triglycerides at weeks 6 and 12.,The statins effective reducing VLDL particle concentration serum triglycerides weeks 6 12.,G0000000|C0360714|C1280519|C0392756|C0523560|C0597177|C0004268|C0229671|C0041004|C0439230|G0000000|C0450371
"Tango and Waltz/Foxtrot significantly improved on the Berg Balance Scale, six minute walk distance, and backward stride length.","Tango Waltz/Foxtrot improved Berg Balance Scale, minute walk distance, backward stride length.",C1332116|G0000000|C0184511|G0000000|C0014653|C0175659|C0439232|C0080331|C0012751|C0439781|G0000000|C1444754
The incidence of positive wound culture was significantly reduced in the study group (1.00 ± 1.25) vs. control (3.53 ± 2.47; p = 0.001).,The incidence positive wound culture reduced study (1.00 ± 1.25) vs. control (3.53 ± 2.47; = 0.001).,G0000000|C0021149|C0439178|C0043250|C0010453|C0392756|C0557651|C0450371|G0000000|C0450371|G0000000|C0243148|C0450371|G0000000|C0450371|G0000000|C1442061
"The primary endpoint is the time of relapse-free survival during the blinded observation period (days 1–365), assessed as the period from the date of assignment/allocation until that of the first relapse following the commencement of investigational drug administration.","The primary endpoint time relapse-free survival blinded observation period (days 1–365), assessed period assignment/allocation relapse commencement investigational drug administration.",G0000000|C0205225|C2349179|C0040223|C0035020|C0038952|C0150108|C0302523|C0439531|C0439228|G0000000|C1516048|C0439531|C1516050|C0035020|G0000000|C1517586|C0013227|C0001554
"No significant difference in intraoperative and postoperative pain scores, intraocular pressure, heart rate, and systolic and diastolic blood pressure between two groups was recorded.","No difference intraoperative postoperative pain scores, intraocular pressure, heart rate, systolic diastolic blood pressure recorded.",G0000000|C1705241|C0456904|C0032790|C0030193|C0449820|C3282905|C0033095|C0018787|C0871208|C0039155|C0012000|C0005767|C0033095|C0034869
"Finally, we helped caregivers to set short and long-term goals for reducing their child’s ETS exposure (e.g., decreasing the number of smoked cigarettes every day; complete or partial smoking bans in the home and car; quitting smoking).","Finally, helped caregivers set short long-term goals reducing child’s ETS exposure (e.g., decreasing smoked cigarettes day; complete partial smoking bans car; quitting smoking).",G0000000|C1269765|C0085537|C0036849|C1282927|C0443252|C0018017|C0392756|G0000000|G0000000|C0274281|G0000000|C0442797|C0037366|C0677453|C0332173|C0205197|C0728938|C0037369|C0105185|C0004381|C0748223|C0037369
"The secondary outcomes include: (1) development of a new or recurrent disease progression event, including all-cause death; (2) changes in antiretroviral treatment defined as switching from first- to second-line therapy; and (3) occurrence of adverse events, including peripheral neuropathy, severe anemia, and diarrhea.","The secondary outcomes include: (1) development recurrent disease progression event, including all-cause death; (2) antiretroviral treatment defined switching first- second-line therapy; (3) occurrence adverse events, including peripheral neuropathy, severe anemia, diarrhea.",G0000000|C0027627|C1274040|C0332257|G0000000|C0243107|C2945760|C0012634|C0242656|C0441471|C0332257|C0015127|C0011065|G0000000|G0000000|C0039798|C1704788|C1707719|C0205435|C0205436|C0039798|G0000000|C0243132|G0000000|C0441471|C0332257|C0205100|C0442874|C0205082|C0002871|C0011991
The cumulative volume of intravenous balanced crystalloids (solid line) and 0.9% sodium chloride (dotted line) between admission to the intensive care unit (ICU) and hospital discharge is shown for patients in the balanced-crystalloids group (Panel A) and the saline group (Panel B).,The cumulative volume intravenous balanced crystalloids (solid line) 0.9% sodium chloride (dotted line) admission intensive care unit (ICU) hospital discharge patients balanced-crystalloids (Panel A) saline (Panel B).,G0000000|C1511559|C0449468|C0348016|C0205415|C0056562|C0205208|C0205132|G0000000|C0037473|C0008203|C0872145|C0205132|C0184666|C0162425|C1947933|C0439148|C0021708|C0019994|C0012621|C0030705|C0205415|C0441833|G0000000|C0036082|C0441833|G0000000
The validated Walking Impairment Questionnaire was used to collect self-reported data on practical aspects of daily walking activities and to complement the treadmill walking data.,The validated Walking Impairment Questionnaire collect self-reported data practical aspects daily walking activities complement treadmill walking data.,G0000000|G0000000|C0080331|C0221099|C0034394|G0000000|C0681906|C1511726|G0000000|C1547011|C0332173|C0080331|C0441655|C0009498|C0184069|C0080331|C1511726
The primary efficacy outcome measure was mean relative and absolute change in disease severity after the intervention assessed by SCORAD [14].,The primary efficacy outcome measure relative absolute change disease severity intervention assessed SCORAD [14].,G0000000|C0205225|C1280519|C1274040|C0079809|C0080103|C0205344|C0392747|C0012634|C0439793|C0886296|C1516048|G0000000|C0450371
"Analyses were then performed to examine the effects of the two treatment conditions up to the 3-month follow-up assessment point on average daily pain intensity for the ITT and efficacy samples, using a similar repeated measures ANOVA strategy to that used in the primary analyses, except that the time variable covered three time points (pretreatment, posttreatment, 3-month follow-up) instead of two.","Analyses performed examine effects treatment conditions 3-month follow-up assessment average daily pain intensity ITT efficacy samples, repeated measures ANOVA strategy primary analyses, time variable covered time (pretreatment, posttreatment, 3-month follow-up) two.",C0002778|C0884358|G0000000|C1280500|C0039798|C0012634|C0332177|C0589120|C1261322|C1510992|C0332173|C0030193|C0522510|G0000000|C1280519|C0370003|C0205341|C0079809|G0000000|C0679199|C0205225|C0002778|C0040223|C0439828|C0439844|C0040223|C1550147|C2709088|C0332177|C0589120|C0205448
Estimation of the 6-month PFS rate was based on the proportion of patients who were alive without documented disease progression at 6 months after the treatment start date.,Estimation 6-month PFS rate based proportion patients alive documented disease progression 6 months treatment start date.,C0680844|C0332177|C0242792|C0871208|C1527178|C1709707|C0030705|C0376558|C1301725|C0012634|C0242656|G0000000|C0439231|C0039798|C0439659|C0011008
"At each visit, the following outcome variables were determined: HRQoL, reported physical activity, height, weight, and body mass index, body composition (percent body fat), pulmonary function (forced expiratory volume in 1 s – FEV1), short-term muscle power, maximal aerobic work rate, and peak oxygen uptake (VO2peak).","At visit, outcome variables determined: HRQoL, reported physical activity, height, weight, body mass index, body composition (percent body fat), pulmonary function (forced expiratory volume 1 – FEV1), short-term muscle power, maximal aerobic rate, peak oxygen uptake (VO2peak).",G0000000|C0545082|C1274040|C0439828|G0000000|G0000000|C0684224|C0031809|C0205177|C0489786|C0005910|C0242821|C0577559|C0918012|C0242821|C0486616|C0439165|C0242821|C0424612|C0024109|C0031843|C0441722|C0231800|C0449468|G0000000|G0000000|G0000000|C0443303|C0026845|C0032863|C0205289|C1510824|C0871208|C0444505|C0030054|C0243144|G0000000
Supplementation improved but did not optimise vitamin D status.,Supplementation improved optimise vitamin D status.,C0242297|C0184511|G0000000|C0042890|C0073187|C0449438
Group B were treated with intralesional injection of the glucantime alone until complete healing of the ulcer or for maximum of 6 weeks.,Group B treated intralesional injection glucantime complete healing ulcer maximum 6 weeks.,C0441833|G0000000|C1522326|C1512954|C0021485|C0061366|C0205197|C0043240|C0041582|C0806909|G0000000|C0439230
"In repeated measures ANOVAs, among the eight pre–post pain measures, there were significant main effects of time for six of the eight measures, including BPI Intensity (F = 29.66, P < 0.001, d = 0.40), BPI Interference (F = 42.16, P < 0.001, d = 0.44), SF-36 Pain (F = 15.16, P < 0.001, d = 0.37), PQAS Paroxysmal Pain (F = 19.88, P < 0.001, d = 0.41), PQAS Deep Pain (F = 9.50, P < 0.01, d = 0.22), and Maladaptive Coping (F = 18.12, P < 0.001, d = 0.35).","In repeated measures ANOVAs, pre–post pain measures, main effects time measures, including BPI Intensity (F = 29.66, P < 0.001, = 0.40), BPI Interference (F = 42.16, P < 0.001, = 0.44), SF-36 Pain (F = 15.16, P < 0.001, = 0.37), PQAS Paroxysmal Pain (F = 19.88, P < 0.001, = 0.41), PQAS Deep Pain (F = 9.50, P < 0.01, = 0.22), Maladaptive Coping (F = 18.12, P < 0.001, = 0.35).",G0000000|C0205341|C0079809|G0000000|G0000000|C0030193|C0079809|C0205225|C1280500|C0040223|C0079809|C0332257|C1443145|C0522510|C0016327|G0000000|C0450371|C0369773|G0000000|C1442061|G0000000|C0450371|C1443145|C0521102|C0016327|G0000000|C0450371|C0369773|G0000000|C1442061|G0000000|C0450371|C0037712|C0030193|C0016327|G0000000|C0450371|C0369773|G0000000|C1442061|G0000000|C0450371|G0000000|C0205311|C0030193|C0016327|G0000000|C0450371|C0369773|G0000000|C1442061|G0000000|C0450371|G0000000|C0205125|C0030193|C0016327|G0000000|C0450371|C0369773|G0000000|C0450371|G0000000|C0450371|C0233532|C0009967|C0016327|G0000000|C0450371|C0369773|G0000000|C1442061|G0000000|C0450371
"Mean changes in FEV1% predicted from baseline to week 24 were 0.964 for CDPI and 0.986 for TSI (table 2, figure 3).","Mean FEV1% predicted baseline week 24 0.964 CDPI 0.986 TSI (table 2, figure 3).",C0444504|G0000000|C0681842|C0168634|C0332174|C0450371|C1442061|G0000000|C1442061|C0040139|C0039224|G0000000|G0000000|G0000000
Maternal vitamin D deficiency may increase the inflammatory reaction [14].,Maternal vitamin D deficiency increase inflammatory reaction [14].,C2347083|C0042890|C0073187|C0011155|C0442805|C0333348|C0443286|C0450371
"The neuropsychological evaluation assessed various cognitive domains: verbal and spatial immediate memory span (Digit Span and Corsi’s Test) (Orsini et al., 1987), episodic memory, immediate and delayed recall (Rey Auditory Verbal Learning Test-RAVLT) (Carlesimo et al., 1996), logical memory, immediate and delayed recall (Carlesimo et al., 2002), non-verbal reasoning (Raven’s Colored Progressive Matrices 47-PM47) (Basso et al., 1987), frontal functionality (Frontal Assessment Battery, FAB) (Apollonio et al., 2005), simple speed processing and complex attention (Trail Making Test A, TMT-A and Trail Making Test B, TMT-B, respectively) (Giovagnoli et al., 1996), visual selective attention (Attentive Matrices) (Spinnler and Tognoni, 1987), verbal fluency, both phonological and semantic (Novelli et al., 1986), visual-constructive abilities (Rey-Osterrieth Complex Figure, copy) (Caffarra et al., 2002), global cognitive functioning (MMSE) (Folstein et al., 1975), and language (Aachener Aphasie Test, AAT) (Luzzatti et al., 1996).","The neuropsychological evaluation assessed cognitive domains: verbal spatial memory span (Digit Span Corsi’s Test) (Orsini al., 1987), episodic memory, delayed recall (Rey Auditory Verbal Learning Test-RAVLT) (Carlesimo al., 1996), logical memory, delayed recall (Carlesimo al., 2002), non-verbal reasoning (Raven’s Colored Progressive Matrices 47-PM47) (Basso al., 1987), frontal functionality (Frontal Assessment Battery, FAB) (Apollonio al., 2005), simple speed processing complex attention (Trail Making Test A, TMT-A Trail Making Test B, TMT-B, respectively) (Giovagnoli al., 1996), visual selective attention (Attentive Matrices) (Spinnler Tognoni, 1987), verbal fluency, phonological semantic (Novelli al., 1986), visual-constructive abilities (Rey-Osterrieth Complex Figure, copy) (Caffarra al., 2002), global cognitive functioning (MMSE) (Folstein al., 1975), language (Aachener Aphasie Test, AAT) (Luzzatti al., 1996).",G0000000|G0000000|C0220825|C1516048|C1516691|C1880389|C0439824|C1428114|C0025260|C1711300|C0582802|C1711300|G0000000|C0022885|G0000000|C0202311|G0000000|C1455761|C0025260|C0205421|C0034770|G0000000|C0439825|C0439824|C0013621|C0022885|G0000000|C0202311|G0000000|C0023963|C0025260|C0205421|C0034770|G0000000|C0202311|G0000000|C0746940|C0684328|G0000000|C0522507|C0205329|C1704639|C0450371|G0000000|C0202311|G0000000|C0205123|C0205245|C0205123|C1261322|C0337088|G0000000|G0000000|C0202311|G0000000|C0205352|C0678536|C1709694|C0439855|C0004268|C1143949|C1881534|C0022885|G0000000|C0040604|C1143949|C1881534|C0022885|G0000000|C0040604|G0000000|G0000000|C0202311|G0000000|C0234621|C0036576|C0004268|C0004268|C1704639|G0000000|G0000000|G0000000|C0439824|C0870569|C0597725|C0036612|G0000000|C0202311|G0000000|C0234621|C0085732|G0000000|C0439855|G0000000|C1948062|G0000000|C0202311|G0000000|C0205246|C1516691|C0205245|C0451306|G0000000|C0202311|G0000000|C0023008|G0000000|G0000000|C0022885|C3537219|G0000000|C0202311|G0000000
"Considering that preserving or improving the patients’ QOL is another important goal of treating advanced NSCLC in addition to clinical benefits such as longer progression free survival, higher tumor response rates, and prolonged overall survival, the results of our study could provide some useful information for clinical practice.","Considering preserving improving patients’ QOL goal treating advanced NSCLC addition clinical benefits progression free survival, tumor response rates, prolonged survival, study provide clinical practice.",C0750591|C0728887|C1272745|G0000000|C0518214|C0018017|C1522326|C0205179|C0007131|C0332287|C0205210|C0814225|C0242656|C0332296|C0038952|C0027651|C0871261|C0871208|C0439590|C0038952|C0557651|C1999230|C0205210|C0237607
"Secondary outcomes included safety and adverse event data, and change in MHFMS score for twelve versus six months of active treatment, body composition, quantitative SMN mRNA levels, maximum ulnar CMAP amplitudes, myometry and PFT measures.","Secondary outcomes included safety adverse event data, change MHFMS score twelve versus months active treatment, body composition, quantitative SMN mRNA levels, maximum ulnar CMAP amplitudes, myometry PFT measures.",C0027627|C1274040|C0332257|C0036043|G0000000|C0441471|C1511726|C0392747|G0000000|C0449820|C0205458|G0000000|C0439231|C0205177|C0039798|C0242821|C0486616|C0392762|G0000000|C0035696|C0441889|C0806909|C0442044|C1413776|C2346753|C0521387|C0024119|C0079809
"Cough resolved more quickly in patients given erythromycin, but no improvement was seen in their level of activity or in how sick they felt in general.","Cough resolved patients erythromycin, improvement level activity sick general.",C0010200|C1514893|C0030705|C0014806|C2986411|C0441889|C0205177|C0221423|C0205246
Proportion of households owning an insecticide-treated bed net (ITN).,Proportion households owning insecticide-treated bed net (ITN).,C1709707|C0020052|G0000000|C0021576|C0004916|C1456447|G0000000
The primary outcome was the comparison between study groups of the mean difference of serum potassium levels between the day after the last dose of treatment and baseline.,The primary outcome comparison study difference serum potassium levels day dose treatment baseline.,G0000000|C0205225|C1274040|C1707455|C0557651|C1705241|C0229671|C0032821|C0441889|C0332173|C0178602|C0039798|C0168634
Kinematic analysis of the movement of the hyoid bone and the angular variation of the epiglottis was performed using Marosis M-view 5.4 (Fig.,Kinematic analysis movement hyoid bone angular variation epiglottis performed Marosis M-view 5.4 (Fig.,C0600169|C0002778|C0026649|C0020417|C0262950|C0205143|C0205419|C0014540|C0884358|G0000000|C0369637|G0000000|C0349966
"Cox proportional hazard models21 were conducted to examine comparative survival rates between the two medication conditions and to test predictors of retention (i.e., age, grams per use day, percent use days, and cannabis-related problems).","Cox proportional hazard models21 conducted examine comparative survival rates medication conditions test predictors retention (i.e., age, grams day, percent days, cannabis-related problems).",G0000000|C0205351|C0598697|G0000000|C0004927|G0000000|G0000000|C0038952|C0871208|C0013227|C0012634|C0022885|C2698872|C0035280|C0683454|C0001779|C0439208|C0332173|C0439165|C0439228|C0024808|C1546466
"Effectiveness of inhaled fluticasone relative to placebo was compared in terms of health status (Chronic Respiratory Disease Questionnaire), exacerbations, and postbronchodilator forced expiratory volume in one second (FEV1), using repeated measurement analysis.","Effectiveness inhaled fluticasone relative placebo compared terms health status (Chronic Respiratory Disease Questionnaire), exacerbations, postbronchodilator forced expiratory volume (FEV1), repeated measurement analysis.",C1280519|C0004048|C0082607|C0080103|C0032042|C1707455|C0233324|C0018684|C0449438|C0205191|C0521346|C0012634|C0034394|G0000000|C2599594|C0441722|C0231800|C0449468|G0000000|C0205341|C0242485|C0002778
Depression was assessed using the Center for Epidemiologic Studies Depression Scale (CES-D) [51].,Depression assessed Center Epidemiologic Studies Depression Scale (CES-D) [51].,C0011570|C1516048|C0205099|C0014507|C0947630|C0011570|C0175659|C2699160|C0450371
"OS = overall survival, PFS = progression free survival, ITT = intend-to-treat.","OS = overall survival, PFS = progression free survival, ITT = intend-to-treat.",G0000000|C0038952|G0000000|C0332296|C0038952|G0000000
"By 6 months of linezolid treatment, 34/39 (87%) had negative sputum cultures.","By 6 months linezolid treatment, 34/39 (87%) negative sputum cultures.",G0000000|G0000000|C0439231|C0663241|C0039798|C0450371|C0450371|C0205160|C0038056|C0010453
"Static balance ability was assessed according to the postural sway path length and speed at the center of pressure (COP) by using the Balancia Software system connected to a computer, and a Wii balance force platform with 4 load cells.","Static balance ability assessed postural sway path length speed center pressure (COP) Balancia Software system connected computer, Wii balance force platform 4 load cells.",C0441463|C0014653|C0085732|C1516048|C0205278|G0000000|C0919386|C1444754|C0678536|C0205099|C0033095|G0000000|G0000000|C0037585|C0449913|C2986575|C0009622|G0000000|C0014653|C0441722|C1710360|G0000000|C1550025|C0007634
"Because these interventions aim to build general skills that children can carry with them throughout life, they have also been employed to prevent substance abuse, internalizing, crime, and risky sexual behavior outcomes and improve general well-being (7, 9, 15, 17), all of which are correlated with externalizing problems.","Because interventions aim build skills children carry life, employed prevent substance abuse, internalizing, crime, risky sexual behavior outcomes improve well-being (7, 9, 15, 17), correlated externalizing problems.",G0000000|C0886296|C1947946|C1707059|C0678856|C0008059|C0206243|C0376558|C0014003|C0309872|C0439861|C0013146|G0000000|C0010325|C0035647|C0036864|C0004927|C1274040|G0000000|C0018684|G0000000|G0000000|C0450371|C0450371|C1707520|G0000000|C1546466
"Survival was assessed at week 64, including patients who had discontinued treatment.","Survival assessed week 64, including patients discontinued treatment.",C0038952|C1516048|C0332174|C0450371|C0332257|C0030705|C1444662|C0039798
The isokinetic test was performed on the dominant leg extensors and tested at an angular velocity of 150°/s.,The isokinetic test performed dominant leg extensors tested angular velocity 150°/s.,G0000000|G0000000|C0022885|C0884358|C1527180|C0023216|C1184148|C0392366|C0205143|C0439830|G0000000
These interventions promote parenting efficacy; enhancing parent confidence and competence with managing infant sleep and crying behaviours [10].,These interventions promote parenting efficacy; enhancing parent confidence competence managing infant sleep crying behaviours [10].,G0000000|C0886296|C0033414|C0085092|C1280519|C2349975|C0030551|C0237529|C0086035|C1273870|C0021270|C0037313|C0010399|C0004927|C0450371
The prevention of falls among older people is a major public health challenge.,The prevention falls people major public health challenge.,G0000000|C0199176|C0000921|C0027361|C0205082|G0000000|C0018684|C0798503
RESULTS—At baseline healthy subjects had higher urinary levels of total cortisol metabolites (TCM) than subjects with asthma.,RESULTS—At baseline healthy subjects urinary levels total cortisol metabolites (TCM) subjects asthma.,G0000000|C0168634|C3898900|C0681850|C0042027|C0441889|C0439175|C0020268|C0870883|C1515884|C0681850|C0004096
FMA: Fugl-Meyer Assessment; MCI: Mild Cognitive Impairment; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; NIHSS: National Institutes of Health Stroke Scale; VFSS: Video-fluoroscopic Swallowing Study; SPSS: Statistical Product and Service Solutions; mRS: modified Rankin Scale.,FMA: Fugl-Meyer Assessment; MCI: Mild Cognitive Impairment; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; NIHSS: National Institutes Health Stroke Scale; VFSS: Video-fluoroscopic Swallowing Study; SPSS: Statistical Product Service Solutions; mRS: modified Rankin Scale.,C2332774|G0000000|C1261322|C0560005|C2945599|C1516691|C0221099|C0451306|C0445542|C1301808|G0000000|C3541265|G0000000|C1516691|C1261322|C3476804|C3245503|C0021622|C0018684|C0038454|C0175659|G0000000|C1660599|C0011167|C0557651|C3813609|C0038215|C1514468|C0557854|C0037633|C1522706|C0392747|G0000000|C0175659
"29 For this reason, we conducted a pilot trial in the clinical context of ARI, whose aims were (1) to assess the feasibility of recruiting family medicine groups (FMGs), FPs and their patients; (2) to develop, adapt and validate DECISION+ training workshops and related material (for a description of DECISION+, see ‘Intervention’); (3) to evaluate physicians’ participation and satisfaction regarding DECISION+; and (4) to estimate the impact of DECISION+ on (i) physicians’ and patients’ decision whether to use antibiotics, (ii) physicians’ and patients’ decisional conflict scores and the level of agreement between those scores, (iii) the prescription profile of antibiotics for ARIs, (iv) FPs’ intention to practice SDM, (v) FPs’ intention to follow clinical practice guidelines for the treatment of ARIs, (vi) FPs’ scores on a script concordance test, and (vii) patients’ decisional regret.","29 For reason, conducted pilot trial clinical context ARI, aims (1) assess feasibility recruiting family medicine (FMGs), FPs patients; (2) develop, adapt validate DECISION+ training workshops material (for description DECISION+, ‘Intervention’); (3) evaluate physicians’ participation satisfaction DECISION+; (4) estimate impact DECISION+ (i) physicians’ patients’ decision antibiotics, (ii) physicians’ patients’ decisional conflict scores level agreement scores, (iii) prescription profile antibiotics ARIs, (iv) FPs’ intention practice SDM, (v) FPs’ intention follow clinical practice guidelines treatment ARIs, (vi) FPs’ scores script concordance test, (vii) patients’ decisional regret.",C0450371|G0000000|C0392360|C0004927|C0473169|C0008976|C0205210|C0449255|C1412533|C1947946|G0000000|C1516048|G0000000|G0000000|C0015576|C0013227|G0000000|C1708010|C0030705|G0000000|G0000000|C2937289|G0000000|C0679006|C0040607|C0242262|C0520510|G0000000|C0678257|C0679006|G0000000|G0000000|C0220825|G0000000|C0679823|C0242428|C0679006|G0000000|C0750572|C1825598|C0679006|C0021966|G0000000|G0000000|C0679006|C0003232|G0000000|G0000000|G0000000|C0679006|C0009671|C0449820|C0441889|C0680240|C0449820|C0439070|C0033080|C1979963|C0003232|C1412533|C0022326|G0000000|C0162425|C0237607|C0643808|G0000000|G0000000|C0162425|C0332283|C0205210|C0237607|C0162791|C0039798|C1412533|C0205999|G0000000|C0449820|C0871893|C0680240|C0022885|C0445385|G0000000|C0679006|C0080101
"Secondary end points included the composite of ESKD, 40% decrease in eGFR, and all-cause death; the composite of ESKD, 50% decrease in eGFR, and all-cause death; and each of ESKD, death due to kidney disease, and all-cause death.","Secondary included composite ESKD, 40% decrease eGFR, all-cause death; composite ESKD, 50% decrease eGFR, all-cause death; ESKD, death kidney disease, all-cause death.",C0027627|C0332257|C0205199|G0000000|C0450371|C0392756|C1739039|C0015127|C0011065|C0205199|G0000000|C0450371|C0392756|C1739039|C0015127|C0011065|G0000000|C0011065|C0022646|C0012634|C0015127|C0011065
"Secondary outcomes were clinical functional outcomes, including basic ADL function, balance, gait functions, and motor functions of the paretic lower limb.","Secondary outcomes clinical functional outcomes, including basic ADL function, balance, gait functions, motor functions paretic lower limb.",C0027627|C1274040|C0205210|C0205245|C1274040|C0332257|C1527178|C0001288|C0031843|C0014653|C0016928|C0542341|C1513492|C0542341|G0000000|C0441994|C0015385
The challenge virus used for this study was rhinovirus type 39.,The challenge virus study rhinovirus type 39.,G0000000|C0798503|C0042776|C0557651|C0035473|C0332307|C0450371
Patient-reported quality of life was similar between the two arms.,Patient-reported quality life arms.,C0747307|C0332306|C0376558|C0206655
LDL cholesterol was calculated as (LDL + HDL cholesterol) from the bottom ultracentrifugation fraction minus HDL cholesterol from the precipitation assay.,LDL cholesterol calculated (LDL + HDL cholesterol) bottom ultracentrifugation fraction minus HDL cholesterol precipitation assay.,G0000000|C0008377|C0444686|G0000000|G0000000|C3715113|C0008377|C1511276|C0041609|C1264633|C0332288|C3715113|C0008377|C0032931|C0005507
"After inclusion in the present study, blood samples of all patients were taken to analyze level of vitamin D. After 12 hours of fasting, level of vitamin D was determined through Liebermann–Burchard method.","After inclusion study, blood samples patients analyze level vitamin D. After 12 hours fasting, level vitamin D determined Liebermann–Burchard method.",G0000000|C0007637|C0557651|C0005767|C0370003|C0030705|G0000000|C0441889|C0042890|C0073187|G0000000|C0450371|C0439227|C0015663|C0441889|C0042890|C0073187|G0000000|G0000000|C0025663
"We assessed tricep skinfold thickness with Holtain skinfold callipers (Holtain, Crymych, UK) and mid-upper arm circumference, which we used to calculate mid-arm muscle circumference.15 We calculated energy and macronutrient intake from four day, unweighed diet diaries by using the Microdiet software (Downlee Systems, Chapel-en-le Frith, UK) and expressed these as a percentage of the recommended daily intake for age and sex.16 We measured spirometric lung function parameters (forced expiratory volume in one second and forced vital capacity) with a portable spirometer (Vitalograph, Buckingham, UK) and expressed them as a percentage of that predicted for age, sex, and height.","We assessed tricep skinfold thickness Holtain skinfold callipers (Holtain, Crymych, UK) mid-upper arm circumference, calculate mid-arm muscle circumference.15 We calculated energy macronutrient intake day, unweighed diet diaries Microdiet software (Downlee Systems, Chapel-en-le Frith, UK) expressed percentage recommended daily intake age sex.16 We measured spirometric lung function parameters (forced expiratory volume forced vital capacity) portable spirometer (Vitalograph, Buckingham, UK) expressed percentage predicted age, sex, height.",G0000000|C1516048|G0000000|C1446851|C1280412|G0000000|C1446851|G0000000|G0000000|G0000000|C0041700|C0444598|C0446516|C0332520|C1441506|C0444598|C0026845|C0332520|G0000000|C0444686|C0424589|C2346926|C1512806|C0332173|G0000000|C0012155|C0376660|G0000000|C0037585|G0000000|C0449913|C0558275|G0000000|C0041700|G0000000|C0439165|C0034866|C0332173|C1512806|C0001779|C0009253|G0000000|C0444706|C0037981|C0024109|C0031843|C0449381|C0441722|C0231800|C0449468|C0441722|C0442732|C1516240|G0000000|C0183441|G0000000|G0000000|C0041700|G0000000|C0439165|C0681842|C0001779|C0009253|C0489786
Patients who achieved the primary end point of the trial (clinical remission; defined by a Simple Clinical Colitis Activity Index (SCCAI) ⩽2 together with a decrement of ⩾1 point in Mayo Endoscopic Score from baseline on repeat sigmoidoscopy at week 12) were called 'responders' and patients who did not achieve the primary end point were called 'non-responders'.,Patients achieved primary trial (clinical remission; defined Simple Clinical Colitis Activity Index (SCCAI) ⩽2 decrement ⩾1 Mayo Endoscopic Score baseline repeat sigmoidoscopy week 12) called 'responders' patients achieve primary called 'non-responders'.,C0030705|G0000000|C0205225|C0008976|C0205210|C0544452|C1704788|C0205352|C0205210|C0009319|C0205177|C0918012|G0000000|G0000000|G0000000|G0000000|C0454788|C0014245|C0449820|C0168634|C0205341|C0037075|C0332174|C0450371|C0679006|G0000000|C0030705|G0000000|C0205225|C0679006|C1518422
"Secondary outcomes were body composition, compliance and condition on follow-up 1 year after cessation of TB therapy and supplementation.","Secondary outcomes body composition, compliance condition follow-up 1 cessation TB therapy supplementation.",C0027627|C1274040|C0242821|C0486616|C0009563|C0012634|C0589120|G0000000|C1880019|G0000000|C0039798|C0242297
"Schedule of enrolment, interventions and assessments The primary outcome, ‘recovery’, in both the control and intervention groups is defined as two consecutive measurements with a MUAC ≥125 mm and no oedema.","Schedule enrolment, interventions assessments The primary outcome, ‘recovery’, control intervention defined consecutive measurements MUAC ≥125 mm oedema.",C0086960|C1516879|C0886296|C1261322|G0000000|C0205225|C1274040|G0000000|C0243148|C0886296|C1704788|C1707491|C0242485|G0000000|G0000000|G0000000|C0013604
"Treatment regimens for patients with cystic fibrosis (CF) are time-consuming and complex, resulting in consistently low adherence rates.","Treatment regimens patients cystic fibrosis (CF) time-consuming complex, consistently low adherence rates.",C0039798|C2945654|C0030705|C0205207|C0016059|C0009738|C3827829|C0439855|G0000000|C0205251|C1510802|C0871208
"Assessments will be taken 3 times over the 3-week period on days 8, 15 and 23.","Assessments 3 times 3-week period days 8, 15 23.",C1261322|G0000000|C0040223|C0332174|C0439531|C0439228|G0000000|C0450371|C0450371
"Relapses, defined as an increase in two or more points on the SCCAI in association with increase in treatment for manifestations of UC by the participant’s physician, occurred at 5 weeks, 32 weeks, and 42 weeks in three subjects who were receiving carrageenan supplements.","Relapses, defined increase SCCAI association increase treatment manifestations UC participant’s physician, occurred 5 weeks, 32 weeks, 42 weeks subjects receiving carrageenan supplements.",C0035020|C1704788|C0442805|G0000000|C0004083|C0442805|C0039798|C0205319|G0000000|G0000000|C0031831|C1709305|G0000000|C0439230|C0450371|C0439230|C0450371|C0439230|C0681850|C1514756|C0007289|C0242295
"An ANCOVA model was used to test efficacy by comparing the MBSR and control groups on all outcomes immediately after the intervention (T2) and 1 month later (T3), while adjusting for baseline scale scores for each variable.","An ANCOVA model test efficacy comparing MBSR control outcomes intervention (T2) 1 month (T3), adjusting baseline scale scores variable.",G0000000|C0814908|C3161035|C0022885|C1280519|C1707455|G0000000|C0243148|C1274040|C0886296|C0041403|G0000000|C0332177|C0041403|G0000000|C0168634|C0175659|C0449820|C0439828
"The 28-day paper and pencil prospective headache diary included (1) use of any headache abortive medication, (2) headache occurrence, (3) headache intensity rated as average pain intensity for that day using a 0- to 10-point scale, (4) headache duration, and (5) associated symptoms for migraine.","The 28-day paper pencil prospective headache diary included (1) headache abortive medication, (2) headache occurrence, (3) headache intensity rated average pain intensity day 0- 10-point scale, (4) headache duration, (5) symptoms migraine.",G0000000|C0450371|C0030351|C0441059|C0023981|C0018681|C0376660|C0332257|G0000000|C0018681|G0000000|C0013227|G0000000|C0018681|C0243132|G0000000|C0018681|C0522510|C0871208|C1510992|C0030193|C0522510|C0332173|G0000000|C0450371|C0175659|G0000000|C0018681|C0449238|G0000000|C0683368|C0149931
"Main outcome measures were the average number of episodes of respiratory tract infections for which patients visited their family physician per patient per year (PPPY), and the percentage of the episodes for which patients were treated with antibiotics during follow-up.","Main outcome measures average episodes respiratory tract infections patients visited family physician patient (PPPY), percentage episodes patients treated antibiotics follow-up.",C0205225|C1274040|C0079809|C1510992|C0332189|C0521346|C1185740|C3714514|C0030705|C0545082|C0015576|C0031831|C0030705|G0000000|C0439165|C0332189|C0030705|C1522326|C0003232|C0589120
"We determined the long term effects, over a period of 10-15 years, of sodium reduction on cardiovascular disease and mortality.","We determined term effects, period 10-15 years, sodium reduction cardiovascular disease mortality.",G0000000|G0000000|C0233324|C1280500|C0439531|C0450371|C0439234|C0037473|C0301630|C0007226|C0012634|C0026565
"After adjustment for confounders, there was no significant difference between the groups in performance on the California Verbal Learning Test, the main cognitive outcome measure, or any secondary cognitive outcomes (a global cognitive score, and domain scores on memory, processing speed, executive function, and delayed recall).","After adjustment confounders, difference performance California Verbal Learning Test, main cognitive outcome measure, secondary cognitive outcomes (a global cognitive score, domain scores memory, processing speed, executive function, delayed recall).",G0000000|C0376209|G0000000|C1705241|C0597198|C0006754|C0439824|C0013621|C0022885|C0205225|C1516691|C1274040|C0079809|C0027627|C1516691|C1274040|G0000000|C0205246|C1516691|C0449820|C1880389|C0449820|C0025260|C1709694|C0678536|C0871735|C0031843|C0205421|C0034770
"In case of a second biopsy (on Day 14), the biopsy was performed on the contralateral muscle.","In biopsy (on Day 14), biopsy performed contralateral muscle.",G0000000|C0005558|G0000000|C0332173|C0450371|C0005558|C0884358|C0441988|C0026845
The best available estimate of the population proportion currently active at the recommended level was that taken from Active People Survey 2 [16] (sub-group NS-SEC 6-8 i.e.,The estimate population proportion active recommended level Active People Survey 2 [16] (sub-group NS-SEC 6-8 i.e.,G0000000|C0750572|C0032659|C1709707|C0205177|C0034866|C0441889|C0205177|C0027361|C0038951|G0000000|C0450371|C0542339|C0038944|G0000000|C0683454
"There were no significant differences in terms of satisfaction, level of reassurance, parental enablement, or the parent’s rating of the “usefulness of any information received in the consultation.” Similar results were found at the univariate level, with a non-significant difference in reconsulting (absolute risk reduction 3.3%, 95% confidence interval −2.7% to 9.3%, P=0.29), and significant differences in antibiotic prescribing (absolute risk reduction 21.3%, number needed to treat 4.7, P<0.001), antibiotic consumption (absolute risk reduction 20.6%, 95% confidence interval 12.7% to 28.5%, number needed to treat 4.9, P<0.001), and future consulting intentions (21.1%, 13.1% to 29.2%, 4.7, P<0.001).","There differences terms satisfaction, level reassurance, parental enablement, parent’s rating “usefulness received consultation.” Similar univariate level, non-significant difference reconsulting (absolute risk reduction 3.3%, 95% confidence interval −2.7% 9.3%, P=0.29), differences antibiotic prescribing (absolute risk reduction 21.3%, treat 4.7, P<0.001), antibiotic consumption (absolute risk reduction 20.6%, 95% confidence interval 12.7% 28.5%, treat 4.9, P<0.001), future consulting intentions (21.1%, 13.1% 29.2%, 4.7, P<0.001).",G0000000|C1705241|C0233324|C0242428|C0441889|C0204558|C0030551|G0000000|G0000000|C0871208|G0000000|C1514756|G0000000|C2348205|G0000000|C0441889|C1518422|C1705241|G0000000|C0205344|C0035647|C0301630|G0000000|C0450371|C0237529|C1272706|G0000000|G0000000|C0369773|C1705241|C0003232|C0278329|C0205344|C0035647|C0301630|C0450371|C0087111|G0000000|C0369773|C0003232|C0009830|C0205344|C0035647|C0301630|C0450371|C0450371|C0237529|C1272706|C0450371|C0450371|C0087111|G0000000|C0369773|C0016884|C0009818|C0162425|C0450371|C0450371|C0450371|G0000000|C0369773
"We investigated associations of tea, coffee, and milk consumption with colorectal cancer risk and attempted to determine if these exposures were differentially associated with the risks of proximal colon, distal colon, and rectal cancers.","We investigated associations tea, coffee, milk consumption colorectal cancer risk attempted determine exposures differentially risks proximal colon, distal colon, rectal cancers.",G0000000|C1292732|C0004083|C0039400|C0009237|C0026131|C0009830|C0555952|C0006826|C0035647|C1516084|G0000000|C0274281|G0000000|C0035647|C0205107|C0009368|C0205108|C0009368|C0205052|C0006826
"After 12 weeks, 78% of subjects treated with naltrexone exhibited an endoscopic response as indicated by a 5-point decline in the Crohn’s disease endoscopy index severity score (CDEIS) from baseline compared to 28% response in placebo-treated controls (p = 0.008), and 33% achieved remission with a CDEIS score <6, whereas only 8% of those on placebo showed the same change.","After 12 weeks, 78% subjects treated naltrexone exhibited endoscopic response 5-point decline Crohn’s disease endoscopy severity score (CDEIS) baseline compared 28% response placebo-treated controls (p = 0.008), 33% achieved remission CDEIS score <6, 8% placebo change.",G0000000|C0450371|C0439230|C0450371|C0681850|C1522326|C0027360|C0015272|C0014245|C0871261|C1552961|G0000000|G0000000|C0012634|C0014245|C0439793|C0449820|G0000000|C0168634|C1707455|C0450371|C0871261|C0032042|C0243148|C0369773|G0000000|C1442061|C0450371|G0000000|C0544452|G0000000|C0449820|G0000000|G0000000|C0032042|C0392747
"Considering that almost half of the study population consisted of patients who received between two and eight previous lines of chemotherapy for ovarian cancer, the finding of median progression-free survival of 19.0 months was striking.","Considering half study population consisted patients received previous lines chemotherapy ovarian cancer, finding median progression-free survival 19.0 months striking.",C0750591|C2825407|C0557651|C0032659|C0332529|C0030705|C1514756|C0205156|C0205132|C0013216|C0205065|C0006826|C0037088|C0549183|C0242656|C0038952|C0450371|C0439231|C0038452
"As ITN coverage increases, vector density, especially indoor resting density, will decrease.","As ITN coverage increases, vector density, indoor resting density, decrease.",G0000000|G0000000|C1551362|C0205217|C0086022|C0178587|G0000000|C0035253|C0178587|C0392756
"(Mark all that apply).” The response choices were “Alcohol (beer, wine, liquor),” “Cigarettes or tobacco,” “Marijuana (pot, weed),” “Inhalants (sniff glue or paint),” and “None of these.” Students were coded as 1 = “having ever used a substance” if they reported using any one of the substances; they were coded as 0 = “never having used one of the substances” if they had not selected any one of the four substances and they had selected “none of these.” Past month’s prevalence was assessed with three items asking students how many “drinks of alcohol (more than a sip of beer, wine, or liquor),” “cigarettes,” or “hits of marijuana (pot, weed)” they had in the last 30 days.","(Mark apply).” The response choices “Alcohol (beer, wine, liquor),” “Cigarettes tobacco,” “Marijuana (pot, weed),” “Inhalants (sniff glue paint),” “None these.” Students coded 1 = “having substance” reported substances; coded 0 = “never substances” selected substances selected “none these.” Past month’s prevalence assessed items students “drinks alcohol (more sip beer, wine, liquor),” “cigarettes,” “hits marijuana (pot, weed)” 30 days.",C0522501|G0000000|G0000000|C0871261|C0008300|G0000000|C0004922|C0043188|G0000000|G0000000|G0000000|G0000000|C0024809|G0000000|G0000000|C1720573|C0017780|G0000000|G0000000|G0000000|C0038492|C0009219|G0000000|G0000000|G0000000|G0000000|C0684224|C0439861|C0009219|G0000000|G0000000|G0000000|G0000000|C1707391|C0439861|C1707391|G0000000|G0000000|C1444637|G0000000|C0033105|C1516048|C1551338|C0038492|G0000000|C0001962|C0205172|C1823796|C0004922|C0043188|G0000000|G0000000|G0000000|C0024808|C0024809|G0000000|C0450371|C0439228
"Activity counts, representing movement, are stored in memory in the device in 1-minute epochs.","Activity counts, representing movement, stored memory device 1-minute epochs.",C0205177|C0439157|C1882932|C0026649|C1698986|C0025260|C0025080|C0439232|C1948053
"A separate survey administered to children 7 years or older assessed the child’s perception of quality of life relating to asthma and of household smoking behavior (estimates of time household members smoked in the home weekly, number of hours of SHS exposure weekly, inside/outside the home and in the car, attitudes towards this exposure).","A separate survey administered children 7 assessed child’s perception quality life relating asthma household smoking behavior (estimates time household smoked weekly, hours SHS exposure weekly, inside/outside car, attitudes exposure).",G0000000|C0443299|C0038951|C1521801|C0008059|G0000000|C1516048|G0000000|C0030971|C0332306|C0376558|C0163712|C0004096|C0020052|C0037369|C0004927|C0750572|C0040223|C0020052|C0037366|C0332174|C0439227|G0000000|C0274281|C0332174|C0205101|C0004381|C0004271|C0274281
"We also examined lifetime marijuana use to assess whether antidrug advertising was associated with delayed initiation, and we examined past-month alcohol use as an outcome that was presumably not directly affected by antidrug advertising.","We examined lifetime marijuana assess antidrug advertising delayed initiation, examined past-month alcohol outcome directly antidrug advertising.",G0000000|C0332128|C4071830|C0024808|C1516048|G0000000|C0001690|C0205421|C0589507|C0332128|C1444637|C0001962|C1274040|C1947931|G0000000|C0001690
"Differences in tumor progression between the two groups within the first 3 months, in particular, might have not registered confounding the secondary endpoint time to progression.","Differences tumor progression 3 months, particular, registered confounding secondary endpoint time progression.",C1705241|C0027651|C0242656|G0000000|C0439231|G0000000|C1514821|G0000000|C0027627|C2349179|C0040223|C0242656
"The primary outcome measure was forced expiratory volume in one second (FEV1), and secondary outcome measures were exercise capacity, dyspnoea with exertion, quality of life, peak expiration flow rate, and respiratory symptoms.","The primary outcome measure forced expiratory volume (FEV1), secondary outcome measures exercise capacity, dyspnoea exertion, quality life, peak expiration flow rate, respiratory symptoms.",G0000000|C0205225|C1274040|C0079809|C0441722|C0231800|C0449468|G0000000|C0027627|C1274040|C0079809|C0015259|C1516240|C0013404|C0015264|C0332306|C0376558|C0444505|C0231800|C0806140|C0871208|C0521346|C0683368
"According to the mean daily diary responses, bepotastine besilate 1.5% provided significantly better relief of evening ocular itch, relief of morning and evening itchy/runny nose, and relief of morning and evening ocular allergy symptoms.","According daily diary responses, bepotastine besilate 1.5% provided relief evening ocular itch, relief morning evening itchy/runny nose, relief morning evening ocular allergy symptoms.",C0680240|C0332173|C0376660|C0871261|C2698371|G0000000|G0000000|C1999230|C0564405|C0587117|C0015392|C0033774|C0564405|C0332170|C0587117|C0033774|C0028429|C0564405|C0332170|C0587117|C0015392|C0002111|C0683368
"The primary efficacy measure is the time to first occurrence of any component of the composite of cardiovascular death, non‐fatal myocardial infarction, non‐fatal stroke, coronary revascularization, and hospitalization for unstable angina.","The primary efficacy measure time occurrence component composite cardiovascular death, non‐fatal myocardial infarction, non‐fatal stroke, coronary revascularization, hospitalization unstable angina.",G0000000|C0205225|C1280519|C0079809|C0040223|C0243132|C0449432|C0205199|C0007226|C0011065|G0000000|C0027061|C0021308|G0000000|C0038454|C0018787|C0581603|C0019993|C0443343|C0002962
"They also had to have an expired carbon monoxide reading <10 ppm and, at 12 months, a salivary cotinine concentration <20 ng/ml.","They expired carbon monoxide reading <10 ppm and, 12 months, salivary cotinine concentration <20 ng/ml.",G0000000|C0011065|C0007009|G0000000|C0034754|C0450371|C0439187|G0000000|C0450371|C0439231|C0442040|C0010194|C0004268|C0450371|C0439275
Mean difference score for nausea and vomiting before and four days after the intervention in two groups was statistically significant (Table 4).,Mean difference score nausea vomiting days intervention statistically (Table 4).,C0444504|C1705241|C0449820|C0027497|C0042963|C0439228|C0886296|C0038215|C0039224|G0000000
"We defined diarrhea as ≥3 loose or watery stools in 24 hours, or a single stool with blood/mucus [22] with a 7-day recall period [23] using a previously published instrument [24].","We defined diarrhea ≥3 loose watery stools 24 hours, single stool blood/mucus [22] 7-day recall period [23] published instrument [24].",G0000000|C1704788|C0011991|G0000000|C0205407|C0443350|C0015733|C0450371|C0439227|C0037179|C0015733|C0005767|C0450371|C0332173|C0034770|C0439531|C0450371|C0034037|C0348000|C0450371
"The groups were similar in gender, the kind of operation and the duration of anesthesia, but the preoperative anxiety was different in Groups 3 and 4 than that in Groups 1 and 2.","The gender, operation duration anesthesia, preoperative anxiety Groups 3 4 Groups 1 2.",G0000000|C0079399|C0543467|C0449238|C0002903|C0445204|C0003467|C0441833|G0000000|G0000000|C0441833|G0000000|G0000000
Local recurrence negatively influenced survival.,Local recurrence negatively influenced survival.,C0205276|C0034897|G0000000|G0000000|C0038952
"Outcomes were defined as success (14 consecutive dry nights within three months), failure (not meeting success criteria) or relapse (more than two wet nights in two consecutive weeks) (8).","Outcomes defined success (14 consecutive dry nights months), failure (not meeting success criteria) relapse (more wet nights consecutive weeks) (8).",C1274040|C1704788|C0597535|C0450371|C1707491|C0011682|C0240526|C0439231|C0231174|C1518422|C0556656|C0597535|C0243161|C0035020|C0205172|C0205381|C0240526|C1707491|C0439230|G0000000
"Children were defined as having recovered when they reached a WHZ ≥−2; otherwise, they were categorized as having continued MAM despite 12 wk of therapy, had developed SAM (WHZ <−3 and/or pedal edema), were transferred to inpatient care, died, or defaulted (did not return for 3 consecutive visits).","Children defined recovered reached WHZ ≥−2; otherwise, categorized continued MAM 12 wk therapy, developed SAM (WHZ <−3 and/or pedal edema), transferred inpatient care, died, defaulted (did return 3 consecutive visits).",C0008059|C1704788|C0521108|C2584321|G0000000|G0000000|G0000000|C0871968|C0549178|C0024671|C0450371|C0332174|C0039798|G0000000|C0036002|G0000000|G0000000|G0000000|C0016504|C0013604|C0348011|C0021562|C1947933|C0011065|C2828024|G0000000|C0332156|G0000000|C1707491|C0545082
"The trial’s co-primary endpoints were mean changes from baseline, as area under the curve (AUC), in forced expiratory volume (FEV1) over 0–12 hours (AUC0–12 h FEV1) with MF/F versus MF, and in morning (AM) pre-dose (trough) FEV1 with MF/F versus F after 13 weeks of treatment.","The trial’s co-primary endpoints baseline, curve (AUC), forced expiratory volume (FEV1) 0–12 hours (AUC0–12 FEV1) MF/F versus MF, morning (AM) pre-dose (trough) FEV1 MF/F versus F 13 weeks treatment.",G0000000|G0000000|C3245499|C2349179|C0168634|C0205134|C0376690|C0441722|C0231800|C0449468|G0000000|G0000000|C0439227|G0000000|G0000000|C0024974|G0000000|C0024974|C0332170|G0000000|C0439565|C0444506|G0000000|C0024974|G0000000|C0016327|C0450371|C0439230|C0039798
The control group for the present study was comprised of this subcohort of women who were free of a history of breast cancer as of 31 July 2007.,The control study comprised subcohort women free history breast cancer 31 July 2007.,G0000000|C0243148|C0557651|C2700400|G0000000|C0043210|C0332296|C0019664|C0006141|C0006826|C0450371|C3829447|G0000000
A total of 1874 children were enrolled.,A total 1874 children enrolled.,G0000000|C0439175|G0000000|C0008059|G0000000
"The secondary objectives are to assess the effects of inosine administration on serum urate (UA) levels, the progression of neurologic disability, the cumulative number of new, active lesions on magnetic resonance imaging (MRI), and changes in serum levels for markers of inflammation.","The secondary objectives assess effects inosine administration serum urate (UA) levels, progression neurologic disability, cumulative new, active lesions magnetic resonance imaging (MRI), serum levels markers inflammation.",G0000000|C0027627|C0018017|C1516048|C1280500|C0021528|C0001554|C0229671|C0729829|C0041580|C0441889|C0242656|C0205494|C0231170|C1511559|C0205314|C0205177|C0221198|C0024488|C0231881|C0011923|C0024485|C0229671|C0441889|C0005516|C0021368
"The study met its primary endpoint showing a significant improvement in time-to-progression (TTP) with DCF compared with CF, and also an improvement in survival, and response rate were reported.","The study met primary endpoint improvement time-to-progression (TTP) DCF compared CF, improvement survival, response rate reported.",G0000000|C0557651|C0268621|C0205225|C2349179|C2986411|C2985467|C0084795|C0030896|C1707455|C0009738|C2986411|C0038952|C0871261|C0871208|C0684224
Quality of caregiving relationship (relative).,Quality caregiving relationship (relative).,C0332306|G0000000|C0439849|C0080103
"Methods: A cluster-randomized controlled trial was conducted in rural Bangladesh to test the effect of two local, ready-to-use foods (chickpea and rice-lentil based) and a fortified blended food (wheat-soy-blend++, WSB++) compared with Plumpy’doz, all with nutrition counselling vs nutrition counselling alone (control) on outcomes of linear growth (length and length-for-age z-score, LAZ), stunting (LAZ < −2), weight-for-length z-score (WLZ) and wasting (WLZ < −2) in children 6–18 months of age.","Methods: A cluster-randomized controlled trial conducted rural Bangladesh test local, ready-to-use foods (chickpea rice-lentil based) fortified blended food (wheat-soy-blend++, WSB++) compared Plumpy’doz, nutrition counselling nutrition counselling (control) outcomes linear growth (length length-for-age z-score, LAZ), stunting (LAZ < −2), weight-for-length z-score (WLZ) wasting (WLZ < −2) children 6–18 months age.",C0025663|G0000000|C1555715|C2587213|C0008976|C0004927|C0240919|C0004732|C0022885|C0205276|C1318963|C0016452|C0950052|C0035567|C1527178|G0000000|C0678946|C0016452|C0043137|G0000000|C1707455|G0000000|C0028707|C0010210|C0028707|C0010210|C0243148|C1274040|C0205132|C0018270|C1444754|C1444754|C0871421|G0000000|C0018273|G0000000|C0005910|C0871421|G0000000|C0006625|G0000000|C0008059|G0000000|C0439231|C0001779
"No clinically relevant differences were found between the CT and APT, or between CT and CBT.","No clinically relevant differences CT APT, CT CBT.",G0000000|G0000000|C2347946|C1705241|C0007673|C0003645|C0007673|C0009244
Mean ROM of the shoulder at baseline and after RT in the control and exercise group.,Mean ROM shoulder baseline RT control exercise group.,C0444504|C4048784|C0037004|C0168634|C0230425|C0243148|C0015259|C0441833
"Pregnancy complications, ultrasound follow-up data, and pregnancy outcomes, including newborn weight and length adjusted for gestational age, occurrence of newborn hypoglycemia (glycemia <2.2 mmol/L), and the type of delivery, were obtained from the electronic medical record system.","Pregnancy complications, ultrasound follow-up data, pregnancy outcomes, including newborn weight length adjusted gestational age, occurrence newborn hypoglycemia (glycemia <2.2 mmol/L), type delivery, electronic medical record system.",C0032961|C0009566|C0041618|C0589120|C1511726|C0032961|C1274040|C0332257|C0021289|C0005910|C1444754|C0456081|C0439671|C0001779|C0243132|C0021289|C0020615|C0005802|G0000000|C1532563|C0332307|C0011209|C0013850|C0199168|C0034869|C0449913
"However, the lowest level of platelet count in dengue fever without bleeding is still controversial.","However, lowest level platelet count dengue fever bleeding controversial.",G0000000|C1708760|C0441889|C0005821|C0750480|C0011311|C0015967|C0019080|C0680243
Diarrhoea was defined as ‘three or more loose stools per day over at least 2 consecutive days’ within 12 days of starting the antibiotics.,Diarrhoea defined ‘three loose stools day 2 consecutive days’ 12 days starting antibiotics.,C0011991|C1704788|G0000000|C0205407|C0015733|C0332173|G0000000|C1707491|G0000000|C0450371|C0439228|C0439659|C0003232
The sporozoite rate of identified An.,The sporozoite rate identified An.,G0000000|C0562648|C0871208|C0205396|G0000000
"The addition of other signs, as in our earlier study, improved the sensitivity but compromised the specificity of our model.21 Table Table22 shows the results of these models.","The addition signs, earlier study, improved sensitivity compromised specificity model.21 Table Table22 models.",G0000000|C0332287|C0220912|C1279919|C0557651|C0184511|C0020517|C2945640|C0037791|C3161035|C0039224|G0000000|C3161035
The diagnosis date was assigned to the earliest event.,The diagnosis assigned earliest event.,G0000000|C0011900|C1516050|C1279919|C0441471
Figure Figure22 shows that in both groups the children's reported exposure to their mothers' tobacco smoke in the home declined steeply from baseline to three months (end of counselling) and then only slightly during follow up.,Figure Figure22 children's reported exposure mothers' tobacco smoke declined steeply baseline months (end counselling) follow up.,G0000000|G0000000|C0008059|C0684224|C0274281|C0026591|C0040329|C0037366|G0000000|G0000000|C0168634|C0439231|C0444930|C0010210|C0332283|G0000000
"Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01) than those given placebo.","Significantly patients Pseudomonas aeruginosa infection receiving fluticasone improvement 24 hour sputum volume (OR 13.5, 95% CI 1.8 100.2, = 0.03) exacerbation frequency (OR 13.3, 95% CI 1.8 100.2, = 0.01) placebo.",G0000000|C0030705|C0033808|G0000000|C0009450|C1514756|C0082607|C2986411|C0450371|C0439227|C0038056|C0449468|G0000000|C0450371|C0450371|C0008107|G0000000|C1442061|G0000000|C0450371|G0000000|C0376249|G0000000|C0450371|C0450371|C0008107|G0000000|C1442061|G0000000|C0450371|C0032042
"At all visits, we measured child length/height and weight.","At visits, measured child length/height weight.",G0000000|C0545082|C0444706|C0008059|C1444754|C0005910
"Asthma severity score was recorded at baseline, 4, 8, 12, 24, 36, 48, 60, and 72 hr unless the patient was discharged from the infirmary earlier.","Asthma severity score recorded baseline, 4, 8, 12, 24, 36, 48, 60, 72 hr patient discharged infirmary earlier.",C0004096|C0439793|C0449820|C0034869|C0168634|G0000000|G0000000|C0450371|C0450371|C0450371|C0450371|C0450371|G0000000|C0030705|C0030685|C0221502|C1279919
Adverse events and serious adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0) according to International Conference on Harmonisation guidelines.,Adverse events adverse events assessed National Cancer Institute Common Terminology Criteria Adverse Events (version 3.0) International Conference Harmonisation guidelines.,G0000000|C0441471|G0000000|C0441471|C1516048|C3245503|C0006826|C0021622|C0205214|C0028275|C0243161|G0000000|C0441471|C0333052|G0000000|C1512888|C0086047|G0000000|C0162791
The primary outcome measure was the effect of study drugs on the length of hospital stay (LOS).,The primary outcome measure study drugs length hospital stay (LOS).,G0000000|C0205225|C1274040|C0079809|C0557651|C0013227|C1444754|C0019994|G0000000|G0000000
"Heart rate, blood pressure, nausea, vomiting, dizziness, and patient's satisfaction were recorded before and after the aromatherapy based on the questionnaire.","Heart rate, blood pressure, nausea, vomiting, dizziness, patient's satisfaction recorded aromatherapy based questionnaire.",C0018787|C0871208|C0005767|C0033095|C0027497|C0042963|C0012833|C0030705|C0242428|C0034869|C0376547|C1527178|C0034394
"Outcome measures were examined before and after the 3-week interventions using the Berg Balance Scale (BBS), Timed Up and Go (TUG) test, and Postural Assessment Scale for Stroke Patients (PASS).","Outcome measures examined 3-week interventions Berg Balance Scale (BBS), Timed Up Go (TUG) test, Postural Assessment Scale Stroke Patients (PASS).",C1274040|C0079809|C0332128|C0332174|C0886296|G0000000|C0014653|C0175659|G0000000|C0392761|G0000000|C1822658|C1319201|C0022885|C0205278|C1261322|C0175659|C0038454|C0030705|C2828386
"Findings also revealed a conditional effect of FPI on children’s expressive language outcomes at 12-month follow up, suggesting that children with baseline language skills below 12 months (N = 24) are most likely to benefit from FPI.","Findings revealed conditional FPI children’s expressive language outcomes 12-month follow up, suggesting children baseline language skills 12 months (N = 24) benefit FPI.",C2607943|C0443289|C1701901|G0000000|G0000000|C0185117|C0023008|C1274040|C0450371|C0332283|G0000000|C1705535|C0008059|C0168634|C0023008|C0678856|C0450371|C0439231|C0369718|G0000000|C0450371|C0814225|G0000000
"Our primary outcome measure was discontinuation of benzodiazepine use, immediately after completion of treatment and up to 1 year later.","Our primary outcome measure discontinuation benzodiazepine use, completion treatment 1 later.",G0000000|C0205225|C1274040|C0079809|C0457454|C0005064|C0042153|C0205197|C0039798|G0000000|C0205087
"The primary outcomes are LAZ and hemoglobin level at 18 months of age, stratified by maternal HIV status.","The primary outcomes LAZ hemoglobin level 18 months age, stratified maternal HIV status.",G0000000|C0205225|C1274040|G0000000|C0019046|C0441889|C0450371|C0439231|C0001779|C0205363|C2347083|C0019682|C0449438
"VO2max, 6MWT distance, leg muscle strength, and femoral neck BMD).","VO2max, 6MWT distance, leg muscle strength, femoral neck BMD).",G0000000|G0000000|C0012751|C0023216|C0026845|C0237897|C0015811|C0027530|G0000000
"Patient outcomes, including pain, sensation, muscle strength, and muscle atrophy were compared between groups.","Patient outcomes, including pain, sensation, muscle strength, muscle atrophy compared groups.",C0030705|C1274040|C0332257|C0030193|C0036658|C0026845|C0237897|C0026845|C0333641|C1707455|C0441833
"When the intervention protocol was completed, the patients were followed in the 8th week after treatment.","When intervention protocol completed, patients 8th week treatment.",G0000000|C0886296|C0442711|C0205197|C0030705|G0000000|C0332174|C0039798
The participant recorded time in and out of bed on a record sheet.,The participant recorded time bed record sheet.,G0000000|C0679646|C0034869|C0040223|C0004916|C0034869|C2349187
The benefits of prednisolone therapy on immune activation and CD4+ T cell counts do not outweigh the risks of adverse events in HIV-infected patients with TB and preserved immune function.,The benefits prednisolone therapy immune activation CD4+ T cell counts outweigh risks adverse events HIV-infected patients TB preserved immune function.,G0000000|C0814225|C0032950|C0039798|C0439662|C1879547|C0285590|C2603360|C0007634|C0439157|G0000000|C0035647|G0000000|C0441471|C0019682|C0030705|G0000000|C0033085|C0439662|C0031843
"Detailed information on exacerbations and associated hospitalizations, and the number of courses of both oral steroids and antibiotics administered for the treatment of exacerbations were collected at each clinic visit.","Detailed exacerbations hospitalizations, courses oral steroids antibiotics administered treatment exacerbations collected clinic visit.",C1522508|G0000000|C0019993|C0750729|C0442027|C0038317|C0003232|C1521801|C0039798|G0000000|C1516695|C0002424|C0545082
"At discharge from the hospital, mean SBP and DBP z-scores were 0.3 (SD 1.3) and 0.2 (SD 0.7) respectively.","At discharge hospital, SBP DBP z-scores 0.3 (SD 1.3) 0.2 (SD 0.7) respectively.",G0000000|C0012621|C0019994|G0000000|C0536221|C0871421|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000
The primary endpoint of this study was clinical cure at EOT (Day 10) in the MITT population.,The primary endpoint study clinical cure EOT (Day 10) MITT population.,G0000000|C0205225|C2349179|C0557651|C0205210|C1880198|G0000000|C0332173|C0450371|G0000000|C0032659
"This study aims to test the efficacy of memantine versus placebo in reducing clinically significant agitation, measured using the Cohen-Mansfield Agitation Score ≥45 (CMAI), [20], [21] at 6 weeks after randomisation and secondarily at 12 weeks.","This study aims test efficacy memantine versus placebo reducing clinically agitation, measured Cohen-Mansfield Agitation Score ≥45 (CMAI), [20], [21] 6 weeks randomisation secondarily 12 weeks.",G0000000|C0557651|C1947946|C0022885|C1280519|C0025242|G0000000|C0032042|C0392756|G0000000|C0085631|C0444706|G0000000|C0085631|C0449820|G0000000|G0000000|C0450371|C0450371|G0000000|C0439230|C0034656|G0000000|C0450371|C0439230
All three parties reported the need for an intervention lasting more than six months.,All parties reported intervention lasting months.,G0000000|C1518904|C0684224|C0886296|C1517741|C0439231
"Newborns were categorized into small-for-gestational age (birth weight < 10th centile), normal, or large-for-gestational-age (LGA) (birth weight > 90th centile) using the Spanish tables of neonatal weight adjusted for sex and gestational age (14).","Newborns categorized small-for-gestational age (birth weight < 10th centile), normal, large-for-gestational-age (LGA) (birth weight > 90th centile) Spanish tables neonatal weight adjusted sex gestational age (14).",C0021289|C0871968|C0700321|C0001779|C0005615|C0005910|G0000000|G0000000|G0000000|C0205307|C0549177|C1428877|C0005615|C0005910|G0000000|G0000000|G0000000|C0086409|C0039224|C1552240|C0005910|C0456081|C0009253|C0439671|C0001779|C0450371
"Upper extremity muscle strength is measured with the JAMAR® grip strength dynamometer [34] and the microFET® hand held dynamometer (HHD) for the elbow flexion, using a standardized measurement protocol [35].","Upper extremity muscle strength measured JAMAR® grip strength dynamometer [34] microFET® hand held dynamometer (HHD) elbow flexion, standardized measurement protocol [35].",C1282910|C0015385|C0026845|C0237897|C0444706|G0000000|C0021400|C0237897|C0180572|C0450371|G0000000|C0018563|C0675390|C0180572|C0085106|C0013769|C0231452|G0000000|C0242485|C0442711|C0450371
"Possible clinically relevant reductions in exacerbation rate (rate ratio 0.67) and FEV1 decline (39 mL/year) occurred in BTS responders, but did not reach statistical significance.","Possible clinically relevant reductions exacerbation rate (rate ratio 0.67) FEV1 decline (39 mL/year) occurred BTS responders, reach statistical significance.",C0332149|G0000000|C2347946|C0301630|G0000000|C0871208|C0871208|C0456603|C0450371|G0000000|G0000000|C0450371|C0439526|C1709305|G0000000|G0000000|C2584321|C0038215|C0237881
Secondary outcomes included temperature at two hours and the time spent in the department.,Secondary outcomes included temperature hours time spent department.,C0027627|C1274040|C0332257|C0005903|C0439227|C0040223|C0680968|C1704729
"Second, (RQ2) we examine whether either campaign increases perceptions that marijuana use is inconsistent with aspirations or autonomy.","Second, (RQ2) examine campaign increases perceptions marijuana inconsistent aspirations autonomy.",C0205436|G0000000|G0000000|G0000000|C0205217|C0030971|C0024808|C0442809|C0004056|C0085862
"Relative to control subjects, ASMA students reported significantly: more confidence to manage their asthma; taking more steps to prevent symptoms; greater use of controller medication and written treatment plans; fewer night awakenings, days with activity limitation, and school absences due to asthma; improved QOL; and fewer acute care visits, emergency department visits, and hospitalizations.","Relative control subjects, ASMA students reported significantly: confidence manage asthma; steps prevent symptoms; controller medication written treatment plans; fewer night awakenings, days activity limitation, school absences asthma; improved QOL; fewer acute care visits, emergency department visits, hospitalizations.",C0080103|C0243148|C0681850|C0066992|C0038492|C0684224|G0000000|C0237529|G0000000|C0004096|C1261552|C0309872|C0683368|C0180112|C0013227|C0043266|C0039798|C0270724|C0205388|C0240526|C1720052|C0439228|C0205177|C0449295|C0036375|C0424530|C0004096|C0184511|C0518214|C0205388|C0205178|C1947933|C0545082|C0013956|C1704729|C0545082|C0019993
"In acupuncture, the acupoints for a specific treatment are selected from a group consisting of local acupoints, distal acupoints and symptomatic acupoints.","In acupuncture, acupoints specific treatment selected consisting local acupoints, distal acupoints symptomatic acupoints.",G0000000|C0001299|C0001302|C0205369|C0039798|C1707391|C0332529|C0205276|C0001302|C0205108|C0001302|C0231220|C0001302
The primary outcome (rate of falls) was compared between arms using negative binomial regression.,The primary outcome (rate falls) compared arms negative binomial regression.,G0000000|C0205225|C1274040|C0871208|C0000921|C1707455|C0206655|C0205160|G0000000|C0684320
"Since the introduction of antimycobacterial combination therapy a number of clinical studies investigated the treatment outcome of BUD patients, in particular healing times, secondary lesions and functional limitations.","Since introduction antimycobacterial combination therapy clinical studies investigated treatment outcome BUD patients, healing times, secondary lesions functional limitations.",C1711239|C1293116|C0360390|C0205195|C0039798|C0205210|C0947630|C1292732|C0039798|C1274040|C2700462|C0030705|C0043240|C0040223|C0027627|C0221198|C0205245|C0449295
"*Adjusted for expanded-criteria donor, delayed graft function, and biopsy-proven acute rejection.","*Adjusted expanded-criteria donor, delayed graft function, biopsy-proven acute rejection.",C0456081|C0205229|C0013018|C0205421|C0181074|C0031843|C0005558|C0205178|C0035015
Various toxicological approaches are being examined to validate the identification of illicit cannabis use in nabiximols prescribed patients (to be described elsewhere).,Various toxicological approaches examined validate identification illicit cannabis nabiximols prescribed patients (to elsewhere).,C0440102|C0205472|C0449445|C0332128|G0000000|C0020792|C0332266|C0024808|C2347556|C0278329|C0030705|G0000000|G0000000
The decision-aid with support app significantly improved continuous abstinence at 6 months compared with information-only app.,The decision-aid support app improved continuous abstinence 6 months compared information-only app.,G0000000|C0086104|C0183683|G0000000|C0184511|C0549178|C3843422|G0000000|C0439231|C1707455|C1533716|G0000000
The primary outcome is hospitalization within 24 h of the start of the experimental therapy for persistent respiratory distress or supplemental oxygen.,The primary outcome hospitalization 24 start experimental therapy persistent respiratory distress supplemental oxygen.,G0000000|C0205225|C1274040|C0019993|C0450371|C0439659|C1517586|C0039798|C0205322|C0521346|C0231303|C2348609|C0030054
"The primary end‐point was the changes in the neuropathic symptom and sign scores from baseline to week 24, assessed by the neuropathy symptom score (NSS), the neuropathy disability score (NDS) and the sum of both (NSS+NDS).","The primary end‐point neuropathic symptom sign scores baseline week 24, assessed neuropathy symptom score (NSS), neuropathy disability score (NDS) sum (NSS+NDS).",G0000000|C0205225|G0000000|C0442874|C1457887|C0311392|C0449820|C0168634|C0332174|C0450371|C1516048|C0442874|C1457887|C0449820|G0000000|C0442874|C0231170|C0449820|C0057753|C1515051|C0057753
This would have represented a 31% reduction in pain scores at rest and a 21% reduction while walking when compared with placebo.,This represented 31% reduction pain scores rest 21% reduction walking compared placebo.,G0000000|C1882932|C0450371|C0301630|C0030193|C0449820|C0035253|C0450371|C0301630|C0080331|C1707455|C0032042
Children were assessed once per fortnight.,Children assessed fortnight.,C0008059|C1516048|G0000000
Impact of intervention 12 months after surgery.,Impact intervention 12 months surgery.,C1825598|C0886296|C0450371|C0439231|C0038894
There is also a potential reduction in health spending as a result of a potential maintenance or increase in functional status and quality of life.,There potential reduction health spending result potential maintenance increase functional status quality life.,G0000000|C3245505|C0301630|C0018684|C0680968|C1274040|C3245505|C0024501|C0442805|C0205245|C0449438|C0332306|C0376558
"Borderline ovarian tumours are low-grade ovarian malignancies with far less aggressive behaviour than invasive ovarian cancer (Bell, 2005; Hart, 2005).","Borderline ovarian tumours low-grade ovarian malignancies aggressive behaviour invasive ovarian cancer (Bell, 2005; Hart, 2005).",C0205189|C0205065|C0027651|C1282907|C0205065|C0006826|C0001807|C0004927|C0205281|C0205065|C0006826|C1706917|G0000000|G0000000|G0000000
This study had several limitations.,This study limitations.,G0000000|C0557651|C0449295
We will look at effect on systolic BP lowering in pre-specified sub-groups: diabetes; atrial fibrillation; and age group.,We systolic BP lowering pre-specified sub-groups: diabetes; atrial fibrillation; age group.,G0000000|C0039155|C0037623|C0441994|C2826245|C0542339|C0011847|C0018792|C0232197|C0001779|C0441833
"For venous samples, we used the formulations described by Ak to estimate arterial values for pH, carbon dioxide, and bicarbonate.27 We used non-paired Student’s t tests to compare arterial and converted venous blood gases.","For venous samples, formulations Ak estimate arterial values pH, carbon dioxide, bicarbonate.27 We non-paired Student’s tests compare arterial converted venous blood gases.",G0000000|C0042449|C0370003|C0524527|C0001905|C0750572|C0003842|C0042295|C0450407|C0007009|C0678717|C0005367|G0000000|C1518422|G0000000|C0022885|C1707455|C0003842|G0000000|C0042449|C0005767|C0017110
"Most of these differences, however, probably reflect modest symptomatic benefit since the clinical importance of the difference in paracetamol consumption is debatable, and there was no significant difference in mean pain scores, episodes of distress, or absence from school.","Most differences, however, reflect modest symptomatic benefit clinical difference paracetamol consumption debatable, difference pain scores, episodes distress, absence school.",C0205393|C1705241|G0000000|C0558058|C4054480|C0231220|C0814225|C0205210|C1705241|C0000970|C0009830|G0000000|C1705241|C0030193|C0449820|C0332189|C0231303|C0332197|C0036375
The day by day averages of the 10 item withdrawal discomfort score calculated from the Marijuana Withdrawal Checklist are shown on Figure 3.,The day day averages 10 item withdrawal discomfort score calculated Marijuana Withdrawal Checklist Figure 3.,G0000000|C0332173|C0332173|C1510992|C0450371|C1551338|C2349954|C0231218|C0449820|C0444686|C0024808|C2349954|C1707357|G0000000|G0000000
"Therapeutic failure rates on day 28 were 13.6%, 10.2% and 0% in the SP, AQ, and SP+AQ groups, respectively.","Therapeutic failure rates day 28 13.6%, 10.2% 0% SP, AQ, SP+AQ groups, respectively.",C0087111|C0231174|C0871208|C0332173|C0450371|C0450371|C0450371|G0000000|C0037747|C0242536|C0037747|C0441833|G0000000
"A similar trend was seen for total cholesterol, triglycerides, glucose, and blood pressure.","A trend total cholesterol, triglycerides, glucose, blood pressure.",G0000000|C1521798|C0439175|C0008377|C0041004|C0017725|C0005767|C0033095
"Secondary outcomes included adherence to treatment, weight gain, and clearance of sputum smears.","Secondary outcomes included adherence treatment, weight gain, clearance sputum smears.",C0027627|C1274040|C0332257|C1510802|C0039798|C0005910|C1517378|C0449297|C0038056|C0444186
"Before the intervention there was no significant difference between weight, height, head circumference, the number of wet diapers and frequency of defecation between the two groups (P > 0.05), yet the number of breast feeding times of the control group was more than the Fenugreek group.","Before intervention difference weight, height, head circumference, wet diapers frequency defecation (P > 0.05), breast feeding times control Fenugreek group.",C0332152|C0886296|C1705241|C0005910|C0489786|C0018670|C0332520|C0205381|C0180416|C0376249|C0011135|C0369773|G0000000|C0450371|C0006141|C0204695|C0040223|C0243148|C0060207|C0441833
We also monitored the duration of delirium.,We monitored duration delirium.,G0000000|C0030695|C0449238|C0011206
"Secondary outcome measurements (Physical fitness and body composition): Physical fitness was evaluated by using the Tecumseh step test, the 6-minute walk test, the 30-second chair-to-standing test, and the push-up test.","Secondary outcome measurements (Physical fitness body composition): Physical fitness evaluated Tecumseh step test, 6-minute walk test, 30-second chair-to-standing test, push-up test.",C0027627|C1274040|C0242485|C0031809|C1456706|C0242821|C0486616|C0031809|C1456706|C0220825|G0000000|C1261552|C0022885|C0439232|C0080331|C0022885|C0450371|C0179847|C0022885|C1719958|C0022885
"They were asked to perform the SF-36 Questionnaire, the 6 minute walk distance test and pain status evaluation according to the Visual analogue scale (VAS).","They perform SF-36 Questionnaire, 6 minute walk distance test pain status evaluation Visual analogue scale (VAS).",G0000000|C0884358|C0037712|C0034394|G0000000|C0439232|C0080331|C0012751|C0022885|C0030193|C0449438|C0220825|C0234621|C0243071|C0175659|C0042815
"Each sign is graded at each site on a four point scale (0-3, representing grades of none, mild, moderate, and severe).","Each sign graded site scale (0-3, representing grades none, mild, moderate, severe).",G0000000|C0311392|C0441800|C0205145|C0175659|G0000000|C1882932|C0441800|G0000000|C2945599|C0205081|C0205082
"Mean pain intensity in the intervention group before, immediately after, 30 minutes and one hour after the intervention were 5.8, 3.1, 2.5 and 2.4, respectively.","Mean pain intensity intervention before, after, 30 minutes hour intervention 5.8, 3.1, 2.5 2.4, respectively.",C0444504|C0030193|C0522510|C0886296|C0332152|G0000000|C0450371|C0439232|C0439227|C0886296|G0000000|G0000000|G0000000|G0000000|G0000000
"The PHQ-9 is a nine-item self-report questionnaire deemed acceptable for the identification of depression in medical care settings, including specialist settings.27 Likewise, the GAD-7, is a self-report seven-item questionnaire with evidenced criterion validity for the detection of generalised anxiety disorder.29 The PHQ-9 and GAD-7 are routinely used in UK primary care Improving Access to Psychological Therapy (IAPT) sites32 to monitor patient outcomes.","The PHQ-9 nine-item self-report questionnaire deemed acceptable identification depression medical care settings, including specialist settings.27 Likewise, GAD-7, self-report seven-item questionnaire evidenced criterion validity detection generalised anxiety disorder.29 The PHQ-9 GAD-7 routinely UK primary care Improving Access Psychological Therapy (IAPT) sites32 monitor patient outcomes.",G0000000|C1879301|C0205455|C0681906|C0034394|G0000000|C1879533|C0020792|C0011570|C0199168|C1947933|C0542559|C0332257|C0087009|C0542559|G0000000|C0270549|C0681906|C0205453|C0034394|C3887511|C0243161|C2349101|C1511790|C0205246|C0003467|C0012634|G0000000|C1879301|C0270549|G0000000|C0041700|C0205225|C1947933|C1272745|C0444454|C0205486|C0039798|G0000000|G0000000|C0030695|C0030705|C1274040
"In conclusion, the laparoscopic technique resulted in a reduction of both the overall morbidity rate and the length of hospital stay, and in a faster recovery of physical and social activity.","In conclusion, laparoscopic technique reduction morbidity rate length hospital stay, faster recovery physical social activity.",G0000000|C1707478|C0031150|C0449851|C0301630|C0026538|C0871208|C1444754|C0019994|G0000000|C0015663|C0237820|C0031809|C0728831|C0205177
"The survey also included 25 selected items from the Personal and Organizational Quality Assessment–Revised (POQA-R) questionnaire,16 an 85-item self-report inventory designed to reflect key psychological and workplace elements indicating the overall quality of one’s experiences within an organization.","The survey included 25 selected items Personal Organizational Quality Assessment–Revised (POQA-R) questionnaire,16 85-item self-report inventory designed reflect key psychological workplace elements indicating quality one’s experiences organization.",G0000000|C0038951|C0332257|C0450371|C1707391|C1551338|C1519021|C0029246|C0332306|G0000000|C0205090|C0034394|C0450371|C0681906|C0021941|C1707689|C0558058|G0000000|C0205486|C0162579|C0013879|G0000000|C0332306|G0000000|C0596545|C0029237
Patients were randomly assigned to receive one of four treatments for 30 months: 1) fluticasone propionate 500 µg bid; 2) fluticasone/salmeterol 500/50 µg bid; 3) fluticasone 500 µg bid (6 months) and followed by placebo (24 months); or 4) placebo bid.,Patients randomly assigned receive treatments 30 months: 1) fluticasone propionate 500 µg bid; 2) fluticasone/salmeterol 500/50 µg bid; 3) fluticasone 500 µg bid (6 months) placebo (24 months); 4) placebo bid.,C0030705|G0000000|C1516050|C1514756|C0087111|C0450371|C0439231|G0000000|C0082607|C0033474|C1442061|G0000000|G0000000|G0000000|C0939232|C1442061|G0000000|G0000000|G0000000|C0082607|C1442061|G0000000|G0000000|G0000000|C0439231|C0032042|C0450371|C0439231|G0000000|C0032042|G0000000
"Poverty increases the risk of infection and disease and, through its effects on nutrition as well as its impact on adherence to treatment, undermines the outcomes of patients on TB treatment.","Poverty increases risk infection disease and, effects nutrition impact adherence treatment, undermines outcomes patients TB treatment.",C0032854|C0205217|C0035647|C0009450|C0012634|G0000000|C1280500|C0028707|C1825598|C1510802|C0039798|G0000000|C1274040|C0030705|G0000000|C0039798
"The secondary outcomes of MCSI score, number of seizures per month and ELDQoL subscale scores for AED side effects, mood and behaviour were also calculated by subtracting baseline values from follow-up values.","The secondary outcomes MCSI score, seizures month ELDQoL subscale scores AED effects, mood behaviour calculated subtracting baseline values follow-up values.",G0000000|C0027627|C1274040|G0000000|C0449820|C0036572|C0332177|G0000000|G0000000|C0449820|C0887457|C1280500|C0026516|C0004927|C0444686|C1719767|C0168634|C0042295|C0589120|C0042295
Reduction in serum albumin was the predominant factor responsible for altering rosiglitazone PK characteristics in resistant FSGS.,Reduction serum albumin predominant factor responsible altering rosiglitazone PK characteristics resistant FSGS.,C0301630|C0229671|C0001924|C1542147|C1521761|C1273518|C0392747|C0289313|G0000000|C1521970|C0332325|C0017668
We hypothesized that infants receiving both interventions would have a lower weight-for-length percentile at 1 year compared with infants in the other three groups as well as lower conditional weight gain during the first year.,We hypothesized infants receiving interventions lower weight-for-length percentile 1 compared infants lower conditional weight gain year.,G0000000|G0000000|C0021270|C1514756|C0886296|C0441994|C0005910|C1264641|G0000000|C1707455|C0021270|C0441994|C1701901|C0005910|C1517378|C0439234
"In this study, “reduced seizures” was defined as a reduction in seizure frequency at the end of the study compared to baseline.","In study, “reduced seizures” defined reduction seizure frequency study compared baseline.",G0000000|C0557651|G0000000|G0000000|C1704788|C0301630|C0036572|C0376249|C0557651|C1707455|C0168634
Lifetime prevalence percentages are reported.,Lifetime prevalence percentages reported.,C4071830|C0033105|C0439165|C0684224
"Patient-reported outcomes (PROs) (fatigue, cognition, anxiety, depression, sleep disturbance, mental health, and physical health) and fitness performance-based measures (Timed Up and Go [TUG], Karnofsky Performance Status, and composite strength scoring) were assessed at baseline and at discharge.","Patient-reported outcomes (PROs) (fatigue, cognition, anxiety, depression, sleep disturbance, mental health, physical health) fitness performance-based measures (Timed Up Go [TUG], Karnofsky Performance Status, composite strength scoring) assessed baseline discharge.",C0747307|C1274040|C3813209|C0015672|C0009240|C0003467|C0011570|C0037313|C2699787|C0229992|C0018684|C0031809|C0018684|C1456706|C0597198|C0079809|C0392761|G0000000|C1822658|C1319201|C0206065|C0597198|C0449438|C0205199|C0237897|C0449820|C1516048|C0168634|C0012621
"The secondary outcomes include monthly seizure frequency, time to first seizure (in days) after enrollment, proportion of patients experiencing seizure freedom for the duration of the study, and quality of life measured by the “Personal Impact of Epilepsy Scale,” all assessed by an independent study nurse.","The secondary outcomes monthly seizure frequency, time seizure (in days) enrollment, proportion patients experiencing seizure freedom duration study, quality life measured “Personal Impact Epilepsy Scale,” assessed independent study nurse.",G0000000|C0027627|C1274040|C0332177|C0036572|C0376249|C0040223|C0036572|G0000000|C0439228|C1516879|C1709707|C0030705|C0237607|C0036572|C0016694|C0449238|C0557651|C0332306|C0376558|C0444706|G0000000|C1825598|C0014544|G0000000|C1516048|C0085862|C0557651|C0028661
"All 15 patients who completed the study contributed AHI and snoring data, but supine time data were not available for one patient because of a position monitoring device upload failure.","All 15 patients completed study contributed AHI snoring data, supine time data patient position monitoring device upload failure.",G0000000|C0450371|C0030705|C0205197|C0557651|C1880177|G0000000|C0037384|C1511726|C0038846|C0040223|C1511726|C0030705|C0733755|C0150369|C0025080|C1710578|C0231174
"The 11 secondary outcomes were four therapy outcome measures17; attention and play ratings; the Vineland socialisation domain; three separate binary variables indicating improvement or no deterioration over 12 months in auditory comprehension, expressive language, and phonology; and a fourth binary variable reflecting whether, at the 12 month follow up, the child satisfied any of the clinical criteria (a reassessment of eligibility for the trial irrespective of the initial clinical criterion on which the child entered the trial).","The 11 secondary outcomes therapy outcome measures17; attention play ratings; Vineland socialisation domain; separate binary variables indicating improvement deterioration 12 months auditory comprehension, expressive language, phonology; fourth binary variable reflecting whether, 12 month follow up, child satisfied clinical criteria (a reassessment eligibility trial irrespective initial clinical criterion child entered trial).",G0000000|C0450371|C0027627|C1274040|C0039798|C1274040|G0000000|C0004268|C0032214|C0871208|C0332020|C0037447|C1880389|C0443299|C1706942|C0439828|G0000000|C2986411|C0868945|C0450371|C0439231|C0439825|C0162340|C0185117|C0023008|C0597725|C0205438|C1706942|C0439828|C0558058|G0000000|C0450371|C0332177|C0332283|G0000000|C0008059|C0242428|C0205210|C0243161|G0000000|G0000000|C0013893|C0008976|G0000000|C0205265|C0205210|C0243161|C0008059|C1521975|C0008976
The skin sensitivity to the allergens decreased also significantly (P < 0.01).,The skin sensitivity allergens decreased (P < 0.01).,G0000000|C0444099|C0020517|C0002092|C0205216|C0369773|G0000000|C0450371
"The outcomes revealed that: (1) specific sight word training had large and significant valid treatment effects on trained irregular words, untrained irregular words, word reading fluency, and word reading comprehension, as well as a moderate and significant treatment effect on nonword reading accuracy, and no treatment effect on nonword reading fluency; (2) specific phonics training had large and significant “valid” treatment effects (i.e., significantly larger than test-retest effects) on trained and untrained irregular words, word and nonword reading fluency, and reading comprehension, as well as a moderate-to-large effect on nonword reading accuracy; and (3) order of training (i.e., phonics-then-sight words; sight words-then-phonics; mixed) had an effect on untrained irregular word reading (significantly better after phonics-then-sight word training, than the reverse) but not on trained irregular words, nonword reading accuracy or fluency, word reading fluency, or reading comprehension (see Table 1 for a summary of the effects found by McArthur et al.","The outcomes revealed that: (1) specific sight word training valid treatment effects trained irregular words, untrained irregular words, word reading fluency, word reading comprehension, moderate treatment nonword reading accuracy, treatment nonword reading fluency; (2) specific phonics training “valid” treatment effects (i.e., larger test-retest effects) trained untrained irregular words, word nonword reading fluency, reading comprehension, moderate-to-large nonword reading accuracy; (3) training (i.e., phonics-then-sight words; sight words-then-phonics; mixed) untrained irregular word reading (significantly phonics-then-sight word training, reverse) trained irregular words, nonword reading accuracy fluency, word reading fluency, reading comprehension (see Table 1 summary effects McArthur al.",G0000000|C1274040|C0443289|G0000000|G0000000|C0205369|C0042789|C1705313|C0040607|C2349099|C0039798|C1280500|C0336809|C0205271|C1705313|G0000000|C0205271|C1705313|C1705313|C0034754|C0870569|C1705313|C0034754|C0162340|C0205081|C0039798|G0000000|C0034754|C0443131|C0039798|G0000000|C0034754|C0870569|G0000000|C0205369|C0871074|C0040607|G0000000|C0039798|C1280500|C0683454|C0549177|C0022885|C1280500|C0336809|G0000000|C0205271|C1705313|C1705313|G0000000|C0034754|C0870569|C0034754|C0162340|C0205081|G0000000|C0034754|C0443131|G0000000|C0040607|C0683454|C0871074|C1705313|C0042789|C1705313|C0205430|G0000000|C0205271|C1705313|C0034754|G0000000|C0871074|C1705313|C0040607|C1555029|C0336809|C0205271|C1705313|G0000000|C0034754|C0443131|C0870569|C1705313|C0034754|C0870569|C0034754|C0162340|C0042789|C0039224|G0000000|C1552616|C1280500|G0000000|C0202311
"Secondary outcomes will include: Mean change in weight and weight-for-length Z-scores (WLZ) Mean intake of energy, fat, iron and zinc from complementary foods Proportion of children consuming foods from 4 or more food groups Proportion of children consuming the recommended number of semi-solid/soft meals and snacks per day Maternal level of knowledge and practice of recommended feeding and health practices  Recumbent length will be measured to the nearest 0.1 cm using a portable wooden infant/child length board (Shorr Productions, Perspective Enterprises, Portage, Missouri) with a fixed head and sliding foot piece.","Secondary outcomes include: Mean change weight weight-for-length Z-scores (WLZ) Mean intake energy, fat, iron zinc complementary foods Proportion children consuming foods 4 food Proportion children consuming recommended semi-solid/soft meals snacks day Maternal level knowledge practice recommended feeding health practices Recumbent length measured nearest 0.1 cm portable wooden infant/child length board (Shorr Productions, Perspective Enterprises, Portage, Missouri) fixed head sliding foot piece.",C0027627|C1274040|C0332257|C0444504|C0392747|C0005910|C0005910|C0871421|G0000000|C0444504|C1512806|C0424589|C0424612|C0302583|C0043481|G0000000|C0016452|C1709707|C0008059|G0000000|C0016452|G0000000|C0016452|C1709707|C0008059|G0000000|C0034866|C0205208|C1998602|C0453863|C0332173|C2347083|C0441889|C0376554|C0237607|C0034866|C0204695|C0018684|C0237607|C0444334|C1444754|C0444706|C0205107|G0000000|G0000000|G0000000|C0557859|C0021270|C1444754|C0972401|G0000000|C0033268|G0000000|G0000000|G0000000|C0026222|C0443218|C0018670|C0332246|C0016504|C2982836
"Participants were assessed at baseline (prerandomization), post-intervention (end of therapy), 6 months, and 12 months (end of study) after randomization by clinicians masked to treatment assignment and standardized in administration of primary and secondary outcome assessments.5 A 12-monthchange in the log-transformed Wolf Motor Function Test (WMFT) time score was the primary outcome.","Participants assessed baseline (prerandomization), post-intervention (end therapy), 6 months, 12 months (end study) randomization clinicians masked treatment assignment standardized administration primary secondary outcome assessments.5 A 12-monthchange log-transformed Wolf Motor Function Test (WMFT) time score primary outcome.",C0679646|C1516048|C0168634|G0000000|C2347647|C0444930|C0039798|G0000000|C0439231|C0450371|C0439231|C0444930|C0557651|C0034656|C0871685|C0150108|C0039798|C1516050|G0000000|C0001554|C0205225|C0027627|C1274040|C1261322|G0000000|C0450371|C1708728|C0325001|C1513492|C0031843|C0022885|G0000000|C0040223|C0449820|C0205225|C1274040
"After lung cancer, prostate cancer (PC) is the most common cancer among men, with nearly a million new cases diagnosed worldwide [1].","After lung cancer, prostate cancer (PC) common cancer men, diagnosed worldwide [1].",G0000000|C0024109|C0006826|C0033572|C0006826|C0031995|C0205214|C0006826|C0025266|C0011900|G0000000|G0000000
The weekly SMS assessment will be sent at a fixed point in time each week (6 p.m. at the weekday of registration for the program).,The weekly SMS assessment fixed time week (6 p.m. weekday registration program).,G0000000|C0332174|G0000000|C1261322|C0443218|C0040223|C0332174|G0000000|C0369773|C0680189|C1514821|C1709697
Chemotherapy toxicity is shown in Table 3.,Chemotherapy toxicity Table 3.,C0013216|C0040539|C0039224|G0000000
"Analyses focus on youth reports of the number of times tobacco was used in the prior 30 days, derived from 7 assessment waves when youth were age 11, 12, 13, 14, 16–17, 18–19, and 22.","Analyses focus youth reports times tobacco prior 30 days, derived 7 assessment waves youth age 11, 12, 13, 14, 16–17, 18–19, 22.",C0002778|C0205234|C0001578|C0684224|C0040223|C0040329|C0332152|C0450371|C0439228|C1441547|G0000000|C1261322|C0678544|C0001578|C0001779|C0450371|C0450371|C0450371|C0450371|G0000000|G0000000|C0450371
No statistically significant differences were observed on the measure of function [(c) ADCS–ADL19].,No statistically differences observed measure function [(c) ADCS–ADL19].,G0000000|C0038215|C1705241|C1441672|C0079809|C0031843|G0000000|G0000000
"We had exact information on clopidogrel use, by individual-level linkage to dispensed prescriptions and complete data on events.","We exact clopidogrel use, individual-level linkage dispensed prescriptions complete data events.",G0000000|C2828393|C0070166|C0042153|C0027361|C0023745|C1880359|C0033080|C0205197|C1511726|C0441471
"Primary endpoints were complete response (CR), grade 4 toxicity, and 90-day treatment-related mortality (TRM).","Primary endpoints complete response (CR), grade 4 toxicity, 90-day treatment-related mortality (TRM).",C0205225|C2349179|C0205197|C0871261|C0201975|C0441800|G0000000|C0040539|C0450371|C0039798|C0026565|G0000000
The same methods and definitions to determine smoking abstinence are used as for the primary outcome.,The methods definitions determine smoking abstinence primary outcome.,G0000000|C0025663|C1550452|G0000000|C0037369|C3843422|C0205225|C1274040
"Secondary outcomes include safety, number of days free of mechanical ventilation, number of days free of renal replacement therapy, intensive care length of stay, in-hospital length of stay, quality of life as evaluated by the EQ-5D and renal replacement therapy dependence at hospital discharge.","Secondary outcomes safety, days free mechanical ventilation, days free renal replacement therapy, intensive care length stay, in-hospital length stay, quality life evaluated EQ-5D renal replacement therapy dependence hospital discharge.",C0027627|C1274040|C0036043|C0439228|C0332296|C0443254|C0035203|C0439228|C0332296|C0022646|C0035139|C0039798|C0162425|C1947933|C1444754|G0000000|C0019994|C1444754|G0000000|C0332306|C0376558|C0220825|C0205163|C0022646|C0035139|C0039798|C0011546|C0019994|C0012621
"All patients were invited for five appointments with the research coordinator, at 15, 30, 60, 90, and 180 days after the randomization.","All patients invited appointments coordinator, 15, 30, 60, 90, 180 days randomization.",G0000000|C0030705|G0000000|C0003629|C1711307|C0450371|C0450371|C0450371|C0450371|C1442061|C0439228|C0034656
"At the scheduled follow-up visits (at 3, 6, 9, 12, 15, or 18 months), caregivers were invited to attend the health center for data collection.","At scheduled follow-up visits (at 3, 6, 9, 12, 15, 18 months), caregivers invited attend health center data collection.",G0000000|C0086960|C0589120|C0545082|G0000000|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0439231|C0085537|G0000000|C1999232|C0018684|C0205099|C1511726|C1516698
"Delirium was defined as the agitation score of ≥4 for more than five minutes, despite all calming efforts done by the parents.","Delirium defined agitation score ≥4 minutes, calming efforts parents.",C0011206|C1704788|C0085631|C0449820|G0000000|C0439232|C0150157|C0015264|C0030551
"Height and weight will be converted into z-scores (HAZ, WAZ) [30].","Height weight converted z-scores (HAZ, WAZ) [30].",C0489786|C0005910|G0000000|C0871421|G0000000|G0000000|C0450371
O: olodaterol; T: tiotropium; CWRCE: constant work-rate cycle ergometry; IC: inspiratory capacity; EET: exercise endurance time.,O: olodaterol; T: tiotropium; CWRCE: constant work-rate cycle ergometry; IC: inspiratory capacity; EET: exercise endurance time.,C0483204|C2934193|C2603360|C0213771|G0000000|C1547014|C0043227|C1511572|C0085143|C0020750|C0004048|C1516240|C1537011|C0015259|C0518031|C0040223
"Overall survival time differed significantly between the study groups in favour of 16 Gy/2 fr (median 8.0 months), compared to 20 Gy/5 fr (median 5.3 months), P=0.016 (Figure 7).","Overall survival time differed study favour 16 Gy/2 fr (median 8.0 months), compared 20 Gy/5 fr (median 5.3 months), P=0.016 (Figure 7).",C0282416|C0038952|C0040223|G0000000|C0557651|C0309049|G0000000|C2348513|C0549183|G0000000|C0439231|C1707455|G0000000|C2348513|C0549183|G0000000|C0439231|C0369773|G0000000|G0000000
"The primary outcome in STAMP was the annual change in central spherical equivalent refractive error measured by cycloplegic autorefraction (Grand Seiko WV-500 autorefractor; Grand Seiko Co., Hiroshima, Japan).40,41 Ten measurements of the right eye were made annually, and were averaged using the power vector method described by Thibos et al.42 Measurements were made 30 minutes after instilling the first of two drops of 1% tropicamide, which were separated by 5 minutes.","The primary outcome STAMP annual change central spherical equivalent refractive error measured cycloplegic autorefraction (Grand Seiko WV-500 autorefractor; Grand Seiko Co., Hiroshima, Japan).40,41 Ten measurements eye annually, averaged power vector method Thibos al.42 Measurements 30 minutes instilling drops 1% tropicamide, separated 5 minutes.",G0000000|C0205225|C1274040|C1823540|C0332181|C0392747|C0205099|C0332501|C0205163|C0429585|C0743559|C0444706|C0010586|G0000000|G0000000|G0000000|C0043127|C1275634|G0000000|G0000000|C3245499|G0000000|C0022341|C0014518|C0242485|C0015392|C0332181|C1510992|C0032863|C0086022|C0025663|G0000000|C0202311|C0242485|C0450371|C0439232|C1720298|C0991568|G0000000|C0041190|C0086972|G0000000|C0439232
"The secondary outcome measurements included the quality of life, measured with the St. George's Respiratory Questionnaire (SGRQ).","The secondary outcome measurements included quality life, measured St. George's Respiratory Questionnaire (SGRQ).",G0000000|C0027627|C1274040|C0242485|C0332257|C0332306|C0376558|C0444706|C0036056|G0000000|C0521346|C0034394|G0000000
The test was completed when patients reached 85% of their estimated maximal heart rate.,The test completed patients reached 85% estimated maximal heart rate.,G0000000|C0022885|C0205197|C0030705|C2584321|C0450371|C0750572|C0205289|C0018787|C0871208
Chronic kidney disease (CKD) patients on renin–angiotensin–aldosterone system inhibitors (RAASi) with serum K+ levels ≥5.1 mEq/L to <6.5 mEq/L (n = 243) received patiromer (4.2 g or 8.4 g BID initially) for 4 weeks (initial treatment phase); the primary efficacy endpoint was mean change in serum K+ from baseline to week 4.,Chronic kidney disease (CKD) patients renin–angiotensin–aldosterone system inhibitors (RAASi) serum K+ levels ≥5.1 mEq/L <6.5 mEq/L (n = 243) received patiromer (4.2 8.4 BID initially) 4 weeks (initial treatment phase); primary efficacy endpoint change serum K+ baseline week 4.,C0205191|C0022646|C0012634|C1561643|C0030705|G0000000|C0449913|C0243077|G0000000|C0229671|C0597277|C0441889|G0000000|C0439375|G0000000|C0439375|C0369718|G0000000|C1442061|C1514756|C4045522|G0000000|G0000000|G0000000|C0205265|G0000000|C0439230|C0205265|C0039798|C0205390|C0205225|C1280519|C2349179|C0392747|C0229671|C0597277|C0168634|C0332174|G0000000
"According to the same severity of the acne in two groups in different study periods, as well as fewer side effects and more patients' satisfaction, the low-dose isotretinoin can be considered in the treatment of acne.","According severity acne study periods, fewer effects patients' satisfaction, low-dose isotretinoin considered treatment acne.",C0680240|C0439793|C0001144|C0557651|C0439531|C0205388|C1280500|C0030705|C0242428|C0445550|C0022265|C0750591|C0039798|C0001144
"There was significant difference among the three groups in mean hospital stay (1.8, 1.5 and 9.7 hours, respectively) and time to work resumption (1.3, 1.1 and 12.7 days, respectively).","There difference hospital stay (1.8, 1.5 9.7 hours, respectively) time resumption (1.3, 1.1 12.7 days, respectively).",G0000000|C1705241|C0019994|G0000000|G0000000|G0000000|G0000000|C0439227|G0000000|C0040223|G0000000|G0000000|G0000000|C0450371|C0439228|G0000000
Change in weight and caloric intake following birth.,Change weight caloric intake birth.,C0392747|C0005910|G0000000|C1512806|C0005615
There were no differences between the two treatments with respect to total number of arrests or misdemeanors during this period (See Table 3).,There differences treatments respect total arrests misdemeanors period (See Table 3).,G0000000|C1705241|C0087111|C0679133|C0439175|C0237477|C0680469|C0439531|C0042789|C0039224|G0000000
"Baseline characteristics by green tea consumption habits, the SMHSa During a mean follow-up of 4.6 years between 2002 and 2008, 243 incident cases of colorectal cancer, including 133 colon and 110 rectal cancers, were identified; 123 patients had early-stage tumors and 93 had late-stage tumors.","Baseline characteristics green tea consumption habits, SMHSa During follow-up 4.6 2002 2008, 243 incident colorectal cancer, including 133 colon 110 rectal cancers, identified; 123 patients early-stage tumors 93 late-stage tumors.",C0168634|C1521970|C0332583|C0039400|C0009830|C0018464|G0000000|G0000000|C0589120|G0000000|G0000000|G0000000|C1442061|C1551358|C0555952|C0006826|C0332257|C1442061|C0009368|C1442061|C0205052|C0006826|C0205396|C1442061|C0030705|C2363430|C0027651|C0450371|C1279941|C0027651
"Secondary outcomes consisted of parent, teacher, and self-reports.","Secondary outcomes consisted parent, teacher, self-reports.",C0027627|C1274040|C0332529|C0030551|C0221457|C0681906
"The primary end point was the evaluation of the beneficial effects of food supplementation with VSL#3 in relapsing mild-to-moderate UC patients, assessed by a decrease in the UCDAI of 50% or more, from baseline to week 8.","The primary evaluation beneficial effects food supplementation VSL#3 relapsing mild-to-moderate UC patients, assessed decrease UCDAI 50% more, baseline week 8.",G0000000|C0205225|C0220825|G0000000|C1280500|C0016452|C0242297|G0000000|C0035020|C1299392|G0000000|C0030705|C1516048|C0392756|G0000000|C0450371|C0205172|C0168634|C0332174|G0000000
"The prespecified primary parameter was loss of therapeutic response (LTR), defined as increase in VAS pain score to <30% reduction from pre-milnacipran exposure or worsening of fibromyalgia requiring alternative treatment.","The prespecified primary parameter loss therapeutic response (LTR), defined increase VAS pain score <30% reduction pre-milnacipran exposure worsening fibromyalgia requiring alternative treatment.",G0000000|G0000000|C0205225|C0549193|C1517945|C0087111|C0871261|C0023978|C1704788|C0442805|C0042815|C0030193|C0449820|C0450371|C0301630|C0332152|C0274281|C0332271|C0016053|G0000000|C1523987|C0039798
"Comparison of the Effects of Tai Chi Versus Usual Care on Change in Outcomes After 12 Weeks FVC = forced vital capacity FRC = functional residual capacity UCSD = University of California, San Diego SOB = shortness of breath CES = Center for Epidemiologic Studies The exit-interview data suggest that the tai chi patients found the program valuable and enjoyable.","Comparison Effects Tai Chi Versus Usual Care Change Outcomes After 12 Weeks FVC = forced vital capacity FRC = functional residual capacity UCSD = University California, San Diego SOB = shortness breath CES = Center Epidemiologic Studies The exit-interview data tai chi patients program valuable enjoyable.",C1707455|C1280500|G0000000|C1720589|G0000000|C3538928|C1947933|C0392747|C1274040|G0000000|C0450371|C0439230|C3714541|G0000000|C0441722|C0442732|C1516240|C0016815|G0000000|C0205245|C1609982|C1516240|G0000000|G0000000|C0041740|C0006754|C1826357|G0000000|C0013404|G0000000|C1282927|C0225386|C0265493|G0000000|C0205099|C0014507|C0947630|G0000000|C0337094|C1511726|G0000000|C1720589|C0030705|C1709697|G0000000|G0000000
Immune responses pre- and postvaccination to MUC-1 were also evaluated using the ELISPOT assay.,Immune responses pre- postvaccination MUC-1 evaluated ELISPOT assay.,C0439662|C0871261|C0332152|G0000000|G0000000|C0220825|C0920508|C0005507
Global improvement at 12 weeks was dichotomized into improved vs no change or worse.,Global improvement 12 weeks dichotomized improved change worse.,C0205246|C2986411|C0450371|C0439230|G0000000|C0184511|C0392747|C0332271
"In addition, data could not be evaluated by dyad, because parent participants were not necessarily related to adolescent participants.","In addition, data evaluated dyad, parent participants adolescent participants.",G0000000|C0332287|C1511726|C0220825|C0870454|C0030551|C0679646|C0205653|C0679646
"Eleven neuroendocrine tumors were also excluded, leaving 77,446 participants in the study.","Eleven neuroendocrine tumors excluded, leaving 77,446 participants study.",C0205457|C0027912|C0027651|C1554077|G0000000|C0450371|C0679646|C0557651
"Hedayati and associates found that 26.7% of the patients in hemodialysis treatment center suffered from depression; 65% of the patients were severe depression, 27% were afflicted to moderate depression, and 8% were experiencing mild depression (Hedayati et al., 2008).","Hedayati associates 26.7% patients hemodialysis treatment center suffered depression; 65% patients severe depression, 27% afflicted moderate depression, 8% experiencing mild depression (Hedayati al., 2008).",G0000000|C0750490|C0450371|C0030705|C0019004|C0039798|C0205099|C0683278|C0011570|C0450371|C0030705|C0205082|C0011570|C0450371|G0000000|C0205081|C0011570|G0000000|C0237607|C2945599|C0011570|G0000000|C0202311|G0000000
"Outcome measures were average daily serves of fruit and vegetables (primary), diet quality index (primary), weekly minutes of physical activity (secondary), number of cigarettes smoked (secondary), the percentage of women meeting health behavior guidelines (fruit, vegetables (primary), physical activity, and smoking (secondary)), and awareness of GWG guidelines (i.e.","Outcome measures average daily serves fruit vegetables (primary), diet quality (primary), weekly minutes physical activity (secondary), cigarettes smoked (secondary), percentage women meeting health behavior guidelines (fruit, vegetables (primary), physical activity, smoking (secondary)), awareness GWG guidelines (i.e.",C1274040|C0079809|C1510992|C0332173|G0000000|C0016767|C0042440|C0205225|C0012155|C0332306|C0205225|C0332174|C0439232|C0031809|C0205177|C0027627|C0677453|C0037366|C0027627|C0439165|C0043210|C0556656|C0018684|C0004927|C0162791|C0016767|C0042440|C0205225|C0031809|C0205177|C0037369|C0027627|C0004448|G0000000|C0162791|C0683454
Behaviors that are reinforced and punished during interactions are posited to be the primary shapers of youth outcomes.,Behaviors reinforced punished interactions posited primary shapers youth outcomes.,C0004927|G0000000|C0458279|C1704675|C0814253|C0205225|G0000000|C0001578|C1274040
"Pain = one or more pain symptoms, 86/223 GBS patients started with pain before onset of weakness 4 weeks after randomization, 58 patients (57%) in the IVIg/placebo group and 51 (49%) in the IVIg/methylprednisolone group reported pain (no significant difference).","Pain = pain symptoms, 86/223 GBS patients started pain onset weakness 4 weeks randomization, 58 patients (57%) IVIg/placebo 51 (49%) IVIg/methylprednisolone reported pain (no difference).",C0030193|G0000000|C0030193|C0683368|C0450371|C0018378|C0030705|C1272689|C0030193|C0206132|C3714552|G0000000|C0439230|C0034656|C0450371|C0030705|C0450371|C0085297|C0450371|C0450371|C0085297|C0684224|C0030193|G0000000|C1705241
"Secondary outcomes at baseline, one and three months are reported in Table 4.","Secondary outcomes baseline, months reported Table 4.",C0027627|C1274040|C0168634|C0439231|C0684224|C0039224|G0000000
"Example of the flip chart HPV, human papillomavirus.","Example flip chart HPV, human papillomavirus.",C1707959|C1413357|C0007963|C0021344|C0086418|C0030358
Prognostic value of Vitamin D level for gestational diabetes prediction The prognostic value of Vitamin D level for gestational diabetes prediction was evaluated using regression analysis.,Prognostic Vitamin D level gestational diabetes prediction The prognostic Vitamin D level gestational diabetes prediction evaluated regression analysis.,C0220901|C0042890|C0073187|C0441889|C0439671|C0011847|C0681842|G0000000|C0220901|C0042890|C0073187|C0441889|C0439671|C0011847|C0681842|C0220825|C0684320|C0002778
The primary objective was vaccine efficacy (VE) against HPV-16/18 associated 6-month persistent infection (PI) and/or cervical intraepithelial neoplasia (CIN) 1+.,The primary objective vaccine efficacy (VE) HPV-16/18 6-month persistent infection (PI) and/or cervical intraepithelial neoplasia (CIN) 1+.,G0000000|C0205225|C0018017|C0042210|C1280519|C0042469|C0021344|C0332177|C0205322|C0009450|C0429863|G0000000|C0027530|C1512942|C0027651|G0000000|G0000000
"Anxiety/pain were assessed with the FLACC scale during the anesthetic moment, as well as heart rate variability and skin conductance before and during the anesthetic moment, between the control and experimental group.","Anxiety/pain assessed FLACC scale anesthetic moment, heart rate variability skin conductance anesthetic moment, control experimental group.",C0003467|C1516048|C4068796|C0175659|C0002932|G0000000|C0018787|C0871208|C2827666|C0444099|G0000000|C0002932|G0000000|C0243148|C1517586|C0441833
The results showed that the interaction effects were observed in quality of sleep and staff encouragement.,The interaction effects observed quality sleep staff encouragement.,G0000000|C1704675|C1280500|C1441672|C0332306|C0037313|C0851286|C0870494
"Before and during the four weeks of study, the signs of breast milk sufficiency were evaluated through measurement of growth parameters and use of follow-up forms for measuring the number of wet diapers in one day, frequency of defecation and infant breast-feeding times in a day.","Before weeks study, signs breast milk sufficiency evaluated measurement growth parameters follow-up forms measuring wet diapers day, frequency defecation infant breast-feeding times day.",C0332152|C0439230|C0557651|C0220912|C0006141|C0026131|C0205410|C0220825|C0242485|C0018270|C0449381|C0589120|C0348078|C0444706|C0205381|C0180416|C0332173|C0376249|C0011135|C0021270|C0006147|C0040223|C0332173
"The unit of analysis was suicide rates, and the intervention was the installation of the barrier.","The unit analysis suicide rates, intervention installation barrier.",G0000000|C0439148|C0002778|C0038661|C0871208|C0886296|G0000000|C1706912
"The secondary outcome measures were: health status FIQ, the Six-Minute Walk Test (6MWT) for endurance33), quality of life scores represented by SF-36 physical and mental component scores34) and depression as assessed by the Beck Depression Inventory (BDI)35).","The secondary outcome measures were: health status FIQ, Six-Minute Walk Test (6MWT) endurance33), quality life scores represented SF-36 physical mental component scores34) depression assessed Beck Depression Inventory (BDI)35).",G0000000|C0027627|C1274040|C0079809|G0000000|C0018684|C0449438|G0000000|C0205452|C0080331|C0022885|G0000000|G0000000|C0332306|C0376558|C0449820|C1882932|C0037712|C0031809|C0229992|C0449432|G0000000|C0011570|C1516048|G0000000|C0011570|C0021941|C0006448
"As one of the primary outcome measures is transplant knowledge, patients’ level of prior LDKT and DDKT education will also be evaluated.","As primary outcome measures transplant knowledge, patients’ level prior LDKT DDKT education evaluated.",G0000000|C0205225|C1274040|C0079809|C0040732|C0376554|G0000000|C0441889|C0332152|G0000000|G0000000|C0013621|C0220825
"Geometric mean of percentage mortality, blood feeding and parity rate for An.","Geometric percentage mortality, blood feeding parity rate An.",C0449829|C0439165|C0026565|C0005767|C0204695|C0030563|C0871208|G0000000
"Both in the preliminary and the main study phase, a follow-up assessment will be conducted at 12 and 24 weeks using these three instruments.","Both preliminary main study phase, follow-up assessment conducted 12 24 weeks instruments.",G0000000|C0439611|C0205225|C0557651|C0205390|C0589120|C1261322|C0004927|C0450371|C0450371|C0439230|C0348000
"In our data, alpha coefficients were 0.88, 0.86, and 0.79 for personal burnout, work related burnout, and client related burnout respectively.","In data, alpha coefficients 0.88, 0.86, 0.79 personal burnout, burnout, client burnout respectively.",G0000000|C1511726|C0439095|C1707429|C0450371|C0450371|C0450371|C1519021|C0476644|C0476644|C0008942|C0476644|G0000000
"Furthermore, we did not find any functional MRI studies of pa-tients with migraine.","Furthermore, functional MRI studies pa-tients migraine.",G0000000|C0205245|C0024485|C0947630|C0030428|C0149931
"The primary outcome is latrine use, including use for the safe disposal of child feces.","The primary outcome latrine use, including safe disposal child feces.",G0000000|C0205225|C1274040|C0023124|C0042153|C0332257|G0000000|C1707797|C0008059|C0015733
Trial registration number ISRCTN15342873.,Trial registration ISRCTN15342873.,C0008976|C1514821|G0000000
External Reviewer Ratings of Simulation Group Fellows Repeated-measures ANOVA over three simulations (pa).,External Reviewer Ratings Simulation Group Fellows Repeated-measures ANOVA simulations (pa).,C0205101|C1709941|C0871208|C0679083|C0441833|G0000000|C0205341|G0000000|C0679083|C0030428
"There were no significant differences among the escitalopram, placebo, and problem-solving therapy groups in stroke characteristics, severity of stroke as measured by the National Institutes of Health Stroke Scale, or severity of impairment in activities of daily living, as measured by the Functional Independence Measure score.","There differences escitalopram, placebo, problem-solving therapy stroke characteristics, severity stroke measured National Institutes Health Stroke Scale, severity impairment activities daily living, measured Functional Independence Measure score.",G0000000|C1705241|C1099456|C0032042|C0033213|C0039798|C0038454|C1521970|C0439793|C0038454|C0444706|C3245503|C0021622|C0018684|C0038454|C0175659|C0439793|C0221099|C0441655|C0332173|C0376558|C0444706|C0205245|C0085862|C0079809|C0449820
"There was no difference between the two groups in mechanical ventilation-free days, renal replacement therapy-free days, length of stay in ICU or length of stay in hospital (Table 3).","There difference mechanical ventilation-free days, renal replacement therapy-free days, length stay ICU length stay hospital (Table 3).",G0000000|C1705241|C0443254|C0035203|C0439228|C0022646|C0035139|C0039798|C0439228|C1444754|G0000000|C0021708|C1444754|G0000000|C0019994|C0039224|G0000000
The primary airway outcome for benefit was the dose of methacholine provoking a fall in forced expiratory volume in 1 second (FEV1) of 20% or more (methacholine PD20) and for systemic adverse effects was overnight urinary cortisol/creatinine (OUCC).,The primary airway outcome benefit dose methacholine provoking fall forced expiratory volume 1 (FEV1) 20% (methacholine PD20) systemic adverse effects overnight urinary cortisol/creatinine (OUCC).,G0000000|C0205225|C0178987|C1274040|C0814225|C0178602|C0600370|G0000000|C0085639|C0441722|C0231800|C0449468|G0000000|G0000000|C0450371|C0600370|G0000000|C0205373|G0000000|C1280500|C0439583|C0042027|C0552387|G0000000
"The estimated GFR (eGFR) was calculated using the modified Schwartz equation for children.32 Patients were considered hypertensive if they had repeated systolic or diastolic blood pressure readings exceeding the 95th percentile, or pre-hypertensive if the blood pressure was between the 90th to 95th percentiles recorded at more than one outpatient visit, or if anti-hypertensive medication was prescribed for blood pressure control.","The estimated GFR (eGFR) calculated modified Schwartz equation children.32 Patients considered hypertensive repeated systolic diastolic blood pressure readings exceeding 95th percentile, pre-hypertensive blood pressure 90th 95th percentiles recorded outpatient visit, anti-hypertensive medication prescribed blood pressure control.",G0000000|C0750572|C0017654|C1739039|C0444686|C0392747|G0000000|C0552449|C0008059|C0030705|C0750591|C0857121|C0205341|C0039155|C0012000|C0005767|C0033095|C0034754|G0000000|G0000000|C1264641|C0332152|C0005767|C0033095|G0000000|G0000000|C1264641|C0034869|C0029921|C0545082|C0003364|C0013227|C0278329|C0005767|C0033095|C0243148
c. Difference in frequency of blood transfusion requirements between the oxpentifylline and control groups during the 4 month study period.,c. Difference frequency blood transfusion requirements oxpentifylline control 4 month study period.,G0000000|C1705241|C0376249|C0005767|C0005841|C1514873|C0030899|C0243148|G0000000|C0332177|C0557651|C0439531
"The primary outcome was the efficacy of probiotic yogurt in prevention of diarrhoea, classified at different levels of severity: for example, less severe (stool frequency ≥2/day for 2 or more days with stool consistency ≥5 on the BSS); more severe (stool frequency ≥3/day for 2 or more days with stool consistency ≥6 on the BSS).","The primary outcome efficacy probiotic yogurt prevention diarrhoea, classified levels severity: example, severe (stool frequency ≥2/day 2 days stool consistency ≥5 BSS); severe (stool frequency ≥3/day 2 days stool consistency ≥6 BSS).",G0000000|C0205225|C1274040|C1280519|C0525033|C0043419|C0199176|C0011991|C0008902|C0441889|C0439793|C1707959|C0205082|C0015733|C0376249|G0000000|G0000000|C0439228|C0015733|C0332529|G0000000|G0000000|C0205082|C0015733|C0376249|G0000000|G0000000|C0439228|C0015733|C0332529|G0000000|G0000000
"In addition, for the two variables that were available before and after the intervention (whether or not smoking status was assessed, and, smoking status – current, former, never), we assessed changes from pre- to post-intervention using chi-square tests.","In addition, variables intervention (whether smoking status assessed, and, smoking status – current, former, never), assessed pre- post-intervention chi-square tests.",G0000000|C0332287|C0439828|C0886296|G0000000|C0037369|C0449438|C1516048|G0000000|C0037369|C0449438|G0000000|C0521116|C0205156|C2003901|C1516048|C0332152|C2347647|C1552646|C0022885
The equivalence limit was defined using the baseline data and choosing an equivalence limit of approximately 1 SD or less of the baseline distribution for muscle strength tests and percent predicted PFTs.,The equivalence limit defined baseline data choosing equivalence limit 1 SD baseline distribution muscle strength tests percent predicted PFTs.,G0000000|C0205163|C0439801|C1704788|C0168634|C1511726|C1707391|C0205163|C0439801|G0000000|C2699239|C0168634|C0520511|C0026845|C0237897|C0022885|C0439165|C0681842|C0024119
Conclusion Penicillin treatment had no beneficial effect in children with sore throat on the average duration of symptoms.,Conclusion Penicillin treatment beneficial children sore throat average duration symptoms.,C1707478|C0030827|C0039798|G0000000|C0008059|C0234233|C0031354|C1510992|C0449238|C0683368
"The secondary outcome indicators were the GOAS total score, AN symptoms or their consequences (BMI, amenorrhea, EDI scores), social adjustment and the number of hospitalizations in the course of follow-up.","The secondary outcome indicators GOAS total score, AN symptoms consequences (BMI, amenorrhea, EDI scores), social adjustment hospitalizations follow-up.",G0000000|C0027627|C1274040|C0021212|C1425957|C0439175|C0449820|G0000000|C0683368|C0686907|G0000000|C0002453|G0000000|C0449820|C0728831|C0376209|C0019993|C0589120
"We have previously documented the effectiveness of this intervention, which delivered a 2‐month supply of Sprinkles, 1 in reducing anaemia for up to 7 months post intervention among children of 9–24 months of age (Menon et al.","We documented effectiveness intervention, delivered 2‐month supply Sprinkles, 1 reducing anaemia 7 months post intervention children 9–24 months age (Menon et al.",G0000000|C1301725|C1280519|C0886296|C1705822|G0000000|C0243163|C1720266|G0000000|C0392756|C0002871|G0000000|C0439231|C0687676|C0886296|C0008059|G0000000|C0439231|C0001779|C1425409|G0000000
"As shown in table 2, there was no significant treatment effect for the primary neuropsychological outcome measure (change in total recall on the SRT) or any other neuropsychological measure.","As table 2, treatment primary neuropsychological outcome measure (change total recall SRT) neuropsychological measure.",G0000000|C0039224|G0000000|C0039798|C0205225|G0000000|C1274040|C0079809|C0392747|C0439175|C0034770|C0234742|G0000000|C0079809
"Secondary outcomes were assessed with the Children's Depression Inventory (CDI), a validated instrument used to assess symptoms of depression in children and adolescents (18), and VAS to assess pain severity based upon the mean of ratings in a 7-day daily diary in which patients rated their average pain severity on a 0–10-cm scale of “no pain” to “worst possible pain.” VAS are validated for use in school-age children and adolescents (14).","Secondary outcomes assessed Children's Depression Inventory (CDI), validated instrument assess symptoms depression children adolescents (18), VAS assess pain severity based ratings 7-day daily diary patients rated average pain severity 0–10-cm scale “no pain” “worst pain.” VAS validated school-age children adolescents (14).",C0027627|C1274040|C1516048|C0008059|C0011570|C0021941|C0282601|G0000000|C0348000|C1516048|C0683368|C0011570|C0008059|C0205653|C0450371|C0042815|C1516048|C0030193|C0439793|C1527178|C0871208|C0332173|C0332173|C0376660|C0030705|C0871208|C1510992|C0030193|C0439793|G0000000|C0175659|G0000000|G0000000|G0000000|G0000000|C0042815|G0000000|C0036375|C0008059|C0205653|C0450371
All of the participants were told to contact the local vaccination site or the Xiangshui County Center for Disease Control and Prevention in a timely manner once influenza-like symptoms appeared.,All participants told contact local vaccination site Xiangshui County Center Disease Control Prevention timely manner influenza-like symptoms appeared.,G0000000|C0679646|G0000000|C0332158|C0205276|C0042196|C0205145|G0000000|C0079170|C0205099|C0012634|C0243148|C0199176|C3827828|G0000000|C0021400|C0683368|C0700364
"In presence of these symptoms, the risk of abdominal wound dehiscence can be reduced to less than one-third by using interrupted sutures.","In presence symptoms, risk abdominal wound dehiscence reduced one-third interrupted sutures.",G0000000|C0150312|C0683368|C0035647|C0000726|C0043250|C0149663|C0392756|C0205447|C0443239|C0038969
"The second endpoints included the diagnostic accuracy of PCT and other laboratory biomarkers the effectiveness of asthma control, secondary ED visits, hospital re-admissions, repeated needs for steroids or dosage increase, needs for antibiotics, WBC count, PCT levels and FEV1%.","The endpoints included diagnostic accuracy PCT laboratory biomarkers effectiveness asthma control, secondary ED visits, hospital re-admissions, repeated steroids dosage increase, antibiotics, WBC count, PCT levels FEV1%.",G0000000|C2349179|C0332257|C0011900|C0443131|C1535922|C0022877|C0005516|C1280519|C0004096|C0243148|C0027627|C3538926|C0545082|C0019994|C1548168|C0205341|C0038317|C0178602|C0442805|C0003232|C0023516|C0750480|C1535922|C0441889|G0000000
"The presence of urinary symptoms and of vaginal symptoms at 3 days, 1–2 weeks, and at ≥1 month was similar between study groups, with overall no marked differences.","The presence urinary symptoms vaginal symptoms 3 days, 1–2 weeks, ≥1 month study groups, marked differences.",G0000000|C0150312|C0042027|C0683368|C0042232|C0683368|G0000000|C0439228|G0000000|C0439230|G0000000|C0332177|C0557651|C0441833|C0522501|C1705241
"The broad aims of this study are to: Determine whether a 12-week FAST programme leads to changes in medial gastrocnemius (MG), lateral gastrocnemius (LG), soleus (SOL) and tibialis anterior (TA) neuromuscular properties, muscle fascicle function and functional mobility in young adults with spastic-type CP compared to young adults with spastic-type CP not receiving FAST (performing daily activity and receiving usual care).","The broad aims study to: Determine 12-week FAST programme leads medial gastrocnemius (MG), lateral gastrocnemius (LG), soleus (SOL) tibialis anterior (TA) neuromuscular properties, muscle fascicle function functional mobility adults spastic-type CP compared adults spastic-type CP receiving FAST (performing daily activity receiving usual care).",G0000000|C0332464|C1947946|C0557651|G0000000|G0000000|C0450371|C0015663|C1709697|C0023175|C0205098|C0242691|C0026410|C0205093|C0242691|C0023128|C0242694|G0000000|C1710422|C0205094|C1506978|C1979768|C0871161|C0026845|C1185741|C0031843|C0205245|C0425245|C0001675|C0026838|C4050020|C1707455|C0001675|C0026838|C4050020|C1514756|C0015663|C0884358|C0332173|C0205177|C1514756|C3538928|C1947933
"The primary outcome is the composite outcome of either BPD or death, as assessed by standard oxygen reduction test at 36 weeks PMA [21].","The primary outcome composite outcome BPD death, assessed standard oxygen reduction test 36 weeks PMA [21].",G0000000|C0205225|C1274040|C0205199|C1274040|G0000000|C0011065|C1516048|C1442989|C0030054|C0301630|C0022885|C0450371|C0439230|C0039654|C0450371
The primary end point for this study was the change-from-baseline hot flash score during treatment week 6 between the 150 mg twice daily target pregabalin treatment and placebo.,The primary study change-from-baseline hot flash score treatment week 6 150 daily target pregabalin treatment placebo.,G0000000|C0205225|C0557651|C0392747|C0444519|C0181637|C0449820|C0039798|C0332174|G0000000|C1442061|C0332173|C1521840|C0657912|C0039798|C0032042
Mean pain intensity for the 2 weeks prior to enrollment needed to be ≥4 on a numerical rating scale of 0 to 10.,Mean pain intensity 2 weeks prior enrollment ≥4 numerical rating scale 0 10.,C0444504|C0030193|C0522510|G0000000|C0439230|C0332152|C1516879|G0000000|C0237753|C0871208|C0175659|G0000000|C0450371
"This study tested the hypotheses that, relative to a control condition receiving no intervention (but maintaining their routine migraine care), participants exposed to the painACTION website would report: (1) reduced frequency and severity of headaches; (2) increased self-efficacy to perform headache self-management; (3) increased use of positive coping strategies; (4) increased internal locus of control; (5) reduced migraine-related emotional distress (e.g., stress, anxiety, and depression); and (6) reduced negative cognition (e.g., catastrophizing).","This study tested hypotheses that, relative control condition receiving intervention (but maintaining routine migraine care), participants exposed painACTION website report: (1) reduced frequency severity headaches; (2) increased self-efficacy perform headache self-management; (3) increased positive coping strategies; (4) increased internal locus control; (5) reduced migraine-related emotional distress (e.g., stress, anxiety, depression); (6) reduced negative cognition (e.g., catastrophizing).",G0000000|C0557651|C0392366|C1512571|G0000000|C0080103|C0243148|C0012634|C1514756|C0886296|G0000000|C0024501|C0205547|C0149931|C1947933|C0679646|C0332157|G0000000|C2349146|C0684224|G0000000|C0392756|C0376249|C0439793|C0018681|G0000000|C0205217|C0600564|C0884358|C0018681|C0086969|G0000000|C0205217|C0439178|C0009967|C0679199|G0000000|C0205217|C0205102|C1708726|C0243148|G0000000|C0392756|C0149931|C0013987|C0231303|G0000000|C0038435|C0003467|C0011570|G0000000|C0392756|C0205160|C0009240|G0000000|C0563150
Median SBP and DBP at one time point were used for analysis to minimise the effect of blood pressure variability.,Median SBP DBP time analysis minimise blood pressure variability.,C0549183|G0000000|C0536221|C0040223|C0002778|G0000000|C0005767|C0033095|C2827666
The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes.,The LNZ-containing regimens effective achieving culture conversions relapse-free outcomes.,G0000000|C0332256|C2945654|C1280519|G0000000|C0010453|C0439836|C0035020|C1274040
"Scores on the Center for Epidemiologic Studies Depression (CESD) index range from 0 to 60, with higher scores indicating more severe depression.","Scores Center Epidemiologic Studies Depression (CESD) range 0 60, scores indicating severe depression.",C0449820|C0205099|C0014507|C0947630|C0011570|C0043208|C1514721|G0000000|C0450371|C0449820|G0000000|C0205082|C0011570
"The St George's Respiratory Questionnaire (SGRQ), COPD Knowledge and Morisky adherence questionnaires were administered to all patients at baseline, 6 and 12 months.","The St George's Respiratory Questionnaire (SGRQ), COPD Knowledge Morisky adherence questionnaires administered patients baseline, 6 12 months.",G0000000|C0036056|G0000000|C0521346|C0034394|G0000000|C0024117|C0376554|G0000000|C1510802|C0034394|C1521801|C0030705|C0168634|G0000000|C0450371|C0439231
"Reliability testing demonstrated day-to-day variation in things like foods and beverages served and teacher feeding practices (with ICCs of 0.06–0.60); however, reliability improved with multiple days of data capture (increasing ICCs to 0.20–0.86) [35].","Reliability testing demonstrated day-to-day variation foods beverages served teacher feeding practices (with ICCs 0.06–0.60); however, reliability improved multiple days data capture (increasing ICCs 0.20–0.86) [35].",C2347947|C0039593|G0000000|C0332173|C0205419|C0016452|C0005329|G0000000|C0221457|C0204695|C0237607|G0000000|C0345905|G0000000|G0000000|C2347947|C0184511|C0439064|C0439228|C1511726|G0000000|C0442808|C0345905|G0000000|C0450371
"Smoking status included 7-day point prevalence abstinence, the primary outcome variable, and 24-hour point prevalence abstinence.","Smoking status included 7-day prevalence abstinence, primary outcome variable, 24-hour prevalence abstinence.",C0037369|C0449438|C0332257|C0332173|C0033105|C3843422|C0205225|C1274040|C0439828|C0450371|C0033105|C3843422
An identification number and a randomisation number were created for each participant.,An identification randomisation created participant.,G0000000|C0020792|C0034656|C1706214|C0679646
"All muscle strength tests were performed on a Biodex System 3 dynamometer (Biodex Medical Systems, Shirley, NY, USA).","All muscle strength tests performed Biodex System 3 dynamometer (Biodex Medical Systems, Shirley, NY, USA).",G0000000|C0026845|C0237897|C0022885|C0884358|G0000000|C0449913|G0000000|C0180572|G0000000|C0199168|C0449913|G0000000|C0027976|C0041703
The mothers completed a smoking habits questionnaire.,The mothers completed smoking habits questionnaire.,G0000000|C0026591|C0205197|C0037369|C0018464|C0034394
"Secondary feasibility outcomes were the number of patients who received physical therapy, the number of days of physical therapy received, timing of initiation of physical therapy, exercises performed during each physical therapy session and duration of these sessions.","Secondary feasibility outcomes patients received physical therapy, days physical therapy received, timing initiation physical therapy, exercises performed physical therapy session duration sessions.",C0027627|G0000000|C1274040|C0030705|C1514756|C0031809|C0039798|C0439228|C0031809|C0039798|C1514756|C0449243|C0589507|C0031809|C0039798|C0015259|C0884358|C0031809|C0039798|C1883016|C0449238|C1883016
An overall average score of 3.37 (SD = 0.32) was found with a minimum average score of 2.56 and a maximum average score of 3.94.,An average score 3.37 (SD = 0.32) minimum average score 2.56 maximum average score 3.94.,G0000000|C1510992|C0449820|C0450371|G0000000|G0000000|C0450371|C1524031|C1510992|C0449820|C0450371|C0806909|C1510992|C0449820|C0450371
"The Center for Epidemiological Studies–Depression Scale (CES-D; Radloff & Teri, 1986) was used as a measure of CG depressive symptoms.","The Center Epidemiological Studies–Depression Scale (CES-D; Radloff & Teri, 1986) measure CG depressive symptoms.",G0000000|C0205099|C0014507|G0000000|C0175659|C2699160|G0000000|G0000000|G0000000|G0000000|C0079809|C0043444|G0000000|C0683368
"The three co-primary endpoints were: a) change in forced expiratory volume in the first second (FEV1) from morning pre-dose at baseline to pre-dose at week 12 for the comparison with formoterol; b) change in FEV1 from morning pre-dose at baseline to 2 hours post-dose at week 12 for the comparison with fluticasone, and c) time to discontinuation due to lack of efficacy from baseline to week 12 for the comparison with placebo.","The co-primary endpoints were: a) change forced expiratory volume (FEV1) morning pre-dose baseline pre-dose week 12 comparison formoterol; b) change FEV1 morning pre-dose baseline 2 hours post-dose week 12 comparison fluticasone, c) time discontinuation lack efficacy baseline week 12 comparison placebo.",G0000000|C3245499|C2349179|G0000000|G0000000|C0392747|C0441722|C0231800|C0449468|G0000000|C0332170|C0439565|C0168634|C0439565|C0332174|C0450371|C1707455|C0060657|G0000000|C0392747|G0000000|C0332170|C0439565|C0168634|G0000000|C0439227|C0439568|C0332174|C0450371|C1707455|C0082607|G0000000|C0040223|C0457454|C0332268|C1280519|C0168634|C0332174|C0450371|C1707455|C0032042
"HELP has been shown to be effective in reducing the incidence, duration and severity of delirium [15] and decreasing health care costs [16-19].","HELP effective reducing incidence, duration severity delirium [15] decreasing health care costs [16-19].",C1269765|C1280519|C0392756|C0021149|C0449238|C0439793|C0011206|C0450371|C0442797|C0018684|C1947933|C0010186|C0450371
"Among post-menopausal women, there were no SNPs significantly associated with breast cancer risk.","Among post-menopausal women, SNPs breast cancer risk.",G0000000|C0232970|C0043210|C0752046|C0006141|C0006826|C0035647
"Morbidity data will be collected weekly and monthly during the intervention and postintervention period, respectively.","Morbidity data collected weekly monthly intervention postintervention period, respectively.",C0026538|C1511726|C1516695|C0332174|C0332177|C0886296|G0000000|C0439531|G0000000
"Secondary outcomes included knowledge of and attitudes toward EC, use of other contraceptive methods, and self-reported pregnancy.","Secondary outcomes included knowledge attitudes EC, contraceptive methods, self-reported pregnancy.",C0027627|C1274040|C0332257|C0376554|C0004271|C3890233|C0009871|C0025663|C0681906|C0032961
The main outcome was the incidence of Stage 2 PU during the 16-week follow-up period.,The main outcome incidence Stage 2 PU 16-week follow-up period.,G0000000|C0205225|C1274040|C0021149|C0205390|G0000000|C0018387|C0450371|C0589120|C0439531
"Clinical benefit was assessed in the intention-to-treat (ITT) population in terms of time to definitive worsening of KPS (a decrease by ⩾1 category compared with baseline without any further improvement); time to definitive weight loss (definitive decrease in weight by ⩾5% compared with baseline); time to definitive worsening of appetite (deterioration of appetite by ⩾1grade on a scale of 1 to 5, where 1=very poor and 5=excellent) and pain-free survival (time from randomisation to first appearance of ⩾grade 1 cancer pain in patients with NCIC-CTG-expanded CTC, version 2, grade 0 cancer pain at baseline).","Clinical benefit assessed intention-to-treat (ITT) population terms time definitive worsening KPS (a decrease ⩾1 category compared baseline improvement); time definitive weight loss (definitive decrease weight ⩾5% compared baseline); time definitive worsening appetite (deterioration appetite ⩾1grade scale 1 5, 1=very poor 5=excellent) pain-free survival (time randomisation appearance ⩾grade 1 cancer pain patients NCIC-CTG-expanded CTC, version 2, grade 0 cancer pain baseline).",C0205210|C0814225|C1516048|C0162425|G0000000|C0032659|C0233324|C0040223|C0443196|C0332271|C0206065|G0000000|C0392756|G0000000|C0683312|C1707455|C0168634|C2986411|C0040223|C0443196|C0005910|C1517945|C0443196|C0392756|C0005910|G0000000|C1707455|C0168634|C0040223|C0443196|C0332271|C0003618|C0868945|C0003618|G0000000|C0175659|G0000000|G0000000|C0442824|C0032854|C1548784|C0908489|C0038952|C0040223|C0034656|C0233426|G0000000|G0000000|C0006826|C0030193|C0030705|C1513885|G0000000|C0333052|G0000000|C0441800|G0000000|C0006826|C0030193|C0168634
"Parasite clearance time (PCT) and fever clearance time (FCT) were defined as the times to the first of two consecutive assessments at which the child was afebrile and slide-negative, respectively.","Parasite clearance time (PCT) fever clearance time (FCT) defined times consecutive assessments child afebrile slide-negative, respectively.",C0030498|C0449297|C0040223|C1535922|C0015967|C0449297|C0040223|G0000000|C1704788|C0040223|C1707491|C1261322|C0008059|C0277797|C0444330|G0000000
The primary endpoint of this study will be changes in the percentage of CD8+ CD38+ HLA-DR+ T-cells which will be used as a marker for the change in the level of T-cell activation.,The primary endpoint study percentage CD8+ CD38+ HLA-DR+ T-cells marker change level T-cell activation.,G0000000|C0205225|C2349179|C0557651|C0439165|C0285590|G0000000|C0019764|C0039194|C0005516|C0392747|C0441889|C0039194|C1879547
The variables that demonstrated interaction effects (p < 0.05) were quality of sleep and staff encouragement.,The variables demonstrated interaction effects (p < 0.05) quality sleep staff encouragement.,G0000000|C0439828|G0000000|C1704675|C1280500|C0369773|G0000000|C0450371|C0332306|C0037313|C0851286|C0870494
"The subjects were requested to record the intensity of menstrual pain by VAS at 1, 2, 3, 6, 12, 24, and 48 h after the onset of bleeding.","The subjects requested record intensity menstrual pain VAS 1, 2, 3, 6, 12, 24, 48 onset bleeding.",G0000000|C0681850|C1272683|C0034869|C0522510|C0025344|C0030193|C0042815|G0000000|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0206132|C0019080
The median time to disease progression/recurrence from start of vaccination was 19.0 months (Kaplan–Meier 95% confidence interval: 9.0 months→∞).,The median time disease progression/recurrence start vaccination 19.0 months (Kaplan–Meier 95% confidence interval: 9.0 months→∞).,G0000000|C0549183|C0040223|C0012634|C0242656|C0439659|C0042196|C0450371|C0439231|G0000000|C0450371|C0237529|C1272706|G0000000|G0000000
"The CMAI-fr 1–7 point scale was transformed to scores 0–6, leading to a maximum total score of 66, and the 1–5 point CMAI-di scale was transformed to scores 0–4, leading to a maximum total score of 44.","The CMAI-fr 1–7 scale transformed scores 0–6, leading maximum total score 66, 1–5 CMAI-di scale transformed scores 0–4, leading maximum total score 44.",G0000000|C2348513|G0000000|C0175659|C1510411|C0449820|G0000000|C0332152|C0806909|C0439175|C0449820|C0450371|G0000000|C3538902|C0175659|C1510411|C0449820|G0000000|C0332152|C0806909|C0439175|C0449820|C0450371
Systolic and diastolic blood pressure was reported on average of two properly measured in the right or left arm supported at the heart level of seated position after 10 min of rest by a trained nurse using a mercury sphygmomanometer (Model Gamma G-7; Heine).16 Fasting plasma glucose was measured by the glucose oxidize method (Pars Azmoon kit).,Systolic diastolic blood pressure reported average properly measured left arm supported heart level seated position 10 min rest trained nurse mercury sphygmomanometer (Model Gamma G-7; Heine).16 Fasting plasma glucose measured glucose oxidize method (Pars Azmoon kit).,C0039155|C0012000|C0005767|C0033095|C0684224|C1510992|G0000000|C0444706|C0205091|C0446516|C1521721|C0018787|C0441889|C0277814|C0733755|C0450371|C0702093|C0035253|C0336809|C0028661|C0025424|C0183427|C3161035|C0017011|C0439267|C0450371|C0015663|C0032105|C0017725|C0444706|C0017725|C0030011|C0025663|C0032405|G0000000|C0812225
The primary feasibility endpoints were (a) time to first mobilization and (b) total duration of motor physical therapy.,The primary feasibility endpoints (a) time mobilization (b) total duration motor physical therapy.,G0000000|C0205225|G0000000|C2349179|G0000000|C0040223|C0185112|G0000000|C0439175|C0449238|C1513492|C0031809|C0039798
"The EPO group also needed lower volumes of blood than the controls—mean (95% CI) 20.1 (6.2-34.2) vs 44.4(29.0-59.7) ml/kg, but the same number of transfusions, 1.3 (0.54-2.06) vs 2.9 (1.84-3.88).","The EPO lower volumes blood controls—mean (95% CI) 20.1 (6.2-34.2) 44.4(29.0-59.7) ml/kg, transfusions, 1.3 (0.54-2.06) 2.9 (1.84-3.88).",G0000000|G0000000|C0441994|C0449468|C0005767|G0000000|C0450371|C0008107|C0450371|C0450371|C0450371|C1300574|C0005841|G0000000|C0450371|G0000000|C0450371
"We evaluated prespecified safety measures (serum lipids, cholesterol, creatinine, urea, bilirubin, liver function tests, blood glucose, and base deficit) from routine clinical tests.","We evaluated prespecified safety measures (serum lipids, cholesterol, creatinine, urea, bilirubin, liver function tests, blood glucose, base deficit) routine clinical tests.",G0000000|C0220825|G0000000|C0036043|C0079809|C0229671|C0023779|C0008377|C0010294|C0041942|C0005437|C0023884|C0031843|C0022885|C0005767|C0017725|C0002055|C0162429|C0205547|C0205210|C0022885
"A self completion questionnaire will be used to collect information on knowledge, patterns and context of use, attitudes and harms experienced in relation to alcohol, tobacco, cannabis and other illicit drug use.","A completion questionnaire collect knowledge, patterns context use, attitudes harms experienced relation alcohol, tobacco, cannabis illicit drug use.",G0000000|C0205197|C0034394|G0000000|C0376554|C0449774|C0449255|C0042153|C0004271|G0000000|C0237607|C0080103|C0001962|C0040329|C0024808|C0332266|C0013227|C0042153
"Indeed, patients reported, above all, shorter sleep onset latency, prolonged sleep time and fewer wake periods.","Indeed, patients reported, all, shorter sleep onset latency, prolonged sleep time fewer wake periods.",G0000000|C0030705|C0684224|G0000000|C1282927|C0037313|C0206132|C0205275|C0439590|C0037313|C0040223|C0205388|C0442696|C0439531
"Clinicians, using input from the caregivers, rated a patient’s change in depressive symptoms from baseline using the modified Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change (mADCS-CGIC), which is an adaptation of the ADCS-CGIC (Schneider et al.","Clinicians, input caregivers, rated patient’s change depressive symptoms baseline modified Alzheimer’s Disease Cooperative Study Clinical Global Impression Change (mADCS-CGIC), adaptation ADCS-CGIC (Schneider al.",C0871685|C1708517|C0085537|C0871208|G0000000|C0392747|G0000000|C0683368|C0168634|C0392747|G0000000|C0012634|C0679729|C0557651|C0205210|C0205246|C0596764|C0392747|G0000000|C0000934|C3641327|G0000000|C0202311
"In comparison with the placebo group, the hydrocortisone group had a significantly lower Lung Injury Score by day 3 (p = 0.003) and throughout the observation period Data for the primary and secondary outcomes are shown in Table 2.","In comparison placebo group, hydrocortisone lower Lung Injury Score day 3 (p = 0.003) observation period Data primary secondary outcomes Table 2.",G0000000|C1707455|C0032042|C0441833|C0020268|C0441994|C0024109|C3263722|C0449820|C0332173|G0000000|G0000000|C0302523|C0439531|C1511726|C0205225|C0027627|C1274040|C0039224|G0000000
"The symptom score contained three dimensions; pain, constipation, and diarrhoea.","The symptom score contained dimensions; pain, constipation, diarrhoea.",G0000000|C1457887|C0449820|C0332256|C0439534|C0030193|C0009806|C0011991
The EOLD–CAD is a 14-item scale developed to assess the condition of the care recipient during the dying process.,The EOLD–CAD 14-item scale developed assess condition care recipient dying process.,G0000000|G0000000|C0450371|C0175659|G0000000|C1516048|C0012634|C1947933|C1709854|C0184532|C1184743
"These outcomes were non-fatal myocardial infarction, non-fatal stroke (haemorrhagic or other), non-fatal or fatal pulmonary embolism, death from a vascular or unknown cause, death from a definitely non-vascular cause, and major extracranial bleeding.","These outcomes non-fatal myocardial infarction, non-fatal stroke (haemorrhagic other), non-fatal fatal pulmonary embolism, death vascular unknown cause, death non-vascular cause, major extracranial bleeding.",G0000000|C1274040|C1518422|C0027061|C0021308|C1518422|C0038454|C0333275|G0000000|C1518422|C1302234|C0024109|C0013922|C0011065|C0005847|C0439673|C0015127|C0011065|C1518422|C0015127|C0205082|C0580586|C0019080
"The participants’ body (hair and head, face, anterior/posterior neck, left/right arms, hands or wrists, upper/lower working clothes and clogs) and the surrounding environment (rubbish bin cover, chair, faucet and sink) were examined using an ultraviolet lamp (CheckPoint, 220–240 V/50 Hz; Glow Tec Ltd., London, England) under dim light.","The participants’ body (hair head, face, anterior/posterior neck, left/right arms, hands wrists, upper/lower clothes clogs) surrounding environment (rubbish bin cover, chair, faucet sink) examined ultraviolet lamp (CheckPoint, 220–240 V/50 Hz; Glow Tec Ltd., London, England) dim light.",G0000000|G0000000|C0242821|C0018494|C0018670|C0015450|C1999039|C0027530|C0205091|C0206655|C0018563|C0043262|C1282910|C0009072|G0000000|C1282914|C0014406|C0017095|C1879840|C0180153|C0179847|G0000000|C0183319|C0332128|C1532472|C0392223|C1155874|G0000000|G0000000|G0000000|C1136140|C0023973|C0014282|C0114346|C0023693
"Every 3 months during the study-period of 12 months, the number of relapses, (gastro-intestinal) side effects and additional medication were noted.","Every 3 months study-period 12 months, relapses, (gastro-intestinal) effects additional medication noted.",G0000000|G0000000|C0439231|C0557651|C0450371|C0439231|C0035020|C0521362|C1280500|C1524062|C0013227|C1316572
The outcome was time between decision to operate and surgical revascularization.,The outcome time decision operate surgical revascularization.,G0000000|C1274040|C0040223|C0679006|C3242339|C0543467|C0581603
Bronchial reactivity to UNDW was found to be significantly decreased in the group treated with nedocromtl starting from day 7.,Bronchial reactivity UNDW decreased treated nedocromtl starting day 7.,C0205039|C0443286|G0000000|C0205216|C1522326|G0000000|C0439659|C0332173|G0000000
"PE group had a tendency for a shorter PICU stay, p = 0.094 with a comparable ability of children to walk unaided within four weeks from PICU discharge (Table (Table2).2).","PE tendency shorter PICU stay, = 0.094 comparable ability children walk unaided weeks PICU discharge (Table (Table2).2).",C0070939|G0000000|C1282927|C1046445|G0000000|G0000000|C1442061|G0000000|C0085732|C0008059|C0080331|C0439846|C0439230|C1046445|C0012621|C0039224|G0000000
"In addition, we will examine the effects on other secondary outcomes including the risks of development of new or recurrent disease progression event, including all-cause mortality; ARV regimen change from first- to second-line therapy; and other adverse events as indicated by incident peripheral neuropathy, severe anemia, or diarrhea.","In addition, examine effects secondary outcomes including risks development recurrent disease progression event, including all-cause mortality; ARV regimen change first- second-line therapy; adverse events incident peripheral neuropathy, severe anemia, diarrhea.",G0000000|C0332287|G0000000|C1280500|C0027627|C1274040|C0332257|C0035647|C0243107|C2945760|C0012634|C0242656|C0441471|C0332257|C0015127|C0026565|G0000000|C0040808|C0392747|C0205435|C0205436|C0039798|G0000000|C0441471|C1551358|C0205100|C0442874|C0205082|C0002871|C0011991
Primary outcome was response [percent reduction in the Hamilton Depression Rating Scale (HDRS)] and remission (HDRS score < 10) at 8 weeks and 12 months post treatment.,Primary outcome response [percent reduction Hamilton Depression Rating Scale (HDRS)] remission (HDRS score < 10) 8 weeks 12 months post treatment.,C0205225|C1274040|C0871261|C0439165|C0301630|G0000000|C0011570|C0871208|C0175659|C1840333|C0544452|C1840333|C0449820|G0000000|C0450371|G0000000|C0439230|C0450371|C0439231|C0687676|C0039798
a BRIEF: Behavior Rating Inventory of Executive Function; SSRS: Social Skills Rating Scale.,BRIEF: Behavior Rating Inventory Executive Function; SSRS: Social Skills Rating Scale.,C1282927|C0004927|C0871208|C0021941|C0871735|C0031843|C2754414|C0728831|C0678856|C0871208|C0175659
Minimal Clinically Important Difference (MCID) for the Clinical COPD Questionnaire (CCQ) by patient referencing.,Minimal Clinically Important Difference (MCID) Clinical COPD Questionnaire (CCQ) patient referencing.,C0547040|G0000000|G0000000|C1705241|G0000000|C0205210|C0024117|C0034394|G0000000|C0030705|C1514811
"Secondary outcomes were ventilator days, ICU days, Short Physical Performance Battery (SPPB) score, 36-item Short-Form Health Surveys (SF-36) for physical and mental health and physical function scale score, Functional Performance Inventory (FPI) score, Mini-Mental State Examination (MMSE) score, and handgrip and handheld dynamometer strength.","Secondary outcomes ventilator days, ICU days, Short Physical Performance Battery (SPPB) score, 36-item Short-Form Health Surveys (SF-36) physical mental health physical function scale score, Functional Performance Inventory (FPI) score, Mini-Mental State Examination (MMSE) score, handgrip handheld dynamometer strength.",C0027627|C1274040|C0087153|C0439228|C0021708|C0439228|C1282927|C0031809|C0597198|C0337088|G0000000|C0449820|C0450371|C2964478|C0018684|C0038951|C0037712|C0031809|C0229992|C0018684|C0031809|C0031843|C0175659|C0449820|C0205245|C0597198|C0021941|G0000000|C0449820|C0445542|C1301808|G0000000|C0451306|C0449820|C1293900|G0000000|C0180572|C0237897
"The endpoints studied were relapse rate, disability assessed by the Kurtzke Expanded Disability Status Scale (EDSS), MRI, and analysis of serum levels of nitrotyrosine, and oxidative and proinflammatory makers.","The endpoints studied relapse rate, disability assessed Kurtzke Expanded Disability Status Scale (EDSS), MRI, analysis serum levels nitrotyrosine, oxidative proinflammatory makers.",G0000000|C2349179|C0557651|C0035020|C0871208|C0231170|C1516048|G0000000|C0205229|C0231170|C0449438|C0175659|C0451246|C0024485|C0002778|C0229671|C0441889|C0047645|C0311404|G0000000|C0554244
"Knee extensor strength and endurance, whole body exercise capacity, and health related quality of life (Chronic Respiratory Disease Questionnaire, CRDQ) were assessed.","Knee extensor strength endurance, body exercise capacity, health quality life (Chronic Respiratory Disease Questionnaire, CRDQ) assessed.",C0022742|C1184148|C0237897|C0518031|C0242821|C0015259|C1516240|C0018684|C0332306|C0376558|C0205191|C0521346|C0012634|C0034394|G0000000|C1516048
Follow up took place at three months using the following outcome measures: patient satisfaction (discharge/refer for further treatment); a visual analogue pain score; the WOMAC lower limb function score; the Hospital Anxiety and Depression scale (HAD); and quadriceps strength.,Follow months outcome measures: patient satisfaction (discharge/refer treatment); visual analogue pain score; WOMAC lower limb function score; Hospital Anxiety Depression scale (HAD); quadriceps strength.,C0332283|C0439231|C1274040|C0079809|C0030705|C0242428|C0012621|C0039798|C0234621|C0243071|C0030193|C0449820|G0000000|C0441994|C0015385|C0031843|C0449820|C0019994|C0003467|C0011570|C0175659|G0000000|C0224440|C0237897
Vertical tick marks represent the progression-free survival time of patients without disease progression.,Vertical tick marks represent progression-free survival time patients disease progression.,C0205128|C0040203|C0522501|C1882932|C0242656|C0038952|C0040223|C0030705|C0012634|C0242656
72 h frequency–volume chart.,72 h frequency–volume chart.,G0000000|G0000000|C0007963
"Over the 6 months of the study, interventions used by pharmacists resulted in improvements in asthma severity/control, adherence to preventer medication, quality of life, asthma knowledge and perceived control of asthma, as well as a decrease in the mean dose of the reliever medication salbutamol and in the number of patients relying solely on a reliever medication.","Over 6 months study, interventions pharmacists improvements asthma severity/control, adherence preventer medication, quality life, asthma knowledge perceived control asthma, decrease dose reliever medication salbutamol patients relying solely reliever medication.",C0205136|G0000000|C0557651|C0886296|C0031323|C2986411|C0004096|C0439793|C1510802|G0000000|C0013227|C0332306|C0376558|C0004096|C0376554|C0030971|C0243148|C0004096|C0392756|C0178602|G0000000|C0013227|C0001927|C0030705|G0000000|G0000000|G0000000|C0013227
"The range of motion values in the flexions of both shoulders, the right knee extension, and the dorsal flexions of both ankles significantly increased only in the exercise therapy intervention group.","The range motion values flexions shoulders, knee extension, dorsal flexions ankles increased exercise therapy intervention group.",G0000000|C1514721|C0026597|C0042295|C0231452|C0037004|C0022742|C0231448|C0205095|C0231452|C0003086|C0205217|C0015259|C0039798|C0886296|C0441833
"We used a linear regression model of height in relation to age, using all available age–height pairs for each participant in each 1-year age span, to determine age-specific growth velocity for each participant during the first 2 years of the trial.","We linear regression model height relation age, age–height pairs participant 1-year age span, determine age-specific growth velocity participant 2 trial.",G0000000|C0205132|C0684320|C3161035|C0489786|C0080103|C0001779|G0000000|C1709450|C0679646|C0439234|C0001779|C1711300|G0000000|C0001779|C0018270|C0439830|C0679646|G0000000|C0008976
"There was, however, no difference in histamine responsiveness when compared before and after the training period.","There was, however, difference histamine responsiveness compared training period.",G0000000|G0000000|G0000000|C1705241|C0019588|C0205342|C1707455|C0040607|C0439531
BPD: Bronchopulmonary dysplasia; ICER: Incremental Cost Effectiveness Ratio; ICU: Intensive Care Unit; LY: Life-years; NHS: National Health System; OW: Ordinary ward; QALY: Quality-Adjusted Life-Years; RSV: Respiratory Syncytial Virus.,BPD: Bronchopulmonary dysplasia; ICER: Incremental Cost Effectiveness Ratio; ICU: Intensive Care Unit; LY: Life-years; NHS: National Health System; OW: Ordinary ward; QALY: Quality-Adjusted Life-Years; RSV: Respiratory Syncytial Virus.,G0000000|C0545675|C0334044|C1852403|C1705117|C0010186|C1280519|C0456603|C0021708|C0162425|C1947933|C0439148|C0023634|C0376558|C0796085|C3245503|C0018684|C0449913|G0000000|G0000000|C1305702|C0080071|C0332306|C0376558|G0000000|C0521346|G0000000|C0042776
"Participants whose cotinine concentration was >15 ng/ml at any given time point were classified as non-responders (using smokeless tobacco or another form of nicotine containing product) for the corresponding end point, even if they reported abstinence from tobacco.","Participants cotinine concentration >15 ng/ml time classified non-responders (using smokeless tobacco form nicotine product) point, reported abstinence tobacco.",C0679646|C0010194|C0004268|C0450371|C0439275|C0040223|C0008902|C1518422|C1524063|C1450035|C0040329|C0348078|C0028040|C1514468|C1552961|C0684224|C3843422|C0040329
"Both groups improved significantly (p<.05) over time on the measures of self-efficacy, health behaviors, fibromyalgia impact and quality of life.","Both improved (p<.05) time measures self-efficacy, health behaviors, fibromyalgia impact quality life.",G0000000|C0184511|C0369773|C0040223|C0079809|C0600564|C0018684|C0004927|C0016053|C1825598|C0332306|C0376558
"Motor development includes the sum of scores from the gross and fine motor subscales; mental development includes the sum of scores from the language, personal–social and cognitive subscales.","Motor development includes sum scores gross fine motor subscales; mental development includes sum scores language, personal–social cognitive subscales.",C1513492|C0243107|C0332257|C1515051|C0449820|C0439806|C0205232|C1513492|G0000000|C0229992|C0243107|C0332257|C1515051|C0449820|C0023008|G0000000|C1516691|G0000000
The cost-effectiveness planes indicated no significant differences in cost-effectiveness between the two groups.,The cost-effectiveness planes differences cost-effectiveness groups.,G0000000|C0010181|C1049866|C1705241|C0010181|C0441833
"Grades 3 and 4 toxicities in the control arm were mainly hematologic (TMZ, n = 4, mainly thrombocytopenia; BCNU, n = 13, both leukopenia and thrombocytopenia; Appendix Table A1).","Grades 3 4 toxicities control arm hematologic (TMZ, = 4, thrombocytopenia; BCNU, = 13, leukopenia thrombocytopenia; Appendix Table A1).",C0441800|G0000000|G0000000|C0600688|C0243148|C0446516|C0018943|C0076080|G0000000|G0000000|C0040034|C0007257|G0000000|C0450371|C0023530|C0040034|C0003617|C0039224|C0336669
Primary outcome is the extent of patients’ involvement in shared decision-making as assessed by the MAPPIN-Odyad (Multifocal approach to the ‘sharing’ in shared decision-making: observer instrument dyad).,Primary outcome extent patients’ involvement shared decision-making assessed MAPPIN-Odyad (Multifocal approach ‘sharing’ shared decision-making: observer instrument dyad).,C0205225|C1274040|C0439792|G0000000|C1314939|C0237876|C0011109|C1516048|C0006360|C0205292|C0449445|G0000000|C0237876|C0011109|C0870992|C0348000|C0870454
"Post-hoc outcomes were the number of days that patients were alive and breathing without ventilator assistance (ventilator-free days), ICU-free and hospital-free days to day 28.16 Adverse events were quantified by deaths, device removals, reintubations, and patient falls during physical therapy (for classification of adverse events, see trial protocol in Supplement 1).","Post-hoc outcomes days patients alive breathing ventilator assistance (ventilator-free days), ICU-free hospital-free days day 28.16 Adverse events quantified deaths, device removals, reintubations, patient falls physical therapy (for classification adverse events, trial protocol Supplement 1).",C0687676|C1274040|C0439228|C0030705|C0376558|C0004048|C0087153|C0018896|C0087153|C0439228|C0021708|C0019994|C0439228|C0332173|C0450371|G0000000|C0441471|C1709793|C0011065|C0025080|C0015252|C0860359|C0030705|C0000921|C0031809|C0039798|G0000000|C0008902|G0000000|C0441471|C0008976|C0442711|C0242295|G0000000
"(x) Positive and Negative Affect, using the Positive and Negative Affect Schedule (PANAS) [31].","(x) Positive Negative Affect, Positive Negative Affect Schedule (PANAS) [31].",G0000000|C0439178|C0205160|C0001721|C0439178|C0205160|C0001721|C0086960|G0000000|C0450371
"At the end of the session, the children were asked to score the pain experienced using the Oucher scale, a validated visual pain scale scoring from 0 (no pain) to 100 (maximum pain).","At session, children score pain experienced Oucher scale, validated visual pain scale scoring 0 (no pain) 100 (maximum pain).",G0000000|C1883016|C0008059|C0449820|C0030193|C0237607|G0000000|C0175659|G0000000|C0234621|C0030193|C0175659|C0449820|G0000000|G0000000|C0030193|C1442061|C0806909|C0030193
This finding may at least partly explain why uptake of only some vaccines was increased.,This finding partly explain uptake vaccines increased.,G0000000|C0037088|G0000000|G0000000|C0243144|C0042210|C0205217
"The primary outcome was area-under-the-curve global severity, with severity assessed twice daily by self report on the Wisconsin Upper Respiratory Symptom Survey (WURSS-21).","The primary outcome area-under-the-curve global severity, severity assessed daily report Wisconsin Upper Respiratory Symptom Survey (WURSS-21).",G0000000|C0205225|C1274040|C0017446|C0205246|C0439793|C0439793|C1516048|C0332173|C0684224|C0043193|C1282910|C0521346|C1457887|C0038951|C0450371
3) Answer if you responded 'yes' to 1. or 2: Is this something with which you would like help?,3) Answer responded 'yes' 1. 2: Is help?,G0000000|C1706817|G0000000|C1549445|G0000000|G0000000|G0000000|C1269765
"Infant measurements included anthropometry, development and rates of infections.","Infant measurements included anthropometry, development rates infections.",C0021270|C0242485|C0332257|C0003188|C0243107|C0871208|C3714514
The secondary outcome measure was reduction of clinical recurrence rate.,The secondary outcome measure reduction clinical recurrence rate.,G0000000|C0027627|C1274040|C0079809|C0301630|C0205210|C0034897|C0871208
"Our need to obtain signed parental consent prior to administration of the HPV vaccine may have resulted in an unforeseen barrier to increased uptake, despite our health messaging intervention.","Our signed parental consent prior administration HPV vaccine unforeseen barrier increased uptake, health messaging intervention.",G0000000|C1519316|C0030551|C1511481|C0332152|C0001554|C0021344|C0042210|G0000000|C1706912|C0205217|C0243144|C0018684|C0470166|C0886296
Both groups will be followed up for 12 months.,Both 12 months.,G0000000|C0450371|C0439231
Increased vigorous physical activity was associated with reductions in body fat.,Increased vigorous physical activity reductions body fat.,C0205217|G0000000|C0031809|C0205177|C0301630|C0242821|C0424612
"Consistent with guidelines,23 participants who failed to respond to the survey, or who failed to provide a CO sample (n = 57, 48, and 42 at 6, 7, and 12 months, respectively), or who provided a CO sample >10 p.p.m.","Consistent guidelines,23 participants failed respond survey, failed provide CO sample (n = 57, 48, 42 6, 7, 12 months, respectively), provided CO sample >10 p.p.m.",C0332290|C0162791|C0679646|C0231175|G0000000|C0038951|C0231175|C1999230|C3245499|C0370003|C0369718|G0000000|C0450371|C0450371|C0450371|G0000000|G0000000|C0450371|C0439231|G0000000|C1999230|C3245499|C0370003|C0450371|C0369773
"Adverse events (AEs), vital signs, and laboratory assessments (clinical chemistry, hematology, cardiac biomarkers and urinalysis) were assessed during the treatment period (G-CSF cell mobilization, apheresis and intramuscular injection) and during the follow-up period at weeks 2, 4, 6, 8 and 12 weeks and 6 and 12 months.","Adverse events (AEs), vital signs, laboratory assessments (clinical chemistry, hematology, cardiac biomarkers urinalysis) assessed treatment period (G-CSF cell mobilization, apheresis intramuscular injection) follow-up period weeks 2, 4, 6, 8 12 weeks 6 12 months.",G0000000|C0441471|C1412268|C0442732|C0220912|C0022877|C1261322|C0205210|C0007996|C0018943|C0018787|C0005516|C0042014|C1516048|C0039798|C0439531|C0079459|C0007634|C0185112|C0005791|C0021492|C0021485|C0589120|C0439531|C0439230|G0000000|G0000000|G0000000|G0000000|C0450371|C0439230|G0000000|C0450371|C0439231
The outcome measures of pre-intervention and 4 and 8 weeks were compared using repeated measures ANOVA.,The outcome measures pre-intervention 4 8 weeks compared repeated measures ANOVA.,G0000000|C1274040|C0079809|C2347663|G0000000|G0000000|C0439230|C1707455|C0205341|C0079809|G0000000
"However, the knowledge of participants about the mounting of ITN only improved slightly in the control from 45.5% to 49.0% [p = 0.51].","However, knowledge participants mounting ITN improved control 45.5% 49.0% [p = 0.51].",G0000000|C0376554|C0679646|C0181909|G0000000|C0184511|C0243148|C0450371|C0450371|G0000000
"Secondary endpoints included progression-free survival (PFS), overall response rate (ORR), overall survival (OS), and biosafety.","Secondary endpoints included progression-free survival (PFS), response rate (ORR), survival (OS), biosafety.",C0027627|C2349179|C0332257|C0242656|C0038952|C0242792|C0871261|C0871208|G0000000|C0038952|C0229090|G0000000
"The primary endpoint was overall safety of deferasirox FCT and deferasirox DT formulations, measured by frequency and severity of adverse events (AEs) and changes in laboratory values from baseline to 24 weeks.","The primary endpoint safety deferasirox FCT deferasirox DT formulations, measured frequency severity adverse events (AEs) laboratory values baseline 24 weeks.",G0000000|C0205225|C2349179|C0036043|C1619629|G0000000|C1619629|C1455430|C0524527|C0444706|C0376249|C0439793|G0000000|C0441471|C1412268|C0022877|C0042295|C0168634|C0450371|C0439230
This is defined as time from AVF creation to abandonment of access.,This defined time AVF creation abandonment access.,G0000000|C1704788|C0040223|C0449215|C0441513|C0870084|C0444454
- Number of falls recorded for the two groups during the 3-month follow-up WBV = Whole Body Vibration.,- Number falls recorded 3-month follow-up WBV = Whole Body Vibration.,G0000000|C0237753|C0000921|C0034869|C0332177|C0589120|G0000000|G0000000|C0444667|C0242821|C0455941
"Two open-ended qualitative questions related to the receipt of pain and palliative care services were included at 6 weeks, 6 months, and 12 months.","Two open-ended qualitative questions receipt pain palliative care services included 6 weeks, 6 months, 12 months.",C0205448|C2827655|C0205556|C1522634|G0000000|C0030193|C0587605|C1947933|C0557854|C0332257|G0000000|C0439230|G0000000|C0439231|C0450371|C0439231
The primary endpoints of the PLUG trial are fistula closure rate and continence.,The primary endpoints PLUG trial fistula closure rate continence.,G0000000|C0205225|C2349179|C0182324|C0008976|C0016169|C0185003|C0871208|C0443192
No difference in toxicity was observed between the two arms.,No difference toxicity observed arms.,G0000000|C1705241|C0040539|C1441672|C0206655
"Peritoneal glucose absorption during the PET was calculated from the infused dialysate volume and glucose concentration during the PET, minus the directly measured volume and glucose concentration of the drained dialysate.","Peritoneal glucose absorption PET calculated infused dialysate volume glucose concentration PET, minus directly measured volume glucose concentration drained dialysate.",C0031153|C0017725|C0000854|C0031268|C0444686|G0000000|C0011947|C0449468|C0017725|C0004268|C0031268|C0332288|C1947931|C0444706|C0449468|C0017725|C0004268|C0013103|C0011947
"The mothers and infants' temperatures were measured and recorded at the start of skin-to-skin contact, half an hour, and one hour after with infrared ray thermometer on the forehead.","The mothers infants' temperatures measured recorded start skin-to-skin contact, half hour, hour infrared ray thermometer forehead.",G0000000|C0026591|C0021270|C0039476|C0444706|C0034869|C0439659|C0444099|C0332158|C2825407|C0439227|C0439227|C1532326|C0086894|C0039818|C0016540
"amean±SD, EG: experimental group, CG: control group After the intervention, the experimental group showed significant improvements in the BBT, grip strength, and the FMA (p<0.05), and a significant decrease in the Jebsen-Taylor test (p<0.05).","amean±SD, EG: experimental group, CG: control After intervention, experimental improvements BBT, grip strength, FMA (p<0.05), decrease Jebsen-Taylor test (p<0.05).",G0000000|C0013715|C1517586|C0441833|C0043444|C0243148|G0000000|C0886296|C1517586|C2986411|G0000000|C0021400|C0237897|C2332774|C0369773|C0392756|G0000000|C0022885|C0369773
"Median time to fever clearance and the proportion of patients with fever clearance on day 1, 2 and 3 are presented in Additional file 2.","Median time fever clearance proportion patients fever clearance day 1, 2 3 Additional file 2.",C0549183|C0040223|C0015967|C0449297|C1709707|C0030705|C0015967|C0449297|C0332173|G0000000|G0000000|G0000000|C1524062|C0016094|G0000000
"FINDINGS: Prior to treatment, 16% of the study participants had active trachoma.","FINDINGS: Prior treatment, 16% study participants active trachoma.",C2607943|C0332152|C0039798|C0450371|C0557651|C0679646|C0205177|C0040592
Wilcoxon signed rank test was used to assess changes from baseline to delivery in blood systolic pressure (SBP).,Wilcoxon signed rank test assess baseline delivery blood systolic pressure (SBP).,G0000000|C1519316|C0699794|C0022885|C1516048|C0168634|C0011209|C0005767|C0039155|C0033095|G0000000
Ramsay sedation scale was used for assessment of sedation level[11].,Ramsay sedation scale assessment sedation level[11].,G0000000|C0235195|C0175659|C1261322|C0235195|C0441889
"Related to all adverse effects questioned, daily somnolence and appetite improved in the 7.5MetDG during at day-7 and -14 evaluations (P<0.005).","Related adverse effects questioned, daily somnolence appetite improved 7.5MetDG day-7 -14 evaluations (P<0.005).",C0439849|G0000000|C1280500|C1522634|C0332173|C0013144|C0003618|C0184511|G0000000|C0332173|C0450371|C0220825|C0369773
"Estimation of relative risks, 95% confidence intervals, and two-sided p values at 6 and 12 months were reported.","Estimation relative risks, 95% confidence intervals, two-sided values 6 12 months reported.",C0680844|C0080103|C0035647|C0450371|C0237529|C1272706|C0205448|C0042295|G0000000|C0450371|C0439231|C0684224
"In the baseline (spring 2005) and follow-up (spring 2007) surveys, a household questionnaire included questions about vulnerability of the household and questions to mothers concerning their education, childcare knowledge, attitudes and practices.","In baseline (spring 2005) follow-up (spring 2007) surveys, household questionnaire included questions vulnerability household questions mothers education, childcare knowledge, attitudes practices.",G0000000|C0168634|C0241232|G0000000|C0589120|C0241232|G0000000|C0038951|C0020052|C0034394|C0332257|C1522634|G0000000|C0020052|C1522634|C0026591|C0013621|C0008067|C0376554|C0004271|C0237607
[4] Clearance of PR was defined as PRSS score of 2 or less.,[4] Clearance PR defined PRSS score 2 less.,G0000000|C0449297|C0279759|C1704788|C1415382|C0449820|G0000000|C0439092
A one-item question was used to assess the provision of fruit and vegetables on menus.,A one-item question assess provision fruit vegetables menus.,G0000000|C0205447|C1522634|C1516048|C1549071|C0016767|C0042440|G0000000
"At monthly follow up visits the plasma β-carotene concentration, total antioxidant capacity, malondialdehyde (MDA) as a marker of lipid peroxidation, and clinical parameters (Shwachmann-Kulczycki score, body mass index (BMI), height, and lung function (FEV1)) were assessed.","At monthly follow visits plasma β-carotene concentration, total antioxidant capacity, malondialdehyde (MDA) marker lipid peroxidation, clinical parameters (Shwachmann-Kulczycki score, body mass (BMI), height, lung function (FEV1)) assessed.",G0000000|C0332177|C0332283|C0545082|C0032105|G0000000|C0004268|C0439175|C0003402|C1516240|C0024643|C0000379|C0005516|C0023779|C0178796|C0205210|C0449381|G0000000|C0449820|C0242821|C0577559|G0000000|C0489786|C0024109|C0031843|G0000000|C1516048
"A study was performed to compare side effects with face mask and nose mask CPAP therapy in patients with SAHS, with and without uvulopalatopharyngoplasty (U3P).","A study performed compare effects mask nose mask CPAP therapy patients SAHS, uvulopalatopharyngoplasty (U3P).",G0000000|C0557651|C0884358|C1707455|C1280500|C0024861|C0028429|C0024861|C0199451|C0039798|C0030705|C0520679|C1535578|G0000000
"The contribution of budesonide to improvements from baseline in pulmonary function and COPD symptoms was demonstrated by the greater efficacy of budesonide/formoterol 320/9 μg compared with formoterol alone for the co-primary variables of pre-dose FEV1 and 1-hour post-dose FEV1, and for dyspnoea and total BCSS scores, supporting use of the higher-dose combination for COPD symptoms.","The contribution budesonide improvements baseline pulmonary function COPD symptoms demonstrated efficacy budesonide/formoterol 320/9 μg compared formoterol co-primary variables pre-dose FEV1 1-hour post-dose FEV1, dyspnoea total BCSS scores, supporting higher-dose combination COPD symptoms.",G0000000|C1880177|C0054201|C2986411|C0168634|C0024109|C0031843|C0024117|C0683368|G0000000|C1280519|C1276807|C1442061|G0000000|C1707455|C0060657|C3245499|C0439828|C0439565|G0000000|C0439227|C0439568|G0000000|C0013404|C0439175|C1412777|C0449820|C0183683|C0444956|C0205195|C0024117|C0683368
"The primary aim of this trial is to determine whether one recommended dietary allowance (RDA) dose of oral multivitamin supplements (including vitamins B-complex, C, and E) given daily for 18 months will: (1) improve immune reconstitution (indicated by CD4 cell count); (2) improve weight gain, and (3) improve quality of life.","The primary aim trial determine recommended dietary allowance (RDA) dose oral multivitamin supplements (including vitamins B-complex, C, E) daily 18 months will: (1) improve immune reconstitution (indicated CD4 cell count); (2) improve weight gain, (3) improve quality life.",G0000000|C0205225|C1947946|C0008976|G0000000|C0034866|C0012155|C0556660|G0000000|C0178602|C0442027|C0301532|C0242295|C0332257|C0042890|C0939261|G0000000|G0000000|C0332173|C0450371|C0439231|G0000000|G0000000|G0000000|C0439662|G0000000|C1444656|C0285590|C0007634|C0750480|G0000000|G0000000|C0005910|C1517378|G0000000|G0000000|C0332306|C0376558
"A repeated-measures analysis of variance for SMWT, 10MWT and TUG and Friedman test for DGI revealed that TOCT and UC didn’t produce a significant improvement over time.","A repeated-measures analysis variance SMWT, 10MWT TUG Friedman test DGI revealed TOCT UC didn’t produce improvement time.",G0000000|C0205341|C0002778|C1711260|G0000000|G0000000|C1319201|G0000000|C0022885|G0000000|C0443289|G0000000|G0000000|G0000000|G0000000|C2986411|C0040223
"Thus we have specified two primary outcomes (related to drinking frequency and drunkenness frequency), alongside secondary and tertiary outcomes, and this is a strength of the trial design.","Thus primary outcomes (related drinking frequency drunkenness frequency), alongside secondary tertiary outcomes, strength trial design.",G0000000|C0205225|C1274040|C0439849|C0001948|C0376249|C0001969|C0376249|G0000000|C0027627|C0205372|C1274040|C0237897|C0008976|C1707689
Serum magnesium levels and blood gases were measured at 0 and 120 minutes in both groups.,Serum magnesium levels blood gases measured 0 120 minutes groups.,C0229671|C0024467|C0441889|C0005767|C0017110|C0444706|G0000000|G0000000|C0441833
The MEMS TrackCap is an electronic monitoring system that measures the time and date a pill bottle and cap were opened.,The MEMS TrackCap electronic monitoring system measures time pill bottle cap opened.,G0000000|C1979923|G0000000|C0013850|C0150369|C0449913|C0079809|C0040223|C0009905|C0179376|C0179586|C0175566
"By day 28, the treated group had a nonsignificant reduction in duration (days) of MV (10.4 ± 9.4 days vs. 12.4 ± 11.0 days; p = 0.16) and vasopressor support (4.8 ± 3.0 days vs. 6.8 ± 5.7 days; p = 0.16), as well as a nonsignificant increase in patients alive on day 28 without organ support.","By day 28, treated nonsignificant reduction duration (days) MV (10.4 ± 9.4 days vs. 12.4 ± 11.0 days; p = 0.16) vasopressor support (4.8 ± 3.0 days vs. 6.8 ± 5.7 days; p = 0.16), nonsignificant increase patients alive day 28 organ support.",G0000000|C0332173|C0450371|C1522326|G0000000|C0301630|C0449238|C0439228|C0428679|G0000000|C0439228|G0000000|G0000000|C0439228|G0000000|C0042397|C0183683|G0000000|C0439228|G0000000|G0000000|C0439228|G0000000|G0000000|C0442805|C0030705|C0376558|C0332173|C0450371|C0178784|C0183683
"Furthermore, with no or minimal confounding from alcohol or tobacco use in Golestan, other risk factors for oesophageal cancer can be better studied there.","Furthermore, minimal confounding alcohol tobacco Golestan, risk factors oesophageal cancer studied there.",G0000000|C0547040|G0000000|C0001962|C0040329|G0000000|C0035647|C1521761|C1522619|C0006826|C0557651|G0000000
(20) to determine the reliability of psychological well-being scale obtained a significant negative correlation between the scale and the Beck depression test scores.,(20) determine reliability psychological well-being scale negative correlation scale Beck depression test scores.,C0450371|G0000000|C2347947|C0205486|C0018684|C0175659|C0205160|C1707520|C0175659|G0000000|C0011570|C0022885|C0449820
"AHI, apnea–hypopnea index; AH, apnea–hypopnea; Arl, arousals; WASO, wake after sleep onset; TST, total sleep time; SE, sleep efficiency; PLMI, periodic limb movement index; OAI, obstructive apnea index; CAI, central apnea index.","AHI, apnea–hypopnea index; AH, apnea–hypopnea; Arl, arousals; WASO, wake sleep onset; TST, total sleep time; SE, sleep efficiency; PLMI, periodic limb movement index; OAI, obstructive apnea index; CAI, central apnea index.",G0000000|G0000000|C0918012|C1836672|G0000000|G0000000|C0003808|G0000000|C0442696|C0037313|C0206132|C1421210|C0439175|C0037313|C0040223|C0036919|C0037313|C0013682|G0000000|C0332182|C0015385|C0026649|C0918012|G0000000|C0549186|C0003578|C0918012|C0064494|C0205099|C0003578|C0918012
"Data related to treatment monitoring and outcomes were collected and assessed as previously described [16, 17].","Data treatment monitoring outcomes collected assessed [16, 17].",C1511726|C0039798|C0150369|C1274040|C1516695|C1516048|C0450371|C0450371
The primary end point was progression-free survival (PFS).,The primary progression-free survival (PFS).,G0000000|C0205225|C0242656|C0038952|C0242792
"Changes in Urinary Excretion of Sodium, Blood Pressure, Renal Function, Plasma Renin Activity, and Serum Aldosterone Between Diets in Patients With IgA Nephropathy Values are mean±SD or median (25th and 75th percentiles).","Changes Urinary Excretion Sodium, Blood Pressure, Renal Function, Plasma Renin Activity, Serum Aldosterone Between Diets Patients With IgA Nephropathy Values mean±SD median (25th 75th percentiles).",C0392747|C0042027|C0221102|C0037473|C0005767|C0033095|C0022646|C0031843|C0032105|C0035094|C0205177|C0229671|C0002006|G0000000|C0012155|C0030705|G0000000|C2825347|C0022658|C0042295|G0000000|C0549183|G0000000|G0000000|C1264641
"(ii) Each participant will be provided with a user-friendly health passport in which the participant and PREVENT staff will maintain documentation regarding health-related appointments, assessment results, medications, BP, cigarettes smoked, lipid profile, blood glucose, body weight, waist circumference, daily physical activity, dietary intake, as well as goal attainment related to these domains.","(ii) Each participant provided user-friendly health passport participant PREVENT staff maintain documentation health-related appointments, assessment results, medications, BP, cigarettes smoked, lipid profile, blood glucose, body weight, waist circumference, daily physical activity, dietary intake, goal attainment domains.",G0000000|G0000000|C0679646|C1999230|C1548600|C0018684|C3242633|C0679646|C0309872|C0851286|C0024501|C0175636|C0018684|C0003629|C1261322|C1274040|C0013227|C0037623|C0677453|C0037366|C0023779|C1979963|C0005767|C0017725|C0242821|C0005910|C0230097|C0332520|C0332173|C0031809|C0205177|C0012155|C1512806|C0018017|G0000000|C1880389
"Third (RQ3), we test whether either campaign reduced marijuana uptake, despite the presence of the other campaign, and (RQ4) whether aspirations and autonomy provide an indirect path between the campaigns and marijuana uptake.","Third (RQ3), test campaign reduced marijuana uptake, presence campaign, (RQ4) aspirations autonomy provide indirect path campaigns marijuana uptake.",C0205437|G0000000|C0022885|G0000000|C0392756|C0024808|C0243144|C0150312|G0000000|G0000000|C0004056|C0085862|C1999230|C0439852|C0919386|G0000000|C0024808|C0243144
"EA was analyzed using a multivariate logistic regression model in which the dependent variable was the presence or absence of EA and the independent variables included the kind of medication, gender, age, weight, the presence of preoperative anxiety, the extubation time and the duration of anesthesia.","EA analyzed multivariate logistic regression model dependent variable presence absence EA independent variables included medication, gender, age, weight, presence preoperative anxiety, extubation time duration anesthesia.",C0014963|C0936012|G0000000|C0242415|C0684320|C3161035|C0851827|C0439828|C0150312|C0332197|C0014963|C0085862|C0439828|C0332257|C0013227|C0079399|C0001779|C0005910|C0150312|C0445204|C0003467|C0553891|C0040223|C0449238|C0002903
"The secondary objectives are: (1) to evaluate the impact of early versus delayed initiation of RRT on key secondary endpoints including: 28-day, 180-day and 1-year mortality; number of days free of mechanical ventilation; number of days free of RRT; ICU length of stay; hospital length of stay; and 90-day and 1-year quality of life as evaluated by the EQ-5D questionnaire; (2) to compare the efficacy and safety of the two strategies in terms of episodes of metabolic disorders, arrhythmia, pulmonary edema, hypotension, hemorrhage and RRT dependence at hospital discharge.","The secondary objectives are: (1) evaluate impact versus delayed initiation RRT key secondary endpoints including: 28-day, 180-day 1-year mortality; days free mechanical ventilation; days free RRT; ICU length stay; hospital length stay; 90-day 1-year quality life evaluated EQ-5D questionnaire; (2) compare efficacy safety strategies terms episodes metabolic disorders, arrhythmia, pulmonary edema, hypotension, hemorrhage RRT dependence hospital discharge.",G0000000|C0027627|C0018017|G0000000|G0000000|C0220825|C1825598|G0000000|C0205421|C0589507|G0000000|G0000000|C0027627|C2349179|C0332257|C0450371|C1442061|C0439234|C0026565|C0439228|C0332296|C0443254|C0035203|C0439228|C0332296|G0000000|C0021708|C1444754|G0000000|C0019994|C1444754|G0000000|C0450371|C0439234|C0332306|C0376558|C0220825|C0205163|C0034394|G0000000|C1707455|C1280519|C0036043|C0679199|C0233324|C0332189|C0311400|C0012634|C0003811|C0024109|C0013604|C0020649|C0019080|G0000000|C0011546|C0019994|C0012621
"Using the time of the cap openings and the scheduled time for the medications to be taken, a medication adherence score was calculated (8).","Using time cap openings scheduled time medications taken, medication adherence score calculated (8).",C1524063|C0040223|C0179586|C0175566|C0086960|C0040223|C0013227|C1883727|C0013227|C1510802|C0449820|C0444686|G0000000
"Comparison of clinical criteria i.e., status of pain, sinus tract, swelling and mobility, at 3 months, and 6 months interval showed a non- significant difference (p<0.05) for each agent [Table/Fig-5].","Comparison clinical criteria i.e., status pain, sinus tract, swelling mobility, 3 months, 6 months interval non- difference (p<0.05) agent [Table/Fig-5].",C1707455|C0205210|C0243161|C0683454|C0449438|C0030193|C0016169|C1185740|C0013604|C0425245|G0000000|C0439231|G0000000|C0439231|C1272706|C1518422|C1705241|C0369773|C0450442|C0039224
"In this study, we applied deep cross-friction massage using the HT-bar to chronic nonspecific low back pain patients and investigated the effects.","In study, applied deep cross-friction massage HT-bar chronic nonspecific low pain patients investigated effects.",G0000000|C0557651|C4048755|C0205125|C2828360|C0024875|C0018510|C0205191|C0205370|C0205251|C0030193|C0030705|C1292732|C1280500
Patients will be seen after 3 and 6 months by an independent blinded assessor who will collect the primary and secondary outcome data.,Patients 3 6 months independent blinded assessor collect primary secondary outcome data.,C0030705|G0000000|G0000000|C0439231|C0085862|C0150108|C1707957|G0000000|C0205225|C0027627|C1274040|C1511726
"Clinical indices—including 24-hour UF volume (UFV), 24-hour urine volume (UV), residual renal function, and dialysis adequacy—were measured at months 1, 6, and 12.","Clinical indices—including 24-hour UF volume (UFV), 24-hour urine volume (UV), residual renal function, dialysis adequacy—were measured months 1, 6, 12.",C0205210|G0000000|C0450371|G0000000|C0449468|G0000000|C0450371|C0042036|C0449468|C0006409|C1609982|C0022646|C0031843|C0011945|G0000000|C0444706|C0439231|G0000000|G0000000|C0450371
"Survival is not only limited by tumor progression, but also by deterioration of liver function as a result of the underlying liver cirrhosis.","Survival limited tumor progression, deterioration liver function result underlying liver cirrhosis.",C0038952|C0439801|C0027651|C0242656|C0868945|C0023884|C0031843|C1274040|G0000000|C0023884|C0023890
"Secondary efficacy measures included: Day 28 cure rate; parasite clearance time, defined as the time from first treatment dose to aparasitemia for two consecutive negative readings taken between 7–25 h apart; fever clearance time, defined as time from first treatment dose to apyrexia for two consecutive normal temperature readings taken between 7–25 h apart; the proportion of patients aparasitemic on Days 1, 2, and 3; and the proportion of patients apyretic on Days 1, 2, and 3.","Secondary efficacy measures included: Day 28 cure rate; parasite clearance time, defined time treatment dose aparasitemia consecutive negative readings 7–25 apart; fever clearance time, defined time treatment dose apyrexia consecutive normal temperature readings 7–25 apart; proportion patients aparasitemic Days 1, 2, 3; proportion patients apyretic Days 1, 2, 3.",C0027627|C1280519|C0079809|C0332257|C0332173|C0450371|C1880198|C0871208|C0030498|C0449297|C0040223|C1704788|C0040223|C0039798|C0178602|G0000000|C1707491|C0205160|C0034754|G0000000|G0000000|C0015967|C0449297|C0040223|C1704788|C0040223|C0039798|C0178602|C0277797|C1707491|C0205307|C0005903|C0034754|G0000000|G0000000|C1709707|C0030705|G0000000|C0439228|G0000000|G0000000|G0000000|C1709707|C0030705|G0000000|C0439228|G0000000|G0000000|G0000000
The participants were requested to complete a detailed questionnaire assessing their menstrual pain and duration.,The participants requested complete detailed questionnaire assessing menstrual pain duration.,G0000000|C0679646|C1272683|C0205197|C1522508|C0034394|C1516048|C0025344|C0030193|C0449238
An illustrative question was: “How many times have your parents talked to you about not drinking alcohol in the last MONTH?” Test-retest reliabilities across family involvement items ranged from 0.82 to 0.93.,An illustrative question was: “How times parents talked drinking alcohol MONTH?” Test-retest reliabilities family involvement items ranged 0.82 0.93.,G0000000|G0000000|C1522634|G0000000|G0000000|C0040223|C0030551|C0037817|C0001948|C0001962|G0000000|C0022885|C2347947|C0015576|C1314939|C1551338|C1514721|C0450371|C0450371
"Recently paradoxical reactions, or immune reconstitution inflammatory syndrome reactions, have been recognized to occur following antibiotic treatment, [6-9] and can be mistaken for treatment failure.","Recently paradoxical reactions, immune reconstitution inflammatory syndrome reactions, recognized occur antibiotic treatment, [6-9] mistaken treatment failure.",C0332185|C0205310|C0443286|C0439662|G0000000|C0333348|C0039082|C0443286|G0000000|C1709305|C0003232|C0039798|G0000000|C0743559|C0039798|C0231174
Median duration of response was not reached with either treatment.,Median duration response reached treatment.,C0549183|C0449238|C0871261|C2584321|C0039798
The baseline geometric mean titers (GMTs) and 1 month postbooster GMTs are shown in Table Table3.3.,The baseline geometric titers (GMTs) 1 month postbooster GMTs Table Table3.3.,G0000000|C0168634|C0449829|C0475208|G0000000|G0000000|C0332177|G0000000|G0000000|C0039224|G0000000
"Duration of mechanical ventilation, length of stay in the intensive care unit, septic shock incidence and 28-day mortality rate were also recorded.","Duration mechanical ventilation, length stay intensive care unit, septic shock incidence 28-day mortality rate recorded.",C0449238|C0443254|C0035203|C1444754|G0000000|C0162425|C1947933|C0439148|C0333534|C0036974|C0021149|C0450371|C0026565|C0871208|C0034869
"It is unclear from previous literature, how and whether age predicts recovery of mental health symptoms.","It unclear previous literature, age predicts recovery mental health symptoms.",G0000000|G0000000|C0205156|C0023866|C0001779|G0000000|C0237820|C0229992|C0018684|C0683368
"Using a randomised controlled trial design, this study compares the effectiveness of the Mediterranean diet to a standard low fat diet in terms of differences in insulin sensitivity, hepatic steatosis and metabolic outcomes in participants with non-alcoholic fatty liver disease.","Using randomised controlled trial design, study compares effectiveness Mediterranean diet standard low fat diet terms differences insulin sensitivity, hepatic steatosis metabolic outcomes participants non-alcoholic fatty liver disease.",C1524063|G0000000|C2587213|C0008976|C1707689|C0557651|C1707455|C1280519|C0240321|C0012155|C1442989|C0205251|C0424612|C0012155|C0233324|C1705241|C0021641|C0020517|C0205054|C0152254|C0311400|C1274040|C0679646|C1518422|G0000000|C0023884|C0012634
"Validated abstinence required reporting smoking no more than five cigarettes in the previous seven days, and a cotinine concentration of less than 15 ng/mL.","Validated abstinence required reporting smoking cigarettes previous days, cotinine concentration 15 ng/mL.",G0000000|C3843422|C1514873|C0700287|C0037369|C0677453|C0205156|C0439228|C0010194|C0004268|C0450371|C0439275
Most of the cognitive domains were assessed using tasks in which speed of response was the main outcome measure.,Most cognitive domains assessed tasks speed response main outcome measure.,C0205393|C1516691|C1880389|C1516048|C3540678|C0678536|C0871261|C0205225|C1274040|C0079809
"Concomitant diseases were hypertension in 8, diabetes mellitus in 4, hypercholesterolemia in 4, ischemic heart disease in 2, and asthma in 1 patient.","Concomitant diseases hypertension 8, diabetes mellitus 4, hypercholesterolemia 4, ischemic heart disease 2, asthma 1 patient.",C0521115|C0012634|C0020538|G0000000|C0011847|G0000000|G0000000|C0020443|G0000000|C0475224|C0018787|C0012634|G0000000|C0004096|G0000000|C0030705
"Nurses were invited to successively complete the Nursing Stress Scale (NSS), the Semantic Differential Attitude Questionnaire and the socio-demographic questionnaire.","Nurses invited successively complete Nursing Stress Scale (NSS), Semantic Differential Attitude Questionnaire socio-demographic questionnaire.",C0028661|G0000000|G0000000|C0205197|C0006147|C0038435|C0175659|G0000000|C0036612|C0443199|C0004271|C0034394|C0011298|C0034394
"The secondary outcomes were Passive Range of Motion (pROM), as the sum of shoulder and elbow movements (shoulder flexion/extension, abduction, intra/extrarotation and elbow extension), to assess the joints excursion which could be considered correlated to spasticity [30], and Motricity Index (MI) that globally assesses impairment in stroke patients [31].","The secondary outcomes Passive Range Motion (pROM), sum shoulder elbow movements (shoulder flexion/extension, abduction, intra/extrarotation elbow extension), assess joints excursion considered correlated spasticity [30], Motricity Index (MI) globally assesses impairment stroke patients [31].",G0000000|C0027627|C1274040|C3686820|C1514721|C0026597|C0015944|C1515051|C0037004|C0013769|C0026649|C0037004|C0444509|C0086505|C0347985|C0013769|C0231448|C1516048|C0022417|G0000000|C0750591|C1707520|C0026838|C0450371|G0000000|C0918012|C3810814|G0000000|C1516048|C0221099|C0038454|C0030705|C0450371
Urine and blood samples for THC and metabolites analysis were collected throughout the study.,Urine blood samples THC metabolites analysis collected study.,C0042036|C0005767|C0370003|C0039663|C0870883|C0002778|C1516695|C0557651
"At 18 months, 30.2% of LC participants reported 6 months of abstinence from smoking, compared with 23.5% in UC (unadjusted, P=.13).","At 18 months, 30.2% LC participants reported 6 months abstinence smoking, compared 23.5% UC (unadjusted, P=.13).",G0000000|C0450371|C0439231|C0450371|G0000000|C0679646|C0684224|G0000000|C0439231|C3843422|C0037369|C1707455|C0450371|G0000000|C1439367|C0369773
Coronary revascularization was confirmed if a coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) was documented in the medical record.,Coronary revascularization confirmed coronary artery bypass grafting (CABG) percutaneous coronary intervention (PCI) documented medical record.,C0018787|C0581603|C0521093|C0018787|C0003842|C0741847|C0332835|C0010055|C0522523|C0018787|C0886296|C4049621|C1301725|C0199168|C0034869
Median time to progression was 2 months (range 1 – 6 months).,Median time progression 2 months (range 1 – 6 months).,C0549183|C0040223|C0242656|G0000000|C0439231|C1514721|G0000000|G0000000|G0000000|C0439231
Staff who only used surgical masks or paper masks did not report any skin reactions.,Staff surgical masks paper masks report skin reactions.,C0851286|C0543467|C0024861|C0030351|C0024861|C0684224|C0444099|C0443286
Changes in Demodex count (A) and OSDI score (B) after eyelid scrub in TTO group and control group.,Changes Demodex count (A) OSDI score (B) eyelid scrub TTO control group.,C0392747|C0323683|C0750480|G0000000|C3896641|C0449820|G0000000|C0015426|G0000000|C0041061|C0243148|C0441833
"Secondary outcomes included the initial quit rate at 14 days, sustained abstinence for 30 days, and sustained abstinence through 12 months (i.e., 6 months after the final incentive disbursement).","Secondary outcomes included initial quit rate 14 days, sustained abstinence 30 days, sustained abstinence 12 months (i.e., 6 months final incentive disbursement).",C0027627|C1274040|C0332257|C0205265|C0748223|C0871208|C0450371|C0439228|C0443318|C3843422|C0450371|C0439228|C0443318|C3843422|C0450371|C0439231|C0683454|G0000000|C0439231|C0205088|C0021147|C0683743
"Postoperative outcome was class I/II (n=5, 83%) or class III over a mean follow-up of 27 months.","Postoperative outcome class I/II (n=5, 83%) class III follow-up 27 months.",C0032790|C1274040|C0456387|C0021966|C0369718|C0450371|C0456387|C0439070|C0589120|C0450371|C0439231
"By contrast, we found a significant increase among respondents to the statewide survey aged 35 to 54 years in physical inactivity (19.4% in the statewide sample were inactive in 2001 vs 27.2% in 2005; P = .02).","By contrast, increase respondents statewide survey aged 35 54 physical inactivity (19.4% statewide sample inactive 2001 27.2% 2005; P = .02).",G0000000|C0009924|C0442805|C0282122|G0000000|C0038951|C0001779|C0450371|C0450371|C0031809|C3890554|C0450371|G0000000|C0370003|C0205254|G0000000|C0450371|G0000000|C0369773|G0000000|C0450371
"Mean overall duration of the mechanical ventilation in the test (n=70) and control group (n=70), including the time on invasive mechanical ventilation.","Mean duration mechanical ventilation test (n=70) control (n=70), including time invasive mechanical ventilation.",C0444504|C0449238|C0443254|C0035203|C0022885|C0369718|C0243148|C0369718|C0332257|C0040223|C0205281|C0443254|C0035203
"The primary objective of part B was to assess the safety and tolerability of GSK2256881, including adverse event (AE) reporting, clinical laboratory tests and immunogenicity, vital signs, electrocardiograms, and physical examinations.","The primary objective B assess safety tolerability GSK2256881, including adverse event (AE) reporting, clinical laboratory tests immunogenicity, vital signs, electrocardiograms, physical examinations.",G0000000|C0205225|C0018017|G0000000|C1516048|C0036043|C3274448|G0000000|C0332257|G0000000|C0441471|C3887670|C0700287|C0205210|C0022877|C0022885|C4054739|C0442732|C0220912|C0013798|C0031809|C0031809
"For invasive bacterial or fungal infections, response was defined as resolution or improvement of clinical evidence of infection.","For invasive bacterial fungal infections, response defined resolution improvement clinical evidence infection.",G0000000|C0205281|C0521009|C0016832|C3714514|C0871261|C1704788|C1514893|C2986411|C0205210|C3887511|C0009450
"Following pulpotomy, all the teeth were restored with stainless steel crown (3M)/light cure glass ionomer cement (GC Fuji I, GC America, Alsip, IL, USA) after 24 h. Children were recalled postoperatively after 24 h for clinical evaluation and after 1 month, 3 months and 6 months both for clinical and radiographical evaluation.","Following pulpotomy, teeth restored stainless steel crown (3M)/light cure glass ionomer cement (GC Fuji I, GC America, Alsip, IL, USA) 24 h. Children recalled postoperatively 24 clinical evaluation 1 month, 3 months 6 months clinical radiographical evaluation.",C0231290|C0034104|C0040426|G0000000|G0000000|C0038239|C0010384|C1421539|C1880198|C0017596|G0000000|C0011343|C3537453|G0000000|C0021966|C3537453|C0002454|G0000000|C0020898|C0041703|C0450371|C0033727|C0008059|C0034770|G0000000|C0450371|C0205210|C0220825|G0000000|C0332177|G0000000|C0439231|G0000000|C0439231|C0205210|C0034571|C0220825
"Adverse events in 12 weeks *gastro-intestinal adverse events were diarrhoea, nausea and ulcus ventriculi.","Adverse events 12 weeks *gastro-intestinal adverse events diarrhoea, nausea ulcus ventriculi.",G0000000|C0441471|C0450371|C0439230|C0521362|G0000000|C0441471|C0011991|C0027497|C0041582|C0038351
"AEs were assessed by the investigator for severity, relationship to the study treatment, and whether the event met criteria as an SAE (ie, not all level 4 AEs, such as laboratory abnormalities, met criteria for SAE).","AEs assessed investigator severity, relationship study treatment, event met criteria SAE (ie, level 4 AEs, laboratory abnormalities, met criteria SAE).",C1412268|C1516048|C0035173|C0439793|C0439849|C0557651|C0039798|C0441471|C0268621|C0243161|C1519255|G0000000|C0441889|G0000000|C1412268|C0022877|C0000768|C0268621|C0243161|C1519255
AIM: To assess delayed antibiotic prescribing as a strategy for reducing the unnecessary use of antibiotics for cough in primary care.,AIM: To assess delayed antibiotic prescribing strategy reducing unnecessary antibiotics cough primary care.,C1947946|C0040363|C1516048|C0205421|C0003232|C0278329|C0679199|C0392756|G0000000|C0003232|C0010200|C0205225|C1947933
Mobility is the key activity underlying functioning and quality of life [6].,Mobility key activity underlying functioning quality life [6].,C0425245|G0000000|C0205177|G0000000|C0205245|C0332306|C0376558|G0000000
"Outcome measures Mothers' reports of community services and local area, family functioning and parenting skills, child health and development, and verbal ability at 36 months.","Outcome measures Mothers' reports community services local area, family functioning parenting skills, child health development, verbal ability 36 months.",C1274040|C0079809|C0026591|C0684224|C0009462|C0557854|C0205276|C0017446|C0015576|C0205245|C0085092|C0678856|C0008059|C0018684|C0243107|C0439824|C0085732|C0450371|C0439231
"Secondary endpoints: Secondary endpoints were glycaemic control assessed by mean HbA1C and mean blood glucose profile; change in BMI-Z-score; change in FEV1% predicted and safety assessed by antibiotic therapy, incidence of adverse events, number of hypoglycaemic episodes, all symptomatic hypoglycaemia, hypoglycaemia that necessitates the help of other persons, hypoglycaemia with unconsciousness or coma and number of blood glucose levels below 50 mg/dl in relation to all blood glucose measurements.","Secondary endpoints: Secondary endpoints glycaemic control assessed HbA1C blood glucose profile; change BMI-Z-score; change FEV1% predicted safety assessed antibiotic therapy, incidence adverse events, hypoglycaemic episodes, symptomatic hypoglycaemia, hypoglycaemia necessitates persons, hypoglycaemia unconsciousness coma blood glucose levels 50 mg/dl relation blood glucose measurements.",C0027627|C2349179|C0027627|C2349179|C0005802|C0243148|C1516048|G0000000|C0005767|C0017725|C1979963|C0392747|C0871421|C0392747|G0000000|C0681842|C0036043|C1516048|C0003232|C0039798|C0021149|G0000000|C0441471|C0020616|C0332189|C0231220|C0020615|C0020615|G0000000|C0027361|C0020615|C0041657|C0009421|C0005767|C0017725|C0441889|C0450371|C0439269|C0080103|C0005767|C0017725|C0242485
Teeth scored as 1 or 2 were considered successful.,Teeth scored 1 2 considered successful.,C0040426|C0449820|G0000000|G0000000|C0750591|C0597535
"Falls, injurious falls, and fractures during follow-up in patients in intervention and control wards.","Falls, injurious falls, fractures follow-up patients intervention control wards.",C0000921|G0000000|C0000921|C0016658|C0589120|C0030705|C0886296|C0243148|C1305702
"Patients were at least 18 years old with PHN for at least 3 months, and an average Numeric Pain Rating Scale (NPRS) score of 3 to 9.","Patients 18 PHN 3 months, average Numeric Pain Rating Scale (NPRS) score 3 9.",C0030705|C0450371|C0032768|G0000000|C0439231|C1510992|C0237753|C0030193|C0871208|C0175659|C1417814|C0449820|G0000000|G0000000
WMFT = Wolf Motor Function Test; FMA = Fugl-Meyer Assessment Test; MCA = middle cerebral artery; CVA = cerebrovascular accident.,WMFT = Wolf Motor Function Test; FMA = Fugl-Meyer Assessment Test; MCA = middle cerebral artery; CVA = cerebrovascular accident.,G0000000|G0000000|C0325001|C1513492|C0031843|C0022885|C2332774|G0000000|G0000000|C1261322|C0022885|C0149566|G0000000|C0444598|G0000000|C0003842|C0038454|G0000000|C1880018|C0000924
"Complete remission was defined as normal stool frequency, no rectal bleeding, a PFA score of 0 (generally healthy), normal endoscopy findings and a PGA score of 0 (quiescent disease activity).","Complete remission defined normal stool frequency, rectal bleeding, PFA score 0 (generally healthy), normal endoscopy findings PGA score 0 (quiescent disease activity).",C0205197|C0544452|C1704788|C0205307|C0015733|C0376249|C0205052|C0019080|C1414168|C0449820|G0000000|G0000000|C3898900|C0205307|C0014245|C2607943|C3541266|C0449820|G0000000|C3820816|C0012634|C0205177
Viral culture and serologic studies were performed to evaluate the presence of rhinovirus infection.,Viral culture serologic studies performed evaluate presence rhinovirus infection.,C0521026|C0010453|C0205473|C0947630|C0884358|C0220825|C0150312|C0035473|C0009450
Patients randomized to the vitamin D group had less knee pain at 12 months on the WOMAC and on the VAS pain scale than did patients who received the placebo (Table 2).,Patients randomized vitamin D knee pain 12 months WOMAC VAS pain scale patients received placebo (Table 2).,C0030705|C0034656|C0042890|C0073187|C0022742|C0030193|C0450371|C0439231|G0000000|C0042815|C0030193|C0175659|C0030705|C1514756|C0032042|C0039224|G0000000
"Follow-up was after 6, 12, and 18 months of intervention.","Follow-up 6, 12, 18 months intervention.",C0589120|G0000000|C0450371|C0450371|C0439231|C0886296
PSA velocity) using biannual PSA measurements.,PSA velocity) biannual PSA measurements.,C3810537|C0439830|G0000000|C3810537|C0242485
"The primary endpoint is quality of oncological resection, measured by radicality of surgery and number of retrieved lymph nodes.","The primary endpoint quality oncological resection, measured radicality surgery retrieved lymph nodes.",G0000000|C0205225|C2349179|C0332306|C0027651|C0015252|C0444706|C0302912|C0038894|G0000000|C0024202|C0746922
This study is designed to answer the question whether any particular type of drain might lower the rate of postoperative pancreatic fistula or other complications.,This study designed answer question type drain lower rate postoperative pancreatic fistula complications.,G0000000|C0557651|C1707689|C1706817|C1522634|C0332307|C0013103|C0441994|C0871208|C0032790|C0030274|C0016169|C0009566
"The primary study outcomes considered were nutrient intake, growth and development measures and secondary outcomes were morbidity, haemoglobin, and maternal knowledge, beliefs and behaviours.","The primary study outcomes considered nutrient intake, growth development measures secondary outcomes morbidity, haemoglobin, maternal knowledge, beliefs behaviours.",G0000000|C0205225|C0557651|C1274040|C0750591|C0678695|C1512806|C0018270|C0243107|C0079809|C0027627|C1274040|C0026538|C0019046|C2347083|C0376554|C0004951|C0004927
The study was approved by the local ethics committee.,The study approved local ethics committee.,G0000000|C0557651|C0205540|C0205276|C0015000|C2699414
"The primary outcome was functional recovery as determined with the use of the Extended Glasgow Outcome Scale9,10 (GOS-E) at 6 months (±30 days) after randomization.","The primary outcome functional recovery determined Extended Glasgow Outcome Scale9,10 (GOS-E) 6 months (±30 days) randomization.",G0000000|C0205225|C1274040|C0205245|C0237820|G0000000|C0231448|G0000000|C1274040|C0450371|C3899193|G0000000|C0439231|G0000000|C0439228|C0034656
"If AOM was suspected by a PHCP, the child was referred to an ENT specialist involved in the trial.","If AOM suspected PHCP, child referred ENT specialist involved trial.",G0000000|C0004519|C0332147|G0000000|C0008059|C0205543|C3889152|C0087009|C1314939|C0008976
The primary endpoint is loss of knee cartilage volume measured by magnetic resonance imaging (MRI) and Western Ontario and McMaster Universities Index of OA (WOMAC) knee pain score.,The primary endpoint loss knee cartilage volume measured magnetic resonance imaging (MRI) Western Ontario McMaster Universities Index OA (WOMAC) knee pain score.,G0000000|C0205225|C2349179|C1517945|C0022742|C0007301|C0449468|C0444706|C0024488|C0231881|C0011923|C0024485|C1705493|C0029040|G0000000|C0041740|C0918012|C0029408|G0000000|C0022742|C0030193|C0449820
The main outcome measures were clinic attendance and patient experience.,The main outcome measures clinic attendance patient experience.,G0000000|C0205225|C1274040|C0079809|C0002424|C2827364|C0030705|C0237607
"Stroke severity was assessed using the Canadian Neurological Scale, a simple, reliable, and validated scale (in which lower scores indicate greater stroke severity) for estimating the neurological status, especially when the National Institutes of Health Stroke Scale is not available.16,17 Baseline motor function was assessed using the Wolf Motor Function Test18 and the Box and Block Test.19 Baseline quality of life was assessed using the Stroke Impact Scale.20 The blinded assessor was trained in the use of these scales.","Stroke severity assessed Canadian Neurological Scale, simple, reliable, validated scale (in lower scores stroke severity) estimating neurological status, National Institutes Health Stroke Scale available.16,17 Baseline motor function assessed Wolf Motor Function Test18 Box Block Test.19 Baseline quality life assessed Stroke Impact Scale.20 The blinded assessor trained scales.",C0038454|C0439793|C1516048|C0238884|C0205494|C0175659|C0205352|C3858758|G0000000|C0175659|G0000000|C0441994|C0449820|C0038454|C0439793|C0750572|C0205494|C0449438|C3245503|C0021622|C0018684|C0038454|C0175659|C0470187|C0168634|C1513492|C0031843|C1516048|C0325001|C1513492|C0031843|G0000000|C0179400|C0028778|C0022885|C0168634|C0332306|C0376558|C1516048|C0038454|C1825598|C0175659|G0000000|C0150108|C1707957|C0336809|C0175659
"In line with hypotheses 1 and 2, at Time 2 (3–4 months post-intervention), disaster preparedness behaviors significantly increased among intervention participants (moderate to large effect size) while mental health symptoms (depression, anxiety, PTSD full scale and avoidance sub-cluster of symptoms) and functional impairment significantly decreased (small to moderate effect sizes).","In hypotheses 1 2, Time 2 (3–4 months post-intervention), disaster preparedness behaviors increased intervention participants (moderate size) mental health symptoms (depression, anxiety, PTSD scale avoidance sub-cluster symptoms) functional impairment decreased (small moderate sizes).",G0000000|C1512571|G0000000|G0000000|C0040223|G0000000|G0000000|C0439231|C2347647|C0012618|C1318963|C0004927|C0205217|C0886296|C0679646|C0205081|C0456389|C0229992|C0018684|C0683368|C0011570|C0003467|C0038436|C0175659|C0870186|C0542339|C0683368|C0205245|C0221099|C0205216|C0700321|C0205081|C0456389
"Thus, the current study examines child mental health symptoms and academic performance as predictors of program engagement.","Thus, current study examines child mental health symptoms academic performance predictors program engagement.",G0000000|C0521116|C0557651|G0000000|C0008059|C0229992|C0018684|C0683368|C1510747|C0597198|C2698872|C1709697|C0425152
"Studies of yoga programs for breast cancer patients showed improvements in physical well-being, social function, emotional health and functional adaption 17.","Studies yoga programs breast cancer patients improvements physical well-being, social function, emotional health functional adaption 17.",C0947630|C0043418|C0376691|C0006141|C0006826|C0030705|C2986411|C0031809|C0018684|C0728831|C0031843|C0013987|C0018684|C0205245|C0000934|C0450371
The primary outcome measure was mortality.,The primary outcome measure mortality.,G0000000|C0205225|C1274040|C0079809|C0026565
"Fugl-Meyer assessment score of paretic upper limb and modified barthel index in patients with acute and subacute stroke Abbreviations: FMA Fugl-Meyer Assessment score, MBI modified Barthel index, T0 before intervention, T10 after tenth session of intervention.","Fugl-Meyer assessment score paretic upper limb modified barthel patients acute subacute stroke Abbreviations: FMA Fugl-Meyer Assessment score, MBI modified Barthel index, T0 intervention, T10 tenth session intervention.",G0000000|C1261322|C0449820|G0000000|C1282910|C0015385|C0392747|G0000000|C0030705|C0205178|C0205365|C0038454|C0000723|C2332774|G0000000|C1261322|C0449820|C2985547|C0392747|G0000000|C0918012|C0041403|C0886296|G0000000|C0205444|C1883016|C0886296
"AT did not improve DFS or overall survival in this population, and was associated with more toxicity.","AT improve DFS survival population, toxicity.",G0000000|G0000000|G0000000|C0038952|C0032659|C0040539
"Four quantitative measures of speech and language, assessed at 6 and 12 months; a binary variable indicating improvement, by 12 months, on the trial entry criterion.","Four quantitative measures speech language, assessed 6 12 months; binary variable indicating improvement, 12 months, trial entry criterion.",C0205450|C0392762|C0079809|C0037817|C0023008|C1516048|G0000000|C0450371|C0439231|C1706942|C0439828|G0000000|C2986411|C0450371|C0439231|C0008976|C1705654|C0243161
Kaplan–Meier curves for TTP according to the assigned arms.,Kaplan–Meier curves TTP assigned arms.,G0000000|C0205134|C0084795|C1516050|C0206655
"The following clinical outcomes will be collected retrospectively for all three phases: Blood creatinine, BUN level, acute and chronic rejection, infection, health-related quality of life and death from the medical record and from primary data collection.","The clinical outcomes collected retrospectively phases: Blood creatinine, BUN level, acute chronic rejection, infection, health-related quality life death medical record primary data collection.",G0000000|C0205210|C1274040|C1516695|G0000000|C0585064|C0005767|C0010294|G0000000|C0441889|C0205178|C0205191|C0035015|C0009450|C0018684|C0332306|C0376558|C0011065|C0199168|C0034869|C0205225|C1511726|C1516698
No patient in either group developed CMV disease after 12 months.,No patient developed CMV disease 12 months.,G0000000|C0030705|G0000000|G0000000|C0012634|C0450371|C0439231
TDI focal score at Week 24 (a) and over 24 weeks (b).,TDI focal score Week 24 (a) 24 weeks (b).,C0205976|C0205234|C0449820|C0332174|C0450371|G0000000|C0450371|C0439230|G0000000
"Thus, vaccination is not expected to reduce craving and withdrawal during a smoking cessation attempt.","Thus, vaccination expected reduce craving withdrawal smoking cessation attempt.",G0000000|C0042196|C1517001|G0000000|C0870371|C2349954|C0037369|C1880019|C1516084
"The FRI rates provided in the present article denote the number of cases of FRI per 100 persons per week, averaged over the 4 weeks during which each housing group was measured.","The FRI rates provided article denote FRI 100 persons week, averaged 4 weeks housing measured.",G0000000|G0000000|C0871208|C1999230|C1706852|G0000000|G0000000|C1442061|C0027361|C0332174|C1510992|G0000000|C0439230|C0020056|C0444706
"There was no difference in weight gain velocity, WAZ or BMIZ scores (Table 5).","There difference weight gain velocity, WAZ BMIZ scores (Table 5).",G0000000|C1705241|C0005910|C1517378|C0439830|G0000000|G0000000|C0449820|C0039224|G0000000
A residual AHI estimate and the 90% pressure (APAP devices) were also obtained from the machine data.,A residual AHI estimate 90% pressure (APAP devices) machine data.,G0000000|C1609982|G0000000|C0750572|C0450371|C0033095|C0000970|C0025080|C0336779|C1511726
Change in the number of words (personally relevant to the participant) named correctly at 6 months from baseline will be measured by a naming task of 100 pictures presented on the computer.,Change (personally relevant participant) named correctly 6 months baseline measured naming task 100 pictures computer.,C0392747|G0000000|C2347946|C0679646|C0027365|G0000000|G0000000|C0439231|C0168634|C0444706|C0233735|C3540678|C1442061|C0441469|C0009622
"From 6 to 18 months there were significantly less cumulative atopic symptoms in the N group compared with the RM group, and significantly less than the PH group up to 6 (N= 25%; PH = 46%) and 9 months (N = 34%, PH = 58%).","From 6 18 months cumulative atopic symptoms N compared RM group, PH 6 (N= 25%; PH = 46%) 9 months (N = 34%, PH = 58%).",G0000000|G0000000|C0450371|C0439231|C1511559|C0392707|C0683368|C0369718|C1707455|C0024851|C0441833|C0450407|G0000000|C0369718|C0450371|C0450407|G0000000|C0450371|G0000000|C0439231|C0369718|G0000000|C0450371|C0450407|G0000000|C0450371
"A subsample of 120 subjects (8 per cluster, 40 per arm) will undergo neurophysiological tests.","A subsample 120 subjects (8 cluster, 40 arm) undergo neurophysiological tests.",G0000000|G0000000|C1442061|C0681850|G0000000|C1555715|C0450371|C0446516|G0000000|C0027901|C0022885
"In this subgroup of patients, severity of pain was judged as: none, severe (analgesics necessary in a way the complaints were acceptable) or extreme (severe complaints despite analgesics; defined as feeling uncomfortable due to pain, not well sleeping due to pain).","In subgroup patients, severity pain judged as: none, severe (analgesics complaints acceptable) extreme (severe complaints analgesics; defined feeling uncomfortable pain, sleeping pain).",G0000000|C1079230|C0030705|C0439793|C0030193|C0221191|G0000000|G0000000|C0205082|C0002771|C0277786|C1879533|C0205403|C0205082|C0277786|C0002771|C1704788|C0013987|G0000000|C0030193|C0037313|C0030193
The median duration of follow-up was 10.5 months in the placebo arm and 10.0 months in the bevacizumab arm.,The median duration follow-up 10.5 months placebo arm 10.0 months bevacizumab arm.,G0000000|C0549183|C0449238|C0589120|C0450371|C0439231|C0032042|C0446516|C0450371|C0439231|C0796392|C0446516
Notes: The withdrawal discomfort is a composite score of 10 items from the behavioral checklist of symptoms with a maximum score or 30.,Notes: The withdrawal discomfort composite score 10 items behavioral checklist symptoms maximum score 30.,C1317574|G0000000|C2349954|C0231218|C0205199|C0449820|C0450371|C1551338|C0004927|C1707357|C0683368|C0806909|C0449820|C0450371
1: Flow of subjects through the study.,1: Flow subjects study.,G0000000|C0806140|C0681850|C0557651
Some of these studies have reported an improved median overall survival and 1-year survival rates.,Some studies reported improved median survival 1-year survival rates.,G0000000|C0947630|C0684224|C0184511|C0549183|C0038952|C0439234|C0038952|C0871208
The advantage of this approach is that it helped to diminish the complication that rescue medication may exert on the observations.,The advantage approach helped diminish complication rescue medication exert observations.,G0000000|G0000000|C0449445|C1269765|C0205216|C0009566|G0000000|C0013227|C0015264|C0302523
A p value <0.05 was considered statistically significant.,A <0.05 considered statistically significant.,G0000000|C0450371|C0750591|C0038215|C0237881
"Participants were considered abstinent if they both reported not smoking in the previous seven days and had exCO≤8.41 Secondary outcomes included smoking abstinence at other time points, smoking intensity (total cigarettes per previous 7 days) and the reduction from baseline thereof, and total cigarettes smoked.","Participants considered abstinent reported smoking previous days exCO≤8.41 Secondary outcomes included smoking abstinence time points, smoking intensity (total cigarettes previous 7 days) reduction baseline thereof, total cigarettes smoked.",C0679646|C0750591|C0457801|C0684224|C0037369|C0205156|C0439228|G0000000|C0027627|C1274040|C0332257|C0037369|C3843422|C0040223|C1552961|C0037369|C0522510|C0439175|C0677453|C0205156|G0000000|C0439228|C0301630|C0168634|G0000000|C0439175|C0677453|C0037366
"Secondary (ADCS–ADL19) and additional efficacy parameters (NPI, VFT) were analyzed using the ANCOVA model.","Secondary (ADCS–ADL19) additional efficacy parameters (NPI, VFT) analyzed ANCOVA model.",C0027627|G0000000|C1524062|C1280519|C0449381|C1412208|G0000000|C0936012|C0814908|C3161035
Primary efficacy endpoint is symptomatic objectified VTE during ALL treatment; secondary efficacy endpoints are overall survival and the composite of symptomatic and asymptomatic objectified VTE.,Primary efficacy endpoint symptomatic objectified VTE ALL treatment; secondary efficacy endpoints survival composite symptomatic asymptomatic objectified VTE.,C0205225|C1280519|C2349179|C0231220|G0000000|C0630906|C0444868|C0039798|C0027627|C1280519|C2349179|C0038952|C0205199|C0231220|C0231221|G0000000|C0630906
Table 4 presents the cumulative number of readmissions in 12 months.,Table 4 cumulative readmissions 12 months.,C0039224|G0000000|C1511559|G0000000|G0000000
"CRITERIA FOR CLINICAL AND RADIOGRAPHIC SCORING* Pathology: Absent Normal functioning Naturally exfoliated Exfoliation prematurely due to ectopic eruption Mobility (physiological) ≤1 mm Pathology: Questionable Percussion sensitivity Chewing sensitivity, short-lasting Gingival inflammation (due to poor oral hygiene) Mobility (physiological) >1 mm but <2 mm Pathology: Initial changes present Chewing sensitivity, long-lasting Gingival swelling (not due to poor oral hygiene) Periodontal pocket formation (no exudate) Mobility >2 mm but <3 mm Pathology: Late changes present Spontaneous pain Gingival swelling (not due to poor oral hygiene) Periodontal pocket formation (exudate) Sinus tract present Mobility ≥3 mm Premature tooth loss, due to pathology Internal root canal form tapering from chamber to the apex PDL/periapical regions; normal width and trabeculation External changes are not allowed (widened periodontal ligament widening (PDL), abnormal inter-radicular trabeculation or variation in radiodensity Internal resorption acceptable (nonperforated) Calcific metamorphosis is acceptable and defined as: uniformly thin root canal; shape (nontapering); variation in radiodensity from canal to canal (one cloudier than the other); dentin bridge formation (one or more canals) External changes are present, but not large Mildly widened PDL Minor inter-radicular radiolucency with trabeculation still present Minor external root resorption; internal resorption changes are acceptable, but not if external change is also present (perforated form) Frank osseous radiolucency present, endangering permanent successor The number of recruited teeth that satisfied the inclusion criteria and entered the study was 252.","CRITERIA FOR CLINICAL AND RADIOGRAPHIC SCORING* Pathology: Absent Normal functioning Naturally exfoliated Exfoliation prematurely ectopic eruption Mobility (physiological) ≤1 mm Pathology: Questionable Percussion sensitivity Chewing sensitivity, short-lasting Gingival inflammation (due poor oral hygiene) Mobility (physiological) >1 mm <2 mm Pathology: Initial Chewing sensitivity, long-lasting Gingival swelling (not poor oral hygiene) Periodontal pocket formation (no exudate) Mobility >2 mm <3 mm Pathology: Late Spontaneous pain Gingival swelling (not poor oral hygiene) Periodontal pocket formation (exudate) Sinus tract Mobility ≥3 mm Premature tooth loss, pathology Internal root canal form tapering chamber apex PDL/periapical regions; normal width trabeculation External allowed (widened periodontal ligament widening (PDL), abnormal inter-radicular trabeculation variation radiodensity Internal resorption acceptable (nonperforated) Calcific metamorphosis acceptable defined as: uniformly thin root canal; shape (nontapering); variation radiodensity canal canal (one cloudier other); dentin bridge formation (one canals) External present, Mildly widened PDL Minor inter-radicular radiolucency trabeculation Minor external root resorption; internal resorption acceptable, external change (perforated form) Frank osseous radiolucency present, endangering permanent successor The recruited teeth satisfied inclusion criteria entered study 252.",C0243161|G0000000|C0205210|G0000000|C0444708|C0449820|C0030664|C0332197|C0205307|C0205245|G0000000|C0237849|C0237849|G0000000|C0574895|C0015230|C0425245|C0205463|G0000000|G0000000|C0030664|C0332241|C0030987|C0020517|C0024888|C0020517|C1282927|C0017562|C0021368|C0678226|C0032854|C0442027|C0020405|C0425245|C0205463|G0000000|G0000000|G0000000|G0000000|C0030664|C0205265|C0024888|C0020517|C0205166|C0017562|C0013604|C1518422|C0032854|C0442027|C0020405|C2960678|G0000000|C0220781|G0000000|C0015388|C0425245|G0000000|G0000000|G0000000|G0000000|C0030664|C0205087|C0205359|C0030193|C0017562|C0013604|C1518422|C0032854|C0442027|C0020405|C2960678|G0000000|C0220781|C0015388|C0016169|C1185740|C0425245|G0000000|G0000000|C0151526|C0040426|C1517945|C0030664|C0205102|C0040452|C0086881|C0348078|C0441640|C0179874|C1522410|C0729269|C0017446|C0205307|C0487742|C2610480|C0205101|C0683607|C0332464|C2960678|C0023685|C0332464|G0000000|C0205161|C0205103|C2610480|C0205419|C3272911|C0205102|C2985494|C1879533|G0000000|C0175895|C0025558|C1879533|C1704788|G0000000|G0000000|C0205168|C0040452|C0086881|C0332479|G0000000|C0205419|C3272911|C0086881|C0086881|C0205447|C0205406|G0000000|C0011429|C0456378|C0220781|C0205447|C0442636|C0205101|C0150312|C0750532|C0332464|G0000000|C0026193|C0205103|C2827491|C2610480|C0026193|C0205101|C0040452|C2985494|C0205102|C2985494|C1879533|C0205101|C0392747|C0549099|C0348078|G0000000|C0262950|C2827491|C0150312|G0000000|C0205355|G0000000|G0000000|G0000000|C0040426|C0242428|C0007637|C0243161|C1521975|C0557651|C1442061
"Assessment of hospital indices did not reveal significant differences in length of hospital stay, ventilator-free days and ICU-free days at day 28 between the two study groups (Table 3).","Assessment hospital indices reveal differences length hospital stay, ventilator-free days ICU-free days day 28 study (Table 3).",C1261322|C0019994|C4033634|C0443289|C1705241|C1444754|C0019994|G0000000|C0087153|C0439228|C0021708|C0439228|C0332173|C0450371|C0557651|C0039224|G0000000
Distribution of endurance time for constant Ẇ exercise tests at visit 2 (n = 459).,Distribution endurance time constant Ẇ exercise tests visit 2 (n = 459).,C0520511|C0518031|C0040223|C1547014|G0000000|C0015259|C0022885|C0545082|G0000000|C0369718|G0000000|C1442061
"The primary end point was antibiotic exposure; secondary end points were clinical recovery, length of hospital stay, clinical and laboratory parameters, spirometry, number of asthma exacerbations, emergency room visits, hospitalizations and need for corticosteroid use due to asthma.","The primary antibiotic exposure; secondary clinical recovery, length hospital stay, clinical laboratory parameters, spirometry, asthma exacerbations, emergency visits, hospitalizations corticosteroid asthma.",G0000000|C0205225|C0003232|C0274281|C0027627|C0205210|C0237820|C1444754|C0019994|G0000000|C0205210|C0022877|C0449381|C0037981|C0004096|G0000000|C0013956|C0545082|C0019993|C0001617|C0004096
The modified Tardieu scale (MTS) was adapted from the original scale developed by Tardieu and colleagues [62].,The modified Tardieu scale (MTS) adapted original scale developed Tardieu colleagues [62].,G0000000|C0392747|G0000000|C0175659|G0000000|C2937289|C0205313|C0175659|G0000000|G0000000|G0000000|C0450371
FRT: Functional reach test.,FRT: Functional reach test.,C1705150|C0205245|C2584321|C0022885
"The refraction was measured with an autorefractor (Retinomax, Nikon) 30 min after one drop of 1% cyclopentolate in each eye.","The refraction measured autorefractor (Retinomax, Nikon) 30 min drop 1% cyclopentolate eye.",G0000000|C0429585|C0444706|C1275634|G0000000|G0000000|C0450371|C0702093|C1321095|G0000000|C0010582|C0015392
"The primary end point of this trial was HIV disease progression—specifically, time from randomization to the date of reaching CD4 cell count less than 200/μL, confirmed within 1 month of the first measurement.","The primary trial HIV disease progression—specifically, time randomization reaching CD4 cell count 200/μL, confirmed 1 month measurement.",G0000000|C0205225|C0008976|C0019682|C0012634|G0000000|C0040223|C0034656|C2584321|C0285590|C0007634|C0750480|G0000000|C0521093|G0000000|C0332177|C0242485
The mortality in the control group was 27.8%.,The mortality control 27.8%.,G0000000|C0026565|C0243148|C0450371
A sustained EDSS progression was defined as a progression that had been confirmed in the course of BENEFIT or BENEFIT follow-up and was sustained up to the 11-year visit.,A sustained EDSS progression defined progression confirmed BENEFIT BENEFIT follow-up sustained 11-year visit.,G0000000|C0443318|C0451246|C0242656|C1704788|C0242656|C0521093|C0814225|C0814225|C0589120|C0443318|C0450371|C0545082
"The outcome measures were time from referral to first outpatient appointment, time from scan to outpatient review and time on waiting list for surgery.","The outcome measures time referral outpatient appointment, time scan outpatient review time waiting list surgery.",G0000000|C1274040|C0079809|C0040223|C0034927|C0029921|C0003629|C0040223|C0034606|C0029921|C0282443|C0040223|C1610166|C0745732|C0038894
"Secondary endpoints were the time to treatment failure (TTF), the 1- and 2-year survival rates, the response rate, and safety.","Secondary endpoints time treatment failure (TTF), 1- 2-year survival rates, response rate, safety.",C0027627|C2349179|C0040223|C0039798|C0231174|C1332112|G0000000|C0439234|C0038952|C0871208|C0871261|C0871208|C0036043
"Endpoints included 0–24 h weighted mean (wm) forced expiratory volume in 1 s (FEV1) (Day 84; primary), trough FEV1 (Day 85; secondary), other lung function endpoints, symptoms, quality of life (QoL) and safety.","Endpoints included 0–24 weighted (wm) forced expiratory volume 1 (FEV1) (Day 84; primary), trough FEV1 (Day 85; secondary), lung function endpoints, symptoms, quality life (QoL) safety.",C2349179|C0332257|G0000000|C0005910|G0000000|C0441722|C0231800|C0449468|G0000000|G0000000|C0332173|C0450371|C0205225|C0444506|G0000000|C0332173|C0450371|C0027627|C0024109|C0031843|C2349179|C0683368|C0332306|C0376558|C0518214|C0036043
"Abbreviatons: ASE, arthritis self‐efficacy scale; FACT‐G, functional assessment of cancer therapy‐general; OEE, outcome expectations from exercise; RAI, rheumatology attitudes index; SEPA, self‐efficacy for physical activity; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities osteoarthritis index.","Abbreviatons: ASE, arthritis self‐efficacy scale; FACT‐G, functional assessment cancer therapy‐general; OEE, outcome expectations exercise; RAI, rheumatology attitudes index; SEPA, self‐efficacy physical activity; VAS, visual analog scale; WOMAC, Western Ontario McMaster Universities osteoarthritis index.",G0000000|G0000000|C0003864|G0000000|C0175659|G0000000|C0205245|C1261322|C0006826|G0000000|G0000000|C1274040|C0679138|C0015259|C3178806|C0035452|C0004271|C0918012|C1424597|G0000000|C0031809|C0205177|C0042815|C0234621|C0243071|C0175659|G0000000|C1705493|C0029040|G0000000|C0041740|C0029408|C0918012
This was not only the case for overall severity assessment by the patients but also for severity and frequency of abdominal pain and severity and frequency of bloating.,This severity assessment patients severity frequency abdominal pain severity frequency bloating.,G0000000|C0439793|C1261322|C0030705|C0439793|C0376249|C0000726|C0030193|C0439793|C0376249|C1291077
"In the treatment group, however, intake of ALA for 12 weeks significantly reduced the plasma level of ADMA, from a mean of 0.37 to 0.31 μmol/L (p=0.04).","In treatment group, however, intake ALA 12 weeks reduced plasma level ADMA, 0.37 0.31 μmol/L (p=0.04).",G0000000|C0039798|C0441833|G0000000|C1512806|C0523459|C0450371|C0439230|C0392756|C0032105|C0441889|G0000000|C0450371|C0450371|G0000000|C0369773
"Based on an ecological framework, evaluation outcomes demonstrated that adequate dose, fidelity, and reach were generally achieved over time; the SM campaign led to substantial increases in walking program participation; and that walkers had positive perceptions of the program in the walking-plus-SM community.","Based ecological framework, evaluation outcomes demonstrated adequate dose, fidelity, reach achieved time; SM campaign led substantial increases walking program participation; walkers positive perceptions program walking-plus-SM community.",C1527178|C0013546|G0000000|C0220825|C1274040|G0000000|C0205410|C0178602|C0680011|C2584321|G0000000|C0040223|C0036154|G0000000|C1708698|G0000000|C0205217|C0080331|C1709697|C0679823|C0043016|C0439178|C0030971|C1709697|C0080331|C0009462
The SGRQ total score was −3.5 (Tio R5–placebo) and −3.8 (Tio R10–placebo) and the Mahler TDI focal score >1 unit.,The SGRQ total score −3.5 (Tio R5–placebo) −3.8 (Tio R10–placebo) Mahler TDI focal score >1 unit.,G0000000|G0000000|C0439175|C0449820|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0205976|C0205234|C0449820|G0000000|C0439148
A secondary outcome of this study was Hb change from days 3 to 30 and day 90 in the placebo arm to determine whether initial antimalaria treatment (CQ-SP or ACT) treatment affected macrophage iron loading in acute clinical malaria and its subsequent release.,A secondary outcome study Hb change days 3 30 day 90 placebo arm determine initial antimalaria treatment (CQ-SP ACT) treatment macrophage iron loading acute clinical malaria subsequent release.,G0000000|C0027627|C1274040|C0557651|C0019046|C0392747|C0439228|G0000000|C0450371|C0332173|C0450371|C0032042|C0446516|G0000000|C0205265|G0000000|C0039798|C0282245|C0079613|C0039798|C0024432|C0302583|C1708715|C0205178|C0205210|C0024530|C0332282|C0030685
Abbreviations: DF=docetaxel with 5-fluorouracil; DI=docetaxel with irinotecan; CI=confidence interval; PR=partial response; CR=complete response; ORR=overall response rate; TTF=time to treatment failure; TTP=time to progression; ITT=intention-to-treat; n.a=not available; PPP=per protocol population.,Abbreviations: DF=docetaxel 5-fluorouracil; DI=docetaxel irinotecan; CI=confidence interval; PR=partial response; CR=complete response; ORR=overall response rate; TTF=time treatment failure; TTP=time progression; ITT=intention-to-treat; n.a=not available; PPP=per protocol population.,C0000723|C0246415|C0016360|C3538902|C0123931|C0008107|C1272706|C0279759|C0871261|C0201975|C0871261|C0282416|C0871261|C0871208|C1332112|C0039798|C0231174|C0084795|C0242656|C0162425|C0369718|C0470187|C0031106|C0442711|C0032659
"At each measurement point, on-site urine cotinine was measured (NicCheck I Test Strips, Mossman Associates Inc.).","At measurement point, on-site urine cotinine measured (NicCheck I Test Strips, Mossman Associates Inc.).",G0000000|C0242485|C1552961|C1720176|C0042036|C0010194|C0444706|G0000000|C0021966|C0022885|C1321564|G0000000|C0750490|G0000000
"“Relapse” was defined as the reappearance of fever and the clinical manifestations of scrub typhus, in the absence of any other identifiable cause, within 30 days after completing therapy as described previously (10).","“Relapse” defined reappearance fever clinical manifestations scrub typhus, absence identifiable cause, 30 days completing therapy (10).",G0000000|C1704788|G0000000|C0015967|C0205210|C0205319|G0000000|C0041471|C0332197|C0205396|C0015127|C0450371|C0439228|C0205197|C0039798|C0450371
Thus average duration of healing of patients in the honey group was significantly lower than that of patients in the SSD group.,Thus average duration healing patients honey lower patients SSD group.,G0000000|C1510992|C0449238|C0043240|C0030705|C0019906|C0441994|C0030705|C0723179|C0441833
Main outcome measures: The co-primary efficacy variables were pre-dose forced expiratory volume in 1 second (FEV1) and 1-hour post-dose FEV1.,Main outcome measures: The co-primary efficacy variables pre-dose forced expiratory volume 1 (FEV1) 1-hour post-dose FEV1.,C0205225|C1274040|C0079809|G0000000|C3245499|C1280519|C0439828|C0439565|C0441722|C0231800|C0449468|G0000000|G0000000|C0439227|C0439568|G0000000
This study was conducted to determine the effect of zinc and vitamin E supplementation on antioxidant status in beta-thalassemic major patients.,This study conducted determine zinc vitamin E supplementation antioxidant status beta-thalassemic major patients.,G0000000|C0557651|C0004927|G0000000|C0043481|C0042890|G0000000|C0242297|C0003402|C0449438|C0330390|C0205082|C0030705
The interval between tea being poured and drunk was inversely associated with risk of oesophageal cancer (table 2).,The interval tea poured drunk inversely risk oesophageal cancer (table 2).,G0000000|C1272706|C0039400|G0000000|C0001969|G0000000|C0035647|C1522619|C0006826|C0039224|G0000000
The first post-test assessment will be carried out one month after the intervention and there will be a long term follow-up two years after the intervention.,The post-test assessment carried month intervention term follow-up intervention.,G0000000|C0687676|C1261322|C0206243|C0332177|C0886296|C0233324|C0589120|C0886296
Quality of life will be evaluated using the SF-36 questionnaire.,Quality life evaluated SF-36 questionnaire.,C0332306|C0376558|C0220825|C0037712|C0034394
"Comparison of Constant shoulder score between the groups at 6 weeks, 3 and 6 months Nine patients (30%) in group 1 had various complications such as malunion with cosmetic deformity, nonunion and restriction of shoulder movements, as compared to 6 patients (20%) in group 2 who had scar-related problems and hardware prominence along with the one malunion (Table 4).","Comparison Constant shoulder score 6 weeks, 3 6 months Nine patients (30%) 1 complications malunion cosmetic deformity, nonunion restriction shoulder movements, compared 6 patients (20%) 2 scar-related hardware prominence malunion (Table 4).",C1707455|C1547014|C0037004|C0449820|G0000000|C0439230|G0000000|G0000000|C0439231|C0205455|C0030705|C0450371|G0000000|C0009566|C3898471|C0010164|C0000768|C3897107|C0443288|C0037004|C0026649|C1707455|G0000000|C0030705|C0450371|G0000000|C0241158|C1523994|C0205402|C3898471|C0039224|G0000000
This method has been used to provide an estimate of CRC mortality in those accepting the first screening test relative to the control group.,This method provide estimate CRC mortality accepting screening test relative control group.,G0000000|C0025663|C1999230|C0750572|C0009402|C0026565|C1272684|C0220908|C0022885|C0080103|C0243148|C0441833
Cannabis use was assessed by urine toxicology and participant self-report.,Cannabis assessed urine toxicology participant self-report.,C0024808|C1516048|C0042036|C0040541|C0679646|C0681906
"Among 170 patients available for matching, the frequency of major cell types (adenocarcinoma, 54.7%; squamous cell carcinoma, 27.1%) was similar to that reported in a previous study conducted in Taiwan [35].","Among 170 patients matching, frequency major cell types (adenocarcinoma, 54.7%; squamous cell carcinoma, 27.1%) reported previous study conducted Taiwan [35].",G0000000|C1442061|C0030705|C0150103|C0376249|C0205082|C0007634|C0332307|C0001418|C0450371|C1182670|C0007634|C0007097|C0450371|C0684224|C0205156|C0557651|C0004927|C0039260|C0450371
Participants were assessed before randomization and 6 and 12 months after the occurrence of stroke by physical therapists who were trained in the use of standardized assessment protocols and were unaware of the participants’ group assignment.8 The primary outcome was the proportion of participants with an improved functional level of walking 1 year after the stroke.,Participants assessed randomization 6 12 months occurrence stroke physical therapists trained standardized assessment protocols unaware participants’ assignment.8 The primary outcome proportion participants improved functional level walking 1 stroke.,C0679646|C1516048|C0034656|G0000000|C0450371|C0439231|C0243132|C0038454|C0031809|C0871525|C0336809|G0000000|C1261322|C0442711|C0150114|G0000000|C1516050|G0000000|C0205225|C1274040|C1709707|C0679646|C0184511|C0205245|C0441889|C0080331|G0000000|C0038454
When assessing the value of a particular anticancer treatment it is important to consider the impact it may have not only on length of survival but also on health related quality of life (HRQOL).,When assessing anticancer treatment impact length survival health quality life (HRQOL).,G0000000|C1516048|G0000000|C0039798|C1825598|C1444754|C0038952|C0018684|C0332306|C0376558|G0000000
Both treatments lead to a marked and significant decrease in SCORAD and pruritus index.,Both treatments lead marked decrease SCORAD pruritus index.,G0000000|C0087111|C0023175|C0522501|C0392756|G0000000|C0033774|C0918012
"These outcomes will be measured at baseline, four, 16 and 26 weeks.","These outcomes measured baseline, four, 16 26 weeks.",G0000000|C1274040|C0444706|C0168634|C0205450|C0450371|C0450371|C0439230
The program could be beneficiary in ADL 6 months after the intervention ended and for the Falls Efficacy Scale International (FES-I) directly after and 3 months post-intervention for the intervention group (IG) compared with the control group (CG) (p<0.05).,The program beneficiary ADL 6 months intervention Falls Efficacy Scale International (FES-I) directly 3 months post-intervention intervention (IG) compared control (CG) (p<0.05).,G0000000|C1709697|C1550502|C0001288|G0000000|C0439231|C0886296|C0000921|C1280519|C0175659|C1512888|C0021966|C1947931|G0000000|C0439231|C2347647|C0886296|C0021027|C1707455|C0243148|C0043444|C0369773
A further analysis was included to investigate for differences in children who had never been listed as registered with an NHS GDP and those whose had been at one time registered (lapsed more than 9 months).,A analysis included investigate differences children listed registered NHS GDP time registered (lapsed 9 months).,G0000000|C0002778|C0332257|C1292732|C1705241|C0008059|C0745732|C1514821|C0796085|C0018340|C0040223|C1514821|G0000000|G0000000|C0439231
"Further, long-term reductions in youth tobacco use from age 11 to age 22 were found for families that engaged with treatment.","Further, long-term reductions youth tobacco age 11 age 22 families engaged treatment.",C1517331|C0443252|C0301630|C0001578|C0040329|C0001779|C0450371|C0001779|C0450371|C0015576|C0425152|C0039798
"symptomatic hypotension (syncope or presyncope) or neurological deterioration (defined as any worsening in NIHSS score); (b) falls during hospitalization and within 3 months of stroke; (c) complications related to immobility (pneumonia, pulmonary embolism, and deep vein thrombosis) at 3 months, and (d) death within 3 months.","symptomatic hypotension (syncope presyncope) neurological deterioration (defined worsening NIHSS score); (b) falls hospitalization 3 months stroke; (c) complications immobility (pneumonia, pulmonary embolism, deep vein thrombosis) 3 months, (d) death 3 months.",C0231220|C0020649|C0039070|C0700200|C0205494|C0868945|C1704788|C0332271|C3476804|C0449820|G0000000|C0000921|C0019993|G0000000|C0439231|C0038454|G0000000|C0009566|C0231441|C0032285|C0024109|C0013922|C0205125|C0042449|C0040053|G0000000|C0439231|C0073187|C0011065|G0000000|C0439231
"Complete follow-up data at 12, 24, 48 and 72 hours were obtained from all patients (Table 2).","Complete follow-up data 12, 24, 48 72 hours patients (Table 2).",C0205197|C0589120|C1511726|C0450371|C0450371|C0450371|C0450371|C0439227|C0030705|C0039224|G0000000
"A finger prick of blood was taken at baseline, at week 12, and again at week 24 to determine haemoglobin concentration.","A finger prick blood baseline, week 12, week 24 determine haemoglobin concentration.",G0000000|C0016129|C0033119|C0005767|C0168634|C0332174|C0450371|C0332174|C0450371|G0000000|C0019046|C0004268
"Moreover we didn’t find differences between groups regarding respiratory function (VT, face mask leak, FiO2), blood gases at 15 minutes and respiratory short-term outcome.","Moreover didn’t differences respiratory function (VT, mask leak, FiO2), blood gases 15 minutes respiratory short-term outcome.",G0000000|G0000000|C1705241|C0521346|C0031843|C0042427|C0024861|C0332234|G0000000|C0005767|C0017110|C0450371|C0439232|C0521346|C0443303|C1274040
"Maternal knowledge and beliefs regarding complementary and responsive feeding were compared among groups at 6, 9, 12 and 15 months of infants’ age.","Maternal knowledge beliefs complementary responsive feeding compared 6, 9, 12 15 months infants’ age.",C2347083|C0376554|C0004951|G0000000|C0205342|C0204695|C1707455|G0000000|G0000000|C0450371|C0450371|C0439231|G0000000|C0001779
"Abbreviations: Visit 1, incremental work rate test; visit 2, constant work rate test at 90% of maximum work rate from visit 1; visit 3, repeat identical constant work rate test; time, endurance time in seconds; Ẇ max, maximum work rate for the incremental exercise test at visit 1; Ẇ con, constant work rate for the exercise tests at visits 2 and 3; GOLD, global initiative for chronic obstructive lung disease.","Abbreviations: Visit 1, incremental rate test; visit 2, constant rate test 90% maximum rate visit 1; visit 3, repeat identical constant rate test; time, endurance time seconds; Ẇ max, maximum rate incremental exercise test visit 1; Ẇ con, constant rate exercise tests visits 2 3; GOLD, global initiative chronic obstructive lung disease.",C0000723|C0545082|G0000000|C1705117|C0871208|C0022885|C0545082|G0000000|C1547014|C0871208|C0022885|C0450371|C0806909|C0871208|C0545082|G0000000|C0545082|G0000000|C0205341|C0205280|C1547014|C0871208|C0022885|C0040223|C0518031|C0040223|C0457385|G0000000|G0000000|C0806909|C0871208|C1705117|C0015259|C0022885|C0545082|G0000000|G0000000|G0000000|C1547014|C0871208|C0015259|C0022885|C0545082|G0000000|G0000000|C0018026|C0205246|C0424093|C0205191|C0549186|C0024109|C0012634
"With intention to treat analysis and after 8 wk of supplementation FPG, HbA1c, HOMA-IR, and insulin levels remained unchanged in the probiotic and placebo group (P > 0.05).","With intention treat analysis 8 wk supplementation FPG, HbA1c, HOMA-IR, insulin levels remained unchanged probiotic placebo (P > 0.05).",G0000000|C0162425|C0087111|C0002778|G0000000|C0242297|G0000000|G0000000|C0022065|C0021641|C0441889|G0000000|C0442739|C0525033|C0032042|C0369773|G0000000|C0450371
Refractive error (cycloplegic autorefraction) and axial length were measured at 6-month intervals.,Refractive error (cycloplegic autorefraction) axial length measured 6-month intervals.,C0429585|C0743559|C0010586|G0000000|C0205131|C1444754|C0444706|C0332177|C1272706
"The interviews included a mix of quantitative and open-ended questions about their experiences with the water jets, implementation and maintenance, and student interaction with the jets.","The interviews included mix quantitative open-ended questions experiences water jets, implementation maintenance, student interaction jets.",G0000000|C0021822|C0332257|C0205430|C0392762|C2827655|C1522634|C0596545|C0043047|C0336862|C1708476|C0024501|C0038492|C1704675|C0336862
"Mood (Hospital Anxiety and Depression Scale), quality of life (SF 36, Functional Outcomes of Sleep Questionnaire), and reaction times (Psychomotor Vigilance Task) were not improved more than sham CPAP.","Mood (Hospital Anxiety Depression Scale), quality life (SF 36, Functional Outcomes Sleep Questionnaire), reaction times (Psychomotor Vigilance Task) improved sham CPAP.",C0026516|C0019994|C0003467|C0011570|C0175659|C0332306|C0376558|C0037712|C0450371|C0205245|C1274040|C0037313|C0034394|C0443286|C0040223|G0000000|C0699864|C3540678|C0184511|C0068899|C0199451
"The corresponding people with dementia reported higher, but not significantly higher, quality of life.","The people dementia reported higher, higher, quality life.",G0000000|C0027361|C0011265|C0684224|C0205250|C0205250|C0332306|C0376558
"A clinical response to therapy was defined as a decrease in the PGA score of at least one point from baseline, plus improvement in at least one other clinical assessment parameter (stool frequency, rectal bleeding, PFA or endoscopy findings) and no worsening in any of the other clinical assessments.","A clinical response therapy defined decrease PGA score baseline, improvement clinical assessment parameter (stool frequency, rectal bleeding, PFA endoscopy findings) worsening clinical assessments.",G0000000|C0205210|C0871261|C0039798|C1704788|C0392756|C3541266|C0449820|C0168634|C2986411|C0205210|C1261322|C0549193|C0015733|C0376249|C0205052|C0019080|C1414168|C0014245|C2607943|C0332271|C0205210|C1261322
The primary outcome assessed was the development of pericardial constriction.,The primary outcome assessed development pericardial constriction.,G0000000|C0205225|C1274040|C1516048|C0243107|C0031050|C0009813
ANOVA = analysis of variance; AP = attention-placebo; CBT = cognitive behavioural therapy; ES = effect size; FIQ = Fibromyalgia Impact Questionnaire; FMS = fibromyalgia syndrome; MANOVA = multivariate analysis of variance; MPI = West Haven-Yale Multidimensional Pain Inventory; OBT = operant behavioral therapy; PRSS = Pain-Related Self-Statements Scale; TBS = Tübingen Pain Behaviour Scale; TP = tender point.,ANOVA = analysis variance; AP = attention-placebo; CBT = cognitive behavioural therapy; ES = size; FIQ = Fibromyalgia Impact Questionnaire; FMS = fibromyalgia syndrome; MANOVA = multivariate analysis variance; MPI = West Haven-Yale Multidimensional Pain Inventory; OBT = operant behavioral therapy; PRSS = Pain-Related Self-Statements Scale; TBS = Tübingen Pain Behaviour Scale; TP = tender point.,G0000000|G0000000|C0002778|C1711260|C3887950|G0000000|C0004268|C0009244|G0000000|C1516691|C0004927|C0039798|C0013754|G0000000|C0456389|G0000000|G0000000|C0016053|C1825598|C0034394|G0000000|G0000000|C0016053|C0039082|C0681926|G0000000|G0000000|C0002778|C1711260|C0663932|G0000000|C1705493|G0000000|C2347299|C0030193|C0021941|G0000000|G0000000|G0000000|C0004927|C0039798|C1415382|G0000000|C0030193|C0036588|C0175659|C0265246|G0000000|G0000000|C0030193|C0004927|C0175659|C0036183|G0000000|C0234234|C1552961
The primary outcome measure in EXACTT will be endurance time at 90% of maximum work rate.,The primary outcome measure EXACTT endurance time 90% maximum rate.,G0000000|C0205225|C1274040|C0079809|G0000000|C0518031|C0040223|C0450371|C0806909|C0871208
"Secondary endpoints were incidence of severe episodes of diarrhea and stool frequency, incidence of respiratory infection (cough), changes in CD4 count in HIV-infected participants, changes in nutritional status, and mortality.","Secondary endpoints incidence severe episodes diarrhea stool frequency, incidence respiratory infection (cough), CD4 count HIV-infected participants, nutritional status, mortality.",C0027627|C2349179|C0021149|C0205082|C0332189|C0011991|C0015733|C0376249|C0021149|C0521346|C0009450|C0010200|C0285590|C0750480|C0019682|C0679646|C1521739|C0449438|C0026565
"Tertiary endpoints included change from baseline to end of treatment and after 8 weeks of follow-up in additional renal parameters, and time to first occurrence of any component of the triple-composite renal endpoint (end-stage renal disease [ESRD], confirmed doubling of SCr from baseline [confirmed at least 4 weeks later] or confirmed increase in SCr of 50% [confirmed within 1 week and leading to discontinuation of treatment]), or the double-composite renal endpoint (ESRD or any doubling of SCr from baseline).","Tertiary endpoints included change baseline treatment 8 weeks follow-up additional renal parameters, time occurrence component triple-composite renal endpoint (end-stage renal disease [ESRD], confirmed doubling SCr baseline [confirmed 4 weeks later] confirmed increase SCr 50% [confirmed 1 week leading discontinuation treatment]), double-composite renal endpoint (ESRD doubling SCr baseline).",C0205372|C2349179|C0332257|C0392747|C0168634|C0039798|G0000000|C0439230|C0589120|C1524062|C0022646|C0449381|C0040223|C0243132|C0449432|C0205174|C0022646|C2349179|C0205088|C0022646|C0012634|C0022661|C0521093|C0205173|C1539487|C0168634|C0521093|G0000000|C0439230|C0205087|C0521093|C0442805|C1539487|C0450371|C0521093|G0000000|C0332174|C0332152|C0457454|C0039798|C0205173|C0022646|C2349179|C0022661|C0205173|C1539487|C0168634
"CD4 and viral load tests were done approximately six-monthly[9,27].","CD4 viral load tests six-monthly[9,27].",C0285590|C0521026|C1550025|C0022885|C0585339
There were no complications such as pneumothorax or hemothorax.,There complications pneumothorax hemothorax.,G0000000|C0009566|C0032326|C0019123
"Variables of interest were gait velocity, cadence, stride length, swing percent and double support percent.","Variables gait velocity, cadence, stride length, swing percent double support percent.",C0439828|C0016928|C0439830|G0000000|G0000000|C1444754|G0000000|C0439165|C0205173|C0183683|C0439165
Mixed-effect model repeated measure analysis was also performed for trough FEV1 at day 84 and rescue use (mean number of puffs/day) over weeks 1–12.,Mixed-effect model repeated measure analysis performed trough FEV1 day 84 rescue (mean puffs/day) weeks 1–12.,C0205430|C3161035|C0205341|C0079809|C0002778|C0884358|C0444506|G0000000|C0332173|C0450371|G0000000|C0444504|C1533107|C0439230|G0000000
"The main outcome measures were mean change in serum 25(OH)D levels, expanded disability status scale (EDSS) score, and number of relapse events during pregnancy and within 6 months after delivery.","The main outcome measures change serum 25(OH)D levels, expanded disability status scale (EDSS) score, relapse events pregnancy 6 months delivery.",G0000000|C0205225|C1274040|C0079809|C0392747|C0229671|C0450371|C0441889|C0205229|C0231170|C0449438|C0175659|C0451246|C0449820|C0035020|C0441471|C0032961|G0000000|C0439231|C0011209
"Observers also used the Philadelphia Geriatric Center Affect Rating Scale to record the predominant type of affect (pleasure, contentment, interest, anger, sadness, anxiety/ fear) evident during every minute [25].","Observers Philadelphia Geriatric Center Affect Rating Scale record predominant type affect (pleasure, contentment, interest, anger, sadness, anxiety/ fear) evident minute [25].",C0870992|C0031525|C1704440|C0205099|C0001721|C0871208|C0175659|C0034869|C1542147|C0332307|C0001721|C0679105|C0423896|C0543488|C0002957|C3536794|C0003467|C0015726|C3887511|C0439232|C0450371
The radar plot “profile” consists of a drawn line connecting the data values for each radius.,The radar plot “profile” consists drawn connecting data values radius.,G0000000|C0034513|G0000000|G0000000|C0332529|C0013113|C2986575|C1511726|C0042295|C0034627
"The primary outcome was time to being assessed as ‘fit’ for discharge with secondary outcomes including time to discharge, incidence of adverse events together with follow up to 28 days assessing patient centred health related outcomes.","The primary outcome time assessed ‘fit’ discharge secondary outcomes including time discharge, incidence adverse events follow 28 days assessing patient centred health outcomes.",G0000000|C0205225|C1274040|C0040223|C1516048|G0000000|C0012621|C0027627|C1274040|C0332257|C0040223|C0012621|C0021149|G0000000|C0441471|C0332283|C0450371|C0439228|C1516048|C0030705|C0205099|C0018684|C1274040
"BMI, body mass index; BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; NRS, numeric rating scale.","BMI, body mass index; BSA, body surface area; EASI, Eczema Area Severity Index; IGA, Investigator's Global Assessment; NRS, numeric rating scale.",G0000000|C0242821|C0577559|C0918012|G0000000|C0242821|C0205148|C0017446|C1516931|C0013595|C0017446|C0439793|C0918012|C2825347|C0035173|C0205246|C1261322|C2240043|C0237753|C0871208|C0175659
"Mucociliary clearance was measured using a radioaerosol technique for 90 minutes after the interventions which comprised 0.9% NaCl + voluntary cough (control), 3.0% NaCl, 7.0% NaCl, and 12% NaCl.","Mucociliary clearance measured radioaerosol technique 90 minutes interventions comprised 0.9% NaCl + voluntary cough (control), 3.0% NaCl, 7.0% NaCl, 12% NaCl.",G0000000|C0449297|C0444706|C0678562|C0449851|C0450371|C0439232|C0886296|C2700400|G0000000|C0037494|G0000000|C0439656|C0010200|C0243148|G0000000|C0037494|G0000000|C0037494|C0450371|C0037494
"Secondary endpoints were various hemoglobin (Hb) levels, change in Hb between time points, length of stay, iron status, morbidity, mortality, and quality of life 4 weeks postsurgery.","Secondary endpoints hemoglobin (Hb) levels, change Hb time points, length stay, iron status, morbidity, mortality, quality life 4 weeks postsurgery.",C0027627|C2349179|C0019046|C0019046|C0441889|C0392747|C0019046|C0040223|C1552961|C1444754|G0000000|C0302583|C0449438|C0026538|C0026565|C0332306|C0376558|G0000000|C0439230|C0032790
Bispectral index system (BIS) is a new noninvasive technique for the evaluation of the depth of sedation.,Bispectral system (BIS) noninvasive technique evaluation depth sedation.,G0000000|C0449913|C0556985|C0205303|C0449851|C0220825|C0205125|C0235195
"Median OS was 15.9 months [95% confidence interval (CI), 11.0–22.5 months] in the RT/temozolomide arm and 16.6 months (95% CI, 14.9–20.1 months) in the vandetanib/RT/temozolomide (log-rank P = 0.75).","Median OS 15.9 months [95% confidence interval (CI), 11.0–22.5 months] RT/temozolomide arm 16.6 months (95% CI, 14.9–20.1 months) vandetanib/RT/temozolomide (log-rank P = 0.75).",C0549183|C0229090|C0450371|C0439231|C0450371|C0237529|C1272706|C0008107|G0000000|C0439231|C0230425|C0446516|C0450371|C0439231|C0450371|C0008107|G0000000|C0439231|C1628324|C1708728|C0369773|G0000000|C0450371
The primary outcome was the mean changes from baseline to week 12 in the frequency of hot flashes recorded in the participant diary.,The primary outcome baseline week 12 frequency hot flashes recorded participant diary.,G0000000|C0205225|C1274040|C0168634|C0332174|C0450371|C0376249|C0444519|C0085635|C0034869|C0679646|C0376660
Quality of life was assessed using the SGRQ.,Quality life assessed SGRQ.,C0332306|C0376558|C1516048|G0000000
"Furthermore, abdominal pain, other gastrointestinal symptoms, or global symptom relief did not differ between both groups after six weeks of treatment.","Furthermore, abdominal pain, gastrointestinal symptoms, global symptom relief weeks treatment.",G0000000|C0000726|C0030193|C0521362|C0683368|C0205246|C1457887|C0564405|C0439230|C0039798
Modified Brock criteria11 (Table 1) were used to assign a rating of hearing loss for each ear.,Modified Brock criteria11 (Table 1) assign rating hearing loss ear.,C0392747|G0000000|G0000000|C0039224|G0000000|C1516050|C0871208|C0018767|C1517945|C0013443
Prostate cancer cases and controls characterization.,Prostate cancer controls characterization.,C0033572|C0006826|C0243148|C1880022
"The primary outcome measures will include self-reported tobacco, alcohol, marijuana and other illicit drug use.","The primary outcome measures self-reported tobacco, alcohol, marijuana illicit drug use.",G0000000|C0205225|C1274040|C0079809|C0681906|C0040329|C0001962|C0024808|C0332266|C0013227|C0042153
"In all these studies, the postprandial (before and during exercise) fatty acid levels did not change significantly with time.","In studies, postprandial (before exercise) fatty acid levels change time.",G0000000|C0947630|C0376674|C0332152|C0015259|G0000000|C0001128|C0441889|C0392747|C0040223
The primary endpoint is relapse-free survival during the observation period.,The primary endpoint relapse-free survival observation period.,G0000000|C0205225|C2349179|C0035020|C0038952|C0302523|C0439531
"We used generalised linear mixed models, with rest home as a random factor, city as a fixed factor, and time as a repeated measure, to investigate whether the intervention was associated with a change in function (late life function and disability index, timed up and go, elderly mobility scale, balance) or quality of life (life satisfaction index, EuroQol) over time and in particular whether this change differed between the social and intervention groups.","We generalised linear mixed models, rest random factor, city fixed factor, time repeated measure, investigate intervention change function (late life function disability index, timed go, elderly mobility scale, balance) quality life (life satisfaction index, EuroQol) time change differed social intervention groups.",G0000000|C0205246|C0205132|C0205430|C3161035|C0035253|C0034656|C1521761|C0008848|C0443218|C1521761|C0040223|C0205341|C0079809|C1292732|C0886296|C0392747|C0031843|C0205087|C0376558|C0031843|C0231170|C0918012|C0392761|C1822658|C0001792|C0425245|C0175659|C0014653|C0332306|C0376558|C0376558|C0242428|C0918012|C0451150|C0040223|C0392747|G0000000|C0728831|C0886296|C0441833
"No significant differences were noted between groups in any of the measured variables: distance walked, RHR, 6MWT HRmax, PCI, FSS, resting SBP, and resting DBP.","No differences measured variables: distance walked, RHR, 6MWT HRmax, PCI, FSS, resting SBP, resting DBP.",G0000000|C1705241|C0444706|C0439828|C0012751|C0080331|C1706649|G0000000|C0744679|C4049621|C0265224|C0035253|G0000000|C0035253|C0536221
"Secondary outcomes included enteral intake at 3 weeks, days to reach 150 ml kg−1 per day, growth indices (weight, head circumference and length) at 3 weeks, days requiring parenteral nutrition and central line access, and the incidence of NEC, sepsis and parental nutrition-associated liver disease.","Secondary outcomes included enteral intake 3 weeks, days reach 150 kg−1 day, growth indices (weight, head circumference length) 3 weeks, days requiring parenteral nutrition central access, incidence NEC, sepsis parental nutrition-associated liver disease.",C0027627|C1274040|C0332257|C1304890|C1512806|G0000000|C0439230|C0439228|C2584321|C1442061|G0000000|C0332173|C0018270|C4033634|C0005910|C0018670|C0332520|C1444754|G0000000|C0439230|C0439228|G0000000|C0030547|C0028707|C0205099|C0444454|C0021149|C0206695|C0036690|C0030551|C0028707|C0023884|C0012634
"Secondary outcomes include: fetal length at 12 and 34 wk; incidence of low birth weight (LBW); neonatal/infant anthropometry 0-6 mo of age; infectious disease morbidity; maternal, fetal, newborn, and infant epigenetics; maternal and infant nutritional status; maternal and infant microbiome; gut inflammatory biomarkers and bioactive and nutritive compounds in breast milk.","Secondary outcomes include: fetal length 12 34 wk; incidence low birth weight (LBW); neonatal/infant anthropometry 0-6 mo age; infectious disease morbidity; maternal, fetal, newborn, infant epigenetics; maternal infant nutritional status; maternal infant microbiome; gut inflammatory biomarkers bioactive nutritive compounds breast milk.",C0027627|C1274040|C0332257|C0015965|C1444754|C0450371|C0450371|C0332174|C0021149|C0205251|C0005615|C0005910|G0000000|C0021289|C0003188|G0000000|C0026544|C0001779|C0009450|C0012634|C0026538|C2347083|C0015965|C0021289|C0021270|C1516924|C2347083|C0021270|C1521739|C0449438|C2347083|C0021270|C1956108|C0017189|C0333348|C0005516|G0000000|G0000000|C0205198|C0006141|C0026131
Comparison of delivery mode in the intervention and control groups.,Comparison delivery mode intervention control groups.,C1707455|C0011209|C1513371|C0886296|C0243148|C0441833
"Secondary outcomes included the time from randomisation to recurrent stroke, myocardial infarction, or death (from any cause).","Secondary outcomes included time randomisation recurrent stroke, myocardial infarction, death (from cause).",C0027627|C1274040|C0332257|C0040223|C0034656|C2945760|C0038454|C0027061|C0021308|C0011065|G0000000|C0015127
"The secondary efficacy end point was the combined incidence of HPV 6- or 11-related persistent infection, cervical, and external genital disease.","The secondary efficacy combined incidence HPV 6- 11-related persistent infection, cervical, external genital disease.",G0000000|C0027627|C1280519|C0205195|C0021149|C0021344|G0000000|C0450371|C0205322|C0009450|C0027530|C0205101|C0559522|C0012634
There was no significant difference in the number of blood transfusions received in the treatment and control groups.,There difference blood transfusions received treatment control groups.,G0000000|C1705241|C0005767|C0005841|C1514756|C0039798|C0243148|C0441833
"A trained clinician rated the patients on the following instruments: (a) Positive and Negative Syndrome Scale (PANSS),[8] (b) Social and Occupational Functioning Scale (SOFS),[9] and (c) Extra Pyramidal Symptoms.","A trained clinician rated patients instruments: (a) Positive Negative Syndrome Scale (PANSS),[8] (b) Social Occupational Functioning Scale (SOFS),[9] (c) Extra Pyramidal Symptoms.",G0000000|C0336809|C0871685|C0871208|C0030705|C0348000|G0000000|C0439178|C0205160|C0039082|C0175659|G0000000|G0000000|C0728831|C0521127|C0205245|C0175659|G0000000|G0000000|G0000000|G0000000|C0683368
"In the Haloperidol Effectiveness in ICU Delirium (Hope-ICU) trial,19 142 patients receiving mechanical ventilation in the ICU were randomly assigned to receive intravenous haloperidol or placebo; the results also showed no effect on days alive without delirium or coma, although there were fewer days with agitated delirium in patients who received haloperidol.","In Haloperidol Effectiveness ICU Delirium (Hope-ICU) trial,19 142 patients receiving mechanical ventilation ICU randomly assigned receive intravenous haloperidol placebo; days alive delirium coma, fewer days agitated delirium patients received haloperidol.",G0000000|C0018546|C1280519|C0021708|C0011206|C0392347|C0008976|C1442061|C0030705|C1514756|C0443254|C0035203|C0021708|G0000000|C1516050|C1514756|C0348016|C0018546|C0032042|C0439228|C0376558|C0011206|C0009421|C0205388|C0439228|C0085631|C0011206|C0030705|C1514756|C0018546
"The secondary outcome measures were SR concentration at 3 months, haemoglobin, serum ferritin (SF) and serum transferrin receptor (STfR) concentrations and proportion of children with VAD, anaemia and iron deficiency at 3 and 6 months.","The secondary outcome measures SR concentration 3 months, haemoglobin, serum ferritin (SF) serum transferrin receptor (STfR) concentrations proportion children VAD, anaemia iron deficiency 3 6 months.",G0000000|C0027627|C1274040|C0079809|C3813610|C0004268|G0000000|C0439231|C0019046|C0229671|C0015879|C0037712|C0229671|C0040679|C0597357|G0000000|C0086045|C1709707|C0008059|C0077973|C0002871|C0302583|C0011155|G0000000|G0000000|C0439231
"At the same time, these young men reported high levels of marijuana and alcohol use, risky sexual behavior, many prior encounters with the criminal justice system and multiple life challenges.","At time, reported levels marijuana alcohol use, risky sexual behavior, prior encounters criminal justice system multiple life challenges.",G0000000|C0040223|C0684224|C0441889|C0024808|C0001962|C0042153|C0035647|C0036864|C0004927|C0332152|C0545082|C0699726|C0022437|C0449913|C0439064|C0376558|C0805586
"Secondary outcomes included 6MWD, C-reactive protein levels, cardiac output, right ventricular size, spirometry parameters such as FEV1, FVC, FEV1/FVC, oxidized low-density lipoprotein (LDL) levels, and patients’ signs and symptoms after 6 months medication consumption.","Secondary outcomes included 6MWD, C-reactive protein levels, cardiac output, ventricular size, spirometry parameters FEV1, FVC, FEV1/FVC, oxidized low-density lipoprotein (LDL) levels, patients’ signs symptoms 6 months medication consumption.",C0027627|C1274040|C0332257|G0000000|C0205332|C0033684|C0441889|C0018787|C1709366|C0018827|C0456389|C0037981|C0449381|G0000000|C3714541|C3714541|C0030011|C0205251|C0023820|G0000000|C0441889|G0000000|C0220912|C0683368|G0000000|C0439231|C0013227|C0009830
It is hypothesised that the MCG will have a higher average ACQ score than the UCG at 3 and 6 months.,It hypothesised MCG average ACQ score UCG 3 6 months.,G0000000|G0000000|C0439211|C1510992|C2919686|C0449820|G0000000|G0000000|G0000000|C0439231
[6].,[6].,G0000000
A greater increase in serum 25(OH)D concentration over the course of treatment was predictive of successful healing of rickets.,A increase serum 25(OH)D concentration treatment predictive successful healing rickets.,G0000000|C0442805|C0229671|C0450371|C0004268|C0039798|C0681890|C0597535|C0043240|C0035579
"This study used questions that asked about youth involvement in violence (e.g., fighting), and substance use (e.g., alcohol and marijuana).","This study questions youth involvement violence (e.g., fighting), substance (e.g., alcohol marijuana).",G0000000|C0557651|C1522634|C0001578|C1314939|C0042693|G0000000|C0424324|C0439861|G0000000|C0001962|C0024808
"The current study failed to demonstrate a therapeutic benefit of highly purified creatine monohydrate in tests of muscle strength, fatigability, forced vital capacity, ALSFRS-R and SF-12, in a large population of patients with ALS.","The current study failed demonstrate therapeutic benefit highly purified creatine monohydrate tests muscle strength, fatigability, forced vital capacity, ALSFRS-R SF-12, population patients ALS.",G0000000|C0521116|C0557651|C0231175|G0000000|C0087111|C0814225|C0205250|C1998793|C0010286|C1572759|C0022885|C0026845|C0237897|C0231230|C0441722|C0442732|C1516240|C0205090|C0037712|C0032659|C0030705|G0000000
The primary outcome measure is the percentage of families curtailing PS exposure in children (parental report verified with the urine cotinine concentrations of the children) after 6 months.,The primary outcome measure percentage families curtailing PS exposure children (parental report verified urine cotinine concentrations children) 6 months.,G0000000|C0205225|C1274040|C0079809|C0439165|C0015576|G0000000|C0242397|C0274281|C0008059|C0030551|C0684224|C1711411|C0042036|C0010194|C0086045|C0008059|G0000000|C0439231
"Significant differences between the control and the therapy group at T2 were detected for the anterior, median and posterior transversal dimensions of the maxilla, the palatal depth, the palatal base arch length, the maxillary arch length and inclination, the midline deviation, the overjet and the overbite.","Significant differences control therapy T2 detected anterior, median posterior transversal dimensions maxilla, palatal depth, palatal base arch length, maxillary arch length inclination, midline deviation, overjet overbite.",C0237881|C1705241|C0243148|C0039798|C0041403|C0442726|C0205094|C0549183|C0205095|C0205106|C0439534|C0024947|C0700374|C0205125|C0700374|C0002055|C0230467|C1444754|C0024947|C0230467|C1444754|G0000000|C0549183|C0012727|C0596028|C1305740
"Peer use of harmful legal products and peer normative beliefs about HLPs are also targeted risk factors, reflecting the importance of combining a focus on norm setting with skills or competency enhancement.","Peer harmful legal products peer normative beliefs HLPs targeted risk factors, reflecting combining focus norm setting skills competency enhancement.",C0679739|G0000000|C1301860|C1514468|C0679739|G0000000|C0004951|C1567160|C1521840|C0035647|C1521761|C0558058|C0336789|C0205234|C0205307|C0542559|C0678856|C0086035|C1627358
Our intervention builds on this work by focusing on career readiness and finding substance use effects for marijuana usage and reduced physical fighting.,Our intervention builds focusing career readiness finding substance effects marijuana usage reduced physical fighting.,G0000000|C0886296|C1707059|C0000936|C0178534|C1318963|C0037088|C0439861|C1280500|C0024808|C0457083|C0392756|C0031809|C0424324
"During the study period, at noon and 8 pm, patients recorded in their daily diary how well the treatment relieved their ocular itch and nasal itchy/runny nose (graded on a 1–5 scale, with 5 being completely relieved) and how well the treatment relieved all of their ocular allergy symptoms (graded on a 1–3 scale, with 3 being completely relieved).","During study period, noon 8 pm, patients recorded daily diary treatment relieved ocular itch nasal itchy/runny nose (graded 1–5 scale, 5 completely relieved) treatment relieved ocular allergy symptoms (graded 1–3 scale, 3 completely relieved).",G0000000|C0557651|C0439531|C0585020|G0000000|C0030266|C0030705|C0034869|C0332173|C0376660|C0039798|C1301771|C0015392|C0033774|C0028429|C0033774|C0028429|G0000000|G0000000|C0175659|G0000000|C0205197|C1301771|C0039798|C1301771|C0015392|C0002111|C0683368|G0000000|G0000000|C0175659|G0000000|C0205197|C1301771
"Day 7 median percentage reductions in Visual Analogue Scale pain score were 60.6%, 71.1% and 68.9% for the T-O, T-G and D-G groups, respectively.","Day 7 median percentage reductions Visual Analogue Scale pain score 60.6%, 71.1% 68.9% T-O, T-G D-G groups, respectively.",C0332173|G0000000|C0549183|C0439165|C0301630|C0234621|C0243071|C0175659|C0030193|C0449820|C0450371|C0450371|C0450371|C2603360|C2603360|C0439267|C0441833|G0000000
"During stay in hospital, the median number of blood transfusions was lower for infants in the R-HuEpo group (difference in medians −2, 95% CI −4, 0).","During stay hospital, median blood transfusions lower infants R-HuEpo (difference medians −2, 95% CI −4, 0).",G0000000|G0000000|C0019994|C0549183|C0005767|C0005841|C0441994|C0021270|C0376541|C1705241|C0549183|G0000000|C0450371|C0008107|G0000000|G0000000
"Main outcome measures: Score of subjective symptom ratings assessed by visual analogue scale; electroneurographic measures (for example, motor distal latency and sensory antidromic nerve conduction velocity).","Main outcome measures: Score subjective symptom ratings assessed visual analogue scale; electroneurographic measures (for example, motor distal latency sensory antidromic nerve conduction velocity).",C0205225|C1274040|C0079809|C0449820|C0439655|C1457887|C0871208|C1516048|C0234621|C0243071|C0175659|C0919612|C0079809|G0000000|C1707959|C1513492|C0205108|C0205275|C0445254|G0000000|C0027740|C0232217|C0439830
The primary endpoint of this exploratory study was the safety of intramuscular injection of Auto-CD34+ cells.,The primary endpoint exploratory study safety intramuscular injection Auto-CD34+ cells.,G0000000|C0205225|C2349179|G0000000|C0557651|C0036043|C0021492|C0021485|C1441488|C0007634
"Following extraction, the treated sample is then assayed using an equilibrium RIA procedure.","Following extraction, treated sample assayed equilibrium RIA procedure.",C0231290|C0185115|C1522326|C0370003|C0005507|C0014653|C0034580|C0184661
"Second, the high usage of ITNs may potentially provide competing or added benefits in reducing clinical malaria and anaemia.","Second, usage ITNs provide competing benefits reducing clinical malaria anaemia.",C0205436|C0457083|G0000000|C1999230|G0000000|C0814225|C0392756|C0205210|C0024530|C0002871
"The parent-rated Repetitive Behavior Scale–Revised comprises 43 items across 6 subscales rated from 0 (not present) to 3 (severe).24 The Aberrant Behavior Checklist–Community version25,26 measures inappropriate behavior on a 4-point severity scale, where 0 indicates not a problem at all and 3 indicates a severe problem.","The parent-rated Repetitive Behavior Scale–Revised comprises 43 items 6 subscales rated 0 (not present) 3 (severe).24 The Aberrant Behavior Checklist–Community version25,26 measures inappropriate behavior 4-point severity scale, 0 3 severe problem.",G0000000|C0030551|G0000000|C0004927|G0000000|C2700400|C0450371|C1551338|G0000000|G0000000|C0871208|G0000000|C1518422|C0150312|G0000000|C0205082|G0000000|C0443127|C0004927|G0000000|C0450371|C0079809|C1548788|C0004927|C1552961|C0439793|C0175659|G0000000|G0000000|C0205082|C0033213
These participants were contacted by phone at the 5-week point of the intervention period to answer any questions and to set up the post-treatment assessment.,These participants contacted phone 5-week intervention period answer questions set post-treatment assessment.,G0000000|C0679646|C0332158|C1515258|C0332174|C0886296|C0439531|C1706817|C1522634|C0036849|C2709088|C1261322
"A significant reduction in wet nights was observed between baseline, end of treatment, and end of follow-up in the 3 groups; p<0.0001 in all groups except between end of treatment and end of follow-up in group 2 (p=0.047).","A reduction wet nights observed baseline, treatment, follow-up 3 groups; p<0.0001 treatment follow-up 2 (p=0.047).",G0000000|C0301630|C0205381|C0240526|C1441672|C0168634|C0039798|C0589120|G0000000|C0441833|C0369773|C0039798|C0589120|G0000000|C0369773
The Wolf Motor Function Test (WMFT) was used for measurement of upper extremity function before and after the intervention in both groups.,The Wolf Motor Function Test (WMFT) measurement upper extremity function intervention groups.,G0000000|C0325001|C1513492|C0031843|C0022885|G0000000|C0242485|C1282910|C0015385|C0031843|C0886296|C0441833
The primary outcome measure was the number of severe exacerbations per subject during the 50-week treatment phase.,The primary outcome measure severe exacerbations subject 50-week treatment phase.,G0000000|C0205225|C1274040|C0079809|C0205082|G0000000|C0681850|C0450371|C0039798|C0205390
"urban form [1], access to greenspace areas for play and active living [2], pedestrian network [3], active transport [4], access to fast food outlets [5]), provision of services (e.g.","urban form [1], access greenspace play active living [2], pedestrian network [3], active transport [4], access fast food outlets [5]), provision services (e.g.",C0442529|C0348078|G0000000|C0444454|G0000000|C0032214|C0205177|C0376558|G0000000|C0450063|C0150775|G0000000|C0205177|C0005528|G0000000|C0444454|C0015663|C0016452|C1709362|G0000000|C1549071|C0557854|G0000000
This group of older people is unlikely to have significant frailty.,This people frailty.,G0000000|C0027361|C0424594
We found that PCT-guided therapy significantly reduced the numbers of patients exposed to antibiotics treatment and duration of antibiotic therapy without adversely affecting patient outcome.,We PCT-guided therapy reduced patients exposed antibiotics treatment duration antibiotic therapy adversely patient outcome.,G0000000|C1535922|C0039798|C0392756|C0030705|C0332157|C0003232|C0039798|C0449238|C0003232|C0039798|G0000000|C0030705|C1274040
"For example, high emotional job demands (e.g.","For example, emotional job demands (e.g.",G0000000|C1707959|C0013987|C0028811|C0441516|G0000000
Baseline serum biomarker values were imputed for 16 participants with missing values at 6 months.,Baseline serum biomarker values imputed 16 participants missing values 6 months.,C0168634|C0229671|C0005516|C0042295|C2699638|C0450371|C0679646|C1551393|C0042295|G0000000|C0439231
Urinary TCM levels were considerably more sensitive to the effects of inhaled corticosteroids than morning serum cortisol or osteocalcin concentrations.,Urinary TCM levels considerably sensitive effects inhaled corticosteroids morning serum cortisol osteocalcin concentrations.,C0042027|C1515884|C0441889|G0000000|C0020517|C1280500|C0004048|C0001617|C0332170|C0229671|C0020268|C0029419|C0086045
There was greater patient satisfaction with the AMP (p < 0.01) than with nCPAP but no difference in reported side effects or compliance.,There patient satisfaction AMP (p < 0.01) nCPAP difference reported effects compliance.,G0000000|C0030705|C0242428|G0000000|C0369773|G0000000|C0450371|G0000000|C1705241|C0684224|C1280500|C0009563
It is possible that the acceptance rate of quitline cessation service would increase with additional EHR enhancements such as iterative cycles of follow-up tracking of smoking status and treatment engagement.,It acceptance rate quitline cessation service increase additional EHR enhancements iterative cycles follow-up tracking smoking status treatment engagement.,G0000000|G0000000|C0871208|G0000000|C1880019|C0557854|C0442805|C1524062|G0000000|C1627358|C1854293|C1511572|C0589120|C0546881|C0037369|C0449438|C0039798|C0425152
"Straudi (Straudi et al., 2013) and colleagues showed walking endurance, as well as spatio-temporal gait parameters improvements after RAGT.","Straudi (Straudi al., 2013) colleagues walking endurance, spatio-temporal gait parameters improvements RAGT.",G0000000|G0000000|C0202311|G0000000|G0000000|C0080331|C0518031|C0442043|C0016928|C0449381|C2986411|G0000000
"The intervention contains five core components, dealing with: (1) migraine specific knowledge (e.g., factual medical information such as phases of the migraine cycle, understanding aura, migraine and the menstrual cycle, and medication overuse headaches); (2) migraine self-management skills (e.g., how to keep a headache diary, recognizing and managing headache triggers, relaxation and biofeedback, and managing migraine-related nausea); (3) emotional coping (e.g., reducing migraine-related anxiety, managing negative thinking, increasing social support, and controlling catastrophizing); (4) communication skills (e.g., describing headache pain, talking with family and co-workers about migraine, effective patient-provider communication); and (5) medication safety (e.g., alcohol and medication, understanding medication side-effects, and medication storage and disposal).","The intervention core components, dealing with: (1) migraine specific knowledge (e.g., factual medical phases migraine cycle, understanding aura, migraine menstrual cycle, medication overuse headaches); (2) migraine self-management skills (e.g., headache diary, recognizing managing headache triggers, relaxation biofeedback, managing migraine-related nausea); (3) emotional coping (e.g., reducing migraine-related anxiety, managing negative thinking, increasing social support, controlling catastrophizing); (4) communication skills (e.g., describing headache pain, talking family co-workers migraine, effective patient-provider communication); (5) medication safety (e.g., alcohol medication, understanding medication side-effects, medication storage disposal).",G0000000|C0886296|C0444669|C0449432|G0000000|G0000000|G0000000|C0149931|C0205369|C0376554|G0000000|G0000000|C0199168|C0585064|C0149931|C1511572|C0162340|C0236018|C0149931|C0025344|C1511572|C0013227|G0000000|C0018681|G0000000|C0149931|C0086969|C0678856|G0000000|C0018681|C0376660|G0000000|C1273870|C0018681|C0032930|C0035028|C0005491|C1273870|C0149931|C0027497|G0000000|C0013987|C0009967|G0000000|C0392756|C0149931|C0003467|C1273870|C0205160|C0039869|C0442808|C0728831|C0183683|C2239193|C0563150|G0000000|C0009452|C0678856|G0000000|G0000000|C0018681|C0030193|C0037817|C0015576|C3245499|C0149931|C1280519|C0030705|C0009452|G0000000|C0013227|C0036043|G0000000|C0001962|C0013227|C0162340|C0013227|C0001688|C0013227|C0337174|C1707797
"At three points (3, 6 and 12 months after transplantation), utilization of health care resources is recorded for every patient.","At (3, 6 12 months transplantation), utilization health care resources recorded patient.",G0000000|G0000000|G0000000|C0450371|C0439231|C0040732|C0042153|C0018684|C1947933|C0035201|C0034869|C0030705
Primary outcomes were hemoglobin concentrations and scores on the Bayley Scales of Infant Development.,Primary outcomes hemoglobin concentrations scores Bayley Scales Infant Development.,C0205225|C1274040|C0019046|C0086045|C0449820|G0000000|C0175659|C0021270|C0243107
Vaccine-related adverse events were rare.,Vaccine-related adverse events rare.,C0042210|G0000000|C0441471|C0521114
"Although not depicted in Figure 2 for ease of presentation, there were significant NBP × risk interactions on symptoms of internalizing disorders, symptoms of externalizing disorders, self-esteem, and substance use at T5.","Although depicted Figure 2 ease presentation, NBP × risk interactions symptoms internalizing disorders, symptoms externalizing disorders, self-esteem, substance T5.",G0000000|G0000000|G0000000|G0000000|C1331418|C0449450|G0000000|G0000000|C0035647|C1704675|C0683368|G0000000|C0012634|C0683368|G0000000|C0012634|C0036597|C0439861|C0041403
"Diagnosed with steroid resistance following the onset of INS and diagnosed with frequent relapse or steroid dependence during or after the completion of immunosuppressive drug therapy (cyclosporine alone or combination of cyclosporine and methylprednisolone, etc.).","Diagnosed steroid resistance onset INS diagnosed frequent relapse steroid dependence completion immunosuppressive drug therapy (cyclosporine combination cyclosporine methylprednisolone, etc.).",C0011900|C0038317|C0237834|C0206132|G0000000|C0011900|C0332183|C0035020|C0038317|C0011546|C0205197|C0021081|C0013227|C0039798|C0010592|C0205195|C0010592|C0025815|C1548556
"Therefore, in the present study, periapical radiolucency, widening of the periodontal ligament, and pulp canal calcification were categorized as a radiographic failure, but the teeth presenting one of these pathologies were not treated immediately, and were observed for the follow-up, as they were aysmptomatic and did not show any sign of clinical failure.","Therefore, study, periapical radiolucency, widening periodontal ligament, pulp canal calcification categorized radiographic failure, teeth pathologies treated immediately, observed follow-up, aysmptomatic sign clinical failure.",G0000000|C0557651|C0729269|C2827491|C0332464|C2960678|C0023685|C0011399|C0086881|C0006660|C0871968|C0444708|C0231174|C0040426|C0030664|C1522326|C0205548|C1441672|C0589120|G0000000|C0311392|C0205210|C0231174
"We analysed selected macronutrients [total energy (kcal), fat (g), carbohydrates (g) and protein (g)] and micronutrients [vitamin A retinol equivalents (μg), vitamin B12 (μg), folate (μg), iron (mg) and zinc (mg)].","We analysed selected macronutrients [total energy (kcal), fat (g), carbohydrates (g) protein (g)] micronutrients [vitamin A retinol equivalents (μg), vitamin B12 (μg), folate (μg), iron (mg) zinc (mg)].",G0000000|G0000000|C1707391|C1518493|C0439175|C0424589|C0439259|C0424612|C0439267|C0007004|C0439267|C0033684|C0439267|C0282575|C0042890|G0000000|C0042839|C0439185|G0000000|C0042890|G0000000|G0000000|C0178638|G0000000|C0302583|C0026410|C0043481|C0026410
Children presented with acute diarrhoea for 3.9 days with 4.3 stools per day.,Children acute diarrhoea 3.9 days 4.3 stools day.,C0008059|C0205178|C0011991|G0000000|C0439228|G0000000|C0015733|C0332173
The atheroma volume and neointimal volume were calculated by the Simpson's method.,The atheroma volume neointimal volume calculated Simpson's method.,G0000000|C0264956|C0449468|C2936380|C0449468|C0444686|G0000000|C0025663
"Parents completed a medication log, and recorded the presence and severity of opioid-related adverse effects and children's reports of pain intensity using a 0 to 10 numeric rating scale.","Parents completed medication log, recorded presence severity opioid-related adverse effects children's reports pain intensity 0 10 numeric rating scale.",C0030551|C0205197|C0013227|C1708728|C0034869|C0150312|C0439793|C0242402|G0000000|C1280500|C0008059|C0684224|C0030193|C0522510|G0000000|C0450371|C0237753|C0871208|C0175659
"Change from baseline score on the 17 item version of the Hamilton depression scale, the Hamilton anxiety scale, the clinical global impressions scale, Zung's self rating depression scale, and SF-36, and adverse events profile.","Change baseline score 17 item version Hamilton depression scale, Hamilton anxiety scale, clinical global impressions scale, Zung's rating depression scale, SF-36, adverse events profile.",C0392747|C0168634|C0449820|C0450371|C1551338|C0333052|G0000000|C0011570|C0175659|G0000000|C0003467|C0175659|C0205210|C0205246|C0596764|C0175659|G0000000|C0871208|C0011570|C0175659|C0037712|G0000000|C0441471|C1979963
"In the third-month control, Laser group had significant improvements on both clinical and NCS parameters (median motor nerve distal latency, median sensory nerve conduction velocities) while splinting group had only symptomatic healing.","In third-month control, Laser improvements clinical NCS parameters (median motor nerve distal latency, median sensory nerve conduction velocities) splinting symptomatic healing.",G0000000|C0205437|C0243148|C0023089|C2986411|C0205210|C0027597|C0449381|C0549183|C1513492|C0027740|C0205108|C0205275|C0549183|C0445254|C0027740|C0232217|C0439830|C0204861|C0231220|C0043240
"Participating kindergarten staff completed questionnaires before and after the intervention about food neophobia, feeding practices, cooking skills, and food-related knowledge and attitudes.","Participating kindergarten staff completed questionnaires intervention food neophobia, feeding practices, cooking skills, food-related knowledge attitudes.",C0679823|C0681406|C0851286|C0205197|C0034394|C0886296|C0016452|G0000000|C0204695|C0237607|C0335326|C0678856|C0016452|C0376554|C0004271
"2010), adolescents were asked to further indicate their typical quantity of alcohol consumption on a scale ranging from 0 “I don't drink alcohol” to 5 “More than 6 drinks.”  Covariates for parent-report data analyses included parent gender (coded 1 for female and 0 for male) and parent educational attainment (coded 1 for college degree and 0 for less than college).","2010), adolescents typical quantity alcohol consumption scale ranging 0 “I drink alcohol” 5 “More 6 drinks.” Covariates parent-report data analyses included parent gender (coded 1 female 0 male) parent educational attainment (coded 1 college degree 0 college).",G0000000|C0205653|C3538928|C1265611|C0001962|C0009830|C0175659|C1514721|G0000000|G0000000|C0452428|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C4054215|C1511726|C0002778|C0332257|C0030551|C0079399|C0009219|G0000000|C0015780|G0000000|C0086582|C0030551|C0587721|G0000000|C0009219|G0000000|C0557806|C0441889|G0000000|C0557806
"The change in the yoga group was statistically significant for FEV1 at 8 wk and PEFR at 2, 4 and 8 wk, as compared to the corresponding baseline values (Table (Table3).3).","The change yoga statistically FEV1 8 wk PEFR 2, 4 8 wk, compared baseline values (Table (Table3).3).",G0000000|C0392747|C0043418|C0038215|G0000000|G0000000|C0332174|C0030735|G0000000|G0000000|G0000000|C0332174|C1707455|C0168634|C0042295|C0039224|G0000000
"The primary efficacy outcome after 6 months of therapy was endometrial hyperplasia or not, assessed by light microscopy.","The primary efficacy outcome 6 months therapy endometrial hyperplasia not, assessed light microscopy.",G0000000|C0205225|C1280519|C1274040|G0000000|C0439231|C0039798|C0227843|C0020507|C1518422|C1516048|C0023693|C0026018
Log-rank test of time to treatment failure through 12 months by treatment (p<0.001).,Log-rank test time treatment failure 12 months treatment (p<0.001).,C1708728|C0022885|C0040223|C0039798|C0231174|C0450371|C0439231|C0039798|C0369773
"Secondary outcomes included patient-reported improvement, satisfaction with current symptoms and care,21 the Stenosis Bothersomeness Index,22,23 and the Low Back Pain Bothersomeness Scale.3 The SF-36 scores range from 0 to 100, with higher scores indicating less severe symptoms; the Oswestry Disability Index ranges from 0 to 100, with lower scores indicating less severe symptoms; the Stenosis Bothersomeness Index ranges from 0 to 24, with lower scores indicating less severe symptoms; and the Low Back Pain Bothersomeness Scale ranges from 0 to 6, with lower scores indicating less severe symptoms.","Secondary outcomes included patient-reported improvement, satisfaction current symptoms care,21 Stenosis Bothersomeness Index,22,23 Low Back Pain Bothersomeness Scale.3 The SF-36 scores range 0 100, scores indicating severe symptoms; Oswestry Disability Index ranges 0 100, lower scores indicating severe symptoms; Stenosis Bothersomeness Index ranges 0 24, lower scores indicating severe symptoms; Low Back Pain Bothersomeness Scale ranges 0 6, lower scores indicating severe symptoms.",C0027627|C1274040|C0332257|C0747307|C2986411|C0242428|C0521116|C0683368|C1947933|C0678234|G0000000|C0918012|C0205251|C0004600|C0030193|G0000000|C0175659|G0000000|C0037712|C0449820|C1514721|G0000000|C1442061|C0449820|G0000000|C0205082|C0683368|G0000000|C0231170|C0918012|C1514721|G0000000|C1442061|C0441994|C0449820|G0000000|C0205082|C0683368|C0678234|G0000000|C0918012|C1514721|G0000000|C0450371|C0441994|C0449820|G0000000|C0205082|C0683368|C0205251|C0004600|C0030193|G0000000|C0175659|C1514721|G0000000|G0000000|C0441994|C0449820|G0000000|C0205082|C0683368
The primary outcome measure was the rate of change in the averaged manual muscle testing score.6 Secondary outcome measures included overall survival and rate of change in the revised ALS functional rating scale (ALSFRS-r).7 Intention to treat analysis was used.,The primary outcome measure rate change averaged manual muscle testing score.6 Secondary outcome measures included survival rate change revised ALS functional rating scale (ALSFRS-r).7 Intention treat analysis used.,G0000000|C0205225|C1274040|C0079809|C0871208|C0392747|C1510992|C0024763|C0026845|C0039593|C0449820|C0027627|C1274040|C0079809|C0332257|C0038952|C0871208|C0392747|C1527075|G0000000|C0205245|C0871208|C0175659|C0205090|C0162425|C0087111|C0002778|C1273517
"Relative differences between the intervention and the control group for anxiety, depression, mental component summary of the 36-item Short-Form Health Survey (SF-36) (MCS), physical component summary of the SF-36 (PCS), dialysis adequacy (Kt/V), Timed Up and Go test (TUG), and the Six-Minute Walk Test (6MWT).","Relative differences intervention control anxiety, depression, mental component summary 36-item Short-Form Health Survey (SF-36) (MCS), physical component summary SF-36 (PCS), dialysis adequacy (Kt/V), Timed Up Go test (TUG), Six-Minute Walk Test (6MWT).",C0080103|C1705241|C0886296|C0243148|C0003467|C0011570|C0229992|C0449432|C1552616|C0450371|C2964478|C0018684|C0038951|C0037712|G0000000|C0031809|C0449432|C1552616|C0037712|C1864389|C0011945|C0205410|C0429662|C0392761|G0000000|C1822658|C0022885|C1319201|C0205452|C0080331|C0022885|G0000000
The study focused on establishing the determinants of clinical response on day 21: incidence of secondary nosocomial infections; number of patients on antibiotic treatment; total number of days of antibiotic treatment; duration of MV; number of patients still under ventilation; number of patients still in ICU; length of stay in ICU on day 21; and mortality rate at 3 months.,The study focused establishing determinants clinical response day 21: incidence secondary nosocomial infections; patients antibiotic treatment; total days antibiotic treatment; duration MV; patients ventilation; patients ICU; length stay ICU day 21; mortality rate 3 months.,G0000000|C0557651|C0205234|C0443211|C1521761|C0205210|C0871261|C0332173|C0450371|C0021149|C0027627|C0019994|C3714514|C0030705|C0003232|C0039798|C0439175|C0439228|C0003232|C0039798|C0449238|C0428679|C0030705|C0035203|C0030705|C0021708|C1444754|G0000000|C0021708|C0332173|C0450371|C0026565|C0871208|G0000000|C0439231
"As of 31 July 2007, 736 cases of incident breast cancer had been identified among the female cohort subjects via this linkage.","As 31 July 2007, 736 incident breast cancer identified female cohort subjects linkage.",G0000000|C0450371|C3829447|G0000000|C1442061|C1551358|C0006141|C0006826|C0205396|C0015780|C0599755|C0681850|C0023745
Continuous abstinence at 6 months was 26.4% (29/110) in the intervention group and 27.6% (32/116) in the control group (P = .8).,Continuous abstinence 6 months 26.4% (29/110) intervention 27.6% (32/116) control (P = .8).,C0549178|C3843422|G0000000|C0439231|C0450371|C0450371|C0886296|C0450371|C0450371|C0243148|C0369773|G0000000|G0000000
Patients remained in the trial for 6 months after which the baseline measures were repeated.,Patients remained trial 6 months baseline measures repeated.,C0030705|G0000000|C0008976|G0000000|C0439231|C0168634|C0079809|C0205341
Symptoms of asthma and atopic dermatitis were recorded using a modified visually-assisted version of the International Study of Asthma and Allergy in Childhood (ISAAC) questionnaire as reported before.,Symptoms asthma atopic dermatitis recorded modified visually-assisted version International Study Asthma Allergy Childhood (ISAAC) questionnaire reported before.,C0683368|C0004096|C0392707|C0011603|C0034869|C0392747|C1269765|C0333052|C1512888|C0557651|C0004096|C0002111|C0231335|G0000000|C0034394|C0684224|C0332152
"Recording was made of the improvement in symptoms, function and electrophysiological studies and the complications of the surgical procedure.","Recording improvement symptoms, function electrophysiological studies complications surgical procedure.",G0000000|C2986411|C0683368|C0031843|C0013865|C0947630|C0009566|C0543467|C0184661
"We investigated the effects of electroacupuncture on maximum cystometric capacity, bladder compliance, detrusor leak point pressure, risk of upper urinary tract damage, frequency of urination, and urinary incontinence.","We investigated effects electroacupuncture maximum cystometric capacity, bladder compliance, detrusor leak pressure, risk upper urinary tract damage, frequency urination, urinary incontinence.",G0000000|C1292732|C1280500|C0013794|C0806909|G0000000|C1516240|C0005682|C0009563|C1180419|C0332234|C0033095|C0035647|C1282910|C0042027|C1185740|C0010957|C0376249|C0042034|C0042027|C0021167
"Similarly, they could not find a difference in tumour stage between the two groups.","Similarly, difference tumour stage groups.",G0000000|C1705241|C0027651|C0205390|C0441833
"Correlations between symptoms of externalizing disorders and symptoms of internalizing disorders, self esteem, substance use, and academic performance at T5 ranged in magnitude from .19 to 44, were statistically significant and in the expected direction.","Correlations symptoms externalizing disorders symptoms internalizing disorders, esteem, substance use, academic performance T5 ranged magnitude .19 44, statistically expected direction.",C1707520|C0683368|G0000000|C0012634|C0683368|G0000000|C0012634|C0679133|C0439861|C0042153|C1510747|C0597198|C0041403|C1514721|C0449286|C0450371|C0450371|C0038215|C1517001|C0449738
"Currently, in the Netherlands, 0.44% of all platelet products are found to be contaminated.6 Transfusion-transmitted bacterial infections with clinical consequences are rare, with estimated incidence of 1 in 70 000 to 1 in 118 000 cases.7 Pathogen-reduction strategies aim to reduce the risk of bacterial contamination of stored platelet products.8 A recent review assessing the effectiveness of pathogen-reduced platelet products in general concluded that pathogen-reduced platelets did not differ from standard platelets with regard to clinically significant or severe bleeding complications or adverse reactions.9 Although the use of pathogen-reduced platelet products (PR-platelet concentrates) is not formally accepted as standard of care everywhere, gradually these products are being implemented in transfusion centres worldwide.","Currently, Netherlands, 0.44% platelet products contaminated.6 Transfusion-transmitted bacterial infections clinical consequences rare, estimated incidence 1 70 000 1 118 000 cases.7 Pathogen-reduction strategies aim reduce risk bacterial contamination stored platelet products.8 A review assessing effectiveness pathogen-reduced platelet products concluded pathogen-reduced platelets standard platelets regard clinically severe bleeding complications adverse reactions.9 Although pathogen-reduced platelet products (PR-platelet concentrates) formally accepted standard care everywhere, gradually products implemented transfusion centres worldwide.",C0521116|C0027778|C0450371|C0005821|C1514468|C0205279|C0005841|C0521009|C3714514|C0205210|C0686907|C0521114|C0750572|C0021149|G0000000|G0000000|G0000000|G0000000|C0868928|C0450254|C0679199|C1947946|G0000000|C0035647|C0521009|C0259846|C1698986|C0005821|C1514468|G0000000|C0282443|C1516048|C1280519|C0450254|C0005821|C1514468|C0917903|C0450254|C0005821|C1442989|C0005821|G0000000|G0000000|C0205082|C0019080|C0009566|G0000000|C0443286|G0000000|C0450254|C0005821|C1514468|C0279759|C1880310|G0000000|C1272684|C1442989|C1947933|G0000000|G0000000|C1514468|G0000000|C0005841|C0205099|G0000000
"Secondary clinical endpoints are as follows: incidence and time to tumor relapse (locoregional relapse, lymph node involvement and distant metastatic spread), Quality of life as reported by EORTC (QLQ-C30 with H&N 35 module), and time from operation to orofacial rehabilitation.","Secondary clinical endpoints follows: incidence time tumor relapse (locoregional relapse, lymph node involvement distant metastatic spread), Quality life reported EORTC (QLQ-C30 H&N 35 module), time operation orofacial rehabilitation.",C0027627|C0205210|C2349179|C0332283|C0021149|C0040223|C0027651|C0035020|G0000000|C0035020|C0024202|C0746922|C1314939|C0443203|C0036525|C0332261|C0332306|C0376558|C0684224|C1516985|G0000000|C0033727|C0450371|C1709061|C0040223|C0543467|C2827582|C0034991
"Secondary outcomes were changes from baseline in (1) viral load among HIV-infected participants, (2) CD4+ cell counts, and (3) body weight.","Secondary outcomes baseline (1) viral load HIV-infected participants, (2) CD4+ cell counts, (3) body weight.",C0027627|C1274040|C0168634|G0000000|C0521026|C1550025|C0019682|C0679646|G0000000|C0285590|C0007634|C0439157|G0000000|C0242821|C0005910
Our second hypothesis specified that the intervention would be differentially effective for viewers with different levels of self-reported previous knowledge about memory loss.,Our hypothesis intervention differentially effective viewers levels self-reported previous knowledge memory loss.,G0000000|C1512571|C0886296|G0000000|C1280519|C1710633|C0441889|C0681906|C0205156|C0376554|C0025260|C1517945
The patients were scheduled to come for follow-up every two weeks.,The patients scheduled follow-up weeks.,G0000000|C0030705|C0086960|C0589120|C0439230
"If the heart rate is < 60/min or remains < 60/min despite all steps of MR SOPA, start CC.","If heart rate < 60/min remains < 60/min steps MR SOPA, start CC.",G0000000|C0018787|C0871208|G0000000|G0000000|G0000000|C1261552|C1417249|G0000000|C0439659|C3538933
The data for these individuals was also excluded [28].,The data individuals excluded [28].,G0000000|C1511726|C0027361|C1554077|C0450371
"One year after the completion of treatment or after defaulting during the course of treatment, patients were actively retrieved to assess the relapse rate or the treatment outcome.","One completion treatment defaulting treatment, patients actively retrieved assess relapse rate treatment outcome.",C0205447|C0205197|C0039798|C2828024|C0039798|C0030705|G0000000|G0000000|C1516048|C0035020|C0871208|C0039798|C1274040
"First, we examined the effects of green tea consumption on the risk of mortality from total, CVD and cancer in a large prospective cohort of Chinese adult men.","First, examined effects green tea consumption risk mortality total, CVD cancer prospective cohort Chinese adult men.",C0205435|C0332128|C1280500|C0332583|C0039400|C0009830|C0035647|C0026565|C0439175|C0007222|C0006826|C0023981|C0599755|C0008120|C0001675|C0025266
"The cover around the phototherapy unit not only did not increase the side effects of phototherapy, but also had a positive impact in reducing duration of jaundice (P. value <0.0001) and duration of hospitalization (P. value <0.0001).","The cover phototherapy unit increase effects phototherapy, positive impact reducing duration jaundice (P. <0.0001) duration hospitalization (P. <0.0001).",G0000000|C0180153|C0031765|C0439148|C0442805|C1280500|C0031765|C0439178|C1825598|C0392756|C0449238|C0022346|C0369773|G0000000|C0449238|C0019993|C0369773|G0000000
"However, ACARIZAX has a positive impact on exacerbations as shown via the quantification of number needed to treat (NNT) to avoid any moderate to severe exacerbation, which was measured during the ICS reduction period of trial, and found to only be 10 for ACARIZAX [21].","However, ACARIZAX positive impact exacerbations quantification treat (NNT) avoid moderate severe exacerbation, measured ICS reduction period trial, 10 ACARIZAX [21].",G0000000|G0000000|C0439178|C1825598|G0000000|C1709793|C0087111|C1417750|G0000000|C0205081|C0205082|G0000000|C0444706|C0022521|C0301630|C0439531|C0008976|C0450371|G0000000|C0450371
More intensive interventions may be more effective but also more costly [10].,More intensive interventions effective costly [10].,C0205172|C0162425|C0886296|C1280519|G0000000|C0450371
The effectiveness of clinical at of treatment Significant difference was p> 0.05 for the two groups Clinical effectiveness 2 weeks after stooping treatment Also no significant difference found by comparing the two groups there was p> 0.05 High clearance rate is also noticed for both drugs after end of treatment and 2 weeks later as shown in Table 3 and Table 4.,The effectiveness clinical treatment Significant difference p> 0.05 Clinical effectiveness 2 weeks stooping treatment Also difference comparing p> 0.05 High clearance rate noticed drugs treatment 2 weeks Table 3 Table 4.,G0000000|C1280519|C0205210|C0039798|C0237881|C1705241|C0369773|C0450371|C0205210|C1280519|G0000000|C0439230|C1830710|C0039798|G0000000|C1705241|C1707455|C0369773|C0450371|C0205250|C0449297|C0871208|G0000000|C0013227|C0039798|G0000000|C0439230|C0039224|G0000000|C0039224|G0000000
The primary outcome measure was a 10 cm visual analog scale of pain (VAS) anchored at its lowest point by the expression “no pain” and at its highest point by the phrase “very severe pain.” Participants were asked to rate their level of pain over the preceding seven days.,The primary outcome measure 10 cm visual analog scale pain (VAS) anchored lowest expression “no pain” phrase “very severe pain.” Participants rate level pain preceding days.,G0000000|C0205225|C1274040|C0079809|G0000000|C0234621|C0243071|C0175659|C0030193|C0042815|C1293132|C1708760|C0185117|G0000000|G0000000|C0600665|G0000000|C0205082|G0000000|C0679646|C0871208|C0441889|C0030193|C0332152|C0439228
"No distinct changes attributable to duloxetine were observed in laboratory test results, blood pressure and pulse rate, body weight, or ECG.","No distinct attributable duloxetine observed laboratory test results, blood pressure pulse rate, body weight, ECG.",G0000000|G0000000|C0596130|C0245561|C1441672|C0022877|C0022885|C1274040|C0005767|C0033095|C0232117|C0871208|C0242821|C0005910|C1623258
"Caregiver depressive symptoms refers to caregiver self-reports about the presence of depressive symptoms, as measured by PHQ-9.","Caregiver depressive symptoms refers caregiver self-reports presence depressive symptoms, measured PHQ-9.",C0085537|G0000000|C0683368|C0205543|C0085537|C0681906|C0150312|G0000000|C0683368|C0444706|C1879301
"The total score is then converted linearly to a 100 point scale, with higher scores indicating improved quality of life 35..","The total score converted linearly 100 scale, scores indicating improved quality life 35..",G0000000|C0439175|C0449820|G0000000|G0000000|C1442061|C0175659|C0449820|G0000000|C0184511|C0332306|C0376558|C0450371
"The primary outcome measures were the mini mental state examination (MMSE) score, the clinician's interview based impression of change plus caregiver input (CIBIC+) score, and the motor subscale of the unified Parkinson's disease rating scale (UPDRS).","The primary outcome measures mini mental examination (MMSE) score, clinician's interview based impression change caregiver input (CIBIC+) score, motor subscale unified Parkinson's disease rating scale (UPDRS).",G0000000|C0205225|C1274040|C0079809|C0445542|C0229992|G0000000|C0451306|C0449820|C0871685|C0021822|C1527178|C0596764|C0392747|C0085537|C1708517|G0000000|C0449820|C1513492|G0000000|C1548174|C1021144|C0012634|C0871208|C0175659|C3639721
"Three items measured this abstinence outcome: (1) When was the last time you smoked, or even tried, a cigarette?","Three items measured abstinence outcome: (1) When time smoked, tried, cigarette?",C0205449|C1551338|C0444706|C3843422|C1274040|G0000000|G0000000|C0040223|C0037366|G0000000|C0677453
"Pre-specified secondary analyses included tests for a chlorhexidine effect for each individual infection comprising the primary outcome, differences in hospital and ICU length of stay as well as rates of healthcare-associated bloodstream infections, blood culture contamination, and cultures positive for multi-drug resistant organisms using a Mann-Whitney U test or Poisson model where appropriate.","Pre-specified secondary analyses included tests chlorhexidine individual infection comprising primary outcome, differences hospital ICU length stay rates healthcare-associated bloodstream infections, blood culture contamination, cultures positive multi-drug resistant organisms Mann-Whitney U test Poisson model appropriate.",C2826245|C0027627|C0002778|C0332257|C0022885|C0008196|C0027361|C0009450|C2700400|C0205225|C1274040|C1705241|C0019994|C0021708|C1444754|G0000000|C0871208|C0086388|C0005775|C3714514|C0005767|C0010453|C0259846|C0010453|C0439178|C0439064|C0332325|C0029235|G0000000|G0000000|C0022885|G0000000|C3161035|C1548787
"To evaluate pain, we used the Brief Pain Inventory (BPI) and the Visual Analog Scale (VAS).","To evaluate pain, Brief Pain Inventory (BPI) Visual Analog Scale (VAS).",C0040363|C0220825|C0030193|C1282927|C0030193|C0021941|C1443145|C0234621|C0243071|C0175659|C0042815
"The presence of edema, existence of peritonitis, catheter infections, exit-site condition and weight gain were observed as the complication control of the participants within 42 days (6 weeks) and 84 days (12 weeks) post-discharge.","The presence edema, existence peritonitis, catheter infections, exit-site condition weight gain observed complication control participants 42 days (6 weeks) 84 days (12 weeks) post-discharge.",G0000000|C0150312|C0013604|C0015276|C0031154|C0085590|C3714514|C0449669|C0012634|C0005910|C1517378|C1441672|C0009566|C0243148|C0679646|C0450371|C0439228|G0000000|C0439230|C0450371|C0439228|C0450371|C0439230|C0687676
"Primary endpoints are use of non-prescribed cannabis (self-reported cannabis use days, urine toxicology), safety measures (adverse events and abuse liability), and cost effectiveness (incremental cost effectiveness in achieving additional Quality Adjusted Life Years).","Primary endpoints non-prescribed cannabis (self-reported cannabis days, urine toxicology), safety measures (adverse events abuse liability), cost effectiveness (incremental cost effectiveness achieving additional Quality Adjusted Life Years).",C0205225|C2349179|C1518422|C0024808|C0681906|C0024808|C0439228|C0042036|C0040541|C0036043|C0079809|G0000000|C0441471|C0013146|G0000000|C0010186|C1280519|C1705117|C0010186|C1280519|G0000000|C1524062|C0332306|C0456081|C0376558|C0439234
The average values of three measures were calculated and used in the analysis.,The average values measures calculated analysis.,G0000000|C1510992|C0042295|C0079809|C0444686|C0002778
The mean difference in scores of erythema and scale and the pruritus were compared in both sides of the face and all the side-effects were reported was the clinical trial registered?,The difference scores erythema scale pruritus compared side-effects reported clinical trial registered?,G0000000|C1705241|C0449820|C0041834|C0175659|C0033774|C1707455|C0001688|C0684224|C0205210|C0008976|C1514821
Aims: To evaluate reduction in mortality after seven screening rounds and the possible influence of compliance on mortality from CRC.,Aims: To evaluate reduction mortality screening rounds influence compliance mortality CRC.,C1947946|C0040363|C0220825|C0301630|C0026565|C0220908|C0332490|C4054723|C0009563|C0026565|C0009402
*Treatment difference in incidence of treatment-emergent adverse events leading to discontinuation (P = 0.56).,*Treatment difference incidence treatment-emergent adverse events leading discontinuation (P = 0.56).,C0039798|C1705241|C0021149|C0039798|G0000000|C0441471|C0332152|C0457454|C0369773|G0000000|C0450371
Neither group showed a significant change in the high-sensitivity C-reactive protein level from baseline to 8 weeks.,Neither change high-sensitivity C-reactive protein level baseline 8 weeks.,G0000000|C0392747|C1441604|C0205332|C0033684|C0441889|C0168634|G0000000|C0439230
The primary endpoint was trough forced expiratory volume in 1 s (FEV1) at day 85 in the per-protocol population.,The primary endpoint trough forced expiratory volume 1 s (FEV1) day 85 per-protocol population.,G0000000|C0205225|C2349179|C0444506|C0441722|C0231800|C0449468|G0000000|G0000000|C0332173|C0450371|C1698058|C0032659
Social deprivation was unrelated to uptake of the first and third HPV vaccinations among first-time invitees.,Social deprivation unrelated uptake HPV vaccinations first-time invitees.,C0728831|C0871712|C0445356|C0243144|C0021344|C0042196|C0205435|G0000000
"Data collection will take place at nine and 18 months, and statistical analysis will employ Student's t test.","Data collection 18 months, statistical analysis employ Student's test.",C1511726|C1516698|C0450371|C0439231|C0038215|C0002778|C0457083|C0038492|C0022885
The patient satisfaction level was assessed and recorded at the end of treatment by visual analogue scale (VAS) for satisfaction.,The patient satisfaction level assessed recorded treatment visual analogue scale (VAS) satisfaction.,G0000000|C0030705|C0242428|C0441889|C1516048|C0034869|C0039798|C0234621|C0243071|C0175659|C0042815|C0242428
"Secondary outcomes were (1) complete resolution of sore throat at 48 hours; (2) duration of moderately bad symptoms recorded by validated 7-day symptom diary, based on a Likert scale for which 0 indicates normal; 1, very little problem; 2, slight problem; 3, moderately bad; 4, bad; 5, very bad; 6, as bad as it could be; (3) patient-reported time to onset of pain relief and time to complete symptom resolution; (4) change in ratings of sore throat pain, pain on swallowing, and difficulty swallowing on a 0- to 100-mm visual analog scale, for which 0 mm indicates no pain and 100 mm, the worst pain imaginable; (5) consumption of delayed antibiotic prescription for sore throat; (6) time missed from work or education; (7) attendance or telephone contact at any health care facility (including GP clinic, urgent care clinic, emergency department, or hospital admission) within 28 days with symptoms or complications associated with sore throat (defined as direct suppurative complications or presentation with sore throat symptoms); and (8) use of over-the-counter medications and prescription medications in the first 7 days.","Secondary outcomes (1) complete resolution sore throat 48 hours; (2) duration moderately bad symptoms recorded validated 7-day symptom diary, based Likert scale 0 normal; 1, problem; 2, slight problem; 3, moderately bad; 4, bad; 5, bad; 6, bad be; (3) patient-reported time onset pain relief time complete symptom resolution; (4) change ratings sore throat pain, pain swallowing, difficulty swallowing 0- 100-mm visual analog scale, 0 mm pain 100 mm, worst pain imaginable; (5) consumption delayed antibiotic prescription sore throat; (6) time missed education; (7) attendance telephone contact health care facility (including GP clinic, urgent care clinic, emergency department, hospital admission) 28 days symptoms complications sore throat (defined direct suppurative complications presentation sore throat symptoms); (8) over-the-counter medications prescription medications 7 days.",C0027627|C1274040|G0000000|C0205197|C1514893|C0234233|C0031354|C0450371|C0439227|G0000000|C0449238|C0205081|C0205169|C0683368|C0034869|G0000000|C0332173|C1457887|C0376660|C1527178|G0000000|C0175659|G0000000|C0205307|G0000000|C0033213|G0000000|C2937276|C0033213|G0000000|C0205081|C0205169|G0000000|C0205169|G0000000|C0205169|G0000000|C0205169|G0000000|G0000000|C0747307|C0040223|C0206132|C0030193|C0564405|C0040223|C0205197|C1457887|C1514893|G0000000|C0392747|C0871208|C0234233|C0031354|C0030193|C0030193|C0011167|C1299586|C0011167|G0000000|C1442061|C0234621|C0243071|C0175659|G0000000|G0000000|C0030193|C1442061|G0000000|C1522166|C0030193|G0000000|G0000000|C0009830|C0205421|C0003232|C0033080|C0234233|C0031354|G0000000|C0040223|C1705492|C0013621|G0000000|C2827364|C0039457|C0332158|C0018684|C1947933|C1547538|C0332257|C3811116|C0002424|C0439609|C1947933|C0002424|C0013956|C1704729|C0019994|C0184666|C0450371|C0439228|C0683368|C0009566|C0234233|C0031354|C1704788|C0439851|C3203360|C0009566|C0449450|C0234233|C0031354|C0683368|G0000000|C0013231|C0013227|C0033080|C0013227|G0000000|C0439228
"It has no known adverse effects in customary, and even substantial, doses [11].","It adverse effects customary, substantial, doses [11].",G0000000|G0000000|C1280500|C3242380|G0000000|C0178602|C0450371
"an unscheduled visit to a doctor, presentation to the emergency department room or admission to hospital, or when oral corticosteroids were used for treatment of asthma).","unscheduled visit doctor, presentation emergency department admission hospital, oral corticosteroids treatment asthma).",C1699701|C0545082|C0031831|C0449450|C0013956|C1704729|C0184666|C0019994|C0442027|C0001617|C0039798|C0004096
It was not possible in this protocol to monitor circadian rhythms other than sleep.,It protocol monitor circadian rhythms sleep.,G0000000|C0442711|C0030695|G0000000|C0871269|C0037313
"These parameters were measured by performance on the following: A 1-h cognitive battery (Rebok et al., 1990) which included the Mini-Mental State Exam (MMSE) (Folstein et al., 1975), Boston Naming Test (BNT) (Kaplan et al., 1983) and Hopkins Verbal Learning Test (HVLT) (Brandt, 1991) assessed cognitive functioning.","These parameters measured performance following: A 1-h cognitive battery (Rebok al., 1990) included Mini-Mental State Exam (MMSE) (Folstein al., 1975), Boston Naming Test (BNT) (Kaplan al., 1983) Hopkins Verbal Learning Test (HVLT) (Brandt, 1991) assessed cognitive functioning.",G0000000|C0449381|C0444706|C0597198|C0231290|G0000000|C0033727|C1516691|C0337088|G0000000|C0202311|G0000000|C0332257|C0445542|C1301808|C0582103|C0451306|G0000000|C0202311|G0000000|C0006037|C0233735|C0022885|G0000000|G0000000|C0202311|G0000000|G0000000|C0439824|C0013621|C0022885|G0000000|G0000000|G0000000|C1516048|C1516691|C0205245
Satisfaction assessment was carried out between 12–24 hours post delivery at rooming-in care unit.,Satisfaction assessment carried 12–24 hours post delivery rooming-in care unit.,C0242428|C1261322|C0206243|G0000000|C0439227|C0687676|C0011209|C1547703|C1947933|C0439148
"Primary (parent report) and secondary (parent, teacher, and child self-report) outcome measures were administered at baseline, 10 weeks, and 10-week follow-up.","Primary (parent report) secondary (parent, teacher, child self-report) outcome measures administered baseline, 10 weeks, 10-week follow-up.",C0205225|C0030551|C0684224|C0027627|C0030551|C0221457|C0008059|C0681906|C1274040|C0079809|C1521801|C0168634|C0450371|C0439230|C0450371|C0589120
Adverse reactions were classified using the World Allergy Organization scale.,Adverse reactions classified World Allergy Organization scale.,G0000000|C0443286|C0008902|C2700280|C0002111|C0029237|C0175659
This was measured as the number of days from the start of the medication to the day of discharge as determined by the attending physician.,This measured days start medication day discharge determined attending physician.,G0000000|C0444706|C0439228|C0439659|C0013227|C0332173|C0012621|G0000000|C1547429|C0031831
"Efficacy and safety were evaluatedafter 1, 2, 4, 6, and 8 weeks with the 17 item version of the Hamilton depression rating scale, the Hamilton anxiety scale, the clinical global impressions scale, and the Zung self rating depression scale.","Efficacy safety evaluatedafter 1, 2, 4, 6, 8 weeks 17 item version Hamilton depression rating scale, Hamilton anxiety scale, clinical global impressions scale, Zung rating depression scale.",C1280519|C0036043|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0439230|C0450371|C1551338|C0333052|G0000000|C0011570|C0871208|C0175659|G0000000|C0003467|C0175659|C0205210|C0205246|C0596764|C0175659|G0000000|C0871208|C0011570|C0175659
The EOLD–SWC is a 10-item scale that was developed for after-death assessment of satisfaction with care by family members of residents with dementia.,The EOLD–SWC 10-item scale developed after-death assessment satisfaction care family residents dementia.,G0000000|G0000000|C0450371|C0175659|G0000000|C0011065|C1261322|C0242428|C1947933|C0015576|C1320928|C0011265
"We compared subjective ratings for sleep quality, mask comfort, and treatment satisfaction and benefit for participants across treatment groups (Table 5).","We compared subjective ratings sleep quality, mask comfort, treatment satisfaction benefit participants treatment (Table 5).",G0000000|C1707455|C0439655|C0871208|C0037313|C0332306|C0024861|C1331418|C0039798|C0242428|C0814225|C0679646|C0039798|C0039224|G0000000
"(Figure 2) Perceived Change Index: Improvement or Worsening in Caregiver Affect, Managing Daily Care, and Somatic Symptoms from Baseline to Weeks 16 (N = 239) and 24 (N = 220) Figure 2a–2c Note: Perceived Change Index was recoded such that 0=no change; >0=improvement; <0=worsening) As to caregiver depression at 16-weeks, we found significantly greater symptomatology (CES-D>8) among control group than ACT caregivers (67.8% vs. 53.0%, Chi Square=5.4, p=.020).","(Figure 2) Perceived Change Index: Improvement Worsening Caregiver Affect, Managing Daily Care, Somatic Symptoms Baseline Weeks 16 (N = 239) 24 (N = 220) Figure 2a–2c Note: Perceived Change Index recoded 0=no change; >0=improvement; <0=worsening) As caregiver depression 16-weeks, symptomatology (CES-D>8) control ACT caregivers (67.8% vs. 53.0%, Chi Square=5.4, p=.020).",G0000000|G0000000|C0030971|C0392747|C0918012|C2986411|C0332271|C0085537|C0001721|C1273870|C0332173|C1947933|C1257909|C0683368|C0168634|C0439230|C0450371|C0369718|G0000000|C1442061|C0450371|C0369718|G0000000|C1442061|G0000000|G0000000|C1316572|C0030971|C0392747|C0918012|G0000000|G0000000|C0392747|C2986411|C0332271|G0000000|C0085537|C0011570|C0450371|G0000000|C2699160|C0243148|C0079613|C0085537|C0450371|G0000000|C0450371|C1720589|C0205120|C0369773
"All participants in both groups in the present study exhibited greater balance control, body symmetry, and functional independence in activities of daily living following the intervention.","All participants study exhibited balance control, body symmetry, functional independence activities daily living intervention.",G0000000|C0679646|C0557651|C0015272|C0014653|C0243148|C0242821|C0332516|C0205245|C0085862|C0441655|C0332173|C0376558|C0886296
"We identified 514 incident cases of PD (324 men, 190 women) during follow-up.","We identified 514 incident PD (324 men, 190 women) follow-up.",G0000000|C0205396|C1442061|C1551358|G0000000|C1442061|C0025266|C1442061|C0043210|C0589120
A total of 1734 dyads were randomly selected to be contacted for the study.,A total 1734 dyads randomly selected contacted study.,G0000000|C0439175|G0000000|C0870454|G0000000|C1707391|C0332158|C0557651
"Body weight, morning peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory volume in one second (FEV1); and also asthma symptoms, number of acute episodes, courses of oral steroids, health status (quality of life).","Body weight, morning peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory volume (FEV1); asthma symptoms, acute episodes, courses oral steroids, health status (quality life).",C0242821|C0005910|C0332170|C0444505|C0231800|C0806140|C0030771|C0441722|C0442732|C1516240|C3714541|C0441722|C0231800|C0449468|G0000000|C0004096|C0683368|C0205178|C0332189|C0750729|C0442027|C0038317|C0018684|C0449438|C0332306|C0376558
"Statistical analysis revealed no carryover effects for all primary outcome parameters (walking abilities: 10MWT: p = 0.805, 6MWT: p = 0.529 and TUG: p = 0.692) as well as for the secondary outcome parameters FAC and BBS (FAC: p = 0.244, BBS: p = 0.949).","Statistical analysis revealed carryover effects primary outcome parameters (walking abilities: 10MWT: = 0.805, 6MWT: = 0.529 TUG: = 0.692) secondary outcome parameters FAC BBS (FAC: = 0.244, BBS: = 0.949).",C0038215|C0002778|C0443289|G0000000|C1280500|C0205225|C1274040|C0449381|C0080331|C0085732|G0000000|G0000000|C1442061|G0000000|G0000000|C1442061|C1319201|G0000000|C1442061|C0027627|C1274040|C0449381|G0000000|G0000000|G0000000|G0000000|C1442061|G0000000|G0000000|C1442061
"Items, including various potential adverse effects, are rated on a five-point scale at baseline and after 5 and 10 weeks [34].","Items, including potential adverse effects, rated five-point scale baseline 5 10 weeks [34].",C1551338|C0332257|C3245505|G0000000|C1280500|C0871208|C0205451|C0175659|C0168634|G0000000|C0450371|C0439230|C0450371
"On the other hand, short regimens allow for more rapid symptom control (Macbeth et al, 1996).","On hand, short regimens rapid symptom control (Macbeth al, 1996).",G0000000|C0018563|C1282927|C2945654|C0456962|C1457887|C0243148|G0000000|C0202311|G0000000
Secondary endpoints were return of spontaneous circulation and admission to hospital.,Secondary endpoints return spontaneous circulation admission hospital.,C0027627|C2349179|C0332156|C0205359|C0005775|C0184666|C0019994
Cumulative 5-year safety and efficacy data of iron chelation therapy with deferasirox in transfusion-dependent patients with SCD are reported here.,Cumulative 5-year safety efficacy data iron chelation therapy deferasirox transfusion-dependent patients SCD reported here.,C1511559|C0439234|C0036043|C1280519|C1511726|C0302583|C3537131|C0039798|C1619629|C1698624|C0030705|G0000000|C0684224|G0000000
Serious adverse events (SAEs) reported during the trial according to randomized groups eTable 3.,Serious adverse events (SAEs) reported trial randomized eTable 3.,C0205404|G0000000|C0441471|C1519255|C0684224|C0008976|C0034656|G0000000|G0000000
"Changes in (A) Multidimensional Fatigue Symptom Inventory–Short Form (MFSI-SF) fatigue scores, (B) vitality scores (36-item short form [SF-36]), (C) depressive symptoms (Center for Epidemiological Studies–Depression [CES-D]), and (D, E, F) lipopolysaccharide-stimulated cytokine production (interleukin-6 [IL-6], tumor necrosis factor alpha [TNF-α], and interleukin-1β [IL-1β]) immediately post treatment and 3 months post treatment in the yoga and control groups.","Changes (A) Multidimensional Fatigue Symptom Inventory–Short Form (MFSI-SF) fatigue scores, (B) vitality scores (36-item short form [SF-36]), (C) depressive symptoms (Center Epidemiological Studies–Depression [CES-D]), (D, E, F) lipopolysaccharide-stimulated cytokine production (interleukin-6 [IL-6], tumor necrosis factor alpha [TNF-α], interleukin-1β [IL-1β]) post treatment 3 months post treatment yoga control groups.",C0392747|G0000000|C2347299|C0015672|C1457887|G0000000|C0348078|C0037712|C0015672|C0449820|G0000000|C0424589|C0449820|C0450371|C1282927|C0348078|C0037712|G0000000|G0000000|C0683368|C0205099|C0014507|G0000000|C2699160|C0073187|G0000000|C0016327|C0023810|C0079189|C0033268|C0021764|C0020898|C0027651|C0027540|C1521761|C0439095|G0000000|G0000000|G0000000|C0687676|C0039798|G0000000|C0439231|C0687676|C0039798|C0043418|C0243148|C0441833
The primary outcome variable is the change in ARAT in the more affected arm from baseline to end of treatment.,The primary outcome variable change ARAT arm baseline treatment.,G0000000|C0205225|C1274040|C0439828|C0392747|C1152215|C0446516|C0168634|C0039798
"The clinical cure rate in the “clinical per protocol” population at TOC (days 13 to 24) was 89.7% (156/174) for azithromycin and 93.7% (177/189) for levofloxacin (treatment difference, −4.0%; 95% confidence interval, −9.7%, 1.7%).","The clinical cure rate “clinical protocol” population TOC (days 13 24) 89.7% (156/174) azithromycin 93.7% (177/189) levofloxacin (treatment difference, −4.0%; 95% confidence interval, −9.7%, 1.7%).",G0000000|C0205210|C1880198|C0871208|G0000000|G0000000|C0032659|C1835664|C0439228|C0450371|C0450371|C0450371|C1442061|C0052796|C0450371|C1442061|C0282386|C0039798|C1705241|G0000000|C0450371|C0237529|C1272706|G0000000|G0000000
Primary outcome measures were symptom scores and change in the dose of methacholine provoking a 20% fall in FEV1 (PD20) during the first 6 months.,Primary outcome measures symptom scores change dose methacholine provoking 20% fall FEV1 (PD20) 6 months.,C0205225|C1274040|C0079809|C1457887|C0449820|C0392747|C0178602|C0600370|G0000000|C0450371|C0085639|G0000000|G0000000|G0000000|C0439231
"Baseline intakes of energy, fat, carbohydrates, protein, folate and vitamin A, but not vitamin B12, iron and zinc were lower in the LNS than control arm.","Baseline intakes energy, fat, carbohydrates, protein, folate vitamin A, vitamin B12, iron zinc lower LNS control arm.",C0168634|C1512806|C0424589|C0424612|C0007004|C0033684|C0178638|C0042890|G0000000|C0042890|G0000000|C0302583|C0043481|C0441994|C0023374|C0243148|C0446516
METHODS: Massachusetts adolescents (n = 529) who at baseline had smoked no more than 1 cigarette were reinterviewed by telephone in 1997.,METHODS: Massachusetts adolescents (n = 529) baseline smoked 1 cigarette reinterviewed telephone 1997.,C0025663|C0024874|C0205653|C0369718|G0000000|C1442061|C0168634|C0037366|G0000000|C0677453|G0000000|C0039457|G0000000
"The following CAP parameters were evaluated: total CAP time, CAP rate, number and duration of CAP sequences, number and duration of A phases, number and duration of B phases, and number and percent of subtypes A1, A2, and A3.","The CAP parameters evaluated: total CAP time, CAP rate, duration CAP sequences, duration A phases, duration B phases, percent subtypes A1, A2, A3.",G0000000|C0179586|C0449381|C0220825|C0439175|C0179586|C0040223|C0179586|C0871208|C0449238|C0179586|C0162326|C0449238|G0000000|C0585064|C0449238|G0000000|C0585064|C0439165|C0449560|C0336669|C0336669|C0336669
"The Berg Balance Scale, Modified Functional Reach Test, Functional Ambulation Category, Modified Ashworth Scale, Fugl-Meyer Assessment, Motricity Index, and Modified Barthel Index were assessed before and after treatment.","The Berg Balance Scale, Modified Functional Reach Test, Functional Ambulation Category, Modified Ashworth Scale, Fugl-Meyer Assessment, Motricity Index, Modified Barthel Index assessed treatment.",G0000000|G0000000|C0014653|C0175659|C0392747|C0205245|C2584321|C0022885|C0205245|C0080331|C0683312|C0392747|G0000000|C0175659|G0000000|C1261322|G0000000|C0918012|C0392747|G0000000|C0918012|C1516048|C0039798
Sharp trocar insertion for laparoscopic procedures carries with it increased risk for vascular and visceral complications and incisional hernia.,Sharp trocar insertion laparoscopic procedures carries increased risk vascular visceral complications incisional hernia.,C1444775|C0041158|C0021107|C0031150|C0025664|C0206243|C0205217|C0035647|C0005847|C0442045|C0009566|C0184898|C0019270
The participants recorded the pain intensity exactly at the time of menstrual pain (before taking the drug) and in 1-2-3-6-12-24-48-72 hours after starting the menstrual pain.,The participants recorded pain intensity time menstrual pain (before drug) 1-2-3-6-12-24-48-72 hours starting menstrual pain.,G0000000|C0679646|C0034869|C0030193|C0522510|C0040223|C0025344|C0030193|C0332152|C0013227|C0450371|C0439227|C0439659|C0025344|C0030193
"Secondary outcome measures included the change in BAI score, total GCS and GCS sub-scale scores, and PGWB ratings.","Secondary outcome measures included change BAI score, total GCS GCS sub-scale scores, PGWB ratings.",C0027627|C1274040|C0079809|C0332257|C0392747|C0234880|C0449820|C0439175|G0000000|G0000000|C0542339|C0449820|G0000000|C0871208
"Predicted scores for condition by moderator interactions effects on 8th-grade smoking prevalence for all schools (first column) and Cohort 2 schools (second column) Smoking 1-month prevalence for levels of susceptibility, smoker image, and tobacco rules by condition in all schools and in cohort 2 schools Mediation analyses examined whether the impact of the intervention on prevalence was mediated by its expected effect on variables.","Predicted scores condition moderator interactions effects 8th-grade smoking prevalence schools (first column) Cohort 2 schools (second column) Smoking 1-month prevalence levels susceptibility, smoker image, tobacco rules condition schools cohort 2 schools Mediation analyses examined impact intervention prevalence mediated expected variables.",C0681842|C0449820|C0012634|G0000000|C1704675|C1280500|C0441800|C0037369|C0033105|C0036375|C0205435|C1185738|C0599755|G0000000|C0036375|C0205436|C1185738|C0037369|C0332177|C0033105|C0441889|C0012655|C0337664|C1704254|C0040329|C0870077|C0012634|C0036375|C0599755|G0000000|C0036375|C0680727|C0002778|C0332128|C1825598|C0886296|C0033105|C0086597|C1517001|C0439828
Readmission and A&E reattendance's over the six months after discharge from hospital were obtained from the hospital computerised information system and general practitioner consultations from practice records.,Readmission A&E reattendance's months discharge hospital hospital computerised system practitioner consultations practice records.,C1548168|G0000000|G0000000|C0439231|C0012621|C0019994|C0019994|G0000000|C0449913|C1709627|C0009818|C0237607|C0034869
Smoking status was based on past-7-day abstinence self-reported via text message.,Smoking status based past-7-day abstinence self-reported text message.,C0037369|C0449438|C1527178|C1444637|C3843422|C0681906|C1527021|C0470166
"aMean±SD, *p<0.05, EG: Experimental Group, CG: Control Group, D-value: Difference-value, BBS: Berg Balance Scale, MBI: Modified Barthel Index, BDI: Beck Depression Inventory This study aimed to examine the effect of virtual reality dance exercise on the balance, ADL, and depressive disorder status of PD patients.","aMean±SD, *p<0.05, EG: Experimental Group, CG: Control Group, D-value: Difference-value, BBS: Berg Balance Scale, MBI: Modified Barthel Index, BDI: Beck Depression Inventory This study aimed examine virtual reality dance exercise balance, ADL, depressive disorder status PD patients.",G0000000|C0369773|C0013715|C1517586|C0441833|C0043444|C0243148|C0441833|C0073187|C1705241|G0000000|G0000000|C0014653|C0175659|C2985547|C0392747|G0000000|C0918012|C0006448|G0000000|C0011570|C0021941|G0000000|C0557651|C1947946|G0000000|C1553497|C0871222|C0010963|C0015259|C0014653|C0001288|G0000000|C0012634|C0449438|G0000000|C0030705
"Secondary efficacy measures were pain severity for 24‐h worst pain and night pain as measured by the 11‐point Numerical Rating Scale, Patient’s Global Impression of Improvement (PGI‐I) Scale29 recorded at weeks 2, 4, 8 and 12, and severity and interference portions of Brief Pain Inventory (BPI)30 recorded at randomization and weeks 2, 4, 8 and 12.","Secondary efficacy measures pain severity 24‐h worst pain night pain measured 11‐point Numerical Rating Scale, Patient’s Global Impression Improvement (PGI‐I) Scale29 recorded weeks 2, 4, 8 12, severity interference portions Brief Pain Inventory (BPI)30 recorded randomization weeks 2, 4, 8 12.",C0027627|C1280519|C0079809|C0030193|C0439793|G0000000|C1522166|C0030193|C0240526|C0030193|C0444706|G0000000|C0237753|C0871208|C0175659|G0000000|C0205246|C0596764|C2986411|G0000000|G0000000|C0034869|C0439230|G0000000|G0000000|G0000000|C0450371|C0439793|C0521102|C0449719|C1282927|C0030193|C0021941|C1443145|C0034869|C0034656|C0439230|G0000000|G0000000|G0000000|C0450371
Kaplan-Meier estimates of A) time to progression and B) overall survival (all-randomized population).,Kaplan-Meier estimates A) time progression B) survival (all-randomized population).,G0000000|C0750572|G0000000|C0040223|C0242656|G0000000|C0038952|C0034656|C0032659
"The respective differences in continuous validated abstinence at 12 months were 11%, 4%, 8% (p=0.25).","The respective differences continuous validated abstinence 12 months 11%, 4%, 8% (p=0.25).",G0000000|G0000000|C1705241|C0549178|G0000000|C3843422|C0450371|C0439231|C0450371|G0000000|G0000000|C0369773
"However, in supplemental analyses, we found that the relation between condition status and delivery mode (reported above) was not mediated by pregnancy complications.","However, supplemental analyses, relation condition status delivery mode (reported above) mediated pregnancy complications.",G0000000|C2348609|C0002778|C0080103|C0012634|C0449438|C0011209|C1513371|C0684224|C1282910|C0086597|C0032961|C0009566
Sustained smoking cessation at 12 months confirmed by a urine cotinine test.,Sustained smoking cessation 12 months confirmed urine cotinine test.,C0443318|C0037369|C1880019|G0000000|C0521093|C0042036|C0010194|C0022885
"Study design Note: Abbreviations: VR, vestibular rehabilitation; RN, registered nurse; CT, conventional therapy; ADL, activities of daily living; FIM®, Functional Independence Measure®; BITC, Behavioral Inattention Test Conventional; PASS, Postural Assessment Scale for Stroke patients.","Study design Note: Abbreviations: VR, vestibular rehabilitation; RN, registered nurse; CT, conventional therapy; ADL, activities daily living; FIM®, Functional Independence Measure®; BITC, Behavioral Inattention Test Conventional; PASS, Postural Assessment Scale Stroke patients.",C0557651|C1707689|C1316572|C0000723|C3476815|C0042606|C0034991|C2827110|C1514821|C0028661|C0007673|C0439858|C0039798|C0001288|C0441655|C0332173|C0376558|G0000000|C0205245|C0085862|G0000000|G0000000|C0004927|C0424101|C0022885|C0439858|C2828386|C0205278|C1261322|C0175659|C0038454|C0030705
"Abbreviations: AChEI, acetylcholinesterase inhibitor; ADAS-cog, Alzheimer Disease Assessment Scale–Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study/Activities of Daily Living; APOE, apolipoprotein E; CAS, Caregiver Activity Survey; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.","Abbreviations: AChEI, acetylcholinesterase inhibitor; ADAS-cog, Alzheimer Disease Assessment Scale–Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study/Activities Daily Living; APOE, apolipoprotein E; CAS, Caregiver Activity Survey; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.",C0000723|G0000000|C0001044|C1999216|C3539026|G0000000|C0012634|C1261322|G0000000|G0000000|C3641947|G0000000|C0012634|C0679729|C2348552|C0332173|C0376558|C0003595|C0003591|G0000000|G0000000|C0085537|C0205177|C0038951|C0451306|C0445542|C1301808|G0000000|C1412208|G0000000|C0021941
The primary outcome was incidence of delirium during the first 8 days after initiation of the study medication.,The primary outcome incidence delirium 8 days initiation study medication.,G0000000|C0205225|C1274040|C0021149|C0011206|G0000000|C0439228|C0589507|C0557651|C0013227
"The criteria for MetS include having ≥3 of the following clinical indicators: increased waist circumference, fasting glucose, triglycerides, and blood pressure (BP) and decreased HDL cholesterol (2).","The criteria MetS ≥3 clinical indicators: increased waist circumference, fasting glucose, triglycerides, blood pressure (BP) decreased HDL cholesterol (2).",G0000000|C0243161|C0812270|G0000000|C0205210|C0021212|C0205217|C0230097|C0332520|C0015663|C0017725|C0041004|C0005767|C0033095|C0037623|C0205216|C3715113|C0008377|G0000000
"Follow-up surveys 12 and 30 months after baseline (retention rate: 81%) documented the transition from never to ever smoking, even just a puff.","Follow-up surveys 12 30 months baseline (retention rate: 81%) documented transition smoking, puff.",C0589120|C0038951|C0450371|C0450371|C0439231|C0168634|C0035280|C0871208|C0450371|C1301725|C0599156|C0037369|C1533107
"From maternal fasting blood samples the concentrations of plasma glucose, 3ß-OH-butyrate, lipids (triglycerides, free fatty acids, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol), insulin, leptin, HbA1c, vitamin A, vitamin D and carotenoids will be determined.","From maternal fasting blood samples concentrations plasma glucose, 3ß-OH-butyrate, lipids (triglycerides, free fatty acids, total cholesterol, density lipoprotein cholesterol low density lipoprotein cholesterol), insulin, leptin, HbA1c, vitamin A, vitamin D carotenoids determined.",G0000000|C2347083|C0015663|C0005767|C0370003|C0086045|C0032105|C0017725|G0000000|C0023779|C0041004|C0332296|G0000000|C0001128|C0439175|C0008377|C0178587|C0023820|C0008377|C0205251|C0178587|C0023820|C0008377|C0021641|C0299583|G0000000|C0042890|G0000000|C0042890|C0073187|C0007271|G0000000
"The outcome measures will be student-reported smoking, alcohol use and illicit drug use.","The outcome measures student-reported smoking, alcohol illicit drug use.",G0000000|C1274040|C0079809|C0038492|C0037369|C0001962|C0332266|C0013227|C0042153
"Results from these trials were mixed; the first trial found no increase in gestation or in infant weight, length, or head circumference at birth with supplementation, although supplementation resulted in greater birth weight in infants of women in their first pregnancy (5).","Results trials mixed; trial increase gestation infant weight, length, head circumference birth supplementation, supplementation birth weight infants women pregnancy (5).",C1274040|C0008976|C0205430|C0008976|C0442805|C0032961|C0021270|C0005910|C1444754|C0018670|C0332520|C0005615|C0242297|C0242297|C0005615|C0005910|C0021270|C0043210|C0032961|G0000000
The effects of manually assisted cough and mechanical insufflation on cough flow physiology are reported in this study.,The effects manually assisted cough mechanical insufflation cough flow physiology reported study.,G0000000|C1280500|C3842330|C1269765|C0010200|C0443254|C0021634|C0010200|C0806140|C0031842|C0684224|C0557651
"not having smoked a puff within the past 30 days), (2) stage of change according to the HAPA [10], (3) a quit attempt within the 6-month period, (4) alcohol consumption assessed by a 7-day drinking calendar, for which participants would need to think about a typical week in the month prior to assessment and recall the number of standard drinks they typically consumed for each day.","smoked puff 30 days), (2) stage change HAPA [10], (3) quit attempt 6-month period, (4) alcohol consumption assessed 7-day drinking calendar, participants typical week month prior assessment recall standard drinks typically consumed day.",C0037366|C1533107|C0450371|C0439228|G0000000|C0205390|C0392747|C1831791|C0450371|G0000000|C0748223|C1516084|C0332177|C0439531|G0000000|C0001962|C0009830|C1516048|C0332173|C0001948|C1516147|C0679646|C3538928|C0332174|C0332177|C0332152|C1261322|C0034770|C1442989|C0452428|G0000000|G0000000|C0332173
"Primary outcomes were the number of SIRS criteria at 24 hours, 48 hours and 72 hours and levels of CRP at 48 hours and 72 hours (CRP peaks at 72 hours8).","Primary outcomes SIRS criteria 24 hours, 48 hours 72 hours levels CRP 48 hours 72 hours (CRP peaks 72 hours8).",C0205225|C1274040|C0242966|C0243161|C0450371|C0439227|C0450371|C0439227|C0450371|C0439227|C0441889|C3890735|C0450371|C0439227|C0450371|C0439227|C3890735|C0444505|C0450371|G0000000
"The secondary outcome was the effects of naltrexone therapy on the disease activity with a clinical response defined as a 10-point decline in the PCDAI score from pretreatment and remission was defined as a score <10 20, 22.","The secondary outcome effects naltrexone therapy disease activity clinical response defined 10-point decline PCDAI score pretreatment remission defined score <10 20, 22.",G0000000|C0027627|C1274040|C1280500|C0027360|C0039798|C0012634|C0205177|C0205210|C0871261|C1704788|C0450371|G0000000|G0000000|C0449820|C1550147|C0544452|C1704788|C0449820|C0450371|C0450371|C0450371
The outcomes were assessed during the first 28 days or until hospital discharge.,The outcomes assessed 28 days hospital discharge.,G0000000|C1274040|C1516048|C0450371|C0439228|C0019994|C0012621
Primary patency was the interval between stent placement and first exchange or death without recurrent jaundice.,Primary patency interval stent placement exchange death recurrent jaundice.,C0205225|C0175566|C1272706|C0038257|C0441587|C0678640|C0011065|C2945760|C0022346
"Families and Schools Together (FAST) is an intensive 8-week multi-family after-school program designed to empower parents, promote child resilience, and increase social capital – relations of trust and shared expectations – within and between families and among parents and school personnel.","Families Schools Together (FAST) intensive 8-week multi-family after-school program designed empower parents, promote child resilience, increase social capital – relations trust shared expectations – families parents school personnel.",C0015576|C0036375|C1883357|C0015663|C0162425|C0332174|C0439064|C0036375|C1709697|C1707689|C0562342|C0030551|C0033414|C0008059|G0000000|C0442805|C0728831|C0006909|G0000000|C0439849|C0237935|C0237876|C0679138|G0000000|C0015576|C0030551|C0036375|C0024752
"Secondary outcomes included the mean changes in sleep architecture, oxygenation variables and Epworth Sleepiness Scale (ESS) scores [22].","Secondary outcomes included sleep architecture, oxygenation variables Epworth Sleepiness Scale (ESS) scores [22].",C0027627|C1274040|C0332257|C0037313|C0003737|C0231940|C0439828|G0000000|C0013144|C0175659|C0206630|C0449820|C0450371
The primary outcome was the average number of episodes of respiratory tract infection during the follow-up period for which patients consulted their physician per patient per year (PPPY) and the proportion of these episodes that resulted in an antibiotic prescription.,The primary outcome average episodes respiratory tract infection follow-up period patients consulted physician patient (PPPY) proportion episodes antibiotic prescription.,G0000000|C0205225|C1274040|C1510992|C0332189|C0521346|C1185740|C0009450|C0589120|C0439531|C0030705|C0009818|C0031831|C0030705|G0000000|C1709707|C0332189|C0003232|C0033080
Note that treatment outcome was determined as change in correct naming at the end of treatment compared to baseline.,Note treatment outcome determined change correct naming treatment compared baseline.,C1316572|C0039798|C1274040|G0000000|C0392747|C2349182|C0233735|C0039798|C1707455|C0168634
"There was no difference in severity of diarrhea between treatment groups at 1, 3, and 6 months.","There difference severity diarrhea treatment 1, 3, 6 months.",G0000000|C1705241|C0439793|C0011991|C0039798|G0000000|G0000000|G0000000|C0439231
It is currently unclear how to maximise arm recovery after stroke.,It unclear maximise arm recovery stroke.,G0000000|G0000000|G0000000|C0446516|C0237820|C0038454
A score of less than 67% classifies older adults as “at risk” of falling [18].,A score 67% classifies adults “at risk” falling [18].,G0000000|C0449820|C0450371|C0008902|C0001675|G0000000|G0000000|C0000921|C0450371
A signed consent form could not be obtained from 24% of the participants who reported a diagnosis of PD.,A signed consent form 24% participants reported diagnosis PD.,G0000000|C1519316|C1511481|C0348078|C0450371|C0679646|C0684224|C0011900|G0000000
"The dependent variables are the dichotomous outcomes such as, infection, acute and chronic rejection, graft loss, and death and numeric outcomes such as creatinine, and BUN.","The dependent variables dichotomous outcomes as, infection, acute chronic rejection, graft loss, death numeric outcomes creatinine, BUN.",G0000000|C0851827|C0439828|C2827654|C1274040|G0000000|C0009450|C0205178|C0205191|C0035015|C0181074|C1517945|C0011065|C0237753|C1274040|C0010294|G0000000
"Eleven months later, we surveyed mothers on their daughters’ HPV vaccine uptake.","Eleven months later, surveyed mothers daughters’ HPV vaccine uptake.",C0205457|C0439231|C0205087|C0038951|C0026591|G0000000|C0021344|C0042210|C0243144
The primary outcome of the trial was the annualized relapse rate (ARR).,The primary outcome trial annualized relapse rate (ARR).,G0000000|C0205225|C1274040|C0008976|G0000000|C0035020|C0871208|G0000000
No significant differences between the treatment groups were observed in the shuttle walking test or any of the other outcome measures.,No differences treatment observed shuttle walking test outcome measures.,G0000000|C1705241|C0039798|C1441672|G0000000|C0080331|C0022885|C1274040|C0079809
"During treatment, physicians recorded side effects at weeks 2, 4, 8, 12, 16, 20 and 24.","During treatment, physicians recorded effects weeks 2, 4, 8, 12, 16, 20 24.",G0000000|C0039798|C0031831|C0034869|C1280500|C0439230|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0450371
CSR ratings are presented in Table 2.,CSR ratings Table 2.,C2699348|C0871208|C0039224|G0000000
BACKGROUND—Previous studies suggest that recurrent episodes of coughing and wheezing occur in up to 75% of infants after acute viral bronchiolitis.,BACKGROUND—Previous studies recurrent episodes coughing wheezing occur 75% infants acute viral bronchiolitis.,G0000000|C0947630|C2945760|C0332189|C0010200|C0043144|C1709305|C0450371|C0021270|C0205178|C0521026|C0006271
The study was powered to detect a difference in the primary end-point (time to first severe exacerbation).,The study powered detect difference primary end-point (time severe exacerbation).,G0000000|C0557651|C0032863|C0442726|C1705241|C0205225|C2349179|C0040223|C0205082|G0000000
"However, confounding of NRT ordering would have been limited because nurses do not order medications.","However, confounding NRT limited nurses medications.",G0000000|G0000000|C1278444|C0439801|C0028661|C0013227
"VAP is connected to longer ICU and hospital stays, additional costs and high mortality, and the risk of developing this condition increases by 1% with each additional day of mechanical ventilation [1,2].","VAP connected ICU hospital stays, additional costs mortality, risk developing condition increases 1% additional day mechanical ventilation [1,2].",G0000000|C2986575|C0021708|C0019994|G0000000|C1524062|C0010186|C0026565|C0035647|G0000000|C0012634|C0205217|G0000000|C1524062|C0332173|C0443254|C0035203|G0000000
Differences in malaria transmission experienced in the two groups will be made by comparing the mean number of mosquitoes (as a proxy for transmission) caught indoors in houses between the intervention groups.,Differences malaria transmission experienced comparing mosquitoes (as proxy transmission) caught indoors houses intervention groups.,C1705241|C0024530|C0040722|C0237607|C1707455|C0026584|G0000000|C0600420|C0040722|C0231617|G0000000|C0442519|C0886296|C0441833
"To get a better sense of dietary quality, we break down the consumption of calories into its various sources: cereals, pulses, fruits and vegetables, eggs, fish and meat, edible oil and others.","To sense dietary quality, break consumption calories sources: cereals, pulses, fruits vegetables, eggs, fish meat, edible oil others.",C0040363|C0036658|C0012155|C0332306|C1881704|C0009830|C1556156|C0449416|C0007757|C0034107|C0016767|C0042440|C0013710|C0016163|C0025017|G0000000|C0028908|C1955473
"Burning discomfort was scored using a visual analog scale (VAS): in the morning before starting the treatment, in the afternoon on the first day of treatment, and at the end of the week of treatment in the morning and in the afternoon.","Burning discomfort scored visual analog scale (VAS): morning starting treatment, afternoon day treatment, week treatment morning afternoon.",C0000912|C0231218|C0449820|C0234621|C0243071|C0175659|C0042815|C0332170|C0439659|C0039798|C0439550|C0332173|C0039798|C0332174|C0039798|C0332170|C0439550
"COPE, Carers of Older People in Europe; EQ-5D, EuroQol 5 dimensions; HADS, Hospital Anxiety and Depression Scale; MCS, mental component score; NPI-D, Neuropsychiatric Inventory Distress Scale; PAC, Positive Aspects of Caring; PANAS, Positive and Negative Affect Schedule; PCS, Physical Component Score; QCPR, Quality of Caregiver–Patient Relationship; SF, short form.","COPE, Carers Older People Europe; EQ-5D, EuroQol 5 dimensions; HADS, Hospital Anxiety Depression Scale; MCS, mental component score; NPI-D, Neuropsychiatric Inventory Distress Scale; PAC, Positive Aspects Caring; PANAS, Positive Negative Affect Schedule; PCS, Physical Component Score; QCPR, Quality Caregiver–Patient Relationship; SF, short form.",C0009967|C0085537|C0580836|C0027361|C0015176|C0205163|C0451150|G0000000|C0439534|C0048008|C0019994|C0003467|C0011570|C0175659|G0000000|C0229992|C0449432|C0449820|C1412208|G0000000|C0021941|C0231303|C0175659|G0000000|C0439178|C1547011|C0150499|G0000000|C0439178|C0205160|C0001721|C0086960|C1864389|C0031809|C0449432|C0449820|G0000000|C0332306|G0000000|C0439849|C0037712|C1282927|C0348078
"Therefore, there should be alternative strategy that empowers the community for effective utilization of LLITN to control the burden of malaria in the population particularly in the vulnerable groups (under-five children and pregnant women).","Therefore, alternative strategy empowers community effective utilization LLITN control burden malaria population vulnerable (under-five children pregnant women).",G0000000|C1523987|C0679199|C0562342|C0009462|C1280519|C0042153|G0000000|C0243148|C2828008|C0024530|C0032659|G0000000|C0205451|C0008059|C0549206|C0043210
"The primary endpoint, time to FRNS will be compared between these two groups using log-rank test.","The primary endpoint, time FRNS compared log-rank test.",G0000000|C0205225|C2349179|C0040223|C0220730|C1707455|C1708728|C0022885
The chapatti‐feeding programme concluded by collection of blood at the end of the 6‐month intervention period.,The chapatti‐feeding programme concluded collection blood 6‐month intervention period.,G0000000|G0000000|C1709697|C0917903|C1516698|C0005767|G0000000|C0886296|C0439531
"Using an exploratory approach we will also gather data on arm function, quality of life, sleep and mood, cognitive scores, and maximal oxygen uptake.","Using exploratory approach gather data arm function, quality life, sleep mood, cognitive scores, maximal oxygen uptake.",C1524063|G0000000|C0449445|G0000000|C1511726|C0446516|C0031843|C0332306|C0376558|C0037313|C0026516|C1516691|C0449820|C0205289|C0030054|C0243144
SNAP latency was measured at the peak of Sensory Action Potential.,SNAP latency measured peak Sensory Action Potential.,G0000000|C0205275|C0444706|C0444505|C0445254|C0441472|C3245505
"There were no statistically significant differences between these two groups in response time, ventilation time, success rate of resuscitation or the Apgar scores at 1 and 5 min after birth between the two groups.","There statistically differences response time, ventilation time, success rate resuscitation Apgar scores 1 5 min birth groups.",G0000000|C0038215|C1705241|C0871261|C0040223|C0035203|C0040223|C0597535|C0871208|C0035273|C0741195|C0449820|G0000000|G0000000|C0702093|C0005615|C0441833
We think higher doses could improve sleep latency and sleep duration.,We doses improve sleep latency sleep duration.,G0000000|C0178602|G0000000|C0037313|C0205275|C0037313|C0449238
"The frequency scale, CMAI-fr, ranges from 1 (never) to 7 (several times per hour), and the disruptiveness scale, CMAI-di, from 1 (not at all) to 5 (extremely).","The frequency scale, CMAI-fr, ranges 1 (never) 7 (several times hour), disruptiveness scale, CMAI-di, 1 (not all) 5 (extremely).",G0000000|C0376249|C0175659|C2348513|C1514721|G0000000|C2003901|G0000000|C0439064|C0040223|C0439227|C0332453|C0175659|C3538902|G0000000|C1518422|G0000000|G0000000|C0205403
"Efficacy was measured as an improvement in motor function determined by the total time elapsed to complete a shorter version of the Wolf Motor Function Test (WMFT).18 This test contains 15 timed and 2 strength tasks (lifting the weighted limb and grip strength), ordered from simple to complex, administered sequentially to each upper extremity and controlling for patient positioning and distance the extremity segment must traverse.","Efficacy measured improvement motor function determined total time elapsed complete shorter version Wolf Motor Function Test (WMFT).18 This test 15 timed 2 strength tasks (lifting weighted limb grip strength), simple complex, administered sequentially upper extremity controlling patient positioning distance extremity segment traverse.",C1280519|C0444706|C2986411|C1513492|C0031843|G0000000|C0439175|C0040223|C1707889|C0205197|C1282927|C0333052|C0325001|C1513492|C0031843|C0022885|C0450371|G0000000|C0022885|C0450371|C0392761|G0000000|C0237897|C3540678|C0206244|C0005910|C0015385|C0021400|C0237897|C0205352|C0439855|C1521801|G0000000|C1282910|C0015385|C2239193|C0030705|C0150305|C0012751|C0015385|C0441635|C2828360
Proportion who had registered after 3 months who at baseline were lapsed or never registered * grp 1 vs grp 2 p < 0.05 This study found that there was no significant increase in registration among children who were not registered with a GDP at baseline in any of the four groups.,Proportion registered 3 months baseline lapsed registered * grp 1 grp 2 < 0.05 This study increase registration children registered GDP baseline groups.,C1709707|C1514821|G0000000|C0439231|C0168634|G0000000|C1514821|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|G0000000|C0557651|C0442805|C1514821|C0008059|C1514821|C0018340|C0168634|C0441833
"Mainly evaluated indexes were negatively converting rate of serum HBV DNA and HbeAg, and the normalization rate of serum ALT.","Mainly evaluated indexes negatively converting rate serum HBV DNA HbeAg, normalization rate serum ALT.",G0000000|C0220825|C0600653|G0000000|G0000000|C0871208|C0229671|G0000000|C0012854|C0019167|C1882115|C0871208|C0229671|C1266129
The mean differences between groups will be compared.Self-efficacy related to healthy lifestyle changes in diet and exercise will be measured and the mean differences between groups will be compared.,The differences compared.Self-efficacy healthy lifestyle diet exercise measured differences compared.,G0000000|C1705241|C1707455|C3898900|C0023676|C0012155|C0015259|C0444706|C1705241|C1707455
Changes in the birth prevalence from the period before to the period after fortification were estimated with Poisson regression.,Changes birth prevalence period period fortification estimated Poisson regression.,C0392747|C0005615|C0033105|C0439531|C0439531|G0000000|C0750572|G0000000|C0684320
"The difference between the angle of ""catch"" (R1) and the full passive range of movement (R2) reflects the potential range available in the joint if spasticity is eliminated [9,63].","The difference angle ""catch"" (R1) passive range movement (R2) reflects potential range joint spasticity eliminated [9,63].",G0000000|C1705241|C0205143|C0231617|C1425688|C3686820|C1514721|C0026649|C1425688|C0558058|C3245505|C1514721|C0022417|C0026838|C0849355|C0450371
Time to diarrhea relief and weight change were compared between the two groups after one week.,Time diarrhea relief weight change compared week.,C0040223|C0011991|C0564405|C0005910|C0392747|C1707455|C0332174
"Studies among South African patients on TB treatment have found that financial constraints are major obstacles to the completion of TB treatment [7,8] and TB preventive therapy [9].","Studies South African patients TB treatment financial constraints major obstacles completion TB treatment [7,8] TB preventive therapy [9].",C0947630|C1710133|C0027567|C0030705|G0000000|C0039798|C0376243|C0443288|C0205082|G0000000|C0205197|G0000000|C0039798|G0000000|G0000000|C0445202|C0039798|G0000000
"Protocol-defined platelet transfusion events (PTEs) (ie, platelet transfusions for a bleeding event or platelets ≤10 × 109/L), overall bleeding, and platelet response according to 2006 International Working Group Hematologic Improvement-Platelet (HI-P)18 criteria also were assessed.","Protocol-defined platelet transfusion events (PTEs) (ie, platelet transfusions bleeding event platelets ≤10 × 109/L), bleeding, platelet response 2006 International Working Group Hematologic Improvement-Platelet (HI-P)18 criteria assessed.",C0442711|C0005821|C0005841|C0441471|G0000000|G0000000|C0005821|C0005841|C0019080|C0441471|C0005821|G0000000|C0019080|C0005821|C0871261|G0000000|C1512888|C0043227|C0441833|C0018943|C2986411|C4054794|C0243161|C1516048
"The AED improvements, anxiety and depression scores, Social Support Rating Scale (SSRS), Family Assessment Device (FAD) and scale of systemic family dynamics (SSFD) were observed after 3-month treatment.","The AED improvements, anxiety depression scores, Social Support Rating Scale (SSRS), Family Assessment Device (FAD) scale systemic family dynamics (SSFD) observed 3-month treatment.",G0000000|C0887457|C2986411|C0003467|C0011570|C0449820|C0728831|C0183683|C0871208|C0175659|C2754414|C0015576|C1261322|C0025080|C1705143|C0175659|C0205373|C0015576|C3826426|G0000000|C1441672|C0332177|C0039798
Adherence to dietary goals was assessed using the daily food check lists and serum fatty acids and carotenoids.,Adherence dietary goals assessed daily food check lists serum fatty acids carotenoids.,C1510802|C0012155|C0018017|C1516048|C0332173|C0016452|C1283174|C0745732|C0229671|G0000000|C0001128|C0007271
"Adolescent outcomes were measured using the Youth Alcohol and Drug Survey (YADS; Werch, Carlson, Pappas, Dunn, & Williams, 1997), a 91-item child self-report measure with subscales examining alcohol, marijuana and cigarette use and intentions to use, alcohol refusal skills and self-efficacy, positive expectancies about alcohol, perceived harmfulness of alcohol, and parenting practices and communication related to alcohol use.","Adolescent outcomes measured Youth Alcohol Drug Survey (YADS; Werch, Carlson, Pappas, Dunn, & Williams, 1997), 91-item child self-report measure subscales examining alcohol, marijuana cigarette intentions use, alcohol refusal skills self-efficacy, positive expectancies alcohol, perceived harmfulness alcohol, parenting practices communication alcohol use.",C0205653|C1274040|C0444706|C0001578|C0001962|C0013227|C0038951|G0000000|G0000000|G0000000|C1442932|G0000000|G0000000|G0000000|G0000000|C0450371|C0008059|C0681906|C0079809|G0000000|C0332128|C0001962|C0024808|C0677453|C0162425|C0042153|C0001962|G0000000|C0678856|C0600564|C0439178|C0679138|C0001962|C0030971|G0000000|C0001962|C0085092|C0237607|C0009452|C0001962|C0042153
"Surgical approach (laparoscopy vs laparotomy), type of surgery (conservative vs radical), execution of adjuvant chemotherapy and performance of lymphadenectomy were not associated with recurrence.","Surgical approach (laparoscopy laparotomy), type surgery (conservative radical), execution adjuvant chemotherapy performance lymphadenectomy recurrence.",C0543467|C0449445|C0031150|C0023038|C0332307|C0038894|G0000000|C0302912|C1278561|C0001551|C0013216|C0597198|C0024203|C0034897
"Secondary outcomes (at 24 months) were: investigations, number and timing of recurrences and deaths.","Secondary outcomes (at 24 months) were: investigations, timing recurrences deaths.",C0027627|C1274040|G0000000|C0450371|C0439231|G0000000|C1261322|C0449243|C0034897|C0011065
Anxiety and depression subscales of HADS had significant differences between the two groups (P < 0.001) in the 4th and 8th week after treatment.,Anxiety depression subscales HADS differences (P < 0.001) 4th 8th week treatment.,C0003467|C0011570|G0000000|C0048008|C1705241|C0369773|G0000000|C1442061|G0000000|G0000000|C0332174|C0039798
Regression Analyses of Perceived Stress Scale (PSS) Scores Statistically significant results are depicted in bold.,Regression Analyses Perceived Stress Scale (PSS) Scores Statistically depicted bold.,C0684320|C0002778|C0030971|C0038435|C0175659|G0000000|C0449820|C0038215|G0000000|G0000000
"However, oral midazolam had superiority neither in sleep onset latency nor in sleep duration when compared to chloral hydrate.","However, oral midazolam superiority sleep onset latency sleep duration compared chloral hydrate.",G0000000|C0442027|C0026056|C0680218|C0037313|C0206132|C0205275|C0037313|C0449238|C1707455|C0077034|C0720930
The serum collected was stored at −70°C for cytokine and CRP assay.,The serum collected stored −70°C cytokine CRP assay.,G0000000|C0229671|C1516695|C1698986|G0000000|C0079189|C3890735|C0005507
"Self-report instruments measuring self-efficacy for health behaviors, health-promotion behaviors, and health-related QOL (SF-36 and the Fibromyalgia Impact Questionnaire) were completed at baseline, 2 months (after the classes), 5 months (after telephone follow-up), and at 8 months.","Self-report instruments measuring self-efficacy health behaviors, health-promotion behaviors, health-related QOL (SF-36 Fibromyalgia Impact Questionnaire) completed baseline, 2 months (after classes), 5 months (after telephone follow-up), 8 months.",C0681906|C0348000|C0444706|C0600564|C0018684|C0004927|C0018738|C0004927|C0018684|C0518214|C0037712|C0016053|C1825598|C0034394|C0205197|C0168634|G0000000|C0439231|G0000000|C0456387|G0000000|C0439231|G0000000|C0039457|C0589120|G0000000|C0439231
"The observed changes in some targeted risk factors supports the conclusion, however, that at least some of the falls reduction was mediated by the interventions.","The observed targeted risk factors supports conclusion, however, falls reduction mediated interventions.",G0000000|C1441672|C1521840|C0035647|C1521761|C0183683|C1707478|G0000000|C0000921|C0301630|C0086597|C0886296
"Enforcement of the home smoking ban was assessed by asking, “How often are your smoking rules broken by someone?” Response options were never, rarely, sometimes, and very often.","Enforcement smoking ban assessed asking, “How smoking rules broken someone?” Response options never, rarely, sometimes, often.",G0000000|C0037369|C0683610|C1516048|G0000000|G0000000|C0037369|C0870077|C1881704|G0000000|C0871261|C1518601|C2003901|C0522498|C1998882|C0332183
"Seven day point abstinence rates at week 26 were not significantly different (1.23, 0.96 to 1.52, P=0.096).","Seven day abstinence rates week 26 (1.23, 0.96 1.52, P=0.096).",C0205453|C0332173|C3843422|C0871208|C0332174|C0450371|C0450371|C0450371|C0450371|C0369773
Relief of associated symptoms and sustained pain relief for 24 hours were also noted.,Relief symptoms sustained pain relief 24 hours noted.,C0564405|C0683368|C0443318|C0030193|C0564405|C0450371|C0439227|C1316572
Activity scores of patients with IBD (score).,Activity scores patients IBD (score).,C0205177|C0449820|C0030705|G0000000|C0449820
Infection was defined as at least a 4-fold increase in RV-39 neutralizing antibody titer and/or recovery of rhinovirus on viral culture.,Infection defined 4-fold increase RV-39 neutralizing antibody titer and/or recovery rhinovirus viral culture.,C0009450|C1704788|C0332462|C0442805|C0035190|G0000000|C0003241|C0475208|G0000000|C0237820|C0035473|C0521026|C0010453
"Similarly, there were no differences in the average maximum serum ammonia concentrations, change from baseline in plasma GLU levels, or average weekly or maximum serum alkaline phosphatase and transaminase concentrations (not shown).","Similarly, differences average maximum serum ammonia concentrations, change baseline plasma GLU levels, average weekly maximum serum alkaline phosphatase transaminase concentrations (not shown).",G0000000|C1705241|C1510992|C0806909|C0229671|C0002607|C0086045|C0392747|C0168634|C0032105|C0061472|C0441889|C1510992|C0332174|C0806909|C0229671|C1979842|C0031678|C0002594|C0086045|C1518422|C1547282
The relationship between demographic characteristics with anxiety and depression The findings of this study show the effect of music therapy on the anxiety and depression of patients with cancer.,The relationship demographic characteristics anxiety depression The findings study music therapy anxiety depression patients cancer.,G0000000|C0439849|C0011298|C1521970|C0003467|C0011570|G0000000|C2607943|C0557651|C0026867|C0039798|C0003467|C0011570|C0030705|C0006826
The sustained abstinence at six months in a pilot study of practice nurse support was 16%.,The sustained abstinence months pilot study practice nurse support 16%.,G0000000|C0443318|C3843422|C0439231|C0473169|C0557651|C0237607|C0028661|C0183683|C0450371
"The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.","The primary incidence cutaneous squamous-cell carcinoma, survival free melanoma progression, response.",G0000000|C0205225|C0021149|C0221912|C0221910|C0007097|C0038952|C0332296|C0025202|C0242656|C0871261
"The daily micturition, nocturia, urinary urgency, and UUI in the treatment group improved more obviously than in the control group (P<0.05) after 60 days of therapy.","The daily micturition, nocturia, urinary urgency, UUI treatment improved control (P<0.05) 60 days therapy.",G0000000|C0332173|C0042034|C0028734|C0042027|C0439609|G0000000|C0039798|C0184511|C0243148|C0369773|C0450371|C0439228|C0039798
"No deep vein thrombosis, infection or wound complication was detected in both groups.","No deep vein thrombosis, infection wound complication detected groups.",G0000000|C0205125|C0042449|C0040053|C0009450|C0043250|C0009566|C0442726|C0441833
Days with worse asthma symptoms were defined as those with either an orange or yellow sticker.,Days worse asthma symptoms defined orange yellow sticker.,C0439228|C0332271|C0004096|C0683368|C1704788|C0440277|C0221205|G0000000
Because EOC patients with small residual disease appear to have a survival advantage when treated with i.p.,Because EOC patients residual disease survival advantage treated i.p.,G0000000|G0000000|C0030705|C1609982|C0012634|C0038952|G0000000|C1522326|C0021966
"Gender, specifically masculinity, is strongly linked to criminal justice involvement.","Gender, masculinity, linked criminal justice involvement.",C0079399|C0042757|C1517892|C0699726|C0022437|C1314939
3WMT = 3-meter walk test; 6MWT = 6-minute walk test; ABC = Activities-specific Balance Confidence Scale; BBS = Berg Balance Scale; DGI = Dynamic Gait Index; FM-LE = Fugl-Meyer Lower Extremity subscale; SLS = single limb stance; TUG = Timed Up and Go.,3WMT = 3-meter walk test; 6MWT = 6-minute walk test; ABC = Activities-specific Balance Confidence Scale; BBS = Berg Balance Scale; DGI = Dynamic Gait Index; FM-LE = Fugl-Meyer Lower Extremity subscale; SLS = single limb stance; TUG = Timed Up Go.,G0000000|G0000000|C0475209|C0080331|C0022885|G0000000|G0000000|C0439232|C0080331|C0022885|C0152244|G0000000|C0441655|C0014653|C0237529|C0175659|G0000000|G0000000|G0000000|C0014653|C0175659|G0000000|G0000000|C0729333|C0016928|C0918012|C3540627|G0000000|G0000000|C0441994|C0015385|G0000000|C0037231|G0000000|C0037179|C0015385|G0000000|C1319201|G0000000|C0392761|G0000000|C1822658
The primary outcome of the trial will be the ACQ score.,The primary outcome trial ACQ score.,G0000000|C0205225|C1274040|C0008976|C2919686|C0449820
Failure to achieve RER.,Failure achieve RER.,C0231174|G0000000|C0230779
"For alcohol and marijuana use, latent variables were created for each substance at baseline and the 6-month follow up using three indicators, including symptoms of abuse, symptoms of dependence, and number of days of reported use over the previous 90 days.","For alcohol marijuana use, latent variables created substance baseline 6-month follow indicators, including symptoms abuse, symptoms dependence, days reported previous 90 days.",G0000000|C0001962|C0024808|C0042153|C0205275|C0439828|C1706214|C0439861|C0168634|C0332177|C0332283|C0021212|C0332257|C0683368|C0013146|C0683368|C0011546|C0439228|C0684224|C0205156|C0450371|C0439228
"In the control districts, this included children in the same two time periods during which there was no intensified case finding.","In control districts, included children time periods intensified finding.",G0000000|C0243148|G0000000|C0332257|C0008059|C0040223|C0439531|G0000000|C0037088
"Consistent with these recommendations, we compared 6 months of nightly eszopiclone treatment to placebo on measures of quality of life, work limitations, fatigue, sleepiness, insomnia severity, and patient-reported sleep and daytime function measurements in patients with primary insomnia.","Consistent recommendations, compared 6 months nightly eszopiclone treatment placebo measures quality life, limitations, fatigue, sleepiness, insomnia severity, patient-reported sleep daytime function measurements patients primary insomnia.",C0332290|C0034866|C1707455|G0000000|C0439231|G0000000|C1436328|C0039798|C0032042|C0079809|C0332306|C0376558|C0449295|C0015672|C0013144|C0917801|C0439793|C0747307|C0037313|C0332169|C0031843|C0242485|C0030705|C0205225|C0917801
"Secondary endpoints included change in 6MWD (ASSET-1), and safety of bosentan in all patients.","Secondary endpoints included change 6MWD (ASSET-1), safety bosentan patients.",C0027627|C2349179|C0332257|C0392747|G0000000|C2371679|C0036043|C0252643|C0030705
"AE, adverse event.","AE, adverse event.",C3887670|G0000000|C0441471
"During empiric antifungal therapy, the study drug was continued.","During empiric antifungal therapy, study drug continued.",G0000000|C1880496|C0003308|C0039798|C0557651|C0013227|C0549178
"The findings supported the first hypothesis that children in the 2 intervention groups would have greater improvements than the attention-control group in selected health outcomes such as visits to the doctor for asthma symptoms, ED visits, and severity of asthma.","The findings supported hypothesis children 2 intervention improvements attention-control selected health outcomes visits doctor asthma symptoms, ED visits, severity asthma.",G0000000|C2607943|C1521721|C1512571|C0008059|G0000000|C0886296|C2986411|C0004268|C1707391|C0018684|C1274040|C0545082|C0031831|C0004096|C0683368|C3538926|C0545082|C0439793|C0004096
"At week 12, there were no significant between-group differences in the mean change from baseline in AQLQ(S) total score.","At week 12, between-group differences change baseline AQLQ(S) total score.",G0000000|C0332174|C0450371|C0441833|C1705241|C0392747|C0168634|C4055434|C0439175|C0449820
"No participant in the control group will be impeded from obtaining mosquito nets from other sources, and malaria incidence in the control villages will be monitored throughout the study for possible case build-up or an outbreak of malaria.","No participant control impeded obtaining mosquito nets sources, malaria incidence control villages monitored study build-up outbreak malaria.",G0000000|C0679646|C0243148|G0000000|C1301820|C0026584|C1423506|C0449416|C0024530|C0021149|C0243148|C0562518|C0030695|C0557651|C2986569|C0012652|C0024530
The following secondary outcomes will reported: (1) the number and length of delirium episodes during hospital stay and the number of days between admission to ward and the occurrence of delirium and (2) the outcome of the patient-reported questionnaires.,The secondary outcomes reported: (1) length delirium episodes hospital stay days admission ward occurrence delirium (2) outcome patient-reported questionnaires.,G0000000|C0027627|C1274040|C0684224|G0000000|C1444754|C0011206|C0332189|C0019994|G0000000|C0439228|C0184666|C1305702|C0243132|C0011206|G0000000|C1274040|C0747307|C0034394
"Secondary outcomes included persistent oral HPV infection, detection of bHSIL at week 52 or later, anal cytological outcomes, and grade 3 or 4 adverse events related to vaccination.","Secondary outcomes included persistent oral HPV infection, detection bHSIL week 52 later, anal cytological outcomes, grade 3 4 adverse events vaccination.",C0027627|C1274040|C0332257|C0205322|C0442027|C0021344|C0009450|C1511790|G0000000|C0332174|C0450371|C0205087|C0003461|C0205471|C1274040|C0441800|G0000000|G0000000|G0000000|C0441471|C0042196
The mechanism by which thermal injury can cause oesophageal cancer is not clear but both direct and indirect effects have been suggested.,The mechanism thermal injury oesophageal cancer direct indirect effects suggested.,G0000000|C0441712|G0000000|C3263722|C1522619|C0006826|C0439851|C0439852|C1280500|C1705535
"Secondary end points included comparison of the 75 mg twice daily target pregabalin treatment change-from-baseline hot flash score versus placebo, comparisons of the change-from-baseline hot flash frequencies between 150 mg twice daily target pregabalin and 75 mg twice daily target pregabalin treatments versus placebo, and comparisons of toxicity profiles, moods (from POMS), and the HFRDIS scores between either treatment arm and placebo.","Secondary included comparison 75 daily target pregabalin treatment change-from-baseline hot flash score versus placebo, comparisons change-from-baseline hot flash frequencies 150 daily target pregabalin 75 daily target pregabalin treatments versus placebo, comparisons toxicity profiles, moods (from POMS), HFRDIS scores treatment arm placebo.",C0027627|C0332257|C1707455|C0450371|C0332173|C1521840|C0657912|C0039798|C0392747|C0444519|C0181637|C0449820|G0000000|C0032042|C1707455|C0392747|C0444519|C0181637|C0439603|C1442061|C0332173|C1521840|C0657912|C0450371|C0332173|C1521840|C0657912|C0087111|G0000000|C0032042|C1707455|C0040539|C1979963|C0026516|G0000000|C0451394|C3641714|C0449820|C0039798|C0446516|C0032042
"[Results] The stance phase symmetry profile, the swing phase symmetry profile, and gait velocity all decreased significantly in the TT group compared with the TRT group.","[Results] The stance phase symmetry profile, swing phase symmetry profile, gait velocity decreased TT compared TRT group.",C1274040|G0000000|G0000000|C0205390|C0332516|C1979963|G0000000|C0205390|C0332516|C1979963|C0016928|C0439830|C0205216|C1452561|C1707455|G0000000|C0441833
The aim of this study is to produce effects on communication skills in real life consultations (level 3) and also to integrate an evaluation of the patients’ views on communication skills.,The aim study produce effects communication skills real life consultations (level 3) integrate evaluation patients’ views communication skills.,G0000000|C1947946|C0557651|G0000000|C1280500|C0009452|C0678856|C0237400|C0376558|C0009818|C0441889|G0000000|G0000000|C0220825|G0000000|C0449911|C0009452|C0678856
The primary endpoint of incidence density informed the estimate of efficacy derived from a relapse control.,The primary endpoint incidence density informed estimate efficacy derived relapse control.,G0000000|C0205225|C2349179|C0021149|C0178587|C1522154|C0750572|C1280519|C1441547|C0035020|C0243148
"Endpoints were overall survival, health-related quality of life (HRQoL), toxicity, and the use of radiotherapy.","Endpoints survival, health-related quality life (HRQoL), toxicity, radiotherapy.",C2349179|C0038952|C0018684|C0332306|C0376558|G0000000|C0040539|C0034619
bmjopen-2015-010691supp_file2.pdf An intention-to-treat (ITT) analysis was used for the primary and secondary outcome data.,bmjopen-2015-010691supp_file2.pdf An intention-to-treat (ITT) analysis primary secondary outcome data.,C1431343|G0000000|C0162425|G0000000|C0002778|C0205225|C0027627|C1274040|C1511726
We used logistic regression to examine the effect of baseline measures of tobacco use history on prolonged abstinence.,We logistic regression examine baseline measures tobacco history prolonged abstinence.,G0000000|C0242415|C0684320|G0000000|C0168634|C0079809|C0040329|C0019664|C0439590|C3843422
"Co-morbid symptoms included fatigue, using the Multidimensional Fatigue Inventory (MFI; [54]), problems with sleep, using a composite of sleep problems from the MOS Sleep Scale (i.e., Index 2) [56], and mood as assessed by the Center for Epidemiological Studies Depression Scale (CES-D; [32] and by the State-Trait Personality Inventory (STPI;[55]) for anxiety.","Co-morbid symptoms included fatigue, Multidimensional Fatigue Inventory (MFI; [54]), sleep, composite sleep MOS Sleep Scale (i.e., Index 2) [56], mood assessed Center Epidemiological Studies Depression Scale (CES-D; [32] State-Trait Personality Inventory (STPI;[55]) anxiety.",C0009488|C0683368|C0332257|C0015672|C2347299|C0015672|C0021941|C1881923|C0450371|C0037313|C0205199|C0037313|C3813178|C0037313|C0175659|C0683454|C0918012|G0000000|C0450371|C0026516|C1516048|C0205099|C0014507|C0947630|C0011570|C0175659|C2699160|C0450371|C1301808|C0003944|C0021941|C0450371|C0003467
Hospital mortality.,Hospital mortality.,C0019994|C0026565
Safety outcomes included the incidence of hypotension during the 72-hour study treatment period and the incidence of hepatic abnormalities during the first 7 days after randomisation.,Safety outcomes included incidence hypotension 72-hour study treatment period incidence hepatic abnormalities 7 days randomisation.,C0036043|C1274040|C0332257|C0021149|C0020649|C0450371|C0557651|C0039798|C0439531|C0021149|C0205054|C0000768|G0000000|C0439228|C0034656
I had a chance to revisit my life with my mother again … thank you so much!,I chance revisit life mother … much!,C0021966|C0237506|G0000000|C0376558|C0026591|G0000000|C0205393
"Neonatal; Gestational age at delivery, delivery at <37 weeks’, delivery at <34 weeks’; birth weight, birth weight >4,000 g, <2,500 g; birth weight >95th <10th and <5th customised birth weight centile, distribution of birth weight, neonatal death, days in special care baby unit, total inpatient days, need for mechanical ventilation and duration, discharge home on O2, suspected and confirmed infection, evidence of intraventricular haemorrhage and other complications, (pulmonary haemorrhage, necrotizing enterocolitis), retinopathy of prematurity, hypoglycaemia.","Neonatal; Gestational age delivery, delivery <37 weeks’, delivery <34 weeks’; birth weight, birth weight >4,000 g, <2,500 g; birth weight >95th <10th <5th customised birth weight centile, distribution birth weight, neonatal death, days special care baby unit, total inpatient days, mechanical ventilation duration, discharge O2, suspected confirmed infection, evidence intraventricular haemorrhage complications, (pulmonary haemorrhage, necrotizing enterocolitis), retinopathy prematurity, hypoglycaemia.",C1552240|C0439671|C0001779|C0011209|C0011209|C0450371|G0000000|C0011209|C0450371|G0000000|C0005615|C0005910|C0005615|C0005910|C1442061|C0439267|C1442061|C0439267|C0005615|C0005910|G0000000|G0000000|G0000000|G0000000|C0005615|C0005910|G0000000|C0520511|C0005615|C0005910|C1552240|C0011065|C0439228|C0205555|C1947933|C0021270|C0439148|C0439175|C0021562|C0439228|C0443254|C0035203|C0449238|C0012621|C0300971|C0332147|C0521093|C0009450|C3887511|C1517569|C0019080|C0009566|C0024109|C0019080|C0439664|C0014356|C0035309|C0021294|C0020615
Times from referral to first outpatient appointment and from scan to outpatient review and time on waiting list for surgery were analysed before and after implementation of these changes.,Times referral outpatient appointment scan outpatient review time waiting list surgery analysed implementation changes.,C0040223|C0034927|C0029921|C0003629|C0034606|C0029921|C0282443|C0040223|C1610166|C0745732|C0038894|G0000000|C1708476|C0392747
eHealth Literacy Scale survey results MIS error rates were low using either type of device.,eHealth Literacy Scale survey MIS error rates low type device.,C1328956|C0023864|C0175659|C0038951|C0687670|C0743559|C0871208|C0205251|C0332307|C0025080
"Clinical research suggested that the normalization rates of serum ALT and TB, and the negative conversion rates of serum HBsAg and HBV DNA were similar to alpha interferon when oxymatrine was applied to treatment of chronic hepatitis B.","Clinical suggested normalization rates serum ALT TB, negative conversion rates serum HBsAg HBV DNA alpha interferon oxymatrine applied treatment chronic hepatitis B.",C0205210|C1705535|C1882115|C0871208|C0229671|C1266129|G0000000|C0205160|C0439836|C0871208|C0229671|C0019168|G0000000|C0012854|C0439095|C0021747|C0069821|C4048755|C0039798|C0205191|C0019158|G0000000
The HoMBReS-2 intervention is promising; it was found efficacious in increasing consistent condom use and HIV testing among a community-based sample of immigrant Latino men.,The HoMBReS-2 intervention promising; efficacious increasing consistent condom HIV testing community-based sample immigrant Latino men.,G0000000|G0000000|C0886296|C1555307|C1280519|C0442808|C0332290|C0009653|C0019682|C0039593|C0009462|C0370003|C0282163|C0086528|C0025266
"The primary endpoint was time to progression (TTP), defined as time from randomization until disease progression (PD) or death from any cause.","The primary endpoint time progression (TTP), defined time randomization disease progression (PD) death cause.",G0000000|C0205225|C2349179|C0040223|C0242656|C0084795|C1704788|C0040223|C0034656|C0012634|C0242656|G0000000|C0011065|C0015127
Cellular immune responses were measured by quantifying T cell proliferation in response to BA7072 and HER500 antigens.,Cellular immune responses measured quantifying T cell proliferation response BA7072 HER500 antigens.,C0007634|C0439662|C0871261|C0444706|C1709793|C2603360|C0007634|C0334094|C0871261|G0000000|G0000000|C0003320
The primary outcome measures were the number of days with respiratory and gastrointestinal symptoms or days with any illness; absences from day care centre because of illness; number of children with upper respiratory tract infections with complications (acute otitis media and sinusitis) and lower respiratory tract infections (acute bronchitis and pneumonia) as diagnosed by a doctor; and antibiotic treatments during the seven month intervention.,The primary outcome measures days respiratory gastrointestinal symptoms days illness; absences day care centre illness; children upper respiratory tract infections complications (acute otitis media sinusitis) lower respiratory tract infections (acute bronchitis pneumonia) diagnosed doctor; antibiotic treatments month intervention.,G0000000|C0205225|C1274040|C0079809|C0439228|C0521346|C0521362|C0683368|C0439228|C0221423|C0424530|C0332173|C1947933|C0205099|C0221423|C0008059|C1282910|C0521346|C1185740|C3714514|C0009566|C0205178|C0029877|C0009458|C0037199|C0441994|C0521346|C1185740|C3714514|C0205178|C0006277|C0032285|C0011900|C0031831|C0003232|C0087111|C0332177|C0886296
"Kidney disease was categorized according to the Kidney Disease Outcomes Quality Initiative guidelines: stage 3 eGFR=30–59 ml/min per 1.73 m2, stage 4 eGFR=15–29 ml/min per 1.73 m2, and stage 5 eGFR<15 ml/min per 1.73 m2 with or without renal replacement therapy (19).","Kidney disease categorized Kidney Disease Outcomes Quality Initiative guidelines: stage 3 eGFR=30–59 ml/min 1.73 m2, stage 4 eGFR=15–29 ml/min 1.73 m2, stage 5 eGFR<15 ml/min 1.73 m2 renal replacement therapy (19).",C0022646|C0012634|C0871968|C0022646|C0012634|C1274040|C0332306|C0424093|C0162791|C0205390|G0000000|G0000000|C0439445|C0450371|C0025885|C0205390|G0000000|G0000000|C0439445|C0450371|C0025885|C0205390|G0000000|C1739039|C0439445|C0450371|C0025885|C0022646|C0035139|C0039798|C0450371
"Conclusion Sodium reduction, previously shown to lower blood pressure, may also reduce long term risk of cardiovascular events.","Conclusion Sodium reduction, lower blood pressure, reduce term risk cardiovascular events.",C1707478|C0037473|C0301630|C0441994|C0005767|C0033095|G0000000|C0233324|C0035647|C0007226|C0441471
"that included a thorough medical history and physical, along with baseline tender point assessment to confirm the diagnosis.","included medical history physical, baseline tender assessment confirm diagnosis.",C0332257|C0199168|C0019664|C0031809|C0168634|C0234234|C1261322|C0521093|C0011900
Median overall survival was not reached at the time of this analysis.,Median survival reached time analysis.,C0549183|C0038952|C2584321|C0040223|C0002778
"Briefly, the study compared the effectiveness of three versus one round of azithromycin MDA in reducing the prevalence of active trachoma and ocular C. trachomatis infection.","Briefly, study compared effectiveness versus round azithromycin MDA reducing prevalence active trachoma ocular C. trachomatis infection.",G0000000|C0557651|C1707455|C1280519|G0000000|C0332490|C0052796|C0000379|C0392756|C0033105|C0205177|C0040592|C0015392|G0000000|C2893398|C0009450
VSC level was measured between 7.00–8.30 a.m. by the sulfide monitor as previously described.,VSC level measured 7.00–8.30 a.m. sulfide monitor described.,G0000000|C0441889|C0444706|G0000000|C2346751|C0038739|C0030695|C1552738
"The pain, stiffness and function subscales of the WOMAC were normalized to a scale of 0 to 100 units (NU) 31.","The pain, stiffness function subscales WOMAC normalized scale 0 100 units (NU) 31.",G0000000|C0030193|C0427008|C0031843|G0000000|G0000000|C1882115|C0175659|G0000000|C1442061|C0439148|C0025932|C0450371
"However, the sex aspect of prevalence of stress-related mental health problems does not seem to apply when considering recovery of symptoms in clinically ill patients.","However, sex aspect prevalence stress-related mental health apply recovery symptoms clinically ill patients.",G0000000|C0009253|C1547011|C0033105|C0038435|C0229992|C0018684|C1632850|C0237820|C0683368|G0000000|C0231218|C0030705
There were no significant differences in rates of polio immunity 1 month after receipt of the IPV booster between study groups (Table (Table2).2).,There differences rates polio immunity 1 month receipt IPV booster study (Table (Table2).2).,G0000000|C1705241|C0871208|C0032371|C0020964|G0000000|C0332177|G0000000|G0000000|C1697762|C0557651|C0039224|G0000000
"Data from other authors9,10 using information derived from expert review of serial audiograms demonstrated that quantifying ototoxicity from the CTC criteria substantially underestimated the true incidence of significant hearing loss.","Data authors9,10 derived expert review serial audiograms demonstrated quantifying ototoxicity CTC criteria underestimated true incidence hearing loss.",C1511726|C0450371|C1441547|G0000000|C0282443|C0031082|C0018786|G0000000|C1709793|C0235280|G0000000|C0243161|G0000000|C0205238|C0021149|C0018767|C1517945
"In the exercise group, there was an increase in the WHOQOL-BREF and shoulder ROM and decrease in BFI and pain score after radiotherapy.","In exercise group, increase WHOQOL-BREF shoulder ROM decrease BFI pain score radiotherapy.",G0000000|C0015259|C0441833|C0442805|G0000000|C0037004|C4048784|C0392756|C2698562|C0030193|C0449820|C0034619
Chi square analysis will be used to compare the proportions of exclusive breastfeeding at 6 months in the two groups.,Chi square analysis compare proportions exclusive breastfeeding 6 months groups.,C1720589|C0205120|C0002778|C1707455|C1709707|C1548966|C0006147|G0000000|C0439231|C0441833
Primary endpoint: Primary endpoint was the change in HbA1c after 24 months of treatment.,Primary endpoint: Primary endpoint change HbA1c 24 months treatment.,C0205225|C2349179|C0205225|C2349179|C0392747|G0000000|C0450371|C0439231|C0039798
The AREDS Cognitive Function Battery included 6 validated and commonly used cognitive tests with 8 components.,The AREDS Cognitive Function Battery included 6 validated commonly cognitive tests 8 components.,G0000000|G0000000|C1516691|C0031843|C0337088|C0332257|G0000000|G0000000|G0000000|C1516691|C0022885|G0000000|C0449432
"The primary outcome was time to first asthma treatment failure (a composite outcome of decline in lung function and increases in use of β-agonists, systemic corticosteroids, and health care).","The primary outcome time asthma treatment failure (a composite outcome decline lung function increases β-agonists, systemic corticosteroids, health care).",G0000000|C0205225|C1274040|C0040223|C0004096|C0039798|C0231174|G0000000|C0205199|C1274040|G0000000|C0024109|C0031843|C0205217|G0000000|C0205373|C0001617|C0018684|C1947933
"Measurements of sympathetic activity by MSNA, heart rate variability and catecholamines will be obtained at baseline and after 30 days.","Measurements sympathetic activity MSNA, heart rate variability catecholamines baseline 30 days.",C0242485|G0000000|C0205177|G0000000|C0018787|C0871208|C2827666|C0007412|C0168634|C0450371|C0439228
"Other secondary outcomes were performance tests—namely, the Motricity index (MI-arm and MI-leg), functional ambulation categories, six minute walk test,14 five metre comfortable walking speed test, timed balance test, timed up and go, modified stairs test, and letter cancellation task.","Other secondary outcomes performance tests—namely, Motricity (MI-arm MI-leg), functional ambulation categories, minute walk test,14 metre comfortable walking speed test, timed balance test, timed go, modified stairs test, letter cancellation task.",G0000000|C0027627|C1274040|C0597198|G0000000|G0000000|C3810814|C3810814|C0205245|C0080331|C0683312|C0439232|C0080331|C0022885|C0475209|G0000000|C0080331|C0678536|C0022885|C0392761|C0014653|C0022885|C0392761|C1822658|C0392747|C1710179|C0022885|C1096774|C0205544|C3540678
"Of these, 18 441 were singleton births with known gestational age between 20 and 43 gestational weeks, of which 1616 were preterm (20-36 weeks) and 471 were very preterm (20-32 weeks).","Of these, 18 441 singleton births gestational age 20 43 gestational weeks, 1616 preterm (20-36 weeks) 471 preterm (20-32 weeks).",G0000000|G0000000|G0000000|C0481462|C0005615|C0439671|C0001779|C0450371|C0450371|C0439671|C0439230|G0000000|C0151526|C0450371|C0439230|C1442061|C0151526|C0450371|C0439230
There is no gold standard for identifying which patients are and which are not misusing their prescription medication.,There gold standard identifying patients misusing prescription medication.,G0000000|C0018026|C1442989|G0000000|C0030705|C0549649|C0033080|C0013227
"Throughout the study, mean serum triglyceride levels remained below the upper limit of normal range (1.6 mmol/L or 142 mg/dL) in both treatment groups for all time points (baseline, day 5, day 8, post day 9, and last visit).","Throughout study, serum triglyceride levels remained upper limit normal range (1.6 mmol/L 142 mg/dL) treatment time (baseline, day 5, day 8, post day 9, visit).",G0000000|C0557651|C0229671|C0041004|C0441889|G0000000|C1282910|C0439801|C0205307|C1514721|G0000000|C1532563|C1442061|C0439269|C0039798|C0040223|C0168634|C0332173|G0000000|C0332173|G0000000|C0687676|C0332173|G0000000|C0545082
The primary outcomes of this study were to evaluate if maternal probiotics supplementation can modulate the cytokine profile and secretory IgA (sIgA) in breast milk and thus to study if differences in breast milk composition can affect lactoferrin and sIgA levels in newborn stool samples.,The primary outcomes study evaluate maternal probiotics supplementation modulate cytokine profile secretory IgA (sIgA) breast milk study differences breast milk composition affect lactoferrin sIgA levels newborn stool samples.,G0000000|C0205225|C1274040|C0557651|C0220825|C2347083|C0525033|C0242297|C0443264|C0079189|C1979963|C1327616|C2825347|C0020838|C0006141|C0026131|C0557651|C1705241|C0006141|C0026131|C0486616|C0001721|C0022942|C0020838|C0441889|C0021289|C0015733|C0370003
"Compared with placebo, neither group showed significant differences in improvement on the agitation inventory either at six weeks or 26 weeks.","Compared placebo, differences improvement agitation inventory weeks 26 weeks.",C1707455|C0032042|C1705241|C2986411|C0085631|C0021941|C0439230|C0450371|C0439230
A total score of 5 to 25 points could be reached.,A total score 5 25 reached.,G0000000|C0439175|C0449820|G0000000|C0450371|C2584321
Girls’ subcutaneous body fat was assessed using the sum of triceps and subscapular skinfold measures.,Girls’ subcutaneous body fat assessed sum triceps subscapular skinfold measures.,G0000000|C0443315|C0242821|C0424612|C1516048|C1515051|C0559502|G0000000|C1446851|C0079809
"A relapse was defined by a new infectious pulmonary event caused by the same pathogen identified in the initial BAL fluid (regardless of its susceptibility profile), associated with clinical and radiological signs of nosocomial pneumonia (occurring ≥4 days of treatment) or a worsening of 2 points of the baseline SOFA score.","A relapse defined infectious pulmonary event caused pathogen identified initial BAL fluid (regardless susceptibility profile), clinical radiological signs nosocomial pneumonia (occurring ≥4 days treatment) worsening 2 baseline SOFA score.",G0000000|C0035020|C1704788|C0009450|C0024109|C0441471|C0015127|C0450254|C0205396|C0205265|C0428249|C0005889|C3641650|C0012655|C1979963|C0205210|C0034599|C0220912|C0019994|C0032285|C1709305|G0000000|C0439228|C0039798|C0332271|G0000000|C0168634|G0000000|C0449820
"To assess disease-specific quality of life, study participants will complete one of the following self-report instruments based on their respective underlying diagnosis: the Kansas City Cardiomyopathy Questionnaire (KCCQ-12); the Clinical COPD Questionnaire (CCQ); or the King’s Brief Interstitial Lung Disease (K-BILD).","To assess disease-specific quality life, study participants complete self-report instruments based respective underlying diagnosis: Kansas City Cardiomyopathy Questionnaire (KCCQ-12); Clinical COPD Questionnaire (CCQ); King’s Brief Interstitial Lung Disease (K-BILD).",C0040363|C1516048|C0012634|C0332306|C0376558|C0557651|C0679646|C0205197|C0681906|C0348000|C1527178|G0000000|G0000000|C0011900|C0022497|C0008848|C0878544|C0034394|C3476798|C0205210|C0024117|C0034394|G0000000|G0000000|C1282927|C0596790|C0024109|C0012634|C0597277
"For children ≤19 years, BMI age-standardized z-scores were calculated according to WHO references.","For children ≤19 years, BMI age-standardized z-scores calculated WHO references.",G0000000|C0008059|G0000000|C0439234|G0000000|C0001779|C0871421|C0444686|G0000000|C1514811
"Lung function, asthma symptoms, airway hyperresponsiveness (PC20 methacholine and adenosine-5'-monophosphate), sputum eosinophil and eosinophilic cationic protein (ECP) levels were measured as lung parameters.","Lung function, asthma symptoms, airway hyperresponsiveness (PC20 methacholine adenosine-5'-monophosphate), sputum eosinophil eosinophilic cationic protein (ECP) levels measured lung parameters.",C0024109|C0031843|C0004096|C0683368|C0178987|G0000000|G0000000|C0600370|C0001465|C0038056|C0014467|C0333930|C0007447|C0033684|C3889675|C0441889|C0444706|C0024109|C0449381
The protection against HIV infection was calculated as 1 − RR.,The protection HIV infection calculated 1 − RR.,G0000000|C1545588|C0019682|C0009450|C0444686|G0000000|G0000000|G0000000
"However, the question remained whether this intermediary effect translated into reductions of problem outcomes such as assaults, automobile crashes, or other forms of injuries.","However, question remained intermediary translated reductions outcomes assaults, automobile crashes, forms injuries.",G0000000|C1522634|G0000000|G0000000|C0040710|C0301630|C1274040|C0004063|C0004381|G0000000|C0348078|C1510467
"The measurements were performed for each participant at 6, 7, 9, 12, 15, and 18 months of age, and the mothers were weighed at 6 months postpartum.","The measurements performed participant 6, 7, 9, 12, 15, 18 months age, mothers weighed 6 months postpartum.",G0000000|C0242485|C0884358|C0679646|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0439231|C0001779|C0026591|G0000000|G0000000|C0439231|C0086839
"Of leukaemia subtypes, 72 (67.3%) were acute myeloid leukaemia (AML), 22 (20.6%) acute lymphocytic leukaemia (ALL), 10 (9.3%) chronic myeloid leukaemia (CML), and 3 (2.8%) chronic lymphocytic leukaemia (CLL).","Of leukaemia subtypes, 72 (67.3%) acute myeloid leukaemia (AML), 22 (20.6%) acute lymphocytic leukaemia (ALL), 10 (9.3%) chronic myeloid leukaemia (CML), 3 (2.8%) chronic lymphocytic leukaemia (CLL).",G0000000|C0023418|C0449560|C0450371|C0450371|C0205178|C0439677|C0023418|C0023467|C0450371|C0450371|C0205178|C0024264|C0023418|C0444868|C0450371|G0000000|C0205191|C0439677|C0023418|C0083528|G0000000|G0000000|C0205191|C0024264|C0023418|C0023434
"The primary clinical end point of the study was response rate, as assessed by RECIST.","The primary clinical study response rate, assessed RECIST.",G0000000|C0205225|C0205210|C0557651|C0871261|C0871208|C1516048|C1709926
Age-related macular degeneration and cognitive impairment are both chronic neurodegenerative disorders affecting an increasing number of persons as they age.,Age-related macular degeneration cognitive impairment chronic neurodegenerative disorders increasing persons age.,C0001779|C0332574|C0011164|C1516691|C0221099|C0205191|G0000000|C0012634|C0442808|C0027361|C0001779
"This study aims to investigate the effect of combining LLINs and IRS with propoxur for the incidence of clinical malaria and the cost-effectiveness of the interventions against malaria and their effect on mosquito behavior, as compared to each intervention alone.","This study aims investigate combining LLINs IRS propoxur incidence clinical malaria cost-effectiveness interventions malaria mosquito behavior, compared intervention alone.",G0000000|C0557651|C1947946|C1292732|C0336789|G0000000|G0000000|C0003640|C0021149|C0205210|C0024530|C0010181|C0886296|C0024530|C0026584|C0004927|C1707455|C0886296|C0205171
The primary efficacy end-point was the change in morning peak expiratory flow (PEF) from baseline (mean of the last 10 days of run-in) to the mean value over the 12-week treatment period.,The primary efficacy end-point change morning peak expiratory flow (PEF) baseline (mean 10 days run-in) 12-week treatment period.,G0000000|C0205225|C1280519|C2349179|C0392747|C0332170|C0444505|C0231800|C0806140|C0030771|C0168634|C0444504|C0450371|C0439228|C3274438|C0450371|C0039798|C0439531
Responses in tumour lesions <50% or increase in size less than 25% was defined as stable disease.,Responses tumour lesions <50% increase size 25% defined stable disease.,C0871261|C0027651|C0221198|C0450371|C0442805|C0456389|C0450371|C1704788|C0205360|C0012634
"Exercise training parameters (resting and maximal blood pressure, heart rate, and oxygen consumption), hemoglobin, glycated hemoglobin, lipid profile, C-reactive protein (CRP), dietary caloric intake, and body weight and composition were secondary outcome variables.","Exercise training parameters (resting maximal blood pressure, heart rate, oxygen consumption), hemoglobin, glycated hemoglobin, lipid profile, C-reactive protein (CRP), dietary caloric intake, body weight composition secondary outcome variables.",C0015259|C0040607|C0449381|C0035253|C0205289|C0005767|C0033095|C0018787|C0871208|C0030054|C0009830|C0019046|C3666909|C0019046|C0023779|C1979963|C0205332|C0033684|C3890735|C0012155|G0000000|C1512806|C0242821|C0005910|C0486616|C0027627|C1274040|C0439828
"Other secondary measures of efficacy were the total scores (investigator ratings) on the Clinical Global Impressions Scale (CGI), the Montgomery-Åsberg Depression Rating Scale (MADRS), and the self rating scores on the Beck Depression Inventory (BDI), the 36-item short form health survey (SF-36), and the patients' global self-rating of efficacy.","Other secondary measures efficacy total scores (investigator ratings) Clinical Global Impressions Scale (CGI), Montgomery-Åsberg Depression Rating Scale (MADRS), rating scores Beck Depression Inventory (BDI), 36-item short form health survey (SF-36), patients' global self-rating efficacy.",G0000000|C0027627|C0079809|C1280519|C0439175|C0449820|C0035173|C0871208|C0205210|C0205246|C0596764|C0175659|C3639708|G0000000|C0011570|C0871208|C0175659|C4054475|C0871208|C0449820|G0000000|C0011570|C0021941|C0006448|C0450371|C1282927|C0348078|C0018684|C0038951|C0037712|C0030705|C0205246|C4054119|C1280519
"No patient had taken any lipid-lowering agent, hormone therapy, or vitamin supplements during the 8 weeks before randomization.","No patient lipid-lowering agent, hormone therapy, vitamin supplements 8 weeks randomization.",G0000000|C0030705|C0023779|C0450442|C0019932|C0039798|C0042890|C0242295|G0000000|C0439230|C0034656
"After 1-year, the patients underwent contrast sensitivity (glare and non-glare under bright and dark conditions), accommodation-related testing, asthenopia questionnaire assessment, and adverse reaction questionnaire assessment.","After 1-year, patients underwent contrast sensitivity (glare non-glare bright dark conditions), accommodation-related testing, asthenopia questionnaire assessment, adverse reaction questionnaire assessment.",G0000000|C0439234|C0030705|G0000000|C0009924|C0020517|C0278215|C1518422|C0423899|C0332582|C0012634|C0000936|C0039593|C0004095|C0034394|C1261322|G0000000|C0443286|C0034394|C1261322
"The secondary efficacy end points were change from baseline in EET during constant work rate cycle ergometry to symptom limitation at 75% of peak work rate (Wmax) and the percentage of inactive patients (<6,000 steps per day) after 8 weeks of treatment.","The secondary efficacy change baseline EET constant rate cycle ergometry symptom limitation 75% peak rate (Wmax) percentage inactive patients (<6,000 steps day) 8 weeks treatment.",G0000000|C0027627|C1280519|C0392747|C0168634|C1537011|C1547014|C0871208|C1511572|C0085143|C1457887|C0449295|C0450371|C0444505|C0871208|G0000000|C0439165|C0205254|C0030705|C1442061|C1261552|C0332173|G0000000|C0439230|C0039798
The reversibility of insomnia-associated impairments of glucose metabolism is unknown.,The reversibility insomnia-associated impairments glucose metabolism unknown.,G0000000|C0449261|C0917801|C0684336|C0017725|C0025519|C0439673
This relates to the changes in everyday life that the individual patients designate as being among the three main consequences of their disease.,This relates everyday life individual patients designate main consequences disease.,G0000000|C0163712|C0332173|C0376558|C0027361|C0030705|G0000000|C0205225|C0686907|C0012634
"After 3 consecutive washes on same day, mosquito mortality decreased to less than 10%.","After 3 consecutive washes day, mosquito mortality decreased 10%.",G0000000|G0000000|C1707491|C0441648|C0332173|C0026584|C0026565|C0205216|C0450371
"Assessments of fatigue, using the Fatigue Severity Scale (FSS),12 were performed at baseline, and weeks 3, 9, 24, 40, and 42.","Assessments fatigue, Fatigue Severity Scale (FSS),12 performed baseline, weeks 3, 9, 24, 40, 42.",C1261322|C0015672|C0015672|C0439793|C0175659|C0265224|C0884358|C0168634|C0439230|G0000000|G0000000|C0450371|C0450371|C0450371
"Furthermore the primary outcome, respiratory distress requiring admission to special care baby unit, is hardly susceptible to maternal influence.","Furthermore primary outcome, respiratory distress requiring admission special care baby unit, susceptible maternal influence.",G0000000|C0205225|C1274040|C0521346|C0231303|G0000000|C0184666|C0205555|C1947933|C0021270|C0439148|C0220898|C2347083|C4054723
"Median OS was 15.9 months (95% CI, 11.0–22.5 months) in the RT/temozolomide arm and 16.6 months (95% CI, 14.9–20.1 months) in the vandetanib/RT/ temozolomide (log-rank P = 0.75; Fig.","Median OS 15.9 months (95% CI, 11.0–22.5 months) RT/temozolomide arm 16.6 months (95% CI, 14.9–20.1 months) vandetanib/RT/ temozolomide (log-rank P = 0.75; Fig.",C0549183|C0229090|C0450371|C0439231|C0450371|C0008107|G0000000|C0439231|C0230425|C0446516|C0450371|C0439231|C0450371|C0008107|G0000000|C0439231|C1628324|C0076080|C1708728|C0369773|G0000000|C0450371|C0349966
Two-dimensional kinematic analysis was used to determine the displacement of the hyoid bone and the angular variation of the epiglottis using human anatomy-based coordinates.,Two-dimensional kinematic analysis determine displacement hyoid bone angular variation epiglottis human anatomy-based coordinates.,C1705052|C0600169|C0002778|G0000000|C0012725|C0020417|C0262950|C0205143|C0205419|C0014540|C0086418|C2987514|C0427184
Comparable HI antibody titers were determined for both vaccines.,Comparable HI antibody titers determined vaccines.,G0000000|C0018619|C0003241|C0475208|G0000000|C0042210
Analyses were also conducted to examine the effect of age on any association between vitamin E or vitamin C and cataract.,Analyses conducted examine age association vitamin E vitamin C cataract.,C0002778|C0004927|G0000000|C0001779|C0004083|C0042890|G0000000|C0042890|G0000000|C0086543
"Autotitration CPAP showed no significant advantage over fixed pressure CPAP based on the outcome measures of AHI, ESS, and CPAP usage.","Autotitration CPAP advantage fixed pressure CPAP based outcome measures AHI, ESS, CPAP usage.",G0000000|C0199451|G0000000|C0443218|C0033095|C0199451|C1527178|C1274040|C0079809|G0000000|C0206630|C0199451|C0457083
"This left 948 controls (556 men, 392 women) and 854 cases (281 with proximal colon cancer [152 men, 129 women], 260 with distal colon cancer [160 men, 100 women], and 313 with rectal cancer [213 men, 100 women]) available for this analysis.","This left 948 controls (556 men, 392 women) 854 (281 proximal colon cancer [152 men, 129 women], 260 distal colon cancer [160 men, 100 women], 313 rectal cancer [213 men, 100 women]) analysis.",G0000000|C0205091|C1442061|C0243148|C1442061|C0025266|C1442061|C0043210|C1442061|C1442061|C0205107|C0009368|C0006826|C1442061|C0025266|C1442061|C0043210|C1442061|C0205108|C0009368|C0006826|C1442061|C0025266|C1442061|C0043210|C1442061|C0205052|C0006826|C1442061|C0025266|C1442061|C0043210|C0002778
"The use of purposeful activity as a non-pharmacological intervention for people with dementia has shown promise for enhancing quality of life (QOL) and reducing behaviors such as agitation and depression (Brooker et al., 2007).","The purposeful activity non-pharmacological intervention people dementia promise enhancing quality life (QOL) reducing behaviors agitation depression (Brooker al., 2007).",G0000000|C1285529|C0205177|C1518422|C0886296|C0027361|C0011265|C1555307|C2349975|C0332306|C0376558|C0518214|C0392756|C0004927|C0085631|C0011570|G0000000|C0202311|G0000000
"Dietary supplements of tyrosine increased plasma tyrosine concentrations; however, no change in test performance was found across the tyrosine and placebo phases of the study.","Dietary supplements tyrosine increased plasma tyrosine concentrations; however, change test performance tyrosine placebo phases study.",C0012155|C0242295|C0041485|C0205217|C0032105|C0041485|C0086045|G0000000|C0392747|C0022885|C0597198|C0041485|C0032042|C0585064|C0557651
"[7] Lesional score was calculated by addition of erythema score, scaling score and number of lesions score, wherein presence or absence of erythema meant an erythema score of 1 and 0 respectively; presence or absence of scaling meant a scaling score of 1 and 0 respectively; <30 lesions was given a score of 1, 30–100 lesions were given a score of 2 and >100 lesions scored 3.","[7] Lesional score calculated addition erythema score, scaling score lesions score, presence absence erythema meant erythema score 1 0 respectively; presence absence scaling meant scaling score 1 0 respectively; <30 lesions score 1, 30–100 lesions score 2 >100 lesions scored 3.",G0000000|C0221198|C0449820|C0444686|C0332287|C0041834|C0449820|C0237849|C0449820|C0221198|C0449820|C0150312|C0332197|C0041834|C0444504|C0041834|C0449820|G0000000|G0000000|G0000000|C0150312|C0332197|C0237849|C0444504|C0237849|C0449820|G0000000|G0000000|G0000000|C0450371|C0221198|C0449820|G0000000|G0000000|C0221198|C0449820|G0000000|C1442061|C0221198|C0449820|G0000000
"For the research, the instruments used were as follows: an Ultrasound (US) machine, a questionnaire on disability designed by Roland and Morris and a scale that measures pain by expression.","For research, instruments follows: Ultrasound (US) machine, questionnaire disability designed Roland Morris scale measures pain expression.",G0000000|C0035168|C0348000|C0332283|C0041618|G0000000|C0336779|C0034394|C0231170|C1707689|G0000000|G0000000|C0175659|C0079809|C0030193|C0185117
"Increases in dietary intakes of vitamin B12, folate and vitamin A documented in the present study were also detected in haematological indicators of micronutrient status (Siega‐Riz et al.","Increases dietary intakes vitamin B12, folate vitamin A documented study detected haematological indicators micronutrient status (Siega‐Riz et al.",C0205217|C0012155|C1512806|C0042890|G0000000|C0178638|C0042890|G0000000|C1301725|C0557651|C0442726|C0018943|C0021212|C0040577|C0449438|G0000000|G0000000
"The primary objectives are to Provide a preliminary estimate of the effectiveness of POD compared with standard care as measured by the incidence of new-onset delirium within 10 days of hospital admission (anticipated primary outcome for a definitive trial) Assess the variability of the incidence of new-onset delirium within 10 days of hospital admission in both treatment groups Estimate the intracluster correlation coefficient and likely cluster size Assess barriers to the delivery of the POD system of care Assess compliance with the POD system of care Estimate recruitment and follow-up rates at both patient and cluster levels Assess the degree of contamination at ward level due to between-ward staff movements Investigate differences in financial costs and benefits between the POD system of care and standard practice  Our secondary objectives are to investigate differences in the number, severity and length of delirium episodes (including persistent delirium); length of stay in hospital; in-hospital mortality; destination at discharge; health-related quality of life and health resource use; physical and social independence; anxiety and depression; and patient experience.","The primary objectives Provide preliminary estimate effectiveness POD compared standard care measured incidence new-onset delirium 10 days hospital admission (anticipated primary outcome definitive trial) Assess variability incidence new-onset delirium 10 days hospital admission treatment Estimate intracluster correlation coefficient cluster size Assess barriers delivery POD system care Assess compliance POD system care Estimate recruitment follow-up rates patient cluster levels Assess degree contamination ward level between-ward staff movements Investigate differences financial costs benefits POD system care standard practice Our secondary objectives investigate differences number, severity length delirium episodes (including persistent delirium); length stay hospital; in-hospital mortality; destination discharge; health-related quality life health resource use; physical social independence; anxiety depression; patient experience.",G0000000|C0205225|C0018017|C1999230|C0439611|C0750572|C1280519|G0000000|C1707455|C1442989|C1947933|C0444706|C0021149|C0746890|C0011206|C0450371|C0439228|C0019994|C0184666|C3840775|C0205225|C1274040|C0443196|C0008976|C1516048|C2827666|C0021149|C0746890|C0011206|C0450371|C0439228|C0019994|C0184666|C0039798|C0750572|G0000000|C1707520|C1707429|C1555715|C0456389|C1516048|C1706912|C0011209|G0000000|C0449913|C1947933|C1516048|C0009563|G0000000|C0449913|C1947933|C0750572|C2949735|C0589120|C0871208|C0030705|C1555715|C0441889|C1516048|C0441889|C0259846|C1305702|C0441889|C1305702|C0851286|C0026649|C1292732|C1705241|C0376243|C0010186|C0814225|G0000000|C0449913|C1947933|C1442989|C0237607|G0000000|C0027627|C0018017|C1292732|C1705241|C0237753|C0439793|C1444754|C0011206|C0332189|C0332257|C0205322|C0011206|C1444754|G0000000|C0019994|C0019994|C0026565|C0079220|C0012621|C0018684|C0332306|C0376558|C0018684|C0035201|C0042153|C0031809|C0728831|C0085862|C0003467|C0011570|C0030705|C0237607
"The observed percentages (see Figure 2) indicate that at the 36-month postbaseline assessment, 1.4% of the adolescents in Familias Unidas + PATH reported smoking in the 90 days prior to assessment, compared to 10% in ESOL + PATH and 14.3% in ESOL + HEART.","The observed percentages (see Figure 2) 36-month postbaseline assessment, 1.4% adolescents Familias Unidas + PATH reported smoking 90 days prior assessment, compared 10% ESOL + PATH 14.3% ESOL + HEART.",G0000000|C1441672|C0439165|C0042789|G0000000|G0000000|C0450371|G0000000|C1261322|G0000000|C0205653|G0000000|G0000000|G0000000|C0919386|C0684224|C0037369|C0450371|C0439228|C0332152|C1261322|C1707455|C0450371|G0000000|G0000000|C0919386|C0450371|G0000000|G0000000|C0018787
"Both groups also improved significantly on one leg stance time, tandem stance time, cadence and double support percent (Table 2) at post-testing.","Both improved leg stance time, tandem stance time, cadence double support percent (Table 2) post-testing.",G0000000|C0184511|C0023216|G0000000|C0040223|C0075804|G0000000|C0040223|G0000000|C0205173|C0183683|C0439165|C0039224|G0000000|C0687676
Incidence and mortality rates were calculated as the number of cases of CRC divided by the person years of observation.,Incidence mortality rates calculated CRC divided person observation.,C0021149|C0026565|C0871208|C0444686|C0009402|C0332849|C0027361|C0302523
Main outcomes measures Survival to hospital discharge; return of spontaneous circulation; admission to hospital.,Main outcomes measures Survival hospital discharge; return spontaneous circulation; admission hospital.,C0205225|C1274040|C0079809|C0038952|C0019994|C0012621|C0332156|C0205359|C0005775|C0184666|C0019994
"Patients with less than complete response (CR) and without disease progression at the end of four cycles could additionally receive dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 from cycle 5 onwards.","Patients complete response (CR) disease progression cycles additionally receive dexamethasone 20 Days 1, 2, 4, 5, 8, 9, 11 12 cycle 5 onwards.",C0030705|C0205197|C0871261|C0201975|C0012634|C0242656|C1511572|G0000000|C1514756|C0011777|C0450371|C0439228|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|C0450371|C1511572|G0000000|G0000000
"Implementation of blood pressure protocol by treatment group Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.","Implementation blood pressure protocol treatment Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.",C1708476|C0005767|C0033095|C0442711|C0039798|C0000723|C0037623|C0005767|C0033095|C0536221|C0012000|C0005767|C0033095|G0000000|C0039155|C0005767|C0033095
The “natural” exophily was 22% and mortality was nil.,The “natural” exophily 22% mortality nil.,G0000000|G0000000|G0000000|C0450371|C0026565|C0442734
"Psycho-social outcomes included lower levels of depressive symptoms (EPDS), distressing flashbacks of the birth and improved parenting confidence (PSOC).","Psycho-social outcomes included lower levels depressive symptoms (EPDS), distressing flashbacks birth improved parenting confidence (PSOC).",C0728831|C1274040|C0332257|C0441994|C0441889|G0000000|C0683368|C0451144|C0231303|C0236720|C0005615|C0184511|C0085092|C0237529|G0000000
Vitamin D deficiency was not a possible risk factor for gestational diabetes in pregnant women.,Vitamin D deficiency risk factor gestational diabetes pregnant women.,C0042890|C0073187|C0011155|C0035647|C1521761|C0439671|C0011847|C0549206|C0043210
"The study was not powered for secondary efficacy variables, including QOL.","The study powered secondary efficacy variables, including QOL.",G0000000|C0557651|C0032863|C0027627|C1280519|C0439828|C0332257|C0518214
"The Disabilities of the Arm, Shoulder and Hand (DASH) and Constant scores will be gathered at the 6 weeks, 3 and 6 months and 1 year postoperative visits by the investigator [15-17].","The Disabilities Arm, Shoulder Hand (DASH) Constant scores gathered 6 weeks, 3 6 months 1 postoperative visits investigator [15-17].",G0000000|C0231170|C0446516|C0037004|C0018563|C2827624|C1547014|C0449820|G0000000|G0000000|C0439230|G0000000|G0000000|C0439231|G0000000|C0032790|C0545082|C0035173|C0450371
"Secondary outcomes will include (at 8 weeks): Number of children seizure free Responder rate, defined as the number showing more than a 50% improvement in seizure frequency compared to baseline (taken as the mean daily seizure frequency over the observation baseline period immediately preceding the 8-week review) Tolerance to KD as assessed by side effect questionnaire and blood results Relationship between medium-chain fatty acids and seizure control  Secondary outcomes will also include (at 12 months): Retention on treatment (the number of participants who remain on the KD, or the prescribed AED, at 12 months) Quality of life (as measured by the Infant Toddler Quality of Life Questionnaire) Neurodevelopmental outcome (as measured by the Vineland Adaptive Behaviour Scales)  Plasma profiles of medium-chain fatty acids will be evaluated at baseline and at 8 weeks.","Secondary outcomes (at 8 weeks): Number children seizure free Responder rate, defined 50% improvement seizure frequency compared baseline (taken daily seizure frequency observation baseline period preceding 8-week review) Tolerance KD assessed questionnaire blood Relationship medium-chain fatty acids seizure control Secondary outcomes (at 12 months): Retention treatment (the participants remain KD, prescribed AED, 12 months) Quality life (as measured Infant Toddler Quality Life Questionnaire) Neurodevelopmental outcome (as measured Vineland Adaptive Behaviour Scales) Plasma profiles medium-chain fatty acids evaluated baseline 8 weeks.",C0027627|C1274040|G0000000|G0000000|C0439230|C0237753|C0008059|C0036572|C0332296|G0000000|C0871208|C1704788|C0450371|C2986411|C0036572|C0376249|C1707455|C0168634|C1883727|C0332173|C0036572|C0376249|C0302523|C0168634|C0439531|C0332152|C0332174|C0282443|C0013220|C0026691|C1516048|C0034394|C0005767|C0439849|C0009458|G0000000|C0001128|C0036572|C0243148|C0027627|C1274040|G0000000|C0450371|C0439231|C0035280|C0039798|G0000000|C0679646|G0000000|C0026691|C0278329|C0887457|C0450371|C0439231|C0332306|C0376558|G0000000|C0444706|C0021270|C0682053|C0332306|C0376558|C0034394|C0599855|C1274040|G0000000|C0444706|C0332020|C0231193|C0004927|C0175659|C0032105|C1979963|C0009458|G0000000|C0001128|C0220825|C0168634|G0000000|C0439230
Ovarian failure was defined as amenorrhea for the preceding 6 months and follicle-stimulating hormone (FSH) levels in the post-menopausal range at 2 years.,Ovarian failure defined amenorrhea preceding 6 months follicle-stimulating hormone (FSH) levels post-menopausal range 2 years.,C0205065|C0231174|C1704788|C0002453|C0332152|G0000000|C0439231|C0018120|C0019932|G0000000|C0441889|C0232970|C1514721|G0000000|C0439234
"The average number of cycles given to patients with a CR was eight (range, two to 26) with methotrexate and four (range, two to 14) with dactinomycin.","The average cycles patients CR (range, 26) methotrexate (range, 14) dactinomycin.",G0000000|C1510992|C1511572|C0030705|C0201975|C1514721|C0450371|C0025677|C1514721|C0450371|C0010934
The primary outcome measure is the time to achieve ROSC defined as a heart rate of > 60/min for 60s defined by cardiac auscultation.,The primary outcome measure time achieve ROSC defined heart rate > 60/min 60s defined cardiac auscultation.,G0000000|C0205225|C1274040|C0079809|C0040223|G0000000|G0000000|C1704788|C0018787|C0871208|G0000000|C0450371|C1704788|C0018787|C0004339
The adjusted mean changes in HbA1c and FPG during the 24 week treatment period as well as the percentage of patients achieving a target HbA1c ≤6.5% (48 mmol/mol) are represented in Fig.,The adjusted HbA1c FPG 24 week treatment period percentage patients achieving target HbA1c ≤6.5% (48 mmol/mol) represented Fig.,G0000000|C0456081|G0000000|G0000000|C0450371|C0332174|C0039798|C0439531|C0439165|C0030705|G0000000|C1521840|G0000000|G0000000|C0450371|C3829066|C1882932|C0349966
All children were examined for clinical signs of rickets.,All children examined clinical signs rickets.,G0000000|C0008059|C0332128|C0205210|C0220912|C0035579
Less anxiety increases the chance of well-being.,Less anxiety increases chance well-being.,C0439092|C0003467|C0205217|C0237506|C0018684
"Assessments will occur at baseline and after eight weeks and will include tests of physical fitness, activity, energy cost of walking, fatigue and quality of life.","Assessments occur baseline weeks tests physical fitness, activity, energy cost walking, fatigue quality life.",C1261322|C1709305|C0168634|C0439230|C0022885|C0031809|C1456706|C0205177|C0424589|C0010186|C0080331|C0015672|C0332306|C0376558
"All participants were scheduled for individual follow up at 6 weeks, and at 3, 6, 12, and 72 months.","All participants scheduled individual follow 6 weeks, 3, 6, 12, 72 months.",G0000000|C0679646|C0086960|C0027361|C0332283|G0000000|C0439230|G0000000|G0000000|C0450371|C0450371|C0439231
"In other studies, discharge criteria have not included defecation or stoma function; such a policy might reduce hospital stay further.5,13 Avoidance of intravenous fluid overloading is an important element in many protocols.","In studies, discharge criteria included defecation stoma function; policy reduce hospital stay further.5,13 Avoidance intravenous fluid overloading element protocols.",G0000000|C0947630|C0012621|C0243161|C0332257|C0011135|C1955856|C0031843|C0242456|G0000000|C0019994|G0000000|C1517331|C0870186|C0348016|C0005889|G0000000|C0013879|C0442711
"Levels of independence and functional limitations were evaluated with regards to Activities of Daily Living using the Barthel Index (Mahony and Barthel, 1965), and disability using the modified Functional Limitation Profile (Pollard and Johnston, 2001), covering items of ambulation, body care, mobility, alertness and communication.","Levels independence functional limitations evaluated Activities Daily Living Barthel Index (Mahony Barthel, 1965), disability modified Functional Limitation Profile (Pollard Johnston, 2001), covering items ambulation, body care, mobility, alertness communication.",C0441889|C0085862|C0205245|C0449295|C0220825|C0441655|C0332173|C0376558|G0000000|C0918012|G0000000|G0000000|G0000000|C0231170|C0392747|C0205245|C0449295|C1979963|G0000000|G0000000|G0000000|C0180153|C1551338|C0080331|C0242821|C1947933|C0425245|C1443086|C0009452
"Logistic regression, adjusting for 5 age groups, was used to examine the secular trends in the prevalence of current smoking and in the quit ratio from 2002 through 2006.","Logistic regression, adjusting 5 age groups, examine secular trends prevalence current smoking quit ratio 2002 2006.",C0242415|C0684320|G0000000|G0000000|C0001779|C0441833|G0000000|C0680194|C0040833|C0033105|C0521116|C0037369|C0748223|C0456603|G0000000|G0000000
Mothers and adolescents completed self-administered surveys at baseline and at 15 months postintervention.,Mothers adolescents completed self-administered surveys baseline 15 months postintervention.,C0026591|C0205653|C0205197|C1519231|C0038951|C0168634|C0450371|C0439231|G0000000
"The Vineland Adaptive Behavior Scales (VABS) [Sparrow and Cicchetti, 1984] is an informant-based scale covering domains of communication, daily living skills, socialization, motor skills, and maladaptive behavior.","The Vineland Adaptive Behavior Scales (VABS) [Sparrow Cicchetti, 1984] informant-based scale covering domains communication, daily living skills, socialization, motor skills, maladaptive behavior.",G0000000|C0332020|C0231193|C0004927|C0175659|C0582680|C0326914|G0000000|G0000000|C1550484|C0175659|C0180153|C1880389|C0009452|C0332173|C0376558|C0678856|C0037447|C1513492|C0678856|C0233532|C0004927
The results showed that the incidence of positive blood culture was considerably reduced in the study group (0.20±0.41) vs. control (0.73±0.96; p = 0.065).,The incidence positive blood culture considerably reduced study (0.20±0.41) vs. control (0.73±0.96; = 0.065).,G0000000|C0021149|C0439178|C0005767|C0010453|G0000000|C0392756|C0557651|G0000000|G0000000|C0243148|G0000000|G0000000|C1442061
Relapse was defined as an increase in CDAI of >100 points.,Relapse defined increase CDAI >100 points.,C0035020|C1704788|C0442805|C0683448|C1442061|C1552961
"Inclusion criteria were age between 18 and 65 years, absence of chronic somatic or psychiatric diseases (other than migraine in the case of migraine patients) and for migraine patients duration of disease at least 1 year, less than 15 days with migraine per month, less than 10 days with acute medication, no prophylactic treatment during the 3 months before onset of the study.","Inclusion criteria age 18 65 years, absence chronic somatic psychiatric diseases (other migraine migraine patients) migraine patients duration disease 1 year, 15 days migraine month, 10 days acute medication, prophylactic treatment 3 months onset study.",C0007637|C0243161|C0001779|C0450371|C0450371|C0439234|C0332197|C0205191|C1257909|C0205487|C0012634|G0000000|C0149931|C0149931|C0030705|C0149931|C0030705|C0449238|C0012634|G0000000|C0439234|C0450371|C0439228|C0149931|C0332177|C0450371|C0439228|C0205178|C0013227|C0355642|C0039798|G0000000|C0439231|C0206132|C0557651
"The primary health outcomes of our study were diarrhoea, clinical acute lower respiratory-tract infections (ALRI), and child growth measured by height, weight and mid-upper-arm circumference.","The primary health outcomes study diarrhoea, clinical acute lower respiratory-tract infections (ALRI), child growth measured height, weight mid-upper-arm circumference.",G0000000|C0205225|C0018684|C1274040|C0557651|C0011991|C0205210|C0205178|C0441994|C0035237|C3714514|G0000000|C0008059|C0018270|C0444706|C0489786|C0005910|C0444598|C0332520
Absence of any soft tissue pathology and sinus tract.,Absence soft tissue pathology sinus tract.,C0332197|C0205358|C0040300|C0030664|C0016169|C1185740
"Mean percentage of correct C-Units, Verbs and Sentences (±SEM) for the 12 aphasic participants at the baseline (T1), at the end of treatment (T10) and at follow-up (1 month after the end of treatment) for the Broca's, Wernicke's and sham condition, respectively (SEM = error standard of the mean).","Mean percentage correct C-Units, Verbs Sentences (±SEM) 12 aphasic participants baseline (T1), treatment (T10) follow-up (1 month treatment) Broca's, Wernicke's sham condition, (SEM = error standard mean).",C0444504|C0439165|C2349182|C0439148|C0871946|C0876929|G0000000|C0450371|C0234461|C0679646|C0168634|C0041403|C0039798|G0000000|C0589120|G0000000|C0332177|C0039798|G0000000|C0043121|C0068899|C0012634|G0000000|G0000000|C0743559|C1442989|C0444504
"Adverse events were also recorded at each school visit, using adapted national EPI forms.","Adverse events recorded school visit, adapted national EPI forms.",G0000000|C0441471|C0034869|C0036375|C0545082|C2937289|C3245503|G0000000|C0348078
This study was therefore limited in that it obviously did not have sufficient power to detect a a smaller difference in lean body mass as well as any effect on CD4 counts and other parameters.,This study limited sufficient power detect difference lean body mass CD4 counts parameters.,G0000000|C0557651|C0439801|C0205410|C0032863|C0442726|C1705241|G0000000|C0242821|C0577559|C0285590|C0439157|C0449381
"The PD technical survival is defined by the discontinuation of PD therapy because of volume overload for >4 weeks under the use of 2.5% Dianeal and fulfilled the following criteria: the elevation of systolic BP >40 mmHg or diastolic BP >20 mmHg, >3 kg increase in body weight within 2 weeks, intractable generalized edema, and >8% increase in cardiothoracic ratio (CTR).","The PD technical survival defined discontinuation PD therapy volume overload >4 weeks 2.5% Dianeal fulfilled criteria: elevation systolic BP >40 mmHg diastolic BP >20 mmHg, >3 increase body weight 2 weeks, intractable generalized edema, >8% increase cardiothoracic ratio (CTR).",G0000000|G0000000|C0449851|C0038952|C1704788|C0457454|G0000000|C0039798|C0449468|G0000000|G0000000|C0439230|G0000000|G0000000|C1550543|C0243161|C0439775|C0039155|C0037623|C0450371|C0439475|C0012000|C0037623|C0450371|C0439475|G0000000|C0442805|C0242821|C0005910|G0000000|C0439230|C0205269|C0205246|C0013604|G0000000|C0442805|C4055270|C0456603|G0000000
"The secondary outcome included axial length (AL) elongation, measured by AL.","The secondary outcome included axial length (AL) elongation, measured AL.",G0000000|C0027627|C1274040|C0332257|C0205131|C1444754|C0202311|G0000000|C0444706|C0202311
There were no serious adverse events attributable to the vaccine.,There adverse events attributable vaccine.,G0000000|G0000000|C0441471|C0596130|C0042210
"BiFlex therapy was also associated with improved functional outcome, indicated by improvement in FOSQ score.","BiFlex therapy improved functional outcome, improvement FOSQ score.",G0000000|C0039798|C0184511|C0205245|C1274040|C2986411|G0000000|C0449820
"Therefore, we used the K-MBI as a measure of basic daily functions and categorized the functional outcome into 4 parts: basic ADL (K-MBI), balance (BBS), ambulatory function, and motor function of the paretic lower limb.","Therefore, K-MBI measure basic daily functions categorized functional outcome 4 parts: basic ADL (K-MBI), balance (BBS), ambulatory function, motor function paretic lower limb.",G0000000|C0597277|C0079809|C1527178|C0332173|C0542341|C0871968|C0205245|C1274040|G0000000|C0449719|C1527178|C0001288|C0597277|C0014653|G0000000|C0439841|C0031843|C1513492|C0031843|G0000000|C0441994|C0015385
Emergency unblinding for toxicity management was permitted.,Emergency unblinding toxicity management permitted.,C0013956|C3897431|C0040539|C0001554|C0329040
"We hypothesized that smoking cessation counseling for caregivers and classroom-based education for children can produce behavior change in caregivers, leading to a reduction in children’s exposure to ETS, and a decrease the urinary cotinine level of the children.","We hypothesized smoking cessation counseling caregivers classroom-based education children produce behavior change caregivers, leading reduction children’s exposure ETS, decrease urinary cotinine level children.",G0000000|G0000000|C0037369|C1880019|C0010210|C0085537|C0870287|C0013621|C0008059|G0000000|C0004927|C0392747|C0085537|C0332152|C0301630|G0000000|C0274281|G0000000|C0392756|C0042027|C0010194|C0441889|C0008059
"Additional end points with specified noninferiority hypotheses were overall survival, prostate cancer–specific survival, time to local progression, and time to biochemical recurrence.","Additional noninferiority hypotheses survival, prostate cancer–specific survival, time local progression, time biochemical recurrence.",C1524062|G0000000|C1512571|C0038952|C0033572|G0000000|C0038952|C0040223|C0205276|C0242656|C0040223|C0205474|C0034897
"For all of the outcome measures proposed a priori, a combination of CBT and amitriptyline resulted in greater reductions in days with headache and migraine-related disability compared with headache education and amitriptyline.","For outcome measures proposed priori, combination CBT amitriptyline reductions days headache migraine-related disability compared headache education amitriptyline.",G0000000|C1274040|C0079809|C1553874|G0000000|C0205195|C0009244|C0002600|C0301630|C0439228|C0018681|C0149931|C0231170|C1707455|C0018681|C0013621|C0002600
This trend continued for both groups after the intervention ended (See Table 2 and Fig.,This trend continued intervention (See Table 2 Fig.,G0000000|C1521798|C0549178|C0886296|C0042789|C0039224|G0000000|C0349966
"Based on our fall data, a sample size of 292 participants per exercise group would be required to detect differences for the number of fallers between the two interventions.42 Our study had several limitations.","Based fall data, sample size 292 participants exercise required detect differences fallers interventions.42 Our study limitations.",C1527178|C0085639|C1511726|C0370003|C0456389|C1442061|C0679646|C0015259|C1514873|C0442726|C1705241|G0000000|C0886296|G0000000|C0557651|C0449295
"Secondary outcomes were the difference in the mean number of hours on each day that physical cooling was used; the difference in the mean arterial pressure, and the difference in the mean intracranial pressure during the 72-hour study treatment period.","Secondary outcomes difference hours day physical cooling used; difference arterial pressure, difference intracranial pressure 72-hour study treatment period.",C0027627|C1274040|C1705241|C0439227|C0332173|C0031809|C0678568|C1273517|C1705241|C0003842|C0033095|C1705241|C0524466|C0033095|C0450371|C0557651|C0039798|C0439531
Approximately 66% of intervention group students planned to quit within the next 12 months compared with 57% of control students.,Approximately 66% intervention students planned quit 12 months compared 57% control students.,C0332232|C0450371|C0886296|C0038492|C1301732|C0748223|C0450371|C0439231|C1707455|C0450371|C0243148|C0038492
"(A) Pain perception at the injection site of IFN-β1a was assessed using the visual analog scale at month 1, and at 6 and 12 months after starting PEA treatment (600 mg/day, p.o.).","(A) Pain perception injection site IFN-β1a assessed visual analog scale month 1, 6 12 months starting PEA treatment (600 mg/day, p.o.).",G0000000|C0030193|C0030971|C0021485|C0205145|G0000000|C1516048|C0234621|C0243071|C0175659|C0332177|G0000000|G0000000|C0450371|C0439231|C0439659|C0030738|C0039798|C1442061|C0439422|C0369773
"Secondary endpoints included OS (in the ITT and MET-positive populations), overall response rate (ORR), and safety.","Secondary endpoints included OS (in ITT MET-positive populations), response rate (ORR), safety.",C0027627|C2349179|C0332257|C0229090|G0000000|G0000000|C0268621|C0032659|C0871261|C0871208|G0000000|C0036043
"Patients also reported if they used the second dose as rescue medication or to treat the relapse of headache within 48 h and the severity of headache 0.5, 1, 1.5 and 2 h after the second dose intake.","Patients reported dose rescue medication treat relapse headache 48 severity headache 0.5, 1, 1.5 2 dose intake.",C0030705|C0684224|C0178602|G0000000|C0013227|C0087111|C0035020|C0018681|C0450371|C0439793|C0018681|G0000000|G0000000|G0000000|G0000000|C0178602|C1512806
"Furthermore, simvastatin had no effect on lung function, quality of life, the rate of severe adverse events, or mortality.","Furthermore, simvastatin lung function, quality life, rate severe adverse events, mortality.",G0000000|C0074554|C0024109|C0031843|C0332306|C0376558|C0871208|C0205082|G0000000|C0441471|C0026565
"Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency ⩽2/year (p = 0.04), and sputum purulence score >5 (p = 0.03).","Logistic regression models revealed response sputum volume fluticasone treatment placebo subgroups patients 24 hour sputum volume <30 (p = 0.04), exacerbation frequency ⩽2/year (p = 0.04), sputum purulence score >5 (p = 0.03).",C0242415|C0684320|C3161035|C0443289|C0871261|C0038056|C0449468|C0082607|C0039798|C0032042|C1079230|C0030705|C0450371|C0439227|C0038056|C0449468|C0450371|C0369773|G0000000|C0450371|G0000000|C0376249|G0000000|C0369773|G0000000|C0450371|C0038056|C0854358|C0449820|G0000000|C0369773|G0000000|C0450371
"During monthly clinic visits, blood samples were obtained for pharmacokinetic analysis, participant diaries were collected, interviews related to quality of life questionnaires were conducted (months 3,6,9, and 12), adverse events and concomitant medications were discussed, and study capsules were dispensed.","During monthly clinic visits, blood samples pharmacokinetic analysis, participant diaries collected, interviews quality life questionnaires conducted (months 3,6,9, 12), adverse events concomitant medications discussed, study capsules dispensed.",G0000000|C0332177|C0002424|C0545082|C0005767|C0370003|C0201734|C0002778|C0679646|C0376660|C1516695|C0021822|C0332306|C0376558|C0034394|C0004927|C0439231|G0000000|C0450371|G0000000|C0441471|C0521115|C0013227|C2584313|C0557651|C0006935|C1880359
Quality of life as measured by the Cornell Brown Scale improved for both groups but the MSA group was significantly better (P < .02).,Quality life measured Cornell Brown Scale improved MSA (P < .02).,C0332306|C0376558|C0444706|G0000000|C0678579|C0175659|C0184511|G0000000|C0369773|G0000000|C0450371
Progression-free survival was significantly improved.,Progression-free survival improved.,C0242656|C0038952|C0184511
"For all analyses, only the assigned study arm was included as a covariate, with the exception of a multivariable analysis performed for the primary outcome of malaria incidence, which also included other covariates that were thought to be potential independent risk factors for malaria.","For analyses, assigned study arm included covariate, exception multivariable analysis performed primary outcome malaria incidence, included covariates potential independent risk factors malaria.",G0000000|C0002778|C1516050|C0557651|C0446516|C0332257|G0000000|C1554961|G0000000|C0002778|C0884358|C0205225|C1274040|C0024530|C0021149|C0332257|G0000000|C3245505|C0085862|C0035647|C1521761|C0024530
"For other measures (cumulative hours of headache on headache days, frequency of headache episodes, and percentage with severe Headache Impact Test (HIT)-6 score, and total HIT-6 and Migraine-Specific Quality of Life Questionnaire scores), there were also large mean improvements from baseline.","For measures (cumulative hours headache headache days, frequency headache episodes, percentage severe Headache Impact Test (HIT)-6 score, total HIT-6 Migraine-Specific Quality Life Questionnaire scores), improvements baseline.",G0000000|C0079809|C1511559|C0439227|C0018681|C0018681|C0439228|C0376249|C0018681|C0332189|C0439165|C0205082|C0018681|C1825598|C0022885|C0272285|C0449820|C0439175|C0272285|C0149931|C0332306|C0376558|C0034394|C0449820|C2986411|C0168634
"Primary treatment outcomes were pain intensity ratings (0–10 NRS) and activity limitations on the Child Activity Limitations Interview, both completed via an online daily diary.","Primary treatment outcomes pain intensity ratings (0–10 NRS) activity limitations Child Activity Limitations Interview, completed online daily diary.",C0205225|C0039798|C1274040|C0030193|C0522510|C0871208|G0000000|C2240043|C0205177|C0449295|C0008059|C0205177|C0449295|C0021822|C0205197|G0000000|C0332173|C0376660
"The primary efficacy parameter was time to loss of therapeutic response (LTR), defined as time from baseline (randomization) to the first double-blind study visit in which a patient had <30% reduction in VAS pain from pre-milnacipran exposure or worsening of fibromyalgia requiring alternative treatment, as judged by the study's principal investigator.","The primary efficacy parameter time loss therapeutic response (LTR), defined time baseline (randomization) double-blind study visit patient <30% reduction VAS pain pre-milnacipran exposure worsening fibromyalgia requiring alternative treatment, judged study's principal investigator.",G0000000|C0205225|C1280519|C0549193|C0040223|C1517945|C0087111|C0871261|C0023978|C1704788|C0040223|C0168634|C0034656|C0013072|C0557651|C0545082|C0030705|C0450371|C0301630|C0042815|C0030193|C0332152|C0274281|C0332271|C0016053|G0000000|C1523987|C0039798|C0221191|C0557651|C0205225|C0035173
"Major outcome measurements included time to improvement in sore throat, time to improvement in cough, time to improvement in activity level, and subjective sense of well-being.","Major outcome measurements included time improvement sore throat, time improvement cough, time improvement activity level, subjective sense well-being.",C0205082|C1274040|C0242485|C0332257|C0040223|C2986411|C0234233|C0031354|C0040223|C2986411|C0010200|C0040223|C2986411|C0205177|C0441889|C0439655|C0036658|C0018684
"The duration of mechanical ventilation, the mortality rates in the intensive care unit, at hospital discharge, and at 7, 14, 28 and 180 days and 1 year after randomization, and adverse events were recorded.","The duration mechanical ventilation, mortality rates intensive care unit, hospital discharge, 7, 14, 28 180 days 1 randomization, adverse events recorded.",G0000000|C0449238|C0443254|C0035203|C0026565|C0871208|C0162425|C1947933|C0439148|C0019994|C0012621|G0000000|C0450371|C0450371|C1442061|C0439228|G0000000|C0034656|G0000000|C0441471|C0034869
"Primary outcome, log-transformed Wolf Motor Function Test (WMFT) time score (left) and secondary outcomes, WMFT time score (center) and patient-reported Stroke Impact Scale (SIS) hand function subscale score (right).","Primary outcome, log-transformed Wolf Motor Function Test (WMFT) time score (left) secondary outcomes, WMFT time score (center) patient-reported Stroke Impact Scale (SIS) hand function subscale score (right).",C0205225|C1274040|C1708728|C0325001|C1513492|C0031843|C0022885|G0000000|C0040223|C0449820|C0205091|C0027627|C1274040|G0000000|C0040223|C0449820|C0205099|C0747307|C0038454|C1825598|C0175659|C1704647|C0018563|C0031843|G0000000|C0449820|C0205090
The primary endpoint will be smoking cessation at eight weeks and six months.,The primary endpoint smoking cessation weeks months.,G0000000|C0205225|C2349179|C0037369|C1880019|C0439230|C0439231
"Details on compliance with study follow-up, HIV-AIDS disease progression, and mortality rates and causes of death are provided in the Supplementary Appendix.","Details compliance study follow-up, HIV-AIDS disease progression, mortality rates death provided Supplementary Appendix.",C1522508|C0009563|C0557651|C0589120|C0497169|C0012634|C0242656|C0026565|C0871208|C0011065|C1999230|G0000000|C0003617
"Although superficial heat therapy, TENS, and US are widely used for chronic low back pain, evidence-based guidelines for the treatment of chronic low back pain do not recommend any of these therapies due to lack of evidence.","Although superficial heat therapy, TENS, US chronic low pain, evidence-based guidelines treatment chronic low pain recommend therapies lack evidence.",G0000000|C0205124|C0018837|C0039798|C0014518|G0000000|C0205191|C0205251|C0030193|C3887511|C0162791|C0039798|C0205191|C0205251|C0030193|C0034866|C0087111|C0332268|C3887511
Expression of TLR2 and TLR4 in peripheral blood monocytes was determined by flow cytometry.,Expression TLR2 TLR4 peripheral blood monocytes determined flow cytometry.,C0185117|G0000000|G0000000|C0205100|C0005767|C0026473|G0000000|C0806140|C0814048
"The sum of component scores yields one global score between 0 and 21, with higher scores indicating worse sleep quality; 2) the Beck Depression Inventory II (BDI)26 which is a 21 item questionnaire used to assess the intensity of depression in clinical and normal patients.","The sum component scores yields global score 0 21, scores indicating worse sleep quality; 2) Beck Depression Inventory II (BDI)26 21 item questionnaire assess intensity depression clinical normal patients.",G0000000|C1515051|C0449432|C0449820|G0000000|C0205246|C0449820|G0000000|C0450371|C0449820|G0000000|C0332271|C0037313|C0332306|G0000000|G0000000|C0011570|C0021941|G0000000|C0006448|C0450371|C1551338|C0034394|C1516048|C0522510|C0011570|C0205210|C0205307|C0030705
"Primary outcomes were asthma self-management, symptom frequency, and quality of life (QOL); secondary outcomes were asthma medical management, school absences, days with activity limitations, and urgent health care use.","Primary outcomes asthma self-management, symptom frequency, quality life (QOL); secondary outcomes asthma medical management, school absences, days activity limitations, urgent health care use.",C0205225|C1274040|C0004096|C0086969|C1457887|C0376249|C0332306|C0376558|C0518214|C0027627|C1274040|C0004096|C0199168|C0001554|C0036375|C0424530|C0439228|C0205177|C0449295|C0439609|C0018684|C1947933|C0042153
"Efficacy, side effects, compliance, and preference were evaluated by a questionnaire and home sleep monitoring.","Efficacy, effects, compliance, preference evaluated questionnaire sleep monitoring.",C1280519|C1280500|C0009563|C0558295|C0220825|C0034394|C0037313|C0150369
"Overall survival, response rate, toxicity, and QOL were secondary end points.","Overall survival, response rate, toxicity, QOL secondary points.",C0282416|C0038952|C0871261|C0871208|C0040539|C0518214|C0027627|C1552961
"SECONDARY AND EXPLORATORY OUTCOMES LDL indicates low density lipoprotein; (SF-36), Medical Outcomes Study short form 36-item self administered questionnaire Possible antioxidant effects of the Ginkgo were investigated using assays involving antibodies to epitopes of oxidized LDL.","SECONDARY AND EXPLORATORY OUTCOMES LDL low density lipoprotein; (SF-36), Medical Outcomes Study short form 36-item administered questionnaire Possible antioxidant effects Ginkgo investigated assays involving antibodies epitopes oxidized LDL.",C0027627|G0000000|G0000000|C1274040|G0000000|C0205251|C0178587|C0023820|C0037712|C0199168|C1274040|C0557651|C1282927|C0348078|C0450371|C1521801|C0034394|C0332149|C0003402|C1280500|C0330205|C1292732|C0005507|C1314939|C0003241|C0003316|C0030011|G0000000
"Office blood pressure was measured three times after 10 min of rest using an automated clinical digital sphygmomanometer (Dynamap, Tampa, FL, USA) with appropriately sized cuff placed around the upper arm at heart level.","Office blood pressure measured times 10 min rest automated clinical digital sphygmomanometer (Dynamap, Tampa, FL, USA) appropriately sized cuff upper arm heart level.",C0442603|C0005767|C0033095|C0444706|C0040223|C0450371|C0702093|C0035253|C0205554|C0205210|C0442015|C0183427|G0000000|G0000000|C1708024|C0041703|G0000000|C0456389|C0441107|C1282910|C0446516|C0018787|C0441889
The primary outcome was whether a CD was inserted on the side of the pneumothorax within 6 hours of diagnosis.,The primary outcome CD inserted pneumothorax 6 hours diagnosis.,G0000000|C0205225|C1274040|C0007928|C0441587|C0032326|G0000000|C0439227|C0011900
"Secondary outcomes were ICU and hospital mortality, incidence of delirium, nurse workload, self-extubation and psychological distress six months after ICU discharge.","Secondary outcomes ICU hospital mortality, incidence delirium, nurse workload, self-extubation psychological distress months ICU discharge.",C0027627|C1274040|C0021708|C0019994|C0026565|C0021149|C0011206|C0028661|C0085122|C0036588|C0205486|C0231303|C0439231|C0021708|C0012621
"There were significant reductions in the frequency and depth of desaturations, the phasic Edi, and in the amount of infant and caretaker movement.","There reductions frequency depth desaturations, phasic Edi, amount infant caretaker movement.",G0000000|C0301630|C0376249|C0205125|C0746961|C0205390|G0000000|C1265611|C0021270|C0335350|C0026649
"Mean time to extubation, defined as time to extubation after discontinuation of anaesthesia, was significantly lesser in the sevoflurane and desflurane groups compared with the isoflurane group (P value=0.001).","Mean time extubation, defined time extubation discontinuation anaesthesia, lesser sevoflurane desflurane compared isoflurane (P value=0.001).",C0444504|C0040223|C0553891|C1704788|C0040223|C0553891|C0457454|C0002903|C0547044|C0074414|C0063252|C1707455|C0022180|C0369773|C1522609
Upper extremity test results The Fugl-Meyer (UE-FM) maximum score is 66.BBT is in # of blocks in 1 min The results of the Functional Test for the upper extremity (UE-FT) are shown in Table 7.,Upper extremity test The Fugl-Meyer (UE-FM) maximum score 66.BBT # blocks 1 min The Functional Test upper extremity (UE-FT) Table 7.,C1282910|C0015385|C0022885|G0000000|G0000000|C3540627|C0806909|C0449820|C0450371|G0000000|C0028778|G0000000|C0702093|G0000000|C0205245|C0022885|C1282910|C0015385|C1881534|C0039224|G0000000
"There was no statistically significant rebound for the first or only episode of clinical malaria, multiple episodes of clinical malaria, mild anaemia, and moderate-to-severe anaemia.","There statistically rebound episode clinical malaria, multiple episodes clinical malaria, mild anaemia, moderate-to-severe anaemia.",G0000000|C0038215|G0000000|C0332189|C0205210|C0024530|C0439064|C0332189|C0205210|C0024530|C2945599|C0002871|C0205081|C0002871
"For this purpose, data about the sleep quantity of the subjects were recorded before and after the experience, and their beneficial sleep period was calculated accordingly.","For purpose, data sleep quantity subjects recorded experience, beneficial sleep period calculated accordingly.",G0000000|C1285529|C1511726|C0037313|C1265611|C0681850|C0034869|C0237607|G0000000|C0037313|C0439531|C0444686|G0000000
"On each visit, all subjects had their blood pressure measured by automatic cuff and the median of 3 values was recorded.","On visit, subjects blood pressure measured automatic cuff median 3 values recorded.",G0000000|C0545082|C0681850|C0005767|C0033095|C0444706|C0205554|C0441107|C0549183|G0000000|C0042295|C0034869
Criteria for classification of hearing loss are summarized in Table 1.,Criteria classification hearing loss summarized Table 1.,C0243161|C0008902|C0018767|C1517945|G0000000|C0039224|G0000000
"Safety monitoring included monthly hemoglobin levels, liver- and kidney-function tests, and pregnancy testing.","Safety monitoring included monthly hemoglobin levels, liver- kidney-function tests, pregnancy testing.",C0036043|C0150369|C0332257|C0332177|C0019046|C0441889|C0023884|C0232804|C0022885|C0032961|C0039593
The secondary end point was toxicity profile.,The secondary toxicity profile.,G0000000|C0027627|C0040539|C1979963
"After 2 months, 12 (35.3%) had > 50% reduction in seizure frequency using ITT analysis, and anybody was seizure-free.","After 2 months, 12 (35.3%) > 50% reduction seizure frequency ITT analysis, seizure-free.",G0000000|G0000000|C0439231|C0450371|C0450371|G0000000|C0450371|C0301630|C0036572|C0376249|G0000000|C0002778|C1299590
"The arithmetic means of mosquito catches per house, entomological inoculation rates before and during the intervention were compared as well as three other outcome parameters: the mean mosquito blood feeding rate, mean mortality and mean parity rates.","The arithmetic mosquito catches house, entomological inoculation rates intervention compared outcome parameters: mosquito blood feeding rate, mortality parity rates.",G0000000|C0871653|C0026584|C0596011|C0442519|C0014386|C0042196|C0871208|C0886296|C1707455|C1274040|C0449381|C0026584|C0005767|C0204695|C0871208|C0026565|C0030563|C0871208
"Therefore, it would be much useful to investigate the bimanual hands function using the grasping and visual-motor integration subtests of the Peabody motor developmental scales in the future.","Therefore, investigate bimanual hands function grasping visual-motor integration subtests Peabody motor developmental scales future.",G0000000|C1292732|C1511117|C0018563|C0031843|C0220843|C0234621|C1158478|G0000000|G0000000|C1513492|C0458003|C0175659|C0016884
"Nutritional levels of zinc supplementation given to HIV-infected adults resulted in a four-fold decrease of the likelihood of immunological failure defined as a drop of CD4+ count <200 cells/mm3 in this randomized, double-blind, placebo-controlled trial after 18 months of use, with no effect on viral load.","Nutritional levels zinc supplementation HIV-infected adults four-fold decrease likelihood immunological failure defined drop CD4+ count <200 cells/mm3 randomized, double-blind, placebo-controlled trial 18 months use, viral load.",C1521739|C0441889|C0043481|C0242297|C0019682|C0001675|C0205450|C0392756|C0033204|C0205470|C0231174|C1704788|C1321095|C0285590|C0750480|C1442061|C0007634|C0034656|C0013072|C1706408|C0008976|C0450371|C0439231|C0042153|C0521026|C1550025
"Efficacy assessments included TWSTRS total (primary end point) and subscale scores at weeks 0, 4, 8, 12; a pain visual analogue scale at weeks 0 and 4; and HRQOL assessed by the SF-36 Health Survey (SF-36; secondary end point) at weeks 0 and 8.","Efficacy assessments included TWSTRS total (primary point) subscale scores weeks 0, 4, 8, 12; pain visual analogue scale weeks 0 4; HRQOL assessed SF-36 Health Survey (SF-36; secondary point) weeks 0 8.",C1280519|C1261322|C0332257|G0000000|C0439175|C0205225|C1552961|G0000000|C0449820|C0439230|G0000000|G0000000|G0000000|C0450371|C0030193|C0234621|C0243071|C0175659|C0439230|G0000000|G0000000|G0000000|C1516048|C0037712|C0018684|C0038951|C0037712|C0027627|C1552961|C0439230|G0000000|G0000000
"Among 10th graders, 18% reported the same (Monitoring the Future, n.d.).","Among 10th graders, 18% reported (Monitoring Future, n.d.).",G0000000|G0000000|G0000000|C0450371|C0684224|C0150369|C0016884|C0369718
"78 Chinese patients with DSM-IV-diagnosed MDD, insomnia complaint, a Hamilton Rating Scale for Depression (HDRS17) score ≤ 18, and fixed antidepressant dosage.","78 Chinese patients DSM-IV-diagnosed MDD, insomnia complaint, Hamilton Rating Scale Depression (HDRS17) score ≤ 18, fixed antidepressant dosage.",C0450371|C0008120|C0030705|C0220952|C1269683|C0917801|C0277786|G0000000|C0871208|C0175659|C0011570|G0000000|C0449820|G0000000|C0450371|C0443218|C0003289|C0178602
We calculated predicted FEV1 from standard tables.21 At randomisation and during clinic visits after treatment participants completed questionnaires on negative and positive trait mood22–24 and quality of life specific to asthma (the asthma bother profile).25  In the diaries participants recorded morning and evening peak expiratory flow as the best of three attempts; perceived asthma severity on a visual analogue scale with high scores indicating worse asthma; and perceived mood on a bipolar scale with high scores indicating better mood.,We calculated predicted FEV1 standard tables.21 At randomisation clinic visits treatment participants completed questionnaires negative positive trait mood22–24 quality life specific asthma (the asthma bother profile).25 In diaries participants recorded morning evening peak expiratory flow attempts; perceived asthma severity visual analogue scale scores indicating worse asthma; perceived mood bipolar scale scores indicating mood.,G0000000|C0444686|C0681842|G0000000|C1442989|C0039224|G0000000|C0034656|C0002424|C0545082|C0039798|C0679646|C0205197|C0034394|C0205160|C0439178|C0599883|G0000000|C0332306|C0376558|C0205369|C0004096|G0000000|C0004096|G0000000|C1979963|G0000000|C0376660|C0679646|C0034869|C0332170|C0587117|C0444505|C0231800|C0806140|C1516084|C0030971|C0004096|C0439793|C0234621|C0243071|C0175659|C0449820|G0000000|C0332271|C0004096|C0030971|C0026516|C0443156|C0175659|C0449820|G0000000|C0026516
Upper-limb function will be measured by using the Upper Arm Function component of the Modified Motor Assessment Scale.,Upper-limb function measured Upper Arm Function component Modified Motor Assessment Scale.,C1140618|C0031843|C0444706|C1282910|C0446516|C0031843|C0449432|C0392747|C1513492|C1261322|C0175659
"Thus, failure to achieve a PSA ≤ 0.2 ng/mL may identify patients who might benefit from earlier intensification of therapy.","Thus, failure achieve PSA ≤ 0.2 ng/mL identify patients benefit earlier intensification therapy.",G0000000|C0231174|G0000000|C3810537|G0000000|G0000000|C0439275|G0000000|C0030705|C0814225|C1279919|G0000000|C0039798
"In harmony with the decrease in IOP, we found a significant decrease in the postoperative vertical (11.75 (0.75) mm) and horizontal (11.75 (0.75) mm) corneal diameters in the trabeculotomy eyes (p<0.1 and p<0.01, respectively) when compared with the preoperative ones (12.18 (0.53) mm and 12.50 (0.59) mm, respectively; table 33).","In harmony decrease IOP, decrease postoperative vertical (11.75 (0.75) mm) horizontal (11.75 (0.75) mm) corneal diameters trabeculotomy eyes (p<0.1 p<0.01, respectively) compared preoperative (12.18 (0.53) mm 12.50 (0.59) mm, respectively; table 33).",G0000000|C0699798|C0392756|C0595921|C0392756|C0032790|C0205128|C0450371|G0000000|C0205126|C0450371|G0000000|C0010031|C1301886|C0040576|C0015392|C0369773|C0369773|G0000000|C1707455|C0445204|C0450371|G0000000|C0450371|G0000000|G0000000|C0039224|C0450371
The use of neuraminidase inhibitors decreases the length of hospital stay and admission to intensive care and/or death.,The neuraminidase inhibitors decreases length hospital stay admission intensive care and/or death.,G0000000|C0027803|C0243077|C0442797|C1444754|C0019994|G0000000|C0184666|C0162425|C1947933|G0000000|C0011065
Diarrhea was graded weekly according the Common Toxicity Criteria (CTC) system.,Diarrhea graded weekly Common Toxicity Criteria (CTC) system.,C0011991|C0441800|C0332174|C0205214|C0040539|C0243161|G0000000|C0449913
"The primary outcome in both stages was decline in the ALS Functional Rating Scale-revised (ALSFRSr) score33, 34 from baseline to 9 months.","The primary outcome stages decline ALS Functional Rating Scale-revised (ALSFRSr) score33, 34 baseline 9 months.",G0000000|C0205225|C1274040|C1306673|G0000000|G0000000|C0205245|C0871208|C0175659|G0000000|G0000000|C0450371|C0168634|G0000000|C0439231
The single patient with P. malariae infection was randomized to artemether-lumefantrine and responded with prompt parasite clearance and an ACPR at days 28 and 42.,The single patient P. malariae infection randomized artemether-lumefantrine responded prompt parasite clearance ACPR days 28 42.,G0000000|C0037179|C0030705|C0369773|G0000000|C0009450|C0034656|C0936150|G0000000|C0871157|C0030498|C0449297|G0000000|C0439228|C0450371|C0450371
The primary end point was the combination of all coronary heart disease events (non-fatal and fatal) and all strokes.,The primary combination coronary heart disease events (non-fatal fatal) strokes.,G0000000|C0205225|C0205195|C0018787|C0018787|C0012634|C0441471|C1518422|C1302234|C0038454
"A 23-item screening-instrument based on the Modified Checklist for Autism in Toddlers (MCHAT) was applied to detect children with a greater range of autistic traits, using a cut-off at two or more out of the six critical items or any three items of the total scale (Dumont-Mathieu & Fein 2005;Snow & Lecavalier 2008).","A 23-item screening-instrument based Modified Checklist Autism Toddlers (MCHAT) applied detect children range autistic traits, cut-off critical items items total scale (Dumont-Mathieu & Fein 2005;Snow & Lecavalier 2008).",G0000000|C0450371|C0220908|C1527178|C0392747|C1707357|C0004352|C0682053|G0000000|C4048755|C0442726|C0008059|C1514721|C0004352|C0599883|C1442160|C1511545|C1551338|C1551338|C0439175|C0175659|G0000000|G0000000|G0000000|C0037386|G0000000|G0000000|G0000000
"Results: The median number of reflux events/hour (1.58 v 1.68), acid reflux events/hour (0.26 v 0.43), minimum distal or proximal pH, total acid clearance time per hour (time with pH below pH 4), and total reflux duration per hour were not significantly different after GI than after placebo.","Results: The median reflux events/hour (1.58 1.68), acid reflux events/hour (0.26 0.43), minimum distal proximal pH, total acid clearance time hour (time pH pH 4), total reflux duration hour GI placebo.",C1274040|G0000000|C0549183|C0017168|C0441471|C0450371|C0450371|C0001128|C0017168|C0441471|C0450371|C0450371|C1524031|C0205108|C0205107|C0450407|C0439175|C0001128|C0449297|C0040223|C0439227|C0040223|C0450407|C0450407|G0000000|C0439175|C0017168|C0449238|C0439227|C1708130|C0032042
"However, follow-up for survival was continued.","However, follow-up survival continued.",G0000000|C0589120|C0038952|C0549178
c. Acute ankle injuries: Patient's Global Assessment of Ankle Injury Scale [27].,c. Acute ankle injuries: Patient's Global Assessment Ankle Injury Scale [27].,G0000000|C0205178|C0003086|C1510467|C0030705|C0205246|C1261322|C0003086|C3263722|C0175659|C0450371
"The emergence agitation rate while in the PACU (the length of period when the agitation scores were 4 or 5/the length of stay in the PACU) for the control group, Group I, was 0.55 ± 0.42, indicating that the emergence agitation signs were apparent for more than half of the period of stay in the PACU.","The emergence agitation rate PACU (the length period agitation scores 4 5/the length stay PACU) control group, Group I, 0.55 ± 0.42, indicating emergence agitation signs apparent half period stay PACU.",G0000000|C0750573|C0085631|C0871208|C0034871|G0000000|C1444754|C0439531|C0085631|C0449820|G0000000|G0000000|C1444754|G0000000|C0034871|C0243148|C0441833|C0441833|C0021966|C0450371|G0000000|C0450371|G0000000|C0750573|C0085631|C0220912|C0750489|C2825407|C0439531|G0000000|C0034871
"Compared with usual care, facilitated family case conferencing for residents with advanced dementia will achieve better family-rated EOL outcomes as defined by: a) better symptom-related comfort in the last 7 days of life; b) more effective symptom management over the last 90 days of life; c) greater family satisfaction with care over the last 90 days of the resident’s life.","Compared usual care, facilitated family conferencing residents advanced dementia achieve family-rated EOL outcomes defined by: a) symptom-related comfort 7 days life; b) effective symptom management 90 days life; c) family satisfaction care 90 days resident’s life.",C1707455|C3538928|C1947933|G0000000|C0015576|G0000000|C1320928|C0205179|C0011265|G0000000|C0015576|G0000000|C1274040|C1704788|G0000000|G0000000|C1457887|C1331418|G0000000|C0439228|C0376558|G0000000|C1280519|C1457887|C0001554|C0450371|C0439228|C0376558|G0000000|C0015576|C0242428|C1947933|C0450371|C0439228|G0000000|C0376558
"The following clinical outcomes (see Table Table22 for definitions) will be evaluated: 1) Transfusion Requirements (red cells, platelets and plasma), 2) Transplant Related Mortality, 3) Maximum grade of acute Graft versus Host Disease [14] 4) Veno-occlusive Disease [15], 5) Serious Infections [16], 6) Bearman Toxicity Score [17], 7) Bleeding [18], 8) Quality of Life [19,20], 9) Number of Hospitalizations and 10) Number of ICU Admissions.","The clinical outcomes (see Table Table22 definitions) evaluated: 1) Transfusion Requirements (red cells, platelets plasma), 2) Transplant Related Mortality, 3) Maximum grade acute Graft versus Host Disease [14] 4) Veno-occlusive Disease [15], 5) Serious Infections [16], 6) Bearman Toxicity Score [17], 7) Bleeding [18], 8) Quality Life [19,20], 9) Number Hospitalizations 10) Number ICU Admissions.",G0000000|C0205210|C1274040|C0042789|C0039224|G0000000|C1550452|C0220825|G0000000|C0005841|C1514873|C0332575|C0007634|C0005821|C0032105|G0000000|C0040732|C0439849|C0026565|G0000000|C0806909|C0441800|C0205178|C0181074|G0000000|C1167395|C0012634|C0450371|G0000000|C1519964|C0012634|C0450371|G0000000|C0205404|C3714514|C0450371|G0000000|G0000000|C0040539|C0449820|C0450371|G0000000|C0019080|C0450371|G0000000|C0332306|C0376558|C0450371|G0000000|C0237753|C0019993|C0450371|C0237753|C0021708|C0184666
"To measure life satisfaction, the Brief Multidimensional Life Satisfaction Scale (BMLSS) was applied.","To measure life satisfaction, Brief Multidimensional Life Satisfaction Scale (BMLSS) applied.",C0040363|C0079809|C0376558|C0242428|C1282927|C2347299|C0376558|C0242428|C0175659|G0000000|C4048755
The wounds were inspected every two days until healing.,The wounds inspected days healing.,G0000000|C0021501|G0000000|C0439228|C0043240
The first procedure involves a rapid extraction of 25(OH) D and other hydroxylated metabolites from serum or plasma with acetonitrile.,The procedure involves rapid extraction 25(OH) D hydroxylated metabolites serum plasma acetonitrile.,G0000000|C0184661|G0000000|C0456962|C0185115|C0450371|C0073187|G0000000|C0870883|C0229671|C0032105|C0050456
"Unfortunately, however, overall participation rates were low (12% of smokers in 24 months) so that the potential benefits of the free cessation programs were not maximized.","Unfortunately, however, participation rates low (12% smokers 24 months) potential benefits free cessation programs maximized.",G0000000|G0000000|C0679823|C0871208|C0205251|C0450371|C0337664|C0450371|C0439231|C3245505|C0814225|C0332296|C1880019|C0376691|G0000000
"Univariate regression analyses also indicated that meibum saturated FA levels (P = .09), Schirmer scores (P < .01), TBUT (P = .01), meibomian gland stenosis (P < .01), meibomian gland blockage (P < .01), fluorescein staining (P < .01), and rose bengal staining (P < .01) were significantly correlated with meibum score.","Univariate regression analyses meibum saturated FA levels (P = .09), Schirmer scores (P < .01), TBUT (P = .01), meibomian gland stenosis (P < .01), meibomian gland blockage (P < .01), fluorescein staining (P < .01), rose bengal staining (P < .01) correlated meibum score.",G0000000|C0684320|C0002778|G0000000|C0522534|G0000000|C0441889|C0369773|G0000000|C0450371|C1875738|C0449820|C0369773|G0000000|C0450371|G0000000|C0369773|G0000000|C0450371|G0000000|C1285092|C0678234|C0369773|G0000000|C0450371|G0000000|C1285092|C1706968|C0369773|G0000000|C0450371|C0060520|C0487602|C0369773|G0000000|C0450371|C0035853|C0444826|C0487602|C0369773|G0000000|C0450371|C1707520|G0000000|C0449820
2003; Heiss et al.,2003; Heiss al.,G0000000|G0000000|C0202311
"The prespecified primary outcome, change in RASS score from immediately before blinded study medication administration (time 0) to 8 hours, was compared between study groups by using the Wilcoxon rank sum test.","The prespecified primary outcome, change RASS score blinded study medication administration (time 0) 8 hours, compared study Wilcoxon rank sum test.",G0000000|G0000000|C0205225|C1274040|C0392747|C0034678|C0449820|C0150108|C0557651|C0013227|C0001554|C0040223|G0000000|G0000000|C0439227|C1707455|C0557651|G0000000|C0699794|C1515051|C0022885
"Past 12-week frequency of substance use was assessed using the Time-Line Follow Back (TLFB; Sobell, Sobell, Litten, & Allen, 1992) at 12, 24, and 36 weeks after the end of treatment by research assistants not blinded to condition (due to staffing and budgetary constraints).","Past 12-week frequency substance assessed Time-Line Follow Back (TLFB; Sobell, Sobell, Litten, & Allen, 1992) 12, 24, 36 weeks treatment assistants blinded condition (due staffing budgetary constraints).",C1444637|C0450371|C0376249|C0439861|C1516048|C0145943|C0332283|C0004600|C0814210|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C0439230|C0039798|C0011327|C0150108|C0012634|C0678226|C0851286|C0006347|C0443288
The primary measure of stress was the Perceived Stress Scale.,The primary measure stress Perceived Stress Scale.,G0000000|C0205225|C0079809|C0038435|C0030971|C0038435|C0175659
"No significant differences were observed in primary endpoints, including changes in atheroma volume index (−12.65% vs. −8.51%, p=0.768) and percent atheroma volume (−4.36% vs. −9.98%, p=0.526), and in secondary endpoints including a change in neointimal volume index (7.84 vs. 4.94 mm3/mm, p=0.087).","No differences observed primary endpoints, including atheroma volume (−12.65% vs. −8.51%, p=0.768) percent atheroma volume (−4.36% vs. −9.98%, p=0.526), secondary endpoints including change neointimal volume (7.84 vs. 4.94 mm3/mm, p=0.087).",G0000000|C1705241|C1441672|C0205225|C2349179|C0332257|C0264956|C0449468|G0000000|G0000000|G0000000|C0369773|C0439165|C0264956|C0449468|G0000000|G0000000|G0000000|C0369773|C0027627|C2349179|C0332257|C0392747|C2936380|C0449468|C0450371|G0000000|C0450371|G0000000|C0369773
(C–E) Effects on hemodynamics.,(C–E) Effects hemodynamics.,G0000000|C1280500|C0019010
"Furthermore, consumption of micronutrient fortified yoghurt reduced the worsening of vitamin A and iodine status that was observed in control group there by showing a significant difference in RBP levels and urinary iodine excretion.","Furthermore, consumption micronutrient fortified yoghurt reduced worsening vitamin A iodine status observed control difference RBP levels urinary iodine excretion.",G0000000|C0009830|C0040577|G0000000|C0043419|C0392756|C0332271|C0042890|G0000000|C0021966|C0449438|C1441672|C0243148|C1705241|C1419339|C0441889|C0042027|C0021966|C0221102
"Prior to the second test, blood samples were drawn to measure the fasting basal levels of GH, IGF-I, adrenocorticotropic hormone (ACTH), and cortisol.","Prior test, blood samples drawn measure fasting basal levels GH, IGF-I, adrenocorticotropic hormone (ACTH), cortisol.",C0332152|C0022885|C0005767|C0370003|C0013113|C0079809|C0015663|C0205112|C0441889|C0033993|C0021665|G0000000|C0019932|C3539087|C0020268
"The distribution of the number of days of illness, days with respiratory and gastrointestinal symptoms, and the symptom scores and days of absence due to illness were skewed to the right and were logarithmically transformed.","The distribution days illness, days respiratory gastrointestinal symptoms, symptom scores days absence illness skewed logarithmically transformed.",G0000000|C0520511|C0439228|C0221423|C0439228|C0521346|C0521362|C0683368|C1457887|C0449820|C0439228|C0332197|C0221423|G0000000|G0000000|C1510411
"The secondary end points were OS, overall response rate (ORR), time-to-treatment failure (TTF), and safety.","The secondary OS, response rate (ORR), time-to-treatment failure (TTF), safety.",G0000000|C0027627|C0229090|C0871261|C0871208|G0000000|C3494202|C0231174|C1332112|C0036043
Subjects’ disposition The primary outcomes of our analyses were the mean variation of ADMA and EDSS score during study in the two groups.,Subjects’ disposition The primary outcomes analyses variation ADMA EDSS score study groups.,G0000000|C0743223|G0000000|C0205225|C1274040|C0002778|C0205419|G0000000|C0451246|C0449820|C0557651|C0441833
"The secondary objectives are (1) to assess the impact on the patient’s median survival time, mood and illness understanding, (2) the impact on informal caregivers’ quality of life, mood, illness understanding and satisfaction with care during treatment and after the death of the patient and (3) to examine whether systematic early integration of palliative care, alongside hospital treatment and treatment characteristics, influences advance care planning and end-of-life decision-making.","The secondary objectives (1) assess impact patient’s median survival time, mood illness understanding, (2) impact informal caregivers’ quality life, mood, illness understanding satisfaction care treatment death patient (3) examine systematic integration palliative care, alongside hospital treatment treatment characteristics, influences advance care planning end-of-life decision-making.",G0000000|C0027627|C0018017|G0000000|C1516048|C1825598|G0000000|C0549183|C0038952|C0040223|C0026516|C0221423|C0162340|G0000000|C1825598|G0000000|G0000000|C0332306|C0376558|C0026516|C0221423|C0162340|C0242428|C1947933|C0039798|C0011065|C0030705|G0000000|G0000000|C0220922|C1158478|C0587605|C1947933|G0000000|C0019994|C0039798|C0039798|C1521970|C4054723|C0725066|C1947933|C0032074|C0444930|C0011109
"Each of these includes several questions which are marked from 1 to 4, four being the worst.","Each includes questions marked 1 4, worst.",G0000000|C0332257|C1522634|C0522501|G0000000|G0000000|C1522166
"In addition, subjects were asked to rate the intensity of acupuncture-evoked sensations after the scan session using the MGH Acupuncture Sensation Scale (MASS) instrument [19].","In addition, subjects rate intensity acupuncture-evoked sensations scan session MGH Acupuncture Sensation Scale (MASS) instrument [19].",G0000000|C0332287|C0681850|C0871208|C0522510|C0001299|C0036658|C0034606|C1883016|G0000000|C0001299|C0036658|C0175659|C0577559|C0348000|C0450371
The co-primary endpoints of both studies were 1-hour morning post-dose forced expiratory volume in 1 s (FEV1) versus aclidinium and morning pre-dose (trough) FEV1 versus formoterol.,The co-primary endpoints studies 1-hour morning post-dose forced expiratory volume 1 (FEV1) versus aclidinium morning pre-dose (trough) FEV1 versus formoterol.,G0000000|C3245499|C2349179|C0947630|C0439227|C0332170|C0439568|C0441722|C0231800|C0449468|G0000000|G0000000|G0000000|C2699757|C0332170|C0439565|C0444506|G0000000|G0000000|C0060657
"Fortification of staple foods is considered an effective and safe strategy to combat micronutrient deficiencies, thereby improving health.","Fortification staple foods considered effective safe strategy combat micronutrient deficiencies, improving health.",G0000000|C0524724|C0016452|C0750591|C1280519|G0000000|C0679199|G0000000|C0040577|C0011155|C1272745|C0018684
"Through these interventions, it is hoped that vaccination uptake will be increased.","Through interventions, hoped vaccination uptake increased.",G0000000|C0886296|C0392347|C0042196|C0243144|C0205217
The magnitude of the effect size of comparing the third and 6th weeks of PUS group and KM group of pain intensity and disability index was shown in Table 4.,The magnitude size comparing 6th weeks PUS KM pain intensity disability Table 4.,G0000000|C0449286|C0456389|C1707455|G0000000|C0439230|C0034161|G0000000|C0030193|C0522510|C0231170|C0039224|G0000000
"Event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS) were defined as recommended [31].","Event-free survival (EFS), relapse-free survival (RFS) survival (OS) defined recommended [31].",C0441471|C0038952|C0242793|C0035020|C0038952|C0341703|C0038952|C0229090|C1704788|C0034866|C0450371
"In those with bilateral symptoms, the arm with the most severe symptoms was chosen, and treatment of this arm was randomised.","In bilateral symptoms, arm severe symptoms chosen, treatment arm randomised.",G0000000|C0238767|C0683368|C0446516|C0205082|C0683368|C1707391|C0039798|C0446516|G0000000
The natural exophily was 34% and mortality was less than 2%.,The natural exophily 34% mortality 2%.,G0000000|C0205296|G0000000|C0450371|C0026565|G0000000
"Results: Peak nocturnal transcutaneous carbon dioxide tension (TcCO2) did not differ between the groups, but the mean (SD) percentage of the night during which TcCO2 was >6.5 kPa decreased in the NIV group (–57.7 (26.1)%) but not in controls (–11.75 (46.1)%; p = 0.049, 95% CI –91.5 to –0.35).","Results: Peak nocturnal transcutaneous carbon dioxide tension (TcCO2) groups, (SD) percentage night TcCO2 >6.5 kPa decreased NIV (–57.7 (26.1)%) controls (–11.75 (46.1)%; = 0.049, 95% CI –91.5 –0.35).",C1274040|C0444505|C0240526|G0000000|C0007009|C0678717|C0233494|G0000000|C0441833|G0000000|C0439165|C0240526|G0000000|G0000000|C0439474|C0205216|C0598902|G0000000|C0450371|C0243148|G0000000|C0450371|G0000000|C1442061|C0450371|C0008107|G0000000|G0000000
"The primary purpose of this trial was to systematically assess the effectiveness of regular Baduanjin exercise on primary prevention of stroke in community elder population through detection of improvement in cerebrovascular function, cardiopulmonary function, and exposure of risk factors for stroke compared with people with usual physical activities.","The primary purpose trial systematically assess effectiveness regular Baduanjin exercise primary prevention stroke community elder population detection improvement cerebrovascular function, cardiopulmonary function, exposure risk factors stroke compared people usual physical activities.",G0000000|C0205225|C1285529|C0008976|G0000000|C1516048|C1280519|C0205272|G0000000|C0015259|C0205225|C0199176|C0038454|C0009462|C0331055|C0032659|C1511790|C2986411|C1880018|C0031843|C0553534|C0031843|C0274281|C0035647|C1521761|C0038454|C1707455|C0027361|C3538928|C0031809|C0441655
"Mortality in hospital, length of stay in hospital, and duration of fever.","Mortality hospital, length stay hospital, duration fever.",C0026565|C0019994|C1444754|G0000000|C0019994|C0449238|C0015967
"These are (1) score on the physical functioning scale of the SF-36 [35], (2) cost-effectiveness using the Euroqol [40] and (3) the score on the 11-item Fatigue Scale [36].","These (1) score physical functioning scale SF-36 [35], (2) cost-effectiveness Euroqol [40] (3) score 11-item Fatigue Scale [36].",G0000000|G0000000|C0449820|C0031809|C0205245|C0175659|C0037712|C0450371|G0000000|C0010181|C0451150|C0450371|G0000000|C0449820|C0450371|C0015672|C0175659|C0450371
"Height for age, weight for age, and weight for height Z-scores were calculated using the WHO Child Growth Standard (WHO Anthro software, version 3.01) [33].","Height age, weight age, weight height Z-scores calculated WHO Child Growth Standard (WHO Anthro software, version 3.01) [33].",C0489786|C0001779|C0005910|C0001779|C0005910|C0489786|C0871421|C0444686|G0000000|C0008059|C0018270|C1442989|G0000000|G0000000|C0037585|C0333052|C0450371|C0450371
The primary outcome was admission to a special care baby unit with respiratory distress.,The primary outcome admission special care baby unit respiratory distress.,G0000000|C0205225|C1274040|C0184666|C0205555|C1947933|C0021270|C0439148|C0521346|C0231303
"Known and suspected risk factors for EA were included as covariates in the model including baseline measurements—age, sex, waist:hip ratio (tertiles), and cigarette smoking (0, <20, 20-40, ≥40 pack-yr)— and measurements repeated during follow-up: nonsteroidal anti-inflammatory drug (NSAID) use (current, intermittent, never) (49), fruit and vegetable consumption, and percent energy from fat.","Known suspected risk factors EA included covariates model including baseline measurements—age, sex, waist:hip ratio (tertiles), cigarette smoking (0, <20, 20-40, ≥40 pack-yr)— measurements repeated follow-up: nonsteroidal anti-inflammatory drug (NSAID) (current, intermittent, never) (49), fruit vegetable consumption, percent energy fat.",C0205309|C0332147|C0035647|C1521761|C0014963|C0332257|G0000000|C3161035|C0332257|C0168634|G0000000|C0009253|C0230097|C0456603|G0000000|C0677453|C0037369|G0000000|C0450371|C0450371|G0000000|G0000000|C0242485|C0205341|C0589120|G0000000|C0003209|C0013227|C0003211|C0521116|C0205267|C2003901|C0450371|C0016767|C0042440|C0009830|C0439165|C0424589|C0424612
"In order to gain reliability of visual analog scale (VAS) in this study, Test-retest method with 1 month interval was used in which 15 students from each group were asked to record the intensity of dysmenorrhea at the start of menstrual pain for two consecutive cycles.","In gain reliability visual analog scale (VAS) study, Test-retest method 1 month interval 15 students record intensity dysmenorrhea start menstrual pain consecutive cycles.",G0000000|C1517378|C2347947|C0234621|C0243071|C0175659|C0042815|C0557651|C0022885|C0025663|G0000000|C0332177|C1272706|C0450371|C0038492|C0034869|C0522510|C0013390|C0439659|C0025344|C0030193|C1707491|C1511572
A brief self-management programme given during a hospital admission for acute asthma was tested to determine whether it would reduce readmission.,A self-management programme hospital admission acute asthma tested determine reduce readmission.,G0000000|C0086969|C1709697|C0019994|C0184666|C0205178|C0004096|C0392366|G0000000|G0000000|C1548168
"Secondary endpoints included pregnancy prevalence, and reported knowledge, behaviour and attitudes.","Secondary endpoints included pregnancy prevalence, reported knowledge, behaviour attitudes.",C0027627|C2349179|C0332257|C0032961|C0033105|C0684224|C0376554|C0004927|C0004271
Some of the sources of SARS transmission are unknown.,Some sources SARS transmission unknown.,G0000000|C0449416|C1175175|C0040722|C0439673
"Teeth were followed up considering clinical (pain, pathological mobility, tenderness to percussion and palpation, and any soft tissue pathology and sinus tract) and radiographical (pathological root resorption, reduced size or healing of existing lesion, and absence of new lesions at the interradicular or periapical area) criteria for 18 months.","Teeth clinical (pain, pathological mobility, tenderness percussion palpation, soft tissue pathology sinus tract) radiographical (pathological root resorption, reduced size healing existing lesion, absence lesions interradicular periapical area) criteria 18 months.",C0040426|C0205210|C0030193|C0030664|C0425245|C0234233|C0030987|C0030247|C0205358|C0040300|C0030664|C0016169|C1185740|C0034571|C0030664|C0040452|C2985494|C0392756|C0456389|C0043240|C2987476|C0221198|C0332197|C0221198|G0000000|C0729269|C0017446|C0243161|C0450371|C0439231
"Assessments were conducted at baseline (average of 2 days before pretest; SD, 0.71; range, 1–4 days), pretest (1 day before intervention), posttest (1 day after intervention), and follow-up (average of 101 days after completion of intervention; SD, 20.14; range, 52–153 days).","Assessments conducted baseline (average 2 days pretest; SD, 0.71; range, 1–4 days), pretest (1 day intervention), posttest (1 day intervention), follow-up (average 101 days completion intervention; SD, 20.14; range, 52–153 days).",C1261322|C0004927|C0168634|C1510992|G0000000|C0439228|C0033101|C2699239|C0450371|C1514721|G0000000|C0439228|C0033101|G0000000|C0332173|C0886296|G0000000|G0000000|C0332173|C0886296|C0589120|C1510992|C1442061|C0439228|C0205197|C0886296|C2699239|C0450371|C1514721|G0000000|C0439228
"Primary outcomes were SF-36 bodily pain (BP) and physical function (PF) scales and the modified Oswestry Disability index (ODI) assessed at 6 weeks, 3 months, 6 months and yearly up to 4 years.","Primary outcomes SF-36 bodily pain (BP) physical function (PF) scales modified Oswestry Disability (ODI) assessed 6 weeks, 3 months, 6 months yearly 4 years.",C0205225|C1274040|C0037712|G0000000|C0030193|C0037623|C0031809|C0031843|C3815179|C0175659|C0392747|G0000000|C0231170|G0000000|C1516048|G0000000|C0439230|G0000000|C0439231|G0000000|C0439231|C0332181|G0000000|C0439234
"Weight and height were measured using a calibrated electronic scale (SR Instruments, Tonowanda, NY) and stadiometer (Genentech Accustat, San Francisco, CA).","Weight height measured calibrated electronic scale (SR Instruments, Tonowanda, NY) stadiometer (Genentech Accustat, San Francisco, CA).",C0005910|C0489786|C0444706|G0000000|C0013850|C0175659|C3813610|C0348000|G0000000|C0027976|G0000000|C0331820|G0000000|C1826357|G0000000|C3887642
"Response to treatment was determined according to the last available assessment documented in the medical record for each patient, and categorized as: “complete” if there was complete resolution of KS lesions; “partial” if there was any reduction in the size and/or number of lesions; “none” if there was no response or a worsening of any lesions; or “unknown” if this information was not recorded.","Response treatment determined assessment documented medical record patient, categorized as: “complete” complete resolution KS lesions; “partial” reduction size and/or lesions; “none” response worsening lesions; “unknown” recorded.",C0871261|C0039798|G0000000|C1261322|C1301725|C0199168|C0034869|C0030705|C0871968|G0000000|G0000000|C0205197|C1514893|C0022773|C0221198|G0000000|C0301630|C0456389|G0000000|C0221198|G0000000|C0871261|C0332271|C0221198|G0000000|C0034869
"Currently, there is no consensus on what changes in HFPTA thresholds are of clinical use.","Currently, consensus HFPTA thresholds clinical use.",C0521116|C0376298|G0000000|C0449864|C0205210|C0042153
The primary outcome is death in hospital within 28 days of injury (cause-specific mortality will also be recorded).,The primary outcome death hospital 28 days injury (cause-specific mortality recorded).,G0000000|C0205225|C1274040|C0011065|C0019994|C0450371|C0439228|C3263722|C0015127|C0026565|C0034869
Comparison of (A) cumulative recurrence rate and (B) survival rate in the control and observation groups.,Comparison (A) cumulative recurrence rate (B) survival rate control observation groups.,C1707455|G0000000|C1511559|C0034897|C0871208|G0000000|C0038952|C0871208|C0243148|C0302523|C0441833
All children were evaluated at 12 and 30 months of age on the basis of physical and neurologic examinations and developmental testing.,All children evaluated 12 30 months age basis physical neurologic examinations developmental testing.,G0000000|C0008059|C0220825|C0450371|C0450371|C0439231|C0001779|C1527178|C0031809|C0205494|C0031809|C0458003|C0039593
The primary outcome of the study was change in pH in venous blood gas samples at 60 and 120 minutes.,The primary outcome study change pH venous blood gas samples 60 120 minutes.,G0000000|C0205225|C1274040|C0557651|C0392747|C0450407|C0042449|C0005767|C0017110|C0370003|C0450371|C1442061|C0439232
"PHYS-STROKE is powered to detect a difference in gait speed of 0.13 m/s, and a difference in Barthel Index of 10 points between the two groups.","PHYS-STROKE powered detect difference gait speed 0.13 m/s, difference Barthel Index 10 groups.",C0038454|C0032863|C0442726|C1705241|C0016928|C0678536|C0450371|C0439493|C1705241|G0000000|C0918012|C0450371|C0441833
"Sleep parameters were assessed after 3, 12, and 24 weeks, by the Pittsburgh Sleep Quality Index (PSQI)36 global score and individual components and by a sleep diary that documented number and duration of midsleep awakenings.","Sleep parameters assessed 3, 12, 24 weeks, Pittsburgh Sleep Quality Index (PSQI)36 global score individual components sleep diary documented duration midsleep awakenings.",C0037313|C0449381|C1516048|G0000000|C0450371|C0450371|C0439230|G0000000|C0037313|C0332306|C0918012|C3697468|C0205246|C0449820|C0027361|C0449432|C0037313|C0376660|C1301725|C0449238|G0000000|C1720052
"Patients on investigational clinical trials and their caregivers experience poor quality of life (QOL), which declines as the disease progresses.","Patients investigational clinical trials caregivers experience poor quality life (QOL), declines disease progresses.",C0030705|C1517586|C0205210|C0008976|C0085537|C0237607|C0032854|C0332306|C0376558|C0518214|G0000000|C0012634|C1272688
"The UTI leading to enrollment was both febrile and symptomatic for 323 children, febrile only in 197 children, and symptomatic only in 86.","The UTI leading enrollment febrile symptomatic 323 children, febrile 197 children, symptomatic 86.",G0000000|C0042029|C0332152|C1516879|C0015967|C0231220|C1442061|C0008059|C0015967|C1442061|C0008059|C0231220|C0450371
The primary endpoint was at 6 weeks with additional follow-up at 3 and 6 months.,The primary endpoint 6 weeks additional follow-up 3 6 months.,G0000000|C0205225|C2349179|G0000000|C0439230|C1524062|C0589120|G0000000|G0000000|C0439231
"Controls were matched (1 : 1) on gender, age (within 1 year), smoking status (current, past, never, unknown) and month of toenail collection.","Controls matched (1 : 1) gender, age (within 1 year), smoking status (current, past, never, unknown) month toenail collection.",C0243148|C0150103|G0000000|C0079399|C0001779|G0000000|G0000000|C0439234|C0037369|C0449438|C0521116|C1444637|C2003901|C0439673|C0332177|C0222007|C1516698
"Long dwell UF volume, long dwell peritoneal creatininine clearance, and peritoneal urea nitrogen clearance were calculated (5).","Long dwell UF volume, dwell peritoneal creatininine clearance, peritoneal urea nitrogen clearance calculated (5).",C0205166|G0000000|G0000000|C0449468|G0000000|C0031153|G0000000|C0449297|C0031153|C0041942|C0028158|C0449297|C0444686|G0000000
"To evaluate if maternal probiotic supplementation modulated the cytokine profile and sIgA in breast milk, two samples of maternal milk were collected by manual extraction: colostrum within 72 h after delivery (T0) and mature milk at 30 days postpartum (T30).","To evaluate maternal probiotic supplementation modulated cytokine profile sIgA breast milk, samples maternal milk collected manual extraction: colostrum 72 delivery (T0) mature milk 30 days postpartum (T30).",C0040363|C0220825|C2347083|C0525033|C0242297|C0443264|C0079189|C1979963|C0020838|C0006141|C0026131|C0370003|C2347083|C0026131|C1516695|C0024763|C0185115|C0009413|C0450371|C0011209|C0041403|C0205286|C0026131|C0450371|C0439228|C0086839|G0000000
"All the pulpotomized teeth were evaluated clinically and radiographically using predetermined criteria[13] (clinical: Pain, tenderness, mobility, swelling, sinus; radiographic: Widening of periodontal ligament space, radiolucency, root resorption, pulp obliteration) after 1, 3, 6, 9, and 12 months.","All pulpotomized teeth evaluated clinically radiographically predetermined criteria[13] (clinical: Pain, tenderness, mobility, swelling, sinus; radiographic: Widening periodontal ligament space, radiolucency, root resorption, pulp obliteration) 1, 3, 6, 9, 12 months.",G0000000|G0000000|C0040426|C0220825|G0000000|G0000000|G0000000|C0243161|C0205210|C0030193|C0234233|C0425245|C0013604|C0016169|C0444708|C0332464|C2960678|C0023685|C1883067|C2827491|C0040452|C2985494|C0011399|C0332465|G0000000|G0000000|G0000000|G0000000|C0450371|C0439231
"PA was assessed using the Community Health Activities Model Program for Seniors questionnaire.35 This questionnaire was developed for use in older adults and is sensitive to change.36 Dietary intake data were averaged from two unannounced 24-hour recalls at each time point using the Nutrition Data System for Research software (Version 2006; Nutrition Coordinating Center, Minneapolis, MN).37,38 Global scores for DQ were generated using the Healthy Eating Index 2005 criteria39 and methods used previously40 (ie, using tallied weighted scores for consumption of total and saturated fat, added fats and sugars, dairy products, protein sources, fruits and vegetables, and whole grains).","PA assessed Community Health Activities Model Program Seniors questionnaire.35 This questionnaire developed adults sensitive change.36 Dietary intake data averaged unannounced 24-hour recalls time Nutrition Data System Research software (Version 2006; Nutrition Coordinating Center, Minneapolis, MN).37,38 Global scores DQ generated Healthy Eating Index 2005 criteria39 methods previously40 (ie, tallied weighted scores consumption total saturated fat, fats sugars, dairy products, protein sources, fruits vegetables, grains).",C0030428|C1516048|C0009462|C0018684|C0441655|C3161035|C1709697|C1456594|C0034394|G0000000|C0034394|G0000000|C0001675|C0020517|C0392747|C0012155|C1512806|C1511726|C1510992|G0000000|C0450371|C0034770|C0040223|C0028707|C1511726|C0449913|C0035168|C0037585|C0333052|G0000000|C0028707|C0427184|C0205099|G0000000|C0026405|C0205246|C0449820|G0000000|C3146294|C3898900|C0013470|C0918012|G0000000|G0000000|C0025663|G0000000|G0000000|G0000000|C0005910|C0449820|C0009830|C0439175|C0522534|C0424612|C0015677|C0242209|C3687582|C1514468|C0033684|C0449416|C0016767|C0042440|C0086369
"To establish the preliminary efficacy of SHARP to improve cognitive, behavioral, psychosocial, and quality of life outcomes.","To establish preliminary efficacy SHARP improve cognitive, behavioral, psychosocial, quality life outcomes.",C0040363|C0443211|C0439611|C1280519|C1444775|G0000000|C1516691|C0004927|C0542298|C0332306|C0376558|C1274040
Patients were included if they spoke English or French and had depression and/or anxiety symptoms as indicated by scores of ≥6 on the Patient Health Questionnaire (PHQ-9) and/or General Anxiety Disorder-7 (GAD-7) scales.,Patients included spoke English French depression and/or anxiety symptoms scores ≥6 Patient Health Questionnaire (PHQ-9) and/or General Anxiety Disorder-7 (GAD-7) scales.,C0030705|C0332257|G0000000|C0376245|C0376246|C0011570|G0000000|C0003467|C0683368|C0449820|G0000000|C0030705|C0018684|C0034394|C1879301|G0000000|C0205246|C0003467|C0012634|C0270549|C0175659
"Children completed measures of self efficacy, coping, and quality of life; parents completed measures of family functioning (adaptability, cohesion), diabetes-related conflict, parent depression and parent coping.","Children completed measures efficacy, coping, quality life; parents completed measures family functioning (adaptability, cohesion), diabetes-related conflict, parent depression parent coping.",C0008059|C0205197|C0079809|C1280519|C0009967|C0332306|C0376558|C0030551|C0205197|C0079809|C0015576|C0205245|C0237451|C0597767|C1261139|C0009671|C0030551|C0011570|C0030551|C0009967
Multiple malaria episodes and hospital admissions were assessed using Generalised Estimating Equations (GEE) Poisson regression models to take into account intra-individual correlation [48].,Multiple malaria episodes hospital admissions assessed Generalised Estimating Equations (GEE) Poisson regression models account intra-individual correlation [48].,C0439064|C0024530|C0332189|C0019994|C0184666|C1516048|C0205246|C0750572|C0552449|G0000000|G0000000|C0684320|C3161035|C2741673|C0347985|C1707520|C0450371
"Furthermore, walking, and Nordic walking improved stride length, gait variability, maximal walking speed, exercise capacity at submaximal level, and PD disease-specific disability on the UPDRS in addition.","Furthermore, walking, Nordic walking improved stride length, gait variability, maximal walking speed, exercise capacity submaximal level, PD disease-specific disability UPDRS addition.",G0000000|C0080331|C0331873|C0080331|C0184511|G0000000|C1444754|C0016928|C2827666|C0205289|C0080331|C0678536|C0015259|C1516240|G0000000|C0441889|G0000000|C0012634|C0231170|C3639721|C0332287
These differences were not statistically significant (log-rank P = 0.260 for PFS and P = 0.217 for OS).,These differences statistically (log-rank P = 0.260 PFS P = 0.217 OS).,G0000000|C1705241|C0038215|C1708728|G0000000|C0242792|G0000000|C0229090
"All patients registered once a day before bed-time (at 23-h) the VAS resembling the pain average of the day, the final daily consumption of oral morphine and the listed adverse effects.","All patients registered day bed-time (at 23-h) VAS resembling pain average day, final daily consumption oral morphine listed adverse effects.",G0000000|C0030705|C1514821|C0332173|C0521112|G0000000|C0450371|C0042815|G0000000|C0030193|C1510992|C0332173|C0205088|C0332173|C0009830|C0442027|C0026549|C0745732|G0000000|C1280500
RESULTS—There were no significant differences between the inhaled steroids on bone markers of bone resorption and formation or bone mineral density.,RESULTS—There differences inhaled steroids bone markers bone resorption formation bone mineral density.,G0000000|C1705241|C0004048|C0038317|C0262950|C0005516|C0262950|C2985494|C0220781|C0262950|C0006660|C0178587
"Secondary outcomes include the duration and severity of delirium, quality of life, length of stay and the use of care services up to three months after hospital discharge.","Secondary outcomes duration severity delirium, quality life, length stay care services months hospital discharge.",C0027627|C1274040|C0449238|C0439793|C0011206|C0332306|C0376558|C1444754|G0000000|C1947933|C0557854|C0439231|C0019994|C0012621
"Secondary outcomes were: 12 weeks CMAI; 6 and 12 weeks Neuropsychiatric symptoms (NPI), Clinical Global Impression Change (CGI-C), Standardised Mini Mental State Examination, Severe Impairment Battery.","Secondary outcomes were: 12 weeks CMAI; 6 12 weeks Neuropsychiatric symptoms (NPI), Clinical Global Impression Change (CGI-C), Standardised Mini Mental State Examination, Severe Impairment Battery.",C0027627|C1274040|G0000000|C0450371|C0439230|G0000000|G0000000|C0450371|C0439230|G0000000|C0683368|C1412208|C0205210|C0205246|C0596764|C0392747|C3639708|G0000000|C0445542|C0229992|C1301808|G0000000|C0205082|C0221099|C0337088
"Communication was assessed with the Peabody Picture Vocabulary Test (which asks individuals to point to a picture after hearing a word and is a standard measure of receptive vocabulary) and the Expressive Vocabulary Test (where the examiner points to a picture and asks the individual to state the name, which is a standard measure of expressive vocabulary).","Communication assessed Peabody Picture Vocabulary Test (which individuals picture hearing word standard measure receptive vocabulary) Expressive Vocabulary Test (where examiner picture individual name, standard measure expressive vocabulary).",C0009452|C1516048|G0000000|C0441468|C0042926|C0022885|G0000000|C0027361|C0441468|C0018767|C1705313|C1442989|C0079809|C0544683|C0042926|C0185117|C0042926|C0022885|G0000000|G0000000|C0441468|C0027361|C0027365|C1442989|C0079809|C0185117|C0042926
"Main outcome measures were child psychopathology, attachment disorder, self esteem, and cost of foster care.","Main outcome measures child psychopathology, attachment disorder, esteem, cost foster care.",C0205225|C1274040|C0079809|C0008059|C0033927|C0185023|C0012634|C0679133|C0010186|C0242298|C1947933
"Comparison of type of surgery in both groups Behaviour during emergence was rated on a 4-point scale:[5,6] 1) calm; 2) not calm but could be easily calmed; 3) not easily calmed, moderately agitated or restless; and 4) combative, excited, or disoriented.","Comparison type surgery Behaviour emergence rated 4-point scale:[5,6] 1) calm; 2) calm easily calmed; 3) easily calmed, moderately agitated restless; 4) combative, excited, disoriented.",C1707455|C0332307|C0038894|C0004927|C0750573|C0871208|C1552961|C0175659|G0000000|C0522165|G0000000|C0522165|C0332219|C0522165|G0000000|C0332219|C0522165|C0205081|C0085631|C0085631|G0000000|C0241845|C0549255|C0233407
The time to first day of poorly controlled asthma was 97 days in the eformoterol group compared with 42 days in the placebo group (p=0.003).,The time day controlled asthma 97 days eformoterol compared 42 days placebo (p=0.003).,G0000000|C0040223|C0332173|C2587213|C0004096|C0450371|C0439228|C0060657|C1707455|C0450371|C0439228|C0032042|C0369773
At this time staff were also responsible for the monthly ascertainment of all falls and fractures of participants already enrolled onto the study.,At time staff responsible monthly ascertainment falls fractures participants enrolled study.,G0000000|C0040223|C0851286|C1273518|C0332177|G0000000|C0000921|C0016658|C0679646|G0000000|C0557651
"Secondary endpoints of interest were length of stay, total days intubated, age at feeding initiation, days to 100ml/kg/day of enteral feeds, as well as rates of necrotizing enterocolitis and sepsis.","Secondary endpoints length stay, total days intubated, age feeding initiation, days 100ml/kg/day enteral feeds, rates necrotizing enterocolitis sepsis.",C0027627|C2349179|C1444754|G0000000|C0439175|C0439228|G0000000|C0001779|C0204695|C0589507|C0439228|C0439418|C1304890|C1510670|C0871208|C0439664|C0014356|C0036690
"Baseline assessment included asthma and medical history, vital signs, physical examination, routine blood tests, chest radiography, spirometry and clinical events related to asthma within the previous year, including asthma exacerbations, need for systemic corticosteroids, ED visits and hospitalizations for asthma.","Baseline assessment included asthma medical history, vital signs, physical examination, routine blood tests, chest radiography, spirometry clinical events asthma previous year, including asthma exacerbations, systemic corticosteroids, ED visits hospitalizations asthma.",C0168634|C1261322|C0332257|C0004096|C0199168|C0019664|C0442732|C0220912|C0031809|G0000000|C0205547|C0005767|C0022885|C0817096|C0034571|C0037981|C0205210|C0441471|C0004096|C0205156|C0439234|C0332257|C0004096|G0000000|C0205373|C0001617|C3538926|C0545082|C0019993|C0004096
Perioperative depressive symptoms (PDS) are common mental comorbidities that influence clinical outcomes and prognosis.,Perioperative depressive symptoms (PDS) common mental comorbidities influence clinical outcomes prognosis.,C1518988|G0000000|C0683368|G0000000|C0205214|C0229992|C0009488|C4054723|C0205210|C1274040|C0033325
"Fifth, due to the certain number of cases in some categories of green tea consumption, we could not perform the analyses for subcategories of CVD and site-specific cancer.","Fifth, categories green tea consumption, perform analyses subcategories CVD site-specific cancer.",C0205439|C0683312|C0332583|C0039400|C0009830|C0884358|C0002778|C1515010|C0007222|C0449604|C0006826
"Functional outcomes were assessed by measuring the upper eyelid margin position below the superior limbus following this scale: very good (<3 mm), good (3–5 mm), poor (>5 mm).8 Aesthetic outcomes were assessed in terms of uniform eyelid contour, eyelid height symmetry between both eyes, and formed eyelid crease as in normal anatomical measures.","Functional outcomes assessed measuring upper eyelid margin position superior limbus scale: (<3 mm), (3–5 mm), poor (>5 mm).8 Aesthetic outcomes assessed terms uniform eyelid contour, eyelid height symmetry eyes, formed eyelid crease normal anatomical measures.",C0205245|C1274040|C1516048|C0444706|C1282910|C0015426|C0205284|C0733755|C1282910|C0443251|C0175659|G0000000|G0000000|G0000000|G0000000|C0032854|G0000000|G0000000|C0014901|C1274040|C1516048|C0233324|C0205375|C0015426|C0302821|C0015426|C0489786|C0332516|C0015392|C0205431|C0015426|G0000000|C0205307|C0220784|C0079809
"In the subgroup with IHC-identified PTEN loss, median PFS was 2.73 months with afatinib plus temozolomide, compared with 1.87 months with temozolomide monotherapy (HR = 0.96; Table 5).","In subgroup IHC-identified PTEN loss, median PFS 2.73 months afatinib temozolomide, compared 1.87 months temozolomide monotherapy (HR = 0.96; Table 5).",G0000000|C1079230|C0021044|C0694888|C1517945|C0549183|C0242792|C0450371|C0439231|C2987648|C0076080|C1707455|C0450371|C0439231|C0076080|G0000000|G0000000|G0000000|C0450371|C0039224|G0000000
1Percentage of informed persons at the time of commencement of the activity.,1Percentage informed persons time commencement activity.,G0000000|C1522154|C0027361|C0040223|G0000000|C0205177
"For both 18F-FCWAY and 18F-FDG PET, there was a significant relation between the clinical scan classification and surgery outcome.","For 18F-FCWAY 18F-FDG PET, relation clinical scan classification surgery outcome.",G0000000|G0000000|C0046056|C0031268|C0080103|C0205210|C0034606|C0008902|C0038894|C1274040
"Interview two (t2; two weeks after baseline) was designed to represent the midway point in either receiving the BIS intervention for the intervention arm or the waiting-list period for the controls; interview three (t3) was designed to represent completion of BIS for the intervention arm, or the end of the waiting-list period prior to commencing BIS for the controls; interview four (t4) was designed to represent the midway point in receiving the BIS intervention for the controls (no t4 was conducted with patients and carers on the intervention arm); and the final interview (t5; eight weeks from baseline) was designed to represent four weeks after BIS for the intervention arm, and the completion of BIS for the controls.","Interview (t2; weeks baseline) designed represent midway receiving BIS intervention intervention arm waiting-list period controls; interview (t3) designed represent completion BIS intervention arm, waiting-list period prior commencing BIS controls; interview (t4) designed represent midway receiving BIS intervention controls (no t4 conducted patients carers intervention arm); final interview (t5; weeks baseline) designed represent weeks BIS intervention arm, completion BIS controls.",C0021822|C0041403|C0439230|C0168634|C1707689|C1882932|G0000000|C1514756|C0556985|C0886296|C0886296|C0446516|C0043010|C0439531|C0243148|C0021822|C0041403|C1707689|C1882932|C0205197|C0556985|C0886296|C0446516|C0043010|C0439531|C0332152|C3274784|C0556985|C0243148|C0021822|C0041403|C1707689|C1882932|G0000000|C1514756|C0556985|C0886296|C0243148|G0000000|C0041403|C0004927|C0030705|C0085537|C0886296|C0446516|C0205088|C0021822|C0041403|C0439230|C0168634|C1707689|C1882932|C0439230|C0556985|C0886296|C0446516|C0205197|C0556985|C0243148
Secondary outcomes will be changes in parental efficacy for protecting children’s oral health and changes in children’s dental behaviors.,Secondary outcomes parental efficacy protecting children’s oral health children’s dental behaviors.,C0027627|C1274040|C0030551|C1280519|G0000000|G0000000|C0442027|C0018684|G0000000|C0011365|C0004927
"study[23] diastolic blood pressure decreased similarly in both groups, but systolic blood pressure decreased only in the almond group.","study[23] diastolic blood pressure decreased groups, systolic blood pressure decreased almond group.",C0557651|C0012000|C0005767|C0033095|C0205216|C0441833|C0039155|C0005767|C0033095|C0205216|C0440286|C0441833
"None of the cancer patients took either TT or ET, Table 1.","None cancer patients TT ET, Table 1.",G0000000|C0006826|C0030705|C1452561|G0000000|C0039224|G0000000
"The secondary efficacy variables included trough FEV1 after one dose (assessed pre-dose on Day 2) and after 29 days, individual time point FEV1 on Day 1 and at Week 12 (change from baseline), peak FEV1 on Day 1 and at Week 12 (assessed between 5 min and 4 h post-dose), and standardised area under the curve (AUC) for FEV1 between 5 min and 4 h, 5 min and 1 h, and 1 h and 4 h at Week 12.","The secondary efficacy variables included trough FEV1 dose (assessed pre-dose Day 2) 29 days, individual time FEV1 Day 1 Week 12 (change baseline), peak FEV1 Day 1 Week 12 (assessed 5 min 4 post-dose), standardised curve (AUC) FEV1 5 min 4 h, 5 min 1 h, 1 4 Week 12.",G0000000|C0027627|C1280519|C0439828|C0332257|C0444506|G0000000|C0178602|C1516048|C0439565|C0332173|G0000000|C0450371|C0439228|C0027361|C0040223|G0000000|C0332173|G0000000|C0332174|C0450371|C0392747|C0168634|C0444505|G0000000|C0332173|G0000000|C0332174|C0450371|C1516048|G0000000|C0702093|G0000000|C0439568|G0000000|C0205134|C0376690|G0000000|G0000000|C0702093|G0000000|C0033727|G0000000|C0702093|G0000000|C0033727|G0000000|G0000000|C0332174|C0450371
"The primary outcome is the composite of stroke and death within 44 days following randomization and stroke ipsilateral to the target vessel thereafter, up to 4 years.","The primary outcome composite stroke death 44 days randomization stroke ipsilateral target vessel thereafter, 4 years.",G0000000|C0205225|C1274040|C0205199|C0038454|C0011065|C0450371|C0439228|C0034656|C0038454|C0441989|C1521840|C0005847|G0000000|G0000000|C0439234
"In scenarios, the reasons for mothers’ fear of natural delivery and CS were discussed.","In scenarios, reasons mothers’ fear natural delivery CS discussed.",G0000000|C0683579|C0392360|G0000000|C0015726|C0205296|C0011209|C0010182|C2584313
Symptoms of depression and anxiety were measured using the Patient Health Questionnaire (PHQ-9) and the General Anxiety Disorder-7 (GAD-7).,Symptoms depression anxiety measured Patient Health Questionnaire (PHQ-9) General Anxiety Disorder-7 (GAD-7).,C0683368|C0011570|C0003467|C0444706|C0030705|C0018684|C0034394|C1879301|C0205246|C0003467|C0012634|C0270549
A difference was found only at the peak amplitude of EMG burst of the temporalis muscles during RMMA episodes.,A difference peak amplitude EMG burst temporalis muscles RMMA episodes.,G0000000|C1705241|C0444505|C2346753|G0000000|C0439818|C0039487|C0026845|G0000000|C0332189
The primary outcome measure was trough FEV1 at Week 12.,The primary outcome measure trough FEV1 Week 12.,G0000000|C0205225|C1274040|C0079809|C0444506|G0000000|C0332174|C0450371
The txt2stop trial demonstrated that smoking-cessation support delivered by text message doubles biochemically verified abstinence at 6 months.,The txt2stop trial demonstrated smoking-cessation support delivered text message doubles biochemically verified abstinence 6 months.,G0000000|G0000000|C0008976|G0000000|C0085134|C0183683|C1705822|C1527021|C0470166|C0205173|G0000000|C1711411|C3843422|G0000000|C0439231
"After wearing glasses, contrast sensitivity and glare contrast sensitivity were assessed at low, medium, and high frequencies under bright and dark conditions.","After wearing glasses, contrast sensitivity glare contrast sensitivity assessed low, medium, frequencies bright dark conditions.",G0000000|G0000000|C0015421|C0009924|C0020517|C0278215|C0009924|C0020517|C1516048|C0205251|C0009458|C0439603|C0423899|C0332582|C0012634
"CAN care assessment need, CHF congestive heart failure, CASA collaborative care to alleviate symptoms and adjust to illness, COPD chronic obstructive pulmonary disease, FACT-G Functional Assessment of Cancer Therapy—General, ILD interstitial lung disease, PCP primary care provider To identify veterans with increased risk for hospitalizations or death, we use a VA-developed prognostic tool, the Care Assessment Need (CAN) score [27].","CAN care assessment need, CHF congestive heart failure, CASA collaborative care alleviate symptoms adjust illness, COPD chronic obstructive pulmonary disease, FACT-G Functional Assessment Cancer Therapy—General, ILD interstitial lung disease, PCP primary care provider To identify veterans increased risk hospitalizations death, VA-developed prognostic tool, Care Assessment Need (CAN) score [27].",G0000000|C1947933|C1261322|C0027552|C0018802|C0742742|C0018787|C0231174|C1384511|C0282116|C1947933|G0000000|C0683368|G0000000|C0221423|C0024117|C0205191|C0549186|C0024109|C0012634|C1707998|C0205245|C1261322|C0006826|G0000000|C0206062|C0596790|C0024109|C0012634|C1535939|C0205225|C1947933|C1138603|C0040363|G0000000|C0042610|C0205217|C0035647|C0019993|C0011065|C1549054|C0220901|C0336791|C1947933|C1261322|C0027552|G0000000|C0449820|C0450371
The ECF regimen resulted in a response and survival advantage compared with FAMTX chemotherapy.,The ECF regimen response survival advantage compared FAMTX chemotherapy.,G0000000|G0000000|C0040808|C0871261|C0038952|G0000000|C1707455|C0051571|C0013216
"Criteria for efficacy assessment were response rate, progression-free survival and overall survival.","Criteria efficacy assessment response rate, progression-free survival survival.",C0243161|C1280519|C1261322|C0871261|C0871208|C0242656|C0038952|C0038952
"The nerve block onset time of the motor nerves was defined as when the radial, median, ulnar, and musculocutaneous nerves scored lower than 3.","The nerve block onset time motor nerves defined radial, median, ulnar, musculocutaneous nerves scored lower 3.",G0000000|C0027740|C0028778|C0206132|C0040223|C1513492|C0027740|C1704788|C0442038|C0549183|C0442044|C0450958|C0027740|C0449820|C0441994|G0000000
"Child externalizing problems at T3+4 were related to increases in symptoms of externalizing disorders, greater substance use, and decreases in academic performance.","Child externalizing T3+4 increases symptoms externalizing disorders, substance use, decreases academic performance.",C0008059|G0000000|C0041403|C0205217|C0683368|G0000000|C0012634|C0439861|C0042153|C0442797|C1510747|C0597198
"The difference between the means of mean sedation score, emergence behaviour score, mean emergence time was statistically highly significant (P<0.001).","The difference sedation score, emergence behaviour score, emergence time statistically highly (P<0.001).",G0000000|C1705241|C0235195|C0449820|C0750573|C0004927|C0449820|C0750573|C0040223|C0038215|C0205250|C0369773
"As well, 4 postintervention patient outcomes were measured, by design only for surgeons and oncologists: patient-centerdness of the visit, satisfaction, psychological distress, and feeling better.","As well, 4 postintervention patient outcomes measured, design surgeons oncologists: patient-centerdness visit, satisfaction, psychological distress, feeling better.",G0000000|C0205170|G0000000|G0000000|C0030705|C1274040|C0444706|C1707689|C0582175|C0259990|C0030705|C0545082|C0242428|C0205486|C0231303|C0013987|C0332272
"Prior and subsequent to the treatment, the SCORAD index was evaluated and the content of Bifidobacterium bifidum in the stool of each infant in the two groups was quantified using 16S rRNA/DNA quantitative polymerase chain reaction analysis.","Prior subsequent treatment, SCORAD evaluated content Bifidobacterium bifidum stool infant quantified 16S rRNA/DNA quantitative polymerase chain reaction analysis.",C0332152|C0332282|C0039798|G0000000|C0220825|C0423896|C0005380|G0000000|C0015733|C0021270|C1709793|C0450371|C0035701|C0392762|C1335439|C0337112|C0443286|C0002778
The primary outcome is the point prevalence abstinence of 7 days at 6 months later.,The primary outcome prevalence abstinence 7 days 6 months later.,G0000000|C0205225|C1274040|C0033105|C3843422|G0000000|G0000000|C0205087
"Baseline measures also included the Hot Flash Related Daily Interference Scale (HFRDIS),2 Center for Epidemiologic Studies Depression Scale (CES-D),10 Hospital Anxiety and Depression Scale-Anxiety Subscale (HADS-A),11 and Medical Outcomes Study Sleep Scale (MOS-Sleep Scale).12 Patients then received either the hypnosis intervention or remained on a no-treatment waiting list for 5 weeks.","Baseline measures included Hot Flash Related Daily Interference Scale (HFRDIS),2 Center Epidemiologic Studies Depression Scale (CES-D),10 Hospital Anxiety Depression Scale-Anxiety Subscale (HADS-A),11 Medical Outcomes Study Sleep Scale (MOS-Sleep Scale).12 Patients received hypnosis intervention remained no-treatment waiting list 5 weeks.",C0168634|C0079809|C0332257|C0444519|C0181637|C0439849|C0332173|C0521102|C0175659|C3641714|C0205099|C0014507|C0947630|C0011570|C0175659|C2699160|C0019994|C0003467|C0011570|C0175659|G0000000|C0048008|C0199168|C1274040|C0557651|C0037313|C0175659|C3813178|C0175659|C0030705|C1514756|C0020587|C0886296|G0000000|C0039798|C1610166|C0745732|G0000000|C0439230
"Group B were treated with intralesional injection of glucantime alone until complete healing of the ulcer or for a maximum of 6 weeks, too.","Group B treated intralesional injection glucantime complete healing ulcer maximum 6 weeks, too.",C0441833|G0000000|C1522326|C1512954|C0021485|C0061366|C0205197|C0043240|C0041582|C0806909|G0000000|C0439230|G0000000
Lower-extremity muscle strength at hospital discharge will be the primary outcome measure.,Lower-extremity muscle strength hospital discharge primary outcome measure.,C0023216|C0026845|C0237897|C0019994|C0012621|C0205225|C1274040|C0079809
"There were no differences for induction of labour, epidural use, neonatal admission to a nursery or satisfaction with birth mode.","There differences induction labour, epidural use, neonatal admission nursery satisfaction birth mode.",G0000000|C1705241|C0205263|C0022864|C0228134|C0042153|C1552240|C0184666|C0028659|C0242428|C0005615|C1513371
"Baseline Demographic and Clinical Characteristics of Individuals with FM n=number of cases, y=years, %=percentage, SD=standard deviation Unadjusted statistics on primary and secondary outcomes by treatment condition over time BPI-Brief Pain Inventory, SF-36=Short Form 36, MFI=Multidimensional Fatigue Inventory, MOS=Medical Outcomes Survey, CES-D=Center for Epidemiological Studies Depression Scale, STPI=State-Trait Personality Inventory, PGIC=Patient Global Impression of Change Note.","Baseline Demographic Clinical Characteristics Individuals FM n=number cases, y=years, %=percentage, SD=standard deviation Unadjusted statistics primary secondary outcomes treatment condition time BPI-Brief Pain Inventory, SF-36=Short Form 36, MFI=Multidimensional Fatigue Inventory, MOS=Medical Outcomes Survey, CES-D=Center Epidemiological Studies Depression Scale, STPI=State-Trait Personality Inventory, PGIC=Patient Global Impression Change Note.",C0168634|C0011298|C0205210|C1521970|C0027361|C3540627|C0369718|C0868928|C0439234|C0439165|C2699239|C0012727|C1439367|C0038215|C0205225|C0027627|C1274040|C0039798|C0012634|C0040223|C1443145|C0030193|C0021941|C0037712|C0348078|C0450371|C1881923|C0015672|C0021941|C3813178|C1274040|C0038951|C2699160|C0014507|C0947630|C0011570|C0175659|C1301808|C0003944|C0021941|C0030705|C0205246|C0596764|C0392747|C1316572
"Patients were recalled after 3, 6, 9 and 12 months for clinical and radiographic evaluation.","Patients recalled 3, 6, 9 12 months clinical radiographic evaluation.",C0030705|C0034770|G0000000|G0000000|G0000000|C0450371|C0439231|C0205210|C0444708|C0220825
We compared the Demodex count and OSDI score change of the two groups.,We compared Demodex count OSDI score change groups.,G0000000|C1707455|C0323683|C0750480|C3896641|C0449820|C0392747|C0441833
aThe number of patients screened for eligibility was not available.,aThe patients screened eligibility available.,G0000000|C0030705|C0220908|C0013893|C0470187
Corneal (p = 0.014) and nasal conjunctival staining (p = 0.043) were reduced with SIME in per‐protocol patients (n = 24).,Corneal (p = 0.014) nasal conjunctival staining (p = 0.043) reduced SIME per‐protocol patients (n = 24).,C0010031|C0369773|G0000000|C1442061|C0028429|C0009758|C0487602|C0369773|G0000000|C1442061|C0392756|G0000000|G0000000|C0030705|C0369718|G0000000|C0450371
"Parental control and restrictiveness were assessed using the Child Feeding Questionnaire (CFQ), at 12 and 24 months.","Parental control restrictiveness assessed Child Feeding Questionnaire (CFQ), 12 24 months.",C0030551|C0243148|C0443288|C1516048|C0008059|C0204695|C0034394|G0000000|C0450371|C0450371|C0439231
Circulating vitamin D2 and D3 were measured in serum using direct ultraviolet detection preceded by organic extraction and high performance liquid chromatography as previously described (50).,Circulating vitamin D2 D3 measured serum direct ultraviolet detection preceded organic extraction performance liquid chromatography (50).,C0175630|C0042890|C3538936|C3538936|C0444706|C0229671|C0439851|C1532472|C1511790|C0332152|C0747055|C0185115|C0597198|C0301571|C0008550|C0450371
The Data Safety Monitoring Committee reviewed all adverse events.,The Data Safety Monitoring Committee reviewed adverse events.,G0000000|C1511726|C0036043|C0150369|C2699414|C0282443|G0000000|C0441471
"Sleep efficiency, spontaneous arousal index, and sleep architecture were unchanged with both therapies.","Sleep efficiency, spontaneous arousal index, sleep architecture unchanged therapies.",C0037313|C0013682|C0205359|C0003808|C0918012|C0037313|C0003737|C0442739|C0087111
The Combination was not better than either agent alone in lessening confirmed EDSS progression or change in MSFC over 36 months.,The Combination agent lessening confirmed EDSS progression change MSFC 36 months.,G0000000|C0205195|C0450442|G0000000|C0521093|C0451246|C0242656|C0392747|G0000000|C0450371|C0439231
"reported that aerobic exercise and strength exercise were similarly effective at improving symptoms, tender point count, fitness depression, and quality of life in FMS39).","reported aerobic exercise strength exercise effective improving symptoms, tender count, fitness depression, quality life FMS39).",C0684224|C1510824|C0015259|C0237897|C0015259|C1280519|C1272745|C0683368|C0234234|C0750480|C1456706|C0011570|C0332306|C0376558|G0000000
"Field workers visited participants at home twice a week to collect information on the number of diarrhoeal stools, days of diarrhoea, dysentery, vomiting, presence of fever (and its intensity and duration), respiratory symptoms, and drug usage through structured pre‐coded questionnaires and a modified Bristol stool form scale (available on the ADCwebsite: http://www.archdischild.com/supplemental).","Field workers visited participants week collect diarrhoeal stools, days diarrhoea, dysentery, vomiting, presence fever (and intensity duration), respiratory symptoms, drug usage structured pre‐coded questionnaires modified Bristol stool form scale (available ADCwebsite: http://www.archdischild.com/supplemental).",C0440042|C0024752|C0545082|C0679646|C0332174|G0000000|C0011991|C0015733|C0439228|C0011991|C0013369|C0042963|C0150312|C0015967|G0000000|C0522510|C0449238|C0521346|C0683368|C0013227|C0457083|C0678594|G0000000|C0034394|C0392747|G0000000|C0015733|C0348078|C0175659|C0470187|G0000000|C1555015
"Secondary endpoints were (i) the composite clinical score adjusted by co-variables (gender, age, and baseline WHO functional class), (ii) all-cause mortality, (iii) cardiovascular mortality, (iv) Kaplan–Meier analysis of major clinical events (as defined above), and (v) number of hospital admissions because of HF requiring intravenous diuretics.","Secondary endpoints (i) composite clinical score adjusted co-variables (gender, age, baseline WHO functional class), (ii) all-cause mortality, (iii) cardiovascular mortality, (iv) Kaplan–Meier analysis major clinical events (as defined above), (v) hospital admissions HF requiring intravenous diuretics.",C0027627|C2349179|C0021966|C0205199|C0205210|C0449820|C0456081|C3245499|C0079399|C0001779|C0168634|G0000000|C0205245|C0456387|G0000000|C0015127|C0026565|C0439070|C0007226|C0026565|C0022326|G0000000|C0002778|C0205082|C0205210|C0441471|G0000000|C1704788|C1282910|G0000000|C0019994|C0184666|C0018488|G0000000|C0348016|C0012798
"Youths reported their alcohol and other substance use by responding to such questions as: “During the past MONTH, how many times have you had a drink of beer or alcohol?” Scaled responses allowed youths to indicate the specific range of occurrences (Centers for Disease Control and Prevention, 1999; Oetting et al., 1994).","Youths reported alcohol substance responding questions as: “During MONTH, times drink beer alcohol?” Scaled responses allowed youths specific range occurrences (Centers Disease Control Prevention, 1999; Oetting al., 1994).",C0001578|C0684224|C0001962|C0439861|G0000000|C1522634|G0000000|G0000000|C0332177|C0040223|C0452428|C0004922|G0000000|C0175659|C0871261|C0683607|C0001578|C0205369|C1514721|C2745955|C0205099|C0012634|C0243148|C0199176|G0000000|G0000000|C0202311|G0000000
"An occupational therapist blinded to patient allocation administered two reliable measures, the Chedoke Arm and Hand Activity Inventory (CAHAI-7) and the Chedoke McMaster Stroke Assessment of the Arm and Hand (CMSA) at admission and discharge.","An occupational therapist blinded patient allocation administered reliable measures, Chedoke Arm Hand Activity Inventory (CAHAI-7) Chedoke McMaster Stroke Assessment Arm Hand (CMSA) admission discharge.",G0000000|C0521127|C0871525|C0150108|C0030705|C1706778|C1521801|C3858758|C0079809|G0000000|C0446516|C0018563|C0205177|C0021941|G0000000|G0000000|G0000000|C0038454|C1261322|C0446516|C0018563|G0000000|C0184666|C0012621
This study shows that the intervention based on the transtheoretical model had no effect on the prevalence of regular smoking.,This study intervention based transtheoretical model prevalence regular smoking.,G0000000|C0557651|C0886296|C1527178|G0000000|C3161035|C0033105|C0205272|C0037369
Secondary outcomes included clinical response for the micro-ITT and ME populations.,Secondary outcomes included clinical response micro-ITT ME populations.,C0027627|C1274040|C0332257|C0205210|C0871261|C0085672|G0000000|C0032659
Preset futility rules were met for time to persistent anal HPV infection and bHSIL after week 52.,Preset futility rules met time persistent anal HPV infection bHSIL week 52.,G0000000|C0086322|C0870077|C0268621|C0040223|C0205322|C0003461|C0021344|C0009450|G0000000|C0332174|C0450371
ARAT = Action Research Arm Test; FIM = Functional Independence Measure; SIS = Stroke Impact Scale; CIMT = constraint-induced movement therapy.,ARAT = Action Research Arm Test; FIM = Functional Independence Measure; SIS = Stroke Impact Scale; CIMT = constraint-induced movement therapy.,C1152215|G0000000|C0441472|C0035168|C0446516|C0022885|C3273671|G0000000|C0205245|C0085862|C0079809|C1704647|G0000000|C0038454|C1825598|C0175659|G0000000|G0000000|C0443288|C0026649|C0039798
The primary efficacy measure was the percentage change in daily proteinuria at 3 months by treatment group (study end).,The primary efficacy measure percentage change daily proteinuria 3 months treatment (study end).,G0000000|C0205225|C1280519|C0079809|C0439165|C0392747|C0332173|C0033687|G0000000|C0439231|C0039798|C0557651|C0444930
Four outcomes were considered: (1) parent's paper-and-pencil reports of the child's past month exposure; (2) hair samples from the child analysed for past month nicotine; (3) hair samples from the child analysed for past month cotinine; and (4) per cent confirmed reducers.,Four outcomes considered: (1) parent's paper-and-pencil reports child's month exposure; (2) hair samples child analysed month nicotine; (3) hair samples child analysed month cotinine; (4) cent confirmed reducers.,C0205450|C1274040|C0750591|G0000000|C0030551|C0030351|C0684224|C0008059|C0332177|C0274281|G0000000|C0018494|C0370003|C0008059|G0000000|C0332177|C0028040|G0000000|C0018494|C0370003|C0008059|G0000000|C0332177|C0010194|G0000000|C0562018|C0521093|G0000000
Minimal Clinically Important Difference (MCID) for the Clinical COPD Questionnaire (CCQ) by criterion referencing.,Minimal Clinically Important Difference (MCID) Clinical COPD Questionnaire (CCQ) criterion referencing.,C0547040|G0000000|G0000000|C1705241|G0000000|C0205210|C0024117|C0034394|G0000000|C0243161|C1514811
"Furthermore, there was a higher incidence of adverse events in the group that did not use sevoflurane.","Furthermore, incidence adverse events sevoflurane.",G0000000|C0021149|G0000000|C0441471|C0074414
Intraoperative and postoperative adverse events was compared among the three procedures by Fisher exact test.,Intraoperative postoperative adverse events compared procedures Fisher exact test.,C0456904|C0032790|G0000000|C0441471|C1707455|C0025664|C0325045|C2828393|C0022885
"Therefore, length of stay in hospital becomes an important characteristic of patient outcomes.","Therefore, length stay hospital characteristic patient outcomes.",G0000000|C1444754|G0000000|C0019994|C1521970|C0030705|C1274040
"vector densities, human biting rates, sporozoite rates, indoor and outdoor feeding behaviours, prevalence and intensity of resistance to pyrethroids, and estimates of entomological inoculation rates (EIR) as measured or estimated through entomological surveillance changes in community-based parasite prevalence incremental impact of combining IRS with LLINs, including assessment of the impact of new nets in year 2 correlation between incidence at community and health facility levels correlation between incidence (community and health facility) and prevalence changes in malaria prevention methods including net use and in health-seeking behaviour.","vector densities, human biting rates, sporozoite rates, indoor outdoor feeding behaviours, prevalence intensity resistance pyrethroids, estimates entomological inoculation rates (EIR) measured estimated entomological surveillance community-based parasite prevalence incremental impact combining IRS LLINs, including assessment impact nets 2 correlation incidence community health facility levels correlation incidence (community health facility) prevalence malaria prevention methods including net health-seeking behaviour.",C0086022|C0178587|C0086418|C0005658|C0871208|C0562648|C0871208|G0000000|G0000000|C0204695|C0004927|C0033105|C0522510|C0237834|C0597329|C0750572|C0014386|C0042196|C0871208|G0000000|C0444706|C0750572|C0014386|C0220920|C0009462|C0030498|C0033105|C1705117|C1825598|C0336789|G0000000|G0000000|C0332257|C1261322|C1825598|C1423506|G0000000|C1707520|C0021149|C0009462|C0018684|C1547538|C0441889|C1707520|C0021149|C0009462|C0018684|C1547538|C0033105|C0024530|C0199176|C0025663|C0332257|C1456447|C0018684|C0004927
The primary outcome is treatment adherence as measured by monthly tablet counts supplemented by two self‐completed questionnaires.,The primary outcome treatment adherence measured monthly tablet counts supplemented self‐completed questionnaires.,G0000000|C0205225|C1274040|C0039798|C1510802|C0444706|C0332177|C0039225|C0439157|C0242295|G0000000|C0034394
"It has been reported that the anti-inflammatory benefits of vitamin D and optimal immune function was seen in individuals with 25(OH)D3 as high as 100 nmol/L [30, 45].","It reported anti-inflammatory benefits vitamin D optimal immune function individuals 25(OH)D3 100 nmol/L [30, 45].",G0000000|C0684224|C0003209|C0814225|C0042890|C0073187|C2698651|C0439662|C0031843|C0027361|C0450371|C1442061|C0439282|C0450371|C0450371
"24 hours after the third dose, an echocardiography was performed, and if PDA persisted, a second course of ibuprofen treatment with three other doses was given.","24 hours dose, echocardiography performed, PDA persisted, ibuprofen treatment doses given.",C0450371|C0439227|C0178602|C0013516|C0884358|C0013274|G0000000|C0020740|C0039798|C0178602|C1442162
"The second phase introduced tDCS as a treatment, utilizing a sham-controlled partial crossover design with 2 weeks (10 days) of stimulation followed by a 2-week and a 2-month follow-up.","The phase introduced tDCS treatment, utilizing sham-controlled partial crossover design 2 weeks (10 days) stimulation 2-week 2-month follow-up.",G0000000|C0205390|C1292748|C3850024|C0039798|G0000000|C0068899|C0728938|C0010366|C1707689|G0000000|C0439230|C0450371|C0439228|C1292856|C0332174|C0332177|C0589120
"Zinc supplementation for 18 months reduced four-fold the likelihood of immunological failure, controlling for age, gender, lack of food, baseline CD4+ cell count, viral load, and antiretroviral therapy (RR=0.24[95%CI:0.10,0.56],p<0.002).","Zinc supplementation 18 months reduced four-fold likelihood immunological failure, controlling age, gender, lack food, baseline CD4+ cell count, viral load, antiretroviral therapy (RR=0.24[95%CI:0.10,0.56],p<0.002).",C0043481|C0242297|C0450371|C0439231|C0392756|C0205450|C0033204|C0205470|C0231174|C2239193|C0001779|C0079399|C0332268|C0016452|C0168634|C0285590|C0007634|C0750480|C0521026|C1550025|G0000000|C0039798|C0450371
Additional diagnostic approaches to increase case registrations also need to be considered.,Additional diagnostic approaches increase registrations considered.,C1524062|C0011900|C0449445|C0442805|C1514821|C0750591
"Efficacy was assessed by headache relief, and headache freedom at 2 h and 24 h. Two-hour headache relief, was noted in 73% in rizatriptan, 53.8% in ibuprofen and 8% in placebo groups.","Efficacy assessed headache relief, headache freedom 2 24 h. Two-hour headache relief, 73% rizatriptan, 53.8% ibuprofen 8% placebo groups.",C1280519|C1516048|C0018681|C0564405|C0018681|C0016694|G0000000|C0450371|C0033727|C0205448|C0018681|C0564405|C0450371|C0297635|C0450371|C0020740|G0000000|C0032042|C0441833
The primary outcome measures were the change in proteinuria and the change in eGFR from baseline to 12 months.,The primary outcome measures change proteinuria change eGFR baseline 12 months.,G0000000|C0205225|C1274040|C0079809|C0392747|C0033687|C0392747|C1739039|C0168634|C0450371|C0439231
"Meibomian gland health and meibum character were determined by assessing the percentage of gland blockage (orifice visible but no meibum expressible) and stenosis (orifice not visible, no meibum expressible) and of grading gross meibum character (Table 3).","Meibomian gland health meibum character determined assessing percentage gland blockage (orifice visible meibum expressible) stenosis (orifice visible, meibum expressible) grading gross meibum character (Table 3).",G0000000|C1285092|C0018684|G0000000|C0007952|G0000000|C1516048|C0439165|C1285092|C1706968|C0444567|C0205379|G0000000|G0000000|C0678234|C0444567|C0205379|G0000000|G0000000|C0441800|C0439806|G0000000|C0007952|C0039224|G0000000
The primary outcome of the study was mortality defined as in hospital death.,The primary outcome study mortality defined hospital death.,G0000000|C0205225|C1274040|C0557651|C0026565|C1704788|C0019994|C0011065
"Patients were assessed at three time points using the Wolf Motor Function Test, Nine-Hole Peg Test, Motor Activity Log and Nottingham Extended Activities of Daily Living.","Patients assessed time Wolf Motor Function Test, Nine-Hole Peg Test, Motor Activity Log Nottingham Extended Activities Daily Living.",C0030705|C1516048|C0040223|C0325001|C1513492|C0031843|C0022885|C0205455|G0000000|C0022885|C1513492|C0205177|C1708728|G0000000|C0231448|C0441655|C0332173|C0376558
49 patients were treated with interferon beta-1b for at least 12 months.,49 patients treated interferon beta-1b 12 months.,C0450371|C0030705|C1522326|C0021747|C0330390|C0450371|C0439231
"Efficacy of this new medication on acute infection episodes was assessed by the percentage of clinical cure in children with clinically active trachoma, shortly after treatment (2 months).","Efficacy medication acute infection episodes assessed percentage clinical cure children clinically active trachoma, shortly treatment (2 months).",C1280519|C0013227|C0205178|C0009450|C0332189|C1516048|C0439165|C0205210|C1880198|C0008059|G0000000|C0205177|C0040592|G0000000|C0039798|G0000000|C0439231
"The Oucher scale was developed to enable children to express themselves concerning their own pain, so that their word is sufficient to determine pain level; nevertheless, our study also obtained mothers' ratings, which were not significantly different from those of their children.","The Oucher scale developed enable children express pain, word sufficient determine pain level; nevertheless, study mothers' ratings, children.",G0000000|G0000000|C0175659|G0000000|C0562342|C0008059|G0000000|C0030193|C1705313|C0205410|G0000000|C0030193|C0441889|G0000000|C0557651|C0026591|C0871208|C0008059
"The treatment lasted for 6 months and every 2 months, the reassessment visit was done by the investigator.","The treatment lasted 6 months 2 months, reassessment visit investigator.",G0000000|C0039798|C1517741|G0000000|C0439231|G0000000|C0439231|G0000000|C0545082|C0035173
Partial remission (PR) was defined as having at least a 50% reduction in UPE compared with baseline or 0.3 g/d ≤ UPE < 3.5 g/d with stable Scr.,Partial remission (PR) defined 50% reduction UPE compared baseline 0.3 g/d ≤ UPE < 3.5 g/d stable Scr.,C0728938|C0544452|C0279759|C1704788|C0450371|C0301630|G0000000|C1707455|C0168634|G0000000|C0439417|G0000000|G0000000|G0000000|G0000000|C0439417|C0205360|C1539487
"Two weeks later, we measured 5 additional secondary outcomes, at which time a research assistant telephoned patients to assess adherence to the decision (a single item asking if the patient maintained the decision made), repeat consultation (a single item asking if the patient had a repeat consult for the same reason), decisional regret (Decisional Regret Scale),18 quality of life (SF-12),19 and intention to engage in shared decision-making in future consultations regarding the use of antibiotics for acute respiratory infections (questions based on the Theory of Planned Behaviour).20 Family physicians’ intentions to engage in shared decision-making and their intentions to adhere to clinical practice guidelines in this context were recorded at baseline and again at the end of the study.","Two weeks later, measured 5 additional secondary outcomes, time assistant telephoned patients assess adherence decision (a single item patient maintained decision made), repeat consultation (a single item patient repeat consult reason), decisional regret (Decisional Regret Scale),18 quality life (SF-12),19 intention engage shared decision-making future consultations antibiotics acute respiratory infections (questions based Theory Planned Behaviour).20 Family physicians’ intentions engage shared decision-making intentions adhere clinical practice guidelines context recorded baseline study.",C0205448|C0439230|C0205087|C0444706|G0000000|C1524062|C0027627|C1274040|C0040223|C0011327|C0039457|C0030705|C1516048|C1510802|C0679006|G0000000|C0037179|C1551338|C0030705|C1314677|C0679006|C1881534|C0205341|C0009818|G0000000|C0037179|C1551338|C0030705|C0205341|C0009818|C0392360|C0679006|C0080101|C0679006|C0080101|C0175659|C0332306|C0376558|C0037712|C0162425|G0000000|C0237876|C0011109|C0016884|C0009818|C0003232|C0205178|C0521346|C3714514|C1522634|C1527178|C0871935|C1301732|C0004927|C0015576|G0000000|C0162425|G0000000|C0237876|C0011109|C0162425|C3714578|C0205210|C0237607|C0162791|C0449255|C0034869|C0168634|C0557651
"The EOLD Scales will be used to measure: a) symptom-related comfort during the last 7 days of life (Comfort Assessment in Dying with Dementia; CAD–EOLD), including physical distress, dying symptoms, emotional distress and wellbeing; b) symptom management in the last 90 days of life (Symptom Management at the End of life in Dementia; SM–EOLD); and c) family satisfaction with care during the last 90 days of life (Satisfaction with Care at the End of life in Dementia; SWC–EOLD).","The EOLD Scales measure: a) symptom-related comfort 7 days life (Comfort Assessment Dying Dementia; CAD–EOLD), including physical distress, dying symptoms, emotional distress wellbeing; b) symptom management 90 days life (Symptom Management End life Dementia; SM–EOLD); c) family satisfaction care 90 days life (Satisfaction Care End life Dementia; SWC–EOLD).",G0000000|G0000000|C0175659|C0079809|G0000000|C1457887|C1331418|G0000000|C0439228|C0376558|C1331418|C1261322|C0184532|C0011265|G0000000|C0332257|C0031809|C0231303|C0184532|C0683368|C0013987|C0231303|C0018684|G0000000|C1457887|C0001554|C0450371|C0439228|C0376558|C1457887|C0001554|C0444930|C0376558|C0011265|G0000000|G0000000|C0015576|C0242428|C1947933|C0450371|C0439228|C0376558|C0242428|C1947933|C0444930|C0376558|C0011265|G0000000
"Demographics of population At baseline, there was no significant difference between the educational intervention and standard of care groups in self-reported measures of knowledge about skin cancer, concern about getting skin cancer, confidence in sun protection preventing skin cancer, willingness to change sun protective behaviors, and sun protection behavior.","Demographics population At baseline, difference educational intervention standard care self-reported measures knowledge skin cancer, concern skin cancer, confidence sun protection preventing skin cancer, willingness change sun protective behaviors, sun protection behavior.",C0011298|C0032659|G0000000|C0168634|C1705241|C0587721|C0886296|C1442989|C1947933|C0681906|C0079809|C0376554|C0444099|C0006826|C2699424|C0444099|C0006826|C0237529|C0038817|C1545588|C0309872|C0444099|C0006826|C0600109|C0392747|C0038817|G0000000|C0004927|C0038817|C1545588|C0004927
"In the early stage of the CNS metastasis process, the BBB is a key point.","In stage CNS metastasis process, BBB key point.",G0000000|C0205390|C3714787|C0027627|C1184743|C0005854|G0000000|C1552961
"We hypothesized that participation in MORE would be associated with significantly greater reductions in pain severity, pain interference, stress symptoms, and desire for opioids than would participation in a SG.","We hypothesized participation MORE reductions pain severity, pain interference, stress symptoms, desire opioids participation SG.",G0000000|G0000000|C0679823|C0205172|C0301630|C0030193|C0439793|C0030193|C0521102|C0038435|C0683368|C0871633|C0242402|C0679823|C0036644
"One patient complained of skin discomfort at the early stage of the first session of the deep cross-friction massage using the HT-bar, but the patient did not complain of any discomfort from the second time on.","One patient complained skin discomfort stage session deep cross-friction massage HT-bar, patient complain discomfort time on.",C0205447|C0030705|G0000000|C0444099|C0231218|C0205390|C1883016|C0205125|C2828360|C0024875|C0018510|C0030705|G0000000|C0231218|C0040223|G0000000
All patients were followed for survival for up to 2 years.,All patients survival 2 years.,G0000000|C0030705|C0038952|G0000000|C0439234
The laboratory studies done at screening were repeated at 12 and 24 months and a second skin biopsy was performed at the 24-month (final) visit.,The laboratory studies screening repeated 12 24 months skin biopsy performed 24-month (final) visit.,G0000000|C0022877|C0947630|C0220908|C0205341|C0450371|C0450371|C0439231|C0444099|C0005558|C0884358|C0450371|C0205088|C0545082
"In both the group treated with 7-mx 0–24 months (n = 28) and the group treated with placebo 0–12 months and 7-mx 12–24 months (n = 33), axial growth rate in the first as well as the second year of treatment was significantly lower compared with the precedent period (p < 0.00001/p = 0.001, first year and p = 0.006/p = 0.001, second year) (Fig.","In treated 7-mx 0–24 months (n = 28) treated placebo 0–12 months 7-mx 12–24 months (n = 33), axial growth rate treatment lower compared precedent period (p < 0.00001/p = 0.001, p = 0.006/p = 0.001, year) (Fig.",G0000000|C1522326|C0025885|G0000000|C0439231|G0000000|C1522326|C0032042|G0000000|C0439231|C0025885|G0000000|C0439231|G0000000|C0205131|C0018270|C0871208|C0039798|C0441994|C1707455|C1882265|C0439531|G0000000|G0000000|C0439234|C0349966
"Among the 66.7% who tested negative for influenza, 30.8% (48/156) tested positive for other viruses: seven for respiratory syncytial virus, nine for parainfluenza, 11 for enterovirus, 10 for rhinovirus, six for adenovirus, and five for metapneumovirus.","Among 66.7% tested negative influenza, 30.8% (48/156) tested positive viruses: respiratory syncytial virus, parainfluenza, 11 enterovirus, 10 rhinovirus, adenovirus, metapneumovirus.",G0000000|C0450371|C0392366|C0205160|C0021400|C0450371|C0450371|C0392366|C0439178|C0042776|C0521346|G0000000|C0042776|C0030389|C0450371|C0014378|C0450371|C0035473|C0001483|C0949907
Secondary outcomes were disease relapse after ACTH dose reduction of ACTH and treatment side effects.,Secondary outcomes disease relapse ACTH dose reduction ACTH treatment effects.,C0027627|C1274040|C0012634|C0035020|C3539087|C0178602|C0301630|C3539087|C0039798|C1280500
"All five components contribute to the score equally yielding a theoretical range of 0–500, with a higher score indicating a worse condition.","All components contribute score equally yielding theoretical range 0–500, score indicating worse condition.",G0000000|C0449432|C1880177|C0449820|G0000000|G0000000|C0871935|C1514721|G0000000|C0449820|G0000000|C0332271|C0012634
"The five patients with TRM had transplantations 22 to 190 days from the last nivolumab dose, all from unrelated donors, and died 36 to 96 days after allo-HCT; four experienced aGVHD.","The patients TRM transplantations 22 190 days nivolumab dose, unrelated donors, died 36 96 days allo-HCT; experienced aGVHD.",G0000000|C0030705|G0000000|C0040732|C0450371|C1442061|C0439228|C3657270|C0178602|C0445356|C0013018|C0011065|C0450371|C0450371|C0439228|C0002144|C0237607|G0000000
The incidence and prevalence of diarrhoea were lower in the zinc and vitamin A groups than in the placebo group.,The incidence prevalence diarrhoea lower zinc vitamin A placebo group.,G0000000|C0021149|C0033105|C0011991|C0441994|C0043481|C0042890|G0000000|C0032042|C0441833
"Secondary outcomes were the CIBIC‐Plus change from baseline, Progressive Deterioration Scale, ADAS‐cogA, Mini‐Mental State Examination and Global Deterioration Scale.","Secondary outcomes CIBIC‐Plus change baseline, Progressive Deterioration Scale, ADAS‐cogA, Mini‐Mental State Examination Global Deterioration Scale.",C0027627|C1274040|G0000000|C0392747|C0168634|C0205329|C0868945|C0175659|G0000000|G0000000|C1301808|G0000000|C0205246|C0868945|C0175659
There were 2 primary outcome measures: change in total recall on the SRT and self-reported memory change.,There 2 primary outcome measures: change total recall SRT self-reported memory change.,G0000000|G0000000|C0205225|C1274040|C0079809|C0392747|C0439175|C0034770|C0234742|C0681906|C0025260|C0392747
"Secondary aims are to examine the impact of the intervention on patient quality of life, symptom distress, unmet supportive care needs, preparation for treatment, psychosexual functioning and vaginal stenosis.","Secondary aims examine impact intervention patient quality life, symptom distress, unmet supportive care needs, preparation treatment, psychosexual functioning vaginal stenosis.",C0027627|C1947946|G0000000|C1825598|C0886296|C0030705|C0332306|C0376558|C1457887|C0231303|C3274904|C1521721|C1947933|C0027552|C1521827|C0039798|G0000000|C0205245|C0042232|C0678234
"IBD can lead to increased rates of missed school or work, medical costs, hospitalizations, surgery, and even death.4,5 Although IBD is not believed to have a psychosocial origin, a number of studies have identified psychosocial variables associated with the disease,6-8 some of which clearly have the potential for significantly affecting the quality of life of IBD patients.9-11 Comparing children with IBD to matched controls, researchers have found more anxiety, depression, social functioning (inter-personal interactions in social situations) problems and family dysfunction in those with IBD.7 Many studies have found depression in particular is increased in youth with IBD compared to controls7 and parents of children with IBD also show increased levels of depression.12 Considerable research has found an association between psychosocial factors, most notably anxiety and/or depression as well as maladaptive coping, and IBD symptoms and symptom severity in children with IBD.7,13-17 Typical of these, recently Reigada et al.18 found that anxiety symptoms were significantly associated with moderate/severe disease activity among children and adolescents with CD.","IBD lead increased rates missed school work, medical costs, hospitalizations, surgery, death.4,5 Although IBD believed psychosocial origin, studies identified psychosocial variables disease,6-8 potential quality life IBD patients.9-11 Comparing children IBD matched controls, researchers anxiety, depression, social functioning (inter-personal interactions social situations) family dysfunction IBD.7 Many studies depression increased youth IBD compared controls7 parents children IBD increased levels depression.12 Considerable association psychosocial factors, notably anxiety and/or depression maladaptive coping, IBD symptoms symptom severity children IBD.7,13-17 Typical these, Reigada al.18 anxiety symptoms moderate/severe disease activity children adolescents CD.",G0000000|C0023175|C0205217|C0871208|C1705492|C0036375|C0043227|C0199168|C0010186|C0019993|C0038894|C0011065|G0000000|G0000000|G0000000|C0542298|C0079946|C0947630|C0205396|C0542298|C0439828|C0012634|C3245505|C0332306|C0376558|G0000000|C0030705|C1707455|C0008059|G0000000|C0150103|C0243148|C0035173|C0003467|C0011570|C0728831|C0205245|C0205103|C1704675|C0728831|G0000000|C0015576|C0031847|G0000000|G0000000|C0947630|C0011570|C0205217|C0001578|G0000000|C1707455|G0000000|C0030551|C0008059|G0000000|C0205217|C0441889|C0011570|G0000000|C0004083|C0542298|C1521761|G0000000|C0003467|G0000000|C0011570|C0233532|C0009967|G0000000|C0683368|C1457887|C0439793|C0008059|C0450371|C3538928|G0000000|G0000000|C0202311|C0003467|C0683368|C0205081|C0012634|C0205177|C0008059|C0205653|C0007928
"Questionnaires were administered by post or were completed on line at one, three, and 12 weeks and six months.","Questionnaires administered post completed one, three, 12 weeks months.",C0034394|C1521801|C0687676|C0205197|C0205447|C0205449|C0450371|C0439230|C0439231
"Vascular death—Within four weeks after stroke, systemic embolism, myocardial infarction, congestive heart failure, or major bleeding or sudden death (observed within one hour after onset of symptoms or patient found dead).","Vascular death—Within weeks stroke, systemic embolism, myocardial infarction, congestive heart failure, major bleeding sudden death (observed hour onset symptoms patient dead).",C0005847|G0000000|C0439230|C0038454|C0205373|C0013922|C0027061|C0021308|C0742742|C0018787|C0231174|C0205082|C0019080|C1276802|C0011065|C1441672|C0439227|C0206132|C0683368|C0030705|C0011065
"Primary outcomes were the General Health Questionnaire (GHQ-20) and the Effective Musculoskeletal Consumer Scale (EC-17), while secondary outcomes included the Fibromyalgia Impact Questionnaire (FIQ) and Self-efficacy scales for pain, function and symptoms (ASES).","Primary outcomes General Health Questionnaire (GHQ-20) Effective Musculoskeletal Consumer Scale (EC-17), secondary outcomes included Fibromyalgia Impact Questionnaire (FIQ) Self-efficacy scales pain, function symptoms (ASES).",C0205225|C1274040|C0205246|C0018684|C0034394|C0450371|C1280519|C0497254|C1707496|C0175659|C3890233|C0027627|C1274040|C0332257|C0016053|C1825598|C0034394|G0000000|C0600564|C0175659|C0030193|C0031843|C0683368|G0000000
"Following the provider consultation, patients will be given a follow-up survey, which consists of questions similar to the baseline survey, including transplant knowledge, preferences of treatment, decisional conflict, and health literacy and numeracy.","Following provider consultation, patients follow-up survey, consists questions baseline survey, including transplant knowledge, preferences treatment, decisional conflict, health literacy numeracy.",C0231290|C1138603|C0009818|C0030705|C0589120|C0038951|C0332529|C1522634|C0168634|C0038951|C0332257|C0040732|C0376554|C0558295|C0039798|C0679006|C0009671|C0018684|C0023864|G0000000
"The primary outcome measure was weight at 34 weeks post-menstrual age (PMA), the oldest age all newborns enrolled were likely to be in the hospital.","The primary outcome measure weight 34 weeks post-menstrual age (PMA), age newborns enrolled hospital.",G0000000|C0205225|C1274040|C0079809|C0005910|C0450371|C0439230|C0687676|C0001779|C0039654|C0001779|C0021289|G0000000|C0019994
"Factors associated with rapid/excessive weight gain include socioeconomic status, maternal age, and infant feeding practices [20,26], which include formula feeding, age of introduction to solids, maternal responsiveness, and overfeeding [1,27-32].","Factors rapid/excessive weight gain socioeconomic status, maternal age, infant feeding practices [20,26], formula feeding, age introduction solids, maternal responsiveness, overfeeding [1,27-32].",C1521761|C0456962|C0005910|C1517378|C0748878|C0449438|C2347083|C0001779|C0021270|C0204695|C0237607|C0450371|C0489829|C0204695|C0001779|C1293116|C0205208|C2347083|C0205342|G0000000|C0450371
The primary hypothesis was that 800 μg QD PM would be superior to placebo with respect to changes from baseline in postbronchodilator FEV1 and either total COPD symptom scores or proportion of subjects with one or more exacerbations during the study.,The primary hypothesis 800 μg QD PM superior placebo respect baseline postbronchodilator FEV1 total COPD symptom scores proportion subjects exacerbations study.,G0000000|C0205225|C1512571|C1442061|G0000000|C0332173|C0030266|C1282910|C0032042|C0679133|C0168634|C2599594|G0000000|C0439175|C0024117|C1457887|C0449820|C1709707|C0681850|G0000000|C0557651
"“Serious vascular event”: non-fatal myocardial infarction, non-fatal stroke, or vascular death.","“Serious vascular event”: non-fatal myocardial infarction, non-fatal stroke, vascular death.",G0000000|C0005847|G0000000|C1518422|C0027061|C0021308|C1518422|C0038454|C0005847|C0011065
"Secondary speech and language outcome measures include: selected subtests from the Apraxia Battery for Adults (Dabul, 2000), the Boston Naming Test (Kaplan, Goodglass, & Weintraub, 1983), and the “cookie theft” picture description task from the Boston Diagnostic Aphasia Examination (Goodglass & Kaplan, 1972; Goodglass, Kaplan, & Barresi, 2000).","Secondary speech language outcome measures include: selected subtests Apraxia Battery Adults (Dabul, 2000), Boston Naming Test (Kaplan, Goodglass, & Weintraub, 1983), “cookie theft” picture description task Boston Diagnostic Aphasia Examination (Goodglass & Kaplan, 1972; Goodglass, Kaplan, & Barresi, 2000).",C0027627|C0037817|C0023008|C1274040|C0079809|C0332257|C1707391|G0000000|C0003635|C0337088|C0001675|G0000000|G0000000|C0006037|C0233735|C0022885|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0441468|C0678257|C3540678|C0006037|C0011900|C0003537|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000
"Treatment was administrated until disease progression, unacceptable toxicity or withdrawal of consent.","Treatment administrated disease progression, unacceptable toxicity withdrawal consent.",C0039798|G0000000|C0012634|C0242656|C1883420|C0040539|C2349954|C1511481
"No significant differences were observed between the two groups in terms of the pre-defined primary and secondary quality of life end points, although large negative effects of chemotherapy were ruled out.","No differences observed terms pre-defined primary secondary quality life points, negative effects chemotherapy ruled out.",G0000000|C1705241|C1441672|C0233324|C0332152|C0205225|C0027627|C0332306|C0376558|C1552961|C0205160|C1280500|C0013216|C1446409|C0439787
We summed weekly intake and then divided the total by the number of days for which entries were made.,We summed weekly intake divided total days entries made.,G0000000|C1515051|C0332174|C1512806|C0332849|C0439175|C0439228|C1705654|C1881534
The degree of patients’ anxiety and depression was assessed by Hospital Anxiety and Depression Scale at baseline and 3 days after music therapy.,The degree patients’ anxiety depression assessed Hospital Anxiety Depression Scale baseline 3 days music therapy.,G0000000|C0441889|G0000000|C0003467|C0011570|C1516048|C0019994|C0003467|C0011570|C0175659|C0168634|G0000000|C0439228|C0026867|C0039798
"CP: Cerebral palsy; CIMT: Constraint induced movement therapy; BIM: training Bimanual training; UL: Upper limb; MUUL: Melbourne Assessment of Unilateral Upper Limb Function; AHA: Assisting Hand Assessment; JTTHF: Jebsen Taylor Test of Hand Function; COPM: Canadian Occupational Performance Measure; LIFE-H: Assessment of Life Habits; CPQOL: Child Cerebral Palsy Quality of Life Questionnaire for Children; FMRI: Functional Magnetic Resonance Imaging; ICF: International Classification of Functioning, Disability and Health.","CP: Cerebral palsy; CIMT: Constraint induced movement therapy; BIM: training Bimanual training; UL: Upper limb; MUUL: Melbourne Assessment Unilateral Upper Limb Function; AHA: Assisting Hand Assessment; JTTHF: Jebsen Taylor Test Hand Function; COPM: Canadian Occupational Performance Measure; LIFE-H: Assessment Life Habits; CPQOL: Child Cerebral Palsy Quality Life Questionnaire Children; FMRI: Functional Magnetic Resonance Imaging; ICF: International Classification Functioning, Disability Health.",C4050020|G0000000|C0522224|G0000000|C0443288|C0205263|C0026649|C0039798|G0000000|C0040607|C1511117|C0040607|C1300557|C1282910|C0015385|G0000000|G0000000|C1261322|C0205092|C1282910|C0015385|C0031843|C0050451|C0557034|C0018563|C1261322|G0000000|G0000000|G0000000|C0022885|C0018563|C0031843|G0000000|C0238884|C0521127|C0597198|C0079809|C0376558|C1261322|C0376558|C0018464|G0000000|C0008059|G0000000|C0522224|C0332306|C0376558|C0034394|C0008059|C0376335|C0205245|C0024488|C0231881|C0011923|G0000000|C1512888|C0008902|C0205245|C0231170|C0018684
"Ocular examinations were conducted before treatment, and 2, 6 and 12 months after treatment.","Ocular examinations conducted treatment, 2, 6 12 months treatment.",C0015392|C0031809|C0004927|C0039798|G0000000|G0000000|C0450371|C0439231|C0039798
Admission discrepancies were defined as any medication clarification related to current home medication made whilst being cared for in an ED.,Admission discrepancies defined medication clarification current medication whilst cared ED.,C0184666|C1290905|C1704788|C0013227|C2986669|C0521116|C0013227|G0000000|C1947933|C3538926
No difference between groups was detected for infective complications.,No difference detected infective complications.,G0000000|C1705241|C0442726|G0000000|C0009566
"Within each group, the change in outcomes (haemoglobin, anaemia, WAZ, WHZ, HAZ, underweight, stunting and wasting) between baseline and post‐supplementation was assessed using mixed effects ANCOVA and logistic regression models for means and proportions, respectively.","Within group, change outcomes (haemoglobin, anaemia, WAZ, WHZ, HAZ, underweight, stunting wasting) baseline post‐supplementation assessed mixed effects ANCOVA logistic regression models proportions, respectively.",G0000000|C0441833|C0392747|C1274040|C0019046|C0002871|G0000000|G0000000|G0000000|C0041667|C0018273|C0006625|C0168634|G0000000|C1516048|C0205430|C1280500|C0814908|C0242415|C0684320|C3161035|C1709707|G0000000
"Secondary outcomes included mRS at 3 months, as well as NIHSS, Barthel ADL Index (BI) [12] and patient satisfaction (five-point Likert scale with 1 best) at 3 and 6 months.","Secondary outcomes included mRS 3 months, NIHSS, Barthel ADL Index (BI) [12] patient satisfaction (five-point Likert scale 1 best) 3 6 months.",C0027627|C1274040|C0332257|C1522706|G0000000|C0439231|C3476804|G0000000|C0001288|C0918012|G0000000|C0450371|C0030705|C0242428|C0205451|G0000000|C0175659|G0000000|C1522427|G0000000|G0000000|C0439231
Secondary endpoints were the safety of the drugs that were used.,Secondary endpoints safety drugs used.,C0027627|C2349179|C0036043|C0013227|C1273517
"The clinical observations were followed up over a period of 3, 6, and 12 months whereas the radiographic outcomes were followed soon after the procedure and after 6 months and 12 months interval.","The clinical observations period 3, 6, 12 months radiographic outcomes procedure 6 months 12 months interval.",G0000000|C0205210|C0302523|C0439531|G0000000|G0000000|C0450371|C0439231|C0444708|C1274040|C0184661|G0000000|C0439231|C0450371|C0439231|C1272706
The change in sputum MPO over the 16-week treatment period was not significantly different between groups.,The change sputum MPO 16-week treatment period groups.,G0000000|C0392747|C0038056|G0000000|C0450371|C0039798|C0439531|C0441833
"A sample size of 210 participants (105 in each arm of the study) was proposed to examine the zinc supplementation effect on immunological failure, defined as any CD4+ count <200 cells/mm3, which was the primary endpoint.","A sample size 210 participants (105 arm study) proposed examine zinc supplementation immunological failure, defined CD4+ count <200 cells/mm3, primary endpoint.",G0000000|C0370003|C0456389|C1442061|C0679646|C1442061|C0446516|C0557651|C1553874|G0000000|C0043481|C0242297|C0205470|C0231174|C1704788|C0285590|C0750480|C1442061|C0007634|C0205225|C2349179
"Neuropsychiatric behaviors, also known as behavioral and psychological symptoms of dementia (BPSD), are common and often considered to be the greatest challenge in dementia care.","Neuropsychiatric behaviors, behavioral psychological symptoms dementia (BPSD), common considered challenge dementia care.",G0000000|C0004927|C0004927|C0205486|C0683368|C0011265|G0000000|C0205214|C0750591|C0798503|C0011265|C1947933
SUBJECTS: 104 children aged 7 to 9 years who had had wheezing in association with symptoms of upper and lower respiratory tract infection in the preceding 12 months.,SUBJECTS: 104 children aged 7 9 wheezing association symptoms upper lower respiratory tract infection preceding 12 months.,C0681850|C1442061|C0008059|C0001779|G0000000|G0000000|C0043144|C0004083|C0683368|C1282910|C0441994|C0521346|C1185740|C0009450|C0332152|C0450371|C0439231
The POMS-SF is a 37-item short form of the Profile of Mood States measuring psychological distress.14 Brief Fatigue Inventory (BFI).,The POMS-SF 37-item short form Profile Mood States measuring psychological distress.14 Brief Fatigue Inventory (BFI).,G0000000|C0451394|C0450371|C1282927|C0348078|C1979963|C0026516|C1301808|C0444706|C0205486|C0231303|C1282927|C0015672|C0021941|C2698562
The data on PSA and disease progression are not yet complete at the time of writing this paper.,The data PSA disease progression complete time writing paper.,G0000000|C1511726|C3810537|C0012634|C0242656|C0205197|C0040223|C0043266|C0030351
Clinical and radiographic criteria for assessing teeth were explained along with a calibration process to the two observers on three initial cases.,Clinical radiographic criteria assessing teeth explained calibration process observers initial cases.,C0205210|C0444708|C0243161|C1516048|C0040426|G0000000|C0006751|C1184743|C0870992|C0205265|C0868928
"The pre- and post-intervention questionnaire contained 25 questions covering sociodemographics, acculturation, exposure to the media campaign, awareness of cervical cancer and beliefs about its causes, and awareness, receipt and intention to receive the Pap test.","The pre- post-intervention questionnaire contained 25 questions covering sociodemographics, acculturation, exposure media campaign, awareness cervical cancer beliefs causes, awareness, receipt intention receive Pap test.",G0000000|C0332152|C2347647|C0034394|C0332256|C0450371|C1522634|C0180153|G0000000|C0000943|C0274281|C0009458|G0000000|C0004448|C0027530|C0006826|C0004951|C0015127|C0004448|G0000000|C0162425|C1514756|C1740167|C0022885
"Questions were extracted from the University of Rochester Cancer Center Symptom Inventory (URCC SI), the Functional Assessment of Chronic Illness Therapy with Fatigue Subscale (FACIT-F), and the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF).","Questions extracted University Rochester Cancer Center Symptom Inventory (URCC SI), Functional Assessment Chronic Illness Therapy Fatigue Subscale (FACIT-F), Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF).",C1522634|C0185115|C0041740|G0000000|C0006826|C0205099|C1457887|C0021941|C1425565|G0000000|C0205245|C1261322|C0205191|C0221423|C0039798|C0015672|G0000000|C3272505|C2347299|C0015672|C1457887|C0021941|C0348078|C0037712
The questionnaire included the Fibromyalgia Impact Questionnaire (FIQ) which was developed to measure the health status and the components that are believed to be most affected by FM [37].,The questionnaire included Fibromyalgia Impact Questionnaire (FIQ) developed measure health status components believed FM [37].,G0000000|C0034394|C0332257|C0016053|C1825598|C0034394|G0000000|G0000000|C0079809|C0018684|C0449438|C0449432|G0000000|C3540627|C0450371
"Further, the intervention provided statistically significant improvement in resilience, stress, anxiety, and overall quality of life.","Further, intervention provided statistically improvement resilience, stress, anxiety, quality life.",C1517331|C0886296|C1999230|C0038215|C2986411|G0000000|C0038435|C0003467|C0332306|C0376558
"Although in this trial efficacy was similar in both arms in terms of progression-free survival, overall survival, and response rate, this trial failed to show benefits in terms of less toxicity for the nonplatinum-based regimen.","Although trial efficacy arms terms progression-free survival, survival, response rate, trial failed benefits terms toxicity nonplatinum-based regimen.",G0000000|C0008976|C1280519|C0206655|C0233324|C0242656|C0038952|C0038952|C0871261|C0871208|C0008976|C0231175|C0814225|C0233324|C0040539|C1527178|C0040808
Measurements were made just proximal to the distal tendon of the biceps brachii.,Measurements proximal distal tendon biceps brachii.,C0242485|C0205107|C0205108|C0039508|C0559499|G0000000
"Parental response to pain behavior was measured using the 13-item Protect subscale of the Adults’ Responses to Children's Symptoms (ARCS).37,38 Sample items of this measure which asses constructs such as parent reinforcement of illness behavior include, “When your child has a stomachache or other GI symptoms, how often do you bring him/her special treats or little gifts?” or “...let him/her stay home from school?” Ratings are made on a 0–4 scale, with higher values indicative of greater solicitousness.","Parental response pain behavior measured 13-item Protect subscale Adults’ Responses Children's Symptoms (ARCS).37,38 Sample items measure asses constructs parent reinforcement illness behavior include, “When child stomachache GI symptoms, bring him/her special treats gifts?” “...let him/her stay school?” Ratings 0–4 scale, values indicative solicitousness.",C0030551|C0871261|C0030193|C0004927|C0444706|C0450371|G0000000|G0000000|G0000000|C0871261|C0008059|C0683368|C1859722|C0370003|C1551338|C0079809|C0324145|C2827421|C0030551|C0035007|C0221423|C0004927|C0332257|G0000000|C0008059|C0221512|C1708130|C0683368|G0000000|G0000000|C0205555|C1292734|G0000000|G0000000|G0000000|G0000000|G0000000|C0871208|G0000000|C0175659|C0042295|G0000000|G0000000
Dynamic balance was evaluated using the functional reach test (FRT).,Dynamic balance evaluated functional reach test (FRT).,C0729333|C0014653|C0220825|C0205245|C2584321|C0022885|C1705150
"The Diabetes Quality of Life Scale for Youth (DQOL) (30) is a modification of the Diabetes Quality of Life Scale (31) used to assess children's and adolescents' perceptions of the impact of intensified regimens on their general satisfaction with life, and on diabetes-related concerns over social, school and peer relationships.","The Diabetes Quality Life Scale Youth (DQOL) (30) modification Diabetes Quality Life Scale (31) assess children's adolescents' perceptions impact intensified regimens satisfaction life, diabetes-related concerns social, school peer relationships.",G0000000|C0011847|C0332306|C0376558|C0175659|C0001578|G0000000|C0450371|C0392747|C0011847|C0332306|C0376558|C0175659|C0450371|C1516048|C0008059|C0205653|C0030971|C1825598|G0000000|C2945654|C0242428|C0376558|C1261139|C2699424|C0728831|C0036375|C0679739|C0439849
"A higher intake of fruit and vegetables has been associated with higher blood nutrient levels, lower oxidative stress and better cognitive function [49].","A intake fruit vegetables blood nutrient levels, lower oxidative stress cognitive function [49].",G0000000|C1512806|C0016767|C0042440|C0005767|C0678695|C0441889|C0441994|C0311404|C0038435|C1516691|C0031843|C0450371
The urinary protein excretion at diagnosis was significantly included as a risk factor in the multivariate analysis for ESRF (Table 5).,The urinary protein excretion diagnosis included risk factor multivariate analysis ESRF (Table 5).,G0000000|C0042027|C0033684|C0221102|C0011900|C0332257|C0035647|C1521761|G0000000|C0002778|G0000000|C0039224|G0000000
"Once a week, during babies' hospitalizations, maternal carboxyhemoglobin saturations were measured using a non-invasive transcutaneous carbon monoxide monitor (Masimo, Irvine, CA, USA).","Once week, babies' hospitalizations, maternal carboxyhemoglobin saturations measured non-invasive transcutaneous carbon monoxide monitor (Masimo, Irvine, CA, USA).",C0585347|C0332174|C0021270|C0019993|C2347083|C0007061|C0522534|C0444706|C0205303|G0000000|C0007009|G0000000|C0030695|G0000000|G0000000|C3887642|C0041703
"Side effects were, in most cases, transient and easily managed, and treatment was well tolerated.","Side effects were, cases, transient easily managed, treatment tolerated.",C0441987|C1280500|G0000000|C0868928|C0040704|C0332219|C1273870|C0039798|G0000000
"[5,7,8,18] These reviews have concluded that there is consistent benefit for patients from gum chewing after the intestinal surgery in the form of decreased time to first flatus, bowel movements, and postoperative hospital stay.","[5,7,8,18] These reviews concluded consistent benefit patients gum chewing intestinal surgery form decreased time flatus, bowel movements, postoperative hospital stay.",C0450371|G0000000|C0282443|C0917903|C0332290|C0814225|C0030705|C0017562|C0024888|C0021853|C0038894|C0348078|C0205216|C0040223|C0016204|C0021853|C0026649|C0032790|C0019994|G0000000
Percent improvement in global sleep quality and subscales from baseline to postintervention on the Pittsburgh Sleep Quality Index.,Percent improvement global sleep quality subscales baseline postintervention Pittsburgh Sleep Quality Index.,C0439165|C2986411|C0205246|C0037313|C0332306|G0000000|C0168634|G0000000|G0000000|C0037313|C0332306|C0918012
The differences in the continuous data (mean platelet count) were compared by using the independent sample “t” test.,The differences continuous data (mean platelet count) compared independent sample “t” test.,G0000000|C1705241|C0549178|C1511726|C0444504|C0005821|C0750480|C1707455|C0085862|C0370003|G0000000|C0022885
"Consistent with the exploratory pilot nature of this study, multiple hypothesis-generating outcomes will be evaluated together with assessments of process feasibility, including: Effects of fibrinogen supplementation (FC and Cryo) on plasma fibrinogen Time to randomisation Time course of fibrinogen levels as measured by FIBTEM and Clauss Fibrinogen (FibC) Transfusion requirements Clinically relevant thromboembolic complications Mortality at several time points including hospital discharge and 90 days  Detailed data collection will occur for the first 7 days of hospital admission and extended follow-up to 90 days (see the SPIRIT figure in Fig.","Consistent exploratory pilot nature study, multiple hypothesis-generating outcomes evaluated assessments process feasibility, including: Effects fibrinogen supplementation (FC Cryo) plasma fibrinogen Time randomisation Time fibrinogen levels measured FIBTEM Clauss Fibrinogen (FibC) Transfusion requirements Clinically relevant thromboembolic complications Mortality time including hospital discharge 90 days Detailed data collection occur 7 days hospital admission extended follow-up 90 days (see SPIRIT figure Fig.",C0332290|G0000000|C0473169|C0349590|C0557651|C0439064|C1512571|C1274040|C0220825|C1261322|C1184743|G0000000|C0332257|C1280500|C0016006|C0242297|C2983605|G0000000|C0032105|C0016006|C0040223|C0034656|C0040223|C0016006|C0441889|C0444706|G0000000|G0000000|C0016006|G0000000|C0005841|C1514873|G0000000|C2347946|C0333214|C0009566|C0026565|C0040223|C0332257|C0019994|C0012621|C0450371|C0439228|C1522508|C1511726|C1516698|C1709305|G0000000|C0439228|C0019994|C0184666|C0231448|C0589120|C0450371|C0439228|C0042789|C0301611|G0000000|C0349966
Characteristics associated with smoking intensity (number of total cigarettes smoked in the previous 7 days) during the first 8 weeks of the study.,Characteristics smoking intensity (number total cigarettes smoked previous 7 days) 8 weeks study.,C1521970|C0037369|C0522510|C0237753|C0439175|C0677453|C0037366|C0205156|G0000000|C0439228|G0000000|C0439230|C0557651
This study aims to assess the effects of music therapy on anxiety and depression among cancer patients through Hospital Anxiety and Depression Scale (HADS) questionnaire.,This study aims assess effects music therapy anxiety depression cancer patients Hospital Anxiety Depression Scale (HADS) questionnaire.,G0000000|C0557651|C1947946|C1516048|C1280500|C0026867|C0039798|C0003467|C0011570|C0006826|C0030705|C0019994|C0003467|C0011570|C0175659|C0048008|C0034394
Abbreviation: RCT=randomised controlled trial.,Abbreviation: RCT=randomised controlled trial.,C0000723|G0000000|C2587213|C0008976
"The Korean version of the Modified Barthel Index is a reliable, valid tool for measuring the ADL of patients in Korea and has a maximal score of 100 indicating complete independence in ADL.","The Korean version Modified Barthel Index reliable, valid tool measuring ADL patients Korea maximal score 100 indicating complete independence ADL.",G0000000|C1556095|C0333052|C0392747|G0000000|C0918012|C3858758|C2349099|C0336791|C0444706|C0001288|C0030705|C0022771|C0205289|C0449820|C1442061|G0000000|C0205197|C0085862|C0001288
"The site of origin and histological cancer type were coded using the International Classification of Diseases for Oncology, Third Edition, with the gallbladder as C23.9, the extrahepatic bile duct as C24.0, overlapping lesions of the biliary tract as C24.8, and unspecified as C24.9; in the present analysis, BTC included all of these subtypes.","The site origin histological cancer type coded International Classification Diseases Oncology, Third Edition, gallbladder C23.9, extrahepatic bile duct C24.0, overlapping lesions biliary tract C24.8, unspecified C24.9; analysis, BTC included subtypes.",G0000000|C0205145|C0079946|C0205462|C0006826|C0332307|C0009219|C1512888|C0008902|C0012634|C0027651|C0205437|C0441792|C0016976|G0000000|C1517058|C0005388|C0687028|G0000000|C0185027|C0221198|C0521378|C1185740|G0000000|C0205370|G0000000|C0002778|C3884533|C0332257|C0449560
Participants in the current trial had a greater burden of disease and comorbidities and had lower muscle strength and exercise capacity than most reported pulmonary rehabilitation studies.,Participants current trial burden disease comorbidities lower muscle strength exercise capacity reported pulmonary rehabilitation studies.,C0679646|C0521116|C0008976|C2828008|C0012634|C0009488|C0441994|C0026845|C0237897|C0015259|C1516240|C0684224|C0024109|C0034991|C0947630
To reduce the incidence of babies in a breech presentation external cephalic version (ECV) and postural management have been used to correct the presentation prior to term.,To reduce incidence babies breech presentation external cephalic version (ECV) postural management correct presentation prior term.,C0040363|G0000000|C0021149|C0021270|C3841404|C0449450|C0205101|C0205096|C0333052|G0000000|C0205278|C0001554|C2349182|C0449450|C0332152|C0233324
"The swimming-based tests comprised of the in-water vertical jump test (VJ), 10 m sprint test, the repeat sprint test (RST) and the Water Polo Intermittent Shuttle Test (WIST) [8], completed in the aforementioned order.","The swimming-based tests comprised in-water vertical jump test (VJ), 10 sprint test, repeat sprint test (RST) Water Polo Intermittent Shuttle Test (WIST) [8], completed aforementioned order.",G0000000|C0039003|C0022885|C2700400|C0043047|C0205128|C0221189|C0022885|G0000000|C0450371|G0000000|C0022885|C0205341|G0000000|C0022885|C1425219|C0043047|G0000000|C0205267|G0000000|C0022885|C2700262|G0000000|C0205197|G0000000|C1705175
Assessment of clinical outcome was undertaken until discharge and included postoperative complications and length of hospital stay.,Assessment clinical outcome undertaken discharge included postoperative complications length hospital stay.,C1261322|C0205210|C1274040|G0000000|C0012621|C0332257|C0032790|C0009566|C1444754|C0019994|G0000000
"Primary endpoints were percentage of abdominal fat and MetS characteristics, and secondary endpoints included insulin, total and LDL cholesterol, inflammatory markers, adipokines, and other measurements of body composition.","Primary endpoints percentage abdominal fat MetS characteristics, secondary endpoints included insulin, total LDL cholesterol, inflammatory markers, adipokines, measurements body composition.",C0205225|C2349179|C0439165|C0000726|C0424612|C0812270|C1521970|C0027627|C2349179|C0332257|C0021641|C0439175|G0000000|C0008377|C0333348|C0005516|C1955907|C0242485|C0242821|C0486616
"The results suggested that, after 3 weeks of BWSTT, improvement in temporal-spatial parameters (increased cadence, stride length and step length, and decreased stride time and step time) is achievable.","The suggested that, 3 weeks BWSTT, improvement temporal-spatial parameters (increased cadence, stride length step length, decreased stride time step time) achievable.",G0000000|C1705535|G0000000|G0000000|C0439230|G0000000|C2986411|C0442043|C0449381|C0205217|G0000000|G0000000|C1444754|C1261552|C1444754|C0205216|G0000000|C0040223|C1261552|C0040223|G0000000
CHANGE OVER 8 WEEKS OF TREATMENT Definition of abbreviations: AQOL = Asthma Quality of Life; CI = confidence interval; ECP = eosinophil cationic protein; NS = not significant; PC20 = provocative concentration causing a 20% fall in FEV1; PEFR = peak expiratory flow rate.,CHANGE OVER 8 WEEKS OF TREATMENT Definition abbreviations: AQOL = Asthma Quality Life; CI = confidence interval; ECP = eosinophil cationic protein; NS = significant; PC20 = provocative concentration causing 20% fall FEV1; PEFR = peak expiratory flow rate.,C0392747|C0205136|G0000000|C0439230|G0000000|C0039798|C1550452|C0000723|G0000000|G0000000|C0004096|C0332306|C0376558|C0008107|G0000000|C0237529|C1272706|C3889675|G0000000|C0014467|C0007447|C0033684|C0038944|G0000000|C0237881|G0000000|G0000000|C0449428|C0004268|C0678227|C0450371|C0085639|G0000000|C0030735|G0000000|C0444505|C0231800|C0806140|C0871208
"At eight weeks, 34 participants completed the 6MWT and the HRQoL questionnaires, 33 completed the ICT and the ECT and 31 completed the physical activity measurements.","At weeks, 34 participants completed 6MWT HRQoL questionnaires, 33 completed ICT ECT 31 completed physical activity measurements.",G0000000|C0439230|C0450371|C0679646|C0205197|G0000000|G0000000|C0034394|C0450371|C0205197|C1512721|C0013806|C0450371|C0205197|C0031809|C0205177|C0242485
"Regarding acceptability, families in the AI reported that they enjoyed the intervention, felt they received good information, and learned skills that improved both adherence and outcomes.","Regarding acceptability, families AI reported enjoyed intervention, received information, learned skills improved adherence outcomes.",G0000000|C0814633|C0015576|C0003353|C0684224|C0018592|C0886296|C1514756|C1533716|C0023185|C0678856|C0184511|C1510802|C1274040
"At 24 months of age, there was no effect of the intervention on height, weight, BMI, BMI z-scores, triceps skinfolds, or triceps + subscapular skinfolds.","At 24 months age, intervention height, weight, BMI, BMI z-scores, triceps skinfolds, triceps + subscapular skinfolds.",G0000000|C0450371|C0439231|C0001779|C0886296|C0489786|C0005910|G0000000|G0000000|C0871421|C0559502|G0000000|C0559502|G0000000|G0000000|G0000000
"Distribution of changes in scores of pain intensity at rest (60-day visit), as measured by a visual analog scale (VAS) among patients with osteoarthritis of the knee.","Distribution scores pain intensity rest (60-day visit), measured visual analog scale (VAS) patients osteoarthritis knee.",C0520511|C0449820|C0030193|C0522510|C0035253|C0450371|C0545082|C0444706|C0234621|C0243071|C0175659|C0042815|C0030705|C0029408|C0022742
"Clinical outcomes were measured using the 17-item Hamilton Depression Rating Scale (HAMD-17), Clinical Global Impression-severity (CGI-S), and Self-rating Depression Scale (SDS) as well as the response and remission rates.","Clinical outcomes measured 17-item Hamilton Depression Rating Scale (HAMD-17), Clinical Global Impression-severity (CGI-S), Self-rating Depression Scale (SDS) response remission rates.",C0205210|C1274040|C0444706|C0450371|G0000000|C0011570|C0871208|C0175659|C0450371|C0205210|C0205246|C0596764|C3639708|C4054119|C0011570|C0175659|C3813719|C0871261|C0544452|C0871208
Methods: The aim of the Big Lung Trial was to confirm the survival benefits seen in the meta-analysis and to assess quality of life and cost in the supportive care setting.,Methods: The aim Big Lung Trial confirm survival benefits meta-analysis assess quality life cost supportive care setting.,C0025663|G0000000|C1947946|C0549177|C0024109|C0008976|C0521093|C0038952|C0814225|C0282458|C1516048|C0332306|C0376558|C0010186|C1521721|C1947933|C0542559
The proportion of children <5 years old living in households where any ITN was used the night before the survey was used as a secondary outcome.,The proportion children <5 years living households ITN night survey secondary outcome.,G0000000|C1709707|C0008059|G0000000|C0376558|C0020052|G0000000|C0240526|C0038951|C0027627|C1274040
"Among lower income women (< $30 000), treatment effects were found at 8 and 12 months postpartum, with respective abstinence rates of 72.2% and 72.1% for FFB and 53.6% and 50.5% for UCC.","Among lower income women (< $30 000), treatment effects 8 12 months postpartum, respective abstinence rates 72.2% 72.1% FFB 53.6% 50.5% UCC.",G0000000|C0441994|C0021162|C0043210|G0000000|C0039798|C1280500|G0000000|C0450371|C0439231|C0086839|G0000000|C3843422|C0871208|C0450371|C0450371|G0000000|C0450371|C0450371|G0000000
"Preterm delivery was defined as delivery occurred at <37 weeks of pregnancy and newborn’s macrosomia was defined as birth weight of >4000 g. To calculate the sample size, we used the standard formula suggested for clinical trials by considering type one error (α) of 0.05 and type two error (β) of 0.20 (power = 80%).","Preterm delivery defined delivery occurred <37 weeks pregnancy newborn’s macrosomia defined birth weight >4000 g. To calculate sample size, standard formula suggested clinical trials type error (α) 0.05 type error (β) 0.20 (power = 80%).",C0151526|C0011209|C1704788|C0011209|C1709305|C0450371|C0439230|C0032961|G0000000|C0158915|C1704788|C0005615|C0005910|G0000000|C0439267|C0040363|C1441506|C0370003|C0456389|C1442989|C0489829|C1705535|C0205210|C0008976|C0332307|C0743559|G0000000|C0450371|C0332307|C0743559|G0000000|C0450371|G0000000
An electronic digital balance (Sartorious Corp) was used to obtain naked infant weight.,An electronic digital balance (Sartorious Corp) naked infant weight.,G0000000|C0013850|C0442015|C0014653|G0000000|C0683758|C0424470|C0021270|C0005910
We chose validated physical and functional capacity tests that would be feasible in this acute leukemia clinical setting.,We chose validated physical functional capacity tests feasible acute leukemia clinical setting.,G0000000|C1707391|G0000000|C0031809|C0205245|C1516240|C0022885|G0000000|C0205178|C0023418|C0205210|C0542559
"The primary hypothesis is that supplementing HBTPM with tailored NCM will lead to greater reduction in SBP and stroke recurrence rate than HBPTM alone at 12 and 24 months, respectively.","The primary hypothesis supplementing HBTPM tailored NCM lead reduction SBP stroke recurrence rate HBPTM 12 24 months, respectively.",G0000000|C0205225|C1512571|C0242295|G0000000|C0402883|C2681389|C0023175|C0301630|G0000000|C0038454|C0034897|C0871208|G0000000|C0450371|C0450371|C0439231|G0000000
"Since esophageal squamous cell carcinoma (ESCC) represents more than 99% of esophageal cancer cases in China [4], this study focused only on ESCC.","Since esophageal squamous cell carcinoma (ESCC) represents 99% esophageal cancer China [4], study focused ESCC.",C1711239|C1522619|C1182670|C0007634|C0007097|C0279626|C1882932|C0450371|C1522619|C0006826|C0008115|G0000000|C0557651|C0205234|C0279626
"The primary outcome was the change in sputum bacterial load, as assessed by quantitative culture.","The primary outcome change sputum bacterial load, assessed quantitative culture.",G0000000|C0205225|C1274040|C0392747|C0038056|C0521009|C1550025|C1516048|C0392762|C0010453
"The primary outcome measures are performance-based measures and rating measures of attention, memory, and executive functions.","The primary outcome measures performance-based measures rating measures attention, memory, executive functions.",G0000000|C0205225|C1274040|C0079809|C0597198|C0079809|C0871208|C0079809|C0004268|C0025260|C0871735|C0542341
Primary endpoint is mean HbA1c after 24 months of treatment.,Primary endpoint HbA1c 24 months treatment.,C0205225|C2349179|G0000000|C0450371|C0439231|C0039798
There was minimal loss to follow up.,There minimal loss follow up.,G0000000|C0547040|C1517945|C0332283|G0000000
"We analyzed the changes of the described test items including the evaluation of cognitive function before and after treatment within VR and control groups using Wilcoxon signed rank test, and we compared the difference of above test items including the evaluation of cognitive function before and after treatment between the VR and control groups using Mann-Whitney test.","We analyzed test items including evaluation cognitive function treatment VR control Wilcoxon signed rank test, compared difference test items including evaluation cognitive function treatment VR control Mann-Whitney test.",G0000000|C0936012|C0022885|C1551338|C0332257|C0220825|C1516691|C0031843|C0039798|C3476815|C0243148|G0000000|C1519316|C0699794|C0022885|C1707455|C1705241|C0022885|C1551338|C0332257|C0220825|C1516691|C0031843|C0039798|C3476815|C0243148|G0000000|C0022885
The cut-off point for the diagnosis of clinical depression in the Zung scale is above 50.,The cut-off diagnosis clinical depression Zung scale 50.,G0000000|C1442160|C0011900|C0205210|C0011570|G0000000|C0175659|C0450371
"Frequency of patients' presentation and admission to hospital; changes in patients' disease-specific quality of life, measured with St George's respiratory questionnaire, over three months after discharge; patients' knowledge of illness, self management, and satisfaction with care at discharge and three months later; frequency of general practitioner and nurse visits and their satisfaction with care.","Frequency patients' presentation admission hospital; patients' disease-specific quality life, measured St George's respiratory questionnaire, months discharge; patients' knowledge illness, management, satisfaction care discharge months later; frequency practitioner nurse visits satisfaction care.",C0376249|C0030705|C0449450|C0184666|C0019994|C0030705|C0012634|C0332306|C0376558|C0444706|C0036056|G0000000|C0521346|C0034394|C0439231|C0012621|C0030705|C0376554|C0221423|C0001554|C0242428|C1947933|C0012621|C0439231|C0205087|C0376249|C1709627|C0028661|C0545082|C0242428|C1947933
"MRI of the edaravone group showed a significant decrease in area of T1-weighted contrast enhancement (1.67 ± 4.69 cm2, p = 0.004) and the T2-weighted edema (5.08 ± 10.32 cm2, p = 0.000).","MRI edaravone decrease T1-weighted contrast enhancement (1.67 ± 4.69 cm2, = 0.004) T2-weighted edema (5.08 ± 10.32 cm2, = 0.000).",C0024485|C0070694|C0392756|C0041403|C0009924|C1627358|C0450371|G0000000|C0450371|G0000000|G0000000|C1442061|C0041403|C0013604|C0450371|G0000000|C0450371|G0000000|G0000000|C1442061
"In contrast, the Performance Test of Activities of Daily Living is a test rather than a rating scale.","In contrast, Performance Test Activities Daily Living test rating scale.",G0000000|C0009924|C0597198|C0022885|C0441655|C0332173|C0376558|C0022885|C0871208|C0175659
Additionally the patients were assessed on Mini mental status examination (MMSE)[20] and this was used as a secondary outcome measure for the study.,Additionally patients assessed Mini mental status examination (MMSE)[20] secondary outcome measure study.,G0000000|C0030705|C1516048|C0445542|C0229992|C0449438|G0000000|C0451306|C0027627|C1274040|C0079809|C0557651
The following oncologic outcomes are investigated in this trial.,The oncologic outcomes investigated trial.,G0000000|C0205478|C1274040|C1292732|C0008976
"Of the 44 retained in the study, two participants (both in the intervention group) developed cancer recurrence during the intervention.","Of 44 retained study, participants (both intervention group) developed cancer recurrence intervention.",G0000000|C0450371|C0333118|C0557651|C0679646|G0000000|C0886296|C0441833|G0000000|C0006826|C0034897|C0886296
"All subjects remained hospitalized for Days 0–3, returning for follow-up assessments on Days 7, 14, 21, 28, 35 and 42.","All subjects remained hospitalized Days 0–3, returning follow-up assessments Days 7, 14, 21, 28, 35 42.",G0000000|C0681850|G0000000|C0701159|C0439228|G0000000|C0332156|C0589120|C1261322|C0439228|G0000000|C0450371|C0450371|C0450371|C0450371|C0450371
"Of the target area injuries, 47% resulted from fires started by children playing with fire (fireplay).","Of target injuries, 47% fires started children playing fire (fireplay).",G0000000|C1521840|C1510467|C0450371|C0016141|C1272689|C0008059|C0032214|C0016141|G0000000
"Overall survival was defined as the time from study enrollment until death or the last contact with the patient, if death did not occur during the study.","Overall survival defined time study enrollment death contact patient, death occur study.",C0282416|C0038952|C1704788|C0040223|C0557651|C1516879|C0011065|C0332158|C0030705|C0011065|C1709305|C0557651
The response rates ranged from 13% to 24%.,The response rates ranged 13% 24%.,G0000000|C0871261|C0871208|C1514721|C0450371|C0450371
"The secondary impairment outcome measure was the Fugl-Meyer Scale for Wrist/Hand (FM W/H; maximum = 24)21 and the Motor Power Scale for Shoulder/Elbow (MP; maximum = 70).22 Other secondary outcomes included the Modified Ashworth Scale, passive movements graded 0 to 5, across 9 muscle groups.23 Disability scales were measured by the Stroke Impact Scale (SIS; maximum = 80; version 2.0)24 and the Action Research Arm Test (ARAT; maximum = 120).25 We also measured shoulder dislocation (Joint Stability = Jt Stab; maximum cm of displacement = 9, 3 principal directions of dislocation),26 pain scale from the Fugl-Meyer (maximum = 24), and the Beck Depression Scale (maximum = 63).","The secondary impairment outcome measure Fugl-Meyer Scale Wrist/Hand (FM W/H; maximum = 24)21 Motor Power Scale Shoulder/Elbow (MP; maximum = 70).22 Other secondary outcomes included Modified Ashworth Scale, passive movements graded 0 5, 9 muscle groups.23 Disability scales measured Stroke Impact Scale (SIS; maximum = 80; version 2.0)24 Action Research Arm Test (ARAT; maximum = 120).25 We measured shoulder dislocation (Joint Stability = Jt Stab; maximum cm displacement = 9, 3 principal directions dislocation),26 pain scale Fugl-Meyer (maximum = 24), Beck Depression Scale (maximum = 63).",G0000000|C0027627|C0221099|C1274040|C0079809|G0000000|C0175659|C0869996|C3540627|C0033727|C0806909|G0000000|C0450371|C1513492|C0032863|C0175659|C0037004|C0024944|C0806909|G0000000|C0450371|G0000000|C0027627|C1274040|C0332257|C0392747|G0000000|C0175659|C3686820|C0026649|C0441800|G0000000|G0000000|G0000000|C0026845|C0441833|C0231170|C0175659|C0444706|C0038454|C1825598|C0175659|C1704647|C0806909|G0000000|C0450371|C0333052|C0450371|C0441472|C0035168|C0446516|C0022885|C1152215|C0806909|G0000000|C1442061|G0000000|C0444706|C0037004|C0012691|C0022417|C0205360|G0000000|G0000000|C0418391|C0806909|G0000000|C0012725|G0000000|G0000000|G0000000|C0205225|C0439755|C0012691|C0030193|C0175659|G0000000|C0806909|G0000000|C0450371|G0000000|C0011570|C0175659|C0806909|G0000000|C0450371
"Two questionnaires were provided via the web tool to all participants for evaluation of depressive symptoms (Montgomery-Åsberg Depression Rating Scale (MADRS-S)) (32,33) and for issues regarding quality of life (PQ23 quality of life questionnaire) (34): at the start of the diary recording and after 5 and 8 months of recording.","Two questionnaires provided web tool participants evaluation depressive symptoms (Montgomery-Åsberg Depression Rating Scale (MADRS-S)) (32,33) issues quality life (PQ23 quality life questionnaire) (34): start diary recording 5 8 months recording.",C0205448|C0034394|C1999230|C0282111|C0336791|C0679646|C0220825|G0000000|C0683368|G0000000|C0011570|C0871208|C0175659|C4054475|C0450371|C0033213|C0332306|C0376558|G0000000|C0332306|C0376558|C0034394|C0450371|C0439659|C0376660|G0000000|G0000000|G0000000|C0439231|G0000000
"The first visit was followed by prospective, daily sleep diary collection of bedtime, sleep latency (SL), number of awakenings (NAW), wake after sleep onset (WASO), total sleep time (TST), and rising time for the duration of participation.","The visit prospective, daily sleep diary collection bedtime, sleep latency (SL), awakenings (NAW), wake sleep onset (WASO), total sleep time (TST), rising time duration participation.",G0000000|C0545082|C0023981|C0332173|C0037313|C0376660|C1516698|C0521112|C0037313|C0205275|G0000000|C1720052|G0000000|C0442696|C0037313|C0206132|G0000000|C0439175|C0037313|C0040223|C1421210|G0000000|C0040223|C0449238|C0679823
No adverse events were reported in the trial.,No adverse events reported trial.,G0000000|G0000000|C0441471|C0684224|C0008976
Survival of all patients (A) and patients with Charlson score >4 (C) at 1 year.,Survival patients (A) patients Charlson score >4 (C) 1 year.,C0038952|C0030705|G0000000|C0030705|G0000000|C0449820|G0000000|G0000000|G0000000|C0439234
"Therapeutic efficacy was assessed based on trunk postural stability, balance, and upper limb motor function.","Therapeutic efficacy assessed based trunk postural stability, balance, upper limb motor function.",C0087111|C1280519|C1516048|C1527178|C0225442|C0205278|C0205360|C0014653|C1282910|C0015385|C1513492|C0031843
We evaluated the effect of screening with flexible sigmoidoscopy on colorectal-cancer incidence and mortality.,We evaluated screening flexible sigmoidoscopy colorectal-cancer incidence mortality.,G0000000|C0220825|C0220908|C0443220|C0037075|C0009402|C0021149|C0026565
"Satisfaction with labour pain relief; memory of labour pain; psychological morbidity/wellbeing; satisfaction with life, and expectation and experience of anxiety and fear.","Satisfaction labour pain relief; memory labour pain; psychological morbidity/wellbeing; satisfaction life, expectation experience anxiety fear.",C0242428|C0022864|C0030193|C0564405|C0025260|C0022864|C0030193|C0205486|C0026538|C0242428|C0376558|C0679138|C0237607|C0003467|C0015726
"Electroneurography, motor distal latency, peak to peak amplitude, and antidromic sensory nerve conduction velocity did not differ significantly between wrists.","Electroneurography, motor distal latency, peak peak amplitude, antidromic sensory nerve conduction velocity wrists.",C0919612|C1513492|C0205108|C0205275|C0444505|C0444505|C2346753|G0000000|C0445254|C0027740|C0232217|C0439830|C0043262
Values for after treatment (12 weeks) and follow-up (24 weeks) are means (SD) ADL=activities of daily living.,Values treatment (12 weeks) follow-up (24 weeks) (SD) ADL=activities daily living.,C0042295|C0039798|C0450371|C0439230|C0589120|C0450371|C0439230|G0000000|C0001288|C0332173|C0376558
"[60,61] Consumption of calcium-Vitamin D supplements for 9 weeks among pregnant women resulted in a significant decrease in serum hs-CRP and DBP and a significant increase in serum Vitamin D, calcium, and plasma TAC levels, but had no effect on pregnancy outcomes, maternal FPG, serum insulin levels, and insulin action as well as plasma total GSH.","[60,61] Consumption calcium-Vitamin D supplements 9 weeks pregnant women decrease serum hs-CRP DBP increase serum Vitamin D, calcium, plasma TAC levels, pregnancy outcomes, maternal FPG, serum insulin levels, insulin action plasma total GSH.",C0450371|C0009830|C0006675|C0073187|C0242295|G0000000|C0439230|C0549206|C0043210|C0392756|C0229671|C3890735|C0536221|C0442805|C0229671|C0042890|C0073187|C0006675|C0032105|C1883257|C0441889|C0032961|C1274040|C2347083|G0000000|C0229671|C0021641|C0441889|C0021641|C0441472|C0032105|C0439175|C0017817
"Of the 461 children initiated on ART, 324 (70%) had at least one viral load measurement post-ART initiation (after a median time of 5.51 months of ART initiation) of whom 291 (90%) ever achieved viral load below 400 copies/ml.","Of 461 children initiated ART, 324 (70%) viral load measurement post-ART initiation (after median time 5.51 months ART initiation) 291 (90%) achieved viral load 400 copies/ml.",G0000000|C1442061|C0008059|C1548602|C0003826|C1442061|C0450371|C0521026|C1550025|C0242485|C0687676|C0589507|G0000000|C0549183|C0040223|C0450371|C0439231|C0003826|C0589507|C1442061|C0450371|G0000000|C0521026|C1550025|C1442061|C1531853
"The cutoff value for clinical remission has been set at ≥170 points and a ≥32-point change in score is considered to be a clinically significant response (Hlavaty et al., 2006).","The cutoff clinical remission set ≥170 ≥32-point change score considered clinically response (Hlavaty al., 2006).",G0000000|C1442160|C0205210|C0544452|C0036849|G0000000|G0000000|C0392747|C0449820|C0750591|G0000000|C0871261|G0000000|C0202311|G0000000
Secondary outcomes were the group difference in the proportion of children with total 25OHD ≥75 nmol/L (30 ng/mL) at 3 months and in total 25OHD values over 6 months.,Secondary outcomes difference proportion children total 25OHD ≥75 nmol/L (30 ng/mL) 3 months total 25OHD values 6 months.,C0027627|C1274040|C1705241|C1709707|C0008059|C0439175|G0000000|G0000000|C0439282|C0450371|C0439275|G0000000|C0439231|C0439175|G0000000|C0042295|G0000000|C0439231
"The 90-minute battery includes seven well-known and widely used tests covering the five cognitive domains as listed below: Controlled Oral Word Association Test (COWAT)23 - verbal fluency and word finding; The Judgment of Line Orientation test (JLO)23 - visuospatial processing; The California Verbal Learning Test, second edition, (CVLT-II)24 - verbal learning and remembering; The Brief Visuospatial Memory Test - Revised (BVMT-R)25 - nonverbal learning and memory; The Paced Auditory Serial Addition Test (PASAT)26 - auditory information processing speed and flexibility as well as calculation abilities; The Symbol Digit Modalities Test (SDMT)27 - complex scanning and visual tracking; and The Sorting Test from the Delis-Kaplan Executive Function System (DKEFS)28 - higher executive function skills.","The 90-minute battery includes well-known tests covering cognitive domains listed below: Controlled Oral Word Association Test (COWAT)23 - verbal fluency word finding; The Judgment Line Orientation test (JLO)23 - visuospatial processing; The California Verbal Learning Test, edition, (CVLT-II)24 - verbal learning remembering; The Brief Visuospatial Memory Test - Revised (BVMT-R)25 - nonverbal learning memory; The Paced Auditory Serial Addition Test (PASAT)26 - auditory processing speed flexibility calculation abilities; The Symbol Digit Modalities Test (SDMT)27 - complex scanning visual tracking; The Sorting Test Delis-Kaplan Executive Function System (DKEFS)28 - executive function skills.",G0000000|C0450371|C0337088|C0332257|C0205170|C0022885|C0180153|C1516691|C1880389|C0745732|G0000000|C2587213|C0442027|C1705313|C0004083|C0022885|C3827022|G0000000|C0439824|C0870569|C1705313|C0037088|G0000000|C0022423|C0205132|C0029266|C0022885|C0450371|G0000000|G0000000|C1709694|G0000000|C0006754|C0439824|C0013621|C0022885|C0441792|C3899729|G0000000|C0439824|C0013621|C0034770|G0000000|C1282927|G0000000|C0025260|C0022885|G0000000|C1527075|C0205090|G0000000|C0746940|C0013621|C0025260|G0000000|C0287990|C0439825|C0031082|C0332287|C0022885|C3898036|G0000000|C0439825|C1709694|C0678536|C0242808|C1441506|C0085732|G0000000|C0679214|C0582802|C0695347|C0022885|C3268430|G0000000|C0439855|C0034606|C0234621|C0546881|G0000000|C0237886|C0022885|G0000000|C0871735|C0031843|C0449913|C0450371|G0000000|C0871735|C0031843|C0678856
"In this scale, a summary score of 1 to 5 is obtained, with a higher score indicating greater symptom severity.38 Secondary outcomes were Functional Status Scale of the Boston Carpal Tunnel Questionnaire,37 Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire,39 pain intensity measured using the numeric rating scale, sensation measured using the Semmes–Weinstein monofilament test, dexterity meassured using the Dellon-modified pick-up test and maximal tip pinch strength.","In scale, summary score 1 5 obtained, score indicating symptom severity.38 Secondary outcomes Functional Status Scale Boston Carpal Tunnel Questionnaire,37 Disabilities Arm, Shoulder Hand (DASH) Questionnaire,39 pain intensity measured numeric rating scale, sensation measured Semmes–Weinstein monofilament test, dexterity meassured Dellon-modified pick-up test maximal pinch strength.",G0000000|C0175659|C1552616|C0449820|G0000000|G0000000|C1301820|C0449820|G0000000|C1457887|C0439793|C0027627|C1274040|C0205245|C0449438|C0175659|C0006037|C0007285|C0337138|C0034394|C0231170|C0446516|C0037004|C0018563|C2827624|C0034394|C0030193|C0522510|C0444706|C0237753|C0871208|C0175659|C0036658|C0444706|G0000000|G0000000|C0022885|C0565699|G0000000|C0392747|C1707391|C0022885|C0205289|C0418416|C0237897
Main outcome measures Complete clearance of all plantar warts at 12 weeks.,Main outcome measures Complete clearance plantar warts 12 weeks.,C0205225|C1274040|C0079809|C0205197|C0449297|C0230463|C1367460|C0450371|C0439230
"Secondary outcomes included low birth weight <2000 g, severe preterm delivery (<34 wk of gestation), small-for-gestational-age (birth weight below the 10th percentile of weight-for-gestational-age by the reference of Brenner et al; 21), fetal death (miscarriage or stillbirths), and infant death during the first 6 wk of life.","Secondary outcomes included low birth weight <2000 g, severe preterm delivery (<34 wk gestation), small-for-gestational-age (birth weight 10th percentile weight-for-gestational-age reference Brenner al; 21), fetal death (miscarriage stillbirths), infant death 6 wk life.",C0027627|C1274040|C0332257|C0205251|C0005615|C0005910|G0000000|C0439267|C0205082|C0151526|C0011209|C0450371|C0332174|C0032961|C0700321|C0005615|C0005910|G0000000|C1264641|C0005910|C1514811|G0000000|C0202311|C0450371|C0015965|C0011065|C0000786|C0595939|C0021270|C0011065|G0000000|C0332174|C0376558
"Primary outcome measures assessed at baseline and week 8 included the Connor Davidson Resilience Scale (CDRS), Perceived Stress Scale (PSS), Smith Anxiety Scale (SAS) and Linear Analog Self Assessment Scale (LASA).","Primary outcome measures assessed baseline week 8 included Connor Davidson Resilience Scale (CDRS), Perceived Stress Scale (PSS), Smith Anxiety Scale (SAS) Linear Analog Self Assessment Scale (LASA).",C0205225|C1274040|C0079809|C1516048|C0168634|C0332174|G0000000|C0332257|G0000000|G0000000|G0000000|C0175659|G0000000|C0030971|C0038435|C0175659|G0000000|C0554249|C0003467|C0175659|C0605290|C0205132|C0243071|C0036588|C1261322|C0175659|C0065034
"A relatively low percentage of study patients, however, had their CD4 cell count monitored in the first year after ART initiation (41.9% in the first 90–210 days and 20.4% in the first 330–390 days).","A low percentage study patients, however, CD4 cell count monitored ART initiation (41.9% 90–210 days 20.4% 330–390 days).",G0000000|C0205251|C0439165|C0557651|C0030705|G0000000|C0285590|C0007634|C0750480|C0030695|C0003826|C0589507|C0450371|G0000000|C0439228|C0450371|G0000000|C0439228
Delirium severity was measured with MDAS.,Delirium severity measured MDAS.,C0011206|C0439793|C0444706|C0000379
ABC = Activities-specific Balance Confidence Scale; Base = baseline assessment period; BBS = Berg Balance Scale; DGI = Dynamic Gait Index; FM-LE = Fugl-Meyer Lower Extremity subscale; Post = posttest assessment period; Pre = pretest assessment period; SIS = Stroke Impact Scale.,ABC = Activities-specific Balance Confidence Scale; Base = baseline assessment period; BBS = Berg Balance Scale; DGI = Dynamic Gait Index; FM-LE = Fugl-Meyer Lower Extremity subscale; Post = posttest assessment period; Pre = pretest assessment period; SIS = Stroke Impact Scale.,C0152244|G0000000|C0441655|C0014653|C0237529|C0175659|C0002055|G0000000|C0168634|C1261322|C0439531|G0000000|G0000000|G0000000|C0014653|C0175659|G0000000|G0000000|C0729333|C0016928|C0918012|C3540627|G0000000|G0000000|C0441994|C0015385|G0000000|C0687676|G0000000|G0000000|C1261322|C0439531|C0332152|G0000000|C0033101|C1261322|C0439531|C1704647|G0000000|C0038454|C1825598|C0175659
"Baseline and 6-month follow-up assessments included measures of career readiness and risk behavior involvement (i.e., physical fighting, alcohol and marijuana use).","Baseline 6-month follow-up assessments included measures career readiness risk behavior involvement (i.e., physical fighting, alcohol marijuana use).",C0168634|C0332177|C0589120|C1261322|C0332257|C0079809|C0178534|C1318963|C0035647|C0004927|C1314939|C0683454|C0031809|C0424324|C0001962|C0024808|C0042153
The generated data were analysed using Statistical Package for Social Sciences (SPSS) version 16.,The generated data analysed Statistical Package Social Sciences (SPSS) version 16.,G0000000|C3146294|C1511726|G0000000|C0038215|C0013194|C0728831|C0036397|C3813609|C0333052|C0450371
The relapse rate in group A in the present study (0.41/person-year) was not inferior to the relapse rates in previous studies.,The relapse rate A study (0.41/person-year) inferior relapse rates previous studies.,G0000000|C0035020|C0871208|G0000000|C0557651|C0450371|C0542339|C0035020|C0871208|C0205156|C0947630
"The primary analysis will compare the observed mean summed ranks of the five efficacy measures listed above in the creatine arm to the placebo arm in a nonparametric GST, adjusted for site27;28.","The primary analysis compare observed summed ranks efficacy measures listed creatine arm placebo arm nonparametric GST, adjusted site27;28.",G0000000|C0205225|C0002778|C1707455|C1441672|C1515051|C0699794|C1280519|C0079809|C0745732|C0010286|C0446516|C0032042|C0446516|G0000000|G0000000|C0456081|C0450371
The primary outcome measure was trough FEV1 (mean of the values at 23 h 15 min and 23 h 45 min after dosing) at Week 12.,The primary outcome measure trough FEV1 (mean values 23 15 min 23 45 min dosing) Week 12.,G0000000|C0205225|C1274040|C0079809|C0444506|G0000000|C0444504|C0042295|C0450371|C0450371|C0702093|C0450371|C0450371|C0702093|G0000000|C0332174|C0450371
"There was a reduction in coughing episodes in both groups, as well as in the cough score after 30minutes of drug or honey administration.","There reduction coughing episodes groups, cough score 30minutes drug honey administration.",G0000000|C0301630|C0010200|C0332189|C0441833|C0010200|C0449820|G0000000|C0013227|C0019906|C0001554
"There were no statistically significant between-group differences for treatment success, treatment failure or patient assessment of medication effectiveness.","There statistically between-group differences treatment success, treatment failure patient assessment medication effectiveness.",G0000000|C0038215|C0441833|C1705241|C0039798|C0597535|C0039798|C0231174|C0030705|C1261322|C0013227|C1280519
"However, the mortality rate of An.","However, mortality rate An.",G0000000|C0026565|C0871208|G0000000
"[20] Furthermore, Vitamin D supplement[21] during pregnancy is necessary.","[20] Furthermore, Vitamin D supplement[21] pregnancy necessary.",C0450371|G0000000|C0042890|C0073187|C0242295|C0032961|G0000000
"Safety and tolerability were assessed by vital signs, safety lab, ECG, and adverse reporting.","Safety tolerability assessed vital signs, safety lab, ECG, adverse reporting.",C0036043|C3274448|C1516048|C0442732|C0220912|C0036043|C0022877|C1623258|G0000000|C0700287
This assumption is supported by findings in another Scandinavian study where parents’ assessment of child development with the ASQ:SE was strongly predicted by maternal stress [113].,This assumption supported findings Scandinavian study parents’ assessment child development ASQ:SE predicted maternal stress [113].,G0000000|G0000000|C1521721|C2607943|C0240951|C0557651|G0000000|C1261322|C0008059|C0243107|C3476780|C0681842|C2347083|C0038435|C1442061
The primary end point of the study was local recurrence.,The primary study local recurrence.,G0000000|C0205225|C0557651|C0205276|C0034897
"At baseline, 65.8% of the combined intervention group and 70.1% of the media-only group reported having already had at least 1 Pap test (Table 2 ▶).","At baseline, 65.8% combined intervention 70.1% media-only reported 1 Pap test (Table 2 ▶).",G0000000|C0168634|C0450371|C0205195|C0886296|C0450371|C0009458|C0684224|G0000000|C1740167|C0022885|C0039224|G0000000|G0000000
Qualitative data collected in 1999–2002 and more recently in 2007/8 suggest that there was little other governmental or non-governmental organisation SRH intervention activity in the trial communities.,Qualitative data collected 1999–2002 2007/8 governmental non-governmental organisation SRH intervention activity trial communities.,C0205556|C1511726|C1516695|G0000000|G0000000|C0018104|C1518422|C0029237|G0000000|C0886296|C0205177|C0008976|C0009462
"PDA, Patent ductus arteriosus; IVH, intraventricular haemorrhage; PVL, periventricular leucomalacia; ROP, retinopathy of prematurity; BPD, bronchopulmonary dysplasia; NEC, necrotising enterocolitis.","PDA, Patent ductus arteriosus; IVH, intraventricular haemorrhage; PVL, periventricular leucomalacia; ROP, retinopathy prematurity; BPD, bronchopulmonary dysplasia; NEC, necrotising enterocolitis.",C0013274|C0030650|C1512083|G0000000|G0000000|C1517569|C0019080|C0023529|G0000000|G0000000|C0035344|C0035309|C0021294|G0000000|C0545675|C0334044|C0206695|C0439664|C0014356
"The end point for disease-free survival was the first occurrence of death from any cause or tuberculosis disease, and the end point for infection-free survival was the first occurrence of death from any cause, tuberculosis disease, or MTB infection.","The disease-free survival occurrence death tuberculosis disease, infection-free survival occurrence death cause, tuberculosis disease, MTB infection.",G0000000|C0012634|C0038952|C0243132|C0011065|C0041296|C0012634|C0009450|C0038952|C0243132|C0011065|C0015127|C0041296|C0012634|G0000000|C0009450
Results: A total of 282 children were enrolled.,Results: A total 282 children enrolled.,C1274040|G0000000|C0439175|C1442061|C0008059|G0000000
"As only the outer surface of the FFR was contaminated with the fluorescent tracer, transfer from the FFR to the hands would only occur if the FFR was doffed improperly by grasping the contaminated surface.","As outer surface FFR contaminated fluorescent tracer, transfer FFR hands occur FFR doffed improperly grasping contaminated surface.",G0000000|C0205101|C0205148|C1412871|C0205279|C0303920|C1522485|C0040671|C1412871|C0018563|C1709305|C1412871|G0000000|G0000000|C0220843|C0205279|C0205148
There was no lower limit for FEV1.,There lower limit FEV1.,G0000000|C0441994|C0439801|G0000000
"Additionally, the study will evaluate whether acupuncture can reduce QOL-related side effects such as fatigue, headache, nausea etc.","Additionally, study evaluate acupuncture reduce QOL-related effects fatigue, headache, nausea etc.",G0000000|C0557651|C0220825|C0001299|G0000000|C0518214|C1280500|C0015672|C0018681|C0027497|C1548556
The primary clinical outcome was the incidence of clinical malaria in study children defined as a history of fever within the last 48 hours or axillary temperature ≥ 37.5°C plus the presence of Plasmodium falciparum identified microscopically.,The primary clinical outcome incidence clinical malaria study children defined history fever 48 hours axillary temperature ≥ 37.5°C presence Plasmodium falciparum identified microscopically.,G0000000|C0205225|C0205210|C1274040|C0021149|C0205210|C0024530|C0557651|C0008059|C1704788|C0019664|C0015967|C0450371|C0439227|C0004454|C0005903|G0000000|G0000000|C0150312|C0032148|G0000000|C0205396|G0000000
"Infection rate within 11 days was significantly associated with tube feeding, mechanical ventilation, treatment, and monocytic HLA-DR levels at baseline (day 1 after stroke onset and before study treatment onset) in univariate PP analysis of the placebo group (Table 5).","Infection rate 11 days tube feeding, mechanical ventilation, treatment, monocytic HLA-DR levels baseline (day 1 stroke onset study treatment onset) univariate PP analysis placebo (Table 5).",C0009450|C0871208|C0450371|C0439228|C0175730|C0204695|C0443254|C0035203|C0039798|C0026473|C0019764|C0441889|C0168634|C0332173|G0000000|C0038454|C0206132|C0557651|C0039798|C0206132|G0000000|C0030375|C0002778|C0032042|C0039224|G0000000
Long term clinical trials evaluating the efficacy of sodium reduction on clinical events have not been conducted because of logistic and feasibility considerations.,Long term clinical trials evaluating efficacy sodium reduction clinical events conducted logistic feasibility considerations.,C0205166|C0233324|C0205210|C0008976|C0220825|C1280519|C0037473|C0301630|C0205210|C0441471|C0004927|C0242415|G0000000|C0518609
"For VAS questionnaire, 100-mm lines were prepared for each item with the left and right edges indicating worst and best states, respectively.","For VAS questionnaire, 100-mm lines prepared item left edges indicating worst states, respectively.",G0000000|C0042815|C0034394|C1442061|C0205132|C4082130|C1551338|C0205091|C0205154|G0000000|C1522166|C1301808|G0000000
This study provides no evidence that ovarian stimulation is associated with an elevated risk of ovarian cancer.,This study evidence ovarian stimulation elevated risk ovarian cancer.,G0000000|C0557651|C3887511|C0205065|C1292856|C0205250|C0035647|C0205065|C0006826
"A special feature of this project is the selection of birth length (length-for-age Z-score, LAZ) as the primary outcome.","A special feature project selection birth length (length-for-age Z-score, LAZ) primary outcome.",G0000000|C0205555|C1521970|C1709701|C0036576|C0005615|C1444754|C1444754|C0871421|G0000000|C0205225|C1274040
"3 months of age, hence adjustment for diet or physical activity variables is not possible).","3 months age, adjustment diet physical activity variables possible).",G0000000|C0439231|C0001779|C0376209|C0012155|C0031809|C0205177|C0439828|C0332149
"The principal secondary endpoint consisted of a composite of cardiovascular death, reinfarction, or stroke.","The principal secondary endpoint consisted composite cardiovascular death, reinfarction, stroke.",G0000000|C0205225|C0027627|C2349179|C0332529|C0205199|C0007226|C0011065|G0000000|C0038454
"Secondary outcomes were the total number of hospital days used up to 12 months and full remission, defined as healthy weight (>95% EBW) and a global Eating Disorder Examination (EDE) score within 1 standard deviation (s.d.)","Secondary outcomes total hospital days 12 months remission, defined healthy weight (>95% EBW) global Eating Disorder Examination (EDE) score 1 standard deviation (s.d.)",C0027627|C1274040|C0439175|C0019994|C0439228|C0450371|C0439231|C0544452|C1704788|C3898900|C0005910|C0450371|G0000000|C0205246|C0013470|C0012634|G0000000|G0000000|C0449820|G0000000|C1442989|C0012727|C0565930
"Lower extremity motor subscale of Fugl Meyer Assessment (FMA), Brunnel Balance Assessment (BBA) and Functional Ambulation Categories (FAC).","Lower extremity motor subscale Fugl Meyer Assessment (FMA), Brunnel Balance Assessment (BBA) Functional Ambulation Categories (FAC).",C0441994|C0015385|C1513492|G0000000|G0000000|G0000000|C1261322|C2332774|G0000000|C0014653|C1261322|C1549949|C0205245|C0080331|C0683312|G0000000
"The 40-item Social Communication Questionnaire was applied to investigate autistic traits at 36 months, with a cut-off score at 15 or more positive items (Rutter 2006;Snow & Lecavalier 2008).","The 40-item Social Communication Questionnaire applied investigate autistic traits 36 months, cut-off score 15 positive items (Rutter 2006;Snow & Lecavalier 2008).",G0000000|C0450371|C0728831|C0009452|C0034394|C4048755|C1292732|C0004352|C0599883|C0450371|C0439231|C1442160|C0449820|C0450371|C0439178|C1551338|G0000000|C0037386|G0000000|G0000000|G0000000
There was no difference in the number of symptom free days.,There difference symptom free days.,G0000000|C1705241|C1457887|C0332296|C0439228
Combination treatment also improved RV function in severe cardiac siderosis.,Combination treatment improved RV function severe cardiac siderosis.,C0205195|C0039798|C0184511|C0035190|C0031843|C0205082|C0018787|C0037061
Primary outcome criterion was the change in the Bronchitis Severity Score (BSS) from day 0 to day 7.,Primary outcome criterion change Bronchitis Severity Score (BSS) day 0 day 7.,C0205225|C1274040|C0243161|C0392747|C0006277|C0439793|C0449820|G0000000|C0332173|G0000000|C0332173|G0000000
"The population attributable risk percentage of preterm delivery attributable to cervical conisation before 28, 33, and 37 weeks of gestation was 2.0%, 1.7%, and 1.2%, respectively.","The population attributable risk percentage preterm delivery attributable cervical conisation 28, 33, 37 weeks gestation 2.0%, 1.7%, 1.2%, respectively.",G0000000|C0032659|C0596130|C0035647|C0439165|C0151526|C0011209|C0596130|C0027530|C0195324|C0450371|C0450371|C0450371|C0439230|C0032961|G0000000|G0000000|G0000000|G0000000
Pain intensity at all the three stages of cervical dilatation was significantly lower in the reflexology group.,Pain intensity stages cervical dilatation lower reflexology group.,C0030193|C0522510|C1306673|C0027530|C0012359|C0441994|C0034945|C0441833
"For instance, the only subjects who participated in phase 2 of the study were those that had an optimal montage identified in phase 1, further limiting the sample size.","For instance, subjects participated phase 2 study optimal montage identified phase 1, limiting sample size.",G0000000|C1550608|C0681850|G0000000|C0205390|G0000000|C0557651|C2698651|G0000000|C0205396|C0205390|G0000000|C0439801|C0370003|C0456389
Incident cataract responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-report confirmed by medical record review.,Incident cataract responsible reduction best-corrected visual acuity 20/30 worse based self-report confirmed medical record review.,C1551358|C0086543|C1273518|C0301630|C4072794|C0234621|C0750509|C0450371|C0332271|C1527178|C0681906|C0521093|C0199168|C0034869|C0282443
"Mortality was reduced in HIV-positive participants from 12 with placebo to 4 with supplementation (P = 0.029 by log-rank test), but this was not due to changes in CD4 count or nutritional status.","Mortality reduced HIV-positive participants 12 placebo 4 supplementation (P = 0.029 log-rank test), CD4 count nutritional status.",C0026565|C0392756|C0019699|C0679646|C0450371|C0032042|G0000000|C0242297|C0369773|G0000000|C1442061|C1708728|C0022885|C0285590|C0750480|C1521739|C0449438
"Solicited local symptoms (ie, those at the injection site) and general symptoms were assessed during the 7-day postvaccination period after each dose of H5N1 vaccine or placebo.","Solicited local symptoms (ie, injection site) symptoms assessed 7-day postvaccination period dose H5N1 vaccine placebo.",G0000000|C0205276|C0683368|G0000000|C0021485|C0205145|C0683368|C1516048|C0332173|G0000000|C0439531|C0178602|G0000000|C0042210|C0032042
Adherence to the guidelines was defined by measures of process as recorded in the patients' records.,Adherence guidelines defined measures process recorded patients' records.,C1510802|C0162791|C1704788|C0079809|C1184743|C0034869|C0030705|C0034869
"The outcome measures also included assessment of pain when walking on a flat surface, investigator's global assessment of treatment response as well as patient's global assessment of treatment satisfaction.","The outcome measures included assessment pain walking flat surface, investigator's global assessment treatment response patient's global assessment treatment satisfaction.",G0000000|C1274040|C0079809|C0332257|C1261322|C0030193|C0080331|C0205324|C0205148|C0035173|C0205246|C1261322|C0039798|C0871261|C0030705|C0205246|C1261322|C0039798|C0242428
"Number (percentage) of children with anaemia at Week 12 and Week 24 of supplementation by treatment groups A, B Within each class of anaemic status at baseline, groups with different letters have significant differences (McNemar Test, P < 0.05).","Number (percentage) children anaemia Week 12 Week 24 supplementation treatment A, B Within class anaemic status baseline, letters differences (McNemar Test, P < 0.05).",C0237753|C0439165|C0008059|C0002871|C0332174|C0450371|C0332174|C0450371|C0242297|C0039798|G0000000|G0000000|G0000000|C0456387|C0857322|C0449438|C0168634|C0282413|C1705241|G0000000|C0022885|C0369773|G0000000|C0450371
"There were no significant differences in the proportion of infants who survived, required oxygen at 28 days, required oxygen at 36 weeks postmenstrual age, survived without chronic lung disease at 36 weeks, survived without significant retinopathy, or who survived without significant intraventricular haemorrhage.","There differences proportion infants survived, required oxygen 28 days, required oxygen 36 weeks postmenstrual age, survived chronic lung disease 36 weeks, survived retinopathy, survived intraventricular haemorrhage.",G0000000|C1705241|C1709707|C0021270|C0310255|C1514873|C0030054|C0450371|C0439228|C1514873|C0030054|C0450371|C0439230|G0000000|C0001779|C0310255|C0205191|C0024109|C0012634|C0450371|C0439230|C0310255|C0035309|C0310255|C1517569|C0019080
"At least 15 sensory nerve action potentials were averaged, and antidromic sensory nerve conduction velocity was calculated as appropriate.","At 15 sensory nerve action potentials averaged, antidromic sensory nerve conduction velocity calculated appropriate.",G0000000|C0450371|C0445254|C0027740|C0441472|C3245505|C1510992|G0000000|C0445254|C0027740|C0232217|C0439830|C0444686|C1548787
Rhinovirus type 39 was used for these studies.,Rhinovirus type 39 studies.,C0035473|C0332307|C0450371|C0947630
"The 19-item Rape Myth Scale (RMS) measured attitudes and generally false beliefs about rape that function to deny and justify male sexual aggression (Lonsway & Fitzgerald, 1995; α = .89).","The 19-item Rape Myth Scale (RMS) measured attitudes false beliefs rape function deny justify male sexual aggression (Lonsway & Fitzgerald, 1995; α = .89).",G0000000|C0450371|C0034668|C0870933|C0175659|C0722978|C0444706|C0004271|C0205237|C0004951|C0034668|C0031843|C2700401|C1552821|C0086582|C0036864|C0001807|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371
"Subjects were followed for three months and had a total of four study visits (baseline and 1 week, 1 month, and 3 months after treatment).","Subjects months total study visits (baseline 1 week, 1 month, 3 months treatment).",C0681850|C0439231|C0439175|C0557651|C0545082|C0168634|G0000000|C0332174|G0000000|C0332177|G0000000|C0439231|C0039798
"At 18 months of age, infant length (trial primary endpoint) is recorded 3 times.","At 18 months age, infant length (trial primary endpoint) recorded 3 times.",G0000000|C0450371|C0439231|C0001779|C0021270|C1444754|C0008976|C0205225|C2349179|C0034869|G0000000|C0040223
"Poverty may cause delays in accessing initial treatment for TB, thus delaying the detection and treatment of TB and its complications.","Poverty delays accessing initial treatment TB, delaying detection treatment TB complications.",C0032854|C0205421|C0444454|C0205265|C0039798|G0000000|C0205421|C1511790|C0039798|G0000000|C0009566
Two indicators were recorded for further analysis: oxygen pressure (pO2) and carbon dioxide pressure (pCO2) in capillary blood.,Two indicators recorded analysis: oxygen pressure (pO2) carbon dioxide pressure (pCO2) capillary blood.,C0205448|C0021212|C0034869|C0002778|C0030054|C0033095|C1418945|C0007009|C0678717|C0033095|G0000000|C0006901|C0005767
"Drinking frequency (days per month), quantity (drinks per occasion), and frequency of high-volume drinking (≥5 drinks per occasion).","Drinking frequency (days month), quantity (drinks occasion), frequency high-volume drinking (≥5 drinks occasion).",C0001948|C0376249|C0439228|C0332177|C1265611|C0452428|C0521114|C0376249|C0205250|C0001948|G0000000|C0452428|C0521114
"SGRQ-C score at week 26, change from baseline in each treatment group (by FAS and PPS).","SGRQ-C score week 26, change baseline treatment (by FAS PPS).",C3826872|C0449820|C0332174|C0450371|C0392747|C0168634|C0039798|G0000000|G0000000|G0000000
No change from baseline in any CFQ-R domain was significant.,No change baseline CFQ-R domain significant.,G0000000|C0392747|C0168634|C0205090|C1880389|C0237881
"Using the eighth grade outcomes, we found no differences between schools in the level or rates of antisocial behavior (F = 1.43, p = .24), alcohol use (F = .79, p = .45), tobacco use (F = .67, p = .51), or marijuana use (F = .66, p = .51).","Using eighth grade outcomes, differences schools level rates antisocial behavior (F = 1.43, = .24), alcohol (F = .79, = .45), tobacco (F = .67, = .51), marijuana (F = .66, = .51).",C1524063|C0205442|C0441800|C1274040|C1705241|C0036375|C0441889|C0871208|C0233523|C0004927|C0016327|G0000000|C0450371|G0000000|C0450371|C0001962|C0016327|G0000000|C0450371|G0000000|C0450371|C0040329|C0016327|G0000000|C0450371|G0000000|C0450371|C0024808|C0016327|G0000000|C0450371|G0000000|C0450371
"The VAS, algometer, ODI, RMDQ, and FBQ scores showed significant differences in groups.","The VAS, algometer, ODI, RMDQ, FBQ scores differences groups.",G0000000|C0042815|G0000000|G0000000|G0000000|G0000000|C0449820|C1705241|C0441833
Correlation between the reduction of 24-hour urine sodium and albumin excretion after low-salt diet (LSD) education.,Correlation reduction 24-hour urine sodium albumin excretion low-salt diet (LSD) education.,C1707520|C0301630|C0450371|C0042036|C0037473|C0001924|C0221102|C0205251|C0012155|C0024334|C0013621
Another 15% of patients had a substantial reduction in seizure frequency (Engel class II outcome).,Another 15% patients substantial reduction seizure frequency (Engel class II outcome).,G0000000|C0450371|C0030705|G0000000|C0301630|C0036572|C0376249|G0000000|C0456387|G0000000|C1274040
We may need to include arm function measured by the ARAT as an eligibility criterion for a Phase III study [25].,We arm function measured ARAT eligibility criterion Phase III study [25].,G0000000|C0446516|C0031843|C0444706|C1152215|C0013893|C0243161|C0205390|C0439070|C0557651|C0450371
"Migraine frequency of both migraine groups for all measurement points n number of patients, M mean value, SD standard deviation Migraine frequency for both migraine groups in the course of the study for a number of migraine attacks and b days with migraine The decline in migraine frequency corresponds to a reduction of 24 and 41 % for number of migraine attacks from the first to the second and the third recording, respectively.","Migraine frequency migraine measurement patients, M value, SD standard deviation Migraine frequency migraine study migraine attacks days migraine The decline migraine frequency corresponds reduction 24 41 % migraine attacks recording, respectively.",C0149931|C0376249|C0149931|C0242485|C0030705|C0369637|C1522609|C2699239|C1442989|C0012727|C0149931|C0376249|C0149931|C0557651|C0149931|C1261512|C0439228|C0149931|G0000000|G0000000|C0149931|C0376249|G0000000|C0301630|C0450371|C0450371|G0000000|C0149931|C1261512|G0000000|G0000000
"Finally, the pain level was scored on a visual analogue scale before and after a 20 minute session of ""real"" or ""sham"" 10 Hz rTMS over the side of the motor cortex corresponding to the hand on the painful side, even if the pain was not experienced in the hand itself.","Finally, pain level scored visual analogue scale 20 minute session ""real"" ""sham"" 10 Hz rTMS motor cortex hand painful side, pain experienced hand itself.",G0000000|C0030193|C0441889|C0449820|C0234621|C0243071|C0175659|C0450371|C0439232|C1883016|C0237400|C0068899|C0450371|C0439482|G0000000|C1513492|C0007776|C0018563|C0030193|C0441987|C0030193|C0237607|C0018563|G0000000
"No difference in adverse events was noted in terms of hyperthermia or hypothermia, weight loss, rash, loose stools or feeding intolerance.","No difference adverse events terms hyperthermia hypothermia, weight loss, rash, loose stools feeding intolerance.",G0000000|C1705241|G0000000|C0441471|C0233324|C0015967|C0020672|C0005910|C1517945|C0015230|C0205407|C0015733|C0204695|C0231199
"Scores for participants in the active intervention group increased by 44 points, an increase exceeding the change in score considered to be a clinically significant response (≥32-point change).","Scores participants active intervention increased 44 points, increase exceeding change score considered clinically response (≥32-point change).",C0449820|C0679646|C0205177|C0886296|C0205217|C0450371|C1552961|C0442805|G0000000|C0392747|C0449820|C0750591|G0000000|C0871261|G0000000|C0392747
"In children with an axillary temperature ≥ 37.5°C or recent history of fever, a rapid diagnostic test (RDT; ICT Malaria Pf Cassette Test; ICT Diagnostics, Cape Town, South Africa) was conducted in the field and treatment was given if it was positive.","In children axillary temperature ≥ 37.5°C history fever, rapid diagnostic test (RDT; ICT Malaria Pf Cassette Test; ICT Diagnostics, Cape Town, South Africa) conducted field treatment positive.",G0000000|C0008059|C0004454|C0005903|G0000000|G0000000|C0019664|C0015967|C0456962|C0011900|C0022885|C0206743|C1512721|C0024530|C3815179|C0450240|C0022885|C1512721|C0011900|C0453952|C0557750|C1710133|C0001737|C0004927|C0440042|C0039798|C0439178
"bSubjects with missing type 2 oral poliovirus vaccine shedding data from at least 1 visit at 28, 29, 30, 31, or 32 weeks of age.","bSubjects missing type 2 oral poliovirus vaccine shedding data 1 visit 28, 29, 30, 31, 32 weeks age.",G0000000|C1551393|C0332307|G0000000|C0442027|C0206435|C0042210|G0000000|C1511726|G0000000|C0545082|C0450371|C0450371|C0450371|C0450371|C0450371|C0439230|C0001779
Time to viral suppression was defined as time from ART initiation to the date of first viral load measure below 400 HIV RNA copies/ml.,Time viral suppression defined time ART initiation viral load measure 400 HIV RNA copies/ml.,C0040223|C0521026|C0221103|C1704788|C0040223|C0003826|C0589507|C0521026|C1550025|C0079809|C1442061|C0019682|C0035668|C1531853
Disease-free survival was defined as the time from CR until the first relapse or death from any cause.,Disease-free survival defined time CR relapse death cause.,C0012634|C0038952|C1704788|C0040223|C0201975|C0035020|C0011065|C0015127
Tumour stage and survival were compared between the two groups.,Tumour stage survival compared groups.,C0027651|C0205390|C0038952|C1707455|C0441833
"In comparison with placebo, erythromycin reduced the median time to improvement of sore throat by 1 day.","In comparison placebo, erythromycin reduced median time improvement sore throat 1 day.",G0000000|C1707455|C0032042|C0014806|C0392756|C0549183|C0040223|C2986411|C0234233|C0031354|G0000000|C0332173
"In Denmark, the length of clopidogrel treatment has followed the change in guidelines, increasing from 6 months in 2002-2003 to 12 months after 2004[10].","In Denmark, length clopidogrel treatment change guidelines, increasing 6 months 2002-2003 12 months 2004[10].",G0000000|C0011318|C1444754|C0070166|C0039798|C0392747|C0162791|C0442808|G0000000|C0439231|G0000000|C0450371|C0439231|C0450371
Several observational studies have evaluated the association of serum 25-hydroxyvitamin D (25 (OH) D) concentration with incidence or severity of respiratory tract infections.,Several observational studies evaluated association serum 25-hydroxyvitamin D (25 (OH) D) concentration incidence severity respiratory tract infections.,C0439064|C1518527|C0947630|C0220825|C0004083|C0229671|C0450371|C0073187|C0450371|C0220853|C0073187|C0004268|C0021149|C0439793|C0521346|C1185740|C3714514
"Carbon Monoxide testing was used to verify abstinence (<10 ppm = abstinent; Bedfont, CO Ecolyzer).","Carbon Monoxide testing verify abstinence (<10 ppm = abstinent; Bedfont, CO Ecolyzer).",C0007009|G0000000|C0039593|C1711411|C3843422|C0450371|C0439187|G0000000|C0457801|G0000000|C3245499|G0000000
The other subscales of the FDDQL and the SF‐36 were defined as secondary end points.,The subscales FDDQL SF‐36 defined secondary points.,G0000000|G0000000|G0000000|G0000000|C1704788|C0027627|C1552961
"Undoubtedly, there will be variation in changes in weight loss, physical activity level, and diet.","Undoubtedly, variation weight loss, physical activity level, diet.",G0000000|C0205419|C0005910|C1517945|C0031809|C0205177|C0441889|C0012155
Data were available for 772 infants for the primary outcome of hospital admission by 24 hours after enrollment.,Data 772 infants primary outcome hospital admission 24 hours enrollment.,C1511726|C1442061|C0021270|C0205225|C1274040|C0019994|C0184666|C0450371|C0439227|C1516879
Comparison of two intervention groups nine months after the initial urinary tests.,Comparison intervention months initial urinary tests.,C1707455|C0886296|C0439231|C0205265|C0042027|C0022885
The primary outcome was the time of first P. aeruginosa acquisition.,The primary outcome time P. aeruginosa acquisition.,G0000000|C0205225|C1274040|C0040223|C0369773|G0000000|C1706701
"The primary outcome was breast cancer awareness measured using a validated questionnaire asking about knowledge of breast cancer symptoms, knowledge that the risk of breast cancer increases with age and breast checking behaviour.","The primary outcome breast cancer awareness measured validated questionnaire knowledge breast cancer symptoms, knowledge risk breast cancer increases age breast checking behaviour.",G0000000|C0205225|C1274040|C0006141|C0006826|C0004448|C0444706|G0000000|C0034394|C0376554|C0006141|C0006826|C0683368|C0376554|C0035647|C0006141|C0006826|C0205217|C0001779|C0006141|C1283174|C0004927
"There were no significant differences between the 2 groups on perceived cognitive deficits (PDQ and MSNSQ), fatigue (MFIS), depression (BDI-II), or social activities (CIQ) (table e-6).","There differences 2 perceived cognitive deficits (PDQ MSNSQ), fatigue (MFIS), depression (BDI-II), social activities (CIQ) (table e-6).",G0000000|C1705241|G0000000|C0030971|C1516691|C2987487|G0000000|G0000000|C0015672|C3810705|C0011570|C0006448|C0728831|C0441655|G0000000|C0039224|G0000000
"Outcome measures will include pain (100 mm VAS and WOMAC 3.1), function (WOMAC 3.1), stiffness (WOMAC 3.1), patient global assessment (100 mm VAS) and quality of life (SF-36).","Outcome measures pain (100 mm VAS WOMAC 3.1), function (WOMAC 3.1), stiffness (WOMAC 3.1), patient global assessment (100 mm VAS) quality life (SF-36).",C1274040|C0079809|C0030193|C1442061|G0000000|C0042815|G0000000|G0000000|C0031843|G0000000|G0000000|C0427008|G0000000|G0000000|C0030705|C0205246|C1261322|C1442061|G0000000|C0042815|C0332306|C0376558|C0037712
"For patients who could not tolerate diarrhea of 2-3 times a day, 1-2 bills of imodium were given daily, but not more than 10 d. Patients were seen before and after 1, 2, 4, 6, 8 wk of treatment.","For patients tolerate diarrhea 2-3 times day, 1-2 bills imodium daily, 10 d. Patients 1, 2, 4, 6, 8 wk treatment.",G0000000|C0030705|G0000000|C0011991|G0000000|C0040223|C0332173|G0000000|C0004895|C0591635|C0332173|C0450371|C0073187|C0030705|G0000000|G0000000|G0000000|G0000000|G0000000|C0332174|C0039798
"We obtained information on suspected or established risk factors for melanoma including age at baseline (years), gender (female, male), education (high school or less, some college, advanced degree), first degree family history melanoma (no, yes), personal history of non-melanoma skin cancer (no, yes), ever had moles removed (no, yes), freckles between ages 10–20 years (no, yes), had ≥ 3 severe sunburns between ages 10–20 years (no, yes), natural red/blond hair between ages 10–20 years (no, yes), and reaction to one-hour in strong sunlight (tan or no sunburn, mild burning, painful sunburn, severe sunburn with blistering).","We suspected established risk factors melanoma including age baseline (years), gender (female, male), education (high school less, college, advanced degree), degree family history melanoma (no, yes), personal history non-melanoma skin cancer (no, yes), moles removed (no, yes), freckles ages 10–20 (no, yes), ≥ 3 severe sunburns ages 10–20 (no, yes), natural red/blond hair ages 10–20 (no, yes), reaction one-hour strong sunlight (tan sunburn, mild burning, painful sunburn, severe sunburn blistering).",G0000000|C0332147|C0443211|C0035647|C1521761|C0025202|C0332257|C0001779|C0168634|C0439234|C0079399|C0015780|C0086582|C0013621|C0205250|C0036375|C0439092|C0557806|C0205179|C0441889|C0441889|C0015576|C0019664|C0025202|G0000000|C1549445|C1519021|C0019664|C1518422|C0444099|C0006826|G0000000|C1549445|C0027960|C0849355|G0000000|C1549445|C0016689|C0001779|G0000000|G0000000|C1549445|G0000000|G0000000|C0205082|C0038814|C0001779|G0000000|G0000000|C1549445|C0205296|C0332575|C0018494|C0001779|G0000000|G0000000|C1549445|C0443286|C0205447|C0442821|C0038817|C0302595|C0038814|C2945599|C0000912|C0030193|C0038814|C0205082|C0038814|C0005758
"Compared with the control group, the observation group had a lower rate of feeding intolerance (P < 0.05), a shorter duration to full enteral feeding and time to complete meconium excretion (P < 0.05), a higher mean number of daily spontaneous bowel movements (P < 0.05), higher body weight (1 793±317 g vs 1 621±138 g; P < 0.05), head circumference (30.5±1.1 cm vs 30.0±1.6 cm; P < 0.05), and body length (43.9±1.2 cm vs 42.1±2.0 cm; P < 0.05), a higher motilin level at 4 and 10 days after feeding (P < 0.05), and a significantly lower infection rate (P < 0.05).","Compared control group, observation lower rate feeding intolerance (P < 0.05), shorter duration enteral feeding time complete meconium excretion (P < 0.05), daily spontaneous bowel movements (P < 0.05), body weight (1 793±317 1 621±138 g; P < 0.05), head circumference (30.5±1.1 cm 30.0±1.6 cm; P < 0.05), body length (43.9±1.2 cm 42.1±2.0 cm; P < 0.05), motilin level 4 10 days feeding (P < 0.05), lower infection rate (P < 0.05).",C1707455|C0243148|C0441833|C0302523|C0441994|C0871208|C0204695|C0231199|C0369773|G0000000|C0450371|C1282927|C0449238|C1304890|C0204695|C0040223|C0205197|C0025047|C0221102|C0369773|G0000000|C0450371|C0332173|C0205359|C0021853|C0026649|C0369773|G0000000|C0450371|C0242821|C0005910|G0000000|G0000000|G0000000|G0000000|C0439267|C0369773|G0000000|C0450371|C0018670|C0332520|G0000000|G0000000|G0000000|G0000000|C0369773|G0000000|C0450371|C0242821|C1444754|G0000000|G0000000|G0000000|G0000000|C0369773|G0000000|C0450371|C0026594|C0441889|G0000000|C0450371|C0439228|C0204695|C0369773|G0000000|C0450371|C0441994|C0009450|C0871208|C0369773|G0000000|C0450371
"Baseline ADAS-cog, while not correlated with age or baseline NAA/Cr ratio, did show a robust correlation with the Mini-Mental State Exam (MMSE), MMSE-extended [11], verbal fluency, and Activities of Daily Living (ADL) measures.","Baseline ADAS-cog, correlated age baseline NAA/Cr ratio, robust correlation Mini-Mental State Exam (MMSE), MMSE-extended [11], verbal fluency, Activities Daily Living (ADL) measures.",C0168634|C3539026|C1707520|C0001779|C0168634|C0067684|C0456603|C2986815|C1707520|C0445542|C1301808|C0582103|C0451306|C0451306|C0450371|C0439824|C0870569|C0441655|C0332173|C0376558|C0001288|C0079809
HPV Vaccine Decision Aid eFigure 4.,HPV Vaccine Decision Aid eFigure 4.,C0021344|C0042210|C0679006|C0449435|G0000000|G0000000
"The PC team met with 20.0% and 34.3% of usual care patients by weeks 12 and 24, respectively.","The PC team met 20.0% 34.3% usual care patients weeks 12 24, respectively.",G0000000|C0031995|C0871489|C0268621|C0450371|C0450371|C3538928|C1947933|C0030705|C0439230|C0450371|C0450371|G0000000
The mean follow-up period for survivors was 12 (5–24) years.,The follow-up period survivors 12 (5–24) years.,G0000000|C0589120|C0439531|C0206194|C0450371|G0000000|C0439234
"For both cataract and subtypes, HRs did not vary significantly over the three age groups.","For cataract subtypes, HRs vary age groups.",G0000000|C0086543|C0449560|G0000000|G0000000|C0001779|C0441833
"Demographics and baseline characteristics, intent-to-treat population Abbreviations: ASEX, Arizona Sexual Experience Scale; BDI, Beck Depression Inventory; BMI, body mass index; EQ-5D, EuroQOL-5D; MASQ, Multiple Ability Self-Report Questionnaire; FIQR, Fibromyalgia Impact Questionnaire-Revised; SD, standard deviation; VAS, visual analog scale.","Demographics baseline characteristics, intent-to-treat population Abbreviations: ASEX, Arizona Sexual Experience Scale; BDI, Beck Depression Inventory; BMI, body mass index; EQ-5D, EuroQOL-5D; MASQ, Multiple Ability Self-Report Questionnaire; FIQR, Fibromyalgia Impact Questionnaire-Revised; SD, standard deviation; VAS, visual analog scale.",C0011298|C0168634|C1521970|C0162425|C0032659|C0000723|G0000000|C0003787|C0036864|C0237607|C0175659|C0006448|G0000000|C0011570|C0021941|G0000000|C0242821|C0577559|C0918012|C0205163|C0451150|G0000000|C0439064|C0085732|C0681906|C0034394|C3641329|C0016053|C1825598|C0034394|C2699239|C1442989|C0012727|C0042815|C0234621|C0243071|C0175659
Adverse events included transient laboratory abnormalities and symptoms associated with cytokine release.,Adverse events included transient laboratory abnormalities symptoms cytokine release.,G0000000|C0441471|C0332257|C0040704|C0022877|C0000768|C0683368|C0079189|C0030685
We collected length of stay at the stroke unit and the convalescence units from the clinical records.,We collected length stay stroke unit convalescence units clinical records.,G0000000|C1516695|C1444754|G0000000|C0038454|C0439148|C0009940|C0439148|C0205210|C0034869
The primary endpoint is the rate of PDS response at 3 days after surgery.,The primary endpoint rate PDS response 3 days surgery.,G0000000|C0205225|C2349179|C0871208|G0000000|C0871261|G0000000|C0439228|C0038894
"End points were response rate, HRQOL and survival.","End response rate, HRQOL survival.",C0444930|C0871261|C0871208|G0000000|C0038952
Primary end-point was median overall survival (OS) from the date of randomization.,Primary end-point median survival (OS) randomization.,C0205225|C2349179|C0549183|C0038952|C0229090|C0034656
"A mixed linear model permitting data to exhibit correlation and non-constant variability was used to determine difference in least square mean total cholesterol, LDL, HDL and serum triglycerides between baseline and higher doses.","A mixed linear model permitting data exhibit correlation non-constant variability determine difference square total cholesterol, LDL, HDL serum triglycerides baseline doses.",G0000000|C0205430|C0205132|C3161035|C0023636|C1511726|C0015272|C1707520|C1518422|C2827666|G0000000|C1705241|C0205120|C0439175|C0008377|G0000000|C3715113|C0229671|C0041004|C0168634|C0178602
This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and its effects on the incidence of clinically significant thrombocytopenic events (CSTEs) in lower risk MDS patients receiving lenalidomide.,This study evaluated safety tolerability thrombopoietin mimetic romiplostim effects incidence clinically thrombocytopenic events (CSTEs) lower risk MDS patients receiving lenalidomide.,G0000000|C0557651|C0220825|C0036043|C3274448|C0040052|C0920591|C2364481|C1280500|C0021149|G0000000|G0000000|C0441471|G0000000|C0441994|C0035647|C3273937|C0030705|C1514756|C1144149
"The primary outcome of this study was ventilator free days (VFD), defined as the number of days within the first 28 days after enrollment on which the patient was alive and breathing without ventilatory assistance, so long as the period of unassisted breathing had lasted at least 48 hrs.","The primary outcome study ventilator free days (VFD), defined days 28 days enrollment patient alive breathing ventilatory assistance, period unassisted breathing lasted 48 hrs.",G0000000|C0205225|C1274040|C0557651|C0087153|C0332296|C0439228|G0000000|C1704788|C0439228|C0450371|C0439228|C1516879|C0030705|C0376558|C0004048|G0000000|C0018896|C0439531|G0000000|C0004048|C1517741|C0450371|G0000000
"We measured all the possible linear growth parameters (weight, length, and MUAC) and computed z-scores (wasting, stunting, and underweight).","We measured linear growth parameters (weight, length, MUAC) computed z-scores (wasting, stunting, underweight).",G0000000|C0444706|C0205132|C0018270|C0449381|C0005910|C1444754|G0000000|C1441526|C0871421|C0006625|C0018273|C0041667
"This study aims to test the effects of yoga on health-related quality of life, life satisfaction, cancer-related fatigue, mindfulness, and spirituality compared to conventional therapeutic exercises during (neo)adjuvant cytotoxic and endocrine therapy in women with breast cancer.","This study aims test effects yoga health-related quality life, life satisfaction, cancer-related fatigue, mindfulness, spirituality compared conventional therapeutic exercises (neo)adjuvant cytotoxic endocrine therapy women breast cancer.",G0000000|C0557651|C1947946|C0022885|C1280500|C0043418|C0018684|C0332306|C0376558|C0376558|C0242428|C2826292|C0015672|C0086045|C0237104|C1707455|C0439858|C0087111|C0015259|C1366752|C0677881|C0014136|C0039798|C0043210|C0006141|C0006826
Incidence of adverse events and long-term mortality and recurrence rate during a 10-year and 30-year follow-up will also be investigated.,Incidence adverse events long-term mortality recurrence rate 10-year 30-year follow-up investigated.,C0021149|G0000000|C0441471|C0443252|C0026565|C0034897|C0871208|C0450371|C0450371|C0589120|C1292732
"In the first 24 hours we recorded the time to temperature first falling below 37.2°C (fever clearance), the time spent without fever over 24 hours, and the proportion of children without fever associated symptoms: discomfort, reduced activity, reduced appetite, and disturbed sleep.","In 24 hours recorded time temperature falling 37.2°C (fever clearance), time spent fever 24 hours, proportion children fever symptoms: discomfort, reduced activity, reduced appetite, disturbed sleep.",G0000000|C0450371|C0439227|C0034869|C0040223|C0005903|C0000921|G0000000|C0015967|C0449297|C0040223|C0680968|C0015967|C0450371|C0439227|C1709707|C0008059|C0015967|C0683368|C0231218|C0392756|C0205177|C0392756|C0003618|G0000000|C0037313
"Symptoms were assessed using the Ocular Surface Disease Index (OSDI) questionnaire, and Schirmer test with anesthesia was performed at baseline and 6 and 12 weeks posttreatment.","Symptoms assessed Ocular Surface Disease Index (OSDI) questionnaire, Schirmer test anesthesia performed baseline 6 12 weeks posttreatment.",C0683368|C1516048|C0015392|C0205148|C0012634|C0918012|C3896641|C0034394|C1875738|C0022885|C0002903|C0884358|C0168634|G0000000|C0450371|C0439230|C2709088
Parallel forms of the Asthma Knowledge Questionnaire might have provided a more stringent test.,Parallel forms Asthma Knowledge Questionnaire provided stringent test.,C2348042|C0348078|C0004096|C0376554|C0034394|C1999230|G0000000|C0022885
"Balance, activities of daily living, and depressive disorder status were assessed before and after the 6-week treatment period using the Berg balance scale, the Modified Barthel Index, and the Beck Depression Inventory.","Balance, activities daily living, depressive disorder status assessed 6-week treatment period Berg balance scale, Modified Barthel Index, Beck Depression Inventory.",C0014653|C0441655|C0332173|C0376558|G0000000|C0012634|C0449438|C1516048|C0332174|C0039798|C0439531|G0000000|C0014653|C0175659|C0392747|G0000000|C0918012|G0000000|C0011570|C0021941
"Routine blood and stool tests were performed before and after 1, 2, 4, 6 and 8 wk of treatment.","Routine blood stool tests performed 1, 2, 4, 6 8 wk treatment.",C0205547|C0005767|C0015733|C0022885|C0884358|G0000000|G0000000|G0000000|G0000000|G0000000|C0332174|C0039798
"Heart rate (HR), mean arterial pressure (MAP) and oxygen saturation (SpO2) were recorded before surgery and every 5 min till the end of surgery.","Heart rate (HR), arterial pressure (MAP) oxygen saturation (SpO2) recorded surgery 5 min till surgery.",C0018787|C0871208|G0000000|C0003842|C0033095|C0024779|C0030054|C0522534|G0000000|C0034869|C0038894|G0000000|C0702093|G0000000|C0038894
"Disease-free survival time, cumulative recurrence rate and cumulative survival rate were calculated in the two groups.","Disease-free survival time, cumulative recurrence rate cumulative survival rate calculated groups.",C0012634|C0038952|C0040223|C1511559|C0034897|C0871208|C1511559|C0038952|C0871208|C0444686|C0441833
Secondary end-points were also assessed after 6 weeks of treatment and included Borg–time slope for intensity of breathing discomfort during CWRCE.,Secondary end-points assessed 6 weeks treatment included Borg–time slope intensity breathing discomfort CWRCE.,C0027627|C2349179|C1516048|G0000000|C0039798|C0332257|G0000000|C0807955|C0522510|C0004048|C0231218|G0000000
A total of 1386 dyads (80% of those contacted) attended the event and participated in the study.,A total 1386 dyads (80% contacted) attended event participated study.,G0000000|C0439175|G0000000|C0870454|C0450371|C0332158|C1456498|C0441471|G0000000|C0557651
"The primary purpose of this procedure was to serve as a bogus pipeline, to encourage honesty in answering the smoking-related question.","The primary purpose procedure serve bogus pipeline, encourage honesty answering smoking-related question.",G0000000|C0205225|C1285529|C0184661|G0000000|G0000000|G0000000|G0000000|C0870663|C1706817|C0037369|C1522634
One patient in the magnesium sulfate group had chest tightness after the third nebulization and facial rash without oropharyngeal involvement; he received intravenous diphenhydramine and both resolved within 30 min.,One patient magnesium sulfate chest tightness nebulization facial rash oropharyngeal involvement; received intravenous diphenhydramine resolved 30 min.,C0205447|C0030705|C0024467|C0038720|C0817096|C0439816|C1659427|C0015450|C0015230|C0521367|C1314939|C1514756|C0348016|C0012522|C1514893|G0000000
"Infection prophylaxis did not affect the incidence of infection upon completion of 2 months of therapy (nor, ultimately, at any time during the subsequent 2 years), the response to therapy (data not shown) or to overall survival (data not shown).","Infection prophylaxis affect incidence infection completion 2 months therapy (nor, ultimately, time subsequent 2 years), response therapy (data shown) survival (data shown).",C0009450|C0033107|C0001721|C0021149|C0009450|C0205197|G0000000|C0439231|C0039798|G0000000|G0000000|C0040223|C0332282|G0000000|C0439234|C0871261|C0039798|C1511726|C1547282|C0038952|C1511726|C1547282
"As shown, maternal age and gestational age at delivery in both the groups were similar and differences between groups were not statistically significant.","As shown, maternal age gestational age delivery differences statistically significant.",G0000000|C1547282|C2347083|C0001779|C0439671|C0001779|C0011209|C1705241|C0038215|C0237881
"One point was given for each mild hot flash, two points for each moderate hot flash, three points for each severe hot flash, and four points for each very severe hot flash.","One mild hot flash, moderate hot flash, severe hot flash, severe hot flash.",C0205447|C2945599|C0444519|C0181637|C0205081|C0444519|C0181637|C0205082|C0444519|C0181637|C0205082|C0444519|C0181637
"The PR program lasted 12 weeks, after which the individuals were evaluated a second time.","The PR program lasted 12 weeks, individuals evaluated time.",G0000000|C0279759|C1709697|C1517741|C0450371|C0439230|C0027361|C0220825|C0040223
"Analysis of clinical parameters included gender, age of seizure onset, epilepsy frequency, duration of epilepsy before surgery, and postoperative seizure outcome classification according to Engel class scale.","Analysis clinical parameters included gender, age seizure onset, epilepsy frequency, duration epilepsy surgery, postoperative seizure outcome classification Engel class scale.",C0002778|C0205210|C0449381|C0332257|C0079399|C0001779|C0036572|C0206132|C0014544|C0376249|C0449238|C0014544|C0038894|C0032790|C0036572|C1274040|C0008902|G0000000|C0456387|C0175659
Treatment failure was defined as nonresponse (<50% reduction in the number of wet nights).,Treatment failure defined nonresponse (<50% reduction wet nights).,C0039798|C0231174|C1704788|G0000000|C0450371|C0301630|C0205381|C0240526
The primary endpoint in the study was the difference in the mean blood glucose levels between the study groups and the occurrence of hyper- and hypoglycemic episodes.,The primary endpoint study difference blood glucose levels study occurrence hyper- hypoglycemic episodes.,G0000000|C0205225|C2349179|C0557651|C1705241|C0005767|C0017725|C0441889|C0557651|C0243132|C0424295|C0020616|C0332189
The primary outcome is change in SPB at 3 and 12 months.,The primary outcome change SPB 3 12 months.,G0000000|C0205225|C1274040|C0392747|C0597729|G0000000|C0450371|C0439231
"In this intention-to-treat study, primary data to be collected will be adherence with therapy (hours of usage at set pressure) per night, and residual AHI on treatment.","In intention-to-treat study, primary data collected adherence therapy (hours usage set pressure) night, residual AHI treatment.",G0000000|C0162425|C0557651|C0205225|C1511726|C1516695|C1510802|C0039798|C0439227|C0457083|C0036849|C0033095|C0240526|C1609982|G0000000|C0039798
"Previous analyses of these data collected by CHWs have demonstrated that diagnostic positivity (DP) for malaria infection, expressed as the proportion of RDT-tested individuals who were found to be positive, was a extremely powerful indicator of malaria risk that allowed numerous important epidemiological phenomena to be clearly illustrated [36].","Previous analyses data collected CHWs demonstrated diagnostic positivity (DP) malaria infection, expressed proportion RDT-tested individuals positive, extremely powerful indicator malaria risk allowed numerous epidemiological phenomena illustrated [36].",C0205156|C0002778|C1511726|C1516695|G0000000|G0000000|C0011900|C0439178|C1531217|C0024530|C0009450|G0000000|C1709707|C0206743|C0027361|C0439178|C0205403|C0032863|C0021212|C0024530|C0035647|C0683607|C0439064|C0014507|C1882365|G0000000|C0450371
"In the RCT, the primary efficacy endpoint was the percentage of patients with a rescue-free bowel movement (RFBM) within four hours after ≥2 of the first 4 doses (i.e., the first week of treatment).","In RCT, primary efficacy endpoint percentage patients rescue-free bowel movement (RFBM) hours ≥2 4 doses (i.e., week treatment).",G0000000|G0000000|C0205225|C1280519|C2349179|C0439165|C0030705|C0332296|C0021853|C0026649|G0000000|C0439227|G0000000|G0000000|C0178602|C0683454|C0332174|C0039798
"HD hyoid displacement, UOD maximal diameters of UES opening We only examined the correlation between the affected and unaffected MEP evoked by ipsilateral cortical stimulation to VFSS parameters (see Fig.","HD hyoid displacement, UOD maximal diameters UES We examined correlation unaffected MEP evoked ipsilateral cortical stimulation VFSS parameters (see Fig.",G0000000|C0020417|C0012725|G0000000|C0205289|C1301886|C0855073|G0000000|C0332128|C1707520|C2986417|C1707163|C1444748|C0441989|C0001613|C1292856|G0000000|C0449381|C0042789|C0349966
Participants or parents (or both) completed standardized measures [the State–Trait Anxiety Inventory for Children (STAIC) and the Child Health Questionnaire–Parent (CHQ-Parent)] before the first and after the final session (collected by BS).,Participants parents (or both) completed standardized measures [the State–Trait Anxiety Inventory Children (STAIC) Child Health Questionnaire–Parent (CHQ-Parent)] final session (collected BS).,C0679646|C0030551|G0000000|G0000000|C0205197|G0000000|C0079809|G0000000|G0000000|C0003467|C0021941|C0008059|G0000000|C0008059|C0018684|G0000000|C4053531|C0205088|C1883016|C1516695|C3814390
"Changes (mean±SD) in cycloplegic autorefraction (SER) and axial length in subjects who completed the 2-year study at each visit DISC, Defocus Incorporated Soft Contact; SER, spherical equivalent refraction; SV, single vision.","Changes (mean±SD) cycloplegic autorefraction (SER) axial length subjects completed 2-year study visit DISC, Defocus Incorporated Soft Contact; SER, spherical equivalent refraction; SV, single vision.",C0392747|G0000000|C0010586|G0000000|C0523888|C0205131|C1444754|C0681850|C0205197|C0439234|C0557651|C0545082|C0180459|G0000000|G0000000|C0205358|C0332158|C0523888|C0332501|C0205163|C0429585|C0013754|C0037179|C0042789
"Analyses of follow-up retention by group revealed that TTM group participants were not significantly more likely to complete surveys than SC group participants at 12 months (χ2 (1) = 3.60, P > 0.05), but were significantly more likely to complete surveys at 18 months (χ2 (1) = 4.84, P < 0.03).","Analyses follow-up retention revealed TTM participants complete surveys SC participants 12 months (χ2 (1) = 3.60, P > 0.05), complete surveys 18 months (χ2 (1) = 4.84, P < 0.03).",C0002778|C0589120|C0035280|C0443289|C0040953|C0679646|C0205197|C0038951|C0282380|C0679646|C0450371|C0439231|G0000000|G0000000|G0000000|C0450371|C0369773|G0000000|C0450371|C0205197|C0038951|C0450371|C0439231|G0000000|G0000000|G0000000|C0450371|C0369773|G0000000|C0450371
"Changes in seasonal mean vector densities, parasite prevalence, and incidence rate of malaria cases detected via ACS before and after intervention were tested by the use of the functional additive model (FAM) [21].","Changes seasonal vector densities, parasite prevalence, incidence rate malaria detected ACS intervention tested functional additive model (FAM) [21].",C0392747|C0439601|C0086022|C0178587|C0030498|C0033105|C0021149|C0871208|C0024530|C0442726|G0000000|C0886296|C0392366|C0205245|C0442796|C3161035|C3541878|C0450371
"The primary outcome was blindly measured with National Institutes of Health Stroke Scale (NIHSS) at week 1, week 3, and week 7.","The primary outcome blindly measured National Institutes Health Stroke Scale (NIHSS) week 1, week 3, week 7.",G0000000|C0205225|C1274040|G0000000|C0444706|C3245503|C0021622|C0018684|C0038454|C0175659|C3476804|C0332174|G0000000|C0332174|G0000000|C0332174|G0000000
"Spatiotemporal gait parameters of (1) cadence; (2) stride length; (3) stride time; (4) step length; (5) step time and gait speed; (6) peak angular flexion and extension; and (7) peak moments flexion and extension were recorded at the hip, knee, and angle joints in the sagittal plane.","Spatiotemporal gait parameters (1) cadence; (2) stride length; (3) stride time; (4) step length; (5) step time gait speed; (6) peak angular flexion extension; (7) peak moments flexion extension recorded hip, knee, angle joints sagittal plane.",G0000000|C0016928|C0449381|G0000000|G0000000|G0000000|G0000000|C1444754|G0000000|G0000000|C0040223|G0000000|C1261552|C1444754|G0000000|C1261552|C0040223|C0016928|C0678536|G0000000|C0444505|C0205143|C0231452|C0231448|G0000000|C0444505|G0000000|C0231452|C0231448|C0034869|C0019552|C0022742|C0205143|C0022417|C0205129|C0444660
"The second part was the Depression Anxiety and Stress Scales (DASS) that is a widely used screening tool to assess symptoms of depression, anxiety, and stress in community settings.","The Depression Anxiety Stress Scales (DASS) screening tool assess symptoms depression, anxiety, stress community settings.",G0000000|C0011570|C0003467|C0038435|C0175659|C0051767|C0220908|C0336791|C1516048|C0683368|C0011570|C0003467|C0038435|C0009462|C0542559
"Due to the relatively low frequency of diagnosis this was only possible for the overall category of neurodevelopmental disorder category and not for the individual types (ASD, ADHD or dyspraxia).","Due low frequency diagnosis category neurodevelopmental disorder category individual types (ASD, ADHD dyspraxia).",C0678226|C0205251|C0376249|C0011900|C0683312|C0599855|C0012634|C0683312|C0027361|C0332307|C0003516|C1263846|C0003635
"Serum samples from weeks 0, 2, 4, 8, 12 and 16 were used for sucrose density gradient lipid fractionation.","Serum samples weeks 0, 2, 4, 8, 12 16 sucrose density gradient lipid fractionation.",C0229671|C0370003|C0439230|G0000000|G0000000|G0000000|G0000000|C0450371|C0450371|C0038636|C0178587|C0439182|C0023779|C0016640
"RRF was measured with daily urine volume, renal creatinine clearance, and weekly Kt/V that were measured at 1 (baseline), 3, 6, 12, 18, and 24 months from the initiation of PD.","RRF measured daily urine volume, renal creatinine clearance, weekly Kt/V measured 1 (baseline), 3, 6, 12, 18, 24 months initiation PD.",C1417252|C0444706|C0332173|C0042036|C0449468|C0022646|C0010294|C0449297|C0332174|C0429662|C0444706|G0000000|C0168634|G0000000|G0000000|C0450371|C0450371|C0450371|C0439231|C0589507|G0000000
"ACQ scores and asthma outcomes at Baseline, 3 and 6 months Values are given as mean (SD) or number (percentages).","ACQ scores asthma outcomes Baseline, 3 6 months Values (SD) (percentages).",C2919686|C0449820|C0004096|C1274040|C0168634|G0000000|G0000000|C0439231|C0042295|G0000000|C0439165
The primary outcome measure was change in their manual muscle testing score.,The primary outcome measure change manual muscle testing score.,G0000000|C0205225|C1274040|C0079809|C0392747|C0024763|C0026845|C0039593|C0449820
"At each clinic visit, a trained technician used a stadiometer (Harpenden 603, Holtain) to measure height, as described in the protocol (available at NEJM.org), and investigators obtained an interim history of participants’ health and medication use.","At clinic visit, trained technician stadiometer (Harpenden 603, Holtain) measure height, protocol (available NEJM.org), investigators interim history participants’ health medication use.",G0000000|C0002424|C0545082|C0336809|C1556020|G0000000|G0000000|C1442061|G0000000|C0079809|C0489786|C0442711|C0470187|C1522486|C0035173|C2827738|C0019664|G0000000|C0018684|C0013227|C0042153
"The primary endpoints of the trial are peak serum levels of both AST and ALT measured within the first 8 days after transplantation, and graft survival based on patients death or announcement for re-transplantation.","The primary endpoints trial peak serum levels AST ALT measured 8 days transplantation, graft survival based patients death announcement re-transplantation.",G0000000|C0205225|C2349179|C0008976|C0444505|C0229671|C0441889|C3891303|C1266129|C0444706|G0000000|C0439228|C0040732|C0181074|C0038952|C1527178|C0030705|C0011065|G0000000|C0556581
Colchicine is well described in the treatment of various aetiologies of pericarditis.,Colchicine treatment aetiologies pericarditis.,C0009262|C0039798|C0015127|C0031046
"Disagreements were resolved by discussion or, in about 5% of cases, with assistance from a third adjudicator.","Disagreements resolved discussion or, 5% cases, assistance adjudicator.",C0680238|C1514893|C0557061|G0000000|G0000000|C0868928|C0018896|C0401783
"Secondary outcome events were non-fatal myocardial infarction (electrocardiographically or laboratory confirmed), retinal infarction, transient ischaemic attack, minor bleeding complication, or non-vascular death.","Secondary outcome events non-fatal myocardial infarction (electrocardiographically laboratory confirmed), retinal infarction, transient ischaemic attack, minor bleeding complication, non-vascular death.",C0027627|C1274040|C0441471|C1518422|C0027061|C0021308|G0000000|C0022877|C0521093|C0035298|C0021308|C0040704|C0475224|C0277793|C0026193|C0019080|C0009566|C1518422|C0011065
Further prospective validation of this model with other datasets is warranted.,Further prospective validation model datasets warranted.,C1517331|C0023981|C1519941|C3161035|C0150098|G0000000
"The sleep quality was assessed using questions including difficulty in falling asleep (the number of nights/week in which the patient experienced difficulty in falling asleep), frequent awakening during sleep (0=none, 1=some of the nights, 2=every night) and quality of sleep (0= good, 1= moderate, 2= unrefreshing).","The sleep quality assessed questions including difficulty falling asleep (the nights/week patient experienced difficulty falling asleep), frequent awakening sleep (0=none, 1=some nights, 2=every night) quality sleep (0= good, 1= moderate, 2= unrefreshing).",G0000000|C0037313|C0332306|C1516048|C1522634|C0332257|C1299586|C0000921|C0424522|G0000000|C0240526|C0030705|C0237607|C1299586|C0000921|C0424522|C0332183|C1720052|C0037313|G0000000|G0000000|C0240526|G0000000|C0240526|C0332306|C0037313|G0000000|C0205170|G0000000|C0205081|G0000000|G0000000
Exploratory outcomes included development of a second disease relapse during the initial 6 months of ACTH and relapse after completion of 12 months of ACTH.,Exploratory outcomes included development disease relapse initial 6 months ACTH relapse completion 12 months ACTH.,G0000000|C1274040|C0332257|C0243107|C0012634|C0035020|C0205265|G0000000|C0439231|C3539087|C0035020|C0205197|C0450371|C0439231|C3539087
A log transformation was used for the substance and delinquency indicators and a square root transformation was used for prosocial behavior and internalizing/externalizing symptoms.,A log transformation substance delinquency indicators square root transformation prosocial behavior internalizing/externalizing symptoms.,G0000000|C1708728|C0040682|C0439861|C0522174|C0021212|C0205120|C0040452|C0040682|G0000000|C0004927|G0000000|C0683368
SGRQ-C total score after 26 weeks.,SGRQ-C total score 26 weeks.,C3826872|C0439175|C0449820|G0000000
"Correlative studies for gene promoter methylation have been reported elsewhere.25 The objectives of the study were to evaluate the efficacy of selenium supplementation in reducing the incidence of lung SPTs in patients who had been treated for stage I NSCLC; to evaluate the qualitative and quantitative toxicity of daily selenium supplementation; and to compare the incidence of specific cancers, mortality from cancer, and overall survival of patients treated with selenium supplementation versus placebo.","Correlative studies gene promoter methylation reported elsewhere.25 The objectives study evaluate efficacy selenium supplementation reducing incidence lung SPTs patients treated stage I NSCLC; evaluate qualitative quantitative toxicity daily selenium supplementation; compare incidence specific cancers, mortality cancer, survival patients treated selenium supplementation versus placebo.",C1511524|C0947630|C0017337|C0086860|C0025723|C0684224|C0450371|G0000000|C0018017|C0557651|C0220825|C1280519|C0036581|C0242297|C0392756|C0021149|C0024109|G0000000|C0030705|C1522326|C0205390|C0021966|C0007131|C0220825|C0205556|C0392762|C0040539|C0332173|C0036581|C0242297|C1707455|C0021149|C0205369|C0006826|C0026565|C0006826|C0038952|C0030705|C1522326|C0036581|C0242297|G0000000|C0032042
"The postoperative seizure outcome was Engel class I/II in 5/6 patients, and class III in the other over a mean follow-up period of 27 months (range 20–38 months).","The postoperative seizure outcome Engel class I/II 5/6 patients, class III follow-up period 27 months (range 20–38 months).",G0000000|C0032790|C0036572|C1274040|G0000000|C0456387|C0021966|G0000000|C0030705|C0456387|C0439070|C0589120|C0439531|C0450371|C0439231|C1514721|G0000000|C0439231
The primary endpoint was percentage of patients with a rescue-free bowel movement (RFBM) within four hours after ≥2 of the first 4 doses in the first week.,The primary endpoint percentage patients rescue-free bowel movement (RFBM) hours ≥2 4 doses week.,G0000000|C0205225|C2349179|C0439165|C0030705|C0332296|C0021853|C0026649|G0000000|C0439227|G0000000|G0000000|C0178602|C0332174
"This collection included baseline patient data, Richmond Agitation and Sedation Scale score (RASS), and Glasgow Coma Scale and Neelon and Champagne Confusion Scale (NEECHAM) as validated scoring systems for agitation, delirium and consciousness score [19].","This collection included baseline patient data, Richmond Agitation Sedation Scale score (RASS), Glasgow Coma Scale Neelon Champagne Confusion Scale (NEECHAM) validated scoring systems agitation, delirium consciousness score [19].",G0000000|C1516698|C0332257|C0168634|C0030705|C1511726|G0000000|C0085631|C0235195|C0175659|C0449820|C0034678|G0000000|C0009421|C0175659|G0000000|G0000000|C0009676|C0175659|G0000000|G0000000|C0449820|C0449913|C0085631|C0011206|C0009791|C0449820|C0450371
"The secondary outcomes will be evaluated by IOP reduction and changes in the morphometric and functional parameters of eyeball: HCD, corneal transparency, CCT, C/D ratio, AL, VA and refraction.","The secondary outcomes evaluated IOP reduction morphometric functional parameters eyeball: HCD, corneal transparency, CCT, C/D ratio, AL, VA refraction.",G0000000|C0027627|C1274040|C0220825|C0595921|C0301630|C0200760|C0205245|C0449381|C0015392|C2000894|C0010031|C0522503|C4049005|C0012358|C0456603|C0202311|C1549054|C0429585
"Patient's pain was measured by the VAS (Visual Analog Scale) score before and after each intervention, and vital sign, complications and level of satisfaction of every patient were recorded before and after aromatherapy.","Patient's pain measured VAS (Visual Analog Scale) score intervention, vital sign, complications level satisfaction patient recorded aromatherapy.",C0030705|C0030193|C0444706|C0042815|C0234621|C0243071|C0175659|C0449820|C0886296|C0442732|C0311392|C0009566|C0441889|C0242428|C0030705|C0034869|C0376547
The results showed that treatment for 12 months with oral azithromycin given 3 days a week led to a significant reduction in the number of pulmonary exacerbations requiring courses of antibiotics.,The treatment 12 months oral azithromycin 3 days week led reduction pulmonary exacerbations requiring courses antibiotics.,G0000000|C0039798|G0000000|C0442027|C0052796|G0000000|C0332174|C1708698|C0301630|C0024109|G0000000|G0000000|C0750729|C0003232
"In addition, significant group mean differences were observed between yoga and control groups over the 8-wk study period in PEFR, FEV1, FEV1/FVC and FEF25–75%.","In addition, differences observed yoga control 8-wk study period PEFR, FEV1, FEV1/FVC FEF25–75%.",G0000000|C0332287|C1705241|C1441672|C0043418|C0243148|C0332174|C0557651|C0439531|C0030735|G0000000|C3714541|G0000000
"Secondary outcomes of interest include health related quality of life as measured by the Hospital Anxiety and Depression Scale, the Stroke Specific Quality of Life scale and WONCA COOP Functional Health Status charts and cardiovascular fitness as measured by a sub-maximal fitness test.","Secondary outcomes health quality life measured Hospital Anxiety Depression Scale, Stroke Specific Quality Life scale WONCA COOP Functional Health Status charts cardiovascular fitness measured sub-maximal fitness test.",C0027627|C1274040|C0018684|C0332306|C0376558|C0444706|C0019994|C0003467|C0011570|C0175659|C0038454|C0205369|C0332306|C0376558|C0175659|G0000000|C3871148|C0205245|C0018684|C0449438|C0684240|C0007226|C1456706|C0444706|C0542339|C1456706|C0022885
Those participants who reported smoking abstinence for the previous 30 days and who had not used other cessation aids were sent a saliva collection device by post.,Those participants reported smoking abstinence previous 30 days cessation aids saliva collection device post.,G0000000|C0679646|C0684224|C0037369|C3843422|C0205156|C0450371|C0439228|C1880019|C0001175|C0036087|C1516698|C0025080|C0687676
The peak amplitude of electromyographic (EMG) activity in the two muscles was also measured.,The peak amplitude electromyographic (EMG) activity muscles measured.,G0000000|C0444505|C2346753|G0000000|G0000000|C0205177|C0026845|C0444706
"We inquired about usual frequency, duration, and number of months of recreational activities performed during the previous 12 (baseline) or 6 (6-month follow-up questionnaire) months.","We inquired usual frequency, duration, months recreational activities performed previous 12 (baseline) 6 (6-month follow-up questionnaire) months.",G0000000|G0000000|C3538928|C0376249|C0449238|C0439231|C0034872|C0441655|C0884358|C0205156|C0450371|C0168634|G0000000|C0332177|C0589120|C0034394|C0439231
"Questionnaires of vitality and positive affect toward the labor were completed three times: before intervention, after the 8th session and after delivery to 2 weeks later by an interview.","Questionnaires vitality positive affect labor completed times: intervention, 8th session delivery 2 weeks interview.",C0034394|C0424589|C0439178|C0001721|C0022864|C0205197|C0040223|C0886296|G0000000|C1883016|C0011209|G0000000|C0439230|C0021822
We compared differences in Hb and ferritin concentrations and prevalence of iron deficiency anaemia (Hb < 100 g L−1 and soluble transferrin receptor concentrations >8.5 mg L−1) from baseline to 8 weeks within and between groups.,We compared differences Hb ferritin concentrations prevalence iron deficiency anaemia (Hb < 100 g L−1 soluble transferrin receptor concentrations >8.5 mg L−1) baseline 8 weeks groups.,G0000000|C1707455|C1705241|C0019046|C0015879|C0086045|C0033105|C0302583|C0011155|C0002871|G0000000|C1749467|C0040679|C0597357|C0086045|G0000000|C0168634|G0000000|C0441833
"Participants completed measures related to latent variables of illness-related distress, social integration, spiritual perspective, family environment, coping, hope-derived meaning and resilience at baseline (T1), post-intervention (T2), and 100-days post-transplant (T3).","Participants completed measures latent variables illness-related distress, social integration, spiritual perspective, family environment, coping, hope-derived meaning resilience baseline (T1), post-intervention (T2), 100-days post-transplant (T3).",C0679646|C0205197|C0079809|C0205275|C0439828|C0221423|C0231303|C0728831|C1158478|G0000000|G0000000|C0015576|C0014406|C0009967|C0392347|C0876919|G0000000|C0168634|C0041403|C2347647|C0041403|C1442061|C0687676|C0041403
Clinical response to the DC vaccine according to neutrophil-to-lymphocyte ratio.,Clinical response DC vaccine neutrophil-to-lymphocyte ratio.,C0205210|C0871261|G0000000|C0042210|C0027950|C0456603
"Abbreviations: ABC-CV, Aberrant Behavior Checklist–Community version; CI, confidence interval; CYBOCS-PDD, Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders; RBS-R, Repetitive Behavior Scale–Revised.","Abbreviations: ABC-CV, Aberrant Behavior Checklist–Community version; CI, confidence interval; CYBOCS-PDD, Children's Yale-Brown Obsessive Compulsive Scales modified pervasive developmental disorders; RBS-R, Repetitive Behavior Scale–Revised.",C0000723|C0152244|C0443127|C0004927|G0000000|C0333052|C0008107|C0237529|C1272706|C0008838|C0008059|C0678579|G0000000|G0000000|C0175659|C0392747|C0205391|C0458003|C0012634|C0392475|G0000000|C0004927|G0000000
"Clinically important endpoints We demonstrated that enrollment of patients into a trial of corticosteroids in pediatric septic shock was potentially feasible as evidenced by the concordance of physicians’ clinical suspicion of septic shock with accepted definitions (24;25), the ability to randomize eligible patients within six hours of their identification, the rate of protocol adherence and the acceptably low rate of open-label steroid use once patients were randomized.","Clinically endpoints We demonstrated enrollment patients trial corticosteroids pediatric septic shock feasible evidenced concordance physicians’ clinical suspicion septic shock accepted definitions (24;25), ability randomize eligible patients hours identification, rate protocol adherence acceptably low rate open-label steroid patients randomized.",G0000000|C2349179|G0000000|G0000000|C1516879|C0030705|C0008976|C0001617|C0030755|C0333534|C0036974|G0000000|C3887511|C0680240|G0000000|C0205210|C0242114|C0333534|C0036974|C1272684|C1550452|C0450371|C0085732|G0000000|C1548635|C0030705|C0439227|C0020792|C0871208|C0442711|C1510802|G0000000|C0205251|C0871208|C1709323|C0038317|C0030705|C0034656
Baseline characteristics of the sample* FM = fibromyalgia; CBT = cognitive–behavioral therapy; FDI = Functional Disability Inventory; VAS = visual analog scale; CDI = Children's Depression Inventory.,Baseline characteristics sample* FM = fibromyalgia; CBT = cognitive–behavioral therapy; FDI = Functional Disability Inventory; VAS = visual analog scale; CDI = Children's Depression Inventory.,C0168634|C1521970|C0370003|C3540627|G0000000|C0016053|C0009244|G0000000|G0000000|C0039798|G0000000|G0000000|C0205245|C0231170|C0021941|C0042815|G0000000|C0234621|C0243071|C0175659|C0282601|G0000000|C0008059|C0011570|C0021941
"Those patients who achieved clinical remission (defined as a mean of <3 stools/day, including a mean of <1 watery stool/day over 1 week) during the last week of the open-label phase were eligible for randomisation into a double-blind, randomised, placebo-controlled, parallel-group, multicentre, 12-month phase for maintenance of clinical remission (figure 1).","Those patients achieved clinical remission (defined <3 stools/day, including <1 watery stool/day 1 week) week open-label phase eligible randomisation double-blind, randomised, placebo-controlled, parallel-group, multicentre, 12-month phase maintenance clinical remission (figure 1).",G0000000|C0030705|G0000000|C0205210|C0544452|C1704788|G0000000|C0015733|C0332257|G0000000|C0443350|C0015733|G0000000|C0332174|C1709323|C0205390|C1548635|C0034656|C0013072|G0000000|C1706408|C2348042|C0439743|C0450371|C0205390|C0024501|C0205210|C0544452|G0000000|G0000000
"Supportive secondary sleep efficacy endpoints included WASO (except the week 1 average, which was the primary endpoint), TST, SL, depth of sleep, quality of sleep, daytime alertness, ability to concentrate, physical well-being, and ability to function.","Supportive secondary sleep efficacy endpoints included WASO (except week 1 average, primary endpoint), TST, SL, depth sleep, quality sleep, daytime alertness, ability concentrate, physical well-being, ability function.",C1521721|C0027627|C0037313|C1280519|C2349179|C0332257|G0000000|G0000000|C0332174|G0000000|C1510992|C0205225|C2349179|C1421210|G0000000|C0205125|C0037313|C0332306|C0037313|C0332169|C1443086|C0085732|C1880310|C0031809|C0018684|C0085732|C0031843
Parents will also report the total time they spend watching television during their leisure-time in a typical week [54].,Parents report total time spend watching television leisure-time typical week [54].,C0030551|C0684224|C0439175|C0040223|C0680968|C2371283|C0039461|C0086542|C3538928|C0332174|C0450371
"Primary endpoint of the study was 12-month survival, secondary endpoints overall survival, time to progression and tumor response according to standard Response Evaluation Criteria In Solid Tumors (RECIST criteria) [13], toxicity according to ECOG criteria [14] and quality of life assessed by means of the FACT-Hep questionnaire [15] (Figure (Figure1).1).","Primary endpoint study 12-month survival, secondary endpoints survival, time progression tumor response standard Response Evaluation Criteria In Solid Tumors (RECIST criteria) [13], toxicity ECOG criteria [14] quality life assessed FACT-Hep questionnaire [15] (Figure (Figure1).1).",C0205225|C2349179|C0557651|C0450371|C0038952|C0027627|C2349179|C0038952|C0040223|C0242656|C0027651|C0871261|C1442989|C0871261|C0220825|C0243161|G0000000|C0205208|C0027651|C1709926|C0243161|C0450371|C0040539|C0430797|C0243161|C0450371|C0332306|C0376558|C1516048|C3641878|C0034394|C0450371|G0000000|G0000000
"On the day of evaluation, research assistants will administer baseline surveys to patients prior to the commencement of their nephrology or transplant surgery consultation.","On day evaluation, assistants administer baseline surveys patients prior commencement nephrology transplant surgery consultation.",G0000000|C0332173|C0220825|C0011327|C1621583|C0168634|C0038951|C0030705|C0332152|G0000000|C0027712|C0040732|C0038894|C0009818
The changes in primary and secondary outcomes at the end of treatment are shown in Table 3.,The primary secondary outcomes treatment Table 3.,G0000000|C0205225|C0027627|C1274040|C0039798|C0039224|G0000000
The ATS recommend four to six drugs for the treatment of MDR-TB.,The ATS recommend drugs treatment MDR-TB.,G0000000|G0000000|C0034866|C0013227|C0039798|G0000000
• Mortality – on ICU and HDU and overall at six months • Infections – counted as participants with new reported infections and Centres for Disease Control (CDC) confirmed infections in the first 14 days [25].,• Mortality – ICU HDU months • Infections – counted participants reported infections Centres Disease Control (CDC) confirmed infections 14 days [25].,G0000000|C0026565|G0000000|C0021708|G0000000|C0439231|G0000000|C3714514|G0000000|C0750480|C0679646|C0684224|C3714514|C0205099|C0012634|C0243148|C0007670|C0521093|C3714514|C0450371|C0439228|C0450371
"Specifically, the objectives of this article were to determine the sustained efficacy of the SafERteens interventions on peer violence (ie, peer aggression, peer victimization, and violence consequences) and alcohol-related variables (alcohol misuse, binge drinking, alcohol-related consequences) at 12 months.","Specifically, objectives article determine sustained efficacy SafERteens interventions peer violence (ie, peer aggression, peer victimization, violence consequences) alcohol-related variables (alcohol misuse, binge drinking, alcohol-related consequences) 12 months.",G0000000|C0018017|C1706852|G0000000|C0443318|C1280519|G0000000|C0886296|C0679739|C0042693|G0000000|C0679739|C0001807|C0679739|C0376695|C0042693|C0686907|C0524349|C0439828|C0001962|C0549649|C0596170|C0001948|C0524349|C0686907|C0450371|C0439231
"In trauma patients in the intensive care unit, TPN supplemented with glutamine does not improve the expression or the functionality of TLRs in peripheral blood monocytes.","In trauma patients intensive care unit, TPN supplemented glutamine improve expression functionality TLRs peripheral blood monocytes.",G0000000|C0043251|C0030705|C0162425|C1947933|C0439148|C1313790|C0242295|C0017797|G0000000|C0185117|C0205245|G0000000|C0205100|C0005767|C0026473
Percent change of glucose and insulin resistance after treatment for 6 weeks Values are presented as the mean ± SE.,Percent change glucose insulin resistance treatment 6 weeks Values ± SE.,C0439165|C0392747|C0017725|C0021641|C0237834|C0039798|G0000000|C0439230|C0042295|G0000000|C0036919
"The Epworth Sleepiness Scale (ESS, [6] was used to assess possible changes in hypersomnolence.","The Epworth Sleepiness Scale (ESS, [6] assess hypersomnolence.",G0000000|G0000000|C0013144|C0175659|C0206630|G0000000|C1516048|C0751229
"Smoking status was biochemically verified at end of treatment and at 2, 6, and 12 months later.","Smoking status biochemically verified treatment 2, 6, 12 months later.",C0037369|C0449438|G0000000|C1711411|C0039798|G0000000|G0000000|C0450371|C0439231|C0205087
"Lower informational and psychosocial supportive care needs and lower symptom distress from baseline to follow-up at 4 weeks post treatment, 2.","Lower informational psychosocial supportive care lower symptom distress baseline follow-up 4 weeks post treatment, 2.",C0441994|C3242430|C0542298|C1521721|C1947933|C0441994|C1457887|C0231303|C0168634|C0589120|G0000000|C0439230|C0687676|C0039798|G0000000
Another Doppler ultrasound was performed on the 7th postoperative day on the same machine for all the patients on bilateral lower limbs to look for DVT.,Another Doppler ultrasound performed 7th postoperative day machine patients bilateral lower limbs DVT.,G0000000|C0554756|C0041618|C0884358|G0000000|C0032790|C0332173|C0336779|C0030705|C0238767|C0441994|C0015385|C0149871
Inflammatory Cytokine and CRP Levels in Infants Removed from the Study** Infant RBC Membrane DHA Levels,Inflammatory Cytokine CRP Levels Infants Removed Study** Infant RBC Membrane DHA Levels,C0333348|C0079189|C3890735|C0441889|C0021270|C0849355|C0557651|C0021270|C0014792|C0025255|C0142831|C0441889
"MET, metabolic equivalent; SD, standard deviation; SMHS, Shanghai Men's Health Study; SWHS, Shanghai Women's Health Study.","MET, metabolic equivalent; SD, standard deviation; SMHS, Shanghai Men's Health Study; SWHS, Shanghai Women's Health Study.",C0268621|C0311400|C0205163|C2699239|C1442989|C0012727|C1824631|G0000000|C0025266|C0018684|C0557651|G0000000|G0000000|C0043210|C0018684|C0557651
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/10/82/prepub Use of entry screening* and interval between confirmation of first imported pandemic influenza A (H1N1) case and confirmation of first untraceable local case We thank Dr LM Ho for technical support.,The pre-publication history paper accessed here: http://www.biomedcentral.com/1471-2334/10/82/prepub Use entry screening* interval confirmation imported pandemic influenza A (H1N1) confirmation untraceable local We Dr LM Ho technical support.,G0000000|C0332152|C0019664|C0030351|C0444454|G0000000|C1555015|C0042153|C1705654|C0220908|C1272706|C0521091|C0699788|C1615608|C0021400|G0000000|G0000000|C0521091|G0000000|C0205276|G0000000|C0013014|C1261082|C0019905|C0449851|C0183683
"“Bacterial superinfection” was defined as positive culture of a bacterial pathogen from a lower respiratory tract specimen (sputum, bronchial/tracheal aspirates or bronchoalveolar lavage) and/or blood samples collected during the acute illness, excluding results from other sites (e.g.","“Bacterial superinfection” defined positive culture bacterial pathogen lower respiratory tract specimen (sputum, bronchial/tracheal aspirates bronchoalveolar lavage) and/or blood samples collected acute illness, excluding sites (e.g.",G0000000|G0000000|C1704788|C0439178|C0010453|C0521009|C0450254|C0441994|C0521346|C1185740|C0370003|C0038056|C0302191|C0370199|G0000000|C0022100|G0000000|C0005767|C0370003|C1516695|C0205178|C0221423|C0332196|C0205145|G0000000
[39] reported no mortality.,[39] reported mortality.,C0450371|C0684224|C0026565
For walking training the exercise intensity was 80% of the average walking speed of the better baseline six-minute walk test (6MWT) and for cycle training the initial intensity was 60% of peak work rate achieved on the incremental cycle test (ICT).,For walking training exercise intensity 80% average walking speed baseline six-minute walk test (6MWT) cycle training initial intensity 60% peak rate achieved incremental cycle test (ICT).,G0000000|C0080331|C0040607|C0015259|C0522510|C0450371|C1510992|C0080331|C0678536|C0168634|C0205452|C0080331|C0022885|G0000000|C1511572|C0040607|C0205265|C0522510|C0450371|C0444505|C0871208|G0000000|C1705117|C1511572|C0022885|C1512721
"Baseline characteristics of body composition, pulmonary function, exercise capacity and peripheral muscle strength in responders and nonresponders to hf-NMES according to changes in exercise endurance (Tlim).","Baseline characteristics body composition, pulmonary function, exercise capacity peripheral muscle strength responders nonresponders hf-NMES exercise endurance (Tlim).",C0168634|C1521970|C0242821|C0486616|C0024109|C0031843|C0015259|C1516240|C0205100|C0026845|C0237897|G0000000|G0000000|C0018488|C0015259|C0518031|G0000000
Process outcomes included: (i) CD4 cell count evaluated between 90 and 210 days post-ART initiation; (ii) CD4 cell count evaluated 330–390 days post-ART initiation; and (iii) a clinical visit at least once per quarter for three of the first four quarters post-ART initiation.,Process outcomes included: (i) CD4 cell count evaluated 90 210 days post-ART initiation; (ii) CD4 cell count evaluated 330–390 days post-ART initiation; (iii) clinical visit quarter quarters post-ART initiation.,C1184743|C1274040|C0332257|C0021966|C0285590|C0007634|C0750480|C0220825|C0450371|C1442061|C0439228|C0687676|C0589507|G0000000|C0285590|C0007634|C0750480|C0220825|G0000000|C0439228|C0687676|C0589507|C0439070|C0205210|C0545082|C2825406|C2825406|C0687676|C0589507
"Change in the Menopause‐Specific Quality of Life Questionnaire (MENQOL), the Female Sexual Function Index, and the Female Sexual Distress Scale, administered from baseline at 3, 6, and 12 months.","Change Menopause‐Specific Quality Life Questionnaire (MENQOL), Female Sexual Function Index, Female Sexual Distress Scale, administered baseline 3, 6, 12 months.",C0392747|G0000000|C0332306|C0376558|C0034394|G0000000|C0015780|C0036864|C0031843|C0918012|C0015780|C0036864|C0231303|C0175659|C1521801|C0168634|G0000000|G0000000|C0450371|C0439231
"The κ scores for the categorical variables significant haemorrhage growth, new intracranial haemorrhage, any mass effect, and new focal cerebral ischaemic lesions were 0.82, 0.32, 0.81, and 0.89 respectively.","The κ scores categorical variables haemorrhage growth, intracranial haemorrhage, mass effect, focal cerebral ischaemic lesions 0.82, 0.32, 0.81, 0.89 respectively.",G0000000|G0000000|C0449820|C0683312|C0439828|C0019080|C0018270|C0524466|C0019080|C0577559|C1280500|C0205234|G0000000|C0475224|C0221198|C0450371|C0450371|C0450371|C0450371|G0000000
The dependent variable was participation in the smoking intervention (yes or no).,The dependent variable participation smoking intervention (yes no).,G0000000|C0851827|C0439828|C0679823|C0037369|C0886296|C1549445|G0000000
The primary end point was days alive without delirium or coma (defined as the number of days that a patient was alive and free from both delirium and coma during the 14-day intervention period).,The primary days alive delirium coma (defined days patient alive free delirium coma 14-day intervention period).,G0000000|C0205225|C0439228|C0376558|C0011206|C0009421|C1704788|C0439228|C0030705|C0376558|C0332296|C0011206|C0009421|C0450371|C0886296|C0439531
"Secondary endpoints were partial remission of the NS by the initial therapy with CSA or CPH pulses in week 24, efficacy of the non-responder protocol, incidence and significance of adverse drug reactions (ADR) and differences in the renal histology after 24 weeks of therapy in patients with an absence of partial or complete remission.","Secondary endpoints partial remission NS initial therapy CSA CPH pulses week 24, efficacy non-responder protocol, incidence significance adverse drug reactions (ADR) differences renal histology 24 weeks therapy patients absence partial complete remission.",C0027627|C2349179|C0728938|C0544452|C0038944|C0205265|C0039798|G0000000|C0054757|C0034107|C0332174|C0450371|C1280519|C1518422|C0442711|C0021149|C0237881|G0000000|C0013227|C0443286|G0000000|C1705241|C0022646|C0019638|C0450371|C0439230|C0039798|C0030705|C0332197|C0728938|C0205197|C0544452
These evaluations were performed by staff blinded to the study protocol.,These evaluations performed staff blinded study protocol.,G0000000|C0220825|C0884358|C0851286|C0150108|C0557651|C0442711
The modified stairs test is an extended version of the Timed up and go test (TUG).,The modified stairs test extended version Timed test (TUG).,G0000000|C0392747|C1710179|C0022885|C0231448|C0333052|C0392761|C0022885|C1319201
"Paradoxical reactions were defined by the presence of one or both of the following features: a) clinical: an initial improvement on antibiotic treatment in the clinical appearance of a M. ulcerans lesion followed by deterioration of the lesion or its surrounding tissues, or the appearance of a new lesion(s), and b) histopathology: examination of excised tissue from the clinical lesion showing evidence of an intense inflammatory reaction consistent with a paradoxical reaction [11].","Paradoxical reactions defined presence features: a) clinical: initial improvement antibiotic treatment clinical appearance M. ulcerans lesion deterioration lesion surrounding tissues, appearance lesion(s), b) histopathology: examination excised tissue clinical lesion evidence intense inflammatory reaction consistent paradoxical reaction [11].",C0205310|C0443286|C1704788|C0150312|C1521970|G0000000|C0205210|C0205265|C2986411|C0003232|C0039798|C0205210|C0233426|C0369637|G0000000|C0221198|C0868945|C0221198|C1282914|C0040300|C0233426|C0221198|G0000000|C0243140|G0000000|G0000000|C0040300|C0205210|C0221198|C3887511|C0522510|C0333348|C0443286|C0332290|C0205310|C0443286|C0450371
The extent of a positive margin was classified as focal or extensive.,The extent positive margin classified focal extensive.,G0000000|C0439792|C0439178|C0205284|C0008902|C0205234|C0205231
The 95% confidence interval for the true difference was 8% to 18% in favor of the SDP group.,The 95% confidence interval true difference 8% 18% favor SDP group.,G0000000|C0450371|C0237529|C1272706|C0205238|C1705241|G0000000|C0450371|C0309049|G0000000|C0441833
[28] estimated that administration of palivizumab was cost effective only when taking into account also the benefits yielded by a decreased risk of recurrent wheezing in RSV infection patients.,[28] estimated administration palivizumab cost effective account benefits yielded decreased risk recurrent wheezing RSV infection patients.,C0450371|C0750572|C0001554|C0672596|C0010186|C1280519|C2741673|C0814225|G0000000|C0205216|C0035647|C2945760|C0043144|G0000000|C0009450|C0030705
"The second home visit was completed 7 days later when the research assistant collected two more child salivary cotinine samples, detached the air nicotine monitors, and conducted a caregiver survey.","The visit completed 7 days assistant collected child salivary cotinine samples, detached air nicotine monitors, conducted caregiver survey.",G0000000|C0545082|C0205197|G0000000|C0439228|C0011327|C1516695|C0008059|C0442040|C0010194|C0370003|C0687118|C0001861|C0028040|C0181904|C0004927|C0085537|C0038951
"The outreach workers systematically evaluated each subject's residence by looking at the condition of paint (intact, fair, or poor) and testing for lead dust levels at baseline and at 12 months.","The outreach workers systematically evaluated subject's residence condition paint (intact, fair, poor) testing lead dust levels baseline 12 months.",G0000000|C0683805|C0024752|G0000000|C0220825|C0681850|C0237096|C0012634|C0030206|C0205266|C2911689|C0032854|C0039593|C0023175|C0013330|C0441889|C0168634|C0450371|C0439231
"Participants were categorised according to whether they reported sufficient physical activity to meet the current United Kingdom physical activity guidelines (at least 150 minutes of moderate-intensity activity per week in bouts of 10 minutes or more, or at least 75 minutes of vigorous-intensity activity per week) [[3]].","Participants categorised reported sufficient physical activity meet current United Kingdom physical activity guidelines (at 150 minutes moderate-intensity activity week bouts 10 minutes more, 75 minutes vigorous-intensity activity week) [[3]].",C0679646|G0000000|C0684224|C0205410|C0031809|C0205177|C1550543|C0521116|C0166872|C1708611|C0031809|C0205177|C0162791|G0000000|C1442061|C0439232|C0205081|C0205177|C0332174|C0741605|C0450371|C0439232|C0205172|C0450371|C0439232|C0522510|C0205177|C0332174|G0000000
Allogeneic blood transfusion confers a risk to the recipient.,Allogeneic blood transfusion confers risk recipient.,C1515895|C0005767|C0005841|G0000000|C0035647|C1709854
"Pain Analog Scores at 3 Hours, 24 Hours, and 1 Week With Regard to 4 Trocar Types, Morcellation Sites, and Hand-Assist Device Sites No injuries occurred to intraabdominal vessels or bowel caused by any of the trocar types.","Pain Analog Scores 3 Hours, 24 Hours, 1 Week With Regard 4 Trocar Types, Morcellation Sites, Hand-Assist Device Sites No injuries occurred intraabdominal vessels bowel caused trocar types.",C0030193|C0243071|C0449820|G0000000|C0439227|C0450371|C0439227|G0000000|C0332174|G0000000|G0000000|G0000000|C0041158|C0332307|C4042900|C0205145|C0018563|C0025080|C0205145|G0000000|C1510467|C1709305|C0230168|C0005847|C0021853|C0015127|C0041158|C0332307
"During the postpartum period, monitoring was increased to once a week (Wednesdays) for the initial 4 weeks, and then biweekly (every other Wednesday) for the next 8 weeks, with abstinence monitoring ending at the end of week 12.","During postpartum period, monitoring increased week (Wednesdays) initial 4 weeks, biweekly (every Wednesday) 8 weeks, abstinence monitoring week 12.",G0000000|C0086839|C0439531|C0150369|C0205217|C0332174|C0585027|C0205265|G0000000|C0439230|C0585332|G0000000|C0585027|G0000000|C0439230|C3843422|C0150369|C0332174|C0450371
Spirometry and UNDW challenge were done at the following times: day−7; day 0; day 1; day 7; day 14; day 28; day 42.,Spirometry UNDW challenge times: day−7; day 0; day 1; day 7; day 14; day 28; day 42.,C0037981|G0000000|C0798503|C0040223|G0000000|C0332173|G0000000|C0332173|G0000000|C0332173|G0000000|C0332173|C0450371|C0332173|C0450371|C0332173|C0450371
Evidences show that vitamin D metabolism is related to diabetes incidence and its exacerbations.,Evidences vitamin D metabolism diabetes incidence exacerbations.,C3887511|C0042890|C0073187|C0025519|C0011847|C0021149|G0000000
"On the other hand, looking at the change from baseline in total UPDRS score (actual change; Fig.","On hand, change baseline total UPDRS score (actual change; Fig.",G0000000|C0018563|C0392747|C0168634|C0439175|C3639721|C0449820|C0237400|C0392747|C0349966
"Biochemical markers of bone turnover (osteocalcin, procollagen type 1 C-terminal propeptide (PICP), immunoreactive free deoxypyridinoline (iFDpd), N-terminal crosslinked telopeptides of type I collagen (NTx)), BMD at the spine and femoral neck, and serum cortisol concentrations were measured at baseline and 12 months later.","Biochemical markers bone turnover (osteocalcin, procollagen type 1 C-terminal propeptide (PICP), immunoreactive free deoxypyridinoline (iFDpd), N-terminal crosslinked telopeptides type I collagen (NTx)), BMD spine femoral neck, serum cortisol concentrations measured baseline 12 months later.",C0205474|C0005516|C0262950|C0031227|C0029419|C0033235|C0332307|G0000000|C1707271|C1709708|C0072052|G0000000|C0332296|C0057455|G0000000|C0369718|C0178576|G0000000|C0332307|C0021966|C0009325|C0285526|G0000000|C0037949|C0015811|C0027530|C0229671|C0020268|C0086045|C0444706|C0168634|C0450371|C0439231|C0205087
"CBV, cerebral blood volume; cTOI, cerebral tissue oxygenation index; HR, heart rate; SpO 2, peripheral arterial oxygen saturation.","CBV, cerebral blood volume; cTOI, cerebral tissue oxygenation index; HR, heart rate; SpO 2, peripheral arterial oxygen saturation.",C0054917|G0000000|C0005767|C0449468|G0000000|G0000000|C0040300|C0231940|C0918012|G0000000|C0018787|C0871208|C1416903|G0000000|C0205100|C0003842|C0030054|C0522534
"Hopefully, this cohort can be updated and reanalyzed later, to allow for longer follow-up time, and continued monitoring of cancer risk in ART women, especially for CNS and ovarian cancer.","Hopefully, cohort updated reanalyzed later, follow-up time, continued monitoring cancer risk ART women, CNS ovarian cancer.",G0000000|C0599755|C1519814|G0000000|C0205087|C0589120|C0040223|C0549178|C0150369|C0006826|C0035647|C0003826|C0043210|C3714787|C0205065|C0006826
"The primary efficacy endpoint was the incidence of clinically significant thrombocytopenic events (CSTEs), defined as Common Terminology Criteria for Adverse Events, Version 3, grade 3 or 4 thrombocytopenia (platelet count < 50 × 109/L), starting on day 15 of the first cycle or by a platelet transfusion at any time during the treatment period.","The primary efficacy endpoint incidence clinically thrombocytopenic events (CSTEs), defined Common Terminology Criteria Adverse Events, Version 3, grade 3 4 thrombocytopenia (platelet count < 50 × 109/L), starting day 15 cycle platelet transfusion time treatment period.",G0000000|C0205225|C1280519|C2349179|C0021149|G0000000|G0000000|C0441471|G0000000|C1704788|C0205214|C0028275|C0243161|G0000000|C0441471|C0333052|G0000000|C0441800|G0000000|G0000000|C0040034|C0005821|C0750480|G0000000|C0450371|G0000000|C1442061|C0439659|C0332173|C0450371|C1511572|C0005821|C0005841|C0040223|C0039798|C0439531
"Observation Endpoints: Primary endpoints of observation: adverse events of cardiovascular diseases, death and stroke within 1 month of interventional or surgical treatment; ipsilateral stroke or death during the 6 months of follow-up.","Observation Endpoints: Primary endpoints observation: adverse events cardiovascular diseases, death stroke 1 month interventional surgical treatment; ipsilateral stroke death 6 months follow-up.",C0302523|C2349179|C0205225|C2349179|C0302523|G0000000|C0441471|C0007226|C0012634|C0011065|C0038454|G0000000|C0332177|C1948041|C0543467|C0039798|C0441989|C0038454|C0011065|G0000000|C0439231|C0589120
The PCR genotyping analysis confirmed the relapse of P. vivax malaria based on the presence of the same genotype that was present at baseline for respective patient.,The PCR genotyping analysis confirmed relapse P. vivax malaria based presence genotype baseline respective patient.,G0000000|C0032520|C1285573|C0002778|C0521093|C0035020|C0369773|G0000000|C0024530|C1527178|C0150312|C0017431|C0168634|G0000000|C0030705
"Families are pre-stratified according to the age of the child, <6 years and ≥6 years, to prevent chance imbalances between the intervention and the control group with respect to age and age-related variables, such as lung function and possible parental attitude towards passive smoking (parents with younger children may evaluate PS exposure differently from parents with older children).","Families pre-stratified age child, <6 ≥6 years, prevent chance imbalances intervention control respect age age-related variables, lung function parental attitude passive smoking (parents children evaluate PS exposure parents children).",C0015576|C0332152|C0001779|C0008059|G0000000|G0000000|C0439234|C0309872|C0237506|C1397014|C0886296|C0243148|C0679133|C0001779|C0001779|C0439828|C0024109|C0031843|C0030551|C0004271|C3686820|C0037369|C0030551|C0008059|C0220825|C0242397|C0274281|C0030551|C0008059
"The scores of individual components were summed, yielding a total FLS score ranging from 0 to 35 [3,4].","The scores individual components summed, yielding total FLS score ranging 0 35 [3,4].",G0000000|C0449820|C0027361|C0449432|C1515051|G0000000|C0439175|G0000000|C0449820|C1514721|G0000000|C0450371|G0000000
"Clinical Parameters before and after Treatment VR: Virtual reality, CBS: Catherine Bergego scale, K-MBI: Korean version of modified Barthel index *p<0.05 The VR group showed a higher increase in the star cancellation test and CBS scores after treatment than the control group (p<0.05), but both groups did not show any difference in the line bisection test and K-MBI before and after treatment (Table 3).","Clinical Parameters Treatment VR: Virtual reality, CBS: Catherine Bergego scale, K-MBI: Korean version modified Barthel *p<0.05 The VR increase star cancellation test CBS scores treatment control (p<0.05), difference bisection test K-MBI treatment (Table 3).",C0205210|C0449381|C0039798|C3476815|C1553497|C0871222|C1439329|G0000000|G0000000|C0175659|C0597277|C1556095|C0333052|C0392747|G0000000|C0369773|G0000000|C3476815|C0442805|C0995242|C0205544|C0022885|C1439329|C0449820|C0039798|C0243148|C0369773|C1705241|C0184905|C0022885|C0597277|C0039798|C0039224|G0000000
The txt2stop trial established that smoking cessation support more than doubles biochemically verified smoking cessation at 6 months.,The txt2stop trial established smoking cessation support doubles biochemically verified smoking cessation 6 months.,G0000000|G0000000|C0008976|C0443211|C0037369|C1880019|C0183683|C0205173|G0000000|C1711411|C0037369|C1880019|G0000000|C0439231
"The evaluation of randomized, double-blind, controlled trial for the safety and efficacy of 2 weeks, twice-daily treatment with (BTF) versus (BFZ) for each patient with versicolor, cruris, and corporis tinea; and 4 weeks to treat tinea of feet & hands.","The evaluation randomized, double-blind, controlled trial safety efficacy 2 weeks, twice-daily treatment (BTF) versus (BFZ) patient versicolor, cruris, corporis tinea; 4 weeks treat tinea feet & hands.",G0000000|C0220825|C0034656|C0013072|C2587213|C0008976|C0036043|C1280519|G0000000|C0439230|C0585361|C0039798|C1424602|G0000000|G0000000|C0030705|G0000000|G0000000|G0000000|C0040247|G0000000|C0439230|C0087111|C0040247|C0016504|G0000000|C0018563
"Totally 272 cases and 544 age, gender-matched controls were included.","Totally 272 544 age, gender-matched controls included.",G0000000|C1442061|C1442061|C0001779|C0079399|C0243148|C0332257
A capillary sample was collected for free oxygen radical test (FORT) examination at baseline and at months 3 and 6.,A capillary sample collected free oxygen radical test (FORT) examination baseline months 3 6.,G0000000|C0006901|C0370003|C1516695|C0332296|C0030054|C0302912|C0022885|G0000000|G0000000|C0168634|C0439231|G0000000|G0000000
The overall difference between treatment groups was significant at day 28 (P = .015) but not by day 63 (P = .176).,The difference treatment day 28 (P = .015) day 63 (P = .176).,G0000000|C1705241|C0039798|C0332173|C0450371|C0369773|G0000000|C1442061|C0332173|C0450371|C0369773|G0000000|C1442061
"The box and block test, 9-hole Pegboard test, grip strength, Brunnstrom stage, Wolf motor function test, Fugl-Meyer assessment, and the Korean version of Modified Barthel Index were performed prior to and two weeks after the treatment.","The box block test, 9-hole Pegboard test, grip strength, Brunnstrom stage, Wolf motor function test, Fugl-Meyer assessment, Korean version Modified Barthel Index performed prior weeks treatment.",G0000000|C0179400|C0028778|C0022885|C0544726|G0000000|C0022885|C0021400|C0237897|G0000000|C0205390|C0325001|C1513492|C0031843|C0022885|G0000000|C1261322|C1556095|C0333052|C0392747|G0000000|C0918012|C0884358|C0332152|C0439230|C0039798
"The primary clinical outcome will be the IBS Symptom Severity Score (SSS) (maximum score 500) at three months, and at 12 month assessing whether there is an overall benefit.","The primary clinical outcome IBS Symptom Severity Score (SSS) (maximum score 500) months, 12 month assessing benefit.",G0000000|C0205225|C0205210|C1274040|C0022104|C1457887|C0439793|C0449820|C0037052|C0806909|C0449820|C1442061|C0439231|C0450371|C0332177|C1516048|C0814225
"This approach is possible because formoterol provides rapid symptom relief, making use of a separate short acting β2-agonist redundant.8–11 When taking an extra puff for symptom relief, an additional dose of ICS and formoterol is administered simultaneously, thereby preventing a deterioration or even an exacerbation.12 Studies testing the SMART concept have shown beneficial effects on the time to first asthma exacerbation, exacerbation rate, and number of days with asthma control compared with other treatment regimens.","This approach formoterol rapid symptom relief, separate short acting β2-agonist redundant.8–11 When extra puff symptom relief, additional dose ICS formoterol administered simultaneously, preventing deterioration exacerbation.12 Studies testing SMART concept beneficial effects time asthma exacerbation, exacerbation rate, days asthma control compared treatment regimens.",G0000000|C0449445|C0060657|C0456962|C1457887|C0564405|C0443299|C1282927|G0000000|G0000000|G0000000|G0000000|G0000000|C1533107|C1457887|C0564405|C1524062|C0178602|C0022521|C0060657|C1521801|C0521115|C0309872|C0868945|C0450371|C0947630|C0039593|G0000000|C0178566|G0000000|C1280500|C0040223|C0004096|G0000000|G0000000|C0871208|C0439228|C0004096|C0243148|C1707455|C0039798|C2945654
"Treatment reduced the severity of rhinorrhea, sneezing, nasal obstruction, sore throat, cough, and headache and reduced nasal mucus production, nasal tissue use, and virus concentrations in nasal secretions.","Treatment reduced severity rhinorrhea, sneezing, nasal obstruction, sore throat, cough, headache reduced nasal mucus production, nasal tissue use, virus concentrations nasal secretions.",C0039798|C0392756|C0439793|C1260880|C0037383|C0028429|C0028778|C0234233|C0031354|C0010200|C0018681|C0392756|C0028429|C0026727|C0033268|C0028429|C0040300|C0042153|C0042776|C0086045|C0028429|C0036537
"Measures considered for this analysis included baseline measures of primary outcome variables (e.g., maternal synchronization, expressive language), putative moderators (e.g., maternal insightfulness classification), socioeconomic characteristics (e.g., family income, ethnicity/race, number of siblings, birth father living with family, home owned/rented, mother born within the US) and baseline variables potentially associated with outcomes (e.g., maternal age, education and employment, non-project interventions & programs, children’s chronological ages, Mullen Scores, ADOS scores, Response to Joint Attention scores).","Measures considered analysis included baseline measures primary outcome variables (e.g., maternal synchronization, expressive language), putative moderators (e.g., maternal insightfulness classification), socioeconomic characteristics (e.g., family income, ethnicity/race, siblings, birth father living family, owned/rented, mother born US) baseline variables outcomes (e.g., maternal age, education employment, non-project interventions & programs, children’s chronological ages, Mullen Scores, ADOS scores, Response Joint Attention scores).",C0079809|C0750591|C0002778|C0332257|C0168634|C0079809|C0205225|C1274040|C0439828|G0000000|C2347083|C0439580|C0185117|C0023008|G0000000|G0000000|G0000000|C2347083|C0233820|C0008902|C0748878|C1521970|G0000000|C0015576|C0021162|C0015031|C0037047|C0005615|C0015671|C0376558|C0015576|C1555586|C0026591|C0005615|G0000000|C0168634|C0439828|C1274040|G0000000|C2347083|C0001779|C0013621|C0014003|C1518422|C0886296|G0000000|C0376691|G0000000|C0008717|C0001779|C0885014|C0449820|C0670018|C0449820|C0871261|C0022417|C0004268|C0449820
"Our trial showed no clinical signs including pain, swelling, pathologic luxation, and tenderness to percussion was observed.","Our trial clinical signs including pain, swelling, pathologic luxation, tenderness percussion observed.",G0000000|C0008976|C0205210|C0220912|C0332257|C0030193|C0013604|C1521733|C0332767|C0234233|C0030987|C1441672
There was no difference in OS between the two arms and PFS was similar in both arms.,There difference OS arms PFS arms.,G0000000|C1705241|C0229090|C0206655|C0242792|C0206655
Change in the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) and change in the Clinical Dementia Rating (CDR) sum of boxes.,Change cognitive subscale Alzheimer’s Disease Assessment Scale (ADAS-cog) change Clinical Dementia Rating (CDR) sum boxes.,C0392747|C1516691|G0000000|G0000000|C0012634|C1261322|C0175659|C3539026|C0392747|C0205210|C0011265|C0871208|G0000000|C1515051|C0179400
"Given the apparently reliable effects of sight word and phonics training on trained irregular word accuracy, nonword reading accuracy, nonword reading fluency, and word reading fluency, but the questionable effects of this training on untrained irregular word accuracy and reading comprehension, it is clear that a randomised controlled trial is now needed to compare the effect of phonics and sight word training to an untrained control group and a trained control group (e.g., maths training).","Given reliable effects sight word phonics training trained irregular word accuracy, nonword reading accuracy, nonword reading fluency, word reading fluency, questionable effects training untrained irregular word accuracy reading comprehension, randomised controlled trial compare phonics sight word training untrained control trained control (e.g., maths training).",C1442162|C3858758|C1280500|C0042789|C1705313|C0871074|C0040607|C0336809|C0205271|C1705313|C0443131|G0000000|C0034754|C0443131|G0000000|C0034754|C0870569|C1705313|C0034754|C0870569|C0332241|C1280500|C0040607|G0000000|C0205271|C1705313|C0443131|C0034754|C0162340|G0000000|C2587213|C0008976|C1707455|C0871074|C0042789|C1705313|C0040607|G0000000|C0243148|C0336809|C0243148|G0000000|C0024934|C0040607
"Furthermore, the following functional outcomes were assessed at baseline and four weeks for Phase 2 participants: Functional Independence Measure (transfers, walking and stairs) [32], Motor Assessment Scale [30], Functional Reach [33], Step Test [38], and 6-min walk test [39].","Furthermore, functional outcomes assessed baseline weeks Phase 2 participants: Functional Independence Measure (transfers, walking stairs) [32], Motor Assessment Scale [30], Functional Reach [33], Step Test [38], 6-min walk test [39].",G0000000|C0205245|C1274040|C1516048|C0168634|C0439230|C0205390|G0000000|C0679646|C0205245|C0085862|C0079809|C0728827|C0080331|C1710179|C0450371|C1513492|C1261322|C0175659|C0450371|C0205245|C2584321|C0450371|C1261552|C0022885|C0450371|C0702093|C0080331|C0022885|C0450371
"Other secondary efficacy end points were peak FEV1, FVC AUC0–3, peak and trough FVC responses at 12 weeks, and rescue medication use over the 12-week treatment period.","Other secondary efficacy peak FEV1, FVC AUC0–3, peak trough FVC responses 12 weeks, rescue medication 12-week treatment period.",G0000000|C0027627|C1280519|C0444505|G0000000|C3714541|G0000000|C0444505|C0444506|C3714541|C0871261|C0450371|C0439230|G0000000|C0013227|C0450371|C0039798|C0439531
Secondary outcomes included the frequency and type of infections and the cumulative amount of prednisolone received in both groups.,Secondary outcomes included frequency type infections cumulative amount prednisolone received groups.,C0027627|C1274040|C0332257|C0376249|C0332307|C3714514|C1511559|C1265611|C0032950|C1514756|C0441833
"Foveal and mean retinal nerve fibre layer (RNFL) thickness was measured using SDOCT (Cirrus-SDOCT, Carl Zeiss, Peabody, Massachusetts, USA).","Foveal retinal nerve fibre layer (RNFL) thickness measured SDOCT (Cirrus-SDOCT, Carl Zeiss, Peabody, Massachusetts, USA).",C0016622|C0035298|C0027740|C0012173|C0934502|G0000000|C1280412|C0444706|G0000000|G0000000|G0000000|G0000000|G0000000|C0024874|C0041703
The primary outcome was state-level confirmation of insured status at 90 days.,The primary outcome state-level confirmation insured status 90 days.,G0000000|C0205225|C1274040|C0683927|C0521091|C1548605|C0449438|C0450371|C0439228
"EDSS, Expanded Disability Status Scale; LESO, last extension study observation.","EDSS, Expanded Disability Status Scale; LESO, extension study observation.",C0451246|C0205229|C0231170|C0449438|C0175659|G0000000|C0231448|C0557651|C0302523
"Vitamin D level was determined in a laboratory by the Liebermann–Burchard method, in which the patient should fast for 12 h and not have a fatty dinner.","Vitamin D level determined laboratory Liebermann–Burchard method, patient fast 12 fatty dinner.",C0042890|C0073187|C0441889|G0000000|C0022877|G0000000|C0025663|C0030705|C0015663|C0450371|G0000000|C2699739
"Our study found that the mean of maximum pain intensity in fennel/vitamin E group was lower than that of ibuprofen group at 1, 2, 3, 6, and 48 h, although based on Wilcoxon test, this difference was statistically significant only in the first and second hours.","Our study maximum pain intensity fennel/vitamin E lower ibuprofen 1, 2, 3, 6, 48 h, based Wilcoxon test, difference statistically hours.",G0000000|C0557651|C0806909|C0030193|C0522510|C0553175|G0000000|C0441994|C0020740|G0000000|G0000000|G0000000|G0000000|C0450371|C0033727|C1527178|G0000000|C0022885|C1705241|C0038215|C0439227
"Adherence and reporting of side effects (staining of the teeth, ease of use, diarrhoea and darkening of stools) were compared between groups.","Adherence reporting effects (staining teeth, ease use, diarrhoea darkening stools) compared groups.",C1510802|C0700287|C1280500|C0487602|C0040426|C1331418|C0042153|C0011991|G0000000|C0015733|C1707455|C0441833
[Results] The postural sway speed and anteroposterior and total postural sway path lengths were significantly decreased in the CVRTT group.,[Results] The postural sway speed anteroposterior total postural sway path lengths decreased CVRTT group.,C1274040|G0000000|C0205278|G0000000|C0678536|G0000000|C0439175|C0205278|G0000000|C0919386|C1444754|C0205216|G0000000|C0441833
"In our study normal vaginal delivery was high, but physiologic delivery was still low and C/S was high.","In study normal vaginal delivery high, physiologic delivery low C/S high.",G0000000|C0557651|C0205307|C0042232|C0011209|C0205250|C0205463|C0011209|C0205251|C0565930|C0205250
"We hypothesize that HELP will reduce delirium incidence during hospital admission and decrease the duration and severity of delirium and length of hospital stays among these older patients, which will lead to reduced health care costs.","We hypothesize HELP reduce delirium incidence hospital admission decrease duration severity delirium length hospital stays patients, lead reduced health care costs.",G0000000|G0000000|C1269765|G0000000|C0011206|C0021149|C0019994|C0184666|C0392756|C0449238|C0439793|C0011206|C1444754|C0019994|G0000000|C0030705|C0023175|C0392756|C0018684|C1947933|C0010186
"Use of tobacco, alcohol, and marijuana; internalizing, externalizing, and total behavioral problems; academic achievement.","Use tobacco, alcohol, marijuana; internalizing, externalizing, total behavioral problems; academic achievement.",C0042153|C0040329|C0001962|C0024808|G0000000|G0000000|C0439175|C0004927|C1546466|C1510747|C0001072
Doses should therefore be substantial so that treatment effects are not missed.,Doses substantial treatment effects missed.,C0178602|G0000000|C0039798|C1280500|C1705492
"The comparison of primary outcome measures (SCT, LBT, PIT) between the treatment and the control group at baseline to 1, 3, and 6 months was assessed by an analysis of covariance.","The comparison primary outcome measures (SCT, LBT, PIT) treatment control baseline 1, 3, 6 months assessed analysis covariance.",G0000000|C1707455|C0205225|C1274040|C0079809|C0860888|C1879922|C0175697|C0039798|C0243148|C0168634|G0000000|G0000000|G0000000|C0439231|C1516048|C0002778|G0000000
"Possible behavioural factors associated with childhood diarrhoea (n = 794), Sheko district rural community, Southwest Ethiopia, January – February 2012 Comparing model and non-model households, a remarkable difference in childhood diarrhoea prevalence was observed.","Possible behavioural factors childhood diarrhoea (n = 794), Sheko district rural community, Southwest Ethiopia, January – February 2012 Comparing model non-model households, remarkable difference childhood diarrhoea prevalence observed.",C0332149|C0004927|C1521761|C0231335|C0011991|G0000000|G0000000|G0000000|C0240919|C0009462|C1710136|C0015024|C3829466|G0000000|C3830166|G0000000|C1707455|C3161035|C1518422|C0020052|G0000000|C1705241|C0231335|C0011991|C0033105|C1441672
"We studied pain relief, labor induction, use of oxytocin, fetal electronic surveillance, Apgar scores, care in neonatal or in intensive care units (a subgroup of care in neonatal units), newborn resuscitation, and perinatal and infant deaths (4 deaths in each group).","We studied pain relief, labor induction, oxytocin, fetal electronic surveillance, Apgar scores, care neonatal intensive care units (a subgroup care neonatal units), newborn resuscitation, perinatal infant deaths (4 deaths group).",G0000000|C0557651|C0030193|C0564405|C0022864|C0205263|C0030095|C0015965|C0013850|C0220920|C0741195|C0449820|C1947933|C1552240|C0162425|C1947933|C0439148|G0000000|C1079230|C1947933|C1552240|C0439148|C0021289|C0035273|C0178795|C0021270|C0011065|G0000000|C0011065|C0441833
Efficacy estimates for HPV infection of at least 6- and 12-month duration were comparable.,Efficacy estimates HPV infection 6- 12-month duration comparable.,C1280519|C0750572|C0021344|C0009450|G0000000|C0450371|C0449238|G0000000
EDSS assessment and brain MRI were performed at baseline and then after one year of therapy.,EDSS assessment brain MRI performed baseline therapy.,C0451246|C1261322|C0006104|C0024485|C0884358|C0168634|C0039798
"Due to exogenous melatonin, sleep parameters such as sleep fragmentation, sleep onset latency and subjective sleep quality improved.","Due exogenous melatonin, sleep parameters sleep fragmentation, sleep onset latency subjective sleep quality improved.",C0678226|C0205101|C0025219|C0037313|C0449381|C0037313|C0332472|C0037313|C0206132|C0205275|C0439655|C0037313|C0332306|C0184511
"The index UTI was febrile and symptomatic in 323 (53%) of the children, febrile only in 197 (32%), symptomatic only in 86 (14%), and with fever and symptoms outside of the 24-hour window of urine collection for 1 child.","The UTI febrile symptomatic 323 (53%) children, febrile 197 (32%), symptomatic 86 (14%), fever symptoms 24-hour window urine collection 1 child.",G0000000|C0042029|C0015967|C0231220|C1442061|C0450371|C0008059|C0015967|C1442061|C0450371|C0231220|C0450371|C0450371|C0015967|C0683368|C0450371|C0557702|C0042036|C1516698|G0000000|C0008059
"At randomization, baseline assessments of medical history, lower urinary tract symptoms (LUTS) using the LUTS Symptoms Scale [45], quality of life (QOL), using the Rand Short-form (SF)-36 [46], serum total PSA and plasma catechin levels were obtained.","At randomization, baseline assessments medical history, lower urinary tract symptoms (LUTS) LUTS Symptoms Scale [45], quality life (QOL), Rand Short-form (SF)-36 [46], serum total PSA plasma catechin levels obtained.",G0000000|C0034656|C0168634|C1261322|C0199168|C0019664|C0441994|C0042027|C1185740|C0683368|C0574785|C0574785|C0683368|C0175659|C0450371|C0332306|C0376558|C0518214|C1555436|C2964478|C0037712|C0450371|C0229671|C0439175|C3810537|C0032105|C0007404|C0441889|C1301820
"The following 8 secondary outcomes were evaluated: the CYBOCS-PDD, a composite measure of the CGI-I and the CYBOCS-PDD (CGI-I score of 1 or 2 and a 25% reduction on the CYBOCS-PDD), and 6 subscales of the Repetitive Behavior Scale.","The 8 secondary outcomes evaluated: CYBOCS-PDD, composite measure CGI-I CYBOCS-PDD (CGI-I score 1 2 25% reduction CYBOCS-PDD), 6 subscales Repetitive Behavior Scale.",G0000000|G0000000|C0027627|C1274040|C0220825|C0008838|C0205199|C0079809|C3639708|C0008838|C3639708|C0449820|G0000000|G0000000|C0450371|C0301630|C0008838|G0000000|G0000000|G0000000|C0004927|C0175659
The consumption of HGI or LGI meals for five consecutive days did not change free fatty acid concentrations from their baseline levels (day 1).,The consumption HGI LGI meals consecutive days change free fatty acid concentrations baseline levels (day 1).,G0000000|C0009830|G0000000|G0000000|C1998602|C1707491|C0439228|C0392747|C0332296|G0000000|C0001128|C0086045|C0168634|C0441889|C0332173|G0000000
"The primary outcome was a major adverse kidney event within 30 days — a composite of death from any cause, new renal-replacement therapy, or persistent renal dysfunction (defined as an elevation of the creatinine level to ≥200% of baseline) — all censored at hospital discharge or 30 days, whichever occurred first.","The primary outcome major adverse kidney event 30 days — composite death cause, renal-replacement therapy, persistent renal dysfunction (defined elevation creatinine level ≥200% baseline) — censored hospital discharge 30 days, whichever occurred first.",G0000000|C0205225|C1274040|C0205082|G0000000|C0022646|C0441471|C0450371|C0439228|G0000000|C0205199|C0011065|C0015127|C1302112|C0039798|C0205322|C0022646|C0031847|C1704788|C0439775|C0010294|C0441889|G0000000|C0168634|G0000000|C3889990|C0019994|C0012621|C0450371|C0439228|G0000000|C1709305|C0205435
"Plasma levels of EPA, DHA, total n-3, total n-6, and the n-6/n-3 ratio were measured at the baseline visit, at 8 weeks (or final study visit), and at 16 weeks (or final maintenance visit).","Plasma levels EPA, DHA, total n-3, total n-6, n-6/n-3 ratio measured baseline visit, 8 weeks (or final study visit), 16 weeks (or final maintenance visit).",C0032105|C0441889|G0000000|C0142831|C0439175|C0369718|C0439175|C0369718|C0369718|C0456603|C0444706|C0168634|C0545082|G0000000|C0439230|G0000000|C0205088|C0557651|C0545082|C0450371|C0439230|G0000000|C0205088|C0024501|C0545082
"All groups had a similar improvement from baseline to 1 year in the distance walked in 6 minutes, the number of steps taken in the community, activities of daily living, physical mobility and social participation, motor recovery, and balance (Table 2).","All improvement baseline 1 distance walked 6 minutes, steps community, activities daily living, physical mobility social participation, motor recovery, balance (Table 2).",G0000000|C2986411|C0168634|G0000000|C0012751|C0080331|G0000000|C0439232|C1261552|C0009462|C0441655|C0332173|C0376558|C0031809|C0425245|C0728831|C0679823|C1513492|C0237820|C0014653|C0039224|G0000000
The Patient Health Questionnaire 8-item Depression Scale (PHQ-8) was used to assess depression symptoms.,The Patient Health Questionnaire 8-item Depression Scale (PHQ-8) assess depression symptoms.,G0000000|C0030705|C0018684|C0034394|C1551338|C0011570|C0175659|C1879301|C1516048|C0011570|C0683368
"From June to December each year, passive case detection was used to monitor clinical cases of malaria.","From June December year, passive detection monitor clinical malaria.",G0000000|C3829443|C3830550|C0439234|C3686820|C1511790|C0030695|C0205210|C0024530
"The relationship of muscle architecture with muscle function suggests that the evaluation of key muscle parameters such as volume, activation level and fascicle behaviour should occur following PRT as a means of examining whether the neuromuscular properties have been altered.","The relationship muscle architecture muscle function suggests evaluation key muscle parameters volume, activation level fascicle behaviour occur PRT examining neuromuscular properties altered.",G0000000|C0439849|C0026845|C0003737|C0026845|C0031843|C1705535|C0220825|G0000000|C0026845|C0449381|C0449468|C1879547|C0441889|C1185741|C0004927|C1709305|C0020687|C0332128|C1979768|C0871161|C0392747
Remission was defined as a CDAI ⩽150 and response as a fall in CDAI of ⩾70 or a CRP <10 mg/l.,Remission defined CDAI ⩽150 response fall CDAI ⩾70 CRP <10 mg/l.,C0544452|C1704788|C0683448|G0000000|C0871261|C0085639|C0683448|G0000000|C3890735|C0450371|C0439268
"Modified CHEOPS (Children's Hospital of Eastern Ontario Pain Scale) Extubation time, Delivery Time, and PONV (Postoperative Nausea, Vomiting) Values of extubation time are mean ± SD.","Modified CHEOPS (Children's Hospital Eastern Ontario Pain Scale) Extubation time, Delivery Time, PONV (Postoperative Nausea, Vomiting) Values extubation time ± SD.",C0392747|G0000000|C0008059|C0019994|C1707877|C0029040|C0030193|C0175659|C0553891|C0040223|C0011209|C0040223|C0520909|C0032790|C0027497|C0042963|C0042295|C0553891|C0040223|G0000000|C2699239
"In addition, subjects who did not complete the study perceived themselves as being more disabled on the QBPDS (t = −2.60, p = .02) and the MPI Interference subscale (t = −2.37, p = .02).","In addition, subjects complete study perceived disabled QBPDS (t = −2.60, = .02) MPI Interference subscale (t = −2.37, = .02).",G0000000|C0332287|C0681850|C0205197|C0557651|C0030971|C0018576|G0000000|C2603360|G0000000|G0000000|G0000000|C0450371|C0663932|C0521102|G0000000|C2603360|G0000000|G0000000|G0000000|C0450371
"We used Poisson regression to analyse the incidence of anaemia, cerebral malaria, hospital admissions, and death.","We Poisson regression analyse incidence anaemia, cerebral malaria, hospital admissions, death.",G0000000|G0000000|C0684320|G0000000|C0021149|C0002871|G0000000|C0024530|C0019994|C0184666|C0011065
"Second, while we noted a statistically significant difference in sleep onset latency as determined by polysomnography, there was no subjective difference in sleep onset latency, other subjective sleep parameters, or subjective measures of daytime functioning.","Second, statistically difference sleep onset latency determined polysomnography, subjective difference sleep onset latency, subjective sleep parameters, subjective measures daytime functioning.",C0205436|C0038215|C1705241|C0037313|C0206132|C0205275|G0000000|C0162701|C0439655|C1705241|C0037313|C0206132|C0205275|C0439655|C0037313|C0449381|C0439655|C0079809|C0332169|C0205245
"At our center, mortality was 22.22%, which is the same as overall mortality in our state.","At center, mortality 22.22%, mortality state.",G0000000|C0205099|C0026565|C0450371|C0026565|C1301808
"Approximately 25 patients per group were needed to provide 80% power to detect a difference between groups in mean weight change from baseline to twelve months of 5 kg (11 pounds) or greater, representing approximately 5% weight loss for an obese female (alpha = 0.05, two-sided, SD = 5.0) [32].","Approximately 25 patients provide 80% power detect difference weight change baseline twelve months 5 (11 pounds) greater, representing 5% weight loss obese female (alpha = 0.05, two-sided, SD = 5.0) [32].",C0332232|C0450371|C0030705|C1999230|C0450371|C0032863|C0442726|C1705241|C0005910|C0392747|C0168634|C0205458|C0439231|G0000000|C0450371|C0439219|C1704243|C1882932|G0000000|C0005910|C1517945|C0028754|C0015780|C0439095|G0000000|C0450371|C0205448|C2699239|G0000000|G0000000|C0450371
"Furthermore, a reduction in objective sleep onset latency, as measured by actigraphy, was displayed after treatment.","Furthermore, reduction objective sleep onset latency, measured actigraphy, displayed treatment.",G0000000|C0301630|C0018017|C0037313|C0206132|C0205275|C0444706|C1171301|C0870432|C0039798
"Primary outcomes included: abstinence at 12 months, and changes in patterns of alcohol use measured by TLFB; intention to quit using, cut back on use, or change the circumstances of use; and reduction of consequences such as alcohol-related injury, driving under the influence, and high-risk behaviors related to alcohol use such as fights, unprotected or unplanned sex, or accepting a ride from a drinking driver.","Primary outcomes included: abstinence 12 months, patterns alcohol measured TLFB; intention quit using, cut use, change circumstances use; reduction consequences alcohol-related injury, driving influence, high-risk behaviors alcohol fights, unprotected unplanned sex, accepting ride drinking driver.",C0205225|C1274040|C0332257|C3843422|C0450371|C0439231|C0449774|C0001962|C0444706|C0814210|C0162425|C0748223|C1524063|C0000925|C0042153|C0392747|G0000000|C0042153|C0301630|C0686907|C0524349|C3263722|C0004379|C4054723|C0332167|C0004927|C0001962|C0424324|G0000000|G0000000|C0009253|C1272684|G0000000|C0001948|C0684312
"Mediators include changes in health behaviors (for example, diet, physical activity, weight loss, medication adherence) and antihypertensive medication intensification.","Mediators health behaviors (for example, diet, physical activity, weight loss, medication adherence) antihypertensive medication intensification.",C0127400|C0018684|C0004927|G0000000|C1707959|C0012155|C0031809|C0205177|C0005910|C1517945|C0013227|C1510802|C0003364|C0013227|G0000000
This measure is not validated and is likely to result in an overestimation of effect.,This measure validated result overestimation effect.,G0000000|C0079809|G0000000|C1274040|G0000000|C1280500
Primary: epidural analgesia.,Primary: epidural analgesia.,C0205225|C0228134|C0002766
The secondary outcomes included relapse rate and changes in the EDSS score.,The secondary outcomes included relapse rate EDSS score.,G0000000|C0027627|C1274040|C0332257|C0035020|C0871208|C0451246|C0449820
"There were no significant changes from baseline to 1-week or 1-month follow-ups in the primary outcomes (pain, anxiety, and alertness).","There baseline 1-week 1-month follow-ups primary outcomes (pain, anxiety, alertness).",G0000000|C0168634|C0332174|C0332177|C0332283|C0205225|C1274040|C0030193|C0003467|C1443086
We will calculate the SF-12 physical and mental health summary scores.,We calculate SF-12 physical mental health summary scores.,G0000000|C1441506|C0037712|C0031809|C0229992|C0018684|C1552616|C0449820
Secondary outcomes included duration of pre-treatment symptoms and proportions of treatment completion between study arms.,Secondary outcomes included duration pre-treatment symptoms proportions treatment completion study arms.,C0027627|C1274040|C0332257|C0449238|C2709094|C0683368|C1709707|C0039798|C0205197|C0557651|C0206655
To examine differences between suicide rates before and after the barrier we carried out Poisson regression analyses.,To examine differences suicide rates barrier carried Poisson regression analyses.,C0040363|G0000000|C1705241|C0038661|C0871208|C1706912|C0206243|G0000000|C0684320|C0002778
The postsurgical follow-up duration ranged between 12 and 26 months (mean 14 months) (Table 1).,The postsurgical follow-up duration ranged 12 26 months (mean 14 months) (Table 1).,G0000000|G0000000|C0589120|C0449238|C1514721|C0450371|C0450371|C0439231|C0444504|C0450371|C0439231|C0039224|G0000000
"While the most common form of parental monitoring is asking the adolescent whether or not diabetes care was completed, Ellis et al.21 showed that only direct supervision and oversight of adolescent diabetes care were related to better diabetes management and metabolic control.","While common form parental monitoring adolescent diabetes care completed, Ellis al.21 direct supervision oversight adolescent diabetes care diabetes management metabolic control.",G0000000|C0205214|C0348078|C0030551|C0150369|C0205653|C0011847|C1947933|C0205197|G0000000|C0202311|C0439851|C0038842|C1273870|C0205653|C0011847|C1947933|C0011847|C0001554|C0311400|C0243148
Caretakers were instructed to feed their children the entire ration of RUTF over the 2 wk period.,Caretakers instructed feed children entire ration RUTF 2 wk period.,C0335350|G0000000|C0204695|C0008059|C0439751|G0000000|G0000000|G0000000|C0332174|C0439531
"CONCLUSIONS—Antibiotic courses allow an improvement in nutritional status in CF patients, with a gain in fat mass.","CONCLUSIONS—Antibiotic courses improvement nutritional status CF patients, gain fat mass.",G0000000|C0750729|C2986411|C1521739|C0449438|C0009738|C0030705|C1517378|C0424612|C0577559
"Therefore, we aimed to investigate the efficacy of chest physiotherapy in prevention of postextubation atelectasis in pediatric patients.","Therefore, aimed investigate efficacy chest physiotherapy prevention postextubation atelectasis pediatric patients.",G0000000|C1947946|C1292732|C1280519|C0817096|C0949766|C0199176|G0000000|C0004144|C0030755|C0030705
"Further, active institutional controls, such as pharmacokinetics consulting services, may have had more time to influence the ordering process.","Further, active institutional controls, pharmacokinetics consulting services, time influence process.",C1517331|C0205177|C0018704|C0243148|C0031327|C0009818|C0557854|C0040223|C4054723|C1184743
"These specimens are: A deep NS specimen for respiratory viruses, respiratory bacterial pathogens (with antibiotic susceptibility testing) and other potentially important respiratory pathogens (M. pneumoniae, Chlamydia spp) at baseline and at the beginning and resolution of an exacerbation.","These specimens are: A deep NS specimen respiratory viruses, respiratory bacterial pathogens (with antibiotic susceptibility testing) respiratory pathogens (M. pneumoniae, Chlamydia spp) baseline resolution exacerbation.",G0000000|C0370003|G0000000|G0000000|C0205125|C0038944|C0370003|C0521346|C0042776|C0521346|C0521009|C0450254|G0000000|C0003232|C0012655|C0039593|C0521346|C0450254|C0369637|C0032285|C0008148|C1424276|C0168634|C1514893|G0000000
"Secondary endpoints included 25(OH)D and other biochemical measures, immunologic biomarkers, relapse events, and Expanded Disability Status Scale (EDSS) score.","Secondary endpoints included 25(OH)D biochemical measures, immunologic biomarkers, relapse events, Expanded Disability Status Scale (EDSS) score.",C0027627|C2349179|C0332257|C0450371|C0205474|C0079809|C0152036|C0005516|C0035020|C0441471|C0205229|C0231170|C0449438|C0175659|C0451246|C0449820
The proportion of time spent in REM sleep as a percentage of total sleep time was similar between conditions (P = 0.38; Table 1).,The proportion time spent REM sleep percentage total sleep time conditions (P = 0.38; Table 1).,G0000000|C1709707|C0040223|C0680968|G0000000|C0037313|C0439165|C0439175|C0037313|C0040223|C0012634|C0369773|G0000000|C0450371|C0039224|G0000000
Primary outcome measure is the physician antibiotic prescription rate for RTI at study period T2 derived from the data of the AOK health insurance company.,Primary outcome measure physician antibiotic prescription rate RTI study period T2 derived data AOK health insurance company.,C0205225|C1274040|C0079809|C0031831|C0003232|C0033080|C0871208|C0035243|C0557651|C0439531|C0041403|C1441547|C1511726|G0000000|C0018684|C0021672|C0683757
"Functional level was measured by the Physical Self-Maintenance Scale (Kent, Kastenbaum, & Sherwood, 1972; Lawton & Brody, 1969) and the Performance Test of Activities of Daily Living (Kuriansky &Gurland, 1976).","Functional level measured Physical Self-Maintenance Scale (Kent, Kastenbaum, & Sherwood, 1972; Lawton & Brody, 1969) Performance Test Activities Daily Living (Kuriansky &Gurland, 1976).",C0205245|C0441889|C0444706|C0031809|C0036588|C0175659|C0454861|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0597198|C0022885|C0441655|C0332173|C0376558|G0000000|G0000000|G0000000
These side effects were temporary and could be alleviated by symptomatic treatment or dose reduction.,These effects temporary alleviated symptomatic treatment dose reduction.,G0000000|C1280500|C0205374|G0000000|C0231220|C0039798|C0178602|C0301630
"The improvement at 4 years in the patients in SPORT who were undergoing surgery for isolated spinal stenosis were also similar to the outcomes of surgery in the Maine Lumbar Spine Study (MLSS) mixed-stenosis (those with and those without degenerative spondylolisthesis) cohort.27 The improvement in the stenosis bothersomeness index, leg pain and low back pain bothersomeness respectively were: −7.6, −2.5 and −1.8 in SPORT vs. −9.4, −3.5 and −1.7 in the MLSS.","The improvement 4 patients SPORT undergoing surgery isolated spinal stenosis outcomes surgery Maine Lumbar Spine Study (MLSS) mixed-stenosis (those degenerative spondylolisthesis) cohort.27 The improvement stenosis bothersomeness index, leg pain low pain bothersomeness were: −7.6, −2.5 −1.8 SPORT vs. −9.4, −3.5 −1.7 MLSS.",G0000000|C2986411|G0000000|C0030705|C0038039|G0000000|C0038894|C0205409|C0521329|C0678234|C1274040|C0038894|C0024497|C0024090|C0037949|C0557651|C0796070|C0205430|G0000000|C0011164|C0038016|C0599755|G0000000|C2986411|C0678234|G0000000|C0918012|C0023216|C0030193|C0205251|C0030193|G0000000|G0000000|G0000000|G0000000|G0000000|C0038039|G0000000|G0000000|G0000000|G0000000|C0796070
"Families were concurrently recruited and stratified to one of two treatment conditions, either the (a) intervention group (IG) or (b) waiting list control before intervention group (WG) to enable within family comparisons before and after intervention in addition to providing a waiting list control period.","Families concurrently recruited stratified treatment conditions, (a) intervention (IG) (b) waiting list control intervention (WG) enable family comparisons intervention addition providing waiting list control period.",C0015576|G0000000|G0000000|C0205363|C0039798|C0012634|G0000000|C0886296|C0021027|G0000000|C1610166|C0745732|C0243148|C0886296|C3495801|C0562342|C0015576|C1707455|C0886296|C0332287|C1999230|C1610166|C0745732|C0243148|C0439531
"The secondary outcomes were the amount of analgesics used in the last week of treatment, the score on Fibromyalgia Impact Questionnaire (FIQ), Pressure Pain Thresholds (PPT), sleep quality and BDNF serum levels.","The secondary outcomes amount analgesics week treatment, score Fibromyalgia Impact Questionnaire (FIQ), Pressure Pain Thresholds (PPT), sleep quality BDNF serum levels.",G0000000|C0027627|C1274040|C1265611|C0002771|C0332174|C0039798|C0449820|C0016053|C1825598|C0034394|G0000000|C0033095|C0030193|C0449864|G0000000|C0037313|C0332306|C3486709|C0229671|C0441889
"There were two deaths(one in each group) between 12 and 30 months of age; the death in the prenatal-surgery group was from coxsackie septicemia, and that in the postnatal-surgery group was from complications of chemotherapy for choroid plexus carcinoma.","There deaths(one group) 12 30 months age; death prenatal-surgery coxsackie septicemia, postnatal-surgery complications chemotherapy choroid plexus carcinoma.",G0000000|C0011065|C0441833|C0450371|C0450371|C0439231|C0001779|C0011065|C0678804|G0000000|C0036690|C0443281|C0009566|C0013216|C0008520|C1184808|C0007097
"General practices exposed to the programme reduced oral antibiotic dispensing for their patients by 14.1 items per 1000 registered patients, while control practices increased antibiotic dispensing by 12.1 items per 1000 registered patients.","General practices exposed programme reduced oral antibiotic dispensing patients 14.1 items 1000 registered patients, control practices increased antibiotic dispensing 12.1 items 1000 registered patients.",C0205246|C0237607|C0332157|C1709697|C0392756|C0442027|C0003232|C1880359|C0030705|C0450371|C1551338|G0000000|C1514821|C0030705|C0243148|C0237607|C0205217|C0003232|C1880359|C0450371|C1551338|G0000000|C1514821|C0030705
"A mean score of >7 indicates severe fatigue, 0 as no fatigue and 1–6 as mild to moderate fatigue.","A score >7 severe fatigue, 0 fatigue 1–6 mild moderate fatigue.",G0000000|C0449820|G0000000|C0205082|C0015672|G0000000|C0015672|G0000000|C2945599|C0205081|C0015672
An additional 33 had insufficient information provided to assess response and date of progression.,An additional 33 insufficient provided assess response progression.,G0000000|C1524062|C0450371|C0205412|C1999230|C1516048|C0871261|C0242656
The secondary end points were the decrement of albuminuria with olmesartan treatment and the decrement of BP and 24-hour urine sodium excretion after LSD education.,The secondary decrement albuminuria olmesartan treatment decrement BP 24-hour urine sodium excretion LSD education.,G0000000|C0027627|G0000000|C0001925|C1098320|C0039798|G0000000|C0037623|C0450371|C0042036|C0037473|C0221102|C0024334|C0013621
The subject's heart rate obtained at minute 3 of the 6MWT and the distance walked was used to calculate the PCI.,The subject's heart rate minute 3 6MWT distance walked calculate PCI.,G0000000|C0681850|C0018787|C0871208|C0439232|G0000000|G0000000|C0012751|C0080331|C1441506|C4049621
§Stage ≥3 on international classification.,§Stage ≥3 international classification.,G0000000|G0000000|C1512888|C0008902
We therefore further examined this hypothesis by taking advantage of two large prospective cohorts of men and women with 514 incident PD cases from sixteen years of follow-up.,We examined hypothesis advantage prospective cohorts women 514 incident PD sixteen follow-up.,G0000000|C0332128|C1512571|G0000000|C0023981|C0599755|C0043210|C1442061|C1551358|G0000000|C3715157|C0589120
Toxicity related to antibiotics were minimal in both groups.,Toxicity antibiotics minimal groups.,C0040539|C0003232|C0547040|C0441833
"So far, very few studies have shown that the use of idebenone can have beneficial effects on myocardial performance (6, 13–16).","So far, studies idebenone beneficial effects myocardial performance (6, 13–16).",C0037640|C0205108|C0947630|C0123163|G0000000|C1280500|C0027061|C0597198|G0000000|G0000000
"Double-blind, randomized, placebo-controlled clinical trial Outpatient clinic and sleep laboratory 60 depressed, insomniac outpatients one week of open-label fluoxetine (FLX), followed by 8 more weeks of FLX combined with either eszopiclone (ESZ) 3 mg or placebo at bedtime The primary HRQOL measure was the daily living and role functioning subscale (DLRF) of the Basis-32.","Double-blind, randomized, placebo-controlled clinical trial Outpatient clinic sleep laboratory 60 depressed, insomniac outpatients week open-label fluoxetine (FLX), 8 weeks FLX combined eszopiclone (ESZ) 3 placebo bedtime The primary HRQOL measure daily living role functioning subscale (DLRF) Basis-32.",C0013072|C0034656|C1706408|C0205210|C0008976|C0029921|C0002424|C0037313|C0022877|C0450371|C0344315|G0000000|C0029921|C0332174|C1709323|C0016365|G0000000|G0000000|C0439230|G0000000|C0205195|C1436328|G0000000|G0000000|C0032042|C0521112|G0000000|C0205225|G0000000|C0079809|C0332173|C0376558|C0035820|C0205245|G0000000|G0000000|C1527178
"From baseline to the six week follow-up, there were statistically significant increases in knowledge, concern about developing skin cancer, recognition of personal risk of developing skin cancer, attitudes about the benefit of sun protection, and willingness to change behavior in the intervention group compared to the standard of care group (p<0.01, Wilcoxon rank sum test).","From baseline week follow-up, statistically increases knowledge, concern developing skin cancer, recognition personal risk developing skin cancer, attitudes benefit sun protection, willingness change behavior intervention compared standard care (p<0.01, Wilcoxon rank sum test).",G0000000|C0168634|C0332174|C0589120|C0038215|C0205217|C0376554|C2699424|G0000000|C0444099|C0006826|C0524637|C1519021|C0035647|G0000000|C0444099|C0006826|C0004271|C0814225|C0038817|C1545588|C0600109|C0392747|C0004927|C0886296|C1707455|C1442989|C1947933|C0369773|G0000000|C0699794|C1515051|C0022885
"Secondary outcome measures included the recovery rate from SAM, the time-to-recovery, the weight gain and the diarrhea longitudinal prevalence at OTP discharge.","Secondary outcome measures included recovery rate SAM, time-to-recovery, weight gain diarrhea longitudinal prevalence OTP discharge.",C0027627|C1274040|C0079809|C0332257|C0237820|C0871208|C0036002|C0040223|C0005910|C1517378|C0011991|C0205127|C0033105|C1418198|C0012621
"Prespecified secondary outcomes were changes in resistance to the three tested antibiotics, changes in FEV1, adherence to therapy, health status as measured by total SGRQ scores and adverse events.","Prespecified secondary outcomes resistance tested antibiotics, FEV1, adherence therapy, health status measured total SGRQ scores adverse events.",G0000000|C0027627|C1274040|C0237834|C0392366|C0003232|G0000000|C1510802|C0039798|C0018684|C0449438|C0444706|C0439175|G0000000|C0449820|G0000000|C0441471
(A) ARAT score.,(A) ARAT score.,G0000000|C1152215|C0449820
"Episodes of respiratory tract infection per patient per year and the proportion of episodes resulting in an antibiotic prescription during baseline and follow-up were calculated with corresponding point estimates and 95% confidence intervals, as was the proportion of episodes that resulted in an antibiotic prescription.","Episodes respiratory tract infection patient proportion episodes antibiotic prescription baseline follow-up calculated estimates 95% confidence intervals, proportion episodes antibiotic prescription.",C0332189|C0521346|C1185740|C0009450|C0030705|C1709707|C0332189|C0003232|C0033080|C0168634|C0589120|C0444686|C0750572|C0450371|C0237529|C1272706|C1709707|C0332189|C0003232|C0033080
"Secondary end points included PFS, overall response rate (ORR), disease control rate, duration of response, patient-reported outcomes, and safety.","Secondary included PFS, response rate (ORR), disease control rate, duration response, patient-reported outcomes, safety.",C0027627|C0332257|C0242792|C0871261|C0871208|G0000000|C0012634|C0243148|C0871208|C0449238|C0871261|C0747307|C1274040|C0036043
"To quantify children’s response to treatment and distress, the following behaviors were selected from commonly coded behaviors in the literature (Blount et al., 1989; Cohen et al., 2005; Elliott et al., 1987): engaging in distraction, deep breathing, crying, screaming, and negative emoting.","To quantify children’s response treatment distress, behaviors selected commonly coded behaviors literature (Blount al., 1989; Cohen al., 2005; Elliott al., 1987): engaging distraction, deep breathing, crying, screaming, negative emoting.",C0040363|C1709793|G0000000|C0871261|C0039798|C0231303|C0004927|C1707391|G0000000|C0009219|C0004927|C0023866|G0000000|C0202311|G0000000|G0000000|C0202311|G0000000|G0000000|C0202311|G0000000|C0425152|C0150189|C0205125|C0004048|C0010399|C0521008|C0205160|G0000000
"Simultaneously, we will assess change in knee pain over time using WOMAC as a co-primary endpoint.","Simultaneously, assess change knee pain time WOMAC co-primary endpoint.",C0521115|C1516048|C0392747|C0022742|C0030193|C0040223|G0000000|C3245499|C2349179
RESULTS—The peak cough expiratory flow rate and cough expiratory volume were not improved by manually assisted cough and mechanical insufflation alone or in combination in normal subjects.,RESULTS—The peak cough expiratory flow rate cough expiratory volume improved manually assisted cough mechanical insufflation combination normal subjects.,G0000000|C0444505|C0010200|C0231800|C0806140|C0871208|C0010200|C0231800|C0449468|C0184511|C3842330|C1269765|C0010200|C0443254|C0021634|C0205195|C0205307|C0681850
Patients achieved withdrawal or reduced their dose by at least 50% after 6 and 12 months.,Patients achieved withdrawal reduced dose 50% 6 12 months.,C0030705|G0000000|C2349954|C0392756|C0178602|C0450371|G0000000|C0450371|C0439231
"Our findings indicate that the intervention had an impact on gross motor, language and personal–social development of children aged 6–18 months as measured by the DMC-II.","Our findings intervention impact gross motor, language personal–social development children aged 6–18 months measured DMC-II.",G0000000|C2607943|C0886296|C1825598|C0439806|C1513492|C0023008|G0000000|C0243107|C0008059|C0001779|G0000000|C0439231|C0444706|G0000000
The primary outcome was 6 months of prolonged abstinence measured at 18 months of follow-up.,The primary outcome 6 months prolonged abstinence measured 18 months follow-up.,G0000000|C0205225|C1274040|G0000000|C0439231|C0439590|C3843422|C0444706|C0450371|C0439231|C0589120
"The aim of this study is to evaluate the effect of two interventions on mental health and health behaviour (alcohol and drug use, smoking, safe sex).","The aim study evaluate interventions mental health health behaviour (alcohol drug use, smoking, safe sex).",G0000000|C1947946|C0557651|C0220825|C0886296|C0229992|C0018684|C0018684|C0004927|C0001962|C0013227|C0042153|C0037369|G0000000|C0009253
The main study outcomes were the safety of prednisolone therapy and the effect of prednisolone therapy on CD4+ T cell counts and HIV RNA levels during treatment for HIV-associated pulmonary TB.,The main study outcomes safety prednisolone therapy prednisolone therapy CD4+ T cell counts HIV RNA levels treatment HIV-associated pulmonary TB.,G0000000|C0205225|C0557651|C1274040|C0036043|C0032950|C0039798|C0032950|C0039798|C0285590|C2603360|C0007634|C0439157|C0019682|C0035668|C0441889|C0039798|C0019682|C0024109|G0000000
"DFS events included local progression, distant metastatic progression, biochemical recurrence as defined by the RTOG Phoenix definition,12 or death from any cause.","DFS events included local progression, distant metastatic progression, biochemical recurrence defined RTOG Phoenix definition,12 death cause.",G0000000|C0441471|C0332257|C0205276|C0242656|C0443203|C0036525|C0242656|C0205474|C0034897|C1704788|C1514695|C0331993|C1550452|C0011065|C0015127
Biochemically confirmed 7-day point prevalence abstinence rates did not differ significantly between treatment arms at any time point (all p > .05; Table 3).,Biochemically confirmed 7-day prevalence abstinence rates treatment arms time (all > .05; Table 3).,G0000000|C0521093|C0332173|C0033105|C3843422|C0871208|C0039798|C0206655|C0040223|G0000000|G0000000|C0450371|C0039224|G0000000
"Secondary outcome measures include standardized self-report questionnaires assessing body image (EORTC QLQ-BR 23 Body image subscale [92]), menopausal symptoms (FACT-ES ESS-18 [93]), marital functioning (MMQ [84]), psychological distress (HADS [94,95]) and HRQL (SF-36 [96,97]).","Secondary outcome measures standardized self-report questionnaires assessing body image (EORTC QLQ-BR 23 Body image subscale [92]), menopausal symptoms (FACT-ES ESS-18 [93]), marital functioning (MMQ [84]), psychological distress (HADS [94,95]) HRQL (SF-36 [96,97]).",C0027627|C1274040|C0079809|G0000000|C0681906|C0034394|C1516048|C0242821|C1704254|C1516985|C1704648|C0450371|C0242821|C1704254|G0000000|C0450371|C0025320|C0683368|C3889662|C0206630|C0450371|C0024841|C0205245|G0000000|C0450371|C0205486|C0231303|C0048008|C0450371|G0000000|C0037712|C0450371
"Birth weight and height and head circumference of children were recorded in a questionnaire, from electronic folder, at the beginning of the study (4 months old), at 6 months old, and at the end of the study (8 months old).","Birth weight height head circumference children recorded questionnaire, electronic folder, study (4 months old), 6 months old, study (8 months old).",C0005615|C0005910|C0489786|C0018670|C0332520|C0008059|C0034869|C0034394|C0013850|C1555709|C0557651|G0000000|C0580836|G0000000|C0580836|C0557651|G0000000|C0580836
"Secondary end points included: (a) the incidence of non-bacterial infections, (b) the incidence of serious infection, the third month OFF of antibiotic prophylaxis, (c) whether protection against infection is associated with an improved response rate and (d) overall survival.","Secondary included: (a) incidence non-bacterial infections, (b) incidence infection, month OFF antibiotic prophylaxis, (c) protection infection improved response rate (d) survival.",C0027627|C0332257|G0000000|C0021149|C1518422|C3714514|G0000000|C0021149|C0009450|C0332177|G0000000|C0003232|C0033107|G0000000|C1545588|C0009450|C0184511|C0871261|C0871208|C0073187|C0038952
Wound flap necrosis for both groups was minor and limited to the wound edge.,Wound flap necrosis minor limited wound edge.,C0043250|C0038925|C0027540|C0026193|C0439801|C0043250|C0205154
We will include the following psychosocial measures: Psychological distress will be measured with the 5-item Mental Health Index of the SF-36 [16].,We psychosocial measures: Psychological distress measured 5-item Mental Health Index SF-36 [16].,G0000000|C0542298|C0079809|C0205486|C0231303|C0444706|C1551338|C0229992|C0018684|C0918012|C0037712|C0450371
"The outcomes including systolic pulmonary arterial hypertension (SPAH), cardiac output (CO), right ventricular size (RVS), CRP, 6 min walk distance test (6MWD), and spirometry parameters were measured after 6 months.","The outcomes including systolic pulmonary arterial hypertension (SPAH), cardiac output (CO), ventricular size (RVS), CRP, 6 min walk distance test (6MWD), spirometry parameters measured 6 months.",G0000000|C1274040|C0332257|C0039155|C0024109|C0003842|C0020538|G0000000|C0018787|C1709366|C3245499|C0018827|C0456389|C0035190|C3890735|G0000000|C0702093|C0080331|C0012751|C0022885|G0000000|C0037981|C0449381|C0444706|G0000000|C0439231
"Newborn’s parents were required to complete an onsite questionnaire survey at baseline, 6 and 12 months.","Newborn’s parents required complete onsite questionnaire survey baseline, 6 12 months.",G0000000|C0030551|C1514873|C0205197|G0000000|C0034394|C0038951|C0168634|G0000000|C0450371|C0439231
A withdrawal discomfort score is computed from 10 of the items found to be most sensitive to subjective states following withdrawal from chronic marihuana use (maximum score of 30).,A withdrawal discomfort score computed 10 items sensitive subjective withdrawal chronic marihuana (maximum score 30).,G0000000|C2349954|C0231218|C0449820|C1441526|C0450371|C1551338|C0020517|C0439655|C2349954|C0205191|C0024808|C0806909|C0449820|C0450371
"The presence of preoperative anaemia is associated with an increased likelihood of the patient receiving peri-operative transfusion and worsened outcomes following surgery, more post-operative complications, delayed recovery and greater length of hospital stay.","The presence preoperative anaemia increased likelihood patient receiving peri-operative transfusion worsened outcomes surgery, post-operative complications, delayed recovery length hospital stay.",G0000000|C0150312|C0445204|C0002871|C0205217|C0033204|C0030705|C1514756|C0347985|C0005841|C1457868|C1274040|C0038894|C0032790|C0009566|C0205421|C0237820|C1444754|C0019994|G0000000
The devices use an “accelerometer” to monitor occurrence and degree of movement-induced accelerations.,The devices “accelerometer” monitor occurrence degree movement-induced accelerations.,G0000000|C0025080|G0000000|C0030695|C0243132|C0441889|C0026649|C0000894
"Secondary outcomes, defined prospectively, included 28-day and 6-month all cause mortality and organ failure free days within the first 28 days.","Secondary outcomes, defined prospectively, included 28-day 6-month mortality organ failure free days 28 days.",C0027627|C1274040|C1704788|G0000000|C0332257|C0450371|C0332177|C0026565|C0178784|C0231174|C0332296|C0439228|C0450371|C0439228
"We will compare the amount of steroids required to maintain complete disease remission at 6 and 24 months, relapse-free period, relapse rate per year as secondary end points.","We compare amount steroids required maintain complete disease remission 6 24 months, relapse-free period, relapse rate secondary points.",G0000000|C1707455|C1265611|C0038317|C1514873|C0024501|C0205197|C0012634|C0544452|G0000000|G0000000|C0035020|C0439531|C0035020|C0871208|C0027627|C1552961
"The primary outcome was self-reported continuous smoking abstinence, objectively verified at 6 months.","The primary outcome self-reported continuous smoking abstinence, objectively verified 6 months.",G0000000|C0205225|C1274040|C0681906|C0549178|C0037369|C3843422|G0000000|C1711411|G0000000|C0439231
The main outcome of interest for phase II is 30-day point prevalence abstinence (ppa) at 9 months.,The main outcome phase II 30-day prevalence abstinence (ppa) 9 months.,G0000000|C0205225|C1274040|C0205390|G0000000|C0450371|C0033105|C3843422|C0031681|G0000000
We are not aware of any studies that correlate direct clinical meaning with specific changes of distance in the dyspnoea scale.,We aware studies correlate direct clinical meaning specific distance dyspnoea scale.,G0000000|C0004448|C0947630|G0000000|C0439851|C0205210|C0876919|C0205369|C0012751|C0013404|C0175659
The study design is summarized in Figure 1.,The study design summarized Figure 1.,G0000000|C0557651|C1707689|G0000000|G0000000|G0000000
"However, patients ≥60 years of age had alterations in basal latency time (mean grade rank, 37.7 vs 56; p = 0.001) and amplitude damage (37 vs 57; p < 0.001).","However, patients ≥60 age alterations basal latency time (mean grade rank, 37.7 56; = 0.001) amplitude damage (37 57; < 0.001).",G0000000|C0030705|G0000000|C0001779|C1515926|C0205112|C0205275|C0040223|C0444504|C0441800|C0699794|C0450371|C0450371|G0000000|C1442061|C2346753|C0010957|C0450371|C0450371|G0000000|C1442061
"Secondary end points were OS, PFS, treatment-related toxicity, disease-associated symptoms, and quality of life.","Secondary OS, PFS, treatment-related toxicity, disease-associated symptoms, quality life.",C0027627|C0229090|C0242792|C0039798|C0040539|C0012634|C0683368|C0332306|C0376558
"Data on residents’ behaviour (CMAI) and cognition (MMSE) were collected before, during and after the intervention.","Data residents’ behaviour (CMAI) cognition (MMSE) collected before, intervention.",C1511726|G0000000|C0004927|G0000000|C0009240|C0451306|C1516695|C0332152|C0886296
Prevalence of teenage smoking 12 months after the start of the intervention.,Prevalence teenage smoking 12 months start intervention.,C0033105|C0001578|C0037369|C0450371|C0439231|C0439659|C0886296
The number needed to treat (NNT) was eight to prevent one case of stridor and 26 to prevent one case of re-intubation.,The treat (NNT) prevent stridor 26 prevent re-intubation.,G0000000|C0087111|C1417750|C0309872|C0038450|C0450371|C0309872|C0556581
"However, it seems that focal injections of BoNT were more effective than TZD to improve in spasticity at elbow and wrist joints.","However, focal injections BoNT effective TZD improve spasticity elbow wrist joints.",G0000000|C0205234|C0021485|G0000000|C1280519|G0000000|G0000000|C0026838|C0013769|C0043262|C0022417
"Children were recruited prospectively from 2 cohorts in the United Kingdom and assessed using the Griffiths Mental Development Scale (1996), aged <24 months.","Children recruited prospectively 2 cohorts United Kingdom assessed Griffiths Mental Development Scale (1996), aged <24 months.",C0008059|G0000000|G0000000|G0000000|C0599755|C0166872|C1708611|C1516048|G0000000|C0229992|C0243107|C0175659|G0000000|C0001779|C0450371|C0439231
"From baseline to endline, significant increases in levels of ferritin (1.19 times), folic acid (1.11 times), retinol (1.07 times), zinc (1.05 times), and iodine (1.32 times) were apparent.","From baseline endline, increases levels ferritin (1.19 times), folic acid (1.11 times), retinol (1.07 times), zinc (1.05 times), iodine (1.32 times) apparent.",G0000000|C0168634|G0000000|C0205217|C0441889|C0015879|C0450371|C0040223|G0000000|C0001128|C0450371|C0040223|C0042839|C0450371|C0040223|C0043481|C0450371|C0040223|C0021966|C0450371|C0040223|C0750489
"Secondary immunogenicity objectives were to assess HI antibody responses (GMT, SPR, SCR, and MGI) stratified by age against the vaccine strain at days 0, 21, 42, 182, and 385; to evaluate whether day 42 responses fulfilled CBER and CHMP immunogenicity licensure criteria; and to describe nAb responses against the vaccine strain and a drifted strain stratified by age at days 0, 21, 42, 182, and 385.","Secondary immunogenicity objectives assess HI antibody responses (GMT, SPR, SCR, MGI) stratified age vaccine strain days 0, 21, 42, 182, 385; evaluate day 42 responses fulfilled CBER CHMP immunogenicity licensure criteria; nAb responses vaccine strain drifted strain stratified age days 0, 21, 42, 182, 385.",C0027627|C4054739|C0018017|C1516048|C0018619|C0003241|C0871261|G0000000|G0000000|C1539487|C1709079|C0205363|C0001779|C0042210|C0080194|C0439228|G0000000|C0450371|C0450371|C1442061|C1442061|C0220825|C0332173|C0450371|C0871261|C1550543|C2826367|G0000000|C4054739|C0023637|C0243161|G0000000|C0871261|C0042210|C0080194|G0000000|C0080194|C0205363|C0001779|C0439228|G0000000|C0450371|C0450371|C1442061|C1442061
Those treated with erythromycin showed no significant differences from the non- treated group in the differential cell counts or concentrations of the cytokines.,Those treated erythromycin differences non- treated differential cell counts concentrations cytokines.,G0000000|C1522326|C0014806|C1705241|C1518422|C1522326|C0443199|C0007634|C0439157|C0086045|C0079189
"Secondary outcomes included mean WHZ change over time, prevalence of stunting at end point defined as height-for-age Z-score (HAZ)<−2, mean HAZ change over time, MUAC change over time, mean hemoglobin concentration at end point, prevalence of anemia at end point (hemoglobin <110 g/l), and morbidity.","Secondary outcomes included WHZ change time, prevalence stunting defined height-for-age Z-score (HAZ)<−2, HAZ change time, MUAC change time, hemoglobin concentration point, prevalence anemia (hemoglobin <110 g/l), morbidity.",C0027627|C1274040|C0332257|G0000000|C0392747|C0040223|C0033105|C0018273|C1704788|C0489786|C0871421|G0000000|G0000000|C0392747|C0040223|G0000000|C0392747|C0040223|C0019046|C0004268|C1552961|C0033105|C0002871|C0019046|C1442061|C0439294|C0026538
"Mean's difference of analgesic usage between groups Pain severity measured on a 10 cm visual analog scalea a Extent of the reduction in pain severity as measured on a 10 cm visual analog scale a Severity of systemic signs associated with dysmenorrhea, as measured on a multidimensional verbal scale score, range (0–3) a Women with dysmenorrhea suffer from increased uterine contractions (6).","Mean's difference analgesic usage Pain severity measured 10 cm visual analog scalea Extent reduction pain severity measured 10 cm visual analog scale Severity systemic signs dysmenorrhea, measured multidimensional verbal scale score, range (0–3) Women dysmenorrhea suffer increased uterine contractions (6).",C0444504|C1705241|C0002771|C0457083|C0030193|C0439793|C0444706|C0450371|G0000000|C0234621|C0243071|G0000000|C0439792|C0301630|C0030193|C0439793|C0444706|C0450371|G0000000|C0234621|C0243071|C0175659|C0439793|C0205373|C0220912|C0013390|C0444706|C2347299|C0439824|C0175659|C0449820|C1514721|G0000000|C0043210|C0013390|C0683278|C0205217|C0042149|C1140999|G0000000
Sleep quality was assessed by using the Pittsburgh Sleep Quality Index and actigraphy pre- and postintervention.,Sleep quality assessed Pittsburgh Sleep Quality Index actigraphy pre- postintervention.,C0037313|C0332306|C1516048|G0000000|C0037313|C0332306|C0918012|C1171301|C0332152|G0000000
"Very low–density lipoprotein cholesterol (VLDL-C) was calculated as triglycerides divided by five, and LDL-C was calculated as total cholesterol minus the sum of HDL-C and VLDL-C.","Very low–density lipoprotein cholesterol (VLDL-C) calculated triglycerides divided five, LDL-C calculated total cholesterol minus sum HDL-C VLDL-C.",C0442824|G0000000|C0023820|C0008377|C0523560|C0444686|C0041004|C0332849|C0205451|G0000000|C0444686|C0439175|C0008377|C0332288|C1515051|C3715113|C0523560
"Measures included paper-and-pencil assessments of knowledge, self-efficacy, and attributions regarding asthma self-management.","Measures included paper-and-pencil assessments knowledge, self-efficacy, attributions asthma self-management.",C0079809|C0332257|C0030351|C1261322|C0376554|C0600564|C0596130|C0004096|C0086969
Adverse events were coded according to the Medical Dictionary for Regulatory Activities version 8.0.,Adverse events coded Medical Dictionary Regulatory Activities version 8.0.,G0000000|C0441471|C0009219|C0199168|C0012108|C0220905|C0441655|C0333052|G0000000
"This comprises quality of life, seizure frequency, time elapsed since last seizure, and impact of epilepsy.","This comprises quality life, seizure frequency, time elapsed seizure, impact epilepsy.",G0000000|C2700400|C0332306|C0376558|C0036572|C0376249|C0040223|C1707889|C0036572|C1825598|C0014544
"Abbreviation: Q, quintiles; SMHS, Shanghai Men's Health Study; SWHS, Shanghai Women's Health Study.","Abbreviation: Q, quintiles; SMHS, Shanghai Men's Health Study; SWHS, Shanghai Women's Health Study.",C0000723|G0000000|C1508496|C1824631|G0000000|C0025266|C0018684|C0557651|G0000000|G0000000|C0043210|C0018684|C0557651
"This short-term randomized controlled trial suggests that there might be a small, but beneficial effect of vitamin D on pain and functional scores in patients with knee OA.","This short-term randomized controlled trial suggests small, beneficial vitamin D pain functional scores patients knee OA.",G0000000|C0443303|C0034656|C2587213|C0008976|C1705535|C0700321|G0000000|C0042890|C0073187|C0030193|C0205245|C0449820|C0030705|C0022742|C0029408
Findings demonstrated overall functional benefits at 4 months in the FBF group and improved walking economy (up to 16 months) in the AE group.,Findings demonstrated functional benefits 4 months FBF improved walking economy (up 16 months) AE group.,C2607943|G0000000|C0205245|C0814225|G0000000|C0439231|G0000000|C0184511|C0080331|C0013556|G0000000|C0450371|C0439231|C3887670|C0441833
"According to the National Immunization Survey, for example, in 1996, 84% of all children17 and 88% of Asian/Pacific Islander18 children 19 to 35 months old had received all 3 doses of the hepatitis B vaccine.","According National Immunization Survey, example, 1996, 84% children17 88% Asian/Pacific Islander18 children 19 35 months received 3 doses hepatitis B vaccine.",C0680240|C3245503|C0020971|C0038951|C1707959|G0000000|C0450371|G0000000|C0450371|C0078988|G0000000|C0008059|C0450371|C0450371|C0439231|C1514756|G0000000|C0178602|C0019158|G0000000|C0042210
"Participants' self assessment of improvement, tender point count, impact of condition measured by fibromyalgia impact questionnaire, and short form McGill pain questionnaire.","Participants' assessment improvement, tender count, impact condition measured fibromyalgia impact questionnaire, short form McGill pain questionnaire.",C0679646|C1261322|C2986411|C0234234|C0750480|C1825598|C0012634|C0444706|C0016053|C1825598|C0034394|C1282927|C0348078|G0000000|C0030193|C0034394
"Data (blood lipid profile, glucose, insulin, 24 h blood pressure) was collected in the beginning and end of both periods (intervention and control), and some variables also in the run-in and run-out periods (weight, body fat percentage, blood pressure, arterial stiffness index, diet and physical activity).","Data (blood lipid profile, glucose, insulin, 24 blood pressure) collected periods (intervention control), variables run-in run-out periods (weight, body fat percentage, blood pressure, arterial stiffness index, diet physical activity).",C1511726|C0005767|C0023779|C1979963|C0017725|C0021641|C0450371|C0005767|C0033095|C1516695|C0439531|C0886296|C0243148|C0439828|C3274438|C0035953|C0439531|C0005910|C0242821|C0424612|C0439165|C0005767|C0033095|C0003842|C0427008|C0918012|C0012155|C0031809|C0205177
"Continuous and point prevalence abstinence from smoking (validated by exhaled carbon monoxide <10 ppm) was measured at discharge from hospital and at 3 and 12 months, and self-reported reduction in cigarette consumption in smokers was assessed at 3 and 12 months.","Continuous prevalence abstinence smoking (validated exhaled carbon monoxide <10 ppm) measured discharge hospital 3 12 months, self-reported reduction cigarette consumption smokers assessed 3 12 months.",C0549178|C0033105|C3843422|C0037369|G0000000|C0231800|C0007009|G0000000|C0450371|C0439187|C0444706|C0012621|C0019994|G0000000|C0450371|C0439231|C0681906|C0301630|C0677453|C0009830|C0337664|C1516048|G0000000|C0450371|C0439231
"Secondary outcomes were comparison of seizure frequency, and KEBAS between the intervention and nonintervention group.","Secondary outcomes comparison seizure frequency, KEBAS intervention nonintervention group.",C0027627|C1274040|C1707455|C0036572|C0376249|G0000000|C0886296|G0000000|C0441833
"The weight, recumbent length/height and haemoglobin of each child and mother were measured at enrollment and at the end of MNP supplementation using standard WHO procedures (World Health Organization 1995).","The weight, recumbent length/height haemoglobin child mother measured enrollment MNP supplementation standard WHO procedures (World Health Organization 1995).",G0000000|C0005910|C0444334|C1444754|C0019046|C0008059|C0026591|C0444706|C1516879|C0282245|C0242297|C1442989|G0000000|C0025664|C2700280|C0018684|C0029237|G0000000
"Percent reduction in HRSD was the primary symptom response endpoint, as well as remission, defined here as HRSD score ≤ 10 (no longer meeting depression criteria) [20, 21].","Percent reduction HRSD primary symptom response endpoint, remission, defined HRSD score ≤ 10 (no meeting depression criteria) [20, 21].",C0439165|C0301630|G0000000|C0205225|C1457887|C0871261|C2349179|C0544452|C1704788|G0000000|C0449820|G0000000|C0450371|G0000000|C0556656|C0011570|C0243161|C0450371|C0450371
"We hypothesize that the combination of dietetic counselling and oral nutritional supplementation in hip fracture patients will improve patients' energy and protein intake, improve their nutritional status, reduce the number of complications and total length of stay in hospital and rehabilitation clinics, and lower health care costs.","We hypothesize combination dietetic counselling oral nutritional supplementation hip fracture patients improve patients' energy protein intake, improve nutritional status, reduce complications total length stay hospital rehabilitation clinics, lower health care costs.",G0000000|G0000000|C0205195|C0012180|C0010210|C0442027|C1521739|C0242297|C0019552|C0016658|C0030705|G0000000|C0030705|C0424589|C0033684|C1512806|G0000000|C1521739|C0449438|G0000000|C0009566|C0439175|C1444754|G0000000|C0019994|C0034991|C0442592|C0441994|C0018684|C1947933|C0010186
The smoking outcome measures were abstinence as verified by measurement of cotinine at 4 and 12 months together with reported number of cigarettes smoked per day.,The smoking outcome measures abstinence verified measurement cotinine 4 12 months reported cigarettes smoked day.,G0000000|C0037369|C1274040|C0079809|C3843422|C1711411|C0242485|C0010194|G0000000|C0450371|C0439231|C0684224|C0677453|C0037366|C0332173
"Each side effect was evaluated on a 4-point scale as none (0), mild (1), moderate (2) or severe (3).","Each evaluated 4-point scale (0), mild (1), moderate (2) severe (3).",G0000000|C0220825|C1552961|C0175659|G0000000|C2945599|G0000000|C0205081|G0000000|C0205082|G0000000
"If a higher sensitivity is required, pulse oximetry has to be used.","If sensitivity required, pulse oximetry used.",G0000000|C0020517|C1514873|C0232117|C0523807|C1273517
"Anxiety symptom ratings were obtained using the Hamilton Anxiety (HAM-A) rating, (27) Beck Anxiety Inventory (BAI), (28) Green Climacteric Scale (GCS), (29) Psychological General Well Being (PGWB) index, (30) and the treatment emergent side effects profile.","Anxiety symptom ratings Hamilton Anxiety (HAM-A) rating, (27) Beck Anxiety Inventory (BAI), (28) Green Climacteric Scale (GCS), (29) Psychological General Well Being (PGWB) index, (30) treatment emergent effects profile.",C0003467|C1457887|C0871208|G0000000|C0003467|C3541258|C0871208|C0450371|G0000000|C0003467|C0021941|C0234880|C0450371|C0332583|C0008943|C0175659|G0000000|C0450371|C0205486|C0205246|C0205170|G0000000|G0000000|C0918012|C0450371|C0039798|C0750573|C1280500|C1979963
"The secondary outcomes were SpO2, HR, VT, face mask leak and FiO2 within the first 15 minutes after birth.","The secondary outcomes SpO2, HR, VT, mask leak FiO2 15 minutes birth.",G0000000|C0027627|C1274040|G0000000|G0000000|C0042427|C0024861|C0332234|G0000000|C0450371|C0439232|C0005615
We are following patients consecutively during treatment at the clinic regarding symptoms of mental health complaints.,We patients consecutively treatment clinic symptoms mental health complaints.,G0000000|C0030705|G0000000|C0039798|C0002424|C0683368|C0229992|C0018684|C0277786
"We addressed the issue of confounding by healthy behaviors through controlling for multiple indicators of healthy behavior in our analysis (e.g., NSAID use, low fat intake, and high fruit and vegetable intake); however, it may be possible that residual confounding remains despite statistical adjustment, resulting in a stronger association being observed.","We addressed issue confounding healthy behaviors controlling multiple indicators healthy behavior analysis (e.g., NSAID use, low fat intake, fruit vegetable intake); however, residual confounding remains statistical adjustment, stronger association observed.",G0000000|C0376649|C0033213|G0000000|C3898900|C0004927|C2239193|C0439064|C0021212|C3898900|C0004927|C0002778|G0000000|C0003211|C0042153|C0205251|C0424612|C1512806|C0016767|C0042440|C1512806|G0000000|C1609982|G0000000|G0000000|C0038215|C0376209|C0442821|C0004083|C1441672
Early treatment discontinuation or death for any cause were considered as treatment failures.,Early treatment discontinuation death considered treatment failures.,C1279919|C0039798|C0457454|C0011065|C0750591|C0039798|C0231174
Receipt of the FPHVS was associated with increased use of electric socket covers and lower accident rates in the second year of life.,Receipt FPHVS increased electric socket covers lower accident rates life.,G0000000|G0000000|C0205217|C0013790|C0224517|C0180153|C0441994|C0000924|C0871208|C0376558
HFIAS = Household Food Insecurity Access Scale; LAZ = length‐for‐age z‐score; LNS = lipid‐based nutrient supplements; WLZ = weight‐for‐length z‐score; WTP = willingness to pay.,HFIAS = Household Food Insecurity Access Scale; LAZ = length‐for‐age z‐score; LNS = lipid‐based nutrient supplements; WLZ = weight‐for‐length z‐score; WTP = willingness pay.,G0000000|G0000000|C0020052|C0016452|C0233497|C0444454|C0175659|G0000000|G0000000|G0000000|G0000000|C0023374|G0000000|G0000000|C0678695|C0242295|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0600109|C0871051
"For the primary outcome, means of change in serum potassium level were compared between study groups using a t test.","For primary outcome, change serum potassium level compared study test.",G0000000|C0205225|C1274040|C0392747|C0229671|C0032821|C0441889|C1707455|C0557651|C0022885
The primary outcome is 30-day point prevalence abstinence (ppa) at 9 months.,The primary outcome 30-day prevalence abstinence (ppa) 9 months.,G0000000|C0205225|C1274040|C0450371|C0033105|C3843422|C0031681|G0000000
"Time-to-treatment failure (TTF) was defined as the time from the date of randomization to the date of failure (progression, death, or any other causes of treatment discontinuation).","Time-to-treatment failure (TTF) defined time randomization failure (progression, death, treatment discontinuation).",C3494202|C0231174|C1332112|C1704788|C0040223|C0034656|C0231174|C0242656|C0011065|C0039798|C0457454
The outcome of interest for this aim (ocular shape) is the change in peripheral refractive error of the right eye.,The outcome aim (ocular shape) change peripheral refractive error eye.,G0000000|C1274040|C1947946|C0015392|C0332479|C0392747|C0205100|C0429585|C0743559|C0015392
FEV1 was measured before and after three and six weeks of treatment; BHR to methacholine (PD20) was measured before and after six weeks of treatment.,FEV1 measured weeks treatment; BHR methacholine (PD20) measured weeks treatment.,G0000000|C0444706|C0439230|C0039798|C0004684|C0600370|G0000000|C0444706|C0439230|C0039798
Sera were collected for immunogenicity measurements at 16–17 time points (schedule-dependent) from baseline to week 52.,Sera collected immunogenicity measurements 16–17 time (schedule-dependent) baseline week 52.,C0229671|C1516695|C4054739|C0242485|G0000000|C0040223|C0086960|C0168634|C0332174|C0450371
"The primary outcome will be the uptake of SDM measured by the patient-reported 9-item Shared Decision Making Questionnaire (SDM-Q-9, [62]).","The primary outcome uptake SDM measured patient-reported 9-item Shared Decision Making Questionnaire (SDM-Q-9, [62]).",G0000000|C0205225|C1274040|C0243144|C0643808|C0444706|C0747307|C1551338|C0237876|C0679006|C1881534|C0034394|C0643808|C0450371
"The probiotic preparations included in the study were well received by nearly all the children, and no adverse events were observed.","The probiotic preparations included study received children, adverse events observed.",G0000000|C0525033|C1521827|C0332257|C0557651|C1514756|C0008059|G0000000|C0441471|C1441672
"Substance Use Prevalence by Study Condition and Wave Note: CO = Control condition; MC = Multicultural condition The 5th grade version of the keepin’ it REAL substance use prevention intervention did not demonstrate a consistent, immediate or short-term effects on participating students’ substance use behaviors or on the expected mediators of the curriculum’s effect on participants’ substance use (i.e., participants’ refusal efficacy, use of resistance strategies, decision-making style, substance use norms, expectancies, or intentions).","Substance Use Prevalence Study Condition Wave Note: CO = Control condition; MC = Multicultural condition The 5th grade version keepin’ REAL substance prevention intervention demonstrate consistent, short-term effects participating students’ substance behaviors expected mediators curriculum’s participants’ substance (i.e., participants’ refusal efficacy, resistance strategies, decision-making style, substance norms, expectancies, intentions).",C0439861|C0042153|C0033105|C0557651|C0012634|C0678544|C1316572|C3245499|G0000000|C0243148|C0012634|C0024403|G0000000|C0282495|C0012634|G0000000|G0000000|C0441800|C0333052|G0000000|C0237400|C0439861|C0199176|C0886296|G0000000|C0332290|C0443303|C1280500|C0679823|G0000000|C0439861|C0004927|C1517001|C0127400|G0000000|G0000000|C0439861|C0683454|G0000000|G0000000|C1280519|C0237834|C0679199|C0011109|C0489654|C0439861|C0205307|C0679138|C0162425
"Model 3 was built considering functional characteristics (cohort, spirometry pattern, severity level, FEV1 and FVC percentages, number of exacerbations and SGRQ scales).","Model 3 built functional characteristics (cohort, spirometry pattern, severity level, FEV1 FVC percentages, exacerbations SGRQ scales).",C3161035|G0000000|C1707059|C0205245|C1521970|C0599755|C0037981|C0449774|C0439793|C0441889|G0000000|C3714541|C0439165|G0000000|G0000000|C0175659
All those who had skin reactions developed them while using N95 masks for an average duration of 8 hr a day and over a mean period of 8.4 months.,All skin reactions developed N95 masks average duration 8 hr day period 8.4 months.,G0000000|C0444099|C0443286|G0000000|G0000000|C0024861|C1510992|C0449238|G0000000|G0000000|C0332173|C0439531|G0000000|C0439231
"The primary outcomes were the Nottingham extended activities of daily living scale and the “global outcome” of deterioration according to the Barthel activities of daily living index, or death.6 Secondary outcomes included the Barthel index, satisfaction with outpatient services,7 resource use (staff time, hospital readmission, provision of equipment and services), and measures of subjective health.3 We aimed to recruit a minimum of 128 patients to achieve an 80% power at 5% significance to detect a nine point difference in the Nottingham scores (66 point version) or a halving of the risk of poor global outcome.","The primary outcomes Nottingham extended activities daily living scale “global outcome” deterioration Barthel activities daily living index, death.6 Secondary outcomes included Barthel index, satisfaction outpatient services,7 resource (staff time, hospital readmission, provision equipment services), measures subjective health.3 We aimed recruit minimum 128 patients achieve 80% power 5% significance detect difference Nottingham scores (66 version) halving risk poor global outcome.",G0000000|C0205225|C1274040|G0000000|C0231448|C0441655|C0332173|C0376558|C0175659|G0000000|G0000000|C0868945|G0000000|C0441655|C0332173|C0376558|C0918012|C0011065|C0027627|C1274040|C0332257|G0000000|C0918012|C0242428|C0029921|C0557854|C0035201|C0851286|C0040223|C0019994|C1548168|C1549071|C0014672|C0557854|C0079809|C0439655|C0018684|G0000000|C1947946|G0000000|C1524031|C1442061|C0030705|G0000000|C0450371|C0032863|G0000000|C0237881|C0442726|C1705241|G0000000|C0449820|C0450371|C0333052|G0000000|C0035647|C0032854|C0205246|C1274040
"Quadriceps muscle strength, thigh lean mass, and physical activity level were assessed at baseline and after three cycles of chemotherapy.","Quadriceps muscle strength, thigh lean mass, physical activity level assessed baseline cycles chemotherapy.",C0224440|C0026845|C0237897|C0039866|G0000000|C0577559|C0031809|C0205177|C0441889|C1516048|C0168634|C1511572|C0013216
The primary outcome was change in the modified Hammersmith Functional Motor Scale (MHFMS) score following six months of treatment.,The primary outcome change modified Hammersmith Functional Motor Scale (MHFMS) score months treatment.,G0000000|C0205225|C1274040|C0392747|C0392747|C0335933|C0205245|C1513492|C0175659|G0000000|C0449820|C0439231|C0039798
"Quality of Life Index – cancer version III [42], which evaluates QOL in terms of an individual’s satisfaction or dissatisfaction with aspects of life that are important to him/her.","Quality Life Index – cancer version III [42], evaluates QOL terms individual’s satisfaction dissatisfaction aspects life him/her.",C0332306|C0376558|C0918012|G0000000|C0006826|C0333052|C0439070|C0450371|C0220825|C0518214|C0233324|G0000000|C0242428|C0870433|C1547011|C0376558|G0000000
The following secondary efficacy variables were evaluated: length of hospitalization from admission to discharge (time of discharge order); VAS score over time; total dose of opioids in the first 8 hours after enrollment into the study and during the entire hospitalization; rate of ACS or pneumonia requiring blood transfusion; proportion discharged in the first 24 hours; proportion returned to ED or hospital within 30 days;; change in nitrate/nitrite levels and methemoglobin levels as measures of NO metabolism and reactions in the blood (Table 2).,The secondary efficacy variables evaluated: length hospitalization admission discharge (time discharge order); VAS score time; total dose opioids 8 hours enrollment study entire hospitalization; rate ACS pneumonia requiring blood transfusion; proportion discharged 24 hours; proportion returned ED hospital 30 days;; change nitrate/nitrite levels methemoglobin levels measures NO metabolism reactions blood (Table 2).,G0000000|C0027627|C1280519|C0439828|C0220825|C1444754|C0019993|C0184666|C0012621|C0040223|C0012621|C1705175|C0042815|C0449820|C0040223|C0439175|C0178602|C0242402|G0000000|C0439227|C1516879|C0557651|C0439751|C0019993|C0871208|G0000000|C0032285|G0000000|C0005767|C0005841|C1709707|C0030685|C0450371|C0439227|C1709707|C0332156|C3538926|C0019994|C0450371|C0439228|C0392747|C0883264|C0441889|C0025635|C0441889|C0079809|C0028128|C0025519|C0443286|C0005767|C0039224|G0000000
"Participants received rehabilitation assessments at week 0 (baseline), week 1, week 3 (after treatment), and week 7 (follow-up).","Participants received rehabilitation assessments week 0 (baseline), week 1, week 3 (after treatment), week 7 (follow-up).",C0679646|C1514756|C0034991|C1261322|C0332174|G0000000|C0168634|C0332174|G0000000|C0332174|G0000000|G0000000|C0039798|C0332174|G0000000|C0589120
"The secondary end‐points included changes in the NSS and in the NDS from baseline at week 12, change in the NCV and amplitude from baseline to week 24, and the reversal rates of affected nerves at week 24.","The secondary end‐points included NSS NDS baseline week 12, change NCV amplitude baseline week 24, reversal rates nerves week 24.",G0000000|C0027627|G0000000|C0332257|G0000000|C0057753|C0168634|C0332174|C0450371|C0392747|C2982003|C2346753|C0168634|C0332174|C0450371|C0443290|C0871208|C0027740|C0332174|C0450371
"The main outcome measures were: Quality of Life (FACT) questionnaire, Beck Depression Inventory (BDI), positive and negative affect scale (PANAS), body mass index (BMI), 7-day recall of physical activity from the Scottish Physical Activity Questionnaire-2 (SPAQ), 12-min walk test and assessment of shoulder mobility.","The main outcome measures were: Quality Life (FACT) questionnaire, Beck Depression Inventory (BDI), positive negative affect scale (PANAS), body mass (BMI), 7-day recall physical activity Scottish Physical Activity Questionnaire-2 (SPAQ), 12-min walk test assessment shoulder mobility.",G0000000|C0205225|C1274040|C0079809|G0000000|C0332306|C0376558|G0000000|C0034394|G0000000|C0011570|C0021941|C0006448|C0439178|C0205160|C0001721|C0175659|G0000000|C0242821|C0577559|G0000000|C0332173|C0034770|C0031809|C0205177|C0240966|C0031809|C0205177|C0034394|G0000000|C0450371|C0080331|C0022885|C1261322|C0037004|C0425245
"The follow-up surveys will be conducted by telephone at 1, 2, 3 and 6 months after the baseline.","The follow-up surveys conducted telephone 1, 2, 3 6 months baseline.",G0000000|C0589120|C0038951|C0004927|C0039457|G0000000|G0000000|G0000000|G0000000|C0439231|C0168634
Treatment continuation is intended until disease progression or unacceptable toxicity.,Treatment continuation intended disease progression unacceptable toxicity.,C0039798|G0000000|C1283828|C0012634|C0242656|C1883420|C0040539
"Moreover, we observed no side effect during the treatment and the patients tolerated the treatment very well.","Moreover, observed treatment patients tolerated treatment well.",G0000000|C1441672|C0039798|C0030705|G0000000|C0039798|C0205170
"The primary outcome was recovery (defined as WHZ≥−2 SD of the WHO standards and absence of oedema of feet) by 16 weeks after enrolment.23 Secondary outcomes included weight gain, time to recovery, prevalence of diarrhoea, acute lower respiratory tract infection (ALRI) and fever, mortality and hospitalisations during the treatment phase (until recovery or 16 weeks after enrolment, whichever was earlier).","The primary outcome recovery (defined WHZ≥−2 SD WHO standards absence oedema feet) 16 weeks enrolment.23 Secondary outcomes included weight gain, time recovery, prevalence diarrhoea, acute lower respiratory tract infection (ALRI) fever, mortality hospitalisations treatment phase (until recovery 16 weeks enrolment, whichever earlier).",G0000000|C0205225|C1274040|C0237820|C1704788|G0000000|C2699239|G0000000|C0038137|C0332197|C0013604|C0016504|G0000000|C1516879|C0027627|C1274040|C0332257|C0005910|C1517378|C0040223|C0237820|C0033105|C0011991|C0205178|C0441994|C0521346|C1185740|C0009450|G0000000|C0015967|C0026565|C0019993|C0039798|C0205390|G0000000|C0237820|G0000000|C1516879|G0000000|C1279919
"Prespecified safety outcomes included death, pneumothorax, intraventricular hemorrhage, and the need for chest compressions or epinephrine during resuscitation.","Prespecified safety outcomes included death, pneumothorax, intraventricular hemorrhage, chest compressions epinephrine resuscitation.",G0000000|C0036043|C1274040|C0332257|C0011065|C0032326|C1517569|C0019080|C0817096|C0332459|C0014563|C0035273
Data at three months.,Data months.,C1511726|C0439231
"In the intragroup comparison, both groups showed significant differences between measurements taken before and after the four weeks of therapy (p<0.05).","In intragroup comparison, differences measurements weeks therapy (p<0.05).",G0000000|G0000000|C1707455|C1705241|C0242485|C0439230|C0039798|C0369773
"The minor bleeding event rate was significantly increased, although the difference in the rate of major bleeding events was not significant.","The minor bleeding event rate increased, difference rate major bleeding events significant.",G0000000|C0026193|C0019080|C0441471|C0871208|C0205217|C1705241|C0871208|C0205082|C0019080|C0441471|C0237881
"Tables 2 and and33 show relative risks (RR) from multivariate survival regression modeling for incidence of distal caries, distal bone loss ≥ 20%, distal probing depth > 4 mm, and any one or more of these disease outcomes on second molars.","Tables 2 and33 relative risks (RR) multivariate survival regression modeling incidence distal caries, distal bone loss ≥ 20%, distal probing depth > 4 mm, disease outcomes molars.",C0039224|G0000000|G0000000|C0080103|C0035647|G0000000|G0000000|C0038952|C0684320|C0870071|C0021149|C0205108|C0011334|C0205108|C0262950|C1517945|G0000000|C0450371|C0205108|C0419358|C0205125|G0000000|G0000000|G0000000|C0012634|C1274040|C0026367
The primary efficacy measure was the percentage change in daily proteinuria at 3 months in children receiving RTX versus those on standard care.,The primary efficacy measure percentage change daily proteinuria 3 months children receiving RTX versus standard care.,G0000000|C0205225|C1280519|C0079809|C0439165|C0392747|C0332173|C0033687|G0000000|C0439231|C0008059|C1514756|C0073081|G0000000|C1442989|C1947933
The primary efficacy endpoint was percentage change in LS BMD at 6 months after initiation of chemotherapy.,The primary efficacy endpoint percentage change LS BMD 6 months initiation chemotherapy.,G0000000|C0205225|C1280519|C2349179|C0439165|C0392747|C0023668|G0000000|G0000000|C0439231|C0589507|C0013216
"The clinical outcome was classified as success (10 to 30% reduction of the size of the ulcer and/or absence of new necrotic tissue), clinical status quo (no change in the size of the lesion or presence of necrotic tissue), or failure (increase in the size of the lesion and presence of new necrotic tissue).","The clinical outcome classified success (10 30% reduction size ulcer and/or absence necrotic tissue), clinical status quo (no change size lesion presence necrotic tissue), failure (increase size lesion presence necrotic tissue).",G0000000|C0205210|C1274040|C0008902|C0597535|C0450371|C0450371|C0301630|C0456389|C0041582|G0000000|C0332197|C0027540|C0040300|C0205210|C0449438|G0000000|G0000000|C0392747|C0456389|C0221198|C0150312|C0027540|C0040300|C0231174|C0442805|C0456389|C0221198|C0150312|C0027540|C0040300
"Body weight was measured at baseline, 6-months, and one-year; all other measures were assessed at baseline and one-year.","Body weight measured baseline, 6-months, one-year; measures assessed baseline one-year.",C0242821|C0005910|C0444706|C0168634|C0439231|C4082117|C0079809|C1516048|C0168634|C4082117
"Thus, using the strict cut-off of 50 ng/ml may increase the probability of false positives when assessing for more recent cannabis use.","Thus, strict cut-off 50 ng/ml increase probability false positives assessing cannabis use.",G0000000|G0000000|C1442160|C0450371|C0439275|C0442805|C0033204|C0205237|C0439178|C1516048|C0024808|C0042153
"Furthermore, we evaluated the compliance to 24-hour urine collection by calculating the predicted urinary creatinine excretion amount to account for collection errors.","Furthermore, evaluated compliance 24-hour urine collection calculating predicted urinary creatinine excretion amount account collection errors.",G0000000|C0220825|C0009563|C0450371|C0042036|C1516698|C1441506|C0681842|C0042027|C0010294|C0221102|C1265611|C2741673|C1516698|C0743559
"Definitions of treatment success, treatment failure, disease recurrence, and immune suppression were as published previously [2], [5].","Definitions treatment success, treatment failure, disease recurrence, immune suppression published [2], [5].",C1550452|C0039798|C0597535|C0039798|C0231174|C0012634|C0034897|C0439662|C0221103|C0034037|G0000000|G0000000
demonstrate a greater reduction in negative mood as measured by the Profile of Mood States- Bipolar (POMS-Bipolar) (2).,demonstrate reduction negative mood measured Profile Mood States- Bipolar (POMS-Bipolar) (2).,G0000000|C0301630|C0205160|C0026516|C0444706|C1979963|C0026516|C1301808|C0443156|C0451394|G0000000
"In patients with a positive HAMA test before the fourth infusion (n = 7), there were no obvious changes in the pattern of adverse events reported after the last infusion.","In patients positive HAMA test fourth infusion (n = 7), obvious pattern adverse events reported infusion.",G0000000|C0030705|C0439178|C1291910|C0022885|C0205438|C0574032|C0369718|G0000000|G0000000|G0000000|C0449774|G0000000|C0441471|C0684224|C0574032
"The primary endpoint is time-to-treatment failure (development of frequent relapses, steroid dependence or steroid resistance).","The primary endpoint time-to-treatment failure (development frequent relapses, steroid dependence steroid resistance).",G0000000|C0205225|C2349179|C3494202|C0231174|C0243107|C0332183|C0035020|C0038317|C0011546|C0038317|C0237834
"MSD was defined as passing three or more loose stools within 24 h, in conjunction with clinical signs of moderate-to-severe dehydration (sunken eyes, loss of skin turgor, or administration of IV fluids), dysentery, or admission to a health facility.","MSD defined passing loose stools 24 h, conjunction clinical signs moderate-to-severe dehydration (sunken eyes, loss skin turgor, administration IV fluids), dysentery, admission health facility.",C0268263|C1704788|G0000000|C0205407|C0015733|C0450371|C0033727|C2699427|C0205210|C0220912|C0205081|C0011175|G0000000|C0015392|C1517945|C0444099|C0277937|C0001554|C0022326|C0302908|C0013369|C0184666|C0018684|C1547538
"Although hospital length of stay was shortened in the low tidal volume group (5.0 vs. 5.5 days; P = 0.16; table 4), this difference did not reach statistical significance.","Although hospital length stay shortened low tidal volume (5.0 vs. 5.5 days; P = 0.16; table 4), difference reach statistical significance.",G0000000|C0019994|C1444754|G0000000|C1282927|C0205251|G0000000|C0449468|G0000000|G0000000|G0000000|C0439228|C0369773|G0000000|C0450371|C0039224|G0000000|C1705241|C2584321|C0038215|C0237881
"Apart from the programmatic rationale for this assumption, biologically-determined time lags in the affected processes suggest that substantial impact upon either adult mosquito density or, even more so, upon malaria infection prevalence cannot be expected any earlier.","Apart programmatic rationale assumption, biologically-determined time lags processes substantial impact adult mosquito density or, so, malaria infection prevalence expected earlier.",G0000000|G0000000|C0392360|G0000000|C0205460|C0040223|C1416797|C1184743|G0000000|C1825598|C0001675|C0026584|C0178587|G0000000|C0037640|C0024530|C0009450|C0033105|C1517001|C1279919
The primary objective of the study was to evaluate the field efficacy of the vaccine in healthy children aged 6 months to 12 years by comparing the rates of microbiologically proven (BACTEC positive) typhoid fever in the vaccinated group with the non-vaccinated group during a period of 1 year post-vaccination surveillance.,The primary objective study evaluate field efficacy vaccine healthy children aged 6 months 12 comparing rates microbiologically proven (BACTEC positive) typhoid fever vaccinated non-vaccinated period 1 post-vaccination surveillance.,G0000000|C0205225|C0018017|C0557651|C0220825|C0440042|C1280519|C0042210|C3898900|C0008059|C0001779|G0000000|C0439231|C0450371|C1707455|C0871208|G0000000|C0456369|G0000000|C0439178|C0041466|C0015967|C1116171|C1518422|C0439531|G0000000|C0687676|C0220920
"Data were collected at baseline and weeks 12, 24, 52, 64, and 104.","Data collected baseline weeks 12, 24, 52, 64, 104.",C1511726|C1516695|C0168634|C0439230|C0450371|C0450371|C0450371|C0450371|C1442061
"Event-free survival at 5 and 10 years amounted to 57% and 53%, respectively.","Event-free survival 5 10 amounted 57% 53%, respectively.",C0441471|C0038952|G0000000|C0450371|C1265611|C0450371|C0450371|G0000000
We did not actively search for adverse events during the study period.,We actively search adverse events study period.,G0000000|G0000000|C1552603|G0000000|C0441471|C0557651|C0439531
"The major secondary end points included OS, overall RR (ORR), TTF, and safety.","The major secondary included OS, RR (ORR), TTF, safety.",G0000000|C0205082|C0027627|C0332257|C0229090|G0000000|G0000000|C1332112|C0036043
"The effects of the treatment conditions on the secondary outcome variables of pain unpleasantness, pain interference, depressive symptoms, and perceived control over pain were examined using the same ANOVA strategy used to assess the effects of treatment on average daily pain intensity, with each outcome measure as the dependent variable in each of four ANOVAs, and time (pretreatment, posttreatment, 3-month follow-up) and treatment condition (HYP and BIO) as the independent variables.","The effects treatment conditions secondary outcome variables pain unpleasantness, pain interference, depressive symptoms, perceived control pain examined ANOVA strategy assess effects treatment average daily pain intensity, outcome measure dependent variable ANOVAs, time (pretreatment, posttreatment, 3-month follow-up) treatment condition (HYP BIO) independent variables.",G0000000|C1280500|C0039798|C0012634|C0027627|C1274040|C0439828|C0030193|G0000000|C0030193|C0521102|G0000000|C0683368|C0030971|C0243148|C0030193|C0332128|G0000000|C0679199|C1516048|C1280500|C0039798|C1510992|C0332173|C0030193|C0522510|C1274040|C0079809|C0851827|C0439828|G0000000|C0040223|C1550147|C2709088|C0332177|C0589120|C0039798|C0012634|C0733682|C3844595|C0085862|C0439828
The primary outcome measure was change from baseline in mean AHI.,The primary outcome measure change baseline AHI.,G0000000|C0205225|C1274040|C0079809|C0392747|C0168634|G0000000
No adjustment to the dosage was made if Hb level increased in response to transfusion.,No adjustment dosage Hb level increased response transfusion.,G0000000|C0376209|C0178602|C0019046|C0441889|C0205217|C0871261|C0005841
At the final follow-up closure rate is determined by clinical examination.,At final follow-up closure rate determined clinical examination.,G0000000|C0205088|C0589120|C0185003|C0871208|G0000000|C0205210|G0000000
The primary efficacy endpoint will be the proportion of patients transfused with any blood product prior to central venous catheterization.,The primary efficacy endpoint proportion patients transfused blood product prior central venous catheterization.,G0000000|C0205225|C1280519|C2349179|C1709707|C0030705|C1549003|C0005767|C1514468|C0332152|C0205099|C0042449|C0007430
"undertook a randomized controlled trial of lead dust control in 275 urban children, followed from six months until 24 months of age, to evaluate the effectiveness of dust control in preventing or limiting elevation of BLLs.","undertook randomized controlled trial lead dust control 275 urban children, months 24 months age, evaluate effectiveness dust control preventing limiting elevation BLLs.",G0000000|C0034656|C2587213|C0008976|C0023175|C0013330|C0243148|C1442061|C0442529|C0008059|C0439231|C0450371|C0439231|C0001779|C0220825|C1280519|C0013330|C0243148|C0309872|C0439801|C0439775|G0000000
"Four outcomes reported here do not meet the definition of a primary outcome: Special Education Placement in grades 1-6 (yes/no), abstracted from school records.","Four outcomes reported meet definition primary outcome: Special Education Placement grades 1-6 (yes/no), abstracted school records.",C0205450|C1274040|C0684224|C1550543|C1550452|C0205225|C1274040|C0205555|C0013621|C0441587|C0441800|G0000000|C1512698|C0000857|C0036375|C0034869
"Furthermore, in the EA treatment group and EA control group, 93 and 92% of patients showed great improvement, respectively, whereas only 84% of the fluoxetine treatment group showed great improvement after 6 weeks of treatment (Ham-D ≤15).","Furthermore, EA treatment EA control group, 93 92% patients improvement, respectively, 84% fluoxetine treatment improvement 6 weeks treatment (Ham-D ≤15).",G0000000|C0014963|C0039798|C0014963|C0243148|C0441833|C0450371|C0450371|C0030705|C2986411|G0000000|C0450371|C0016365|C0039798|C2986411|G0000000|C0439230|C0039798|C1570167|G0000000
"Acupuncture is effective and safe in relieving headache, preventing relapse and reducing migraine associated symptoms and has been used worldwide for the treatment of migraine attacks [27,41].","Acupuncture effective safe relieving headache, preventing relapse reducing migraine symptoms worldwide treatment migraine attacks [27,41].",C0001299|C1280519|G0000000|C0332303|C0018681|C0309872|C0035020|C0392756|C0149931|C0683368|G0000000|C0039798|C0149931|C1261512|C0450371
"Comparison of Treatment Group Means Over Time on Function Measures No significant effect of treatment over time was found on the Performance Test of Activities of Daily Living F(3,59) = 2.16, p = .12.","Comparison Treatment Group Means Over Time Function Measures No treatment time Performance Test Activities Daily Living F(3,59) = 2.16, = .12.",C1707455|C0039798|C0441833|C1704970|C0205136|C0040223|C0031843|C0079809|G0000000|C0039798|C0040223|C0597198|C0022885|C0441655|C0332173|C0376558|C0016327|G0000000|C0450371|G0000000|C0450371
"The secondary endpoints were the nocturnal BP dipping patterns, average SBP and DBP levels, and average daytime and nighttime SBP and DBP levels.","The secondary endpoints nocturnal BP dipping patterns, average SBP DBP levels, average daytime nighttime SBP DBP levels.",G0000000|C0027627|C2349179|C0240526|C0037623|C0337426|C0449774|C1510992|G0000000|C0536221|C0441889|C1510992|C0332169|C0240526|G0000000|C0536221|C0441889
Data collection methods are detailed elsewhere.11 We collected data for 13 months before and 24 months after we gave away the alarms.,Data collection methods detailed elsewhere.11 We collected data 13 months 24 months alarms.,C1511726|C1516698|C0025663|C1522508|C0450371|G0000000|C1516695|C1511726|C0450371|C0439231|C0450371|C0439231|C0336648
"Measurement of plasma 25(OH)-D (Liaison RIA automated platform, Diasorin, Minnesota, USA) was undertaken centrally (MRC Human Nutrition Research, Cambridge, UK) in a single batch at the end of the study.","Measurement plasma 25(OH)-D (Liaison RIA automated platform, Diasorin, Minnesota, USA) undertaken centrally (MRC Human Nutrition Research, Cambridge, UK) single batch study.",C0242485|C0032105|C0450371|C0683597|C0034580|C0205554|C1710360|G0000000|C0026183|C0041703|G0000000|G0000000|C1540289|C0086418|C0028707|C0035168|G0000000|C0041700|C0037179|C1550176|C0557651
Absence of inter-radicular or periapical radiolucency Absence of internal resorption Absence of abnormal canal calcification  The statistical analysis was done using SPSS (Statistical Package for Social Sciences) Version 15.0 statistical Analysis Software.,Absence inter-radicular periapical radiolucency Absence internal resorption Absence abnormal canal calcification The statistical analysis SPSS (Statistical Package Social Sciences) Version 15.0 statistical Analysis Software.,C0332197|C0205103|C0729269|C2827491|C0332197|C0205102|C2985494|C0332197|C0205161|C0086881|C0006660|G0000000|C0038215|C0002778|C3813609|C0038215|C0013194|C0728831|C0036397|C0333052|C0450371|C0038215|C0002778|C0037585
Follow-up linear contrasts were used to make specific comparisons between groups at 12 and 24 weeks.,Follow-up linear contrasts specific comparisons 12 24 weeks.,C0589120|C0205132|C0009924|C0205369|C1707455|C0450371|C0450371|C0439230
"These include parent reports of the number of school staff they felt comfortable approaching (staff contacts), the number of parents of their child’s friends they knew (intergenerational closure; Coleman, 1988), the degree to which they agreed that they shared expectations for their child with other parents, whether they regularly discussed school with their child, and whether they regularly participated in school activities.","These parent reports school staff comfortable approaching (staff contacts), parents child’s friends (intergenerational closure; Coleman, 1988), degree agreed shared expectations child parents, regularly discussed school child, regularly participated school activities.",G0000000|C0030551|C0684224|C0036375|C0851286|G0000000|C0449445|C0851286|C4036459|C0030551|G0000000|C0079382|C0598500|C0185003|G0000000|G0000000|C0441889|C3641827|C0237876|C0679138|C0008059|C0030551|G0000000|C2584313|C0036375|C0008059|G0000000|G0000000|C0036375|C0441655
BOWEL FUNCTION * Values given in mean (standard error of the mean).,BOWEL FUNCTION * Values (standard error mean).,C0021853|C0031843|G0000000|C0042295|C1442989|C0743559|C0444504
Global QOL was measured by the City of Hope Quality of Life Instruments for Patients or Caregivers; problem solving skills were measured by the Social Problem Solving Inventory-Revised.,Global QOL measured City Hope Quality Life Instruments Patients Caregivers; solving skills measured Social Problem Solving Inventory-Revised.,C0205246|C0518214|C0444706|C0008848|C0392347|C0332306|C0376558|C0348000|C0030705|C0085537|G0000000|C0678856|C0444706|C0728831|C0033213|G0000000|C0021941
[11] The severity of dysmenorrhea was assessed by a verbal multidimensional scoring (VMS) system and by a visual analog scale (VAS).,[11] The severity dysmenorrhea assessed verbal multidimensional scoring (VMS) system visual analog scale (VAS).,C0450371|G0000000|C0439793|C0013390|C1516048|C0439824|C2347299|C0449820|G0000000|C0449913|C0234621|C0243071|C0175659|C0042815
Knowledge about memory loss.,Knowledge memory loss.,C0376554|C0025260|C1517945
"Although this initial RCT is a small study, MAAT participants appear to improve on one measure of quality of life and verbal memory performance relative to no treatment controls and rate MAAT with high satisfaction.","Although initial RCT study, MAAT participants improve measure quality life verbal memory performance relative treatment controls rate MAAT satisfaction.",G0000000|C0205265|G0000000|C0557651|G0000000|C0679646|G0000000|C0079809|C0332306|C0376558|C0439824|C0025260|C0597198|C0080103|C0039798|C0243148|C0871208|G0000000|C0242428
"Peak IC and FEV1 on Day 1, and trough IC and FEV1 after 21 days were other secondary endpoints.","Peak IC FEV1 Day 1, trough IC FEV1 21 days secondary endpoints.",C0444505|C0020750|G0000000|C0332173|G0000000|C0444506|C0020750|G0000000|C0450371|C0439228|C0027627|C2349179
A total of 125 participants had an advanced adenoma recurrence and 629 participants had nonadvanced recurrent adenomas during follow-up.,A total 125 participants advanced adenoma recurrence 629 participants nonadvanced recurrent adenomas follow-up.,G0000000|C0439175|C1442061|C0679646|C0205179|C0001430|C0034897|C1442061|C0679646|G0000000|C2945760|C0001430|C0589120
"Dietary intake, physical activity levels, gestational weight gain knowledge, smoking cessation, and intention to breastfeed were assessed at service-entry and 12 weeks later.","Dietary intake, physical activity levels, gestational weight gain knowledge, smoking cessation, intention breastfeed assessed service-entry 12 weeks later.",C0012155|C1512806|C0031809|C0205177|C0441889|C0439671|C0005910|C1517378|C0376554|C0037369|C1880019|C0162425|C0006147|C1516048|C0557854|C0450371|C0439230|C0205087
"The change in mean dentin thickness at any time interval in sequential images at 6 months and 12 months did not differ significantly in both groups (P > 0.05) but the difference in total increment from baseline to 12 months in Group-1 was more than Group-2, and this value was found to be statistically significant [Tables [Tables22 and and33].","The change dentin thickness time interval sequential images 6 months 12 months (P > 0.05) difference total increment baseline 12 months Group-1 Group-2, statistically [Tables [Tables22 and33].",G0000000|C0392747|C0011429|C1280412|C0040223|C1272706|C1548958|C1704254|G0000000|C0439231|C0450371|C0439231|C0369773|G0000000|C0450371|C1705241|C0439175|C1705117|C0168634|C0450371|C0439231|C0441857|C0441857|C0038215|C0039224|G0000000|G0000000
Patients were referred to the medical center 5–7 days after the start of treatment for reevaluation of clinical and Laboratory symptoms.,Patients referred medical center 5–7 days start treatment reevaluation clinical Laboratory symptoms.,C0030705|C0205543|C0199168|C0205099|G0000000|C0439228|C0439659|C0039798|C0681840|C0205210|C0022877|C0683368
"The purpose of this study is to determine the effect of lifestyle interventions on improving dietary habits and lifestyle behaviors, ensuring gestational weight gain (GWG) within recommended levels and limiting postpartum weight retention (PWR).","The purpose study determine lifestyle interventions improving dietary habits lifestyle behaviors, ensuring gestational weight gain (GWG) recommended levels limiting postpartum weight retention (PWR).",G0000000|C1285529|C0557651|G0000000|C0023676|C0886296|C1272745|C0012155|C0018464|C0023676|C0004927|C0218063|C0439671|C0005910|C1517378|G0000000|C0034866|C0441889|C0439801|C0086839|C0005910|C0035280|G0000000
"Subjects were evaluated using three exams: a biomechanical examination of the impaired limb with the ARM Guide, a characterization of free reaching, and clinical tests of functional performance.","Subjects evaluated exams: biomechanical examination impaired limb ARM Guide, characterization free reaching, clinical tests functional performance.",C0681850|C0220825|C0582103|G0000000|G0000000|C0221099|C0015385|C0446516|C0181090|C1880022|C0332296|C2584321|C0205210|C0022885|C0205245|C0597198
The primary outcome was the number of proctor ‘assists’ required per colonoscopy.,The primary outcome proctor ‘assists’ required colonoscopy.,G0000000|C0205225|C1274040|G0000000|G0000000|C1514873|C0009378
"Aono's four point scale at 5 (T5), 15 (T15) and 30 (T30) minutes after emergence.","Aono's scale 5 (T5), 15 (T15) 30 (T30) minutes emergence.",G0000000|C0175659|G0000000|C0041403|C0450371|G0000000|C0450371|G0000000|C0439232|C0750573
Participants randomized to the control group were asked to avoid changing their exercise behavior during the study when compared with what they were doing at time of study enrollment.,Participants randomized control avoid changing exercise behavior study compared time study enrollment.,C0679646|C0034656|C0243148|G0000000|C0392747|C0015259|C0004927|C0557651|C1707455|C0040223|C0557651|C1516879
Corticomotor excitability changes as measured by motor evoked potential amplitudes (MEP).,Corticomotor excitability measured motor evoked potential amplitudes (MEP).,G0000000|C0235169|C0444706|C1513492|C1444748|C3245505|C2346753|C1707163
The procedure was considered a failure if the operator was unable to cannulate the vein within three attempts; an attempt being defined as the introducer needle's entry into the skin and its removal from the skin.,The procedure considered failure operator unable cannulate vein attempts; attempt defined introducer needle's entry skin removal skin.,G0000000|C0184661|C0750591|C0231174|C1705273|C1299582|G0000000|C0042449|C1516084|C1516084|C1704788|C0456642|C0027551|C1705654|C0444099|C0015252|C0444099
Primary endpoints: L-OS is defined as the new onset of at least 2 clinical symptoms with a positive blood culture (noted after Day of life 3) and identification of an organism known to be a cause of sepsis rather than a contaminant.,Primary endpoints: L-OS defined onset 2 clinical symptoms positive blood culture (noted Day life 3) identification organism sepsis contaminant.,C0205225|C2349179|C0439394|C1704788|C0206132|G0000000|C0205210|C0683368|C0439178|C0005767|C0010453|G0000000|C0332173|C0376558|G0000000|C0020792|C0029235|C0036690|C2827365
"The best spectacle-corrected visual acuity (BSCVA) was assessed at enrolment, 3 weeks and 3 months.","The spectacle-corrected visual acuity (BSCVA) assessed enrolment, 3 weeks 3 months.",G0000000|C0015421|C0234621|C0750509|G0000000|C1516048|C1516879|G0000000|C0439230|G0000000|C0439231
The intervention affected the prevalence of smokeless tobacco among grade 9 boys at time 2.,The intervention prevalence smokeless tobacco grade 9 boys time 2.,G0000000|C0886296|C0033105|C1450035|C0040329|C0441800|G0000000|C0870221|C0040223|G0000000
"There were no significant safety findings; however, there was a significantly higher number of adverse events in the pregabalin treatment group.","There safety findings; however, adverse events pregabalin treatment group.",G0000000|C0036043|C2607943|G0000000|G0000000|C0441471|C0657912|C0039798|C0441833
All patients were screened for deep vein thrombosis and the functional outcomes were evaluated at 6 months after surgery.,All patients screened deep vein thrombosis functional outcomes evaluated 6 months surgery.,G0000000|C0030705|C0220908|C0205125|C0042449|C0040053|C0205245|C1274040|C0220825|G0000000|C0439231|C0038894
"As a result, researchers and clinicians are beginning to implement a variety of intervention approaches for teenagers who smoke and want to quit.","As result, researchers clinicians implement variety intervention approaches teenagers smoke quit.",G0000000|C1274040|C0035173|C0871685|G0000000|C1883525|C0886296|C0449445|C0205653|C0037366|C0748223
"A global assessment of treatment efficacy was assessed using a 5-point rating scale (1 = very good, 5 = worsening of symptoms) on day 14, and rescue medication use was determined by counting the number of tablets taken during the treatment and follow-up periods.","A global assessment treatment efficacy assessed 5-point rating scale (1 = good, 5 = worsening symptoms) day 14, rescue medication determined counting tablets treatment follow-up periods.",G0000000|C0205246|C1261322|C0039798|C1280519|C1516048|C1552961|C0871208|C0175659|G0000000|G0000000|C0205170|G0000000|G0000000|C0332271|C0683368|C0332173|C0450371|G0000000|C0013227|G0000000|C0750480|C0039225|C0039798|C0589120|C0439531
"After receiving the reports, the Xiangshui County Center for Disease Control and Prevention was responsible for epidemiology surveys and specimen collection.","After receiving reports, Xiangshui County Center Disease Control Prevention responsible epidemiology surveys specimen collection.",G0000000|C1514756|C0684224|G0000000|C0079170|C0205099|C0012634|C0243148|C0199176|C1273518|C0014507|C0038951|C0370003|C1516698
"This crossover, randomized double-blind study was designed to determine as primary outcomes, in preschool children with CF: the effects of an inhaled hypertonic solution on spirometry (measured as follows: forced volume vital capacity – FVC, forced expiratory volume in 1 s - FEV1 and forced expiratory flow 25–75% - FEF25-75) and airways resistance assessed by The Interrupter technique (Rint).","This crossover, randomized double-blind study designed determine primary outcomes, preschool children CF: effects inhaled hypertonic solution spirometry (measured follows: forced volume vital capacity – FVC, forced expiratory volume 1 - FEV1 forced expiratory flow 25–75% - FEF25-75) airways resistance assessed The Interrupter technique (Rint).",G0000000|C0010366|C0034656|C0013072|C0557651|C1707689|G0000000|C0205225|C1274040|C0424930|C0008059|C0009738|C1280500|C0004048|G0000000|C0037633|C0037981|C0444706|C0332283|C0441722|C0449468|C0442732|C1516240|G0000000|C3714541|C0441722|C0231800|C0449468|G0000000|G0000000|G0000000|C0441722|C0231800|C0806140|G0000000|G0000000|C0450371|C0178987|C0237834|C1516048|G0000000|C1708543|C0449851|G0000000
Primary outcome measures included changes in one-carbon cycle intermediates within each treatment arm (by paired t-test) and between treatment arms (by independent samples t-test).,Primary outcome measures included one-carbon cycle intermediates treatment arm (by paired t-test) treatment arms (by independent samples t-test).,C0205225|C1274040|C0079809|C0332257|C0205447|C1511572|C0205103|C0039798|C0446516|G0000000|C1709450|C0871472|C0039798|C0206655|G0000000|C0085862|C0370003|C0871472
We also evaluated the change in the agitation inventory score from baseline to 26 weeks and the changes in severe impairment battery score.,We evaluated change agitation inventory score baseline 26 weeks severe impairment battery score.,G0000000|C0220825|C0392747|C0085631|C0021941|C0449820|C0168634|C0450371|C0439230|C0205082|C0221099|C0337088|C0449820
"Point prevalence and continuous abstinence at the 12-month follow-up, by treatment intensity.","Point prevalence continuous abstinence 12-month follow-up, treatment intensity.",C1552961|C0033105|C0549178|C3843422|C0450371|C0589120|C0039798|C0522510
"The survey included 15 items from the Perceived Stress Scale, a reliable and valid psychological instrument designed to measure perceptions of stress (defined as how unpredictable, uncontrollable and overloaded respondents find their lives) over a short period (i.e., 1 to 2 months).14,15 The questions in the Perceived Stress Scale are of a general nature, not specific to any subpopulation, and are considered valid across sex and age categories.","The survey included 15 items Perceived Stress Scale, reliable valid psychological instrument designed measure perceptions stress (defined unpredictable, uncontrollable overloaded respondents lives) short period (i.e., 1 2 months).14,15 The questions Perceived Stress Scale nature, specific subpopulation, considered valid sex age categories.",G0000000|C0038951|C0332257|C0450371|C1551338|C0030971|C0038435|C0175659|C3858758|C2349099|C0205486|C0348000|C1707689|C0079809|C0030971|C0038435|C1704788|G0000000|G0000000|G0000000|C0282122|C0595998|C1282927|C0439531|C0683454|G0000000|G0000000|C0439231|G0000000|C1522634|C0030971|C0038435|C0175659|C0349590|C0205369|C1257890|C0750591|C2349099|C0009253|C0001779|C0683312
"These approaches have only modest success, with 6–12 month abstinence rates of 20-30% [5,6].","These approaches modest success, 6–12 month abstinence rates 20-30% [5,6].",G0000000|C0449445|C4054480|C0597535|G0000000|C0332177|C3843422|C0871208|C0450371|G0000000
The Interference Subscale of the Multidimensional Pain Inventory (MPI) (47).,The Interference Subscale Multidimensional Pain Inventory (MPI) (47).,G0000000|C0521102|G0000000|C2347299|C0030193|C0021941|C0663932|C0450371
"Follow-up appointments were scheduled at 12 weeks, 52 weeks and 2 years.","Follow-up appointments scheduled 12 weeks, 52 weeks 2 years.",C0589120|C0003629|C0086960|C0450371|C0439230|C0450371|C0439230|G0000000|C0439234
A total of 2402 cigarette smokers identified at baseline were surveyed 12 and 24 months later to assess participation in programs and cessation.,A total 2402 cigarette smokers identified baseline surveyed 12 24 months assess participation programs cessation.,G0000000|C0439175|G0000000|C0677453|C0337664|C0205396|C0168634|C0038951|C0450371|C0450371|C0439231|C1516048|C0679823|C0376691|C1880019
"Primary outcomes were the Assisting Hand Assessment and the Canadian Occupational Performance Measure at baseline, and 1 week, 2 and 6 months postintervention.","Primary outcomes Assisting Hand Assessment Canadian Occupational Performance Measure baseline, 1 week, 2 6 months postintervention.",C0205225|C1274040|C0557034|C0018563|C1261322|C0238884|C0521127|C0597198|C0079809|C0168634|G0000000|C0332174|G0000000|G0000000|C0439231|G0000000
"[1,2,3] Acute emesis is seen most commonly with radiotherapy lasting 30 min to 4 h.[4] Although, the toxicity during radiotherapy is always self-limited but decreases patient compliance, increases the cost of care, and may alter therapeutic results by increasing generally treatment period.","[1,2,3] Acute emesis commonly radiotherapy lasting 30 min 4 h.[4] Although, toxicity radiotherapy self-limited decreases patient compliance, increases cost care, alter therapeutic increasing treatment period.",G0000000|C0205178|C0042963|G0000000|C0034619|C1517741|C0450371|C0702093|G0000000|C0228505|G0000000|C0040539|C0034619|C0036588|C0442797|C0030705|C0009563|C0205217|C0010186|C1947933|C0392747|C0087111|C0442808|C0039798|C0439531
The primary clinical outcome was the last clinic systolic BP for patients with poorly controlled hypertension at baseline (>130/80 mmHg).,The primary clinical outcome clinic systolic BP patients controlled hypertension baseline (>130/80 mmHg).,G0000000|C0205225|C0205210|C1274040|C0002424|C0039155|C0037623|C0030705|C2587213|C0020538|C0168634|C1442061|C0439475
"104 adolescents with epilepsy, aged 13–20 years old, were included from December 2009 to December 2010, the enrolled patients were with anxiety [Hamilton Anxiety Scale (HAMA) score ≥14 points] or depression [Hamilton Depression Scale (HAMD) score ≥20 points].","104 adolescents epilepsy, aged 13–20 old, included December 2009 December 2010, enrolled patients anxiety [Hamilton Anxiety Scale (HAMA) score ≥14 points] depression [Hamilton Depression Scale (HAMD) score ≥20 points].",C1442061|C0205653|C0014544|C0001779|G0000000|C0580836|C0332257|C3830550|G0000000|C3830550|G0000000|G0000000|C0030705|C0003467|G0000000|C0003467|C0175659|C1291910|C0449820|G0000000|C1552961|C0011570|G0000000|C0011570|C0175659|G0000000|C0449820|G0000000|C1552961
Physical strength was assessed with a grip strength and a standing broad jump test.,Physical strength assessed grip strength standing broad jump test.,C0031809|C0237897|C1516048|C0021400|C0237897|C0231472|C0332464|C0221189|C0022885
"Hypothesis 1:Over time, adolescents randomized to Familias Unidas + PATH will be less likely to report (a) alcohol use, (b) cigarette use, and (c) illicit drug use during the 90 days prior to each assessment point compared with adolescents randomized to ESOL + PATH or ESOL + HEART.","Hypothesis 1:Over time, adolescents randomized Familias Unidas + PATH report (a) alcohol use, (b) cigarette use, (c) illicit drug 90 days prior assessment compared adolescents randomized ESOL + PATH ESOL + HEART.",C1512571|C0205136|C0040223|C0205653|C0034656|G0000000|G0000000|G0000000|C0919386|C0684224|G0000000|C0001962|C0042153|G0000000|C0677453|C0042153|G0000000|C0332266|C0013227|C0450371|C0439228|C0332152|C1261322|C1707455|C0205653|C0034656|G0000000|G0000000|C0919386|G0000000|G0000000|C0018787
Approval for the study was obtained from the Medical Ethics Committee of the Xiangshui County Center for Disease Control and Prevention.,Approval study Medical Ethics Committee Xiangshui County Center Disease Control Prevention.,C0205540|C0557651|C0199168|C0015000|C2699414|G0000000|C0079170|C0205099|C0012634|C0243148|C0199176
"The Fibromyalgia Impact Questionnaire (FIQ) comprises 3 sections—function, impact, and symptoms—that are summed to generate an overall score.","The Fibromyalgia Impact Questionnaire (FIQ) comprises 3 sections—function, impact, symptoms—that summed generate score.",G0000000|C0016053|C1825598|C0034394|G0000000|C2700400|G0000000|G0000000|C1825598|G0000000|C1515051|G0000000|C0449820
"At baseline and 6-months, adolescents were asked whether they used any alcohol and/or marijuana in the prior 3 months, how long they had been using alcohol and/or marijuana, whether they had at least one drink in the past 7 days and past 30 days, total number of drinks they consumed in the past 7 days and past 30 days, whether they had consumed 5 or more drinks in a row in the past 2 weeks and past 30 days, and total number of days and times per day they used marijuana in the past 7 and 30 days.","At baseline 6-months, adolescents alcohol and/or marijuana prior 3 months, alcohol and/or marijuana, drink 7 days 30 days, total drinks consumed 7 days 30 days, consumed 5 drinks row 2 weeks 30 days, total days times day marijuana 7 30 days.",G0000000|C0168634|C0439231|C0205653|C0001962|G0000000|C0024808|C0332152|G0000000|C0439231|C0001962|G0000000|C0024808|C0452428|G0000000|C0439228|C0450371|C0439228|C0439175|C0452428|G0000000|G0000000|C0439228|C0450371|C0439228|G0000000|G0000000|C0452428|C1552840|G0000000|C0439230|C0450371|C0439228|C0439175|C0439228|C0040223|C0332173|C0024808|G0000000|C0450371|C0439228
"To test our primary hypothesis, we compared the longitudinal trajectories of our primary outcome (ED visits) and secondary outcomes (ICS adherence, asthma symptom frequency, hospitalizations, and oral steroid use) for each intervention group with those for the UC group.","To test primary hypothesis, compared longitudinal trajectories primary outcome (ED visits) secondary outcomes (ICS adherence, asthma symptom frequency, hospitalizations, oral steroid use) intervention UC group.",C0040363|C0022885|C0205225|C1512571|C1707455|C0205127|G0000000|C0205225|C1274040|C3538926|C0545082|C0027627|C1274040|C0022521|C1510802|C0004096|C1457887|C0376249|C0019993|C0442027|C0038317|C0042153|C0886296|G0000000|C0441833
Rheumatoid arthritis (RA) has been known to be associated with increased risk of cardiovascular disease (CVD).,Rheumatoid arthritis (RA) increased risk cardiovascular disease (CVD).,G0000000|C0003864|C3538806|C0205217|C0035647|C0007226|C0012634|C0007222
"Furthermore, the difference between end of training and 6 month after the training will be investigated within each treatment group concerning the BBT, MAL, SIS, FAT, MRS, and the BI as well as the WMFT scores.","Furthermore, difference training 6 month training investigated treatment BBT, MAL, SIS, FAT, MRS, BI WMFT scores.",G0000000|C1705241|C0040607|G0000000|C0040607|C1292732|C0039798|G0000000|C3540595|C1704647|C0424612|C1522706|G0000000|G0000000|C0449820
"There was no significant effect of group allocation alone on the visual analogue ‘sad’ item, Visual Analogue Self-Esteem Scale, Nottingham Leisure Questionnaire or Carer Strain Index when baseline values and communication impairment were controlled for.","There allocation visual analogue ‘sad’ item, Visual Analogue Self-Esteem Scale, Nottingham Leisure Questionnaire Carer Strain Index baseline values communication impairment controlled for.",G0000000|C1706778|C0234621|C0243071|G0000000|C1551338|C0234621|C0243071|C0036597|C0175659|G0000000|C0086542|C0034394|C0085537|C0080194|C0918012|C0168634|C0042295|C0009452|C0221099|C2587213|G0000000
These are the first 36 month longitudinal data using the 6 minute walk test and North Star Ambulatory Assessment in Duchenne muscular dystrophy.,These 36 month longitudinal data 6 minute walk test North Star Ambulatory Assessment Duchenne muscular dystrophy.,G0000000|C0450371|C0332177|C0205127|C1511726|G0000000|C0439232|C0080331|C0022885|C1709269|C0995242|C0439841|C1261322|G0000000|C0026845|C0333606
"Secondary endpoints include the duration of POD (total number of days and percentage of patients with duration of POD longer than 2 days; for patients who have POD on day 5, daily clinical assessments are continued until the symptoms resolve or until the patient is discharged), the severity of POD (assessed with the delirium severity measure based on CAM (CAM-S) [40], use of physical restraints, postoperative cognitive function as analyzed with the MMSE at postoperative day 3, day 5, the day before discharge and at 6 months post surgery, and preoperative and postoperative ADL functioning as analyzed with the Katz ADL scale at baseline and the day before discharge and at 6 months post surgery.","Secondary endpoints duration POD (total days percentage patients duration POD 2 days; patients POD day 5, daily clinical assessments continued symptoms resolve patient discharged), severity POD (assessed delirium severity measure based CAM (CAM-S) [40], physical restraints, postoperative cognitive function analyzed MMSE postoperative day 3, day 5, day discharge 6 months post surgery, preoperative postoperative ADL functioning analyzed Katz ADL scale baseline day discharge 6 months post surgery.",C0027627|C2349179|C0449238|G0000000|C0439175|C0439228|C0439165|C0030705|C0449238|G0000000|G0000000|C0439228|C0030705|G0000000|C0332173|G0000000|C0332173|C0205210|C1261322|C0549178|C0683368|C2699488|C0030705|C0030685|C0439793|G0000000|C1516048|C0011206|C0439793|C0079809|C1527178|C0597815|C0597815|C0450371|C0031809|C0337184|C0032790|C1516691|C0031843|C0936012|C0451306|C0032790|C0332173|G0000000|C0332173|G0000000|C0332173|C0012621|G0000000|C0439231|C0687676|C0038894|C0445204|C0032790|C0001288|C0205245|C0936012|G0000000|C0001288|C0175659|C0168634|C0332173|C0012621|G0000000|C0439231|C0687676|C0038894
SQ was measured using the PSQI.,SQ measured PSQI.,C0560749|C0444706|C3697468
"The primary outcome measure of change in QMGS at day 14 from baseline was 4.0 (p = < 0.0001) for the whole patient group, without a significant difference between treatments: 3.2 ± 4.1 (95% confidence interval [CI] 2–4.5) unit decrease in QMGS for the IVIg group and 4.7 ± 4.9 (95% CI 3.2–6.2) unit change for the PLEX group (p = 0.13) as shown in table 2.","The primary outcome measure change QMGS day 14 baseline 4.0 (p = < 0.0001) patient group, difference treatments: 3.2 ± 4.1 (95% confidence interval [CI] 2–4.5) unit decrease QMGS IVIg 4.7 ± 4.9 (95% CI 3.2–6.2) unit change PLEX (p = 0.13) table 2.",G0000000|C0205225|C1274040|C0079809|C0392747|G0000000|C0332173|C0450371|C0168634|G0000000|C0369773|G0000000|G0000000|G0000000|C0030705|C0441833|C1705241|C0087111|G0000000|G0000000|G0000000|C0450371|C0237529|C1272706|C0008107|G0000000|C0439148|C0392756|G0000000|C0085297|G0000000|G0000000|G0000000|C0450371|C0008107|G0000000|C0439148|C0392747|G0000000|C0369773|G0000000|C0450371|C0039224|G0000000
"Effectiveness indexes results regarding Motor Activity Log (A), Fugl-Meyer Assessment (B) and Stroke Specific Quality of Life (C) scores between CMIT1.5h_direct group and CIMT3h_direct group pre-to-post treatment and pre-to-6 months after treatment.","Effectiveness indexes Motor Activity Log (A), Fugl-Meyer Assessment (B) Stroke Specific Quality Life (C) scores CMIT1.5h_direct CIMT3h_direct pre-to-post treatment pre-to-6 months treatment.",C1280519|C0600653|C1513492|C0205177|C1708728|G0000000|G0000000|C1261322|G0000000|C0038454|C0205369|C0332306|C0376558|G0000000|C0449820|C2247463|C0439851|C0332152|C0039798|C0332152|C0439231|C0039798
“Cure” was defined as the resolution of fever within 5 days after initiating the antimicrobial treatment.,“Cure” defined resolution fever 5 days initiating antimicrobial treatment.,G0000000|C1704788|C1514893|C0015967|G0000000|C0439228|C1548602|C1136254|C0039798
To determine the protective effects of memantine on cognitive function in patients receiving whole-brain radiotherapy (WBRT).,To determine protective effects memantine cognitive function patients receiving whole-brain radiotherapy (WBRT).,C0040363|G0000000|G0000000|C1280500|C0025242|C1516691|C0031843|C0030705|C1514756|C1269537|C0034619|C1520143
Treatment success rate (TSR) was the sum of cure and treatment completion rate.,Treatment success rate (TSR) sum cure treatment completion rate.,C0039798|C0597535|C0871208|C0814199|C1515051|C1880198|C0039798|C0205197|C0871208
Recipients of renal transplants in whom rituximab is administered for desensitization do not appear to be at an increased risk for acute cellular rejection.,Recipients renal transplants rituximab administered desensitization increased risk acute cellular rejection.,C1709854|C0022646|C0332835|C0393022|C1521801|C0178702|C0205217|C0035647|C0205178|C0007634|C0035015
VASI Score.,VASI Score.,G0000000|C0449820
"Efficacy assessments will include communicational, psychological and physiological measures.","Efficacy assessments communicational, psychological physiological measures.",C1280519|C1261322|C0009452|C0205486|C0205463|C0079809
"Maternal education was positively associated with child dietary diversity in the same model at impact only (B=0·06, se(B)=0·01, β=0·15, P<0·001).","Maternal education positively child dietary diversity model impact (B=0·06, se(B)=0·01, β=0·15, P<0·001).",C2347083|C0013621|G0000000|C0008059|C0012155|C1880371|C3161035|C1825598|G0000000|G0000000|G0000000|G0000000
"HR, heart rate; CPP, cerebral perfusion pressure; ICP, intracranial pressure; MAP, mean arterial pressure.","HR, heart rate; CPP, cerebral perfusion pressure; ICP, intracranial pressure; MAP, arterial pressure.",G0000000|C0018787|C0871208|C0205770|G0000000|C0031001|C0033095|C1881201|C0524466|C0033095|C0024779|C0003842|C0033095
"The secondary outcomes were any bleeding (including major, CRNM, and any other reported bleeding) and the time to occurrence of death, ischaemic or non–ischaemic stroke, MI, or other systemic embolism.","The secondary outcomes bleeding (including major, CRNM, reported bleeding) time occurrence death, ischaemic non–ischaemic stroke, MI, systemic embolism.",G0000000|C0027627|C1274040|C0019080|C0332257|C0205082|G0000000|C0684224|C0019080|C0040223|C0243132|C0011065|C0475224|G0000000|C0038454|C3810814|C0205373|C0013922
"During the first home visit, the research assistant collected two salivary cotinine samples from the child and attached two air nicotine monitors.","During visit, assistant collected salivary cotinine samples child attached air nicotine monitors.",G0000000|C0545082|C0011327|C1516695|C0442040|C0010194|C0370003|C0008059|C3714578|C0001861|C0028040|C0181904
Separate immunogenicity and safety analyses were performed for subjects who had received as their first dose a vaccine which may have been temperature-deviated.,Separate immunogenicity safety analyses performed subjects received dose vaccine temperature-deviated.,C0443299|C4054739|C0036043|C0002778|C0884358|C0681850|C1514756|C0178602|C0042210|C0005903
"CRC, colorectal cancer.","CRC, colorectal cancer.",C0009402|C0555952|C0006826
"If data from the wrist accelerometer and data from the activity log indicated that the subject was still being monitored, then the waist data were treated as valid and not removed as nonwear time.","If data wrist accelerometer data activity log subject monitored, waist data treated valid removed nonwear time.",G0000000|C1511726|C0043262|C0178951|C1511726|C0205177|C1708728|C0681850|C0030695|C0230097|C1511726|C1522326|C2349099|C0849355|G0000000|C0040223
"Secondary outcome measurements on the level of body functions include dystonia, spasticity, pain, comfort and sleep-related breathing disorders.","Secondary outcome measurements level body functions dystonia, spasticity, pain, comfort sleep-related breathing disorders.",C0027627|C1274040|C0242485|C0441889|C0242821|C0542341|C0013421|C0026838|C0030193|C1331418|C0037313|C0004048|C0012634
Daily hot flash composite scores (average hot flash severity × hot flash frequency) were also averaged to produce a single baseline score for each participant.7 The women were not given any supplements during this 1-week run-in period.,Daily hot flash composite scores (average hot flash severity × hot flash frequency) averaged produce single baseline score participant.7 The women supplements 1-week run-in period.,C0332173|C0444519|C0181637|C0205199|C0449820|C1510992|C0444519|C0181637|C0439793|G0000000|C0444519|C0181637|C0376249|C1510992|G0000000|C0037179|C0168634|C0449820|C0679646|G0000000|C0043210|C0242295|C0332174|C3274438|C0439531
The primary end-point was self-reported abstinence and exhaled carbon monoxide levels of less than 10 parts per million (ppm) at 12 and 52 weeks and 2 years.,The primary end-point self-reported abstinence exhaled carbon monoxide levels 10 (ppm) 12 52 weeks 2 years.,G0000000|C0205225|C2349179|C0681906|C3843422|C0231800|C0007009|G0000000|C0441889|C0450371|C0439187|C0450371|C0450371|C0439230|G0000000|C0439234
We conducted this study to evaluate the safety and tolerability of romiplostim and its effects on the incidence of clinically significant thrombocytopenic events (CSTEs) in patients with low or intermediate-1-risk (“lower-risk”) MDS receiving lenalidomide therapy.,We conducted study evaluate safety tolerability romiplostim effects incidence clinically thrombocytopenic events (CSTEs) patients low intermediate-1-risk (“lower-risk”) MDS receiving lenalidomide therapy.,G0000000|C0004927|C0557651|C0220825|C0036043|C3274448|C2364481|C1280500|C0021149|G0000000|G0000000|C0441471|G0000000|C0030705|C0205251|C3640764|G0000000|C3273937|C1514756|C1144149|C0039798
"This study found no difference between participants in whom Lactobacilli had colonized and those in whom Lactobacilli had not colonized in terms of vaginal pH, reported symptoms, or clinical treatment [5].","This study difference participants Lactobacilli colonized Lactobacilli colonized terms vaginal pH, reported symptoms, clinical treatment [5].",G0000000|C0557651|C1705241|C0679646|C0022938|G0000000|C0022938|G0000000|C0233324|C0042232|C0450407|C0684224|C0683368|C0205210|C0039798|G0000000
"Polysomnography, the Pediatric Quality of Life inventory, the Sleep-Related Breathing Scale of the Pediatric Sleep Questionnaire, the 18-item Obstructive Sleep Apnea QoL instrument, and the modified Epworth Sleepiness Scale were completed at baseline and 7 months.","Polysomnography, Pediatric Quality Life inventory, Sleep-Related Breathing Scale Pediatric Sleep Questionnaire, 18-item Obstructive Sleep Apnea QoL instrument, modified Epworth Sleepiness Scale completed baseline 7 months.",C0162701|C0030755|C0332306|C0376558|C0021941|C0037313|C0004048|C0175659|C0030755|C0037313|C0034394|C0450371|C0549186|C0037313|C0003578|C0518214|C0348000|C0392747|G0000000|C0013144|C0175659|C0205197|C0168634|G0000000|C0439231
"Nottingham extended activities of daily living score and “global outcome” (deterioration according to the Barthel activities of daily living index, or death).","Nottingham extended activities daily living score “global outcome” (deterioration Barthel activities daily living index, death).",G0000000|C0231448|C0441655|C0332173|C0376558|C0449820|G0000000|G0000000|C0868945|G0000000|C0441655|C0332173|C0376558|C0918012|C0011065
"The CRP determined the clinical significance of each discrepancy by giving a low, moderate or high designation based on the potential for patient harm.","The CRP determined clinical significance discrepancy low, moderate designation based potential patient harm.",G0000000|C3890735|G0000000|C0205210|C0237881|C1290905|C0205251|C0205081|C0600091|C1527178|C3245505|C0030705|G0000000
"The P value was 0.0363 at 3 mo, 0.1197 at 6 mo, and 0.3259 at 9 mo.","The P 0.0363 3 mo, 0.1197 6 mo, 0.3259 9 mo.",G0000000|C0369773|G0000000|G0000000|C0026544|G0000000|G0000000|C0026544|G0000000|G0000000|C0026544
"Secondary endpoints included the evaluation of both formulations on selected GI AEs (diarrhea, constipation, nausea, vomiting, and abdominal pain) during treatment, estimation of treatment compliance, evaluation of both formulations on patient satisfaction, palatability, and GI symptoms using PROs and evaluation of the PK of both formulations.","Secondary endpoints included evaluation formulations selected GI AEs (diarrhea, constipation, nausea, vomiting, abdominal pain) treatment, estimation treatment compliance, evaluation formulations patient satisfaction, palatability, GI symptoms PROs evaluation PK formulations.",C0027627|C2349179|C0332257|C0220825|C0524527|C1707391|C1708130|C1412268|C0011991|C0009806|C0027497|C0042963|C0000726|C0030193|C0039798|C0680844|C0039798|C0009563|C0220825|C0524527|C0030705|C0242428|G0000000|C1708130|C0683368|C3813209|C0220825|G0000000|C0524527
Measures of state anxiety and posttraumatic stress symptoms served as outcomes.,Measures anxiety posttraumatic stress symptoms served outcomes.,C0079809|C0003467|G0000000|C0038435|C0683368|G0000000|C1274040
The Berg Balance Scale (BBS) and the timed up and go (TUG) test were used to assess functional balance.,The Berg Balance Scale (BBS) timed (TUG) test assess functional balance.,G0000000|G0000000|C0014653|C0175659|G0000000|C0392761|C1319201|C0022885|C1516048|C0205245|C0014653
"Until now, no head-to-head trials have been available to determine whether erlotinib is superior to gefitinib in terms of response rate or survival.","Until now, head-to-head trials determine erlotinib superior gefitinib terms response rate survival.",G0000000|C1948052|C0018670|C0008976|G0000000|C1135135|C1282910|C1122962|C0233324|C0871261|C0871208|C0038952
"Secondary efficacy outcomes were ACPR on day 28 without correction for reinfection, ACPR on day 42 with and without correction by genotyping, recrudescence and reinfection rates over 42 days, parasite clearance time (defined as time from first dose to a parasitaemia, determined by two consecutive negative readings 7–25 h apart), fever clearance time (defined as time from first dose to apyrexia, determined by two consecutive normal readings 7–25 h apart), and the proportion of patients with parasite or fever clearance on day 1, 2 and 3.","Secondary efficacy outcomes ACPR day 28 correction reinfection, ACPR day 42 correction genotyping, recrudescence reinfection rates 42 days, parasite clearance time (defined time dose parasitaemia, determined consecutive negative readings 7–25 apart), fever clearance time (defined time dose apyrexia, determined consecutive normal readings 7–25 apart), proportion patients parasite fever clearance day 1, 2 3.",C0027627|C1280519|C1274040|G0000000|C0332173|C0450371|C1705565|C0205339|G0000000|C0332173|C0450371|C1705565|C1285573|C0086898|C0205339|C0871208|C0450371|C0439228|C0030498|C0449297|C0040223|C1704788|C0040223|C0178602|C0242723|G0000000|C1707491|C0205160|C0034754|G0000000|G0000000|C0015967|C0449297|C0040223|C1704788|C0040223|C0178602|C0277797|G0000000|C1707491|C0205307|C0034754|G0000000|G0000000|C1709707|C0030705|C0030498|C0015967|C0449297|C0332173|G0000000|G0000000|G0000000
The scores of SGRQ were obtained before the program and 14 weeks later.,The scores SGRQ program 14 weeks later.,G0000000|C0449820|G0000000|C1709697|C0450371|C0439230|C0205087
"Tumor responses were graded as CR, PR, stable, or progression using previously described criteria (18).","Tumor responses graded CR, PR, stable, progression criteria (18).",C0027651|C0871261|C0441800|C0201975|C0279759|C0205360|C0242656|C0243161|C0450371
"To summarize, for each respondent, there are a total of 38 scores: 5 dependent variables (perceived effectiveness, perceived realism, learning, and positive and negative emotional responses) for each of 6 PSAs; 5 mean scores, 1 for each dependent variable (averaged over the 6 PSAs to which the respondent was exposed); and the 3 scores from part 3 (danger, harmfulness, and perceived norms).","To summarize, respondent, total 38 scores: 5 dependent variables (perceived effectiveness, perceived realism, learning, positive negative emotional responses) 6 PSAs; 5 scores, 1 dependent variable (averaged 6 PSAs respondent exposed); 3 scores 3 (danger, harmfulness, perceived norms).",C0040363|G0000000|C0282122|C0439175|C0450371|C0449820|G0000000|C0851827|C0439828|C0030971|C1280519|C0030971|C0237815|C0013621|C0439178|C0205160|C0013987|C0871261|G0000000|C3810537|G0000000|C0449820|G0000000|C0851827|C0439828|C1510992|G0000000|C3810537|C0282122|C0332157|G0000000|C0449820|G0000000|G0000000|G0000000|C0030971|C0205307
"Secondary measures included the Medical Outcomes Study (MOS) SF-36 Physical Functioning Scale (MOS-PF), the Chronic Pain Self-Efficacy Scale (CPSE), the Beck Depression Inventory (BDI), and the Beck Anxiety Inventory (BAI).","Secondary measures included Medical Outcomes Study (MOS) SF-36 Physical Functioning Scale (MOS-PF), Chronic Pain Self-Efficacy Scale (CPSE), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI).",C0027627|C0079809|C0332257|C0199168|C1274040|C0557651|C3813178|C0037712|C0031809|C0205245|C0175659|C3813178|C0205191|C0030193|C0600564|C0175659|G0000000|G0000000|C0011570|C0021941|C0006448|G0000000|C0003467|C0021941|C0234880
Changes in microflora composition at different stages in the two groups.,Changes microflora composition stages groups.,C0392747|C2985398|C0486616|C1306673|C0441833
Sociodemographics; smoking history; 30-day point prevalence.,Sociodemographics; smoking history; 30-day prevalence.,G0000000|C0037369|C0019664|C0450371|C0033105
"Secondary outcomes included flow mediated vasodilation (FMVD), a measure of antioxidant status as assessed by determining antibody levels to epitopes of oxidized LDL, and questionnaires addressing walking impairment and quality of life.","Secondary outcomes included flow mediated vasodilation (FMVD), measure antioxidant status assessed determining antibody levels epitopes oxidized LDL, questionnaires addressing walking impairment quality life.",C0027627|C1274040|C0332257|C0806140|C0086597|C0042401|G0000000|C0079809|C0003402|C0449438|C1516048|G0000000|C0003241|C0441889|C0003316|C0030011|G0000000|C0034394|C0376649|C0080331|C0221099|C0332306|C0376558
in their analyses of skin lesion or cancer status in relation to future internal cancer risk [62].,analyses skin lesion cancer status relation future internal cancer risk [62].,C0002778|C0444099|C0221198|C0006826|C0449438|C0080103|C0016884|C0205102|C0006826|C0035647|C0450371
Twelve weeks of treatment with roxithromycin alone or in combination with doxycycline was tolerable but did not reduce the frequency of exacerbations in patients with COPD either during the treatment period or in the subsequent 48 weeks.,Twelve weeks treatment roxithromycin combination doxycycline tolerable reduce frequency exacerbations patients COPD treatment period subsequent 48 weeks.,C0205458|C0439230|C0039798|C0035891|C0205195|C0013090|C4053931|G0000000|C0376249|G0000000|C0030705|C0024117|C0039798|C0439531|C0332282|C0450371|C0439230
"In the present study, the primary outcomes measures –all related to analgesic effect- were: a drop in VAS score to ≤3 at point B (4 hours after receiving the medication), participant's global evaluation of the drug, absence from school, the use of a rescue medication, and in those who continued the treatment, the pain intensity difference (PID) at certain points after start of medication and its sum (SPID).","In study, primary outcomes measures –all analgesic effect- were: drop VAS score ≤3 B (4 hours receiving medication), participant's global evaluation drug, absence school, rescue medication, continued treatment, pain intensity difference (PID) start medication sum (SPID).",G0000000|C0557651|C0205225|C1274040|C0079809|G0000000|C0002771|C1280500|G0000000|C1321095|C0042815|C0449820|G0000000|G0000000|G0000000|C0439227|C1514756|C0013227|C0679646|C0205246|C0220825|C0013227|C0332197|C0036375|G0000000|C0013227|C0549178|C0039798|C0030193|C0522510|C1705241|C0242172|C0439659|C0013227|C1515051|C2826264
Secondary outcome measures included 50% or greater improvement in BDI scores at 3 months and change in quality of life (PCS and MCS) over 3 months.,Secondary outcome measures included 50% improvement BDI scores 3 months change quality life (PCS MCS) 3 months.,C0027627|C1274040|C0079809|C0332257|C0450371|C2986411|C0006448|C0449820|G0000000|C0439231|C0392747|C0332306|C0376558|C1864389|G0000000|G0000000|C0439231
This difference was marginally significant at 30 months (p = .052).,This difference marginally 30 months (p = .052).,G0000000|C1705241|G0000000|C0450371|C0439231|C0369773|G0000000|C1442061
Table Table33 summarises the results at 4 and 12 months for patients who completed the 12 month assessments.,Table Table33 summarises 4 12 months patients completed 12 month assessments.,C0039224|G0000000|G0000000|G0000000|C0450371|C0439231|C0030705|C0205197|C0450371|C0332177|C1261322
"A higher zinc intake was associated with 42 % reduction in the risk of lung cancer (top tertile vs. first tertile: HR 0.58, 95 % CI 0.35; 0.94, P-for trend = 0.039, Table 3) after adjustment for age, sex, alcohol intake, BMI, smoking status, physical activity, DHD-index, processed and unprocessed red meat, energy intake, HRT, presence of diabetes mellitus, socioeconomic status, family history of cancer and dietary intake of other minerals.","A zinc intake 42 % reduction risk lung cancer (top tertile vs. tertile: HR 0.58, 95 % CI 0.35; 0.94, P-for trend = 0.039, Table 3) adjustment age, sex, alcohol intake, BMI, smoking status, physical activity, DHD-index, processed unprocessed red meat, energy intake, HRT, presence diabetes mellitus, socioeconomic status, family history cancer dietary intake minerals.",G0000000|C0043481|C1512806|C0450371|G0000000|C0301630|C0035647|C0024109|C0006826|C1704458|G0000000|G0000000|G0000000|G0000000|C0450371|C0450371|G0000000|C0008107|C0450371|C0450371|C0369773|C1521798|G0000000|C1442061|C0039224|G0000000|C0376209|C0001779|C0009253|C0001962|C1512806|G0000000|C0037369|C0449438|C0031809|C0205177|C0344247|C1522240|C1709843|C0332575|C0025017|C0424589|C1512806|C0282402|C0150312|C0011847|G0000000|C0748878|C0449438|C0015576|C0019664|C0006826|C0012155|C1512806|C0026162
"Secondary outcomes are satisfaction with care, unmet needs, continuity of care and health resource use.","Secondary outcomes satisfaction care, unmet needs, continuity care health resource use.",C0027627|C1274040|C0242428|C1947933|C3274904|C0027552|C0595960|C1947933|C0018684|C0035201|C0042153
"Demographic characteristics of experimental and control group The comparison of post graduate institute-general well-being measure scores, which showed significant difference between pre- and post-test for experimental and control group The comparison of dysfunction scores of checklist for basic living skills between pre- and post-test for experimental and control group The comparison of scores between pre- and post-test in Indian disability evaluation and assessment scale for the experimental and control group Though there have not been many yoga studies conducted on patients suffering from schizophrenia to support the present findings, yoga therapy could bring a significant improvement in the areas of general well-being, basic living skills, interpersonal activities, communication and, understanding, discipline, and could help to inculcate positive outlook toward life.","Demographic characteristics experimental control The comparison post graduate institute-general well-being measure scores, difference pre- post-test experimental control The comparison dysfunction scores checklist basic living skills pre- post-test experimental control The comparison scores pre- post-test Indian disability evaluation assessment scale experimental control Though yoga studies conducted patients suffering schizophrenia support findings, yoga therapy bring improvement well-being, basic living skills, interpersonal activities, communication and, understanding, discipline, inculcate positive outlook life.",C0011298|C1521970|C1517586|C0243148|G0000000|C1707455|C0687676|C0588053|C0021622|C0018684|C0079809|C0449820|C1705241|C0332152|C0687676|C1517586|C0243148|G0000000|C1707455|C0031847|C0449820|C1707357|C1527178|C0376558|C0678856|C0332152|C0687676|C1517586|C0243148|G0000000|C1707455|C0449820|C0332152|C0687676|C1524069|C0231170|C0220825|C1261322|C0175659|C1517586|C0243148|G0000000|C0043418|C0947630|C0004927|C0030705|C0683278|C0036341|C0183683|C2607943|C0043418|C0039798|G0000000|C2986411|C0018684|C1527178|C0376558|C0678856|C3476070|C0441655|C0009452|G0000000|C0162340|C0237070|G0000000|C0439178|C0004271|C0376558
Children who used WDTA were able to provide a more extensive array of behavioral strategies for asthma management.,Children WDTA provide extensive array behavioral strategies asthma management.,C0008059|G0000000|C1999230|C0205231|C1510941|C0004927|C0679199|C0004096|C0001554
Use of companions during labour is associated with earlier time to breastfeeding initiation among first-time mothers in Nigeria.,Use companions labour earlier time breastfeeding initiation first-time mothers Nigeria.,C0042153|C0335343|C0022864|C1279919|C0040223|C0006147|C0589507|C0205435|C0026591|C0028075
"All clinical variables and PEFR were recorded at 0, 15, 60, 75, and 120 minutes.","All clinical variables PEFR recorded 0, 15, 60, 75, 120 minutes.",G0000000|C0205210|C0439828|C0030735|C0034869|G0000000|C0450371|C0450371|C0450371|G0000000
"HADS, Hospital Anxiety and Depression Scale; IES, Impact of Event Scale; RDAS, Revised Dyadic Adjustment Scale; SD = standard deviation.","HADS, Hospital Anxiety Depression Scale; IES, Impact Event Scale; RDAS, Revised Dyadic Adjustment Scale; SD = standard deviation.",C0048008|C0019994|C0003467|C0011570|C0175659|G0000000|C1825598|C0441471|C0175659|C0524786|C1527075|C0870454|C0376209|C0175659|C2699239|G0000000|C1442989|C0012727
"Assessments of objective and subjective sleepiness, symptoms, cognitive performance, and psychological well being were performed on the last day of each treatment and compared.","Assessments objective subjective sleepiness, symptoms, cognitive performance, psychological performed day treatment compared.",C1261322|C0018017|C0439655|C0013144|C0683368|C1516691|C0597198|C0205486|C0884358|C0332173|C0039798|C1707455
The primary outcome measure was serum bicarbonate level at 4 h. Secondary outcomes included safety and tolerability.,The primary outcome measure serum bicarbonate level 4 h. Secondary outcomes included safety tolerability.,G0000000|C0205225|C1274040|C0079809|C0229671|C0005367|C0441889|G0000000|C0033727|C0027627|C1274040|C0332257|C0036043|C3274448
"Fifth-graders (N = 1714) self-reported on lifetime substance use, violence, and voluntary sexual activity.","Fifth-graders (N = 1714) self-reported lifetime substance use, violence, voluntary sexual activity.",C0205439|C0369718|G0000000|G0000000|C0681906|C4071830|C0439861|C0042153|C0042693|C0439656|C0036864|C0205177
Few studies have evaluated the benefit of providing exercise to underprivileged older adults at risk for falls.,Few studies evaluated benefit providing exercise underprivileged adults risk falls.,C0205388|C0947630|C0220825|C0814225|C1999230|C0015259|C0012613|C0001675|C0035647|C0000921
"Other secondary objectives were comparisons of IND/GLY with placebo in terms of peak IC and FEV1 on Day 1, and trough IC and FEV1 after 21 days, with average physical activity level analysed as an exploratory endpoint.","Other secondary objectives comparisons IND/GLY placebo terms peak IC FEV1 Day 1, trough IC FEV1 21 days, average physical activity level analysed exploratory endpoint.",G0000000|C0027627|C0018017|C1707455|C4049864|C0032042|C0233324|C0444505|C0020750|G0000000|C0332173|G0000000|C0444506|C0020750|G0000000|C0450371|C0439228|C1510992|C0031809|C0205177|C0441889|G0000000|G0000000|C2349179
After both treatments the time needed to control the seizure was registered by the practitioner.,After treatments time control seizure registered practitioner.,G0000000|C0087111|C0040223|C0243148|C0036572|C1514821|C1709627
Participants were asked to rate their low back function and pain “today” as measured by the Roland Morris Disability Questionnaire (primary outcome) and an 11-point Numeric Pain Rating Scale (secondary outcome).,Participants rate low function pain “today” measured Roland Morris Disability Questionnaire (primary outcome) 11-point Numeric Pain Rating Scale (secondary outcome).,C0679646|C0871208|C0205251|C0031843|C0030193|G0000000|C0444706|G0000000|G0000000|C0231170|C0034394|C0205225|C1274040|C0450371|C0237753|C0030193|C0871208|C0175659|C0027627|C1274040
"Vaccination generates a long-lasting immune response, which is strongly enhanced by recall administrations.","Vaccination generates long-lasting immune response, enhanced recall administrations.",C0042196|G0000000|C0205166|C0439662|C0871261|C2349975|C0034770|C0001554
Depressed patients with scores of 17 or more on the 17 items of the Hamilton Depression Rating Scale were treated with the antidepressant drug paroxetine.,Depressed patients scores 17 17 items Hamilton Depression Rating Scale treated antidepressant drug paroxetine.,C0344315|C0030705|C0449820|C0450371|C0450371|C1551338|G0000000|C0011570|C0871208|C0175659|C1522326|C0003289|C0013227|C0070122
"Body weight did not change in either group, but there was a modest but statistically significant reduction in mean total body water in the intervention group (0.50 L, p<0.01) compared with no change in the control group (0.26 L, not statistically significant.).","Body weight change group, modest statistically reduction total body water intervention (0.50 L, p<0.01) compared change control (0.26 L, statistically significant.).",C0242821|C0005910|C0392747|C0441833|C4054480|C0038215|C0301630|C0439175|C0242821|C0043047|C0886296|G0000000|C0369773|C1707455|C0392747|C0243148|G0000000|C0038215|C0237881
"Outcome measures such as the Jebsen-Taylor Hand Function Test (JTHFT), Action research Arm Test (ARAT), Fugl-Meyer Upper Extremity Motor Assessment/Hand subcomponent (FMUE/FMH), grip and pinch strengths were collected at baseline, post-treatment and one-month post-treatment.","Outcome measures Jebsen-Taylor Hand Function Test (JTHFT), Action Arm Test (ARAT), Fugl-Meyer Upper Extremity Motor Assessment/Hand subcomponent (FMUE/FMH), grip pinch strengths collected baseline, post-treatment one-month post-treatment.",C1274040|C0079809|G0000000|C0018563|C0031843|C0022885|G0000000|C0441472|C0446516|C0022885|C1152215|G0000000|C1282910|C0015385|C1513492|C1261322|G0000000|G0000000|C0021400|C0418416|C0808080|C1516695|C0168634|C2709088|C4082115|C2709088
"However, low back pain patients are relatively dissatisfied with their medical care [6], especially in comparison to care provided by non-physician's [7-10].","However, low pain patients dissatisfied medical care [6], comparison care provided non-physician's [7-10].",G0000000|C0205251|C0030193|C0030705|C0870433|C0199168|C1947933|G0000000|C1707455|C1947933|C1999230|C1518422|C0450371
"Subsequent to signed informed consent, research coordinators administered questionnaires by telephone at baseline; at 6, 12, 18, and 24 weeks; and every 12 weeks thereafter until death or study completion.","Subsequent signed informed consent, coordinators administered questionnaires telephone baseline; 6, 12, 18, 24 weeks; 12 weeks death study completion.",C0332282|C1519316|C1522154|C1511481|C1711307|C1521801|C0034394|C0039457|C0168634|G0000000|C0450371|C0450371|C0450371|C0439230|C0450371|C0439230|C0011065|C0557651|C0205197
"Because Cox hazard survival analysis is not satisfactory for describing ICU patient mortality over time [33], we performed a competing risks analysis to confirm our results.","Because Cox hazard survival analysis satisfactory describing ICU patient mortality time [33], performed competing risks analysis confirm results.",G0000000|G0000000|C0598697|C0038952|C0002778|C0205410|G0000000|C0021708|C0030705|C0026565|C0040223|C0450371|C0884358|G0000000|C0035647|C0002778|C0521093|C1274040
"In Kenya, like in other LMICs, although almost all children are breastfed, poor maternal, infant and young child nutrition (MIYCN) practices are widely documented.","In Kenya, LMICs, children breastfed, poor maternal, infant child nutrition (MIYCN) practices documented.",G0000000|C0022558|G0000000|C0008059|C0006147|C0032854|C2347083|C0021270|C0008059|C0028707|G0000000|C0237607|C1301725
"Variables to include in the multivariate model were selected a priori including age, gender, race (white, black, other), education, family history of bladder cancer, smoking (never; former, quit>10yrs prior to start of VITAL; former, quit <10 yrs prior to start of VITAL; current), pack years (never smoker and tertiles), and fruit and vegetable intake (quartiles).","Variables multivariate model selected priori including age, gender, race (white, black, other), education, family history bladder cancer, smoking (never; former, quit>10yrs prior start VITAL; former, quit <10 yrs prior start VITAL; current), pack (never smoker tertiles), fruit vegetable intake (quartiles).",C0439828|G0000000|C3161035|C1707391|G0000000|C0332257|C0001779|C0079399|C0034510|C0007457|C0005680|G0000000|C0013621|C0015576|C0019664|C0005682|C0006826|C0037369|C2003901|C0205156|C0748223|C0332152|C0439659|C0442732|C0205156|C0748223|C0450371|G0000000|C0332152|C0439659|C0442732|C0521116|C1968515|C2003901|C0337664|G0000000|C0016767|C0042440|C1512806|C2828255
"At 1 and 4 weeks after intervention, the levels of MDA in the observation group were 1.65±0.15 and 1.21±0.11 nmol/ml, the levels of SOD were 1.36±0.11 and 0.35±0.05 µU/ml, and the total antioxidant capacity was 2.11±0.12 and 3.56±0.14 U/mg, which were significantly increased to those in the control group (P<0.05) (Fig.","At 1 4 weeks intervention, levels MDA observation 1.65±0.15 1.21±0.11 nmol/ml, levels SOD 1.36±0.11 0.35±0.05 µU/ml, total antioxidant capacity 2.11±0.12 3.56±0.14 U/mg, increased control (P<0.05) (Fig.",G0000000|G0000000|G0000000|C0439230|C0886296|C0441889|C0000379|C0302523|G0000000|G0000000|C0439300|C0441889|G0000000|G0000000|G0000000|G0000000|C0439175|C0003402|C1516240|G0000000|G0000000|C1638407|C0205217|C0243148|C0369773|C0349966
2Percentage of uninformed persons or informed during the activity.,2Percentage uninformed persons informed activity.,G0000000|C0562357|C0027361|C1522154|C0205177
The primary outcome will be change in National Institutes of Health Stroke Scale scores at 30 and 90 days after TH.,The primary outcome change National Institutes Health Stroke Scale scores 30 90 days TH.,G0000000|C0205225|C1274040|C0392747|C3245503|C0021622|C0018684|C0038454|C0175659|C0449820|C0450371|C0450371|C0439228|C0039725
"In our study, the 5-year survival rates differed by about 10 percentage points (78% vs. 66%, p=0.002).","In study, 5-year survival rates differed 10 percentage (78% vs. 66%, p=0.002).",G0000000|C0557651|C0439234|C0038952|C0871208|G0000000|C0450371|C0439165|C0450371|G0000000|C0450371|C0369773
"Total serum [25(OH)D] was measured with the Diasorin Liaison Total assay in the laboratory of Reinhold Vieth in Toronto [14], which meets the International Vitamin D External Quality Assessment Scheme (DEQAS) performance targets [15].","Total serum [25(OH)D] measured Diasorin Liaison Total assay laboratory Reinhold Vieth Toronto [14], meets International Vitamin D External Quality Assessment Scheme (DEQAS) performance targets [15].",C0439175|C0229671|C0450371|C0444706|G0000000|C0683597|C0439175|C0005507|C0022877|G0000000|G0000000|G0000000|C0450371|C1550543|C1512888|C0042890|C0073187|C0205101|C0332306|C1261322|C1519193|G0000000|C0597198|C1521840|C0450371
"Overall survival, MDS progression to AML, adverse events, and antibodies to romiplostim or thrombopoietin were assessed during the 58-week study period, which included the time in follow-up for patients who discontinued study drug early.","Overall survival, MDS progression AML, adverse events, antibodies romiplostim thrombopoietin assessed 58-week study period, included time follow-up patients discontinued study drug early.",C0282416|C0038952|C3273937|C0242656|C0023467|G0000000|C0441471|C0003241|C2364481|C0040052|C1516048|C0450371|C0557651|C0439531|C0332257|C0040223|C0589120|C0030705|C1444662|C0557651|C0013227|C1279919
"Since it is impractical to use goniometers with young children, Passive range of motion and active range of motion were rated on a 4-point scale for 20 commonly measured movements immediately before and after treatment.","Since impractical goniometers children, Passive range motion active range motion rated 4-point scale 20 commonly measured movements treatment.",C1711239|G0000000|C0181061|C0008059|C3686820|C1514721|C0026597|C0205177|C1514721|C0026597|C0871208|C1552961|C0175659|C0450371|G0000000|C0444706|C0026649|C0039798
Standard WHO tumor response criteria were used.,Standard WHO tumor response criteria used.,C1442989|G0000000|C0027651|C0871261|C0243161|C1273517
"The concept of visual analogue scale (VAS), which consisted of a 10 cm line with 0 equalling ‘no pain at all’ or ‘no nausea’, and 10 equalling ‘the worst possible pain’ or ‘worst possible nausea’ was introduced previously.","The concept visual analogue scale (VAS), consisted 10 cm 0 equalling ‘no pain all’ ‘no nausea’, 10 equalling ‘the worst pain’ ‘worst nausea’ introduced previously.",G0000000|C0178566|C0234621|C0243071|C0175659|C0042815|C0332529|G0000000|G0000000|C0205163|G0000000|C0030193|G0000000|G0000000|G0000000|C0450371|C0205163|G0000000|C1522166|G0000000|G0000000|G0000000|C1292748|G0000000
Shortening of median duration of sore throat (days).,Shortening median duration sore throat (days).,C0441636|C0549183|C0449238|C0234233|C0031354|C0439228
"We analyzed the incidence of local complications (pancreatic necrosis and peripancreatic necrosis, defined by the revised Atlanta classification7), systemic complications (persistent organ failure, defined by the revised Atlanta classification7), the incidence of moderate-to-severe disease according to the revised Atlanta classification, need for intensive care unit (ICU) admission, nutritional support, invasive treatment, as well as hospital stay and mortality.","We analyzed incidence local complications (pancreatic necrosis peripancreatic necrosis, defined revised Atlanta classification7), systemic complications (persistent organ failure, defined revised Atlanta classification7), incidence moderate-to-severe disease revised Atlanta classification, intensive care unit (ICU) admission, nutritional support, invasive treatment, hospital stay mortality.",G0000000|C0936012|C0021149|C0205276|C0009566|C0030274|C0027540|C0442162|C0027540|C1704788|C1527075|C2993063|G0000000|C0205373|C0009566|C0205322|C0178784|C0231174|C1704788|C1527075|C2993063|G0000000|C0021149|C0205081|C0012634|C1527075|C2993063|C0008902|C0162425|C1947933|C0439148|C0021708|C0184666|C1521739|C0183683|C0205281|C0039798|C0019994|G0000000|C0026565
"The observed change on the RDQ, the primary outcome measure without any correction was +0.04 ± 2.90 for the WL, -2.25 ± 4.51 for APT, -2.65 ± 4.66 for CBT and -2.27 ± 4.19 for CT, respectively.","The observed change RDQ, primary outcome measure correction +0.04 ± 2.90 WL, -2.25 ± 4.51 APT, -2.65 ± 4.66 CBT -2.27 ± 4.19 CT, respectively.",G0000000|C1441672|C0392747|C3639717|C0205225|C1274040|C0079809|C1705565|C0450371|G0000000|C0450371|G0000000|C0450371|G0000000|C0450371|C0003645|C0450371|G0000000|C0450371|C0009244|C0450371|G0000000|C0450371|C0007673|G0000000
"Nor were there significant differences between the three treatment groups in the quality of patients’ final week of life, as measured by ratings provided by study partners of deceased patients.","Nor differences treatment quality patients’ final week life, measured ratings provided study partners deceased patients.",G0000000|C1705241|C0039798|C0332306|G0000000|C0205088|C0332174|C0376558|C0444706|C0871208|C1999230|C0557651|C0682323|C0011065|C0030705
"funestus bites, and presumably malaria transmission, across different times of the night and across indoor and outdoor compartments of their living environment was calculated by weighting HLC measurements of indoor and outdoor biting rates for each hour of the night by the estimated proportion of humans indoors and outdoors during that time period, exactly as previously described [39].","funestus bites, malaria transmission, times night indoor outdoor compartments living environment calculated weighting HLC measurements indoor outdoor biting rates hour night estimated proportion humans indoors outdoors time period, [39].",G0000000|C0005658|C0024530|C0040722|C0040223|C0240526|G0000000|G0000000|C1185625|C0376558|C0014406|C0444686|C0005910|C1415593|C0242485|G0000000|G0000000|C0005658|C0871208|C0439227|C0240526|C0750572|C1709707|C0086418|G0000000|C1709359|C0040223|C0439531|C0450371
"The 2 co-primary outcome measures were the rate of change over 18 months on the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog)16 and on the Clinical Dementia Rating (CDR) sum of boxes.17 The ADAS-cog is a 70-point scale that evaluates memory, attention, language, orientation, and praxis, with higher scores indicating greater impairment.","The 2 co-primary outcome measures rate change 18 months cognitive subscale Alzheimer’s Disease Assessment Scale (ADAS-cog)16 Clinical Dementia Rating (CDR) sum boxes.17 The ADAS-cog 70-point scale evaluates memory, attention, language, orientation, praxis, scores indicating impairment.",G0000000|G0000000|C3245499|C1274040|C0079809|C0871208|C0392747|C0450371|C0439231|C1516691|G0000000|G0000000|C0012634|C1261322|C0175659|C3539026|C0205210|C0011265|C0871208|G0000000|C1515051|C0179400|G0000000|C3539026|C0450371|C0175659|C0220825|C0025260|C0004268|C0023008|C0029266|C1864829|C0449820|G0000000|C0221099
The significant negative effect of diabetes duration on contrast sensitivity between 6 and 18 cycles per degree is consistent with other studies.,The negative diabetes duration contrast sensitivity 6 18 cycles degree consistent studies.,G0000000|C0205160|C0011847|C0449238|C0009924|C0020517|G0000000|C0450371|C1511572|C0441889|C0332290|C0947630
We analyzed the between-group difference in the primary outcome (incidence of delirium during the first 8 days after initiation of the study medication) using a χ2 test.,We analyzed between-group difference primary outcome (incidence delirium 8 days initiation study medication) χ2 test.,G0000000|C0936012|C0441833|C1705241|C0205225|C1274040|C0021149|C0011206|G0000000|C0439228|C0589507|C0557651|C0013227|G0000000|C0022885
"The secondary endpoint of this study was to assess the evidence of benefit in terms of an improved clinical course measured by pO2/FiO2 ratio, radiological improvement, TRM score, length of hospital stay, length of ICU stay, mortality and decreasing levels of systemic inflammatory response (IL-6, TNF-α, IL-8, IL-10 and CRP).","The secondary endpoint study assess evidence benefit terms improved clinical measured pO2/FiO2 ratio, radiological improvement, TRM score, length hospital stay, length ICU stay, mortality decreasing levels systemic inflammatory response (IL-6, TNF-α, IL-8, IL-10 CRP).",G0000000|C0027627|C2349179|C0557651|C1516048|C3887511|C0814225|C0233324|C0184511|C0205210|C0444706|C1418945|C0456603|C0034599|C2986411|G0000000|C0449820|C1444754|C0019994|G0000000|C1444754|C0021708|G0000000|C0026565|C0442797|C0441889|C0205373|C0333348|C0871261|C0020898|G0000000|C0020898|C0020898|C3890735
"We consider the methods employed in this study to be effective, efficient and reproducible for the reduction of blood loss and knee joint swelling, which has the potential to reduce patient discomfort after TKA.","We methods employed study effective, efficient reproducible reduction blood loss knee joint swelling, potential reduce patient discomfort TKA.",G0000000|C0025663|C0014003|C0557651|C1280519|C0442799|C1514863|C0301630|C0005767|C1517945|C0022742|C0022417|C0013604|C3245505|G0000000|C0030705|C0231218|G0000000
Non-responders were telephoned to record their questionnaire responses.,Non-responders telephoned record questionnaire responses.,C1518422|C0039457|C0034869|C0034394|C0871261
"Self-report is well accepted practice in studies of this type and research indicates little inconsistency between self report and other measures of drug use [39,40] The instrument will collect information on knowledge, patterns and context of use, attitudes and harms experienced in relation to alcohol, tobacco, cannabis and other illicit drug use.","Self-report accepted practice studies type inconsistency report measures drug [39,40] The instrument collect knowledge, patterns context use, attitudes harms experienced relation alcohol, tobacco, cannabis illicit drug use.",C0681906|C1272684|C0237607|C0947630|C0332307|C0442809|C0684224|C0079809|C0013227|C0450371|G0000000|C0348000|G0000000|C0376554|C0449774|C0449255|C0042153|C0004271|G0000000|C0237607|C0080103|C0001962|C0040329|C0024808|C0332266|C0013227|C0042153
"Independent 2-way ANOVAs (post-hoc testing: Tukey’s) were used to compare: i) the energy intake of each food for individual participants across the testing conditions, ii) the average individual energy content per serving, across food types and testing conditions and iii) the number of servings for each individual across food types and testing conditions.","Independent 2-way ANOVAs (post-hoc testing: Tukey’s) compare: i) energy intake food individual participants testing conditions, ii) average individual energy content serving, food types testing conditions iii) servings individual food types testing conditions.",C0085862|G0000000|G0000000|C0687676|C0039593|G0000000|C1707455|C0021966|C0424589|C1512806|C0016452|C0027361|C0679646|C0039593|C0012634|G0000000|C1510992|C0027361|C0424589|C0423896|C1519269|C0016452|C0332307|C0039593|C0012634|C0439070|C1519269|C0027361|C0016452|C0332307|C0039593|C0012634
Treatment effect on neonatal mortality was done on 2 populations.,Treatment neonatal mortality 2 populations.,C0039798|C1552240|C0026565|G0000000|C0032659
"The calculations and cutoffs employed to determine deficiency levels related to anemia, iron deficiency anemia, plasma ferritin, folic acid, iodine, vitamins A, B12 and D, and zinc are presented in Table 2.","The calculations cutoffs employed determine deficiency levels anemia, iron deficiency anemia, plasma ferritin, folic acid, iodine, vitamins A, B12 D, zinc Table 2.",G0000000|C1441506|C1442160|C0014003|G0000000|C0011155|C0441889|C0002871|C0302583|C0011155|C0002871|C0032105|C0015879|G0000000|C0001128|C0021966|C0042890|G0000000|G0000000|C0073187|C0043481|C0039224|G0000000
"These study results showed that using white plastic cover around the phototherapy unit increases the effects of phototherapy in reducing bilirubin level of serum and decreases duration of infants’ hospitalization, without increasing phototherapy side effects.","These study white plastic cover phototherapy unit increases effects phototherapy reducing bilirubin level serum decreases duration infants’ hospitalization, increasing phototherapy effects.",G0000000|C0557651|C0007457|C0032167|C0180153|C0031765|C0439148|C0205217|C1280500|C0031765|C0392756|C0005437|C0441889|C0229671|C0442797|C0449238|G0000000|C0019993|C0442808|C0031765|C1280500
"Participants were visited at baseline (1st visit), at week 4 (2nd visit) and at the end of intervention at week 8 (3rd visit).","Participants visited baseline (1st visit), week 4 (2nd visit) intervention week 8 (3rd visit).",C0679646|C0545082|C0168634|G0000000|C0545082|C0332174|G0000000|G0000000|C0545082|C0886296|C0332174|G0000000|G0000000|C0545082
The range of scores is 6 (high fatigue) to 52 (low fatigue).,The range scores 6 (high fatigue) 52 (low fatigue).,G0000000|C1514721|C0449820|G0000000|C0205250|C0015672|C0450371|C0205251|C0015672
"Secondary safety endpoints are the incidence of clinically relevant non-major bleeding and minor bleeding, the burden of LMWH injections, and adverse skin reactions.","Secondary safety endpoints incidence clinically relevant non-major bleeding minor bleeding, burden LMWH injections, adverse skin reactions.",C0027627|C0036043|C2349179|C0021149|G0000000|C2347946|C1518422|C0019080|C0026193|C0019080|C2828008|C0019139|C0021485|G0000000|C0444099|C0443286
"Primary outcome measures were changes in self-reported QOL, fatigue, and weight from baseline to 6 months.","Primary outcome measures self-reported QOL, fatigue, weight baseline 6 months.",C0205225|C1274040|C0079809|C0681906|C0518214|C0015672|C0005910|C0168634|G0000000|C0439231
PARTICIPANTS: Eighty-seven men and women with major depression and an initial score of > or = 16 on the Hamilton Rating Scale for Depression (Ham-D).,PARTICIPANTS: Eighty-seven women major depression initial score > = 16 Hamilton Rating Scale Depression (Ham-D).,C0679646|C3816958|C0043210|C0205082|C0011570|C0205265|C0449820|G0000000|G0000000|C0450371|G0000000|C0871208|C0175659|C0011570|C1570167
"Primary outcome measures are gestational weight gain, fasting glucose and insulin sensitivity, with a range of obstetric secondary outcome measures including birth weight.","Primary outcome measures gestational weight gain, fasting glucose insulin sensitivity, range obstetric secondary outcome measures including birth weight.",C0205225|C1274040|C0079809|C0439671|C0005910|C1517378|C0015663|C0017725|C0021641|C0020517|C1514721|C0205484|C0027627|C1274040|C0079809|C0332257|C0005615|C0005910
"The baseline evaluation included a chemistry panel; intact PTH; 25-hydroxyvitamin D; bone-specific alkaline phosphatase (BSAP), a marker of bone formation; and serum C-telopeptide of type I collagen (CTX), a marker of bone resorption.","The baseline evaluation included chemistry panel; intact PTH; 25-hydroxyvitamin D; bone-specific alkaline phosphatase (BSAP), marker bone formation; serum C-telopeptide type I collagen (CTX), marker bone resorption.",G0000000|C0168634|C0220825|C0332257|C0007996|C0441833|C0205266|G0000000|C0450371|C0073187|C0262950|C1979842|C0031678|C0312399|C0005516|C0262950|C0220781|C0229671|C0631180|C0332307|C0021966|C0009325|C0631180|C0005516|C0262950|C2985494
"Secondary outcomes include body image, marital functioning, psychological distress, menopausal symptoms, and health-related quality of life.","Secondary outcomes body image, marital functioning, psychological distress, menopausal symptoms, health-related quality life.",C0027627|C1274040|C0242821|C1704254|C0024841|C0205245|C0205486|C0231303|C0025320|C0683368|C0018684|C0332306|C0376558
"The 4 groups showed similar improvements in weeks 5 to 8; however, there was a significant reduction of migraine days during weeks 13–16 [9].","The 4 improvements weeks 5 8; however, reduction migraine days weeks 13–16 [9].",G0000000|G0000000|C2986411|C0439230|G0000000|G0000000|G0000000|C0301630|C0149931|C0439228|C0439230|G0000000|G0000000
Serious TEAEs were to be reported immediately (n = 0).,Serious TEAEs reported (n = 0).,C0205404|G0000000|C0684224|C0369718|G0000000|G0000000
"We will assess recovery rate as a primary outcome and coverage, defaulting, death, length of stay, average weekly weight gain and average weekly mid-upper arm circumference (MUAC) gain as secondary outcomes.","We assess recovery rate primary outcome coverage, defaulting, death, length stay, average weekly weight gain average weekly mid-upper arm circumference (MUAC) gain secondary outcomes.",G0000000|C1516048|C0237820|C0871208|C0205225|C1274040|C1551362|C2828024|C0011065|C1444754|G0000000|C1510992|C0332174|C0005910|C1517378|C1510992|C0332174|C0444598|C0446516|C0332520|G0000000|C1517378|C0027627|C1274040
Stool consistency and white and red blood cell count in stool were also assessed.,Stool consistency white red blood cell count stool assessed.,C0015733|C0332529|C0007457|C0332575|C0005767|C0007634|C0750480|C0015733|C1516048
"Outcomes included the number and severity of VMS, MENQOL questionnaire, Beck Depression Inventory, Spielberg State-Trait Anxiety Instrument, Pittsburgh Quality Sleep Index, 24 hour urine cortisol and metabolites, and ACTH stimulation testing.","Outcomes included severity VMS, MENQOL questionnaire, Beck Depression Inventory, Spielberg State-Trait Anxiety Instrument, Pittsburgh Quality Sleep Index, 24 hour urine cortisol metabolites, ACTH stimulation testing.",C1274040|C0332257|C0439793|G0000000|G0000000|C0034394|G0000000|C0011570|C0021941|G0000000|C1301808|C0003467|C0348000|G0000000|C0332306|C0037313|C0918012|C0450371|C0439227|C0042036|C0020268|C0870883|C3539087|C1292856|C0039593
"The IA visits included administration of: 1) the Montgomery-Asberg Depression Rating Scale (MADRS), and 2) a rating of global distress and impairment for depression and substance abuse using the Clinical Global Impression (CGI) for severity (e.g., 1 = not ill to 7 = extremely ill) (Montgomery & Asberg, 1979; National Institute of Mental Health, 1985).","The IA visits included administration of: 1) Montgomery-Asberg Depression Rating Scale (MADRS), 2) rating global distress impairment depression substance abuse Clinical Global Impression (CGI) severity (e.g., 1 = ill 7 = extremely ill) (Montgomery & Asberg, 1979; National Institute Mental Health, 1985).",G0000000|C0694634|C0545082|C0332257|C0001554|G0000000|G0000000|G0000000|C0011570|C0871208|C0175659|C4054475|G0000000|C0871208|C0205246|C0231303|C0221099|C0011570|C0439861|C0013146|C0205210|C0205246|C0596764|C3639708|C0439793|G0000000|G0000000|G0000000|C0231218|G0000000|G0000000|C0205403|C0231218|G0000000|G0000000|G0000000|G0000000|C3245503|C0021622|C0229992|C0018684|G0000000
Clinical improvement was defined as a decrease in CAI by at least 1 point from baseline to the individual study end.,Clinical improvement defined decrease CAI 1 baseline individual study end.,C0205210|C2986411|C1704788|C0392756|C0064494|G0000000|C0168634|C0027361|C0557651|C0444930
Uptake and adherence to smoking cessation will be monitored by weekly carbon monoxide exhalation measurements (breath test).,Uptake adherence smoking cessation monitored weekly carbon monoxide exhalation measurements (breath test).,C0243144|C1510802|C0037369|C1880019|C0030695|C0332174|C0007009|G0000000|C0231800|C0242485|C0225386|C0022885
"The primary outcome measures were tuberculosis disease and death in HIV-infected children and latent tuberculosis infection, tuberculosis disease, and death in HIV-uninfected children within 96 to 108 weeks after randomization.","The primary outcome measures tuberculosis disease death HIV-infected children latent tuberculosis infection, tuberculosis disease, death HIV-uninfected children 96 108 weeks randomization.",G0000000|C0205225|C1274040|C0079809|C0041296|C0012634|C0011065|C0019682|C0008059|C0205275|C0041296|C0009450|C0041296|C0012634|C0011065|C0019682|C0008059|C0450371|C1442061|C0439230|C0034656
"A quarter to a half of people over 85 years have frailty and are at significantly increased risk of falls, disability, care home admission and death (2, 3).","A quarter half people 85 frailty increased risk falls, disability, care admission death (2, 3).",G0000000|C2825406|C2825407|C0027361|C0450371|C0424594|C0205217|C0035647|C0000921|C0231170|C1947933|C0184666|C0011065|G0000000|G0000000
The primary efficacy endpoint was the proportion of patients achieving a reduction of at least 4 units in the SGRQ total score at study end (Month 9).,The primary efficacy endpoint proportion patients achieving reduction 4 units SGRQ total score study (Month 9).,G0000000|C0205225|C1280519|C2349179|C1709707|C0030705|G0000000|C0301630|G0000000|C0439148|G0000000|C0439175|C0449820|C0557651|C0332177|G0000000
"In the last quarter of the 12 month follow-up, 71 children were seizure free after one year's treatment.","In quarter 12 month follow-up, 71 children seizure free year's treatment.",G0000000|C2825406|C0450371|C0332177|C0589120|C0450371|C0008059|C0036572|C0332296|C0439234|C0039798
The primary outcome for the cost-effectiveness component of the study will be EQ-5D [27].,The primary outcome cost-effectiveness component study EQ-5D [27].,G0000000|C0205225|C1274040|C0010181|C0449432|C0557651|C0205163|C0450371
"Amongst those receiving No MAC and No HH Counseling, 8 Weeks of Medication with No Maintenance Counseling resulted in the lowest abstinence rates (15%); 8 Weeks of Medication with Maintenance Counseling, or 26 Weeks of Medication with No Maintenance Counseling, resulted in intermediate quit rates (31% and 32% respectively), and 26 Weeks of Medication with Maintenance Counseling resulted in the highest quit rates (44% at Week 52).","Amongst receiving No MAC No HH Counseling, 8 Weeks Medication No Maintenance Counseling lowest abstinence rates (15%); 8 Weeks Medication Maintenance Counseling, 26 Weeks Medication No Maintenance Counseling, intermediate quit rates (31% 32% respectively), 26 Weeks Medication Maintenance Counseling quit rates (44% Week 52).",G0000000|C1514756|G0000000|C3538559|G0000000|C0062941|C0010210|G0000000|C0439230|C0013227|G0000000|C0024501|C0010210|C1708760|C3843422|C0871208|C0450371|G0000000|C0439230|C0013227|C0024501|C0010210|C0450371|C0439230|C0013227|G0000000|C0024501|C0010210|C0205103|C0748223|C0871208|C0450371|C0450371|G0000000|C0450371|C0439230|C0013227|C0024501|C0010210|C0748223|C0871208|C0450371|C0332174|C0450371
Adverse events were slightly more common in the budesonide pMDI group – although this was not thought to be clinically relevant – and the majority of patients who reported aggravated asthma as an adverse event were in this treatment group.,Adverse events common budesonide pMDI – clinically relevant – majority patients reported aggravated asthma adverse event treatment group.,G0000000|C0441471|C0205214|C0054201|G0000000|G0000000|G0000000|C2347946|G0000000|C0680220|C0030705|C0684224|C0436331|C0004096|G0000000|C0441471|C0039798|C0441833
The main objective of this study was to assess the impact of a nutrition education (NE) programme aimed at promoting improved IYCF behaviours in combination with an agriculture intervention on children’s dietary diversity and nutritional status.,The main objective study assess impact nutrition education (NE) programme aimed promoting improved IYCF behaviours combination agriculture intervention children’s dietary diversity nutritional status.,G0000000|C0205225|C0018017|C0557651|C1516048|C1825598|C0028707|C0013621|C0028219|C1709697|C1947946|C0033414|C0184511|G0000000|C0004927|C0205195|C0001829|C0886296|G0000000|C0012155|C1880371|C1521739|C0449438
"For the sanitation intervention, enumerators asked if respondents believed that contact with feces posed a threat to their health and what the respondent had done, if anything, to dispose of the most recent child defecation.","For sanitation intervention, enumerators respondents believed contact feces posed threat health respondent done, anything, dispose child defecation.",G0000000|C0036172|C0886296|G0000000|C0282122|G0000000|C0332158|C0015733|G0000000|C0749385|C0018684|C0282122|G0000000|G0000000|C1707797|C0008059|C0011135
Average duration to return to daily activities was 16 days for Group 1 patients whereas the delay in return to normal activities was longer in Group 2 patients (average 20 days).,Average duration return daily activities 16 days Group 1 patients delay return normal activities Group 2 patients (average 20 days).,C1510992|C0449238|C0332156|C0332173|C0441655|C0450371|C0439228|C0441833|G0000000|C0030705|C0205421|C0332156|C0205307|C0441655|C0441833|G0000000|C0030705|C1510992|C0450371|C0439228
Active larviciding and ITN use were treated as categorical independent variables in the model evaluating the impact of these control measures on adult mosquito density and human parasitaemia.,Active larviciding ITN treated categorical independent variables model evaluating impact control measures adult mosquito density human parasitaemia.,C0205177|G0000000|G0000000|C1522326|C0683312|C0085862|C0439828|C3161035|C0220825|C1825598|C0243148|C0079809|C0001675|C0026584|C0178587|C0086418|C0242723
"Child QOL was measured by the Diabetes Quality of Life Scale which has 3 subscales to assess youth perceptions of the impact of T1D management (21 items), their general satisfaction with life (18 items), and worries related to T1D (8 items).","Child QOL measured Diabetes Quality Life Scale 3 subscales assess youth perceptions impact T1D management (21 items), satisfaction life (18 items), worries T1D (8 items).",C0008059|C0518214|C0444706|C0011847|C0332306|C0376558|C0175659|G0000000|G0000000|C1516048|C0001578|C0030971|C1825598|G0000000|C0001554|C0450371|C1551338|C0242428|C0376558|C0450371|C1551338|C0233481|G0000000|G0000000|C1551338
Mean change from baseline in VAS pain scores (LOCF).,Mean change baseline VAS pain scores (LOCF).,C0444504|C0392747|C0168634|C0042815|C0030193|C0449820|C2825507
Both nominated supervisors and room leaders were asked to report on their service’s implementation of the seven healthy eating and physical activity policies and practices using items validated in a previous sample of 42 Australian childcare services [51].,Both nominated supervisors leaders report service’s implementation healthy eating physical activity policies practices items validated previous sample 42 Australian childcare services [51].,G0000000|G0000000|C0403172|G0000000|C0684224|G0000000|C1708476|C3898900|C0013470|C0031809|C0205177|C0242456|C0237607|C1551338|G0000000|C0205156|C0370003|C0450371|C0238711|C0008067|C0557854|C0450371
Results are reported as mean±SD.,Results reported mean±SD.,C1274040|C0684224|G0000000
"Panel G shows the incidence of acute graft-versus-host disease (GVHD) of grades II to IV, and Panel H the incidence of chronic GVHD.","Panel G incidence acute graft-versus-host disease (GVHD) grades II IV, Panel H incidence chronic GVHD.",C0441833|C0439267|C0021149|C0205178|C0181074|C0012634|G0000000|C0441800|G0000000|C0022326|C0441833|C0033727|C0021149|C0205191|G0000000
These included: (A) stool consistency ≥5 and stool frequency ≥2/day for more than 2 days; (B) stool consistency ≥5 and stool frequency ≥3/day for more than 2 days; (C) stool consistency ≥6 and stool frequency ≥2/day for more than 2 days; and (D) stool consistency ≥6 and stool frequency ≥3/day for more than 2 days.,These included: (A) stool consistency ≥5 stool frequency ≥2/day 2 days; (B) stool consistency ≥5 stool frequency ≥3/day 2 days; (C) stool consistency ≥6 stool frequency ≥2/day 2 days; (D) stool consistency ≥6 stool frequency ≥3/day 2 days.,G0000000|C0332257|G0000000|C0015733|C0332529|G0000000|C0015733|C0376249|G0000000|G0000000|G0000000|C0015733|C0332529|G0000000|C0015733|C0376249|G0000000|G0000000|G0000000|C0015733|C0332529|G0000000|C0015733|C0376249|G0000000|G0000000|C0073187|C0015733|C0332529|G0000000|C0015733|C0376249|G0000000|G0000000
Normalization of liver enzymes occurred in 44% of patients who had elevated pretreatment ALT levels.,Normalization liver enzymes occurred 44% patients elevated pretreatment ALT levels.,C1882115|C0023884|C0014442|C1709305|C0450371|C0030705|C0205250|C1550147|C1266129|C0441889
"The primary end point of this study was progression-free survival (PFS) rate at 6 months, and secondary end-points were PFS, toxicity, response rate (RR), and overall survival (OS).","The primary study progression-free survival (PFS) rate 6 months, secondary end-points PFS, toxicity, response rate (RR), survival (OS).",G0000000|C0205225|C0557651|C0242656|C0038952|C0242792|C0871208|G0000000|C0439231|C0027627|C2349179|C0242792|C0040539|C0871261|C0871208|G0000000|C0038952|C0229090
"The primary measurement tools were the City of Hope (COH) Quality of Life (QOL) Instruments for Patients or Caregivers31 and the Social Problem Solving Inventory-Revised.32,33 Patients and caregivers completed baseline psychometric evaluation and demographic information.","The primary measurement tools City Hope (COH) Quality Life (QOL) Instruments Patients Caregivers31 Social Problem Solving Inventory-Revised.32,33 Patients caregivers completed baseline psychometric evaluation demographic information.",G0000000|C0205225|C0242485|C0336791|C0008848|C0392347|C0265223|C0332306|C0376558|C0518214|C0348000|C0030705|G0000000|C0728831|C0033213|G0000000|C0021941|C0030705|C0085537|C0205197|C0168634|C0033920|C0220825|C0011298|C1533716
Caregiver recruitment (only one caregiver per patient) had to be completed at least during baseline assessment (T1) at the participant’s home.,Caregiver recruitment (only caregiver patient) completed baseline assessment (T1) participant’s home.,C0085537|C2949735|C0205171|C0085537|C0030705|C0205197|C0168634|C1261322|C0041403|G0000000|C0442519
Mean change in sputum myeloperoxidase (MPO) over 16 weeks by treatment group.,Mean change sputum myeloperoxidase (MPO) 16 weeks treatment group.,C0444504|C0392747|C0038056|C0027021|G0000000|C0450371|C0439230|C0039798|C0441833
(i) Children’s Hand-Use Experience Questionnaire (CHEQ) The CHEQ is a Rasch analysed questionnaire for children and youth (6 to 18 years) that examines their experience of using their impaired hand during bimanual activities [86].,(i) Children’s Hand-Use Experience Questionnaire (CHEQ) The CHEQ Rasch analysed questionnaire children youth (6 18 years) examines experience impaired hand bimanual activities [86].,C0021966|G0000000|C0018563|C0237607|C0034394|G0000000|G0000000|G0000000|G0000000|G0000000|C0034394|C0008059|C0001578|G0000000|C0450371|C0439234|G0000000|C0237607|C0221099|C0018563|C1511117|C0441655|C0450371
"The outcome measures were sociodemographic data, quality of life (Fibromyalgia Impact Questionnaire), pain (McGill-Melzack questionnaire; and Visual Analogue Scale), pressure algometry (Wagner FPI10 algometer) and depression (Beck Inventory).","The outcome measures sociodemographic data, quality life (Fibromyalgia Impact Questionnaire), pain (McGill-Melzack questionnaire; Visual Analogue Scale), pressure algometry (Wagner FPI10 algometer) depression (Beck Inventory).",G0000000|C1274040|C0079809|G0000000|C1511726|C0332306|C0376558|C0016053|C1825598|C0034394|C0030193|G0000000|C0034394|C0234621|C0243071|C0175659|C0033095|G0000000|G0000000|G0000000|G0000000|C0011570|G0000000|C0021941
Table 2 shows the 1-year change from baseline serum creatinine concentration for all three groups.,Table 2 1-year change baseline serum creatinine concentration groups.,C0039224|G0000000|C0439234|C0392747|C0168634|C0229671|C0010294|C0004268|C0441833
"We defined point prevalence abstinence as a self report of not having smoked at all for the past week and an expired carbon monoxide reading <10 ppm or, for the 12 month outcome, a salivary cotinine concentration <20 ng/ml.","We defined prevalence abstinence report smoked week expired carbon monoxide reading <10 ppm or, 12 month outcome, salivary cotinine concentration <20 ng/ml.",G0000000|C1704788|C0033105|C3843422|C0684224|C0037366|C0332174|C0011065|C0007009|G0000000|C0034754|C0450371|C0439187|G0000000|C0450371|C0332177|C1274040|C0442040|C0010194|C0004268|C0450371|C0439275
"A culturally-adapted, lay-led self-management education programme improves self-efficacy, self-care behaviour and health status in Bangladeshis with chronic disease.","A culturally-adapted, lay-led self-management education programme improves self-efficacy, self-care behaviour health status Bangladeshis chronic disease.",G0000000|C0010453|C1708698|C0086969|C0013621|C1709697|C0184511|C0600564|C0036592|C0004927|C0018684|C0449438|C0422784|C0205191|C0012634
Table 5 shows the dietary profile of participants at the start of the study according to randomized treatment arm.,Table 5 dietary profile participants start study randomized treatment arm.,C0039224|G0000000|C0012155|C1979963|C0679646|C0439659|C0557651|C0034656|C0039798|C0446516
"AP, attention-placebo; CBT, cognitive behaviour therapy; ES, effect size; FIQ, Fibromyalgia Impact Questionnaire, MPI, Multidimensional Pain Inventory; OBT, operant behavior therapy; PRSS, Pain Related Self-Statements Scale.","AP, attention-placebo; CBT, cognitive behaviour therapy; ES, size; FIQ, Fibromyalgia Impact Questionnaire, MPI, Multidimensional Pain Inventory; OBT, operant behavior therapy; PRSS, Pain Related Self-Statements Scale.",C3887950|C0004268|C0009244|C1516691|C0004927|C0039798|C0013754|C0456389|G0000000|C0016053|C1825598|C0034394|C0663932|C2347299|C0030193|C0021941|G0000000|G0000000|C0004927|C0039798|C1415382|C0030193|C0439849|C0036588|C0175659
"There was again no association between malaria incidence and Vgsc-1014F frequency (P = 0.59), between infection prevalence and Vgsc-1014F frequency (P = 0.39), between malaria incidence and bioassay survivorship (P = 0.85), and between infection prevalence and bioassay survivorship (P = 0.98).","There association malaria incidence Vgsc-1014F frequency (P = 0.59), infection prevalence Vgsc-1014F frequency (P = 0.39), malaria incidence bioassay survivorship (P = 0.85), infection prevalence bioassay survivorship (P = 0.98).",G0000000|C0004083|C0024530|C0021149|G0000000|C0376249|C0369773|G0000000|C0450371|C0009450|C0033105|G0000000|C0376249|C0369773|G0000000|C0450371|C0024530|C0021149|C0005507|C0038952|C0369773|G0000000|C0450371|C0009450|C0033105|C0005507|C0038952|C0369773|G0000000|C0450371
"Secondary outcome measures include: (1) adherence to the asthma action plan, (2) rate of planned and unplanned visits to healthcare providers for asthma issues, (3) usage patterns of Healthy.me and attrition rates, (4) asthma control and asthma exacerbation scores, and (5) impact of asthma on life and competing demands, and days lost from work.","Secondary outcome measures include: (1) adherence asthma action plan, (2) rate planned unplanned visits healthcare providers asthma issues, (3) usage patterns Healthy.me attrition rates, (4) asthma control asthma exacerbation scores, (5) impact asthma life competing demands, days lost work.",C0027627|C1274040|C0079809|C0332257|G0000000|C1510802|C0004096|C0441472|C0270724|G0000000|C0871208|C1301732|G0000000|C0545082|C0086388|C1138603|C0004096|C0033213|G0000000|C0457083|C0449774|C3898900|C0004277|C0871208|G0000000|C0004096|C0243148|C0004096|G0000000|C0449820|G0000000|C1825598|C0004096|C0376558|G0000000|C0441516|C0439228|C0745777|C0043227
Patients completed the St George’s Respiratory Questionnaire (SGRQ) at baseline and weeks 12 and 26 to evaluate changes in health status.,Patients completed St George’s Respiratory Questionnaire (SGRQ) baseline weeks 12 26 evaluate health status.,C0030705|C0205197|C0036056|G0000000|C0521346|C0034394|G0000000|C0168634|C0439230|C0450371|C0450371|C0220825|C0018684|C0449438
Comparisons between self reported cessation rates and those obtained under bogus pipeline conditions or with biochemical verification suggested significant falsification of cessation among participants.,Comparisons reported cessation rates bogus pipeline conditions biochemical verification suggested falsification cessation participants.,C1707455|C0684224|C1880019|C0871208|G0000000|G0000000|C0012634|C0205474|C0237944|C1705535|C0233524|C1880019|C0679646
"Relapse was defined as recurrent tumor detected on imaging and a serial elevation in the serum alpha-fetoprotein level (⩾3 consecutive rising values at a minimum of weekly intervals) or as recurrent tumor detected on imaging, with a normal serum alpha-fetoprotein level, and histologically confirmed on biopsy.","Relapse defined recurrent tumor detected imaging serial elevation serum alpha-fetoprotein level (⩾3 consecutive rising values minimum weekly intervals) recurrent tumor detected imaging, normal serum alpha-fetoprotein level, histologically confirmed biopsy.",C0035020|C1704788|C2945760|C0027651|C0442726|C0011923|C0031082|C0439775|C0229671|C0002210|C0441889|G0000000|C1707491|G0000000|C0042295|C1524031|C0332174|C1272706|C2945760|C0027651|C0442726|C0011923|C0205307|C0229671|C0002210|C0441889|C0205462|C0521093|C0005558
"Secondary end points included measures of treatment success; length of hospital stay; clinical, laboratory and spirometry outcomes at discharge; and results of spirometry at the 12-month follow-up examination, as well as the results of the Asthma Control Test (ACT) [19], the results of the Asthma Quality of Life Questionnaire (AQLQ) [20] at the 12-month follow-up visit and the clinical events during the 12-month follow-up period, including numbers of asthma exacerbations, ED visits, hospitalizations and need for systemic corticosteroid use for treatment of asthma.","Secondary included measures treatment success; length hospital stay; clinical, laboratory spirometry outcomes discharge; spirometry 12-month follow-up examination, Asthma Control Test (ACT) [19], Asthma Quality Life Questionnaire (AQLQ) [20] 12-month follow-up visit clinical events 12-month follow-up period, including asthma exacerbations, ED visits, hospitalizations systemic corticosteroid treatment asthma.",C0027627|C0332257|C0079809|C0039798|C0597535|C1444754|C0019994|G0000000|C0205210|C0022877|C0037981|C1274040|C0012621|C0037981|C0450371|C0589120|G0000000|C0004096|C0243148|C0022885|C0079613|C0450371|C0004096|C0332306|C0376558|C0034394|C4055434|C0450371|C0450371|C0589120|C0545082|C0205210|C0441471|C0450371|C0589120|C0439531|C0332257|C0004096|G0000000|C3538926|C0545082|C0019993|C0205373|C0001617|C0039798|C0004096
Changes in total staphylococci and Staphylococcus aureus skin counts were also assessed.,Changes total staphylococci Staphylococcus aureus skin counts assessed.,C0392747|C0439175|C0038170|C0038170|G0000000|C0444099|C0439157|C1516048
Sleep latency and efficiency were measured objectively using the same accelerometer used for measuring physical activity by transferring to the wrist when in bed.,Sleep latency efficiency measured objectively accelerometer measuring physical activity transferring wrist bed.,C0037313|C0205275|C0013682|C0444706|G0000000|C0178951|C0444706|C0031809|C0205177|C1540850|C0043262|C0004916
"Other secondary outcomes (e.g., CGI-C, UPDRS, ESS at 100 mg twice daily) are classified as Class II level of evidence.","Other secondary outcomes (e.g., CGI-C, UPDRS, ESS 100 daily) classified Class II level evidence.",G0000000|C0027627|C1274040|G0000000|C3639708|C3639721|C0206630|C1442061|C0332173|C0008902|C0456387|G0000000|C0441889|C3887511
Fifty of these completed a second such questionnaire at three months.,Fifty completed questionnaire months.,C3816723|C0205197|C0034394|C0439231
Percent change of lipid and apolipoprotein after treatment for 6 weeks.,Percent change lipid apolipoprotein treatment 6 weeks.,C0439165|C0392747|C0023779|C0003591|C0039798|G0000000|C0439230
"For assessing intervention effects, the primary outcomes are maternal weight gain, fasting glucose levels and insulin sensitivity.","For assessing intervention effects, primary outcomes maternal weight gain, fasting glucose levels insulin sensitivity.",G0000000|C1516048|C0886296|C1280500|C0205225|C1274040|C2347083|C0005910|C1517378|C0015663|C0017725|C0441889|C0021641|C0020517
The primary end point will be the occurrence of disease relapse or need of steroids or CNI to maintain complete remission within 12 months of randomisation.,The primary occurrence disease relapse steroids CNI maintain complete remission 12 months randomisation.,G0000000|C0205225|C0243132|C0012634|C0035020|C0038317|C1425101|C0024501|C0205197|C0544452|G0000000|C0034656
"For the oral hygiene index, significant differences were found at 1, 2, and 6 weeks.","For oral hygiene index, differences 1, 2, 6 weeks.",G0000000|C0442027|C0020405|C0918012|C1705241|G0000000|G0000000|G0000000|C0439230
"In conclusion, study results indicate that among patients suffering from chronic pain MORE reduces pain severity and functional interference for up to 3 months following treatment, and decreases sympathetic stress arousal, desire for opioids, and disordered opioid use at the end of treatment.","In conclusion, study patients suffering chronic pain MORE reduces pain severity functional interference 3 months treatment, decreases sympathetic stress arousal, desire opioids, disordered opioid treatment.",G0000000|C1707478|C0557651|C0030705|C0683278|C0205191|C0030193|C0205172|G0000000|C0030193|C0439793|C0205245|C0521102|G0000000|C0439231|C0039798|C0442797|G0000000|C0038435|C0003808|C0871633|C0242402|C0012634|C0242402|C0039798
Direct hand-to-hand contact is an important mechanism of transmission of rhinovirus infection.,Direct hand-to-hand contact mechanism transmission rhinovirus infection.,C0439851|C0018563|C0332158|C0441712|C0040722|C0035473|C0009450
These patients' data were eliminated from analyses of treatment gains.,These patients' data eliminated analyses treatment gains.,G0000000|C0030705|C1511726|C0849355|C0002778|C0039798|C1517378
"MAIN OUTCOME MEASURES—The perceptions of customers and pharmacy personnel of the pharmacy support and self-reported smoking cessation rates for the two groups of customers at one, four, and nine months.","MAIN OUTCOME MEASURES—The perceptions customers pharmacy personnel pharmacy support self-reported smoking cessation rates customers one, four, months.",C0205225|C1274040|G0000000|C0030971|C2981734|C0031321|C0024752|C0031321|C0183683|C0681906|C0037369|C1880019|C0871208|C2981734|C0205447|C0205450|C0439231
"Secondary outcomes included asthma severity scores at pre‐specified times after randomization, need for revisit, readmission to infirmary care, and admission to pediatric ICU within 2 wk after discharge.","Secondary outcomes included asthma severity scores pre‐specified times randomization, revisit, readmission infirmary care, admission pediatric ICU 2 wk discharge.",C0027627|C1274040|C0332257|C0004096|C0439793|C0449820|G0000000|C0040223|C0034656|G0000000|C1548168|C0221502|C1947933|C0184666|C0030755|C0021708|G0000000|C0332174|C0012621
"Apart from EORTC QLQ-C30's fatigue symptom scale, we also used the 15-item Cancer Fatigue Scale (CFS-D) [26].","Apart EORTC QLQ-C30's fatigue symptom scale, 15-item Cancer Fatigue Scale (CFS-D) [26].",G0000000|C1516985|G0000000|C0015672|C1457887|C0175659|C0450371|C0006826|C0015672|C0175659|C0015674|C0450371
No other signs improved the sensitivity without compromising specificity.,No signs improved sensitivity compromising specificity.,G0000000|C0220912|C0184511|C0020517|C2945640|C0037791
Continued smoking abstinence was assessed at 8 and 26 weeks postpartum.,Continued smoking abstinence assessed 8 26 weeks postpartum.,C0549178|C0037369|C3843422|C1516048|G0000000|C0450371|C0439230|C0086839
"The primary outcome was total sleep time (TST) and secondary measures included wake after sleep onset (WASO), number of awakenings and quality of sleep, among others.","The primary outcome total sleep time (TST) secondary measures included wake sleep onset (WASO), awakenings quality sleep, others.",G0000000|C0205225|C1274040|C0439175|C0037313|C0040223|C1421210|C0027627|C0079809|C0332257|C0442696|C0037313|C0206132|G0000000|C1720052|C0332306|C0037313|C1955473
"All patients were monitored before and after nebulization (each 20 minutes) for peak expiratory flow rate (PEFR), respiratory rate (RR), heart rate (HR), blood pressure, pulsus paradoxus, oxygen saturation, clinical examination, and Fischl index.","All patients monitored nebulization (each 20 minutes) peak expiratory flow rate (PEFR), respiratory rate (RR), heart rate (HR), blood pressure, pulsus paradoxus, oxygen saturation, clinical examination, Fischl index.",G0000000|C0030705|C0030695|C1659427|G0000000|C0450371|C0439232|C0444505|C0231800|C0806140|C0871208|C0030735|C0521346|C0871208|G0000000|C0018787|C0871208|G0000000|C0005767|C0033095|C0034107|G0000000|C0030054|C0522534|C0205210|G0000000|G0000000|C0918012
"Validity testing demonstrated generally good agreement between self-report and observation for foods and beverages served and nutrition policy (with correlations of 0.25–0.85), but lower agreement with teacher practices (correlations of 0.004–0.46) [35].","Validity testing demonstrated agreement self-report observation foods beverages served nutrition policy (with correlations 0.25–0.85), lower agreement teacher practices (correlations 0.004–0.46) [35].",C2349101|C0039593|G0000000|C0680240|C0681906|C0302523|C0016452|C0005329|G0000000|C0028707|C0242456|G0000000|C1707520|G0000000|C0441994|C0680240|C0221457|C0237607|C1707520|G0000000|C0450371
None of the patients developed NEC and ROP during the study period.,None patients developed NEC ROP study period.,G0000000|C0030705|G0000000|C0206695|C0035344|C0557651|C0439531
We defined global QoL at week 9 as the primary HRQoL-endpoint.,We defined global QoL week 9 primary HRQoL-endpoint.,G0000000|C1704788|C0205246|C0518214|C0332174|G0000000|C0205225|C2349179
"The primary outcome measure was microbiological response, change in P. aeruginosa sputum density, calculated as log10 of end-of-treatment density minus log10 of screening density, in CFU/g.","The primary outcome measure microbiological response, change P. aeruginosa sputum density, calculated log10 end-of-treatment density minus log10 screening density, CFU/g.",G0000000|C0205225|C1274040|C0079809|C0025953|C0871261|C0392747|C0369773|G0000000|C0038056|C0178587|C0444686|G0000000|C0444930|C0178587|C0332288|G0000000|C0220908|C0178587|C0314587
"Manual muscle tests (MMT), Manual Function Tests (MFT), Brunnstrom stage, and the Korean version of Modified Barthel Index (K-MBI) were used to measure the strength and function of upper extremity.","Manual muscle tests (MMT), Manual Function Tests (MFT), Brunnstrom stage, Korean version Modified Barthel Index (K-MBI) measure strength function upper extremity.",C0024763|C0026845|C0022885|C0046370|C0024763|C0031843|C0022885|C1822742|G0000000|C0205390|C1556095|C0333052|C0392747|G0000000|C0918012|C0597277|C0079809|C0237897|C0031843|C1282910|C0015385
The primary outcome measurements focus on infant immune development.,The primary outcome measurements focus infant immune development.,G0000000|C0205225|C1274040|C0242485|C0205234|C0021270|C0439662|C0243107
The parity rate of morphologically identified An.,The parity rate morphologically identified An.,G0000000|C0030563|C0871208|G0000000|C0205396|G0000000
"As shown, the survival distributions for the two arms were not significantly different [p=0.67 for 1-year overall survival; 88.5% vs. 81.2%, p=0.37 for 1-year relapse-free survival].The medication was well tolerated by all patients.","As shown, survival distributions arms [p=0.67 1-year survival; 88.5% vs. 81.2%, p=0.37 1-year relapse-free survival].The medication tolerated patients.",G0000000|C1547282|C0038952|C0037775|C0206655|C0369773|C0439234|C0038952|C0450371|G0000000|C0450371|C0369773|C0439234|C0035020|C0038952|C0013227|G0000000|C0030705
"Additionally, there was no correlation (longitudinally) between changes in drinking and changes in cannabis use over time, based on days of heavy drinking per week and days of cannabis use per week.","Additionally, correlation (longitudinally) drinking cannabis time, based days heavy drinking week days cannabis week.",G0000000|C1707520|G0000000|C0001948|C0024808|C0040223|C1527178|C0439228|C0439539|C0001948|C0332174|C0439228|C0024808|C0332174
Potential confounders were evaluated by assessing their associations with both dietary variables and adenoma recurrence.,Potential confounders evaluated assessing associations dietary variables adenoma recurrence.,C3245505|G0000000|C0220825|C1516048|C0004083|C0012155|C0439828|C0001430|C0034897
"The main outcome measures were duration of inpatient stay and croup scores at 30 minutes, one, two, four, 12, and 24hours.","The main outcome measures duration inpatient stay croup scores 30 minutes, one, two, four, 12, 24hours.",G0000000|C0205225|C1274040|C0079809|C0449238|C0021562|G0000000|C0010380|C0449820|C0450371|C0439232|C0205447|C0205448|C0205450|C0450371|G0000000
None of the subject attained complete healing with povidone iodine in 6 weeks.,None subject attained complete healing povidone iodine 6 weeks.,G0000000|C0681850|G0000000|C0205197|C0043240|C0032856|C0021966|G0000000|C0439230
The primary outcome was the comparison between study groups of the mean difference in serum potassium levels between the day after the last dose of treatment (day 7) and baseline (day 0).,The primary outcome comparison study difference serum potassium levels day dose treatment (day 7) baseline (day 0).,G0000000|C0205225|C1274040|C1707455|C0557651|C1705241|C0229671|C0032821|C0441889|C0332173|C0178602|C0039798|C0332173|G0000000|C0168634|C0332173|G0000000
"After exclusion of those with missing responses or with a prior history of cancer, 14 409 subjects in Cohort 1 and 20 595 in Cohort 2 remained.","After exclusion missing responses prior history cancer, 14 409 subjects Cohort 1 20 595 Cohort 2 remained.",G0000000|C0680251|C1551393|C0871261|C0332152|C0019664|C0006826|G0000000|C0681850|C0599755|G0000000|G0000000|C0599755|G0000000|G0000000
Physicians in both groups will also undergo assessment on adherence to BP management protocols (Fig.,Physicians undergo assessment adherence BP management protocols (Fig.,C0031831|G0000000|C1261322|C1510802|C0037623|C0001554|C0442711|C0349966
Patients in both groups were assessed at home eight weeks after the initial assessment.,Patients assessed weeks initial assessment.,C0030705|C1516048|C0439230|C0205265|C1261322
"SAEs, medically significant adverse events, pIMDs and pregnancy were reported throughout the study.","SAEs, medically adverse events, pIMDs pregnancy reported study.",C1519255|G0000000|G0000000|C0441471|G0000000|C0032961|C0684224|C0557651
Secondary outcomes were changes in other immune cell subtypes (outlined below).,Secondary outcomes immune cell subtypes (outlined below).,C0027627|C1274040|C0439662|C0007634|C0449560|G0000000|G0000000
"adult patients diagnosed with an incurable, metastatic cancer [ICD 10 C 1–80 plus ICD 10 C 78–79]) are referred to a PC physician at their center at least once within eight weeks of the initial diagnosis.","adult patients diagnosed incurable, metastatic cancer [ICD 10 C 1–80 ICD 10 C 78–79]) referred PC physician center weeks initial diagnosis.",C0001675|C0030705|C0011900|G0000000|C0036525|C0006826|C0021122|C0450371|G0000000|G0000000|C0021122|C0450371|G0000000|G0000000|C0205543|C0031995|C0031831|C0205099|C0439230|C0205265|C0011900
"During treatment, patients were monitored weekly, and earlier completion was permitted if remission was achieved before this deadline.","During treatment, patients monitored weekly, earlier completion permitted remission achieved deadline.",G0000000|C0039798|C0030705|C0030695|C0332174|C1279919|C0205197|C0329040|C0544452|G0000000|G0000000
MRI: magnetic resonance imaging; WOMAC: Western Ontario McMaster Universities Osteoarthritis Index; 25-(OHD)D: 25-hydroxy-vitamin D; FFQ: food frequency questionnaire.,MRI: magnetic resonance imaging; WOMAC: Western Ontario McMaster Universities Osteoarthritis Index; 25-(OHD)D: 25-hydroxy-vitamin D; FFQ: food frequency questionnaire.,C0024485|C0024488|C0231881|C0011923|G0000000|C1705493|C0029040|G0000000|C0041740|C0029408|C0918012|C0450371|C0450371|C0073187|G0000000|C0016452|C0376249|C0034394
Primary endpoint was incidence density (events/person-year) of first relapse by P. vivax in the year following radical cure.,Primary endpoint incidence density (events/person-year) relapse P. vivax radical cure.,C0205225|C2349179|C0021149|C0178587|C0441471|C0035020|C0369773|G0000000|C0302912|C1880198
"However, this increase did not translate into the improvements in patient’s response or survival.","However, increase translate improvements patient’s response survival.",G0000000|C0442805|C0040710|C2986411|G0000000|C0871261|C0038952
"Unexpectedly, those with a great deal of knowledge about memory loss also were very satisfied, which may be because they received affirmation of their beliefs.","Unexpectedly, deal knowledge memory loss satisfied, received affirmation beliefs.",G0000000|G0000000|C0376554|C0025260|C1517945|C0242428|C1514756|G0000000|C0004951
"[Results] There were significant improvements between pre- and post- intervention in both groups, in the BBT, grip strength, and the upper limb and lower lims sub-items of the FMA.","[Results] There improvements pre- post- intervention groups, BBT, grip strength, upper limb lower lims sub-items FMA.",C1274040|G0000000|C2986411|C0332152|C0687676|C0886296|C0441833|G0000000|C0021400|C0237897|C1282910|C0015385|C0441994|C0449205|C0542339|C2332774
Six of the subjects were positive for vaccine-induced Lm-specific responses.,Six subjects positive vaccine-induced Lm-specific responses.,C0205452|C0681850|C0439178|C0042210|C1261082|C0871261
"Clinical resolution rates in the PP population at the test of cure visit (TOC, 5–24 days post‐therapy, primary efficacy end point) were 90.2% (248/275) for moxifloxacin and 90.7% (262/289) for ofloxacin plus metronidazole (95% CI: −5.7% to 4.0%).","Clinical resolution rates PP population test cure visit (TOC, 5–24 days post‐therapy, primary efficacy point) 90.2% (248/275) moxifloxacin 90.7% (262/289) ofloxacin metronidazole (95% CI: −5.7% 4.0%).",C0205210|C1514893|C0871208|C0030375|C0032659|C0022885|C1880198|C0545082|C1835664|G0000000|G0000000|C0205225|C1280519|C1552961|C0450371|C1442061|C0536495|C0450371|C1442061|C0028902|C0025872|C0450371|C0008107|G0000000|G0000000
The purpose of gathering this information was to document whether each of the treatment groups had equivalent credibility.,The purpose gathering document treatment equivalent credibility.,G0000000|C1285529|G0000000|C1301746|C0039798|C0205163|C0870373
"Secondary endpoints included the incidence of clinical episodes of malaria during the surveillance period, outpatient attendances, the prevalence of parasitaemia and splenomegaly, nutritional status at the end of the malaria transmission season and compliance with the treatment regimen.","Secondary endpoints included incidence clinical episodes malaria surveillance period, outpatient attendances, prevalence parasitaemia splenomegaly, nutritional status malaria transmission season compliance treatment regimen.",C0027627|C2349179|C0332257|C0021149|C0205210|C0332189|C0024530|C0220920|C0439531|C0029921|C2827364|C0033105|C0242723|C0038002|C1521739|C0449438|C0024530|C0040722|C0036497|C0009563|C0039798|C0040808
Discrepancies were identified using a systematic approach (i.e.,Discrepancies identified systematic approach (i.e.,C1290905|C0205396|C0220922|C0449445|C0683454
"The lesions of 84.5% of the patients were healed without complications, 3.9% had secondary lesions, and 11.6%, a lower proportion than in other studies, had functional limitations.","The lesions 84.5% patients healed complications, 3.9% secondary lesions, 11.6%, lower proportion studies, functional limitations.",G0000000|C0221198|C0450371|C0030705|C0205249|C0009566|G0000000|C0027627|C0221198|C0450371|C0441994|C1709707|C0947630|C0205245|C0449295
"Lower baseline physical activity rates improved to levels comparable to those of African Americans statewide (2001, P<.001; 2005, P=.38), and comparable fruit and vegetable consumption rates became significantly higher (2001, P=.68; 2005, P<.001).","Lower baseline physical activity rates improved levels comparable African Americans statewide (2001, P<.001; 2005, P=.38), comparable fruit vegetable consumption rates (2001, P=.68; 2005, P<.001).",C0441994|C0168634|C0031809|C0205177|C0871208|C0184511|C0441889|G0000000|C0027567|C0596070|G0000000|G0000000|C0369773|G0000000|C0369773|G0000000|C0016767|C0042440|C0009830|C0871208|G0000000|C0369773|G0000000|C0369773
The follow-up visits were spaced out to once every 3 months after 2 years.,The follow-up visits spaced 3 months 2 years.,G0000000|C0589120|C0545082|C1883067|G0000000|C0439231|G0000000|C0439234
"The primary endpoint of this study was freedom from any bone fracture (FABF), measured from the date of randomization to the date of documented bone fracture(s), defined as ABF.","The primary endpoint study freedom bone fracture (FABF), measured randomization documented bone fracture(s), defined ABF.",G0000000|C0205225|C2349179|C0557651|C0016694|C0262950|C0016658|C2247303|C0444706|C0034656|C1301725|C0262950|C0016658|C1704788|G0000000
"Secondary outcome measures are as follows: Poor outcome, defined as death or major disability, is defined as a score of 3 to 6 on the modified Rankin scale at 90 days after onset of TH.","Secondary outcome measures follows: Poor outcome, defined death major disability, defined score 3 6 modified Rankin scale 90 days onset TH.",C0027627|C1274040|C0079809|C0332283|C0032854|C1274040|C1704788|C0011065|C0205082|C0231170|C1704788|C0449820|G0000000|G0000000|C0392747|G0000000|C0175659|C0450371|C0439228|C0206132|C0039725
Cancer-specific distress was assessed using the intrusion subscale of the Impact of Event Scale (IES).,Cancer-specific distress assessed intrusion subscale Impact Event Scale (IES).,C0006826|C0231303|C1516048|C2825978|G0000000|C1825598|C0441471|C0175659|G0000000
"Analysis of agitation scale scores in their original 1–4 ordinal scale (i.e., not dichotomized to ≥3 vs <3) and pain scores at each time point (arousal, transfer from Phase I to Phase II PACU and discharge from Phase II PACU) is also not statistically significantly different between groups.","Analysis agitation scale scores original 1–4 ordinal scale (i.e., dichotomized ≥3 <3) pain scores time (arousal, transfer Phase I Phase II PACU discharge Phase II PACU) statistically groups.",C0002778|C0085631|C0175659|C0449820|C0205313|G0000000|C0439080|C0175659|C0683454|G0000000|G0000000|G0000000|C0030193|C0449820|C0040223|C0003808|C0040671|C0205390|C0021966|C0205390|G0000000|C0034871|C0012621|C0205390|G0000000|C0034871|C0038215|C0441833
There are many biologically acceptable mechanisms by which the maternal vitamin D status can impact the risk of preeclampsia.,There biologically acceptable mechanisms maternal vitamin D status impact risk preeclampsia.,G0000000|C0205460|C1879533|C0441712|C2347083|C0042890|C0073187|C0449438|C1825598|C0035647|C0032914
MAIN OUTCOME MEASURE—A fall in 75% of coughs from baseline.,MAIN OUTCOME MEASURE—A fall 75% coughs baseline.,C0205225|C1274040|G0000000|C0085639|C0450371|C0010200|C0168634
"Secondary outcome measures were the incidence and median duration of vomiting, fever (>37.5°C), and the number of hospital admissions in each group.","Secondary outcome measures incidence median duration vomiting, fever (>37.5°C), hospital admissions group.",C0027627|C1274040|C0079809|C0021149|C0549183|C0449238|C0042963|C0015967|G0000000|C0019994|C0184666|C0441833
"For the primary and secondary outcomes, a modified intent-to-treat (mITT) analysis was used to focus on only those patients with a baseline serum bicarbonate level ≤22 mEq/L.","For primary secondary outcomes, modified intent-to-treat (mITT) analysis focus patients baseline serum bicarbonate level ≤22 mEq/L.",G0000000|C0205225|C0027627|C1274040|C0392747|C0162425|G0000000|C0002778|C0205234|C0030705|C0168634|C0229671|C0005367|C0441889|G0000000|C0439375
Results Mixed model analysis showed statistically significant (P≤0.05) differences in outcomes among the four added treatments for both the primary outcome (migraines/30 days) and the two secondary outcomes (change in migraine days/30 days and change in migraine specific quality of life scores).,Results Mixed model analysis statistically (P≤0.05) differences outcomes treatments primary outcome (migraines/30 days) secondary outcomes (change migraine days/30 days change migraine specific quality life scores).,C1274040|C0205430|C3161035|C0002778|C0038215|G0000000|C1705241|C1274040|C0087111|C0205225|C1274040|C0149931|C0439228|C0027627|C1274040|C0392747|C0149931|C0439228|C0439228|C0392747|C0149931|C0205369|C0332306|C0376558|C0449820
"Participant characteristics at baseline Note: BCTQ = Boston Carpal Tunnel Questionnaire, DASH = Disabilities of the Arm, Shoulder and Hand Questionnaire, DMMPUT = Dellon-modified Moberg pick-up test, FSS = Functional Status Scale, NRS = numeric rating scale, SSS = Symptom Severity Scale, SWMT = Semmes–Weinstein Monofilament Test.","Participant characteristics baseline Note: BCTQ = Boston Carpal Tunnel Questionnaire, DASH = Disabilities Arm, Shoulder Hand Questionnaire, DMMPUT = Dellon-modified Moberg pick-up test, FSS = Functional Status Scale, NRS = numeric rating scale, SSS = Symptom Severity Scale, SWMT = Semmes–Weinstein Monofilament Test.",C0679646|C1521970|C0168634|C1316572|G0000000|G0000000|C0006037|C0007285|C0337138|C0034394|C2827624|G0000000|C0231170|C0446516|C0037004|C0018563|C0034394|G0000000|G0000000|C0392747|G0000000|C1707391|C0022885|C0265224|G0000000|C0205245|C0449438|C0175659|C2240043|G0000000|C0237753|C0871208|C0175659|C0037052|G0000000|C1457887|C0439793|C0175659|G0000000|G0000000|G0000000|G0000000|C0022885
"Secondary outcome measures included Migraine Disability Assessment (MIDAS) [22], assessing migraine related disability, a higher score reflecting more severe disability (>21 = severe disability); Headache Impact Test [23] (HIT-6), assessing the impact of headache, score range is 36–78, with a higher score reflecting higher impact; Hospital Anxiety and Depression Scale (HADS) [24], a state-based measure of anxiety and depression, where for each subscale a score of ≥11 shows probable presence of a mood disorder [25]; Brief Illness Perceptions Questionnaire (B-IPQ) [26], assessing the degree to which headaches are perceived as threatening or benign, a higher score reflects a more threatening view of headache; and EuroQol (EQ-5D) [27], assessing health-related quality of life across five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression).","Secondary outcome measures included Migraine Disability Assessment (MIDAS) [22], assessing migraine disability, score reflecting severe disability (>21 = severe disability); Headache Impact Test [23] (HIT-6), assessing impact headache, score range 36–78, score reflecting impact; Hospital Anxiety Depression Scale (HADS) [24], state-based measure anxiety depression, subscale score ≥11 probable presence mood disorder [25]; Brief Illness Perceptions Questionnaire (B-IPQ) [26], assessing degree headaches perceived threatening benign, score reflects threatening view headache; EuroQol (EQ-5D) [27], assessing health-related quality life dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression).",C0027627|C1274040|C0079809|C0332257|C0149931|C0231170|C1261322|C1309950|C0450371|C1516048|C0149931|C0231170|C0449820|C0558058|C0205082|C0231170|C0450371|G0000000|C0205082|C0231170|C0018681|C1825598|C0022885|C0450371|C0272285|C1516048|C1825598|C0018681|C0449820|C1514721|G0000000|C0449820|C0558058|C1825598|C0019994|C0003467|C0011570|C0175659|C0048008|C0450371|C1301808|C0079809|C0003467|C0011570|G0000000|C0449820|G0000000|C0033204|C0150312|C0026516|C0012634|C0450371|C1282927|C0221423|C0030971|C0034394|G0000000|C0450371|C1516048|C0441889|C0018681|C0030971|G0000000|C0205183|C0449820|C0558058|G0000000|C0449911|C0018681|C0451150|C0205163|C0450371|C1516048|C0018684|C0332306|C0376558|C0439534|C0425245|C0036592|C3538928|C0441655|C0030193|C0338908
")?” If a subject responded affirmatively to any one question (or indicated an age when they first used marijuana), lifetime marijuana use was scored a “1”, while an indication of never using marijuana resulted in a score of “0”.",")?” If subject responded affirmatively question (or age marijuana), lifetime marijuana scored “1”, indication marijuana score “0”.",G0000000|G0000000|C0681850|G0000000|G0000000|C1522634|G0000000|C0001779|C0024808|C4071830|C0024808|C0449820|G0000000|C0392360|C0024808|C0449820|G0000000
"All patients are reviewed in the outpatient department by the treating surgeon and investigator at 2 and 6 weeks, 3 and 6 months and 1 year after surgery.","All patients reviewed outpatient department treating surgeon investigator 2 6 weeks, 3 6 months 1 surgery.",G0000000|C0030705|C0282443|C0029921|C1704729|C1522326|C0582175|C0035173|G0000000|G0000000|C0439230|G0000000|G0000000|C0439231|G0000000|C0038894
"Note that adolescents in the intervention condition were somewhat elevated on alcohol quantity at pretest; thus, their decrease in alcohol quantity, although contrasting with the increase for control teens, resulted in comparable mean scores across conditions at posttest.","Note adolescents intervention condition elevated alcohol quantity pretest; thus, decrease alcohol quantity, contrasting increase control teens, comparable scores conditions posttest.",C1316572|C0205653|C0886296|C0012634|C0205250|C0001962|C1265611|C0033101|G0000000|C0392756|C0001962|C1265611|C0449900|C0442805|C0243148|C0205653|G0000000|C0449820|C0012634|G0000000
(B) Average change in weight over time.,(B) Average change weight time.,G0000000|C1510992|C0392747|C0005910|C0040223
Open-label treatment with nicotine patch therapy was provided to all subjects for 8 weeks.,Open-label treatment nicotine patch therapy provided subjects 8 weeks.,C1709323|C0039798|C0028040|C0332461|C0039798|C1999230|C0681850|G0000000|C0439230
"In conclusion, conventional chest physiotherapy seems to be effective in the prevention of postextubation atelectasis in pediatric patients.","In conclusion, conventional chest physiotherapy effective prevention postextubation atelectasis pediatric patients.",G0000000|C1707478|C0439858|C0817096|C0949766|C1280519|C0199176|G0000000|C0004144|C0030755|C0030705
"Secondary outcomes were time to first exacerbation (from diary cards and medical records), reported symptoms, peak expiratory flow rate and reliever inhaler use (from diary cards), and lung function and health related quality of life (at follow up visits).","Secondary outcomes time exacerbation (from diary cards medical records), reported symptoms, peak expiratory flow rate reliever inhaler (from diary cards), lung function health quality life (at follow visits).",C0027627|C1274040|C0040223|G0000000|G0000000|C0376660|C3275277|C0199168|C0034869|C0684224|C0683368|C0444505|C0231800|C0806140|C0871208|G0000000|C0021461|G0000000|C0376660|C3275277|C0024109|C0031843|C0018684|C0332306|C0376558|G0000000|C0332283|C0545082
Serum samples were stored at −80°C until assayed.,Serum samples stored −80°C assayed.,C0229671|C0370003|C1698986|G0000000|C0005507
Present study aimed to investigate effect of an educational program on pregnant women’s fear of normal vaginal delivery.,Present study aimed investigate educational program pregnant women’s fear normal vaginal delivery.,C0150312|C0557651|C1947946|C1292732|C0587721|C1709697|C0549206|G0000000|C0015726|C0205307|C0042232|C0011209
"Common parent concerns centre on the amount and pattern of their infant’s sleep, strategies for settling, and how to best manage infant crying [5].","Common parent concerns centre amount pattern infant’s sleep, strategies settling, manage infant crying [5].",C0205214|C0030551|C2699424|C0205099|C1265611|C0449774|G0000000|C0037313|C0679199|C1266099|G0000000|C0021270|C0010399|G0000000
"At baseline and months 6, 12, 18, 24, 30, and 36, a random sample of 100 children aged 0–5 years per community (or all children if a given community had fewer than 100 children) were selected from the most recent census for examination.","At baseline months 6, 12, 18, 24, 30, 36, random sample 100 children aged 0–5 community (or children community fewer 100 children) selected census examination.",G0000000|C0168634|C0439231|G0000000|C0450371|C0450371|C0450371|C0450371|C0450371|C0034656|C0370003|C1442061|C0008059|C0001779|G0000000|C0009462|G0000000|C0008059|C0009462|C0205388|C1442061|C0008059|C1707391|C0007663|G0000000
"Patient characteristics, side effects (itching, erythema, burning, and scaling), and patient satisfaction (excellent, good, fair, poor) were recorded using a checklist.","Patient characteristics, effects (itching, erythema, burning, scaling), patient satisfaction (excellent, good, fair, poor) recorded checklist.",C0030705|C1521970|C1280500|C0033774|C0041834|C0000912|C0237849|C0030705|C0242428|C1548784|C0205170|C2911689|C0032854|C0034869|C1707357
Prevalence of ST use was determined based on baseline questionnaire data.,Prevalence ST determined based baseline questionnaire data.,C0033105|C0036056|G0000000|C1527178|C0168634|C0034394|C1511726
"Baseline and follow-up measurements of BP and blood lipids at 1 and 12 months post-discharge, respectively, was performed by a health care professional at the patients’ closest health care facility and reported to the study team.","Baseline follow-up measurements BP blood lipids 1 12 months post-discharge, respectively, performed health care professional patients’ closest health care facility reported study team.",C0168634|C0589120|C0242485|C0037623|C0005767|C0023779|G0000000|C0450371|C0439231|C0687676|G0000000|C0884358|C0018684|C1947933|C0679924|G0000000|C1522666|C0018684|C1947933|C1547538|C0684224|C0557651|C0871489
those suffering from anaemia (Hb< 12 gm%).,suffering anaemia (Hb< 12 gm%).,C0683278|C0002871|C0019046|C0450371|C0017480
"Age, gender, length of hospitalization, the numbers of patients exposed to antibiotics treatment, duration of antibiotic treatment, cases of mechanical ventilation, outcome were retrieved from electronic medical records.","Age, gender, length hospitalization, patients exposed antibiotics treatment, duration antibiotic treatment, mechanical ventilation, outcome retrieved electronic medical records.",C0001779|C0079399|C1444754|C0019993|C0030705|C0332157|C0003232|C0039798|C0449238|C0003232|C0039798|C0443254|C0035203|C1274040|G0000000|C0013850|C0199168|C0034869
Post hoc pairwise comparisons revealed that electroacupuncture and minimal acupuncture were more efficacious than placebo acupuncture in ISI and PSQI at 1 week and 4 week post-treatment.,Post hoc pairwise comparisons revealed electroacupuncture minimal acupuncture efficacious placebo acupuncture ISI PSQI 1 week 4 week post-treatment.,C0687676|G0000000|G0000000|C1707455|C0443289|C0013794|C0547040|C0001299|C1280519|C0032042|C0001299|G0000000|C3697468|G0000000|C0332174|G0000000|C0332174|C2709088
"Serum 25(OH)D3 was measured by high-performance liquid chromatography tandem mass spectroscopy (LC-MS/MS), which showed that only 25(OH)D3 was obtained in the serum samples, 25(OH)D2 was not detectable in any serum samples [18, 19].","Serum 25(OH)D3 measured high-performance liquid chromatography tandem mass spectroscopy (LC-MS/MS), 25(OH)D3 serum samples, 25(OH)D2 detectable serum samples [18, 19].",C0229671|C0450371|C0444706|C0205250|C0301571|C0008550|C0075804|C0577559|C0037812|C0872318|C0450371|C0229671|C0370003|C0450371|C3830527|C0229671|C0370003|C0450371|C0450371
Final clinic BP and laboratory values were defined as the last value during the study period.,Final clinic BP laboratory values defined study period.,C0205088|C0002424|C0037623|C0022877|C0042295|C1704788|C0557651|C0439531
"[16] compared a resistance exercise intervention with a usual care plus attention control with health education intervention in 67 patients, and found positive effects of the exercise program on fatigue and functional ability, and no significant group x time interaction effect for physical activity, physical fatigue, muscle strength and quality of life [16].","[16] compared resistance exercise intervention usual care attention control health education intervention 67 patients, positive effects exercise program fatigue functional ability, time interaction physical activity, physical fatigue, muscle strength quality life [16].",C0450371|C1707455|C0237834|C0015259|C0886296|C3538928|C1947933|C0004268|C0243148|C0018684|C0013621|C0886296|C0450371|C0030705|C0439178|C1280500|C0015259|C1709697|C0015672|C0205245|C0085732|C0040223|C1704675|C0031809|C0205177|C0031809|C0015672|C0026845|C0237897|C0332306|C0376558|C0450371
"The primary outcomes of the ophthalmologic measures for effectiveness of the oral nutraceutical formulation were the Schirmer test and fluorescein tear breakup time; the secondary measure was dry eye symptoms.43 The expression of a set of cytokines/chemokines in reflex tear samples obtained by the gentle rubbing method was assayed by the Multiplex System (Luminex® R-200; Luminex Corporation, Austin, TX, USA).","The primary outcomes ophthalmologic measures effectiveness oral nutraceutical formulation Schirmer test fluorescein tear breakup time; secondary measure dry eye symptoms.43 The expression set cytokines/chemokines reflex tear samples gentle rubbing method assayed Multiplex System (Luminex® R-200; Luminex Corporation, Austin, TX, USA).",G0000000|C0205225|C1274040|C0029087|C0079809|C1280519|C0442027|C1518478|C0524527|C1875738|C0022885|C0060520|C0039409|G0000000|C0040223|C0027627|C0079809|C0011682|C0015392|C0683368|G0000000|C0185117|C0036849|C0079189|C0034929|C0039409|C0370003|C0720654|G0000000|C0025663|C0005507|G0000000|C0449913|G0000000|C0205090|G0000000|C0683758|C0605411|C0041403|C0041703
"Each patient was evaluated within 24 h before the first TMS session, and within 24 h after the last TMS session, using the Auditory Hallucinations Rating Scale (AHRS) [2], the Scale for the Assessment of Positive Symptoms (SAPS), the Scale for the Assessment of Negative Symptoms (SANS), the Clinical Global Impressions scale (CGI), and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).","Each patient evaluated 24 TMS session, 24 TMS session, Auditory Hallucinations Rating Scale (AHRS) [2], Scale Assessment Positive Symptoms (SAPS), Scale Assessment Negative Symptoms (SANS), Clinical Global Impressions scale (CGI), Quality Life Enjoyment Satisfaction Questionnaire (Q-LES-Q).",G0000000|C0030705|C0220825|C0450371|G0000000|C1883016|C0450371|G0000000|C1883016|C0439825|C0018524|C0871208|C0175659|G0000000|G0000000|C0175659|C1261322|C0439178|C0683368|C1705598|C0175659|C1261322|C0205160|C0683368|C1424214|C0205210|C0205246|C0596764|C0175659|C3639708|C0332306|C0376558|C0018592|C0242428|C0034394|C0227192
The definition of major and minor hemorrhage met internationally defined standards (Online Supplementary Table S2).35–37 Secondary safety outcomes were event-free survival and overall survival.,The definition major minor hemorrhage met internationally defined standards (Online Supplementary Table S2).35–37 Secondary safety outcomes event-free survival survival.,G0000000|C1550452|C0205082|C0026193|C0019080|C0268621|G0000000|C1704788|C0038137|G0000000|G0000000|C0039224|G0000000|C0027627|C0036043|C1274040|C0441471|C0038952|C0038952
"In addition, changes in menstrual cycles including duration of menses and interval of cycles were asked.","In addition, menstrual cycles including duration menses interval cycles asked.",G0000000|C0332287|C0025344|C1511572|C0332257|C0449238|C0025344|C1272706|C1511572|G0000000
"The effectiveness of this intervention in reducing the severity of post-stroke depression, improving participation status and health-related quality of life is examined.","The effectiveness intervention reducing severity post-stroke depression, improving participation status health-related quality life examined.",G0000000|C1280519|C0886296|C0392756|C0439793|C0687676|C0011570|C1272745|C0679823|C0449438|C0018684|C0332306|C0376558|C0332128
"Other predefined exploratory end points were percentage of patients alive and progression free at 6 months, annualized survival rates, quality of life, Mini-Mental State Examination, and Karnofsky performance score.","Other predefined exploratory percentage patients alive progression free 6 months, annualized survival rates, quality life, Mini-Mental State Examination, Karnofsky performance score.",G0000000|G0000000|G0000000|C0439165|C0030705|C0376558|C0242656|C0332296|G0000000|C0439231|G0000000|C0038952|C0871208|C0332306|C0376558|C0445542|C1301808|G0000000|C0206065|C0597198|C0449820
"Ear assessments and nasopharyngeal carriage at the end of therapy ≸AOM, AOMwiP or CSOM; ‡ AOMwiP, dry perforation or CSOM; §AOMwiP or CSOM; ¥ Spn Streptococcus pneumoniae.","Ear assessments nasopharyngeal carriage therapy ≸AOM, AOMwiP CSOM; ‡ AOMwiP, dry perforation CSOM; §AOMwiP CSOM; ¥ Spn Streptococcus pneumoniae.",C0013443|C1261322|C0027442|G0000000|C0039798|G0000000|G0000000|G0000000|G0000000|G0000000|C0011682|C0549099|G0000000|G0000000|G0000000|G0000000|C2350019|C0038402|C0032285
"Overall, fever prevalence (axillary temperature > 37.5°C) and reported fever episodes during the last 48 hours were also significantly lower and mean body weight was significantly higher during the post-intervention compared to the pre-intervention survey (p<0.001), but there were no significant differences between control and intervention groups (p=0.204).","Overall, fever prevalence (axillary temperature > 37.5°C) reported fever episodes 48 hours lower body weight post-intervention compared pre-intervention survey (p<0.001), differences control intervention (p=0.204).",C0282416|C0015967|C0033105|C0004454|C0005903|G0000000|G0000000|C0684224|C0015967|C0332189|C0450371|C0439227|C0441994|C0242821|C0005910|C2347647|C1707455|C2347663|C0038951|C0369773|C1705241|C0243148|C0886296|C0369773
"Across both EXP and CONTROL conditions, a similar large percentage of youth showed complete abstinence from alcohol and cannabis during the 36 week follow up period.","Across EXP CONTROL conditions, percentage youth complete abstinence alcohol cannabis 36 week follow period.",G0000000|C1417055|C0243148|C0012634|C0439165|C0001578|C0205197|C3843422|C0001962|C0024808|C0450371|C0332174|C0332283|C0439531
"This composite endpoint was defined as the time to first need for therapeutic puncture or death after treatment, whichever occurred first.","This composite endpoint defined time therapeutic puncture death treatment, whichever occurred first.",G0000000|C0205199|C2349179|C1704788|C0040223|C0087111|C0033119|C0011065|C0039798|G0000000|C1709305|C0205435
"There were no group differences in the time to recovery from acute respiratory failure, duration of weaning from mechanical ventilation, or duration of assisted breathing that includes the use of noninvasive ventilation post-endotracheal extubation (Table 2).","There differences time recovery acute respiratory failure, duration weaning mechanical ventilation, duration assisted breathing includes noninvasive ventilation post-endotracheal extubation (Table 2).",G0000000|C1705241|C0040223|C0237820|C0205178|C0521346|C0231174|C0449238|C0043084|C0443254|C0035203|C0449238|C1269765|C0004048|C0332257|C0205303|C0035203|C0687676|C0553891|C0039224|G0000000
"Quality of life in both groups was measured a day before, and at the end of the eight weeks period by the instrument of the National Medical Center and Beckman Research Institute.","Quality life measured day before, weeks period instrument National Medical Center Beckman Research Institute.",C0332306|C0376558|C0444706|C0332173|C0332152|C0439230|C0439531|C0348000|C3245503|C0199168|C0205099|G0000000|C0035168|C0021622
"Since many sepsis episodes occurred in the first week of life (Figure 2), and many of the infants had not received the intervention (LF or placebo) until the beginning of oral feeds, we have explored as a secondary analysis the effect of LF on sepsis using in the model time since the start of the treatment.","Since sepsis episodes occurred week life (Figure 2), infants received intervention (LF placebo) oral feeds, explored secondary analysis LF sepsis model time start treatment.",C1711239|C0036690|C0332189|C1709305|C0332174|C0376558|G0000000|G0000000|C0021270|C1514756|C0886296|C1416933|C0032042|C0442027|C1510670|G0000000|C0027627|C0002778|C1416933|C0036690|C3161035|C0040223|C0439659|C0039798
"Alcohol consumption outcomes Serum gamma-glutamyl transferase (GGT), a biological marker available for evaluation of the severity of current drinking, was used to provide objective evidence of change in alcohol consumption at study entry and at 6 months only.","Alcohol consumption outcomes Serum gamma-glutamyl transferase (GGT), biological marker evaluation severity current drinking, provide objective evidence change alcohol consumption study entry 6 months only.",C0001962|C0009830|C1274040|C0229671|C0017011|C0040676|C1415053|C0005532|C0005516|C0220825|C0439793|C0521116|C0001948|C1999230|C0018017|C3887511|C0392747|C0001962|C0009830|C0557651|C1705654|G0000000|C0439231|C0205171
This model fit the data better.,This model fit data better.,G0000000|C3161035|C0036572|C1511726|C0332272
Safety assessments were performed continuously.,Safety assessments performed continuously.,C0036043|C1261322|C0884358|G0000000
The primary outcome was the change in nausea and vomiting scores (mean of post-treatment scores minus baseline scores).,The primary outcome change nausea vomiting scores (mean post-treatment scores minus baseline scores).,G0000000|C0205225|C1274040|C0392747|C0027497|C0042963|C0449820|C0444504|C2709088|C0449820|C0332288|C0168634|C0449820
"A one-way ANOVA was performed in order to compare evoked acupuncture sensations, as well as the MASS Index (a composite metric of deqi sensation) between groups.","A one-way ANOVA performed compare evoked acupuncture sensations, MASS Index (a composite metric deqi sensation) groups.",G0000000|C0205447|G0000000|C0884358|C1707455|C1444748|C0001299|C0036658|C0577559|C0918012|G0000000|C0205199|C0699680|G0000000|C0036658|C0441833
"MVPT, motor-free visual perception test; SCT, star cancellation test; LBT, line bisection test; CBS, Catherine Bergego Scale; K-MBI, Korean version of the Modified Barthel Index; FAC, Functional Ambulation Classification.","MVPT, motor-free visual perception test; SCT, star cancellation test; LBT, bisection test; CBS, Catherine Bergego Scale; K-MBI, Korean version Modified Barthel Index; FAC, Functional Ambulation Classification.",G0000000|C1513492|C0234621|C0030971|C0022885|C0860888|C0995242|C0205544|C0022885|C1879922|C0184905|C0022885|C1439329|G0000000|G0000000|C0175659|C0597277|C1556095|C0333052|C0392747|G0000000|C0918012|G0000000|C0205245|C0080331|C0008902
"If ET was diagnosed, data on age of onset were elicited.","If ET diagnosed, data age onset elicited.",G0000000|G0000000|C0011900|C1511726|C0001779|C0206132|C0449265
We used Visual Analogue Scale (VAS) tool for ranking the intensity of the pain.,We Visual Analogue Scale (VAS) tool ranking intensity pain.,G0000000|C0234621|C0243071|C0175659|C0042815|C0336791|C0699794|C0522510|C0030193
"Secondary depression outcomes included MDD criteria based on the SCID, self-rated improvement in depression symptoms as measured by the Patient Global Impression (PGI),62 and Satisfaction with Depression Care as measured on a 1 (very satisfied) to 7 (very dissatisfied) Likert scale.63 Therapeutic alliance was assessed with the Working Alliance Inventory-Short Form.64 Interrater reliability for the HAMD-17, SCID and MINI were ≥90%.","Secondary depression outcomes included MDD criteria based SCID, self-rated improvement depression symptoms measured Patient Global Impression (PGI),62 Satisfaction Depression Care measured 1 (very satisfied) 7 (very dissatisfied) Likert scale.63 Therapeutic alliance assessed Working Alliance Inventory-Short Form.64 Interrater reliability HAMD-17, SCID MINI ≥90%.",C0027627|C0011570|C1274040|C0332257|C1269683|C0243161|C1527178|C0085110|C0036588|C2986411|C0011570|C0683368|C0444706|C0030705|C0205246|C0596764|C0523816|C0242428|C0011570|C1947933|C0444706|G0000000|C0442824|C0242428|G0000000|C0442824|C0870433|G0000000|C0175659|C0087111|C0680207|C1516048|C0043227|C0680207|C0021941|C0348078|G0000000|C2347947|C0450371|C0085110|C0445542|G0000000
"However, there are no data that ovarian cancer screening is effective in reducing the risk of developing ovarian cancer, or in dying from ovarian cancer38.","However, data ovarian cancer screening effective reducing risk developing ovarian cancer, dying ovarian cancer38.",G0000000|C1511726|C0205065|C0006826|C0220908|C1280519|C0392756|C0035647|G0000000|C0205065|C0006826|C0184532|C0205065|G0000000
"Asthma control will be evaluated by calculating the amount of fast acting beta agonists recorded as dispensed in the provincial drug database, and asthma quality of life using the Mini Asthma Related Quality of Life Questionnaire.","Asthma control evaluated calculating amount fast acting beta agonists recorded dispensed provincial drug database, asthma quality life Mini Asthma Related Quality Life Questionnaire.",C0004096|C0243148|C0220825|C1441506|C1265611|C0015663|G0000000|C0330390|C0243192|C0034869|C1880359|G0000000|C0013227|C0242356|C0004096|C0332306|C0376558|C0445542|C0004096|C0439849|C0332306|C0376558|C0034394
"Partial remission was defined as the resolution of edema, an increase of serum albumin concentration to >35 g/l and persisting proteinuria between 4 and 40 mg/m2 per hour.","Partial remission defined resolution edema, increase serum albumin concentration >35 g/l persisting proteinuria 4 40 mg/m2 hour.",C0728938|C0544452|C1704788|C1514893|C0013604|C0442805|C0229671|C0001924|C0004268|C0450371|C0439294|G0000000|C0033687|G0000000|C0450371|C0026410|C0439227
"Nevertheless 97% of patients in the chloroquine arm were parasite free and afebrile by day 2, and there were no recurrences in either arm before day 28, suggesting that P. vivax remains sensitive to chloroquine in the study area, which included locations both north and south of the Hindu Kush divide of central Afghanistan.","Nevertheless 97% patients chloroquine arm parasite free afebrile day 2, recurrences arm day 28, suggesting P. vivax remains sensitive chloroquine study area, included locations north south Hindu Kush divide central Afghanistan.",G0000000|C0450371|C0030705|C0008269|C0446516|C0030498|C0332296|C0277797|C0332173|G0000000|C0034897|C0446516|C0332173|C0450371|C1705535|C0369773|G0000000|G0000000|C0020517|C0008269|C0557651|C0017446|C0332257|C0450429|C1709269|C1710133|C0019550|G0000000|C0332849|C0205099|C0001732
Subclinical atherosclerosis progression across 3 vascular beds was assessed using high-resolution B-mode ultrasonography to measure carotid artery intima-media thickness (primary outcome) and multidetector spiral computed tomography to measure aortic and coronary artery calcium (secondary outcome).,Subclinical atherosclerosis progression 3 vascular beds assessed high-resolution B-mode ultrasonography measure carotid artery intima-media thickness (primary outcome) multidetector spiral computed tomography measure aortic coronary artery calcium (secondary outcome).,C0205211|C0003850|C0242656|G0000000|C0005847|C0004916|C1516048|C1719039|C1513371|C0041618|C0079809|C0741968|C0003842|C0162864|C1280412|C0205225|C1274040|G0000000|C0522554|C1441526|C0040395|C0079809|C0003483|C0018787|C0003842|C0006675|C0027627|C1274040
"Self-report outcomes include measures of depression (Patient Health Questionnaire-9), anxiety (Generalised Anxiety Disorder-7), quality of life (Euro-QoL), service use (client service receipt inventory) and illness cognitions (brief illness perception questionnaire).","Self-report outcomes measures depression (Patient Health Questionnaire-9), anxiety (Generalised Anxiety Disorder-7), quality life (Euro-QoL), service (client service receipt inventory) illness cognitions (brief illness perception questionnaire).",C0681906|C1274040|C0079809|C0011570|C0030705|C0018684|C0034394|C0003467|C0205246|C0003467|C0012634|C0332306|C0376558|C1533125|C0557854|C0008942|C0557854|G0000000|C0021941|C0221423|C0009240|C1282927|C0221423|C0030971|C0034394
Presence and severity of pain were collected prospectively at randomization and after 4 weeks.,Presence severity pain collected prospectively randomization 4 weeks.,C0150312|C0439793|C0030193|C1516695|G0000000|C0034656|G0000000|C0439230
Finding from the current study demonstrated that self-reported point prevalence abstinence in the intervention arm was significantly higher than those in the control arm at 3 and 6 months.,Finding current study demonstrated self-reported prevalence abstinence intervention arm control arm 3 6 months.,C0037088|C0521116|C0557651|G0000000|C0681906|C0033105|C3843422|C0886296|C0446516|C0243148|C0446516|G0000000|G0000000|C0439231
Markers of Inflammation: CRP & ESR.,Markers Inflammation: CRP & ESR.,C0005516|C0021368|C3890735|G0000000|C3811131
"As part of the baseline questionnaire, participants also reported on personal characteristics including age, gender, ethnicity, education, height, weight, recreational physical activity, cigarette smoking, alcohol consumption, family history of cancer, and medical history.","As baseline questionnaire, participants reported personal characteristics including age, gender, ethnicity, education, height, weight, recreational physical activity, cigarette smoking, alcohol consumption, family history cancer, medical history.",G0000000|C0168634|C0034394|C0679646|C0684224|C1519021|C1521970|C0332257|C0001779|C0079399|C0015031|C0013621|C0489786|C0005910|C0034872|C0031809|C0205177|C0677453|C0037369|C0001962|C0009830|C0015576|C0019664|C0006826|C0199168|C0019664
"Compared with usual care, in follow-up Year 1 the SDM care management intervention increased the total days' supply of controller medication acquired by the patient by an average of 77 days and by 9.6 beclomethasone canister equivalents, increased the quality of life score by 0.4 points, decreased asthma-related physician visits per year by 0.4 visits, reduced albuterol acquisition by 1.6 canister equivalents, increased the FEV1:FEV6 ratio by an average of 2.8 percentage points, and doubled the likelihood of having well controlled asthma.","Compared usual care, follow-up Year 1 SDM care management intervention increased total days' supply controller medication acquired patient average 77 days 9.6 beclomethasone canister equivalents, increased quality life score 0.4 points, decreased asthma-related physician visits 0.4 visits, reduced albuterol acquisition 1.6 canister equivalents, increased FEV1:FEV6 ratio average 2.8 percentage points, doubled likelihood controlled asthma.",C1707455|C3538928|C1947933|C0589120|C0439234|G0000000|C0643808|C1947933|C0001554|C0886296|C0205217|C0439175|C0439228|C0243163|C0180112|C0013227|C0439661|C0030705|C1510992|C0450371|C0439228|G0000000|C0004905|C0336640|C0439185|C0205217|C0332306|C0376558|C0449820|G0000000|C1552961|C0205216|C0004096|C0031831|C0545082|G0000000|C0545082|C0392756|C0001927|C1706701|G0000000|C0336640|C0439185|C0205217|G0000000|C0456603|C1510992|G0000000|C0439165|C1552961|C0205173|C0033204|C2587213|C0004096
"Secondary end points included hospital readmission, admission to the intensive care unit, change in lung function (ΔFEV1), length of hospital stay, and death from any cause.","Secondary included hospital readmission, admission intensive care unit, change lung function (ΔFEV1), length hospital stay, death cause.",C0027627|C0332257|C0019994|C1548168|C0184666|C0162425|C1947933|C0439148|C0392747|C0024109|C0031843|G0000000|C1444754|C0019994|G0000000|C0011065|C0015127
Quality of life will be assessed at the end of weeks 4 and 8.,Quality life assessed weeks 4 8.,C0332306|C0376558|C1516048|C0439230|G0000000|G0000000
"GEE model evaluation of comparison between groups and times Note: Abbreviations: GEE, generalized estimating equations; SE, standard error; CI, confidence interval; BITC, Behavioral Inattention Test Conventional; VR, vestibular rehabilitation; ADL, activities of daily living; FIM®, Functional Independence Measure®; PASS, Postural Assessment Scale for Stroke patients.","GEE model evaluation comparison times Note: Abbreviations: GEE, generalized estimating equations; SE, standard error; CI, confidence interval; BITC, Behavioral Inattention Test Conventional; VR, vestibular rehabilitation; ADL, activities daily living; FIM®, Functional Independence Measure®; PASS, Postural Assessment Scale Stroke patients.",G0000000|C3161035|C0220825|C1707455|C0040223|C1316572|C0000723|G0000000|C0205246|C0750572|C0552449|C0036919|C1442989|C0743559|C0008107|C0237529|C1272706|G0000000|C0004927|C0424101|C0022885|C0439858|C3476815|C0042606|C0034991|C0001288|C0441655|C0332173|C0376558|G0000000|C0205245|C0085862|G0000000|C2828386|C0205278|C1261322|C0175659|C0038454|C0030705
Progression-free survival.,Progression-free survival.,C0242656|C0038952
Changes in lung function.,Changes lung function.,C0392747|C0024109|C0031843
"Adverse events included deaths, cardiovascular events, cerebrovascular events, arterial revascularization procedures and cancers.","Adverse events included deaths, cardiovascular events, cerebrovascular events, arterial revascularization procedures cancers.",G0000000|C0441471|C0332257|C0011065|C0007226|C0441471|C1880018|C0441471|C0003842|C0581603|C0025664|C0006826
Rates of exacerbations and structural and functional outcomes at age 5 years *FEV1 z score determined from normal values (http://www.lungfunction.org/growinglungs).,Rates exacerbations structural functional outcomes age 5 years *FEV1 score determined normal values (http://www.lungfunction.org/growinglungs).,C0871208|G0000000|C0678594|C0205245|C1274040|C0001779|G0000000|G0000000|C0449820|G0000000|C0205307|C0042295|C1555015
‘physical’ and ‘mental’) were also not significantly different between groups at all time points tested.,‘physical’ ‘mental’) time tested.,G0000000|G0000000|C0040223|C0392366
"In both groups, acne severity index (ASI) was calculated before and at week 2, 4, 6, and 8 of the treatment.","In groups, acne severity (ASI) calculated week 2, 4, 6, 8 treatment.",G0000000|C0441833|C0001144|C0439793|C0450981|C0444686|C0332174|G0000000|G0000000|G0000000|G0000000|C0039798
"In the case group, the greatest and lowest changes were related to attention score and mean corpuscular haemoglobin concentration, respectively (Table III).","In group, lowest attention score corpuscular haemoglobin concentration, (Table III).",G0000000|C0441833|C1708760|C0004268|C0449820|C1880182|C0019046|C0004268|C0039224|C0439070
"The gait with RAS 10% slower than the baseline significantly decreased the gait velocity to 35.6±19.5 cm/sec, cadence to 70.8±20.6 steps/min, stride length on the affected side to 59.4±18.9 cm, and the stride length on the unaffected side to 59.2±18.7 cm.","The gait RAS 10% slower baseline decreased gait velocity 35.6±19.5 cm/sec, cadence 70.8±20.6 steps/min, stride length 59.4±18.9 cm, stride length unaffected 59.2±18.7 cm.",G0000000|C0016928|C0034678|C0450371|C0439834|C0168634|C0205216|C0016928|C0439830|G0000000|G0000000|G0000000|C1261552|G0000000|C1444754|G0000000|G0000000|C1444754|C2986417|G0000000
"Secondary outcome measures included the Timed Up and Go Test (TUG), the Berg Balance Scale (BBS), the Functional Ambulation Category (FAC), and the Stroke Impact Scale 16 (SIS-16).","Secondary outcome measures included Timed Up Go Test (TUG), Berg Balance Scale (BBS), Functional Ambulation Category (FAC), Stroke Impact Scale 16 (SIS-16).",C0027627|C1274040|C0079809|C0332257|C0392761|G0000000|C1822658|C0022885|C1319201|G0000000|C0014653|C0175659|G0000000|C0205245|C0080331|C0683312|G0000000|C0038454|C1825598|C0175659|C0450371|C1704647
"For the 3 H5N1 vaccine lots, group GMT ratios were calculated using an analysis of covariance model; vaccine lots were considered equivalent if the 2-sided 95% CIs for all of the GMT ratios were between 0.67 and 1.5.","For 3 H5N1 vaccine lots, GMT ratios calculated analysis covariance model; vaccine lots considered equivalent 2-sided 95% CIs GMT ratios 0.67 1.5.",G0000000|G0000000|G0000000|C0042210|C1115660|G0000000|C0456603|C0444686|C0002778|G0000000|C3161035|C0042210|C1115660|C0750591|C0205163|C0457012|C0450371|C1504308|G0000000|C0456603|C0450371|G0000000
"The amplitudes of bilateral submental motor evoked potentials (MEPs) induced by transcranial magnetic stimulations over bilateral motor cortex, diameters of UES opening (UOD) and maximal displacement of hyoid (HD) were all assessed at baseline and the endpoint of treatments.","The amplitudes bilateral submental motor evoked potentials (MEPs) induced transcranial magnetic stimulations bilateral motor cortex, diameters UES (UOD) maximal displacement hyoid (HD) assessed baseline endpoint treatments.",G0000000|C2346753|C0238767|C1550310|C1513492|C1444748|C3245505|C1707163|C0205263|C0442348|C0024488|C1292856|C0238767|C1513492|C0007776|C1301886|C0855073|G0000000|C0205289|C0012725|C0020417|G0000000|C1516048|C0168634|C2349179|C0087111
Other general solicited symptoms were observed in <20% of children.,Other solicited symptoms observed <20% children.,G0000000|G0000000|C0683368|C1441672|C0450371|C0008059
There were no significant differences between the groups in attendances by GPs and carers or in health status measured eight weeks after the initial assessment.,There differences attendances GPs carers health status measured weeks initial assessment.,G0000000|C1705241|C2827364|C0272302|C0085537|C0018684|C0449438|C0444706|C0439230|C0205265|C1261322
"The primary end-points were the time to successful extubation, defined as the time from inclusion until successful extubation (followed by 72 hours without ventilator support) and the total duration of mechanical ventilation.","The primary end-points time successful extubation, defined time inclusion successful extubation (followed 72 hours ventilator support) total duration mechanical ventilation.",G0000000|C0205225|C2349179|C0040223|C0597535|C0553891|C1704788|C0040223|C0007637|C0597535|C0553891|C0332283|C0450371|C0439227|C0087153|C0183683|C0439175|C0449238|C0443254|C0035203
Women with a history of cancer or hysterectomy were not eligible.,Women history cancer hysterectomy eligible.,C0043210|C0019664|C0006826|C0020699|C1548635
"We counted the person-years of follow-up for each individual from 1 January 1995 until the date of diagnosis of lung cancer, date of withdrawal from the NHI, date of death, or the end of the study period (31 December 2001), whichever occurred first.","We counted person-years follow-up individual 1 January 1995 diagnosis lung cancer, withdrawal NHI, death, study period (31 December 2001), whichever occurred first.",G0000000|C0750480|C0027361|C0589120|C0027361|G0000000|C3829466|G0000000|C0011900|C0024109|C0006826|C2349954|G0000000|C0011065|C0557651|C0439531|C0450371|C3830550|G0000000|G0000000|C1709305|C0205435
"We hypothesize that the DRD2 polymorphisms: rs1799732; rs6277; rs1800497, which have been associated with colorectal cancer, may be similarly associated with colorectal adenoma recurrence in the Polyp Prevention Trial (PPT).","We hypothesize DRD2 polymorphisms: rs1799732; rs6277; rs1800497, colorectal cancer, colorectal adenoma recurrence Polyp Prevention Trial (PPT).",G0000000|G0000000|G0000000|C0032529|G0000000|G0000000|G0000000|C0555952|C0006826|C0555952|C0001430|C0034897|C0032584|C0199176|C0008976|G0000000
"The EIR is calculated as the product of the human biting rate (HBR) and the sporozoite rate (SR), where HBR is the number of bites from a malaria vector species per year and SR is the prevalence of the malaria parasite infective stage (sporozoite) in the local malaria vector population [84].","The EIR calculated product human biting rate (HBR) sporozoite rate (SR), HBR bites malaria vector species SR prevalence malaria parasite infective stage (sporozoite) local malaria vector population [84].",G0000000|G0000000|C0444686|C1514468|C0086418|C0005658|C0871208|G0000000|C0562648|C0871208|C3813610|G0000000|C0005658|C0024530|C0086022|C1705920|C3813610|C0033105|C0024530|C0030498|G0000000|C0205390|C0562648|C0205276|C0024530|C0086022|C0032659|C0450371
"The lack of good quality research into the 'classic' drugs for IBS has also been highlighted in guidelines for IBS, i.e.","The lack quality 'classic' drugs IBS highlighted guidelines IBS, i.e.",G0000000|C0332268|C0332306|C0439658|C0013227|C0022104|G0000000|C0162791|C0022104|C0683454
49 (24%) of 204 previously noncompliant patients became compliant (average nightly use ≥4 hours) after standard interventions.,49 (24%) 204 noncompliant patients compliant (average nightly ≥4 hours) standard interventions.,C0450371|C0450371|C1442061|C0457432|C0030705|C0566588|C1510992|G0000000|G0000000|C0439227|C1442989|C0886296
*mRS range from 0 (best) to 6; BI range from 0 to 100 (best); NIHSS range from 0 (best) to 34; patient satisfaction range from 1 (best) to 5.,*mRS range 0 (best) 6; BI range 0 100 (best); NIHSS range 0 (best) 34; patient satisfaction range 1 (best) 5.,C1522706|C1514721|G0000000|C1522427|G0000000|G0000000|C1514721|G0000000|C1442061|C1522427|C3476804|C1514721|G0000000|C1522427|C0450371|C0030705|C0242428|C1514721|G0000000|C1522427|G0000000
Differences in the incidence of adverse events between groups was tested using a χ2 test at an α of .05.,Differences incidence adverse events tested χ2 test α .05.,C1705241|C0021149|G0000000|C0441471|C0392366|G0000000|C0022885|G0000000|C0450371
"Secondary outcome measures are (1) time to take 20 steps, (or number of steps taken, if this is not achieved) and maximum heart rate reached on a step-test [41]; (ii) scores on the anxiety and depression scales of the HADS [42] to provide measures of depression and anxiety; (iii) scores a brief four-item sleep scale [43].","Secondary outcome measures (1) time 20 steps, (or steps taken, achieved) maximum heart rate reached step-test [41]; (ii) scores anxiety depression scales HADS [42] provide measures depression anxiety; (iii) scores four-item sleep scale [43].",C0027627|C1274040|C0079809|G0000000|C0040223|C0450371|C1261552|G0000000|C1261552|C1883727|G0000000|C0806909|C0018787|C0871208|C2584321|C0087028|C0450371|G0000000|C0449820|C0003467|C0011570|C0175659|C0048008|C0450371|C1999230|C0079809|C0011570|C0003467|C0439070|C0449820|C0205450|C0037313|C0175659|C0450371
"Primary endpoint was twelve-month survival, secondary endpoints overall survival (OS), time to progression (TTP), tumor response, safety and quality of life.","Primary endpoint twelve-month survival, secondary endpoints survival (OS), time progression (TTP), tumor response, safety quality life.",C0205225|C2349179|C0205458|C0038952|C0027627|C2349179|C0038952|C0229090|C0040223|C0242656|C0084795|C0027651|C0871261|C0036043|C0332306|C0376558
In probiotic supplemented children there was a meaningfully lower rate of nausea/vomiting and diarrhea during treatment.,In probiotic supplemented children meaningfully lower rate nausea/vomiting diarrhea treatment.,G0000000|C0525033|C0242295|C0008059|G0000000|C0441994|C0871208|C0027498|C0011991|C0039798
Objective cognitive tests were administered at T3 but not T2 to avoid practice effects through repeated exposure within a relatively short period.,Objective cognitive tests administered T3 T2 avoid practice effects repeated exposure short period.,C0018017|C1516691|C0022885|C1521801|C0041403|C0041403|G0000000|C0237607|C1280500|C0205341|C0274281|C1282927|C0439531
Higher scores indicate better health-related quality of life.,Higher scores health-related quality life.,C0205250|C0449820|C0018684|C0332306|C0376558
"Drop-outs had poorer health than completers on baseline global FM impact, pain, physical dysfunction, fatigue, and negative affect (all p < .10) but not on other measures (all p > .30).","Drop-outs poorer health completers baseline global FM impact, pain, physical dysfunction, fatigue, negative affect (all < .10) measures (all > .30).",C1321095|C0032854|C0018684|G0000000|C0168634|C0205246|C3540627|C1825598|C0030193|C0031809|C0031847|C0015672|C0205160|C0001721|G0000000|G0000000|C0450371|C0079809|G0000000|G0000000|C0450371
The secondary cognitive measures showed a statistically significant 2 point benefit on the Mini Mental Status Examination and no change on the Mattis Dementia Rating Scale (MDRS).,The secondary cognitive measures statistically 2 benefit Mini Mental Status Examination change Mattis Dementia Rating Scale (MDRS).,G0000000|C0027627|C1516691|C0079809|C0038215|G0000000|C0814225|C0445542|C0229992|C0449438|G0000000|C0392747|G0000000|C0011265|C0871208|C0175659|G0000000
None of the objective cognitive function tests were significantly correlated at p <0.05 with self-reported cognitive function or any of the secondary outcomes.,None objective cognitive function tests correlated <0.05 self-reported cognitive function secondary outcomes.,G0000000|C0018017|C1516691|C0031843|C0022885|C1707520|C0450371|C0681906|C1516691|C0031843|C0027627|C1274040
"Specifically, girls’ food group intake, nutrient intakes, diet quality, body mass index (BMI), and skinfold thickness were compared for the 2 groups.","Specifically, girls’ food intake, nutrient intakes, diet quality, body mass (BMI), skinfold thickness compared 2 groups.",G0000000|G0000000|C0016452|C1512806|C0678695|C1512806|C0012155|C0332306|C0242821|C0577559|G0000000|C1446851|C1280412|C1707455|G0000000|C0441833
Secondary outcomes were perinatal variables.,Secondary outcomes perinatal variables.,C0027627|C1274040|C0178795|C0439828
"Secondary outcomes included the time to the first exacerbation, the severity of exacerbations, the number of acute cardiovascular events, quality of life, and changes in spirometric variables.","Secondary outcomes included time exacerbation, severity exacerbations, acute cardiovascular events, quality life, spirometric variables.",C0027627|C1274040|C0332257|C0040223|G0000000|C0439793|G0000000|C0205178|C0007226|C0441471|C0332306|C0376558|C0037981|C0439828
Time point was before menstruation and the first day until the fourth day of menstruation.,Time menstruation day fourth day menstruation.,C0040223|C0025344|C0332173|C0205438|C0332173|C0025344
"We compared death, loss to follow-up, mean CD4 change from down-referral eligibility and viral load rebound by 12-months of follow-up by down-referral status.","We compared death, loss follow-up, CD4 change down-referral eligibility viral load rebound 12-months follow-up down-referral status.",G0000000|C1707455|C0011065|C1517945|C0589120|C0285590|C0392747|C0034927|C0013893|C0521026|C1550025|G0000000|C0450371|C0589120|C0034927|C0449438
"The examiner assessed the balance and gait function of subjects with the BBS (Berg Balance Scale) and PASS (Postural Assessment Scale for Stroke Patients), and TUG (Timed Up and Go) test before and after the intervention.","The examiner assessed balance gait function subjects BBS (Berg Balance Scale) PASS (Postural Assessment Scale Stroke Patients), TUG (Timed Up Go) test intervention.",G0000000|G0000000|C1516048|C0014653|C0016928|C0031843|C0681850|G0000000|G0000000|C0014653|C0175659|C2828386|C0205278|C1261322|C0175659|C0038454|C0030705|C1319201|C0392761|G0000000|C1822658|C0022885|C0886296
The primary end point for CRASH-3 is death in hospital within 28 days.,The primary CRASH-3 death hospital 28 days.,G0000000|C0205225|G0000000|C0011065|C0019994|C0450371|C0439228
"Overground walking velocity as measured in the 6-minute walk test and velocity in the 10-m walk test was slower in women, in older participants, in those with larger lesions (for the 10-m walk test fastest pace), and at higher baseline NIHSS score (Table 3).","Overground walking velocity measured 6-minute walk test velocity 10-m walk test slower women, participants, larger lesions (for 10-m walk test fastest pace), baseline NIHSS score (Table 3).",G0000000|C0080331|C0439830|C0444706|C0439232|C0080331|C0022885|C0439830|C0450371|C0080331|C0022885|C0439834|C0043210|C0679646|C0549177|C0221198|G0000000|C0450371|C0080331|C0022885|C0015663|C0287990|C0168634|C3476804|C0449820|C0039224|G0000000
"Comparison of manual group’s gingival, plaque, and oral hygiene index scores at 1, 2, and 6 weeks Notes:P-value is <0.0001.","Comparison manual group’s gingival, plaque, oral hygiene scores 1, 2, 6 weeks Notes:P-value <0.0001.",C1707455|C0024763|G0000000|C0017562|C0011389|C0442027|C0020405|C0449820|G0000000|G0000000|G0000000|C0439230|C1317574|G0000000
"There was no significant difference in sex, age, FVC, FEV1 or O2 saturation at baseline between the groups (Table 1).","There difference sex, age, FVC, FEV1 O2 saturation baseline (Table 1).",G0000000|C1705241|C0009253|C0001779|C3714541|G0000000|C0300971|C0522534|C0168634|C0039224|G0000000
Primary efficacy variable was the cure (no active trachoma (TF0)) at day 60.,Primary efficacy variable cure (no active trachoma (TF0)) day 60.,C0205225|C1280519|C0439828|C1880198|G0000000|C0205177|C0040592|C0076364|C0332173|C0450371
"The behavioral distress of groups was assessed before, during and after the intervention by Observational Scale of Behavioral Distress–Revised (OSBD-R).","The behavioral distress assessed before, intervention Observational Scale Behavioral Distress–Revised (OSBD-R).",G0000000|C0004927|C0231303|C1516048|C0332152|C0886296|C1518527|C0175659|C0004927|G0000000|C0205090
"At baseline and 6 months, the inflammatory markers such as interleukin- (IL-)8, neutrophil elastase (NE), matrix metalloproteinase- (MMP)9, hyaluronidase (HA), and type IV collagen in sputum were measured, along with the detection of dilated bronchus by throat computed tomography scan, and assessed the exacerbation.","At baseline 6 months, inflammatory markers interleukin- (IL-)8, neutrophil elastase (NE), matrix metalloproteinase- (MMP)9, hyaluronidase (HA), type IV collagen sputum measured, detection dilated bronchus throat computed tomography scan, assessed exacerbation.",G0000000|C0168634|G0000000|C0439231|C0333348|C0005516|C0021764|C0020898|C0027950|C0030306|C0028219|C1704640|C0025543|C0623362|C0020197|C0018510|C0332307|C0022326|C0009325|C0038056|C0444706|C1511790|C0700124|C0006255|C0031354|C1441526|C0040395|C0034606|C1516048|G0000000
"For the water intervention, enumerators collected samples of household stored water and tested it for the presence of free and total chlorine using Hach color wheels (Loveland, CO) immediately after leaving the household.","For water intervention, enumerators collected samples household stored water tested presence free total chlorine Hach color wheels (Loveland, CO) leaving household.",G0000000|C0043047|C0886296|G0000000|C1516695|C0370003|C0020052|C1698986|C0043047|C0392366|C0150312|C0332296|C0439175|C0008209|C1323560|C0009393|C1710669|G0000000|C3245499|G0000000|C0020052
"Primary outcomes were based on the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus statement recommendations for moderate (30% or greater pain reduction) and substantial (50% or greater pain reduction) improvement.24 Such reductions are highly sensitive and specific in predicting global impression of change in chronic pain patients25 and provide tangible evidence for clinical applications.26  Patient-based secondary outcomes27 were measured at baseline and at weeks 4, 8, and 12, using the Roland-Morris Disability Questionnaire (RMDQ),28 Medical Outcomes Study Short Form-36 Health Survey general health scale (SF-36 GH),29 number of lost work days in the past 4 weeks because of low back pain, and satisfaction with back care on a 5-point Likert scale.","Primary outcomes based Initiative Methods, Measurement, Pain Assessment Clinical Trials (IMMPACT) consensus statement recommendations moderate (30% pain reduction) substantial (50% pain reduction) improvement.24 Such reductions highly sensitive specific predicting global impression change chronic pain patients25 provide tangible evidence clinical applications.26 Patient-based secondary outcomes27 measured baseline weeks 4, 8, 12, Roland-Morris Disability Questionnaire (RMDQ),28 Medical Outcomes Study Short Form-36 Health Survey health scale (SF-36 GH),29 lost days 4 weeks low pain, satisfaction care 5-point Likert scale.",C0205225|C1274040|C1527178|C0424093|C0025663|C0242485|C0030193|C1261322|C0205210|C0008976|G0000000|C0376298|C1710187|C0034866|C0205081|C0450371|C0030193|C0301630|G0000000|C0450371|C0030193|C0301630|C2986411|G0000000|C0301630|C0205250|C0020517|C0205369|G0000000|C0205246|C0596764|C0392747|C0205191|C0030193|G0000000|C1999230|G0000000|C3887511|C0205210|C0185125|C1709483|C0027627|G0000000|C0444706|C0168634|C0439230|G0000000|G0000000|C0450371|G0000000|C0231170|C0034394|C0450371|C0199168|C1274040|C0557651|C1282927|C0348078|C0018684|C0038951|C0018684|C0175659|C0037712|C0033993|C0745777|C0439228|G0000000|C0439230|C0205251|C0030193|C0242428|C1947933|C1552961|G0000000|C0175659
The primary outcome was hospitalisation.,The primary outcome hospitalisation.,G0000000|C0205225|C1274040|C0019993
The indoor resting density was determined as the average number of anopheline females collected per house per night (f/h/n).,The indoor resting density determined average anopheline females collected house night (f/h/n).,G0000000|G0000000|C0035253|C0178587|G0000000|C1510992|G0000000|C0015780|C1516695|C0442519|C0240526|C0016327
Treatment failure was considered when remission was not achieved at week 4.,Treatment failure considered remission achieved week 4.,C0039798|C0231174|C0750591|C0544452|G0000000|C0332174|G0000000
The values of outcome measures are given in Tables Tables 3–6.,The values outcome measures Tables Tables 3–6.,G0000000|C0042295|C1274040|C0079809|C0039224|C0039224|G0000000
"All adverse events, oxygenation index, incidence of thrombocytopenia, all cause mortality, duration of ventilation, intensive care and antibiotic treatment, and ANC recovery were compared between the two groups.","All adverse events, oxygenation index, incidence thrombocytopenia, mortality, duration ventilation, intensive care antibiotic treatment, ANC recovery compared groups.",G0000000|G0000000|C0441471|C0231940|C0918012|C0021149|C0040034|C0026565|C0449238|C0035203|C0162425|C1947933|C0003232|C0039798|C0948762|C0237820|C1707455|C0441833
"The primary efficacy variable was the time to VOC resolution, modified from the poloxomer-188trial,42 defined by all of the following criteria being met: freedom from parenteral opioid use for at least 5 hours; pain relief [VAS scores ≤6 cm maintained during 2 consecutive readings obtained at least 2 hours apart, each at least 3 hours after the last dose of parenteral opioids]; ability to walk (except for chronically non-ambulatory participants); and agreement of the physician, and patient and parent or guardian that residual pain was low enough to be manageable at home.","The primary efficacy variable time VOC resolution, modified poloxomer-188trial,42 defined criteria met: freedom parenteral opioid 5 hours; pain relief [VAS scores ≤6 cm maintained 2 consecutive readings 2 hours apart, 3 hours dose parenteral opioids]; ability walk (except chronically non-ambulatory participants); agreement physician, patient parent guardian residual pain low manageable home.",G0000000|C0205225|C1280519|C0439828|C0040223|G0000000|C1514893|C0392747|C0450371|C1704788|C0243161|C0268621|C0016694|C0030547|C0242402|G0000000|C0439227|C0030193|C0564405|C0042815|C0449820|G0000000|G0000000|C1314677|G0000000|C1707491|C0034754|G0000000|C0439227|G0000000|G0000000|C0439227|C0178602|C0030547|C0242402|C0085732|C0080331|G0000000|G0000000|C0560046|C0679646|C0680240|C0031831|C0030705|C0030551|C0023226|C1609982|C0030193|C0205251|G0000000|C0442519
○ A recurrent vivax parasitaemia within 28 days is potentially a recrudescent infection.,○ A recurrent vivax parasitaemia 28 days recrudescent infection.,G0000000|G0000000|C2945760|G0000000|C0242723|C0450371|C0439228|C0086898|C0009450
"LDL: low-density lipoprotein, HDL: high-density lipoprotein The main results of this study can be summarized as follows: addition of ω-3 PUFA to statin therapy in CAD patients requiring stent implantation did not have any effect on atheroma volume index, change in percent atheroma volume, neointimal volume index, late loss, and in-stent restenosis rates.","LDL: low-density lipoprotein, HDL: high-density lipoprotein The main study summarized follows: addition ω-3 PUFA statin therapy CAD patients requiring stent implantation atheroma volume index, change percent atheroma volume, neointimal volume index, late loss, in-stent restenosis rates.",G0000000|C0205251|C0023820|C3715113|C0205250|C0023820|G0000000|C0205225|C0557651|G0000000|C0332283|C0332287|G0000000|C0032615|C0360714|C0039798|C3813548|C0030705|G0000000|C0038257|C0021107|C0264956|C0449468|C0918012|C0392747|C0439165|C0264956|C0449468|C2936380|C0449468|C0918012|C0205087|C1517945|C0150312|C0333186|C0871208
"In one patient from the USG group in whom initial cannulation failed, catheterization had to be done on the other side because the guide wire could not be passed after successful needle puncture under USG guidance.","In patient USG initial cannulation failed, catheterization guide wire passed successful needle puncture USG guidance.",G0000000|C0030705|G0000000|C0205265|C0917707|C0231175|C0007430|C0181090|C0005978|C2828386|C0597535|C0027551|C0033119|G0000000|C0150600
"Our secondary hypothesis was that the intervention would improve aerobic capacity, overall health status and activity limitations, the two latter variables assessed by the FIQ total score and the FIQ Physical.","Our secondary hypothesis intervention improve aerobic capacity, health status activity limitations, variables assessed FIQ total score FIQ Physical.",G0000000|C0027627|C1512571|C0886296|G0000000|C1510824|C1516240|C0018684|C0449438|C0205177|C0449295|C0439828|C1516048|G0000000|C0439175|C0449820|G0000000|C0031809
"The cognitive battery consisted of the Stroop Color-Word Test−Victoria version, the CVLT-II, the COWAT, and the 2-second version of the Paced Auditory Serial Addition Task (PASAT).","The cognitive battery consisted Stroop Color-Word Test−Victoria version, CVLT-II, COWAT, 2-second version Paced Auditory Serial Addition Task (PASAT).",G0000000|C1516691|C0337088|C0332529|G0000000|C0009393|G0000000|C0333052|C3899729|C3827022|C0205436|C0333052|C0287990|C0439825|C0031082|C0332287|C3540678|C3898036
"An increased attention to dietary intake and nutritional status in elderly women with a hip fracture reduced mortality during hospital stay and after four months follow up, by 60% and 43% respectively [3].","An increased attention dietary intake nutritional status elderly women hip fracture reduced mortality hospital stay months follow up, 60% 43% [3].",G0000000|C0205217|C0004268|C0012155|C1512806|C1521739|C0449438|C0001792|C0043210|C0019552|C0016658|C0392756|C0026565|C0019994|G0000000|C0439231|C0332283|G0000000|C0450371|C0450371|G0000000
"Specifically, decreases in serum triglycerides and LDL cholesterol, accompanied by increases in HDL with green tea consumption suggest a metabolic shift consistent with a reduction in cardiovascular risk in this population.","Specifically, decreases serum triglycerides LDL cholesterol, accompanied increases HDL green tea consumption metabolic shift consistent reduction cardiovascular risk population.",G0000000|C0442797|C0229671|C0041004|G0000000|C0008377|G0000000|C0205217|C3715113|C0332583|C0039400|C0009830|C0311400|C0333051|C0332290|C0301630|C0007226|C0035647|C0032659
After ischemia the endothelial-dependent dilatation of blood vessels was measured for 5 min.,After ischemia endothelial-dependent dilatation blood vessels measured 5 min.,G0000000|C0022116|C0014257|C0012359|C0005767|C0005847|C0444706|G0000000|C0702093
"Furthermore, it will also explore changes in physical activity with exercise and any impact on post-operative outcome measures.","Furthermore, explore physical activity exercise impact post-operative outcome measures.",G0000000|G0000000|C0031809|C0205177|C0015259|C1825598|C0032790|C1274040|C0079809
Box plots of changes in global symptom score (GSS) at (A) two weeks and (B) eight weeks.,Box plots global symptom score (GSS) (A) weeks (B) weeks.,C0179400|G0000000|C0205246|C1457887|C0449820|C0017495|G0000000|C0439230|G0000000|C0439230
"After training, a set of two consecutive 24‐hour diaries (48 hours total) were completed before day 1 (day of randomization), serving as the baseline diary score, and repeated before the week 2, week 4, week 6 and week 8 visits.","After training, set consecutive 24‐hour diaries (48 hours total) completed day 1 (day randomization), serving baseline diary score, repeated week 2, week 4, week 6 week 8 visits.",G0000000|C0040607|C0036849|C1707491|G0000000|C0376660|C0450371|C0439227|C0439175|C0205197|C0332173|G0000000|C0332173|C0034656|C1519269|C0168634|C0376660|C0449820|C0205341|C0332174|G0000000|C0332174|G0000000|C0332174|G0000000|C0332174|G0000000|C0545082
We took the Roland and Morris disability questionnaire as the primary outcome.,We Roland Morris disability questionnaire primary outcome.,G0000000|G0000000|G0000000|C0231170|C0034394|C0205225|C1274040
"The secondary outcome measures included stool frequency, consistency of stools determined using the seven-point Bristol Stool Form Scale [7] (1 for hard lumps to 7 for watery stools—for details, see Table 1), need for antibiotic therapy (yes/no), vomiting (yes/no; how many times), diarrhea recurrence, tolerance of the study products, need for hospitalization (yes/no, how long), need for unscheduled intravenous rehydration therapy (yes/no, how long), and adverse events.","The secondary outcome measures included stool frequency, consistency stools determined seven-point Bristol Stool Form Scale [7] (1 hard lumps 7 watery stools—for details, Table 1), antibiotic therapy (yes/no), vomiting (yes/no; times), diarrhea recurrence, tolerance study products, hospitalization (yes/no, long), unscheduled intravenous rehydration therapy (yes/no, long), adverse events.",G0000000|C0027627|C1274040|C0079809|C0332257|C0015733|C0376249|C0332529|C0015733|G0000000|C0205453|G0000000|C0015733|C0348078|C0175659|G0000000|G0000000|C0018599|C0577559|G0000000|C0443350|G0000000|C1522508|C0039224|G0000000|C0003232|C0039798|C1512698|C0042963|C1512698|C0040223|C0011991|C0034897|C0013220|C0557651|C1514468|C0019993|C1512698|C0205166|C1699701|C0348016|C0034997|C0039798|C1512698|C0205166|G0000000|C0441471
"Parental smoking, engagement in tobacco treatment, and home and car smoking policies 8 weeks later.","Parental smoking, engagement tobacco treatment, car smoking policies 8 weeks later.",C0030551|C0037369|C0425152|C0040329|C0039798|C0004381|C0037369|C0242456|G0000000|C0439230|C0205087
"The median 4-month progression free survival was 99 and 98 days, respectively (P=0.679).","The median 4-month progression free survival 99 98 days, (P=0.679).",G0000000|C0549183|C0332177|C0242656|C0332296|C0038952|C0450371|C0450371|C0439228|C0369773
"In 3a, absolute MEP amplitudes for the agonist and antagonist muscles to the physically practice direction is shown at baseline (pre) and after (post) each intervention in the 3 sessions.","In 3a, absolute MEP amplitudes agonist antagonist muscles physically practice direction baseline (pre) (post) intervention 3 sessions.",G0000000|C1420849|C0205344|C1707163|C2346753|C2987634|C0231491|C0026845|G0000000|C0237607|C0449738|C0168634|C0332152|C0687676|C0886296|G0000000|C1883016
(4) Only one hepatitis B shot is needed to protect a person against hepatitis B.,(4) Only hepatitis B shot protect person hepatitis B.,G0000000|C0205171|C0019158|G0000000|C0021485|G0000000|C0027361|C0019158|G0000000
"PES had no significant effects on secondary measures of swallowing and feeding, including radiological aspiration (PAS) at 12 weeks, and clinical dysphagia (DSRS) and feeding route at weeks 2 and 12 (Table (Table3;3; Table II in the online-only Data Supplement).","PES effects secondary measures swallowing feeding, including radiological aspiration (PAS) 12 weeks, clinical dysphagia (DSRS) feeding route weeks 2 12 (Table (Table3;3; Table II online-only Data Supplement).",C0016504|C1280500|C0027627|C0079809|C0011167|C0204695|C0332257|C0034599|C0220787|C0030125|C0450371|C0439230|C0205210|C0011168|C0596468|C0204695|C0013153|C0439230|G0000000|C0450371|C0039224|G0000000|C0039224|G0000000|C0205171|C1511726|C0242295
"After completing a baseline assessment, participants were randomly allocated to either the intervention or control condition.","After completing baseline assessment, participants randomly allocated intervention control condition.",G0000000|C0205197|C0168634|C1261322|C0679646|G0000000|G0000000|C0886296|C0243148|C0012634
Fungal infection is less in the study group (P = 0.001).,Fungal infection study (P = 0.001).,C0016832|C0009450|C0557651|C0369773|G0000000|C1442061
Primary endpoints were mean change in serum calcium at each vitamin D dose and a comparison of serum calcium between groups.,Primary endpoints change serum calcium vitamin D dose comparison serum calcium groups.,C0205225|C2349179|C0392747|C0229671|C0006675|C0042890|C0073187|C0178602|C1707455|C0229671|C0006675|C0441833
"Admission to neonatal care unit (and reason) Neonatal composite morbidity, including birth trauma (fracture, brachial plexus injury, cephalohaematoma, subgaleal haematoma), hypoxic ischaemic encephalopathy, sepsis, respiratory distress requiring continuous positive airway pressure support, hypoglycaemia requiring dextrose treatment (buccal or intravenous) Initiation and establishment of breast feeding, including feeding in first two postnatal weeks (collected by phone call at 6 weeks and questionnaires) Infant anthropometry and body composition at 5 months of age, as detailed above Infant feeding over first 5 months (breast feeding, formula use, complementary feeding with solids) Feeding behaviour as assessed by BEBQ scores [69] Infant Nutritional intake at 5 months, estimated from a four day food frequency questionnaire  Other secondary outcomes include: Attendance at study visits Adherence to probiotic/placebo regime Cost effectiveness of the intervention  A total of 220 participants will be recruited.","Admission neonatal care unit (and reason) Neonatal composite morbidity, including birth trauma (fracture, brachial plexus injury, cephalohaematoma, subgaleal haematoma), hypoxic ischaemic encephalopathy, sepsis, respiratory distress requiring continuous positive airway pressure support, hypoglycaemia requiring dextrose treatment (buccal intravenous) Initiation establishment breast feeding, including feeding postnatal weeks (collected phone call 6 weeks questionnaires) Infant anthropometry body composition 5 months age, detailed Infant feeding 5 months (breast feeding, formula use, complementary feeding solids) Feeding behaviour assessed BEBQ scores [69] Infant Nutritional intake 5 months, estimated day food frequency questionnaire Other secondary outcomes include: Attendance study visits Adherence probiotic/placebo regime Cost effectiveness intervention A total 220 participants recruited.",C0184666|C1552240|C1947933|C0439148|G0000000|C0392360|C1552240|C0205199|C0026538|C0332257|C0005615|C0043251|C0016658|C0445456|C1184808|C3263722|C0007722|G0000000|C0018944|C0242184|C0475224|C0006111|C0036690|C0521346|C0231303|G0000000|C0549178|C0439178|C0178987|C0033095|C0183683|C0020615|G0000000|C0017725|C0039798|C0442010|C0348016|C0589507|G0000000|C0006141|C0204695|C0332257|C0204695|C0443281|C0439230|C1516695|C1515258|C0679006|G0000000|C0439230|C0034394|C0021270|C0003188|C0242821|C0486616|G0000000|C0439231|C0001779|C1522508|C0021270|C0204695|G0000000|C0439231|C0006141|C0204695|C0489829|C0042153|G0000000|C0204695|C0205208|C0204695|C0004927|C1516048|G0000000|C0449820|C0450371|C0021270|C1521739|C1512806|G0000000|C0439231|C0750572|C0332173|C0016452|C0376249|C0034394|G0000000|C0027627|C1274040|C0332257|C2827364|C0557651|C0545082|C1510802|C0525033|G0000000|C0010186|C1280519|C0886296|G0000000|C0439175|C1442061|C0679646|G0000000
"The authors reported that in the probiotic/smectite group compared with the probiotic alone group, there was a significantly shorter duration of fluid stools, shorter duration of intravenous rehydration, shorter duration of hospitalization, shorter duration of fever >38 °C, and greater weight gain.","The authors reported probiotic/smectite compared probiotic group, shorter duration fluid stools, shorter duration intravenous rehydration, shorter duration hospitalization, shorter duration fever >38 °C, weight gain.",G0000000|C3812881|C0684224|C0525033|C1707455|C0525033|C0441833|C1282927|C0449238|C0005889|C0015733|C1282927|C0449238|C0348016|C0034997|C1282927|C0449238|C0019993|C1282927|C0449238|C0015967|C0450371|G0000000|C0005910|C1517378
"Assessment parameters were calculated as follows; 1- Functional status was calculated with the Fibromyalgia Impact Questionnaire (FIQ), which measures 10 different features, namely physical disability, feeling good, loss of work day, difficulty in working, pain, fatigue, feeling fresh, stiffness, anxiety, and depression.","Assessment parameters calculated follows; 1- Functional status calculated Fibromyalgia Impact Questionnaire (FIQ), measures 10 features, physical disability, feeling good, loss day, difficulty working, pain, fatigue, feeling fresh, stiffness, anxiety, depression.",C1261322|C0449381|C0444686|C0332283|G0000000|C0205245|C0449438|C0444686|C0016053|C1825598|C0034394|G0000000|C0079809|C0450371|C1521970|C0031809|C0231170|C0013987|C0205170|C1517945|C0332173|C1299586|C0043227|C0030193|C0015672|C0013987|C0443224|C0427008|C0003467|C0011570
"However, plasma zinc concentrations in early pregnancy were positively correlated with serum ferritin (r = 0.137, p = 0.051) and serum iron (r = 0.261, p = 0.001).","However, plasma zinc concentrations pregnancy positively correlated serum ferritin (r = 0.137, = 0.051) serum iron (r = 0.261, = 0.001).",G0000000|C0032105|C0043481|C0086045|C0032961|G0000000|C1707520|C0229671|C0015879|C0205090|G0000000|C1442061|G0000000|C1442061|C0229671|C0302583|C0205090|G0000000|C1442061|G0000000|C1442061
"Visually evoked potentials, visual field, retinal nerve fiber layer (RNFL) thickness, and health outcomes were also assessed.","Visually evoked potentials, visual field, retinal nerve fiber layer (RNFL) thickness, health outcomes assessed.",G0000000|C1444748|C3245505|C0234621|C0440042|C0035298|C0027740|C0012173|C0934502|G0000000|C1280412|C0018684|C1274040|C1516048
"Clinical signs and symptoms of malaria were assessed at screening, Days 1, 2 and 3 and at other visits if indicated.","Clinical signs symptoms malaria assessed screening, Days 1, 2 3 visits indicated.",C0205210|C0220912|C0683368|C0024530|C1516048|C0220908|C0439228|G0000000|G0000000|G0000000|C0545082|C1444656
Poststroke depression has been shown in numerous studies to be associated with both impaired recovery in activities of daily living and increased mortality.,Poststroke depression numerous studies impaired recovery activities daily living increased mortality.,G0000000|C0011570|C0439064|C0947630|C0221099|C0237820|C0441655|C0332173|C0376558|C0205217|C0026565
"For women in the DC group, the significant change in diastolic BP occurred by week 12.","For women DC group, change diastolic BP occurred week 12.",G0000000|C0043210|G0000000|C0441833|C0392747|C0012000|C0037623|C1709305|C0332174|C0450371
Cancers were identified by linkage to the Cancer Registry of Norway.,Cancers identified linkage Cancer Registry Norway.,C0006826|C0205396|C0023745|C0006826|C0034975|C0028423
"Among young persons with chronic migraine, the use of CBT plus amitriptyline resulted in greater reductions in days with headache and migraine-related disability compared with use of headache education plus amitriptyline.","Among persons chronic migraine, CBT amitriptyline reductions days headache migraine-related disability compared headache education amitriptyline.",G0000000|C0027361|C0205191|C0149931|C0009244|C0002600|C0301630|C0439228|C0018681|C0149931|C0231170|C1707455|C0018681|C0013621|C0002600
"Only two studies which aim to control the GWG through lifestyle interventions including only pregnancy period and examine the effect of the interventions on the extended dietary outcomes (such as daily energy, macro and micro food components intake, and vegetable and fruit consumption) as in this study were found [13, 16].","Only studies aim control GWG lifestyle interventions including pregnancy period examine interventions extended dietary outcomes (such daily energy, macro micro food components intake, vegetable fruit consumption) study [13, 16].",C0205171|C0947630|C1947946|C0243148|G0000000|C0023676|C0886296|C0332257|C0032961|C0439531|G0000000|C0886296|C0231448|C0012155|C1274040|G0000000|C0332173|C0424589|C2984010|C0085672|C0016452|C0449432|C1512806|C0042440|C0016767|C0009830|C0557651|C0450371|C0450371
"Duloxetine also exerted significant improvements over the placebo in nearly all secondary outcome measures including 24‐h worst pain, night pain, Brief Pain Inventory (BPI) pain scores, Patient’s Global Impression of Improvement (PGI‐I) and health outcome measures, namely, various BPI interference scores.","Duloxetine exerted improvements placebo secondary outcome measures including 24‐h worst pain, night pain, Brief Pain Inventory (BPI) pain scores, Patient’s Global Impression Improvement (PGI‐I) health outcome measures, namely, BPI interference scores.",C0245561|C0015264|C2986411|C0032042|C0027627|C1274040|C0079809|C0332257|G0000000|C1522166|C0030193|C0240526|C0030193|C1282927|C0030193|C0021941|C1443145|C0030193|C0449820|G0000000|C0205246|C0596764|C2986411|G0000000|C0018684|C1274040|C0079809|G0000000|C1443145|C0521102|C0449820
We also hypothesized that the direct effects of the intervention on substance use and delinquent behavior would persist even in the context of the indirect effects of prosocial skills and placement stability because of the direct emphasis of the intervention on the prevention of the two primary outcomes.,We hypothesized direct effects intervention substance delinquent behavior persist context indirect effects prosocial skills placement stability direct emphasis intervention prevention primary outcomes.,G0000000|G0000000|C0439851|C1280500|C0886296|C0439861|C0522175|C0004927|G0000000|C0449255|C0439852|C1280500|G0000000|C0678856|C0441587|C0205360|C0439851|G0000000|C0886296|C0199176|C0205225|C1274040
"The primary outcome end-point of the study being reported here was the number of decayed primary teeth, defined as cavitated carious lesions.","The primary outcome end-point study reported decayed primary teeth, defined cavitated carious lesions.",G0000000|C0205225|C1274040|C2349179|C0557651|C0684224|C1265875|C0205225|C0040426|C1704788|C1510420|G0000000|C0221198
"Hamilton depression rating scale, clinical global impression scale, and patient's global impression scale.","Hamilton depression rating scale, clinical global impression scale, patient's global impression scale.",G0000000|C0011570|C0871208|C0175659|C0205210|C0205246|C0596764|C0175659|C0030705|C0205246|C0596764|C0175659
"To evaluate quality of life (QoL), the German version of the European Organization of Research and Treatment of Cancer QoL questionnaire EORTC QLQ-C30 and its breast-cancer-specific module EORTC QLQ-BR23 were administered at baseline, after the intervention and 3 months after the intervention.","To evaluate quality life (QoL), German version European Organization Research Treatment Cancer QoL questionnaire EORTC QLQ-C30 breast-cancer-specific module EORTC QLQ-BR23 administered baseline, intervention 3 months intervention.",C0040363|C0220825|C0332306|C0376558|C0518214|C1556085|C0333052|C0239307|C0029237|C0035168|C0039798|C0006826|C0518214|C0034394|C1516985|G0000000|C0006142|C1709061|C1516985|G0000000|C1521801|C0168634|C0886296|G0000000|C0439231|C0886296
The primary outcome measure for the study was response rates according to the 17-item Hamilton Depression Rating Scale (HAM-D-17)17.,The primary outcome measure study response rates 17-item Hamilton Depression Rating Scale (HAM-D-17)17.,G0000000|C0205225|C1274040|C0079809|C0557651|C0871261|C0871208|C0450371|G0000000|C0011570|C0871208|C0175659|C1570167
"In the same subsample of children for whom motor milestones were assessed, there was no impact of iron+folic acid or zinc on nutritional status measured 4 y later (22).","In subsample children motor milestones assessed, impact iron+folic acid zinc nutritional status measured 4 (22).",G0000000|G0000000|C0008059|C1513492|C2347129|C1516048|C1825598|C0302583|C0001128|C0043481|C1521739|C0449438|C0444706|G0000000|C0450371
A vaccine-induced response was defined as at least a 3-fold increase in response after vaccination compared with the baseline sample.,A vaccine-induced response defined 3-fold increase response vaccination compared baseline sample.,G0000000|C0042210|C0871261|C1704788|C0332462|C0442805|C0871261|C0042196|C1707455|C0168634|C0370003
Main outcome measures Primary outcomes were the time without fever (<37.2°C) in the first four hours after the first dose was given and the proportion of children reported as being normal on the discomfort scale at 48 hours.,Main outcome measures Primary outcomes time fever (<37.2°C) hours dose proportion children reported normal discomfort scale 48 hours.,C0205225|C1274040|C0079809|C0205225|C1274040|C0040223|C0015967|G0000000|C0439227|C0178602|C1709707|C0008059|C0684224|C0205307|C0231218|C0175659|C0450371|C0439227
"Correlations of blood levels of docosahexaenoic acid (DHA) and mercury at baseline, and hair mercury at 12-week follow-up, with dietary intake of fish, DHA, and mercury among 59 pregnant women enrolled in the Food for Thought study.","Correlations blood levels docosahexaenoic acid (DHA) mercury baseline, hair mercury 12-week follow-up, dietary intake fish, DHA, mercury 59 pregnant women enrolled Food Thought study.",C1707520|C0005767|C0441889|G0000000|C0001128|C0142831|C0025424|C0168634|C0018494|C0025424|C0450371|C0589120|C0012155|C1512806|C0016163|C0142831|C0025424|C0450371|C0549206|C0043210|G0000000|C0016452|C0039869|C0557651
"To evaluate the efficacy of real rTMS versus sham rTMS in the treatment of chronic tinnitus by means of a change of tinnitus severity according to the tinnitus questionnaire of Goebel & Hiller ([30], a self-rating questionnaire; baseline versus day 12).","To evaluate efficacy real rTMS versus sham rTMS treatment chronic tinnitus change tinnitus severity tinnitus questionnaire Goebel & Hiller ([30], self-rating questionnaire; baseline versus day 12).",C0040363|C0220825|C1280519|C0237400|G0000000|G0000000|C0068899|G0000000|C0039798|C0205191|C0040264|C0392747|C0040264|C0439793|C0040264|C0034394|G0000000|G0000000|G0000000|C0450371|C4054119|C0034394|C0168634|G0000000|C0332173|C0450371
"The primary outcome was opioid-positive urine test results at weeks 4, 8, and 12.","The primary outcome opioid-positive urine test weeks 4, 8, 12.",G0000000|C0205225|C1274040|C0242402|C0042036|C0022885|C0439230|G0000000|G0000000|C0450371
Neither a clinical or histologic response to GTE intervention was associated with oral cancer development.,Neither clinical histologic response GTE intervention oral cancer development.,G0000000|C0205210|C0205462|C0871261|G0000000|C0886296|C0442027|C0006826|C0243107
"Our findings indicate that both treatment groups demonstrated statistically significant improvements in the primary treatment outcome of headache frequency as well as statistically significant improvements on secondary outcomes of headache pain intensity, activity limitations, depressive symptoms and parent protective behaviors from pre-treatment to immediate post-treatment.","Our findings treatment demonstrated statistically improvements primary treatment outcome headache frequency statistically improvements secondary outcomes headache pain intensity, activity limitations, depressive symptoms parent protective behaviors pre-treatment post-treatment.",G0000000|C2607943|C0039798|G0000000|C0038215|C2986411|C0205225|C0039798|C1274040|C0018681|C0376249|C0038215|C2986411|C0027627|C1274040|C0018681|C0030193|C0522510|C0205177|C0449295|G0000000|C0683368|C0030551|G0000000|C0004927|C2709094|C2709088
Severe toxicity did not occur.,Severe toxicity occur.,C0205082|C0040539|C1709305
Demographic Characteristics of the Participants of This Study All participants underwent three-dimensional foot scanning and pedobarography.,Demographic Characteristics Participants This Study All participants underwent three-dimensional foot scanning pedobarography.,C0011298|C1521970|C0679646|G0000000|C0557651|G0000000|C0679646|G0000000|C0450363|C0016504|C0034606|G0000000
"Secondary outcomes included 1) seizure freedom, defined as having no seizures during the 3-month period immediately prior to the 6-month follow-up point; 2) Work and Social Adjustment Scale (WASAS) scores18,19; 3) Hospital Anxiety and Depression Scale (HADS) scores20-22; and 4) a modified Client Service Receipt Inventory23 measuring patients' health service use and employment during the 6 months prior to treatment and in the 6-month follow-up period.","Secondary outcomes included 1) seizure freedom, defined seizures 3-month period prior 6-month follow-up point; 2) Work Social Adjustment Scale (WASAS) scores18,19; 3) Hospital Anxiety Depression Scale (HADS) scores20-22; 4) modified Client Service Receipt Inventory23 measuring patients' health service employment 6 months prior treatment 6-month follow-up period.",C0027627|C1274040|C0332257|G0000000|C0036572|C0016694|C1704788|C0036572|C0332177|C0439531|C0332152|C0332177|C0589120|C1552961|G0000000|C0043227|C0728831|C0376209|C0175659|G0000000|C0450371|G0000000|C0019994|C0003467|C0011570|C0175659|C0048008|C0450371|G0000000|C0392747|C0008942|C0557854|G0000000|G0000000|C0444706|C0030705|C0018684|C0557854|C0014003|G0000000|C0439231|C0332152|C0039798|C0332177|C0589120|C0439531
They reported reduced depression in the exercise group (average 0.5 points on the Cornell Scale for Depression in Dementia) and increased depression (average 0.5 points on the Cornell Scale for Depression in Dementia) for the usual care group.,They reported reduced depression exercise (average 0.5 Cornell Scale Depression Dementia) increased depression (average 0.5 Cornell Scale Depression Dementia) usual care group.,G0000000|C0684224|C0392756|C0011570|C0015259|C1510992|G0000000|G0000000|C0175659|C0011570|C0011265|C0205217|C0011570|C1510992|G0000000|G0000000|C0175659|C0011570|C0011265|C3538928|C1947933|C0441833
"At least 18 months after completion of chemotherapy, mean FSH levels were 19.0 mIU/mL in the control arm and 15.7 mIU/mL (P= .46) in the triptorelin arm.","At 18 months completion chemotherapy, FSH levels 19.0 mIU/mL control arm 15.7 mIU/mL (P= .46) triptorelin arm.",G0000000|C0450371|C0439231|C0205197|C0013216|G0000000|C0441889|C0450371|C0439457|C0243148|C0446516|C0450371|C0439457|C0369773|C0450371|C0077275|C0446516
Quality of life improved similarly in both groups.,Quality life improved groups.,C0332306|C0376558|C0184511|C0441833
Comparison of scores in the two arms of the study revealed no statistically significant differences after 12 or 24 months of follow-up.,Comparison scores arms study revealed statistically differences 12 24 months follow-up.,C1707455|C0449820|C0206655|C0557651|C0443289|C0038215|C1705241|C0450371|C0450371|C0439231|C0589120
Mortality rates with resistant An.,Mortality rates resistant An.,C0026565|C0871208|C0332325|G0000000
"However, back pain clearly has a considerable cost to society.","However, pain considerable cost society.",G0000000|C0030193|G0000000|C0010186|C0037455
"Secondary outcomes were perceived burden (Zarit Burden score), distress due to problem behaviours (NPI-D) and severity of the behavioural problems in the person with dementia (NPI-S), and functional ability of the subject (EASI).","Secondary outcomes perceived burden (Zarit Burden score), distress behaviours (NPI-D) severity behavioural person dementia (NPI-S), functional ability subject (EASI).",C0027627|C1274040|C0030971|C2828008|G0000000|C2828008|C0449820|C0231303|C0004927|C1412208|C0439793|C0004927|C0027361|C0011265|C1412208|C0205245|C0085732|C0681850|C1516931
"The 7-day point prevalence cessation rates at the end of the intervention (0 month) and at follow-up (1, 3, and 6 months) are displayed in Table 2.","The 7-day prevalence cessation rates intervention (0 month) follow-up (1, 3, 6 months) displayed Table 2.",G0000000|C0332173|C0033105|C1880019|C0871208|C0886296|G0000000|C0332177|C0589120|G0000000|G0000000|G0000000|C0439231|C0870432|C0039224|G0000000
Schematic hypothesis for how flavanols reduce N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) levels and improve cardiac function in chronic heart failure.,Schematic hypothesis flavanols reduce N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) levels improve cardiac function chronic heart failure.,G0000000|C1512571|C2348678|G0000000|G0000000|G0000000|C0597421|C0030956|G0000000|C0441889|G0000000|C0018787|C0031843|C0205191|C0018787|C0231174
"All changes (Δ: initial – at 3 months) of RA characteristics, including disease activity (mean ΔDAS-28-ESR and ΔRAPID3) and functional disability (mean ΔHAQ), related to RA over time were not significantly different between the two groups.","All (Δ: initial – 3 months) RA characteristics, including disease activity (mean ΔDAS-28-ESR ΔRAPID3) functional disability (mean ΔHAQ), RA time groups.",G0000000|G0000000|C0205265|G0000000|G0000000|C0439231|C3538806|C1521970|C0332257|C0012634|C0205177|C0444504|G0000000|G0000000|C0205245|C0231170|C0444504|G0000000|C3538806|C0040223|C0441833
Tumour response occurred in 19% (95% CI 13–27) of gemcitabine patients.,Tumour response occurred 19% (95% CI 13–27) gemcitabine patients.,C0027651|C0871261|C1709305|C0450371|C0450371|C0008107|G0000000|C0045093|C0030705
"We calculated differences in adult height for each active treatment group, as compared with placebo, using multiple linear regression with adjustment for demographic characteristics, asthma features, and height at trial entry.","We calculated differences adult height active treatment group, compared placebo, multiple linear regression adjustment demographic characteristics, asthma features, height trial entry.",G0000000|C0444686|C1705241|C0001675|C0489786|C0205177|C0039798|C0441833|C1707455|C0032042|C0439064|C0205132|C0684320|C0376209|C0011298|C1521970|C0004096|C1521970|C0489786|C0008976|C1705654
"Even so, average monthly seizure frequency, time to the first seizure after randomization, and the proportion of subjects in either arm who experienced seizure freedom throughout the trial period were chosen as (clinical) secondary outcomes.","Even so, average monthly seizure frequency, time seizure randomization, proportion subjects arm experienced seizure freedom trial period chosen (clinical) secondary outcomes.",G0000000|C0037640|C1510992|C0332177|C0036572|C0376249|C0040223|C0036572|C0034656|C1709707|C0681850|C0446516|C0237607|C0036572|C0016694|C0008976|C0439531|C1707391|C0205210|C0027627|C1274040
"The following were assessed as secondary efficacy variables: the change in FEV1 at t = 3, 15, 60, 90 and 180 minutes after the last intake of study medication; the change in respiratory rate at 180 minutes; the proportion of patients with treatment success at 90 and 180 minutes; the proportion of patients with treatment failure at 180 minutes; and the effectiveness of the study medication at 3 and 15 minutes.","The assessed secondary efficacy variables: change FEV1 = 3, 15, 60, 90 180 minutes intake study medication; change respiratory rate 180 minutes; proportion patients treatment success 90 180 minutes; proportion patients treatment failure 180 minutes; effectiveness study medication 3 15 minutes.",G0000000|C1516048|C0027627|C1280519|C0439828|C0392747|G0000000|G0000000|G0000000|C0450371|C0450371|C0450371|C1442061|C0439232|C1512806|C0557651|C0013227|C0392747|C0521346|C0871208|C1442061|C0439232|C1709707|C0030705|C0039798|C0597535|C0450371|C1442061|C0439232|C1709707|C0030705|C0039798|C0231174|C1442061|C0439232|C1280519|C0557651|C0013227|G0000000|C0450371|C0439232
"In contrast, the number of exacerbation-free months takes account of the fact that the added years of life are partly lived free of exacerbations.","In contrast, exacerbation-free months takes account life partly lived free exacerbations.",G0000000|C0009924|C0332296|C0439231|C1515187|C2741673|C0376558|G0000000|C1548795|C0332296|G0000000
"Although the LPA participants reported greater perceived improvement at each follow-up, they did not differ from controls on pain, physical activity, tenderness, fatigue, depression, or the 6-minute walk test.","Although LPA participants reported perceived improvement follow-up, controls pain, physical activity, tenderness, fatigue, depression, 6-minute walk test.",G0000000|C1096202|C0679646|C0684224|C0030971|C2986411|C0589120|C0243148|C0030193|C0031809|C0205177|C0234233|C0015672|C0011570|C0439232|C0080331|C0022885
Persistent infection was defined as two or more Pa-positive cultures after the first quarter of therapy.,Persistent infection defined Pa-positive cultures quarter therapy.,C0205322|C0009450|C1704788|C0030428|C0010453|C2825406|C0039798
"The peak incidence is between 6 and 18 months of age, and stunting with moderate underweight is the most common presentation (National Statistical Office and ORC Macro 2001; Maleta et al.","The peak incidence 6 18 months age, stunting moderate underweight common presentation (National Statistical Office ORC Macro 2001; Maleta et al.",G0000000|C0444505|C0021149|G0000000|C0450371|C0439231|C0001779|C0018273|C0205081|C0041667|C0205214|C0449450|C3245503|C0038215|C0442603|C1167125|C2984010|G0000000|G0000000|G0000000
"To determine the validity of the questionnaire designed by the researcher, it was revised and approved by five faculty members of psychiatric nursing, one PhD of nursing, three psychiatric nurses, two psychiatrists, and six psychologists.","To determine validity questionnaire designed researcher, revised approved faculty psychiatric nursing, PhD nursing, psychiatric nurses, psychiatrists, psychologists.",C0040363|G0000000|C2349101|C0034394|C1707689|C0035173|C1527075|C0205540|C0015535|C0205487|C0006147|G0000000|C0006147|C0205487|C0028661|C0033872|C0033908
"For the 10 trials involving the proper doffing of FFRs with contaminated hands (examining the transfer from hands to the head), 100% of subjects transferred contamination to the head, face, and/or hair areas when FFRs without tabs were used.","For 10 trials involving proper doffing FFRs contaminated hands (examining transfer hands head), 100% subjects transferred contamination head, face, and/or hair FFRs tabs used.",G0000000|C0450371|C0008976|C1314939|G0000000|G0000000|C1412871|C0205279|C0018563|C0332128|C0040671|C0018563|C0018670|C1442061|C0681850|C0348011|C0259846|C0018670|C0015450|G0000000|C0018494|C1412871|C0039225|C1273517
Outcome will be dichotomized and defined as good (mRS 0 to 2) or poor (mRS 3 to 6).,Outcome dichotomized defined (mRS 0 2) poor (mRS 3 6).,C1274040|G0000000|C1704788|C1522706|G0000000|G0000000|C0032854|C1522706|G0000000|G0000000
"The NY-ESO-1 tumor antigen is frequently expressed in ovarian cancer and melanoma, eliciting both cellular and humoral immune responses in a proportion of patients with advanced NY-ESO-1-expressing tumors (3, 10).","The NY-ESO-1 tumor antigen frequently expressed ovarian cancer melanoma, eliciting cellular humoral immune responses proportion patients advanced NY-ESO-1-expressing tumors (3, 10).",G0000000|C0027976|C0027651|C0003320|C0332183|G0000000|C0205065|C0006826|C0025202|C0449265|C0007634|C0020168|C0439662|C0871261|C1709707|C0030705|C0205179|C0027976|C0027651|G0000000|C0450371
"Secondary outcomes included time to recovery, rate of adverse events (allergic reactions, vomiting, and diarrhea), and rates of gain in weight, length, and MUAC.","Secondary outcomes included time recovery, rate adverse events (allergic reactions, vomiting, diarrhea), rates gain weight, length, MUAC.",C0027627|C1274040|C0332257|C0040223|C0237820|C0871208|G0000000|C0441471|C0700624|C0443286|C0042963|C0011991|C0871208|C1517378|C0005910|C1444754|G0000000
"From the 42 participants recruited, 38 participants completed neuropsychological testing at both baseline and 16 weeks.","From 42 participants recruited, 38 participants completed neuropsychological testing baseline 16 weeks.",G0000000|C0450371|C0679646|G0000000|C0450371|C0679646|C0205197|G0000000|C0039593|C0168634|C0450371|C0439230
Clinical Global Impressions – Improvement – Independent Evaluator.,Clinical Global Impressions – Improvement – Independent Evaluator.,C0205210|C0205246|C0596764|G0000000|C2986411|G0000000|C0085862|C1707957
The primary outcomes of the study are shown in Figure 2 and Table 4.,The primary outcomes study Figure 2 Table 4.,G0000000|C0205225|C1274040|C0557651|G0000000|G0000000|C0039224|G0000000
"The incidences of anaemia and hospital admissions are probably underestimated in both the placebo and IPTi groups in our study, and thus the public health impact of IPTi on these outcomes may also be underestimated; more cases may have been prevented than we were able to detect.","The incidences anaemia hospital admissions underestimated placebo IPTi study, public health impact IPTi outcomes underestimated; prevented detect.",G0000000|C0021149|C0002871|C0019994|C0184666|G0000000|C0032042|G0000000|C0557651|G0000000|C0018684|C1825598|G0000000|C1274040|G0000000|C0309872|C0442726
"Change in Motor Performance After Intensive Training Note: Interval motor evaluation for 3 preliminary evaluations (Pre1, Pre2, Pre3), a calculated average admission (Avg), midpoint (Mid), discharge (Dis), and follow-up (FU) for the primary measures (mean ± SEM).","Change Motor Performance After Intensive Training Note: Interval motor evaluation 3 preliminary evaluations (Pre1, Pre2, Pre3), calculated average admission (Avg), midpoint (Mid), discharge (Dis), follow-up (FU) primary measures (mean ± SEM).",C0392747|C1513492|C0597198|G0000000|C0162425|C0040607|C1316572|C1272706|C1513492|C0220825|G0000000|C0439611|C0220825|G0000000|G0000000|G0000000|C0444686|C1510992|C0184666|G0000000|G0000000|C0444598|C0012621|C0451119|C0589120|C0016360|C0205225|C0079809|C0444504|G0000000|G0000000
Length was measured following standard techniques using a portable Seca infantometer (0.1 cm precision) and a Seca electronic scale (5 g precision).,Length measured standard techniques portable Seca infantometer (0.1 cm precision) Seca electronic scale (5 precision).,C1444754|C0444706|C1442989|C0025664|G0000000|G0000000|G0000000|G0000000|G0000000|C1547902|G0000000|C0013850|C0175659|G0000000|C1547902
"Secondary efficacy end points included duration of delirium, time to freedom from mechanical ventilation (defined as extubation that was followed by at least a 48-hour period during which the patient was alive and free from mechanical ventilation), time to final successful ICU discharge (defined as the last ICU discharge during the index hospitalization that was followed by at least a 48-hour period during which the patient was alive and outside the ICU), time to ICU readmission, time to successful hospital discharge (defined as discharge that was followed by at least a 48-hour period during which the patient was alive and outside the hospital), and 30-day and 90-day survival.","Secondary efficacy included duration delirium, time freedom mechanical ventilation (defined extubation 48-hour period patient alive free mechanical ventilation), time final successful ICU discharge (defined ICU discharge hospitalization 48-hour period patient alive ICU), time ICU readmission, time successful hospital discharge (defined discharge 48-hour period patient alive hospital), 30-day 90-day survival.",C0027627|C1280519|C0332257|C0449238|C0011206|C0040223|C0016694|C0443254|C0035203|C1704788|C0553891|C0450371|C0439531|C0030705|C0376558|C0332296|C0443254|C0035203|C0040223|C0205088|C0597535|C0021708|C0012621|C1704788|C0021708|C0012621|C0019993|C0450371|C0439531|C0030705|C0376558|C0021708|C0040223|C0021708|C1548168|C0040223|C0597535|C0019994|C0012621|C1704788|C0012621|C0450371|C0439531|C0030705|C0376558|C0019994|C0450371|C0450371|C0038952
"The individual components of total MI, total stroke, and total coronary heart disease events (MI, coronary revascularization, and CHD death) were pre-specified secondary end points.","The individual components total MI, total stroke, total coronary heart disease events (MI, coronary revascularization, CHD death) pre-specified secondary points.",G0000000|C0027361|C0449432|C0439175|C3810814|C0439175|C0038454|C0439175|C0018787|C0018787|C0012634|C0441471|C3810814|C0018787|C0581603|C0280604|C0011065|C2826245|C0027627|C1552961
The cancer fatigue scale was prepared by the researchers.,The cancer fatigue scale prepared researchers.,G0000000|C0006826|C0015672|C0175659|C4082130|C0035173
"The primary outcome was change in Richmond Agitation-Sedation Scale (RASS) score (range, −5 [unarousable] to 4 [very agitated or combative]) from baseline to 8 hours after treatment administration.","The primary outcome change Richmond Agitation-Sedation Scale (RASS) score (range, −5 [unarousable] 4 [very agitated combative]) baseline 8 hours treatment administration.",G0000000|C0205225|C1274040|C0392747|G0000000|C0085631|C0175659|C0034678|C0449820|C1514721|G0000000|G0000000|G0000000|C0442824|C0085631|C0241845|C0168634|G0000000|C0439227|C0039798|C0001554
The 7.5-month point prevalence and prolonged abstinence rates by state are displayed in Table 3.,The 7.5-month prevalence prolonged abstinence rates displayed Table 3.,G0000000|C0332177|C0033105|C0439590|C3843422|C0871208|C0870432|C0039224|G0000000
"Main study end points were changes from baseline in haemoglobin (Hb) level, transfusion requirements, and QOL.","Main study baseline haemoglobin (Hb) level, transfusion requirements, QOL.",C0205225|C0557651|C0168634|C0019046|C0019046|C0441889|C0005841|C1514873|C0518214
The study was powered to show differences between varenicline and placebo for point-prevalence abstinence at week 52.,The study powered differences varenicline placebo point-prevalence abstinence week 52.,G0000000|C0557651|C0032863|C1705241|C1569608|C0032042|C1552961|C3843422|C0332174|C0450371
"The primary outcome events were defined as follows: Stroke—Classified as not disabling, minor disabling, or major disabling and as ischaemic or haemorrhagic (based on computed tomography).","The primary outcome events defined follows: Stroke—Classified disabling, minor disabling, major disabling ischaemic haemorrhagic (based computed tomography).",G0000000|C0205225|C1274040|C0441471|C1704788|C0332283|G0000000|G0000000|C0026193|G0000000|C0205082|G0000000|C0475224|C0333275|C1527178|C1441526|C0040395
"The objective of this study was to evaluate the effect of administration of oral cholecalciferol, 100 000 IU every 2 months, and 1 g/day calcium on serum 25-hydroxyvitamin D concentrations, serum and urine calcium, and HIV disease progression during a 12-month period.","The objective study evaluate administration oral cholecalciferol, 100 000 IU 2 months, 1 g/day calcium serum 25-hydroxyvitamin D concentrations, serum urine calcium, HIV disease progression 12-month period.",G0000000|C0018017|C0557651|C0220825|C0001554|C0442027|C0008318|C1442061|C1442061|C0049272|G0000000|C0439231|G0000000|C0439417|C0006675|C0229671|C0450371|C0073187|C0086045|C0229671|C0042036|C0006675|C0019682|C0012634|C0242656|C0450371|C0439531
"There is empirical evidence showing that recovery from work is positively related to employees' health and well-being [12-15], as well as to job performance [16].","There empirical evidence recovery positively employees' health well-being [12-15], job performance [16].",G0000000|C1880496|C3887511|C0237820|G0000000|C0024752|C0018684|C0018684|C0450371|C0028811|C0597198|C0450371
"The primary endpoint in all studies was change from baseline in trough FEV1 on day 169, defined as the mean of the FEV1 values obtained 23 and 24 h after dosing on day 168.","The primary endpoint studies change baseline trough FEV1 day 169, defined FEV1 values 23 24 dosing day 168.",G0000000|C0205225|C2349179|C0947630|C0392747|C0168634|C0444506|G0000000|C0332173|C1442061|C1704788|G0000000|C0042295|C0450371|C0450371|G0000000|C0332173|C1442061
"a) Vascular occlusive events (myocardial infarction (MI), pulmonary embolism (PE), clinical evidence of deep vein thrombosis (DVT)) b) Stroke c) Disability assessed using the DRS and Patient Orientated Outcome measures d) Seizures e) Neurosurgical intervention f) Days in intensive care g) Other adverse events will be described A cost-utility analysis performed from a health care perspective will be conducted.","a) Vascular occlusive events (myocardial infarction (MI), pulmonary embolism (PE), clinical evidence deep vein thrombosis (DVT)) b) Stroke c) Disability assessed DRS Patient Orientated Outcome measures d) Seizures e) Neurosurgical intervention f) Days intensive care g) Other adverse events A cost-utility analysis performed health care perspective conducted.",G0000000|C0005847|C1947917|C0441471|C0027061|C0021308|C3810814|C0024109|C0013922|C0070939|C0205210|C3887511|C0205125|C0042449|C0040053|C0149871|G0000000|C0038454|G0000000|C0231170|C1516048|C3887968|C0030705|C0424013|C1274040|C0079809|C0073187|C0036572|G0000000|G0000000|C0886296|C0016327|C0439228|C0162425|C1947933|C0439267|G0000000|G0000000|C0441471|G0000000|C0010186|C0002778|C0884358|C0018684|C1947933|G0000000|C0004927
Tailoring based on HFOs in the ioECoG could improve the chance of seizure freedom.,Tailoring based HFOs ioECoG improve chance seizure freedom.,C0402883|C1527178|G0000000|G0000000|G0000000|C0237506|C0036572|C0016694
"Time to progression and overall survival (OS) curves were obtained using the Kaplan–Meier method (Cox, 1972).","Time progression survival (OS) curves Kaplan–Meier method (Cox, 1972).",C0040223|C0242656|C0038952|C0229090|C0205134|G0000000|C0025663|G0000000|G0000000
"The main outcome measure was intensity of cannabis use, as measured by the number of joints per week.","The main outcome measure intensity cannabis use, measured joints week.",G0000000|C0205225|C1274040|C0079809|C0522510|C0024808|C0042153|C0444706|C0022417|C0332174
"Additional outcome measures were airway hyperresponsiveness, lung function, daily dose of inhaled corticosteroids (ICS), number of exacerbations, number of additional visits to the general practitioner, absence from school, functional health status, and disease specific quality of life.","Additional outcome measures airway hyperresponsiveness, lung function, daily dose inhaled corticosteroids (ICS), exacerbations, additional visits practitioner, absence school, functional health status, disease specific quality life.",C1524062|C1274040|C0079809|C0178987|G0000000|C0024109|C0031843|C0332173|C0178602|C0004048|C0001617|C0022521|G0000000|C1524062|C0545082|C1709627|C0332197|C0036375|C0205245|C0018684|C0449438|C0012634|C0205369|C0332306|C0376558
"Therefore, this study aimed to investigate the effect of role play education on primiparous women's fear of natural delivery and their decision on the mode of delivery.","Therefore, study aimed investigate role play education primiparous women's fear natural delivery decision mode delivery.",G0000000|C0557651|C1947946|C1292732|C0035820|C0032214|C0013621|C0033150|C0043210|C0015726|C0205296|C0011209|C0679006|C1513371|C0011209
"Person-years of follow-up were counted from the date of recruitment to the date of diagnosis of prostate cancer, death, migration out of Singapore, or 31 December 2007, whichever occurred first.","Person-years follow-up counted recruitment diagnosis prostate cancer, death, migration Singapore, 31 December 2007, whichever occurred first.",C0027361|C0589120|C0750480|C2949735|C0011900|C0033572|C0006826|C0011065|C0600210|C0037173|C0450371|C3830550|G0000000|G0000000|C1709305|C0205435
Balance was assessed using the Berg balance scale (BBS).,Balance assessed Berg balance scale (BBS).,C0014653|C1516048|G0000000|C0014653|C0175659|G0000000
"The primary outcome will be a latent variable related to indices of use of NIV equipment and adherence to treatment regime: the effects on change from baseline in acceptance to NIV in COPD patients at 3, 6 and 12 months as measured by weekly means and standard deviations of hours of use of NIV as recorded by the ventilator and changes in adherence defined as the difference between prescribed and effective NIV hours.","The primary outcome latent variable indices NIV equipment adherence treatment regime: effects change baseline acceptance NIV COPD patients 3, 6 12 months measured weekly standard deviations hours NIV recorded ventilator adherence defined difference prescribed effective NIV hours.",G0000000|C0205225|C1274040|C0205275|C0439828|C4033634|C0598902|C0014672|C1510802|C0039798|G0000000|C1280500|C0392747|C0168634|G0000000|C0598902|C0024117|C0030705|G0000000|G0000000|C0450371|C0439231|C0444706|C0332174|C1442989|C0012727|C0439227|C0598902|C0034869|C0087153|C1510802|C1704788|C1705241|C0278329|C1280519|C0598902|C0439227
"In this study, the combination group’s drinking behavior functions were better than those of the action training and action observation groups, and the action training group’s number of drinking behavior motions increased more than those of the action observation group after the experiment and one week after the experiment, though not significantly.","In study, combination group’s drinking behavior functions action training action observation groups, action training group’s drinking behavior motions increased action observation experiment week experiment, significantly.",G0000000|C0557651|C0205195|G0000000|C0001948|C0004927|C0542341|C0441472|C0040607|C0441472|C0302523|C0441833|C0441472|C0040607|G0000000|C0001948|C0004927|C0026597|C0205217|C0441472|C0302523|C0681814|C0332174|C0681814|G0000000
"Outcomes were measured in terms of motor recovery (lower extremity subscale of Fugl Meyer assessment [FMA]), balance (Brunnel Balance assessment [BBA]) and mobility (functional ambulation categories [FAC]).","Outcomes measured terms motor recovery (lower extremity subscale Fugl Meyer assessment [FMA]), balance (Brunnel Balance assessment [BBA]) mobility (functional ambulation categories [FAC]).",C1274040|C0444706|C0233324|C1513492|C0237820|C0441994|C0015385|G0000000|G0000000|G0000000|C1261322|C2332774|C0014653|G0000000|C0014653|C1261322|C1549949|C0425245|C0205245|C0080331|C0683312|G0000000
Mass treatment occurred 2 days after baseline in each village.,Mass treatment occurred 2 days baseline village.,C0577559|C0039798|C1709305|G0000000|C0439228|C0168634|C0562518
"Secondary outcome measures include health outcomes, social functioning, housing stability and contact with police services.","Secondary outcome measures health outcomes, social functioning, housing stability contact police services.",C0027627|C1274040|C0079809|C0018684|C1274040|C0728831|C0205245|C0020056|C0205360|C0332158|C0085098|C0557854
"Then gestational age, intensity of nausea and frequency of vomiting were matched in these women.","Then gestational age, intensity nausea frequency vomiting matched women.",C1883708|C0439671|C0001779|C0522510|C0027497|C0376249|C0042963|C0150103|C0043210
"Secondary AMD outcomes analyzed as part of the clinical trial included development of neovascular AMD, incidence of GA (not necessarily in the center of the macula), progression to advanced AMD with an associated visual acuity decrease of at least 15 letters, and worsening of AMD classification in Category 2 participants to Category 3 or 4 during follow-up.","Secondary AMD outcomes analyzed clinical trial included development neovascular AMD, incidence GA (not center macula), progression advanced AMD visual acuity decrease 15 letters, worsening AMD classification Category 2 participants Category 3 4 follow-up.",C0027627|C3539530|C1274040|C0936012|C0205210|C0008976|C0332257|C0243107|C4068891|C3539530|C0021149|C0016993|C1518422|C0205099|C0227662|C0242656|C0205179|C3539530|C0234621|C0750509|C0392756|C0450371|C0282413|C0332271|C3539530|C0008902|C0683312|G0000000|C0679646|C0683312|G0000000|G0000000|C0589120
"The primary outcomes measures will include changes in somatosensory processing as measured by the ERP paradigm, improvements in reaching ability as measured by kinematics of reach assessment, and improvements in fine motor development as measured by BSIDIII.","The primary outcomes measures somatosensory processing measured ERP paradigm, improvements reaching ability measured kinematics reach assessment, improvements fine motor development measured BSIDIII.",G0000000|C0205225|C1274040|C0079809|G0000000|C1709694|C0444706|C1997354|C0681797|C2986411|C2584321|C0085732|C0444706|C0600169|C2584321|C1261322|C2986411|C0205232|C1513492|C0243107|C0444706|G0000000
Neuroendocrine mediation of the stress process was defined by salivary cortisol and DHEA levels.,Neuroendocrine mediation stress process defined salivary cortisol DHEA levels.,C0027912|C0680727|C0038435|C1184743|C1704788|C0442040|C0020268|C0011185|C0441889
"Herkowitz and Kurz 7 reported absolute improvements of 33% for back pain and 55% for leg pain (6-point scales) at an average of 3 years, similar to the changes of 26% and 36 %, respectively (7-point scales), seen in SPORT at 4 years.","Herkowitz Kurz 7 reported absolute improvements 33% pain 55% leg pain (6-point scales) average 3 years, 26% 36 %, (7-point scales), SPORT 4 years.",G0000000|G0000000|G0000000|C0684224|C0205344|C2986411|C0450371|C0030193|C0450371|C0023216|C0030193|C1552961|C0175659|C1510992|G0000000|C0439234|C0450371|C0450371|G0000000|C1552961|C0175659|C0038039|G0000000|C0439234
CONSORT flow diagram of the participants Depression was assessed using Beck Depression Inventory (BDI).,CONSORT flow diagram participants Depression assessed Beck Depression Inventory (BDI).,G0000000|C0806140|C0681494|C0679646|C0011570|C1516048|G0000000|C0011570|C0021941|C0006448
"Key inclusion criteria were: subjects on stable maintenance asthma medications for at least 4 weeks before entry, baseline Asthma Quality of Life Questionnaire (AQLQ) score 6.25 or lower (a higher AQLQ score represents better quality of life) (11), prebronchodilator FEV1 ≥60% of predicted, airway hyperresponsiveness (methacholine PC20 <8 mg/ml), at least 2 days of asthma symptoms during the 4-week baseline period, and being a nonsmoker for at least 1 year with less than 10 pack-years smoking history.","Key inclusion criteria were: subjects stable maintenance asthma medications 4 weeks entry, baseline Asthma Quality Life Questionnaire (AQLQ) score 6.25 lower (a AQLQ score represents quality life) (11), prebronchodilator FEV1 ≥60% predicted, airway hyperresponsiveness (methacholine PC20 <8 mg/ml), 2 days asthma symptoms 4-week baseline period, nonsmoker 1 10 pack-years smoking history.",G0000000|C0007637|C0243161|G0000000|C0681850|C0205360|C0024501|C0004096|C0013227|G0000000|C0439230|C1705654|C0168634|C0004096|C0332306|C0376558|C0034394|C4055434|C0449820|C0450371|C0441994|G0000000|C4055434|C0449820|C1882932|C0332306|C0376558|C0450371|C2599602|G0000000|G0000000|C0681842|C0178987|G0000000|C0600370|G0000000|G0000000|C0439294|G0000000|C0439228|C0004096|C0683368|C0332174|C0168634|C0439531|C0337672|G0000000|C0450371|C1277691|C0037369|C0019664
Of the three components of breast cancer awareness the PEP Intervention had the most marked effect compared with usual care on knowledge that the risk of breast cancer increases with age.,Of components breast cancer awareness PEP Intervention marked compared usual care knowledge risk breast cancer increases age.,G0000000|C0449432|C0006141|C0006826|C0004448|C1335057|C0886296|C0522501|C1707455|C3538928|C1947933|C0376554|C0035647|C0006141|C0006826|C0205217|C0001779
"The statistical significance level, α, was chosen as 0.05 There were significant improvements after the intervention in both groups, in the BBT, grip strength, and the upper limb and lower limb sub-items of the FMA (p<0.05).","The statistical significance level, α, chosen 0.05 There improvements intervention groups, BBT, grip strength, upper limb lower limb sub-items FMA (p<0.05).",G0000000|C0038215|C0237881|C0441889|G0000000|C1707391|C0450371|G0000000|C2986411|C0886296|C0441833|G0000000|C0021400|C0237897|C1282910|C0015385|C0441994|C0015385|C0542339|C2332774|C0369773
"The severity of ROP was graded according to the international classification of ROP.32 All surviving infants were regularly evaluated every 3 months through a standardized nervous system examination, and a final examination at 18 months of corrected age was performed to evaluate motor functions and mental developmental index (MDI) using the Bayley Scales of Infant Development (2nd edition).","The severity ROP graded international classification ROP.32 All surviving infants regularly evaluated 3 months standardized nervous system examination, final examination 18 months corrected age performed evaluate motor functions mental developmental (MDI) Bayley Scales Infant Development (2nd edition).",G0000000|C0439793|C0035344|C0441800|C1512888|C0008902|C0035344|G0000000|C0310255|C0021270|G0000000|C0220825|G0000000|C0439231|G0000000|C0027769|C0449913|G0000000|C0205088|G0000000|C0450371|C0439231|C0205202|C0001779|C0884358|C0220825|C1513492|C0542341|C0229992|C0458003|C0993596|G0000000|C0175659|C0021270|C0243107|G0000000|C0441792
"The median time to appearance of P. vivax parasitaemia was longer in the MAS3 group (40 days; range, 13–43 days) than in the ALN group (28 days; range, 14–43 days; P < 0.001).","The median time appearance P. vivax parasitaemia MAS3 (40 days; range, 13–43 days) ALN (28 days; range, 14–43 days; P < 0.001).",G0000000|C0549183|C0040223|C0233426|C0369773|G0000000|C0242723|G0000000|C0450371|C0439228|C1514721|G0000000|C0439228|C0729594|C0450371|C0439228|C1514721|G0000000|C0439228|C0369773|G0000000|C1442061
The Kaplan-Meier curves for progression free survival are presented in Figure 2B.,The Kaplan-Meier curves progression free survival Figure 2B.,G0000000|G0000000|C0205134|C0242656|C0332296|C0038952|G0000000|C1420850
"For yellow oleander poisoning, the secondary outcome was the proportion of patients with cardiac dysrhythmias requiring anti-digoxin Fab (indications: 3° heart block, Mobitz type II 2° block, sinus bradycardia with heart rate <35 bpm, and sinus arrest or block with sinus pauses >3 secs) or serum potassium greater than 6.0 [23].","For yellow oleander poisoning, secondary outcome proportion patients cardiac dysrhythmias requiring anti-digoxin Fab (indications: 3° heart block, Mobitz type II 2° block, sinus bradycardia heart rate <35 bpm, sinus arrest block sinus pauses >3 secs) serum potassium 6.0 [23].",G0000000|C0221205|C0331097|C0032343|C0027627|C1274040|C1709707|C0030705|C0018787|C0003811|G0000000|C0012265|G0000000|C0392360|G0000000|C0018787|C0028778|G0000000|C0332307|G0000000|G0000000|C0028778|C0016169|C0428977|C0018787|C0871208|C0450371|G0000000|C0016169|C0237477|C0028778|C0016169|C0488347|G0000000|C0457385|C0229671|C0032821|G0000000|C0450371
"Because the purpose of OT is to promote a sense of self, new ways to accomplish basic pleasant tasks, maintaining such therapy over a longer period may bring potential benefits on the different domains we plan to assess such as patient’s quality of life, apathy, depressive symptoms, functional impairment as well as caregiver feelings of burden and sense of competence.","Because purpose OT promote sense self, accomplish basic pleasant tasks, maintaining therapy period bring potential benefits domains plan assess patient’s quality life, apathy, depressive symptoms, functional impairment caregiver feelings burden sense competence.",G0000000|C1285529|C1318464|C0033414|C0036658|C0036588|G0000000|C1527178|C2987187|C3540678|C0024501|C0039798|C0439531|G0000000|C3245505|C0814225|C1880389|C0270724|C1516048|G0000000|C0332306|C0376558|C0085632|G0000000|C0683368|C0205245|C0221099|C0085537|C0013987|C2828008|C0036658|C0086035
"There were no statistical differences (p > 0.05) in heart rate, blood pressure, and perceived exertion between subjects in the two study sessions.","There statistical differences (p > 0.05) heart rate, blood pressure, perceived exertion subjects study sessions.",G0000000|C0038215|C1705241|C0369773|G0000000|C0450371|C0018787|C0871208|C0005767|C0033095|C0030971|C0015264|C0681850|C0557651|C1883016
"Length of stay in hospital and duration of fever were significantly shorter in the intervention group than in the control group (P=0.01 and P=0.04, respectively).","Length stay hospital duration fever shorter intervention control (P=0.01 P=0.04, respectively).",C1444754|G0000000|C0019994|C0449238|C0015967|C1282927|C0886296|C0243148|C0369773|C0369773|G0000000
"Impact of cognitive behavioral self efficacy (SE) on depression & anxiety  We tested the impact of condition assignment upon anxiety, depression and self efficacy (see Table 4).","Impact cognitive behavioral efficacy (SE) depression & anxiety We tested impact condition assignment anxiety, depression efficacy (see Table 4).",C1825598|C1516691|C0004927|C1280519|C0036919|C0011570|G0000000|C0003467|G0000000|C0392366|C1825598|C0012634|C1516050|C0003467|C0011570|C1280519|C0042789|C0039224|G0000000
The TTP was defined as the time at which progression was evident according to the definitions of mRECIST in follow-up MRI or CT (extrahepatic disease).,The TTP defined time progression evident definitions mRECIST follow-up MRI CT (extrahepatic disease).,G0000000|C0084795|C1704788|C0040223|C0242656|C3887511|C1550452|G0000000|C0589120|C0024485|C0007673|C1517058|C0012634
"The model was adjusted for age, education, income, smoking status (men only), alcohol consumption (men only), family history of liver cancer, body mass index (BMI), total physical activity, total energy intake, total vegetable intake, total fruit intake, total red meat intake, total egg intake, total fish intake, total soy intake, vitamin E intake, history of diabetes, history of viral hepatitis/chronic liver disease, history of cholelithiasis, cholecystectomy, menopausal status (women only), and ever had oral contraceptive (women only).","The model adjusted age, education, income, smoking status (men only), alcohol consumption (men only), family history liver cancer, body mass (BMI), total physical activity, total energy intake, total vegetable intake, total fruit intake, total red meat intake, total egg intake, total fish intake, total soy intake, vitamin E intake, history diabetes, history viral hepatitis/chronic liver disease, history cholelithiasis, cholecystectomy, menopausal status (women only), oral contraceptive (women only).",G0000000|C3161035|C0456081|C0001779|C0013621|C0021162|C0037369|C0449438|C0025266|C0205171|C0001962|C0009830|C0025266|C0205171|C0015576|C0019664|C0023884|C0006826|C0242821|C0577559|G0000000|C0439175|C0031809|C0205177|C0439175|C0424589|C1512806|C0439175|C0042440|C1512806|C0439175|C0016767|C1512806|C0439175|C0332575|C0025017|C1512806|C0439175|C0013710|C1512806|C0439175|C0016163|C1512806|C0439175|C0037733|C1512806|C0042890|G0000000|C1512806|C0019664|C0011847|C0019664|C0521026|C0019158|C0023884|C0012634|C0019664|C0008350|C0008320|C0025320|C0449438|C0043210|C0205171|C0442027|C0009871|C0043210|C0205171
"This study will provide new information on the potential for arm ergometry to form part of a treatment regimen for Polio survivors and will examine the impact on physical fitness, activity, body composition, fatigue, pain, muscle strength, and health related quality of life.","This study provide potential arm ergometry form treatment regimen Polio survivors examine impact physical fitness, activity, body composition, fatigue, pain, muscle strength, health quality life.",G0000000|C0557651|C1999230|C3245505|C0446516|C0085143|C0348078|C0039798|C0040808|C0032371|C0206194|G0000000|C1825598|C0031809|C1456706|C0205177|C0242821|C0486616|C0015672|C0030193|C0026845|C0237897|C0018684|C0332306|C0376558
"The diagnosis of C-AOM required at least 2 clinical symptoms (ear pain, ear discharge, hearing loss, fever, lethargy, irritability, anorexia, vomiting or diarrhea) which had started within the previous 5 d and were reported by the PHCP; and either altered visual appearance of the tympanic membrane (e.g., redness, bulging, loss of light reflex) or the presence of middle ear effusion as observed by the ENT specialist.","The diagnosis C-AOM required 2 clinical symptoms (ear pain, ear discharge, hearing loss, fever, lethargy, irritability, anorexia, vomiting diarrhea) started previous 5 reported PHCP; altered visual appearance tympanic membrane (e.g., redness, bulging, loss light reflex) presence middle ear effusion observed ENT specialist.",G0000000|C0011900|C0004519|C1514873|G0000000|C0205210|C0683368|C0013443|C0030193|C0013443|C0012621|C0018767|C1517945|C0015967|C0023380|C0022107|C0003123|C0042963|C0011991|C1272689|C0205156|G0000000|C0684224|G0000000|C0392747|C0234621|C0233426|C0041445|C0025255|G0000000|C0041834|C0038999|C1517945|C0023693|C0034929|C0150312|C0444598|C0013443|C0013687|C1441672|C3889152|C0087009
"Comparison of costs with Roland-Morris disability score (number of activities impaired by pain), days in pain, and quality adjusted life years (QALYs).","Comparison costs Roland-Morris disability score (number activities impaired pain), days pain, quality adjusted life (QALYs).",C1707455|C0010186|G0000000|C0231170|C0449820|C0237753|C0441655|C0221099|C0030193|C0439228|C0030193|C0332306|C0456081|C0376558|C0080071
Fracture incidence and total mortality by cause.,Fracture incidence total mortality cause.,C0016658|C0021149|C0439175|C0026565|C0015127
"The occurrence and severity (absent, 0; mild, 1; moderate, 2; severe, 3; very severe, 4) of sneezing, runny nose, nasal obstruction, sore throat, cough, headache, malaise, and chilliness were recorded between 6 and 8 a.m for 5 days after virus inoculation.","The occurrence severity (absent, 0; mild, 1; moderate, 2; severe, 3; severe, 4) sneezing, runny nose, nasal obstruction, sore throat, cough, headache, malaise, chilliness recorded 6 8 a.m 5 days virus inoculation.",G0000000|C0243132|C0439793|C0332197|G0000000|C2945599|G0000000|C0205081|G0000000|C0205082|G0000000|C0205082|G0000000|C0037383|G0000000|C0028429|C0028429|C0028778|C0234233|C0031354|C0010200|C0018681|C0231218|C0812387|C0034869|G0000000|G0000000|C2346751|G0000000|C0439228|C0042776|C0042196
All prescription errors identified by the clinical pharmacist and agreed upon by the cardiologist were collected.,All prescription errors identified clinical pharmacist agreed cardiologist collected.,G0000000|C0033080|C0743559|C0205396|C0205210|C0031323|C3641827|C0175906|C1516695
(A) The incidence of CMV disease was similar in both groups.,(A) The incidence CMV disease groups.,G0000000|G0000000|C0021149|G0000000|C0012634|C0441833
"We excluded patients who had already been critically ill for >72 hours since the opportunity to administer early cognitive and physical therapy had passed, those who had been in the ICU for more than 5 days in the previous 30 days, those were unlikely to benefit from rehabilitation targeting acute declines in cognitive or functional status due to a moribund state, severe pre-existing dementia or physical disability in activities of daily living (e.g., bathing, dressing, etc.","We excluded patients critically ill >72 hours opportunity administer cognitive physical therapy passed, ICU 5 days previous 30 days, benefit rehabilitation targeting acute declines cognitive functional status moribund state, severe pre-existing dementia physical disability activities daily living (e.g., bathing, dressing, etc.",G0000000|C1554077|C0030705|G0000000|C0231218|C0450371|C0439227|G0000000|C1621583|C1516691|C0031809|C0039798|C2828386|C0021708|G0000000|C0439228|C0205156|C0450371|C0439228|C0814225|C0034991|C1521840|C0205178|G0000000|C1516691|C0205245|C0449438|C0424547|C1301808|C0205082|C2347662|C0011265|C0031809|C0231170|C0441655|C0332173|C0376558|G0000000|C0150141|C0013119|C1548556
"Trocars used in laparoscopic surgery occasionally produce serious complications, such as major vascular injury, abdominal wall bleeding, visceral injury or incisional hernia.","Trocars laparoscopic surgery occasionally produce complications, major vascular injury, abdominal wall bleeding, visceral injury incisional hernia.",C0041158|C0031150|C0038894|C1998882|G0000000|C0009566|C0205082|C0005847|C3263722|C0000726|C0677535|C0019080|C0442045|C3263722|C0184898|C0019270
"Secondary outcomes were recurrent wheezing (≥2 episodes of reported wheezing since birth), wheeze in the year prior to assessment (ISAAC), wheeze with a positive asthma predictive index (loose criteria) [21], reported history of bronchodilator use, eczema ever (ISAAC), eczema in the year prior to assessment (ISAAC), allergic rhinitis, history of doctor diagnosed food allergy, history of lower respiratory tract infection (LRTI) (any of bronchiolitis, bronchitis, croup, pneumonia or an otherwise unspecified chest infection) and history of >4 episodes of upper respiratory tract infections (URTI) per year (defined as a positive answer to the question ‘how often does your child have an upper respiratory tract infection, with at least two of the following symptoms: cough, runny nose and fever?’).","Secondary outcomes recurrent wheezing (≥2 episodes reported wheezing birth), wheeze prior assessment (ISAAC), wheeze positive asthma predictive (loose criteria) [21], reported history bronchodilator use, eczema (ISAAC), eczema prior assessment (ISAAC), allergic rhinitis, history doctor diagnosed food allergy, history lower respiratory tract infection (LRTI) (any bronchiolitis, bronchitis, croup, pneumonia unspecified chest infection) history >4 episodes upper respiratory tract infections (URTI) (defined positive answer question ‘how child upper respiratory tract infection, symptoms: cough, runny nose fever?’).",C0027627|C1274040|C2945760|C0043144|G0000000|C0332189|C0684224|C0043144|C0005615|C0043144|C0332152|C1261322|G0000000|C0043144|C0439178|C0004096|C0681890|C0205407|C0243161|C0450371|C0684224|C0019664|C0006280|C0042153|C0013595|G0000000|C0013595|C0332152|C1261322|G0000000|C0700624|C0035455|C0019664|C0031831|C0011900|C0016452|C0002111|C0019664|C0441994|C0521346|C1185740|C0009450|C0149725|G0000000|C0006271|C0006277|C0010380|C0032285|C0205370|C0817096|C0009450|C0019664|G0000000|C0332189|C1282910|C0521346|C1185740|C3714514|G0000000|C1704788|C0439178|C1706817|C1522634|G0000000|C0008059|C1282910|C0521346|C1185740|C0009450|C0683368|C0010200|G0000000|C0028429|G0000000
Hyperactive delirium is rare in the pure form and is associated with a better overall prognosis [2].,Hyperactive delirium rare pure form prognosis [2].,C0424295|C0011206|C0521114|C2247561|C0348078|C0033325|G0000000
Hypoglycaemia was defined as symptoms suggestive of low blood glucose confirmed by a self-monitored blood glucose measurement <3.1 mmol/l plasma glucose equivalent.,Hypoglycaemia defined symptoms suggestive low blood glucose confirmed self-monitored blood glucose measurement <3.1 mmol/l plasma glucose equivalent.,C0020615|C1704788|C0683368|C0332299|C0205251|C0005767|C0017725|C0521093|C0588436|C0005767|C0017725|C0242485|G0000000|C1532563|C0032105|C0017725|C0205163
"The participants were evaluated blindly using the Hamilton Depression and Anxiety Rating Scale, the Beck Depression Rating Scale, and the Albany Panic and Phobia Questionnaire (APPQ).","The participants evaluated blindly Hamilton Depression Anxiety Rating Scale, Beck Depression Rating Scale, Albany Panic Phobia Questionnaire (APPQ).",G0000000|C0679646|C0220825|G0000000|G0000000|C0011570|C0003467|C0871208|C0175659|G0000000|C0011570|C0871208|C0175659|G0000000|C0030318|C0349231|C0034394|G0000000
The primary parameter of measurement was the proportion of subjects with a clinical response as indicated by a 70-point decline in the CDAI score from baseline [25].,The primary parameter measurement proportion subjects clinical response 70-point decline CDAI score baseline [25].,G0000000|C0205225|C0549193|C0242485|C1709707|C0681850|C0205210|C0871261|C0450371|G0000000|C0683448|C0449820|C0168634|C0450371
"It’s important to note that the TSC intervention included sparse behaviour change messaging to increase latrine use, including use by children, or for safe disposal of child faeces.","It’s note TSC intervention included sparse behaviour change messaging increase latrine use, including children, safe disposal child faeces.",G0000000|C1316572|G0000000|C0886296|C0332257|G0000000|C0004927|C0392747|C0470166|C0442805|C0023124|C0042153|C0332257|C0008059|G0000000|C1707797|C0008059|C0015733
"Our primary outcome measures were the Wolf Motor Function Test (WMFT)28 and the Motor Activity Log (MAL)–Amount,29 which are commonly used to assess change in upper-extremity function after intensive treatments like CIT.19 The WMFT is an upper-extremity functional capacity test, comprising a series of 15 timed tasks that require movement at all joints.","Our primary outcome measures Wolf Motor Function Test (WMFT)28 Motor Activity Log (MAL)–Amount,29 commonly assess change upper-extremity function intensive treatments CIT.19 The WMFT upper-extremity functional capacity test, comprising series 15 timed tasks require movement joints.",G0000000|C0205225|C1274040|C0079809|C0325001|C1513492|C0031843|C0022885|C0450371|C1513492|C0205177|C1708728|G0000000|G0000000|C1516048|C0392747|C1140618|C0031843|C0162425|C0087111|C0523573|G0000000|G0000000|C1140618|C0205245|C1516240|C0022885|C2700400|C0205549|C0450371|C0392761|C3540678|G0000000|C0026649|C0022417
"Peritoneal ultrafiltration volume increased and D/P creatinine decreased during the study, but did not differ between groups (Supplemental Figures 4 and 5).","Peritoneal ultrafiltration volume increased D/P creatinine decreased study, (Supplemental Figures 4 5).",C0031153|C0041612|C0449468|C0205217|C1512024|C0010294|C0205216|C0557651|C2348609|G0000000|G0000000|G0000000
"There were statistically significant differences in the changes in the WHOQOL, BFI, shoulder ROM, and pain score between the groups.","There statistically differences WHOQOL, BFI, shoulder ROM, pain score groups.",G0000000|C0038215|C1705241|G0000000|C2698562|C0037004|C4048784|C0030193|C0449820|C0441833
Subjects were queried for adverse events during the same clinical visits.,Subjects queried adverse events clinical visits.,C0681850|C1522634|G0000000|C0441471|C0205210|C0545082
"No significant difference was found in asthma control, morning peak flow, peak flow variability, or symptoms.","No difference asthma control, morning peak flow, peak flow variability, symptoms.",G0000000|C1705241|C0004096|C0243148|C0332170|C0444505|C0806140|C0444505|C0806140|C2827666|C0683368
Cigarette smoking and alcohol use were not significantly related to the risk of either single or multiple stomach cancer.,Cigarette smoking alcohol risk single multiple stomach cancer.,C0677453|C0037369|C0001962|C0035647|C0037179|C0439064|C0038351|C0006826
"Trocar-related events during the operative procedure, such as gas leakage, trocar dislodgment, problems in handling the reducer mechanism and failure of trocar seal integrity, were documented.","Trocar-related events operative procedure, gas leakage, trocar dislodgment, handling reducer mechanism failure trocar seal integrity, documented.",C0041158|C0441471|C1882154|C0184661|C0017110|C0015376|C0041158|G0000000|C0018578|G0000000|C0441712|C0231174|C0041158|C0036492|C0205266|C1301725
"Outcomes will be measured at baseline, at the end of 3-month intervention and after 9 months postintervention follow-up.","Outcomes measured baseline, 3-month intervention 9 months postintervention follow-up.",C1274040|C0444706|C0168634|C0332177|C0886296|G0000000|C0439231|G0000000|C0589120
"Furthermore, our results using the modified FIM and GOS scores showed that progesterone administration remarkably enhanced functional recovery 6 months after injury and reduced the mortality of the patients with acute severe TBI (GCS = 6 to 8), although there was no statistical significance in the outcome improvement for GCS = 3 to 5 patients with and without progesterone treatment.","Furthermore, modified FIM GOS scores progesterone administration remarkably enhanced functional recovery 6 months injury reduced mortality patients acute severe TBI (GCS = 6 8), statistical significance outcome improvement GCS = 3 5 patients progesterone treatment.",G0000000|C0392747|C3273671|G0000000|C0449820|C0033308|C0001554|G0000000|C2349975|C0205245|C0237820|G0000000|C0439231|C3263722|C0392756|C0026565|C0030705|C0205178|C0205082|C0876926|G0000000|G0000000|G0000000|G0000000|C0038215|C0237881|C1274040|C2986411|G0000000|G0000000|G0000000|G0000000|C0030705|C0033308|C0039798
"The AD Assessment Scale–Cognition (ADAS-Cog), Instrumental Activities of Daily Living (IADL), Mini–Mental State Examination (MMSE), sleep, as assessed by the Pittsburgh Sleep Quality Index (PSQI) and a daily sleep diary, and safety parameters were measured.","The AD Assessment Scale–Cognition (ADAS-Cog), Instrumental Activities Daily Living (IADL), Mini–Mental State Examination (MMSE), sleep, assessed Pittsburgh Sleep Quality Index (PSQI) daily sleep diary, safety parameters measured.",G0000000|G0000000|C1261322|G0000000|C3539026|G0000000|C0441655|C0332173|C0376558|C0150641|G0000000|C1301808|G0000000|C0451306|C0037313|C1516048|G0000000|C0037313|C0332306|C0918012|C3697468|C0332173|C0037313|C0376660|C0036043|C0449381|C0444706
Adherence to the nutrition intervention is defined for this study as collecting 1 kg per month of the fortified food as documented by the health centers.,Adherence nutrition intervention defined study collecting 1 month fortified food documented health centers.,C1510802|C0028707|C0886296|C1704788|C0557651|C1516698|G0000000|C0332177|G0000000|C0016452|C1301725|C0018684|C0205099
"We predict that the intervention will not only improve maternal sensitivity but will also improve a child’s responsiveness to their mother, attachment security, attachment organization and child development.","We predict intervention improve maternal sensitivity improve child’s responsiveness mother, attachment security, attachment organization child development.",G0000000|G0000000|C0886296|G0000000|C2347083|C0020517|G0000000|G0000000|C0205342|C0026591|C0185023|C1519222|C0185023|C0029237|C0008059|C0243107
Secondary efficacy outcome measures were by patient microbiological response in the micro-ITT and ME populations at TOC.,Secondary efficacy outcome measures patient microbiological response micro-ITT ME populations TOC.,C0027627|C1280519|C1274040|C0079809|C0030705|C0025953|C0871261|C0085672|G0000000|C0032659|C1835664
"All four had local recurrence and therefore were treated again at our institute, three by wide resection and one by curettage.","All local recurrence treated institute, wide resection curettage.",G0000000|C0205276|C0034897|C1522326|C0021622|C0332464|C0015252|C0010468
LOS was the cause of one death which occurred in placebo group.,LOS death occurred placebo group.,G0000000|C0011065|C1709305|C0032042|C0441833
"The median length of hospital stay was 4 days in both groups, and the number of posthospitalization healthcare visits was similar.","The median length hospital stay 4 days groups, posthospitalization healthcare visits similar.",G0000000|C0549183|C1444754|C0019994|G0000000|G0000000|C0439228|C0441833|G0000000|C0086388|C0545082|C2348205
"An increased risk of ovarian cancer following treatment has been suggested in previous studies (7, 8), while more recent studies suggest no association (9, 10) (Table 1).","An increased risk ovarian cancer treatment suggested previous studies (7, 8), studies association (9, 10) (Table 1).",G0000000|C0205217|C0035647|C0205065|C0006826|C0039798|C1705535|C0205156|C0947630|G0000000|G0000000|C0947630|C0004083|G0000000|C0450371|C0039224|G0000000
"When looking at the short-term effects of MET, worst pain over the past 24 hours seems to be the most significant, while current pain, worst pain provocation test, and answers to pain provocation tests showed no major changes in 24 hours.","When short-term effects MET, worst pain 24 hours significant, current pain, worst pain provocation test, answers pain provocation tests major 24 hours.",G0000000|C0443303|C1280500|C0268621|C1522166|C0030193|C0450371|C0439227|C0237881|C0521116|C0030193|C1522166|C0030193|C0449428|C0022885|C1706817|C0030193|C0449428|C0022885|C0205082|C0450371|C0439227
The primary outcome variable was the frequency of moderate and severe exacerbations (defined below) over the 48-week post treatment period.,The primary outcome variable frequency moderate severe exacerbations (defined below) 48-week post treatment period.,G0000000|C0205225|C1274040|C0439828|C0376249|C0205081|C0205082|G0000000|C1704788|G0000000|C0450371|C0687676|C0039798|C0439531
"To test the hypothesis that in patients who have chronic motor impairment following stroke, specific rehabilitation therapy that improves arm function is associated with reorganization of cortical networks.","To test hypothesis patients chronic motor impairment stroke, specific rehabilitation therapy improves arm function reorganization cortical networks.",C0040363|C0022885|C1512571|C0030705|C0205191|C1513492|C0221099|C0038454|C0205369|C0034991|C0039798|C0184511|C0446516|C0031843|C0680829|C0001613|C1882071
"Based on the WHO-ICF model, the outcomes are body structure/function, activity limitation, and participation restriction measures.","Based WHO-ICF model, outcomes body structure/function, activity limitation, participation restriction measures.",C1527178|G0000000|C3161035|C1274040|C0242821|C0683614|C0205177|C0449295|C0679823|C0443288|C0079809
"Cisplatin has played a prominent role in the treatment of NSCLC, despite a relatively unimpressive single-agent response rate and a relatively severe toxicity profile.","Cisplatin played prominent role treatment NSCLC, unimpressive single-agent response rate severe toxicity profile.",C0008838|C0600138|C0205402|C0035820|C0039798|C0007131|G0000000|C0037179|C0871261|C0871208|C0205082|C0040539|C1979963
Secondary endpoints included the reversal of shock and the amount of nursing workload required to maintain strict normoglycemia.,Secondary endpoints included reversal shock amount nursing workload required maintain strict normoglycemia.,C0027627|C2349179|C0332257|C0443290|C0036974|C1265611|C0006147|C0085122|C1514873|C0024501|G0000000|C0580545
"‡At 3 months, n = 19 for fDSMP group.","‡At 3 months, = 19 fDSMP group.",G0000000|G0000000|C0439231|G0000000|C0450371|G0000000|C0441833
Additional file 1: Table S1.,Additional file 1: Table S1.,C1524062|C0016094|G0000000|C0039224|C1519428
Efficacy was evaluated with daily Numeric Pain Rating Scale (NPRS) scores throughout the 12-week study period.,Efficacy evaluated daily Numeric Pain Rating Scale (NPRS) scores 12-week study period.,C1280519|C0220825|C0332173|C0237753|C0030193|C0871208|C0175659|C1417814|C0449820|C0450371|C0557651|C0439531
Groups were not significantly different at baseline or month 2.,Groups baseline month 2.,C0441833|C0168634|C0332177|G0000000
"Self-report tests consisted of the short form Functional Performance Inventory (FPI),14 and the physical functioning scale of the medical outcomes study 36- Item Short Form Health Survey (SF-36 PFS).15 Health-related quality of life was measured using the SF-36 physical health survey (SF-36 PHS) and mental health survey (SF-36 MHS) component summary scores and Mini-Mental State Examination (MMSE) score.","Self-report tests consisted short form Functional Performance Inventory (FPI),14 physical functioning scale medical outcomes study 36- Item Short Form Health Survey (SF-36 PFS).15 Health-related quality life measured SF-36 physical health survey (SF-36 PHS) mental health survey (SF-36 MHS) component summary scores Mini-Mental State Examination (MMSE) score.",C0681906|C0022885|C0332529|C1282927|C0348078|C0205245|C0597198|C0021941|C0450371|C0031809|C0205245|C0175659|C0199168|C1274040|C0557651|C0450371|C1551338|C1282927|C0348078|C0018684|C0038951|C0037712|C0242792|C0018684|C0332306|C0376558|C0444706|C0037712|C0031809|C0018684|C0038951|C0037712|C0265220|C0229992|C0018684|C0038951|C0037712|C0024591|C0449432|C1552616|C0449820|C0445542|C1301808|G0000000|C0451306|C0449820
"Increases the continuous abstinence rate at third and sixth months (secondary outcomes), 3.","Increases continuous abstinence rate sixth months (secondary outcomes), 3.",C0205217|C0549178|C3843422|C0871208|C0205440|C0439231|C0027627|C1274040|G0000000
"Gestational weight gain and postpartum weight retention in the control versus the intervention group GWG = Gestational weight gain, IOM = Institute of Medicine, pp = postpartum.","Gestational weight gain postpartum weight retention control versus intervention GWG = Gestational weight gain, IOM = Institute Medicine, = postpartum.",C0439671|C0005910|C1517378|C0086839|C0005910|C0035280|C0243148|G0000000|C0886296|G0000000|G0000000|C0439671|C0005910|C1517378|C1955637|G0000000|C0021622|C0013227|G0000000|C0086839
"Assessments of activated CD4+ CD38+ and CD8+ CD38+ cell subsets will allow, for the first time, a more precise definition of which cell subpopulation(s) may change with ER niacin.","Assessments activated CD4+ CD38+ CD8+ CD38+ cell subsets allow, time, precise definition cell subpopulation(s) change ER niacin.",C1261322|C1879547|C0285590|G0000000|C0285590|G0000000|C0007634|C1515021|C0683607|C0040223|C1547902|C1550452|C0007634|C1257890|C0392747|C3810541|C0027996
‡Odds ratio additionally adjusted for baseline weight and sodium excretion.,‡Odds ratio additionally adjusted baseline weight sodium excretion.,G0000000|C0456603|G0000000|C0456081|C0168634|C0005910|C0037473|C0221102
"Only results on alcohol measures are reported herein, which were collected using the Adolescent Drinking Questionnaire.8 This questionnaire is scored on an 8-point scale and taps into drinking frequency (days per month), quantity (drinks per occasion), frequency of high-volume drinking (≥5 drinks per occasion), and frequency of intoxication (feeling “drunk” or “very, very high”) in the previous 3 months.","Only alcohol measures reported herein, collected Adolescent Drinking Questionnaire.8 This questionnaire scored 8-point scale taps drinking frequency (days month), quantity (drinks occasion), frequency high-volume drinking (≥5 drinks occasion), frequency intoxication (feeling “drunk” “very, high”) previous 3 months.",C0205171|C0001962|C0079809|C0684224|G0000000|C1516695|C0205653|C0001948|C0034394|G0000000|C0034394|C0449820|C1552961|C0175659|C0034115|C0001948|C0376249|C0439228|C0332177|C1265611|C0452428|C0521114|C0376249|C0205250|C0001948|G0000000|C0452428|C0521114|C0376249|C0728899|C0013987|G0000000|G0000000|G0000000|C0205156|G0000000|C0439231
"Data were collected in one-minute recoding epochs using the Proportional Integrating Measure (PIM, low sensitivity) operation mode.","Data collected one-minute recoding epochs Proportional Integrating Measure (PIM, low sensitivity) operation mode.",C1511726|C1516695|C0205447|G0000000|C1948053|C0205351|G0000000|C0079809|C0812214|C0205251|C0020517|C0543467|C1513371
"These variables included child sex and birth weight, gestational age at delivery, delivery mode, post-birth mother and newborn length of hospital stay, and complications of pregnancy and delivery.","These variables included child sex birth weight, gestational age delivery, delivery mode, post-birth mother newborn length hospital stay, complications pregnancy delivery.",G0000000|C0439828|C0332257|C0008059|C0009253|C0005615|C0005910|C0439671|C0001779|C0011209|C0011209|C1513371|C0687676|C0026591|C0021289|C1444754|C0019994|G0000000|C0009566|C0032961|C0011209
Analysis of the primary end-point (global symptom relief) was done according to an intent-to-treat (ITT) basis.,Analysis primary end-point (global symptom relief) intent-to-treat (ITT) basis.,C0002778|C0205225|C2349179|C0205246|C1457887|C0564405|C0162425|G0000000|C1527178
"Trends in the four physical activity parameters (total steps/day, percentage time being inactive, percentage time active at moderate or high intensity, and peak performance) also tracked changes observed in the laboratory exercise performance tests (Table 3); MOBILE-SM participants increased their physical activity over six months whereas MOBILE-C showed a decline.","Trends physical activity parameters (total steps/day, percentage time inactive, percentage time active moderate intensity, peak performance) tracked observed laboratory exercise performance tests (Table 3); MOBILE-SM participants increased physical activity months MOBILE-C decline.",C0040833|C0031809|C0205177|C0449381|C0439175|C1261552|C0439165|C0040223|C0205254|C0439165|C0040223|C0205177|C0205081|C0522510|C0444505|C0597198|C0040594|C1441672|C0022877|C0015259|C0597198|C0022885|C0039224|G0000000|C0231435|C0679646|C0205217|C0031809|C0205177|C0439231|C0231435|G0000000
"Pain intensity will be analyzed using a visual analogue scale and the McGill Pain Questionnaire, and pain thresholds will be punctuated using a digital algometer.","Pain intensity analyzed visual analogue scale McGill Pain Questionnaire, pain thresholds punctuated digital algometer.",C0030193|C0522510|C0936012|C0234621|C0243071|C0175659|G0000000|C0030193|C0034394|C0030193|C0449864|G0000000|C0442015|G0000000
"Secondary outcome measures included analyses of the change in laboratory findings, including faecal calprotectin (FCAL).","Secondary outcome measures included analyses change laboratory findings, including faecal calprotectin (FCAL).",C0027627|C1274040|C0079809|C0332257|C0002778|C0392747|C0022877|C2607943|C0332257|C0015733|C0950624|G0000000
"On completing the study, nurses checked paper and electronic medical records to extract data on all non-study related practice consultations, and accident & emergency department consultations for asthma, hospital admissions for asthma, and details of the number of courses of oral steroids prescribed during the study period.","On completing study, nurses checked paper electronic medical records extract data non-study practice consultations, accident & emergency department consultations asthma, hospital admissions asthma, details courses oral steroids prescribed study period.",G0000000|C0205197|C0557651|C0028661|C1283174|C0030351|C0013850|C0199168|C0034869|C2828366|C1511726|C1518422|C0237607|C0009818|C0000924|G0000000|C0013956|C1704729|C0009818|C0004096|C0019994|C0184666|C0004096|C1522508|C0750729|C0442027|C0038317|C0278329|C0557651|C0439531
BP and weight data in pregnancy are shown in Table 2.,BP weight data pregnancy Table 2.,C0037623|C0005910|C1511726|C0032961|C0039224|G0000000
"Both groups were fed for 4 consecutive weeks and were compared in terms of incidence rate of feeding intolerance, time to establish full enteral feeding, time to complete meconium excretion, number of spontaneous bowel movements, growth and development, motilin level at 4 and 10 days after feeding, and incidence rate of infection.","Both fed 4 consecutive weeks compared terms incidence rate feeding intolerance, time establish enteral feeding, time complete meconium excretion, spontaneous bowel movements, growth development, motilin level 4 10 days feeding, incidence rate infection.",G0000000|C0342895|G0000000|C1707491|C0439230|C1707455|C0233324|C0021149|C0871208|C0204695|C0231199|C0040223|C0443211|C1304890|C0204695|C0040223|C0205197|C0025047|C0221102|C0205359|C0021853|C0026649|C0018270|C0243107|C0026594|C0441889|G0000000|C0450371|C0439228|C0204695|C0021149|C0871208|C0009450
"Older age, African ancestry, and family history of prostate cancer are well-established risk factors for prostate cancer and all are non-modifiable.","Older age, African ancestry, family history prostate cancer well-established risk factors prostate cancer non-modifiable.",C0580836|C0001779|C0027567|G0000000|C0015576|C0019664|C0033572|C0006826|C0205170|C0035647|C1521761|C0033572|C0006826|C1518422
"Immediately before and after each intervention/control session, participants had their blood pressure and anxiety measured.","Immediately intervention/control session, participants blood pressure anxiety measured.",C0205548|C0886296|C1883016|C0679646|C0005767|C0033095|C0003467|C0444706
"For example, if the first clinic cortisol was collected at 9 a.m., then the first baseline sample was collected at 9 a.m. Cortisol responsivity as an outcome was measured by the percentage of change in cortisol levels between the matched clinic and baseline cortisol samples.","For example, clinic cortisol collected 9 a.m., baseline sample collected 9 a.m. Cortisol responsivity outcome measured percentage change cortisol levels matched clinic baseline cortisol samples.",G0000000|C1707959|C0002424|C0020268|C1516695|G0000000|C2346751|C0168634|C0370003|C1516695|G0000000|C2346751|C0020268|C2371924|C1274040|C0444706|C0439165|C0392747|C0020268|C0441889|C0150103|C0002424|C0168634|C0020268|C0370003
1).,1).,G0000000
"With respect to repeated point prevalence measures at one year, there were 3/59 (5.1%) of participants in the intervention group and 2/57 (3.5%) in the control group who were also quitters at both 3 and 6 months.","With respect repeated prevalence measures year, 3/59 (5.1%) participants intervention 2/57 (3.5%) control quitters 3 6 months.",G0000000|C0679133|C0205341|C0033105|C0079809|C0439234|C0450371|G0000000|C0679646|C0886296|C0450371|G0000000|C0243148|G0000000|G0000000|G0000000|C0439231
Self-reported point prevalence abstinence will be bioverified with salivary cotinine (Nicalert™) and expired CO at home visits following the telephone assessments.,Self-reported prevalence abstinence bioverified salivary cotinine (Nicalert™) expired CO visits telephone assessments.,C0681906|C0033105|C3843422|G0000000|C0442040|C0010194|G0000000|C0011065|C3245499|C0545082|C0039457|C1261322
Adverse Events at 6 Months.,Adverse Events 6 Months.,G0000000|C0441471|G0000000|C0439231
"Vascular death was defined as death from stroke, myocardial infarction, or other vascular causes or sudden unexpected death.","Vascular death defined death stroke, myocardial infarction, vascular sudden unexpected death.",C0005847|C0011065|C1704788|C0011065|C0038454|C0027061|C0021308|C0005847|C1276802|C4055646|C0011065
Similar findings were found for the North Star Ambulatory Assessment.,Similar findings North Star Ambulatory Assessment.,C2348205|C2607943|C1709269|C0995242|C0439841|C1261322
"An individual could be assigned a score of 0, 0.25, 0.50, 0.75, or 1 point each day.","An individual assigned score 0, 0.25, 0.50, 0.75, 1 day.",G0000000|C0027361|C1516050|C0449820|G0000000|C0450371|C0450371|C0450371|G0000000|C0332173
"Paradoxical intention-treated patients appeared to have greater improvements in anxiety scores (z=2.43, p<0.015) and conversion symptoms (t=2.27, p=0.034) than the diazepam-treated patients.","Paradoxical intention-treated patients appeared improvements anxiety scores (z=2.43, p<0.015) conversion symptoms (t=2.27, p=0.034) diazepam-treated patients.",C0205310|C0162425|C0030705|C0700364|C2986411|C0003467|C0449820|C0450371|C0369773|C0439836|C0683368|C2603360|C0369773|C0012010|C0030705
"Nasal mucus weights were determined for 24-h periods [10] Side effects and safetySymptoms of nasal irritation, nasal dryness, blood-tinged nasal mucus, and any other complaints were recorded for all subjects.","Nasal mucus weights determined 24-h periods [10] Side effects safetySymptoms nasal irritation, nasal dryness, blood-tinged nasal mucus, complaints recorded subjects.",C0028429|C0026727|C0043100|G0000000|C0450371|C0439531|C0450371|C0441987|C1280500|G0000000|C0028429|C0441723|C0028429|C1512080|C0005767|C0028429|C0026727|C0277786|C0034869|C0681850
"The primary outcomes of the study are gestational weight gain, fasting glucose and insulin sensitivity in late pregnancy.","The primary outcomes study gestational weight gain, fasting glucose insulin sensitivity late pregnancy.",G0000000|C0205225|C1274040|C0557651|C0439671|C0005910|C1517378|C0015663|C0017725|C0021641|C0020517|C0205087|C0032961
"FEV1 (%), forced expiratory flow 25-75 (FEF25-75, %), and FVC were recorded and expressed as percent of predicted value.","FEV1 (%), forced expiratory flow 25-75 (FEF25-75, %), FVC recorded expressed percent predicted value.",G0000000|G0000000|C0441722|C0231800|C0806140|C0450371|C0450371|G0000000|C3714541|C0034869|G0000000|C0439165|C0681842|C1522609
"Participants recorded headache information in a daily diary that included time headaches started and ended, type of headache (Migraine, Tension, Other), headache severity (1 = Mild, 2 = Moderate, 3 = Severe), and number of hours subject was totally disabled (unable to perform any activities) and partially disabled (at least 50% impaired functioning).","Participants recorded headache daily diary included time headaches started ended, type headache (Migraine, Tension, Other), headache severity (1 = Mild, 2 = Moderate, 3 = Severe), hours subject totally disabled (unable perform activities) partially disabled (at 50% impaired functioning).",C0679646|C0034869|C0018681|C0332173|C0376660|C0332257|C0040223|C0018681|C1272689|C1272693|C0332307|C0018681|C0149931|C0233494|G0000000|C0018681|C0439793|G0000000|G0000000|C2945599|G0000000|G0000000|C0205081|G0000000|G0000000|C0205082|C0439227|C0681850|G0000000|C0018576|C1299582|C0884358|C0441655|G0000000|C0018576|G0000000|C0450371|C0221099|C0205245
Main outcome measure Number of days with frequent cough after the randomisation visit.,Main outcome measure Number days frequent cough randomisation visit.,C0205225|C1274040|C0079809|C0237753|C0439228|C0332183|C0010200|C0034656|C0545082
"In theory, if tranexamic acid reduces intracranial haemorrhage after traumatic brain injury without increasing the risk of ischaemic lesions, it could substantially improve patient outcomes.","In theory, tranexamic acid reduces intracranial haemorrhage traumatic brain injury increasing risk ischaemic lesions, improve patient outcomes.",G0000000|C0871935|G0000000|C0001128|G0000000|C0524466|C0019080|C0332663|C0006104|C3263722|C0442808|C0035647|C0475224|C0221198|G0000000|C0030705|C1274040
The primary endpoint was 2 hour post-dose FEV1 at endpoint.,The primary endpoint 2 hour post-dose FEV1 endpoint.,G0000000|C0205225|C2349179|G0000000|C0439227|C0439568|G0000000|C2349179
Figure Changes in Fatigue Severity Scale (FSS) score by treatment arm during 40 weeks of treatment and 2-week washout period (A) All subjects; (B) subjects considered not fatigued at baseline; (C) subjects considered fatigued at baseline.,Figure Changes Fatigue Severity Scale (FSS) score treatment arm 40 weeks treatment 2-week washout period (A) All subjects; (B) subjects considered fatigued baseline; (C) subjects considered fatigued baseline.,G0000000|C0392747|C0015672|C0439793|C0175659|C0265224|C0449820|C0039798|C0446516|C0450371|C0439230|C0039798|C0332174|C1710661|C0439531|G0000000|G0000000|C0681850|G0000000|C0681850|C0750591|C0015672|C0168634|G0000000|C0681850|C0750591|C0015672|C0168634
"CMV disease or symptomatic CMV infection was defined by the following: CMV viral syndrome, localized invasive CMV disease, or disseminated CMV disease.","CMV disease symptomatic CMV infection defined following: CMV viral syndrome, localized invasive CMV disease, disseminated CMV disease.",G0000000|C0012634|C0231220|G0000000|C0009450|C1704788|C0231290|G0000000|C0521026|C0039082|C0392752|C0205281|G0000000|C0012634|C0205221|G0000000|C0012634
"After a median follow-up of 42 months, median PFS was 10.2 and 10.8 months (p = 0.74), while median OS was 20.0 and 25.3 months (p = 0.099), for groups A and B, respectively.","After median follow-up 42 months, median PFS 10.2 10.8 months (p = 0.74), median OS 20.0 25.3 months (p = 0.099), A B, respectively.",G0000000|C0549183|C0589120|G0000000|C0549183|C0242792|C0450371|G0000000|G0000000|C0549183|C0229090|C0450371|G0000000|G0000000|G0000000|G0000000|G0000000
These measures were not prospectively registered.,These measures prospectively registered.,G0000000|C0079809|G0000000|C1514821
"Demographic and baseline characteristics from the integrated population of the two phase III HIV-DSP studies NPRS Numeric Pain Rating Scale, SD standard deviation.","Demographic baseline characteristics integrated population phase III HIV-DSP studies NPRS Numeric Pain Rating Scale, SD standard deviation.",C0011298|C0168634|C1521970|G0000000|C0032659|C0205390|C0439070|C0019682|C0947630|C1417814|C0237753|C0030193|C0871208|C0175659|C2699239|C1442989|C0012727
"There was no difference in OS between patients treated with capecitabine–cisplatin plus either bevacizumab or placebo, and PFS was similar in both arms.","There difference OS patients treated capecitabine–cisplatin bevacizumab placebo, PFS arms.",G0000000|C1705241|C0229090|C0030705|C1522326|G0000000|C0796392|C0032042|C0242792|C0206655
"6MWT has been shown to be a reliable method to assess walking performance in individuals with stroke.32 Hand-held dynamometry (Nicholas MMT, Lafayette Instruments, Lafayette, IN, USA) was used to evaluate isometric knee extension strength.","6MWT reliable method assess walking performance individuals stroke.32 Hand-held dynamometry (Nicholas MMT, Lafayette Instruments, Lafayette, IN, USA) evaluate isometric knee extension strength.",G0000000|C3858758|C0025663|C1516048|C0080331|C0597198|C0027361|C0038454|C0018563|G0000000|G0000000|C0046370|G0000000|C0348000|G0000000|G0000000|C0041703|C0220825|G0000000|C0022742|C0231448|C0237897
The primary outcome for this study is asthma control (ACQ6).,The primary outcome study asthma control (ACQ6).,G0000000|C0205225|C1274040|C0557651|C0004096|C0243148|G0000000
The detection limit was 2.3 logCFU/g feces.,The detection limit 2.3 logCFU/g feces.,G0000000|C1511790|C0439801|G0000000|C0439267|C0015733
Baseline blood samples were drawn from 352 children to measure SR concentration (vitamin A status) along with SF concentration and transferring receptor concentration (iron status) and haemoglobin concentration.,Baseline blood samples drawn 352 children measure SR concentration (vitamin A status) SF concentration transferring receptor concentration (iron status) haemoglobin concentration.,C0168634|C0005767|C0370003|C0013113|C1442061|C0008059|C0079809|C3813610|C0004268|C0042890|G0000000|C0449438|C0037712|C0004268|C1540850|C0597357|C0004268|C0302583|C0449438|C0019046|C0004268
"As illustrated in Figure Figure2,2, there was variability among participants with respect to both direction and rate of change in [Na].","As illustrated Figure Figure2,2, variability participants respect direction rate change [Na].",G0000000|G0000000|G0000000|G0000000|C2827666|C0679646|C0679133|C0449738|C0871208|C0392747|C0597484
"Symptomatic influenza-like illness was characterized by at least 1 respiratory symptom (cough or nasal congestion) plus at least 1 systemic symptom (fever or feverishness, chills, or body aches).","Symptomatic influenza-like illness characterized 1 respiratory symptom (cough nasal congestion) 1 systemic symptom (fever feverishness, chills, body aches).",C0231220|C0021400|C0221423|C1880022|G0000000|C0521346|C1457887|C0010200|C0028429|C0700148|G0000000|C0205373|C1457887|C0015967|C0015967|C0085593|C0242821|C0234238
"The health coaching intervention had a significant effect on the main outcome (rates of COPD hospitalization at 1, 3, and 6 months post–hospital discharge), but this effect faded at 12 months (Table 2).","The health coaching intervention main outcome (rates COPD hospitalization 1, 3, 6 months post–hospital discharge), faded 12 months (Table 2).",G0000000|C0018684|C0557773|C0886296|C0205225|C1274040|C0871208|C0024117|C0019993|G0000000|G0000000|G0000000|C0439231|G0000000|C0012621|G0000000|C0450371|C0439231|C0039224|G0000000
"Parameters that were recorded included respiratory rate (RR), heart rate (HR), arterial blood gas analysis (ABGA) and severity of illness as assessed by APACHE (acute physiology and chronic health evaluation) II score at presentation.","Parameters recorded included respiratory rate (RR), heart rate (HR), arterial blood gas analysis (ABGA) severity illness assessed APACHE (acute physiology chronic health evaluation) II score presentation.",C0449381|C0034869|C0332257|C0521346|C0871208|G0000000|C0018787|C0871208|G0000000|C0003842|C0005767|C0017110|C0002778|G0000000|C0439793|C0221423|C1516048|C0243030|C0205178|C0031842|C0205191|C0018684|C0220825|G0000000|C0449820|C0449450
"At 12 months, data were available on 994/1334 (75%) and 990/1334 (74%) participants; 640/1334 (48%) participants indicated 'No change' at four weeks.","At 12 months, data 994/1334 (75%) 990/1334 (74%) participants; 640/1334 (48%) participants 'No change' weeks.",G0000000|C0450371|C0439231|C1511726|C1442061|C0450371|C1442061|C0450371|C0679646|C1442061|C0450371|C0679646|G0000000|C0392747|C0439230
Trough FEV1 on day 1 and at weeks 12 and 26 (full analysis set).,Trough FEV1 day 1 weeks 12 26 (full analysis set).,C0444506|G0000000|C0332173|G0000000|C0439230|C0450371|C0450371|C0443225|C0002778|C0036849
"After the pandemic of SARS in 2003, only a few isolated cases of SARS, involving laboratory workers or animals, have been reported.","After pandemic SARS 2003, isolated SARS, involving laboratory workers animals, reported.",G0000000|C1615608|C1175175|G0000000|C0205409|C1175175|C1314939|C0022877|C0024752|C0003062|C0684224
"Exhaled breath condensate (EBC) and blood samples were collected for nitrite, nitrate, tumor necrosis factor α, interleukins-1β, 6, 8, 10, 11, neutrophil elastase (NE), and Clara Cell protein 16 (CC16) measurements, at the onset of ventilation and 60 min later.","Exhaled breath condensate (EBC) blood samples collected nitrite, nitrate, tumor necrosis factor α, interleukins-1β, 6, 8, 10, 11, neutrophil elastase (NE), Clara Cell protein 16 (CC16) measurements, onset ventilation 60 min later.",C0231800|C0225386|G0000000|G0000000|C0005767|C0370003|C1516695|C0028137|C0028125|C0027651|C0027540|C1521761|G0000000|G0000000|G0000000|G0000000|C0450371|C0450371|C0027950|C0030306|C0028219|G0000000|C0007634|C0033684|C0450371|G0000000|C0242485|C0206132|C0035203|C0450371|C0702093|C0205087
The current study extended this line of research to evaluate contemplation of change and family history of drug problems as moderators of marijuana prevention efficacy.,The current study extended evaluate contemplation change family history drug moderators marijuana prevention efficacy.,G0000000|C0521116|C0557651|C0231448|C0220825|G0000000|C0392747|C0015576|C0019664|C0013227|G0000000|C0024808|C0199176|C1280519
"FMA-LL: paretic lower limb score of the Fugl-Meyer assessment; BBS: Berg balance test; 6MWT: 6-minute walk test; K-MBI: Korean version of the Modified Barthel Index Clinical characteristics including lower-extremity motor control (FMA-LL), balance (BBS) and gait endurance (6MWT distance) before and after the intervention are described in Table 2.","FMA-LL: paretic lower limb score Fugl-Meyer assessment; BBS: Berg balance test; 6MWT: 6-minute walk test; K-MBI: Korean version Modified Barthel Index Clinical characteristics including lower-extremity motor control (FMA-LL), balance (BBS) gait endurance (6MWT distance) intervention Table 2.",C2332774|G0000000|C0441994|C0015385|C0449820|G0000000|C1261322|G0000000|G0000000|C0014653|C0022885|G0000000|C0439232|C0080331|C0022885|C0597277|C1556095|C0333052|C0392747|G0000000|C0918012|C0205210|C1521970|C0332257|C0023216|C1513492|C0243148|C2332774|C0014653|G0000000|C0016928|C0518031|G0000000|C0012751|C0886296|C0039224|G0000000
"(DOCX) (DOCX) Acupuncture has been commonly used for preventing migraine attacks and relieving pain during a migraine, although there is limited knowledge on the physiological mechanism behind this method.","(DOCX) (DOCX) Acupuncture commonly preventing migraine attacks relieving pain migraine, limited knowledge physiological mechanism method.",G0000000|G0000000|C0001299|G0000000|C0309872|C0149931|C1261512|C0332303|C0030193|C0149931|C0439801|C0376554|C0205463|C0441712|C0025663
"Unlike for DEX, we did not find any difference in ACTH or androstenedione concentrations during treatment with HC and PDN.","Unlike DEX, difference ACTH androstenedione concentrations treatment HC PDN.",G0000000|G0000000|C1705241|C3539087|C0002860|C0086045|C0039798|C0020268|G0000000
The timing of the primary outcome was 8 hours from when the blinded study medication was administered.,The timing primary outcome 8 hours blinded study medication administered.,G0000000|C0449243|C0205225|C1274040|G0000000|C0439227|C0150108|C0557651|C0013227|C1521801
"A linear mixed-effect model was used to analyze the changes at 4, 12, and 24 weeks.","A linear mixed-effect model analyze 4, 12, 24 weeks.",G0000000|C0205132|C0205430|C3161035|G0000000|G0000000|C0450371|C0450371|C0439230
Secondary outcome variables were cortical and posterior subcapsular opacities and nuclear colour changes; best corrected visual acuity change; myopic shift; and failure of treatment.,Secondary outcome variables cortical posterior subcapsular opacities nuclear colour changes; corrected visual acuity change; myopic shift; failure treatment.,C0027627|C1274040|C0439828|C0001613|C0205095|C0205152|C0029053|C0521447|C0009393|C0392747|C0205202|C0234621|C0750509|C0392747|C0027092|C0333051|C0231174|C0039798
"In this trial significant and clinically meaningful results were reported in patient global assessment, a pain and symptom visual analogue scale, WOMAC function and stiffness and overall WOMAC score.","In trial clinically meaningful reported patient global assessment, pain symptom visual analogue scale, WOMAC function stiffness WOMAC score.",G0000000|C0008976|G0000000|C0876919|C0684224|C0030705|C0205246|C1261322|C0030193|C1457887|C0234621|C0243071|C0175659|G0000000|C0031843|C0427008|G0000000|C0449820
"If respondents met any one of three following conditions, the respondents are defined as “engaging in regular physical activity”: (1) engaging in 150 mins/week or more of walking, (2) engaging in daily flexibility activity, or (3) engaging 2 or more days/week in muscle-strengthening activities.","If respondents met conditions, respondents defined “engaging regular physical activity”: (1) engaging 150 mins/week walking, (2) engaging daily flexibility activity, (3) engaging 2 days/week muscle-strengthening activities.",G0000000|C0282122|C0268621|C0012634|C0282122|C1704788|G0000000|C0205272|C0031809|G0000000|G0000000|C0425152|C1442061|C0556975|C0080331|G0000000|C0425152|C0332173|C0242808|C0205177|G0000000|C0425152|G0000000|C0677547|C0026845|C0441655
Participants rated their dyspnea for these same activities at 3 and 6 months.,Participants rated dyspnea activities 3 6 months.,C0679646|C0871208|C0013404|C0441655|G0000000|G0000000|C0439231
"Treatment emergent AEs were recorded until 4 weeks after the last dose, with the exception of SAEs, which were collected through week 52.","Treatment emergent AEs recorded 4 weeks dose, exception SAEs, collected week 52.",C0039798|C0750573|C1412268|C0034869|G0000000|C0439230|C0178602|C1554961|C1519255|C1516695|C0332174|C0450371
Kaplan-Meier methodology was used to assess PFS and OS.,Kaplan-Meier methodology assess PFS OS.,G0000000|C0969625|C1516048|C0242792|C0229090
"Secondary outcomes included adherence to treatment, weight gain, symptomatic improvement in all patients, and sputum smear clearance in the subgroup with positive smear test results.","Secondary outcomes included adherence treatment, weight gain, symptomatic improvement patients, sputum smear clearance subgroup positive smear test results.",C0027627|C1274040|C0332257|C1510802|C0039798|C0005910|C1517378|C0231220|C2986411|C0030705|C0038056|C0444186|C0449297|C1079230|C0439178|C0444186|C0022885|C1274040
"The associations of contralateral prophylactic mastectomy on breast cancer–specific survival were estimated, with further analyses by age, disease stage, and estrogen receptor status.","The associations contralateral prophylactic mastectomy breast cancer–specific survival estimated, analyses age, disease stage, estrogen receptor status.",G0000000|C0004083|C0441988|C0355642|C0024881|C0006141|G0000000|C0038952|C0750572|C0002778|C0001779|C0012634|C0205390|C0014939|C0597357|C0449438
"Mean arterial blood pressure, heart rate, SpO2, ICP and calculated CPP were continuously measured.","Mean arterial blood pressure, heart rate, SpO2, ICP calculated CPP continuously measured.",C0444504|C0003842|C0005767|C0033095|C0018787|C0871208|G0000000|C1881201|C0444686|C0205770|G0000000|C0444706
"Values of NIHSS, FMA, VFSS, MoCA, and MMSE were compared by repeated measures ANOVA across two to four testing timepoints (week 0, week 1, week 3, and week 7).","Values NIHSS, FMA, VFSS, MoCA, MMSE compared repeated measures ANOVA testing timepoints (week 0, week 1, week 3, week 7).",C0042295|C3476804|C2332774|G0000000|C3541265|C0451306|C1707455|C0205341|C0079809|G0000000|C0039593|C2348792|C0332174|G0000000|C0332174|G0000000|C0332174|G0000000|C0332174|G0000000
"Conclusions Use of automated external defibrillators by first responders did not significantly increase survival to discharge from hospital, although it did improve return of spontaneous circulation and admission to hospital.","Conclusions Use automated external defibrillators responders increase survival discharge hospital, improve return spontaneous circulation admission hospital.",C1707478|C0042153|C0205554|C0205101|C0180307|G0000000|C0442805|C0038952|C0012621|C0019994|G0000000|C0332156|C0205359|C0005775|C0184666|C0019994
The primary endpoint was time to progression (TTP).,The primary endpoint time progression (TTP).,G0000000|C0205225|C2349179|C0040223|C0242656|C0084795
"We also measured the duration from attainment of full PO feeds to discharge [6 days (No OCP) vs 5 days (OCP), p = 0.55], and the time to full PO feeds [47 days (No OCP) vs 39 days (OCP), p = 0.25].","We measured duration attainment PO feeds discharge [6 days (No OCP) 5 days (OCP), = 0.55], time PO feeds [47 days (No OCP) 39 days (OCP), = 0.25].",G0000000|C0444706|C0449238|G0000000|C0032729|C1510670|C0012621|G0000000|C0439228|G0000000|C1282359|G0000000|C0439228|C1282359|G0000000|C0450371|C0040223|C0032729|C1510670|C0450371|C0439228|G0000000|C1282359|C0450371|C0439228|C1282359|G0000000|C0450371
"Patients were evaluated based on the scores from the Timed Up-and-Go Test, the Berg Balance Scale (BBS), and the Unified Parkinson’s Disease Rating Scale-II (UPDRS-II).","Patients evaluated based scores Timed Up-and-Go Test, Berg Balance Scale (BBS), Unified Parkinson’s Disease Rating Scale-II (UPDRS-II).",C0030705|C0220825|C1527178|C0449820|C0392761|C1822658|C0022885|G0000000|C0014653|C0175659|G0000000|C1548174|G0000000|C0012634|C0871208|C0175659|C3639721
"The efficacies of the two treatment protocols were also compared by observing secondary endpoints such as 1-year postoperative severe restenosis, hemodynamic disorders and high-perfusion syndrome, which did not differ significantly in the two groups either.","The efficacies treatment protocols compared observing secondary endpoints 1-year postoperative severe restenosis, hemodynamic disorders high-perfusion syndrome, either.",G0000000|C1280519|C0039798|C0442711|C1707455|C1441672|C0027627|C2349179|C0439234|C0032790|C0205082|C0333186|C0019010|C0012634|C0205250|C0039082|C3844638
"Data were compared according to the methodology used to estimate LE, and the methodologies are assessed according to their underlying assumptions and empirical base.","Data compared methodology estimate LE, methodologies assessed underlying assumptions empirical base.",C1511726|C1707455|C0969625|C0750572|C0023190|C0969625|C1516048|G0000000|G0000000|C1880496|C0002055
"In addition to the primary outcome, secondary outcome variables included the number of subsequent episodes and anaemia rates during and up to 2 weeks post-treatment as well as any notable adverse events.","In addition primary outcome, secondary outcome variables included subsequent episodes anaemia rates 2 weeks post-treatment notable adverse events.",G0000000|C0332287|C0205225|C1274040|C0027627|C1274040|C0439828|C0332257|C0332282|C0332189|C0002871|C0871208|G0000000|C0439230|C2709088|G0000000|G0000000|C0441471
Visual analog scale (VAS)11) was also used to evaluate pain intensity.,Visual analog scale (VAS)11) evaluate pain intensity.,C0234621|C0243071|C0175659|C0042815|C0220825|C0030193|C0522510
"The movement of the hyoid bone was measured in both horizontal and vertical sections in the two consecutive frames (frame for X, Y-coordinates; the upper left corner of the square is the hyoid bone; the line indicates the epiglottis on the right of the image)13).","The movement hyoid bone measured horizontal vertical sections consecutive frames (frame X, Y-coordinates; upper left corner square hyoid bone; epiglottis image)13).",G0000000|C0026649|C0020417|C0262950|C0444706|C0205126|C0205128|C0152060|C1707491|C0180979|C0080089|G0000000|C1704670|C1282910|C0205091|C1879655|C0205120|C0020417|C0262950|C0014540|C1704254
"Patients were included in the study if aged 18–70 years and diagnosed with UC in remission (clinical activity index (CAI) ⩽4, endoscopic index (EI) ⩽4, and no signs of acute inflammation on histological examination).","Patients included study aged 18–70 diagnosed UC remission (clinical activity (CAI) ⩽4, endoscopic (EI) ⩽4, signs acute inflammation histological examination).",C0030705|C0332257|C0557651|C0001779|G0000000|C0011900|G0000000|C0544452|C0205210|C0205177|C0064494|G0000000|C0014245|C0022067|G0000000|C0220912|C0205178|C0021368|C0205462|G0000000
"For each medication discrepancy or episode of non-adherence, adjudicators graded the potential for harm if left uncorrected; if the likelihood of potential harm exceeded 50%, it was counted as a potential ADE.","For medication discrepancy episode non-adherence, adjudicators graded potential harm left uncorrected; likelihood potential harm exceeded 50%, counted potential ADE.",G0000000|C0013227|C1290905|C0332189|C1518422|C0401783|C0441800|C3245505|G0000000|C0205091|C4072785|C0033204|C3245505|G0000000|G0000000|C0450371|C0750480|C3245505|C0057163
"Baseline low back pain disability and changes in disability from baseline to 2 weeks were measured with the Roland-Morris Disability Questionnaire, a 24-item scale with possible scores ranging from 0 (minimal disability) to 24 (severe disability).20 Questions were modified to include leg pain as well as back pain.","Baseline low pain disability disability baseline 2 weeks measured Roland-Morris Disability Questionnaire, 24-item scale scores ranging 0 (minimal disability) 24 (severe disability).20 Questions modified leg pain pain.",C0168634|C0205251|C0030193|C0231170|C0231170|C0168634|G0000000|C0439230|C0444706|G0000000|C0231170|C0034394|C0450371|C0175659|C0449820|C1514721|G0000000|C0547040|C0231170|C0450371|C0205082|C0231170|C1522634|C0392747|C0023216|C0030193|C0030193
"At each visit, ocular symptoms (itching, tearing) were graded by the subject, ocular signs (redness, eyelid swelling, chemosis) were graded by the investigator, using ordinal grading scales (Table 22).).","At visit, ocular symptoms (itching, tearing) graded subject, ocular signs (redness, eyelid swelling, chemosis) graded investigator, ordinal grading scales (Table 22).).",G0000000|C0545082|C0015392|C0683368|C0033774|C0039409|C0441800|C0681850|C0015392|C0220912|C0041834|C0015426|C0013604|C0271298|C0441800|C0035173|C0439080|C0441800|C0175659|C0039224|C0450371
There is increasing evidence that the immune system has the ability to recognize tumor-associated antigens expressed in human malignancies and to induce antigen-specific humoral and cellular immune responses to these targets.,There increasing evidence immune system ability recognize tumor-associated antigens expressed human malignancies induce antigen-specific humoral cellular immune responses targets.,G0000000|C0442808|C3887511|C0439662|C0449913|C0085732|G0000000|C0027651|C0003320|G0000000|C0086418|C0006826|C0205263|C0456981|C0020168|C0007634|C0439662|C0871261|C1521840
The pain of children was assessed by Wong pain face scale and also general behaviors of the samples were evaluated by the researcher.,The pain children assessed Wong pain scale behaviors samples evaluated researcher.,G0000000|C0030193|C0008059|C1516048|G0000000|C0030193|C0175659|C0004927|C0370003|C0220825|C0035173
All patients were followed at accredited cystic fibrosis centers with standardized procedures for quarterly measurement of clinical outcomes including BMI and pulmonary function.,All patients accredited cystic fibrosis centers standardized procedures quarterly measurement clinical outcomes including BMI pulmonary function.,G0000000|C0030705|C0680883|C0205207|C0016059|C0205099|G0000000|C0025664|C0332179|C0242485|C0205210|C1274040|C0332257|G0000000|C0024109|C0031843
Failure was defined as any subsequent episode of vivax malaria over 11 months of observation.,Failure defined subsequent episode vivax malaria 11 months observation.,C0231174|C1704788|C0332282|C0332189|G0000000|C0024530|C0450371|C0439231|C0302523
The overall difference between treatment groups at day 63 was significant (P < .001).,The difference treatment day 63 (P < .001).,G0000000|C1705241|C0039798|C0332173|C0450371|C0369773|G0000000|C1442061
"Reaching a CD4 cell count less than 200/μL until May 2008; after this date, reaching a CD4 cell count of 250/μL or less, consistent with the standard of care in Botswana for initiation of ART at the time of the study.","Reaching CD4 cell count 200/μL May 2008; date, reaching CD4 cell count 250/μL less, consistent standard care Botswana initiation ART time study.",C2584321|C0285590|C0007634|C0750480|G0000000|G0000000|G0000000|C0011008|C2584321|C0285590|C0007634|C0750480|G0000000|C0439092|C0332290|C1442989|C1947933|C0006041|C0589507|C0003826|C0040223|C0557651
This analysis used a last-observation-carried-forward approach (LOCF) and included only participants who reported pre-intervention GDS values ≥10.,This analysis last-observation-carried-forward approach (LOCF) included participants reported pre-intervention GDS values ≥10.,G0000000|C0002778|C1517741|C0449445|C2825507|C0332257|C0679646|C0684224|C2347663|C0451184|C0042295|G0000000
"In high-grade chondrosarcomas, local recurrence undoubtedly compromises survival [13].","In high-grade chondrosarcomas, local recurrence undoubtedly compromises survival [13].",G0000000|C0205082|C0008479|C0205276|C0034897|G0000000|C2945640|C0038952|C0450371
"We will conduct analyses for each of the outcomes separately (that is, number of hospital admissions and number of emergency department visits).","We conduct analyses outcomes separately (that is, hospital admissions emergency department visits).",G0000000|C0004927|C0002778|C1274040|G0000000|G0000000|G0000000|C0019994|C0184666|C0013956|C1704729|C0545082
"For neonates cyanosis was predictive of hypoxaemia, but tachypnoea or inability to feed were not.","For neonates cyanosis predictive hypoxaemia, tachypnoea inability feed not.",G0000000|C0021289|C0010520|C0681890|C0700292|C0231835|G0000000|C0204695|C1518422
Health status as measured by the Chronic Respiratory Questionnaire (CRQ) at baseline and at 12–14 weeks postcompletion of the programme.,Health status measured Chronic Respiratory Questionnaire (CRQ) baseline 12–14 weeks postcompletion programme.,C0018684|C0449438|C0444706|C0205191|C0521346|C0034394|G0000000|C0168634|G0000000|G0000000|C1709697
"Patients whose initial provider was a generalist were 12% less likely to have a CD4 cell count 90–210 days after ART initiation, although little difference was found in CD4 cell count monitoring 330–390 days after ART initiation.","Patients initial provider generalist 12% CD4 cell count 90–210 days ART initiation, difference CD4 cell count monitoring 330–390 days ART initiation.",C0030705|C0205265|C1138603|C0017319|C0450371|C0285590|C0007634|C0750480|G0000000|C0439228|C0003826|C0589507|C1705241|C0285590|C0007634|C0750480|C0150369|G0000000|C0439228|C0003826|C0589507
"MENQOL Results (Exit - Entry) All data is presented as mean ± SD Abbreviations as previous There were no group differences between entry and exit in the Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI).","MENQOL Results (Exit - Entry) All data ± SD Abbreviations previous There differences entry exit Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI) State-Trait Anxiety Inventory (STAI).",G0000000|C1274040|C0337094|G0000000|C1705654|G0000000|C1511726|G0000000|C2699239|C0000723|C0205156|G0000000|C1705241|C1705654|C0337094|G0000000|C0037313|C0332306|C0918012|C3697468|G0000000|C0011570|C0021941|C0006448|C1301808|C0003467|C0021941|C0683457
"21 All secondary outcomes were selected a priori and included time to recovery from acute respiratory failure, duration of weaning from mechanical ventilation, neurological testing, PICU and hospital lengths of stay, in-hospital mortality, sedation-related adverse events, sedative exposure, and occurrence of iatrogenic withdrawal (eTable 4).","21 All secondary outcomes selected priori included time recovery acute respiratory failure, duration weaning mechanical ventilation, neurological testing, PICU hospital lengths stay, in-hospital mortality, sedation-related adverse events, sedative exposure, occurrence iatrogenic withdrawal (eTable 4).",C0450371|G0000000|C0027627|C1274040|C1707391|G0000000|C0332257|C0040223|C0237820|C0205178|C0521346|C0231174|C0449238|C0043084|C0443254|C0035203|C0205494|C0039593|C1046445|C0019994|C1444754|G0000000|C0019994|C0026565|C0235195|G0000000|C0441471|C0020592|C0274281|C0243132|C0439669|C2349954|G0000000|G0000000
The primary endpoint was the incidence of biopsy-proven prostate cancer over the course of the study.,The primary endpoint incidence biopsy-proven prostate cancer study.,G0000000|C0205225|C2349179|C0021149|C0005558|C0033572|C0006826|C0557651
Groups were not significantly different for other cognitive variables.,Groups cognitive variables.,C0441833|C1516691|C0439828
"Carer-QoL = Carer-related Quality of Life questionnaire; CES-D = Centre for Epidemiological Studies – Depression Scale; GSCL = Giessen Subjective Complaints List / Subscale Pain in Limbs; LTS = Leisure Time Satisfaction Measure; RMBPC = Revised Memory and Behaviour Problems Checklist/ subscale frequency; SCQ = Sense of Competence Questionnaire – subscale 2: Satisfaction with one’s own performance as a caregiver; SPSI-R:S = Social Problem-Solving Inventory – revised / subscale: Negative problem orientation; Time burden questionnaire = Including three dimensions of care (1. body care, nutrition, mobility 2. household help IADLs (e.g.","Carer-QoL = Carer-related Quality Life questionnaire; CES-D = Centre Epidemiological Studies – Depression Scale; GSCL = Giessen Subjective Complaints List / Subscale Pain Limbs; LTS = Leisure Time Satisfaction Measure; RMBPC = Revised Memory Behaviour Problems Checklist/ subscale frequency; SCQ = Sense Competence Questionnaire – subscale 2: Satisfaction one’s performance caregiver; SPSI-R:S = Social Problem-Solving Inventory – revised / subscale: Negative orientation; Time burden questionnaire = Including dimensions care (1. body care, nutrition, mobility 2. household IADLs (e.g.",G0000000|C0332306|C0376558|C0034394|G0000000|C0014507|C0947630|G0000000|C0011570|C0175659|G0000000|C0439655|C0277786|C0745732|G0000000|G0000000|C0030193|C0015385|G0000000|C0040223|C0242428|C0079809|G0000000|C0025260|C0004927|C1546466|C1707357|G0000000|C0376249|G0000000|C0086035|C0034394|G0000000|G0000000|G0000000|C0242428|G0000000|C0597198|C0085537|G0000000|C0033213|C0021941|G0000000|C1527075|G0000000|G0000000|C0205160|C0029266|C0040223|C2828008|G0000000|C0439534|C1947933|G0000000|C0242821|C1947933|C0028707|C0425245|G0000000|C0020052|C1290928|G0000000
The results of the prognostic value of Vitamin D level for gestational diabetes prediction are shown in Table 2.,The prognostic Vitamin D level gestational diabetes prediction Table 2.,G0000000|C0220901|C0042890|C0073187|C0441889|C0439671|C0011847|C0681842|C0039224|G0000000
"The secondary endpoints included the change from baseline in the frequencies of migraine days, moderate/severe headache days, headache episodes, migraine episodes, and acute headache medication intakes, as well as the change from baseline in total cumulative hours of headache on headache days and the percent of patients with severe (≥60) HIT-6 score.","The secondary endpoints included change baseline frequencies migraine days, moderate/severe headache days, headache episodes, migraine episodes, acute headache medication intakes, change baseline total cumulative hours headache headache days percent patients severe (≥60) HIT-6 score.",G0000000|C0027627|C2349179|C0332257|C0392747|C0168634|C0439603|C0149931|C0439228|C0205081|C0018681|C0439228|C0018681|C0332189|C0149931|C0332189|C0205178|C0018681|C0013227|C1512806|C0392747|C0168634|C0439175|C1511559|C0439227|C0018681|C0018681|C0439228|C0439165|C0030705|C0205082|G0000000|C0272285|C0449820
A post hoc analysis was performed to assess the proportion of patients free from new or enlarging T2 lesions on brain MRI scans at the end of the study for the per-protocol participants of the group receiving the most effective intervention versus placebo.,A post hoc analysis performed assess proportion patients free enlarging T2 lesions brain MRI scans study per-protocol participants receiving effective intervention versus placebo.,G0000000|C0687676|G0000000|C0002778|C0884358|C1516048|C1709707|C0030705|C0332296|C0442800|C0041403|C0221198|C0006104|C0024485|C0034606|C0557651|C1698058|C0679646|C1514756|C1280519|C0886296|G0000000|C0032042
"Seizure outcome was measured as “seizure remission,” defined as no seizures during the last quarter of 12 month follow-up.","Seizure outcome measured “seizure remission,” defined seizures quarter 12 month follow-up.",C0036572|C1274040|C0444706|G0000000|G0000000|C1704788|C0036572|C2825406|C0450371|C0332177|C0589120
"Interproximal alveolar bone loss was measured from full mouth radiographs with a Schei ruler (Schei et al., 1959).","Interproximal alveolar bone loss measured mouth radiographs Schei ruler (Schei al., 1959).",G0000000|C1440080|C0262950|C1517945|C0444706|C0226896|C1306645|G0000000|C0522637|G0000000|C0202311|G0000000
"To measure caregiver upset with problem behaviors overall, we derived a mean score by averaging caregiver responses across all occurring behaviors as described above with higher scores indicating greater upset (α=.78 for sample).","To measure caregiver upset behaviors overall, derived score averaging caregiver responses occurring behaviors scores indicating upset (α=.78 sample).",C0040363|C0079809|C0085537|C3887804|C0004927|C0282416|C1441547|C0449820|C1510992|C0085537|C0871261|C1709305|C0004927|C0449820|G0000000|C3887804|G0000000|C0370003
"During assessments, participants were evaluated using the Unified Parkinson’s Disease Rating Scale Motor Subscale 3 (UPDRS) 15, Berg Balance Scale (BBS) 16, and the Timed Up and Go test (TUG) 17.","During assessments, participants evaluated Unified Parkinson’s Disease Rating Scale Motor Subscale 3 (UPDRS) 15, Berg Balance Scale (BBS) 16, Timed Up Go test (TUG) 17.",G0000000|C1261322|C0679646|C0220825|C1548174|G0000000|C0012634|C0871208|C0175659|C1513492|G0000000|G0000000|C3639721|C0450371|G0000000|C0014653|C0175659|G0000000|C0450371|C0392761|G0000000|C1822658|C0022885|C1319201|C0450371
asserted the value of probiotic treatment of vulvovaginal symptoms for 1–3 days after the second menstrual cycle [5].,asserted probiotic treatment vulvovaginal symptoms 1–3 days menstrual cycle [5].,G0000000|C0525033|C0039798|C0042997|C0683368|G0000000|C0439228|C0025344|C1511572|G0000000
All subjects underwent a daytime function testing at the beginning and after 12 months of the initiation of CPAP treatment.,All subjects underwent daytime function testing 12 months initiation CPAP treatment.,G0000000|C0681850|G0000000|C0332169|C0031843|C0039593|C0450371|C0439231|C0589507|C0199451|C0039798
The change in BMI percentile was calculated.,The change BMI percentile calculated.,G0000000|C0392747|G0000000|C1264641|C0444686
[6] Almost all breast cancer patients experience fatigue during the course of treatment and the intensity of fatigue increases during the course of chemotherapy and radiotherapy.,[6] Almost breast cancer patients experience fatigue treatment intensity fatigue increases chemotherapy radiotherapy.,G0000000|C3828842|C0006141|C0006826|C0030705|C0237607|C0015672|C0039798|C0522510|C0015672|C0205217|C0013216|C0034619
"Furthermore, given the small or modest effect found in the majority of the interventions aimed at enhancing parental sensitivity or in reducing attachment insecurity (Berlin et al., 2016), we added the analysis of two moderating variables – maternal emotional availability on children’s outcomes and maternal neurobiological markers on maternal emotional availability – in order to better explain the factors implied in the individual differences obtained in response to the intervention.","Furthermore, modest majority interventions aimed enhancing parental sensitivity reducing attachment insecurity (Berlin al., 2016), analysis moderating variables – maternal emotional availability children’s outcomes maternal neurobiological markers maternal emotional availability – explain factors implied individual differences response intervention.",G0000000|C4054480|C0680220|C0886296|C1947946|C2349975|C0030551|C0020517|C0392756|C0185023|C0233497|C0005125|C0202311|G0000000|C0002778|C0205081|C0439828|G0000000|C2347083|C0013987|C0470187|G0000000|C1274040|C2347083|C0027817|C0005516|C2347083|C0013987|C0470187|G0000000|G0000000|C1521761|G0000000|C0027361|C1705241|C0871261|C0886296
FIM = Functional Independence Measure; GCS = Glasgow Coma Scale; GOS = Glasgow Outcome Scale; ICP = intracranial pressure; TBI = traumatic brain injury.,FIM = Functional Independence Measure; GCS = Glasgow Coma Scale; GOS = Glasgow Outcome Scale; ICP = intracranial pressure; TBI = traumatic brain injury.,C3273671|G0000000|C0205245|C0085862|C0079809|G0000000|G0000000|G0000000|C0009421|C0175659|G0000000|G0000000|G0000000|C1274040|C0175659|C1881201|G0000000|C0524466|C0033095|C0876926|G0000000|C0332663|C0006104|C3263722
Overall I'm happy with my life.,Overall I'm happy life.,C0282416|C0021966|C0018592|C0376558
"In addition, the subjects in the intervention group were more likely to be abstinent (using verified 4-week point prevalence abstinence) at the end of three and six months.","In addition, subjects intervention abstinent (using verified 4-week prevalence abstinence) months.",G0000000|C0332287|C0681850|C0886296|C0457801|C1524063|C1711411|C0332174|C0033105|C3843422|C0439231
"The observed complication control of participants within 42 days (6 weeks) and 84 days (12 weeks) post-discharge included presence of edema, existence of peritonitis, catheter infections and weight gain.","The observed complication control participants 42 days (6 weeks) 84 days (12 weeks) post-discharge included presence edema, existence peritonitis, catheter infections weight gain.",G0000000|C1441672|C0009566|C0243148|C0679646|C0450371|C0439228|G0000000|C0439230|C0450371|C0439228|C0450371|C0439230|C0687676|C0332257|C0150312|C0013604|C0015276|C0031154|C0085590|C3714514|C0005910|C1517378
"We assessed 30-day perioperative harms and the prevalence of urinary incontinence and erectile and bowel dysfunction at 2 years, which was based on self-reported dysfunction that was at least moderate in severity.","We assessed 30-day perioperative harms prevalence urinary incontinence erectile bowel dysfunction 2 years, based self-reported dysfunction moderate severity.",G0000000|C1516048|C0450371|C1518988|G0000000|C0033105|C0042027|C0021167|C0030847|C0021853|C0031847|G0000000|C0439234|C1527178|C0681906|C0031847|C0205081|C0439793
"In addition, a Numerical Rating Scale of Pain on activity was completed.","In addition, Numerical Rating Scale Pain activity completed.",G0000000|C0332287|C0237753|C0871208|C0175659|C0030193|C0205177|C0205197
"Two trials used a half-standardized treatment protocol in which acupoints were selected from a group of acupoints according to traditional Chinese acupuncture principles [22,25].","Two trials half-standardized treatment protocol acupoints selected acupoints traditional Chinese acupuncture principles [22,25].",C0205448|C0008976|C2825407|C0039798|C0442711|C0001302|C1707391|C0001302|C0443324|C0008120|C0001299|G0000000|C0450371
"Given the high risk for vascular re-events in acute stroke and the available effective strategies in secondary prevention, the INSPIRE-TMS support program has the potential to lead to a relevant reduction of recurrent events and a prolongation of the event-free survival time.","Given risk vascular re-events acute stroke effective strategies secondary prevention, INSPIRE-TMS support program potential lead relevant reduction recurrent events prolongation event-free survival time.",C1442162|C0035647|C0005847|C0556581|C0205178|C0038454|C1280519|C0679199|C0027627|C0199176|G0000000|C0183683|C1709697|C3245505|C0023175|C2347946|C0301630|C2945760|C0441471|C0439590|C0441471|C0038952|C0040223
No difference was found in the subsequent need for readmission.,No difference subsequent readmission.,G0000000|C1705241|C0332282|C1548168
All of the events were considered to be unrelated to the study procedure.,All events considered unrelated study procedure.,G0000000|C0441471|C0750591|C0445356|C0557651|C0184661
[6] Crapo-predicted normals for FEV1 were used.,[6] Crapo-predicted normals FEV1 used.,G0000000|C0681842|C0205307|G0000000|C1273517
The economic evaluation was limited to the perspective of the NHS.,The economic evaluation limited perspective NHS.,G0000000|C0013556|C0220825|C0439801|G0000000|C0796085
The primary end point was clinical response.,The primary clinical response.,G0000000|C0205225|C0205210|C0871261
"The majority of cases had transitional cell carcinoma, but all histology types were included.","The majority transitional cell carcinoma, histology types included.",G0000000|C0680220|C1182674|C0007634|C0007097|C0019638|C0332307|C0332257
"Rituximab did not reduce proteinuria at 3 months (change, −12% [95% confidence interval, −73% to 110%]; P=0.77 in analysis of covariance model adjusted for baseline proteinuria).","Rituximab reduce proteinuria 3 months (change, −12% [95% confidence interval, −73% 110%]; P=0.77 analysis covariance model adjusted baseline proteinuria).",C0393022|G0000000|C0033687|G0000000|C0439231|C0392747|G0000000|C0450371|C0237529|C1272706|G0000000|C1442061|C0369773|C0002778|G0000000|C3161035|C0456081|C0168634|C0033687
"We measured severity of pain by Visual Analogue Scale (VAS) (Gould, 1996) that they marked on the line the point that they feel represents their perception of their pain and its duration by Cox Menstrual Scale that can be used to assess the frequency and duration of symptoms of dysmenorrheal (Jafary, 2004), in three times; at the beginning of study, one month and two months after taking the drugs or placebo.","We measured severity pain Visual Analogue Scale (VAS) (Gould, 1996) marked feel represents perception pain duration Cox Menstrual Scale assess frequency duration symptoms dysmenorrheal (Jafary, 2004), times; study, month months drugs placebo.",G0000000|C0444706|C0439793|C0030193|C0234621|C0243071|C0175659|C0042815|G0000000|G0000000|C0522501|C0013987|C1882932|C0030971|C0030193|C0449238|G0000000|C0025344|C0175659|C1516048|C0376249|C0449238|C0683368|C0013390|G0000000|G0000000|C0040223|C0557651|C0332177|C0439231|C0013227|C0032042
"Secondary outcomes were activities of daily living, health related quality of life and depression.","Secondary outcomes activities daily living, health quality life depression.",C0027627|C1274040|C0441655|C0332173|C0376558|C0018684|C0332306|C0376558|C0011570
"Repeated measures analysis of variance or Friedman test was used to determine changes in sputum and plasma biomarker values at the three time points (Weeks 0, 4, and 12) and paired Student t test or Wilcoxon matched-pair signed rank test was used to determine changes in sputum and plasma biomarker values at Weeks 0 and 12 for normally or nonnormally distributed values, respectively.","Repeated measures analysis variance Friedman test determine sputum plasma biomarker values time (Weeks 0, 4, 12) paired Student test Wilcoxon matched-pair signed rank test determine sputum plasma biomarker values Weeks 0 12 nonnormally distributed values, respectively.",C0205341|C0079809|C0002778|C1711260|G0000000|C0022885|G0000000|C0038056|C0032105|C0005516|C0042295|C0040223|C0439230|G0000000|G0000000|C0450371|C1709450|C0038492|C0022885|G0000000|C0150103|C1519316|C0699794|C0022885|G0000000|C0038056|C0032105|C0005516|C0042295|C0439230|G0000000|C0450371|G0000000|C1704711|C0042295|G0000000
"Data will also be collected on demographics, the overall prevalence of delirium, duration and severity of delirium, sleep quality, participation in physiotherapy sessions, ICU and hospital LOS, morbidity and mortality, and healthcare costs.","Data collected demographics, prevalence delirium, duration severity delirium, sleep quality, participation physiotherapy sessions, ICU hospital LOS, morbidity mortality, healthcare costs.",C1511726|C1516695|C0011298|C0033105|C0011206|C0449238|C0439793|C0011206|C0037313|C0332306|C0679823|C0949766|C1883016|C0021708|C0019994|G0000000|C0026538|C0026565|C0086388|C0010186
"The 6-month PFS rate in the erlotinib arm was 11.4% (95% CI, 4.6% to 21.5%), and it was 24% in the control arm.","The 6-month PFS rate erlotinib arm 11.4% (95% CI, 4.6% 21.5%), 24% control arm.",G0000000|C0332177|C0242792|C0871208|C1135135|C0446516|C0450371|C0450371|C0008107|G0000000|C0450371|C0450371|C0243148|C0446516
"Primary health risk behavior measures included items assessing the frequency and quantity of alcohol, cigarette and marijuana use, scored as 30-day frequency (ranging from 1=0 days through 11=28–30 days) and 30-day quantity (ranging from 1=0 drinks/cigarettes/marijuana times used per day through 12=11 or more drinks/31 or more cigarettes/31 or more times using marijuana).","Primary health risk behavior measures included items assessing frequency quantity alcohol, cigarette marijuana use, scored 30-day frequency (ranging 1=0 days 11=28–30 days) 30-day quantity (ranging 1=0 drinks/cigarettes/marijuana times day 12=11 drinks/31 cigarettes/31 times marijuana).",C0205225|C0018684|C0035647|C0004927|C0079809|C0332257|C1551338|C1516048|C0376249|C1265611|C0001962|C0677453|C0024808|C0042153|C0449820|C0450371|C0376249|C1514721|G0000000|C0439228|G0000000|C0439228|C0450371|C1265611|C1514721|G0000000|C0452428|C0040223|C0332173|C0450371|C0452428|C0677453|C0040223|C0024808
The primary outcome was a change in the 24-h urinary protein excretion at 24 weeks.,The primary outcome change 24-h urinary protein excretion 24 weeks.,G0000000|C0205225|C1274040|C0392747|C0450371|C0042027|C0033684|C0221102|C0450371|C0439230
Patients with an initial croup score above 3 demonstrated a significant improvement in symptoms at two hours (95% CI 1 to 3).,Patients initial croup score 3 demonstrated improvement symptoms hours (95% CI 1 3).,C0030705|C0205265|C0010380|C0449820|G0000000|G0000000|C2986411|C0683368|C0439227|C0450371|C0008107|G0000000|G0000000
Oral midazolam had superiority neither in sleep onset latency nor in sleep duration when compared to chloral hydrate.,Oral midazolam superiority sleep onset latency sleep duration compared chloral hydrate.,C0442027|C0026056|C0680218|C0037313|C0206132|C0205275|C0037313|C0449238|C1707455|C0077034|C0720930
"Intervention), Covarying Social Desirability, and Pretest Scores Across All Men Note: RMS = Rape Myth Scale; IRMA-SF = Short form version of the Illinois Rape Myth Acceptance Scale; RES = Rape Empathy Scale; SRAES = Sex-Related Alcohol Expectancies Scale; ASA = Attraction to Sexual Aggression; M-SES = Modified Sexual Experiences Survey.","Intervention), Covarying Social Desirability, Pretest Scores Across All Men Note: RMS = Rape Myth Scale; IRMA-SF = Short form version Illinois Rape Myth Acceptance Scale; RES = Rape Empathy Scale; SRAES = Sex-Related Alcohol Expectancies Scale; ASA = Attraction Sexual Aggression; M-SES = Modified Sexual Experiences Survey.",C0886296|G0000000|C0728831|G0000000|C0033101|C0449820|G0000000|G0000000|C0025266|C1316572|C0722978|G0000000|C0034668|C0870933|C0175659|C0021073|G0000000|C1282927|C0348078|C0333052|C0020898|C0034668|C0870933|G0000000|C0175659|C2347379|G0000000|C0034668|C0013989|C0175659|G0000000|G0000000|C0036864|C0001962|C0679138|C0175659|C0004057|G0000000|C2346874|C0036864|C0001807|C0369637|G0000000|C0392747|C0036864|C0596545|C0038951
Descriptive statistics were used to summarise trial parameters indicative of intervention feasibility and acceptability.,Descriptive statistics summarise trial parameters indicative intervention feasibility acceptability.,C0678257|C0038215|G0000000|C0008976|C0449381|G0000000|C0886296|G0000000|C0814633
"Clinical assessments were performed at baseline and at the end of therapy (EOT), defined as Day 10 for both groups, or within 24 hours after the last dose of blinded study drug therapy if discontinued early.","Clinical assessments performed baseline therapy (EOT), defined Day 10 groups, 24 hours dose blinded study drug therapy discontinued early.",C0205210|C1261322|C0884358|C0168634|C0039798|G0000000|C1704788|C0332173|C0450371|C0441833|C0450371|C0439227|C0178602|C0150108|C0557651|C0013227|C0039798|C1444662|C1279919
The primary analysis was the comparisons between TENS treatments were completed using a mixed model approach which accounts for the repeated measures collected through the crossover design.,The primary analysis comparisons TENS treatments completed mixed model approach accounts repeated measures collected crossover design.,G0000000|C0205225|C0002778|C1707455|C0014518|C0087111|C0205197|C0205430|C3161035|C0449445|C2741673|C0205341|C0079809|C1516695|C0010366|C1707689
The first post-test assessment will be carried out one month after the intervention and there will be a long term follow-up assessment two years after the intervention.,The post-test assessment carried month intervention term follow-up assessment intervention.,G0000000|C0687676|C1261322|C0206243|C0332177|C0886296|C0233324|C0589120|C1261322|C0886296
"Two models were run; in each, 30-day point prevalence was regressed on study group and all covariates.","Two models run; each, 30-day prevalence regressed study covariates.",C0205448|C3161035|C0035953|G0000000|C0450371|C0033105|C0700186|C0557651|G0000000
"In the original STAR report, no difference between treatment groups was noted for the secondary endpoints: ischemic heart disease, stroke, and osteoporotic fractures.","In original STAR report, difference treatment secondary endpoints: ischemic heart disease, stroke, osteoporotic fractures.",G0000000|C0205313|C0995242|C0684224|C1705241|C0039798|C0027627|C2349179|C0475224|C0018787|C0012634|C0038454|G0000000|C0016658
"muscle thickness, cross-sectional area, and pennation angle5, 6).","muscle thickness, cross-sectional area, pennation angle5, 6).",C0026845|C1280412|C0552389|C0017446|G0000000|G0000000|G0000000
"Each year they were asked to report about the frequency with which they used alcohol, tobacco, and marijuana during the previous month (e.g., How many alcoholic drinks did you have last month?).","Each report frequency alcohol, tobacco, marijuana previous month (e.g., How alcoholic drinks month?).",G0000000|C0684224|C0376249|C0001962|C0040329|C0024808|C0205156|C0332177|G0000000|G0000000|C0687725|C0452428|C0332177
Duration of diarrhoea was the time in hours from the first to the last abnormal (loose or liquid) stools preceding a normal stool output.,Duration diarrhoea time hours abnormal (loose liquid) stools preceding normal stool output.,C0449238|C0011991|C0040223|C0439227|C0205161|C0205407|C0301571|C0015733|C0332152|C0205307|C0015733|C1709366
"Adjusted for family history of prostate cancer, diabetes, body mass index, and prostate-specific antigen in statistical model.","Adjusted family history prostate cancer, diabetes, body mass index, prostate-specific antigen statistical model.",C0456081|C0015576|C0019664|C0033572|C0006826|C0011847|C0242821|C0577559|C0918012|C0033572|C0003320|C0038215|C3161035
"Seated systolic and diastolic BP (mmHg) was measured by a registered nurse using a standard sphygmomanometer (Baumanometer® Desk Model, Copiague, NY, U.S.).","Seated systolic diastolic BP (mmHg) measured registered nurse standard sphygmomanometer (Baumanometer® Desk Model, Copiague, NY, U.S.).",C0277814|C0039155|C0012000|C0037623|C0439475|C0444706|C1514821|C0028661|C1442989|C0183427|G0000000|G0000000|C3161035|G0000000|C0027976|C0041703
"[10,11] In this study, the drug side effects (such as drowsiness or dizziness) were the secondary outcome.","[10,11] In study, drug effects (such drowsiness dizziness) secondary outcome.",C0450371|G0000000|C0557651|C0013227|C1280500|G0000000|C0013144|C0012833|C0027627|C1274040
"For the sample as a whole, we found that the FFBs produced a differential abstinence of 11% compared with UCC at 8 months postpartum, but statistical significance was not maintained through 12 months.","For sample whole, FFBs produced differential abstinence 11% compared UCC 8 months postpartum, statistical significance maintained 12 months.",G0000000|C0370003|C0444667|G0000000|G0000000|C0443199|C3843422|C0450371|C1707455|G0000000|G0000000|C0439231|C0086839|C0038215|C0237881|C1314677|C0450371|C0439231
"Secondary end points included time to intracranial failure (eTable 1 in Supplement 2), QOL, toxic effects, functional independence, cognitive outcomes for individual cognitive assessments, long-term cognitive status, and overall survival.","Secondary included time intracranial failure (eTable 1 Supplement 2), QOL, toxic effects, functional independence, cognitive outcomes individual cognitive assessments, long-term cognitive status, survival.",C0027627|C0332257|C0040223|C0524466|C0231174|G0000000|G0000000|C0242295|G0000000|C0518214|C0600688|C1280500|C0205245|C0085862|C1516691|C1274040|C0027361|C1516691|C1261322|C0443252|C1516691|C0449438|C0038952
Baseline demographic and clinical characteristics Data are expressed as mean ± SD unless otherwise indicated um-PEA = Ultramicronized palmitoylethanolamide; EDSS = Expanded Disability Status Scale; VAS = Visual Analog Scale; MSQoL = Multiple Sclerosis Quality of Life-54 Ultramicronized palmitoylethanolamide (PEA) treatment reduces pain perception but not erythema at interferon (IFN)-β1a injection site.,Baseline demographic clinical characteristics Data expressed mean ± SD um-PEA = Ultramicronized palmitoylethanolamide; EDSS = Expanded Disability Status Scale; VAS = Visual Analog Scale; MSQoL = Multiple Sclerosis Quality Life-54 Ultramicronized palmitoylethanolamide (PEA) treatment reduces pain perception erythema interferon (IFN)-β1a injection site.,C0168634|C0011298|C0205210|C1521970|C1511726|G0000000|G0000000|G0000000|C0069964|G0000000|C0231170|C0449438|C0175659|G0000000|C0243071|C0175659|G0000000|C0036429|C0332306|C0376558|G0000000|C0069964|C0030738|C0039798|G0000000|C0030193|C0030971|C0041834|C0021747|G0000000|C0021485|C0205145
Both the total myalgic score and number of tender points were lower at 3-month follow-up.,Both total myalgic score tender lower 3-month follow-up.,G0000000|C0439175|C0231528|C0449820|C0234234|C0441994|C0332177|C0589120
Participants self-completed the North of England asthma symptom scale at baseline and 3 months later.,Participants self-completed North England asthma symptom scale baseline 3 months later.,C0679646|C0036588|C1709269|C0014282|C0004096|C1457887|C0175659|C0168634|G0000000|C0439231|C0205087
The follow-up observation consisted of recording the number of fallers in the community setting after 6 months.,The follow-up observation consisted recording fallers community setting 6 months.,G0000000|C0589120|C0302523|C0332529|G0000000|G0000000|C0009462|C0542559|G0000000|C0439231
In both 2005 and 2006 there was a clear peak of infection prevalence in or around May (Figure 4F).,In 2005 2006 peak infection prevalence May (Figure 4F).,G0000000|G0000000|G0000000|C0444505|C0009450|C0033105|G0000000|G0000000|G0000000
Main infant outcome is infant growth pattern.,Main infant outcome infant growth pattern.,C0205225|C0021270|C1274040|C0021270|C0018270|C0449774
"We selected a priori potential confounders for the adjusted models: age (continuous), gender, ethnicity (white, non-white), education (<=high school graduate, some college, college or advanced degree), total energy intake (tertiles), BMI (<25, 25–30, >=30 kg/m2), recreational physical activity (tertiles of MET for all recreational activities), cigarette smoking status (never, former, recent, current), total alcohol consumption (tertiles of average daily alcohol intake), family history of pancreatic cancer (yes/no) and use of medication for diabetes (yes/no).","We selected priori potential confounders adjusted models: age (continuous), gender, ethnicity (white, non-white), education (<=high school graduate, college, college advanced degree), total energy intake (tertiles), BMI (<25, 25–30, >=30 kg/m2), recreational physical activity (tertiles MET recreational activities), cigarette smoking status (never, former, recent, current), total alcohol consumption (tertiles average daily alcohol intake), family history pancreatic cancer (yes/no) medication diabetes (yes/no).",G0000000|C1707391|G0000000|C3245505|G0000000|C0456081|C3161035|C0001779|C0549178|C0079399|C0015031|C0007457|C1518422|C0013621|C0205250|C0036375|C0588053|C0557806|C0557806|C0205179|C0441889|C0439175|C0424589|C1512806|G0000000|G0000000|C0450371|G0000000|C0450371|C0022718|C0034872|C0031809|C0205177|G0000000|C0268621|C0034872|C0441655|C0677453|C0037369|C0449438|C2003901|C0205156|C0332185|C0521116|C0439175|C0001962|C0009830|G0000000|C1510992|C0332173|C0001962|C1512806|C0015576|C0019664|C0030274|C0006826|C1512698|C0013227|C0011847|C1512698
"Disability indicates the incidence of moderate or severe disability, which is defined as survival with at least 1 of the following complications: cerebral palsy, MDI < 70, deafness, or blindness.","Disability incidence moderate severe disability, defined survival 1 complications: cerebral palsy, MDI < 70, deafness, blindness.",C0231170|C0021149|C0205081|C0205082|C0231170|C1704788|C0038952|G0000000|C0009566|G0000000|C0522224|C0993596|G0000000|C0450371|C0011053|C0456909
"Clinical assessments (heart rate, temperature, blood pressure, body weight, oxygen therapy) were performed daily from day 0 (prestudy visit) until study termination, either on day 15 or following the last infusion of study treatment (posttreatment).","Clinical assessments (heart rate, temperature, blood pressure, body weight, oxygen therapy) performed daily day 0 (prestudy visit) study termination, day 15 infusion study treatment (posttreatment).",C0205210|C1261322|C0018787|C0871208|C0005903|C0005767|C0033095|C0242821|C0005910|C0030054|C0039798|C0884358|C0332173|C0332173|G0000000|G0000000|C0545082|C0557651|C1549081|C0332173|C0450371|C0574032|C0557651|C0039798|C2709088
"Infant weight, length, head circumference, and mid-upper arm circumference are measured at every postnatal visit.","Infant weight, length, head circumference, mid-upper arm circumference measured postnatal visit.",C0021270|C0005910|C1444754|C0018670|C0332520|C0444598|C0446516|C0332520|C0444706|C0443281|C0545082
"Among men with a PSA value that was greater than 10 ng per milliliter and possibly among those with intermediate-risk or high-risk prostate cancer (as determined according to the PSA value, local histologic findings, and stage), absolute reductions in all-cause mortality with radical prostatectomy ranged from 6.7 to 13.2 percentage points.","Among PSA 10 ng milliliter intermediate-risk high-risk prostate cancer (as determined PSA value, local histologic findings, stage), absolute reductions all-cause mortality radical prostatectomy ranged 6.7 13.2 percentage points.",G0000000|C3810537|C0450371|C0028074|C0439242|C3640764|C0332167|C0033572|C0006826|G0000000|G0000000|C3810537|C1522609|C0205276|C0205462|C2607943|C0205390|C0205344|C0301630|C0015127|C0026565|C0302912|C0033573|C1514721|G0000000|C0450371|C0439165|C1552961
No adverse events were observed during the study period.,No adverse events observed study period.,G0000000|G0000000|C0441471|C1441672|C0557651|C0439531
"During ∼5 years of follow-up, 243 incident cases of colorectal cancer were identified.","During ∼5 follow-up, 243 incident colorectal cancer identified.",G0000000|G0000000|C0589120|C1442061|C1551358|C0555952|C0006826|C0205396
"Furthermore, PFS was also evaluated by KRAS mutational status.","Furthermore, PFS evaluated KRAS mutational status.",G0000000|C0242792|C0220825|C0022457|C0026882|C0449438
"In this randomised study, we showed that MBSR improved menopause‐specific quality of life over both the short‐ and long‐term in women with at least two moderate‐to‐severe menopausal symptoms after RRSO; however, MBSR did not improve sexual functioning or sexual distress.","In randomised study, MBSR improved menopause‐specific quality life short‐ long‐term women moderate‐to‐severe menopausal symptoms RRSO; however, MBSR improve sexual functioning sexual distress.",G0000000|G0000000|C0557651|G0000000|C0184511|G0000000|C0332306|C0376558|G0000000|G0000000|C0043210|G0000000|C0025320|C0683368|G0000000|G0000000|G0000000|G0000000|C0036864|C0205245|C0036864|C0231303
"reported absolute improvements in back pain at 2 years of 18% on an 11-point scale, as compared with 17% on a 7-point scale in the SPORT, and an improvement in leg pain of 16%, as compared with 17% in the SPORT.","reported absolute improvements pain 2 18% 11-point scale, compared 17% 7-point scale SPORT, improvement leg pain 16%, compared 17% SPORT.",C0684224|C0205344|C2986411|C0030193|G0000000|C0450371|C0450371|C0175659|C1707455|C0450371|C1552961|C0175659|C0038039|C2986411|C0023216|C0030193|C0450371|C1707455|C0450371|C0038039
"Adjusted Estimates of Program Effects on Children's Academic Performance There were no statistically significant program effects on children's sustained attention, externalizing or total behavioral problems, or conduct grades.","Adjusted Estimates Program Effects Children's Academic Performance There statistically program effects children's sustained attention, externalizing total behavioral problems, conduct grades.",C0456081|C0750572|C1709697|C1280500|C0008059|C1510747|C0597198|G0000000|C0038215|C1709697|C1280500|C0008059|C0443318|C0004268|G0000000|C0439175|C0004927|C1546466|C0004927|C0441800
Every woman was invited to fill a food diary each month and to undergo a clinical evaluation and laboratory exams.,Every woman invited fill food diary month undergo clinical evaluation laboratory exams.,G0000000|C0043210|G0000000|C1708059|C0016452|C0376660|C0332177|G0000000|C0205210|C0220825|C0022877|C0582103
"After a one year follow up period, severity and frequency of abdominal pain had improved similarly in all groups.","After follow period, severity frequency abdominal pain improved groups.",G0000000|C0332283|C0439531|C0439793|C0376249|C0000726|C0030193|C0184511|C0441833
Progression-free survival was defined as the time from date of randomization to the earlier of disease progression or death due to any cause.,Progression-free survival defined time randomization earlier disease progression death cause.,C0242656|C0038952|C1704788|C0040223|C0034656|C1279919|C0012634|C0242656|C0011065|C0015127
"Secondary outcomes included endotracheal intubation, recurrent seizures, and timing of treatment relative to the cessation of convulsive seizures.","Secondary outcomes included endotracheal intubation, recurrent seizures, timing treatment relative cessation convulsive seizures.",C0027627|C1274040|C0332257|C0599554|C0021925|C2945760|C0036572|C0449243|C0039798|C0080103|C1880019|C0234531|C0036572
"We evaluated hospital admission up to 24 hours to avoid transient improvement, which could delay hospitalization by a few hours without clinical pertinence.19 Secondary outcomes were admission within 28 days, changes in the RDAI score,18 duration of symptoms, length of hospital stay for hospitalized infants, and adverse events, such as bronchospasm, desaturation, excessive coughing, apnea, and cyanosis, which were recorded using a standardized medical record abstraction form.","We evaluated hospital admission 24 hours avoid transient improvement, delay hospitalization hours clinical pertinence.19 Secondary outcomes admission 28 days, RDAI score,18 duration symptoms, length hospital stay hospitalized infants, adverse events, bronchospasm, desaturation, excessive coughing, apnea, cyanosis, recorded standardized medical record abstraction form.",G0000000|C0220825|C0019994|C0184666|C0450371|C0439227|G0000000|C0040704|C2986411|C0205421|C0019993|C0439227|C0205210|C0450371|C0027627|C1274040|C0184666|C0450371|C0439228|G0000000|C0449820|C0449238|C0683368|C1444754|C0019994|G0000000|C0701159|C0021270|G0000000|C0441471|C0006266|C0746961|C0442802|C0010200|C0003578|C0010520|C0034869|G0000000|C0199168|C0034869|C0679195|C0348078
"Breast cancer: For the 12 patients enrolled, median time to progression was 2.5 months (1 – 37+) and median overall survival was 13.7 months.","Breast cancer: For 12 patients enrolled, median time progression 2.5 months (1 – 37+) median survival 13.7 months.",C0006141|C0006826|G0000000|C0450371|C0030705|G0000000|C0549183|C0040223|C0242656|G0000000|C0439231|G0000000|G0000000|C0450371|C0549183|C0038952|C0450371|C0439231
Anticipatory guidance around the management of sleep and crying problems in early infancy has been shown to improve both infant behaviour and parent symptoms of postnatal depression.,Anticipatory guidance management sleep crying infancy improve infant behaviour parent symptoms postnatal depression.,G0000000|C0150600|C0001554|C0037313|C0010399|C0231330|G0000000|C0021270|C0004927|C0030551|C0683368|C0443281|C0011570
The primary outcome was adherence to the guideline-based care suggestions.,The primary outcome adherence guideline-based care suggestions.,G0000000|C0205225|C1274040|C1510802|C0162791|C1947933|C0038659
"Prevalence and incidence estimates from previous studies in Mwanza Region were used to predict an HIV seroprevalence and HSV-2 seroprevalence of, respectively, 2% and 25% in males and 5% and 35% in females [23],[33],[34].","Prevalence incidence estimates previous studies Mwanza Region predict HIV seroprevalence HSV-2 seroprevalence of, respectively, 2% 25% males 5% 35% females [23],[33],[34].",C0033105|C0021149|C0750572|C0205156|C0947630|G0000000|C0017446|G0000000|C0019682|C0600367|C0019348|C0600367|G0000000|G0000000|G0000000|C0450371|C0086582|G0000000|C0450371|C0015780|C0450371
The primary efficacy outcome was a composite of death or the first occurrence of cardiac tamponade requiring pericardiocentesis or constrictive pericarditis.,The primary efficacy outcome composite death occurrence cardiac tamponade requiring pericardiocentesis constrictive pericarditis.,G0000000|C0205225|C1280519|C1274040|C0205199|C0011065|C0243132|C0018787|C0332459|G0000000|C0191234|C0009813|C0031046
"In our study, both mannitol and HS provided acceptable brain relaxation.","In study, mannitol HS provided acceptable brain relaxation.",G0000000|C0557651|C0024730|G0000000|C1999230|C1879533|C0006104|C0035028
"Secondary outcomes included proportions of measured fever (Axillary temp > 37.5 °C), malaria prevalence and reported fever during the last 48 hours, mean malaria parasite densities mean haemoglobin values, and mean weight.","Secondary outcomes included proportions measured fever (Axillary temp > 37.5 °C), malaria prevalence reported fever 48 hours, malaria parasite densities haemoglobin values, weight.",C0027627|C1274040|C0332257|C1709707|C0444706|C0015967|C0004454|C0039476|G0000000|C0450371|G0000000|C0024530|C0033105|C0684224|C0015967|C0450371|C0439227|C0024530|C0030498|C0178587|C0019046|C0042295|C0005910
"In addition, children who had an institutional provider or no provider at all were less likely to have had 3 doses of hepatitis B vaccine than children with either a Vietnamese or non-Vietnamese provider.","In addition, children institutional provider provider 3 doses hepatitis B vaccine children Vietnamese non-Vietnamese provider.",G0000000|C0332287|C0008059|C0018704|C1138603|C1138603|G0000000|C0178602|C0019158|G0000000|C0042210|C0008059|C0042660|C1518422|C1138603
"The results of the study indicated that there was no significant difference before the intervention in depression, anxiety and stress mean scores in the two groups.","The study difference intervention depression, anxiety stress scores groups.",G0000000|C0557651|C1705241|C0886296|C0011570|C0003467|C0038435|C0449820|C0441833
The 1-repetition maximum (1-RM) for leg press will be used to determine changes in lower extremity muscle strength.,The 1-repetition maximum (1-RM) leg press determine lower extremity muscle strength.,G0000000|C0205341|C0806909|C0024851|C0023216|G0000000|G0000000|C0441994|C0015385|C0026845|C0237897
"Survey items 1–9) Attitudes about concern of developing skin cancer and personal risk of skin cancer, importance of skin cancer and sun protection, attitude about having a tan, confidence that sun protection prevents skin cancer and confidence in using sun protection (concern of developing skin cancer Part Five.","Survey items 1–9) Attitudes concern developing skin cancer personal risk skin cancer, skin cancer sun protection, attitude tan, confidence sun protection prevents skin cancer confidence sun protection (concern developing skin cancer Part Five.",C0038951|C1551338|G0000000|C0004271|C2699424|G0000000|C0444099|C0006826|C1519021|C0035647|C0444099|C0006826|C0444099|C0006826|C0038817|C1545588|C0004271|C0302595|C0237529|C0038817|C1545588|C0309872|C0444099|C0006826|C0237529|C0038817|C1545588|C2699424|G0000000|C0444099|C0006826|C0449719|C0205451
COPD patients were selected by clinical criteria and the presence of bronchial hyper-responsiveness (BHR).,COPD patients selected clinical criteria presence bronchial hyper-responsiveness (BHR).,C0024117|C0030705|C1707391|C0205210|C0243161|C0150312|C0205039|C0424295|C0004684
"Main maternal outcomes include: (a) maternal responsiveness, (b) feeding style, and (c) feeding practices.","Main maternal outcomes include: (a) maternal responsiveness, (b) feeding style, (c) feeding practices.",C0205225|C2347083|C1274040|C0332257|G0000000|C2347083|C0205342|G0000000|C0204695|C0489654|G0000000|C0204695|C0237607
Antenatal hypnosis is associated with a reduced need for pharmacological interventions during childbirth.,Antenatal hypnosis reduced pharmacological interventions childbirth.,C2828394|C0020587|C0392756|C0031330|C0886296|C0005615
A stable infection was considered to be a failure.,A stable infection considered failure.,G0000000|C0205360|C0009450|C0750591|C0231174
"The primary endpoint, mean trough FEV1 after 26 weeks (imputed with the last observation carried forward), was analyzed using a mixed model.","The primary endpoint, trough FEV1 26 weeks (imputed observation carried forward), analyzed mixed model.",G0000000|C0205225|C2349179|C0444506|G0000000|C0450371|C0439230|C2699638|C0302523|C0206243|C0439780|C0936012|C0205430|C3161035
Patients who completed adjuvant treatment underwent tumor imaging every 3 months until tumor progression.,Patients completed adjuvant treatment underwent tumor imaging 3 months tumor progression.,C0030705|C0205197|C0001551|C0039798|G0000000|C0027651|C0011923|G0000000|C0439231|C0027651|C0242656
"The primary endpoint was the occurrence of a seizure, and the secondary endpoint was the occurrence of adverse reactions to phenytoin.","The primary endpoint occurrence seizure, secondary endpoint occurrence adverse reactions phenytoin.",G0000000|C0205225|C2349179|C0243132|C0036572|C0027627|C2349179|C0243132|G0000000|C0443286|C0031507
"A self-reported checklist was used to collect information on the number of sedative drugs taken for dysmenorrhea, pain severity, and the systemic symptoms associated with menstruation.","A self-reported checklist collect sedative drugs dysmenorrhea, pain severity, systemic symptoms menstruation.",G0000000|C0681906|C1707357|G0000000|C0020592|C0013227|C0013390|C0030193|C0439793|C0205373|C0683368|C0025344
"The primary outcome was the absolute change in inflammatory neuropathy cause and treatment (INCAT) sensory score (ISS)20 between baseline and month 12 (chosen as an appropriate interval to capture clinical changes), calculated as the sum of evaluation of pinprick sensation on the most affected site on the upper (0–4) and lower (0–4) limbs; evaluation of the vibration generated by a Rydel-Seiffer graduated tuning fork; and evaluation of 2-point discrimination by the index finger.","The primary outcome absolute change inflammatory neuropathy treatment (INCAT) sensory score (ISS)20 baseline month 12 (chosen interval capture clinical changes), calculated sum evaluation pinprick sensation site upper (0–4) lower (0–4) limbs; evaluation vibration generated Rydel-Seiffer graduated tuning fork; evaluation 2-point discrimination finger.",G0000000|C0205225|C1274040|C0205344|C0392747|C0333348|C0442874|C0039798|G0000000|C0445254|C0449820|C1845118|C0168634|C0332177|C0450371|C1707391|C1272706|G0000000|C0205210|C0392747|C0444686|C1515051|C0220825|G0000000|C0036658|C0205145|C1282910|G0000000|C0441994|G0000000|C0015385|C0220825|C0455941|C3146294|G0000000|C0588053|G0000000|C0491931|C0220825|C1552961|C0012632|C0016129
"This study assessed the effectiveness of a culturally sensitive, mobile medical app to increase knowledge of skin cancer and sun protection, attitudes about the importance of skin cancer and sun protection, recognition of personal risk of developing skin cancer, willingness to change sun protection behavior, and use of sun protection.","This study assessed effectiveness culturally sensitive, mobile medical app increase knowledge skin cancer sun protection, attitudes skin cancer sun protection, recognition personal risk developing skin cancer, willingness change sun protection behavior, sun protection.",G0000000|C0557651|C1516048|C1280519|C0010453|C0020517|C0231435|C0199168|G0000000|C0442805|C0376554|C0444099|C0006826|C0038817|C1545588|C0004271|C0444099|C0006826|C0038817|C1545588|C0524637|C1519021|C0035647|G0000000|C0444099|C0006826|C0600109|C0392747|C0038817|C1545588|C0004927|C0038817|C1545588
"In this study, recurrence was defined as the absence of satisfactory relief of overall IBS symptoms and abdominal discomfort/pain for three or more out of four consecutive weeks.","In study, recurrence defined absence satisfactory relief IBS symptoms abdominal discomfort/pain consecutive weeks.",G0000000|C0557651|C0034897|C1704788|C0332197|C0205410|C0564405|C0022104|C0683368|C0000726|C0231218|C1707491|C0439230
"Nowadays, cesarean section rate is increasing in Iran and throughout the world.","Nowadays, cesarean rate increasing Iran world.",G0000000|C3841297|C0871208|C0442808|C0022065|C2700280
There were two primary outcomes: (1) the proportion of children presenting with fever who received AL and (2) the proportion of children classified as nonsevere pneumonia that received early and appropriate treatment.,There primary outcomes: (1) proportion children fever received AL (2) proportion children classified nonsevere pneumonia received treatment.,G0000000|C0205225|C1274040|G0000000|C1709707|C0008059|C0015967|C1514756|C0202311|G0000000|C1709707|C0008059|C0008902|G0000000|C0032285|C1514756|C0039798
Primary outcomes are the change in number of words (of personal relevance) named correctly at six months and improvement in functional conversation.,Primary outcomes change (of personal relevance) named correctly months improvement functional conversation.,C0205225|C1274040|C0392747|G0000000|C1519021|C2347946|C0027365|G0000000|C0439231|C2986411|C0205245|C0871703
"not having smoked a puff within the past 7 days), (2) cigarette consumption (number of cigarettes smoked on a typical day for daily smokers, typical number of smoking days per month, and number of cigarettes smoked on a typical smoking day for occasional smokers).","smoked puff 7 days), (2) cigarette consumption (number cigarettes smoked typical day daily smokers, typical smoking days month, cigarettes smoked typical smoking day occasional smokers).",C0037366|C1533107|G0000000|C0439228|G0000000|C0677453|C0009830|C0237753|C0677453|C0037366|C3538928|C0332173|C0332173|C0337664|C3538928|C0037369|C0439228|C0332177|C0677453|C0037366|C3538928|C0037369|C0332173|C0521114|C0337664
"At 24 months, SRM exhibited greater abstinence than TSH (p = .021).","At 24 months, SRM exhibited abstinence TSH (p = .021).",G0000000|C0450371|C0439231|C1420404|C0015272|C3843422|G0000000|C0369773|G0000000|C1442061
"Primary outcome (first of stroke, myocardial infarction or vascular death) rates, assessed after a mean follow-up of 4.7 years, were not significantly different between treatment groups (2.1% vs. 1.9% per patient-year, respectively) but stroke was decreased by 41%, albeit delayed for one- to two-years.","Primary outcome (first stroke, myocardial infarction vascular death) rates, assessed follow-up 4.7 years, treatment (2.1% vs. 1.9% patient-year, respectively) stroke decreased 41%, albeit delayed one- two-years.",C0205225|C1274040|C0205435|C0038454|C0027061|C0021308|C0005847|C0011065|C0871208|C1516048|C0589120|G0000000|C0439234|C0039798|G0000000|G0000000|G0000000|C0030705|G0000000|C0038454|C0205216|C0450371|G0000000|C0205421|C0205447|C0205448
The rates were not standardized for age.,The rates standardized age.,G0000000|C0871208|G0000000|C0001779
The primary endpoint was the Cleveland Clinic Score (CCS) after self-training at home with either 3T or LFS in two 20-minute sessions per day for 6 months.,The primary endpoint Cleveland Clinic Score (CCS) self-training 3T LFS 20-minute sessions day 6 months.,G0000000|C0205225|C2349179|C0454845|C0002424|C0449820|C3272108|C0036588|C4053561|C0085390|C0450371|C1883016|C0332173|G0000000|C0439231
Post 1 occurred immediately postintervention and Post 2 occurred 6 months after the intervention.,Post 1 occurred postintervention Post 2 occurred 6 months intervention.,C0687676|G0000000|C1709305|G0000000|C0687676|G0000000|C1709305|G0000000|C0439231|C0886296
Changes (Δ) in exercise capacity and muscle strength in COPD patients after hf-NMES and sham stimulation.,Changes (Δ) exercise capacity muscle strength COPD patients hf-NMES sham stimulation.,C0392747|G0000000|C0015259|C1516240|C0026845|C0237897|C0024117|C0030705|C0018488|C0068899|C1292856
Patients with active asthma not reviewed in the previous year were identified from the practice computer database and sent three invitations (by post or as memos with repeat prescriptions) over the study period.,Patients active asthma reviewed previous identified practice computer database invitations (by post memos repeat prescriptions) study period.,C0030705|C0205177|C0004096|C0282443|C0205156|C0205396|C0237607|C0009622|C0242356|C2826348|G0000000|C0687676|C1422348|C0205341|C0033080|C0557651|C0439531
"Time course of heart rate, MAP, ICP and the CPP for the two different treatment groups *p < 0.05, **p < 0.0001 compared with start infusion.","Time heart rate, MAP, ICP CPP treatment *p < 0.05, **p < 0.0001 compared start infusion.",C0040223|C0018787|C0871208|C0024779|C1881201|C0205770|C0039798|C0369773|G0000000|C0450371|C0369773|G0000000|G0000000|C1707455|C0439659|C0574032
Compare the discharge readiness and readmission rates in both intervention groups at the end of 2 h of observation and within 24 h following discharge respectively.,Compare discharge readiness readmission rates intervention 2 observation 24 discharge respectively.,C1707455|C0012621|C1318963|C1548168|C0871208|C0886296|G0000000|C0302523|C0450371|C0012621|G0000000
"Direct health care costs include costs related to study treatment, non-study health care health provider use, medication utilization, and hospitalizations for LBP or NP.","Direct health care costs costs study treatment, non-study health care health provider use, medication utilization, hospitalizations LBP NP.",C0439851|C0018684|C1947933|C0010186|C0010186|C0557651|C0039798|C1518422|C0018684|C1947933|C0018684|C1138603|C0042153|C0013227|C0042153|C0019993|C1505993|C0065827
"Further, 15% more women are receiving good care (70% or greater criterion attainment) at ALARM hospitals when compared to control hospitals.","Further, 15% women receiving care (70% criterion attainment) ALARM hospitals compared control hospitals.",C1517331|C0450371|C0043210|C1514756|C1947933|C0450371|C0243161|G0000000|C0336648|C0019994|C1707455|C0243148|C0019994
Both artemisinin-based combinations effected rapid fever and parasite clearance.,Both artemisinin-based combinations effected rapid fever parasite clearance.,G0000000|C0052430|C0453882|C1280500|C0456962|C0015967|C0030498|C0449297
"Furthermore, not all EPS or muscle biopsy evaluations could be performed as scheduled.","Furthermore, EPS muscle biopsy evaluations performed scheduled.",G0000000|G0000000|C0026845|C0005558|C0220825|C0884358|C0086960
"Thus, the specific walking training was superior to the flexibility and relaxation programme regarding walking speed, stride length and gait variability.","Thus, specific walking training superior flexibility relaxation programme walking speed, stride length gait variability.",G0000000|C0205369|C0080331|C0040607|C1282910|C0242808|C0035028|C1709697|C0080331|C0678536|G0000000|C1444754|C0016928|C2827666
The primary SOM in this study is the Freezing of Gait Questionnaire (FOGQ) [31].,The primary SOM study Freezing Gait Questionnaire (FOGQ) [31].,G0000000|C0205225|C0037640|C0557651|C0016701|C0016928|C0034394|G0000000|C0450371
Specific aim 3 will determine whether changes in ocular shape differ between children wearing single vision and each add power of soft bifocal contact lenses to test the hypothesis that peripheral myopic defocus globally slows eye growth.,Specific aim 3 determine ocular shape children wearing single vision add power soft bifocal contact lenses test hypothesis peripheral myopic defocus globally slows eye growth.,C0205369|C1947946|G0000000|G0000000|C0015392|C0332479|C0008059|G0000000|C0037179|C0042789|C1883712|C0032863|C0205358|C1275647|C0332158|C0023317|C0022885|C1512571|C0205100|C0027092|G0000000|G0000000|C0439834|C0015392|C0018270
Abstinence was confirmed by measurement of exhaled carbon monoxide (eCO).,Abstinence confirmed measurement exhaled carbon monoxide (eCO).,C3843422|C0521093|C0242485|C0231800|C0007009|G0000000|C2675227
This form was filled in by the specialist registrar himself to avoid having patients using their A4 explanation sheet to fill in the questionnaire.,This form filled specialist registrar avoid patients A4 explanation sheet fill questionnaire.,G0000000|C0348078|C1708059|C0087009|C0557514|G0000000|C0030705|C0336669|C0681841|C2349187|C1708059|C0034394
"In visual perception tests, motor free visual perception test (MVPT) scores showed a significant increase of approximately 17% in the experimental group after the intervention.","In visual perception tests, motor free visual perception test (MVPT) scores increase 17% experimental intervention.",G0000000|C0234621|C0030971|C0022885|C1513492|C0332296|C0234621|C0030971|C0022885|G0000000|C0449820|C0442805|C0450371|C1517586|C0886296
"All of the patients were assessed with Hospital Anxiety and Depression Scale (HADS) and WHO-QOL-BREF questionnaires; further, Rhodes index was used to evaluate nausea and vomiting (N/V) status.","All patients assessed Hospital Anxiety Depression Scale (HADS) WHO-QOL-BREF questionnaires; further, Rhodes evaluate nausea vomiting (N/V) status.",G0000000|C0030705|C1516048|C0019994|C0003467|C0011570|C0175659|C0048008|C0518214|C0034394|C1517331|C0454812|C0220825|C0027497|C0042963|C0369718|C0449438
"Secondary outcome measures include delirium severity and duration assessed with the Delirium Rating Scale Revised 98; number of delirium-free days; adverse events; hospital length-of-stay; all-cause mortality; new institutionalisation; (Instrumental) Activities of Daily Living assessed with the Katz Index of ADL, and Lawton IADL scale; cognitive function assessed with the Six-item Cognitive Impairment Test, and the Dutch short form Informant Questionnaire on Cognitive Decline in the Elderly.","Secondary outcome measures delirium severity duration assessed Delirium Rating Scale Revised 98; delirium-free days; adverse events; hospital length-of-stay; all-cause mortality; institutionalisation; (Instrumental) Activities Daily Living assessed Katz Index ADL, Lawton IADL scale; cognitive function assessed Six-item Cognitive Impairment Test, Dutch short form Informant Questionnaire Cognitive Decline Elderly.",C0027627|C1274040|C0079809|C0011206|C0439793|C0449238|C1516048|C0011206|C0871208|C0175659|C1527075|C0450371|C0011206|C0439228|G0000000|C0441471|C0019994|C1444754|C0015127|C0026565|C0021629|G0000000|C0441655|C0332173|C0376558|C1516048|G0000000|C0918012|C0001288|G0000000|C0150641|C0175659|C1516691|C0031843|C1516048|C0205452|C1516691|C0221099|C0022885|C0013331|C1282927|C0348078|C1550484|C0034394|C1516691|G0000000|C0001792
The Korean version of the Modified Barthel Index was used to evaluate activities of daily living (ADL) function12).,The Korean version Modified Barthel Index evaluate activities daily living (ADL) function12).,G0000000|C1556095|C0333052|C0392747|G0000000|C0918012|C0220825|C0441655|C0332173|C0376558|C0001288|G0000000
Stroke was defined as major stroke on the basis of clinical data or if the NIHSS score was 9 or higher 90 days after the procedure.,Stroke defined major stroke basis clinical data NIHSS score 9 90 days procedure.,C0038454|C1704788|C0205082|C0038454|C1527178|C0205210|C1511726|C3476804|C0449820|G0000000|C0450371|C0439228|C0184661
"Using the ‘Digimodel’ software, the orthodontic measurements in the maxilla and mandible and for the midline deviation, the overjet and overbite were recorded.","Using ‘Digimodel’ software, orthodontic measurements maxilla mandible midline deviation, overjet overbite recorded.",C1524063|G0000000|C0037585|C0332276|C0242485|C0024947|C0024687|C0549183|C0012727|C0596028|C1305740|C0034869
Changes in representational areas were prevented or reversed by focused motor training in primates with concurrent improvements in motor function.,Changes representational prevented reversed focused motor training primates concurrent improvements motor function.,C0392747|C1882932|C0309872|C1555029|C0205234|C1513492|C0040607|C0033147|C0205420|C2986411|C1513492|C0031843
Exclusion criteria were: pregnancy or lactation; severe clinical anaemia (<7g/dl); P. falciparum and/or P. vivax (mixed infections); intake of any antimalarial drug in the 2 weeks prior to consultation; patients unavailable for the duration of follow up (11 months); patients with concomitant infections or disease likely to mask treatment response.,Exclusion criteria were: pregnancy lactation; severe clinical anaemia (<7g/dl); P. falciparum and/or P. vivax (mixed infections); intake antimalarial drug 2 weeks prior consultation; patients unavailable duration follow (11 months); patients concomitant infections disease mask treatment response.,C0680251|C0243161|G0000000|C0032961|C0006147|C0205082|C0205210|C0002871|C0017209|C0369773|G0000000|G0000000|C0369773|G0000000|C0205430|C3714514|C1512806|C0003374|C0013227|G0000000|C0439230|C0332152|C0009818|C0030705|C0686905|C0449238|C0332283|C0450371|C0439231|C0030705|C0521115|C3714514|C0012634|C0024861|C0039798|C0871261
Correlations of myocardial T2* with ventricular function were performed using the Spearman's rank test.,Correlations myocardial T2* ventricular function performed Spearman's rank test.,C1707520|C0027061|C0041403|C0018827|C0031843|C0884358|G0000000|C0699794|C0022885
Nor did the study find an effect of the intervention on the severity of delirium.,Nor study intervention severity delirium.,G0000000|C0557651|C0886296|C0439793|C0011206
"Because we were interested in targeting women with low fish consumption for the parent RCT, whose goal was to increase intake of DHA from fish, we included only women who reported consuming fish up to 2 times per month, but who had no contraindications to fish consumption such as allergy, or self-restrictions such as vegetarian diet.","Because targeting women low fish consumption parent RCT, goal increase intake DHA fish, included women reported consuming fish 2 times month, contraindications fish consumption allergy, self-restrictions vegetarian diet.",G0000000|C1521840|C0043210|C0205251|C0016163|C0009830|C0030551|G0000000|C0018017|C0442805|C1512806|C0142831|C0016163|C0332257|C0043210|C0684224|G0000000|C0016163|G0000000|C0040223|C0332177|C0079164|C0016163|C0009830|C0002111|C0036588|C0042441|C0012155
"Additional efficacy end points included the percentage of inactive patients (<6,000 steps per day) after 4 weeks of treatment; change from baseline in physical activity parameters after 4 and 8 weeks of treatment; inspiratory capacity (IC) during constant work rate cycle ergometry; change from baseline in Daily PROactive Physical Activity in COPD (D-PPAC) questionnaire scores (total, amount, and difficulty) after 4 and 8 weeks of treatment; and pulmonary function variables after 4 weeks of treatment (pre-dose FEV1 and FVC, post-dose FRC, pre- and post-dose specific airway conductance [sGaw], and residual volume [RV]).","Additional efficacy included percentage inactive patients (<6,000 steps day) 4 weeks treatment; change baseline physical activity parameters 4 8 weeks treatment; inspiratory capacity (IC) constant rate cycle ergometry; change baseline Daily PROactive Physical Activity COPD (D-PPAC) questionnaire scores (total, amount, difficulty) 4 8 weeks treatment; pulmonary function variables 4 weeks treatment (pre-dose FEV1 FVC, post-dose FRC, pre- post-dose specific airway conductance [sGaw], residual volume [RV]).",C1524062|C1280519|C0332257|C0439165|C0205254|C0030705|C1442061|C1261552|C0332173|G0000000|C0439230|C0039798|C0392747|C0168634|C0031809|C0205177|C0449381|G0000000|G0000000|C0439230|C0039798|C0004048|C1516240|C0020750|C1547014|C0871208|C1511572|C0085143|C0392747|C0168634|C0332173|G0000000|C0031809|C0205177|C0024117|C0432215|C0034394|C0449820|C0439175|C1265611|C1299586|G0000000|G0000000|C0439230|C0039798|C0024109|C0031843|C0439828|G0000000|C0439230|C0039798|C0439565|G0000000|C3714541|C0439568|C0016815|C0332152|C0439568|C0205369|C0178987|G0000000|C0429677|C1609982|C0449468|C0035190
Primary outcome: levels of anxiety and depression.,Primary outcome: levels anxiety depression.,C0205225|C1274040|C0441889|C0003467|C0011570
The survey carried out after the intervention also determined players' exposure to PEP.,The survey carried intervention determined players' exposure PEP.,G0000000|C0038951|C0206243|C0886296|G0000000|G0000000|C0274281|C1335057
"After the base line assessment applying primary outcome measures such as PGI general well-being measure, checklist for basic living skills, and IDEAS, one group was assigned for yoga therapy along with Pharmacotherapy (experimental group, n=15), and the other group for Pharmacotherapy alone (control group, n=15).","After base assessment applying primary outcome measures PGI well-being measure, checklist basic living skills, IDEAS, assigned yoga therapy Pharmacotherapy (experimental group, n=15), Pharmacotherapy (control group, n=15).",G0000000|C0002055|C1261322|C1632850|C0205225|C1274040|C0079809|C0523816|C0018684|C0079809|C1707357|C1527178|C0376558|C0678856|C0459920|C1516050|C0043418|C0039798|C0013216|C1517586|C0441833|C0369718|C0013216|C0243148|C0441833|C0369718
"However, the improvements in subjective sleepiness (ESS) and quality of life did not differ between our treatment arms.","However, improvements subjective sleepiness (ESS) quality life treatment arms.",G0000000|C2986411|C0439655|C0013144|C0206630|C0332306|C0376558|C0039798|C0206655
"At 6 months after treatment, the remission rates were 74.3% in the RTX group and 31.3% in the control group (P = .003).","At 6 months treatment, remission rates 74.3% RTX 31.3% control (P = .003).",G0000000|G0000000|C0439231|C0039798|C0544452|C0871208|C0450371|C0073081|C0450371|C0243148|G0000000
Diagnosis of a neurodevelopmental disorder was made independently of the research team.,Diagnosis neurodevelopmental disorder independently team.,C0011900|C0599855|C0012634|G0000000|C0871489
"Similarly on third visit, date of stoppage of diarrhoea in case of inter-current recovery, weight of child, daily record of frequency and consistency of stools, tolerance and acceptability of treatment were recorded in the study record forms.","Similarly visit, stoppage diarrhoea inter-current recovery, weight child, daily record frequency consistency stools, tolerance acceptability treatment recorded study record forms.",G0000000|C0545082|G0000000|C0011991|C0205103|C0237820|C0005910|C0008059|C0332173|C0034869|C0376249|C0332529|C0015733|C0013220|C0814633|C0039798|C0034869|C0557651|C0034869|C0348078
Evidence of mild exacerbations (an increase in the number of times the reliever was used above baseline of >1 on 2 consecutive days) and severe exacerbations (oral steroid use or hospitalisation) was gained from patient-held diary card data and retrospective analysis of health records.,Evidence mild exacerbations (an increase times reliever baseline >1 2 consecutive days) severe exacerbations (oral steroid hospitalisation) gained patient-held diary card data retrospective analysis health records.,C3887511|C2945599|G0000000|G0000000|C0442805|C0040223|G0000000|C0168634|G0000000|G0000000|C1707491|C0439228|C0205082|G0000000|C0442027|C0038317|C0019993|C1517378|C0030705|C0376660|C3275277|C1511726|C0035363|C0002778|C0018684|C0034869
"○ After 28 days, a recurrent vivax parasitaemia is more likely to represent a relapse.","○ After 28 days, recurrent vivax parasitaemia represent relapse.",G0000000|G0000000|C0450371|C0439228|C2945760|G0000000|C0242723|C1882932|C0035020
"The evaluating parameters included the visual analogue scale (VAS) pain score, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire scores, and electromyographic (EMG) nerve conduction velocity (NCV) determinations.","The evaluating parameters included visual analogue scale (VAS) pain score, Functional Assessment Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire scores, electromyographic (EMG) nerve conduction velocity (NCV) determinations.",G0000000|C0220825|C0449381|C0332257|C0234621|C0243071|C0175659|C0042815|C0030193|C0449820|C0205245|C1261322|C0006826|C0039798|C0027651|C0441833|C3899177|C0034394|C0449820|G0000000|G0000000|C0027740|C0232217|C0439830|C2982003|C0680730
The primary outcome is the combined endpoint of bronchopulmonary dysplasia or death at 36 weeks post-menstrual age.,The primary outcome combined endpoint bronchopulmonary dysplasia death 36 weeks post-menstrual age.,G0000000|C0205225|C1274040|C0205195|C2349179|C0545675|C0334044|C0011065|C0450371|C0439230|C0687676|C0001779
Berg balance scale (BBS) and Timed Up-and-Go (TUG) tests were used for assessing balance as part of the primary outcome.,Berg balance scale (BBS) Timed Up-and-Go (TUG) tests assessing balance primary outcome.,G0000000|C0014653|C0175659|G0000000|C0392761|C1822658|C1319201|C0022885|C1516048|C0014653|C0205225|C1274040
"Outcome was determined by using measures of trunk postural stability, balance ability, and upper limb motor function.","Outcome determined measures trunk postural stability, balance ability, upper limb motor function.",C1274040|G0000000|C0079809|C0225442|C0205278|C0205360|C0014653|C0085732|C1282910|C0015385|C1513492|C0031843
"For children aged 1 month to 5 years with ALRI, the clinical signs best predicting hypoxaemia were cyanosis, respiratory rate >60, poor feeding, or reduced spontaneous activity; in those without ALRI the best predictors were cyanosis, respiratory rate >60 per minute, and inability to feed, but the positive predictive value was much lower than for children with ALRI.","For children aged 1 month 5 ALRI, clinical signs predicting hypoxaemia cyanosis, respiratory rate >60, poor feeding, reduced spontaneous activity; ALRI predictors cyanosis, respiratory rate >60 minute, inability feed, positive predictive lower children ALRI.",G0000000|C0008059|C0001779|G0000000|C0332177|G0000000|G0000000|C0205210|C0220912|G0000000|C0700292|C0010520|C0521346|C0871208|C0450371|C0032854|C0204695|C0392756|C0205359|C0205177|G0000000|C2698872|C0010520|C0521346|C0871208|C0450371|C0439232|G0000000|C0204695|C0439178|C0681890|C0441994|C0008059|G0000000
"First, the BCTQ and DASH scores of each patient were assessed repetitively for both hands at the same time preoperatively and 3 months after carpal tunnel release.","First, BCTQ DASH scores patient assessed repetitively hands time preoperatively 3 months carpal tunnel release.",C0205435|G0000000|C2827624|C0449820|C0030705|C1516048|G0000000|C0018563|C0040223|G0000000|G0000000|C0439231|C0007285|C0337138|C0030685
"Spectral domain optical coherence tomography scans were performed with the Spectralis® HRA+OCT (software version 5.4.7.0, Heidelberg Engineering, Heidelberg, Germany), in a pattern of 20° × 15° (5.8 mm × 4.3 mm) raster scans consisting of 19 high-resolution line scans, each composed of 50 averaged frame.","Spectral domain optical coherence tomography scans performed Spectralis® HRA+OCT (software version 5.4.7.0, Heidelberg Engineering, Heidelberg, Germany), pattern 20° × 15° (5.8 mm × 4.3 mm) raster scans consisting 19 high-resolution scans, composed 50 averaged frame.",C1883073|C1880389|C0042789|C4068804|C0040395|C0034606|C0884358|G0000000|C1619700|C0037585|C0333052|G0000000|G0000000|C0014279|G0000000|C0017480|C0449774|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0034606|C0332529|C0450371|C1719039|C0034606|G0000000|C0450371|C1510992|C0080089
"Mean change in FEV1(L) from pre-dose at baseline to pre-dose and 2-hour post-dose at week 12, (LOCF), time to discontinuation due to lack of efficacy and study duration for each treatment group, Full Analysis Set b.i.d.","Mean change FEV1(L) pre-dose baseline pre-dose 2-hour post-dose week 12, (LOCF), time discontinuation lack efficacy study duration treatment group, Full Analysis Set b.i.d.",C0444504|C0392747|C0439394|C0439565|C0168634|C0439565|C0439227|C0439568|C0332174|C0450371|C2825507|C0040223|C0457454|C0332268|C1280519|C0557651|C0449238|C0039798|C0441833|C0443225|C0002778|C0036849|C0152277
"Assessments included timed floor walks (8 m), the Berg balance test, the motor (ambulatory) component of the Functional Independence Measure (FIM), and indices of volitional paretic ankle control derived using robot-measured positional data.","Assessments included timed floor walks (8 m), Berg balance test, motor (ambulatory) component Functional Independence Measure (FIM), indices volitional paretic ankle control derived robot-measured positional data.",C1261322|C0332257|C0392761|C0016249|C0600108|G0000000|C0369637|G0000000|C0014653|C0022885|C1513492|C0439841|C0449432|C0205245|C0085862|C0079809|C3273671|C4033634|C0042950|G0000000|C0003086|C0243148|C1441547|C0336537|C0240795|C1511726
"The Clinical Global Impression, Improvement (CGI–I) and the Modified (nine-item) Simpson– Angus Scale were applied daily.","The Clinical Global Impression, Improvement (CGI–I) Modified (nine-item) Simpson– Angus Scale applied daily.",G0000000|C0205210|C0205246|C0596764|C2986411|G0000000|C0392747|C0205455|G0000000|G0000000|C0175659|C4048755|C0332173
"Even in places where ocular chlamydial infection has been reduced, the risk of trichiasis and blindness persists.","Even ocular chlamydial infection reduced, risk trichiasis blindness persists.",G0000000|C0015392|C0008148|C0009450|C0392756|C0035647|C0221259|C0456909|G0000000
The primary outcome measure will be the difference in haemoglobin concentration between the oxpentifylline and control groups at the end of the 4 month study period.,The primary outcome measure difference haemoglobin concentration oxpentifylline control 4 month study period.,G0000000|C0205225|C1274040|C0079809|C1705241|C0019046|C0004268|C0030899|C0243148|G0000000|C0332177|C0557651|C0439531
"Of the 359/400 known pregnancy outcomes there were 330 live births (three sets of twins); two medical terminations, two stillbirths, 22 miscarriages, and five terminations.","Of 359/400 pregnancy outcomes 330 live births (three sets twins); medical terminations, stillbirths, 22 miscarriages, terminations.",G0000000|C1442061|C0032961|C1274040|C1442061|C1548795|C0005615|C0205449|C0036849|C0041427|C0199168|C1549081|C0595939|C0450371|C0000786|C1549081
"The muscles assessed included the elbow flexors, hip flexors, hip abductors, hip extensors, knee extensors, and knee flexors.","The muscles assessed included elbow flexors, hip flexors, hip abductors, hip extensors, knee extensors, knee flexors.",G0000000|C0026845|C1516048|C0332257|C0013769|C1879367|C0019552|C1879367|C0019552|G0000000|C0019552|C1184148|C0022742|C1184148|C0022742|C1879367
"Video-fluoroscopic swallowing study (VFSS) for swallowing ability evaluation The functional dysphagia scale is based on the VFSS in stroke patients, which is a sensitive and specific method for quantifying the severity of dysphagia [24,25].","Video-fluoroscopic swallowing study (VFSS) swallowing ability evaluation The functional dysphagia scale based VFSS stroke patients, sensitive specific method quantifying severity dysphagia [24,25].",C1660599|C0011167|C0557651|G0000000|C0011167|C0085732|C0220825|G0000000|C0205245|C0011168|C0175659|C1527178|G0000000|C0038454|C0030705|C0020517|C0205369|C0025663|C1709793|C0439793|C0011168|C0450371
"Rescue medication use was calculated as an average use of short acting β2-agonists per day (puffs/day) for 2 wk, hence, there are five time points.","Rescue medication calculated average short acting β2-agonists day (puffs/day) 2 wk, hence, time points.",G0000000|C0013227|C0444686|C1510992|C1282927|G0000000|G0000000|C0332173|C1533107|G0000000|C0332174|G0000000|C0040223|C1552961
The primary outcome was assessed by comparing the rates of infection-associated relapses (relapses occurring in the week after the 7-day intervention period) and expressed as episodes/patient per yr.,The primary outcome assessed comparing rates infection-associated relapses (relapses occurring week 7-day intervention period) expressed episodes/patient yr.,G0000000|C0205225|C1274040|C1516048|C1707455|C0871208|C0009450|C0035020|C0035020|C1709305|C0332174|C0332173|C0886296|C0439531|G0000000|C0332189|C0439234
The radius length gives the magnitude of each sensor response.,The radius length magnitude sensor response.,G0000000|C0034627|C1444754|C0449286|C0183210|C0871261
The primary outcome measure was the duration of mechanical ventilation and secondary outcome measures were length of PICU stay and ability to walk unaided within four weeks of PICU discharge.,The primary outcome measure duration mechanical ventilation secondary outcome measures length PICU stay ability walk unaided weeks PICU discharge.,G0000000|C0205225|C1274040|C0079809|C0449238|C0443254|C0035203|C0027627|C1274040|C0079809|C1444754|C1046445|G0000000|C0085732|C0080331|C0439846|C0439230|C1046445|C0012621
CBCA: Criterion based clinical audit; MDR: Maternal death review; EmOC: Emergency obstetrical care.,CBCA: Criterion based clinical audit; MDR: Maternal death review; EmOC: Emergency obstetrical care.,G0000000|C0243161|C1527178|C0205210|C1704774|G0000000|C2347083|C0011065|C0282443|G0000000|C0013956|C0028773|C1947933
"Baseline values for outcome measures FIQ, fibromyalgia impact questionnaire; NRS-PI, numerical rating scale pain intensity; PSQI, Pittsburgh Sleep Quality Index Effects of CFQ practice on pain, function and sleep.","Baseline values outcome measures FIQ, fibromyalgia impact questionnaire; NRS-PI, numerical rating scale pain intensity; PSQI, Pittsburgh Sleep Quality Index Effects CFQ practice pain, function sleep.",C0168634|C0042295|C1274040|C0079809|G0000000|C0016053|C1825598|C0034394|C2240043|C0237753|C0871208|C0175659|C0030193|C0522510|C3697468|G0000000|C0037313|C0332306|C0918012|C1280500|G0000000|C0237607|C0030193|C0031843|C0037313
"Relative to the reference arm, the adjusted risk of first progression or death (PFS) ranged from 0.984 to 1.066 for the experimental regimens (Fig 3A).","Relative reference arm, adjusted risk progression death (PFS) ranged 0.984 1.066 experimental regimens (Fig 3A).",C0080103|C1514811|C0446516|C0456081|C0035647|C0242656|C0011065|C0242792|C1514721|C1442061|C1442061|C1517586|C2945654|C0349966|C1420849
"Patients with a history of spontaneous pain, tooth tender to percussion, absence of underlying permanent teeth, internal/external root resorption, apical/furcal lesions, sinus tract, periodontal pocket >3mm, physiologic or pathologic luxation, and/or presence of abscess were excluded from the study.","Patients history spontaneous pain, tooth tender percussion, absence underlying permanent teeth, internal/external root resorption, apical/furcal lesions, sinus tract, periodontal pocket >3mm, physiologic pathologic luxation, and/or presence abscess excluded study.",C0030705|C0019664|C0205359|C0030193|C0040426|C0234234|C0030987|C0332197|G0000000|C0205355|C0040426|C0205102|C0040452|C2985494|C0205111|C0221198|C0016169|C1185740|C2960678|G0000000|G0000000|C0205463|C1521733|C0332767|G0000000|C0150312|C0000833|C1554077|C0557651
The rate of change in [Na] did not differ significantly between treatment groups.,The rate change [Na] treatment groups.,G0000000|C0871208|C0392747|C0597484|C0039798|C0441833
"Variables measured at clinic visits (FEV1) and from diaries (asthma visual analogue score (VAS), peak expiratory flow (PEF), mood, symptoms, use of bronchodilator).","Variables measured clinic visits (FEV1) diaries (asthma visual analogue score (VAS), peak expiratory flow (PEF), mood, symptoms, bronchodilator).",C0439828|C0444706|C0002424|C0545082|G0000000|C0376660|C0004096|C0234621|C0243071|C0449820|C0042815|C0444505|C0231800|C0806140|C0030771|C0026516|C0683368|C0006280
The daily 24-hour peritoneal glucose absorption was calculated as the infused dialysate volume and glucose concentration during the 24-hour period minus the directly measured volume and glucose concentration of the 24-hour drained effluent.,The daily 24-hour peritoneal glucose absorption calculated infused dialysate volume glucose concentration 24-hour period minus directly measured volume glucose concentration 24-hour drained effluent.,G0000000|C0332173|C0450371|C0031153|C0017725|C0000854|C0444686|G0000000|C0011947|C0449468|C0017725|C0004268|C0450371|C0439531|C0332288|C1947931|C0444706|C0449468|C0017725|C0004268|C0450371|C0013103|G0000000
"HRs (95 % CI) were estimated by using Cox’s proportional hazard model adjusted for age, gender, alcohol intake (continuous), body mass index (continuous), smoking status (never smokers, former smokers <15 pack-years, former smoker ≥15 pack-years, current smoker <27.5 pack-years, current smoker ≥27.5 pack-years), physical activity (continuous), Dutch healthy diet-index (continuous), dietary processed meat intake (continuous), dietary unprocessed red meat intake (continuous), total energy intake (continuous), hormone replacement therapy (yes vs. no), diabetes mellitus (yes vs. no), education status (low, intermediate, high), income status (low, intermediate, high), total energy adjusted sum of other minerals (excluding the mineral under investigation) (continuous), family history of cancer (yes vs. no) and heme or non-heme iron (according to the exposure under investigation).","HRs (95 % CI) estimated Cox’s proportional hazard model adjusted age, gender, alcohol intake (continuous), body mass (continuous), smoking status (never smokers, smokers <15 pack-years, smoker ≥15 pack-years, current smoker <27.5 pack-years, current smoker ≥27.5 pack-years), physical activity (continuous), Dutch healthy diet-index (continuous), dietary processed meat intake (continuous), dietary unprocessed red meat intake (continuous), total energy intake (continuous), hormone replacement therapy (yes vs. no), diabetes mellitus (yes vs. no), education status (low, intermediate, high), income status (low, intermediate, high), total energy adjusted sum minerals (excluding mineral investigation) (continuous), family history cancer (yes vs. no) heme non-heme iron (according exposure investigation).",G0000000|C0450371|G0000000|C0008107|C0750572|G0000000|C0205351|C0598697|C3161035|C0456081|C0001779|C0079399|C0001962|C1512806|C0549178|C0242821|C0577559|C0549178|C0037369|C0449438|C2003901|C0337664|C0337664|C0450371|C1277691|C0337664|G0000000|C1277691|C0521116|C0337664|C0450371|C1277691|C0521116|C0337664|G0000000|C1277691|C0031809|C0205177|C0549178|C0013331|C3898900|C0012155|C0549178|C0012155|C1522240|C0025017|C1512806|C0549178|C0012155|C1709843|C0332575|C0025017|C1512806|C0549178|C0439175|C0424589|C1512806|C0549178|C0019932|C0035139|C0039798|C1549445|G0000000|G0000000|C0011847|G0000000|C1549445|G0000000|G0000000|C0013621|C0449438|C0205251|C0205103|C0205250|C0021162|C0449438|C0205251|C0205103|C0205250|C0439175|C0424589|C0456081|C1515051|C0026162|C0332196|C0006660|C0220825|C0549178|C0015576|C0019664|C0006826|C1549445|G0000000|G0000000|C0018966|C1518422|C0302583|C0680240|C0274281|C0220825
The mean (range) fever clearance time was 2.5 (2–3) days and the mean parasite clearance time was 3.1 (3–4) days.,The (range) fever clearance time 2.5 (2–3) days parasite clearance time 3.1 (3–4) days.,G0000000|C1514721|C0015967|C0449297|C0040223|G0000000|G0000000|C0439228|C0030498|C0449297|C0040223|G0000000|G0000000|C0439228
The percentage of total sleep time with an SaO2 less than 90% was 5% ± 10% (Table 1).,The percentage total sleep time SaO2 90% 5% ± 10% (Table 1).,G0000000|C0439165|C0439175|C0037313|C0040223|G0000000|C0450371|G0000000|G0000000|C0450371|C0039224|G0000000
"Both groups were statistically different in the view of gestational age, birth-weight, and neonatal Apgar score (Table 2).","Both statistically view gestational age, birth-weight, neonatal Apgar score (Table 2).",G0000000|C0038215|C0449911|C0439671|C0001779|C0005612|C1552240|C0741195|C0449820|C0039224|G0000000
"More specifically, it measures the concordance between respondents’ scripts and the scripts of a panel of experts.","More specifically, measures concordance respondents’ scripts scripts panel experts.",C0205172|G0000000|C0079809|C0680240|G0000000|C0871893|C0871893|C0441833|G0000000
"The trial will determine whether FES-assisted cycling, or cycling alone compared to standard care will improve muscle mass, strength and physical function.","The trial determine FES-assisted cycling, cycling compared standard care improve muscle mass, strength physical function.",G0000000|C0008976|G0000000|C1269765|C1511572|C1511572|C1707455|C1442989|C1947933|G0000000|C0026845|C0577559|C0237897|C0031809|C0031843
"The primary end point was the objective tumour response, as assessed by RECIST version 1.1.","The primary objective tumour response, assessed RECIST version 1.1.",G0000000|C0205225|C0018017|C0027651|C0871261|C1516048|C1709926|C0333052|G0000000
"Physical activity level was also analysed using MET values to calculate participants’ total MET-minutes per week of moderate-intensity walking, moderate-intensity physical activity, and vigorous-intensity physical activity, using the IPAQ-SV scoring methods for calculating physical activity levels [[31]].","Physical activity level analysed MET values calculate participants’ total MET-minutes week moderate-intensity walking, moderate-intensity physical activity, vigorous-intensity physical activity, IPAQ-SV scoring methods calculating physical activity levels [[31]].",C0031809|C0205177|C0441889|G0000000|C0268621|C0042295|C1441506|G0000000|C0439175|C0268621|C0332174|C0205081|C0080331|C0205081|C0031809|C0205177|C0522510|C0031809|C0205177|C0013754|C0449820|C0025663|C1441506|C0031809|C0205177|C0441889|C0450371
"All signals were digitalized at 128 Hz using commercial software (Harmonie, Stellate, Montreal, Canada), as described elsewhere.4 Sleep stages, sleep arousals, and RMMA/SB episodes were scored according to standard criteria.7,22,24,25 CAP was scored according to the published rules.26 Each CAP phase A was visually detected during NREM sleep on the C3A2 derivation by the use of Somnologica (Embla, Germany), then classified into subtypes A1, A2, or A3.","All signals digitalized 128 Hz commercial software (Harmonie, Stellate, Montreal, Canada), elsewhere.4 Sleep stages, sleep arousals, RMMA/SB episodes scored standard criteria.7,22,24,25 CAP scored published rules.26 Each CAP phase A visually detected NREM sleep C3A2 derivation Somnologica (Embla, Germany), classified subtypes A1, A2, A3.",G0000000|C1710082|C0554831|C1442061|C0439482|C0680536|C0037585|G0000000|C0205141|G0000000|C0006823|G0000000|C0037313|C1306673|C0037313|C0003808|C0038111|C0332189|C0449820|C1442989|C0243161|C0179586|C0449820|C0034037|C0870077|G0000000|C0179586|C0205390|G0000000|G0000000|C0442726|G0000000|C0037313|G0000000|C0805874|G0000000|C0591441|C0017480|C0008902|C0449560|C0336669|C0336669|C0336669
"Considering our findings and all these aspects, we believe that any new drug with some activity in melanoma should be evaluated also for its effect on CNS metastasis incidence.","Considering findings aspects, drug activity melanoma evaluated CNS metastasis incidence.",C0750591|C2607943|C1547011|C0013227|C0205177|C0025202|C0220825|C3714787|C0027627|C0021149
All dyads completed 6 month follow up assessments to assess alcohol use-related outcomes.,All dyads completed 6 month follow assessments assess alcohol use-related outcomes.,G0000000|C0870454|C0205197|G0000000|C0332177|C0332283|C1261322|C1516048|C0001962|C0042153|C1274040
"The BMI z-score is a value that takes into consideration age, sex, and the ongoing growth of children and adolescents [15].","The BMI z-score takes consideration age, sex, ongoing growth children adolescents [15].",G0000000|G0000000|C0871421|C1515187|C0518609|C0001779|C0009253|C0549178|C0018270|C0008059|C0205653|C0450371
A literature review indicated that there were few RCTs of smoking cessation text messaging interventions with biochemically verified continuous smoking abstinence at 6 months as an outcome.,A literature review RCTs smoking cessation text messaging interventions biochemically verified continuous smoking abstinence 6 months outcome.,G0000000|C0023866|C0282443|G0000000|C0037369|C1880019|C1527021|C0470166|C0886296|G0000000|C1711411|C0549178|C0037369|C3843422|G0000000|C0439231|C1274040
The primary efficacy end point was clinical remission defined as a reduction in stool frequency or stool weight of >50%.,The primary efficacy clinical remission defined reduction stool frequency stool weight >50%.,G0000000|C0205225|C1280519|C0205210|C0544452|C1704788|C0301630|C0015733|C0376249|C0015733|C0005910|C0450371
"The main efficacy variable was benzodiazepine use at 12 months, although data was also taken at 6 months.","The main efficacy variable benzodiazepine 12 months, data 6 months.",G0000000|C0205225|C1280519|C0439828|C0005064|C0450371|C0439231|C1511726|G0000000|C0439231
"MAIN OUTCOME MEASURES—Clinical improvement, echocardiographic and radiologic pericardial fluid resolution, and death.","MAIN OUTCOME MEASURES—Clinical improvement, echocardiographic radiologic pericardial fluid resolution, death.",C0205225|C1274040|G0000000|C2986411|C0013516|C0034599|C0031050|C0005889|C1514893|C0011065
"There were no significant between-group differences in the rates of air leak in the first 14 days, pneumothorax during the hospital stay, necrotizing enterocolitis requiring medical or surgical treatment, patent ductus arteriosus requiring surgery, severe intraventricular hemorrhage, or severe retinopathy of prematurity, as defined according to the new type 1 threshold in the Early Treatment for Retinopathy of Prematurity study (ETROP; ClinicalTrials.gov number, {""type"":""clinical-trial"",""attrs"":{""text"":""NCT00027222"",""term_id"":""NCT00027222""}}NCT00027222)18 or according to the need for surgical intervention among survivors.","There between-group differences rates air leak 14 days, pneumothorax hospital stay, necrotizing enterocolitis requiring medical surgical treatment, patent ductus arteriosus requiring surgery, severe intraventricular hemorrhage, severe retinopathy prematurity, defined type 1 threshold Early Treatment Retinopathy Prematurity study (ETROP; ClinicalTrials.gov number, {""type"":""clinical-trial"",""attrs"":{""text"":""NCT00027222"",""term_id"":""NCT00027222""}}NCT00027222)18 surgical intervention survivors.",G0000000|C0441833|C1705241|C0871208|C0001861|C0332234|C0450371|C0439228|C0032326|C0019994|G0000000|C0439664|C0014356|G0000000|C0199168|C0543467|C0039798|C0030650|C1512083|G0000000|G0000000|C0038894|C0205082|C1517569|C0019080|C0205082|C0035309|C0021294|C1704788|C0332307|G0000000|C0449864|C1279919|C0039798|C0035309|C0021294|C0557651|G0000000|C1419208|C0237753|C0332307|C0543467|C0886296|C0206194
"We did not perform swabbing for ocular chlamydia, so we could not examine the relationship between conjunctival chlamydial infection and conjunctival infection with other bacteria.","We perform swabbing ocular chlamydia, examine relationship conjunctival chlamydial infection conjunctival infection bacteria.",G0000000|C0884358|C0183753|C0015392|C0008148|G0000000|C0439849|C0009758|C0008148|C0009450|C0009758|C0009450|C0004611
"Seizure severity was assessed by the National Hospital Seizure Severity Scale (NHS3),[14] which was administered during an interview with the parents or a witness to the seizures; it contains seven seizure-related factors and generates a score from 1 to 27.","Seizure severity assessed National Hospital Seizure Severity Scale (NHS3),[14] administered interview parents witness seizures; seizure-related factors generates score 1 27.",C0036572|C0439793|C1516048|C3245503|C0019994|C0036572|C0439793|C0175659|C0450371|C1521801|C0021822|C0030551|C0682356|C0036572|C0036572|C1521761|G0000000|C0449820|G0000000|C0450371
Progression free survival for all 124 patients treated with chemoimmunotherapy (i.v.,Progression free survival 124 patients treated chemoimmunotherapy (i.v.,C0242656|C0332296|C0038952|C1442061|C0030705|C1522326|C2986423|C0021966
"The progression free survival after 1 year was assumed to be 40% (chemoimmunotherapy) and 20% (chemotherapy), respectively.","The progression free survival 1 assumed 40% (chemoimmunotherapy) 20% (chemotherapy), respectively.",G0000000|C0242656|C0332296|C0038952|G0000000|C3242379|C0450371|C2986423|C0450371|C0013216|G0000000
"Regarding the impact of MMN on biomarkers of status in the original cohort study, after 6 months of supplementation, there was a positive effect in reducing anaemia in both groups and there was an improvement of zinc status in the multiple micronutrients group [71].","Regarding impact MMN biomarkers status original cohort study, 6 months supplementation, positive reducing anaemia improvement zinc status multiple micronutrients [71].",G0000000|C1825598|G0000000|C0005516|C0449438|C0205313|C0599755|C0557651|G0000000|C0439231|C0242297|C0439178|C0392756|C0002871|C2986411|C0043481|C0449438|C0439064|C0282575|C0450371
This effect was associated with a differential corticomotor excitability change in the muscles acting as agonist and antagonist of the trained/observed movements.,This differential corticomotor excitability change muscles acting agonist antagonist trained/observed movements.,G0000000|C0443199|G0000000|C0235169|C0392747|C0026845|G0000000|C2987634|C0231491|C0336809|C0026649
"NA, not applicable; FEV1, forced expiratory volume in 1 s; FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity; BMQ, Brief Medication Questionnaire; AQLQ, Asthma‐related Quality of Life Questionnaire; CQ, Consumer Asthma Knowledge Questionnaire; PCAQ, Perceived Control of Asthma Questionnaire; reliever, short‐acting β2 agonists or anticholinergic bronchodilators; preventer, inhaled corticosteroids, theophylline derivatives, cromolyns, leucotriene receptor antagonists or oral corticosteroids; LABA, long‐acting β2 agonists.","NA, applicable; FEV1, forced expiratory volume 1 s; FEV1/FVC, forced expiratory volume 1 s/forced vital capacity; BMQ, Brief Medication Questionnaire; AQLQ, Asthma‐related Quality Life Questionnaire; CQ, Consumer Asthma Knowledge Questionnaire; PCAQ, Perceived Control Asthma Questionnaire; reliever, short‐acting β2 agonists anticholinergic bronchodilators; preventer, inhaled corticosteroids, theophylline derivatives, cromolyns, leucotriene receptor antagonists oral corticosteroids; LABA, long‐acting β2 agonists.",C0597484|C1272460|G0000000|C0441722|C0231800|C0449468|G0000000|C3714541|C0441722|C0231800|C0449468|G0000000|C0442732|C1516240|G0000000|C1282927|C0013227|C0034394|C4055434|G0000000|C0332306|C0376558|C0034394|C0282245|C1707496|C0004096|C0376554|C0034394|G0000000|C0030971|C0243148|C0004096|C0034394|G0000000|G0000000|G0000000|C0243192|C0242896|C0006280|G0000000|C0004048|C0001617|C0039771|C0243072|G0000000|C0023545|C0597357|C0243076|C0442027|C0001617|G0000000|G0000000|G0000000|C0243192
"Therefore, it can be concluded that storage of information and attitude change remained until after delivery.","Therefore, concluded storage attitude change remained delivery.",G0000000|C0917903|C0337174|C0004271|C0392747|G0000000|C0011209
Follow-up assessments occurred every 6 months through 30 months.,Follow-up assessments occurred 6 months 30 months.,C0589120|C1261322|C1709305|G0000000|C0439231|C0450371|C0439231
"General infections (urinary tract infection, respiratory tract infection), flap anastomosis complications (venous or arterial), and wound complications (dehiscence, tissue necrosis, haematoma, chyle leak, salivary fistula or wound infection) were recorded.","General infections (urinary tract infection, respiratory tract infection), flap anastomosis complications (venous arterial), wound complications (dehiscence, tissue necrosis, haematoma, chyle leak, salivary fistula wound infection) recorded.",C0205246|C3714514|C0042027|C1185740|C0009450|C0521346|C1185740|C0009450|C0038925|C0332853|C0009566|C0042449|C0003842|C0043250|C0009566|C0149663|C0040300|C0027540|C0018944|C0008730|C0332234|C0442040|C0016169|C0043250|C0009450|C0034869
Some women also suffer from depression during this period.2 Studies have shown that depression during pregnancy may disrupt fetal growth.,Some women suffer depression period.2 Studies depression pregnancy disrupt fetal growth.,G0000000|C0043210|C0683278|C0011570|C0439531|C0947630|C0011570|C0032961|C0332454|C0015965|C0018270
The mean dietary diversity score based on nine food groups was 2.0±1.2 for children aged 6–59 months.,The dietary diversity score based food 2.0±1.2 children aged 6–59 months.,G0000000|C0012155|C1880371|C0449820|C1527178|C0016452|G0000000|C0008059|C0001779|G0000000|C0439231
We ascertained the incidence of fracture through self report by questionnaire.,We ascertained incidence fracture report questionnaire.,G0000000|G0000000|C0021149|C0016658|C0684224|C0034394
"In the trial, children were administered IPV-bOPV-bOPV (n = 48), IPV-IPV-bOPV (n = 54), or IPV-IPV-IPV (n = 50) at 8, 16, and 24 weeks of age and then challenged with mOPV2 at 28 weeks.","In trial, children administered IPV-bOPV-bOPV (n = 48), IPV-IPV-bOPV (n = 54), IPV-IPV-IPV (n = 50) 8, 16, 24 weeks age challenged mOPV2 28 weeks.",G0000000|C0008976|C0008059|C1521801|G0000000|C0369718|G0000000|C0450371|G0000000|C0369718|G0000000|C0450371|G0000000|C0369718|G0000000|C0450371|G0000000|C0450371|C0450371|C0439230|C0001779|C0798503|G0000000|C0450371|C0439230
"These included pain at rest, pain on passive stretch, pain on palpation, and possibility of single foot leaning.","These included pain rest, pain passive stretch, pain palpation, possibility single foot leaning.",G0000000|C0332257|C0030193|C0035253|C0030193|C3686820|C0600080|C0030193|C0030247|C0332149|C0037179|C0016504|G0000000
A major concern for any CRC screening programme is the number of colonoscopies generated.,A major concern CRC screening programme colonoscopies generated.,G0000000|C0205082|C2699424|C0009402|C0220908|C1709697|C0009378|C3146294
Predictable onset of inside-cycle migraine 4.,Predictable onset inside-cycle migraine 4.,C2371925|C0206132|C1511572|C0149931|G0000000
"Three and six months after completing probiotic treatment period, the PedsQL™ questionnaires were again completed by the same nurse, using the same questionnaire.","Three months completing probiotic treatment period, PedsQL™ questionnaires completed nurse, questionnaire.",C0205449|C0439231|C0205197|C0525033|C0039798|C0439531|G0000000|C0034394|C0205197|C0028661|C0034394
"Current results highlight that engagement with the FCU predicts large long-term reductions in tobacco-use from age 11 through age 22, thereby extending prior analyses of the FCU, which examined treatment effects to age 16–17 (14).","Current highlight engagement FCU predicts long-term reductions tobacco-use age 11 age 22, extending prior analyses FCU, examined treatment effects age 16–17 (14).",C0521116|G0000000|C0425152|G0000000|G0000000|C0443252|C0301630|C0040335|C0001779|C0450371|C0001779|C0450371|C0439792|C0332152|C0002778|G0000000|C0332128|C0039798|C1280500|C0001779|G0000000|C0450371
"Main outcome measures included effectiveness of pain relief defined as drop of VAS to 3 or less, patient's global evaluation of the drug, absence from school, the use of a rescue medication, and, in those who continued the treatment, the pain intensity difference (PID) at different points after start of medication and its sum (SPID).","Main outcome measures included effectiveness pain relief defined drop VAS 3 less, patient's global evaluation drug, absence school, rescue medication, and, continued treatment, pain intensity difference (PID) start medication sum (SPID).",C0205225|C1274040|C0079809|C0332257|C1280519|C0030193|C0564405|C1704788|C1321095|C0042815|G0000000|C0439092|C0030705|C0205246|C0220825|C0013227|C0332197|C0036375|G0000000|C0013227|G0000000|C0549178|C0039798|C0030193|C0522510|C1705241|C0242172|C0439659|C0013227|C1515051|C2826264
"WBRT + SRS is an effective, safe tool in treatment of patients with 1 to 3 brain metastses improving the brain local control, but further studies with larger number of patients is recommended.","WBRT + SRS effective, safe tool treatment patients 1 3 brain metastses improving brain local control, studies larger patients recommended.",G0000000|C1280519|G0000000|C0336791|C0039798|C0030705|G0000000|G0000000|C0006104|G0000000|C1272745|C0006104|C0205276|C0243148|C0947630|C0549177|C0030705|C0034866
The follow up data were collected at least three months after the last intervention.,The follow data collected months intervention.,G0000000|C0332283|C1511726|C1516695|C0439231|C0886296
"An RIA manufactured by Diasorin Corporation and developed in the Hollis laboratory was used to measure total circulating 1,25(OH)2D concentration (56).","An RIA manufactured Diasorin Corporation developed Hollis laboratory measure total circulating 1,25(OH)2D concentration (56).",G0000000|C0034580|C0870840|G0000000|C0683758|G0000000|C1256218|C0022877|C0079809|C0439175|C0175630|C0450371|C0004268|C0450371
"The two groups did not differ significantly with regard to the number of ventilator days, LOS, or ICU or in-hospital mortality (Table (Table1).1).","The regard ventilator days, LOS, ICU in-hospital mortality (Table (Table1).1).",G0000000|G0000000|C0087153|C0439228|G0000000|C0021708|C0019994|C0026565|C0039224|G0000000
"Both treatments produced statistically similar reductions in acne lesions, and acne severity.","Both treatments produced statistically reductions acne lesions, acne severity.",G0000000|C0087111|G0000000|C0038215|C0301630|C0001144|C0221198|C0001144|C0439793
The percent change in BMD from baseline to 36 months between treatment arms was compared using a two-sample t-test with a significance level of 0.05.,The percent change BMD baseline 36 months treatment arms compared two-sample t-test significance level 0.05.,G0000000|C0439165|C0392747|G0000000|C0168634|C0450371|C0439231|C0039798|C0206655|C1707455|C0205448|C0871472|C0237881|C0441889|C0450371
"In its entirety, OS was not significantly different between the two sequencing strategies.","In entirety, OS sequencing strategies.",G0000000|C0439751|C0229090|C1294197|C0679199
"This modified scale has been used in another trial assessing wrist function after fracture.15 The scale has been found to be highly reliable,19,20 have excellent construct validity and be responsive to change.17–20 It has been validated in populations of children 5 to 15 years old with fractures and other musculoskeletal problems.17 Secondary outcome measures included fracture angulation, measured at weeks 1 and 4; wrist pain, measured at weeks 1, 4 and 6 with the use of the Faces Pain Scale – Revised;21,22 weekly use of the splint, if applicable, measured on a Likert scale; range of motion, measured at week 6 with a goniometer;23,24 grip strength, measured at week 6 with a dynamometer; and patient preference for their device, measured at week 6.","This modified scale trial assessing wrist function fracture.15 The scale highly reliable,19,20 excellent construct validity responsive change.17–20 It validated populations children 5 15 fractures musculoskeletal problems.17 Secondary outcome measures included fracture angulation, measured weeks 1 4; wrist pain, measured weeks 1, 4 6 Faces Pain Scale – Revised;21,22 weekly splint, applicable, measured Likert scale; range motion, measured week 6 goniometer;23,24 grip strength, measured week 6 dynamometer; patient preference device, measured week 6.",G0000000|C0392747|C0175659|C0008976|C1516048|C0043262|C0031843|C0016658|G0000000|C0175659|C0205250|C3858758|C1548784|C2827421|C2349101|C0205342|G0000000|G0000000|G0000000|C0032659|C0008059|G0000000|C0450371|C0016658|C0497254|C1546466|C0027627|C1274040|C0079809|C0332257|C0016658|C0333179|C0444706|C0439230|G0000000|G0000000|C0043262|C0030193|C0444706|C0439230|G0000000|G0000000|G0000000|C0015450|C0030193|C0175659|G0000000|C1527075|C0332174|C0038009|C1272460|C0444706|G0000000|C0175659|C1514721|C0026597|C0444706|C0332174|G0000000|C0181061|C0021400|C0237897|C0444706|C0332174|G0000000|C0180572|C0030705|C0558295|C0025080|C0444706|C0332174|G0000000
"Child mental health symptoms did not predict engagement, as suggested by the Health Beliefs Model.","Child mental health symptoms predict engagement, suggested Health Beliefs Model.",C0008059|C0229992|C0018684|C0683368|G0000000|C0425152|C1705535|C0018684|C0004951|C3161035
"This included the Visual Analog Scale (VAS), a 10-cm line anchored at one end by the descriptor ‘No Pain’ and at the other by the words ‘Worst Pain Imaginable.’  Table 1 specifies the schedule for additional clinical assessments.","This included Visual Analog Scale (VAS), 10-cm anchored descriptor ‘No Pain’ ‘Worst Pain Imaginable.’ Table 1 specifies schedule additional clinical assessments.",G0000000|C0332257|C0234621|C0243071|C0175659|C0042815|C0450371|C1293132|C0282354|G0000000|G0000000|G0000000|C0030193|G0000000|C0039224|G0000000|C1521902|C0086960|C1524062|C0205210|C1261322
Surgical and pathologic response was better with TCF but there was no difference in survival rate between two groups.,Surgical pathologic response TCF difference survival rate groups.,C0543467|C1521733|C0871261|G0000000|C1705241|C0038952|C0871208|C0441833
It appears that mAD co-therapy can decrease 2.19 times more seizure reduction in comparison with control groups.,It appears mAD co-therapy decrease 2.19 times seizure reduction comparison control groups.,G0000000|C0700364|C0002957|C0033972|C0392756|C0450371|C0040223|C0036572|C0301630|C1707455|C0243148|C0441833
"Diary card data were also used to calculate the number of mild asthma exacerbation days (a day with either a morning PEF <80% of the run-in average value or a night with awakenings due to asthma symptoms), the number of asthma control days (a night and day with no asthma symptoms and a night with no awakenings due to asthma symptoms), the number of severe asthma exacerbations (deterioration in asthma resulting in hospitalisation or emergency room treatment or need for oral glucocorticosteroid treatment for at least 3 days), and the time to first severe asthma exacerbation.","Diary card data calculate mild asthma exacerbation days (a day morning PEF <80% run-in average night awakenings asthma symptoms), asthma control days (a night day asthma symptoms night awakenings asthma symptoms), severe asthma exacerbations (deterioration asthma hospitalisation emergency treatment oral glucocorticosteroid treatment 3 days), time severe asthma exacerbation.",C0376660|C3275277|C1511726|C1441506|C2945599|C0004096|G0000000|C0439228|G0000000|C0332173|C0332170|C0030771|C0450371|C3274438|C1510992|C0240526|C1720052|C0004096|C0683368|C0004096|C0243148|C0439228|G0000000|C0240526|C0332173|C0004096|C0683368|C0240526|C1720052|C0004096|C0683368|C0205082|C0004096|G0000000|C0868945|C0004096|C0019993|C0013956|C0039798|C0442027|G0000000|C0039798|G0000000|C0439228|C0040223|C0205082|C0004096|G0000000
**Hazard ratio additionally adjusted for baseline weight and sodium excretion.,**Hazard ratio additionally adjusted baseline weight sodium excretion.,C0598697|C0456603|G0000000|C0456081|C0168634|C0005910|C0037473|C0221102
Once a week each mother enrolled in the study was asked by the primary investigator whether she was still smoke free or had resumed smoking.,Once week mother enrolled study primary investigator smoke free resumed smoking.,C0585347|C0332174|C0026591|G0000000|C0557651|C0205225|C0035173|C0037366|C0332296|C1550028|C0037369
"After adjustment for gestational age, center, and familial clustering, the rates of the primary outcome of death or bronchopulmonary dysplasia as assessed according to the physiological definition did not differ significantly between the two groups.","After adjustment gestational age, center, familial clustering, rates primary outcome death bronchopulmonary dysplasia assessed physiological definition groups.",G0000000|C0376209|C0439671|C0001779|C0205099|C0015576|C0009085|C0871208|C0205225|C1274040|C0011065|C0545675|C0334044|C1516048|C0205463|C1550452|C0441833
"Secondary outcomes were antibiotic prescribing during 28 days’ follow-up, reconsultation, clinical recovery, and patients’ satisfaction and enablement.","Secondary outcomes antibiotic prescribing 28 days’ follow-up, reconsultation, clinical recovery, patients’ satisfaction enablement.",C0027627|C1274040|C0003232|C0278329|C0450371|G0000000|C0589120|G0000000|C0205210|C0237820|G0000000|C0242428|G0000000
Both the Numerical Rating Scale of Pain and the Xerostomia Inventory were completed by the patient who was not blinded to treatment arm.,Both Numerical Rating Scale Pain Xerostomia Inventory completed patient blinded treatment arm.,G0000000|C0237753|C0871208|C0175659|C0030193|C0043352|C0021941|C0205197|C0030705|C0150108|C0039798|C0446516
This pilot trial showed that supplementation of infant diets with DHA is safe and fulfilled the pre-study goal of increasing infant RBC DHA levels by at least 20%.,This pilot trial supplementation infant diets DHA safe fulfilled pre-study goal increasing infant RBC DHA levels 20%.,G0000000|C0473169|C0008976|C0242297|C0021270|C0012155|C0142831|G0000000|C1550543|C1527048|C0018017|C0442808|C0021270|C0014792|C0142831|C0441889|C0450371
"Proportion of children consuming the recommended number of semi-solid/soft meals and snacks per day according to WHO [8, 51] will be determined at ages 9, 12, and 15 months in intervention villages and at 12 and 15 months in control villages.","Proportion children consuming recommended semi-solid/soft meals snacks day WHO [8, 51] determined ages 9, 12, 15 months intervention villages 12 15 months control villages.",C1709707|C0008059|G0000000|C0034866|C0205208|C1998602|C0453863|C0332173|G0000000|G0000000|C0450371|G0000000|C0001779|G0000000|C0450371|C0450371|C0439231|C0886296|C0562518|C0450371|C0450371|C0439231|C0243148|C0562518
"MSQoL = Migraine-specific quality of life; VAS, visual-analogue scale.","MSQoL = Migraine-specific quality life; VAS, visual-analogue scale.",G0000000|C0332306|C0376558|C0042815|C0234621|C0175659
"Participants completed the Social Problem-Solving Inventory-Revised, Beck Depression Inventory-II, Profile of Mood States, and Impact of Event Scale-Revised pre-, post-treatment, and 3 months after completion of the intervention.","Participants completed Social Problem-Solving Inventory-Revised, Beck Depression Inventory-II, Profile Mood States, Impact Event Scale-Revised pre-, post-treatment, 3 months completion intervention.",C0679646|C0205197|C0728831|C0033213|C0021941|G0000000|C0011570|C0021941|C1979963|C0026516|C1301808|C1825598|C0441471|C0175659|C0332152|C2709088|G0000000|C0439231|C0205197|C0886296
The primary outcomes of this study were the change in the proportion of IFN-γ+ and interleukin (IL)-17+CD4+ T cells in the high- vs low-dose group and the relative frequency of adverse events between the 2 groups.,The primary outcomes study change proportion IFN-γ+ interleukin (IL)-17+CD4+ T cells high- low-dose relative frequency adverse events 2 groups.,G0000000|C0205225|C1274040|C0557651|C0392747|C1709707|G0000000|C0021764|C0020898|C2603360|C0007634|C0205250|C0445550|C0080103|C0376249|G0000000|C0441471|G0000000|C0441833
"Men and women aged 18–75 years with a histologically and endoscopically confirmed diagnosis of established or first attack of ulcerative colitis (clinical activity index (CAI)>4 and endoscopic index (EI)⩾4 at baseline, both according to Rachmilewitz21), and having an extent of disease >15 cm from the anus were entered in the study.","Men women aged 18–75 histologically endoscopically confirmed diagnosis established attack ulcerative colitis (clinical activity (CAI)>4 endoscopic (EI)⩾4 baseline, Rachmilewitz21), extent disease >15 cm anus entered study.",C0025266|C0043210|C0001779|G0000000|C0205462|G0000000|C0521093|C0011900|C0443211|C0277793|C0041582|C0009319|C0205210|C0205177|C0064494|C0014245|G0000000|C0168634|G0000000|C0439792|C0012634|C0450371|G0000000|C0003461|C1521975|C0557651
"Perceived efficacy, comfort, incidence of urinary leakage and preference were assessed.","Perceived efficacy, comfort, incidence urinary leakage preference assessed.",C0030971|C1280519|C1331418|C0021149|C0042027|C0015376|C0558295|C1516048
"Functional based exercise should be a focus for interventions to protect older, high risk people from falling and to improve and maintain functional capacity.","Functional based exercise focus interventions protect older, risk people falling improve maintain functional capacity.",C0205245|C1527178|C0015259|C0205234|C0886296|G0000000|C0580836|C0035647|C0027361|C0000921|G0000000|C0024501|C0205245|C1516240
Data was collected by self-recorded symptoms according to the Rhodes index.,Data collected self-recorded symptoms Rhodes index.,C1511726|C1516695|C0036588|C0683368|C0454812|C0918012
"Effect of Treatment on Risk of Loss of Visual Acuity Score of 15 Letters or More From Baseline (Participants Without Age-Related Macular Degeneration Only)*  Analyses of each type of a lens event—nuclear opacity, cortical opacity, PSC opacity, and cataract surgery—were performed.","Effect Treatment Risk Loss Visual Acuity Score 15 Letters More From Baseline (Participants Without Age-Related Macular Degeneration Only)* Analyses type lens event—nuclear opacity, cortical opacity, PSC opacity, cataract surgery—were performed.",C1280500|C0039798|C0035647|C1517945|C0234621|C0750509|C0449820|C0450371|C0282413|C0205172|G0000000|C0168634|C0679646|G0000000|C0001779|C0332574|C0011164|C0205171|C0002778|C0332307|C0023317|G0000000|C0029053|C0001613|C0029053|C0566602|C0029053|C0086543|G0000000|C0884358
It is used for labor pain.,It labor pain.,G0000000|C0022864|C0030193
"Maternal responsiveness, maternal feeding style, and appropriate feeding practices are three critical components in the development of infant feeding self-regulation [7].","Maternal responsiveness, maternal feeding style, feeding practices critical components development infant feeding self-regulation [7].",C2347083|C0205342|C2347083|C0204695|C0489654|C0204695|C0237607|C1511545|C0449432|C0243107|C0021270|C0204695|C0684274|G0000000
"Secondary outcomes included physical performance, frailty, muscle strength and inflammatory biomarkers to characterize the effect of the interventions.","Secondary outcomes included physical performance, frailty, muscle strength inflammatory biomarkers characterize interventions.",C0027627|C1274040|C0332257|C0031809|C0597198|C0424594|C0026845|C0237897|C0333348|C0005516|G0000000|C0886296
The brain relaxation scores at various intraoperative time frames were comparable among the three groups (P > 0.05).,The brain relaxation scores intraoperative time frames comparable (P > 0.05).,G0000000|C0006104|C0035028|C0449820|C0456904|C0040223|C0180979|G0000000|C0369773|G0000000|C0450371
"Abbreviations: ASE, arthritis self‐efficacy scale; FACT‐G, functional assessment of cancer therapy‐general; OEE, outcome expectations from exercise; RAI, rheumatology attitudes index; SEPA, self‐efficacy for physical activity; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities osteoarthritis index.","Abbreviations: ASE, arthritis self‐efficacy scale; FACT‐G, functional assessment cancer therapy‐general; OEE, outcome expectations exercise; RAI, rheumatology attitudes index; SEPA, self‐efficacy physical activity; VAS, visual analog scale; WOMAC, Western Ontario McMaster Universities osteoarthritis index.",C0000723|G0000000|C0003864|G0000000|C0175659|G0000000|C0205245|C1261322|C0006826|G0000000|G0000000|C1274040|C0679138|C0015259|C3178806|C0035452|C0004271|C0918012|C1424597|G0000000|C0031809|C0205177|C0042815|C0234621|C0243071|C0175659|G0000000|C1705493|C0029040|G0000000|C0041740|C0029408|C0918012
• General health status is measured in both studies by the Medical Outcomes Study Short Form 36-item Health Survey (SF-36 D) [35].,• General health status measured studies Medical Outcomes Study Short Form 36-item Health Survey (SF-36 D) [35].,G0000000|C0205246|C0018684|C0449438|C0444706|C0947630|C0199168|C1274040|C0557651|C1282927|C0348078|C0450371|C0018684|C0038951|C0037712|C0073187|C0450371
"The side effects and complications, such as blood vessel puncture, intravascular injection, overdose, dyspnea, Horner's syndrome, and pneumothorax, were noted.","The effects complications, blood vessel puncture, intravascular injection, overdose, dyspnea, Horner's syndrome, pneumothorax, noted.",G0000000|C1280500|C0009566|C0005767|C0005847|C0033119|C0442123|C0021485|C0029944|C0013404|G0000000|C0039082|C0032326|C1316572
The primary outcome is the proportion of individuals with tobacco abstinence at 6 months after the end of the therapy.,The primary outcome proportion individuals tobacco abstinence 6 months therapy.,G0000000|C0205225|C1274040|C1709707|C0027361|C0040329|C3843422|G0000000|C0439231|C0039798
"Clinical assessment was performed every day, and the axillary temperature was recorded and blood smears were examined on admission and every 12 hr until parasite and fever clearance, and then at day 3, 7, 14, 21 and 28, respectively.","Clinical assessment performed day, axillary temperature recorded blood smears examined admission 12 hr parasite fever clearance, day 3, 7, 14, 21 28, respectively.",C0205210|C1261322|C0884358|C0332173|C0004454|C0005903|C0034869|C0005767|C0444186|C0332128|C0184666|C0450371|G0000000|C0030498|C0015967|C0449297|C0332173|G0000000|G0000000|C0450371|C0450371|C0450371|G0000000
"However, no differences in clinical efficacy were seen after 12 months of supplementation.","However, differences clinical efficacy 12 months supplementation.",G0000000|C1705241|C0205210|C1280519|C0450371|C0439231|C0242297
"Consistent with our expectations, intervention-induced increases in parental monitoring predicted reductions in conduct problems, but not increases in positive self-concept.","Consistent expectations, intervention-induced increases parental monitoring predicted reductions conduct problems, increases positive self-concept.",C0332290|C0679138|C0886296|C0205217|C0030551|C0150369|C0681842|C0301630|C0004927|C1546466|C0205217|C0439178|C0036594
The HPV vaccine is offered alongside other vaccines in the national school vaccination program (e.g.,The HPV vaccine offered alongside vaccines national school vaccination program (e.g.,G0000000|C0021344|C0042210|C1444648|G0000000|C0042210|C3245503|C0036375|C0042196|C1709697|G0000000
All 10 patients who received budesonide had a reduction in stool frequency and/or stool weight of more than 50% whereas only two patients on placebo had a similar response (p<0.001).,All 10 patients received budesonide reduction stool frequency and/or stool weight 50% patients placebo response (p<0.001).,G0000000|C0450371|C0030705|C1514756|C0054201|C0301630|C0015733|C0376249|G0000000|C0015733|C0005910|C0450371|C0030705|C0032042|C0871261|C0369773
"Time to first moderate or severe COPD exacerbation was evaluated using a Cox Proportional Hazards model adjusted for age, sex and COPD severity at screening.","Time moderate severe COPD exacerbation evaluated Cox Proportional Hazards model adjusted age, sex COPD severity screening.",C0040223|C0205081|C0205082|C0024117|G0000000|C0220825|G0000000|C0205351|C0598697|C3161035|C0456081|C0001779|C0009253|C0024117|C0439793|C0220908
The primary outcome was the cognitive composite score.,The primary outcome cognitive composite score.,G0000000|C0205225|C1274040|C1516691|C0205199|C0449820
All suspected unexpected serious adverse reactions will also be reported in accordance with the International Conference on Harmonisation (ICH) GCP and the Danish Medicines Agency guidelines.,All suspected unexpected adverse reactions reported International Conference Harmonisation (ICH) GCP Danish Medicines Agency guidelines.,G0000000|C0332147|C4055646|G0000000|C0443286|C0684224|C1512888|C0086047|G0000000|C0019191|G0000000|G0000000|C0013227|C0237463|C0162791
Four pain diaries were administered: Diary 1 collected data for the first 30 days; Diaries 2–4 each collected data for 60 days.,Four pain diaries administered: Diary 1 collected data 30 days; Diaries 2–4 collected data 60 days.,C0205450|C0030193|C0376660|C1521801|C0376660|G0000000|C1516695|C1511726|C0450371|C0439228|C0376660|G0000000|C1516695|C1511726|C0450371|C0439228
The primary outcome was the mean group change in total serum 25OHD from baseline (Δ25OHD) to 3 months.,The primary outcome change total serum 25OHD baseline (Δ25OHD) 3 months.,G0000000|C0205225|C1274040|C0392747|C0439175|C0229671|G0000000|C0168634|G0000000|G0000000|C0439231
Primary outcomes were seizures and adverse events (AEs).,Primary outcomes seizures adverse events (AEs).,C0205225|C1274040|C0036572|G0000000|C0441471|C1412268
CES-D = Center for Epidemiological Studies Depression Scale; MCS = mental health component scores; PCS = physical health component scores.,CES-D = Center Epidemiological Studies Depression Scale; MCS = mental health component scores; PCS = physical health component scores.,C2699160|G0000000|C0205099|C0014507|C0947630|C0011570|C0175659|G0000000|G0000000|C0229992|C0018684|C0449432|C0449820|C1864389|G0000000|C0031809|C0018684|C0449432|C0449820
"Both the groups were monitored for Haemoglobin estimation, compliance and adverse drug reactions, if any.","Both monitored Haemoglobin estimation, compliance adverse drug reactions, any.",G0000000|C0030695|C0019046|C0680844|C0009563|G0000000|C0013227|C0443286|G0000000
"Nebulised budesonide was also associated with a 33% reduction in the length of stay (95% CI 2% to 63%) when the confounding variables of age, initial croup score, and coryzal symptoms were taken into consideration.","Nebulised budesonide 33% reduction length stay (95% CI 2% 63%) confounding variables age, initial croup score, coryzal symptoms consideration.",G0000000|C0054201|C0450371|C0301630|C1444754|G0000000|C0450371|C0008107|G0000000|C0450371|G0000000|C0439828|C0001779|C0205265|C0010380|C0449820|C0009443|C0683368|C0518609
"[37] Others have shown that the use of Vitamin D3 supplements significantly reduced HOMA-IR index, serum insulin, and glucose concentrations in elderly people with impaired fasting glucose.","[37] Others Vitamin D3 supplements reduced HOMA-IR index, serum insulin, glucose concentrations elderly people impaired fasting glucose.",C0450371|C1955473|C0042890|C3538936|C0242295|C0392756|C0022065|C0918012|C0229671|C0021641|C0017725|C0086045|C0001792|C0027361|C0221099|C0015663|C0017725
"The revised curriculum also held down current (past month) and regular (weekly) smoking, producing 23% reductions in both measures of use (P < .01).","The revised curriculum held current (past month) regular (weekly) smoking, producing 23% reductions measures (P < .01).",G0000000|C1527075|C0010478|C0675390|C0521116|C1444637|C0332177|C0205272|C0332174|C0037369|G0000000|C0450371|C0301630|C0079809|C0369773|G0000000|C0450371
"The secondary aims of the study were to evaluate the effect of the intervention on body composition, physical fitness, and concentrations of serum biomarkers linked to cancer risk and prognosis.","The secondary aims study evaluate intervention body composition, physical fitness, concentrations serum biomarkers linked cancer risk prognosis.",G0000000|C0027627|C1947946|C0557651|C0220825|C0886296|C0242821|C0486616|C0031809|C1456706|C0086045|C0229671|C0005516|C1517892|C0006826|C0035647|C0033325
Proportion of households with a mounted insecticide-treated bed net (ITN).,Proportion households mounted insecticide-treated bed net (ITN).,C1709707|C0020052|C0449878|C0021576|C0004916|C1456447|G0000000
"The correlation among the FLACC scale, heart rate, and skin conductance was evaluated using the linear regression model, with a value of p ≤ 0.05 considered as statistically significant.","The correlation FLACC scale, heart rate, skin conductance evaluated linear regression model, ≤ 0.05 considered statistically significant.",G0000000|C1707520|C4068796|C0175659|C0018787|C0871208|C0444099|G0000000|C0220825|C0205132|C0684320|C3161035|G0000000|C0450371|C0750591|C0038215|C0237881
"Possible clinically relevant reductions in exacerbation rate (rate ratio 0.67) and FEV1 decline (39 mL/year) occurred in responders, but did not reach statistical significance.","Possible clinically relevant reductions exacerbation rate (rate ratio 0.67) FEV1 decline (39 mL/year) occurred responders, reach statistical significance.",C0332149|G0000000|C2347946|C0301630|G0000000|C0871208|C0871208|C0456603|C0450371|G0000000|G0000000|C0450371|C0439526|C1709305|G0000000|C2584321|C0038215|C0237881
The primary endpoint was OS; secondary endpoints included progression-free survival (PFS) and safety.,The primary endpoint OS; secondary endpoints included progression-free survival (PFS) safety.,G0000000|C0205225|C2349179|C0229090|C0027627|C2349179|C0332257|C0242656|C0038952|C0242792|C0036043
"Therefore, results are reported using invasive disease-free survival (IDFS, in the following only DFS) as defined according to the Standardized Definitions for Efficacy End Points (STEEP) criteria (Hudis et al, 2007) as efficacy end point (with DFS including all invasive ipsilateral, regional, contralateral and distant disease recurrences, second primary tumours, and death from any cause as events, while all non-invasive in situ cancer events were excluded).","Therefore, reported invasive disease-free survival (IDFS, DFS) defined Standardized Definitions Efficacy End Points (STEEP) criteria (Hudis al, 2007) efficacy (with DFS including invasive ipsilateral, regional, contralateral distant disease recurrences, primary tumours, death events, non-invasive situ cancer events excluded).",G0000000|C0684224|C0205281|C0012634|C0038952|G0000000|G0000000|C1704788|G0000000|C1550452|C1280519|C0444930|C1552961|G0000000|C0243161|G0000000|C0202311|G0000000|C1280519|G0000000|G0000000|C0332257|C0205281|C0441989|C0205147|C0441988|C0443203|C0012634|C0034897|C0205225|C0027651|C0011065|C0441471|C0205303|G0000000|C0006826|C0441471|C1554077
"Adequate prior information to estimate the need for additional health care in the prednisolone group and, therefore, to calculate statistical power, was not available.","Adequate prior estimate additional health care prednisolone and, therefore, calculate statistical power, available.",C0205410|C0332152|C0750572|C1524062|C0018684|C1947933|C0032950|G0000000|G0000000|C1441506|C0038215|C0032863|C0470187
"Unfortunately, there are few resources for those patients who have chronic pain and a history of prescription opioid misuse.","Unfortunately, resources patients chronic pain history prescription opioid misuse.",G0000000|C0035201|C0030705|C0205191|C0030193|C0019664|C0033080|C0242402|C0549649
"Measures consisted of a demographic data sheet, as well as measures assessing pain intensity and pain interference (Pain Intensity and Pain Interference Subscales of the BPI adapted for persons with disability20 and the Pain subscale of the Medical Outcomes Study 36-item Short Form Health Survey (SF-36)21), pain quality (Paroxysmal, Deep, and Surface Pain subscales of the Pain Quality Assessment Scale (PQAS)22), pain beliefs and pain coping (Maladaptive and Adaptive Coping subscales of the Two-Item Measures of Pain Beliefs and Coping Strategies23,24), health-related disability (Physical and Mental Component Summaries (PCS & MCS, respectively) of the Medical Outcomes Study 12-item Short Form Health Survey (SF-12)25), and distress (10-item short form of the Center for Epidemiologic Studies-Depression scale (CES-D-10),26 10-item Perceived Stress Scale (PSS-10),27 and the Short-Form State-Trait Anxiety Inventory (SF-STAI-6)28).","Measures consisted demographic data sheet, measures assessing pain intensity pain interference (Pain Intensity Pain Interference Subscales BPI adapted persons disability20 Pain subscale Medical Outcomes Study 36-item Short Form Health Survey (SF-36)21), pain quality (Paroxysmal, Deep, Surface Pain subscales Pain Quality Assessment Scale (PQAS)22), pain beliefs pain coping (Maladaptive Adaptive Coping subscales Two-Item Measures Pain Beliefs Coping Strategies23,24), health-related disability (Physical Mental Component Summaries (PCS & MCS, respectively) Medical Outcomes Study 12-item Short Form Health Survey (SF-12)25), distress (10-item short form Center Epidemiologic Studies-Depression scale (CES-D-10),26 10-item Perceived Stress Scale (PSS-10),27 Short-Form State-Trait Anxiety Inventory (SF-STAI-6)28).",C0079809|C0332529|C0011298|C1511726|C2349187|C0079809|C1516048|C0030193|C0522510|C0030193|C0521102|C0030193|C0522510|C0030193|C0521102|G0000000|C1443145|C2937289|C0027361|G0000000|C0030193|G0000000|C0199168|C1274040|C0557651|C0450371|C1282927|C0348078|C0018684|C0038951|C0037712|C0030193|C0332306|C0205311|C0205125|C0205148|C0030193|G0000000|C0030193|C0332306|C1261322|C0175659|C0450371|C0030193|C0004951|C0030193|C0009967|C0233532|C0231193|C0009967|G0000000|C0205448|C0079809|C0030193|C0004951|C0009967|C0450371|C0018684|C0231170|C0031809|C0229992|C0449432|C1552616|C1864389|G0000000|G0000000|G0000000|C0199168|C1274040|C0557651|C0450371|C1282927|C0348078|C0018684|C0038951|C0037712|C0231303|C0450371|C1282927|C0348078|C0205099|C0014507|C0947630|C0175659|C2699160|C0450371|C0030971|C0038435|C0175659|C0450371|C2964478|C1301808|C0003467|C0021941|C0037712
"We found, however, no difference between the intervention and control villages in self-reported handwashing behaviour, spot-check hygiene conditions, or the prevalence of child diarrhoea, clinical acute lower respiratory infections or child growth.","We found, however, difference intervention control villages self-reported handwashing behaviour, spot-check hygiene conditions, prevalence child diarrhoea, clinical acute lower respiratory infections child growth.",G0000000|C0150312|G0000000|C1705241|C0886296|C0243148|C0562518|C0681906|C0018581|C0004927|C0329155|C0020405|C0012634|C0033105|C0008059|C0011991|C0205210|C0205178|C0441994|C0521346|C3714514|C0008059|C0018270
"Changes in serum levels of free IGF-1, pain rating on a 0- to 100-mm scale, pain threshold, and 6-minute walk test (6MWT) were examined.","Changes serum levels free IGF-1, pain rating 0- 100-mm scale, pain threshold, 6-minute walk test (6MWT) examined.",C0392747|C0229671|C0441889|C0332296|C0037657|C0030193|C0871208|G0000000|C1442061|C0175659|C0030193|C0449864|C0439232|C0080331|C0022885|G0000000|C0332128
"MAIN OUTCOME MEASURES: Patient completed Barthel index, Frenchay activities index, general health questionnaire, hospital anxiety and depression scale, social adjustment scale, mental adjustment to stroke scale, and patient satisfaction questionnaire; carer completed Frenchay activities index, general health questionnaire, hospital anxiety and depression scale, social adjustment scale, caregiving bassles scale, and carer satisfaction questionnaire.","MAIN OUTCOME MEASURES: Patient completed Barthel index, Frenchay activities index, health questionnaire, hospital anxiety depression scale, social adjustment scale, mental adjustment stroke scale, patient satisfaction questionnaire; carer completed Frenchay activities index, health questionnaire, hospital anxiety depression scale, social adjustment scale, caregiving bassles scale, carer satisfaction questionnaire.",C0205225|C1274040|C0079809|C0030705|C0205197|G0000000|C0918012|G0000000|C0441655|C0918012|C0018684|C0034394|C0019994|C0003467|C0011570|C0175659|C0728831|C0376209|C0175659|C0229992|C0376209|C0038454|C0175659|C0030705|C0242428|C0034394|C0085537|C0205197|G0000000|C0441655|C0918012|C0018684|C0034394|C0019994|C0003467|C0011570|C0175659|C0728831|C0376209|C0175659|G0000000|G0000000|C0175659|C0085537|C0242428|C0034394
Our outcome of smoking more than one cigarette a week could be insensitive to changes between the arms.,Our outcome smoking cigarette week insensitive arms.,G0000000|C1274040|C0037369|C0677453|C0332174|C0237677|C0206655
"In the TENS group, a marked reduction in NRS was observed 1 week after treatment, but the NRS steadily increased to nearly baseline levels 3 months after treatment (Figure 1).","In TENS group, marked reduction NRS observed 1 week treatment, NRS steadily increased baseline levels 3 months treatment (Figure 1).",G0000000|C0014518|C0441833|C0522501|C0301630|C2240043|C1441672|G0000000|C0332174|C0039798|C2240043|G0000000|C0205217|C0168634|C0441889|G0000000|C0439231|C0039798|G0000000|G0000000
"Secondary outcomes included the proportion of patients with a mild neurologic deficit or none (NIHSS score, ≤6) and the following safety measures, assessed at day 7 after thrombolysis: fatal and nonfatal symptomatic intracranial hemorrhage, fatal and nonfatal symptomatic edema from an original brain infarction, fatal and nonfatal recurrent ischemic stroke, death from any cause, neurologic deterioration (defined as a increase of ≥4 points in the NIHSS score), and fatal and nonfatal extracerebral events.","Secondary outcomes included proportion patients mild neurologic deficit (NIHSS score, ≤6) safety measures, assessed day 7 thrombolysis: fatal nonfatal symptomatic intracranial hemorrhage, fatal nonfatal symptomatic edema original brain infarction, fatal nonfatal recurrent ischemic stroke, death cause, neurologic deterioration (defined increase ≥4 NIHSS score), fatal nonfatal extracerebral events.",C0027627|C1274040|C0332257|C1709707|C0030705|C2945599|C0205494|C0162429|C3476804|C0449820|G0000000|C0036043|C0079809|C1516048|C0332173|G0000000|C0520997|C1302234|G0000000|C0231220|C0524466|C0019080|C1302234|G0000000|C0231220|C0013604|C0205313|C0006104|C0021308|C1302234|G0000000|C2945760|C0475224|C0038454|C0011065|C0015127|C0205494|C0868945|C1704788|C0442805|G0000000|C3476804|C0449820|C1302234|G0000000|G0000000|C0441471
The primary outcome is birth length.,The primary outcome birth length.,G0000000|C0205225|C1274040|C0005615|C1444754
"Secondary outcomes included differences in self-reported and biologically-confirmed cessation at interim visits, number of visits attended and quit attempts, smoking rates at interim visits, and changes in Fagerstrom score and self-efficacy.","Secondary outcomes included differences self-reported biologically-confirmed cessation interim visits, visits attended quit attempts, smoking rates interim visits, Fagerstrom score self-efficacy.",C0027627|C1274040|C0332257|C1705241|C0681906|C0205460|C1880019|C2827738|C0545082|C0545082|C1456498|C0748223|C1516084|C0037369|C0871208|C2827738|C0545082|G0000000|C0449820|C0600564
Use of epidural analgesia for labour pain relief.,Use epidural analgesia labour pain relief.,C0042153|C0228134|C0002766|C0022864|C0030193|C0564405
"Wolf MFT: Wolf Motor Function Test, NHPT: Nine Hole Peg Test, MAL: Motor Activity Log, NEADL: Nottingham Extended Activities of Daily Living.","Wolf MFT: Wolf Motor Function Test, NHPT: Nine Hole Peg Test, MAL: Motor Activity Log, NEADL: Nottingham Extended Activities Daily Living.",C0325001|C1822742|C0325001|C1513492|C0031843|C0022885|C1832615|C0205455|C0544726|G0000000|C0022885|C3540595|C1513492|C0205177|C1708728|G0000000|G0000000|C0231448|C0441655|C0332173|C0376558
"Second Hand Smoke Exposure (SHSe) Second Hand Smoke Exposure (SHSe) was objectively measured with two passive nicotine monitors (dosimetry) placed for one week during each of the two measurement periods (baseline and after call 5), one in the room in which the child spent the most time and one worn by the child.","Second Hand Smoke Exposure (SHSe) Second Hand Smoke Exposure (SHSe) objectively measured passive nicotine monitors (dosimetry) week measurement periods (baseline call 5), child spent time worn child.",C0205436|C0018563|C0037366|C0274281|G0000000|C0205436|C0018563|C0037366|C0274281|G0000000|G0000000|C0444706|C3686820|C0028040|C0181904|C0034603|C0332174|C0242485|C0439531|C0168634|C0679006|G0000000|C0008059|C0680968|C0040223|G0000000|C0008059
"urban planning, architecture, health, police and transport) to help facilitate policy change It is predicted that a community-led intervention (working with the community and multiple agencies collectively to achieve beneficial change in a given factor) will increase the proportion of the target population who are physically active (taking part on at least 3 days/week in moderate intensity sport and active leisure) by 10% more (after a two year of intervention).","urban planning, architecture, health, police transport) facilitate policy change It predicted community-led intervention (working community multiple agencies collectively achieve beneficial change factor) increase proportion target population physically active (taking 3 days/week moderate intensity sport active leisure) 10% (after intervention).",C0442529|C0032074|C0003737|C0018684|C0085098|C0005528|G0000000|C0242456|C0392747|G0000000|C0681842|C0009462|C0886296|C0043227|C0009462|C0439064|C0237463|G0000000|G0000000|G0000000|C0392747|C1521761|C0442805|C1709707|C1521840|C0032659|G0000000|C0205177|C1515187|G0000000|C0677547|C0205081|C0522510|C0038039|C0205177|C0086542|C0450371|G0000000|C0886296
"In particular, we evaluated the expression of Treg-related markers in lesional skin and the proliferative capacity of T cells together with the percentage of Tregs in blood.","In particular, evaluated expression Treg-related markers lesional skin proliferative capacity T cells percentage Tregs blood.",G0000000|G0000000|C0220825|C0185117|C1267822|C0005516|C0221198|C0444099|C0334094|C1516240|C2603360|C0007634|C0439165|G0000000|C0005767
"Secondary efficacy parameters included time to next paracentesis, ascites signs and symptoms and OS.","Secondary efficacy parameters included time paracentesis, ascites signs symptoms OS.",C0027627|C1280519|C0449381|C0332257|C0040223|C0034115|C0003962|C0220912|C0683368|C0229090
"Response rates, the primary end point, were 47% with wTCF and 26% with wTX.","Response rates, primary point, 47% wTCF 26% wTX.",C0871261|C0871208|C0205225|C1552961|C0450371|G0000000|C0450371|C1825263
Caregivers were interviewed at each visit about the acceptability of the RUTF.,Caregivers interviewed visit acceptability RUTF.,C0085537|C0021822|C0545082|C0814633|G0000000
"Hospital mortality rates, according to time of tracheostomy, were described for each retrospective study and a meta-analysis was performed.","Hospital mortality rates, time tracheostomy, retrospective study meta-analysis performed.",C0019994|C0026565|C0871208|C0040223|C0040590|C0035363|C0557651|C0282458|C0884358
"Based on subject diary records, the superiority of ketotifen in relieving signs and symptoms including itching, redness, and tearing was observed from the beginning of treatment and was most marked during the first 4 days (Fig 33).).","Based subject diary records, superiority ketotifen relieving signs symptoms including itching, redness, tearing observed treatment marked 4 days (Fig 33).).",C1527178|C0681850|C0376660|C0034869|C0680218|C0022642|C0332303|C0220912|C0683368|C0332257|C0033774|C0041834|C0039409|C1441672|C0039798|C0522501|G0000000|C0439228|C0349966|C0450371
"Outcome measures included the 6-min walk test, the 10 m walk test, Functional Independence Measure, SF-36 physical functioning and the Tinetti scale.","Outcome measures included 6-min walk test, 10 m walk test, Functional Independence Measure, SF-36 physical functioning Tinetti scale.",C1274040|C0079809|C0332257|C0702093|C0080331|C0022885|G0000000|C0080331|C0022885|C0205245|C0085862|C0079809|C0037712|C0031809|C0205245|G0000000|C0175659
Children will receive interventions for 3 months based on WHO recommendations and then be followed up for 9 months post intervention.,Children receive interventions 3 months based WHO recommendations 9 months post intervention.,C0008059|C1514756|C0886296|G0000000|C0439231|C1527178|G0000000|C0034866|G0000000|C0439231|C0687676|C0886296
Up to three children per household were randomly selected for testing.,Up children household randomly selected testing.,G0000000|C0008059|C0020052|G0000000|C1707391|C0039593
"In contrast to the plasma DHA results, blood and hair mercury concentrations were correlated (r= 0.35 to 0.52) with fish intake and estimated mercury intake from fish regardless of the method of dietary assessment (Table 3).","In contrast plasma DHA results, blood hair mercury concentrations correlated (r= 0.35 0.52) fish intake estimated mercury intake fish method dietary assessment (Table 3).",G0000000|C0009924|C0032105|C0142831|C1274040|C0005767|C0018494|C0025424|C0086045|C1707520|C0205090|C0450371|C0450371|C0016163|C1512806|C0750572|C0025424|C1512806|C0016163|C0025663|C0012155|C1261322|C0039224|G0000000
"Outcome measures included Berg Balance Scale (BBS), the Functional Reaching Test (FRT), and the Timed Up and Go (TUG) test (for dynamic balance ability), postural sway (for static balance ability), and 10 meter walking velocity (10 mWV) for gait ability.","Outcome measures included Berg Balance Scale (BBS), Functional Reaching Test (FRT), Timed Up Go (TUG) test (for dynamic balance ability), postural sway (for static balance ability), 10 meter walking velocity (10 mWV) gait ability.",C1274040|C0079809|C0332257|G0000000|C0014653|C0175659|G0000000|C0205245|C2584321|C0022885|C1705150|C0392761|G0000000|C1822658|C1319201|C0022885|G0000000|C0729333|C0014653|C0085732|C0205278|G0000000|G0000000|C0441463|C0014653|C0085732|C0450371|C0475209|C0080331|C0439830|C0450371|G0000000|C0016928|C0085732
Efficacy assessments included the mean percent change from baseline in Numeric Pain Rating Scale (NPRS) scores to Weeks 2–12.,Efficacy assessments included percent change baseline Numeric Pain Rating Scale (NPRS) scores Weeks 2–12.,C1280519|C1261322|C0332257|C0439165|C0392747|C0168634|C0237753|C0030193|C0871208|C0175659|C1417814|C0449820|C0439230|G0000000
"During the first three days of menstruation, the pain severity of each sample was measured three times a day on a 10 cm visual analog scale (VAS) at the time the sample felt the most pain during the hours of 8–13, 13–18, 18–24 o'clock (every 8 hr a day) and was classified as “mild” (score of 1–2), “moderate” (3–7), or “severe” (8–10, 39).","During days menstruation, pain severity sample measured times day 10 cm visual analog scale (VAS) time sample pain hours 8–13, 13–18, 18–24 o'clock (every 8 hr day) classified “mild” (score 1–2), “moderate” (3–7), “severe” (8–10, 39).",G0000000|C0439228|C0025344|C0030193|C0439793|C0370003|C0444706|C0040223|C0332173|C0450371|G0000000|C0234621|C0243071|C0175659|C0042815|C0040223|C0370003|C0030193|C0439227|G0000000|G0000000|G0000000|C0483204|G0000000|G0000000|G0000000|C0332173|C0008902|G0000000|C0449820|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371
"The sustained smoking cessation rate achieved by following AHCPR guidelines was 11% at 9 months, which compares favorably with historical results.","The sustained smoking cessation rate achieved AHCPR guidelines 11% 9 months, compares favorably historical results.",G0000000|C0443318|C0037369|C1880019|C0871208|G0000000|C0080268|C0162791|C0450371|G0000000|C0439231|C1707455|G0000000|C1552658|C1274040
"For measuring QOL, the Iranian version of the Short Form Health Survey (SF-36) was applied.","For measuring QOL, Iranian version Short Form Health Survey (SF-36) applied.",G0000000|C0444706|C0518214|C1553355|C0333052|C1282927|C0348078|C0018684|C0038951|C0037712|C4048755
Lung function.,Lung function.,C0024109|C0031843
"Results: TCEMS improved both the quadriceps strength (by 39.0 (20.4)% v 9.0 (8.1)%, p=0.046) and hamstring muscle strength (by 33.9 (13.0)% v 2.9 (4.7)%, p=0.038) in the treated (n=9) and sham treated (n=9) groups, respectively.","Results: TCEMS improved quadriceps strength (by 39.0 (20.4)% 9.0 (8.1)%, p=0.046) hamstring muscle strength (by 33.9 (13.0)% 2.9 (4.7)%, p=0.038) treated (n=9) sham treated (n=9) groups, respectively.",C1274040|G0000000|C0184511|C0224440|C0237897|G0000000|C0450371|C0450371|G0000000|G0000000|C0369773|C0584895|C0026845|C0237897|G0000000|C0450371|C0450371|G0000000|G0000000|C0369773|C1522326|C0369718|C0068899|C1522326|C0369718|C0441833|G0000000
The main outcome will be the percentage of wounds healed after 8 weeks.,The main outcome percentage wounds healed 8 weeks.,G0000000|C0205225|C1274040|C0439165|C0021501|C0205249|G0000000|C0439230
"Additional secondary objectives include the effect of tiotropium treatment on other lung function variables, patient and physician global evaluations, worker productivity as assessed by the Work Productivity and Activity Impairment questionnaire [19], and the use of rescue medication.","Additional secondary objectives tiotropium treatment lung function variables, patient physician global evaluations, worker productivity assessed Work Productivity Activity Impairment questionnaire [19], rescue medication.",C1524062|C0027627|C0018017|C0213771|C0039798|C0024109|C0031843|C0439828|C0030705|C0031831|C0205246|C0220825|C1306056|C0033269|C1516048|C0043227|C0033269|C0205177|C0221099|C0034394|C0450371|G0000000|C0013227
"Retrospective patient preference for HaH care was 96.3% in the domiciliary arm and 59.3% in the conventional arm; carer preference figures were 85.7% and 42.9%, respectively.","Retrospective patient preference HaH care 96.3% domiciliary arm 59.3% conventional arm; carer preference figures 85.7% 42.9%, respectively.",C0035363|C0030705|C0558295|G0000000|C1947933|C0450371|C0338047|C0446516|C0450371|C0439858|C0446516|C0085537|C0558295|G0000000|C0450371|C0450371|G0000000
"Secondary outcomes were time to first COPD exacerbation, reported symptoms, peak expiratory flow rate and reliever inhaler use, and lung function and health related quality of life.","Secondary outcomes time COPD exacerbation, reported symptoms, peak expiratory flow rate reliever inhaler use, lung function health quality life.",C0027627|C1274040|C0040223|C0024117|G0000000|C0684224|C0683368|C0444505|C0231800|C0806140|C0871208|G0000000|C0021461|C0042153|C0024109|C0031843|C0018684|C0332306|C0376558
"The main outcome measures were lipopolysaccharide-stimulated production of proinflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β), and scores on the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the vitality scale from the Medical Outcomes Study 36-item Short Form (SF-36), and the Center for Epidemiological Studies-Depression (CES-D) scale.","The main outcome measures lipopolysaccharide-stimulated production proinflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), scores Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), vitality scale Medical Outcomes Study 36-item Short Form (SF-36), Center Epidemiological Studies-Depression (CES-D) scale.",G0000000|C0205225|C1274040|C0079809|C0023810|C0033268|G0000000|C0079189|C0021764|C0020898|C0027651|C0027540|C1521761|C0439095|G0000000|G0000000|G0000000|C0449820|C2347299|C0015672|C1457887|C0021941|C0348078|C0037712|C0424589|C0175659|C0199168|C1274040|C0557651|C0450371|C1282927|C0348078|C0037712|C0205099|C0014507|C0947630|C2699160|C0175659
"Children are followed for 2 years to ascertain recurrent febrile or symptomatic UTI, renal scarring, prophylaxis failure, antimicrobial resistance, medication adherence, and quality of life measures.","Children 2 ascertain recurrent febrile symptomatic UTI, renal scarring, prophylaxis failure, antimicrobial resistance, medication adherence, quality life measures.",C0008059|G0000000|G0000000|C2945760|C0015967|C0231220|C0042029|C0022646|C0008767|C0033107|C0231174|C1136254|C0237834|C0013227|C1510802|C0332306|C0376558|C0079809
"Overall survival rates of the entire group at 5 and 10 years were 72% and 69%, respectively.","Overall survival rates entire 5 10 72% 69%, respectively.",C0282416|C0038952|C0871208|C0439751|G0000000|C0450371|C0450371|C0450371|G0000000
"In this study, reductions in the swing phase symmetry profile, the stance phase symmetry profile, and velocity were found in the TT group which were significant when compared with the TRT group (p<0.05).","In study, reductions swing phase symmetry profile, stance phase symmetry profile, velocity TT compared TRT (p<0.05).",G0000000|C0557651|C0301630|G0000000|C0205390|C0332516|C1979963|G0000000|C0205390|C0332516|C1979963|C0439830|C1452561|C1707455|G0000000|C0369773
"Drug efficacy was assessed by date of treatment allocation, time to first seizure after randomisation, time to withdrawal from treatment because of adverse effects, and date of last follow-up.","Drug efficacy assessed treatment allocation, time seizure randomisation, time withdrawal treatment adverse effects, follow-up.",C0013227|C1280519|C1516048|C0039798|C1706778|C0040223|C0036572|C0034656|C0040223|C2349954|C0039798|G0000000|C1280500|C0589120
"In Early Food for Future Health, we seek to provide parents with anticipatory guidance on when, what and how on three levels: Promote accurate knowledge and skills about child nutrition and eating-development (when, what) Convey knowledge on how to promote an early healthy diet and early beneficial eating habits On an overarching level, emphasize a general parenting style that is sensitive to the child’s cues and needs  To promote knowledge about infant nutrition and facilitate sensitive feeding behavior, Early Food for Future Health draws upon elements from attachment-theory, social cognitive theory and the framework of anticipatory guidance.","In Early Food Future Health, seek provide parents anticipatory guidance when, levels: Promote accurate knowledge skills child nutrition eating-development (when, what) Convey knowledge promote healthy diet beneficial eating habits On overarching level, emphasize parenting style sensitive child’s cues To promote knowledge infant nutrition facilitate sensitive feeding behavior, Early Food Future Health draws elements attachment-theory, social cognitive theory framework anticipatory guidance.",G0000000|C1279919|C0016452|C0016884|C0018684|G0000000|C1999230|C0030551|G0000000|C0150600|G0000000|C0441889|C0033414|C0443131|C0376554|C0678856|C0008059|C0028707|C0013470|G0000000|G0000000|G0000000|C0376554|C0033414|C3898900|C0012155|G0000000|C0013470|C0018464|G0000000|G0000000|C0441889|G0000000|C0085092|C0489654|C0020517|G0000000|C0010439|C0040363|C0033414|C0376554|C0021270|C0028707|G0000000|C0020517|C0204695|C0004927|C1279919|C0016452|C0016884|C0018684|C0013113|C0013879|C0185023|C0728831|C1516691|C0871935|G0000000|G0000000|C0150600
"For patients without complications, the median length of hospital stay was 8 days (range 5–11); for those with a complication, it was 11 days (range 3–34;P < .001).","For patients complications, median length hospital stay 8 days (range 5–11); complication, 11 days (range 3–34;P < .001).",G0000000|C0030705|C0009566|C0549183|C1444754|C0019994|G0000000|G0000000|C0439228|C1514721|G0000000|C0009566|C0450371|C0439228|C1514721|G0000000|G0000000|C1442061
"Secondary outcomes included: IDA and serum ferritin concentrations at the end of 8 weeks; and adherence, ease of use and side effects (diarrhoea, staining of the teeth and darker stools) during the 8‐week study period.","Secondary outcomes included: IDA serum ferritin concentrations 8 weeks; adherence, ease effects (diarrhoea, staining teeth darker stools) 8‐week study period.",C0027627|C1274040|C0332257|C0020789|C0229671|C0015879|C0086045|G0000000|C1510802|C1331418|C1280500|C0011991|C0487602|C0040426|C0332582|C0015733|G0000000|C0557651|C0439531
"Secondary outcomes included reported adverse effects experienced during therapy with focus on nausea (only sometimes and trivial versus often and annoying), pain (only sometimes and trivial versus often and annoying), vaginal bleeding (more or <10 days per month).","Secondary outcomes included reported adverse effects experienced therapy focus nausea (only trivial versus annoying), pain (only trivial versus annoying), vaginal bleeding (more <10 days month).",C0027627|C1274040|C0332257|C0684224|G0000000|C1280500|C0237607|C0039798|C0205234|C0027497|C0205171|G0000000|G0000000|G0000000|C0030193|C0205171|G0000000|G0000000|G0000000|C0042232|C0019080|C0205172|C0450371|C0439228|C0332177
Applications for accesss to the data can be made via the website https://www.iddo.org/data-sharing/accessing-data/accessing-ebola-data Healthcare and other front-line workers are at particular risk of infection with Ebola virus (EBOV).,Applications accesss data website https://www.iddo.org/data-sharing/accessing-data/accessing-ebola-data Healthcare front-line workers risk infection Ebola virus (EBOV).,C0185125|G0000000|C1511726|C2349146|C1555015|C0086388|C0205094|C0024752|C0035647|C0009450|C0282687|C0042776|C0949892
There are several possible explanations for why rates of suicide by jumping did not decrease in Toronto after the barrier was erected.,There explanations rates suicide jumping decrease Toronto barrier erected.,G0000000|C0681841|C0871208|C0038661|C0221189|C0392756|G0000000|C1706912|C0522014
"Secondary measures were the immediate treatment responses: parasite clearance, fever clearance, incidence of adverse events, and degree of anaemia.","Secondary measures treatment responses: parasite clearance, fever clearance, incidence adverse events, degree anaemia.",C0027627|C0079809|C0039798|C0871261|C0030498|C0449297|C0015967|C0449297|C0021149|G0000000|C0441471|C0441889|C0002871
A satisfaction survey was administered and a semistructured exit interview was conducted at the final visit.,A satisfaction survey administered semistructured exit interview conducted final visit.,G0000000|C0242428|C0038951|C1521801|G0000000|C0337094|C0021822|C0004927|C0205088|C0545082
"Study outcome measures are described in the companion paper.20 Briefly, the primary outcome of the study is endurance time during an endurance shuttle walk test to symptom limitation after 8 weeks of therapy.","Study outcome measures companion paper.20 Briefly, primary outcome study endurance time endurance shuttle walk test symptom limitation 8 weeks therapy.",C0557651|C1274040|C0079809|C0031268|C0030351|G0000000|C0205225|C1274040|C0557651|C0518031|C0040223|C0518031|G0000000|C0080331|C0022885|C1457887|C0449295|G0000000|C0039798
(B) FMA score.,(B) FMA score.,G0000000|C2332774|C0449820
The study medication was accompanied with a randomization list.,The study medication accompanied randomization list.,G0000000|C0557651|C0013227|G0000000|C0034656|C0745732
Ocular tolerance was similar for all groups.,Ocular tolerance groups.,C0015392|C0013220|C0441833
Approximately 20 mL urine samples were collected twice a day (a.m. and p.m.) for days 4 to 7 after the oral isotope administration.,Approximately 20 mL urine samples collected day (a.m. p.m.) days 4 7 oral isotope administration.,C0332232|C0450371|C0439526|C0042036|C0370003|C1516695|C0332173|C2346751|C0369773|C0439228|G0000000|G0000000|C0442027|C0022262|C0001554
"Changes in FEV1% predicted at week 24 (intention-to-treat population) Data logarithmically transformed, ANCOVA analysis.","Changes FEV1% predicted week 24 (intention-to-treat population) Data logarithmically transformed, ANCOVA analysis.",C0392747|G0000000|C0681842|C0332174|C0450371|C0162425|C0032659|C1511726|G0000000|C1510411|C0814908|C0002778
"Efficacy, a secondary outcome measure, was evaluated with the Wolf Motor Function Test, Box and Block Test, and Stroke Impact Scale at 4 weeks after intervention.","Efficacy, secondary outcome measure, evaluated Wolf Motor Function Test, Box Block Test, Stroke Impact Scale 4 weeks intervention.",C1280519|C0027627|C1274040|C0079809|C0220825|C0325001|C1513492|C0031843|C0022885|C0179400|C0028778|C0022885|C0038454|C1825598|C0175659|G0000000|C0439230|C0886296
"“How many days did poor physical or mental health keeps you from doing your usual activities, such as self-care, work, or recreation?” (Activity limitation).","“How days poor physical mental health usual activities, self-care, work, recreation?” (Activity limitation).",G0000000|C0439228|C0032854|C0031809|C0229992|C0018684|C3538928|C0441655|C0036592|C0043227|G0000000|C0205177|C0449295
"Infants receiving breast milk with no other liquids or solids with the exception of recommended vitamin D 400 IU supplementation were categorized as exclusively breastfed.24 Infants receiving breast milk and other liquids or solids were categorized as partially breastfed (high, >80%; medium, 20–80%; low <20%) based on relative quantity of breast milk consumed.25  Maternal and infant serum were analyzed for 25-hydroxyvitamin D [25(OH)D], a metabolite of vitamin D that serves as the principle circulating reservoir and indicator of overall vitamin D status, by enzyme immunoassay (Immunodiagnostic Systems Ltd., Gaithersburg, MD).","Infants receiving breast milk liquids solids exception recommended vitamin D 400 IU supplementation categorized exclusively breastfed.24 Infants receiving breast milk liquids solids categorized partially breastfed (high, >80%; medium, 20–80%; low <20%) based relative quantity breast milk consumed.25 Maternal infant serum analyzed 25-hydroxyvitamin D [25(OH)D], metabolite vitamin D serves principle circulating reservoir indicator vitamin D status, enzyme immunoassay (Immunodiagnostic Systems Ltd., Gaithersburg, MD).",C0021270|C1514756|C0006141|C0026131|C0302908|C0205208|C1554961|C0034866|C0042890|C0073187|C1442061|C0049272|C0242297|C0871968|G0000000|C0006147|C0021270|C1514756|C0006141|C0026131|C0302908|C0205208|C0871968|G0000000|C0006147|C0205250|C0450371|C0009458|G0000000|C0205251|C0450371|C1527178|C0080103|C1265611|C0006141|C0026131|C0450371|C2347083|C0021270|C0229671|C0936012|C0450371|C0073187|C0450371|C0870883|C0042890|C0073187|G0000000|G0000000|C0175630|C0442537|C0021212|C0042890|C0073187|C0449438|C0014442|C0020980|C0021052|C0449913|C1136140|G0000000|G0000000
"A stratified analysis of the effect of oseltamivir treatment on outcome after controlling for possible confounding by the presence or absence of neutropenia at hospital admission (as a marker of severity) still found evidence of a beneficial effect of oseltamivir treatment (Mantel-Haenszel summary OR, 0.15; 95% CI, 0.0260–893; P = .034).","A stratified analysis oseltamivir treatment outcome controlling confounding presence absence neutropenia hospital admission (as marker severity) evidence beneficial oseltamivir treatment (Mantel-Haenszel summary OR, 0.15; 95% CI, 0.0260–893; P = .034).",G0000000|C0205363|C0002778|C0874161|C0039798|C1274040|C2239193|G0000000|C0150312|C0332197|C0023530|C0019994|C0184666|G0000000|C0005516|C0439793|C3887511|G0000000|C0874161|C0039798|G0000000|C1552616|G0000000|C0450371|C0450371|C0008107|G0000000|C0369773|G0000000|C1442061
"We also assessed whether the effect of supplements was modified by baseline characteristics, including BMI at entry to this study, haemoglobin (<11, ≥ 11 g dL−1), cluster of differentiation 4 (CD4) count as a marker of immune status with the median as the cut‐off (<775, ≥ 775 cells mm−3) and malaria infection (malaria at baseline vs. no malaria), prematurity (defined as birth before 37 weeks of gestation.","We assessed supplements modified baseline characteristics, including BMI entry study, haemoglobin (<11, ≥ 11 g dL−1), cluster differentiation 4 (CD4) count marker immune status median cut‐off (<775, ≥ 775 cells mm−3) malaria infection (malaria baseline vs. malaria), prematurity (defined birth 37 weeks gestation.",G0000000|C1516048|C0242295|C0392747|C0168634|C1521970|C0332257|G0000000|C1705654|C0557651|C0019046|C0450371|G0000000|G0000000|C1555715|C0007589|G0000000|C0285590|C0750480|C0005516|C0439662|C0449438|C0549183|G0000000|C1442061|G0000000|C0007634|G0000000|C0024530|C0009450|C0024530|C0168634|G0000000|C0024530|C0021294|C1704788|C0005615|G0000000|C0032961
Miscarriage is the most prevalent adverse outcome of pregnancy.,Miscarriage prevalent adverse outcome pregnancy.,C0000786|C0033105|G0000000|C1274040|C0032961
Follow-up had to be >2 years to be considered seizure free.,Follow-up >2 considered seizure free.,C0589120|G0000000|C0750591|C0036572|C0332296
The primary endpoint was overall response rate (ORR).,The primary endpoint response rate (ORR).,G0000000|C0205225|C2349179|C0871261|C0871208|G0000000
Two additional patients in the active arm who did not show confirmed improvement in the first 12 months showed confirmed improvement at 24 months.,Two additional patients active arm confirmed improvement 12 months confirmed improvement 24 months.,C0205448|C1524062|C0030705|C0205177|C0446516|C0521093|C2986411|G0000000|C0521093|C2986411|G0000000
"Assessment of fatigue was done using the cancer fatigue scale, which measured fatigue in physical and functional aspects, affective, and cognitive areas.","Assessment fatigue cancer fatigue scale, measured fatigue physical functional aspects, affective, cognitive areas.",C1261322|C0015672|C0006826|C0015672|C0175659|C0444706|C0015672|C0031809|C0205245|C1547011|G0000000|C1516691|C0205146
The primary efficacy variable of this study was the change from baseline to the entire treatment period in average pre-dose morning PEF.,The primary efficacy variable study change baseline entire treatment period average pre-dose morning PEF.,G0000000|C0205225|C1280519|C0439828|C0557651|C0392747|C0168634|C0439751|C0039798|C0439531|C1510992|C0439565|C0332170|C0030771
"Amount and effects of self-hypnosis and relaxation practice after treatment were assessed via telephone interview by a research assistant blind to treatment condition at 1-, 2-, and 3-months posttreatment by asking participants to indicate, during the past 30 days: (a) the number of days they listened to the audio recording they were given; (b) on those days they listened to the audio recording, the usual number of times they listened; (c) the amount of pain relief they experienced when they listened to the audio recording (on a 0–10 scale, with 0 = No relief and 10 = Complete relief); and (d) the hours of relief they usually experienced after listening to the recording.","Amount effects self-hypnosis relaxation practice treatment assessed telephone interview assistant blind treatment condition 1-, 2-, 3-months posttreatment participants indicate, 30 days: (a) days listened audio recording given; (b) days listened audio recording, usual times listened; (c) amount pain relief experienced listened audio recording (on 0–10 scale, 0 = No relief 10 = Complete relief); (d) hours relief experienced listening recording.",C1265611|C1280500|C0679660|C0035028|C0237607|C0039798|C1516048|C0039457|C0021822|C0011327|C0150108|C0039798|C0012634|G0000000|G0000000|C0439231|C2709088|C0679646|G0000000|C0450371|C0439228|G0000000|C0439228|C0004309|C3273156|G0000000|C1442162|G0000000|C0439228|C0004309|C3273156|G0000000|C3538928|C0040223|C0004309|G0000000|C1265611|C0030193|C0564405|C0237607|C0004309|C3273156|G0000000|G0000000|G0000000|C0175659|G0000000|G0000000|G0000000|C0564405|C0450371|G0000000|C0205197|C0564405|C0073187|C0439227|C0564405|C0237607|C0004309|G0000000
The time horizon is 12 months.,The time horizon 12 months.,G0000000|C0040223|G0000000|C0450371|C0439231
The other patient was treated conservatively with total parenteral nutrition and antibiotics.,The patient treated conservatively total parenteral nutrition antibiotics.,G0000000|C0030705|C1522326|G0000000|C0439175|C0030547|C0028707|C0003232
We defined a paradoxical reaction as 2 consecutive increases in lesion size after 1 initial decrease.,We defined paradoxical reaction 2 consecutive increases lesion size 1 initial decrease.,G0000000|C1704788|C0205310|C0443286|G0000000|C1707491|C0205217|C0221198|C0456389|G0000000|C0205265|C0392756
"Overall, 22 (42%) of the children given spray experienced no acute otitis media during the study and had a normal tympanic membrane at the last valid visit compared with 12 (22%) of the children given placebo (table).","Overall, 22 (42%) children spray experienced acute otitis media study normal tympanic membrane valid visit compared 12 (22%) children placebo (table).",C0282416|C0450371|C0450371|C0008059|C1704413|C0237607|C0205178|C0029877|C0009458|C0557651|C0205307|C0041445|C0025255|C2349099|C0545082|C1707455|C0450371|C0450371|C0008059|C0032042|C0039224
"Third, although the self-reported abstinence outcome was conservatively defined, biochemical verification of adolescent smoking cessation would have been ideal.","Third, self-reported abstinence outcome conservatively defined, biochemical verification adolescent smoking cessation ideal.",C0205437|C0681906|C3843422|C1274040|G0000000|C1704788|C0205474|C0237944|C0205653|C0037369|C1880019|C1512612
An analysis of responder rate was also performed to assess the percentage of patients achieving HbA1c ≤6.5% (48 mmol/mol) and <7.0% (53 mmol/mol).,An analysis responder rate performed assess percentage patients achieving HbA1c ≤6.5% (48 mmol/mol) <7.0% (53 mmol/mol).,G0000000|C0002778|G0000000|C0871208|C0884358|C1516048|C0439165|C0030705|G0000000|G0000000|G0000000|C0450371|C3829066|G0000000|C0450371|C3829066
Patients were reassessed at 4 and 12 months.,Patients reassessed 4 12 months.,C0030705|G0000000|G0000000|C0450371|C0439231
The primary endpoint was the percentage of patients achieving clinical remission defined as a CAI⩽4 at the end of the study (with the “last observation carried forward” (LOCF) approach) in each of the two groups.,The primary endpoint percentage patients achieving clinical remission defined CAI⩽4 study (with “last observation carried forward” (LOCF) approach) groups.,G0000000|C0205225|C2349179|C0439165|C0030705|G0000000|C0205210|C0544452|C1704788|G0000000|C0557651|G0000000|G0000000|C0302523|C0206243|G0000000|C2825507|C0449445|C0441833
"Data are presented as mean ± SD of Auditory Hallucinations Rating Scale (AHRS) (A), Scale for the Assessment of Positive Symptoms (SAPS) (B), Scale for the Assessment of Negative Symptoms (SANS) (C), Clinical Global Impressions (CGI) scale (D), and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (E).","Data ± SD Auditory Hallucinations Rating Scale (AHRS) (A), Scale Assessment Positive Symptoms (SAPS) (B), Scale Assessment Negative Symptoms (SANS) (C), Clinical Global Impressions (CGI) scale (D), Quality Life Enjoyment Satisfaction Questionnaire (Q-LES-Q) (E).",C1511726|G0000000|C2699239|C0439825|C0018524|C0871208|C0175659|G0000000|G0000000|C0175659|C1261322|C0439178|C0683368|C1705598|G0000000|C0175659|C1261322|C0205160|C0683368|C1424214|G0000000|C0205210|C0205246|C0596764|C3639708|C0175659|C0073187|C0332306|C0376558|C0018592|C0242428|C0034394|C0227192|G0000000
"Abstinence at 3, 6, and 18 months using the ‘Russell Standard’, a recently suggested standard for smoking cessation trials [42].","Abstinence 3, 6, 18 months ‘Russell Standard’, suggested standard smoking cessation trials [42].",C3843422|G0000000|G0000000|G0000000|G0000000|G0000000|C1705535|C1442989|C0037369|C1880019|C0008976|C0450371
The primary endpoint was clinical and histologic response of high-risk OPLs at 12 weeks to three different doses of GTE compared with placebo.,The primary endpoint clinical histologic response high-risk OPLs 12 weeks doses GTE compared placebo.,G0000000|C0205225|C2349179|C0205210|C0205462|C0871261|C0332167|G0000000|C0450371|C0439230|C0178602|G0000000|C1707455|C0032042
"Independent factors were determined using multivariate Cox regression models; age, sex, type/subtype of virus, NAI use, NAI treatment propensity score, bacterial superinfection, and systemic corticosteroid and statin use (all variables significant in the univariate comparisons) were included as covariates (model 1) [3, 5, 7, 8, 13].","Independent factors determined multivariate Cox regression models; age, sex, type/subtype virus, NAI use, NAI treatment propensity score, bacterial superinfection, systemic corticosteroid statin (all variables univariate comparisons) included covariates (model 1) [3, 5, 7, 8, 13].",C0085862|C1521761|G0000000|G0000000|G0000000|C0684320|C3161035|C0001779|C0009253|C0332307|C0042776|C3537218|C0042153|C3537218|C0039798|G0000000|C0449820|C0521009|C0038826|C0205373|C0001617|C0360714|G0000000|C0439828|G0000000|C1707455|C0332257|G0000000|C3161035|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371
The participants were selected by purposefully method sampling.,The participants selected purposefully method sampling.,G0000000|C0679646|C1707391|G0000000|C0025663|C0441621
"Table S2 ¦ Changes in the neuropathy symptom score (NSS), the neuropathy disability score (NDS), and the sum of both comparing baseline and week 12 and week 24 in the per‐protocol set population.","Table S2 ¦ Changes neuropathy symptom score (NSS), neuropathy disability score (NDS), sum comparing baseline week 12 week 24 per‐protocol set population.",C0039224|C1519428|G0000000|C0392747|C0442874|C1457887|C0449820|G0000000|C0442874|C0231170|C0449820|C0057753|C1515051|C1707455|C0168634|C0332174|C0450371|C0332174|C0450371|G0000000|C0036849|C0032659
Length of stay was similar for both groups.,Length stay groups.,C1444754|G0000000|C0441833
We expect at least 70% follow-up at 9 months.,We expect 70% follow-up 9 months.,G0000000|G0000000|C0450371|C0589120|G0000000
"As definition of poor outcome, the endpoints of death and admission to intensive care were combined; and as a further outcome, length of stay was used.","As definition poor outcome, endpoints death admission intensive care combined; outcome, length stay used.",G0000000|C1550452|C0032854|C1274040|C2349179|C0011065|C0184666|C0162425|C1947933|C0205195|C1274040|C1444754|G0000000|C1273517
"Clinically administered and patient-reported outcomes were used in a standardized order (The Fatigue Scale for Motor and Cognitive Functions (FSMC), Trunk Impairment Scale (TIS), The Timed Sit-To-Stand test (TstS), Postural Sway, Berg Balance Scale (BBS), Falls Efficacy Scale–International (FES-I), the 12-item MS Walking Scale (MSWS), Timed Up and Go (TUG), 10-m walk test (10WT) and 2-minute walk test (2MWT)).","Clinically administered patient-reported outcomes standardized (The Fatigue Scale Motor Cognitive Functions (FSMC), Trunk Impairment Scale (TIS), The Timed Sit-To-Stand test (TstS), Postural Sway, Berg Balance Scale (BBS), Falls Efficacy Scale–International (FES-I), 12-item MS Walking Scale (MSWS), Timed Up Go (TUG), 10-m walk test (10WT) 2-minute walk test (2MWT)).",G0000000|C1521801|C0747307|C1274040|G0000000|G0000000|C0015672|C0175659|C1513492|C1516691|C0542341|G0000000|C0225442|C0221099|C0175659|C0475413|G0000000|C0392761|C0596013|C0022885|C1421210|C0205278|G0000000|G0000000|C0014653|C0175659|G0000000|C0000921|C1280519|G0000000|C0021966|C0450371|C0039676|C0080331|C0175659|C2347078|C0392761|G0000000|C1822658|C1319201|C0450371|C0080331|C0022885|G0000000|C0439232|C0080331|C0022885|G0000000
The gold standards used to diagnose CIPNM are electrophysiological stimulation (EPS) and muscle biopsy.,The gold standards diagnose CIPNM electrophysiological stimulation (EPS) muscle biopsy.,G0000000|C0018026|C0038137|C0011900|G0000000|C0013865|C1292856|G0000000|C0026845|C0005558
"Table 3 presents unadjusted means averaged over the 12-month follow-up and adjusted risk ratios for symptom days, night awakenings, days with activity restriction, and self-reported school absences due to asthma.","Table 3 unadjusted averaged 12-month follow-up adjusted risk ratios symptom days, night awakenings, days activity restriction, self-reported school absences asthma.",C0039224|G0000000|C1439367|C1510992|C0450371|C0589120|C0456081|C0035647|C0456603|C1457887|C0439228|C0240526|C1720052|C0439228|C0205177|C0443288|C0681906|C0036375|C0424530|C0004096
"During follow up visits, the pulpotomized teeth were considered to be succussfully treated if they had no symptoms of pain, tenderness to percussion, swelling, fistulation or pathologic mobility clinically and no evidence of radicular radiolucency, internal or external root resorption or periodontal ligament space widening radiographically.","During follow visits, pulpotomized teeth considered succussfully treated symptoms pain, tenderness percussion, swelling, fistulation pathologic mobility clinically evidence radicular radiolucency, internal external root resorption periodontal ligament space widening radiographically.",G0000000|C0332283|C0545082|G0000000|C0040426|C0750591|G0000000|C1522326|C0683368|C0030193|C0234233|C0030987|C0013604|G0000000|C1521733|C0425245|G0000000|C3887511|C0040452|C2827491|C0205102|C0205101|C0040452|C2985494|C2960678|C0023685|C1883067|C0332464|G0000000
"Of the 234 deep nasal swabs obtained, 33.3% (n=78) tested positive for influenza; 43.6% (n=34) were influenza A and 56.4% (n=44) were influenza B.","Of 234 deep nasal swabs obtained, 33.3% (n=78) tested positive influenza; 43.6% (n=34) influenza A 56.4% (n=44) influenza B.",G0000000|C1442061|C0205125|C0028429|C0183753|C1301820|C0450371|C0369718|C0392366|C0439178|C0021400|C0450371|C0369718|C0021400|G0000000|C0450371|C0369718|C0021400|G0000000
Normal urinary protein excretion is defined as less than 0.2 g/1.73 m2 per day.,Normal urinary protein excretion defined 0.2 g/1.73 m2 day.,C0205307|C0042027|C0033684|C0221102|C1704788|G0000000|C0439267|C0025885|C0332173
"ICERs were calculated as additional cost per patient to prevent 1 exacerbation, compared with the next most expensive option.","ICERs calculated additional cost patient prevent 1 exacerbation, compared expensive option.",C1852403|C0444686|C1524062|C0010186|C0030705|C0309872|G0000000|G0000000|C1707455|C0680864|C1518601
Anthropometric and Bayley II outcomes for the ELBW newborns at 18−22 months are presented in Table 2.,Anthropometric Bayley II outcomes ELBW newborns 18−22 months Table 2.,C0003188|G0000000|G0000000|C1274040|C0456065|C0021289|G0000000|C0439231|C0039224|G0000000
cure or treatment completion rate was calculated as the number of patients cured or treatment completed divided by the total number of patients reported expressed as a percentage.,cure treatment completion rate calculated patients cured treatment completed divided total patients reported expressed percentage.,C1880198|C0039798|C0205197|C0871208|C0444686|C0030705|C1880198|C0039798|C0205197|C0332849|C0439175|C0030705|C0684224|G0000000|C0439165
"For the SF-36 Physical Component Scale, there was an improvement in the whole study group at 3 and 6 months follow-up compared with baseline values without any significant changes between the IG and CG.","For SF-36 Physical Component Scale, improvement study 3 6 months follow-up compared baseline values IG CG.",G0000000|C0037712|C0031809|C0449432|C0175659|C2986411|C0557651|G0000000|G0000000|C0439231|C0589120|C1707455|C0168634|C0042295|C0021027|C0043444
"Smoking status was assessed at the baseline and follow-up surveys according to responses to the following question: “How many cigarettes have you smoked in your life?” (responses included “None”, “Just a few puffs”, ”One to 19 cigarettes (less than one pack)”, “20 to 100 cigarettes (one to five packs)”, “More than 100 cigarettes (more than five packs)”.","Smoking status assessed baseline follow-up surveys responses question: “How cigarettes smoked life?” (responses included “None”, “Just puffs”, ”One 19 cigarettes (less pack)”, “20 100 cigarettes (one packs)”, “More 100 cigarettes (more packs)”.",C0037369|C0449438|C1516048|C0168634|C0589120|C0038951|C0871261|C1522634|G0000000|C0677453|C0037366|G0000000|C0871261|C0332257|G0000000|G0000000|G0000000|G0000000|C0450371|C0677453|C0439092|G0000000|G0000000|C1442061|C0677453|C0205447|G0000000|G0000000|C1442061|C0677453|C0205172|G0000000
"After enrolment, the total serum bilirubin was measured every 12 hours and whenever the serum bilirubin level reached 12.5 mg/dl or was less than that, the infant was discharge from the hospital.","After enrolment, total serum bilirubin measured 12 hours serum bilirubin level reached 12.5 mg/dl that, infant discharge hospital.",G0000000|C1516879|C0439175|C0229671|C0005437|C0444706|C0450371|C0439227|C0229671|C0005437|C0441889|C2584321|C0450371|C0439269|G0000000|C0021270|C0012621|C0019994
Sleep efficiency was calculated as percentage of TST of the time spent in bed after lights out.,Sleep efficiency calculated percentage TST time spent bed lights out.,C0037313|C0013682|C0444686|C0439165|C1421210|C0040223|C0680968|C0004916|C0023693|C0439787
"Reliability analyses for MVV and MIP were r = 0.979 and r = 0.986, respectively.","Reliability analyses MVV MIP = 0.979 = 0.986, respectively.",C2347947|C0002778|C0024967|C2350701|G0000000|C1442061|G0000000|C1442061|G0000000
The study suggests beneficial effects of the music therapy programme on the symptoms of dementia and occupational disruptiveness as measured by the NPI.,The study suggests beneficial effects music therapy programme symptoms dementia occupational disruptiveness measured NPI.,G0000000|C0557651|C1705535|G0000000|C1280500|C0026867|C0039798|C1709697|C0683368|C0011265|C0521127|C0332453|C0444706|C1412208
"The QOL-CS is a 41-item self-report rating scale that assesses four domains of quality of life (physical, psychological, social and spiritual) on an 11-point scale, where 0 represents the worst possible outcome and 10 the best possible outcome.","The QOL-CS 41-item self-report rating scale assesses domains quality life (physical, psychological, social spiritual) 11-point scale, 0 represents worst outcome 10 outcome.",G0000000|C0518214|C0450371|C0681906|C0871208|C0175659|C1516048|C1880389|C0332306|C0376558|C0031809|C0205486|C0728831|G0000000|C0450371|C0175659|G0000000|C1882932|C1522166|C1274040|C0450371|C1274040
"Adverse events (AEs) were examined after 30 minutes, 1 month and clinical events were observed till 12 months post-vaccination.","Adverse events (AEs) examined 30 minutes, 1 month clinical events observed till 12 months post-vaccination.",G0000000|C0441471|C1412268|C0332128|C0450371|C0439232|G0000000|C0332177|C0205210|C0441471|C1441672|G0000000|C0450371|C0439231|C0687676
"Following randomization, patients underwent a general exam as well as a study-specific examination of the injured joint including swelling, skin condition, functional impairment, pain at rest, pain on passive stretch, pain on pressure, and pain on single foot leaning.","Following randomization, patients underwent exam study-specific examination injured joint including swelling, skin condition, functional impairment, pain rest, pain passive stretch, pain pressure, pain single foot leaning.",C0231290|C0034656|C0030705|G0000000|C0582103|C0557651|G0000000|C0332664|C0022417|C0332257|C0013604|C0444099|C0012634|C0205245|C0221099|C0030193|C0035253|C0030193|C3686820|C0600080|C0030193|C0033095|C0030193|C0037179|C0016504|G0000000
This study suggested that CIMT is effective in improving grasp and dissociated movement items of outcome tool while there was no superiority observed of CIMT over BMT in weight bearing and protective extension items.,This study suggested CIMT effective improving grasp dissociated movement items outcome tool superiority observed CIMT BMT weight bearing protective extension items.,G0000000|C0557651|C1705535|G0000000|C1280519|C1272745|C0220843|G0000000|C0026649|C1551338|C1274040|C0336791|C0680218|C1441672|G0000000|C0005961|C0005910|C1704689|G0000000|C0231448|C1551338
"1997, 1999).","1997, 1999).",G0000000|G0000000
"For that, it may suffice to know that the overall results for these “other high risk” categories show substantial reductions in myocardial infarction, stroke, and vascular death.","For that, suffice “other risk” categories substantial reductions myocardial infarction, stroke, vascular death.",G0000000|G0000000|G0000000|G0000000|G0000000|C0683312|G0000000|C0301630|C0027061|C0021308|C0038454|C0005847|C0011065
"Median follow-up time was 18 months (range, 5 to 43 months) from completion of last chemotherapy and 22 months after initiation of chemotherapy.","Median follow-up time 18 months (range, 5 43 months) completion chemotherapy 22 months initiation chemotherapy.",C0549183|C0589120|C0040223|C0450371|C0439231|C1514721|G0000000|C0450371|C0439231|C0205197|C0013216|C0450371|C0439231|C0589507|C0013216
"Secondary delirium-related outcomes included the incidence of delirium that developed during ICU admission, the time to delirium occurrence, the proportion of 12 hour ICU shifts without delirium, and among those subjects who developed delirium, the duration of delirium until if first resolved for ≥ 12 hours.","Secondary delirium-related outcomes included incidence delirium developed ICU admission, time delirium occurrence, proportion 12 hour ICU shifts delirium, subjects developed delirium, duration delirium resolved ≥ 12 hours.",C0027627|C0011206|C1274040|C0332257|C0021149|C0011206|G0000000|C0021708|C0184666|C0040223|C0011206|C0243132|C1709707|C0450371|C0439227|C0021708|C0333051|C0011206|C0681850|G0000000|C0011206|C0449238|C0011206|C1514893|G0000000|C0450371|C0439227
Overall improvement or treatment success was defined as either complete remission or a clinical response to therapy.,Overall improvement treatment success defined complete remission clinical response therapy.,C0282416|C2986411|C0039798|C0597535|C1704788|C0205197|C0544452|C0205210|C0871261|C0039798
"The Shwachmann-Kulczycki score, lung function, and BMI did not show any changes in either of the treatment groups.","The Shwachmann-Kulczycki score, lung function, BMI treatment groups.",G0000000|G0000000|C0449820|C0024109|C0031843|G0000000|C0039798|C0441833
"The NPI scores were found not to be associated with the primary sleep variables (all unadjusted P =.15), and so were not included in any model of analysis.","The NPI scores primary sleep variables (all unadjusted P =.15), included model analysis.",G0000000|C1412208|C0449820|C0205225|C0037313|C0439828|G0000000|C1439367|C0369773|C0450371|C0332257|C3161035|C0002778
"The present study seeks to investigate the hypothesis that increasing energy expenditure by aerobic exercise will have cardiovascular benefits, including decreased blood pressure, decreased heart rate, and increased exercise tolerance, and will result in a decrease in proteinuria in obese diabetic patients with CKD.","The study seeks investigate hypothesis increasing energy expenditure aerobic exercise cardiovascular benefits, including decreased blood pressure, decreased heart rate, increased exercise tolerance, result decrease proteinuria obese diabetic patients CKD.",G0000000|C0557651|G0000000|C1292732|C1512571|C0442808|C0424589|C0015316|C1510824|C0015259|C0007226|C0814225|C0332257|C0205216|C0005767|C0033095|C0205216|C0018787|C0871208|C0205217|C0015259|C0013220|C1274040|C0392756|C0033687|C0028754|C0241863|C0030705|C1561643
Any events not recorded at the time they occurred were recorded at this ward round.,Any events recorded time occurred recorded ward round.,G0000000|C0441471|C0034869|C0040223|C1709305|C0034869|C1305702|C0332490
"Number of red blood cell and platelet transfusions during transplantation, number of attempts at and total number of days of stem cell collection, time to recovery after transplantation, and response to intensive therapy for multiple myeloma.","Number red blood cell platelet transfusions transplantation, attempts total days stem cell collection, time recovery transplantation, response intensive therapy multiple myeloma.",C0237753|C0332575|C0005767|C0007634|C0005821|C0005841|C0040732|C1516084|C0439175|C0439228|C0242767|C0007634|C1516698|C0040223|C0237820|C0040732|C0871261|C0162425|C0039798|C0439064|C0026764
LS mean change from baseline in trough FEV1 up to day 169 (ITT population).,LS change baseline trough FEV1 day 169 (ITT population).,C0023668|C0392747|C0168634|C0444506|G0000000|C0332173|C1442061|G0000000|C0032659
"All enrolled patients will be followed to determine mortality, continued need for RRT or renal recovery until death or discharge from hospital (whichever occurs first) and at 28, 90, 180 days and 1 year after randomization.","All enrolled patients determine mortality, continued RRT renal recovery death discharge hospital (whichever occurs first) 28, 90, 180 days 1 randomization.",G0000000|G0000000|C0030705|G0000000|C0026565|C0549178|G0000000|C0022646|C0237820|C0011065|C0012621|C0019994|G0000000|C1709305|C0205435|C0450371|C0450371|C1442061|C0439228|G0000000|C0034656
Plots were generated by the Kaplan-Meier method and progression free survival was measured from start of therapy.,Plots generated Kaplan-Meier method progression free survival measured start therapy.,G0000000|C3146294|G0000000|C0025663|C0242656|C0332296|C0038952|C0444706|C0439659|C0039798
"Summary scores on the physical and mental components of the Medical Outcomes Study 36 Item ShortForm Health Survey (SF36) range from 0 to 100, with higher scores indicating better health status.","Summary scores physical mental components Medical Outcomes Study 36 Item ShortForm Health Survey (SF36) range 0 100, scores indicating health status.",C1552616|C0449820|C0031809|C0229992|C0449432|C0199168|C1274040|C0557651|C0450371|C1551338|G0000000|C0018684|C0038951|G0000000|C1514721|G0000000|C1442061|C0449820|G0000000|C0018684|C0449438
Glucose metabolism in chronic primary insomnia patients (n=20).,Glucose metabolism chronic primary insomnia patients (n=20).,C0017725|C0025519|C0205191|C0205225|C0917801|C0030705|C0369718
To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy.,To investigate benfotiamine urinary albumin excretion (UAE) tubular damage marker kidney injury molecule-1 (KIM-1) patients type 2 diabetes nephropathy.,C0040363|C1292732|C0053116|C0042027|C0001924|C0221102|C1519789|C0332208|C0010957|C0005516|C0022646|C3263722|C0567416|G0000000|C0030705|C0332307|G0000000|C0011847|C0022658
"Data on mood, quality of life, illness understanding and satisfaction with care of the informal caregivers will be obtained by self-assessment instruments: HADS, PHQ-9, the Short Form-36 Health Survey (SF-36) a questionnaire for illness understanding and by the FAMCARE respectively [25].","Data mood, quality life, illness understanding satisfaction care informal caregivers self-assessment instruments: HADS, PHQ-9, Short Form-36 Health Survey (SF-36) questionnaire illness understanding FAMCARE [25].",C1511726|C0026516|C0332306|C0376558|C0221423|C0162340|C0242428|C1947933|G0000000|C0085537|C0036591|C0348000|C0048008|C1879301|C1282927|C0348078|C0018684|C0038951|C0037712|C0034394|C0221423|C0162340|G0000000|C0450371
"The secondary outcomes of the BELIEF study reported in this paper tested the efficacy of the intervention in reducing caesarean section, induction of labour (amniotomy, prostaglandin or syntocinon), epidural use in labour and neonatal admission to special care or intensive care nursery.","The secondary outcomes BELIEF study reported paper tested efficacy intervention reducing caesarean section, induction labour (amniotomy, prostaglandin syntocinon), epidural labour neonatal admission special care intensive care nursery.",G0000000|C0027627|C1274040|C0004951|C0557651|C0684224|C0030351|C0392366|C1280519|C0886296|C0392756|C3841297|C0152060|C0205263|C0022864|G0000000|C0033554|C0592155|C0228134|C0022864|C1552240|C0184666|C0205555|C1947933|C0162425|C1947933|C0028659
Evidence of construct validity was established during test development[87] and criterion validity with strong correlations between the LIFE-H and PEDI and Functional Independence Measure for Children (WeeFIM)[88].,Evidence construct validity established test development[87] criterion validity strong correlations LIFE-H PEDI Functional Independence Measure Children (WeeFIM)[88].,C3887511|C2827421|C2349101|C0443211|C0022885|C0243107|C0243161|C2349101|C0442821|C1707520|C0376558|G0000000|C0205245|C0085862|C0079809|C0008059|C0450371
"Seven patients failed to attend for review of healing after completing antibiotic treatment, so neither the time to complete healing nor the rate of healing could be calculated.","Seven patients failed attend review healing completing antibiotic treatment, time complete healing rate healing calculated.",C0205453|C0030705|C0231175|C1999232|C0282443|C0043240|C0205197|C0003232|C0039798|C0040223|C0205197|C0043240|C0871208|C0043240|C0444686
"The second dose had to be taken either as rescue medication, when the severity of headache was still moderate (score 2) or severe (score 3) at 2 h after dosing, or to treat the relapse of headache, that is if the severity of headache was 0 (no headache) or 1 (mild headache) at 2 h and the headache returned within 48 h of initial dosing.","The dose rescue medication, severity headache moderate (score 2) severe (score 3) 2 dosing, treat relapse headache, severity headache 0 (no headache) 1 (mild headache) 2 headache returned 48 initial dosing.",G0000000|C0178602|G0000000|C0013227|C0439793|C0018681|C0205081|C0449820|G0000000|C0205082|C0449820|G0000000|G0000000|G0000000|C0087111|C0035020|C0018681|C0439793|C0018681|G0000000|G0000000|C0018681|G0000000|C2945599|C0018681|G0000000|C0018681|C0332156|C0450371|C0205265|G0000000
"The primary endpoint was the incidence of clinically significant thrombocytopenic events, defined by grade 3 or 4 thrombocytopenia starting on day 15 of the first cycle or platelet transfusion at any time during the 4-cycle treatment period.","The primary endpoint incidence clinically thrombocytopenic events, defined grade 3 4 thrombocytopenia starting day 15 cycle platelet transfusion time 4-cycle treatment period.",G0000000|C0205225|C2349179|C0021149|G0000000|G0000000|C0441471|C1704788|C0441800|G0000000|G0000000|C0040034|C0439659|C0332173|C0450371|C1511572|C0005821|C0005841|C0040223|C1511572|C0039798|C0439531
The primary end point was the clinical response (cure or failure) in the “clinical per protocol” population at test of cure (days 13 to 24).,The primary clinical response (cure failure) “clinical protocol” population test cure (days 13 24).,G0000000|C0205225|C0205210|C0871261|C1880198|C0231174|G0000000|G0000000|C0032659|C0022885|C1880198|C0439228|C0450371|C0450371
"Although the exact mechanism of migraine is still unclear, there is plenty of neuroimaging evidence showing that migraine is a central nervous system disorder [4]–[6].","Although exact mechanism migraine unclear, plenty neuroimaging evidence migraine central nervous system disorder [4]–[6].",G0000000|C2828393|C0441712|C0149931|G0000000|G0000000|C0679575|C3887511|C0149931|C0205099|C0027769|C0449913|C0012634|G0000000
"Comparison of Migraine Disability Assessment (MIDAS) scores before and after the intervention in the two groups of patients with migraine MIDAS: Migraine Disability Assessment; SD: Standard deviation The mean total MIDAS score in the experimental group was 28.1 ± 17.5, which corresponds to MIDAS grade IV (severe disability).","Comparison Migraine Disability Assessment (MIDAS) scores intervention patients migraine MIDAS: Migraine Disability Assessment; SD: Standard deviation The total MIDAS score experimental 28.1 ± 17.5, corresponds MIDAS grade IV (severe disability).",C1707455|C0149931|C0231170|C1261322|C1309950|C0449820|C0886296|C0030705|C0149931|C1309950|C0149931|C0231170|C1261322|C2699239|C1442989|C0012727|G0000000|C0439175|C1309950|C0449820|C1517586|C0450371|G0000000|C0450371|G0000000|C1309950|C0441800|C0022326|C0205082|C0231170
"Quadriceps and hamstring muscle strength, exercise capacity, and peak oxygen uptake were measured at baseline and after 6 weeks of stimulation.","Quadriceps hamstring muscle strength, exercise capacity, peak oxygen uptake measured baseline 6 weeks stimulation.",C0224440|C0584895|C0026845|C0237897|C0015259|C1516240|C0444505|C0030054|C0243144|C0444706|C0168634|G0000000|C0439230|C1292856
The efficacy of the treatment was assessed using two measures: The Strengths and Weaknesses in ADHD and Normal Behaviors (SWAN) and Conners’ rating scales completed by the parents or caregivers and the teachers.,The efficacy treatment assessed measures: The Strengths Weaknesses ADHD Normal Behaviors (SWAN) Conners’ rating scales completed parents caregivers teachers.,G0000000|C1280519|C0039798|C1516048|C0079809|G0000000|C0808080|C3714552|C1263846|C0205307|C0004927|C0325528|G0000000|C0871208|C0175659|C0205197|C0030551|C0085537|C0221457
"Secondary endpoints will include functional fitness assessed by the Senior’s Fitness Test, QoL assessed by the European Organisation of Research and Treatment of Cancer, and symptom management assessed by the M.D.","Secondary endpoints functional fitness assessed Senior’s Fitness Test, QoL assessed European Organisation Research Treatment Cancer, symptom management assessed M.D.",C0027627|C2349179|C0205245|C1456706|C1516048|G0000000|C1456706|C0022885|C0518214|C1516048|C0239307|C0029237|C0035168|C0039798|C0006826|C1457887|C0001554|C1516048|C1512018
The amplitude of motor evoked potentials (MEPs) induced by TMS are used extensively and reliably to assess the effect of swallowing treatments on corticobulbar excitability [15–18].,The amplitude motor evoked potentials (MEPs) induced TMS extensively reliably assess swallowing treatments corticobulbar excitability [15–18].,G0000000|C2346753|C1513492|C1444748|C3245505|C1707163|C0205263|G0000000|G0000000|G0000000|C1516048|C0011167|C0087111|G0000000|C0235169|G0000000
"The primary endpoint was the time to resolution of painful crisis, defined by: 1) freedom from parenteral opioid use for 5 hours; 2) pain relief as assessed by visual analog pain scale scores ≤ 6 cm; 3) ability to walk; and 4) patient and family’s decision, with physician consensus, that the remaining pain could be managed at home.","The primary endpoint time resolution painful crisis, defined by: 1) freedom parenteral opioid 5 hours; 2) pain relief assessed visual analog pain scale scores ≤ 6 cm; 3) ability walk; 4) patient family’s decision, physician consensus, remaining pain managed home.",G0000000|C0205225|C2349179|C0040223|C1514893|C0030193|C0231224|C1704788|G0000000|G0000000|C0016694|C0030547|C0242402|G0000000|C0439227|G0000000|C0030193|C0564405|C1516048|C0234621|C0243071|C0030193|C0175659|C0449820|G0000000|G0000000|G0000000|G0000000|C0085732|C0080331|G0000000|C0030705|G0000000|C0679006|C0031831|C0376298|C1527428|C0030193|C1273870|C0442519
There was no treatment effect on the change in log protein-to-creatinine ratio according to tertile of baseline serum creatinine concentration.,There treatment change log protein-to-creatinine ratio tertile baseline serum creatinine concentration.,G0000000|C0039798|C0392747|C1708728|C0369901|C0456603|G0000000|C0168634|C0229671|C0010294|C0004268
"The secondary clinical endpoints will be (1) P. falciparum parasite rates, (2) prevalence of splenomegaly, (3) prevalence of anemia, and (4) an incidence of respiratory infection, measured as a cough and either a raised age-specific respiratory rate or chest indrawing.","The secondary clinical endpoints (1) P. falciparum parasite rates, (2) prevalence splenomegaly, (3) prevalence anemia, (4) incidence respiratory infection, measured cough raised age-specific respiratory rate chest indrawing.",G0000000|C0027627|C0205210|C2349179|G0000000|C0369773|G0000000|C0030498|C0871208|G0000000|C0033105|C0038002|G0000000|C0033105|C0002871|G0000000|C0021149|C0521346|C0009450|C0444706|C0010200|C0442818|C0001779|C0521346|C0871208|C0817096|G0000000
One hundred and seventy-five of the 355 eligible women (49%) completed the interview.,One seventy-five 355 eligible women (49%) completed interview.,C0205447|C3816957|C1442061|C1548635|C0043210|C0450371|C0205197|C0021822
Samples that were positive on all three ELISAs were regarded as “positive” and all others as “negative” [18].,Samples positive ELISAs regarded “positive” “negative” [18].,C0370003|C0439178|C0014441|G0000000|G0000000|G0000000|C0450371
"We observed a suggestion of a positive linear relationship between increasing quintile of vitamin C and the risk of total thyroid cancer and the papillary and follicular subtypes, but no evidence of an association between thyroid cancer risk and calcium, folate, vitamin E, vitamin D, magnesium, or zinc intakes.","We observed suggestion positive linear relationship increasing quintile vitamin C risk total thyroid cancer papillary follicular subtypes, evidence association thyroid cancer risk calcium, folate, vitamin E, vitamin D, magnesium, zinc intakes.",G0000000|C1441672|C0038659|C0439178|C0205132|C0439849|C0442808|C1508496|C0042890|G0000000|C0035647|C0439175|C0040132|C0006826|C0205312|C0439682|C0449560|C3887511|C0004083|C0040132|C0006826|C0035647|C0006675|C0178638|C0042890|G0000000|C0042890|C0073187|C0024467|C0043481|C1512806
"To assess the performance of daily living, we utilized section II of the Unified Parkinson Disease Rating Scale (UPDRS-II), which includes speech, salivation, swallowing, handwriting, handling, dressing, hygiene, changing position in bed, falling, freezing, walking, tremor and sensory complaints.","To assess performance daily living, utilized II Unified Parkinson Disease Rating Scale (UPDRS-II), includes speech, salivation, swallowing, handwriting, handling, dressing, hygiene, changing position bed, falling, freezing, walking, tremor sensory complaints.",C0040363|C1516048|C0597198|C0332173|C0376558|G0000000|G0000000|C1548174|C1021144|C0012634|C0871208|C0175659|C3639721|C0332257|C0037817|C0036104|C0011167|C0018582|C0018578|C0013119|C0020405|C0392747|C0733755|C0004916|C0000921|C0016701|C0080331|C0040822|C0445254|C0277786
"Even so, all but one case of pneumonia and all the hospital admissions occurred in the placebo group.","Even so, pneumonia hospital admissions occurred placebo group.",G0000000|C0037640|C0032285|C0019994|C0184666|C1709305|C0032042|C0441833
Patients completed LCI and spirometry at baseline and 90 min post treatment.,Patients completed LCI spirometry baseline 90 min post treatment.,C0030705|C0205197|C0231990|C0037981|C0168634|G0000000|C0687676|C0039798
There was no significant difference in adverse events between the two groups.,There difference adverse events groups.,G0000000|C1705241|G0000000|C0441471|C0441833
"Disease assessments were performed using computed tomography or magnetic resonance imaging at baseline, every 8 weeks for the first year, then every 12 weeks until disease progression or treatment discontinuation.","Disease assessments performed computed tomography magnetic resonance imaging baseline, 8 weeks year, 12 weeks disease progression treatment discontinuation.",C0012634|C1261322|C0884358|C1441526|C0040395|C0024488|C0231881|C0011923|C0168634|G0000000|C0439230|C0439234|C0450371|C0439230|C0012634|C0242656|C0039798|C0457454
Response rate for relief of overall IBS symptoms and for relief of abdominal discomfort/pain during both first and repeated treatment.,Response rate relief IBS symptoms relief abdominal discomfort/pain repeated treatment.,C0871261|C0871208|C0564405|C0022104|C0683368|C0564405|C0000726|C0231218|C0205341|C0039798
No clinically significant adverse events were reported in the combination group.,No clinically adverse events reported combination group.,G0000000|G0000000|G0000000|C0441471|C0684224|C0205195|C0441833
"Smaller increases in satisfaction were observed for patients who had more provider visits, longer visits, more improvement in low back pain disability, and more confidence in treatment.","Smaller increases satisfaction observed patients provider visits, visits, improvement low pain disability, confidence treatment.",C0547044|C0205217|C0242428|C1441672|C0030705|C1138603|C0545082|C0545082|C2986411|C0205251|C0030193|C0231170|C0237529|C0039798
"The primary endpoints were safety and tolerability of motavizumab and palivizumab administered sequentially during the same RSV season, as assessed by summarizing adverse events (AEs), serious AEs (SAEs), and laboratory evaluations.","The primary endpoints safety tolerability motavizumab palivizumab administered sequentially RSV season, assessed summarizing adverse events (AEs), AEs (SAEs), laboratory evaluations.",G0000000|C0205225|C2349179|C0036043|C3274448|C2713599|C0672596|C1521801|G0000000|G0000000|C0036497|C1516048|G0000000|G0000000|C0441471|C1412268|C1412268|C1519255|C0022877|C0220825
"Secondary outcome measures will be changes in knowledge, attitude, behaviour and self-efficacy of parents towards the oral health of their child and differences in nutritional and dietary patterns between groups.","Secondary outcome measures knowledge, attitude, behaviour self-efficacy parents oral health child differences nutritional dietary patterns groups.",C0027627|C1274040|C0079809|C0376554|C0004271|C0004927|C0600564|C0030551|C0442027|C0018684|C0008059|C1705241|C1521739|C0012155|C0449774|C0441833
The principal outcome measure was the mean change in clinical severity score at the end of 2 h of observation.,The principal outcome measure change clinical severity score 2 observation.,G0000000|C0205225|C1274040|C0079809|C0392747|C0205210|C0439793|C0449820|G0000000|C0302523
"Intermediate indicators include measures of nutrition and development, and intermediate indicators including dietary diversity, household food security, maternal knowledge of child care and feeding practices, and home stimulation practices.","Intermediate indicators measures nutrition development, intermediate indicators including dietary diversity, household food security, maternal knowledge child care feeding practices, stimulation practices.",C0205103|C0021212|C0079809|C0028707|C0243107|C0205103|C0021212|C0332257|C0012155|C1880371|C0020052|C0016452|C1519222|C2347083|C0376554|C0008059|C1947933|C0204695|C0237607|C1292856|C0237607
Repeated measures analysis of changes in PANSS Total Score.,Repeated measures analysis PANSS Total Score.,C0205341|C0079809|C0002778|G0000000|C0439175|C0449820
▪ Days free from pain.,▪ Days free pain.,G0000000|C0439228|C0332296|C0030193
"Secondary end points included overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), and toxicity.","Secondary included survival (OS), progression-free survival (PFS), time treatment failure (TTF), toxicity.",C0027627|C0332257|C0038952|C0229090|C0242656|C0038952|C0242792|C0040223|C0039798|C0231174|C1332112|C0040539
The primary end point of the study was the percentage of patients with at least one exacerbation within 6 months after the index exacerbation.,The primary study percentage patients exacerbation 6 months exacerbation.,G0000000|C0205225|C0557651|C0439165|C0030705|G0000000|G0000000|C0439231|G0000000
Primary outcomes measures were frequency and severity of medically attended injuries.,Primary outcomes measures frequency severity medically attended injuries.,C0205225|C1274040|C0079809|C0376249|C0439793|G0000000|C1456498|C1510467
"The primary outcome of interest was weight loss (body mass, BMI, % fat), and secondary outcomes included physical function (exercise capacity), quality of life (Function After Cancer Therapy—Breast (FACT-B)), cytokines (C-reactive protein (CRP), TNF-α, IL-6), and adipokine profile (leptin, adiponectin, insulin).","The primary outcome weight loss (body mass, BMI, % fat), secondary outcomes included physical function (exercise capacity), quality life (Function After Cancer Therapy—Breast (FACT-B)), cytokines (C-reactive protein (CRP), TNF-α, IL-6), adipokine profile (leptin, adiponectin, insulin).",G0000000|C0205225|C1274040|C0005910|C1517945|C0242821|C0577559|G0000000|G0000000|C0424612|C0027627|C1274040|C0332257|C0031809|C0031843|C0015259|C1516240|C0332306|C0376558|C0031843|G0000000|C0006826|G0000000|C3899183|C0079189|C0205332|C0033684|C3890735|G0000000|C0020898|C1955907|C1979963|C0299583|C0389071|C0021641
"The score lower than 14 defines the minimum level of depression, between 14 to 19 is considered mild, 20 to 28 is moderate, and 29 to 63 is interpreted as a high level of depression.","The score lower 14 defines minimum level depression, 14 19 considered mild, 20 28 moderate, 29 63 interpreted level depression.",G0000000|C0449820|C0441994|C0450371|G0000000|C1524031|C0441889|C0011570|C0450371|C0450371|C0750591|C2945599|C0450371|C0450371|C0205081|C0450371|C0450371|C1285553|C0441889|C0011570
The trial reported that erythromycin did improve the composite primary outcome (death or major cerebral abnormality on ultrasound prior to discharge or chronic lung disease defined as needing oxygen therapy at 36/40 post conceptual age) in singleton babies born to women after PROM.,The trial reported erythromycin improve composite primary outcome (death major cerebral abnormality ultrasound prior discharge chronic lung disease defined oxygen therapy 36/40 post conceptual age) singleton babies born women PROM.,G0000000|C0008976|C0684224|C0014806|G0000000|C0205199|C0205225|C1274040|C0011065|C0205082|G0000000|C1704258|C0041618|C0332152|C0012621|C0205191|C0024109|C0012634|C1704788|C0030054|C0039798|C0450371|C0687676|C1706427|C0001779|C0481462|C0021270|C0005615|C0043210|C0015944
Effectiveness of three doses of mumps vaccine has not been evaluated.,Effectiveness doses mumps vaccine evaluated.,C1280519|C0178602|C0026780|C0042210|C0220825
No patient was withdrawn for adverse events.,No patient withdrawn adverse events.,G0000000|C0030705|C0424092|G0000000|C0441471
"Other secondary efficacy outcomes included the hours per study day spent agitated, the proportion of 12 hour ICU shifts without coma and without either coma or delirium, and among study days a continuous sedative was administered, the proportion of days DA protocol criteria was met and DA was completed, subjects ever receiving early mobilization, use of dexmedetomidine or non-study antipsychotic therapy, days of mechanical ventilation, duration of both ICU and hospital stay, and both ICU and hospital death.","Other secondary efficacy outcomes included hours study day spent agitated, proportion 12 hour ICU shifts coma coma delirium, study days continuous sedative administered, proportion days DA protocol criteria met DA completed, subjects receiving mobilization, dexmedetomidine non-study antipsychotic therapy, days mechanical ventilation, duration ICU hospital stay, ICU hospital death.",G0000000|C0027627|C1280519|C1274040|C0332257|C0439227|C0557651|C0332173|C0680968|C0085631|C1709707|C0450371|C0439227|C0021708|C0333051|C0009421|C0009421|C0011206|C0557651|C0439228|C0549178|C0020592|C1521801|C1709707|C0439228|C0011318|C0442711|C0243161|C0268621|C0011318|C0205197|C0681850|C1514756|C0185112|C0113293|C1518422|C0040615|C0039798|C0439228|C0443254|C0035203|C0449238|C0021708|C0019994|G0000000|C0021708|C0019994|C0011065
There were no adverse events reported.,There adverse events reported.,G0000000|G0000000|C0441471|C0684224
Pain intensity was assessed with Visual Analogue Scale.,Pain intensity assessed Visual Analogue Scale.,C0030193|C0522510|C1516048|C0234621|C0243071|C0175659
No cows' milk was given during the first nine months of life and no egg and fish up to 12 months of age.,No cows' milk months life egg fish 12 months age.,G0000000|C3539595|C0026131|C0439231|C0376558|C0013710|C0016163|C0450371|C0439231|C0001779
"The assessment was performed three times: before the intervention, immediately after the completion of the intervention, and one week later.","The assessment performed times: intervention, completion intervention, week later.",G0000000|C1261322|C0884358|C0040223|C0886296|C0205197|C0886296|C0332174|C0205087
"Instead, the CMT reduction needed over 3 months to be significant.","Instead, CMT reduction 3 months significant.",G0000000|G0000000|C0301630|G0000000|C0439231|C0237881
We arranged contact with the participants on 10 occasions during the study and an additional follow up after 6 years.,We arranged contact participants 10 occasions study additional follow 6 years.,G0000000|C1546854|C0332158|C0679646|C0450371|C0521114|C0557651|C1524062|C0332283|G0000000|C0439234
Two imputation models were performed: one for 7-day and one for 30-day point prevalence abstinence.,Two imputation models performed: 7-day 30-day prevalence abstinence.,C0205448|C2699638|C3161035|C0884358|C0332173|C0450371|C0033105|C3843422
Secondary outcomes included disease-specific quality of life (QoL) and measured physical activity at 6 and 12 months.,Secondary outcomes included disease-specific quality life (QoL) measured physical activity 6 12 months.,C0027627|C1274040|C0332257|C0012634|C0332306|C0376558|C0518214|C0444706|C0031809|C0205177|G0000000|C0450371|C0439231
"The teeth were considered to be radiographically successful in the absence of abnormal root resorption, internal root resorption, furcation involvement, and periapical bone destruction.","The teeth considered radiographically successful absence abnormal root resorption, internal root resorption, furcation involvement, periapical bone destruction.",G0000000|C0040426|C0750591|G0000000|C0597535|C0332197|C0205161|C0040452|C2985494|C0205102|C0040452|C2985494|C2825929|C1314939|C0729269|C0262950|C1261381
"Furthermore, no differences between treatment groups were found in two studies investigating detection thresholds for brush, punctate stimulation, vibration and warmth in patients with post-herpetic neuralgia at 4 and 12 weeks after patch application [8], [29].","Furthermore, differences treatment studies investigating detection thresholds brush, punctate stimulation, vibration warmth patients post-herpetic neuralgia 4 12 weeks patch application [8], [29].",G0000000|C1705241|C0039798|C0947630|C1292732|C1511790|C0449864|C0179445|C0205330|C1292856|C0455941|C0392197|C0030705|C0687676|C0027796|G0000000|C0450371|C0439230|C0332461|C0185125|G0000000|C0450371
The primary efficacy parameter was the percentage of patients rating themselves as “much improved” or “very much improved” on the Patient Global Impression of Change (PGIC) at the final visit.,The primary efficacy parameter percentage patients rating “much improved” “very improved” Patient Global Impression Change (PGIC) final visit.,G0000000|C0205225|C1280519|C0549193|C0439165|C0030705|C0871208|G0000000|G0000000|G0000000|G0000000|C0030705|C0205246|C0596764|C0392747|G0000000|C0205088|C0545082
CRP was measured using the Dade Turbitimer.,CRP measured Dade Turbitimer.,C3890735|C0444706|C0046889|G0000000
"Additional measures derived from the polysomnography included the sleep efficiency (time in bed divided by time asleep), the AHI, and the periodic limb movement index.21 The Pittsburgh Sleep Quality Index (PSQI), which assesses sleep quality and is responsive to changes in insomnia,28,29 was used to provide a global measure of overall sleep quality.","Additional measures derived polysomnography included sleep efficiency (time bed divided time asleep), AHI, periodic limb movement index.21 The Pittsburgh Sleep Quality Index (PSQI), assesses sleep quality responsive insomnia,28,29 provide global measure sleep quality.",C1524062|C0079809|C1441547|C0162701|C0332257|C0037313|C0013682|C0040223|C0004916|C0332849|C0040223|C0424522|G0000000|C0332182|C0015385|C0026649|C0918012|G0000000|G0000000|C0037313|C0332306|C0918012|C3697468|C1516048|C0037313|C0332306|C0205342|C0917801|C1999230|C0205246|C0079809|C0037313|C0332306
"This unique system allowed secondary analysis based upon the time since last registration, giving the opportunity to look at differences in children had never been registered and those who had lapsed from previous registration.","This unique system allowed secondary analysis based time registration, opportunity differences children registered lapsed previous registration.",G0000000|C1710548|C0449913|C0683607|C0027627|C0002778|C1527178|C0040223|C1514821|G0000000|C1705241|C0008059|C1514821|G0000000|C0205156|C1514821
"Percent changes from baseline in lipid profiles after treatment for 6 weeks, including LDL-C, are shown in Fig.","Percent baseline lipid profiles treatment 6 weeks, including LDL-C, Fig.",C0439165|C0168634|C0023779|C1979963|C0039798|G0000000|C0439230|C0332257|G0000000|C0349966
"Other outcome measures will include an alternative dichotomization of the mRS (0 to 3 versus 4 to 6), the score on the Barthel index (BI) at 3 months [17], and body temperature at 24 hours from start of treatment.","Other outcome measures alternative dichotomization mRS (0 3 versus 4 6), score Barthel (BI) 3 months [17], body temperature 24 hours start treatment.",G0000000|C1274040|C0079809|C1523987|G0000000|C1522706|G0000000|G0000000|G0000000|G0000000|G0000000|C0449820|G0000000|G0000000|G0000000|C0439231|C0450371|C0242821|C0005903|C0450371|C0439227|C0439659|C0039798
Fugl-Meyer assessment was conducted on all subjects to evaluate the motor functions of the upper extremity before and after treatment and the power of wrist and hand was measured in the manual muscle test.,Fugl-Meyer assessment conducted subjects evaluate motor functions upper extremity treatment power wrist hand measured manual muscle test.,G0000000|C1261322|C0004927|C0681850|C0220825|C1513492|C0542341|C1282910|C0015385|C0039798|C0032863|C0043262|C0018563|C0444706|C0024763|C0026845|C0022885
"Data on the number and length of hospital admissions and treatments, visits to outpatient clinics, emergency rooms, and general practitioners are applied in the evaluation of economic consequences of the intervention.","Data length hospital admissions treatments, visits outpatient clinics, emergency rooms, practitioners applied evaluation economic consequences intervention.",C1511726|C1444754|C0019994|C0184666|C0087111|C0545082|C0029921|C0442592|C0013956|C1547703|C1709627|C4048755|C0220825|C0013556|C0686907|C0886296
Each of these trials had a substudy to examine the impact of supplementation on motor milestone attainment.,Each trials substudy examine impact supplementation motor milestone attainment.,G0000000|C0008976|G0000000|G0000000|C1825598|C0242297|C1513492|C2347129|G0000000
"The questionnaires of this study consisted of individual characteristics and Depression, Anxiety and Stress Scale (DASS-42).","The questionnaires study consisted individual characteristics Depression, Anxiety Stress Scale (DASS-42).",G0000000|C0034394|C0557651|C0332529|C0027361|C1521970|C0011570|C0003467|C0038435|C0175659|C0051767
"At the end of the study, patients who have received yoga had lower scores on PANSS, HDRS as well as CGIS [Table 3].","At study, patients received yoga lower scores PANSS, HDRS CGIS [Table 3].",G0000000|C0557651|C0030705|C1514756|C0043418|C0441994|C0449820|G0000000|C1840333|C3639708|C0039224|G0000000
"We estimated 11 participants per group (n = 44), a sample larger than existing adult stroke stimulation12 and pediatric CIMT trials.20,29 The primary outcome of change in AHA from baseline to 6 months was analyzed on an intention-to-treat basis using a 2-way analysis of variance to explore effects of rTMS and CIMT using an “at the margins” approach.14 We used a linear mixed effects model with repeated measures to examine interactions of time (change at 1 week, 2 months, and 6 months) with treatment group for each outcome expressed as β coefficient (95% confidence intervals).","We estimated 11 participants (n = 44), sample larger existing adult stroke stimulation12 pediatric CIMT trials.20,29 The primary outcome change AHA baseline 6 months analyzed intention-to-treat basis 2-way analysis variance explore effects rTMS CIMT “at margins” approach.14 We linear mixed effects model repeated measures examine interactions time (change 1 week, 2 months, 6 months) treatment outcome expressed β coefficient (95% confidence intervals).",G0000000|C0750572|C0450371|C0679646|C0369718|G0000000|C0450371|C0370003|C0549177|C2987476|C0001675|C0038454|G0000000|C0030755|G0000000|C0008976|G0000000|C0205225|C1274040|C0392747|C0050451|C0168634|G0000000|C0439231|C0936012|C0162425|C1527178|G0000000|C0002778|C1711260|G0000000|C1280500|G0000000|G0000000|G0000000|G0000000|C0449445|G0000000|C0205132|C0205430|C1280500|C3161035|C0205341|C0079809|G0000000|C1704675|C0040223|C0392747|G0000000|C0332174|G0000000|C0439231|G0000000|C0439231|C0039798|C1274040|G0000000|G0000000|C1707429|C0450371|C0237529|C1272706
(b) Complete resolution of actinic keratoses at 6 months following treatment.,(b) Complete resolution actinic keratoses 6 months treatment.,G0000000|C0205197|C1514893|C0439681|C0022593|G0000000|C0439231|C0039798
Panel A shows the cumulative number of severe exacerbations that occurred in each study group over the course of 50 weeks.,Panel A cumulative severe exacerbations occurred study 50 weeks.,C0441833|G0000000|C1511559|C0205082|G0000000|C1709305|C0557651|C0450371|C0439230
Kaplan-Meier method is used to summarize time to FRNS.,Kaplan-Meier method summarize time FRNS.,G0000000|C0025663|G0000000|C0040223|C0220730
"Eight infants were found to have tuberculosis within the 1-year follow-up period (n = 5 MVA85A; n = 3 control), of whom 1 was M. tuberculosis culture positive and 7 were diagnosed on clinical/radiographic grounds and tuberculosis contact history.","Eight infants tuberculosis 1-year follow-up period (n = 5 MVA85A; = 3 control), 1 M. tuberculosis culture positive 7 diagnosed clinical/radiographic grounds tuberculosis contact history.",C0205454|C0021270|C0041296|C0439234|C0589120|C0439531|C0369718|G0000000|G0000000|G0000000|G0000000|G0000000|C0243148|G0000000|C0369637|C0041296|C0010453|C0439178|G0000000|C0011900|C0205210|G0000000|C0041296|C0332158|C0019664
"OUTCOME MEASURE: Cataract extraction, ascertained from the National Hospital Discharge Registry.","OUTCOME MEASURE: Cataract extraction, ascertained National Hospital Discharge Registry.",C1274040|C0079809|C0086543|C0185115|G0000000|C3245503|C0019994|C0012621|C0034975
To assess the impact of service utilisation data were extracted from the routinely collected hospital database.,To assess impact service utilisation data extracted routinely collected hospital database.,C0040363|C1516048|C1825598|C0557854|C0042153|C1511726|C0185115|G0000000|C1516695|C0019994|C0242356
"All villages had also participated in a trial of pneumococcal conjugate vaccine and were part of that study’s control arm, where children under 5 years of age received PCV-7 [27].","All villages participated trial pneumococcal conjugate vaccine study’s control arm, children 5 age received PCV-7 [27].",G0000000|C0562518|G0000000|C0008976|C0038410|C0301869|C0042210|G0000000|C0243148|C0446516|C0008059|G0000000|C0001779|C1514756|C1882252|C0450371
IBS affects 10-22% of the UK population.,IBS 10-22% UK population.,C0022104|C0450371|C0041700|C0032659
"Using the mean costs and health outcomes in each trial arm, the incremental cost per 1) extra patient achieving a clinically meaningful improvement in the Kessler Distress Scale and 2) QALYs gained of the early treatment group compared with delayed treatment groups will be calculated; results will be plotted on a cost-effectiveness plane.","Using costs health outcomes trial arm, incremental cost 1) extra patient achieving clinically meaningful improvement Kessler Distress Scale 2) QALYs gained treatment compared delayed treatment calculated; plotted cost-effectiveness plane.",C1524063|C0010186|C0018684|C1274040|C0008976|C0446516|C1705117|C0010186|G0000000|G0000000|C0030705|G0000000|G0000000|C0876919|C2986411|G0000000|C0231303|C0175659|G0000000|C0080071|C1517378|C0039798|C1707455|C0205421|C0039798|C0444686|G0000000|C0010181|C0444660
"Resolution of symptoms in the first week, eradication of bacteria after two weeks, and recurrences of sore throat after two, four, and six months.","Resolution symptoms week, eradication bacteria weeks, recurrences sore throat two, four, months.",C1514893|C0683368|C0332174|G0000000|C0004611|C0439230|C0034897|C0234233|C0031354|C0205448|C0205450|C0439231
The reason for the differences in immune responses is not known at this time.,The reason differences immune responses time.,G0000000|C0392360|C1705241|C0439662|C0871261|C0040223
"Other outcomes that were evaluated at each assessment were tender point sensitivity as measured with a standardized 18-point tender point examination using dolorimetry, physician's global assessment on a 0–10-cm VAS (higher scores indicate doing better), HRQOL using the Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales and PedsQL Rheumatology Module (19,20), and sleep quality (average 0–10-cm VAS rating from a 1-week daily diary).","Other outcomes evaluated assessment tender sensitivity measured standardized 18-point tender examination dolorimetry, physician's global assessment 0–10-cm VAS (higher scores better), HRQOL Pediatric Quality Life Inventory (PedsQL) Generic Core Scales PedsQL Rheumatology Module (19,20), sleep quality (average 0–10-cm VAS rating 1-week daily diary).",G0000000|C1274040|C0220825|C1261322|C0234234|C0020517|C0444706|G0000000|C0450371|C0234234|G0000000|G0000000|C0031831|C0205246|C1261322|G0000000|C0042815|C0205250|C0449820|C0332272|G0000000|C0030755|C0332306|C0376558|C0021941|C2698752|C0085155|C0444669|C0175659|C2698752|C0035452|C1709061|C0450371|C0037313|C0332306|C1510992|G0000000|C0042815|C0871208|C0332174|C0332173|C0376660
Sleep parameters were investigated by means of actigraphy.,Sleep parameters investigated actigraphy.,C0037313|C0449381|C1292732|C1171301
"Secondary efficacy endpoints in the RCT included the percentage of patients with the first RFBM within four hours after the first dose, the percentage of patients with an RFBM within four hours after ≥4 of the maximum 7 doses, the number of bowel movements within 24 hours after dosing per week, the number of RFBMs within 24 hours after dosing per week, the percentage of patients using rescue laxatives, the time to first RFBM after the first dose of study drug, and the time to RFBM within 24 hours after each dose.","Secondary efficacy endpoints RCT included percentage patients RFBM hours dose, percentage patients RFBM hours ≥4 maximum 7 doses, bowel movements 24 hours dosing week, RFBMs 24 hours dosing week, percentage patients rescue laxatives, time RFBM dose study drug, time RFBM 24 hours dose.",C0027627|C1280519|C2349179|G0000000|C0332257|C0439165|C0030705|G0000000|C0439227|C0178602|C0439165|C0030705|G0000000|C0439227|G0000000|C0806909|G0000000|C0178602|C0021853|C0026649|C0450371|C0439227|G0000000|C0332174|G0000000|C0450371|C0439227|G0000000|C0332174|C0439165|C0030705|G0000000|C0282090|C0040223|G0000000|C0178602|C0557651|C0013227|C0040223|G0000000|C0450371|C0439227|C0178602
The stimulation of calf muscle during surgery may help in preventing DVT.,The stimulation calf muscle surgery preventing DVT.,G0000000|C1292856|C0230445|C0026845|C0038894|C0309872|C0149871
"More specifically, this overall hypothesis parallels the belief that if this therapy is more comfortable for the patient, he or she will be encouraged to use it more, and the greater utilization might translate to greater treatment efficacy and improvements in alertness, vigilance, and quality of life.","More specifically, hypothesis parallels belief therapy comfortable patient, encouraged more, utilization translate treatment efficacy improvements alertness, vigilance, quality life.",C0205172|G0000000|C1512571|C2348042|C0004951|C0039798|G0000000|C0030705|G0000000|C0205172|C0042153|C0040710|C0039798|C1280519|C2986411|C1443086|C0699864|C0332306|C0376558
"After treatment, significant reductions were observed in functional limitations, patient's main complaints and pain intensity for all three active treatments compared to the WL.","After treatment, reductions observed functional limitations, patient's main complaints pain intensity active treatments compared WL.",G0000000|C0039798|C0301630|C1441672|C0205245|C0449295|C0030705|C0205225|C0277786|C0030193|C0522510|C0205177|C0087111|C1707455|G0000000
All outcomes are collected at pretest and at post-test after 5 weeks of intervention.,All outcomes collected pretest post-test 5 weeks intervention.,G0000000|C1274040|C1516695|C0033101|C0687676|G0000000|C0439230|C0886296
"Monthly mean density of adult Anopheles mosquitoes in sentinel houses in non-LCI and LCI sites in relation to rainfall, Kenya, 2004–2007a LCI, larval control intervention.","Monthly density adult Anopheles mosquitoes sentinel houses non-LCI LCI sites relation rainfall, Kenya, 2004–2007a LCI, larval control intervention.",C0332177|C0178587|C0001675|C0003117|C0026584|C0950580|C0442519|C1518422|C0231990|C0205145|C0080103|G0000000|C0022558|G0000000|C0231990|C0023047|C0243148|C0886296
